



Federal Register

4-15-04

Vol. 69 No. 73

Thursday

Apr. 15, 2004

United States
Government
Printing Office
SUPERINTENDENT
OF DOCUMENTS
Washington, DC 20402

OFFICIAL BUSINESS
Penalty for Private Use, \$300

PERIODICALS

Postage and Fees Paid
U.S. Government Printing Office
(ISSN 0097-6326)

*****3-DIGIT 481
A FR BONNI346B MAR 05 R
BONNIE COLVIN
PROQUEST I & L
PO BOX 1346
ANN ARBOR MI 48106



Federal Register

4-15-04

Vol. 69 No. 73

Thursday

Apr. 15, 2004

Pages 19921-20536



The **FEDERAL REGISTER** (ISSN 0097-6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, www.archives.gov.

The seal of the National Archives and Records Administration authenticates the **Federal Register** as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** www.access.gpo.gov/nara, available through GPO Access, is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

For more information about GPO Access, contact the GPO Access User Support Team, call toll free 1-888-293-6498; DC area 202-512-1530; fax at 202-512-1262; or via email at gpoaccess@gpo.gov. The Support Team is available between 7:00 a.m. and 9:00 p.m. Eastern Time, Monday-Friday, except official holidays.

The annual subscription price for the **Federal Register** paper edition is \$699, or \$764 for a combined **Federal Register**, **Federal Register Index** and **List of CFR Sections Affected (LSA)** subscription; the microfiche edition of the **Federal Register** including the **Federal Register Index** and **LSA** is \$264. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is \$10.00 for each issue, or \$10.00 for each group of pages as actually bound; or \$2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 40% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, bookstore@gpo.gov.

There are no restrictions on the republication of material appearing in the **Federal Register**.

How To Cite This Publication: Use the volume number and the page number. Example: 69 FR 12345.

Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington DC 20402, along with the entire mailing label from the last issue received.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:

Paper or fiche 202-512-1800
Assistance with public subscriptions 202-512-1806

General online information 202-512-1530; 1-888-293-6498

Single copies/back copies:

Paper or fiche 202-512-1800
Assistance with public single copies 1-866-512-1800
(Toll-Free)

FEDERAL AGENCIES

Subscriptions:

Paper or fiche 202-741-6005
Assistance with Federal agency subscriptions 202-741-6005

What's NEW!

Federal Register Table of Contents via e-mail

Subscribe to FEDREGTOC, to receive the **Federal Register** Table of Contents in your e-mail every day.

If you get the HTML version, you can click directly to any document in the issue.

To subscribe, go to <http://listserv.access.gpo.gov> and select:

Online mailing list archives

FEDREGTOC-L

Join or leave the list

Then follow the instructions.

What's NEW!

Regulations.gov, the award-winning Federal eRulemaking Portal

Regulations.gov is the one-stop U.S. Government web site that makes it easy to participate in the regulatory process.

Try this fast and reliable resource to find all rules published in the **Federal Register** that are currently open for public comment. Submit comments to agencies by filling out a simple web form, or use available email addresses and web sites.

The Regulations.gov e-democracy initiative is brought to you by NARA, GPO, EPA and their eRulemaking partners.

Visit the web site at: <http://www.regulations.gov>



Printed on recycled paper.

Contents

Federal Register

Vol. 69, No. 73

Thursday, April 15, 2004

Agriculture Department

See Animal and Plant Health Inspection Service

See Forest Service

Alcohol, Tobacco, Firearms, and Explosives Bureau

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 20038–20039

Animal and Plant Health Inspection Service

PROPOSED RULES

Plant-related quarantine, domestic:

Mexican fruit fly, 19950

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 19970–19972

Centers for Medicare & Medicaid Services

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 20010–20012

Citizenship and Immigration Services Bureau

RULES

Immigration:

Benefit application fee schedule; adjustment, 20527–20536

Civil Rights Commission

NOTICES

Meetings; State advisory committees:

Minnesota, 19972–19973

Nevada, 19973

Coast Guard

RULES

Outer Continental Shelf activities;

Gulf of Mexico; safety zones, 19933–19934

Commerce Department

See Economic Development Administration

See National Oceanic and Atmospheric Administration

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 19973

Commission of Fine Arts

NOTICES

Meetings, 19988–19989

Economic Development Administration

NOTICES

Grants and cooperative agreements; availability, etc.:

University Center Program, 19973–19975

Education Department

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 19989

Employee Benefits Security Administration

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 20039–20041

Employment and Training Administration

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 20041

Energy Department

See Federal Energy Regulatory Commission

NOTICES

Meetings:

Environmental Management Site-Specific Advisory Board—

Rocky Flats, CO, 19989–19990

Environmental Protection Agency

RULES

Air pollutants, hazardous; national emission standards: Pulp and paper industry, 19943–19946

Air quality implementation plans; approval and promulgation; various States:

District of Columbia, Maryland and Virginia, 19937–19939

Maryland, 19939–19943

PROPOSED RULES

Air pollutants, hazardous; national emission standards:

Pulp and paper industry, 19968–19969

Air quality implementation plans; approval and promulgation; various States:

Maryland, 19968

NOTICES

Meetings:

Environmental Policy and Technology National Advisory Council; teleconference, 20006–20007

National Environmental Justice Advisory Council, 20007

Reports and guidance documents; availability, etc.:

TCSA Confidential Business Information Protection Manual; revised, 20007–20008

Water pollution control:

Marine discharges of vessel sewage, prohibition; petitions, etc.—

Connecticut, 20008–20009

Federal Aviation Administration

RULES

Class E airspace, 19922–19924

PROPOSED RULES

Airworthiness directives:

BAE Systems (Operations) Ltd., 19954–19956

Fokker, 19950–19952

Saab, 19952–19954

Short Brothers, 19956–19958

Class E airspace, 19958–19963

Jet routes, 19963–19964

NOTICES

Air traffic operating and flight rules, etc:

High density airports; takeoff and landing slots, slot exemption lottery, and slot allocation procedures—

International slots for winter 2004/2005 scheduling season; submission deadline, 20109–20110

Exemption petitions; summary and disposition, 20110–20111

Federal Communications Commission**RULES**

Radio services, special:

Maritime services—

Automated Maritime Telecommunications System;
stations licensing process, 19947–19949**Federal Energy Regulatory Commission****NOTICES**

Electric rate and corporate regulation filings, 19996–20003

Hydroelectric applications, 20004–20006

Applications, hearings, determinations, etc.:

ANR Pipeline Co., 19990

CenterPoint Energy Gas Transmission Co., 19990

Hamilton, OH, et al., 19990–19991

Southern Star Central Gas Pipeline, Inc., 19991

Styrka Energy Fund Ltd. et al., 19991–19992

Texas Gas Transmission, LLC, 19992

Transcontinental Gas Pipe Line Corp., 19992–19996

Federal Motor Carrier Safety Administration**NOTICES**Agency information collection activities; proposals,
submissions, and approvals, 20111**Federal Reserve System****RULES**Availability of funds and collection of checks (Regulation
CC):Check processing operations restructuring; routing
symbols reassigned, 19921–19922**NOTICES**

Banks and bank holding companies:

Formations, acquisitions, and mergers, 20009–20010

Federal Trade Commission**NOTICES**

Meetings:

Radio frequency identification; applications and
implications for consumers; public workshop,
20523–20525**Fine Arts Commission***See* Commission of Fine Arts**Fish and Wildlife Service****PROPOSED RULES**Alaska National Interest Lands Conservation Act; Title VIII
implementation (subsistence priority):Federal Subsistence Regional Advisory Councils;
membership qualifications, 19964–19968**Food and Drug Administration****NOTICES**

Animal drugs, feeds, and related products:

Ceftiofur, 20012

Human drugs:

Best Pharmaceuticals for Children Act—

Pediatric studies; referral of Zonegran, Wellbutrin,
Zyban, and Renagel to Foundation for National
Institutes of Health, 20012–20013

Memorandums of understanding:

Korea; Maritime Affairs and Fisheries Ministry; fresh and
frozen aquacultured molluscan shellfish exported to
U.S.; safety and quality, 20013–20023**Forest Service****PROPOSED RULES**Alaska National Interest Lands Conservation Act; Title VIII
implementation (subsistence priority):Federal Subsistence Regional Advisory Councils;
membership qualifications, 19964–19968**Health and Human Services Department***See* Centers for Medicare & Medicaid Services*See* Food and Drug Administration*See* National Institutes of Health**NOTICES**

Meetings:

Physical Fitness and Sports, President's Council, 20024

Homeland Security Department*See* Citizenship and Immigration Services Bureau*See* Coast Guard**Indian Affairs Bureau****NOTICES**Indian tribes, acknowledgement of existence
determinations, etc.:Burt Lake Band of Ottawa and Chippewa Indians, Inc.,
20027–20029**Interior Department***See* Fish and Wildlife Service*See* Indian Affairs Bureau*See* Land Management Bureau*See* Minerals Management Service*See* Reclamation Bureau**RULES**Permanent program and abandoned mine land reclamation
plan submissions:

Missouri, 19927–19932

NOTICES

Environmental statements; notice of intent:

Truckee River Operating Agreement, CA and NV, 20025–
20027**International Trade Commission****NOTICES**

Import investigations:

Tissue paper products and crepe paper products from—
China, 20037–20038**Justice Department***See* Alcohol, Tobacco, Firearms, and Explosives Bureau**Labor Department***See* Employee Benefits Security Administration*See* Employment and Training Administration*See* Veterans Employment and Training Service**NOTICES**Agency information collection activities; proposals,
submissions, and approvals, 20039**Land Management Bureau****NOTICES**

Environmental statements; notice of intent:

Teton County, MT; Blackleaf Project, 20029–20030

Realty actions; sales, leases, etc.:

Nevada, 20030–20033

Minerals Management Service**NOTICES**

Outer Continental Shelf operations:

Cook Inlet Alaska—

Oil and gas lease sales, 20033–20037

National Highway Traffic Safety Administration**NOTICES**

Motor vehicle safety standards; exemption petitions, etc.:
Toyota Motor Corp., 20112–20114

National Institutes of Health**NOTICES**

Inventions, Government-owned; availability for licensing,
20023

Meetings:

Interagency Autism Coordinating Committee, 20023–
20024

National Institute of Environmental Health Sciences,
20010, 20024–20025

Patent licenses; non-exclusive, exclusive, or partially
exclusive:

Biolex, Inc., 20025

National Oceanic and Atmospheric Administration**NOTICES**

Endangered and threatened species:

Anadromous fish take—

Puget Sound Treaty Tribes and Washington Fish and
Wildlife Department; Puget Sound chinook salmon,
19975

Species of concern list; establishment, additions to list,
and identification factors; candidate species list
revised, 19975–19979

Fishery conservation and management:

Atlantic highly migratory species—

Vessel monitoring systems; use by pelagic longline
vessels, 19979–19982

Grants and cooperative agreements; availability, etc.:

New England Fishery Management Council; sea scallop
research projects, 19983–19984

Meetings:

New England Fishery Management Council, 19984–19985

Permits:

Marine mammals, 19985

Vessel monitoring systems; approved mobile transmitting
units and communications service providers; list,
19985–19988

Nuclear Regulatory Commission**NOTICES**

Environmental statements; availability, etc.:

U.S. Armed Forces, 20075–20078

Applications, hearings, determinations, etc.:

Progress Energy Carolinas, Inc., 20073–20075

Nuclear Waste Technical Review Board**NOTICES**

Meetings:

Yucca Mountain, NV; potential for localized corrosion
during periods of above boiling temperatures in
planned repository, 20078–20079

Ocean Policy Commission**NOTICES**

Reports and guidance documents; availability, etc.:

National ocean policy; preliminary report; comment
request, 20079

Pension Benefit Guaranty Corporation**RULES**

Single-employer plans:

Allocation of assets—

Interest assumptions for valuing and paying benefits,
19925–19927

NOTICES

Single-employer and multiemployer plans:

Interest rates and assumptions, 20079–20080

Reclamation Bureau**NOTICES**

Meetings:

Glen Canyon Dam Adaptive Management Work Group,
20037

Securities and Exchange Commission**NOTICES**

Investment Company Act of 1940:

ING USA Annuity & Life Insurance Co. et al., 20081–
20089

Self-regulatory organizations; proposed rule changes:

American Stock Exchange LLC, 20089–20091

National Association of Securities Dealers, Inc., 20091–
20094

Pacific Exchange, Inc, 20094–20095

Social Security Administration**RULES**

Social security benefits:

Federal old age, survivors, and disability insurance—

Primary insurance amounts; cost-of-living increases,
19924–19925

State Department**NOTICES**

Grants and cooperative agreements; availability, etc.:

African Workforce Development Program, 20095–20099

Tibet Professional, Educational and Cultural Exchange
Projects, 20099–20103

Turkey; Professional Exchange Programs, 20103–20109

Meetings:

Eastern Europe and Independent States of Former Soviet
Union Study Advisory Committee, 20109

Transportation Department

See Federal Aviation Administration

See Federal Motor Carrier Safety Administration

See National Highway Traffic Safety Administration

NOTICES

Meetings:

Transportation Labor-Management Board, 20109

Treasury Department**NOTICES**

Agency information collection activities; proposals,
submissions, and approvals, 20114–20115

Veterans Affairs Department**RULES**

Board of Veterans' Appeals:

Appeals regulations and rules of practice—

Veterans Health Administration; medical opinions,
19935–19937

NOTICES

Inventions, Government-owned; availability for licensing,
20115–20116

Medical benefits:

Medical care or services, reasonable charges; 2004
methodology changes, 20117–20521

Veterans Employment and Training Service**NOTICES**

Grants and cooperative agreements; availability, etc.:

Veterans' Workforce Investment Program, 20042–20073

Separate Parts In This Issue**Part II**

Veterans Affairs Department, 20117-20521

Part III

Federal Trade Commission, 20523-20525

Part IVHomeland Security Department, Citizenship and
Immigration Services Bureau, 20527-20536**Reader Aids**

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents LISTSERV electronic mailing list, go to <http://listserv.access.gpo.gov> and select Online mailing list archives, FEDREGTOC-L. Join or leave the list (or change settings); then follow the instructions.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

7 CFR**Proposed Rules:**

301.....19950

8 CFR

103.....20528

12 CFR

229.....19921

14 CFR71 (2 documents)19922,
19923**Proposed Rules:**39 (4 documents)19950,
19952, 19954, 1995671 (5 documents)19958,
19960, 19961, 19962, 19963**20 CFR**

404.....19924

29 CFR4022.....19925
4044.....19925**30 CFR**

925.....19927

33 CFR

147.....19933

36 CFR**Proposed Rules:**

242.....19964

38 CFR

20.....19935

40 CFR52 (2 documents)19937,
19939

63.....19943

Proposed Rules:

52.....19968


63.....19968

47 CFR

80.....19947

50 CFR**Proposed Rules:**

100.....19964



Rules and Regulations

Federal Register

Vol. 69, No. 73

Thursday, April 15, 2004

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

FEDERAL RESERVE SYSTEM

12 CFR Part 229

[Regulation CC; Docket No. R-1190]

Availability of Funds and Collection of Checks

AGENCY: Board of Governors of the Federal Reserve System.

ACTION: Final rule; technical amendment.

SUMMARY: The Board of Governors is amending appendix A of Regulation CC to delete the reference to the Charleston check processing office of the Federal Reserve Bank of Richmond and reassign the Federal Reserve routing symbols currently listed under that office to the Cincinnati office of the Federal Reserve Bank of Cleveland. These amendments reflect the restructuring of check processing operations within the Federal Reserve System.

DATES: The final rule will become effective on June 26, 2004.

FOR FURTHER INFORMATION CONTACT: Jack K. Walton II, Assistant Director (202) 452-2660, or Joseph P. Baressi, Senior Financial Services Analyst (202) 452-3959, Division of Reserve Bank Operations and Payment Systems; or Adrienne G. Threatt, Counsel (202) 452-3554, Legal Division. For users of Telecommunications Devices for the Deaf (TDD) only, contact (202) 263-4869.

SUPPLEMENTARY INFORMATION: Regulation CC establishes the maximum period a depository bank may wait between receiving a deposit and making the deposited funds available for withdrawal.¹ A depository bank generally must provide faster availability for funds deposited by a

“local check” than by a “nonlocal check.” A check drawn on a bank is considered local if it is payable by or at a bank located in the same Federal Reserve check processing region as the depository bank. A check drawn on a nonbank is considered local if it is payable through a bank located in the same Federal Reserve check processing region as the depository bank. Checks that do not meet the requirements for “local” checks are considered “nonlocal.”

Appendix A to Regulation CC contains a routing number guide that assists banks in identifying local and nonlocal banks and thereby determining the maximum permissible hold periods for most deposited checks. The appendix includes a list of each Federal Reserve check processing office and the first four digits of the routing number, known as the Federal Reserve routing symbol, of each bank that is served by that office. Banks whose Federal Reserve routing symbols are grouped under the same office are in the same check processing region and thus are local to one another.

As explained in detail in the Board’s final rule published in the *Federal Register* on May 28, 2003, the Federal Reserve Banks decided in early 2003 to reduce the number of locations at which they process checks.² As part of this restructuring process, the Charleston office of the Federal Reserve Bank of Richmond will cease processing checks on June 26, 2004. As of that date, banks with routing symbols currently assigned to the Charleston office for check processing purposes will be reassigned to the Cincinnati office of the Federal Reserve Bank of Cleveland. As a result of this change, some checks that are drawn on and deposited at banks located in the Charleston and Cincinnati check processing regions and that currently are nonlocal checks will become local checks subject to faster availability schedules. Also, after June 26, 2004, the restructured Cincinnati check processing region will cross Federal Reserve District lines. Banks

² See 68 FR 31592, May 28, 2003. In addition to the general advance notice of future amendments previously provided by the Board, as well as the Board’s notices of final amendments, the Reserve Banks are striving to inform affected depository institutions of the exact date of each office transition at least 120 days in advance. The Reserve Banks’ communications to affected depository institutions are available at www.frbservices.org.

located in that region therefore no longer will be able to determine that a check is nonlocal solely because the paying bank for that check is located in another Federal Reserve District.

To assist banks in identifying local and nonlocal banks, the Board accordingly is amending the lists of routing symbols associated with the Federal Reserve Banks of Richmond and Cleveland to reflect the transfer of operations from the Federal Reserve Bank of Richmond’s Charleston office to the Federal Reserve Bank of Cleveland’s Cincinnati office. These amendments are effective June 26, 2004, to coincide with the effective date of the underlying check processing changes. The Board is providing advance notice of these amendments to give affected banks ample time to make any needed processing changes. The advance notice will also enable affected banks to amend their availability schedules and related disclosures, if necessary, and provide their customers with notice of these changes.³ The Federal Reserve routing symbols assigned to all other Federal Reserve branches and offices will remain the same at this time. The Board of Governors, however, intends to issue similar notices at least 60 days prior to the elimination of check operations at some other Reserve Bank offices, as described in the May 2003 *Federal Register* document.

Administrative Procedure Act

The Board has not followed the provisions of 5 U.S.C. 553(b) relating to notice and public participation in connection with the adoption of this final rule. The revisions to the appendices are technical in nature, and the routing symbol revisions are required by the statutory and regulatory definitions of “check-processing region.” Because there is no substantive change on which to seek public input, the Board has determined that the section 553(b) notice and comment procedures are unnecessary.

Paperwork Reduction Act

In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3506; 5 CFR part 1320, Appendix A.1), the Board has reviewed the final rule under

³ Section 229.18(e) of Regulation CC requires that banks notify account holders who are consumers within 30 days after implementing a change that improves the availability of funds.

¹ For purposes of Regulation CC, the term “bank” refers to any depository institution, including commercial banks, savings institutions, and credit unions.

authority delegated to the Board by the Office of Management and Budget. This technical amendment to appendix A of Regulation CC will delete the reference to the Charleston check processing office of the Federal Reserve Bank of Richmond and reassign the routing symbols listed under that office to the Cincinnati office of the Federal Reserve Bank of Cleveland. The depository institutions that are located in the affected check processing regions and that include the routing numbers in their disclosure statements would be required to notify customers of the resulting change in availability under § 229.18(e). However, because all paperwork collection procedures associated with Regulation CC already are in place, the Board anticipates that no additional burden will be imposed as a result of this rulemaking.

List of Subjects in 12 CFR Part 229

Banks, Banking, Federal Reserve System, Reporting and recordkeeping requirements.

Authority and Issuance

■ For the reasons set forth in the preamble, the Board is amending 12 CFR part 229 to read as follows:

PART 229—AVAILABILITY OF FUNDS AND COLLECTION OF CHECKS (REGULATION CC)

■ 1. The authority citation for part 229 continues to read as follows:

Authority: 12 U.S.C. 4001 *et seq.*

■ 2. The Fourth and Fifth Federal Reserve District routing symbol lists in appendix A are revised to read as follows:

Appendix A To Part 229—Routing Number Guide To Next-Day Availability Checks and Local Checks

* * * * *

Fourth Federal Reserve District

[Federal Reserve Bank of Cleveland]

Head Office

0410	2410
0412	2412
0430	2430
0432	2432
0433	2433
0434	2434

Cincinnati Branch

0420	2420
0421	2421
0422	2422
0423	2423
0515	2515
0519	2519

Columbus Office

0440	2440
------	------

0441	2441
0442	2442

Fifth Federal Reserve District

[Federal Reserve Bank of Richmond]

Baltimore Branch

0510	2510
0514	2514
0520	2520
0521	2521
0522	2522
0540	2540
0550	2550
0560	2560
0570	2570

Charlotte Branch

0530	2530
0531	2531

Columbia Office

0532	2532
0539	2539

* * * * *

By order of the Board of Governors of the Federal Reserve System, acting through the Secretary of the Board under delegated authority, April 9, 2004.

Jennifer J. Johnson,
Secretary of the Board.

[FR Doc. 04-8527 Filed 4-14-04; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2004-16914; Airspace Docket No. 04-AAL-01]

Establishment of Class E Airspace; Akhiok, AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: This action establishes Class E airspace at Akhiok, AK to provide adequate controlled airspace to contain aircraft executing a new Standard Instrument Approach Procedure (SIAP) and a new Departure Procedure. This Rule results in new Class E airspace upward from 700 feet (ft.) and 1,200 feet above the surface at Akhiok, AK.

DATES: *Effective Date:* 0901 UTC, June 10, 2004.

FOR FURTHER INFORMATION CONTACT: Jesse Patterson, AAL-538G, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513-7587; telephone number (907) 271-5898; fax: (907) 271-2850; e-mail: Jesse.ctr.Patterson@faa.gov. Internet address: <http://www.alaska.faa.gov/at>.

SUPPLEMENTARY INFORMATION:

History

On Tuesday, February 3, 2004, the FAA proposed to revise part 71 of the Federal Aviation Regulations (14 CFR part 71) to create new Class E airspace upward from 700 ft. and 1,200 ft. above the surface at Akhiok, AK (69 FR 5093). The action was proposed in order to add Class E airspace sufficient in size to contain aircraft while executing a new Standard Instrument Approach Procedure and a new Departure Procedure for the Akhiok Airport. The new approach is Area Navigation-Global Positioning System (RNAV GPS) A original. The new departure procedure is the JOGMO ONE RNAV Departure. New Class E controlled airspace extending upward from 700 feet and 1,200 feet above the surface in the Akhiok Airport area is established by this action. Interested parties were invited to participate in this rulemaking proceeding by submitting written comments on the proposal to the FAA. No public comments have been received, thus, the rule is adopted as proposed.

The area will be depicted on aeronautical charts for pilot reference. The coordinates for this airspace docket are based on North American Datum 83. The Class E airspace areas designated as 700/1200 foot transition areas are published in paragraph 6005 of FAA Order 7400.9L, *Airspace Designations and Reporting Points*, dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designation listed in this document will be revoked and revised subsequently in the Order.

The Rule

This revision to 14 CFR part 71 establishes Class E airspace at Akhiok, Alaska. This additional Class E airspace was created to accommodate aircraft executing a new SIAP and will be depicted on aeronautical charts for pilot reference. The intended effect of this rule is to provide adequate controlled airspace for IFR operations at Akhiok Airport, Akhiok, Alaska.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is

so minimal. Since this a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

■ In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

■ 1. The authority citation for 14 CFR part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

■ 2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9L, *Airspace Designations and Reporting Points*, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

* * * * *
Paragraph 6005 Class E airspace extending upward from 700 feet or more above the surface of the earth.
 * * * * *

AAL AK E5 Akhiok, AK [New]

Akhiok Airport, AK
 (lat. 56°56'19" N., long. 154°10'57" W.)

That airspace extending upward from 700 feet above the surface within a 6.3-mile radius of the Akhiok Airport and that airspace extending upward from 1,200 feet above the surface within an area bounded by 57°11' N. 154°10'30" W. to 56°47' N. 153°36' W. to 56°35' N. 154°04' W. to 56°35' N. 154°25' W. to 56°56'30" N. 154°55' W. to point of beginning.

* * * * *

Issued in Anchorage, AK, on April 1, 2004.

Judith G. Heckl,

Manager, Air Traffic Division, Alaskan Region.

[FR Doc. 04–8504 Filed 4–14–04; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA–2003–16833; Airspace Docket No. 03–AAL–26]

Establishment of Class E Airspace; King Cove, AK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: This action establishes Class E airspace at King Cove, AK to provide adequate controlled airspace to contain aircraft executing a new Standard Instrument Approach Procedure (SIAP) and a Textual Departure Procedure. This Rule results in new Class E airspace upward from 700 feet (ft.) above the surface at King Cove, AK.

DATES: *Effective Date:* 0901 UTC, June 10, 2004.

FOR FURTHER INFORMATION CONTACT: Jesse Patterson, AAL–538G, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513–7587; telephone number (907) 271–5898; fax: (907) 271–2850; e-mail: Jesse.ctr.patterson@faa.gov. Internet address: <http://www.alaska.faa.gov/at>.

SUPPLEMENTARY INFORMATION:

History

On Tuesday, February 3, 2004, the FAA proposed to revise part 71 of the Federal Aviation Regulations (14 CFR part 71) to create new Class E airspace upward from 700ft. above the surface at King Cove, AK (69 FR 5094). The action was proposed in order to add Class E airspace sufficient in size to contain aircraft while executing a new SIAP and Textual Departure Procedure for the King Cove Airport. The new approach is Area Navigation-Global Positioning System (RNAV GPS) A original. New Class E controlled airspace extending upward from 700 feet above the surface within a 6.5-mile radius of the King Cove Airport and that airspace extending 1.2 miles either side of the 103 bearing from King Cove Airport from the 6.5-mile radius out to 8.75 miles excluding that airspace within the Cold Bay, Alaska Class E airspace area is established by this action. Interested parties were invited to participate in this rulemaking proceeding by submitting written comments on the proposal to the FAA. No public comments have been received, thus, the rule is adopted as proposed.

The area will be depicted on aeronautical charts for pilot reference.

The coordinates for this airspace docket are based on North American Datum 83. The Class E airspace areas designated as 700/1200 foot transition areas are published in paragraph 6005 of FAA Order 7400.9L, *Airspace Designations and Reporting Points*, dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designation listed in this document will be revoked and revised subsequently in the Order.

The Rule

This revision to 14 CFR part 71 establishes Class E airspace at King Cove, Alaska. This additional Class E airspace was created to accommodate aircraft executing a new SIAP and will be depicted on aeronautical charts for pilot reference. The intended effect of this rule is to provide adequate controlled airspace for IFR operations at King Cove Airport, King Cove, Alaska.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) Is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

■ In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

■ 1. The authority citation for 14 CFR part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

■ 2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9L, *Airspace Designations and Reporting Points*, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

* * * * *

Paragraph 6005 *Class E airspace extending from 700 feet or more above the surface of the earth.*

* * * * *

AAL AK E5 King Cove, AK [New]

King Cove Airport, AK
(lat. 55°06'59" N., long. 162°15'58" W.)

That airspace extending upward from 700 feet above the surface within a 6.5-mile radius of the King Cove Airport and that airspace extending 1.2 miles either side of the 103 bearing from King Cove Airport from the 6.5-mile radius out to 8.75 miles excluding that airspace within the Cold Bay Class E airspace area.

* * * * *

Issued in Anchorage, AK, on March 31, 2004.

Judith G. Heckl,

Manager, Air Traffic Division, Alaskan Region.

[FR Doc. 04-8503 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

SOCIAL SECURITY ADMINISTRATION**20 CFR Part 404**

RIN 0960-AF14

Title II Cost of Living Increases in Primary Insurance Amounts

AGENCY: Social Security Administration.
ACTION: Final rules.

SUMMARY: We are revising our rules dealing with automatic cost-of-living increases to primary insurance amounts under title II of the Social Security Act (the Act). The revisions remove the restriction in our previous rules that allowed cost-of-living increases based on rises in the Consumer Price Index (CPI) or the Average Wage Index (AWI) only if either the CPI or AWI increased by 3 percent or more during the prescribed measuring period. The 3-percent restriction was eliminated by legislation enacted in 1986. We are also adding clarifying language that, when rounding an increase in the CPI or AWI, we round five one-hundredths and above to the next higher tenth of a percent.

EFFECTIVE DATES: These regulations are effective April 15, 2004.

ADDRESSES: Electronic Version: The electronic file of this document is

available on the date of publication in the **Federal Register** at <http://www.gpoaccess.gov/fr/index.html>. It is also available on the Internet site for SSA (i.e., Social Security Online) at <http://policy.ssa.gov/prpublic.nsf/LawsRegs>.

FOR FURTHER INFORMATION CONTACT:

Regarding this **Federal Register** document—Robert J. Augustine, Social Insurance Specialist, Office of Regulations, Social Security Administration, Room 100, Altmeyer Building, 6401 Security Boulevard, Baltimore, MD 21235-6401, (410) 965-0020 or TTY (410) 966-5609. For information on eligibility or filing for benefits: Call our national toll-free number, 1-800-772-1213 or TTY 1-800-325-0778 or visit our Internet Web site, Social Security Online, at <http://www.socialsecurity.gov>.

SUPPLEMENTARY INFORMATION:**Background**

The primary insurance amount is the basic figure we use to find the monthly Social Security benefit amount we pay to workers and their family members. Under section 215(i) of the Act, primary insurance amounts are automatically increased each year if there has been an increase in the CPI or AWI over the specified measuring period. Under the law in effect prior to the enactment of Public Law 99-509 on October 21, 1986, we could increase primary insurance amounts only if either the CPI or AWI rose by 3.0 percent or more over the specified measuring period. Section 9001 of Public Law 99-509 removed the 3-percent restriction from the law. However, we have not previously revised our regulations to reflect this legislative change. This revision conforms our rules on cost-of-living increases to current law. This rule also provides clarification on how we round increases in the CPI or AWI to the nearest tenth when the calculated increase is exactly halfway between tenths of one percent.

Explanation of Changes

We have revised §§ 404.273 through 404.275 and § 404.278 by removing all references to the 3-percent restriction on cost-of-living increases.

We have also added a new paragraph (c) to § 404.275 to clarify that, when rounding the percentage increase in the cost of living to the nearest tenth of a percent, we round five one-hundredths and above to the next higher tenth of a percent and otherwise round down to the next lower tenth of a percent. For example, we round an increase of 3.15 percent up to a 3.2 percent increase. We

have redesignated current paragraph (c) as paragraph (d).

Regulatory Procedures

Pursuant to section 702(a)(5) of the Social Security Act, 42 U.S.C. 902(a)(5), as amended by section 102 of Public Law 103-296, SSA follows the Administrative Procedure Act (APA) rulemaking procedures specified in 5 U.S.C. 553 in the development of its regulations. The APA provides exceptions to its notice and public comment procedures when an agency finds there is good cause for dispensing with such procedures on the basis that they are impracticable, unnecessary, or contrary to the public interest.

In the case of these final rules, we have determined that, under 5 U.S.C. 553(b)(B), good cause exists for dispensing with the notice and public comment procedures in this case. Good cause exists because these regulations merely conform our rules on cost-of-living increases to current law and reflect our current interpretation on rounding. These regulations contain no substantive changes of interpretation. Therefore, opportunity for prior comment is unnecessary, and we are issuing these regulations as final rules.

In addition, we find good cause for dispensing with the 30-day delay in the effective date of a substantive rule, provided for by 5 U.S.C. 553(d). As explained above, we are not making any substantive changes in the cost-of-living increase provisions. However, without these changes, our rules will conflict with current law and may mislead the public. In addition, we are codifying our current interpretation on rounding into our regulations. Therefore, we find that it is in the public interest to make these rules effective upon publication.

Executive Order 12866, as Amended by Executive Order 13258

We have consulted with the Office of Management and Budget (OMB) and determined that these final rules do not meet the criteria for a significant regulatory action under Executive Order 12866, as amended by Executive Order 13258. Thus, they were not subject to OMB review. We have also determined that these final rules meet the plain language requirement of Executive Order 12866, as amended by Executive Order 13258.

Regulatory Flexibility Act

We certify that these final rules will not have a significant economic impact on a substantial number of small entities. Therefore, a regulatory flexibility analysis as provided in the

Regulatory Flexibility Act, as amended, is not required.

Paperwork Reduction Act

These final rules impose no additional reporting or recordkeeping requirements requiring OMB clearance.

(Catalog of Federal Domestic Assistance Program Nos. 96.001, Social Security—Disability Insurance; 96.002, Social Security—Retirement Insurance; 96.004, Social Security—Survivors Insurance)

List of Subjects in 20 CFR Part 404

Administrative practice and procedure, Blind, Disability benefits, Old-age, Survivors and disability insurance, Reporting and recordkeeping requirements, Social Security.

Dated: March 30, 2004.

Jo Anne B. Barnhart,
Commissioner of Social Security.

■ For the reasons set forth in the preamble, we are amending subpart C of part 404 of Title 20 of the Code of Federal Regulations as follows:

PART 404—FEDERAL OLD-AGE, SURVIVORS AND DISABILITY INSURANCE (1950—)

Subpart C—[Amended]

■ 1. The authority citation for subpart C of part 404 continues to read as follows:

Authority: Secs. 202(a), 205(a), 215, and 702(a)(5) of the Social Security Act (42 U.S.C. 402(a), 405(a), 415, and 902(a)(5)).

■ 2. Sections 404.273, 404.274 and 404.275 are revised to read as follows:

§ 404.273 When are automatic cost-of-living increases effective?

We make automatic cost-of-living increases if the applicable index, either the CPI or the AWI, rises over a specified measuring period (see the rules on measuring periods in § 404.274). If the cost-of-living increase is to be based on an increase in the CPI, the increase is effective in December of the year in which the measuring period ends. If the increase is to be based on an increase in the AWI, the increase is effective in December of the year after the year in which the measuring period ends.

§ 404.274 What are the measuring periods we use to calculate cost-of-living increases?

(a) *General.* Depending on the OASDI fund ratio, we measure the rise in one index or in both indexes during the applicable measuring period (described in paragraphs (b) and (c) of this section) to determine whether there will be an automatic cost-of-living increase and if so, its amount.

(b) *Measuring period based on the CPI—(1) When the period begins.* The measuring period we use for finding the amount of the CPI increase begins with the later of—

(i) Any calendar quarter in which an *ad hoc* benefit increase is effective; or

(ii) The third calendar quarter of any year in which the last automatic increase became effective.

(2) *When the period ends.* The measuring period ends with the third calendar quarter of the following year. If this measuring period ends in a year after the year in which an *ad hoc* increase was enacted or took effect, there can be no cost-of-living increase at that time. We will extend the measuring period to the third calendar quarter of the next year.

(c) *Measuring period based on the AWI—(1) When the period begins.* The measuring period we use for finding the amount of the AWI increase begins with the later of—

(i) The calendar year before the year in which an *ad hoc* benefit increase is effective; or

(ii) The calendar year before the year in which the last automatic increase became effective.

(2) *When the period ends.* The measuring period ends with the following year. If this measuring period ends in a year in which an *ad hoc* increase was enacted or took effect, there can be no cost-of-living increase at that time. We will extend the measuring period to the next calendar year.

§ 404.275 How is an automatic cost-of-living increase calculated?

(a) *Increase based on the CPI.* We compute the average of the CPI for the quarters that begin and end the measuring period by adding the three monthly CPI figures (which are published to one decimal place), dividing the total by 3, and rounding the result to the nearest 0.1. If the average for the ending quarter is higher than the average for the beginning quarter, we divide the average for the ending quarter by the average for the beginning quarter to determine the percentage increase in the CPI over the measuring period.

(b) *Increase based on the AWI.* If the AWI for the year that ends the measuring period is higher than the AWI for the year which begins the measuring period and all the other conditions for an AWI-based increase are met, we divide the higher AWI by the lower AWI to determine the percentage increase in the AWI.

(c) *Rounding rules.* We round the increase from the applicable paragraph (a) or (b) of this section to the nearest 0.1 percent by rounding 0.05 percent

and above to the next higher 0.1 percent and otherwise rounding to the next lower 0.1 percent. For example, if the applicable index is the CPI and the increase in the CPI is 3.15 percent, we round the increase to 3.2 percent. We then apply this percentage increase to the amounts described in § 404.271 and round the resulting dollar amounts to the next lower multiple of \$0.10 (if not already a multiple of \$0.10).

(d) *Additional increase.* See § 404.278 for the additional increase that is possible.

§ 404.278 [Amended]

■ 3. In § 404.278, remove the parenthetical phrase at the end of paragraph (a)(2).

[FR Doc. 04-8573 Filed 4-14-04; 8:45 am]

BILLING CODE 4191-02-P

PENSION BENEFIT GUARANTY CORPORATION

29 CFR Parts 4022 and 4044

Benefits Payable in Terminated Single-Employer Plans; Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing and Paying Benefits

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Final rule.

SUMMARY: The Pension Benefit Guaranty Corporation's regulations on Benefits Payable in Terminated Single-Employer Plans and Allocation of Assets in Single-Employer Plans prescribe interest assumptions for valuing and paying benefits under terminating single-employer plans. This final rule amends the regulations to adopt interest assumptions for plans with valuation dates in May 2004. Interest assumptions are also published on the PBGC's Web site (<http://www.pbgc.gov>).

EFFECTIVE DATE: May 1, 2004.

FOR FURTHER INFORMATION CONTACT:

Harold J. Ashner, Assistant General Counsel, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street, NW., Washington, DC 20005, (202) 326-4024. (TTY/TDD users may call the Federal relay service toll-free at 1-800-877-8339 and ask to be connected to (202) 326-4024.)

SUPPLEMENTARY INFORMATION: The PBGC's regulations prescribe actuarial assumptions—including interest assumptions—for valuing and paying plan benefits of terminating single-employer plans covered by title IV of the Employee Retirement Income

Security Act of 1974. The interest assumptions are intended to reflect current conditions in the financial and annuity markets.

Three sets of interest assumptions are prescribed: (1) A set for the valuation of benefits for allocation purposes under section 4044 (found in Appendix B to part 4044), (2) a set for the PBGC to use to determine whether a benefit is payable as a lump sum and to determine lump-sum amounts to be paid by the PBGC (found in Appendix B to part 4022), and (3) a set for private-sector pension practitioners to refer to if they wish to use lump-sum interest rates determined using the PBGC's historical methodology (found in Appendix C to part 4022).

Accordingly, this amendment (1) adds to Appendix B to part 4044 the interest assumptions for valuing benefits for allocation purposes in plans with valuation dates during May 2004, (2) adds to Appendix B to part 4022 the interest assumptions for the PBGC to use for its own lump-sum payments in plans with valuation dates during May 2004, and (3) adds to Appendix C to part 4022 the interest assumptions for private-sector pension practitioners to refer to if they wish to use lump-sum interest rates determined using the PBGC's historical methodology for valuation dates during May 2004.

For valuation of benefits for allocation purposes, the interest assumptions that the PBGC will use (set forth in Appendix B to part 4044) will be 3.90 percent for the first 20 years following

the valuation date and 5.00 percent thereafter. These interest assumptions represent a decrease (from those in effect for April 2004) of 0.10 percent for the first 20 years following the valuation date and are otherwise unchanged.

The interest assumptions that the PBGC will use for its own lump-sum payments (set forth in Appendix B to part 4022) will be 3.00 percent for the period during which a benefit is in pay status and 4.00 percent during any years preceding the benefit's placement in pay status. These interest assumptions are unchanged from those in effect for April 2004.

For private-sector payments, the interest assumptions (set forth in Appendix C to part 4022) will be the same as those used by the PBGC for determining and paying lump sums (set forth in Appendix B to part 4022).

The PBGC has determined that notice and public comment on this amendment are impracticable and contrary to the public interest. This finding is based on the need to determine and issue new interest assumptions promptly so that the assumptions can reflect, as accurately as possible, current market conditions.

Because of the need to provide immediate guidance for the valuation and payment of benefits in plans with valuation dates during May 2004, the PBGC finds that good cause exists for making the assumptions set forth in this amendment effective less than 30 days after publication.

The PBGC has determined that this action is not a "significant regulatory action" under the criteria set forth in Executive Order 12866.

Because no general notice of proposed rulemaking is required for this amendment, the Regulatory Flexibility Act of 1980 does not apply. See 5 U.S.C. 601(2).

List of Subjects

29 CFR Part 4022

Employee benefit plans, Pension insurance, Pensions, Reporting and recordkeeping requirements.

29 CFR Part 4044

Employee benefit plans, Pension insurance, Pensions.

■ In consideration of the foregoing, 29 CFR parts 4022 and 4044 are amended as follows:

PART 4022—BENEFITS PAYABLE IN TERMINATED SINGLE-EMPLOYER PLANS

■ 1. The authority citation for part 4022 continues to read as follows:

Authority: 29 U.S.C. 1302, 1322, 1322b, 1341(c)(3)(D), and 1344.

■ 2. In appendix B to part 4022, Rate Set 127, as set forth below, is added to the table. (The introductory text of the table is omitted.)

Appendix B to Part 4022—Lump Sum Interest Rates for PBGC Payments

* * * * *

Rate set	For plans with a valuation date		Immediate annuity rate (percent)	Deferred annuities (percent)				
	On or after	Before		i_1	i_2	i_3	n_1	n_2
127	5-1-04	6-1-04	3.00	4.00	4.00	4.00	7	8

■ 3. In appendix C to part 4022, Rate Set 127, as set forth below, is added to the table. (The introductory text of the table is omitted.)

Appendix C to Part 4022—Lump Sum Interest Rates for Private-Sector Payments

* * * * *

Rate set	For plans with a valuation date		Immediate annuity rate (percent)	Deferred annuities (percent)				
	On or after	Before		i_1	i_2	i_3	n_1	n_2
127	5-1-04	6-1-04	3.00	4.00	4.00	4.00	7	8

PART 4044—ALLOCATION OF ASSETS IN SINGLE-EMPLOYER PLANS

■ 4. The authority citation for part 4044 continues to read as follows:

Authority: 29 U.S.C. 1301(a), 1302(b)(3), 1341, 1344, 1362.

■ 5. In appendix B to part 4044, a new entry, as set forth below, is added to the table. (The introductory text of the table is omitted.)

Appendix B to Part 4044—Interest Rates Used to Value Benefits

* * * * *

For valuation dates occurring in the month—	The values of i_t are:					
	i_t	for $t =$	i_t	for $t =$	i_t	for $t =$
May 20040390	1–20	.0500	>20	N/A	N/A

Issued in Washington, DC, on this 8th day of April 2004.

Joseph H. Grant,

Deputy Executive Director and Chief Operating Officer, Pension Benefit Guaranty Corporation.

[FR Doc. 04–8588 Filed 4–14–04; 8:45 am]

BILLING CODE 7708–01–P

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation and Enforcement

30 CFR Part 925

Clarification of Substituted Federal Enforcement for Parts of Missouri's Permanent Regulatory Program and Findings on the Status of Missouri's Permanent Regulatory Program

AGENCY: Office of Surface Mining Reclamation and Enforcement, Interior.

ACTION: Final rule; clarification.

SUMMARY: On November 21, 1980, the Secretary of the Interior (the Secretary) conditionally approved the Missouri permanent regulatory program (Missouri program) under the Surface Mining Control and Reclamation Act of 1977 (SMCRA or the Act). On August 4, 2003, we, the Office of Surface Mining Reclamation and Enforcement (OSM), notified the Governor of Missouri that serious problems existed that were adversely affecting the Missouri Department of Natural Resources, Air and Land Protection Division, Land Reclamation Program's (MLRP) implementation and enforcement of the Missouri program. In accordance with the provisions of 30 CFR 733.12(f), we announced our decision, effective August 22, 2003, to institute direct Federal enforcement for those portions of the Missouri program that the MLRP could not adequately implement and enforce. With the substitution of Federal enforcement authority, we outlined a process by which Missouri could regain full authority for its program.

This document clarifies the portions of the Missouri program that we directly enforce and sets forth our findings regarding the status of those portions of Missouri's program for which we required remedial actions.

This rule is being made effective immediately in order to expedite the actions required of the State to resume full authority for its approved program.

EFFECTIVE DATE: April 15, 2004.

FOR FURTHER INFORMATION CONTACT: John W. Coleman, Mid-Continent Regional Coordinating Center, Office of Surface Mining, 501 Belle Street, Alton, Illinois 62002. Telephone: (618) 463–6460.

SUPPLEMENTARY INFORMATION:

- I. Background on the Missouri Program
- II. Clarification of OSM's August 22, 2003, Decision to Substitute Federal Enforcement for Parts of the Missouri Program
- III. OSM's Decision
- IV. Disposition of Comments
- V. Procedural Determinations

I. Background on the Missouri Program

Section 503(a) of the Act permits a State to assume primacy for the regulation of surface coal mining and reclamation operations on non-Federal and non-Indian lands within its borders by demonstrating that its State program includes, among other things, "a State law which provides for the regulation of surface coal mining and reclamation operations in accordance with the requirements of this Act * * *; and rules and regulations consistent with regulations issued by the Secretary pursuant to this Act." See 30 U.S.C. 1253(a)(1) and (7). On the basis of these criteria, the Secretary conditionally approved the Missouri program on November 21, 1980. You can find background information on the Missouri program, including the Secretary's findings, the disposition of comments, and conditions of approval, in the November 21, 1980, **Federal Register** (45 FR 77017). You can also find later actions concerning the Missouri program and program amendments at 30 CFR 925.10, 925.12, 925.15, 925.16, 925.17, 925.18, and 925.19.

The Abandoned Mine Land Reclamation (AMLR) Program was established by Title IV of the Act (30 U.S.C. 1201 *et seq.*) in response to concerns over extensive environmental damage caused by past coal mining activities. The program is funded by a reclamation fee collected on each ton of coal that is produced. The money collected is used to finance the reclamation of abandoned coal mines

and for other authorized activities.

Section 405 of the Act allows States and Indian Tribes to assume exclusive responsibility for reclamation activity within the State or on Indian lands if they develop and submit to the Secretary for approval, a program (often referred to as a plan) for the reclamation of abandoned coal mines. Section 405(c) of the Act also requires States to have an approved State regulatory program before the Secretary can approve a State program for the reclamation of abandoned coal mines. On the basis of these criteria, the Secretary approved the Missouri plan on January 29, 1982. You can find background information on the Missouri plan, including the Secretary's findings, the disposition of comments, and the approval of the plan in the January 29, 1982, **Federal Register** (47 FR 4253). You can find later actions concerning the Missouri plan and amendments to the plan at 30 CFR 925.25.

Section 410 of SMCRA authorizes the Secretary to use funds under the AMLR program to abate or control emergency situations in which adverse effects of past coal mining pose an immediate danger to the public health, safety, or general welfare. In a **Federal Register** notice dated September 29, 1982 (47 FR 42729), we invited States to amend their AMLR plans for the purpose of undertaking emergency reclamation programs on our behalf. We approved Missouri's assumption of the AMLR emergency program on June 24, 1998. You can find background information, including our findings, the disposition of comments, and the approval of the Missouri AMLR emergency program in the June 24, 1998, **Federal Register** (63 FR 34277).

On June 19, 2003, the MLRP notified us that the Missouri Legislature passed House Bill (HB) 6 that appropriated funds for the Missouri program. In HB 6, the Missouri Legislature did not fully fund the Missouri program for the period beginning July 1, 2003, and ending June 30, 2004. The Governor of Missouri signed the appropriation bill on May 30, 2003 (Administrative Record No. MO–664).

On July 2, 2003, we met with the MLRP at the Missouri Department of Natural Resources' office in Jefferson City, Missouri (Administrative Record

No. MO-664.1). During the meeting, the MLRP made a presentation describing the recently approved appropriation bill. HB 6 contained a severe cut in general revenue dollars available as State matching funds for the regulatory program. The MLRP advised us that the moneys that are available for the regulatory program would only be used for bond forfeiture reclamation activities. Also, the MLRP advised us that the State Legislature appropriated funds for the AMLR program. In addition, the MLRP explained that as of July 18, 2003, existing regulatory program staff, with the exception of four full-time employees, would be transferred to other programs and that it would not be able to implement and maintain its inspection, enforcement, permitting, or bond release responsibilities under the currently approved Missouri program. The four full-time employees would perform the bond forfeiture reclamation activities that were funded by the State Legislature. The MLRP indicated that it would try to gain full program funding from the Missouri Legislature for fiscal year 2005.

On July 11, 2003, the MLRP notified the Missouri coal operators that the Legislature had decided, through the budget process, to withhold funding and staffing for the Missouri program. The MLRP also notified the operators that after July 18, 2003, it would no longer be available for surface coal mining and reclamation regulatory issues (Administrative Record No. MO-664.2).

On July 21, 2003, the Governor of Missouri notified us that the State of Missouri is experiencing difficult budget and revenue shortfalls (Administrative Record No. MO-664.3). As a result of the revenue shortfalls, he requested assistance with permit reviews, inspection activities, and general oversight of the active coal mining operations in the State. He indicated that Missouri continues to have adequate funding and staff available to maintain design and reclamation efforts for bond forfeiture sites, as well as sufficient funding and staff to maintain the AMLR program, including the emergency program. He also indicated that he was hopeful his request would be temporary and that he would continue to work with the Legislature in an attempt to assure adequate funding for all of Missouri's regulatory program responsibilities.

On August 4, 2003, we notified the Governor of Missouri that we were obligated, in accordance with 30 CFR 733.12(e), to substitute Federal enforcement for those portions of the Missouri program that were not fully

funded and staffed (Administrative Record No. MO-664.4). We cited Missouri's failure to fund and staff the Missouri program in several areas including inspection, enforcement, permitting, and bonding activities.

On August 22, 2003, we announced our decision to substitute Federal enforcement for portions of the Missouri program (68 FR 50944). On the same day, we announced a public comment period and opportunity for a hearing on Missouri's implementation of its program and our substitution of Federal enforcement. We did not hold a public hearing because no one requested one. The public comment period ended on September 22, 2003. We received comments from one industry group and the Missouri Land Reclamation Commission (Commission).

II. Clarification of OSM's August 22, 2003, Decision To Substitute Federal Enforcement for Parts of the Missouri Program

A. Direct Federal Enforcement of the Missouri Program

1. Effective August 22, 2003, we suspended the authority of the MLRP to implement all portions of the Missouri permanent regulatory program except bond forfeiture reclamation activities. We determined that the MLRP does have sufficient funding and staff to implement and maintain bond forfeiture reclamation activities. We also determined that the MLRP does not have adequate staff and resources to implement all other aspects of its program. In place of the MLRP's suspended authority, we substituted direct Federal enforcement and assumed responsibility to implement, administer, and enforce those portions of the Missouri program that were not fully funded and staffed, including inspection, enforcement, permitting, and bonding. After substituting direct Federal enforcement, we received a letter dated November 19, 2003, from the Missouri Land Reclamation Commission commenting that it would be beneficial for members of the public if we provide clarification for some of our August 22, 2003, decisions on direct Federal enforcement of the Missouri program (MO-664.15). We are, therefore, providing clarification on our August 22, 2003, decisions.

a. In the introductory paragraph of 30 CFR 925.17, we stated that the MLRP will have authority to take administrative actions to process outstanding violations to a final disposition (including issuing proposed assessments, assessing penalties, holding informal conferences and

hearings, and collecting penalties). However, any actions by the MLRP to terminate or vacate enforcement actions will not take effect until we approve them. In this document we are clarifying that the MLRP does not need our approval to terminate or vacate enforcement actions. We will conduct inspections of all permitted sites and, if a violation exists, we will take appropriate Federal enforcement action.

We also stated that with respect to bond forfeiture actions initiated before August 22, 2003, the MLRP will have the authority to perform bond forfeiture reclamation activities. In this document we are clarifying that bond forfeiture reclamation activities include, but are not limited to, issuing show-cause orders, revoking permits, initiating proceedings to declare bonds forfeited, and administering reclamation in lieu of bond forfeiture. The MLRP will have the authority to perform bond forfeiture reclamation activities initiated after August 22, 2003, if show-cause orders to revoke permits were initiated before August 22, 2003, and those show-cause orders subsequently result in forfeiture of the bond. We are revising the introductory paragraph of 30 CFR 925.17 to reflect this decision.

b. At 30 CFR 925.17(a), we specified that we will conduct inspections of all coal exploration and surface coal mining and reclamation operations, including bond release inspections, in accordance with sections 517, 518, 521, 525, and 526 of SMCRA (30 U.S.C. 1267, 1268, 1271, 1275, and 1276), 30 CFR parts 842 through 845, and 43 CFR part 4. We are clarifying in this document that we will use the Federal inspection and enforcement requirements contained in the above referenced statutory and regulatory provisions to determine compliance with the substantive requirements of the Missouri program, including the performance standards contained in Missouri's laws and regulations. We are revising 30 CFR 925.17(a) to reflect this decision.

c. At 30 CFR 925.17(c), we provided that we will impose civil and criminal sanctions, as appropriate, for violations of the approved Missouri program in accordance with sections 517, 518, 521, 525, and 526 of SMCRA, 30 CFR parts 843 through 845, and 43 CFR part 4. We are clarifying in this document that we will impose civil and criminal sanctions for those violations that are issued by us. We are also correcting our regulation reference by adding a reference to 30 CFR parts 846 and 847 concerning individual civil penalties and alternative enforcement, respectively.

We are revising 30 CFR 925.17(c) to reflect this decision.

d. At 30 CFR 925.17(i), we specified that we will review and make decisions on performance bond release requests for new and existing permits in accordance with the Missouri program at section 444.875 of the Missouri Surface Coal Mining Law (MSCML) and 10 Code of State Regulations (CSR) 40-7.021. For existing bonds, we will make the required determinations for the amount of the bond to be released and submit the determinations to the MLRP for release. We are clarifying in this document that we will make the required determinations for the amount of the bond to be released and submit the determinations to the MLRP. The MLRP will present our bond release determinations for the amount of existing bonds to be released to the Missouri Land Reclamation Commission, who will make a final decision on the release. We are revising 30 CFR 925.17(i) to reflect this decision.

e. At 30 CFR 925.17(k), we provided that administrative and judicial review of our enforcement actions, permitting decisions, and performance bond determinations will be in accordance with 43 CFR part 4. We are clarifying in this document that administrative and judicial review of final bond release decisions made by the Commission for existing performance bonds will be subject to the procedures specified in Missouri's laws and regulations at section 444.875 of MSCML and 10 CSR 40-7.021(4). Administrative and judicial review of final bond release decisions made by us for new performance bonds will be subject to the procedures specified in the Federal regulations at 43 CFR part 4. We are revising 30 CFR 925.17(k) to reflect this decision.

2. Today we are revising 30 CFR 925.17 to clarify that on August 22, 2003, we also substituted direct Federal enforcement and assumed responsibility to implement, administer, and enforce those portions of the Missouri program concerning training, examination, and certification of blasters; areas unsuitable for mining; and small operator assistance.

a. We will review and issue decisions on applications for blaster certification in accordance with the approved Missouri program at sections 444.855.2(15)(d) and 444.905.4 of MSCML and 10 CSR 40-3.160. The applicants must submit OSM Form 74 when applying for blaster certification. Administrative and judicial review of our decisions will be in accordance with 43 CFR part 4.

b. We will review and issue decisions on petitions to have areas designated as

unsuitable for surface coal mining operations in accordance with the approved Missouri program at section 444.890 of MSCML and 10 CSR 40-5.020. Judicial review of our decisions will be in accordance with sections 526(a)(2) and (b) of SMCRA (30 U.S.C. 1276(a)(2) and (b)) and 30 CFR 775.13.

c. We will review and issue decisions on applications for small operator assistance in accordance with section 507(c) of SMCRA (30 U.S.C. 1257(c)) and the approved Missouri program at 10 CSR 40-8.050. Administrative and judicial review of our decisions will be in accordance with 43 CFR part 4.

B. Findings on the Status of the Remedial Actions Codified at 30 CFR 925.18

In order for the MLRP to demonstrate its intent and capability to fully implement the Missouri program as approved by the Secretary, we required the MLRP to complete certain remedial actions, which we codified at 30 CFR 925.18.

1. 30 CFR 925.18(a)—By August 22, 2003, the MLRP was to submit to us a list of all outstanding enforcement actions specifying the abatement date set for each cited violation.

On July 22, 2003, the Missouri Attorney General's office provided us with a complete copy of all outstanding enforcement actions (Administrative Record No. MO-664.13).

The notices of violation and cessation orders specified the abatement date set for each cited violation. Therefore, we are removing the required remedial action codified at 30 CFR 925.18(a).

2. 30 CFR 925.18(b)—In accordance with the requirements of the approved Missouri program, the MLRP was to complete administrative disposition of all enforcement actions that were initiated before August 22, 2003. We are clarifying in this document that the MLRP may conduct penalty assessments, hold informal conferences and hearings, collect penalties, and terminate or vacate enforcement actions. We will inspect the sites and if a violation exists, we will take appropriate Federal enforcement action.

On November 25, 2003, the MLRP notified us that it had completed administrative disposition of five enforcement actions that were initiated before August 22, 2003 (Administrative Record No. MO-664.17). Additionally, on February 18, 2004, the MLRP notified us that it had completed administrative disposition of six more enforcement actions (Administrative Record No. MO-664.18A).

3. 30 CFR 925.18(c)—Not later than September 22, 2003, the MLRP was to

submit to us a plan to reassume full authority for the Missouri program.

On September 19, 2003, the MLRP submitted information on the time frames necessary to reassume full authority for the Missouri program (Administrative Record No. MO-664.11). The MLRP indicated that the first opportunity to correct the funding and staffing shortage would be in January 2004 when the State Legislature reconvenes. At that time, the Legislature would decide whether or not to restore the necessary funding and staff for the MLRP. The earliest the MLRP could reassume authority will be July 1, 2004. Based on the information provided by the MLRP, we are changing the date for submitting a specific plan that addresses funding, staffing, and adherence to the provisions of the Missouri program. We are changing the date from September 22, 2003, to within 30 days of the date on which we have received and acknowledged an accurate description of available funding for the regulatory program. We are revising the required remedial action codified at 30 CFR 925.18(c) to reflect this decision.

4. 30 CFR 925.18(d)—Starting on November 20, 2003, the MLRP was to submit to us a report once every three months on its progress in obtaining full funding for the Missouri program.

After considering the information on time frames for obtaining funding for the Missouri program that the MLRP sent to us on September 19, 2003, we are changing the starting date and reporting frequency for this report from November 20, 2003, to April 1, 2004, and from every three months to monthly. We are revising the required remedial action codified at 30 CFR 925.18(d) to reflect this decision.

5. 30 CFR 925.18(e)—Effective September 8, 2003, the MLRP was to take all steps necessary to ensure that all records, documents, correspondence, inspector logs, etc. were made secure and to supply copies of all documents to us upon request.

Beginning in July 2003, the MLRP provided access to all materials that were requested by us (Administrative Record No. MO-664.13). The MLRP also provided us with copies of all items, such as permit review documents and bond release applications, that were pending when the funding for the State program was lost. Therefore, we are removing the required remedial action codified at 30 CFR 925.18(e).

III. OSM's Decision

Based on our discussions in II.A, we are amending 30 CFR 925.17 to clarify our substitution of direct Federal enforcement for parts of the Missouri

program. We are also, based upon our findings in II.B, amending 30 CFR 925.18 to clarify and to modify the schedule for certain state remedial actions.

We will continue monitoring MLRP's progress in resuming full authority for all aspects of the approved Missouri program. Failure by the MLRP to seek and obtain full authority for the Missouri program or failure by the MLRP to perform satisfactorily in the areas in which it retains enforcement authority will result in additional Federal action.

We find that good cause exists under 5 U.S.C. 553(d)(3) to make this final rule effective immediately. Section 503(a)(3) of SMCRA requires that a State's program demonstrate that the State regulatory authority has sufficient administrative and technical personnel and sufficient funding to enable the State to regulate surface coal mining and reclamation operations in accordance with the requirements of SMCRA. Effective July 18, 2003, Missouri no longer had sufficient administrative and technical personnel or adequate funding to implement, maintain, and enforce its approved program. Therefore, we substituted Federal enforcement for parts of the Missouri program effective August 22, 2003. The clarifications and modifications made in this document are necessary to ensure the protection of the public through effective control of surface coal mining and reclamation operations in the State.

IV. Disposition of Comments

During the public comment period, we received comments from Continental Coal, Inc. (CCI) (Administrative Record No. MO-664.12) and the Missouri Land Reclamation Commission (Administrative Record Nos. 664.15). These comments were reviewed and considered by OSM in making the decisions announced today. This document provides a summary and response to the issues raised by the commenters.

A. CCI provided several comments on our decision to substitute Federal enforcement instead of withdrawing approval of the State program.

Comment 1: CCI's first comment dealt with us not providing sufficient justification for not withdrawing approval of the Missouri program. CCI felt that Missouri's intent to take steps to resolve the funding and staffing issues is not sufficient justification considering the budget difficulties in Missouri. CCI stated, "While the intent of the MLRP may be valid, truthful and well-intentioned, it is a function of budget realities, legislative desire, and

legislative direction that will dictate restoration of funding and participation."

We agree that no one can predict State legislative actions. However, as discussed in the August 22, 2003, final rule (68 FR 50944-50945), both the MLRP and the Governor of Missouri indicated intent to take steps to resolve the funding and staffing issues of the Missouri program. We also considered the intent of Congress when making our decision to substitute Federal enforcement rather than withdrawing program approval. At section 101(f) of SMCRA, Congress expressed its belief that because of the diversity in terrain, climate, biologic, chemical, and other physical conditions in areas subject to mining operations, the primary governmental responsibility for developing, authorizing, issuing, and enforcing regulations for surface mining and reclamation operations subject to SMCRA should rest with the States. In support of this congressional intent, we expressed our belief that it is preferable that States hold the primary responsibility for regulating surface coal mining and reclamation operations in the August 22, 2003, final rule (68 FR 50944). As stated in the August 22, 2003, final rule (68 FR 50945), failure by the MLRP to seek and obtain full authority for the Missouri program or failure by the MLRP to perform satisfactorily in the areas in which it retains enforcement authority will result in additional Federal action.

Comment 2: CCI's second comment dealt with us providing the MLRP with the authority to take administrative actions to process outstanding violations to a final disposition. CCI does not believe the Missouri General Assembly provided appropriation for these activities.

For example, your notice provides that: The MLRP will have the authority to take administrative actions to process outstanding violations to a final disposition (including issuing proposed assessments, assessment of penalties, holding of formal conferences and hearings, and collecting penalties). Effectively, there is a presumption that MLRP will misappropriate funds to carry forth this action, which has been unappropriated. While the cause "will" does provide the choice, OSM does not provide in its notice the answer to the obvious question, "What if they can't?" We contend that Missouri cannot spend resources in this area without proper appropriation, and for the federal government to expect them to do so is inappropriate.

As clarified in section II above, the MLRP may terminate or vacate enforcement actions initiated before August 22, 2003. We would inspect the applicable sites and determine whether Federal enforcement actions would

be issued to replace those terminated or vacated by the State. Missouri continues to have authority to process outstanding violations to final disposition. Any enforcement actions we take will be under the Federal regulations.

We also clarified in section II above that the bond forfeiture reclamation activities that were fully funded include, but are not limited to, issuing show-cause orders, revoking permits, initiating proceedings to declare bonds forfeited, and administering reclamation in lieu of bond forfeiture. Missouri has authority to perform bond forfeiture reclamation activities initiated before August 22, 2003, and bond forfeiture reclamation activities initiated after August 22, 2003, if show-cause orders to revoke permits were initiated before August 22, 2003, and those actions subsequently result in forfeiture of the bond.

Comment 3. CCI's third comment concerned our decision to enforce Missouri's statutes and regulations. CCI stated, "We are also troubled by OSM's apparent strategy to utilize Missouri statutes (see 30 CFR Part 925.17(e)) and Missouri regulations in their reviews." CCI does not believe that the Federal government can enforce State law. CCI pointed out that Missouri law provides unique appeal procedures.

We disagree that we cannot enforce the Missouri program. The Federal regulation at 30 CFR 733.12(f), concerning substituted Federal enforcement, requires us to enforce the State program. A State program is a compilation of State statutes, regulations, and policy. We may also adopt additional regulations if necessary to enforce the State program. CCI is correct that Missouri law provides unique appeal procedures. It has been our policy since 1984 in substituting Federal enforcement to use Federal administrative review regulations in place of the State's administrative review process. Therefore, we adopted the Federal statutes and regulations pertaining to administrative review by reference at 30 CFR 925.17. Also, the Federal regulation at 30 CFR 733.12(f)(2)(iii) requires us to conduct inspections and issue notices, orders and assessments of penalties in accordance with the Federal regulations at subchapter L. Therefore, we also adopted these regulations by reference at 30 CFR 925.17.

B. The Commission provided a comment on program funding and comments on clarification of the August 22, 2003, Federal Register final rule.

Comment 1. The Commission's first comment concerned State funding for Fiscal Year 2004. In its letter of

November 19, 2003, the Commission stated that the Missouri General Assembly decreased the amount of State funding for the State's surface coal mining program for Fiscal Year 2004, as compared with Fiscal Year 2003, but monies were in fact appropriated for the activities that are being conducted by the Commission's staff in Fiscal Year 2004.

We agree with this comment in that funds were appropriated for the bond forfeiture reclamation activities that are being conducted by the MLRP. These activities include issuing show-cause orders, revoking permits, initiating proceedings to declare bonds forfeited, and administering reclamation in lieu of bond forfeiture.

Comment 2. The Commission's second comment concerned clarification of our August 22, 2003, decisions on direct Federal enforcement of the Missouri program. The Commission stated that it believes that it would be beneficial for members of the public to be made aware of the clarifications obtained from us by the Commission's staff regarding activities to be undertaken directly by us in Missouri during the interim period prior to reinstatement of full funding for the Missouri program.

We agree with the Commission that clarification of our August 22, 2003, substitution of Federal enforcement is needed. Therefore, we provided clarification of our actions and the State's remedial actions in section II above and in 30 CFR 925.17 and 925.18.

V. Procedural Determinations

Executive Order 12630—Takings

This rule does not have takings implications. This determination is based on the analysis performed for the counterpart Federal regulation.

Executive Order 12866—Regulatory Planning and Review

This rule is exempted from review by the Office of Management and Budget (OMB) under Executive Order 12866.

Executive Order 12988—Civil Justice Reform

The Department of the Interior has conducted the reviews required by section 3 of Executive Order 12988 and has determined that this rule meets the applicable standards of subsections (a) and (b) of that section. However, these standards are not applicable to the actual language of State regulatory programs and program amendments because each program is drafted and promulgated by a specific State, not by OSM. Under sections 503 and 505 of

SMCRA (30 U.S.C. 1253 and 1255) and the Federal regulations at 30 CFR 730.11, 732.15, and 732.17(h)(10), decisions on proposed State regulatory programs and program amendments submitted by the States must be based solely on a determination of whether the submittal is consistent with SMCRA and its implementing Federal regulations and whether the other requirements of 30 CFR Parts 730, 731, and 732 have been met.

Executive Order 13132—Federalism

This rule does not have Federalism implications. SMCRA delineates the roles of the Federal and State governments with regard to the regulation of surface coal mining and reclamation operations. One of the purposes of SMCRA is to "establish a nationwide program to protect society and the environment from the adverse effects of surface coal mining operations." Section 503(a)(1) of SMCRA requires that State laws regulating surface coal mining and reclamation operations be "in accordance with" the requirements of SMCRA, and section 503(a)(7) requires that State programs contain rules and regulations "consistent with" regulations issued by the Secretary pursuant to SMCRA.

Executive Order 13175—Consultation and Coordination With Indian Tribal Governments

In accordance with Executive Order 13175, we have evaluated the potential effects of this rule on Federally-recognized Indian tribes and have determined that the rule does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes. This determination is based on the fact that the Missouri program does not regulate coal exploration and surface coal mining and reclamation operations on Indian lands. Therefore, the Missouri program has no effect on Federally-recognized Indian tribes.

Executive Order 13211—Regulations That Significantly Affect The Supply, Distribution, or Use of Energy

On May 18, 2001, the President issued Executive Order 13211 which requires agencies to prepare a Statement of Energy Effects for a rule that is (1) considered significant under Executive Order 12866, and (2) likely to have a significant adverse effect on the supply, distribution, or use of energy. Because this rule is exempt from review under

Executive Order 12866 and is not expected to have a significant adverse effect on the supply, distribution, or use of energy, a Statement of Energy Effects is not required.

National Environmental Policy Act

This rule does not require an environmental impact statement because section 702(d) of SMCRA (30 U.S.C. 1292(d)) provides that agency decisions on proposed State regulatory program provisions do not constitute major Federal actions within the meaning of section 102(2)(C) of the National Environmental Policy Act (42 U.S.C. 4332(2)(C)).

Paperwork Reduction Act

This rule does not contain information collection requirements that require approval by OMB under the Paperwork Reduction Act (44 U.S.C. 3507 *et seq.*).

Regulatory Flexibility Act

The Department of the Interior certifies that the substitution of Federal enforcement for portions of Missouri's permanent regulatory program will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). The rule is not expected to result in additional costs to the regulated industry.

Small Business Regulatory Enforcement Fairness Act

This rule is not a major rule under 5 U.S.C. 804(2), the Small Business Regulatory Enforcement Fairness Act. This rule: (a) Does not have an annual effect on the economy of \$100 million; (b) Will not cause a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; and (c) Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises. This determination is based upon the fact that the rule is not expected to result in additional costs to the regulated industry.

Unfunded Mandates

The substitution of Federal enforcement for portions of Missouri's permanent regulatory program will not impose an unfunded mandate on State, local, or tribal governments or the private sector of \$100 million or more in any given year. This determination is based upon the nature of the action being taken.

List of Subjects in 30 CFR Part 925

Intergovernmental relations, Surface mining, Underground mining.

Dated: April 5, 2004.

Patricia E. Morrison,

Acting Assistant Secretary, Land and Minerals Management.

■ For the reasons set out in the preamble, 30 CFR part 925 is amended as set forth below:

PART 925—MISSOURI

■ 1. The authority citation for part 925 continues to read as follows:

Authority: 30 U.S.C. 1201 *et seq.*

■ 2. Section 925.17 is amended by revising the introductory paragraph and paragraphs (a), (c), (i), and (k) and adding paragraphs (l), (m), and (n) to read as follows:

§ 925.17 Direct Federal Enforcement of the Missouri Program.

Starting on August 22, 2003, OSM will directly implement, administer and enforce the Missouri program requirements to the extent outlined below in accordance with the enforcement provisions of SMCRA and the Federal regulations. The authority of the Missouri Department of Natural Resources, Air and Land Protection Division, Land Reclamation Program (MLRP) to implement the Missouri regulatory program is suspended with regard to those provisions listed below, with the following exceptions. With respect to State enforcement actions initiated before August 22, 2003, the MLRP will have authority to take administrative actions to process outstanding violations to a final disposition (including issuing proposed assessments, assessing penalties, holding informal conferences and hearings, and collecting penalties). For enforcement actions that are terminated or vacated, OSM will inspect the sites and if a violation exists, we will take appropriate Federal enforcement action. With respect to bond forfeiture actions initiated before August 22, 2003, the MLRP will have authority to perform bond forfeiture reclamation activities. Bond forfeiture reclamation activities include, but are not limited to, issuing show-cause orders, revoking permits, initiating proceedings to declare bonds forfeited, and administering reclamation in lieu of bond forfeiture. The MLRP will have authority to perform bond forfeiture reclamation activities initiated after August 22, 2003, if show-cause orders to revoke permits were initiated before August 22, 2003, and those show-cause orders subsequently result in forfeiture of the bond.

(a) OSM will conduct inspections of all coal exploration and surface coal mining and reclamation operations, including bond release sites, in accordance with sections 517, 518, 521, 525, and 526 of SMCRA (30 U.S.C. 1267, 1268, 1271, 1275, and 1276), 30 CFR parts 842 through 845, and 43 CFR part 4. With respect to enforcement actions initiated by the MLRP before August 22, 2003, OSM will conduct follow-up inspections at all sites with outstanding violations on or after the abatement dates specified in the State-issued notices of violation. As required by 30 CFR 733.12(f)(2)(iii), OSM will conduct inspections to determine compliance with the substantive requirements of the approved Missouri program.

* * * * *

(c) OSM will impose civil and criminal sanctions, as appropriate, for violations of the Missouri program in accordance with sections 517, 518, 521, 525, and 526 of SMCRA (30 U.S.C. 1267, 1268, 1271, 1275, and 1276), 30 CFR parts 843 through 847, and 43 CFR part 4 for those violations issued by OSM.

* * * * *

(i) OSM will review and make decisions on performance bond release requests for new and existing permits in accordance with the Missouri program at section 444.875 of MSCML and 10 CSR 40-7.021. For existing bonds, OSM will make the required determinations for the amount of the bond to be released and will submit the determinations to the MLRP. The MLRP will present OSM's bond release determinations for the amount of the bond to be released to the Missouri Land Reclamation Commission, who will make a final decision on the release.

* * * * *

(k) Administrative and judicial review of OSM's enforcement actions, performance bond release determinations, and final decisions on all other actions, including permitting, certification of blasters, and small operator assistance, will be in accordance with 43 CFR part 4. Administrative and judicial review of final bond release decisions made by the Commission for existing performance bonds will be subject to the procedures specified in the Missouri program at section 444.875 of MSCML and 10 CSR 40-7.021(4).

(l) OSM will review and issue decisions on applications for blaster certification in accordance with the approved Missouri program at sections 444.855.2(15)(d) and 444.905.4 of MSCML and 10 CSR 40-3.160. The applicants must submit OSM Form 74 to

OSM when applying for blaster certification. Administrative and judicial review of our decisions will be in accordance with 43 CFR part 4.

(m) OSM will review and issue decisions on petitions to have areas designated as unsuitable for surface coal mining operations in accordance with the approved Missouri program at section 444.890 of MSCML and 10 CSR 40-5.020. Judicial review of our decisions will be in accordance with sections 526(a)(2) and (b) of SMCRA (30 U.S.C. 1276(a)(2) and (b)) and 30 CFR 775.13.

(n) OSM will review and issue decisions on applications for small operator assistance in accordance with section 507(c) of SMCRA (30 U.S.C. 1257(c)) and the approved Missouri program at 10 CSR 40-8.050. Administrative and judicial review of our decisions will be in accordance with 43 CFR part 4.

■ 3. Section 925.18 is amended by removing and reserving paragraphs (a) and (e) and revising paragraphs (b), (c), and (d) to read as follows:

§ 925.18 State Remedial actions.

* * * * *

(a) [Removed and reserved]

(b) In accordance with the requirements of the approved Missouri program, the MLRP will complete administrative disposition of all enforcement actions that were initiated before the effective date of this decision. The MLRP may conduct penalty assessments, hold informal conferences and hearings, collect penalties, and terminate or vacate enforcement actions.

(c) Within 30 days of the date on which OSM has received and acknowledged an accurate description of available funding for the regulatory program, the MLRP must submit to OSM a plan to reassume full authority for the Missouri program. At a minimum, the proposal must provide specific and adequate provisions that address the following problems:

* * * * *

(d) Starting on April 1, 2004, the MLRP must submit to OSM a report once a month on its progress in obtaining full funding for the Missouri program.

(e) [Removed and reserved]

[FR Doc. 04-8587 Filed 4-14-04; 8:45 am]

BILLING CODE 4310-05-P

DEPARTMENT OF HOMELAND SECURITY**Coast Guard****33 CFR Part 147**

[CGD08-03-040]

RIN 1625-AA79

Safety Zone; Outer Continental Shelf Facility in the Gulf of Mexico for Garden Banks 783

AGENCY: Coast Guard, DHS.

ACTION: Final rule.

SUMMARY: The Coast Guard is establishing a safety zone around a petroleum and gas production facility in Garden Banks 783 "A" of the Outer Continental Shelf in the Gulf of Mexico while the facility is being constructed and after the construction is completed. The construction site and facility need to be protected from vessels operating outside the normal shipping channels and fairways, and placing a safety zone around this area will significantly reduce the threat of allisions, oil spills and releases of natural gas. This rule prohibits all vessels from entering or remaining in the specified area around the facility's location except for attending vessels, vessels under 100 feet in length overall not engaged in towing and vessels authorized by the Eighth Coast Guard District Commander.

DATES: This final rule is effective May 17, 2004.

ADDRESSES: Comments and material received from the public, as well as documents indicated in this preamble as being available in the docket, are part of docket [CGD08-03-040] and are available for inspection or copying at Commander, Eighth Coast Guard District (m), Hale Boggs Federal Bldg., 501 Magazine Street, New Orleans, LA, between 8 a.m. and 3:30 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Lieutenant (LT) Kevin Lynn, Project Manager for Eighth Coast Guard District Commander, Hale Boggs Federal Bldg., 501 Magazine Street, New Orleans, LA 70130, telephone (504) 589-6271.

SUPPLEMENTARY INFORMATION:**Regulatory History**

On January 20, 2004, we published a notice of proposed rulemaking (NPRM) entitled "Safety Zone; Outer Continental Shelf Facility in the Gulf of Mexico for Garden Banks 783" in the **Federal Register** (69 FR 2691). We received no comments on the proposed rule. No public hearing was requested, and none was held.

Background and Purpose

The Coast Guard is establishing a safety zone around a petroleum and gas production facility in the Gulf of Mexico: Magnolia Tension Leg Platform (TLP), Garden Banks 783 "A" (GB 783 "A"), located at position 27°12'13.86" N, 92°12'09.36" W. This safety zone will be in effect while the facility is being constructed and after the construction is completed.

This safety zone is in the deepwater area of the Gulf of Mexico. For the purposes of this regulation it is considered to be in waters of 304.8 meters (1,000 feet) or greater depth extending to the limits of the Exclusive Economic Zone (EEZ) contiguous to the territorial sea of the United States and extending to a distance up to 200 nautical miles from the baseline from which the breadth of the sea is measured. Navigation in the area of the safety zone consists of large commercial shipping vessels, fishing vessels, cruise ships, tugs with tows and the occasional recreational vessel. The deepwater area of the Gulf of Mexico also includes an extensive system of fairways. The fairway nearest the safety zone is the Gulf Safety Fairway—Aransas Pass Safety Fairway to Southwest Pass Safety Fairway. Significant amounts of vessel traffic occur in or near the various fairways in the deepwater area.

ConocoPhillips requested that the Coast Guard establish a safety zone in the Gulf of Mexico around the Magnolia TLP construction site and for the zone to remain in effect after construction is completed.

The request for the safety zone was made due to the high level of shipping activity around the site of the facility, safety concerns for the integrity of the structure, and the environment. ConocoPhillips indicated that the location, production level, and personnel levels on board the facility make it highly likely that any allision with the facility during and after construction would result in a catastrophic event.

The Coast Guard has evaluated ConocoPhillips's information and concerns against Eighth Coast Guard District criteria developed to determine if an Outer Continental Shelf facility qualifies for a safety zone. Several factors were considered to determine the necessity of a safety zone for the Magnolia TLP construction site and for a safety zone to remain in effect after the facility is completed: (1) The construction site is located approximately 39 nautical miles south of the Gulf Safety Fairway—Aransas Pass Safety Fairway to Southwest Pass

Safety Fairway; (2) the facility will have a high daily production capacity of petroleum oil and gas; (3) the facility will be manned; and (4) the facility will be a tension leg platform.

We conclude that the risk of allision to the facility and the potential for loss of life and damage to the environment resulting from such an accident during and following the construction of Magnolia TLP warrants the establishment of this safety zone. This regulation will significantly reduce the threat of allisions, oil spills and natural gas releases and increases the safety of life, property, and the environment in the Gulf of Mexico. This regulation is issued pursuant to 14 U.S.C. 85 and 43 U.S.C. 1333 as set out in the authority citation for 33 CFR part 147.

Discussion of Comments and Changes

We received no comments on the proposed rule. Therefore, we have not made any change in the final rule.

Regulatory Evaluation

This rule is not a "significant regulatory action" under section 3(f) of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not significant under the regulatory policies and procedures of the Department of Homeland Security (DHS).

We expect the economic impact of this rule to be so minimal that a full regulatory evaluation under the regulatory policies and procedures of DHS is unnecessary. The impacts on routine navigation are expected to be minimal because the safety zone will not overlap any of the safety fairways within the Gulf of Mexico.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601-612), we have considered whether this rule would have a significant economic impact on a substantial number of small entities. The term "small entities" comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

The Coast Guard certifies under 5 U.S.C. 605(b) that this rule will not have a significant economic impact on a substantial number of small entities. Since the construction site for the Magnolia TLP is located far offshore, few privately owned fishing vessels and recreational boats/yachts operate in the

area. This rule will not impact an attending vessel or vessels less than 100 feet in length overall not engaged in towing. Alternate routes are available for all other vessels impacted by this rule. Use of an alternate route may cause a vessel to incur a delay of four to ten minutes in arriving at their destinations depending on how fast the vessel is traveling. Therefore, the Coast Guard expects the impact of this regulation on small entities to be minimal.

If you think that your business, organization, or governmental jurisdiction qualifies as a small entity and that this rule would have a significant economic impact on it, please submit a comment (see ADDRESSES) explaining why you think it qualifies and to what degree this rule would economically affect it.

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), we offered to assist small entities in understanding this rule so that they can better evaluate its effects on them and participate in the rulemaking.

Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1-888-REG-FAIR (1-888-734-3247).

Collection of Information

This rule calls for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).

Federalism

A rule has implications for federalism under Executive Order 13132. Federalism, if it has a substantial direct effect on State or local governments and would either preempt State law or impose a substantial direct cost of compliance on them. We have analyzed this rule under that Order and have determined that it does not have implications for federalism.

Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions

that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of \$100,000,000 or more in any one year. Though this rule will not result in such expenditure, we discuss the effects of this rule elsewhere in this preamble.

Taking of Private Property

This rule will not effect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not create an environmental risk to health or risk to safety that may disproportionately affect children.

Indian Tribal Governments

This rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

Energy Effects

We have analyzed this rule under Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use. We have determined that it is not a "significant energy action" under that Order because it is not a "significant regulatory action" under Executive Order 12866 and is not likely to have a significant adverse effect on the supply, distribution, or use of energy. The Administrator of the Office of Information and Regulatory Affairs has not designated it as a significant energy action. Therefore, it does not require a Statement of Energy Effects under Executive Order 13211.

Environment

We have analyzed this rule under Commandant Instruction M16475.1D, which guides the Coast Guard in

complying with the National Environmental Policy Act of 1969 (NEPA) (42 U.S.C. 4321-4370f), and have concluded that there are no factors in this case that would limit the use of categorical exclusion under section 2.B.2 of the Instruction. Therefore, this rule is categorically excluded, under figure 2-1 paragraph (34)(g), of the instruction, from further environmental documentation because this rule is not expected to result in any significant environmental impact as described in NEPA.

A final "Environmental Analysis Check List" and a final "Categorical Exclusion Determination" are available in the docket where indicated under ADDRESSES.

List of Subjects in 33 CFR Part 147

Continental shelf, Marine safety, Navigation (water).

■ For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 147 as follows:

PART 147—SAFETY ZONES

■ 1. The authority citation for part 147 continues to read as follows:

Authority: 14 U.S.C. 85; 43 U.S.C. 1333; Department of Homeland Security Delegation No. 0170.1.

■ 2. Add § 147.835 to read as follows:

§ 147.835 Magnolia TLP Safety Zone.

(a) *Description.* Magnolia TLP, Garden Banks 783 "A" (GB 783 "A"), located at position 27°12'13.86"N, 92°12'09.36"W. The area within 500 meters (1640.4 feet) from each point on the structure's outer edge is a safety zone. These coordinates are based upon [NAD 83].

(b) *Regulation.* No vessel may enter or remain in this safety zone except the following:

- (1) An attending vessel;
- (2) A vessel under 100 feet in length overall not engaged in towing; or
- (3) A vessel authorized by the Commander, Eighth Coast Guard District.

Dated: April 5, 2004.

R.F. Duncan,

Rear Admiral, U.S. Coast Guard, Commander, Eighth Coast Guard District.

[FR Doc. 04-8497 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-15-P

DEPARTMENT OF VETERANS AFFAIRS**38 CFR Part 20**

RIN 2900-AK52

Board of Veterans' Appeals: Rules of Practice—Medical Opinions From the Veterans Health Administration**AGENCY:** Department of Veterans Affairs.**ACTION:** Final rule.

SUMMARY: This document adopts as a final rule, with one exception, the interim final rule that amended the Department of Veterans Affairs (VA) Appeals Regulation clarifying that the Board of Veterans' Appeals (Board) may obtain medical opinions from appropriate health care professionals in VA's Veterans Health Administration. The exception is inclusion of citation to statutory authority that was omitted from the interim rule and updating the previously cited statutory authority to reflect recent legislation.

DATES: *Effective Date:* This final rule is effective as of July 23, 2001.

FOR FURTHER INFORMATION CONTACT: Steven L. Keller, Senior Deputy Vice Chairman, Board of Veterans' Appeals (012), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420 (202-565-5978).

SUPPLEMENTARY INFORMATION: The Board of Veterans' Appeals (Board) is an administrative body that decides appeals from denial of claims for veterans benefits.

On July 23, 2001, VA published an interim final rule with request for comments to clarify that under 38 CFR 20.901(a), the Board may obtain medical opinions from appropriate health care professionals within the Department's Veterans Health Administration (VHA) rather than solely from the Under Secretary for Health (formerly known as the Chief Medical Director) (66 FR 38158).

After publication of the interim final rule, it was brought to our attention that citation to the primary authority for this regulation, 38 U.S.C. 7109, was omitted from the regulatory text, and that the statute we had cited, 38 U.S.C. 5107(a), had been amended by the Veterans Claims Assistance Act of 2000 (VCAA), Public Law 106-475, 114 Stat. 2096. Therefore, the only change we have made is to change the authority citation to include section 7109 and to refer to the statute as amended by the VCAA. The substance and effect of the final regulation does not change.

We received comments from a veterans' service organization and an

association of veterans' advocates. Both groups opposed the interim final rule and urged VA to rescind the rule. The reasons for their opposition fell into five categories: (1) Alleged lack of statutory authority and conflict with 38 U.S.C. 7109; (2) alleged conflict with the VCAA; (3) alleged conflict with 38 CFR 4.2, Interpretation of examination reports; (4) alleged violation of due process; and (5) alleged defects that would result in the rule being implemented in an arbitrary and unfair fashion. We do not agree with these objections and will address them in turn.

1. Alleged Lack of Statutory Authority and Conflicts With 38 U.S.C. 7109

38 U.S.C. 7109 provides that when, in the judgment of the Board, an expert medical opinion (in addition to that available within the Department), is warranted by the medical complexity or controversy involved in an appealed case, the Board may secure an advisory medical opinion from one or more independent medical experts who are not employees of the Department.

We received comments asserting that VA lacks statutory authority for the rule and that section 7109 does not authorize the Board to obtain medical opinions from VHA. The commenters believe that the phrase "in addition to that available within the Department" means evidence already obtained by the agency of original jurisdiction (AOJ) and does not mean that the Board may request opinions from VHA. In the same vein, a commenter asserts that section 7109 "expressly prohibits the obtaining of medical opinions from VA employees."

We disagree. There is no legal basis to support the conclusion that the phrase "in addition to that available within the Department," limits the Board to obtaining medical opinions only from experts outside of VA. Rather, 38 U.S.C. 7109 acknowledges the Board's authority to request opinions from within the Department, when such opinions are deemed necessary. Indeed, the legislative history of current section 7109 clearly reflects such Congressional intent. In reporting the bill that eventually became section 7109 (it was redesignated from section 4009 in May 1991), the Senate Committee on Finance explained that the bill made no reference to the Board's authority to obtain an advisory opinion from the VA Chief Medical Director because "this is a matter within Agency discretion and ample authority for this practice now exists." S. Rep. No. 87-1844 (1962), reprinted at 1962 U.S.C.C.A.N. 2585, 2586.

In addition, Congressional approval of the practice of obtaining medical opinions through VHA is quite apparent in the legislative history accompanying the enactment of the Veterans Judicial Review Act, Pub. L. 100-687, Div. A, § 101, 102 Stat. 4105 (1988) (VJRA). In discussing changes made to section 7109, "[t]he Committees also note with approval the current practice of obtaining [medical expert] opinions through the Department of Medicine and Surgery [VHA's former name]." See 134 Cong. Rec. S16653 (1988), reprinted in 1988 U.S.C.C.A.N. 5834, 5842.

The Secretary believes that there is ample evidence of the Board's authority to obtain medical opinions from both inside and outside VA. Therefore, we make no changes based upon the foregoing comments.

2. Alleged Conflict With the VCAA

The VCAA requires the Secretary of Veterans Affairs to provide certain types of assistance in connection with a claim for benefits. One commenter argues that the amendment to 38 CFR 20.901(a) is ultra vires and conflicts with the VCAA in that it "creates de facto a super Regional Office" by allowing the Board to perform the RO's duty as codified by the VCAA. Both commenters assert that the amendment to 38 CFR 20.901(a) alters BVA's jurisdiction by allowing the Board to develop the record. They contend that this is an alteration that violates VA's obligations to assist the claimant and deprives claimants of one review on appeal. In this regard they assert that the VCAA requires "the Agency not the Board [to] fully and sympathetically develop the claim" and that while Congress gave the Board clear authority and responsibility in appellate matters "it gave the Board no authority to develop the record in routine matters." The VCAA changed nothing about 38 U.S.C. 7109(a), which expressly permits the Board to obtain medical opinions from outside VA and acknowledges its authority to obtain opinions from VHA. Section 7109(a) provides as follows:

When, in the judgment of the Board, expert medical opinion, in addition to that available within the Department, is warranted by the medical complexity or controversy involved in an appeal case, the Board may secure an advisory medical opinion from one or more independent medical experts who are not employees of the Department.

The phrase "in addition to that available within the Department" makes plain that the Board has discretion to use the source that it deems most appropriate. The Federal Circuit endorsed this analysis in *Disabled American Veterans v. Principi*, 327 F.3d

1339 (Fed. Cir. 2003), where it stated as follows:

[W]hen Congress intended to authorize the Board to obtain additional evidence without 'one review on appeal to the Secretary,' it knew how to do so. Congress has provided express statutory authority to permit the Board to obtain additional evidence, such as expert medical opinions in specific cases. See, e.g., 38 U.S.C. 5107(a) (2000) (authorizing Board to obtain medical opinions from the VA's Under Secretary for Health (formerly the Chief Medical Director)); 38 U.S.C. 7109 (2000) (authorizing Board to obtain independent medical opinions from outside the VA); 38 CFR 20.901(a) (2002) (authorizing Board to obtain opinions from the Veterans Health Administration) * * *.

Disabled American Veterans v. Principi, 327 F.3d at 1347-48.

In addressing the impact and effect of the Federal Circuit's decision in *Disabled American Veterans*, the VA Office of the General Counsel issued a precedential opinion wherein it found that the Board is not prohibited from obtaining and considering evidence so long as a waiver is obtained. Otherwise, the matter has to be returned to the agency of original jurisdiction for initial consideration of the new evidence. VAOPGCPREC 1-2003 (May 21, 2003).

Moreover, in an earlier precedential opinion, the VA General Counsel determined that medical opinions from VHA belonged to a special class of evidence that the Board is allowed to consider without reference to the agency of original jurisdiction, provided that the claimant is given an opportunity to review and respond to such evidence before a decision is rendered. VAOPGCPREC 16-92 (July 24, 1992); see also 38 CFR 20.903(a) (1992).

The above-mentioned VA General Counsel opinions, along with the Federal Circuit's discussion of the Board's authority under 38 U.S.C. 7109 in *Disabled American Veterans v. Principi*, support the view that the Board has the authority to obtain medical opinions from medical professionals employed either inside or outside the Department.

Another comment asserts that 38 U.S.C. 5103A, which was created by the VCAA, delineates VA's general duty to assist and, in so doing, does not give the Board the authority to develop the record by obtaining a medical opinion. The commenter contends that 38 CFR 20.901(a) allows the Board to circumvent the duty-to-assist provisions that are set forth under section 5103A. We have reviewed the VCAA, to include section 5103A, and find there is nothing in the VCAA that would prevent the Board from obtaining medical opinions under 38 CFR 20.901(a).

This view is bolstered by the U.S. Court of Appeals for Veterans Claims (Veterans Court) in both *Winsett v. West*, 11 Vet App. 420, 426 (1998), *aff'd*, 217 F.3d 854 (Fed. Cir. 1999) (unpublished decision), *cert. denied*, 120 S. Ct. 1251 (2000), and *Perry v. Brown*, 9 Vet App. 2, 6 (1996). In *Perry*, further evidentiary development was needed, and the court, citing 38 U.S.C. 5107(a) (before its amendment by the VCAA) and 7109, stated that "[t]he Board may seek to obtain that development itself through a VA [VHA] or non-VA [independent medical expert] opinion, or through a remand to the [regional office] for it to obtain an [independent medical expert] opinion, or to provide for a VA examination of the veteran." 9 Vet. App. at 6 (citations omitted). In *Winsett*, the Veterans Court expressly held that section 7109 does not preclude the Board from obtaining a medical opinion "not rendered by an independent source," 11 Vet. App. at 426, and noted both that "whether the Board chooses to refer a particular case for an independent medical opinion is entirely within its discretion" and that "[i]t is uncontested that the Board has the authority * * * to obtain an expert medical opinion irrespective of section 7109," *id.*

Thus, in light of the case law and the opinions from OGC, we reject the comment that 38 CFR part 1 901(a) conflicts with VA statutes governing development of claims, to include the VCAA, and we make no changes based upon this assertion.

3. Alleged Conflict With 38 CFR 4.2, Interpretation of Examination Reports

38 CFR 4.2 states, in pertinent part, that an examination report that does not contain sufficient detail to allow the rating board to evaluate a disability should be returned as inadequate. One commenter argues that § 20.901(a) subverts this process by allowing the Board to request an expert medical opinion rather than remanding the matter for additional development. The commenter asserts that, if a medical question is complex or controversial, the Board should remand the matter to the AOJ to obtain medical opinions.

A request for an opinion under § 20.901(a) does not circumvent the need to remand an appeal if an examination is inadequate. The decision to obtain an expert medical opinion under § 20.901(a) is made only after the Board has determined that the report of any examination is adequate. The request for a medical opinion is not a substitute for an adequate examination. It is, rather, a tool the Board is authorized to use to gain a better

understanding of a particularly complex or controversial medical issue, thereby enabling it to render an informed decision.

4. Alleged Violation of Due Process

The commenters argue that the rule violates due process rights because a claimant will not have notice of an opinion obtained under § 20.901(a) and an opportunity to respond. These comments are unfounded. Section 20.903(a) of title 38, Code of Federal Regulations, requires the Board, if it requests a medical opinion under § 20.901, to notify the appellant, to furnish a copy of any opinion obtained, and to allow 60 days for response, which may include submission of additional evidence or argument. In view of these due process guarantees, we make no change based on that comment.

5. Alleged Defects That Would Result in the Rule Being Implemented in an Arbitrary and Unfair Fashion

Pursuant to the amended § 20.901(a), the Board may obtain medical opinions from appropriate health care professionals within the VHA rather than solely from the Under Secretary for Health. One commenter argues that this improperly broadens the scope of the Board's authority to request VHA opinions. The change is said to be arbitrary and unfair to claimants because Board members are not in the position to know either what expertise exists in VHA or who the best expert is for a particular question. The commenter maintains that the selection of a physician qualified to render a medical opinion is a process that should be overseen by VHA management.

As we explained in the interim final rule, VHA Directive 2000-049 (December 13, 2000) allocates the responsibilities in this process between VHA and the Board. 66 FR at 38159. This directive, which is publicly available (<http://www.va.gov/publ/direc/health/direct/12000049.pdf>), allows the Board to elect a VA facility to generate a medical opinion. However, the Board must choose from a list of medical centers created and provided by VHA. Further, the ultimate selection of the physician asked to render the opinion is left to the Office of the Chief of Staff of that facility. In other words, the selection of the physician is a process that is in fact overseen by VHA management. Accordingly, we made no change based on this comment.

Administrative Procedure Act

This document, with the exception of a change to the authority citation,

adopts as a final rule an interim final rule that is already in effect. Accordingly, we have concluded under 5 U.S.C. 553 that there is good cause for dispensing with a delayed effective date because such procedure is impracticable, unnecessary, and contrary to the public interest.

Unfunded Mandates

The Unfunded Mandates Reform Act requires, at 2 U.S.C. 1532, that agencies prepare an assessment of anticipated costs and benefits before developing any rule that may result in an expenditure by State, local, or tribal governments, in the aggregate, or by the private sector, of \$100 million or more in any given year. This final rule would have no such effect on State, local, or tribal governments, or the private sector.

Executive Order 12866

The Office of management and Budget has reviewed this document under Executive Order 12866.

Regulatory Flexibility Act

The Secretary hereby certifies that this final rule will not have a significant economic impact on a substantial number of small entities as they are defined in the Regulatory Flexibility Act, 5 U.S.C. 601-612. Only VA beneficiaries could be directly affected. Therefore, pursuant to 5 U.S.C. 605(b), this final rule is exempt from the initial and final regulatory flexibility analysis requirements of sections 603 and 604.

Paperwork Reduction Act

The Secretary hereby certifies that this final rule contains no provisions constituting a collection of information under the Paperwork Reduction Act (44 U.S.C. 3501-3521).

List of Subjects in 38 CFR Part 20

Administrative practice and procedure, Claims, Veterans.

Approved: February 2, 2004.

Anthony J. Principi,
Secretary of Veterans Affairs.

■ For the reasons set out in the preamble, the interim final rule amending 38 CFR part 20 which was published at 66 FR 38158 on July 23, 2001 is adopted as a final rule with the the following change:

PART 20—BOARD OF VETERANS' APPEALS: RULES OF PRACTICE

■ 1. The authority citation for part 20 continues to read as follows:

Authority: 38 U.S.C. 501(a) and as noted in specific sections.

■ 2. In § 20.901, the authority citation at the end of paragraph (a) is revised to read as follows:

§ 20.901. Rule 901. Medical opinions and opinions of the General Counsel.

* * * * *

(Authority: 38 U.S.C. 5103A(d), 7109)

[FR Doc. 04-8564 Filed 4-14-04; 8:45 am]

BILLING CODE 8320-01-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[DC052-7007, MD143-3102, VA129-5065; FRL-7645-1]

Approval and Promulgation of Air Quality Implementation Plans; District of Columbia, Maryland, Virginia; Post 1996 Rate-of-Progress Plans and One-Hour Ozone Attainment Demonstrations

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule; notice of stay.

SUMMARY: The EPA is taking immediate final action to indefinitely stay, pending completion of judicial review, a conditional approval promulgated on April 17, 2003. On February 3, 2004, the United States Court of Appeals filed an opinion that vacated and remanded the April 17, 2003 final action insofar as it granted conditional approval, and denied a petition for review of other parts of the April 17, 2003 final rule. The Petitioner filed a timely petition for rehearing on an issue not related to the vacatur of the conditional approval. The intended effect of this action is to stay any potential application of the April 17, 2003 conditional approval until the date that the litigation concludes.

EFFECTIVE DATE: Effective April 15, 2004. 40 CFR 52.473, 52.1072(e) and 52.2450(b) are stayed indefinitely.

ADDRESSES: Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

FOR FURTHER INFORMATION CONTACT: Christopher Cripps, (215) 814-2179, or by e-mail at cripps.christopher@epa.gov.

SUPPLEMENTARY INFORMATION:

I. What Is the Background for This Action?

On April 17, 2003 (68 FR 19106), EPA published a final rulemaking granting

three conditional approvals of Metropolitan Washington, DC severe ozone nonattainment area (DC Area) State Implementation Plan (SIP) revisions submitted by the District of Columbia, the State of Maryland and the Commonwealth of Virginia (the States).¹ The April 17, 2003 final action conditionally approved those SIP revisions identified in Table 1 of the final rule contingent on each of the States submitting a revised SIP by April 17, 2004 to satisfy certain specifically enumerated conditions. These conditions were codified at 40 CFR 52.473 in the case of the District of Columbia; 40 CFR 52.1072(e) in the case of Maryland; and 40 CFR 52.2450(b) in the case of Virginia. See 68 FR at 19131-19133. In the final action EPA noted that if a State should fail to meet any condition for approval by April 17, 2004, that State's conditional approval would be treated as a disapproval pursuant to CAA section 110(k). See 68 FR 19106, April 17, 2003, as corrected by 68 FR 264958, May 16, 2003. Conversely, if the States were to fulfill the conditions by April 17, 2004, EPA would initiate rulemaking to convert the conditional approval to a full approval of the SIP.

The Sierra Club filed petitions for review of the April 17, 2003, final rule with the United States Courts of Appeals for the Fourth Circuit and District of Columbia Circuit. The cases were consolidated in the United States Court of Appeal for the District of Columbia Circuit (the Court). On February 3, 2004, the Court filed an opinion that vacated and remanded EPA's conditional approval action insofar as it granted conditional approval based on what the Court found to be defective commitment letters. The Court also denied the petition for review in all other respects. See *Sierra Club v. EPA*, 356 F.3d 296 (D.C. Cir. 2004).

On March 19, 2004, the Sierra Club filed a "Petition for Panel Rehearing" requesting the Court to reconsider one issue addressed in a footnote of the opinion. This issue is not related to vacatur of the conditional approval, and if the Court were to reverse its initial decision in EPA's favor, that reversal would not in any way affect the vacatur of the conditional approval.

II. What Is the Effect of the Petition for Rehearing?

If no petition for rehearing had been filed, the Federal Rules of Appellate Procedure direct the Court to have issued its "mandate" by March 26, 2004.

¹ Under Section 302(d) of the Clean Air Act the term "State" includes the District of Columbia.

The "mandate" is nothing more than "a certified copy of the judgment, a copy of the court's opinion, if any, and any direction about costs." Fed. R. App. P. 41(a). The filing of the petition for rehearing automatically stayed the issuance of the mandate. Fed. R. App. P. 41(d)(1). Because the mandate has not been issued, the Court retains jurisdiction over this matter until the petition for rehearing is either (1) denied, or (2) granted and ultimately resolved on the merits. The vacatur of the conditional approval will not be remanded to EPA until such time as the Court officially relinquishes its jurisdiction by issuing the mandate. Until this matter is officially remanded to EPA, we cannot remove the conditional approval from 40 CFR 52.473, 40 CFR 52.1072(e) and 40 CFR 52.2450(b).

Until such time as the rulemaking is officially remanded to EPA pursuant to the February 3, 2004 decision and EPA removes the conditional approval from the States' SIPs, there is a technical argument that EPA could ignore the Court's February 3, 2004 decision and either promulgate a rulemaking to convert the conditional approval to a full approval if the States fulfill their commitments, or, if the States fail to fulfill their commitments, treat the SIP as a disapproval pursuant to section 110(k)(4) of the Clean Air Act.

In light of the court's opinion vacating the conditional approval, which will not be disturbed by any action on the petition for rehearing, EPA does not believe that it should take action to either convert these SIPs to fully approved status, or to treat them as being disapproved pending issuance of the mandate. Either action by EPA would be inconsistent with the Court's filed opinion, which determined that EPA's conditional approval was not authorized by the Clean Air Act. Further, neither EPA nor the Petitioner have taken any action to seek reversal of the Court's decision vacating the conditional approval.

III. Basis for Exception From Notice and Comment Rulemaking

Under section 553(b)(3)(B) of the Administrative Procedures Act (APA), 5 U.S.C. 553(b)(3)(B), when an Agency finds good cause to exist, it may issue a rule without first providing notice and comment.

The Court filed its opinion vacating the conditional approval on February 3, 2004. The Petitioner filed its petition for rehearing on March 19, 2004, staying the mandate that would have issued by March 26, 2004, less than a month before the conditional approval

compliance deadline of April 17, 2004. It is impractical for EPA, in less than one month, to do notice and comment rulemaking clarifying that it will not be taking an action inconsistent with the Court's February 3, 2004 opinion. Further, EPA concludes that it would not be in the public interest to allow any action to proceed in conflict with the opinion of the court issued on February 3, 2004. Therefore, EPA believes that it has good cause to issue this stay without notice and comment.

IV. Basis for Issuing Stay

Pursuant to section 705 of the APA, 5 U.S.C. 705, "when an agency finds that justice so requires, it may postpone the effective date of actions taken by it, pending judicial review." Neither the Petitioner nor EPA have asked the Court to reverse the vacatur of the conditional approval. The judicial review of EPA's final rulemaking for now remains pending for reasons entirely unrelated to the Court's decision to vacate the conditional approval. EPA believes that it is in the interest of justice for the Agency to clarify that it intends to take no action inconsistent with the Court's February 3, 2004 opinion simply because this matter cannot be officially remanded to the Agency at the present time. This stay clarifies that EPA will neither treat as disapproved nor take an action to convert to full approval any of the three States' SIPs that were subject to the vacated conditional approval during the pendency of the petition for rehearing, regardless of any SIP submissions that the States may or may not make in compliance with the conditional approval that has been vacated by the Court.

V. Effective Date of Stay

This action shall be effective on publication pursuant to section 553(d) of the APA, 5 U.S.C. 553(d). Although APA section 553(d) specifies that a rulemaking ordinarily must be published 30 days prior to its effective date, APA section 553(d)(1) allows for an exception, among other reasons, if the rulemaking relieves a restriction or "as otherwise provided by the agency for good cause found and published with the rule." 5 U.S.C. 553(d)(1). Staying the conditional approval, and hence the April 17, 2004 date for submittal of the SIP revisions relieves restriction imposed on the States of submitting SIP revisions, and relieves EPA of the statutory restriction to take action on any already-submitted SIP revisions, both of which could be contrary to the Court's holding in *Sierra Club v. EPA*, 356 F.3d 296 (DC Cir. 2004). EPA believes that it would not be appropriate

for any actions to be taken inconsistent with a filed U.S. Court of Appeals decision even if the court's mandate has not issued because of a petition for rehearing on an unrelated matter. Further, clarifying that neither EPA nor the States will have to take an action on or after April 17, 2004 that would be inconsistent with the filed opinion of the Court is additional good cause as explained above with respect to good cause for taking action without prior proposal justifying that the stay should be effective on publication. See 5 U.S.C. 553(d)(3).

VI. Final Action

EPA is staying 40 CFR 52.473, 40 CFR 52.1072(e) and 40 CFR 52.2450(b) as follows:

Effective April 15, 2004, 40 CFR 52.473 is stayed indefinitely. In a future action published in the **Federal Register** EPA will lift this stay and/or vacate the conditional approval after the issuance of the mandate by the U.S. Court of Appeals for the District of Columbia Circuit in a manner consistent with any order the Court may issue in *Sierra Club v. EPA* (No. 03-1084, DC Cir.).

Effective April 15, 2004, 40 CFR 52.1072(e) is stayed indefinitely. In a future action published in the **Federal Register** EPA will lift this stay and/or vacate the conditional approval after the issuance of the mandate by the U.S. Court of Appeals for the District of Columbia Circuit in a manner consistent with any order the Court may issue in *Sierra Club v. EPA* (No. 03-1084, DC Cir.).

Effective April 15, 2004, 40 CFR 52.2450(b) is stayed indefinitely. In a future action published in the **Federal Register** EPA will lift this stay and/or vacate the conditional approval after the issuance of the mandate by the U.S. Court of Appeals for the District of Columbia Circuit in a manner consistent with any order the Court may issue in *Sierra Club v. EPA* (No. 03-1084, DC Cir.).

VII. Statutory and Executive Order Reviews

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355, May 22, 2001). This action merely stays the applicability of a currently promulgated

rule. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule stays the applicability of a currently promulgated rule and does not impose any additional enforceable duty beyond that already required, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). This rule also does not have tribal implications because it will not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000). This action also does not have Federalism implications because it does not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999). This action merely stays the applicability of a currently promulgated rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve State choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. This rule does not impose an information collection burden under the provisions of the

Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801, *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. However, section 808 provides that any rule for which the issuing agency for good cause finds (and incorporates the finding and a brief statement of reasons therefore in the rule) that notice and public procedure thereon are impracticable, unnecessary, or contrary to the public interest, shall take effect at such time as the agency promulgating the rule determines. 5 U.S.C. 808(2). As stated previously, the EPA has made such a good cause finding, including the reasons therefore, and established an effective date of April 15, 2004. The EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This rule is not a "major rule" as defined by 5 U.S.C. 804(2).

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by June 14, 2004. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action indefinitely staying the April 17, 2003 conditional approval of the District of Columbia's, Maryland's and Virginia's SIP revisions for the D.C. Area may not be challenged later in proceedings to enforce its requirements. (*See* section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Intergovernmental relations, Nitrogen dioxide, Ozone, Volatile organic compounds.

Dated: April 2, 2004.

Donald S. Welsh,

Regional Administrator, Region III.

[FR Doc. 04-8096 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[MD161-3110a; FRL-7648-3]

Approval and Promulgation of Air Quality Implementation Plans; Maryland; Revisions to the 2005 ROP Plan for the Cecil County Portion of the Philadelphia-Wilmington-Trenton 1-Hour Ozone Nonattainment Area to Reflect the Use of MOBILE6

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: EPA is approving State Implementation Plan (SIP) revisions submitted by the State of Maryland. These revisions amend the 2005 rate-of-progress (ROP) plan in the Maryland SIP for the Cecil County portion of the Philadelphia-Wilmington-Trenton nonattainment severe 1-hour ozone nonattainment area. The intent of these revisions is to update the Cecil County 2005 ROP plan's mobile emissions inventories and motor vehicle emissions budgets (MVEBs) to reflect the use of MOBILE6 and to amend the contingency measures associated with that plan. These revisions are being approved in accordance with the Clean Air Act (the Act).

DATES: This rule is effective on June 1, 2004, without further notice, unless EPA receives adverse written comment by May 17, 2004. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Submit your comments, identified by MD161-3110 by one of the following methods:

A. Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

B. E-mail: Budney.Larry@epa.gov

C. Mail: Larry Budney, Mailcode 3AP23, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. MD161-3110. EPA's policy is that all comments received will be included in the public docket without change, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through regulations.gov or e-mail. The federal regulations.gov Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and at the Maryland Department of the Environment, 1800 Washington Boulevard, Suite 705, Baltimore, Maryland 21230.

FOR FURTHER INFORMATION CONTACT: Larry Budney, Mail Code 3AP23, Energy, Radiation and Indoor Environment Branch, U.S. Environmental Protection Agency, 1650 Arch Street, Philadelphia Pennsylvania 19103, (215) 814-2184, or by e-mail at Budney.Larry@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Clean Air Act Requirements

The Clean Air Act (the Act) requires that for certain ozone nonattainment areas, states are to submit plans demonstrating a reduction in volatile organic compound (VOC) emissions of at least three percent per year, grouped in consecutive three year periods, through the area's specified attainment

date. This is known as the rate-of-progress, commonly referred to as ROP, requirement of the Act. The first ROP requirement covers the period 1990-1996 and is commonly known as the 15 Percent Plan. Subsequent ROP milestone years are grouped in three year intervals beginning after 1996. The ROP milestone years for Cecil County are 1999, 2002, and 2005. To qualify for SIP credit in ROP plans, emission reduction measures, whether mandatory under the Act or adopted at the state's discretion, must ensure real, permanent and enforceable emission reductions.

Section 172(c)(9) of the Act requires moderate and above ozone nonattainment areas to adopt contingency measures to be implemented should the area fail to achieve ROP or to attain by its attainment date. In addition, section 182(c)(9) of the Act requires serious and above areas to adopt contingency measures which would be implemented if the area fails to meet any applicable milestone. States are required to develop contingency measures in the event an area fails to meet ROP in a given milestone year.

Under EPA's transportation conformity rule, like an attainment plan, an ROP plan is referred to as a control strategy SIP (62 FR 43780, August 1, 1997). A control strategy SIP identifies and establishes the MVEBs to which an area's transportation improvement program and long range transportation plan must conform. Conformity to a control strategy SIP means that transportation activities will not produce new air quality violations, worsen existing violations, or delay timely attainment of the relevant national ambient air quality standard (NAAQS), the 1-hour standard for ozone in this case. Maryland is required to identify MVEBs for both NO_x and VOCs in the Cecil County ROP plans for all milestone years.

On September 19, 2001 (66 FR 48209), EPA approved a 2005 ROP plan the Cecil County portion of the Philadelphia area which was based on the EPA emissions model MOBILE5. That plan included mobile source emissions inventories for 1990 and 2005 and MVEBs budgets for the milestone year 2005.

II. The Revisions to the Cecil County, Maryland 2005 ROP Plan

On March 8, 2004, the State of Maryland submitted a SIP revision to EPA. This SIP revision, submitted by the Maryland Department of the Environment (MDE), amends the Cecil County 2005 ROP plan to reflect the use of the MOBILE6 emissions model. This

SIP revision revises the 1990 and 2005 motor vehicle emissions inventories and explicitly identifies the 2005 MVEBs developed using the MOBILE6 emissions model. The March 8, 2004 submittal also amends the contingency measures associated with the 2005 ROP plan for Cecil County. The revised 2005 ROP Plan for Cecil County submitted on March 8, 2004, continues to demonstrate that the 2005 requirement for ROP is met.

A. The Emission Inventories

Table 1 summarizes the revised motor vehicle emissions inventories for Cecil County in tons per day (tpd). The revised 1990 base year inventories were updated using the MOBILE6 model. The 2005 inventories were developed using MOBILE6 and the latest planning assumptions, including 2002 vehicle registration data, vehicle miles traveled (VMT), speeds, fleet mix, and 2005 SIP control measures. Only VOC inventories are addressed here because Cecil County's ROP Plan does not rely on any NO_x substitution to meet the 2005 ROP emission reduction target for VOC.

TABLE 1.—PROJECTED UNCONTROLLED MOTOR VEHICLE VOC EMISSIONS INVENTORIES IN CECIL COUNTY'S 2005 ROP PLAN

Nonattainment area	1990 VOC (tpd)	2005 VOC (tpd)
Cecil County	8.59	5.00

EPA has articulated its policy regarding the use of MOBILE6 in SIP development in its "Policy Guidance on the Use of MOBILE6 for SIP Development and Transportation Conformity"¹ EPA's policy guidance required the State to consider whether growth and control strategy assumptions for non-motor vehicle sources (*i.e.*, point, area, and non-road mobile sources) were still accurate at the time the March 8, 2004, submittal was developed. Maryland reviewed the growth and control strategy assumptions for non-motor vehicle sources, revised those which were not current and concluded that the remaining assumptions continue to be valid for the 2005 ROP plan. Maryland's March 8, 2004 submittal satisfies the conditions outlined in EPA's MOBILE6 Policy guidance, and demonstrates that the new levels of motor vehicle emissions

¹ Memorandum, "Policy Guidance of the Use of MOBILE6 for SIP development and Transportation Conformity," issued January 18, 2002. A copy of this memorandum can be found on EPA's Web site at <http://www.epa.gov/otaq/transp/traqconf.htm>.

calculated using MOBILE6 continue to support ROP for the projected attainment of the 1-hour ozone NAAQS by the attainment date of 2005 for the Cecil County portion of the Philadelphia-Wilmington-Trenton area. EPA is approving these revisions to the 1990 and 2005 motor vehicle emission inventories of the 2005 ROP plan for Cecil County, Maryland.

B. The Revised Motor Vehicle Emissions Budgets (MVEBs)

Table 2 summarizes the revised MVEBs identified in MDE's March 8, 2004, submittal to EPA. These MVEBs were developed using the latest planning assumptions, including 2002 vehicle registration data, VMT, speeds, fleet mix, and 2005 SIP control measures. Maryland's March 8, 2004, submittal satisfies the conditions outlined in EPA's MOBILE6 Policy guidance, and demonstrates that the new levels of motor vehicle emissions calculated using MOBILE6 continue to support ROP for the projected attainment of the 1-hour NAAQS for ozone by Cecil County's November 15, 2005 attainment date. These MOBILE6-based 2005 ROP MVEBs, as shown Table 2, replace the previously approved MOBILE5-based MVEBs in the 2005 ROP plan for Cecil County. EPA is approving these MOBILE6-based budgets as revisions to the Cecil County 2005 ROP plan.

TABLE 2.—MARYLAND MOTOR VEHICLE EMISSION BUDGETS FOR CECIL COUNTY

Nonattainment area	2005 ROP	
	VOC (tpd)	NO _x (tpd)
Cecil County	3.0	11.3

C. Demonstration That the 2005 Rate-of-Progress Target Continues To Be Met

The State of Maryland's March 8, 2004 submittal of the revised 2005 ROP plan for Cecil County details how the 2005 ROP emission reduction target is calculated in tons of VOC per day. For the year 2005, it also projects what the uncontrolled VOC emissions from all sources (point, mobile, and area) would be, the calculated creditable VOC reductions from all Federal measures and SIP-approved emission control measures, and the emission level obtained from implementation of those measures. The revised 2005 ROP Plan for Cecil County submitted on March 8, 2004 continues to demonstrate that the 2005 ROP target level is met. EPA is approving the MOBILE6-based revisions

to the 1990 and 2005 motor vehicle emissions inventories and the 2005 MVEBs of the 2005 ROP plan for Cecil County because that plan continues to demonstrate that the required ROP target level for 2005 is met. Table 3 summarizes the ROP demonstration.

TABLE 3.—SUMMARY OF 2005 ROP DEMONSTRATION FOR CECIL COUNTY

Cecil County 2005 ROP Plan	VOC tpd
Projected Uncontrolled Emissions from All Sources of VOC (includes growth)	17.26
Reductions From All Creditable Emission Control Measures	9.86
Emission Level Obtained (uncontrolled emissions minus emission reductions from creditable control measures)	* 7.41
Projected 2005 ROP Target Level Surplus Emission Reductions (target level minus emission level obtained)	7.73
	0.32

*Note: Numbers are rounded.

D. Contingency Measures

Section 172(c)(9) of the Act requires moderate and above ozone nonattainment areas to adopt contingency measures that would have to be implemented should the area fail to achieve ROP or to attain by its attainment date. In addition, section 182(c)(9) of the Act requires serious and above areas to adopt contingency measures which would be implemented if the area fails to meet any applicable milestone. EPA previously approved the 2005 ROP plan for Cecil County (66 FR 48209, September 19, 2001) including contingency measures. In the March 8, 2004, revision to Cecil County's 2005 plan, Maryland outlines its approach for using the NO_x reductions from its SIP-approved rule banning open burning for contingency purposes. EPA encourages the early implementation of required control measures and of contingency measures as a means of guarding against failure to meet a milestone. EPA allows for the substitution of NO_x emission reductions for VOC in contingency plans for ROP provided NO_x reductions are necessary for attainment. The emission reduction measures listed to meet the 2005 target level for VOCs are expected to result in more emission reductions than are needed to meet ROP requirements (see Table 3). Maryland's March 8, 2004, submittal indicates that it is now dedicating all of the VOC emission reductions from its control measures to control strategy portion of the 2005 ROP plan to ensure that the ROP requirement (emission reduction target) is met. If contingency measure

credits are needed in the future to ensure that the 2005 reduction in VOC emissions has been met, the excess NO_x emission reductions achieved through the open burning ban rule will be used. If needed, a reduction of 0.74 tpd of NO_x from the open-burning ban rule is available to meet the VOC contingency requirement of the 2005 ROP plan utilizing NO_x substitution. The open burning ban rule was adopted and implemented as a part of the Maryland SIP's attainment demonstration for the Philadelphia area approved by EPA (66 FR 54977, October 29, 2001), which demonstrated that NO_x reductions are needed for attainment. EPA is approving the revisions to the contingency measures associated with the 2005 ROP plan for Cecil County.

III. EPA's Evaluation of the March 8, 2004 SIP Revisions

On March 8, 2004, the State of Maryland submitted SIP revisions to EPA for review and approval. These SIP revisions update the Cecil County 2005 ROP plan's mobile source emissions inventories and MVEBs to reflect the use of MOBILE6, and amend the contingency measures associated with that plan. EPA has evaluated Maryland's March 8, 2004, SIP revision submittal amending Cecil County's 2005 ROP plan for consistency with the Act, applicable EPA regulations, policies and guidance. The revised Cecil County 2005 ROP continues to demonstrate that the three percent per year emissions reduction requirement of section 182(b)(1) of the Act has been met. All control measures in the ROP demonstration have been adopted and implemented by the State of Maryland or are Federal measures being implemented at the national level. All state control measures have been approved by EPA into the Maryland SIP and are permanent and enforceable. A Technical Support Document (TSD) has been prepared to support this rulemaking action. Copies of the TSD may be obtained by contacting Larry Budney at Mail Code 3AP23, Energy, Radiation and Indoor Environment Branch, U.S. Environmental Protection Agency, 1650 Arch Street, Philadelphia Pennsylvania 19103, by phone at (215) 814-2184, or by e-mail at Budney.Larry@epa.gov.

IV. Final Action

EPA is approving the SIP revisions submitted by the State of Maryland on March 8, 2004. These revisions amend the Cecil County 2005 ROP plan to update the plan's 1990 and 2005 motor vehicle emissions inventories and MVEBs to reflect the use of the MOBILE6 emissions model. The

revisions also amend the contingency measures associated with the Cecil County 2005 ROP plan. The revised 2005 ROP for Cecil County submitted on March 8, 2004 continues to demonstrate that the required ROP emission reduction target for year 2005 is met. EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the "Proposed Rules" section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective on June 1, 2004, without further notice unless EPA receives adverse comment by May 17, 2004. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time.

V. Statutory and Executive Order Reviews

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355, May 22, 2001). This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). This rule also does not have tribal implications because it will not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the

distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000). This action also does not have Federalism implications because it does not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999). This action merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This rule is not a "major rule" as defined by 5 U.S.C. 804(2).

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by June 14, 2004.

Filing a petition for reconsideration by the Administrator of this final rule approving revisions to the motor vehicle emission inventories and MVEBs of the 2005 ROP plan for Cecil County, Maryland to reflect the use of the MOBILE6 does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Intergovernmental relations, Nitrogen dioxide, Ozone, Reporting and recordkeeping requirements, Volatile organic compounds.

Dated: April 7, 2004.

Judith M. Katz,

Acting Regional Administrator, Region III.

■ 40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

■ 1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart V—Maryland

■ 2. Section 52.1076 is amended by adding paragraph (f)(3) to read as follows:

§ 52.1076 Control strategy plans for attainment and rate-of-progress: Ozone.

* * * * *

(f) * * *

(3) EPA approves revisions to the Maryland State Implementation Plan, submitted by the Secretary of the Maryland Department of the Environment on March 8, 2004, for the rate-of-progress (ROP) plan for year 2005 for the Cecil County portion of the Philadelphia-Wilmington-Trenton 1-hour ozone nonattainment area. These revisions update Cecil County's 2005 ROP plan's 1990 and 2005 motor vehicle emissions inventories and motor vehicle emissions budgets to reflect the use of the MOBILE6 emissions model, establish motor vehicle emissions budgets of 3.0 tons per day (tpd) of volatile organic compounds and 11.3 tpd of nitrogen oxides, and amend the

contingency measures associated with the 2005 ROP plan for Cecil County.

[FR Doc. 04-8580 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[VA001-1001a; FRL-7648-4]

Approval of Section 112(l) Authority for Hazardous Air Pollutants; Equivalency by Permit Provisions; National Emission Standards for Hazardous Air Pollutants From the Pulp and Paper Industry; Commonwealth of Virginia

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: The EPA is approving a request from the Commonwealth of Virginia's Department of Environmental Quality (DEQ) for authority to implement and enforce state permit terms and conditions in place of those of the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Pulp and Paper Industry, with respect to the operations of International Paper Company's Franklin Mill, located in Franklin, Virginia. Thus, the EPA is hereby granting the Virginia DEQ the authority to implement and enforce alternative requirements in the form of Clean Air Act (CAA) Title V permit terms and conditions after EPA has approved the State's alternative requirements. The EPA is approving this request because it has found that the Virginia DEQ has satisfied the requirements for approval set forth at 40 CFR part 63, subpart E, entitled, "Approval of State Programs and Delegation of Federal Authorities."

DATES: This rule is effective on June 14, 2004 without further notice, unless EPA receives adverse written comment by May 6, 2004. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Submit your comments, identified by VA001-1001, by one of the following methods:

A. Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

B. E-mail: Campbell.Dave@epa.gov.

C. Mail: David J. Campbell, Chief, Permits and Technical Assessment Branch, Mailcode 3AP11, U.S. Environmental Protection Agency,

Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. VA001-1001. EPA's policy is that all comments received will be included in the public docket without change, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through regulations.gov or e-mail. The federal regulations.gov Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Copies of all comments should also be sent to the Virginia Department of Environmental Quality. Copies of written comments should be sent to John M. Daniel, Jr., Director, Air Division, Virginia Department of Environmental Quality, P.O. Box 10009, Richmond, Virginia 23240. Copies of electronic comments should be sent to jmdaniel@deq.state.va.us. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and the Virginia Department of Environmental Quality, 629 East Main Street, Richmond, Virginia 23219.

FOR FURTHER INFORMATION CONTACT: Ray Chalmers, (215) 814-2061, or by e-mail at chalmers.ray@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to section 112 of the Clean Air Act (CAA), the Environmental Protection Agency (EPA) promulgates NESHAP for various categories of air pollution sources. On April 15, 1998, EPA promulgated a NESHAP for the Pulp and Paper Industry, as codified at 40 CFR part 63, subpart S, §§ 63.440 through 63.459. (See, 63 FR 18504.) International Paper Company operates a pulp and paper mill called the Franklin Mill, located in Franklin, Virginia, which is subject to the requirements of this NESHAP.

Under section 112(l) of the CAA, EPA may approve State or local rules or programs to be implemented and enforced in place of certain otherwise applicable Federally promulgated CAA section 112 rules, emission standards, or requirements. EPA's approval of State and local rules or programs under section 112(l) is governed by regulations found at 40 CFR part 63, subpart E. (See, 65 FR 55810, dated September 14, 2000). Under the provisions of subpart E found at 40 CFR 63.94, a State or local air pollution control agency may seek approval, for affected sources permitted by the State or local agency under a CAA Title V permitting program developed pursuant to the EPA regulations found at 40 CFR part 70, of State or local CAA Title V permit terms and conditions to be implemented and enforced in lieu of specified existing and future Federal CAA section 112 rules, emissions standards, or requirements. This option is referred to as the equivalency by permit (EBP) option. To receive EPA approval using this option, the State or local agency must meet the requirements of 40 CFR 63.91 and 63.94.

Approval of alternative requirements under the EBP process comprises three steps. The first step is EPA granting "up-front approval" of a State's EBP program. (See, 40 CFR 63.94(a) and (b).) The second step is EPA review and approval of the State's proposed alternative CAA section 112 requirements in the form of pre-draft permit terms and conditions. (See, 40 CFR 63.94(c) and (d).) The third step is incorporation of the approved pre-draft permit terms and conditions into a specific CAA Title V permit and the CAA Title V permit issuance process itself. (See, 40 CFR 63.94(e).)

The first step, obtaining EPA's "up-front approval" of a State's EBP program, enables EPA to ensure that: (1) A State meets the criteria at 40 CFR 63.91(d) for up-front approval common to all approval options; (2) a legal

foundation exists for a State to replace the otherwise applicable Federal section 112 requirements with alternative, Federally enforceable requirements that will be reflected in final CAA Title V permit terms and conditions; and, (3) the specific source(s) and Federal emission standard(s) for which a State will be accepting delegation under the EBP program are clearly specified.

The second step, having EPA review and approve the State's alternative CAA section 112 requirements, provides EPA with an opportunity to ensure that the State's proposed pre-draft CAA Title V permit terms and conditions reflect all of the requirements of the otherwise applicable Federal requirements and are equivalent to those requirements. The approval criteria used by EPA are set forth at 40 CFR 63.94(d). If the EPA finds that the pre-draft CAA Title V permit terms and conditions submitted by the State meet the criteria of paragraph (d), EPA approves the State's alternative requirements (by approving the pre-draft permit terms and conditions) and notifies the State in writing of the approval.

The third step, requiring incorporation of the approved pre-draft permit terms and conditions into a specific CAA Title V permit and the CAA Title V permit issuance process itself, serves to make the requirements legally effective. EPA's final approval of the State's proposed alternative requirements that substitute for the Federal standard does not occur until the completion of step three.

On November 21, 2003 the Virginia DEQ requested delegation of authority to implement and enforce State CAA Title V permit terms and requirements for International Paper Company's Franklin Mill as an alternative to those of the NESHAP for the Pulp and Paper Industry found at 40 CFR part 63, subpart S. The Virginia DEQ states in its request that it intends for the submittal to fulfill only the requirements of step one of the EBP process, pertaining to obtaining "up-front approval" of its program. The Virginia DEQ explains that it will later fulfill steps two and three of the EBP process by submitting substitute CAA Title V operating permit terms and conditions for EPA review and approval, and then proceeding with the CAA Title V permit issuance process. The Virginia DEQ sought this authority pursuant to the provisions of 40 CFR 63.94 and 63.91, and the Virginia DEQ submitted information addressing the requirements of those sections.

II. Analysis of State's Submittal

EPA has reviewed the Virginia DEQ's submittal and has concluded that the Virginia DEQ meets the requirements for "up-front approval" of its EBP program which are specified at 40 CFR 63.94(b) and 63.91(d). The requirements a State or local agency must meet can be summarized as follows: (1) Identify the source(s) for which the State seeks authority to implement and enforce alternative requirements; (2) request delegation (or have delegation) for any remaining sources required to be permitted by the State under 40 CFR part 70 that are in the same category as the source(s) for which it wishes to establish alternative requirements; (3) identify all existing and future CAA section 112 emission standards for which the State is seeking authority to implement and enforce alternative requirements; (4) demonstrate that the State has an approved CAA Title V operating permits program that permits the affected sources; and, (5) demonstrate that the State meets the general approval criteria set forth at 40 CFR 63.91(d).

EPA lists each requirement below and after each requirement explains its reasons for concluding that the Virginia DEQ meets the requirement:

A. Identify the Source(s) for Which the State Is Seeking Authority To Implement and Enforce Alternative Requirements

The Virginia DEQ identified International Paper Company's Franklin Mill, a pulp and paper mill located in Franklin, Virginia, as the source for which it is seeking authority to implement and enforce alternative requirements. According to the Virginia DEQ, International Paper Company's Franklin Mill is one of four operating pulp and paper mills in Virginia subject to 40 CFR part 63, subpart S. The Virginia DEQ reports that none of the other companies operating pulp and paper mills in Virginia have contacted the State regarding an interest in the EBP process.

B. Request or Have Delegation for Any Remaining Sources Required To Be Issued CAA Title V Permits by the State and That Are in the Same Category as the Source(s) for Which It Seeks To Establish Alternative Requirements

The Virginia DEQ is currently delegated the authority to implement and enforce the Federal requirements of 40 CFR part 63, subpart S for all pulp and paper mills. Subpart S applies to "the owner or operator of processes that produce pulp, paper, or paperboard;

that are located at a plant site that is a major source. * * *" (See, 40 CFR 63.440.) On January 26, 1999, EPA announced in the *Federal Register* that it had delegated to the Virginia DEQ the authority to implement and enforce EPA's NESHAP standards for all affected sources of hazardous air pollutants (HAPs), as defined in 40 CFR part 63, for all source categories which are located at major sources. (See, 64 FR 3938.) EPA also delegated to the Virginia DEQ the authority to implement and enforce all future EPA NESHAP standards applicable to such sources, on the condition that the Virginia DEQ legally adopt such new standards with only approved wording changes and that the Virginia DEQ provide notice to EPA of such adoption. The Virginia DEQ subsequently adopted additional standards, and notified EPA that it had adopted these additional standards. The additional standards that the State adopted included 40 CFR part 63, subpart S.

C. Identify All Existing and Future Federal Section 112 Rules for Which the State Is Seeking Authority To Implement and Enforce Alternative Requirements

In its November 21, 2003 submittal, the Virginia DEQ requested only the authority to implement and enforce State permit requirements for International Paper Company's Franklin Mill as alternatives to the Federal requirements applicable to that Mill found at 40 CFR part 63, subpart S. The Virginia DEQ confirmed that there are no other existing and future Federal CAA section 112 rules for which the State is seeking authority to implement and enforce alternative requirements.

D. Demonstrate That the State Has an Approved CAA Title V Permits Program and That the Program Permits the Affected Source(s)

EPA granted final full approval to Virginia's CAA Title V operating permits program on December 4, 2001 (66 FR 62961), and under this approved program the Virginia DEQ has the authority to issue CAA Title V permits to all major stationary sources. In its November 21, 2003 submittal, the Virginia DEQ confirmed that International Paper Company's Franklin Mill is a CAA Title V source and that it is subject to the State's CAA Title V permits program. The Virginia DEQ noted the International Paper Company had submitted a CAA Title V permit application, and that the Virginia DEQ was reviewing this application.

E. Demonstrate That the State Meets the General Approval Criteria Found at 40 CFR Section 63.91(d)

The provisions of 40 CFR 63.91(d) specify that "Interim or final CAA Title V program approval will satisfy the criteria set forth in § 63.91(d), up-front approval criteria." As discussed in item D. above, EPA has fully approved Virginia's CAA Title V operating permits program.

F. Virginia's Voluntary Environmental Assessment Privilege Law

In 1995, Virginia adopted legislation that provides, subject to certain conditions, for an environmental assessment (audit) "privilege" for voluntary compliance evaluations performed by a regulated entity. The legislation further addresses the relative burden of proof for parties either asserting the privilege or seeking disclosure of documents for which the privilege is claimed. Virginia's legislation also provides, subject to certain conditions, for a penalty waiver for violations of environmental laws when a regulated entity discovers such violations pursuant to a voluntary compliance evaluation and voluntarily discloses such violations to the Commonwealth and takes prompt and appropriate measures to remedy the violations. Virginia's Voluntary Environmental Assessment Privilege Law, Va. Code Sec. 10.1-1198, provides a privilege that protects from disclosure documents and information about the content of those documents that are the product of a voluntary environmental assessment. The Privilege Law does not extend to documents or information: (1) That are generated or developed before the commencement of a voluntary environmental assessment; (2) that are prepared independently of the assessment process; (3) that demonstrate a clear, imminent and substantial danger to the public health or environment; or (4) that are required by law.

On January 12, 1997, the Commonwealth of Virginia Office of the Attorney General provided a legal opinion that states that the Privilege law, Va. Code Sec. 10.1-1198, precludes granting a privilege to documents and information "required by law," including documents and information "required by Federal law to maintain program delegation, authorization or approval," since Virginia must "enforce Federally authorized environmental programs in a manner that is no less stringent than their Federal counterparts * * *". The opinion concludes that "[r]egarding § 10.1-1198, therefore,

documents or other information needed for civil or criminal enforcement under one of these programs could not be privileged because such documents and information are essential to pursuing enforcement in a manner required by Federal law to maintain program delegation, authorization or approval."

Virginia's Immunity law, Va. Code Sec. 10.1-1199, provides that "[t]o the extent consistent with requirements imposed by Federal law," any person making a voluntary disclosure of information to a state agency regarding a violation of an environmental statute, regulation, permit, or administrative order is granted immunity from administrative or civil penalty. The Attorney General's January 12, 1997 opinion states that the quoted language renders this statute inapplicable to enforcement of any Federally authorized programs, since "no immunity could be afforded from administrative, civil, or criminal penalties because granting such immunity would not be consistent with Federal law, which is one of the criteria for immunity."

Therefore, EPA has determined that Virginia's Privilege and Immunity statutes will not preclude the Commonwealth from enforcing its CAA Title V program consistent with the Federal requirements. In any event, because EPA has also determined that a state audit privilege and immunity law can affect only state enforcement and cannot have any impact on Federal enforcement authorities, EPA may at any time invoke its authority under the Clean Air Act, including, for example, sections 113, 167, 205, 211 or 213, to enforce the requirements or prohibitions of the state plan, independently of any state enforcement effort. In addition, citizen enforcement under section 304 of the Clean Air Act is likewise unaffected by this, or any, state audit privilege or immunity law.

III. Final Action

EPA is granting the Virginia DEQ "up-front" approval of an EBP program under which the Virginia DEQ may establish and enforce alternative State requirements for International Paper Company's Franklin Mill in lieu of those of the NESHAP for the Pulp and Paper Industry found at 40 CFR part 63, subpart S. The Virginia DEQ may only establish alternative requirements for the Franklin Mill which are equivalent to and at least as stringent as the otherwise applicable Federal requirements. (See, 40 CFR 63.94(d).) The VA DEQ must, in order to establish alternative requirements for the Franklin Mill under its EPA approved EBP program: (1) Submit to EPA for

review pre-draft CAA Title V permit terms specifying alternative requirements which are at least as stringent as the otherwise applicable Federal requirements, (2) obtain EPA's written approval of the alternative pre-draft CAA Title V permit requirements, and (3) issue a CAA Title V permit for the Franklin Mill which contains the approved alternative requirements. (See, 40 CFR 63.94(c) and (e).) Until EPA has approved the alternative permit terms and conditions and the Virginia DEQ has issued a final CAA Title V permit incorporating them, International Paper Company's Franklin Mill will remain subject to the Federal NESHAP requirements found at 40 CFR part 63, subpart S.

EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the "Proposed Rules" section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve if adverse comments are filed. This rule will be effective on June 14, 2004 without further notice unless EPA receives adverse comment by May 6, 2004. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time.

IV. Statutory and Executive Order Reviews

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355, May 22, 2001). This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose

any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). This rule also does not have tribal implications because it will not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000). This action also does not have Federalism implications because it does not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999). This action merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997), because it is not economically significant.

EPA's role in reviewing this submittal is to approve a State request for authority to establish State permit terms and conditions to be implemented and enforced in lieu of specified existing and future Federal rules, emissions standards or requirements promulgated under CAA section 112, for those affected sources permitted by the State under a program meeting the requirements of CAA part 70, provided that the request meets the criteria of the CAA. In this context, in the absence of a prior existing requirement for a State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a State's submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, in reviewing this submission, to use VCS in place of a State submission that otherwise satisfies the provisions of the CAA. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272) do not apply. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 804 exempts from section 801 the following types of rules: (1) Rules of particular applicability; (2) rules relating to agency management or personnel; and (3) rules of agency organization, procedure, or practice that do not substantially affect the rights or obligations of non-agency parties. 5 U.S.C. 804(3). EPA is not required to submit a rule report regarding today's action under section 801 because this is a rule of particular applicability establishing source-specific requirements for International Paper Company's Franklin Mill located in Franklin, Virginia.

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by June 14, 2004. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action granting the Virginia DEQ "up-front" approval of an EBP program under which the Virginia DEQ may establish and enforce alternative State requirements for International Paper Company's Franklin Mill in lieu of those of the NESHAP for the Pulp and Paper Industry found at 40 CFR part 63, subpart S may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 63

Environmental protection, Administrative practice and procedure, Air pollution control, Hazardous substances, Intergovernmental relations, Reporting and recordkeeping requirements.

Dated: April 6, 2004.

Thomas Voltaggio,
Acting Regional Administrator, Region III.

■ 40 CFR part 63 is amended as follows:

PART 63—[AMENDED]

■ 1. The authority citation for part 63 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart E—Approval of State Programs and Delegation of Federal Authorities

■ 2. Section 63.99 is amended by adding paragraph (a)(46)(iii) to read as follows:

§ 63.99 Delegated Federal authorities.

(a) * * *

(46) Virginia

* * * * *

(iii) EPA has granted the Virginia Department of Environmental Quality (DEQ) "up-front" approval to implement an Equivalency by Permit (EBP) program under which the Virginia DEQ may establish and enforce alternative State requirements for International Paper Company's Franklin Mill in lieu of those of the National Emissions Standard for Hazardous Air Pollutants (NESHAP) for the Pulp and Paper Industry found at 40 CFR part 63, subpart S. The Virginia DEQ may only establish alternative requirements for the Franklin Mill which are equivalent to and at least as stringent as the otherwise applicable Federal requirements. The VA DEQ must, in order to establish alternative requirements for the Franklin Mill under its EPA approved EBP program: (1) Submit to EPA for review pre-draft Clean Air Act (CAA) Title V permit terms specifying alternative requirements which are at least as stringent as the otherwise applicable Federal requirements, (2) obtain EPA's written approval of the alternative pre-draft CAA Title V permit requirements, and (3) issue a CAA Title V permit for the Franklin Mill which contains the approved alternative requirements. Until EPA has approved the alternative permit terms and conditions and the Virginia DEQ has issued a final CAA Title V permit incorporating them, International Paper Company's Franklin Mill will remain subject to the Federal NESHAP requirements found at 40 CFR part 63, subpart S.

* * * * *

[FR Doc. 04-8581 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

**FEDERAL COMMUNICATIONS
COMMISSION**
47 CFR Part 80

[PR Docket No. 92-257; RM-9664; FCC 03-270]

Maritime Communications

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: In this document, the Commission addresses petitions for reconsideration of the *Second Memorandum Opinion and Order and Fifth Report and Order* in this proceeding. The reconsideration petitions pertain to the Commission's decisions regarding the licensing approach for spectrum allotted to Automated Maritime Telecommunications System (AMTS) stations, including application processing issues and the incumbent co-channel interference protection standard. Based on the record now presented to the Commission, it believes that reconsideration of the AMTS incumbent co-channel interference protection standard is warranted. Therefore, in the *Third Memorandum Opinion and Order*, the Commission adopts a larger interference contour, which will better preserve AMTS incumbent systems' current operating parameters and afford licensees with an opportunity to construct fill-in stations.

DATES: Effective May 17, 2004.

FOR FURTHER INFORMATION CONTACT:

Jeffrey Tobias, Jeff.Tobias@FCC.gov, Public Safety and Critical Infrastructure Division, Wireless Telecommunications Bureau, (202) 418-0680, or TTY (202) 418-7233.

SUPPLEMENTARY INFORMATION: The Commission's *Third Memorandum Opinion and Order*, PR Docket No. 92-257, FCC 03-270, was adopted October 31, 2003, and released on November 18, 2003. The full text of this Commission's *Third Memorandum Opinion and Order* is available for inspection and copying during normal business hours in the FCC Reference Center, Room CY-A257, 445 12th Street, SW., Washington, DC. The complete text may be purchased from the Commission's copy contractor, Qualex International, Inc., Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC 20037. The full text may also be downloaded at: <http://www.fcc.gov/Wireless/Orders/2003/fcc03270.txt>. Alternative formats are available to persons with disabilities by contacting Brian Millin at (202) 418-7426 or TTY (202) 418-7365.

Synopsis of the MO&O

1. The Commission denied two petitions for reconsideration of the Commission's decision to dismiss AMTS applications the processing of which had been suspended because they were mutually exclusive with other applications and/or the relevant filing period had not expired as of November 16, 2000. The Commission stated that § 1.934 of the Commission's rules did not obligate the Wireless Telecommunications Bureau to automatically dismiss mutually exclusive applications that did not comply with certain technical AMTS requirements prior to accepting them for filing.

2. The Commission granted in part a petition for reconsideration of the *Second Memorandum Opinion and Order and Fifth Report and Order* 67 FR 48560 (July 25, 2002), co-channel interference protection standard of 10 dB protection to the incumbent's predicted 38 dBu contour. The Commission concluded that it would be possible for a geographic licensee to interpose a facility between co-system incumbent base stations if the incumbent stations are provided 10 dB protection. Consequently, based on this further review, it decided that geographic area licensees should provide 18 dB protection to an incumbent's service contour, in order to be assured of protecting incumbents' continuity of service.

Final Regulatory Flexibility Analysis

3. As required by the Regulatory Flexibility Act (RFA), a Final Regulatory Flexibility Analysis (IRFA) was incorporated into the *Second Memorandum Opinion and Order and Fifth Report and Order* in this proceeding. See 5 U.S.C. 603. The RFA, see 5 U.S.C. 601 *et seq.*, has been amended by the Contract With America Advancement Act of 1996, Public Law 104-121, 110 Stat. 847 (1996) (CWAAA). Title II of the CWAAA is the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA). In view of the fact that we have adopted a further rule amendment in the *Third Memorandum Opinion and Order*, we have included this Supplemental Final Regulatory Flexibility Analysis (SFRFA). The present SFRFA conforms to the RFA.

A. Need for, and Objectives of the Third Memorandum Opinion and Order

4. In the *Third Memorandum Opinion and Order*, we amend a rule regarding co-channel interference protection that was adopted in the *Second*

Memorandum Opinion and Order and Fifth Report and Order. We believe that this rule amendment supports the objectives that the Commission has established for this proceeding (i.e., to increase the number and types of communications services available to the maritime community and improve the safety of life and property at sea, and that the potential benefits to the maritime community exceed any negative effects that may result from the promulgation of rules for this purpose).

B. Summary of Significant Issues Raised by Public Comments in Response to the FRFA

5. We received no comments in response to the FRFA in the *Second Memorandum Opinion and Order and Fifth Report and Order*. However, we continue to believe that the policies and rules adopted in the *Second Memorandum Report and Order and Fifth Report and Order* will better enable small entities to compete for licenses in the AMTS band.

C. Description and Estimate of the Number of Small Entities to Which Rules Will Apply

6. The RFA directs agencies to provide a description of and, where feasible, an estimate of the number of small entities that may be affected by the proposed rules, if adopted. 5 U.S.C. 603(b)(3). The RFA generally defines the term "small entity" as having the same meaning as the terms "small business," "small organization," and "small governmental jurisdiction." 5 U.S.C. 601(6). In addition, the term "small business" has the same meaning as the term "small business concern" under the Small Business Act. 5 U.S.C. 601(3) (incorporating by reference the definition of "small business concern" in 15 U.S.C. 632). Pursuant to the RFA, the statutory definition of a small business applies "unless an agency, after consultation with the Office of Advocacy of the Small Business Administration and after opportunity for public comment, establishes one or more definitions of such term which are appropriate to the activities of the agency and publishes such definition(s) in the *Federal Register*." 5 U.S.C. 601(3). A small business concern is one which: (i) is independently owned and operated; (ii) is not dominant in its field of operation; and (iii) satisfies any additional criteria established by the Small Business Administration (SBA). Small Business Act, 15 U.S.C. 632 (1996). A small organization is generally "any not-for-profit enterprise which is independently owned and operated and

is not dominant in its field." 5 U.S.C. 601(4).

7. The rules adopted in this proceeding will affect licensees using AMTS spectrum. In the *Third Report and Order* in this proceeding, the Commission defined the term "small entity" specifically applicable to public coast station licensees as any entity employing fewer than 1,500 persons, based on the definition under the Small Business Administration rules applicable to radiotelephone service providers. Since the size data provided by the Small Business Administration does not enable us to make a meaningful estimate of the number of AMTS licensees that are small businesses, we have used the 1992 Census of Transportation, Communications, and Utilities, conducted by the Bureau of the Census, which is the most recent information available. This document shows that only 12 radiotelephone firms out of a total of 1,178 such firms that operated in 1992 had 1,000 or more employees. There are three AMTS public coast station licensees and approximately thirteen high seas public coast station licensees. Based on the rules adopted in this proceeding, it is unlikely that more than seven licensees will be authorized in the future. Therefore, for purposes of our evaluations and conclusions in this SFRFA, we estimate that there are approximately twenty-three AMTS and high seas public coast station licensees that are small businesses, as that term is defined by the Small Business Administration.

D. Description of Projected Reporting, Recordkeeping, and Other Compliance Requirements

8. The *Third Memorandum Opinion and Order* imposes no new reporting, recordkeeping or other compliance requirements not previously adopted in this proceeding.

E. Steps Taken To Minimize Significant Economic Impact on Small Entities, and Significant Alternatives Considered

9. The RFA requires an agency to describe any significant alternatives that it has considered in reaching its proposed approach, which may include the following four alternatives: (i) The establishment of differing compliance or reporting requirements or timetables that take into account the resources available to small entities; (ii) the clarification, consolidation, or simplification of compliance or reporting requirements under the rule for small entities; (iii) the use of performance, rather than design, standards; and (4) an exemption from

coverage of the rule, or any part thereof, for small entities.

10. The rule amendment adopted in this *Third Memorandum Opinion and Order* will have no significant economic impact on small entities. The Commission in this proceeding has considered comments on implementing broad changes to the maritime service rules. It has adopted alternatives which minimize burdens placed on small entities. In the *Second Memorandum Report and Order and Fifth Report and Order*, it decided to adopt for AMTS the small business provisions that were adopted in the auction of VHF public coast spectrum. Specifically, the Commission has concluded that AMTS small businesses will receive a bidding credit of 25 percent and very small businesses will receive a bidding credit of 35 percent. It has defined small businesses as those entities, together with their affiliates and controlling interests, with not more than fifteen million dollars in average gross revenues for the preceding three years, and very small businesses as those entities, together with their affiliates and controlling interests, with not more than three million dollars in average gross revenues for the preceding three years. These small business size standards have been approved by the U.S. Small Business Administration, pursuant to section 3 of the Small Business Act. See Letter from Aida Alvarez, Administrator, Small Business Administration, to Margaret W. Wiener, Chief, Auctions and Industry Analysis Division, Wireless Telecommunications Bureau, Federal Communications Commission (dated November 3, 2000) (approving size standards for AMTS and high seas public coast services); see also 15 U.S.C. 632(a)(2) (establishment of size standards by federal agencies); 13 CFR 121.90(b) (promulgation of special size standards by federal agencies).

11. *Report to Congress:* The Commission will send a copy of the *Third Memorandum Opinion and Order*, including this SFRFA, in a report to be sent to Congress pursuant to the Congressional Review Act. See 5 U.S.C. 801(a)(1)(A). In addition, the Commission will send a copy of the *Third Memorandum Opinion and Order*, including this SFRFA, to the Chief Counsel for Advocacy of the Small Business Administration.

12. The Commission's Consumer Information Bureau, Reference Information Center, shall send a copy of this *Third Memorandum Opinion and Order*, including the Supplemental Final Regulatory Flexibility Analysis, to the Chief Counsel for Advocacy of the Small Business Administration.

List of Subjects in 47 CFR Part 80

Communications equipment, Radio.
Federal Communications Commission.
Marlene H. Dortch,
Secretary.

Final Rules

■ For the reasons discussed in the preamble, the Federal Communications Commission amends 47 CFR Part 80 as follows:

PART 80—STATIONS IN THE MARITIME SERVICES

■ 1. The authority citation for part 80 continues to read as follows:

Authority: Secs. 4, 303, 307(e), 309, and 332, 48 Stat. 1066, 1082, as amended; 47 U.S.C. 154, 303, 307(e), 309, and 332, unless otherwise noted. Interpret or apply 48 Stat. 1064-1068, 1081-1105, as amended; 47 U.S.C. 151-155, 301-609; 3 UST 3450, 3 UST 4726, 12 UST 2377.

■ 2. Section 80.385 is amended by revising paragraph (b)(1) to read as follows:

§ 80.385 Frequencies for automated systems.

* * * * *

(b) * * *

(1) The AMTS geographic area licensee must locate its stations at least 120 kilometers from the stations of co-channel site-based AMTS licensees. Shorter separations between such stations will be considered by the Commission on a case-by-case basis upon submission of a technical analysis indicating that at least 18 dB protection will be provided to a site-based licensee's predicted 38 dBu signal level contour. The site-based licensee's predicted 38 dBu signal level contour shall be calculated using the F(50, 50) field strength chart for Channels 7-13 in § 73.699 (Fig. 10) of this chapter, with a 9 dB correction for antenna height differential. The 18 dB protection to the site-based licensee's predicted 38 dBu signal level contour shall be calculated using the F(50, 10) field strength chart for Channels 7-13 in § 73.699 (Fig. 10a) of this chapter, with a 9 dB correction factor for antenna height differential.

* * * * *

■ 3. Section 80.475(a) is amended by adding new paragraphs (a)(1) and (a)(2) to read as follows:

§ 80.475 Scope of service of the Automated Maritime Telecommunications System (AMTS).

(a) * * *

(1) Applicants proposing to locate a coast station transmitter within 169 kilometers (105 miles) of a channel 13

TV station or within 129 kilometers (80 miles) of a channel 10 TV station or with an antenna height greater than 61 meters (200 feet), must submit an engineering study clearly showing the means of avoiding interference with television reception within the grade B contour, *see* § 80.215(h) of this chapter, unless the proposed station's predicted

interference contour is fully encompassed by the composite interference contour of the applicant's existing system, or the proposed station's predicted interference contour extends the system's composite interference contour over water only (disregarding uninhabited islands).

(2) Additionally, applicants required to submit the above specified must give

written notice of the filing of such applications(s) to the television stations which may be affected. A list of the notified television stations must be submitted with the subject applications.

* * * * *

[FR Doc. 04-8598 Filed 4-14-04; 8:45 am]

BILLING CODE 6712-01-P

Proposed Rules

Federal Register

Vol. 69, No. 73

Thursday, April 15, 2004

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

7 CFR Part 301

[Docket No. 03-059-2]

Mexican Fruit Fly; Interstate Movement of Regulated Articles

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Proposed rule; reopening of comment period.

SUMMARY: We are reopening the comment period for our proposed rule that would amend the Mexican fruit fly regulations by, among other things, removing a provision that allows regulated articles to be moved interstate from a regulated area without a certificate or limited permit when they are moved into States other than commercial citrus-producing States. This action will allow interested persons additional time to prepare and submit comments.

DATES: We will consider all comments that we receive on or before May 17, 2004.

ADDRESSES: You may submit comments by any of the following methods:

- *Postal Mail/Commercial Delivery:*

Please send four copies of your comment (an original and three copies) to Docket No. 03-059-1, Regulatory Analysis and Development, PPD, APHIS, Station 3C71, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 03-059-1.

- *E-mail:* Address your comment to regulations@aphis.usda.gov. Your comment must be contained in the body of your message; do not send attached files. Please include your name and address in your message and "Docket No. 03-059-1" on the subject line.

- *Agency Web site:* Go to <http://www.aphis.usda.gov/ppd/rad/cominst.html> for a form you can use to

submit an e-mail comment through the APHIS Web site.

- *Federal eRulemaking Portal:* Go to <http://www.regulations.gov> and follow the instructions for locating this docket and submitting comments.

Reading Room: You may read any comments that we receive on this docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: You may view APHIS documents published in the Federal Register and related information, including the names of groups and individuals who have commented on APHIS dockets, on the Internet at <http://www.aphis.usda.gov/ppd/rad/webrepor.html>.

FOR FURTHER INFORMATION CONTACT: Mr. Michael B. Stefan, Director of Emergency Programs, PPD, APHIS, 4700 River Road Unit 134, Riverdale, MD 20737-1236; (301) 734-4387.

SUPPLEMENTARY INFORMATION:

Background

On February 18, 2004, we published in the *Federal Register* (69 FR 7607-7611, Docket No. 03-059-1) a proposal to amend the Mexican fruit fly regulations in 7 CFR 301, which impose restrictions on the interstate movement of regulated articles from regulated areas.

Comments on the proposed rule were required to be received on or before April 19, 2004. We are reopening the comment period on Docket No. 03-059-1 for an additional 30 days. This action will allow interested persons additional time to prepare and submit comments.

Authority: 7 U.S.C. 7701-7772; 7 CFR 2.22, 2.80, and 371.3.

Section 301.75-15 also issued under Sec. 204, Title II, Pub. L. 106-113, 113 Stat. 1501A-293; sections 301.75-15 and 301.75-16 also issued under Sec. 203, Title II, Pub. L. 106-224, 114 Stat. 400 (7 U.S.C. 1421 note).

Done in Washington, DC, this 12th day of April 2004.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 04-8558 Filed 4-14-04; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-223-AD]

RIN 2120-AA63

Airworthiness Directives; Fokker Model F.28 Mark 0070 and 0100 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the superseding of an existing airworthiness directive (AD), applicable to certain Fokker Model F.28 Mark 0070 series airplanes, that currently requires a one-time inspection to detect loose bolts attaching the gustlock counter-bracket to the pulley on the elevator tension regulator (control) assembly, and corrective action if necessary. This action would instead require a modification of the elevator tension control mechanism. This action would also revise the applicability to include additional airplanes. The actions specified by the proposed AD are intended to prevent restricted elevator movement and consequent reduced controllability of the airplane. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by May 17, 2004.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-223-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227-1232. Comments

may also be sent via the Internet using the following address: *9-anm-nprmcomment@faa.gov*. Comments sent via fax or the Internet must contain "Docket No. 2002-NM-223-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Fokker Services B.V., P.O. Box 231, 2150 AE Nieuw-Vennep, the Netherlands. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT: Tom Rodriguez, Aerospace Engineer, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-1137; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.

Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments

submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002-NM-223-AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-223-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

Discussion

On May 3, 2000, the FAA issued AD 2000-09-11, amendment 39-11720 (65 FR 30529, May 12, 2000), for certain Fokker Model F.28 Mark 0070 series airplanes. That AD currently requires a one-time inspection to detect loose bolts attaching the gustlock counter-bracket to the pulley on the elevator tension regulator (control) assembly, and corrective action if necessary. That action was prompted by issuance of mandatory continuing airworthiness information by the Civil Aviation Authority—The Netherlands (CAA-NL), which is the airworthiness authority for the Netherlands. At that time, only airplanes manufactured after a certain change in the production process were subject to the identified unsafe condition. The requirements of AD 2000-09-11 are intended to prevent restricted elevator movement and consequent reduced controllability of the airplane.

Actions Since Issuance of Previous Rule

Since that AD was issued, the CAA-NL reported that further investigation of the subject bolts revealed an oversize grip length. The manufacturer has since developed a modification to address the problem and obviate the need for the inspection and inadequate associated corrective action. Further, it has been determined that the identified unsafe condition may also exist on certain Fokker Model F.28 Mark 0100 series airplanes. The limited range of elevator deflection resulting from the oversize bolts, if not corrected, could result in restricted elevator movement and consequent reduced controllability of the airplane.

Explanation of Relevant Service Information

Fokker Services B.V. has issued Service Bulletin SBF100-27-081 and Component Service Bulletin D78179-27-017, both dated January 1, 2002. The service bulletins describe procedures for modifying the elevator tension control

mechanism. The modification involves replacing a bolt in the adjuster bracket with a bolt having a shorter grip length, which is intended to improve its clamping capability. Accomplishment of the actions specified in either service bulletin is intended to adequately address the identified unsafe condition. The CAA-NL classified the service bulletins as mandatory and issued Dutch airworthiness directive 2002-058, dated April 29, 2002, to ensure the continued airworthiness of these airplanes in the Netherlands.

FAA's Conclusions

These airplane models are manufactured in the Netherlands and are type certificated for operation in the United States under the provisions of § 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the CAA-NL has advised us of the situation described above. We have examined the findings of the CAA-NL, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would supersede AD 2000-09-11 to require modification of the elevator tension control mechanism.

Change in Labor Rate

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from \$60 per work hour to \$65 per work hour. The cost impact information, below, reflects this increase in the specified hourly labor rate.

Cost Impact

This proposed AD would affect about 75 airplanes of U.S. registry. The proposed actions would take about 1 work hour per airplane, at an average labor rate of \$65 per work hour. Required parts would be provided to operators at no cost. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be \$4,875, or \$65 per airplane.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39-11720 (65 FR

30529, May 12, 2000), and by adding a new airworthiness directive (AD), to read as follows:

Fokker Services B.V.: Docket 2002-NM-223-AD. Supersedes AD 2000-09-11, Amendment 39-11720.

Applicability: Model F.28 Mark 0070 and 0100 series airplanes, certificated in any category, equipped with elevator tension control assemblies having any part number (P/N) D78179-405, -407, -409, -411, or 413.

Compliance: Required as indicated, unless accomplished previously.

To prevent restricted elevator movement and consequent reduced controllability of the airplane, accomplish the following:

Modification

(a) Within 18 months after the effective date of this AD, modify the elevator tension control mechanism in accordance with the Accomplishment Instructions of Fokker Service Bulletin SBF100-27-081, dated January 1, 2002; or Fokker Component Service Bulletin D78179-27-017, dated January 1, 2002.

Parts Installation

(b) As of the effective date of this AD, no person may install an elevator tension control assembly on any airplane, unless the assembly has been modified and reidentified in accordance with the requirements of this AD.

Alternative Methods of Compliance

(c) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM-116, FAA, Transport Airplane Directorate, is authorized to approve alternative methods of compliance for this AD.

Note 1: The subject of this AD is addressed in Dutch airworthiness directive 2002-058, dated April 29, 2002.

Issued in Renton, Washington, on April 1, 2004.

Kalene C. Yanamura,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 04-8538 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-182-AD]

RIN 2120-AA64

Airworthiness Directives; Saab Model SAAB SF340A and SAAB 340B Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness

directive (AD) that is applicable to certain Saab Model SAAB SF340A and SAAB 340B series airplanes. This proposal would require replacement of the retract actuator bracket attachment bolt (RABAB) of the main landing gear (MLG) with a new RABAB, and reidentification of the MLG shock strut. This action is necessary to prevent failure of the RABAB, which could result in loosening of the actuator bracket and consequent failure of the MLG to retract, with considerable damage to other landing gear parts, including the MLG trunnion fitting. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by May 17, 2004.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-182-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227-1232. Comments may also be sent via the Internet using the following address: 9-anm-nprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2002-NM-182-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Saab Aircraft AB, SAAB Aircraft Product Support, S-581.88, Linköping, Sweden. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT:

Rosanne Ryburn, Aerospace Engineer; International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2139; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date

for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002-NM-182-AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-182-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

Discussion

The Luftfartsverket (LFV), which is the airworthiness authority for Sweden, notified the FAA that an unsafe condition may exist on certain Saab Model SAAB SF340A and SAAB 340B series airplanes. The LFV advises that it has received reports of failures of the retract actuator bracket attachment bolt (RABAB) of the main landing gear (MLG) due to hydrogen embrittlement. This can be caused by failure to fully de-embrittle after electroplating the RABAB during manufacture. This condition, if not corrected, could result in loosening of the retract actuator bracket and consequent failure of the MLG to retract, with considerable damage to other landing gear parts, including the MLG trunnion fitting.

Explanation of Relevant Service Information

Saab has issued Service Bulletin 340-32-124, Revision 01, dated May 21, 2002, including as Attachments 1 and 2, APPH Ltd. Service Bulletins AIR83022-32-28 and AIR83064-32-08, both dated January 2002, which describes procedures for replacement of the RABAB with a new RABAB.

Saab has also issued Service Bulletin 340-32-125, dated April 29, 2002, including as Attachments 1 and 2, APPH Ltd. Service Bulletins AIR83022-32-29 and AIR83064-32-09, both dated April 2002, which describes procedures for reidentification of the MLG shock strut.

Accomplishment of the actions specified in the service bulletins is intended to adequately address the identified unsafe condition. The LFV classified these service bulletins as mandatory and issued Swedish airworthiness directive 1-173, dated March 4, 2002, to ensure the continued airworthiness of these airplanes in Sweden.

FAA's Conclusions

These airplane models are manufactured in Sweden and are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the LFV has kept the FAA informed of the situation described above. The FAA has examined the findings of the LFV, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in the Saab service bulletins described previously.

Cost Impact

The FAA estimates that 281 airplanes of U.S. registry would be affected by this proposed AD, that it would take approximately 7 work hours per airplane to accomplish the proposed actions, and that the average labor rate is \$65 per work hour. Required parts would be supplied at no cost by the manufacturer. Based on these figures,

the cost impact of the proposed AD on U.S. operators is estimated to be \$127,855, or \$455 per airplane.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Saab Aircraft AB: Docket 2002-NM-182-AD.

Applicability: Model SAAB SF340A series airplanes, serial numbers (S/Ns) 004 through 159 inclusive; and Model SAAB 340B series airplanes, S/Ns 160 through 459 inclusive; certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To prevent failure of the retract actuator bracket attachment bolt (RABAB) and in loosening of the retract actuator bracket and consequent failure of the MLG to retract, with considerable damage to other landing gear parts, including the MLG trunnion fitting, accomplish the following:

Replacement/Reidentification

(a) Within 12 months after the effective date of this AD, perform the actions specified in paragraphs (a)(1) and (a)(2) of this AD.

(1) Replace the existing RABAB with a new RABAB in accordance with the Accomplishment Instructions of Saab Service Bulletin 340-32-124, Revision 01, dated May 21, 2002, including Attachments 1 and 2, both dated January 2002.

Note 1: APPH Ltd. Service Bulletins AIR83022-32-28 and AIR83064-32-08, both dated January 2002, comprising Attachments 1 and 2, are incorporated into Saab Service Bulletin 340-32-124 as additional sources of service information.

(2) Reidentify the MLG shock strut by replacing the nameplate with a new nameplate, or adding the Source Control Number to the existing nameplate; in accordance with the Accomplishment Instructions of Saab Service Bulletin 340-32-125, dated April 29, 2002, including Attachments 1 and 2, both dated April 2002.

Note 2: APPH Ltd. Service Bulletins AIR83022-32-29 and AIR83064-32-09, both dated April 2002, comprising Attachments 1 and 2, are incorporated into Saab Service Bulletin 340-32-125 as additional sources of service information.

Parts Installation

(b) As of the effective date of this AD, no person may install a RABAB, part number (P/N) AIR83022-5 through -18, or P/N AIR83064 (any suffix), on any airplane.

Special Flight Permits

(c) Special flight permits are not allowed as specified in section 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199).

Alternative Methods of Compliance

(d) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM-116, FAA, is authorized to approve alternative methods of compliance (AMGCs) for this AD.

Note 3: The subject of this AD is addressed in Swedish airworthiness directive 1-173, dated March 4, 2002.

Issued in Renton, Washington, on April 6, 2004.

Kevin M. Mullin,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 04-8537 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION**Federal Aviation Administration****14 CFR Part 39**

[Docket No. 2003-NM-94-AD]

RIN 2120-AA64

Airworthiness Directives; BAE Systems (Operations) Limited Model BAe 146 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to all BAE Systems (Operations) Limited Model BAe 146 series airplanes. This proposal would require repetitive detailed inspections of the inside of each air conditioning sound-attenuating duct, and corrective actions as necessary. This action is necessary to prevent impairment of the operational skills and abilities of the flightcrew caused by the inhalation of agents released from oil or oil breakdown products, which could result in reduced controllability of the airplane. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by May 17, 2004.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-94-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227-1232. Comments may also be sent via the Internet using the following address: 9-anm-nprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2003-NM-94-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from British Aerospace Regional Aircraft American Support, 13850 Mclearen Road, Herndon, Virginia 20171. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT:

Todd Thompson, Aerospace Engineer, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-1175; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:**Comments Invited**

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2003-NM-94-AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-94-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

Discussion

The Civil Aviation Authority (CAA), which is the airworthiness authority for the United Kingdom, notified the FAA that an unsafe condition may exist on all BAE Systems (Operations) Limited Model BAe 146 series airplanes. The CAA advises that incidents have been reported involving impaired performance of the flightcrew. The impaired performance may have resulted from the flightcrew's inhalation of agents released from the breakdown of oil, which leaked and contaminated the environmental control system; or from unidentified cabin/flight deck odors. The preliminary investigations did not provide substantiating evidence indicating that the inhalation of oil or oil breakdown products could impair flightcrew performance. However, more extensive investigations are being done to determine the nature of any agents that may be released into the cabin/flight deck environments and to identify any necessary corrective actions. While these investigations are being done, oil leaks and cabin/flight deck odors should be regarded as potential threats to flight safety. The possibility of odors and toxic fumes entering the cabin/flight deck, if not corrected, could result in impairment of the operational skills and abilities of the flightcrew, caused by the inhalation of agents released from oil or oil breakdown products, which could result in reduced controllability of the airplane.

Explanation of Relevant Service Information

BAE Systems (Operations) Limited has issued Inspection Service Bulletin ISB.21-156, dated October 31, 2002, which describes procedures for repetitive inspections of each air conditioning sound-attenuating duct for the presence of oil contamination, and corrective action as necessary. These procedures include inspecting for signs of contamination on the inside of the mixing chamber duct/filter housing of each air conditioning sound-attenuating duct. The service bulletin also includes the criteria for distinguishing between normal contamination and oil contamination on the inside of the ducts to determine if a duct should be considered contaminated. The rejection criteria include:

- Squeezing the inner and outer skins of the sound-attenuating duct together. Any evidence of oil seepage through the inner surface of the duct is unacceptable.

- Using the sense of smell. Any strong and obvious odor of oil, sweaty socks, "locker rooms," or rancid cheese may indicate the presence of oils or oil breakdown products. The service bulletin recommends that operators determine if any odor from the duct is consistent with previous flightcrew or passenger complaints of odor in the flight deck/cabin.

The corrective actions include replacing any contaminated sound-attenuating duct with new parts, and cleaning the mixing chamber duct/filter housing.

The CAA classified this service bulletin as mandatory and issued British airworthiness directive 003-10-2002 to ensure the continued airworthiness of these airplanes in the United Kingdom.

Related AD

The FAA has issued a related AD, AD 2004-05-11, amendment 39-13506 (69 FR 11297, March 10, 2004), which is applicable to all BAE Systems (Operations) Limited Model BAe 146 series airplanes. Among other things, that AD requires repetitive general visual inspections of the inside of the condenser regenerative air ducts, air cycle machine turbine outlet, and the jet pump ducts on each air conditioning pack to detect oil and/or oil breakdown products. This action proposes a detailed inspection of the inside of each of the four air conditioning sound-attenuating ducts for the presence of contamination from oil and/or oil breakdown products on the same model airplanes.

FAA's Conclusions

This airplane model is manufactured in the United Kingdom and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the CAA has kept the FAA informed of the situation described above. The FAA has examined the findings of the CAA, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed AD

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in the service bulletin described previously, except as discussed below.

Differences Among the British Airworthiness Directive, Service Bulletin, and Proposed AD

The British airworthiness directive and the service bulletin both specify that the inspection should be done at the next "A-check," or within 500 flights after November 30, 2002; and repeated at every "C-check." Because "A-check" and "C-check" schedules vary among operators, this proposed AD would require accomplishment of the inspection within 120 days or 500 flight cycles after the effective date of this proposed AD, whichever is first, and repetitive inspections thereafter at intervals not to exceed 4,000 flight cycles. We find that a compliance time of 120 days or 500 flight cycles after the effective date of the AD, whichever is first, and repetitive inspections thereafter at intervals not to exceed 4,000 flight cycles, are appropriate for affected airplanes to continue to operate without compromising safety. Although the Accomplishment Instructions of the service bulletin specify to report inspection results to the manufacturer, this proposed AD does not require that action.

Clarification of Type of Inspection

The British airworthiness directive and the service bulletin specify that operators do an inspection of the inside of each air conditioning sound-attenuating duct. This proposed AD requires a "detailed" inspection. Note 1 has been included in this proposed AD to define this type of inspection.

Interim Action

This is considered to be interim action until final action is identified, at which time the FAA may consider further rulemaking.

Cost Impact

We estimate that 20 airplanes of U.S. registry would be affected by this proposed AD, and that it would take approximately 5 work hours per airplane to accomplish the proposed inspections. The average labor rate is \$65 per work hour. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be

\$6,500, or \$325 per airplane, per inspection cycle.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES**.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

BAE Systems (Operations) Limited
(Formerly British Aerospace Regional Aircraft); Docket 2003-NM-94-AD.

Applicability: All Model BAe 146 series airplanes, certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To prevent impairment of the operational skills and abilities of the flightcrew caused by the inhalation of agents released from oil or oil breakdown products, which could result in reduced controllability of the airplane, accomplish the following:

Repetitive Inspections and Corrective Action

(a) Within 120 days or 500 flight cycles after the effect date of this AD, whichever is first: Do a detailed inspection of the inside of each of the four air conditioning sound-attenuating ducts for the presence of oil contamination, and corrective actions as applicable. Do all of the applicable actions per BAE Systems (Operations) Limited Inspection Service Bulletin ISB.21-156, dated October 31, 2002. Any corrective action must be done before further flight. Repeat the inspection thereafter at intervals not to exceed 4,000 flight cycles.

Note 1: For the purposes of this AD, a detailed inspection is defined as: "An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required."

Submission of Information Not Required

(b) Although the service bulletin specifies to report inspection results to the manufacturer, this AD does not include such a requirement.

Alternative Methods of Compliance

(c) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM-116, FAA, Transport Airplane Directorate, is authorized to approve alternative methods of compliance for this AD.

Note 2: The subject of this AD is addressed in British airworthiness directive 003-10-2002.

Issued in Renton, Washington, on April 6, 2004.

Kevin M. Mullin,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.
[FR Doc. 04-8536 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2003-NM-235-AD]

RIN 2120-AA64

Airworthiness Directives; Short Brothers Model SD3-SHERPA Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to certain Short Brothers Model SD3-SHERPA series airplanes. This proposal would require a repetitive detailed inspection of the stub wing shear decks for corrosion and abnormal wear on and around the retaining pin in the main landing gear (MLG) forward pintle pin; and corrective action, if necessary. This proposed AD also provides an optional terminating action. These actions are necessary to detect and correct corrosion and abnormal wear to the top and bottom shear decks, which could result in damage to the MLG and consequent reduced controllability of the airplane on landing. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by May 17, 2004.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-235-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227-1232. Comments may also be sent via the Internet using the following address: 9-anm-nprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2003-NM-235-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Short Brothers, Airworthiness & Engineering Quality, P.O. Box 241, Airport Road, Belfast BT3 9DZ, Northern Ireland. This information may

be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT:

Todd Thompson, Aerospace Engineer; International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-1175; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.

- For each issue, state what specific change to the proposed AD is being requested.

- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2003-NM-235-AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-235-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

Discussion

The Civil Aviation Authority (CAA), which is the airworthiness authority for the United Kingdom, notified the FAA that an unsafe condition may exist on certain Short Brothers Model SD3-SHERPA series airplanes. The CAA advises that a report has been received stating that corrosion and abnormal wear to the top and bottom shear decks was found on and around the retaining pin in the main landing gear (MLG) forward pintle pin, due to loss of the retaining pin circlip, which allowed migration of the retaining pin. This condition, if not corrected, could result in damage to the MLG and consequent reduced controllability of the airplane on landing.

Explanation of Relevant Service Information

Short Brothers has issued Short Brothers Service Bulletin SD3 SHERPA-53-6, dated May 2003, which describes procedures for repetitive detailed inspections of the stub wing shear decks for corrosion and abnormal wear on and around the retaining pin in the MLG forward pintle pin; and corrective action, if necessary. The corrective action involves blending out corrosion, installing bushings in the affected shear deck, performing a visual inspection of the MLG pintle pin and sleeve for defects, and repairing any defects, as applicable. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition. The CAA classified this service bulletin as mandatory and issued airworthiness directive 004-05-2003, dated August 2003, to ensure the continued airworthiness of these airplanes in the United Kingdom.

Short Brothers has also issued Service Bulletin SD3 SHERPA-32-4, dated July 2003. That service bulletin describes procedures for replacement of the retaining pin and circlip with a new retaining pin, washer, castellated nut, and cotter pin, which would eliminate the need for repetitive detailed inspections of that retaining pin.

FAA's Conclusions

This airplane model is manufactured in the United Kingdom and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the CAA has kept the FAA informed of the situation described above. The FAA has

examined the findings of the CAA, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in Short Brothers Service Bulletin SD3 SHERPA-53-6 described previously, except as discussed below.

Differences Among Proposed Rule, British Airworthiness Directive, and Referenced Service Bulletin

Although Service Bulletin SD3 SHERPA-53-6 specifies that operators may contact the manufacturer for disposition of certain corrective actions, this proposal would require operators to perform those actions per a method approved by either the FAA or the CAA or its delegated agent. In light of the type of repair that would be required to address the unsafe condition, and consistent with existing bilateral airworthiness agreements, we have determined that, for this proposed AD, a repair approved by either the FAA or the CAA (or its delegated agent) would be acceptable for compliance with this proposed AD.

Operators should note that, although the referenced service bulletin describes procedures for reporting inspection results to the manufacturer, this proposed AD would not require that action. The FAA does not need this information from operators.

Operators should note that the British airworthiness directive specifies that initial inspection of the stub wing shear decks for corrosion and abnormal wear on and around the retaining pin in the MLG forward pintle pin should be accomplished no later than October 31, 2003 (which equates to a compliance time of 3 months after the effective date of the British airworthiness directive). In developing an appropriate compliance time for this proposed AD, the FAA considered not only the safety implications and the CAA's recommendations, but also the manufacturer's recommendations. In light of all of these factors, the FAA finds that the initial inspection must be accomplished within 6 months after the effective date of this AD, which represents an appropriate interval of time allowable for affected airplanes to

continue to operate without compromising safety.

Cost Impact

The FAA estimates that 16 airplanes of U.S. registry would be affected by this proposed AD, that it would take approximately 13 work hours per airplane per inspection to accomplish the proposed repetitive inspections, and that the average labor rate is \$65 per work hour. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be \$13,520, or \$845 per airplane, per inspection.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

If an operator chooses to accomplish the optional terminating action rather than continue the repetitive detailed inspections, it would take about 12 work hours per stub wing (2 stub wings per airplane) to accomplish the replacement of the retaining pin and circlip with a new retaining pin with castellated nut and cotter pin; at an average labor rate of \$65 per work hour. Required parts would cost about \$2,400 per stub wing. Based on these figures, we estimate the cost of this optional terminating action to be \$6,360 per airplane.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory

Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Short Brothers PLC: Docket 2003–NM–235–AD.

Applicability: Model SD3–SHERPA series airplanes, except those which have embodied Short Brothers Service Bulletin SD3 SHERPA–32–4, dated July 2003; certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To detect and correct corrosion and abnormal wear to the top and bottom shear decks, which could result in damage to the main landing gear (MLG) and consequent reduced controllability of the airplane on landing, accomplish the following:

Repetitive Inspections

(a) Within 6 months after the effective date of this AD, and continuing at intervals not to exceed 6 months, perform a detailed inspection of the stub wing shear decks to detect corrosion and/or abnormal wear according to the Accomplishment Instructions of Short Brothers Service Bulletin SD3 SHERPA–53–6, dated May 2003.

Note 1: For the purposes of this AD, a detailed inspection is defined as: "An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required."

Repair

(b) If any corrosion and/or abnormal wear is discovered during the inspection required

by paragraph (a) of this AD, before further flight, perform corrective actions in accordance with the Accomplishment Instructions of Short Brothers Service Bulletin SD3 SHERPA–53–6, dated May 2003, Part B and/or Part C as applicable; except where the service bulletin specifies that operators should contact the manufacturer for disposition of certain repair conditions, before further flight, repair those conditions per a method approved by the Manager, International Branch, ANM116, Transport Airplane Directorate, FAA; or the UK-CAA or its delegated agent.

Optional Terminating Action

(c) Performance of the optional terminating action, which includes replacement of the retaining pin and circlip with a new retaining pin, washer, castellated nut and cotter pin per the Accomplishment Instructions of Short Brothers Service Bulletin SD3 SHERPA–32–4, dated July 2003, terminates the requirement for repetitive detailed inspections specified in paragraph (a) of this AD.

No Reporting Requirement

(d) Operators should note that, although Short Brothers Service Bulletin SD3 SHERPA–53–6, dated May 2003, describes procedures for reporting inspection results to the manufacturer, this AD does not require that action.

Alternative Methods of Compliance

(e) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM116, FAA, Transport Airplane Directorate, is authorized to approve alternative methods of compliance for this AD.

Note 2: The subject of this AD is addressed in British airworthiness directive 004–05–2003, dated August 2003.

Issued in Renton, Washington, on April 1, 2004.

Kalene C. Yanamura,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.
[FR Doc. 04–8534 Filed 4–14–04; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA–2004–16963; Airspace Docket No. 04–AGL–01]

Proposed Modification of class E Airspace; Urbana, OH

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This document proposes to modify Class E airspace at Urbana, Ohio. Standard Instrument Approach Procedures (SIAPS) have been developed for Grimes Field, Urbana,

Ohio. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing these approaches. This action would increase the area of the existing controlled airspace for Grimes Field.

DATES: Comments must be received on or before May 31, 2004.

ADDRESSES: Send comments on the proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590-0001. You must identify the docket Number FAA-2004-16963/Airspace Docket No. 04-AGL-01, at the beginning of your comments. You may also submit comments on the internet at <http://dms.dot.gov>. You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Dockets Office between 9 am. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Office (telephone 1-800-647-5527) is on the plaza level of the Department of Transportation NASSIF Building at the above address.

An informal docket may also be examined during normal business hours at the office of the Regional Air Traffic Division, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018.

FOR FURTHER INFORMATION CONTACT: Patricia A. Graham, Air Traffic Division, Airspace Branch, AGL-520, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018, telephone (847) 294-7568.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal. Communications should identify both docket numbers and be submitted in triplicate to the address listed above. Commenters wishing the FAA to acknowledge receipt of their comments on this document must submit with those comments a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket No. FAA-2004-16963/Airspace Docket No. 04-AGL-

01." The postcard will be date/time stamped and returned to the commenter. All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained in this action may be changed in light of comments received. All comments submitted will be available for examination in the Rules Docket, FAA, Great Lakes Region, Office of the Regional Counsel, 2300 East Devon Avenue, Des Plaines, Illinois, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of NPRM's

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's Web page at <http://www.faa.gov> or the Superintendent of Document's Web page at <http://www.access.gpo.gov/nara>.

Additionally, any person may obtain a copy of this notice by submitted a request to the Federal Aviation Administration, Office of Air Traffic Airspace Management, ATA-400, 800 Independence Avenue, SW., Washington, DC 20591, or by calling (202) 267-8783. Communications must identify both docket numbers for this notice. Persons interested in being placed on a mailing list for future NPRM's should contact the FAA's Office of Rulemaking, (202) 267-9677, to request a copy of Advisory Circular No. 11-2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedure.

The Proposal

The FAA is considering an amendment to 14 CFR part 71 to modify Class E airspace at Wilmington Clinton Field, OH, for Wilmington Clinton Field. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing instrument approach procedures. The area would be depicted on appropriate aeronautical charts. Class E airspace areas extending upward from 700 feet or more above the surface of the earth are published in paragraph 6005 of FAA Order 7400.9L dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E designations listed in this document would be published subsequently in the Order.

The FAA has determined that this proposed regulation only involves an establishment body of technical regulations for which frequent and routing amendments are necessary to keep them operationally current. Therefore this, proposed regulation—(1) Is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9L, Airspace Designations and Reporting Points, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

* * * * *

Paragraph 6005 Class E Airspace Areas Extending Upward From 700 Feet or More Above the Surface of the Earth.

* * * * *

AGL OH E5 Urbana, OH [Revised]

Urbana, Grimes Field, OH
(Lat. 40°07'57" N., long. 83°45'12" W.)

That airspace extending upward from 700 feet above the surface within an 8.2-mile radius of Urbana, Grimes Field, excluding that airspace within the Dayton, OH Class E airspace area.

* * * * *

Issued in Des Plaines, Illinois, on March 17, 2004.

Nancy B. Shelton,

Manager, Air Traffic Division, Great Lakes Region.

[FR Doc. 04-8510 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2004-17095; Airspace Docket No. 04-AGL-04]

Proposed Modification of Class E Airspace; Kalamazoo, MI

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This document proposes to modify Class E airspace at Kalamazoo, MI. A Global Positioning System (GPS) Standard Instrument Approach Procedure (SIAP) 150° helicopter point in space approach, has been developed for Burgess Hospital, Kalamazoo, MI. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing this approach. This action would increase the area of the existing controlled airspace for Kalamazoo/Battle Creek International Airport.

DATES: Comments must be received on or before May 31, 2004.

ADDRESSES: Send comments on the proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590-0001. You must identify the docket number FAA-2004-17095/Airspace Docket No. 04-AGL-04, at the beginning of your comments. You may also submit comments on the internet at <http://dms.dot.gov>. You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Dockets Office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Office (telephone 1-800-647-5527) is on the plaza level of the Department of Transportation NASSIF Building at the above address.

An informal docket may also be examined during normal business hours at the office of the Regional Air Traffic Division, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018.

FOR FURTHER INFORMATION CONTACT: Patricia A. Graham, Air Traffic Division, Airspace Branch, AGL-520, Federal

Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018. telephone (847) 294-7568.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal.

Communications should identify both docket numbers and be submitted in triplicate to the address listed above. Comments wishing the FAA to acknowledge receipt of their comments on this document must submit with those comments a self-addressed, stamped postcard on which the following statement is made:

"Comments to Docket No. FAA-2004-17095/Airspace Docket No. 04-AGL-04." The postcard will be date/time stamped and returned to the commenter. All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained in this action may be changed in light of comments received. All comments submitted will be available for examination in the Rules Docket, FAA, Great Lakes Region, Office of the Regional Counsel, 2300 East Devon Avenue, Des Plaines, Illinois, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of NPRM's

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's Web page at <http://www.faa.gov> or the Superintendent of Document's Web page at <http://www.access.gpo.gov/nara>.

Additionally, any person may obtain a copy of this notice by submitting a request to the Federal Aviation Administration, Office of Air Traffic Airspace Management, ATA-400, 800 Independence Avenue, SW., Washington, DC 20591, or by calling (202) 267-8783. Communications must identify both docket numbers for this notice. Persons interested in being

placed on a mailing list for future NPRM's should contact the FAA's Office of Rulemaking, (202) 267-9677, to request a copy of Advisory Circular No. 11-2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedure.

The Proposal

The FAA is considering an amendment to 14 CFR part 71 to modify Class E airspace at Kalamazoo, MI, for Kalamazoo/Battle Creek International Airport. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing instrument approach procedures. The area would be depicted on appropriate aeronautical charts. Class E airspace areas extending upward from 700 feet or more above the surface of the earth are published in paragraph 6005 of FAA Order 7400.9L dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E designations listed in this document would be published subsequently in the Order.

The FAA has determined that this proposed regulation only involves an establishment body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore this, proposed regulation—(1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9L, Airspace Designations and Reporting Points, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

* * * * *

Paragraph 6005 Class E Airspace Areas Extending Upward From 700 Feet or More Above the Surface of the Earth

* * * * *

AGL MI E5 Kalamazoo, MI [Revised]

Kalamazoo/Battle Creek International Airport, MI
(Lat. 42°14'06" N., long. 85°33'07" W.)
Kalamazoo, Burgess Hospital, MI
Point in Space Coordinates
(Lat. 42°19'44" N., long. 85°34'47" W.)

That airspace extending upward from 700 feet above the surface within a 6.6-mile radius of the Kalamazoo/Battle Creek International Airport and within a 6-mile radius of the Point in space serving the Burgess Hospital.

* * * * *

Issued in Des Plaines, Illinois, on March 17, 2004.

Nancy B. Shelton,

Manager, Air Traffic Division, Great Lakes Region.

[FR Doc. 04-8509 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2004-17094; Airspace Docket No. 04-AGL-03]

Proposed Establishment of Class E Airspace; Northwood, ND

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This document proposes to establish Class E airspace at Northwood, ND. A Standard Instrument Approach Procedure (SIAP) has been developed for Northwood Municipal-Vince Field Airport, Northwood, ND. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing this approach. This action would establish an area of the controlled airspace for Northwood Municipal-Vince Field Airport.

DATES: Comments must be received on or before May 31, 2004.

ADDRESSES: Send comments on the proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590-0001. You must identify the docket Number FAA-2004-17094/Airspace Docket No. 04-AGL-03, at the beginning of your comments. You may also submit comments on the Internet at <http://dms.dot.gov>. You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Dockets Office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Office (telephone 1-800-647-5527) is on the plaza level of the Department of Transportation NASSIF Building at the above address.

An informal docket may also be examined during normal business hours at the office of the Regional Air Traffic Division, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018.

FOR FURTHER INFORMATION CONTACT: Patricia A. Graham, Air Traffic Division, Airspace Branch, AGL-520, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018, telephone (847) 294-7568.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal. Communications should identify both docket numbers and be submitted in triplicate to the address listed above. Commenters wishing the FAA to acknowledge receipt of their comments on this document must submit with those comments a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket No. FAA-2004-17094/Airspace Docket No. 04-AGL-03." The postcard will be date/time stamped and returned to the commenter. All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained

in this action may be changed in light of comments received. All comments submitted will be available for examinations in the Rules Docket, FAA Great Lakes Region, Office of the Regional Counsel, 2300 East Devon Avenue, Des Plaines, Illinois, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of NPRM's

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's Web page at <http://www.faa.gov> or the Superintendent of Document's Web page at <http://www.access.gpo.gov/nara>.

Additionally, any person may obtain a copy of this notice by submitting a request to the Federal Aviation Administration, Office of Air Traffic Airspace Management ATA-400, 800 Independence Avenue, S.W., Washington, DC 20591, or by calling (202) 267-8783. Communications must identify both docket numbers for this notice. Persons interested in being placed on a mailing list for future NPRM's should contact the FAA's Office of Rulemaking, (202) 267-9677, to request a copy of Advisory Circular No. 11-2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedure.

The Proposal

The FAA is considering an amendment to 14 CFR part 71 to establish Class E airspace at Northwood, ND, for Northwood Municipal-Vince Field Airport. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing instrument approach procedures. The area would be depicted on appropriate aeronautical charts. Class E airspace areas extending upward from 700 feet or more above the surface of the earth are published in paragraph 6005 of FAA Order 7400.9L dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E designations listed in this document would be published subsequently in the Order.

The FAA has determined that this proposed regulation only involves an establishment body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore this proposed regulation—(1) is not a "significant regulatory action"

under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9L, Airspace Designations and Reporting Points, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

* * * * *

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AGL ND E5 Northwood, ND [New]

Northwood, Northwood Municipal-Vince Field Airport, ND
(Lat. 47°43'27" N., long. 97°35'26" W.)

That airspace extending upward from 700 feet above the surface within a 6.3-mile radius of the Northwood Municipal-Vince Field Airport.

* * * * *

Issued in Des Plaines, Illinois, on March 17, 2004.

Nancy B. Shelton,
Manager, Air Traffic Division, Great Lakes Region.

[FR Doc. 04–8508 Filed 4–14–04; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA–2004–17096; Airspace Docket No. 04–AGL–05]

Proposed Modification of Class E Airspace: South Haven, MI

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This document proposes to modify Class E airspace at South Haven, MI. A Global Positioning System (GPS) Standard Instrument Approach Procedure (SIAP) 160° helicopter point in space approach, has been developed for Watervliet Community Hospital, Watervliet, MI. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing this approach. This action would increase the area of the existing controlled airspace for South Haven Regional Airport.

DATES: Comments must be received on or before May 31, 2004.

ADDRESSES: Send comments on the proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590–0001. You must identify the docket number FAA–2004–17096/Airspace Docket No. 04–AGL–05, at the beginning of your comments. You may also submit comments on the internet at <http://dms.dot.gov>. You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Dockets Office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Office (telephone 1–800–647–5527) is on the plaza level of the Department of Transportation NASSIF Building at the above address.

An informal docket may also be examined during normal business hours at the Office of the Regional Air Traffic Division, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018.

FOR FURTHER INFORMATION CONTACT: Patricia A. Graham, Air Traffic Division, Airspace Branch, AGL–520, Federal Aviation Administration, 2300 East Devon Avenue, Des Plaines, Illinois 60018, telephone (847) 294–7568.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking

by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic environmental, and energy-related aspects of the proposal. Communications should identify both docket numbers and be submitted in triplicate to the address listed above. Commenters wishing the FAA to acknowledge receipt of their comments on this document must submit with those comments a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket No. FAA–2004–17096 Airspace Docket No. 04–AGL–05." The postcard will be date/time stamped and returned to the commenter. All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained in this action may be changed in light of comments received. All comments submitted will be available for examination in the Rules Docket, FAA, Great Lakes Region, Office of the Regional Counsel, 2300 East Devon Avenue, Des Plaines, Illinois, both before and after the closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of NPRM's

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's Web page at <http://www.faa.gov> or the Superintendent of Document's Web page at <http://www.access.gpo.gov/nara>.

Additionally, any person may obtain a copy of this notice by submitting a request to the Federal Aviation Administration, Office of Air Traffic Airspace Management, ATA–400, 800 Independence Avenue, SW., Washington, DC 20591, or by calling (202) 267–8783. Communications must identify both docket numbers for this notice. Persons interested in being placed on a mailing list for future NPRM's should contact the FAA's Office of Rulemaking, (202) 267–9677, to request a copy of Advisory Circular No. 11–2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedure.

The Proposal

The FAA is considering an amendment to 14 CFR part 71 to modify Class E airspace at South Haven, MI, for South Haven Area Regional Airport. Controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing instrument approach procedures. The area would be depicted on appropriate aeronautical charts. Class E airspace areas extending upward from 700 feet or more above the surface of the earth are published in paragraph 6005 of FAA Order 7400.9L dated September 2, 2003, and effective September 16, 2003, which is incorporated by reference in 14 CFR 71.1. The Class E designations listed in this document would be published subsequently in the Order.

The FAA has determined that this proposed regulation only involves an establishment body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore this, proposed regulation—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; AIRWAYS; ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation

Administration Order 7400.9L, Airspace Designations and Reporting Points, dated September 23, 2003, and effective September 16, 2003, is amended as follows:

* * * * *

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AGL MI E5 South Haven, MI [Revised]

South Haven Area Regional Airport, MI (Lat. 42°21'03" N., long. 86°15'22" W.) Pullman VORTAC

(Lat. 42°27'56" N., long. 86°06'21" W.)

Watervliet, Watervliet Community Hospital, MI—Point in Space Coordinates

(Lat. 39°37'53" N., long. 86°48'50" W.)

That airspace extending upward from 700 feet above the surface within a 6.6-mile radius of South Haven Area Regional Airport and within 1.3 miles each side of the Pullman VORTAC 224° radial extending from the 6.6-mile radius of the VORTAC, and within a 6.6-mile radius of the Point in space serving the Watervliet Community Hospital, excluding that airspace within the South Bend, IN, Class E airspace area.

* * * * *

Issued in Des Plaines, Illinois, on March 17, 2004.

Nancy B. Shelton,

Manager, Air Traffic Division, Great Lakes Region.

[FR Doc. 04–8507 Filed 4–14–04; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA–2003–16091; Airspace Docket No. 03–ACE–74]

RIN 2120–AA66

Proposed Establishment of Jet Route 187 and Revision of Jet Routes 180 and 181; MO

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This action proposes to establish Jet Route 187 (J–187) from the Memphis, TN, Very High Frequency Omni-directional Range/Tactical Air Navigation (VORTAC) to the Foristell, MO, VORTAC. This action also proposes to extend J–180 from the Little Rock, AR, VORTAC to the Foristell VORTAC and realign J–181 between the Neosho Very High Frequency Omni-directional Range/Distance Measuring Equipment (VOR/DME) and the BAYLI

intersection. This proposed action would enhance the management of aircraft operations over the St. Louis, MO, area.

DATES: Comments must be received on or before June 1, 2004.

ADDRESSES: Send comments on this proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590–0001. You must identify FAA Docket No. FAA–2003–16091 and Airspace Docket No. 03–ACE–74 at the beginning of your comments. You may also submit comments on the Internet at <http://dms.dot.gov>.

FOR FURTHER INFORMATION CONTACT: Steve Rohring, Airspace and Rules, Office of System Operations and Safety, AT0–R, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone: (202) 267–8783.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal.

Communications should identify both docket numbers (FAA Docket No. FAA–2003–16091 and Airspace Docket No. 03–ACE–74) and be submitted in triplicate to the Docket Management System (see **ADDRESSES** section for address and phone number). You may also submit comments through the Internet at <http://dms.dot.gov>.

Commenters wishing the FAA to acknowledge receipt of their comments on this notice must submit with those comments a self-addressed, stamped postcard on which the following statement is made: “Comments to FAA Docket No. FAA–2003–16091 and Airspace Docket No. 03–ACE–74.” The postcard will be date/time stamped and returned to the commenter.

All communications received on or before the specified closing date for comments will be considered before taking action on the proposed rule. The proposal contained in this notice may be changed in light of comments received. All comments submitted will be available for examination in the public docket both before and after the

closing date for comments. A report summarizing each substantive public contact with FAA personnel concerned with this rulemaking will be filed in the docket.

Availability of NPRM's

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's Web page at <http://www.faa.gov>, or the Superintendent of Document's Web page at <http://www.gpoaccess.gov/fr/index.html>.

You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Docket Office (see ADDRESSES section for address and phone number) between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. An informal docket may also be examined during normal business hours at the office of the Regional Air Traffic Division, Federal Aviation Administration, Central Region Headquarters, 901 Locust, Kansas City, MO 64106-2641.

Persons interested in being placed on a mailing list for future NPRM's should call the FAA's Office of Rulemaking, (202) 267-9677, for a copy of Advisory Circular No. 11-2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedure.

History

As part of the National Airspace Redesign project, a review of aircraft operations has identified a need to revise the jet route structure over the St. Louis, MO, area. The FAA believes that establishing a new jet route, J-187, and revising the existing J-180 and J-181 would enhance the management of aircraft operations destined for the Lambert-St. Louis International Airport and the Chicago O'Hare International Airport.

The Proposal

The FAA is proposing an amendment to title 14 Code of Federal Regulations (14 CFR) part 71 (part 71) to establish J-187 and revise J-180 and J-181 in the St. Louis, MO, area. Specifically, this action proposes to establish J-187 from the Memphis, TN, VORTAC to the Foristell, MO, VORTAC. The FAA also proposes to revise J-180 by extending it from the Little Rock, AR, VORTAC to the Foristell VORTAC and to revise J-181 by realigning the segments between the Neosho Very High Frequency VOR/DME and the BAYLI intersection. This action would enhance the management

of aircraft operations over the St. Louis, MO, area.

The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this proposed regulation: (1) Is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under Department of Transportation (DOT) Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

In consideration of the foregoing, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of FAA Order 7400.9L, Airspace Designations and Reporting Points, dated September 2, 2003, and effective September 16, 2003, is amended as follows:

Paragraph 2004—Jet Routes

* * * * *

J-187 (New)

From Memphis, TN; Foristell, MO.
* * * * *

J-180 (Revised)

From Humble, TX; Daisetta, TX; Sawmill, LA; Little Rock, AR; Foristell, MO.
* * * * *

J-181 (Revised)

From Ranger, TX; Okmulgee, OK; Neosho, MO; Hallsville, MO; INT Hallsville 053°

(047°M) and Bradford, IL, 219° (219°M) radials; to Bradford.

* * * * *

Issued in Washington, DC, on March 30, 2004.

Reginald C. Matthews,

Manager, Airspace and Rules.

[FR Doc. 04-8506 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF AGRICULTURE

Forest Service

36 CFR Part 242

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

50 CFR Part 100

RIN 1018-AT58

Subsistence Management Regulations for Public Lands in Alaska

AGENCIES: Forest Service, Agriculture; Fish and Wildlife Service, Interior.

ACTION: Proposed rule.

SUMMARY: This proposed rule would clarify the membership qualifications for Federal Subsistence Regional Advisory Councils established under Subsistence Management Regulations. The rulemaking is necessary because of a judgment by the U.S. District Court for Alaska. The proposed rule would also remove the definition of "regulatory year" from Subpart A and place it in Subpart D of the regulations.

DATES: The Federal Subsistence Board must receive your written public comments on this proposed rule no later than June 1, 2004. Because the U.S. District Court is requiring prompt action on the membership qualifications for Regional Advisory Councils, no extension of this review deadline will be granted.

The Federal Subsistence Board will hold a public meeting on May 19, 2004, to receive comments on this proposed rule. See **SUPPLEMENTARY INFORMATION** for additional information on the public meeting.

ADDRESSES: You may submit electronic comments to Subsistence@fws.gov. See **SUPPLEMENTARY INFORMATION** for file formats and other information about electronic filing. You may submit written comments and proposals to the Office of Subsistence Management, 3601 C Street, Suite 1030, Anchorage, Alaska 99503.

FOR FURTHER INFORMATION CONTACT: Chair, Federal Subsistence Board, c/o

U.S. Fish and Wildlife Service, Attention: Thomas H. Boyd, Office of Subsistence Management; (907) 786-3888. For questions specific to National Forest System lands, contact Steve Kessler, Regional Subsistence Program Leader, USDA, Forest Service, Alaska Region, (907) 786-3592.

SUPPLEMENTARY INFORMATION:

Public Review Process—Regulation Comments and Public Meeting

Electronic filing of comments: You may submit electronic comments to Subsistence@fws.gov. Please submit your comments as either an MS Word or WordPerfect file, avoiding the use of any special characters and any form of encryption.

The Federal Subsistence Board (Board) will receive comments on this proposed rule during a public meeting to be held at the Millennium Alaska Hotel in Anchorage on May 19, 2004, at 1:30 p.m. You may provide oral testimony before the Board at that time. The Board will then review all comments received and forward its recommendations to the Secretary of the Interior and the Secretary of Agriculture (Secretaries) for final action.

Background

Title VIII of the Alaska National Interest Lands Conservation Act (ANILCA) (16 U.S.C. 3111-3126) requires that the Secretaries implement a program to grant a preference for subsistence uses of fish and wildlife resources on public lands, unless the State of Alaska enacts and implements laws of general applicability that are consistent with ANILCA and that provide for the subsistence definition, preference, and participation specified in Sections 803, 804, and 805 of ANILCA. The State implemented a program that the Department of the Interior previously found to be consistent with ANILCA. However, in December 1989, the Alaska Supreme Court ruled in *McDowell v. State of Alaska* that the rural preference in the State subsistence statute violated the Alaska Constitution. The Court's ruling in *McDowell* required the State to delete the rural preference from the subsistence statute and, therefore, negated State compliance with ANILCA. The Court stayed the effect of the decision until July 1, 1990.

As a result of the *McDowell* decision, the Department of the Interior and the Department of Agriculture (Departments) assumed, on July 1, 1990, responsibility for implementation of Title VIII of ANILCA on public lands. On June 29, 1990, the Temporary Subsistence Management Regulations

for Public Lands in Alaska were published in the **Federal Register** (55 FR 27114). With the State unable to create a program in compliance with Title VIII by May 29, 1992, the Departments published a final rule in the **Federal Register** (57 FR 22940). On January 8, 1999 (64 FR 1276), the Departments published a final rule to extend jurisdiction to include waters in which there exists a Federal reserved water right. This amended rule became effective October 1, 1999, and conformed the Federal Subsistence Management Program to the Ninth Circuit's ruling in *Alaska v. Babbitt*. Consistent with Subparts A, B, and C of these regulations, as revised January 8, 1999 (64 FR 1276), the Departments established a Federal Subsistence Board (Board) to administer the Federal Subsistence Management Program. The Board's composition includes a Chair appointed by the Secretary of the Interior with concurrence of the Secretary of Agriculture; the Alaska Regional Director, U.S. Fish and Wildlife Service; the Alaska Regional Director, U.S. National Park Service; the Alaska State Director, U.S. Bureau of Land Management; the Alaska Regional Director, U.S. Bureau of Indian Affairs; and the Alaska Regional Forester, USDA Forest Service. Through the Board, these agencies participate in the development of Federal Subsistence Management Regulations (Subparts A, B, C, and D).

The Board has reviewed this proposed rule. Because this rule relates to public lands managed by an agency or agencies in both the Departments of Agriculture and the Interior, identical text will be incorporated into 36 CFR part 242 and 50 CFR part 100.

Applicability of Subparts A, B, and C

Subparts A, B, and C (unless otherwise amended) of the Subsistence Management Regulations for Public Lands in Alaska, 50 CFR 100.1 to 100.24 and 36 CFR 242.1 to 242.24, remain effective and apply to this rule. Therefore, all definitions located at 50 CFR 100.4 and 36 CFR 242.4 will apply to regulations found in this subpart.

Federal Subsistence Regional Advisory Councils

Pursuant to the Record of Decision, Subsistence Management Regulations for Federal Public Lands in Alaska, April 6, 1992, and the Subsistence Management Regulations for Federal Public Lands in Alaska, 36 CFR 242.11 (1999) and 50 CFR 100.11 (1999), and for the purposes identified therein, Alaska is divided into 10 subsistence resource regions, each of which is represented by a Federal Subsistence

Regional Advisory Council (RAC). The Regional Councils provide a forum for rural residents with personal knowledge of local conditions and resource requirements to have a meaningful role in the subsistence management of fish and wildlife on Alaska public lands. The Regional Council members represent varied geographical areas, cultures, interests, and resource users within each region. A Regional Council member must be a resident of the region in which he or she is appointed and be knowledgeable about the region and subsistence uses of the public lands therein.

In 1998, Safari Club International and others filed suit in the U.S. District Court for the District of Alaska challenging the Board's customary and traditional use determination process, specific customary and traditional use determinations, and the balance of membership on the Regional Councils required by the Federal Advisory Committee Act (FACA) of 1972, Public Law 92-463, 86 Stat. 770, (*Safari Club v. Demientieff*, No. A98-0414-CV). In the meantime, the Secretary of the Interior, as part of a national review of advisory councils and in response to inquiries related to the Federal Subsistence Regional Advisory Councils in Alaska, requested the Board to examine its process for selecting nominees, and "see that" groups such as "residents of non-rural areas, commercial users of fish and wildlife resources and sportsmen are represented on the RACs." Based on Board recommendations coming from that in-depth examination, the Secretary of the Interior with concurrence of the Secretary of Agriculture in 2002 increased the size of nine of the Regional Councils; established the goal of making appointments to the Regional Council so as to achieve, where possible, a representation goal of 70% subsistence users and 30% sport/commercial users; revised the application/evaluation/selection process and forms; and approved a 3-year implementation period.

The Native Village of Venetie Tribal Government *et al.* were permitted to intervene in the Safari Club case and to challenge the 70/30 ratio representational goals established by the Secretaries. In January 2004, the U.S. District Court for Alaska entered an order dismissing the first two of Safari Club's claims and staying proceeding on the balance of Regional Council membership. The court did note in part with respect to the Regional Councils "that a council comprised of only subsistence users is not fairly balanced. Subsistence users are not the only

persons directly affected by regional advisory council recommendations and subsistence users are not the only persons who might be interested in the management of fish and wildlife on federal lands * * * Non-subsistence users of fish and wildlife are directly affected by management of fish and wildlife for subsistence uses and have a legitimate interest in the proper scientific management of same * * * While all points of view and all persons directly affected are not entitled to representation on a FACA committee, in this instance, a cross-section of those affected by fish and wildlife management on federal public lands must be, in a reasonable and fair manner, afforded representation on regional advisory councils."

In ruling on a cross-claim of the Native Village of Venetie, the Court invalidated the Secretaries' policy of a goal of a 70/30 (subsistence users/sport and commercial users) membership ratio for failure to procedurally comply with the provisions of the Administrative Procedure Act found at 5 U.S.C. 553, and found that the policy should have been put before the public for comment in a rulemaking process. The District Court also ordered that the Secretaries promptly initiate and conclude a rulemaking to promulgate an appropriate Regional Council regulation consistent with FACA after compliance with 5 U.S.C. 553. This rulemaking will provide a clear mechanism and focus for public comments either directly in writing, or orally at the May 2004 public hearing.

The underlying purpose of the proposed change to § ____ .11(b), while complying with the District Court's order, is to ensure continued compliance with both the fairly balanced representational requirements of FACA and the requirements and purposes of Title VIII of ANILCA in the appointments to the Regional Councils. In the proposed change, the Secretaries recognize that some persons with interests other than subsistence uses are entitled under FACA to be represented on the Regional Councils, while recognizing that Congress intended in Title VIII for rural Alaska residents "who have personal knowledge of local conditions and requirements * * * to have a meaningful role in the management of fish and wildlife and of subsistence uses on public lands in Alaska," and that Congress also intended that "large urban population centers" not be allowed to dominate the Regional Council system. The 70/30 representational goals of the proposed change to § ____ .11(b) would assure the appropriate representation and

meaningful majority role for rural Alaska residents, while providing an appropriate representation for the interests of nonrural residents and nonsubsistence users.

The proposed change to § ____ .11(b) would establish goals only in recognition that the actual appointments are dependent on the submission of applications by and nominations of highly qualified individuals, and the actual appointment by the Secretaries of specific individuals. The change would also require the Board to identify to the Secretaries the interest(s) that the applicant would represent. The Secretaries will retain their role in making the appointments to the Regional Councils. Other alternatives to the proposed change could be considered or could be developed based on comments received. However, the final action resulting in a change to § ____ .11(b) must be consistent with FACA and ANILCA.

Additionally, we propose that the definition of "regulatory year" for fish and shellfish fisheries be modified to mean April 1 through March 31, and that the placement of this definition be shifted from § ____ .4 to § ____ .25. This change in dates will allow more opportunity for development of public booklets informing subsistence users of regulatory changes, and the shift in placement of the definition within the regulations will allow the Board more flexibility to make adjustments in the future.

Conformance With Statutory and Regulatory Authorities

National Environmental Policy Act Compliance

A Draft Environmental Impact Statement (DEIS) for developing a Federal Subsistence Management Program was distributed for public comment on October 7, 1991. That document described the major issues associated with Federal subsistence management as identified through public meetings, written comments, and staff analysis, and examined the environmental consequences of four alternatives. Proposed regulations (Subparts A, B, and C) that would implement the preferred alternative were included in the DEIS as an appendix. The DEIS and the proposed administrative regulations presented a framework for an annual regulatory cycle regarding subsistence hunting and fishing regulations (Subpart D). The Final Environmental Impact Statement (FEIS) was published on February 28, 1992.

Based on the public comment received, the analysis contained in the FEIS, and the recommendations of the Federal Subsistence Board and the Department of the Interior's Subsistence Policy Group, the Secretary of the Interior, with the concurrence of the Secretary of Agriculture, through the U.S. Department of Agriculture-Forest Service, implemented Alternative IV as identified in the DEIS and FEIS (Record of Decision on Subsistence Management for Federal Public Lands in Alaska (ROD), signed April 6, 1992). The DEIS and the selected alternative in the FEIS defined the administrative framework of an annual regulatory cycle for subsistence hunting and fishing regulations. The final rule for Subsistence Management Regulations for Public Lands in Alaska, Subparts A, B, and C (57 FR 22940, published May 29, 1992, and amended January 8, 1999, 64 FR 1276; June 12, 2001, 66 FR 31533; May 7, 2002, 67 FR 30559; and February 18, 2003, 68 FR 7703) implemented the Federal Subsistence Management Program and included a framework for an annual cycle for subsistence hunting and fishing regulations.

Compliance With Section 810 of ANILCA

The intent of all Federal subsistence regulations is to accord subsistence uses of fish and wildlife on public lands a priority over the taking of fish and wildlife on such lands for other purposes, unless restriction is necessary to conserve healthy fish and wildlife populations. A Section 810 analysis was completed as part of the FEIS process. The final Section 810 analysis determination appeared in the April 6, 1992, ROD, which concluded that the Federal Subsistence Management Program may have some local impacts on subsistence uses, but the program is not likely to significantly restrict subsistence uses.

Paperwork Reduction Act

These proposed changes do not contain information collection requirements subject to Office of Management and Budget (OMB) approval under the Paperwork Reduction Act of 1995. We may not conduct or sponsor, and you are not required to respond to, an information collection request unless it displays a currently valid OMB control number.

Other Requirements

Economic Effects—This rule is not a significant rule subject to OMB review under Executive Order 12866. This rulemaking will impose no significant costs on small entities; this rule is

administrative in nature only and does not restrict any existing sport or commercial fishery on the public lands, and subsistence fisheries will continue at essentially the same levels as they presently occur. The number of businesses and the amount of trade that will result from this Federal land related activity is unknown but expected to be insignificant.

The Regulatory Flexibility Act of 1980 (5 U.S.C. 601 *et seq.*) requires preparation of flexibility analyses for rules that will have a significant economic effect on a substantial number of small entities, which include small businesses, organizations, or governmental jurisdictions. The Departments certify that this rulemaking will not have a significant economic effect on a substantial number of small entities within the meaning of the Regulatory Flexibility Act. Under the Small Business Regulatory Enforcement Fairness Act (5 U.S.C. 801 *et seq.*), this rule is not a major rule. It does not have an effect on the economy of \$100 million or more, will not cause a major increase in costs or prices for consumers, and does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises.

Title VIII of ANILCA requires the Secretaries to administer a subsistence priority on public lands. The scope of this program is limited by definition to certain public lands. Likewise, these regulations have no potential takings of private property implications as defined by Executive Order 12630.

The Secretaries have determined and certify pursuant to the Unfunded Mandates Reform Act, 2 U.S.C. 1502 *et seq.*, that this rulemaking will not impose a cost of \$100 million or more in any given year on local or State governments or private entities. The implementation of this rule is by Federal agencies and there is no cost imposed on any State or local entities or tribal governments.

The Secretaries have determined that these regulations meet the applicable standards provided in Sections 3(a) and 3(b)(2) of Executive Order 12988 regarding civil justice reform.

In accordance with Executive Order 13132, the rule does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. Title VIII of ANILCA precludes the State from exercising subsistence management authority over fish and wildlife resources on Federal lands unless their program meets certain requirements.

In accordance with the President's memorandum of April 29, 1994, "Government-to-Government Relations with Native American Tribal Governments" (59 FR 22951), Executive Order 13175, and 512 DM 2, we have evaluated possible effects on Federally recognized Indian tribes and have determined that there are no effects. The Bureau of Indian Affairs is a participating agency in this rulemaking.

On May 18, 2001, the President issued Executive Order 13211 on regulations that significantly affect energy supply, distribution, or use. This Executive Order requires agencies to prepare Statements of Energy Effects when undertaking certain actions. As this rule is not a significant regulatory action under Executive Order 13211, affecting energy supply, distribution, or use, this action is not a significant action and no Statement of Energy Effects is required.

Drafting Information

William Knauer drafted these regulations under the guidance of Thomas H. Boyd of the Office of Subsistence Management, Alaska Regional Office, U.S. Fish and Wildlife Service, Anchorage, Alaska. Taylor Brelsford, Alaska State Office, Bureau of Land Management; Greg Bos, Carl Jack, and Rod Simmons, Alaska Regional Office, U.S. Fish and Wildlife Service; Sandy Rabinowitch and Bob Gerhard, Alaska Regional Office, National Park Service; Warren Eastland and Dr. Glenn Chen, Alaska Regional Office, Bureau of Indian Affairs; and Steve Kessler, USDA-Forest Service, provided additional guidance.

List of Subjects

36 CFR Part 242

Administrative practice and procedure, Alaska, Fish, National forests, Public lands, Reporting and recordkeeping requirements, Wildlife.

50 CFR Part 100

Administrative practice and procedure, Alaska, Fish, National forests, Public lands, Reporting and recordkeeping requirements, Wildlife.

For the reasons presented in the preamble, the Federal Subsistence Board proposes to amend Title 36, part 242, and Title 50, part 100, of the Code of Federal Regulations, as set forth below.

PART ____—SUBSISTENCE MANAGEMENT REGULATIONS FOR PUBLIC LANDS IN ALASKA [AMENDED]

1. The authority citation for both 36 CFR part 242 and 50 CFR part 100 continues to read as follows:

Authority: 16 U.S.C. 3, 472, 551, 668dd, 3101–3126; 18 U.S.C. 3551–3586; 43 U.S.C. 1733.

2. In Subpart A of 36 CFR part 242 and 50 CFR part 100, § ____.4, the definition of "Regulatory year" is removed.

3. In Subpart B of 36 CFR part 242 and 50 CFR part 100, § ____.11(b) is revised to read as follows:

§ ____.11 Regional advisory councils.

(a) * * *

(b) *Establishment of Regional Councils; membership.* (1) The Board will establish the number of members for each Regional Council. To ensure that each Council represents a diversity of interests, the Board will strive to ensure that 70 percent of the members represent subsistence interests within a region and 30 percent of the members represent commercial and sport interests within a region. A Regional Council member must be a resident of the region in which he or she is appointed and must be knowledgeable about the region and subsistence uses of the public lands therein. The Board will accept nominations and make recommendations to the Secretaries for membership on the Regional Councils. In making their recommendations, the Board will identify the interest(s) the applicants propose to represent on the respective Regional Councils. The Secretary of the Interior with the concurrence of the Secretary of Agriculture will make the appointments to the Regional Councils.

* * * * *

4. In Subpart D of 36 CFR part 242 and 50 CFR part 100, § ____.25(a) is amended by adding the definition "Regulatory year" immediately before the definition "Ring net" to read as follows:

§ ____.25 Subsistence taking of fish, wildlife, and shellfish: general regulations.

(a) * * *

Regulatory year means July 1 through June 30, except for fish and shellfish for which it means April 1 through March 31.

* * * * *

Dated: April 9, 2004.
Gale A Norton,
Secretary of the Interior, Department of the Interior.

Dated: February 23, 2004.
Steven A. Brink,
Regional Forester, Acting, USDA-Forest Service.
 [FR Doc. 04-8569 Filed 4-14-04; 8:45 am]
 BILLING CODE 3410-11-P; 4310-55-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 22

[MD161-3110b; FRL-7648-2]

Approval and Promulgation of Air Quality Implementation Plans; Maryland; Revisions to the 2005 ROP Plan for the Cecil County Portion of the Philadelphia-Wilmington-Trenton 1-Hour Ozone Nonattainment Area to Reflect the Use of MOBILE6

AGENCY: Environmental Protection Agency (EPA).
ACTION: Proposed rule.

SUMMARY: EPA proposes to approve State Implementation Plan (SIP) revisions submitted by the State of Maryland. These revisions amend the 2005 rate-of-progress (ROP) plan in the Maryland SIP for the Cecil County portion of the Philadelphia-Wilmington-Trenton nonattainment severe 1-hour ozone nonattainment area (the Philadelphia area). The intent of these revisions is to update Cecil County's 2005 ROP plan's mobile emissions inventories and motor vehicle emissions budgets (MVEBs) to reflect the use of MOBILE6. In the Final Rules section of this *Federal Register*, EPA is approving the State's SIP submittal as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. A detailed rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties interested in commenting on this action should do so at this time.
DATES: Comments must be received in writing by May 17, 2004.

ADDRESSES: Submit your comments, identified by MD161-3110 by one of the following methods:

A. Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

B. E-mail: Budney.Larry@epa.gov.

C. Mail: Larry Budney, Mailcode 3AP23, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. MD161-3110. EPA's policy is that all comments received will be included in the public docket without change, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through [regulations.gov](http://www.regulations.gov) or e-mail. The Federal [regulations.gov](http://www.regulations.gov) Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through [regulations.gov](http://www.regulations.gov), your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and the Maryland Department of the Environment, 1800 Washington Boulevard, Suite 705, Baltimore, Maryland, 21230.

FOR FURTHER INFORMATION CONTACT: Larry Budney, (215) 814-2184, or by e-mail at Budney.Larry@epa.gov.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action, with the same title, that is located in the "Rules and Regulations" section of this *Federal Register* publication.

Dated: April 7, 2004.

Judith M. Katz,
Acting Regional Administrator, Region III.
 [FR Doc. 04-8578 Filed 4-14-04; 8:45 am]
 BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[VA001-1001b; FRL-7648-5]

Approval of Section 112(l) Authority for Hazardous Air Pollutants; Equivalency by Permit Provisions; National Emission Standards for Hazardous Air Pollutants From the Pulp and Paper Industry; Commonwealth of Virginia

AGENCY: Environmental Protection Agency (EPA).
ACTION: Proposed rule.

SUMMARY: The EPA is proposing to approve a request from the Commonwealth of Virginia's Department of Environmental Quality (DEQ) for authority to implement and enforce State permit terms and conditions in place of those of the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Pulp and Paper Industry, with respect to the operations of International Paper Company's Franklin Mill, located in Franklin, Virginia. Thus, the EPA is proposing to grant the Virginia DEQ the authority to implement and enforce alternative requirements in the form of Clean Air Act (CAA) Title V permit terms and conditions after EPA has approved the State's alternative requirements. In the Final Rules section of this *Federal Register*, EPA is approving the State's submittal as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. A detailed rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties

interested in commenting on this action should do so at this time.

DATES: Comments must be received in writing by May 6, 2004.

ADDRESSES: Submit your comments, identified by VA001-1001, by one of the following methods:

A. Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

B. E-mail: Campbell.Dave@epa.gov.

C. Mail: David J. Campbell, Chief, Permits and Technical Assessment Branch, Mailcode 3AP11, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. VA001-1001. EPA's policy is that all comments received will be included in the public docket without change, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise

protected through regulations.gov or e-mail. The federal regulations.gov Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Copies of all comments should also be sent to the Virginia Department of Environmental Quality, P.O. Box 10009, Richmond, Virginia 23240. Copies of written comments should be sent to John M. Daniel, Jr., Director, Air Division, Virginia Department of Environmental Quality, P.O. Box 10009, Richmond, Virginia 23240. Copies of electronic comments should be sent to

jmdaniel@deq.state.va.us. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and the Virginia Department of Environmental Quality, 629 East Main Street, Richmond, Virginia, 23219.

FOR FURTHER INFORMATION CONTACT: Ray Chalmers, (215) 814-2061, or by e-mail at chalmers.ray@epa.gov.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action approving the Virginia DEQ's request for "up-front" approval of an EBP program under which the Virginia DEQ may establish and enforce alternative State requirements for International Paper Company's Franklin Mill in lieu of those of the NESHAP for the Pulp and Paper Industry found at 40 CFR part 63, subpart S, with the same title, that is located in the "Rules and Regulations" section of this **Federal Register** publication.

Dated: April 6, 2004.

Thomas Voltaggio,

Acting Regional Administrator, Region III.

[FR Doc. 04-8582 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

Notices

Federal Register

Vol. 69, No. 73

Thursday, April 15, 2004

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 04-024-1]

Notice of Request for Extension of Approval of an Information Collection

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection in support of credit account approval for reimbursable services.

DATES: We will consider all comments that we receive on or before June 14, 2004.

ADDRESSES: You may submit comments by any of the following methods:

- *Postal Mail/Commercial Delivery:* Please send four copies of your comment (an original and three copies) to Docket No. 04-024-1, Regulatory Analysis and Development, PPD, APHIS, Station 3C71, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 04-024-1.

- *E-mail:* Address your comment to regulations@aphis.usda.gov. Your comment must be contained in the body of your message; do not send attached files. Please include your name and address in your message and "Docket No. 04-024-1" on the subject line.

- *Agency Web site:* Go to <http://www.aphis.usda.gov/ppd/rad/cominst.html> for a form you can use to submit an e-mail comment through the APHIS Web site.

Reading Room: You may read any comments that we receive on this

docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: You may view APHIS documents published in the *Federal Register* and related information, including the names of groups and individuals who have commented on APHIS dockets, on the Internet at <http://www.aphis.usda.gov/ppd/rad/webrepor.html>.

FOR FURTHER INFORMATION CONTACT: For information regarding credit account approval for reimbursable services, contact Mrs. Kris Caraher, User Fees Section Head, FMD, MRPBS, APHIS, 4700 River Road Unit 54, Riverdale, MD 20737-1232; (301) 734-5743. For copies of more detailed information on the information collection, contact Mrs. Celeste Sickles, APHIS' Information Collection Coordinator, at (301) 734-7477.

SUPPLEMENTARY INFORMATION:

Title: Credit Account Approval for Reimbursable Services.

OMB Number: 0579-0055.

Type of Request: Extension of approval of an information collection.

Abstract: The services of a Federal inspector to clear imported and exported agricultural commodities for animal and plant health purposes are paid for by user fees during regular working hours. If an importer wishes to have shipments cleared at other hours, such services will usually be provided on a reimbursable overtime basis, unless already covered by a user fee. Exporters wishing cargo to be certified during nonworking hours may also utilize this procedure.

Many importers and exporters who require inspection services are repeat customers who request that we bill them. We need to collect certain information to conduct a credit check on prospective applicants to ensure creditworthiness prior to extending credit services and to prepare billings. Also, the Debt Collection Improvement Act of 1996, as amended (31 U.S.C. 3332), requires that agencies collect tax identification numbers from all persons doing business with the Government for

purposes of collecting delinquent debts. APHIS Form 192 is used to collect this information and must be completed before credit is extended.

We are asking the Office of Management and Budget (OMB) to approve our use of this information collection for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning this information collection activity. These comments will help us:

(1) Evaluate whether the information collection is necessary for the proper performance of our agency's functions, including whether the information will have practical utility;

(2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.

Estimate of burden: The public reporting burden for this collection of information is estimated to average 0.25 hours per response.

Respondents: Importers, exporters, or brokers who wish to set up an account for billing of inspection services provided during nonworking hours.

Estimated annual number of respondents: 256.

Estimated annual number of responses per respondent: 1.

Estimated annual number of responses: 256.

Estimated total annual burden on respondents: 64 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Done in Washington, DC, this 9th day of April 2004.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 04-8559 Filed 4-14-04; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 04-026-1]

Notice of Request for Extension of Approval of an Information Collection

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection in support of regulations for the interstate movement of regulated articles from quarantined areas in order to prevent the spread of the West Indian fruit fly to noninfested areas of the United States.

DATES: We will consider all comments that we receive on or before June 14, 2004.

ADDRESSES: You may submit comments by any of the following methods:

- **Postal Mail/Commercial Delivery:** Please send four copies of your comment (an original and three copies) to Docket No. 04-026-1, Regulatory Analysis and Development, PPD, APHIS, Station 3C71, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 04-026-1.
- **E-mail:** Address your comment to regulations@aphis.usda.gov. Your comment must be contained in the body of your message; do not send attached files. Please include your name and address in your message and "Docket No. 04-026-1" on the subject line.
- **Agency Web site:** Go to <http://www.aphis.usda.gov/ppd/rad/cominst.html> for a form you can use to submit an e-mail comment through the APHIS Web site.

Reading Room: You may read any comments that we receive on this docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room

hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: You may view APHIS documents published in the **Federal Register** and related information, including the names of groups and individuals who have commented on APHIS dockets, on the Internet at <http://www.aphis.usda.gov/ppd/rad/webrepor.html>.

FOR FURTHER INFORMATION CONTACT: For information on the West Indian fruit fly regulations, contact Mr. Michael B. Stefan, Director, Emergency Programs, PPQ, APHIS, 4700 River Road Unit 134, Riverdale, MD 20737-1236; (301) 734-4387. For copies of more detailed information on the information collection, contact Mrs. Celeste Sickles, APHIS' Information Collection Coordinator, at (301) 734-7477.

SUPPLEMENTARY INFORMATION:

Title: West Indian Fruit Fly.

OMB Number: 0579-0170.

Type of Request: Extension of approval of an information collection.

Abstract: The Plant Protection Act (7 U.S.C. 7701-7772) authorizes the Secretary of Agriculture, either independently or in cooperation with States, to carry out operations or measures to detect, eradicate, suppress, control, prevent, or retard the spread of plant pests, such as West Indian fruit fly, that are new to or not widely distributed within the United States.

The West Indian fruit fly, *Anastrepha obliqua* (Macquart), is a very destructive pest of fruits and vegetables, including carambola, grapefruit, guava, limes, mangoes, oranges, passion fruit, peaches, and pears. This pest can cause serious economic losses by lowering the yield and quality of these fruits and vegetables and, in some cases, by damaging seedlings and young plants. Heavy infestations can result in complete loss of these crops.

Regulations in 7 CFR 301.98 through 301.98-10 restrict the interstate movement of regulated articles from quarantined areas to prevent the spread of the West Indian fruit fly to noninfested areas of the United States and require the use of certain information collection activities in the form of certificates or limited permits and compliance agreements.

We are asking the Office of Management and Budget (OMB) to approve our use of these information collection activities for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as

affected agencies) concerning our information collection. These comments will help us:

(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the information collection on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.

Estimate of burden: The public reporting burden for this collection of information is estimated to average 1 hour per response.

Respondents: State and county cooperators (inspectors) and producers, handlers, and movers of regulated fruit and vegetables.

Estimated annual number of respondents: 37.

Estimated annual number of responses per respondent: 1.

Estimated annual number of responses: 37.

Estimated total annual burden on respondents: 37 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Done in Washington, DC, this 9th day of April 2004.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 04-8560 Filed 4-14-04; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 04-027-1]

Notice of Request for Extension of Approval of an Information Collection

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection to gather data on West Nile virus.

DATES: We will consider all comments that we receive on or before June 14, 2004.

ADDRESSES: You may submit comments by any of the following methods:

- Postal Mail/Commercial Delivery: Please send four copies of your comment (an original and three copies) to Docket No. 04-027-1, Regulatory Analysis and Development, PPD, APHIS, Station 3C71, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 04-027-1.

- E-mail: Address your comment to regulations@aphis.usda.gov. Your comment must be contained in the body of your message; do not send attached files. Please include your name and address in your message and "Docket No. 04-027-1" on the subject line.

- Agency Web Site: Go to <http://www.aphis.usda.gov/ppd/rad/cominst.html> for a form you can use to submit an e-mail comment through the APHIS Web site.

Reading Room: You may read any comments that we receive on this docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: You may view APHIS documents published in the **Federal Register** and related information, including the names of groups and individuals who have commented on APHIS dockets, on the Internet at <http://www.aphis.usda.gov/ppd/rad/webrepor.html>.

FOR FURTHER INFORMATION CONTACT: For information regarding the West Nile virus surveillance project, contact Dr. Tim Cordes, Senior Staff Veterinarian, Certification and Control Team, NCAHP, VS, APHIS, 4700 River Road Unit 46, Riverdale, MD 20737; (301) 734-3279. For copies of more detailed information on the information collection, contact Mrs. Celeste Sickles,

APHIS' Information Collection Coordinator, at (301) 734-7477.

SUPPLEMENTARY INFORMATION:

Title: West Nile Virus Surveillance Project.

OMB Number: 0579-0162.

Type of Request: Extension of approval of an information collection.

Abstract: The Animal and Plant Health Inspection Service of the U.S. Department of Agriculture regulates the importation and interstate movement of animals and animal products, and conducts various other activities to protect the health of our Nation's livestock and poultry. Disease surveillance plays an important role in protecting the health of the U.S. livestock and poultry populations.

One such surveillance program gathers information concerning outbreaks of West Nile virus (WNV) in the United States. WNV, although not considered to be a national epidemic, has potential to cause economic harm to the U.S. equine industry due to possible trade restrictions that could be imposed by other countries. The goal of the WNV surveillance project is to collect data from equine owners and to analyze this data to explain equine or premises risk factors for WNV infection.

Gathering this data entails the use of two information collection activities in the form of an owner/operator agreement to participate in the survey and a WNV data collection form.

We are asking the Office of Management and Budget (OMB) to approve our use of these information collection activities for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning this information collection activity. These comments will help us:

- (1) Evaluate whether the information collection is necessary for the proper performance of our agency's functions, including whether the information will have practical utility;

- (2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;

- (3) Enhance the quality, utility, and clarity of the information to be collected; and

- (4) Minimize the burden of the collection of information on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.

Estimate of burden: The public reporting burden for this collection of

information is estimated to average 1.125 hours per response.

Respondents: Equine owners.

Estimated annual number of respondents: 420.

Estimated annual number of responses per respondent: 2.

Estimated annual number of responses: 840.

Estimated total annual burden on respondents: 945 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Done in Washington, DC, this 9th day of April, 2004.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 04-8561 Filed 4-14-04; 8:45 am]

BILLING CODE 3410-34-P

COMMISSION ON CIVIL RIGHTS

Agenda and Notice of Public Meeting of the Minnesota Advisory Committee

Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights, that the Minnesota Advisory Committee will convene a meeting on Thursday, April 29, 2004, from 9 a.m. to 5 p.m., at the Minneapolis Urban League, 2100 Plymouth Avenue, North, Minneapolis, Minnesota 55411. The purpose of the meeting is to hold a press conference to release the Committee's report, *Minneapolis-St. Paul News Coverage of Minority Communities* and to discuss civil rights issues and plan future activities.

Persons desiring additional information, or planning a presentation to the Committee, should contact Constance M. Davis, Director of the Midwestern Regional Office 312-353-8311 (TDD 312-353-8362). Hearing-impaired persons who will attend the meeting and require the services of a sign language interpreter should contact the Regional Office at least ten (10) working days before the scheduled date of the meeting.

The meeting will be conducted pursuant to the provisions of the rules and regulations of the Commission.

Dated at Washington, DC, March 30, 2004.

Ivy L. Davis,

Chief, Regional Programs Coordination Unit.

[FR Doc. 04-8597 Filed 4-14-04; 8:45 am]

BILLING CODE 6335-01-P

COMMISSION ON CIVIL RIGHTS

Agenda and Notice of Public Meeting of the Nevada Advisory Committee

Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights, that a conference call of the Nevada State Advisory Committee in the Western Region will convene at 10 a.m. (P.d.t.) and adjourn at 11:30 a.m., Friday, May 7, 2004. The purpose of the conference call is to discuss the status of the civil rights project being considered by the State Advisory Committee.

This conference call is available to the public through the following call-in number: 1-800-659-8294, access code number 23186014. Any interested member of the public may call this number and listen to the meeting. Callers can expect to incur charges for calls not initiated using the provided call-in number or over wireless lines and the Commission will not refund any incurred charges. Callers will incur no charge for calls using the call-in number over land-line connections. Persons with hearing impairments may also follow the proceedings by first calling the Federal Relay Service at 1-800-977-8339 and providing the Service with the conference call number and access code.

To ensure that the Commission secures an appropriate number of lines for the public, persons are asked to register by contacting Thomas Pilla of the Western Regional Office, (213) 894-3437, by 3 p.m. on Thursday, May 6, 2004.

The meeting will be conducted pursuant to the provisions of the rules and regulations of the Commission.

Dated at Washington, DC, April 12, 2004.

Ivy L. Davis,

Chief, Regional Programs Coordination Unit.

[FR Doc. 04-8596 Filed 4-14-04; 8:45 am]

BILLING CODE 6335-01-P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce (DOC) has submitted to the Office of Management and Budget (OMB), for clearance, the following proposal for collection of information under

provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35).

Agency: Bureau of Industry and Security (BIS).

Title: Report of Requests for Restrictive Trade Practice or Boycott, Single or Multiple Transactions.

Agency Form Number: 621P, 6051P, 6051P-a.

OMB Approval Number: 0694-0012.

Type of Request: Extension of a currently approved collection of information.

Burden: 1,371 hours.

Average Time Per Response: 67 minutes per response.

Number of Respondents: 1,243 respondents.

Needs and Uses: Used to carefully and accurately monitor requests for participation in foreign boycotts against countries friendly to the U.S. which are received by U.S. persons. Used to note trends in such boycott activity and to assist in carrying out U.S. policy of opposition to such boycotts.

Affected Public: Individuals, businesses or other for-profit institutions.

Respondent's Obligation: Mandatory.

OMB Desk Officer: David Rostker.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482-0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230.

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Room 10202, New Executive Office Building, Washington, DC 20230.

Dated: April 9, 2004.

Madeleine Clayton,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 04-8490 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-DT-P

DEPARTMENT OF COMMERCE

Economic Development Administration

[Docket No. 991215339-3300-09]

University Center (UC) Program

AGENCY: Economic Development Administration (EDA) Department of Commerce (DOC).

ACTION: Notice and request for proposals.

SUMMARY: EDA is soliciting competition proposals for FY 2004 University Center

funding in the areas served by its Denver and Austin regional offices. EDA's mission is to help our partners across the Nation create wealth and minimize poverty by promoting a favorable business involvement to attract private capital investment and higher-skill, higher-wage jobs through world-class capacity-building, planning, infrastructure, research grants and strategic initiatives. With funding from EDA, institutions of higher education establish and operate University Centers, which provide technical assistance to public and private sector organizations with the goal of enhancing local economic development. EDA has traditionally renewed an award to a University Center on an annual basis as long as it maintained a satisfactory level of performance and Congress appropriated funds for the program. With the competition announced in this notice for University Centers in the regions served by EDA's Austin and Denver regional offices, EDA is beginning to phase in competition for University Center funding.

DATES: Proposals must be received at the appropriate EDA regional office by 5 p.m. local time on Friday, May 14, 2004.

ADDRESSES: For proponents in Arkansas, Louisiana, New Mexico, Oklahoma, and Texas, please send proposals to: Economic Development Administration, Austin Regional Office, 327 Congress Avenue, Suite 200, Austin, Texas 78701, 512-381-8144.

For proponents in Colorado, Iowa, Kansas, Missouri, Montana, Nebraska, North Dakota, South Dakota, Utah, and Wyoming, please send proposals to: Economic Development Administration, Denver Regional Office, 1244 Speer Boulevard, Room 670, Denver, Colorado 80204, 303-844-4715.

Full text of the Federal Funding Opportunity announcement can be accessed at EDA's Web site, <http://www.eda.gov>.

FOR FURTHER INFORMATION CONTACT: For additional information or a copy of the Federal Funding Opportunity announcement for this request for proposals, contact the appropriate EDA regional office listed above in the ADDRESSES section.

SUPPLEMENTARY INFORMATION:

Electronic Access: EDA is not currently able to accept electronic submission of proposal packages. However, the full funding opportunity announcement for the FY 2004 University Center competition is available through EDA's Web site, <http://www.eda.gov>, and through Grants.gov at <http://www.grants.gov>.

Funding Availability: The amount of University Center funding available through this announcement for competition in FY 2004 is \$795,217 in the Denver regional office and \$978,502 in the Austin regional office.

Anticipated annual awards for University Centers under the FY 2004 competition are in the \$75,000 to \$200,000 range. Regional offices may, however, choose to fund proposals under this competition outside that range.

Statutory Authority: Pub. L. 89-136, as amended by Pub. L. 105-393, 42 U.S.C. 3121, *et seq.*

CFDA: 11.303, Economic Development—Technical Assistance.

Eligibility: Eligible applicants and eligible recipients of EDA financial assistance are defined at 13 CFR 300.2. For the University Center program, EDA considers all accredited institutions of higher education as eligible applicants.

For FY 2004 the University Center competition is open to eligible applicants in areas served by EDA's Denver regional office and Austin regional office. The Denver regional office serves the states of Colorado, Iowa, Kansas, Missouri, Montana, Nebraska, North Dakota, South Dakota, Utah and Wyoming. The Austin region serves the states of Arkansas, Louisiana, New Mexico, Oklahoma and Texas.

Cost Sharing Requirements: Any institution of higher education seeking EDA funding under this announcement must provide financial support for its proposed University Center. Ordinarily, the proposed budget for the University Center is shared on a 50/50 basis between EDA and the applicant. The proposed budget may be shared on a 75/25 basis between EDA and the applicant if the project is not feasible without, and merits, a reduction or waiver of the non-Federal share.

In addition, a project is eligible for a supplemental grant increasing the Federal share up to and including 75 percent when the applicant is able to demonstrate that:

(1) It cannot provide the higher match because there is a lack of available non-Federal resources due, for instance, to the pressing demand for its use elsewhere;

(2) the project is addressing major causes of distress in the area to be served and requires the unique characteristics of the applicant, which will not participate if it must provide all or part of a 50 percent non-Federal share; or

(3) The project is for the benefit of local, State, regional or national economic development efforts and will

be of no or only incidental benefit to the recipient. See 13 CFR 307.7(c).

Funds from other Federal awards may not be considered matching funds. The nature of contribution (cash versus in-kind) and the amount of matching funds will be taken into consideration in the review process. Cash contributions are preferred.

Intergovernmental Review: Applications under this program are subject to Executive Order 12372, "Intergovernmental Review of Federal Programs."

Evaluation and Selection Procedures: EDA's Denver and Austin regional offices will conduct an initial administrative and technical review of each proposal package to determine its completeness and compliance with the requirements.

EDA's Denver and Austin regional offices will then conduct an internal review of each proposal meeting the requirements of this solicitation. This review will be conducted by a minimum of three EDA staff using the criteria provided in the "Evaluation Criteria" section below. Successful proponents under this competition solicitation will be invited to submit a complete application by the Denver or Austin regional office.

Evaluation Criteria: EDA investments in proposed University Centers will be competitively evaluated on their ability to meet or exceed the following investment policy guidelines (each criterion will be given equivalent weight):

(1) Be market-based and results driven. An investment in an EDA University Center will capitalize on the university's competitive strengths and will bolster regional economic competitiveness, resulting in tangible, quantifiable improvements in regional economic health—such as increased numbers of higher-skill, higher-wage jobs, increased tax revenue or increased private sector investment.

(2) Have strong organizational leadership. An investment will have strong leadership, relevant project management experience, and a significant commitment of human resources talent to ensure a high-performing University Center.

(3) Advance productivity, innovation and entrepreneurship. An investment in a proposed University Center will embrace the principles of entrepreneurship, enhance regional industry clusters, and leverage and link technology innovators (university research) with the private sector to create the conditions for greater productivity, innovation and higher-skill, higher-wage job creation.

(4) Look beyond the immediate economic horizon, anticipate economic changes, and diversify the local and regional economy. A University Center's activities will be part of an overarching, long-term comprehensive economic development strategy that enhances a region's success in achieving a rising standard of living.

In making its recommendations on which institutions should be invited to submit a full application, the EDA review team will strive to avoid the concentration of program funding in a single or very limited number of geographic areas. For that reason, EDA cannot predict a minimum ranking of a successful proposal.

Selection Factors: EDA expects to fund the highest ranking proposals submitted under this competition solicitation. However, EDA may select proposals out of order for several reasons, including: (1) Availability of funding; (2) Geographic balance in distribution of funds; (3) Program priorities and policy factors as set out in the full funding opportunity announcement; or (4) Applicant's performance under previous awards.

The Department of Commerce Pre-Award Notification Requirements for Grants and Cooperative Agreements

The Department of Commerce Pre-Award Notification Requirements for Grants and Cooperative Agreements contained in the **Federal Register** notice of October 1, 2001 (66 FR 49917), as amended by the **Federal Register** notice published on October 30, 2002 (67 FR 66109), are applicable to this solicitation.

Paperwork Reduction Act

This document contains collection-of-information requirements subject to the Paperwork Reduction Act (PRA). The use of Form ED-900P has been approved by OMB under the control number 0610-0094. Notwithstanding any other provision of law, no person is required to respond to, nor shall any person be subject to a penalty for failure to comply with, a collection of information subject to the requirements of the PRA unless that collection of information displays a currently valid OMB control number.

Executive Order 12866

This notice has been determined to be not significant for purposes of Executive Order 12866.

Executive Order 13132 (Federalism)

It has been determined that this notice does not contain policies with

Federalism implications as that term is defined in Executive Order 13132.

Administrative Procedure Act/ Regulatory Flexibility Act

Prior notice and an opportunity for public comments are not required by the Administrative Procedure Act or any other law for notices concerning grants, benefits, and contracts (5 U.S.C. 553(a)(2)). Because notice and opportunity for comment are not required pursuant to 5 U.S.C. 553 or any other law, the analytical requirements of the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*) are inapplicable. Therefore, a regulatory flexibility analysis has not been prepared.

Dated: April 9, 2004.

Mary Pleffner,

Acting Assistant Secretary for Economic Development.

[FR Doc. 04-8547 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-24-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 032604B]

Endangered and Threatened Species; Take of Anadromous Fish

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of availability and request for comment.

SUMMARY: The Puget Sound Treaty Tribes and the Washington Department of Fish and Wildlife submitted to NMFS, pursuant to the protective regulations promulgated for Puget Sound chinook salmon under the Endangered Species Act (ESA), a jointly developed Resource Management Plan (RMP). The RMP specifies the future management of commercial, recreational and tribal salmon fisheries potentially affecting listed Puget Sound chinook salmon from May 1, 2004, through April 30, 2010. This document serves to notify the public of the availability for comment of the proposed evaluation of the Secretary of Commerce (Secretary) as to how the RMP addresses the criteria in the ESA.

DATES: Written comments on the Secretary's proposed evaluation must be received at the appropriate address or fax number (see **ADDRESSES**) no later than 5 p.m. Pacific Daylight Time on May 17, 2004.

ADDRESSES: Comments and requests for copies of the proposed evaluation

should be addressed to Keith Schultz, Sustainable Fisheries Division, National Marine Fisheries Service, 7600 Sand Point Way NE, Seattle, Washington 98115-0070, or faxed to (206) 526-6736. Comments on this proposed evaluation may be submitted by e-mail. The mailbox address for providing e-mail comments is *PSHARVEST.nwr@noaa.gov*. Include in the subject line the following document identifier: "PSHARVEST proposed evaluation". The document is also available on the internet at *www.nwr.noaa.gov/1sustfsh/limit6/lmt6sbmt.htm*.

FOR FURTHER INFORMATION CONTACT: Susan Bishop, Puget Sound Team Leader, at phone number: (206) 526-4587, or e-mail: *susan.bishop@noaa.gov*.

SUPPLEMENTARY INFORMATION: This notice is relevant to the Puget Sound chinook salmon (*Oncorhynchus tshawytscha*) Evolutionarily Significant Unit (ESU).

Background

The Puget Sound Treaty Tribes and the Washington Department of Fish and Wildlife have provided to NMFS a jointly developed Resource Management Plan for Puget Sound chinook salmon. The RMP encompasses fisheries within the area defined by the Puget Sound Chinook Salmon ESU, as well as the western Strait of Juan de Fuca, which is not within the ESU. Harvest objectives specified in the RMP account for fisheries-related mortality throughout the migratory range of Puget Sound chinook salmon from Oregon and Washington to Southeast Alaska. The RMP also includes implementation, monitoring and evaluation procedures designed to ensure fisheries are consistent with these objectives.

As required by Sec. 223.203(b)(6) of the ESA 4(d) rule (50 CFR 223.203), the Secretary must determine pursuant to 50 CFR 223.209, and pursuant to the government-to-government processes therein, whether the RMP for Puget Sound chinook salmon would appreciably reduce the likelihood of survival and recovery of the Puget Sound chinook salmon and other affected threatened ESUs. The Secretary must consider how the RMP addresses the criteria in Sec. 223.203(b)(4) in making that determination.

Authority

Under section 4(d) of the ESA, 16 U.S.C. 1533(d), the Secretary is required to adopt such regulations as he deems necessary and advisable for the conservation of the species listed as threatened. The ESA salmon and

steelhead 4(d) rule (65 FR 42422, July 10, 2000) specifies categories of activities that contribute to the conservation of listed salmonids or are governed by a program that adequately limits impacts on listed salmonids, and sets out the criteria for such activities. The rule further provides that the prohibitions of paragraph (a) of the rule do not apply to actions undertaken in compliance with a resource management plan developed jointly within the continuing jurisdiction of United States v. Washington by the Puget Sound Treaty Tribes and the State of Washington (joint plan) and determined by the Secretary to be in accordance with the provisions of 50 CFR sec. 223.203(b)(6).

Dated: March 30, 2004.

Susan Pultz,

Acting Chief, Endangered Species Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 04-8115 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 020304D]

Endangered and Threatened Species; Establishment of Species of Concern List, Addition of Species to Species of Concern List, Description of Factors for Identifying Species of Concern, and Revision of Candidate Species List Under the Endangered Species Act

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of establishment of species of concern list, addition of species to species of concern list, description of factors for identifying species of concern, and revision of candidate species list.

SUMMARY: NMFS establishes a species of concern list, places 45 species on this list, describes the factors it will consider when identifying species of concern, and revises the candidate species list. NMFS also solicits information and comments concerning the status of, research and stewardship opportunities for, and the factors for identifying species of concern.

DATES: These actions are effective on April 15, 2004.

ADDRESSES: Send comments and documentation regarding the status of any species of concern to the Chief of

Endangered Species, NMFS, Office of Protected Resources, 1315 East-West Highway, F/PR3, Silver Spring, MD 20910. Comments may also be submitted by e-mail. The mailbox address for providing e-mail comments is soc.list@noaa.gov. Include in the subject line of the e-mail comment the following document identifier: Species of Concern List.

FOR FURTHER INFORMATION CONTACT:

Marta Nammack at (301)713-1401, ext. 180, marta.nammack@noaa.gov.

SUPPLEMENTARY INFORMATION: The regulations implementing section 4 of the ESA (5 U.S.C. 1533) define "candidate" as "any species being considered by the Secretary [of Commerce or Interior] for listing as an endangered or a threatened species, but not yet the subject of a proposed rule" (50 CFR 424.02). Such a designation does not confer any procedural or substantive protections of the ESA on the candidate species.

In the past, NMFS also has placed species on its candidate species list for other reasons. In particular, NMFS has used this list to: (1) identify species potentially at risk; (2) increase public awareness about those species; (3) identify data deficiencies and uncertainties in species' status and threats; (4) stimulate cooperative research efforts to obtain the information necessary to evaluate species status and threats; and (5) foster voluntary efforts to provide stewardship for the species before an ESA listing as threatened or endangered becomes warranted. Other NMFS candidate species are those for which an ESA biological status review has determined that listing under the ESA is "not warranted" under section 4(b)(3)(B)(i) but for which significant concerns or uncertainties remain regarding their biological status and/or threats. In fact, the majority of NMFS' candidate species are not being considered actively for listing under the ESA. Rather, they have been identified as candidates because of concerns or great uncertainties regarding biological status and threats. The last version of the candidate species list was published in 1999 (64 FR 33466; June 23, 1999).

NMFS recognizes that using the candidate species list for these broader purposes may give the inaccurate impression that all these species are being considered for listing under the ESA. At the same time, there is value in publicly identifying species that, although they are not being considered for listing, are nevertheless of concern for reasons identified above. To restore the candidate species list to its original

meaning while still maintaining a publicly available list of other species of concern, NMFS is establishing a Species of Concern list, transferring 25 species from the candidate species list to this list, placing 20 additional species on this list, and removing 12 other species from the candidate species list. This will clarify that NMFS has concerns or insufficient information about species of concern, but is not actively considering listing them under the ESA.

NMFS will hereafter limit use of the term "candidate species" to refer to (1) species that are the subject of a petition to list and for which NMFS has determined that listing may be warranted, pursuant to section 4(b)(3)(A), and (2) species for which NMFS has determined, following a status review, that listing is warranted (whether or not they are the subject of a petition). This limited use of the term is consistent with NMFS' regulatory definition of "candidate species." NMFS will use the term "species of concern" to identify species about which NMFS has some concerns regarding status and threats, but for which insufficient information is available to indicate a need to list the species under the ESA. This may include species for which NMFS has determined, following a biological status review, that listing under the ESA is "not warranted," pursuant to ESA section 4(b)(3)(B)(i), but for which significant concerns or uncertainties remain regarding their status and/or threats. Species can qualify as both species of concern and candidate species. This discussion is limited to species under NMFS jurisdiction and does not apply to the regulatory practices of the U.S. Fish and Wildlife Service.

Factors for Identifying Species of Concern

In previous revisions of its candidate species list, NMFS identified candidate species by considering their biological status, determined by both demography and genetic composition of the species. Demographic concerns would occur when there is a significant decline in abundance or range from historical levels, and genetic concerns included outbreeding and inbreeding depression resulting from poor hatchery practices or substantially reduced numbers of natural individuals: NMFS will consider these demographic and genetic diversity concerns, as further elaborated by the following factors, in identifying species of concern: abundance and productivity; distribution; and life-history characteristics. These factors will be considered with regard to existing threats. More details on these factors

can be viewed on our web site: <http://www.nmfs.noaa.gov/pr/species/concern>.

The factors discussed above were considered in previous revisions of NMFS' candidate species list, though they were not published until 1997 (62 FR 37560; July 14, 1997). They were also considered in identifying the species of concern. NMFS will hereafter consider these factors for future revisions of the species of concern list. The weight given to certain factors may differ among species. When data are incomplete for any factor, as is often the case, it may still be appropriate to add a species to the species of concern list when there are existing threats. NMFS will review the best available information for the relevant factors and threats on a case by case basis and use its best professional judgment in deciding whether a species or population should be considered a species of concern. NMFS may conduct ESA status reviews on each species of concern as agency resources permit.

Species of Concern

Applying the factors described above, NMFS has transferred 25 candidate species to the species of concern list and identified 20 additional species as species of concern. Twelve additional species are removed from the candidate species list. Rationale for identifying the following species of concern is available at <http://www.nmfs.noaa.gov/pr/species/concern>. Table 1 at the end of this Notice lists the species of concern. Two species of concern are also considered to be candidate species because they are undergoing status reviews in response to an ESA petition to list them.

In some cases, vertebrate populations may be "species of concern" even though a determination on whether they qualify as "species" under the ESA has not yet been made. The ESA defines species as including "any subspecies of fish or wildlife or plants, and any distinct population segment of any species of vertebrate fish or wildlife which interbreeds when mature." Two policies describe the criteria for identifying distinct population segments (DPS): NMFS' Policy on Applying the Definition of Species Under the [ESA] to Pacific Salmon (criteria for evolutionarily significant units (ESUs) of Pacific salmon) (56 FR 58612, November 20, 1991); and NMFS' and U.S. Fish and Wildlife Service's (FWS) joint Policy Regarding the Recognition of Distinct Vertebrate Population Segments Under the ESA (61 FR 4722, February 7, 1996). In general, NMFS will determine whether a population

satisfies the criteria for a DPS after conducting an ESA status review.

NMFS may conduct status reviews on species that are not the subject of a petition. As with a petitioned species, initiation of a status review does not mean that an ESA listing is imminent. Even after a status review has been conducted, it is possible that the available information will be insufficient to make a determination on the status of the species. In such cases, NMFS will continue gathering new information as it becomes available, and the species may become or remain a species of concern.

Identifying 45 Species of Concern

Transferring 25 Candidate Species to the Species of Concern List

NMFS transfers 25 species from the most recently published candidate species list (64 FR 33466; June 23, 1999) to the Species of Concern list. See the cited Federal Register notices for details.

Four of these species underwent status reviews that resulted in "not warranted" findings under ESA section 4(b)(3)(B)(i) and were identified as candidate species because of remaining concerns and uncertainties. These species now meet the definition of species of concern instead: Cook Inlet beluga whale (*Delphinapterus leucas*) (65 FR 38778; June 22, 2000), barndoor skate (*Raja laevis*) (67 FR 61055; September 27, 2002), Georgia Basin Pacific hake (*Merluccius productus*) DPS (65 FR 70514; November 24, 2000), and bocaccio (*Sebastes paucispinis*) (67 FR 69704; November 19, 2002).

In addition, NMFS denied a petition to list the largemouth sawfish (*Pristis pristis*) without conducting a status review because the petition did not present sufficient information indicating that listing may be warranted; however, because NMFS was concerned about the status of this species, it was added to the candidate species list (65 FR 12959; March 10, 2000). It no longer considered a candidate species, but it meets the definition of a species of concern, as those concerns still remain.

Fourteen other species of concern that were on NMFS' 1999 candidate species list are currently undergoing status reviews. Thirteen of these status reviews were initiated by NMFS and not in response to a petition and therefore do not qualify as candidate species: dusky shark (*Carcharhinus obscurus*), sand tiger shark (*Odontaspis taurus*), night shark (*Carcharinus signatus*), Alabama shad (*Alosa alabamae*), Atlantic Gulf (*Salmo salar*) populations in the Gulf of Maine that were not included in the

endangered Gulf of Maine DPS listing (65 FR 69459; November 17, 2000), mangrove rivulus (*Rivulus marmoratus*), saltmarsh topminnow (*Fundulus jenkinsi*), opossum pipefish (*Microphis brachyurus lineatus*), goliath grouper (*Epinephelus itajara*, formerly the jewfish, officially changed by the American Fisheries Society on January 24, 2001), Nassau grouper (*Epinephelus striatus*), black abalone (*Haliotis cracherodii*), elkhorn coral (*Acropora palmata*), and staghorn coral (*Acropora cervicornis*). The Lower Columbia River coho salmon (*Oncorhynchus kisutch*) ESU (was the Southwest Washington/Lower Columbia River coho salmon ESU until results of an earlier status review indicated that the Lower Columbia River coho salmon population was an ESU) is undergoing a status review in response to a petition (65 FR 66221, November 3, 2000) and, therefore, qualifies as both a species of concern and a candidate species.

Six other species from the 1999 candidate species list not yet undergoing status reviews will now be considered species of concern instead: Atlantic sturgeon (*Acipenser oxyrinchus oxyrinchus*), Puget Sound/Strait of Georgia coho salmon (*Oncorhynchus kisutch*) ESU, Oregon Coast steelhead (*Oncorhynchus mykiss*) ESU, key silverside (*Menidia conchorum*), speckled hind (*Epinephelus drummondhayi*), and warsaw grouper (*Epinephelus nigritus*).

Adding 20 Other Species of Concern

NMFS has identified 20 other species of concern. Four of these species (northern and southern DPSs of green sturgeon (*Acipenser medirostris*), 68 FR 4,433, January 29, 2003; white marlin (*Tetrapturus albidus*), 67 FR 57204, September 9, 2002, and Central Valley fall and late fall-run chinook salmon ESU (*Oncorhynchus tshawytscha*), 64 FR 50394, September 16, 1999) underwent status reviews after NMFS received petitions to list them. NMFS found that none of these species warranted listing as threatened or endangered under the ESA, but sufficient concerns remained to justify adding them to the candidate species list. The last revision of the candidate species list was published before these determinations were made, so these species never appeared in a published list of candidate species. Now these species qualify as species of concern, but not candidate species. One additional species (Oregon Coast coho salmon ESU (*Oncorhynchus kisutch*)) is currently undergoing a status review as a result of a new petition (67 FR 48601, July 25, 2002) and is therefore both a

species of concern and a candidate species.

The 15 new species of concern for which status reviews have not yet been initiated are: thorny skate (*Raja radiata*), rainbow smelt (east coast) (*Osmerus mordax*), cusk (Brosme brosmes), striped croaker (*Bairdiella sanctaeluciae*), humphead wrasse (Cheilinus undulatus), bumphead parrotfish (*Bolbometopon muricatum*), Atlantic wolffish (*Anarhichas lupus*), cowcod (*Sebastes levis*), Atlantic halibut (*Hippoglossus hippoglossus*), inarticulate brachiopod (*Lingula reevii*), pink abalone (*Haliotis corrugata*), green abalone (*Haliotis fulgens*), pinto abalone (*Haliotis kamtschatkana*), Hawaiian coral (*Montipora dilatata*), and ivory bush coral (*Oculina varicosa*).

Removing 12 Species From the Candidate Species List

In addition to the 25 species transferred from the candidate species list to the species of concern list, NMFS has removed 12 species from the candidate species list. NMFS reviewed the status of the following eight species/populations pursuant to petitions to list, made "not warranted" determinations, and removed them from the candidate species list: Gulf of Maine harbor porpoise (*Phocoena phocoena*) (64 FR 480; January 5, 1999), Puget Sound Pacific herring (*Clupea pallasii*) (66 FR 17659; April 13, 2001), Klamath Mountains Province ESU of steelhead (*Oncorhynchus mykiss*) (66 FR 17845; April 4, 2001), Puget Sound Pacific cod (*Gadus macrocephalus*) (65 FR 70514; November 24, 2000), Puget Sound walleye pollock (*Theragra chalcogramma*) (65 FR 70514; November 24, 2000), and Puget Sound brown (*Sebastes auriculatus*), copper (*S. caurinus*), and quillback rockfish (*S. maliger*) (66 FR 17659; April 13, 2001). Three species were listed as threatened or endangered after status reviews were conducted: smalltooth sawfish (*Pristis pectinata*) (68 FR 15674; April 1, 2003), Northern California steelhead (*Oncorhynchus mykiss*) ESU (65 FR 36074; June 7, 2000) and white abalone (*Haliotis sorenseni*) (66 FR 29046; May 29, 2001). Finally, NMFS turned jurisdiction of searun cutthroat trout (*Oncorhynchus clarki*) over to FWS; therefore, the Oregon Coastal ESU of searun cutthroat trout is no longer a NMFS candidate species (65 FR 21376; April 21, 2000).

Two species remain on NMFS' candidate species list: the Lower Columbia River coho salmon ESU and the Oregon Coast coho salmon ESU.

Species of Concern Table

Table 1 below contains a complete list of NMFS' species of concern. Any species of concern identified after this revision will be listed on our web page (<http://www.nmfs.noaa.gov/pr/species/concern>) and not published in the Federal Register. If the species is undergoing a status review, this will also be noted. Information on candidate species will be available on the same web site.

In Table 1, the common name appears as the first entry followed by the

scientific name, the family name, and the area of concern. This area denotes the general geographic boundaries of the species or the vertebrate population for which concern has been expressed. Results of status reviews may narrow the geographic areas or populations of concern in the future. It is important to note that the species of concern list is limited by the information available.

Comments Solicited

NMFS solicits information on the biology of and threats to, relevant research and stewardship opportunities

for, and the factors NMFS considers in identifying species of concern (see ADDRESSES). This information will help guide NMFS in: future revisions of the species of concern list, allocation of resources for species of concern, and further refinement of the factors considered in identifying species of concern. There is no deadline for submitting such information.

Dated: April 7, 2004.

Wanda L. Cain,

Acting Deputy Director, Office of Protected Resources, National Marine Fisheries Service.

TABLE 1 - SPECIES OF CONCERN LIST

Common Name	Scientific Name	Family	Area of Concern ¹
Marine Mammals beluga whale ^{2,3}	<i>Delphinapterus leucas</i>	Monodontidae	Pacific-AK (Cook Inlet population).
Fishes dusky shark ²	<i>Carcharhinus obscurus</i>	Carcharhinidae	Atlantic, Gulf of Mexico-Western North Atlantic DPS.
sand tiger shark ²	<i>Odontaspis taurus</i>	Odontaspidae	Atlantic, Gulf of Mexico.
night shark ²	<i>Carcharhinus signatus</i>	Carcharhinidae	Atlantic, Gulf of Mexico.
largetooth sawfish ²	<i>Pristis pristis</i>	Pristidae	Atlantic-TX, FL.
banddoor skate ^{2,3}	<i>Raja laevis</i>	Rajidae	Atlantic-Newfoundland, Canada to Cape Hatteras, NC.
thorny skate	<i>Raja radiata</i>	Rajidae	Atlantic-West Greenland to NY
Atlantic sturgeon ²	<i>Acipenser oxyrinchus oxyrinchus</i>	Acipenseridae	Atlantic-Labrador to St. Johns R., FL; anadromous.
green sturgeon ³	<i>Acipenser medirostris</i>	Acipenseridae	Pacific-northern DPS (including coastal spawning populations from the Eel River north, to the Klamath and Rogue rivers) and southern DPS (includes Sacramento River spawning population); anadromous.
Alabama shad ²	<i>Alosa alabamae</i>	Clupeidae	Gulf of Mexico-AL, FL, anadromous.
coho salmon ²	<i>Oncorhynchus kisutch</i>	Salmonidae	Pacific-Puget Sound/Strait of Georgia, ² Lower Columbia River, ² 4 and Oregon Coast ⁴ coho ESUs; anadromous.
steelhead trout ²	<i>Oncorhynchus mykiss</i>	Salmonidae	Pacific-OR Coast ESU; ² anadromous.
chinook salmon ³	<i>Oncorhynchus tshawytscha</i>	Salmonidae	Pacific-Central Valley fall and late fall-run ESU
Atlantic salmon ²	<i>Salmo salar</i>	Salmonidae	Atlantic-Gulf of Maine (other populations in streams and rivers within the range of the listed Gulf of Maine Atlantic salmon DPS); anadromous.
rainbow smelt	<i>Osmerus mordax</i>	Osmeridae	Atlantic-Labrador to NJ; anadromous.
cusk	<i>Brosme brosme</i>	Gadidae	Atlantic-Gulf of Maine.
Pacific hake ^{2,3}	<i>Merluccius productus</i>	Gadidae	Pacific-Georgia Basin DPS.
mangrove rivulus ²	<i>Rivulus marmoratus</i>	Aplocheilidae	Atlantic-FL, estuarine.
saltmarsh topminnow ²	<i>Fundulus jenkinsi</i>	Cyprinodontidae	Atlantic-TX, LA, MS, AL, FL.
key silverside ²	<i>Menidia conchorum</i>	Atherinidae	Atlantic-Florida Keys.
opossum pipefish ²	<i>Microphis brachyurus lineatus</i>	Syngnathidae	Atlantic-Florida (Indian River Lagoon).
striped croaker	<i>Bairdiella saxatilis</i>	Sciaenidae	Atlantic-FL, Antilles and Caribbean from Costa Rica to Guyana.
humphead wrasse	<i>Cheilinus undulatus</i>	Labridae	Indo-Pacific-Red Sea to the Tuamotus, north to the Ryukyus, east to Wake Islands, south to New Caledonia, throughout Micronesia; includes U.S. territories of Guam and American Samoa.
bumphead parrotfish	<i>Bolbometopon muricatum</i>	Scaridae	Indo-Pacific-Red Sea and East Africa to the Line Islands and Samoa; north to Yaeyama, south to the Great Barrier Reef and New Caledonia; Paulau, Caroline, Mariana in Micronesia; in U.S. it occurs in Guam, American Samoa, CNMI and the Pacific Remote Island Areas (Wake Islands).
Atlantic wolffish	<i>Anarhichas lupus</i>	Anarhichadidae	Atlantic-Georges Bank and western Gulf of Maine.
white marlin ³	<i>Tetrapturus albidus</i>	Istiophoridae	Atlantic.
cowcod	<i>Sebastes levis</i>	Scorpaenidae	Pacific-Central OR to central Baja California and Guadalupe Island, Mexico.
bocaccio ^{2,3}	<i>Sebastes paucispinis</i>	Scorpaenidae	Pacific-Southern DPS (Northern CA to Mexico).

TABLE 1 - SPECIES OF CONCERN LIST—Continued

Common Name	Scientific Name	Family	Area of Concern ¹
Atlantic halibut	<i>Hippoglossus hippoglossus</i>	Pleuronectidae	Atlantic-Labrador to southern New England.
speckled hind ²	<i>Epinephelus drummondhayi</i>	Serranidae	Atlantic-NC to Gulf of Mexico.
goliath grouper ²	<i>Epinephelus itajara</i>	Serranidae	Atlantic-NC southward to Gulf of Mexico.
warsaw grouper ²	<i>Epinephelus nigritus</i>	Serranidae	Atlantic-MA southward to Gulf of Mexico.
Nassau grouper ²	<i>Epinephelus striatus</i>	Serranidae	Atlantic-NC southward to Gulf of Mexico.
<i>Brachiopoda</i>			
inarticulate brachiopod	<i>Lingula reevii</i>	Lingulidae	Pacific-Hawaii, only Kaneohe Bay.
<i>Mollusks</i>			
pink abalone	<i>Haliotis corrugata</i>	Haliotidae	Pacific-Point Conception, CA, to Bahia de Tortuga, Baja California.
black abalone ²	<i>Haliotis cracherodii</i>	Haliotidae	Pacific-OR, CA, Baja California.
green abalone	<i>Haliotis fulgens</i>	Haliotidae	Pacific-Point Conception, CA, to Bahia Magdalena, Baja California.
pinto abalone	<i>Haliotis kamtschatkana</i>	Haliotidae	Pacific-Sitka, AK, to Point Conception, CA.
<i>Anthozoans (Corals)</i>			
elkhorn coral ²	<i>Acropora palmata</i>	Acroporidae	western Atlantic-Caribbean.
staghorn coral ²	<i>Acropora cervicornis</i>	Acroporidae	western Atlantic-Caribbean.
Hawaiian reef coral	<i>Montipora dilatata</i>	Acroporidae	Pacific-Hawaii (Kaneohe Bay, Midway atoll, and Maro Reef).
ivory bush coral	<i>Oculina varicosa</i>	Oculinidae	Atlantic-West Indies, Bermuda, NC, FL, Gulf of Mexico, Caribbean.

¹ Defines the general geographic area or populations of concern for the species.

² Formerly on 1999 candidate species list

³ Status review has been conducted, "not warranted" finding resulted, but concerns still remain.

⁴ Also considered a candidate species because it is undergoing a status review in response to a petition to list.

DPS = distinct population segment, which is a species for purposes of the ESA.

ESU = evolutionarily significant unit, which is a DPS or species for purposes of the ESA

[FR Doc. 04-8593 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 030304C]

Vessel Monitoring Systems (VMS); Approved Mobile Transmitting Units for Use in all of the Atlantic Highly Migratory Species (HMS) Fisheries Requiring VMS

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notification of NOAA-approved VMS.

SUMMARY: This document provides notice of VMS approved by NOAA for use by vessels participating in all of the Atlantic HMS fisheries requiring VMS and sets forth relevant features of each monitoring system. A VMS is required to be installed and operating on all vessels that have been issued an HMS permit pursuant to 50 CFR 635.4 and that have pelagic longline gear on board. In the near future, VMS will also be required on vessels that have a directed shark limited access permit pursuant to 635.4 and either gillnet or bottom longline gear on board. This notice is necessary to provide approval of certain

VMS units and providers for use in these Atlantic HMS fisheries, and supercedes all previous type approval notices for the Atlantic HMS Fisheries.

ADDRESSES: To obtain copies of the list of NOAA-approved VMS mobile transmitting units and VMS communications service providers, or to obtain information regarding the status of VMS systems being evaluated by NOAA for approval, write to NOAA Fisheries, Office for Law Enforcement (OLE), 8484 Georgia Avenue, Suite 415, Silver Spring, MD 20910.

Completed activation forms must be sent to NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, or faxed to 727-570-5355.

For service provider contact information see the **SUPPLEMENTARY INFORMATION** section of this notice under the heading "VMS Provider Addresses."

FOR FURTHER INFORMATION CONTACT: For current listing information contact Mark Oswell, Outreach Specialist, phone: 301-427-2300, fax: 301-427-2055. For questions regarding VMS installation, activation forms, and status of evaluations contact Jonathan Pinkerton, National VMS Program Manager, phone: 301-427-2300, fax: 301-427-2055. For questions regarding VMS unit activation, contact Beverly Lambert, Southeast Division VMS Program Manager at 727-570-5344.

The public may acquire this notice, activation procedures, and relevant

updates by contacting the Southeast Enforcement Division VMS staff, phone 727-570-5344, fax 727-570-5355.

SUPPLEMENTARY INFORMATION: The list of satellite transceivers and communications service providers approved for use in the Atlantic HMS fisheries is provided below. Activation guidelines are also provided for each unit or service listed in this notice.

I. VMS Mobile Transceiver Units

A. Inmarsat-C Transceivers

The Inmarsat-C satellite communications VMS transmitting units that meet the minimum technical requirements for the Atlantic HMS Fisheries are the Thrane & Thrane Fishery "Capsat" (part number TT-3022D-NMFS) and the Thrane & Thrane Fishery "Mini-C" (part number TT-3026-NMFS); Trimble Galaxy TNL7005 (part number 17760-45) with software v5.1; and Trimble Galaxy Courier TNL8005 (part number 30090-45) with software v5.1. Both Trimble units use antenna part number 25132-01 and must run software version 5.1, or later. Those vessels using earlier versions of Trimble software (5.0, and earlier) must contact their Trimble-Authorized Support Dealer to upgrade to firmware version 5.10 or 5.10a, and set the parameters equivalent to software version 5.1, or later. Addresses for the Thrane & Thrane distributor (LandSea Systems) and the Trimble dealer contact are provided in this notice under the

heading VMS Provider Addresses. While both Trimble units are approved for use, they are no longer being manufactured. Units still may be available for purchase at Trimble-authorized dealers.

A1. Thrane & Thrane Fishery "Capsat" TT-3022D-NMFS

The TT-3022D-NMFS transceiver consists of an integrated GPS/Inmarsat-C unit in the wheelhouse and an antenna mounted atop the vessel. The unit is factory pre-configured for NMFS VMS operations (non-Global Maritime Distress & Safety System (non-GMDSS)). Satellite commissioning services are provided by LandSea Systems.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is a car radio-sized transceiver using a floating 10 to 32 Volts DC (VDC) power supply. The unit is configured for automatic reduced position transmissions when the vessel is stationary (i.e., in port). It allows for port stays without power drain or power shut down, and the unit restarts normal position transmission automatically when the vessel goes to sea.

The outside antenna, model TT-3005M, is a compact omni-directional Inmarsat-C/GPS antenna, providing operation down to +/-15 degrees of elevation.

A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company. Another available option is the ability to send and receive private e-mail and other messages with the purchase and installation of an input device such as a laptop, personal computer, or message display terminal.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA, although they may be supported by other parties.

A2. Thrane & Thrane Fishery "Mini-C" TT-3026-NMFS

The TT-3026-NMFS transceiver consists of an integrated GPS/Inmarsat-C unit mounted atop the vessel. The unit is factory pre-configured for NMFS VMS operations (non-Global Maritime Distress & Safety System (non-GMDSS)). Satellite commissioning services are provided by LandSea Systems.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is an integrated transceiver/antenna/GPS design using a floating 10 to 32 VDC power supply, and is configured for automatic reduced

position transmissions when the vessel is stationary (i.e., in port). It allows for port stays without power drain or power shut down, and restarts normal position transmission automatically when the vessel goes to sea.

The TT-3026-NMFS provides operation down to +/-15 degree angles. Although the unit has the capability of two-way communication to send and receive private e-mail and other messages, it can only perform these operations when additional equipment that is not required by NMFS is purchased (i.e., a laptop, personal computer, or message display terminal). A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA, though they may be supported by other parties.

A vessel owner wishing to purchase either of these systems may contact the entity identified in this notice under the heading VMS Provider Addresses. The owner should identify themselves as a vessel owner in an "Atlantic HMS Fisheries," so the transceiver set can be configured for HMS fisheries.

To use the TT-3022D-NMFS or the TT-3026-NMFS, the vessel owner must establish an Inmarsat-C system use contract with a NOAA-approved Inmarsat-C communications service provider. The owner will be required to complete Inmarsat-C "Registration for Service Activation for Maritime Mobile Earth Station," and should consult with LandSea Systems when completing the form.

LandSea Systems will perform the following services before shipment: (1) configure the transceiver according to OLE specifications for Atlantic HMS Fisheries, (2) download the predetermined NMFS position reporting and broadcast command identification numbers into the unit, (3) test the unit to ensure proper operation when installation of the unit has been completed on the vessel, and (4) forward the Inmarsat service provider and the transceiver identifying information to OLE.

The vessel owner is required to fax or mail the Activation Form directly to NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, fax 727-570-5355.

A3. Trimble Galaxy TNL7005

The Trimble Galaxy TNL7005 (part number 17760-45, Software v5.1) transceiver consists of an integrated

GPS/Inmarsat-C unit in the wheelhouse and an antenna mounted atop the vessel. The unit is factory pre-configured for NMFS VMS operations (non-GMDSS). The installation will be performed by Trimble-authorized support dealers and must be paid by the owner.

Automatic GPS position reporting starts after coordination with the communications service provider. Although the unit contains push buttons to request emergency assistance from United States search and rescue authorities, search and rescue authorities can use the transceiver to communicate with the vessel only when additional equipment that is not required by NMFS is purchased (i.e., a message terminal display).

A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company. Another available option is the ability to send/receive private e-mail and other messages with the purchase and installation of an input device, such as a laptop or personal computer.

A4. Trimble Galaxy Courier TNL8005

The Trimble Galaxy Courier TNL8005 (part number 30090-45, software v5.1) transceiver has the same features as the Trimble Galaxy TNL7005, except that it also includes an integrated computer for messaging, including Internet e-mail. The unit is factory pre-configured for NMFS VMS operations, and it is GMDSS.

A vessel owner wishing to purchase this system should contact the entity identified under VMS Provider Addresses for Trimble Galaxy Courier Information. The owner should identify himself or herself as a vessel owner in the "Atlantic HMS fishery."

In addition to purchasing an approved Trimble transceiver (TNL7005 or TNL8005) and an antenna for the HMS fishery, the vessel owner must establish an Inmarsat-C system use contract with an approved Inmarsat-C communications service provider. The transceiver must be commissioned with the service provider.

The installation of the transceiver and antenna must be performed by Trimble trained and Trimble authorized support dealers and must be paid by the owner. To set up the transceiver for NMFS VMS operations, the owner will (1) turn on the power of the vessel transceiver, (2) contact the Inmarsat-C system communications service provider, (3) have the service provider download the pre-determined NMFS position reporting and broadcast commands from the provider's control center to the

vessel transceiver via satellite, and (4) confirm with the service provider that periodic position reports are now automatically being sent to NOAA. The service provider will confirm service activation by forwarding to the NOAA Office for Law Enforcement the following identifying information: (1) Trimble transceiver serial number, (2) Inmarsat identification number, (3) Data Network Identification (DNID) and member numbers, (4) Enhanced Network Identification (ENID) numbers, (5) owner name, (6) vessel name, and (7) vessel documentation or registration number.

B. ORBCOMM Transceivers

The ORBCOMM satellite communications VMS transmitting unit that meets the minimum technical requirements for the Atlantic HMS Fisheries is the Stellar ST2500G (part number ST2500G-NMFS). The address for ORBCOMM Value Added Resellers (VAR) and their regional sales outlets around the country are provided under the heading VMS Provider Addresses.

The Stellar ST2500G-NMFS transceiver consists of an integrated GPS/ORBCOMM satellite communicator mounted in the wheelhouse and antennas mounted atop the vessel. The unit is pre-configured and tested for NMFS VMS operations. Satellite commissioning services are available from several VMS providers.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is a car radio-sized transceiver powered by any 12 to 32 VDC power supply. It is factory configured for automatic reduced position transmissions when the vessel is stationary (i.e., in port) which allows for port stays without power drain or unit shut down. The unit restarts normal position transmission automatically when the vessel goes to sea.

The ST2500G has an omni-directional VHF antenna, providing operation from +/-5 degrees above the horizon. A configuration option is available to automatically send position reports to a private e-mail address or to a secure web site where the data is displayed on a map and in tabular form. Another available option is the ability to send and receive private e-mail from a laptop, personal computer or specific handheld devices. A complete list of devices, supported operating systems and available software solutions can be obtained from any ORBCOMM Value Added Reseller.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA,

though they may be supported by other parties.

A vessel owner wishing to purchase the Stellar ST2500G transceiver will be required to complete an ORBCOMM "Provisioning" form via the Internet at www.orbcomm.com. If assistance is required, the owner may consult with the VAR or one of the entities identified in this notice under the heading VMS Provider Addresses. The unit will be configured specifically for the Atlantic HMS fisheries.

The ORBCOMM VMS VAR will perform the following services before shipment: (1) configure the transceiver according to OLE specifications for the Atlantic HMS Fisheries, (2) download the predetermined NMFS position reporting applications into the unit, (3) test the unit to ensure proper operation prior to shipping, and (4) forward the service provider and the transceiver identifying information to OLE and test the unit when the installation has been completed on the vessel.

II. Communications Service Providers

OLE has approved the below-listed communications service providers: ORBCOMM, Stratos, Telenor, and Xantic satellite communications services.

A. ORBCOMM

NMFS recommends, for vendor warranty and customer service purposes, that the vessel owner and the VAR have on record the following identifying information: (1) signed and dated receipts and contracts, (2) satellite communicator identification number, (3) VAR customer number, (identification number/unit surname name combination), (4) e-mail address of satellite communicator (surname@ORBComm.net), (5) owner name, (6) vessel name, and (7) vessel documentation or registration number.

VMS units must be installed in accordance with vendor instructions and specifications. Installation can be performed by experienced crew, a VAR, or an electronics specialist. All installation costs are paid by the owner. The vessel owner is required to fax or mail the activation form directly to NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, fax 727-570-5355.

The owner must confirm the Stellar ST2500G-NMFS operation and communications service to ensure that position reports are automatically sent to and received by OLE before leaving on their first fishing trip requiring VMS. OLE does not regard the fishing vessel as meeting the requirements until

position reports are automatically received. For confirmation purposes, contact NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, Phone 727-570-5344, fax 727-570-5355.

ORBCOMM is a store-and-forward data messaging service allowing users to send and receive information virtually anywhere in the world. ORBCOMM supports a wide variety of applications including plain text Internet-based e-mail, position and weather reporting, and remote equipment monitoring and control. Mariners can use ORBCOMM free of charge to send critical safety at-sea messages as part of the U.S. Coast Guard's Automated Mutual-Assistance Vessel Rescue System. VMS services are being sold through specific ORBCOMM VARs.

ORBCOMM customer service supports the security and privacy of vessel accounts and messages by requiring password authentication of vessel owners or agents and OLE personnel to prevent unauthorized changes or inquiries, and by separating private messages from OLE messages. (OLE presently requires VMS-related position reports, only.)

Billing is separated between accounts for the vessel owner and OLE. VMS position reports and vessel-initiated messaging are paid by the vessel owner. Messaging initiated from OLE operations center is paid by OLE.

ORBCOMM provides customer service through its VARs to establish and support two-way transmission of transceiver unit configuration commands between the transceiver and land-based control centers. This supports OLE's message needs and, optionally, fishermen's private e-mail needs.

The owner should refer to and follow the configuration, installation, and service activation procedures for the Stellar ST2500G-NMFS satellite communicator.

B. INMARSAT-C Communications Providers

NMFS recommends, for vendor warranty and customer service purposes, that the vessel owner, Stratos, Telenor and Xantic have on record the following identifying information: (1) Signed and dated receipts and contracts, (2) transceiver serial number, (3) Stratos, Telenor or Xantic customer number, user name and password, (4) e-mail address of transceiver, (5) Inmarsat identification number, (6) owner name, (7) vessel name, (8) vessel documentation or registration number;

and (9) mobile earth station license (FCC license).

VMS units must be installed in accordance with vendor instructions and specifications and can be performed by experienced crew or by an electronics specialist, costs are paid by the owner. The vessel owner is required to fax or mail the VMS Activation Form directly to NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, fax 727-570-5355.

The owner must confirm the TT-3022D-NMFS or TT-3026-NMFS operation and communications service to ensure that position reports are automatically sent to and received by OLE before leaving on their first fishing trip under VMS. OLE does not regard the fishing vessel as meeting the requirements until position reports are automatically received. For confirmation purposes, contact NOAA Enforcement, Koger Building, Room 130, 9721 Executive Center Drive North, St. Petersburg, FL 33702, voice 727-570-5344, fax 727-570-5355.

B1. Telenor Satellite Services

Inmarsat-C is a store-and-forward data messaging service, and allows users to send and receive information virtually anywhere in the world, on land, at sea, and in the air. Inmarsat-C supports a wide-variety of applications including Internet-based e-mail, position and weather reporting, a free daily news service, and remote equipment monitoring and control. Mariners can use Inmarsat-C free of charge to send critical safety at-sea messages as part of the U.S. Coast Guard's Automated Mutual-Assistance Vessel Rescue System and NOAA's Shipboard Environmental Acquisition System programs.

Telenor Vessel Monitoring System Services is being sold through LandSea Systems, Inc. For the LandSea and Telenor addresses, look in this notice under the heading VMS Provider Addresses.

B2. Xantic

Xantic is a provider of vessel monitoring services to the fishing industry. By installing a NOAA-approved Inmarsat-C transceiver on the vessel, fishermen can send and receive e-mail to and from land. The transceiver automatically sends vessel position reports to OLE, and is fully compliant with Coast Guard search and rescue centers. Xantic vessel monitoring system services are being sold through LandSea Systems, Inc. For the LandSea and Xantic addresses, look in this notice

under the heading VMS Provider Addresses.

Telenor and Xantic products and services are offered through LandSea Systems who supports the security and privacy of vessel accounts and messages by requiring password authentication for vessel owners or agents, by preventing unauthorized changes or inquiries, and by separating of private messages from OLE messages. (OLE currently requires VMS-related position reports, only.)

Billing is separated between accounts for the vessel owner and the OLE. VMS position reports and vessel-initiated messaging are paid by the vessel owner. Messaging initiated from OLE operations center is paid by NOAA.

LandSea Systems provides customer service for Telenor and Xantic users to support and establish two-way transmission of transceiver unit configuration commands between the transceiver and land-based control centers. This supports OLE's message needs and, optionally, fishermen's private message needs. A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company.

B3. Stratos

Stratos provides all Inmarsat services globally and has extensive experience in the provision of Inmarsat-C messaging and tracking services. Stratos has distributors situated throughout the United States that can provide equipment, installation, commissioning and all other necessary services in compliance with NMFS requirements.

By installing an OLE approved Inmarsat-C transceiver on the vessel in accordance with vendor instructions and specifications and OLE requirements, fishermen can also easily send and receive e-mail, to and from land and can also setup individual crewmember accounts onboard for e-mail to family and friends without billing to the vessel, but direct billing to crewmember.

Vessel owners wishing to use Stratos, Telenor or Xantic services must purchase an Inmarsat-C transceiver approved for the fishery. The owner must complete an Inmarsat-C system use contract with Stratos, Telenor or Xantic, obtain a mobile earth station license (FCC requirement). The transceiver must be commissioned with Inmarsat according to Stratos, Telenor or Xantic's instructions. The owner should refer to and follow the configuration, installation, and service activation procedures for the specific transceiver purchased.

III. VMS Provider Addresses

For ORBCOMM and Stellar ST2500G-NMFS information, contact: ORBCOMM, LLC, 21700 Atlantic Boulevard, Dulles, VA 20166 USA; voice: 800-ORBCOMM (USA) or 703-433-6300; fax: 703-433-6400; or website: www.ORBCOMM.com.

For Stratos service or to locate the nearest Stratos distributor, contact sales@stratosglobal.com, +1-888-766-1313. In Seattle contact Dave Brengelmann at 1-506-633-5888 dave.brengelmann@stratosglobal.com or in Florida contact Roberto Darias at 1-954-217-2277, or e-mail roberto.darias@stratosglobal.com.

For Thrane & Thrane TT-3022D-NMFS or TT-3026-NMFS information, contact Tom Kelly, Marine Products, LandSea Systems, Inc., 509 Viking Drive, Suite K, L & M, Virginia Beach, VA 23452; voice: 757-463-9557; fax: 757-463-9581, e-mail: TMK@LandSeaSystems.com; website: <http://www.landseasystems.com>.

For Telenor or Xantic information, contact LandSea Systems Inc., Donna Sherman, 509 Viking Drive, Suite K, L, M, Virginia Beach, VA 23452; voice: 757 463-9557; fax: 757 463-9581 e-mail: airtime@landseasystems.com. Telenor and Xantic Customer Service, contact the address above or e-mail: KCR@LandSeaSystems.com. Alternate Telenor contact: Courtney Coleman, Manager COMSAT-C Services Marketing, 6560 Rock Spring Dr., Bethesda, MD 20817; phone: 301-838-7720; e-mail: courtney.coleman@telenor-usa.com.

Alternate Xantic contacts include: Folef Hooft Graafland, 6100 Hollywood Boulevard, Suite 410, Hollywood, FL 33024; voice: (954) 962-9908 ext. 11; fax: (954) 962-1164; cellular: (954) 214-2609; e-mail: folef.hooftgraafland@Xantic.net; Andre Cortese, 1211 Connecticut Ave., NW, Suite 504, Washington, DC 20036; telephone number: 202-785-5615; e-mail: andre.cortese@Xantic.net; and Bobbie Thach, 1211 Connecticut Ave, NW Suite 504, Washington, DC 20036; voice: (202) 785-5614; fax: (202) 785-5616; e-mail: bobbie.thach@Xantic.net.

Authority: 16 U.S.C. 1801, *et seq.*

Date: April 9, 2004.

William T. Hogarth,

*Assistant Administrator for Fisheries,
National Marine Fisheries Service.*

[FR Doc. 04-8590 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[Docket No. 040210050-4108-02; I.D. 031904B]

RIN 0648-AN16

2004 Atlantic Sea Scallop Research Set-Aside Program

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice and request for proposals.

SUMMARY: NMFS announces that for fishing year 2004 the New England Fishery Management Council (Council) may set aside portions of the total allowable catch (TAC) and Days-at-Sea (DAS) allowance in the sea scallop fishery to be used for sea scallop research endeavors under a research set-aside (RSA) program. The RSA program provides a mechanism to fund research and compensate vessel owners through the sale of fish harvested under the research quota. Vessels participating in an approved research project may be authorized by the Northeast Regional Administrator, NMFS, to harvest and to land species in excess of any imposed trip limit or during fishery closures. Landings from such trips would be sold to generate funds that would help defray the costs associated with research projects. No Federal funds would be provided for research under this notification.

DATES: Proposals must be received by NMFS no later than 5 p.m. EST, May 17, 2004.

ADDRESSES: Proposals must be submitted to NMFS, Northeast Regional Office, One Blackburn Drive, Gloucester, MA 01930.

FOR FURTHER INFORMATION CONTACT: For a copy of the full funding opportunity announcement for this request for proposals and/or an application kit contact Sandra Stone or Andrew Applegate, New England Fishery Management Council, phone (978) 465-0492, or Peter Christopher (see **ADDRESSES**), by phone (978) 281-9288, fax (978) 281-9135, or email Peter.Christopher@noaa.gov. The text of the full funding opportunity announcement can also be accessed via NOAA's website at <http://www.ofa.noaa.gov/amd/SOLINDEX.HTML>.

SUPPLEMENTARY INFORMATION: NMFS announces that for fishing year 2004 the

Council may set aside portions of the TAC and DAS allowance in the sea scallop fishery to be used for sea scallop research endeavors under a RSA program. The RSA program provides a mechanism to fund research and compensate vessel owners through the sale of fish harvested under the research quota. Vessels participating in an approved research project may be authorized by the Regional Administrator to harvest and to land species in excess of any imposed trip limit or during fishery closures. Landings from such trips would be sold to generate funds that would help defray the costs associated with research projects. No Federal funds would be provided for research under this notification.

Research proposals are, therefore, sought to utilize the two set-asides proposed in Amendment 10 to the Atlantic Sea Scallop FMP (69 FR 8915): (1) the research TAC set-aside for the Hudson Canyon area of 375,800 lb (170.5 mt), with a value of \$1,525,748.00, presuming that scallops are valued at \$4.06 per pound; and (2) the DAS set-aside for the open fishing areas of 233 DAS with an average catch rate of 1,550 lb/DAS. Given the estimated value of \$4.06 per lb, the open area set-aside would be valued at approximately \$1,466,269.00. Thus, if Amendment 10 is approved, the total value of the set-asides that would be available for scallop-related research would be \$2,992,017.00 (51 percent from Hudson Canyon Area access, and 49 percent from the open area DAS set-aside). Researchers must specify the amount of set-aside (TAC or DAS, as appropriate) sought from each area.

The proposed rule for Amendment 10 was published at 69 FR 8915 on February 26, 2004, and public comment regarding the implementing regulations ended March 29, 2004. The final rule for Amendment 10 including the approved numbers will be published in the **Federal Register**. NOAA will also update the funding opportunity announcement to include the final numbers for the 2004 Atlantic Sea Scallop Research Set-Aside Program which can be accessed via NOAA's web site at: <http://www.ofa.noaa.gov/amd/SOLINDEX.HTML>.

There may be additional research set-aside available from the Groundfish Closed Areas, if the Joint Framework to the Northeast Multispecies FMP and Atlantic Sea Scallop FMP is approved and implemented. The proposed rule for the Joint Framework will be published in the **Federal Register** in near future for public comment. Researchers are urged to request set-aside from these areas

(Groundfish Closed Areas) as well. The Joint Framework, if approved and implemented, would specify that the total TAC set-aside for scallop research from the Groundfish Closed Areas access program in the 2004 fishing year would be 322,272 lb (146.2 mt), an amount of scallops that would have an approximate value of \$1,308,424.00. The Joint Framework, if approved and implemented, would specify that this set-aside would be applicable to research in Closed Area II (167,904 lb (76.16 mt) worth approximately \$681,690) and the Nantucket Lightship Closed Area (154,368 lb (70 mt) worth approximately \$626,734). Researchers are instructed to clearly indicate in their proposals whether or not their research would be applicable to more than one area.

Background: Amendment 10 would continue a Scallop Area Access Program for the Hudson Canyon and includes provisions to allow access to portions of the Groundfish Closed Areas (subject to NMFS' approval of the Joint Framework to establish TACs and measures to minimize groundfish bycatch). Under the proposed area access program, limited access sea scallop vessels would be allowed to land scallops in excess of the proposed possession limit, or to take additional trips above those proposed in the program, and use the proceeds of the excess catch or additional trips to offset the costs of the research proposals submitted in response to this notice. The proposed access areas would remain open until one of four events triggered a closure: (a) The fishing year ends (February 28, 2005); (b) finfish catches exceed TACs established by the Joint Framework; (c) the vessels use all of the trips authorized under the access program; or (d), the fishing season, as established by the Joint Framework, ends.

In addition, Amendment 10 would expand the RSA program to all areas where scallop fishing occurs, including regular open fishing areas. Two percent of the total allowable DAS allocations would be set-aside for scallop related research activities, before determining annual fishing allocations for limited access scallop vessels. This pool of DAS would become available for authorized research projects, under which vessels may participate in scallop research programs and/or conduct trips to compensate for research expenses incurred. The vessel may be authorized to conduct additional trips of a specified duration that would not be counted against the vessel's annual DAS allocation, or DAS may be added to a vessel's annual DAS allocation as compensation. Research applicants

must specify which method would apply, should their proposal be funded.

Vessels participating in an approved project, and fishing in the Sea Scallop Access Areas, would be authorized by the Regional Administrator to do one or more of the following: Take additional trips into the areas and/or to land scallops in excess of the proposed 18,000-lb (8,164.7-kg) possession limit; make a trip of specified duration without counting against the vessel's 2004 DAS allocation; or be allocated additional DAS which would be added to the vessel's 2004 DAS allocation.

Electronic Access: <http://www.Grants.gov>.

Funding Availability: No Federal funds are provided for research under this notification. The Federal Government may issue an Exempted Fishing Permit (EFP) or Letter of Acknowledgment (LOA), as applicable, which may provide special fishing privileges in response to research proposals selected under this program.

Statutory Authority: Issuing grants is consistent with sections 303(b)(11), 402(e), and 404 of the Magnuson-Stevens Fishery Conservation and Management Act, 16 U.S.C. 1853(b)(11), 16 U.S.C. 1881a(e), and 16 U.S.C. 1881(c), respectively.

CFDA: 11.454, Unallied Management Projects

Eligibility: Eligible applicants are institutions of higher education, hospitals, other nonprofits, commercial organizations, individuals, State, local and Indian tribal governments. Federal agencies or institutions are not eligible to receive Federal assistance under this notice. Also, a person is not eligible to submit an application under this program if he/she is an employee of any Federal agency or a Regional Fishery Management Council. However, Council members who are not Federal employees may submit an application.

Cost Sharing Requirements: None.

Intergovernmental Review: Required, if applicable. Applications under this program are subject to Executive Order 12372, "Intergovernmental Review of Federal Programs."

Limitation of Liability: In no event will NOAA or the Department of Commerce be responsible for proposal preparation costs if these programs are cancelled because of other agency priorities. Publication of this announcement does not oblige NOAA to award any specific project or to provide special fishing privileges.

National Environmental Policy Act (NEPA): NOAA must analyze the potential environmental impacts, as required by the NEPA, for applicant projects or proposals which are seeking

NOAA federal assistance opportunities including special fishing privileges. Detailed information on NOAA compliance with NEPA can be found at the following NOAA NEPA website: <http://www.nepa.noaa.gov/>, including our NOAA Administrative Order 216-6 for NEPA, http://www.nepa.noaa.gov/NAO216_6_TOC.pdf, and the Council on Environmental Quality implementation regulations, http://ceq.eh.doe.gov/nepa/regs/ceq/toc_ceq.htm.

Consequently, as part of an applicant's package, and under their description of their program activities, applicants are required to provide detailed information on the activities to be conducted, locations, sites, species and habitat to be affected, possible construction activities, and any environmental concerns that may exist (e.g., the use and disposal of hazardous or toxic chemicals, introduction of non-indigenous species, impacts to endangered and threatened species, aquaculture projects, and impacts to coral reef systems). In addition to providing specific information that will serve as the basis for any required impact analyses, applicants may also be requested to assist NOAA in drafting of a NEPA document (e.g. an environmental assessment), if NOAA determines that an environmental analysis is required. Applicants will also be required to cooperate with NOAA in identifying and implementing feasible measures to reduce or avoid any identified adverse environmental impacts of their proposal. The failure to do so shall be grounds for the denial of an application.

Evaluation and Selection Procedures: NOAA published its first omnibus notice announcing the availability of grant funds for both projects and fellowships/scholarship/ internships for Fiscal Year 2004 in the **Federal Register** on June 30, 2003 (68 FR 38678). The evaluation criteria and selection procedures contained in the June 30, 2003, omnibus notice are applicable to this solicitation. For a copy of the June 30, 2003, omnibus notice please go to: <http://www.ofa.noaa.gov/amd/SOLINDEX.HTML>.

The Department of Commerce Pre-Award Notification Requirements for Grants and Cooperative Agreements: The Department of Commerce Pre-Award Notification Requirements for Grants and Cooperative Agreements contained in the **Federal Register** notice of October 1, 2001 (66 FR 49917), as amended by the **Federal Register** notice published on October 30, 2002 (67 FR 66109), are applicable to this solicitation.

Classification

Paperwork Reduction Act: This document contains collection-of-information requirements subject to the Paperwork Reduction Act (PRA). The use of Standard Forms 424 and 424A, 424B, SF-LLL, and CD-346 has been approved by OMB under the respective control numbers 0348-0043, 0348-0044, 0348-0040, 0348-0046, and 0605-0001. Notwithstanding any other provision of law, no person is required to respond to, nor shall any person be subject to a penalty for failure to comply with, a collection of information subject to the requirements of the PRA unless that collection of information displays a currently valid OMB control number.

Executive Order 12866: This notice has been determined to be not significant for purposes of Executive Order 12866.

Executive Order 13132 (Federalism): It has been determined that this notice does not contain policies with Federalism implications as that term is defined in Executive Order 13132.

Administrative Procedure Act/Regulatory Flexibility Act: Prior notice and an opportunity for public comments are not required by the Administrative Procedure Act or any other law for notices concerning grants, benefits, and contracts (5 U.S.C. section 553(a)(2)). Because notice and opportunity for comment are not required pursuant to 5 U.S.C. 553 or any other law, the analytical requirements of the Regulatory Flexibility Act (5 U.S.C. section 601 et seq) are inapplicable. Therefore, a regulatory flexibility analysis has not been prepared.

Dated: April 9, 2004.

William T. Hogarth,

*Assistant Administrator for Fisheries,
National Marine Fisheries Service.*

[FR Doc. 04-8592 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 040904B]

New England Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meetings.

SUMMARY: The New England Fishery Management Council (Council) is scheduling a public meeting of its

Research Steering and Joint Enforcement Oversight Committee and Advisory Panel in April and May, 2004 to consider actions affecting New England fisheries in the exclusive economic zone (EEZ).

Recommendations from these groups will be brought to the full Council for formal consideration and action, if appropriate.

DATES: The meetings will be held on April 30, 2004 and May 4, 2004. See **SUPPLEMENTARY INFORMATION** for specific dates and times.

ADDRESSES: The meetings will be held in Wakefield and Newburyport, MA. See **SUPPLEMENTARY INFORMATION** for specific locations.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.

FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; telephone: (978) 465-0492.

SUPPLEMENTARY INFORMATION:

Meeting Dates and Agendas

Friday, April 30, 2004 at 9:30 a.m.
Research Steering Committee Meeting.
Location: Sheraton Colonial, One Audubon Road, Wakefield, MA 01880; telephone: (781) 245-9300.

The Research Steering Committee will hear an informal presentation on the status of NOAA Fisheries cooperative cod tagging program and review project objectives. The Committee will also complete work on a policy to incorporate new research results into the management process and initiate a discussion on the disposition of catch and the use of days-at-sea when vessels are engaged in cooperative research. They will address the possibility of allowing the use of B-days, as defined in Amendment 13 to the Northeast Multispecies Fishery Management Plan, for cooperative research purposes. Finally, the Committee will develop a list of priorities and activities for 2004.

Tuesday, May 4, 2004 at 9:30 a.m.
Joint Enforcement Oversight Committee and Advisory Panel Meeting.

Location: New England Fishery Management Council Office, 50 Water Street, Newburyport, MA 01950; telephone: (978) 465-0492.

The Enforcement Committee and Advisors will review the current penalty schedule, and make recommendations with respect to egregious violations.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically

listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see **ADDRESSES**) at least 5 days prior to the meeting dates.

Dated: April 12, 2004.

Alan D. Risenhoover,
Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. E4-854 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 040604A]

Marine Mammals; File No. 881-1724

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Issuance of permit.

SUMMARY: Notice is hereby given that the Alaska SeaLife Center, 301 Railway Avenue, Seward, Alaska 99664, has been issued a permit to import and export marine mammal parts for purposes of scientific research.

ADDRESSES: The permit and related documents are available for review upon written request or by appointment in the following office(s):

Permits, Conservation and Education Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301)713-2289; fax (301)713-0376; and Alaska Region, NMFS, P.O. Box 21668, Juneau, AK 99802-1668; phone (907)586-7221; fax (907)586-7249.

FOR FURTHER INFORMATION CONTACT: Amy Sloan or Ruth Johnson, (301)713-2289.

SUPPLEMENTARY INFORMATION: On December 17, 2003, notice was published in the *Federal Register* (68 FR 70234) that a request for a scientific research permit to take parts from the following species: Antarctic fur seal (*Arctocephalus gazella*), Australian fur seal (*Arctocephalus pusillus*), Australian sea lion (*Neophoca cinerea*),

California sea lion (*Zalophus californianus*), harbor seal (*Phoca vitulina*), northern fur seal (*Callorhinus ursinus*), ribbon seal (*Phoca fasciata*), ringed seal (*Phoca hispida*), Southern fur seal (*Arctocephalus australis*), Southern sea lion (*Otaria flavescens*), Steller sea lion (*Eumetopias jubatus*), beluga whale (*Delphinapterus leucas*), bowhead whale (*Balaena mysticetus*), gray whale (*Eschrichtius robustus*), humpback whale (*Megaptera novaeangliae*), killer whale (*Orcinus orca*), and sperm whale (*Physeter catodon*) had been submitted by the above-named organization. The requested permit has been issued under the authority of the Marine Mammal Protection Act of 1972, as amended (16 U.S.C. 1361 *et seq.*), the Regulations Governing the Taking and Importing of Marine Mammals (50 CFR part 216), the Endangered Species Act of 1973, as amended (ESA; 16 U.S.C. 1531 *et seq.*), the regulations governing the taking, importing, and exporting of endangered and threatened species (50 CFR parts 222-226), and the Fur Seal Act of 1966, as amended (16 U.S.C. 1151 *et seq.*).

The applicant has been authorized to import and export specimen samples (hard and soft parts) from the above-named species for a number of projects to study marine mammal population ecology, diet and nutrition, reproductive physiology, toxicology, and health. The applicant has been issued a five-year permit.

Issuance of this permit, as required by the ESA, was based on a finding that such permit (1) was applied for in good faith, (2) will not operate to the disadvantage of the endangered species which is the subject of this permit, and (3) is consistent with the purposes and policies set forth in section 2 of the ESA.

Dated: April 9, 2004.

Stephen L. Leathery,
Chief, Permits, Conservation and Education Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 04-8594 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 030304D]

Vessel Monitoring Systems (VMS); Approved Mobile Transmitting Units for Use in Alaska Fisheries Requiring VMS

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and

Atmospheric Administration (NOAA), Commerce.

ACTION: Notification of NOAA-approved VMS.

SUMMARY: This document provides notice of NOAA-approved VMS for use by vessels participating in Alaska fisheries requiring VMS, and sets forth relevant features of the monitoring systems.

ADDRESSES: To obtain copies of the list of NOAA-approved VMS mobile transmitting units and VMS communications service providers, or to obtain information regarding the status of VMS systems being evaluated by NOAA, write to NOAA Fisheries, Office for Law Enforcement (OLE), 8484 Georgia Avenue, Suite 415, Silver Spring, MD 20910.

Completed activation forms, must be sent to NOAA Enforcement, P.O. Box 21767, 709 W. 9th Street, Room M09C, Juneau, AK 99802-1767, or faxed to 907-586-7703.

For service provider contact information, see the **SUPPLEMENTARY INFORMATION** section of this notice, under section III, VMS Provider Addresses.

FOR FURTHER INFORMATION CONTACT: For current listing information contact Mark Oswell, Outreach Specialist, phone: 301-427-2300, fax: 301-427-2055. For questions regarding VMS installation, activation forms, and status of evaluations contact Jonathan Pinkerton, National VMS Program Manager, phone: 301-427-2300, fax: 301-427-2055. For questions regarding VMS unit activation or to acquire this notice, activation procedures, and relevant updates contact the Alaska Enforcement Division VMS staff, phone: 907-586-7225, fax: 907-586-7703.

SUPPLEMENTARY INFORMATION: The sections below list the satellite transceivers and communications service providers approved for use in the Alaska fisheries requiring the use of VMS. Activation guidelines are also provided for each unit or service listed in this notice.

I. VMS Mobile Transceiver Units

A. ArgoNet Mar GE

North American Collection and Location by Satellite, Inc. (NACLS) is the sole point-of-contact for the ArgoNet service. NACLS provides: Installation of the ArgoNet MAR GE transmitter on the vessel, the ArgoNet satellite service, and delivery of position reports to OLE and the vessel owner.

Please note that any "assistance" or "emergency" functions integrated into a

VMS unit are not supported by NOAA, although they may be supported by other parties.

New ArgoNet installations are prohibited on or after the published date of this notice. Units installed prior to the published date of this notice are approved to the end of their service life.

B. INMARSAT-C Transceivers

The INMARSAT-C satellite communications VMS transmitting units that meet the minimum technical requirements for Alaska fisheries requiring VMS are the Thrane & Thrane Fishery "Capsat" (part number TT-3022D-NMFS) and the Thrane & Thrane Fishery "Mini-C" (part number TT-3026-NMFS). The address for the Thrane & Thrane distributor (LandSea Systems) is provided under the heading VMS Provider Addresses.

B1. Thrane & Thrane Fishery "Capsat" TT-3022D-NMFS

The TT-3022D-NMFS transceiver consists of an integrated GPS/Inmarsat-C unit in the wheelhouse and an antenna mounted atop the vessel. The unit is factory pre-configured for NMFS VMS operations (non-Global Maritime Distress & Safety System (non-GMDSS)). Satellite commissioning services are provided by LandSea Systems.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is a car radio-sized transceiver using a floating 10 to 32 volts DC (VDC) power supply. The unit is configured for automatic reduced position transmissions when the vessel is stationary (i.e., in port). It allows for port stays without power drain or power shut down, and the unit restarts normal position transmission automatically when the vessel goes to sea.

The outside antenna, model TT-3005M, is a compact omni-directional Inmarsat-C/GPS antenna, providing operation down to +/-15 degrees of elevation.

A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company. Another available option is the ability to send and receive private e-mail and other messages with the purchase and installation of an input device such as a laptop, personal computer, or message display terminal.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA, although they may be supported by other parties.

B2. Thrane & Thrane Fishery "Mini-C" TT-3026-NMFS

The TT-3026-NMFS transceiver consists of an integrated GPS/Inmarsat-C unit mounted atop the vessel. The unit is factory pre-configured for NMFS VMS operations (non-Global Maritime Distress & Safety System (non-GMDSS)). Satellite commissioning services are provided by LandSea Systems.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is an integrated transceiver/antenna/GPS design using a floating 10 to 32 VDC power supply, and is configured for automatic reduced position transmissions when the vessel is stationary (i.e., in port). It allows for port stays without power drain or power shut down, and restarts normal position transmission automatically when the vessel goes to sea.

The TT-3026-NMFS provides operation down to +/-15 degree angles. Although the unit has the capability of two-way communication to send and receive private e-mail and other messages, it can only perform these operations when additional equipment that is not required by NMFS is purchased (i.e., a laptop, personal computer, or message display terminal). A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA, though they may be supported by other parties.

A vessel owner wishing to purchase either of these systems may contact the entity identified in this notice under the heading VMS Provider Addresses. The owner should identify themselves as a vessel owner in an "Alaska fishery requiring VMS," so the transceiver set can be configured for Alaska fisheries.

To use the TT-3022D-NMFS or the TT-3026-NMFS, the vessel owner must establish an Inmarsat-C system use contract with an NMFS-approved Inmarsat-C communications service provider. The owner will be required to complete Inmarsat-C "Registration for Service Activation for Maritime Mobile Earth Station," and should consult with LandSea Systems when completing the form.

LandSea Systems will perform the following services before shipment: (1) configure the transceiver according to OLE specifications for Alaska fisheries requiring VMS, (2) download the predetermined NMFS position reporting and broadcast command identification

numbers into the unit, (3) test the unit to ensure proper operation when installation of the unit has been completed on the vessel, and (4) forward the Inmarsat service provider and the transceiver identifying information to OLE.

The vessel owner is required to fax or mail the Alaska VMS Activation Form directly to Alaska Enforcement Division VMS, P.O. Box 21767, Juneau, AK 99802-1767, phone 907-586-7225, fax 907-586-7703.

C. ORBCOMM Transceivers

The ORBCOMM satellite communications VMS transmitting unit that meets the minimum technical requirements for Alaska fisheries requiring VMS is the Stellar ST2500G (part number ST2500G-NMFS). The address for ORBCOMM Value Added Resellers (VAR) and their regional sales outlets around the country are provided under the heading VMS Provider Addresses.

The Stellar ST2500G-NMFS transceiver consists of an integrated GPS/ORBCOMM satellite communicator mounted in the wheelhouse and antennas mounted atop the vessel. The unit is pre-configured and tested for NMFS VMS operations. Satellite commissioning services are available from several VMS providers.

Automatic GPS position reporting starts after transceiver installation and power activation onboard the vessel. The unit is a car radio-sized transceiver powered by any 12 to 32 VDC power supply. It is factory configured for automatic reduced position transmissions when the vessel is stationary (i.e., in port) which allows for port stays without power drain or unit shut down. The unit restarts normal position transmission automatically when the vessel goes to sea.

The ST2500G has an omni-directional VHF antenna, providing operation from +/-5 degrees above the horizon. A configuration option is available to automatically send position reports to a private e-mail address or to a secure web site where the data is displayed on a map and in tabular form. Another available option is the ability to send and receive private e-mail from a laptop, personal computer or specific handheld devices. A complete list of devices, supported operating systems and available software solutions can be obtained from any ORBCOMM Value Added Reseller.

Please note that any "assistance" or "emergency" functions integrated into a VMS unit are not supported by NOAA, though they may be supported by other parties.

A vessel owner wishing to purchase the Stellar ST2500G transceiver will be required to complete an ORBCOMM "Provisioning" form via the Internet at www.orbcomm.com. If assistance is required, the owner may consult with the VAR or one of the entities identified in this notice under the heading VMS Provider Addresses. The unit will be configured specifically for Alaska fisheries requiring VMS.

The ORBCOMM VMS VAR will perform the following services before shipment: (1) configure the transceiver according to OLE specifications for Alaska fisheries requiring VMS, (2) download the predetermined NMFS position reporting applications into the unit, (3) test the unit to ensure proper operation prior to shipping, and (4) forward the service provider and the transceiver identifying information to OLE and test the unit when the installation has been completed on the vessel.

II. Communications Service Providers

OLE has approved the below-listed communications service providers: ORBCOMM, Stratos, Telenor, and Xantic satellite communications services.

A. ORBCOMM

NMFS recommends, for vendor warranty and customer service purposes, that the vessel owner and the VAR have on record the following identifying information: (1) signed and dated receipts and contracts, (2) satellite communicator identification number, (3) VAR customer number, (identification number/unit surname name combination), (4) e-mail address of satellite communicator (surname@ORBCOMM.net), (5) owner name, (6) vessel name, and (7) vessel documentation or registration number.

VMS units must be installed in accordance with vendor instructions and specifications. Installation can be performed by experienced crew, a VAR, or an electronics specialist. All installation costs are paid by the owner. The vessel owner is required to fax or mail the Alaska VMS Activation Form directly to Alaska Enforcement Division VMS, P.O. Box 21767, Juneau, AK 99802-1767, phone 907-586-7225, fax 907-586-7703.

The owner must confirm the Stellar ST2500G-NMFS operation and communications service to ensure that position reports are automatically sent to and received by OLE before leaving on their first fishing trip requiring VMS. OLE does not regard the fishing vessel as meeting the requirements until position reports are automatically

received. For confirmation purposes, owners must contact the Alaska Enforcement Division VMS staff, phone 907-586-7225, fax 907-586-7703.

ORBCOMM is a store-and-forward data messaging service allowing users to send and receive information virtually anywhere in the world. ORBCOMM supports a wide variety of applications including plain text Internet-based e-mail, position and weather reporting, and remote equipment monitoring and control. Mariners can use ORBCOMM free of charge to send critical safety at-sea messages as part of the U.S. Coast Guard's Automated Mutual-Assistance Vessel Rescue System. VMS services are being sold through specific ORBCOMM VARs.

ORBCOMM customer service supports the security and privacy of vessel accounts and messages by requiring password authentication of vessel owners or agents and OLE personnel to prevent unauthorized changes or inquiries, and by separating private messages from OLE messages. (OLE presently requires VMS-related position reports, only.)

Billing is separated between accounts for the vessel owner and OLE. VMS position reports and vessel-initiated messaging are paid by the vessel owner. Messaging initiated from OLE operations center is paid by OLE.

ORBCOMM provides customer service through its VARs to establish and support two-way transmission of transceiver unit configuration commands between the transceiver and land-based control centers. This supports OLE's message needs and, optionally, fishermen's private e-mail needs.

The owner should refer to and follow the configuration, installation, and service activation procedures for the Stellar ST2500G-NMFS satellite communicator.

B. INMARSAT-C Communications Providers

NMFS recommends, for vendor warranty and customer service purposes, that the vessel owner, Stratos, Telenor and Xantic have on record the following identifying information: (1) Signed and dated receipts and contracts, (2) transceiver serial number, (3) Stratos, Telenor or Xantic customer number, user name and password, (4) e-mail address of transceiver, (5) Inmarsat identification number, (6) owner name, (7) vessel name, (8) vessel documentation or registration number, and (9) mobile earth station license (FCC license).

VMS units must be installed in accordance with vendor instructions

and specifications and can be performed by experienced crew or by an electronics specialist, costs are paid by the owner. The vessel owner is required to fax or mail the Alaska VMS Activation Fax directly to Alaska Enforcement Division VMS, P.O. Box 21767, Juneau, AK 99802-1767, phone 907-586-7225, fax 907-586-7703.

The owner must confirm the TT-3022D-NMFS or TT-3026-NMFS operation and communications service to ensure that position reports are automatically sent to and received by OLE before leaving on their first fishing trip under VMS. OLE does not regard the fishing vessel as meeting the requirements until position reports are automatically received. For confirmation purposes, contact Alaska Enforcement Division VMS staff, phone 907-586-7225, fax 907-586-7703.

B1. Telenor-Satellite Services

Inmarsat-C is a store-and-forward data messaging service, and allows users to send and receive information virtually anywhere in the world, on land, at sea, and in the air. Inmarsat-C supports a wide-variety of applications including Internet-based e-mail, position and weather reporting, a free daily news service, and remote equipment monitoring and control. Mariners can use Inmarsat-C free of charge to send critical safety at-sea messages as part of the U.S. Coast Guard's Automated Mutual-Assistance Vessel Rescue System and NOAA's Shipboard Environmental Acquisition System programs.

Telenor Vessel Monitoring System Services is being sold through LandSea Systems, Inc. For the LandSea and Telenor addresses, look in this notice under the heading VMS Provider Addresses.

B2. Xantic

Xantic is a provider of vessel monitoring services to the fishing industry. By installing an OLE-approved Inmarsat-C transceiver on the vessel, fishermen can send and receive e-mail, to and from land. The transceiver automatically sends vessel position reports to OLE, and is fully compliant with Coast Guard search and rescue centers. Xantic vessel monitoring system services are being sold through LandSea Systems, Inc. For the LandSea and Xantic addresses, look in this notice under the heading VMS Provider Addresses.

Telenor and Xantic products and services are offered through LandSea Systems who supports the security and privacy of vessel accounts and messages by requiring password authentication

for vessel owners or agents, and OLE personnel to prevent unauthorized changes or inquiries, and separating of private messages from OLE messages. (OLE currently requires VMS-related position reports, only.)

Billing is separated between accounts for the vessel owner and the OLE. VMS position reports and vessel-initiated messaging are paid by the vessel owner. Messaging initiated from OLE operations center is paid by NOAA.

LandSea Systems provides customer service for Telenor and Xantic users to support and establish two-way transmission of transceiver unit configuration commands between the transceiver and land-based control centers. This supports OLE's message needs and, optionally, fishermen's private message needs. A configuration option is available to automatically send position reports to a private e-mail address, such as a fleet management company.

B3. Stratos

Stratos provides all Inmarsat services globally and has extensive experience in the provision of Inmarsat-C messaging and tracking services. Stratos has distributors situated throughout the United States that can provide equipment, installation, commissioning and all other necessary services in compliance with NMFS requirements.

By installing an OLE approved Inmarsat-C transceiver on the vessel in accordance with vendor instructions and specifications and OLE requirements, fishermen can also easily send and receive e-mail, to and from land and can also setup individual crew member accounts onboard for e-mail to family and friends without billing to the vessel, but direct billing to crew member.

Vessel owners wishing to use Stratos, Telenor or Xantic services must purchase an Inmarsat-C transceiver approved for the fishery. The owner must complete an Inmarsat-C system use contract with Stratos, Telenor or Xantic, obtain a mobile earth station license (FCC requirement). The transceiver must be commissioned with Inmarsat according to Stratos, Telenor or Xantic's instructions. The owner should refer to and follow the configuration, installation, and service activation procedures for the specific transceiver purchased.

III. VMS Provider Addresses

For ORBCOMM and Stellar ST2500G-NMFS information, contact:

ORBCOMM, LLC, 21700 Atlantic Boulevard, Dulles, VA 20166 USA;

voice: 800-ORBCOMM (USA) or 703-433-6300; fax: 703-433-6400; or website www.ORBCOMM.com.

For Stratos service or to locate the nearest Stratos distributor, contact sales@stratosglobal.com, 1-888-766-1313. In Seattle, Dave Brengelmann at 1-506-633-5888

dave.brengelmann@stratosglobal.com or in Florida, Roberto Darias, 1-954-217-2277, or e-mail:

roberto.darias@stratosglobal.com.

For Thrane & Thrane TT-3022D-NMFS or TT-3026-NMFS information, contact Tom Kelly, Marine Products, LandSea Systems, Inc., 509 Viking Drive, Suite K, L & M, Virginia Beach, VA 23452; voice: 757-463-9557; fax: 757-463-9581, e-mail:

TMK@LandSeaSystems.com; website: <http://www.landseasystems.com>.

For Telenor or Xantic information, contact LandSea Systems Inc., Donna Sherman, 509 Viking Drive, Suite K, L, M, Virginia Beach, VA 23452; voice: 757-463-9557; fax: 757-463-9581 e-mail:

airtime@landseasystems.com. Telenor and Xantic Customer Service, contact the address above or e-mail:

TMK@LandSeaSystems.com. For alternate Telenor, contact Courtney Coleman, Manager COMSAT-C Services Marketing, 6560 Rock Spring Dr., Bethesda, MD 20817; phone: 301-838-7720; e-mail:

courtney.coleman@telenor-usa.com. For alternate Xantic, contacts Folef Hooft Graafland, 6100 Hollywood Boulevard, Suite 410, Hollywood, FL 33024; voice: (954) 962-9908 ext. 11; fax: (954) 962-1164; cellular: (954) 214-2609; e-mail: folef.hooftgraafland@Xantic.net; Andre Cortese, 1211 Connecticut Ave., NW, Suite 504, Washington, DC 20036; telephone number: 202-785-5615; e-mail: andre.cortese@Xantic.net; Bobbie Thach, 1211 Connecticut Ave, NW Suite 504, Washington, DC 20036; voice: (202) 785-5614; fax: (202) 785-5616; e-mail: bobbie.thach@Xantic.net.

Authority: 16 U.S.C. 1801, *et seq.*

Date: April 9, 2004.

William T. Hogarth,

Assistant Administrator for Fisheries, National Marine Fisheries Service.

[FR Doc. 04-8591 Filed 4-14-04; 8:45 am]

BILLING CODE 3510-22-S

COMMISSION OF FINE ARTS

Notice of Meeting

The next meeting of the Commission of Fine Arts is scheduled for 15 April 2004, at 10 a.m. in the Commission's offices at the National Building Museum, Suite 312, Judiciary Square,

401 F Street, NW., Washington, DC 20001-2728. Items of discussion affecting the appearance of Washington, DC, may include buildings, parks and memorials.

Draft agendas and additional information regarding the Commission are available on our Web site: www.cfa.gov. Inquiries regarding the agenda and requests to submit written or oral statements should be addressed to Charles H. Atherton, Secretary, Commission of Fine Arts, at the above address or call 202-504-2200. Individuals requiring sign language interpretation for the hearing impaired should contact the Secretary at least 10 days before the meeting date.

Dated in Washington, DC, on March 30, 2004.

Charles H. Atherton,
Secretary.

[FR Doc. 04-8533 Filed 4-14-04; 8:45 am]
BILLING CODE 6330-01-M

DEPARTMENT OF EDUCATION

Submission for OMB Review; Comment Request

AGENCY: Department of Education.

SUMMARY: The Acting Leader, Regulatory Information Management Group, Office of the Chief Information Officer invites comments on the submission for OMB review as required by the Paperwork Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before May 17, 2004.

ADDRESSES: Written comments should be addressed to the Office of Information and Regulatory Affairs, Attention: ED Desk Officer, Department of Education, Office of Management and Budget, 725 17th Street, NW., Room 10235, New Executive Office Building, Washington, DC 20503 or faxed to (202) 395-6974.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Acting Leader, Regulatory Information

Management Group, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g. new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment.

Dated: April 9, 2004.

Jeanne Van Vlandren,
Acting Leader, Regulatory Information Management Group, Office of the Chief Information Officer.

Office of Postsecondary Education

Type of Review: Reinstatement.

Title: Teacher Quality Enhancement Grants for Partnerships Program (TQE-P): Application Guide for the TQE Grants Competition.

Frequency: Annually.

Affected Public: Not-for-profit institutions; Businesses or other for-profit; State, local, or tribal gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden:

Responses: 275.

Burden Hours: 25,800.

Abstract: This application is for use by Partnerships to apply for new awards under the Teacher Quality Enhancement Grants for Partnerships Program.

Requests for copies of the submission for OMB review; comment request may be accessed from <http://edicsweb.ed.gov>, by selecting the "Browse Pending Collections" link and by clicking on link number 2248. When you access the information collection, click on "Download Attachments" to view. Written requests for information should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202-4651 or to the e-mail address vivan.reese@ed.gov. Requests may also be electronically mailed to the Internet address OCIO_RIMC@ed.gov or faxed to 202-708-9346. Please specify the complete title of the information collection when making your request.

Comments regarding burden and/or the collection activity requirements should be directed to Joseph Schubart at his e-mail address Joe.Schubart@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1-800-877-8339.

[FR Doc. 04-8526 Filed 4-14-04; 8:45 am]

BILLING CODE 4000-01-P

DEPARTMENT OF ENERGY

Environmental Management Site-Specific Advisory Board, Rocky Flats

AGENCY: Department of Energy.

ACTION: Notice of open meeting.

SUMMARY: This notice announces a meeting of the Environmental Management Site-Specific Advisory Board (EM SSAB), Rocky Flats. The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770) requires that public notice of these meetings be announced in the *Federal Register*.

DATES: Thursday, May 6, 2004, 6 p.m. to 9 p.m.

ADDRESSES: College Hill Library, Room L211, Front Range Community College, 3705 West 112th Avenue, Westminster, CO.

FOR FURTHER INFORMATION CONTACT: Ken Korkia, Board/Staff Coordinator, Rocky Flats Citizens Advisory Board, 10808 Highway 93, Unit B, Building 60, Room 107B, Golden, CO, 80403; telephone (303) 966-7855; fax (303) 966-7856.

SUPPLEMENTARY INFORMATION: *Purpose of the Board:* The purpose of the Board is to make recommendations to DOE and its regulators in the areas of environmental restoration, waste management, and related activities.

Tentative Agenda:

1. Board Discussion and Approval of Recommendations on the Draft Interim Measure/Interim Remedial Action for the 903 Pad Lip Area
2. Board Education Session on Groundwater Modeling
3. Report on the April 21-22 EM SSAB Chairs Meeting
4. Other Board business may be conducted as necessary

Public Participation: The meeting is open to the public. Written statements may be filed with the Board either before or after the meeting. Individuals who wish to make oral statements pertaining to agenda items should contact Ken Korkia at the address or telephone number listed above. Requests must be received at least five days prior to the meeting and reasonable provisions will be made to include the presentation in the agenda. The Deputy Designated Federal Officer is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business. Each individual wishing to make public comment will be provided a maximum of five minutes to present their comments.

Minutes: The minutes of this meeting will be available for public review and copying at the office of the Rocky Flats Citizens Advisory Board, 10808

Highway 93, Unit B, Building 60, Room 107B, Golden, CO 80403; telephone (303) 966-7855. Hours of operations are 7:30 a.m. to 4 p.m., Monday through Friday. Minutes will also be made available by writing or calling Ken Korkia at the address or telephone number listed above. Board meeting minutes are posted on RFCAB's Web site within one month following each meeting at: <http://www.rfcab.org/Minutes.HTML>.

Issued at Washington, DC on April 12, 2004.

Rachel M. Samuel,

Deputy Committee Management Officer.

[FR Doc. 04-8572 Filed 4-14-04; 8:45 am]

BILLING CODE 6450-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP99-301-111]

ANR Pipeline Company; Notice Of Negotiated Rate Filing

April 8, 2004.

Take notice that on April 2, 2004, ANR Pipeline Company (ANR) tendered for filing and approval amendments to two agreements for service under Rate Schedule FSS between ANR and Wisconsin Public Service Corporation which change the contract quantities and rates under the two negotiated rate agreements between the parties.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed in accordance with section 154.210 of the Commission's regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission

strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-843 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP96-200-120]

CenterPoint Energy Gas Transmission Company; Notice of Compliance Filing

April 8, 2004.

Take notice that on April 5, 2004, CenterPoint Energy Gas Transmission Company (CEGT) tendered for filing as part of its FERC Gas Tariff, Sixth Revised Volume No. 1, the following tariff sheets to be effective June 1, 2004:

Second Revised Sheet No. 1
 First Revised Sheet No. 126
 First Revised Sheet No. 146
 First Revised Sheet No. 177
 First Revised Sheet No. 209
 First Revised Sheet No. 756
 First Revised Sheet No. 757
 First Revised Sheet No. 758
 First Revised Sheet No. 759
 First Revised Sheet No. 760
 First Revised Sheet No. 761
 First Revised Sheet No. 762
 First Revised Sheet No. 763
 First Revised Sheet No. 764
 Sheet Nos. 765-769
 First Revised Sheet No. 786

CEGT states that the purpose of this filing is to comply with the Commission's Order on Compliance Filings in Docket Nos. RP96-200-092, 097, 101-108, 110-111, 113, and 118, CenterPoint Energy Gas Transmission Company, 106 FERC ¶ 61,213 (2004).

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with section 385.211 of the Commission's rules and regulations. All such protests must be filed in accordance with section 154.210 of the Commission's regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary link. Enter the docket number excluding the last three digits in the docket

number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-852 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP04-254-000]

City of Hamilton, Ohio v. Texas Eastern Transmission, L.P.; Notice of Complaint

April 9, 2004.

Take notice that on April 7, 2004, the City of Hamilton, Ohio (Hamilton) filed a complaint against Texas Eastern Transmission, L.P. (Texas Eastern) pursuant to sections 5(a), 13, 14, and 16 of the Natural Gas Act, 15 U.S.C. 717d(a), 717l, 717m, and 717o, and rule 206 of the rules and regulations of the Federal Energy Regulatory Commission, 18 CFR 385.206 (2003). Hamilton alleges that Texas Eastern is violating Commission policy on market center development by employing a rate design and applying its tariff provisions in a way that severely impedes the natural formation of market centers and inhibits the flexible commercial interchange of natural gas. Hamilton alleges further that Texas Eastern's rate structure requires customers to pay for more transportation than they need because it is based on overly-expansive zones. Hamilton also alleges that Texas Eastern's rates violate the Commission's regulations by constraining shippers' rights to segmentation due to application of multiple fuel use charges, and violate the Commission's policies regarding backhauls.

Any person desiring to be heard or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding.

Any person wishing to become a party must file a motion to intervene. The answer to the complaint and all comments, interventions or protests must be filed on or before the comment date. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or for TTY, contact (202) 502-8659. The answer to the complaint, comments, protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Comment Date: April 29, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-837 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-98-000]

Southern Star Central Gas Pipeline, Inc.; Notice of Application

April 8, 2004.

On March 30, 2004, Southern Star Central Gas Pipeline, Inc. (Southern Star), 3800 Frederica Street, Owensboro, Kentucky 43201, filed an application in the above referenced docket, pursuant to sections 7(b) of the Natural Gas Act (NGA), and part 157 of the Federal Energy Regulatory Commission's (Commission) rules and regulations for an order permitting and approving the abandonment of four Type 26 compressor engines and auxiliary equipment at the Hugoton Compressor Station located in Grant County, Kansas. Southern Star states that the four Cooper Bessemer Type 26 compressor engines are no longer required to provide the service for which they were originally installed due to production decline from the Kansas-Hugoton Gas Field. Southern Star asserts that the horsepower additions at the Hugoton station approved by the Commission in 1968 and 1997 are more than sufficient to move Southern Star's current

contractual obligations as well as any anticipated future volumes. Furthermore, the Type 26 compressor engines are now inefficient to operate and maintain and, consequently, are no longer used and useful.

Southern Star states that the reclaim will include the twelve (12) engines previously abandoned and disconnected in 1968 and 1997 that still remain in the same place. The building housing of all of the Type 26 engines will be removed except for one section that will be used for storage. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the "e-Library" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, contact FERC at FERCOnlineSupport@ferc.gov or call toll-free, (866) 208-3676, or for TTY, (202) 502-8659.

Any questions regarding this application should be directed to David N. Roberts, Manager, Regulatory Affairs, at (270) 853-4654.

There are two ways to become involved in the Commission's review of this project. First, any person wishing to obtain legal status by becoming a party to the proceedings for this project should, on or before the comment date stated below file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a motion to intervene in accordance with the requirements of the Commission's rules of practice and procedure (18 CFR 385.214 or 385.211) and the regulations under the NGA (18 CFR 157.10). A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies of all documents filed by the applicant and by all other parties. A party must submit 14 copies of filings made in the proceeding with the Commission and must mail a copy to the applicant and to every other party. Only parties to the proceeding can ask for court review of Commission orders in the proceeding.

However, a person does not have to intervene in order to have comments considered. The second way to participate is by filing with the Secretary of the Commission, as soon as possible, an original and two copies of comments in support of or in opposition to this project. The Commission will consider these comments in determining the appropriate action to be taken, but the filing of a comment alone will not serve to make the filer a party to the proceeding. The Commission's rules require that persons filing

comments in opposition to the project provide copies of their protests only to the party or parties directly involved in the protest.

Persons who wish to comment only on the environmental review of this project should submit an original and two copies of their comments to the Secretary of the Commission. Environmental commenters will be placed on the Commission's environmental mailing list, will receive copies of the environmental documents, and will be notified of meetings associated with the Commission's environmental review process. Environmental commenters will not be required to serve copies of filed documents on all other parties. However, the non-party commenters will not receive copies of all documents filed by other parties or issued by the Commission (except for the mailing of environmental documents issued by the Commission) and will not have the right to seek court review of the Commission's final order.

Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Comment Date: April 29, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-850 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket Nos. ER04-577-000 and ER04-578-000]

Styrka Energy Fund Ltd., Styrka Energy Fund LLC; Notice Of Issuance Of Order

April 9, 2004.

Styrka Energy Fund Ltd. and Styrka Energy Fund LLC (together, Styrka) filed applications for market-based rate authority, with accompanying rate schedules. The proposed market-based rate schedules provide for wholesale sales of capacity, energy and ancillary services at market-based rates. Styrka also requested waiver of various Commission regulations. In particular, Styrka requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Styrka.

On April 7, 2004, pursuant to delegated authority, the Director, Division of Tariffs and Market Development—South, granted the request for blanket approval under part 34, subject to the following:

Any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Styrka should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214).

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is May 7, 2004.

Absent a request to be heard in opposition by the deadline above, Styrka is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Styrka, compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Styrka's issuances of securities or assumptions of liability.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "e-Library" link. Enter the docket number excluding the last three digits in the docket number filed to access the document. Comments, protests, and interventions may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-838 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-99-000]

Texas Gas Transmission, LLC; Notice of Request Under Blanket Authorization

April 8, 2004.

Take notice that on April 1, 2004, Texas Gas Transmission, LLC (Texas Gas), P.O. Box 20008, Owensboro, Kentucky 42304, filed in Docket No. CP04-99-000 a request pursuant to Sections 157.205 and 157.208(b) of the Commission's regulations under the Natural Gas Act (18 CFR 157.205 and 157.216) for authorization to replace the existing turbine at the Jeffersontown Compressor Station of Texas Gas in Jefferson County, Kentucky, under the authorization issued in Docket No. CP82-479-000 pursuant to section 7 of the Natural Gas Act, all as more fully described in the request.

Copies of this request are on file with the Commission and are available for public inspection. This filing may also be viewed on the Web at <http://www.ferc.gov> using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or for TTY, contact (202) 502-8659.

Texas Gas asserts that the proposed replacement is necessary in order to reduce nitrogen oxide emissions at the Texas Gas Jeffersontown Compressor Station in Jefferson County, Kentucky. Texas Gas states that the existing turbine/compressor package (T-1 unit) is rated at 12,090 NEMA horsepower. Texas Gas states further that the T-1 unit will be replaced with a new Solar Mars Model 100-T15000S gas turbine packaged with a Solar C652 two-stage gas compressor (T-2 unit). The T-2 unit, it is said, is rated at 13,330 NEMA horsepower. Texas Gas points out that the replacement would result in a net increase in the installed horsepower at the Jeffersontown of 1,240 HP. Texas Gas concludes that the additional horsepower at Jeffersontown would not increase the overall capacity of the pipeline system, as no additional gas can flow through the upstream constraints at Greenville, nor continue to flow through Jeffersontown through the downstream constraints through Dillsboro.

Texas Gas maintains that the estimated cost to install the replacement

unit would be \$13.5 million and would be financed from funds generated internally.

Any person or the Commission's Staff may, within 45 days after the issuance of the instant notice by the Commission, file pursuant to rule 214 of the Commission's procedural rules (18 CFR 385.214) a motion to intervene or notice of intervention and, pursuant to section 157.205 of the Commission's Regulations under the Natural Gas Act (NGA) (18 CFR 157.205) a protest to the request. If no protest is filed within the time allowed therefore, the proposed activity shall be deemed to be authorized effective the day after the time allowed for protest. If a protest is filed and not withdrawn within 30 days after the time allowed for filing a protest, the instant request shall be treated as an application for authorization pursuant to Section 7 of the NGA.

Comments, protests and interventions may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-851 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-92-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-92-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to Atmos Energy Corporation, formerly known as United Cities Gas Company, (Atmos) under Transco's Rate Schedule FS.

Transco states that it entered into a firm sales agreement with United Cities Gas Company, Georgia Division, on August 1, 1991, under which Transco sells gas to Atmos under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the

agreement (FS Agreement). Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Atmos with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-844 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-93-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-93-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to Southern Union Company (Southern Union) under Transco's Rate Schedule FS. In such application, Transco states that it entered into a firm sales agreement with Pennsylvania Gas & Water Company on August 1, 1991, under which Transco sells gas to Southern Union, successor to Pennsylvania Gas & Water Company, under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement).

Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Southern Union with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission

strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-845 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-94-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-94-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to Philadelphia Gas Works (PGW) under Transco's Rate Schedule FS.

Transco states that it entered into a firm sales agreement with PGW on August 1, 1991, under which Transco sells gas to PGW under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement).

Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25,

2003, Transco provided PGW with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-846 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-95-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-95-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to Piedmont Natural Gas Company, Inc. (Piedmont) under Transco's Rate Schedule FS. In such application, Transco states that it entered into a firm sales agreement with North Carolina Natural Gas Corporation on August 1, 1991, under which Transco sells gas to Piedmont, successor to North Carolina Natural Gas Corporation, under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement).

Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Piedmont with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission

strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-847 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-96-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-96-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to City of Danville, Virginia (Danville) under Transco's Rate Schedule FS, as more fully set forth in the application which is on file with the Commission and open to public inspection.

Transco states that it entered into a firm sales agreement with Danville on August 1, 1991, under which Transco sells gas to Danville under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement).

Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Danville with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-848 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-97-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-97-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to Town of Liberty, Mississippi (Liberty) under Transco's Rate Schedule FS. In such application, Transco states that it entered into a firm sales agreement with Liberty on August 1, 1991, under which Transco sells gas to Liberty under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement).

Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Liberty with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-849 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP04-91-000]

Transcontinental Gas Pipe Line Corporation; Notice of Application for Abandonment of Service

April 8, 2004.

Take notice that on March 30, 2004, Transcontinental Gas Pipe Line Corporation (Transco), filed in Docket No. CP04-91-000 an application, in abbreviated form, pursuant to section 7(b) of the Natural Gas Act, as amended, and part 157 of the rules and regulations of the Federal Energy Regulatory Commission, for an order permitting and approving abandonment of certain firm sales service provided to City of Butler, Alabama (Butler) under Transco's Rate Schedule FS.

Transco states that it entered into a firm sales agreement with Butler on August 1, 1991, under which Transco sells gas to Butler under Rate Schedule FS, with Buyer's Daily Sales Entitlement amount listed on Exhibit "A" to the agreement (FS Agreement). Transco states that the Primary Term of the FS Agreement ended on March 31, 2001. By letter dated March 25, 2003, Transco provided Butler with a two-year notice to terminate the subject FS Agreement as of April 1, 2005.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with sections 385.214 or 385.211 of the Commission's rules and regulations. All such motions or protests must be filed on or before the date as indicated below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at <http://www.ferc.gov> using the eLibrary. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659. The Commission strongly encourages electronic filings. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the e-Filing link.

Take further notice that, pursuant to the authority contained in and subject to the jurisdiction conferred upon the Commission by sections 7 and 15 of the Natural Gas Act and the Commission's rules of practice and procedure, a hearing will be held without further notice before the Commission on this application if no petition is filed within the time required herein, and the Commission on its own review of the matter finds that a grant of the abandonment is required by the public convenience and necessity. If a protest or petition for leave to intervene is timely filed, or if the Commission on its own motion believes that a formal hearing is required, further notice of such hearing will be duly given. Under this procedure, unless otherwise advised, it will be unnecessary for Transco to appear or to be represented at the hearing.

Comment Date: April 23, 2004.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-853 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC04-89-000, et al.]

Erie Boulevard Hydropower, L.P., et al.; Electric Rate and Corporate Filings

April 5, 2004.

The following filings have been made with the Commission. The filings are listed in ascending order within each docket classification.

1. Erie Boulevard Hydropower, L.P. and Orion Power New York GP II, Inc.

[Docket No. EC04-89-000]

Take notice that on April 2, 2004, Erie Boulevard Hydropower, L.P. (Erie) and Orion Power New York GP II, Inc. (GP II), pursuant to section 203 of the Federal Power Act, filed with the Commission an application seeking an order authorizing an internal corporate reorganization.

Comment Date: April 23, 2004.

2. Michigan Electric Transmission Company, LLC

[Docket No. ER03-1341-001]

Take notice that on March 30, 2004, Michigan Electric Transmission Company, LLC, (METC) in compliance with the Commission's order issued November 17, 2003, in Docket No. ER03-1341-000, submitted schedules showing its actual weighted average cost of long-term debt for calendar year 2003.

Copies of this filing were served on all parties included on the Commission's official service list established in this proceeding.

Comment Date: April 20, 2004.

3. PJM Interconnection, L.L.C.

[Docket No. ER04-378-002]

Take notice that on March 30, 2004, PJM Interconnection, L.L.C. (PJM) submitted for filing an errata to its March 25, 2004, compliance filing in Docket No. ER04-378-001 to revise the designation of the substitute construction service agreement among PJM, U.S. General Services Administration, White Oak Federal Research Center, and Potomac Electric Power Company submitted in the compliance filing.

PJM states that copies of this filing were served upon persons designated on the official service list compiled by the Secretary in this proceeding and the parties to the agreements.

Comment Date: April 20, 2004.

4. Hartford Steam Company

[Docket No. ER04-582-001]

Take notice that on March 30, 2004, Hartford Steam Company (Hartford Steam) filed an amendment to its February 25, 2004, Application for Acceptance of Initial Rate Schedule and Certain Waivers and Blanket Authorizations. Hartford Steam requests an effective date of February 25, 2004.

Comment Date: April 20, 2004.

5. Southwest Power Pool, Inc.

[Docket No. ER04-658-001]

Take notice that on March 30, 2004, Southwest Power Pool, Inc. (SPP) filed certain corrections to the proposed changes to the SPP Open Access Transmission Tariff (Tariff) filed with the Commission on March 17, 2004, in Docket No. ER04-658-000. SPP seeks an effective date of April 1, 2004, for these changes.

SPP has served a copy of its transmittal letter on each of its Members and Customers, and on all affected state commissions.

Comment Date: April 20, 2004.

6. New Light Energy, LLC

[Docket No. ER04-683-000]

Take notice that on March 30, 2004, New Light Energy, LLC (New Light) petitioned the Commission for acceptance of New Light Rate Schedule FERC Electric Tariff Original Volume No. 1; the granting of certain blanket approvals, including the authority to sell electricity at market-based rates; and the waiver of certain Commission regulations. New Light states that it intends to engage in wholesale electric power and energy purchases and sales as a marketer. New Light further states that it is not in the business of generating or transmitting electric power.

Comment Date: April 20, 2004.

7. Capital Center Generating Company, LLC

[Docket No. ER04-684-000]

Take notice that on March 30, 2004, Capital Center Generating Company, LLC (CCGC), submitted a Notice of Cancellation of its Rate Schedule FERC No. 1. CCGC states that it proposes to cancel Rate Schedule FERC No. 1 because CCGC no longer operates or sells power from the 6.5 MW gas-fired generating facility that it owns. CCGC requests an effective date of March 26, 2004.

Comment Date: April 20, 2004.

8. WPS Resources Operating Companies

[Docket No. ER04-685-000]

Take notice that on March 30, 2004, WPS Resources Operating Companies, on behalf of Wisconsin Public Service Corporation and Upper Peninsula Power Company (collectively, WPS Resources), tendered for filing a notice of cancellation and a revised service agreement cover sheet (Cancellation Documents) to terminate a service agreement between WPS Resources and Consolidated Water Power Company under WPS Resources' open access transmission tariff, FERC Electric Tariff, First Revised Volume No. 1. WPS Resources requests an effective date of March 1, 2004.

WPS Resources states that copies of the filing were served upon CWP, the Public Service Commission of Wisconsin and the Michigan Public Service Commission.

Comment Date: April 20, 2004.**9. Aleph One, Inc.**

[Docket No. ER04-686-000]

Take notice that on March 30, 2004, Aleph One, Inc. (Aleph One) petitioned the Commission to accept for filing Aleph One's FERC Electric Tariff No. 1 (Tariff No. 1) and grant Aleph One the blanket authority to make market-based sales of energy, capacity and ancillary services under its Tariff No. 1 and grant Aleph One such waivers and authorizations as have been granted by the Commission to other entities authorized to transact at market-based rates. Aleph One requests an effective date of March 31, 2004.

Comment Date: April 20, 2004.**10. PJM Interconnection, L.L.C.**

[Docket No. ER04-687-000]

Take notice that on March 30, 2004, PJM Interconnection, L.L.C. (PJM) submitted revisions to the Reliability Assurance Agreement Among Load-Serving Entities in The PJM Control Area and PJM West Reliability Assurance Agreement Among Long-Serving Entities in the PJM West Region to make minor modifications to the timing for approval of changes in the forecast pool requirement under such agreements. PJM requests an effective date of May 30, 2004, for the proposed revisions.

PJM states that copies of the filing were served on all PJM members and the utility regulatory commissions in the PJM region.

Comment Date: April 20, 2004.**Standard Paragraph**

Any person desiring to intervene or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. All such motions or protests should be filed on or before the comment date, and, to the extent applicable, must be served on the applicant and on any other person designated on the official service list. This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "FERRIS" link. Enter the docket number excluding the last three digits in the docket number filed to access the document. For assistance, call (202) 502-8222 or TTY, (202) 502-8659. Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Magalie R. Salas,*Secretary.*

[FR Doc. E4-835 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY**Federal Energy Regulatory Commission**

[Docket No. ER97-4335-007, et al.]

GEN-SYS Energy, et al.; Electric Rate and Corporate Filings

April 6, 2004.

The following filings have been made with the Commission. The filings are listed in ascending order within each docket classification.

1. GEN-SYS Energy

[Docket No. ER97-4335-007]

Take notice that on April 1, 2004, GEN-SYS Energy (GEN-SYS) submitted a compliance filing pursuant to the Commission's order issued March 2, 2004, in Docket No. ER97-4335-006.

Comment Date: April 22, 2004.**2. ISO New England Inc.**

[Docket No. ER02-2153-007]

Take notice that on April 1, 2004, ISO New England Inc. (ISO) submitted a compliance report pursuant to the Commission's order dated July 31, 2002, issued in Docket No. ER02-2153-000.

ISO states that copies of the filing have been served upon all parties to this proceeding and the New England utility regulatory agencies, and electronically upon the New England Power Pool participants.

Comment Date: April 22, 2004.**3. New England Power Pool, ISO New England Inc.**

[Docket No. ER02-2330-026]

Take notice that on March 31, 2004, ISO New England Inc. (ISO) submitted a Status Report on Development of Day-Ahead Demand Response Program in compliance with the Commission's November 17, 2003 Order on Requests for Rehearing and Compliance Filing, 105 FERC ¶ 61,211.

The ISO states that copies of the filing have been served on all parties to the above-captioned proceeding.

Comment Date: April 21, 2004.**4. San Diego Gas & Electric Company**

[Docket No. ER03-601-003]

Take notice that on April 1, 2004, San Diego Gas & Electric Company (SDG&E) tendered for filing its refund report pursuant to the Commission's Order Approving Uncontested Settlement, issued December 18, 2003, in Docket No. ER03-601-000, 105 FERC ¶ 61,301 (2003).

SDG&E states that copies of the filing were served on the California Public Utilities Commission, the California Independent System Operator, and all other parties in Docket No. ER03-601-000.

Comment Date: April 22, 2004.**5. New York Independent System Operator, Inc.**

[Docket No. ER04-230-004]

Take notice that on April 1, 2004, the New York Independent System Operator, Inc. (NYISO) submitted responses to the questions posed by the Commission's March 18, 2004, letter in Docket No. ER04-230-002 regarding the NYISO's Emergency Request for Rehearing in this proceeding.

The NYISO states that a copy of this filing has been served on all parties named on the official service list for this proceeding.

Comment Date: April 22, 2004.

6. Conectiv Bethlehem, LLC

[Docket No. ER04-231-002]

Take notice that on April 1, 2004, Conectiv Bethlehem, LLC (CBLLC), submitted a compliance filing pursuant to the Commission's March 24, 2004, order in Docket Nos. ER04-231-000 and 001, 106 FERC ¶ 61,272.

CBLLC states that copies of the filing were served upon the official service list in this proceeding.

Comment Date: April 22, 2004.

7. Duke Energy Lee, LLC

[Docket No. ER04-641-001]

Take notice that on April 1, 2004, Duke Energy Lee, LLC (Duke Lee) tendered for filing a supplement to its March 12, 2004, filing in ER04-641-000. Duke Lee requests an effective date of the date Commonwealth Edison Company (ComEd) joints PJM.

Comment Date: April 22, 2004.

8. Pacific Gas and Electric Company

[Docket No. ER04-688-000]

Take notice that on March 31, 2004, Pacific Gas and Electric Company (PG&E) tendered for filing, both on behalf of itself and Southern California Edison Company (SCE) a proposed Notice of Cancellation of PG&E Rate Schedule FERC No. 35 and SCE Rate Schedule No. 37. PG&E states that PG&E and SCE propose to terminate service they provide under the Contract with California Companies for Extra High Voltage Transmission and Exchange Service, Contract No. 14-006-200-2947A, between the Western Area Power Administration (Western) and PG&E, San Diego Gas & Electric Company (SDG&E) and SCE as of the date this contract expires, which is January 1, 2005.

PG&E states that copies of this filing have been served on Western, SCE, SDG&E, the California Public Utilities Commission and the California Independent System Operator Corporation.

Comment Date: April 21, 2004.

9. Pacific Gas and Electric Company

[Docket No. ER04-689-000]

Take notice that on March 31, 2004, Pacific Gas and Electric Company (PG&E) tendered for filing, both on behalf of itself and Southern California Edison Company (SCE) proposed Notices of Cancellation of PG&E Rate Schedule FERC Nos. 36 and 37 and SCE Rate Schedule FERC Nos. 38 and 39. PG&E states that PG&E and SCE propose to terminate service they provide under the Contract Between California Companies and State of California Department of Water Resources for Extra

High Voltage Transmission and Exchange Service and the Contract Between California Companies and Sacramento Municipal Utility District for Extra High Voltage Transmission and Exchange Service as of the date these contracts expire, which is January 1, 2005.

PG&E states that copies of this filing have been served on California Department of Water Resources, Sacramento Municipal Utility District, the California Public Utilities Commission, the California Independent System Operator Corporation, SCE and San Diego Gas & Electric Company.

Comment Date: April 21, 2004.

10. Pacific Gas and Electric Company

[Docket No. ER04-690-000]

Take notice that on March 31, 2004, Pacific Gas and Electric Company (PG&E) tendered for filing proposed Notices of Cancellation of PG&E Rate Schedule FERC Nos. 79, 63, 81, 126, 151 and 152 (between Western Area Power Administration (Western) and PG&E) and Notices of Cancellation of FERC Nos. 75 and 76 (between PG&E and Calaveras Public Power Agency and Tuolumne County Public Power Agency, respectively.) PG&E states that it proposes to terminate service it provides under these rate schedules as of the date the contracts between Western and PG&E expire, which is January 1, 2005. Included in the filing is one redesignated agreement and three proposed unexecuted replacement agreements, all between PG&E and Western.

PG&E states that copies of this filing have been served on Western, Calaveras Public Power Agency, Tuolumne County Public Power Agency, the California Public Utilities Commission, the California Independent System Operator Corporation, and all other affected parties.

Comment Date: April 21, 2004.

11. Alabama Power Company

[Docket No. ER04-692-000]

Take notice that on March 31, 2004, Alabama Power Company (APC) filed Revision No. 9 to Rate Schedule REA-1 of APC's FERC Electric Tariff, Original Volume No. 1. APC states that the revision sets forth the agreement between APC and Black Warrior Electric Membership Corporation and Tombigbee Electric Cooperative, Inc. regarding a rate increase. APC requests an effective date of July 1, 2004.

Comment Date: April 21, 2004.

12. Pacific Gas and Electric Company

[Docket No. ER04-693-000]

Take notice that on March 31, 2004, Pacific Gas and Electric Company (PG&E) tendered for filing a proposed Notice of Cancellation of PG&E Rate Schedule FERC No. 146. PG&E states that it proposes to terminate service it provides under the Coordinated Operations Agreement between Southern California Edison Company (SCE) and the Participants in the California-Oregon Transmission Project Governing the Coordinated Operation of the Pacific AC Intertie and the California-Oregon Transmission Project as of the date this contract expires, which is January 1, 2005. Included in the filing is a proposed unexecuted successor agreement.

PG&E states that copies of this filing have been served on the California Public Utilities Commission, Western Area Power Administration, Transmission Agency of Northern California, Carmichael Water District, City of Shasta Lake, City of Vernon, San Diego Gas & Electric Company, SCE, San Juan Suburban Water District, the California Independent System Operator Corporation and Bonneville Power Administration.

Comment Date: April 21, 2004.

13. Vermont Electric Cooperative, Inc.

[Docket No. ER04-694-000]

Take notice that on March 31, 2004, Vermont Electric Cooperative, Inc. (VEC) tendered for filing pursuant to section 205 of the Federal Power Act an Application for Market-Based Rate Authority. VEC requests an effective date of January 1, 2003.

VEC states that copies of the filing were mailed to the Vermont Public Service Board, the Vermont Department of Public Service, and the Secretary and General Counsel of New England Power Pool.

Comment Date: April 21, 2004.

14. New York Independent System Operator, Inc.

[Docket No. ER04-696-000]

Take notice that on March 31, 2004, the New York Independent System Operator, Inc. (NYISO), filed proposed revisions to the NYISO's Market Administration and Control Area Services Tariff (Services Tariff) and Open Access Transmission Tariff (OATT). NYISO states that the proposed revisions are intended to remove a condition on the application of certain rules limiting the extent to which prices at the Hydro Quebec external proxy bus can move to non-competitive levels.

NYISO has requested an effective date of May 30, 2004.

NYISO states that copies of this filing were served on all parties that have executed Service Agreements under the NYISO's OATT or Services Tariff, the New York State Public Service Commission and the electric utility regulatory agencies in New Jersey and Pennsylvania.

Comment Date: April 21, 2004.

15. New England Power Pool

[Docket No. ER04-697-000]

Take notice that on April 2, 2004, the New England Power Pool (NEPOOL) Participants Committee filed the One Hundred Third Agreement Amending New England Power Pool Agreement (the 103 Agreement) which amends and restates NEPOOL's existing Financial Assurance Policies and Billing Policy to implement a system for the weekly billing of and payment for charges in NEPOOL's hourly markets, and makes a conforming change to section 8.2 of the NEPOOL Open Access Transmission Tariff (the NEPOOL Tariff). NEPOOL seeks a June 1, 2004, effective date for these amendments.

The NEPOOL Participants Committee states that copies of these materials were sent to NEPOOL Participants and the New England State governors and regulatory commissions.

Comment Date: April 22, 2004.

16. Pacific Gas and Electric Company

[Docket No. ER04-700-000]

Take notice that on April 1, 2004, Pacific Gas and Electric Company (PG&E) tendered for filing a Coordinated Operations and Interconnection Agreement (COIA) between PG&E, Trans-Elect NTD Path 15 LLC and Western Area Power Administration.

PG&E states that copies of this filing have been served upon the California Public Utilities Commission and the California Independent System Operator Corporation and all parties on the official service list in Docket ER02-1672-000.

Comment Date: April 22, 2004.

17. American Electric Power Service Corporation

[Docket No. ER04-701-000]

Take notice that on April 1, 2004, American Electric Power Service Corporation (AEPSC) submitted for filing notices of succession reflecting the changes in name from Central Power and Light Company to AEP Texas Central Company and from West Texas Utilities Company to AEP Texas North Company.

Comment Date: April 22, 2004.

Standard Paragraph

Any person desiring to intervene or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. All such motions or protests should be filed on or before the comment date, and, to the extent applicable, must be served on the applicant and on any other person designated on the official service list. This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "FERRIS" link. Enter the docket number excluding the last three digits in the docket number filed to access the document. For assistance, call (202) 502-8222 or TTY, (202) 502-8659. Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-836 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC04-91-000, et al.]

Pacificorp, et al.; Electric Rate and Corporate Filings

April 8, 2004.

The following filings have been made with the Commission. The filings are listed in ascending order within each docket classification.

1. Pacificorp, Avista Corporation, Puget Sound Energy, Inc., and 2677588 Washington LLC

[Docket No. EC04-91-000]

Take notice that on April 6, 2004, Pacificorp, Avista Corporation, Puget Sound Energy, Inc., and 2677588 Washington LLC, (collectively, Applicants), filed with the Federal Energy Regulatory Commission an application pursuant to section 203 of

the Federal Power Act for authorization of a disposition of jurisdictional facilities whereby 2677588 Washington LLC, a limited liability company formed by TransAlta USA Inc. would purchase the Skookumchuck dam, hydroelectric facility and related assets (the Project). The Applicants states that the Project consists generally of an earth-fill dam, a one-megawatt hydroelectric generating facility and related equipment located in the vicinity of Centralia, Washington. Applicants do not believe that the proposed transaction requires section 203 approval, but nevertheless submit this Application to eliminate any doubt about jurisdictional assets prior to the closing of the sale. Applicants further states that the proposed sale does not require 2677588 Washington LLC to participate as an Applicant, but the purchaser nevertheless joins in this Application in order to ensure timely closing of the transaction.

Comment Date: April 27, 2004.

2. Oklaunion Electric Generating Cooperative, Inc.

[Docket No. EG04-52-000]

On April 6, 2004, Oklaunion Electric Generating Cooperative, Inc. (OEGC) filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to part 365 of the Commission's regulations.

OEGC states that pursuant to a Purchase and Sale Agreement dated as of January 31, 2004, OEGC will obtain an undivided 7.81% ownership interest in the Oklaunion Power Station, a 690 MW coal-fired facility located in Wilbarger County, Texas. OEGC further states that this purchase could occur as early as May 13, 2004. Golden Spread Electric Cooperative, Inc., OEGC's sole member, will purchase the output of the facility.

Comment Date: April 27, 2004.

3. MEP Pleasant Hill, LLC

[Docket No. ER99-2858-001]

Take notice that on April 5, 2004, MEP Pleasant Hill, LLC (MEPPH) pursuant to the Commission's order issued on June 17, 1999, in Docket No. ER99-2858-000, submitted for filing a notification of change in status regarding the facts the Commission relied upon in granting approval of market-based rates for MEPPH.

Comment Date: April 26, 2004.

4. Exelon Generation Company, LLC

[Docket Nos. ER01-948-000 and ER01-1008-000]

Take notice that on February 13, 2004, Exelon Generating Company, LLC

(Exelon Generation) submitted a filing withdrawing the power sales agreements between Commonwealth Edison Company, an affiliate of Exelon Generation, and Entergy-Koch Trading, LP¹ filed on January 12, 2001, in Docket No. ER01-1008-000 and January 19, 2001, in Docket No. ER01-1008-000.

Exelon Generation states that a copy of the filing has been served on the parties on the Commission's service list in these proceedings.

Comment Date: April 19, 2004.

5. Magnolia Energy LP

[Docket No. ER01-1335-003]

Take notice that on April 5, 2004, Magnolia Energy LP (Magnolia), submitted for filing with the Commission its triennial updated market analysis and revisions to its FERC Electric Tariff, Original Volume No. 1 to incorporate the Market Behavior Rules set forth in *Investigation of Terms and Conditions of Public Utility Market-Based Rate Authorizations*, 105 FERC ¶ 61,218 (2003).

Comment Date: April 26, 2004.

6. PJM Interconnection, L.L.C.

[Docket No. ER04-367-002]

Take notice that on April 2, 2004, PJM Interconnection, L.L.C. (PJM) and Commonwealth Edison Company and Commonwealth Edison Company of Indiana, Inc. (ComEd) submitted a compliance filing pursuant to the Commission's March 18, 2004, Order in this proceeding, 106 FERC ¶ 61,252 (2004). PJM and ComEd requested an effective date of May 1, 2004.

PJM and ComEd state that copies of the filing were served on all PJM members, the utility regulatory commissions in the PJM region, and all persons on the service list for this proceeding.

Comment Date: April 13, 2004.

7. Midwest Independent Transmission System Operator, Inc., and PJM Interconnection, L.L.C.

[Docket No. ER04-375-001]

Take notice that on April 2, 2004, the Midwest Independent Transmission System Operator, Inc. (Midwest ISO) and PJM Interconnection, L.L.C. (PJM) submitted a compliance filing pursuant to an order issued on March 18, 2004, in Docket No. ER04-375-000, 106 FERC ¶ 61,251.

Midwest ISO and PJM state that copies of the filing were served upon all

persons on the service list in this docket, as well as all PJM members, and each state electric utility regulatory commission in the PJM regions. Service upon Midwest ISO members and other stakeholders was requested to be waived; however, the filing is available on the Midwest ISO Internet site.

Comment Date: April 23, 2004.

8. Commonwealth Edison Company

[Docket No. ER04-589-001]

Take notice that on April 6, 2004, Commonwealth Edison Company (ComEd) submitted a filing withdrawing Original Service Agreement Nos. 767 through 779 under ComEd's FERC Electric Rate Tariff, Second Revised Volume No. 5. The service agreements were filed with the Commission on February 26, 2004.

ComEd states that a copy of the filing has been served on the parties on the Commission's service list and the Illinois Commerce Commission.

Comment Date: April 27, 2004.

9. Commonwealth Edison Company

[Docket No. ER04-594-000]

Take notice that on April 6, 2004, Commonwealth Edison Company (ComEd) submitted a filing withdrawing Original Service Agreement Nos. 780 through 784 under ComEd's FERC Electric Rate Tariff, Second Revised Volume No. 5. The service agreements were filed with the Commission on February 27, 2004.

ComEd states that a copy of the filing has been served on the parties on the Commission's service list and the Illinois Commerce Commission.

Comment Date: April 27, 2004.

10. Entergy Services, Inc.

[Docket No. ER04-699-000]

Take notice that on April 1, 2004, Entergy Services, Inc., on behalf of Entergy Arkansas, Inc., Entergy Gulf States, Inc., Entergy Louisiana, Inc., Entergy Mississippi, Inc., and Entergy New Orleans, Inc. (collectively, Entergy), filed proposed revisions to the Entergy Open Access Transmission Tariff (OATT), FERC Electric Tariff Second Revised Volume No. 3. Entergy states that the proposed revisions are designed to achieve greater independence and efficiency in the provision of transmission service, and the pricing of that service, on the Entergy system.

Comment Date: May 17, 2004.

11. Virginia Electric and Power Company

[Docket No. ER04-702-000]

Take notice that on April 2, 2004, Virginia Electric and Power Company

(Dominion Virginia Power) tendered for filing an Amended Contract designated as Second Revised Rate Schedule FERC No. 132, Service Agreement for Network Integration Transmission Service and Network Operating Agreement, designated as Service Agreement No. 381, and Service Agreement for Firm Point-To-Point Transmission Service, designated as Service Agreement No. 382. Dominion Virginia Power requests an effective date of January 1, 2004.

Comment Date: April 23, 2004.

12. MidAmerican Energy Company

[Docket No. ER04-703-000]

Take notice that on April 2, 2004, MidAmerican Energy Company (MidAmerican), tendered for filing with the Commission an Electric Interconnection Agreement between MidAmerican Energy Company and Northwest Iowa Power Cooperative, which incorporates the Third Amendment to the Agreement dated March 9, 2004. MidAmerican requests an effective date of the later of the effective date of the acceptance of this Agreement by the Commission or the approval of this Agreement, incorporating the Fifth Amendment by the Administrator of the Rural Utilities Service or the successor in interest to the Administrator, if the approval of the Administrator or such successor is required by law.

MidAmerican states that it has served a copy of the filing on the Iowa Utilities Board, the Illinois Commerce Commission and the South Dakota Public Utilities Commission.

Comment Date: April 23, 2004.

13. Premcor Generating LLC

[Docket No. ER04-704-000]

Take notice that on April 2, 2004, Premcor Generating LLC submitted for filing notification that Williams Generating Memphis, LLC was sold to Premcor Refining Group Inc. and the name has been changed to Premcor Generating LLC.

Comment Date: April 23, 2004.

14. Fitchburg Gas and Electric Light Company

[Docket No. ER04-707-000]

Take notice that on April 2, 2004, Fitchburg Gas and Electric Light Company (FG&E) tendered for filing pursuant to Commission Order No. 618 and section 205 of the Federal Power Act proposed changes in its transmission depreciation rates for its Pool Transmission Facilities that are indirectly subject to the formula rate in the New England Power Pool's open access transmission tariff. FG&E requests a June 1, 2004, effective date.

¹ ComEd's original counterparty to the agreement was CNG Power Services Corporation (CNG), but CNG subsequently assigned the agreement to Entergy Power and Marketing Corporation, which now is known as Entergy-Koch Trading, LP.

FG&E states that copies of the filing were served upon New England Power Company, ISO New England, Inc. and the Massachusetts Department of Telecommunications and Energy.

Comment Date: April 23, 2004.

15. Horsehead Corp.

[Docket No. ER04-708-000]

Take notice that on April 2, 2004, Horsehead Corp. (Horsehead) filed with the Commission a Notice of Succession adopting the FERC Electric Tariff, Original Volume No. 1 of Horsehead Industries, Inc. (Tariff) and a revised Tariff reflecting the name change from Horsehead Industries, Inc. to Horsehead Corp.

Comment Date: April 23, 2004.

16. Deseret Generation & Transmission Co-operative, Inc.

[Docket No. ER04-709-000]

Take notice that on April 2, 2004, Deseret Generation & Transmission Co-operative, Inc. (Deseret) tendered for filing an amendment to First Revised Service Agreement No. 5 under Deseret's FERC Electric Tariff, Original Volume 1, an Agreement for Large Industrial Rate between Deseret and one of its members, Moon Lake Electric Association, Inc. Deseret requests an effective date of May 1, 2004.

Deseret states that copies of this filing have been served upon Deseret's member cooperatives.

Comment Date: April 23, 2004.

17. PJM Interconnection, L.L.C.

[Docket No. ER04-710-000]

Take notice that on April 2, 2004, PJM Interconnection, L.L.C. (PJM), submitted for filing an executed interconnection service agreement (ISA) among PJM, PPL Susquehanna, L.L.C. and PPL Electric Utilities Corporation and notices of cancellation of an ISA that has been superseded. PJM requests a waiver of the Commission's 60-day notice requirement to permit a March 4, 2004, effective date for the ISA and the notices of cancellation.

PJM states that copies of this filing were served upon the parties to the agreements and the State regulatory commissions within the PJM region.

Comment Date: April 23, 2004.

18. Florida Keys Electric Cooperative Association, Inc.

[Docket No. ER04-713-000]

Take notice that on April 5, 2004, Florida Keys Electric Cooperative Association, Inc. (FKEC) tendered for filing a revised rate for non-firm transmission service provided to Keys Electric Services, Key West, Florida

(KES) in accordance with the terms and conditions of the Long-Term Joint Investment Transmission Agreement between the Parties.

FKEC states that a copy of this filing has been served on KES and the Florida Public Service Commissioner.

Comment Date: April 26, 2004.

19. American Electric Power Service Corporation

[Docket No. ER04-715-000]

Take notice that on April 5, 2004, the American Electric Power Service Corporation (AEPSC), as agent for Indiana Michigan Power Company (I&M), tendered for filing a Modification to the Letter Agreement (Agreement) between I&M and Northern Indiana Public Service Company. AEP requests an effective date of April 5, 2004.

AEPSC states that a copy of the filing was served upon Northern Indiana Public Service Company and the Indiana Utility Regulatory Commission and Michigan Public Service Commission.

Comment Date: April 26, 2004.

20. Atlantic City Electric Company

[Docket No. ER04-716-000]

Take notice that on April 5, 2004, Atlantic City Electric Company (Atlantic) tendered for filing an executed Interconnection Agreement between Atlantic and the City of Vineland, New Jersey (Vineland). Atlantic also tendered for filing a Notice of Cancellation of its Rate Schedule No. 74. Atlantic requests an effective date of March 20, 2004.

Atlantic states that copies of the filing were served upon Vineland and the State of New Jersey Board of Public Utilities.

Comment Date: April 26, 2004.

21. EcoEléctrica, L.P.

[Docket No. QF95-328-006]

Take notice that on April 2, 2004, EcoEléctrica, L.P. (EcoEléctrica) filed with the Federal Energy Regulatory Commission an application for recertification as a qualifying cogeneration facility (QF) pursuant to 292.207(b) of the Commission's regulations. No determination has been made that the submittal constitutes a complete filing.

EcoEléctrica states that the cogeneration facility (Facility) is located in Peñuelas, Puerto Rico and uses natural gas as its primary energy source. The Facility consists of two nominally rated 171,690 kW combustion turbine generators in combined-cycle, two multi-pressure heat recovery steam generators, and a single cylinder, single

flow, nominally rated 214,000 kW reheat steam turbine generator set and has a maximum gross electric power production capacity of 578 MW. The facility is interconnected with the Puerto Rico Electric Power Authority (PREPA). EcoEléctrica sells electric energy to PREPA. PREPA provides backup power, maintenance power and interruptible power to the Facility.

Comment Date: April 26, 2004.

Standard Paragraph

Any person desiring to intervene or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. All such motions or protests should be filed on or before the comment date, and, to the extent applicable, must be served on the applicant and on any other person designated on the official service list. This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "FERRIS" link. Enter the docket number excluding the last three digits in the docket number filed to access the document. For assistance, call (202) 502-8222 or TTY, (202) 502-8659. Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Magalie R. Salas,

Secretary.

[FR Doc. E4-855 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC04-90-000, et al.]

Portland General Electric Company, et al.; Electric Rate and Corporate Filings

April 7, 2004.

The following filings have been made with the Commission. The filings are listed in ascending order within each docket classification.

1. Portland General Electric Company and Oregon Electric Utility Company, LLC

[Docket No. EC04-90-000]

Take notice that on April 6, 2004, Portland General Electric Company (Portland General), an electric utility wholly owned by Enron Corp. (Enron) and Oregon Electric Utility Company, LLC (Oregon Electric), a newly formed Oregon limited liability company owned by funds managed by Texas Pacific Group, a private equity investment firm (collectively, the Applicants) filed with the Federal Energy Regulatory Commission pursuant to section 203 of the Federal Power Act for authorization of a transfer in control over Portland General that will result from the proposed sale by Enron to Oregon Electric of one hundred percent (100%) of Enron's ownership interest in Portland General.

Comment Date: April 27, 2004.

2. The Cincinnati Gas & Electric Company and PSI Energy, Inc.

[Docket Nos. ER96-2504-009 and ER96-2506-007]

Take notice that on April 1, 2004, the Cincinnati Gas & Electric Company and PSI Energy, Inc. (Cinergy Operating Companies) submitted corrections to their December 17, 2003, compliance filing amending the Cinergy Operating Companies' joint long-form market based rate tariff to incorporate the Commission's new market behavioral rules in accordance with the Commission's order issued November 17, 2003, in Docket Nos. EL01-118-000 and 001, 105 FERC ¶ 61,218 (2003).

Comment Date: April 22, 2004.

3. Old Dominion Electric Cooperative

[Docket No. ER97-4314-009]

Take notice that on April 1, 2004, Old Dominion Electric Cooperative (Old Dominion) submitted for filing a compliance filing in response to the Commission's order issued March 2, 2004, in Docket No. ER97-4314-008.

Old Dominion states that copies of this filing have been served (1) on each of Old Dominion's member cooperatives, (2) on the public service commissions in the Commonwealth of Virginia and the states of Delaware and Maryland and (3) on the official service list in Docket No. ER97-4314.

Comment Date: April 22, 2004.

4. Southern Company Services, Inc.

[Docket No. ER02-851-014]

Take notice that on March 17, 2004, Southern Company Services, Inc. submitted a Notification of Errata to Filing of Settlement, along with revised

tariff sheets, to correct errors concerning the formula rate for calculating transmission charges under Southern Companies' Open Access Transmission Tariff.

Comment Date: April 15, 2004.

5. PJM Interconnection, L.L.C., PJM Interconnection, L.L.C., and Midwest Independent System Operator, Inc.

[Docket Nos. ER04-521-001 and ER04-375-002]

Take notice that on April 5, 2004, PJM Interconnection, L.L.C. (PJM) and the Midwest Independent System Operator, Inc. (Midwest ISO) tendered a letter advising the Commission that the North American Electric Reliability Council (NERC) has approved, without modification, the reliability plans of PJM and the Midwest ISO. The parties filed this letter to meet the condition in the Commission's orders to make a filing describing the outcome of NERC's review along with any conditions imposed by NERC or changes to the filing required by NERC's action. PJM and Midwest ISO request that the Commission accept this submission by April 27, 2004.

Comment Date: April 13, 2004.

6. Hartford Steam Company

[Docket No. ER04-582-002]

Take notice that on April 1, 2004, Hartford Steam Company (Hartford Steam) submitted an errata filing to correct the inadvertent omission, from its March 30, 2004, filing amending its Application For Acceptance of Initial Rate Schedule of Hartford Steam Company and Certain Waivers and Blanket Authorizations, which was filed on February 25, 2004, in Docket No. ER04-582-000.

Hartford Steam states that copies of this errata filing have also been served on the parties to this proceeding.

Comment Date: April 22, 2004.

7. American Transmission Company LLC

[Docket No. ER04-695-000]

Take notice that on March 31, 2004, American Transmission Company LLC (ATCLLC) tendered for filing a Distribution-Transmission Interconnection Agreement between ATCLLC and the City of Juneau, as local distribution company. ATCLLC requests an effective date of March 11, 2004.

Comment Date: April 22, 2004.

8. Tor Power, Inc.

[Docket No. ER04-698-000]

Take notice that on April 1, 2004, Tor Power, LLC (Tor) petitioned the Commission for acceptance of Tor's

FERC Rate Schedule No. 1; the granting of certain blanket approvals, including the authority to sell electricity at market-based rates; and the waiver of certain Commission regulations. Tor states that it intends to engage in wholesale electric power and energy purchases and sales as a marketer and that it is not in the business of generating or transmitting electric power.

Comment Date: April 22, 2004.

9. Inland Pacific Resources Inc.

[Docket No. ER04-705-000]

Take notice that on April 2, 2004, Inland Pacific Resources Inc., (IPR), a subsidiary of Terasen Gas Inc. (Terasen) (formerly known as BC Gas Inc.), tendered for filing a Notice of Cancellation of its FERC Electric Rate Schedule No. 1. Terasen Gas requests an effective date of March 1, 2004.

Comment Date: April 23, 2004.

10. Dynegy Power Marketing, Inc.

[Docket No. ER04-711-000]

Take notice that on April 2, 2004, Dynegy Power Marketing, Inc. (DYPM) submitted for filing Rate Schedule FERC No.4, which is a market-based Power Purchase Agreement (the Interim PPA) between DYPM and its affiliate, Illinois Power Company (Illinois Power). DYPM states that the Interim PPA will go into effect only if the proposed sale of Illinois Power to Ameren Corporation (Ameren) in Docket No. EC04-81-000 is not completed by December 31, 2004, and will remain in effect until the earlier of the date the sale of Illinois Power is consummated or December 31, 2006 (the date of the expiration of the retail rate freeze in effect in the State of Illinois). DYPM requested that the Interim PPA be made effective as of January 1, 2005.

Comment Date: April 23, 2004.

11. Virginia Electric and Power Company

[Docket No. ER04-712-000]

Take notice that on April 2, 2004, Virginia Electric and Power Company, doing business as Dominion Virginia Power, tendered for filing tariff sheets in Virginia Electric and Power Company's FERC Electric Tariff, Second Revised Volume No. 5 (OATT) that provide Backup Supply Service for Retail Transmission Customers in Schedule 10 and delete Attachment L containing the rates terms and conditions for transmission service and ancillary services under Dominion Virginia Power's Retail Access Pilot Program. Dominion Virginia Power requests waiver of the Commission's notice of

filing requirements to allow the tariff sheets to become effective as of the date of the Virginia State Corporation Commission's (SCC) final order in Case No. PUE-2003-00118.

Dominion Virginia Power states that copies of the filing were served upon Dominion Virginia Power's customers under its OATT, the SCC and the North Carolina Utilities Commission.

Comment Date: April 23, 2004.

12. Florida Power & Light Company—New England Division

[Docket No. ER04-714-000]

Take notice that on April 1, 2004, Florida Power & Light Company—New England Divisions (FPL-NED), pursuant to section 205(c) of the Federal Power Act and section 35.13 of the Commission's regulations, tendered for filing its Open Access Transmission Tariff. FPL-NED states the purpose of this local network service tariff is to set forth the terms and conditions of local network service over FPL-NED's non-Pool Transmission Facilities located in the New England Power Pool (NEPOOL) control area, and to establish the rates for local network service.

Comment Date: April 22, 2004.

Standard Paragraph

Any person desiring to intervene or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with rules 211 and 214 of the Commission's rules of practice and procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. All such motions or protests should be filed on or before the comment date, and, to the extent applicable, must be served on the applicant and on any other person designated on the official service list. This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "FERRIS" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, call (202) 502-8222 or TTY, (202) 502-8659. Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The

Commission strongly encourages electronic filings.

Magalie R. Salas,

Secretary.

[FR Doc. E4-856 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Application for Non-Project Use of Project Lands and Waters and Soliciting Comments, Motions to Intervene, and Protests

April 9, 2004.

Take notice that the following application has been filed with the Commission and is available for public inspection:

a. *Application Type:* Non-project use of project lands and waters.

b. *Project No.:* 1490-034.

c. *Date Filed:* March 24, 2004.

d. *Applicant:* Brazos River Authority.

e. *Name of Project:* Morris Sheppard Hydroelectric Project.

f. *Location:* The project is located on the Possum Kingdom Reservoir on the Brazos River in Palo Pinto County, Texas. This project does not occupy any Federal or tribal lands.

g. *Filed Pursuant to:* Federal Power Act, 16 U.S.C. 791 (a) 825(r) and 799 and 801.

h. *Applicant Contact:* Mr. Gary Gwyn, Brazos River Authority, P.O. Box 7555, 4400 Cobbs Drive, Waco, Texas, 76714, (817) 776-1441.

i. *FERC Contact:* Any questions on this notice should be addressed to Brittany Schoenen at (202) 502-6097, or e-mail address: bschoenen@ferc.gov.

j. *Deadline for Filing Comments and or Motions:* May 10, 2004.

All documents (original and eight copies) should be filed with: Ms. Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington DC 20426. Please include the project number (P-1490-034) on any comments or motions filed. Comments, protests, and interventions may be filed electronically via the Internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages e-filings.

k. *Description of Request:* Brazos River Authority (Authority) is seeking Commission approval of the existing 154-slip Bluff Creek Marina and approval to permit the addition of 12 boat slips to the marina. Most of the

boat slips would be available for rental to the public.

l. *Location of the Application:* This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or for TTY, contact (202) 502-8659.

m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.

n. *Comments, Protests, or Motions to Intervene* — Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of rules of practice and procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

o. *Filing and Service of Responsive Documents* — Any filings must bear in all capital letters the title "COMMENTS", "RECOMMENDATIONS FOR TERMS AND CONDITIONS", "PROTEST", OR "MOTION TO INTERVENE", as applicable, and the Project Number of the particular application to which the filing refers. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. *Agency Comments* — Federal, State, and local agencies are invited to file comments on the described applications. A copy of the applications may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-839 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory
CommissionNotice of Application for Non-Project
Use of Project Lands and Waters and
Soliciting Comments, Motions to
Intervene, and Protests

April 9, 2004.

Take notice that the following application has been filed with the Commission and is available for public inspection:

a. *Application Type*: Non-project use of project lands and waters.

b. *Project No.*: 1490-035.

c. *Date Filed*: March 24, 2004.

d. *Applicant*: Brazos River Authority.

e. *Name of Project*: Morris Sheppard Hydroelectric Project.

f. *Location*: The project is located on the Possum Kingdom Reservoir on the Brazos River in Palo Pinto County, Texas. This project does not occupy any Federal or tribal lands.

g. *Filed Pursuant to*: Federal Power Act, 16 U.S.C. 791 (a) 825(r) and 799 and 801.

h. *Applicant Contact*: Mr. Gary Gwyn, Brazos River Authority, P.O. Box 7555, 4400 Cobbs Drive, Waco, Texas, 76714, (817) 776-1441.

i. *FERC Contact*: Any questions on this notice should be addressed to Brittany Schoenen at (202) 502-6097, or e-mail address: bschoenen@ferc.gov.

j. *Deadline for Filing Comments and or Motions*: May 10, 2004.

All documents (original and eight copies) should be filed with: Ms. Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington DC 20426. Please include the project number (P-1490-035) on any comments or motions filed. Comments, protests, and interventions may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages e-filings.

k. *Description of Request*: Brazos River Authority (Authority) is seeking Commission approval of the existing 124-slip Cliffs Marina and approval to permit the addition of 76 boat slips to the marina. Twenty-four slips will be added initially, and 52 slips will be added as public demand warrants. Most of the boat slips would be available for rental to the public.

l. *Location of the Application*: This filing is available for review at the Commission or may be viewed on the Commission's Web site at <http://www.ferc.gov>, using the "eLibrary" link.

Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or for TTY, contact (202) 502-8659.

m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.

n. *Comments, Protests, or Motions to Intervene*— Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of rules of practice and procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

o. *Filing and Service of Responsive Documents*— Any filings must bear in all capital letters the title "COMMENTS", "RECOMMENDATIONS FOR TERMS AND CONDITIONS", "PROTEST", OR "MOTION TO INTERVENE", as applicable, and the Project Number of the particular application to which the filing refers. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. *Agency Comments*—Federal, State, and local agencies are invited to file comments on the described applications. A copy of the applications may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-840 Filed 4-14-04; 8:45 am].

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory
Commission

[Project No. 2738-054]

New York State Electric & Gas
Corporation; Notice of Application
Tendered for Filing With the
Commission, Soliciting Additional
Study Requests, and Establishing
Procedural Schedule for Relicensing
and a Deadline for Submission of Final
Amendments

April 9, 2004.

Take notice that the following hydroelectric license application has been filed with the Commission and is available for public inspection.

a. *Type of Application*: New major license.

b. *Project No.*: P-2738-054.

c. *Date Filed*: April 5, 2004.

d. *Applicant*: New York State Electric & Gas Corporation (NYSEG).

e. *Name of Project*: Saranac River Hydroelectric Project.

f. *Location*: On the Saranac River, in Clinton County, New York. The project does not occupy Federal lands of the United States.

g. *Filed Pursuant to*: Federal Power Act 16 U.S.C. 791(a)-825(r).

h. *Applicant Contact*: Carol Howland, New York State Electric & Gas Corporation, Corporate Drive, Kirkwood Industrial Park, P.O. Box 5224, Binghamton, NY, 13902 (607) 762-8881.

i. *FERC Contact*: Tom Dean (202) 502-6041.

j. *Cooperating Agencies*: We are asking Federal, State, and local agencies and Indian tribes with jurisdiction and/or special expertise with respect to environmental issues to cooperate with us in the preparation of the environmental document. Agencies who would like to request cooperating status should follow the instructions for filing comments described in item l below. The Commission policy is that entities that cooperate in preparing an environmental document cannot also file a motion to intervene to become a party to the proceeding. See 94 FERC ¶61,076 (2001).

k. Pursuant to section 4.32(b)(7) of 18 CFR of the Commission's regulations, if any resource agency, Indian tribe, or person believes that an additional scientific study should be conducted in order to form a factual basis for complete analysis of the application on its merit, the resource agency, Indian tribe, or person must file a request for a study with the Commission not later than 60 days after the date of the

application filing and serve a copy of the request on the applicant.

1. Deadline for filing additional study requests and requests for cooperating agency status: June 4, 2004.

All documents (original and eight copies) should be filed with: Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

The Commission's rules of practice require all intervenors filing documents with the Commission to serve a copy of that document on each person on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

Additional study requests may be filed electronically via the Internet in lieu of paper. The Commission strongly encourages electronic filing. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site (<http://www.ferc.gov>) under the "e-Filing" link.

m. The application is not ready for environmental analysis at this time.

n. *Project Description:* The project consists of the following four developments:

The High Falls Development consists of the following existing facilities: (1) A 63-foot-high, 274-foot-long concrete gravity dam with spillway topped with 5-foot-high flashboards; (2) a 110-foot-long eastern wingwall and a 320-foot-long western wingwall; (3) a 46-acre reservoir; (4) an 800-foot-long, 19-foot-wide forebay canal; (5) a 11-foot by 12-foot, 3,581-foot-long tunnel; (6) a 10-foot-diameter, 1,280-foot-long penstock; (7) three 6-foot-diameter, 150-foot-long penstocks; (8) a 30-foot-diameter surge tank; (9) a powerhouse containing three generating units with a total installed capacity of 15,000 kW; (10) a 50-foot-long, 6.9-kV transmission line; and (11) other appurtenances.

The Cadyville Development consists of the following existing facilities: (1) A 50-foot-high, 237-foot-long concrete gravity dam with spillway topped with 2.7-foot-high flashboards; (2) a 200-acre reservoir; (3) a 58-foot-long, 20-foot-wide intake; (4) a 10-foot-diameter, 1,554-foot-long penstock; (5) a powerhouse containing three generating units with a total installed capacity of 5,525 kW; (6) a 110-foot-long, 6.6-kV transmission line; and (7) other appurtenances.

The Mill C Development consists of the following existing facilities: (1) A 43-foot-high, 202-foot-long stone masonry dam with spillway topped

with 2-foot-high flashboards; (2) a 7.9-acre reservoir; (3) a 37-foot-long, 18-foot-wide intake; (4) a 11.5-foot to 10-foot-diameter, 494-foot-long penstock; (5) a 11.1-foot to 10-foot-diameter, 84-foot-long penstocks; (6) one powerhouse containing two generating units with a total installed capacity of 2,250 kW; (7) another powerhouse containing a single generating unit with an installed capacity of 3,800 kW; (8) a 700-foot-long, 6.6-kV transmission line; and (9) other appurtenances.

The Kents Falls Development consists of the following existing facilities: (1) A 59-foot-high, 172-foot-long concrete gravity dam with spillway topped with 3.5-foot-high flashboards; (2) a 34-acre reservoir; (3) a 29-foot-long, 22-foot-wide intake; (4) a 11-foot-diameter, 2,652-foot-long penstock; (5) three 6-foot-diameter, 16-foot-long penstocks; (6) a 28-foot-diameter surge tank; (7) a powerhouse containing two generating units with a total installed capacity of 12,400 kW; (8) a 390-foot-long, 6.6-kV transmission line; and (9) other appurtenances.

o. A copy of the application is on file with the Commission and is available for public inspection. This filing may also be viewed on the Web at <http://www.ferc.gov> using the "eLibrary" link—select "Docket #" and follow the instructions. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll free at (866) 208-3676 or for TTY, contact (202) 502-8659. A copy is also available for inspection and reproduction at the address in item h above.

p. You may also register online at <http://www.ferc.gov/esubscribenow.htm> to be notified via e-mail of new filings and issuances related to this or other pending projects. For assistance, contact FERC Online Support. To view upcoming FERC events, go to www.ferc.gov and click on "View Entire Calendar."

q. With this notice, we are initiating consultation with the New York State Historic Preservation Officer (SHPO), as required by section 106, National Historic Preservation Act, and the regulations of the Advisory Council on Historic Preservation, 36 CFR 800.4.

r. *Procedural Schedule and Final Amendments:* The application will be processed according to the following Hydro Licensing Schedule. Revisions to the schedule will be made as appropriate. The Commission staff proposes to issue one environmental assessment (EA) rather than issue a draft and final EA. Comments, terms and conditions, recommendations, prescriptions, and reply comments, if

any, will be addressed in the EA. Staff intends to give at least 30 days for entities to comment on the EA, and will take into consideration all comments received on the EA before final action is taken on the license application.

Issue Acceptance or Deficiency Letter, July 2004

Issue Scoping Document, November 2004
Notice that application is ready for environmental analysis, January 2005
Notice of the availability of the EA, July 2005
Ready for Commission decision on the application, December 2005

Final amendments to the application must be filed with the Commission no later than 30 days from the issuance date of the notice of ready for environmental analysis.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-841 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Declaration of Intention and Soliciting Comments, Protests, and/or Motions To Intervene

April 9, 2004.

Take notice that the following application has been filed with the Commission and is available for public inspection:

a. *Application Type:* Declaration of Intention.

b. *Docket No.:* DI04-5-000.

c. *Date Filed:* March 11, 2004.

d. *Applicant:* Florida Hydro Power and Light Company, 171 Comfort Road, Palatka, FL 32177, telephone (386) 328-2470.

e. *Name of Project:* Gulf Stream Ocean Current Electricity Project.

f. *Location:* The proposed Gulf Stream Ocean Current Electricity Project, a cluster of electricity production units (EPU) connected by undersea transmission cables to a series of monitoring stations, would be located in a 1,000 square mile area on and off the Florida coast between Miami and Palm Beach. The initial project land station will be located on Singer Island in the City of Riviera Beach, Palm Beach County, Florida, connected by a transmission line to an EPU more than 3 miles offshore in the Atlantic Ocean.

g. *Filed Pursuant to:* Section 23(b)(1) of the Federal Power Act, 16 U.S.C. 817(b).

h. *Applicant Contact:* Michael J. Hoover, Florida Hydro Power and Light Company, 171 Comfort Road, Palatka,

FL 32177, telephone (386) 328-2470, fax (386) 328-2558, e-mail: mhoover@law.tulane.edu.

i. *FERC Contact:* Any questions on this notice should be addressed to Henry Ecton (202) 502-8768, or e-mail address: henry.ecton@ferc.gov.

j. *Deadline for Filing Comments and/or Motions:* May 10, 2004.

All documents (original and eight copies) should be filed with: Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. Comments, protests, and interventions may be filed electronically via the Internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site at <http://www.ferc.gov> under the "e-Filing" link.

Please include the docket number (DI04-5-000) on any comments or motions filed.

k. *Description of Project:* The proposed Gulf Stream Ocean Current Electricity Project would anchor a cluster of Electricity Production Units (EPU) more than three miles offshore, in a 1,000-square-mile area off the Florida coast between Miami and Palm Beach. Each EPU is approximately 240 feet long, with two counter-rotating fiberglass blades, and will incorporate buoyancy and anchoring systems, electrical generators, and transmission cables. The units would be anchored to the sea floor at a depth of more than 200 feet, eight per mile, and would generate approximately three megawatts of electricity, using the Gulf Stream current. The units would be connected to on-shore monitoring stations via undersea transmission cables. These on-shore stations will monitor pressure, temperature, vibration, RPM, and power output, and would be connected to an interstate power grid. The initial project would be located more than three miles offshore of the City of Riviera Beach, with a transmission line connecting to a land station on Singers Island. This land station would be connected to an interstate grid.

When a Declaration of Intention is filed with the Federal Energy Regulatory Commission, the Federal Power Act requires the Commission to investigate and determine if the interests of interstate or foreign commerce would be affected by the project. The Commission also determines whether or not the project: (1) Would be located on a navigable waterway; (2) would occupy or affect public lands or reservations of the United States; (3) would utilize surplus water or water power from a government dam; or (4) if applicable, has involved or would involve any construction subsequent to 1935 that

may have increased or would increase the project's head or generating capacity, or have otherwise significantly modified the project's pre-1935 design or operation.

l. *Locations of the Application:* Copies of this filing are on file with the Commission and are available for public inspection. This filing may be viewed on the Web at <http://www.ferc.gov> using the "e-Library" link, select "Docket#" and follow the instructions. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at (866) 208-3676, or TTY, contact (202) 502-8659.

m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.

n. *Comments, Protests, or Motions to Intervene*—Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of rules of practice and procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

o. *Filing and Service of Responsive Documents*—Any filings must bear in all capital letters the title "COMMENTS", "PROTESTS", AND/OR "MOTIONS TO INTERVENE", as applicable, and the Docket Number of the particular application to which the filing refers. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. *Agency Comments*—Federal, State, and local agencies are invited to file comments on the described application. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

[FR Doc. E4-842 Filed 4-14-04; 8:45 am]

BILLING CODE 6717-01-P

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7647-8]

EPA National Advisory Council for Environmental Policy and Technology—Compliance Assistance Advisory Committee; Notification of Public Advisory Committee Teleconference Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notification of Public Advisory Committee Teleconference Meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, Pub. L. 92-463, notice is hereby given that the Compliance Assistance Advisory Committee (CAAC) under the National Advisory Council for Environmental Policy and Technology (NACEPT) will meet in a public teleconference on Monday, May 10, 2004, from 1 p.m. to 3 p.m. eastern time. The meeting will be hosted out of Conference Room #6148, U.S. EPA, Ariel Rios Federal Building, 1200 Pennsylvania Avenue, NW., Washington, DC 20004. The meeting is open to the public, however, due to limited space, seating will be on a registration-only basis. For further information regarding the teleconference meeting, or how to register and obtain the phone number, please contact the individuals listed below.

Background: NACEPT is a federal advisory committee under the Federal Advisory Committee Act, Pub. L. 92-463. NACEPT provides advice and recommendations to the Administrator and other EPA officials on a broad range of domestic and international environmental policy issues. NACEPT consists of a representative cross-section of EPA's partners and principle constituents who provide advice and recommendations on policy issues and serves as a sounding board for new strategies that the Agency is developing. Additional information concerning the NACEPT can be found on our Web site (<http://www.epa.gov/ocem>). The CAAC, a subcommittee of NACEPT, provides a Federal advisory forum from which the Agency can receive valuable multi-stakeholder advice and recommendations on enhancing EPA's compliance assistance program. Purpose of Meeting: The CAAC will review and comment on the work done to date on: (1) Strengthening the national compliance assistance network; (2) developing and testing performance measurement systems to demonstrate the effectiveness of compliance assistance; and (3) integration of

compliance assistance into policies and practices of EPA and compliance assistance providers.

FOR FURTHER INFORMATION CONTACT: Members of the public wishing to gain access to the conference room on the day of the meeting or to obtain the teleconference phone number must contact Ms. Joanne Berman, Designated Federal Officer for the CAAC, U.S. Environmental Protection Agency (2224A), Office of Enforcement and Compliance Assurance, 1200 Pennsylvania Avenue, NW., Washington, DC 20460; telephone/voice mail at (202) 564-7064, fax at (202) 564-7083; or via e-mail at berman.joanne@epa.gov. The agenda and materials for the meeting will be available to the public upon request. Written comments from the public are welcome before, during or after the meeting. Individuals requiring special accommodation at this meeting, including wheelchair access to the conference room, should contact Ms. Berman at least five business days prior to the meeting so that appropriate arrangements can be made.

Dated: April 9, 2004.

Michael M. Stahl,

Director, Office of Compliance.

[FR Doc. 04-8575 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7647-9]

National Environmental Justice Advisory Council's (NEJAC) Puerto Rico Subcommittee; Notification of Public Comment Meeting (All Times Are Eastern Standard Time)

The Environmental Protection Agency Region II will sponsor a National Environmental Justice Advisory Council (NEJAC) Puerto Rico Subcommittee Public Meeting on Cumulative Risks and Impacts on May 7, 2004, in Ponce, Puerto Rico. Specifically, the public meeting will be held at the Inter American University—Ponce Campus, Room 123 Academic Building, located on Highway #1, Sabanetas Ward, Mercedita, Ponce. The meeting will start at 6:30 p.m. with a short presentation by the PR Subcommittee Chair on the draft report prepared by a work group of the NEJAC entitled Ensuring Risk Reduction in Communities with Multiple Stressors: Environmental Justice and Cumulative Impacts. The presentation will be followed by a public comment period pertaining to environmental justice issues associated to cumulative

risks and cumulative impacts on the island. The public meeting is scheduled to end at 8:30 p.m. A broad range of stakeholders and constituent groups from all of Puerto Rico are invited to participate to help develop general recommendations to address environmental justice issues related to cumulative risks and impacts on the island of Puerto Rico. A report and recommendations from the meeting will be prepared by the Puerto Rico Subcommittee and submitted to NEJAC for review and consideration in their final deliberations of the draft report. The NEJAC will then provide its comments to the EPA Administrator.

Members of the public who wish to make a brief oral presentation should pre-register by contacting Tere Rodríguez, Designated Federal Official, at (787) 977-5864 by May 4, 2004, to have time reserved on the agenda. Individuals or groups making oral presentations will be limited to a total time of five minutes. Written comments of no more than 10 pages should be received by May 4, 2004. Send your written comments to: Tere Rodríguez, Designated Federal Official (DFO) of the Puerto Rico Subcommittee, Caribbean Environmental Protection Division, U.S. Environmental Protection Agency, Centro Europa Building, Suite 417, 1492 Ponce De Leon Avenue, Stop 22, San Juan, PR 00907-4127. After May 4, you should hand deliver 15 copies of your written comments to the DFO at the meeting. For more information please call (787) 977-5864.

Tere Rodríguez,

Designated Federal Official, Puerto Rico Subcommittee, National Environmental Justice Advisory Council.

[FR Doc. 04-8577 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[OPPT-2003-0052; FRL-7323-8]

TSCA Confidential Business Information; Revised Security Manual; Notice of Availability

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of availability.

SUMMARY: EPA has adopted revisions to its procedures for handling confidential business information (CBI) under the Toxic Substances Control Act (TSCA). These revised procedures are set forth in a new *TSCA CBI Protection Manual* for Federal employees and contractors, the

availability of which is announced by this notice.

DATES: The requirements of the revised TSCA CBI Protection Manual were effective January 28, 2004.

ADDRESSES: The revised *TSCA CBI Protection Manual* is available for the public to view at the EPA Docket Center (Room B102), EPA West Building, 1301 Constitution Avenue, NW, Washington, DC 20460

FOR FURTHER INFORMATION CONTACT: For general information contact: Barbara Cunningham, Director, Environmental Assistance Division (7408M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (202) 554-1404; e-mail address: TSCA-Hotline@EPA.gov.

For technical information contact: Harry Lewis, Information Management Division (7407M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (202) 564-8642; e-mail address: lewis.harry@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general. Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the technical person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Copies of this Document and Other Related Information?

1. *Docket.* EPA has established an official public docket for this action under docket identification (ID) number OPPT-2003-0052. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the EPA Docket Center, Rm. B102-Reading Room, EPA West, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center is open from 8:30 a.m. to

4:30 p.m., Monday through Friday, excluding legal holidays. The EPA Docket Center Reading Room telephone number is (202) 566-1744 and the telephone number for the OPPT Docket, which is located in EPA Docket Center, is (202) 566-0280.

2. *Electronic access.* You may access this **Federal Register** document electronically through the EPA Internet under the **Federal Register** listings at <http://www.epa.gov/fedrgstr/>. The revised TSCA CBI Protection Manual is available for the public to view at the EPA Docket Center (Room B102), EPA West Building, 1301 Constitution Avenue, NW, Washington, DC 20460

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at <http://www.epa.gov/edocket/> to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select "search," then key in the appropriate docket ID number.

Certain types of information will not be placed in the EPA Dockets. Information claimed as CBI and other information whose disclosure is restricted by statute, which is not included in the official public docket, will not be available for public viewing in EPA's electronic public docket. EPA's policy is that copyrighted material will not be placed in EPA's electronic public docket but will be available only in printed, paper form in the official public docket. To the extent feasible, publicly available docket materials will be made available in EPA's electronic public docket. When a document is selected from the index list in EPA Dockets, the system will identify whether the document is available for viewing in EPA's electronic public docket. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. EPA intends to work towards providing electronic access to all of the publicly available docket materials through EPA's electronic public docket.

II. What Action is the Agency Taking?

EPA is issuing this notice to announce the availability of the revised TSCA security manual for Federal employees and contractors. The revised TSCA CBI

Protection Manual supersedes the previous edition of the TSCA Confidential Business Information Security Manual (April 1995). The revised manual includes changes and refinements in existing procedures developed since the publication of the previous manual. Several changes to the manual have been made as a result of EPA's continuing efforts to improve the procedures for handling TSCA CBI. None of these changes reduce the overall level of protection afforded TSCA CBI. Changes and clarifications include the following examples: (1) Updated and detailed rules for working with TSCA CBI on computers, including use of the EPA TSCA CBI secure local area network; (2) clarification that, notwithstanding supplemental administrative access requirements, legal access to TSCA CBI is conferred to Federal employees with a job-related need under Section 14 of TSCA; (3) clause in the Preface providing the Director of the Information Management Division, OPPT, with the authority to grant exceptions to prescribed procedures in the Manual in justified "extraordinary circumstances;" (4) expansion of the working papers exemption to TSCA CBI Document Control Officer (DCO) recordkeeping from only allowing an author/creator exclusive physical possession of their personal papers, to allowing them to be under the author/creator's control while in the temporary physical possession of another TSCA CBI authorized person; (5) clarifying the authority of the OPPT DCO to delegate TSCA CBI mailouts and receipts to other DCOs at EPA Headquarters; (6) detailed guidelines incorporating mandatory criteria for working with TSCA CBI in a personal residence; (7) change from annual audits required for contractor DCOs, to contractor and Federal baseline comprehensive audits followed by quadrennial comprehensive audits and annual transaction audits; and (8) for new-access contractor employees, replacement of Minimum Background Investigation (MBI) with National Agency Check and Inquiry (NACI) investigation. The Agency's policy on revisions to TSCA CBI security manuals was announced in the **Federal Register** of November 14, 1985 (50 FR 47108). EPA is publishing this notice in accordance with the requirements of that policy. EPA is printing and distributing copies of the revised manual to affected EPA offices. The provisions of the revised manual were effective January 28, 2004.

List of Subjects

Environmental protection,
Confidential business information.

Dated: April 1, 2004.

Charles M. Auer,

*Director, Office of Pollution Prevention and
Toxics.*

[FR Doc. 04-8459 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-S

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7648-1]

Connecticut Marine Sanitation Device Standard; Receipt of Petition

Notice is hereby given that a petition has been received from the State of Connecticut requesting a determination of the Regional Administrator, U. S. Environmental Protection Agency, pursuant to section 312(f)(3) of Public Law 92-500 as amended by Public Law 95-217 and Public Law 100-4, that adequate facilities for the safe and sanitary removal and treatment of sewage from all vessels are reasonably available for the area between Wamphassuc Point and Eastern Point, including portions of Fishers Island Sound, Pine Island Bay, Baker Cove, Mumford Cove, West Cove, Mystic Harbor, Mystic River, Quiambog Cove, lower portions of the Poquonnock River and lower portions of Palmer Cove in the State of Connecticut, to qualify as a "No Discharge Area" (NDA). The area covered under this petition extends from Eastern Point, Groton at (41°19'08.94" N by 72°04'31.09" W) due south to the boundary between Connecticut and New York at (41°15'54.55" N by 72°04'31.09" W), then northeasterly following the boundary between Connecticut and New York to (41°17'26.34" N × 72°01'10.94" W) then continuing northeasterly following the boundary between Connecticut and New York to (41°18'37.84" N × 71°55'47.63" W) then south east following the boundary between Connecticut and New York to a point due south of Wamphassuc Point at (41°18'28.99" N by 71°55'15.75" W), then due north past Noyes shoal to Wamphassuc Point (41°19'40.63" N by 71°55'15.75" W).

The State of Connecticut has certified that there are 13 pumpout units at 11 facilities located in Mystic, Noank, and Groton to service vessels within the proposed NDA. A list of the facilities, phone numbers, locations, and hours of operation is appended at the end of this petition. Of the 13 current facilities, nine are fixed shore-based facilities, two

are mobile carts, one is a mobile trailer mounted unit, and one is a mobile pumpout boat. Two facilities provide portable toilet holding tank dump stations. The majority of pumpout facilities discharge to town sewage systems, the carts and one other facility discharge into storage tanks which a licensed seepage hauler services. In addition, the majority of marinas provide public restrooms for boaters and other clientele.

The State of Connecticut used three different methods to estimate vessel population in the proposed NDA, and used the highest estimate of 3700 in their calculations to determine the number of pumpout facilities needed to adequately serve the boating public. The transient vessel population is estimated to be 200 at any point in time during the

boating season, which is included in the total figure. Of the estimated total of 3700 vessels using this area at any given time, approximately 1300 are of a size that may have sewage holding tanks and need pumpout services. The State has determined that the 13 pumpout facilities currently in service in the proposed NDA are sufficient to meet the potential demand and prevent the discharge of vessel sewage into coastal waters.

The coastline and coastal waters within the proposed NDA contain a variety of rich natural habitats and support a wide diversity of species, providing a range of recreational and commercial activities. There are 25 public beaches, 11 public boat ramps, and 4 parks or wildlife management areas within the proposed NDA. Both

recreational and commercial shell fishermen use the area for the harvest of hard clams, some oysters, and soft shell clams. In addition, fishing is commonplace and the species found in the area are smelt, small cod, flounder, scup, menhaden, and white perch.

Comments and reviews regarding this request for action may be filed on or before June 1, 2004. Such communications, or requests for information or a copy of the applicant's petition, should be addressed to Ann Rodney, U. S. Environmental Protection Agency—New England Region, One Congress Street, Suite 1100, CWQ, Boston, MA 02114-2023. Telephone: (617) 918-1538.

Dated: April 6, 2004.

Robert W. Varney,
Regional Administrator, Region 1.

Name	Location	Contact info.	Hours of operation	Mean low water depth	Fee
Shennecossett Yacht Club	Pine Island Bay	VHF CH 68, 860-445-7892	June-Sept., 9 a.m.-6 p.m.	7 feet	Members Free \$5 for non-members.
Pine Island Marina	Pine Island	VHF CH 68, 860-445-9729	Apr.-Nov., 9 a.m.-5 p.m.	8 feet	Free (portable cart).
Spicer's Noank Marina	Mystic Harbor West Cove	VHF CH 68, 860-536-4978	Apr.-Nov., 9 a.m.-5 p.m.	6 feet	Free self service portable cart \$20 Service by marina staff with portable cart free dump station).
Noank Shipyard	Mystic Harbor	VHF CH 9, 860-536-9651	Year round, 8 a.m.-4:30 p.m.	15 feet	\$5, free for customers.
Noank Village Boatyard	Mystic River, Noank	VHF CH 68, 860-536-1770	May-Dec., 8:30 a.m.-5 p.m.	8 feet	\$5 token for self service at stationary \$30 mobile service (1 stationary 1 portable).
Mystic Shipyard	Mystic Harbor	VHF CH 9, 68 860-536-6588	June-Sept., 8 a.m.-5 p.m., May-Oct., M-F 8 a.m.-5 p.m.	10 feet	Free.
Mystic Seaport Pumpouts	Mystic River	VHF CH 68, 860-572-0711	July-Aug., 8 a.m.-7 p.m., May, June, Sept., & Oct., 8 a.m.-4 p.m.	15 feet	Free (2 pumpouts).
Mystic Shipyard East	Mystic River	VHF CH 9, 68 860-536-4882	May-Oct., 8 a.m.-4 p.m.	3 feet	\$5, free for customers.
Brewer Yacht Yard at Mystic	Mystic River	860-536-2293	May-Nov., Sun-Thur. 8 a.m.-5 p.m., Fri.-Sat. 8 a.m.-8 p.m.	11 feet	\$5, free for customers.
Brower's Cove Marina	Mystic River	860-536-8864	Year Round 9 a.m.-5 p.m.	N/A (dump station only).	Free.
Mystic River Marina	Mystic River	VHF CH9, 860-536-3123	May-Sept., 8 a.m.-5 p.m.	9 feet	\$5.
Groton, Noank, Mystic Pumpout boat	Mystic River	VHF CH 68, 860-460-7336, 860-448-4084	Memorial Day-Oct., Sat., Sun. & Mon., holidays 10 a.m.-6 p.m.	N/A (boat)	Free.

[FR Doc. 04-8576 Filed 4-14-04; 8:45 am]

BILLING CODE 6560-50-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or

bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 10, 2004.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *The South Financial Group*, Greenville, South Carolina; to merge with CNB Florida Bancshares, Inc., Jacksonville, Florida, and thereby indirectly acquire CNB National Bank, Lake City, Florida.

2. *The South Financial Group*, Greenville, South Carolina; to merge with Florida Banks, Inc., Jacksonville, Florida and thereby indirectly acquire Florida Bank, National Association, Tampa, Florida.

In connection with this application, Applicant also has applied to acquire FB Financial Services, Inc., Jacksonville, Florida, and thereby engage in securities brokerage activities pursuant to section 225.28(b)(7)(i) of Regulation Y.

Board of Governors of the Federal Reserve System, April 9, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04-8528 Filed 4-14-04; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel Studies of Chemical Disposition in Mammals.

Date: May 28, 2004.

Time: 8:30 a.m. to 5:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: Nat. Inst. of Environmental Health Sciences, Building 101, Rodbell Auditorium, 111 T. W. Alexander Drive, Research Triangle Park, NC 27709.

Contact Person: RoseAnne M. McGee, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, P.O. Box 12233, MD EC-30, Research Triangle Park, NC 27709, (919) 541-0752.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: April 8, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-8495 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS-10082 OMB #0938-0898]

Emergency Clearance: Public Information Collection Requirements Submitted to the Office of Management and Budget (OMB)

AGENCY: Centers for Medicare and Medicaid Services, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare and Medicaid Services (CMS) (formerly known as the Health Care Financing Administration (HCFA)), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

We are, however, requesting an emergency review of the information collection referenced below. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, we have submitted to the Office of Management and Budget (OMB) the following requirements for emergency review. We are requesting an emergency review because the collection of this information is needed before the expiration of the normal time limits under OMB's regulations at 5 CFR Part 1320. The unanticipated lapse in the approval of this collection prior to implementation has resulted in the necessity to have the collection reinstated on an emergency basis. The information collection to be reinstated has not been modified from the version submitted to OMB under the regular PRA clearance process and approved on July 28, 2003.

CMS is requesting OMB review and approval of this collection within 15 days from the date of this publication, with an 180-day approval period.

Written comments and recommendations will be accepted from the public if received by the individuals designated below within 14 days from the date of this publication. (Note: An Emergency Federal Register Notice for this collection was published on March 19, 2004; however, due to a technical discrepancy with the material submitted to OMB which has since been corrected, OMB has requested that CMS republish the notice. All information below is identical to the material published on March 19th.)

Type of Information Collection

Request: Reinstatement without change.

Title of Information Collection:

Survey of States Performance Measurement Reporting Capability.

Form No.: CMS-10082 (OMB# 0938-0898).

Use: Because of the wide variability of Medicaid and SCHIP financing and service delivery approaches, there is little common ground from which to develop uniform reporting on performance measures by states. While CMS has decided on the first seven measures to be used, the ability of states to calculate those measures using HEDIS directly or HEDIS specifications (e.g., when calculating measures from fee-for-service claims data) is highly variable. Current efforts are focused on assessing the capability of each state to report on the selected measures and on helping states to make necessary adjustments in order to be able to report measures uniformly so that state-to-state comparisons can be made. To accomplish this, states will be requested to report available numerator and denominator data for the seven core HEDIS measures via a survey instrument created for this purpose. The data will be requested for each state's Medicaid and SCHIP programs by delivery system.

Frequency: Once.

Affected Public: State, local, and tribal government.

Number of Respondents: 51.

Total Annual Responses: 51.

Total Annual Hours: 2,360.

We have submitted a copy of this notice to OMB for its review of these information collections.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, E-mail your request, including your address, phone number, OMB number, and CMS document identifier, to jburke3@cms.hhs.gov, or call the Reports Clearance Office on (410) 786-4194.

Interested persons are invited to send comments regarding the burden or any other aspect of these collections of

information requirements. However, as noted above, comments on these information collection and recordkeeping requirements must be mailed and/or faxed to the designees referenced below, within 14 days of publication of this notice:

Centers for Medicare and Medicaid Services, Office of Strategic Operations and Regulatory Affairs, Room C5-14-03, 7500 Security Boulevard, Baltimore, MD 21244-1850, Fax Number: (410) 786-0262, Attn: Melissa Musotto CMS-10082, and,
Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Fax Number: (202) 395-6974 or (202) 395-5167, Attn: Katherine T. Astrich, CMS Desk Officer 0938-0898.

Dated: April 8, 2004.

John P. Burke III,

CMS Reports Clearance Officer, Paperwork Reduction Act Team Leader, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development and Issuances.

[FR Doc. 04-8530 Filed 4-14-04; 8:45 am]

BILLING CODE 4120-03-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS-250-254 and CMS-1964]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Centers for Medicare and Medicaid Services, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare and Medicaid Services (CMS) (formerly known as the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of

automated collection techniques or other forms of information technology to minimize the information collection burden.

1. Type of Information Request: Extension of a currently approved collection.

Title of Information Collection: Medicare Secondary Payer Information Collection and Supporting Regulations in 42 CFR 411.25, 489.2, and 489.20.

Form Number: CMS-250 through CMS-254 (OMB# 0938-0214).

Use: Medicare Secondary Payer (MSP) is essentially the same concept known in the private insurance industry as coordination of benefits and refers to those situations where Medicare does not have primary responsibility for paying the medical expenses of a Medicare beneficiary. Medicare intermediaries and carriers must collect information to perform various tasks to detect and process MSP cases.

Frequency: On occasion and Other: One time.

Affected Public: Individuals or households, Business or other for-profit, and not-for-profit institutions.

Number of Respondents: 134,553,682.

Total Annual Responses: 134,553,682;

Total Annual Hours Requested: 1,114,839.

2. Type of Information Collection Request: Revision of a currently approved collection.

Title of Information Collection: Request for Review of Part B Medicare Claim and Supporting Regulations in 42 CFR 405.807.

Form No.: CMS-1964 (OMB# 0938-0033).

Use: This form is the preferred manner to enable appellants to request a Part B review by a carrier.

Frequency: Other: as needed.

Affected Public: Individuals or Households, and not-for-profit institutions.

Number of Respondents: 6,860,000.

Total Annual Responses: 6,860,000.

Total Annual Hours: 1,715,000.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS Web site address at <http://cms.hhs.gov/regulations/prc/default.asp>, or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch,

Attention: Brenda Aguilar, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: April 8, 2004.

John P. Burke, III,

Paperwork Reduction Act Team Leader, CMS Reports Clearance Officer, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development and Issuances.

[FR Doc. 04-8531 Filed 4-14-04; 8:45 am]

BILLING CODE 4120-03-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Notice of Approval of New Animal Drug Application; Ceftiofur

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice that it has approved a supplemental new animal drug application (NADA) filed by Pharmacia & Upjohn, Co. The supplemental NADA provided revised susceptibility information for equine pathogens listed in the clinical microbiology section of labeling for ceftiofur sodium sterile powder for injection and added interpretive criteria. The applicable section of the regulations did not require amendment.

FOR FURTHER INFORMATION CONTACT:

Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7540, e-mail: melanie.berson@fda.gov.

SUPPLEMENTARY INFORMATION: Pharmacia & Upjohn, Co., 7000 Portage Rd., Kalamazoo, MI 49001-0199, filed a supplement to NADA 140-338 which provides for the veterinary prescription use of NAXCEL (ceftiofur sodium) Sterile Powder for Injection. The supplemental NADA provided updated susceptibility data for equine respiratory pathogens listed in the clinical microbiology section of labeling and added the National Committee for Clinical Laboratory Standards' interpretive criteria for equine isolates. In accordance with section 512(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(i)) and 21 CFR 514.105(a) and 514.106(a), FDA is providing notice that this supplemental NADA is approved as of February 27, 2004. The basis of approval is discussed in the freedom of information (FOI) summary.

In accordance with the FOI provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: March 19, 2004.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 04-8513 Filed 4-14-04; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N-0158]

Referral of ZONEGRAN (Zonisamide), WELLBUTRIN and ZYBAN (Bupropion), and RENAGEL (Sevelamer) for the Conduct of Pediatric Studies

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the referral of ZONEGRAN (zonisamide), WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer) to the Foundation for the National Institutes of Health (the Foundation) for the conduct of pediatric studies. FDA referred these drugs to the Foundation on November 14, 2003, and is publishing this notice of the referrals.

FOR FURTHER INFORMATION CONTACT:

Grace Carmouze, Center for Drug Evaluation and Research (HFD-960), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7777.

SUPPLEMENTARY INFORMATION:

I. Background

In accordance with section 4 of the BPCA (Public Law 107-109), FDA is announcing the referral to the Foundation of the written requests for the conduct of pediatric studies for ZONEGRAN (zonisamide),

WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer). Enacted on January 4, 2002, the BPCA reauthorizes, with certain important changes, the exclusivity incentive program described in section 505A of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355a). Section 505A of the act permits certain applications to obtain 6 months of exclusivity if, in accordance with the requirements of the statute, the sponsor submits requested information relating to the use of the drug in the pediatric population.

The BPCA established additional mechanisms for obtaining information on the safe and effective use of drugs in pediatric patients. Specifically, section 4 of the BPCA amends section 505A(d) of the act to create a referral process to obtain studies for drugs that have patent or exclusivity protection, but for which the sponsor has declined to conduct the pediatric studies in response to a written request by FDA. Under section 4 of the BPCA, if the Secretary of Health and Human Services (the Secretary) determines that there is a continuing need for the pediatric studies described in the written request and the sponsors of the products with patent or exclusivity protection have declined to conduct the studies, the Secretary shall refer the drug to the Foundation, established under section 499 of the Public Health Service Act (42 U.S.C. 290(b)), for the conduct of the pediatric studies described in the written request (21 U.S.C. 355a(d)(4)(B)(i)). In addition, the BPCA requires public notice of the name of the drug, name of the manufacturer, and indications to be studied pursuant to the referrals.

In accordance with section 4 of the BPCA, FDA is announcing that it has referred the written request for pediatric studies for ZONEGRAN (zonisamide), WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer) to the Foundation. On July 3, 2002, FDA issued a written request for pediatric studies to Elan Pharmaceuticals, the holder of approved applications for ZONEGRAN (zonisamide) that have market exclusivity. The studies described in the written request were for adjunctive therapy in the treatment of partial seizures in the pediatric population. Elan Pharmaceuticals declined to conduct the requested studies. FDA has determined that there is a continuing need for information relating to the use of ZONEGRAN (zonisamide) in the pediatric population.

On July 2, 2002, FDA issued a written request for pediatric studies to GlaxoSmithKline, the holder of approved applications for orally

administered WELLBUTRIN and ZYBAN (bupropion) that have market exclusivity. The studies described in the written request were for the indications of depression and smoking cessation in the pediatric population.

GlaxoSmithKline declined to conduct the requested studies. FDA has determined that there is a continuing need for information relating to the use of WELLBUTRIN and ZYBAN (bupropion) in the pediatric population.

On July 3, 2002, FDA issued a written request for pediatric studies to GelTex Pharmaceuticals, the holder of approved applications for RENAGEL (sevelamer) that have market exclusivity. The studies described in the written request were for the indication of hyperphosphatemia in the pediatric population. GelTex Pharmaceuticals declined to conduct the requested studies. FDA has determined that there is a continuing need for information relating to the use of RENAGEL (sevelamer) in the pediatric population.

Consistent with the provisions of the BPCA, on November 14, 2003, FDA referred to the Foundation the written requests for the conduct of the pediatric studies for ZONEGRAN (zonisamide), WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer).

Dated: April 7, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 04-8514 Filed 4-14-04; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-04-8006]

Memorandum of Understanding Between the Department of Health and Human Services of the United States Through the Food and Drug Administration and the Ministry of Maritime Affairs and Fisheries of the Republic of Korea Covering the Safety and Quality of Fresh and Frozen Aquacultured Molluscan Shellfish Exported From the Republic of Korea to the United States of America

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between the Department of Health and Human Services of the United States of America through the Food and Drug Administration (FDA) and the Ministry of Maritime Affairs and Fisheries of the Republic of Korea. This understanding is in keeping with the beneficial and cooperative work conducted under the terms of a 1988 MOU concerning the safety and quality of molluscan shellfish exported to the United States from the Republic of Korea. The purpose of the

MOU is to establish the set of guidelines to be implemented for assuring that molluscan shellfish exported from the Republic of Korea and offered for import into the United States of America are safe for human consumption and are harvested, processed, transported, and labeled in accordance with the provision of the U.S. National Shellfish Sanitation Program and the applicable requirements of the U.S. Federal Food and Drug and Cosmetic Act, the U.S. Public Health Service Act, the U.S. Fair Packaging and Labeling Act, and title 21 of the U.S. Code of Federal Regulations.

DATES: The agreement became effective October 28, 2003.

FOR FURTHER INFORMATION CONTACT: Paul W. Distefano, Center for Food Safety and Applied Nutrition (HFS-417), Food and Drug Administration, College Park, MD 20740, 301-436-1410.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this MOU.

Dated: March 24, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

BILLING CODE 4160-01-S

MEMORANDUM OF UNDERSTANDING

BETWEEN THE

MINISTRY OF MARITIME AFFAIRS AND FISHERIES
OF THE REPUBLIC OF KOREA

AND THE

DEPARTMENT OF HEALTH AND HUMAN SERVICES OF THE UNITED STATES OF
AMERICA THROUGH THE FOOD AND DRUG ADMINISTRATIONCOVERING THE SAFETY AND QUALITY OF FRESH AND FRESH FROZEN
MOLLUSCAN SHELLFISH EXPORTED FROM THE REPUBLIC OF KOREA
TO THE UNITED STATES OF AMERICA

The Ministry of Maritime Affairs and Fisheries (MOMAF) of the Republic of Korea and the Department of Health and Human Services of the United States of America, through the Food and Drug Administration (FDA), hereinafter referred as "The Participants,"

Desiring to safeguard public health and to ensure the safety and quality of fresh and fresh frozen molluscan shellfish that are or may be exported into the United States of America;

Wishing to maintain the long standing cooperation begun on November 24, 1972 when the Government of the United States of America signed a Shellfish Sanitation Agreement with the Government of the Republic of Korea in which both governments agreed to cooperate in seeking to assure that molluscan shellfish are safe and wholesome;

In keeping with the beneficial and cooperative work conducted under the terms of a 1998 Memorandum of Understanding concerning the safety and quality of molluscan shellfish exported to the United States of America from the Republic of Korea;

Recognizing that the Participants have held technical consultations leading to the successful development and implementation of an effective molluscan shellfish sanitation program in the Republic of Korea for molluscan shellfish;

Recognizing that nothing in this Memorandum of Understanding (MOU) will in any way abrogate the responsibility or authority of the FDA under section 801 of the Federal Food, Drug, and Cosmetic Act to examine, and, where appropriate, refuse admission of, any food product being offered for entry into the United States of America or to comply with and enforce any other law administered by the FDA; and

Acknowledging that the FDA recognizes the Korean Shellfish Sanitation Program (KSSP) and finds that the KSSP adequately meets U.S. National Shellfish Sanitation Program (NSSP) guidelines, and that MOMAF retains the overall responsibility for the KSSP and coordinates participation of the Korean Government in the Molluscan Shellfish Program

Have hereby reached the following understanding:

ARTICLE I Purpose

The purpose of this MOU is to establish the set of guidelines to be implemented for assuring that molluscan shellfish exported from the Republic of Korea and offered for import into the United States of America are safe for human consumption and are harvested, processed, transported, and labeled in accordance with the provisions of the NSSP Model Ordinance and the applicable requirements of the U.S. Federal Food, Drug, and Cosmetic Act, the U.S. Public Health Service Act, the U.S. Fair Packaging and Labeling Act, and Title 21 of the U.S. Code of Federal Regulations.

ARTICLE II Definitions

For the purpose of this MOU the words listed below will have the following meaning:

1. Approved means the classification used to identify a growing area where the harvest of molluscan shellfish for direct marketing is allowed.
2. Central file means the single location where MOMAF maintains a copy of all information, data, reports, and maps associated with the KSSP.
3. Lot of shellstock means a collection of bulk shellstock or containers of shellstock of no more than one day's harvest from a single defined growing area harvested by one or more harvesters.
4. Lot of shucked molluscan shellfish means a collection of containers of shucked molluscan shellfish of no more than one day's harvest from a single defined growing area, produced under conditions as nearly uniform as possible, and designated by a common container code or marking.
5. Marine biotoxins means any poisonous compound produced by marine microorganisms and accumulated by shellstock.
6. Korean Shellfish Sanitation Program (KSSP) means the regulatory control program in the Republic of Korea designed to ensure the safety of molluscan shellfish intended for export

to the United States of America through the implementation of control measures set forth in the NSSP.

7. Molluscan Shellfish, means all edible species of oysters, clams, mussels, and whole or roe on scallops; either shucked or in the shell, fresh or fresh frozen, whole or in part.
8. National Shellfish Sanitation Program (NSSP) means the cooperative state (domestic and foreign)-FDA-industry program to ensure the safety and quality of molluscan shellfish intended for human consumption. Guidelines for ensuring the safety and quality of molluscan shellfish are set forth in the NSSP Model Ordinance.
9. Patrol means the active control of molluscan shellfish harvesting to ensure that only molluscan shellfish from approved areas are harvested, processed, and shipped.
10. Relay means the transfer of shellstock from unapproved areas to approved areas for the purpose of reducing pathogens as measured by the coliform indicator group or poisonous or deleterious substances that may be present in the shellstock by using the ambient environment as the treatment process.
11. Sanitary Survey Report means the written evaluation report of all environmental factors, including actual and potential pollution sources, which have a bearing on the water quality in a molluscan shellfish growing area.
12. Shellstock means live molluscan shellfish in the shell.

ARTICLE III Obligations of the Participants

A. RESPONSIBILITIES OF MOMAF

1. MOMAF assumes the commitment of overall responsibility for the coordination and implementation of the KSSP.
2. MOMAF intends to:
 - a. Maintain legal, administrative, safety, quality, and sanitary controls over molluscan shellfish intended for export to the United States of America by certified Korean processors.
 - b. Ensure that the KSSP conforms to the NSSP, including, but not limited to:
 - i. classifying molluscan shellfish growing waters;
 - ii. preparing sanitary survey reports and maintaining sanitary survey reports and all related data in the central file;

- iii. updating sanitary survey reports annually and triennially for the purpose of ensuring the proper classification of each molluscan shellfish growing area;
- iv. approving and supervising harvesting and relaying operations and ensuring proper labeling and identification of molluscan shellfish in accordance with the NSSP;
- v. restricting the harvest of molluscan shellfish from unapproved growing areas, controlling the harvest of molluscan shellfish from unapproved growing areas, and taking enforcement action against persons or firms harvesting from unapproved growing areas;
- vi. prohibiting the harvest of molluscan shellfish from growing areas in response to contamination emergencies and for rescinding such prohibitions when water quality data or marine biotoxin analyses demonstrate that the area meets NSSP approved area criteria;
- vii. recalling unsafe molluscan shellfish when the responsible processor fails to carry out the necessary product recall;
- viii. maintaining NSSP conforming laboratories certified to participate in the KSSP;
- ix. inspecting processors that process fresh or fresh frozen molluscan shellfish for export to the United States of America to ensure compliance with NSSP controls;
- x. certifying processors exporting fresh or fresh frozen molluscan shellfish to the United States of America in accordance with the NSSP for listing on FDA's Interstate Certified Shellfish Shippers List (ICSSL);
- xi. notifying FDA of the name, location and certification number of KSSP certified processors exporting to the United States of America on Form FD-3038, "Shellfish Dealer Certification";
- xii. canceling the certification of any processor that:
 - operates out of compliance with the NSSP;
 - ships molluscan shellfish from unapproved growing areas; or
 - ships molluscan shellfish that otherwise do not conform to the requirements of the U.S. Federal Food, Drug, and Cosmetic Act,

the U.S. Public Health Service Act, the U.S. Fair Packaging and Labeling Act, or Title 21 of the U.S. Code of Federal Regulations.

- fails to recall molluscan shellfish determined to be unsafe for human consumption;
 - xiii. ensuring that each container in a lot of molluscan shellfish certified for export to the United States of America is properly labeled in accordance with the NSSP;
 - xiv. maintaining a central file of all KSSP records, including an English version of all sanitary survey reports, patrol reports, and laboratory evaluation reports and make them available to FDA upon request;
 - xv. providing FDA evaluation reports, interpretations, laboratory quality assurance program information, and other molluscan shellfish program information from FDA to federal government agencies having responsibility for the KSSP;
 - xvi. reviewing, at least annually, the level of conformity with the NSSP and summarizing the findings in a written report and providing an English translation of the report to FDA annually;
 - xvii. providing FDA with information concerning current or potential public health problems affecting molluscan shellfish intended for export to the United States of America; and
 - xviii. making travel arrangements in the Republic of Korea for, and conducting joint inspections with, FDA evaluation officers at FDA's request. Providing transportation for FDA officials while in the Republic of Korea.
- c. Permit the harvesting of molluscan shellfish for processing by KSSP certified processors and shipment to the United States of America only from growing areas approved by MOMAF with concurrence from the FDA.
- d. Within 30 days of written notification from FDA of NSSP deficiencies, develop a written Corrective Action Plan, and submit it to FDA for review and concurrence. If a Plan is not developed within 30 days, FDA will remove Korean processors from the ICSSL and/or take other appropriate action to prevent molluscan shellfish from the Republic of Korea from entering the United States of America. In case of a serious public health threat, this 30 day period may be reduced or eliminated. Such action should remain in effect until all KSSP deficiencies have been corrected and FDA has determined that the KSSP is in compliance with the NSSP.

3. MOMAF may designate a KSSP laboratory evaluation officer to:
 - a. certify laboratories participating in the KSSP;
 - b. periodically evaluate certified KSSP laboratories to verify compliance with the NSSP and maintain laboratory quality assurance procedures;
 - c. maintain a marine biotoxin monitoring program for growing areas where molluscan shellfish are harvested for export to the United States of America;
 - d. maintain a split-sample program among KSSP laboratories for evaluating uniform microbiological laboratory practices;
 - e. notify FDA of laboratories not in compliance with the NSSP; and
 - f. prevent KSSP laboratories not in compliance with the NSSP from participating in the KSSP.
4. MOMAF should update the KSSP Model Ordinance to be consistent with published NSSP Model Ordinance revisions. MOMAF should provide an English version of all updates to FDA for review and concurrence.
5. Any change in responsibility from MOMAF to another authority must be reported to FDA within 30 days of such change. A change from MOMAF to a new authority may require re-evaluation of the KSSP by FDA.

B. RESPONSIBILITIES OF THE FDA

FDA intends to:

1. Accept the Republic of Korea as a participant in the NSSP and the Interstate Shellfish Sanitation Conference (ISSC), cooperative research programs, seminars, training courses, and other NSSP activities and have MOMAF certify Korean processors for inclusion in FDA's ICSSL.
2. Publish the names, locations, and certification numbers of Korean firms certified by MOMAF in the ICSSL upon receipt of Form FD-3038.
3. Provide training and technical assistance to MOMAF, subject to the availability of funds and personnel for such purposes.
4. Inform MOMAF of the reasons for any detention of certified molluscan shellfish shipments from the Republic of Korea.

5. Participate with MOMAF in joint evaluations of the KSSP. Joint evaluations will be conducted to ascertain the level of conformity with the requirements of the NSSP and with the responsibilities specified in this MOU. FDA should pay round trip transportation expenses between the United States of America and the Republic of Korea and the per diem of the members of the FDA evaluation team while in the Republic of Korea.
6. Notify MOMAF of NSSP deficiencies and request that MOMAF submit, within 30 days, a written Corrective Action Plan to FDA for review and concurrence. If a Plan is not developed within 30 days or if the deficiencies are not corrected in accordance with the Plan, FDA will remove Korean processors from the ICSSL and/or take other appropriate action to prevent Korean molluscan shellfish from entering the United States of America. In case of a serious public health threat, this 30-day period may be reduced or eliminated. Such action should remain in effect until all NSSP deficiencies have been corrected and FDA has determined that the KSSP is in compliance with the NSSP.
7. Remove individual Korean processors from the ICSSL when it is determined by FDA or MOMAF that a processor is not in compliance with the NSSP or when an imminent health hazard exists with a processor's product.
8. Report any change in responsibility from FDA to another federal authority to MOMAF within 30 days of such change.

ARTICLE IV

Technical Information Exchange

The working language for documents exchanged under this MOU should be English. The Participants plan to share expertise, provide assistance, and exchange information. Such mutual cooperation may include, but is not be limited to:

1. Exchanging information concerning proposed and final changes in KSSP operations and procedures including, but not limited to:
 - a. methods and procedures for sampling;
 - b. methods of analysis;
 - c. methods of confirmation;
 - d. administrative guidelines, tolerances, specification standards, and nomenclature;
 - e. reference standards; and
 - f. inspection procedures.

2. Providing written notification to the other Participant within 30 days of changes in liaison officers. Changing liaison officers does not otherwise constitute a change in the provisions of this MOU.
3. Facilitating the exchange of information between MOMAF and U.S. Federal and State agencies concerned with the introduction and proliferation of exotic organisms that might be carried by Korean molluscan shellfish.

ARTICLE V Liaison Officers

In order to obtain an adequate follow up of the cooperation activities derived from this MOU, the liaison officers will be

A. For MOMAF:

Director, Fisheries Policy Bureau
Ministry of Maritime Affairs and Fisheries (MOMAF)
50 Chungjeong-no, Seodaemun-gu
120-715, Seoul, Korea
Telephone: 82 2 3148-6800

First Secretary for Maritime Affairs and Fisheries
Embassy of the Republic of Korea
2450 Massachusetts Avenue
Washington, D.C. 20008
The United States of America
Telephone: 01 202 939-5676

B. For the Food and Drug Administration:

Director, Office of Seafood
Center for Food Safety and Applied Nutrition
Food and Drug Administration,
5100 Paint Branch Parkway (HFS-400)
College Park, MD 20740
The United States of America
Telephone: 01 301 436-2300

ARTICLE VI

Final Dispositions

Activities under this MOU commence upon signature by both Participants and continue for five (5) years. It may be extended with written consent of both Participants.

The Participants intend to evaluate the MOU during the five-year period. It may be amended by written consent of both Participants, specifying the date in which the activities will commence.

All activities undertaken pursuant to this MOU are to be conducted in accordance with the laws and regulations of the United States of America and the Republic of Korea and are subject to the availability of personnel, resources, and appropriated funds.

This MOU is not intended to create any obligations under international or other law.

IN WITNESS WHEREOF the undersigned, being duly authorized by their respective Government agencies, have signed this Memorandum of Understanding.

Signed at Washington, D. C. ^{and Rockville, Maryland} on this twenty-eighth day of October 2003 in duplicate in the English language. _N

FOR THE MINISTRY OF MARITIME
AFFAIRS AND FISHERIES OF THE
REPUBLIC OF KOREA

FOR THE FOOD AND DRUG
ADMINISTRATION, DEPARTMENT OF
HEALTH AND HUMAN SERVICES OF
THE UNITED STATES OF AMERICA

On behalf of the Ambassador,
Jung Hwa Choo
Economic Minister

On behalf of the Commissioner
Murray H. Lumpkin
Principal Associate
Commissioner

HAN SUNG-JOO

Ambassador to the United States
Embassy of the Republic of Korea

MARK B. McCLELLAN, M.D., Ph.D.

Commissioner of Food and Drugs

[FR Doc. 04-8443 Filed 4-14-04; 8:45 am]
BILLING CODE 4160-01-C

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide C16Y

K.E. Csaky (NEI), M.L. Ponce (NEI), H. Kleinman (NIDCR)
PCT Application No. PCT/US04/04142 filed 12 Feb 2004 (DHHS Reference No. E-008-2004/0-PCT-01)
Licensing Contact: Susan Rucker; 301/435-4478; *ruckersu@mail.nih.gov*.

This application relates to the field of anti-angiogenesis. In particular, the application describes and claims compositions and methods useful for treating diseases associated with angiogenesis such as macular degeneration (AMD), diabetic retinopathy, neovascular glaucoma and cancers associated with solid tumors particularly, breast cancer. The compositions and methods offer alternatives to other ocular anti-angiogenic agents currently in development due to their ease of manufacture and mode of action on an integrin pathway.

The compositions and methods utilize a synthetic peptide of between 8 and 12

amino acid residues derived from a region of the $\gamma 1$ chain of laminin-1 that binds to endothelial cell integrins $\alpha v \beta 3$ and $\alpha 5 \beta 1$. The preferred embodiment, designated C16Y, is 12 amino acids in length and is easily prepared by conventional peptide synthesis. The anti-angiogenic properties of the C16Y peptide have been demonstrated in an *in vitro* model of choroidal neovascularization and in tumor-bearing mice.

This work has been published, in part at ML Ponce et al., Cancer Research 63(16): 5060 (Aug 15, 2003).

Hybrid Adeno-Retroviral Vector for the Transformation of Cells

Changyu Zheng, Brian C. O'Connell, Bruce J. Baum (NIDCR)

U.S. Provisional Application No. 60/179,327 filed 31 Jan 2000 (DHHS Reference No. E-258-1998/0-US-01); PCT Application No. PCT/US01/03026 filed 30 Jan 2001 (DHHS Reference No. E-258-1998/0-PCT-02); U.S. Patent Application No. 10/182,644 filed 30 Jul 2002 (DHHS Reference No. E-258-1998/0-US-03)

Licensing Contact: Jesse Kindra; 301/435-5559; *kindraj@mail.nih.gov*.

The invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation, either *in vivo* or *in vitro*. The hybrid vectors have an adenoviral backbone with retroviral long terminal repeats (LTRs). Such vectors are capable of transforming dividing or non-dividing cells and integrate stably into the chromosome providing a means of efficient, reliable, long-term gene expression. The vector was packaged as a recombinant adenovirus and delivered to the target cell. Unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest, and retroviral structural proteins are not required.

This work has been published, in part, in: Zheng *et al.*, Nature Biotechnol. (2000 Feb) 18(2):176-180; Zheng *et al.*, Biochem. Biophys. Res. Commun. (2002 Feb 15) 291(1):34-40; Zheng *et al.*, Biochem. Biophys. Res. Commun. (2003 Jan 3) 300(1):115-20; Zheng *et al.*, Virology (2003 Sep 1) 313(2):460-72.

Antitumor Macrocyclic Lactones

Michael R. Boyd (NCI)

U.S. Patent No. 6,353,019 issued 05 Mar 2002 (DHHS Reference No. E-244-1997/0-US-07) and related foreign patent applications; and

Vacuolar-Type (H⁺)-ATPase-Inhibiting Compounds and Uses Thereof

Michael R. Boyd (NCI)

U.S. Patent Application No. 09/914,708 filed 31 Aug 2001 (DHHS Reference No. E-244-1997/3-US-06) and related foreign patent applications
Licensing Contact: George Pipia; 301/435-5560; *pipia@mail.nih.gov*.

This technology covers a broad composition of matter which includes the salicylalamides, lobatamides, and numerous other structurally related small molecules which have been shown to inhibit mammalian vacuolar ATPase at low nanomolar concentrations. The compounds are also potent inhibitors of cancer cell growth, with particular specificity for melanoma, osteosarcoma and selected lung, colon and CNS tumor cell lines. Experimental tumor and pharmacokinetic studies are underway to select the most effective analogs for further development. The potential of these compounds to inhibit invasion and metastasis to bone sites is also under investigation.

Dated: April 7, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-8493 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Meeting; Interagency Autism Coordinating Committee

The National Institutes of Health (NIH) hereby announces a meeting of the Interagency Autism Coordinating Committee (IACC) to be held on May 11, 2004, on the NIH campus in Bethesda, Maryland.

The Children's Health Act of 2000 (Pub. L. 106-310), Title I, Section 104, mandated the establishment of an Interagency Autism Coordinating Committee (IACC) to coordinate autism research and other efforts within the Department of Health and Human Services (DHHS). In April 2001, Secretary Tommy Thompson delegated the authority to establish the IACC to the NIH. The National Institute of Mental Health (NIMH) at the NIH has been designated the lead for this activity.

The IACC meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such

as sign language interpretation or other reasonable accommodations, should notify the contact person listed below in advance of the meeting.

Name of Committee: Interagency Autism Coordinating Committee.

Date: May 11, 2004.

Time: 9 a.m.-4:30 p.m.

Agenda: Discussion of autism activities across Federal agencies.

Place: National Institutes of Health, Building 31, Conference Room 10 (6th floor), 31 Center Drive, Bethesda, Maryland 20892.

Contact Person: Ann Wagner, Ph.D., Division of Services and Intervention Research, National Institute of Mental Health, NIH, 6001 Executive Boulevard, Room 7142, MSC 9633, Bethesda, Maryland 20892, e-mail: awagner@mail.nih.gov, Phone: (301) 443-4283.

Any member of the public interested in presenting oral comments to the committee may notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Presentations may be limited to 5 minutes; both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding his/her statement to the contact person listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information about the meeting and registration forms are also available online on the NIMH homepage at <http://www.nimh.nih.gov/autismiac/index.cfm>.

Dated: April 7, 2004.

Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 04-8494 Filed 4-14-04; 8:45 am]
BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

President's Council on Physical Fitness and Sports

AGENCY: Office of the Secretary, Office of Public Health and Science, HHS.

ACTION: Notice of meeting.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human

Services (DHHS) is hereby giving notice that the President's Council on Physical Fitness and Sports will hold a meeting. This meeting is open to the public. A description of the Council's functions is included also with this notice.

DATES: May 5, 2004, from 8:30 a.m. to 4 p.m.

ADDRESSES: Department of Health and Human Services, Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW., Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Melissa Johnson, Executive Director, President's Council on Physical Fitness and Sports, Hubert H. Humphrey Building, Room 738H, 200 Independence Avenue, SW., Washington, DC 20201, (202) 690-5187.

SUPPLEMENTARY INFORMATION: The President's Council on Physical Fitness and Sports (PCPFS) was established originally by Executive Order 10673, dated July 16, 1956. PCPFS was established by President Eisenhower after published reports indicated that American boys and girls were unfit compared to the children of Western Europe. Authorization to continue Council operations was given at appropriate intervals by subsequent Executive Orders. The Council has undergone two name changes and several reorganizations. Presently, the PCPFS is a program office located organizationally in the Office of Public Health and Science within the Office of the Secretary in the U.S. Department of Health and Human Services.

On June 6, 2002, President Bush signed Executive Order 13256 to reestablish the PCPFS. Executive Order 13256 was established to expand the focus of the Council. This directive instructed the Secretary to develop and coordinate a national program to enhance physical activity and sports participation. The Council currently operates under the stipulations of the new directive. The primary functions of the Council include: (1) To advise the President, through the Secretary, on the progress made in carrying out the provisions of the enacted directive and recommend actions to accelerate progress; (2) to advise the Secretary on ways and means to enhance opportunities for participation in physical fitness and sports, and, where possible, to promote and assist in the facilitation and/or implementation of such measures; (3) to advise the Secretary regarding opportunities to extend and improve physical activity/fitness and sports programs and services at the national, state and local levels; and (4) to monitor the need for the enhancement of programs and

educational and promotional materials sponsored, overseen, or disseminated by the Council and advise the Secretary, as necessary, concerning such needs.

The PCPFS holds at a minimum, one meeting in the calendar year to (1) Assess ongoing Council activities and (2) discuss and plan future projects and programs.

Dated: April 9, 2004.

Melissa Johnson,
Executive Director, President's Council on Physical Fitness and Sports.
[FR Doc. 04-8595 Filed 4-14-04; 8:45 am]
BILLING CODE 4150-35-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Environmental Health Sciences Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Environmental Health Sciences Council.

Date: May 17, 2004.

Open: 8:30 a.m. to 2 p.m.

Agenda: Discussion of program policies and issues.

Place: Sheraton Imperial Hotel and Convention Center, 4700 Emperor Boulevard, The Empire Room (DE), Durham, NC 27703.

Closed: 2 p.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Sheraton Imperial Hotel and Convention Center, 4700 Emperor Boulevard, The Empire Room (DE), Durham, NC 27703.

Contact Person: Anne P. Sassman, PhD, Director, Division of Extramural Research

and Training, National Institute of Environmental Health Sciences, National Institutes of Health, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-7723.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.niehs.nih.gov/dert/c-agenda.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards, 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: April 8, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-8496 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Human Monoclonal Antibody Therapeutics for the Treatment of Hepatitis C (HCV) Infections

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in: United States Patent Application 60/250,561 and its foreign equivalents entitled "Monoclonal Antibodies Specific For The E2 Glycoprotein Of Hepatitis C Virus and Their Use In The Diagnosis, Treatment, and Prevention of HCV" filed December 1, 2000, to Biorex, Inc., having a place of business in Pittsboro, NC. The patent rights in this invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 14, 2004, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan Ano, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail: anos@mail.nih.gov; telephone: (301) 435-5515; facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

This invention relates to human monoclonal antibodies that exhibit immunological binding affinity for the hepatitis C virus E2 glycoprotein and are cross-reactive against different hepatitis C virus (HCV) strains. These antibodies may be used in passive immunoprophylaxis for the prevention of hepatitis C virus infection and/or in passive immunotherapy for the treatment of hepatitis C.

The licensed territory will be worldwide excluding Europe, India, and Japan. This notice should be considered a modification of the **Federal Register** notice originally published in 68 FR 10744, March 6, 2003.

The field of use may be limited to development of human monoclonal antibody biotherapeutics for the prevention and/or treatment of HCV infections.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 7, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-8492 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF THE INTERIOR

Truckee River Operating Agreement, California and Nevada

AGENCY: U.S. Department of the Interior.

ACTION: Notice of intent to prepare a revised draft environmental impact statement/environmental impact report.

SUMMARY: Pursuant to the National Environmental Policy Act (NEPA) of 1969, as amended, the Council on Environmental Quality (CEQ) regulations, the California Environmental Quality Act (CEQA), and the California State CEQA guidelines, the U.S. Department of the Interior (Interior) and the California Department of Water Resources (DWR) intend to prepare a revised draft environmental impact statement/environmental impact report (revised Draft EIS/EIR) for the Draft Truckee River Operating Agreement (TROA) which would implement Section 205(a) of the Truckee-Carson-Pyramid Lake Water Rights Settlement Act of 1990, Title II of Pub. L. 101-618 (Settlement Act). Scoping meetings were held for the original draft EIS/EIR and no additional scoping meetings are planned.

ADDRESSES: Kenneth Parr, Bureau of Reclamation (Reclamation), 705 North Plaza Street, Room 320, Carson City, Nevada 89701-4015, e-mail: kparr@mp.usbr.gov; or Michael Cooney, DWR, Central District, 3251 S Street, Sacramento, California 95816-7017, e-mail: mikec@water.ca.gov.

FOR FURTHER INFORMATION CONTACT: Kenneth Parr, Reclamation, telephone: 775-882-3436, TDD 775-882-3436, or fax 775-882-7592; or Michael Cooney, DWR, telephone: 916-227-7606. Information is also available at Reclamation's Web site at: <http://www.usbr.gov/mp/tra/>.

SUPPLEMENTARY INFORMATION:

Background

Section 205(a) of the Settlement Act directs the Secretary of the Interior (Secretary), in conjunction with others, to negotiate an operating agreement governing operation of federal Truckee River reservoirs and other specified matters. Interior, U.S. Department of Justice, States of California and Nevada, Pyramid Lake Paiute Tribe, Sierra Pacific Power Company, Truckee Meadows Water Authority, and other entities in California and Nevada completed a draft of the TROA in October 2003. The Draft TROA is the first of a number of steps required before TROA can be implemented. The Draft TROA is now available to the public in advance of completion of the revised

Draft EIS/EIR. The Draft TROA can be viewed at <http://www.usbr.gov/mp/troa/docs/TROAdraft.pdf>.

TROA would, in part, (1) Enhance conditions for threatened and endangered fishes throughout the Truckee River basin; (2) increase municipal and industrial (M&I) drought protection for Truckee Meadows (Reno-Sparks metropolitan area); (3) improve river water quality downstream from Sparks, Nevada; and (4) enhance stream flows and recreational opportunities in the Truckee River basin. At the time TROA takes effect, the Settlement Act provides that a permanent allocation between California and Nevada of water in the Lake Tahoe, Truckee River and Carson River basins will also take effect. The allocation of those waters has been a long-standing issue between the two States; implementation of TROA resolves that issue. In addition, Section 205 of the Settlement Act requires that TROA, among other things, implement the provisions of the Preliminary Settlement Agreement as modified by the Ratification Agreement and ensure that water is stored and released from federal Truckee River reservoirs to satisfy the exercise of water rights in conformance with the Orr Ditch decree and Truckee River General Electric decree. The Preliminary Settlement Agreement as modified by the Ratification Agreement was a 1989 agreement between Sierra Pacific Power Company and the Pyramid Lake Paiute Tribe to change the operation of federal reservoirs and Sierra Pacific's exercise of its Truckee River water rights to (1) improve spawning conditions for threatened and endangered fish species (cui-ui and Lahontan cutthroat trout) and (2) provide additional M&I water for Truckee Meadows during drought situations.

Before TROA can be approved by the Secretary and the State of California, and signed by other negotiating parties, potential environmental effects of the agreement must be analyzed pursuant to NEPA and CEQA. Accordingly, Interior and DWR will jointly prepare a revised Draft EIS/EIR for that purpose. The revised Draft EIS/EIR is expected to be released for public comment in the summer of 2004.

An initial Draft EIS/EIR was prepared and released for public review in February 1998. Since then, ongoing negotiations have substantially modified the proposed agreement, resulting in the need to prepare a revised Draft EIS/EIR.

Current Activities

With the public release of the Draft TROA by the negotiators, a new analysis can begin. This analysis will be based

on current conditions as well as three alternatives: (1) No Action Alternative (current management continuing in the future, without TROA); (2) Local Water Supply Alternative (changed management in the future, without TROA); and (3) TROA in the future. A Notice of Availability/Notice of Completion will be filed and published announcing (1) the release of the revised Draft EIS/EIR, (2) dates for a public comment period, and (3) locations of hearings that will provide public involvement opportunities. Section 205 of the Settlement Act also requires that any final TROA be issued as a Federal Regulation. Accordingly, and concurrently with the preparation of the revised Draft EIS/EIR, a draft regulation is being prepared which will be issued for public comments by publication in the **Federal Register**.

Once public comments on the revised Draft EIS/EIR and draft TROA regulation have been received, the lead agencies will send any comments that might relate to provisions of the draft TROA regulation to the negotiators. Comments on the revised Draft EIS/EIR will be addressed in the final environmental analysis of TROA, together with any changes thereto, and a Final EIS/EIR will be published. The Secretary cannot sign a final TROA until a Record of Decision has been completed. The State of California cannot sign TROA until it has considered and certified the Final EIS/EIR in conjunction with making any necessary findings pursuant to CEQA. These and other steps, including approval by the Orr Ditch and Truckee River General Electric Courts, must be completed before TROA may be implemented. TROA will also be published as a Federal Regulation.

Description of Alternatives

No Action Alternative (No Action)

Under No Action, Truckee River reservoir operations would remain unchanged from current operations and would be consistent with existing court decrees, agreements, and regulations that currently govern surface water management (i.e., operating reservoirs in the Truckee River and Lake Tahoe basins and maintaining stream flows) in the Truckee River basin. Truckee Meadows Water Authority's (TMWA) existing programs for surface water rights acquisition and groundwater pumping for M&I use would continue. Groundwater pumping and water conservation in Truckee Meadows, however, would satisfy a greater proportion of projected future M&I demand than under current conditions. Groundwater pumping in California

would also increase to satisfy a greater projected future M&I demand.

Local Water Supply Alternative (LWSA)

All elements of Truckee River reservoir operations, river flow management, Truckee River hydroelectric plant operations, minimum reservoir releases, reservoir spill and precautionary release criteria, and water exportation from the upper Truckee River basin and Lake Tahoe basin under LWSA would be the same as described under No Action. The principal differences between No Action and LWSA would be the source of water used for M&I purposes, extent of water conservation, implementation of a groundwater recharge program in Truckee Meadows, and assumptions regarding governmental decisions concerning approval of new water supply proposals.

TROA Alternative (TROA)

TROA would modify existing operations of all designated reservoirs to enhance coordination and flexibility while ensuring that existing water rights are served and flood control and dam safety requirements are met. TROA would incorporate, modify, or replace various provisions of the Truckee River Agreement (TRA) and the Tahoe-Prosser Exchange Agreement (TPEA). TROA would supersede all requirements of any agreements concerning the operation of all reservoirs, including those of TRA and TPEA, and would become the sole operating agreement for all designated reservoirs.

All reservoirs would continue to be operated under TROA for the same purposes as under current operations and with most of the same reservoir storage priorities as under No Action and LWSA. The Settlement Act requires that TROA avoid adverse impacts to Orr Ditch decree water rights.

The primary difference between TROA and the other alternatives is that TROA would expand opportunities for storing and managing other categories of water not addressed under the current permit or license of a reservoir (i.e., credit water). Signatories to TROA generally would be allowed to accumulate credit water in storage by retaining or capturing water in a reservoir that would have otherwise been released from storage or passed through the reservoir to serve a downstream water right (e.g., retaining Floriston Rate water that would have been released to serve an Orr Ditch decree water right). In cases with a change in the place or type of use, such storage could take place only after a transfer in accordance with applicable

State water law. Once accumulated, credit water would be classified by category with a record kept of its storage, exchange, and release. Credit water generally would be retained in storage or exchanged among the reservoirs until needed to satisfy its beneficial use. The Interim Storage Agreement (negotiated in accordance with Section 205(b)(3) of the Settlement Act) would no longer be necessary and so would be superseded by new storage agreements between the Bureau of Reclamation and TROA signatories.

Dated: April 8, 2004.

Willie R. Taylor,

Director, Office of Environmental Policy and Compliance.

[FR Doc. 04-8570 Filed 4-14-04; 8:45 am]

BILLING CODE 4310-MN-P

DEPARTMENT OF THE INTERIOR

Bureau of Indian Affairs

Proposed Finding Against Federal Acknowledgment of the Burt Lake Band of Ottawa and Chippewa Indians, Inc.

AGENCY: Bureau of Indian Affairs, Interior.

ACTION: Notice of proposed finding.

SUMMARY: Pursuant to 25 CFR 83.10(h), notice is hereby given that the Assistant Secretary—Indian Affairs proposes to determine that the Burt Lake Band of Ottawa and Chippewa Indians, Inc., 6461 East Brutus Road, P.O. Box 206, Brutus, Michigan, c/o Mr. Carl L. Frazier, is not an Indian tribe within the meaning of Federal law. This notice is based on a determination that the petitioner does not satisfy criteria 83.7(a), 83.7(b), 83.7(c) and 83.7(e), and thus, does not meet the requirements for a government-to-government relationship with the United States.

DATES: As provided by 25 CFR 83.10(i), any individual or organization wishing to challenge or support the proposed finding may submit factual or legal arguments and evidence to rebut or support the evidence relied upon, within 180 calendar days from the date of publication of this notice. Interested and informed parties who make submissions to the Assistant Secretary must also provide copies to the petitioner.

ADDRESSES: Comments on the proposed finding and/or requests for a copy of the report of the summary evaluation of the evidence should be addressed to the Office of the Assistant Secretary—Indian Affairs, 1951 Constitution Avenue, NW., Washington, DC 20240,

Attention: Office of Federal Acknowledgment, Mail Stop 34B-SIB. The names and addresses of commenters generally are available to the public.

FOR FURTHER INFORMATION CONTACT: R. Lee Fleming, Director, Office of Federal Acknowledgment, (202) 513-7650.

SUPPLEMENTARY INFORMATION: This notice is published in the exercise of authority delegated by the Secretary of the Interior to the Assistant Secretary—Indian Affairs by 209 DM.

The Burt Lake Band of Ottawa and Chippewa Indians, Inc. (BLB), petitioner #101, submitted a letter of intent to petition for Federal acknowledgment on September 6, 1985. The Assistant Secretary—Indian Affairs (AS-IA) placed the BLB on active consideration on December 16, 2002.

The BLB petitioner claims that it is a successor to a Cheboygan band of Ottawa and Chippewa Indians who signed treaties with the United States in Washington on March 28, 1836, and in Detroit on July 31, 1855. The Cheboygan band had a historical village on Burt Lake near the northern tip of Michigan's Lower Peninsula on land acquired between 1846 and 1849, from the United States land office, patented to the Governor of Michigan in trust for the Cheboygan band. The band lost title to this village through tax sales, and in 1900, the purchaser burned it. The village residents dispersed, but a portion of them settled in an exclusive Indian settlement on "Indian Road," near the historical village. In 1977, Margaret Martell in Lansing, Michigan, began to organize the descendants of residents of Indian Road. In 1984, descendants of John B. Vincent (1816-1903) joined the petitioner. The available evidence does not demonstrate that these descendants interacted with Indians at Burt Lake or any other Indian group prior to 1984. Just 46 percent of the petitioner's 490 members descend from the historical Cheboygan band, and 48 percent descend from John B. Vincent.

The proposed finding concludes that the petitioner is not eligible to be evaluated under section 83.8 of the regulations as a previously acknowledged Indian entity. Although Indians at Burt Lake were acknowledged as a tribe as recently as 1917, most of the petitioner's members do not descend from the previously acknowledged entity. Therefore, the petitioner is not the same tribal entity, or a portion that has evolved from the entity, that was previously acknowledged. This finding may be the result of substantial changes in the petitioner's membership since the

preliminary determination. An evaluation under section 83.7 rather than section 83.8 does not result in a different finding on any criterion. Whether the petitioner is eligible to be evaluated under section 83.8 of the regulations is subject to reconsideration at the time of the final determination.

The BLB petitioner does not meet criterion 83.7(a), which requires that it has been identified as an American Indian entity on a substantially continuous basis since 1900. The BLB petitioner's membership has two main components, descendants of the historical Cheboygan band, all of whom also descend from a resident of the Indian settlement at Burt Lake about 1900, and a larger number of descendants of John B. Vincent, who was not a member of the historical band or a resident of the historical settlement. The case record contains some identifications prior to 1956, of an Indian settlement at Burt Lake or an Indian entity consisting of descendants of the historical band. The record, however, does not contain identifications of any Indian entity consisting of Vincent's descendants prior to 1979. A Burt Lake band organization that has become the current petitioner has been identified since 1978, and since 1984, identifications of that Indian entity have identified a group that consists of both Vincent descendants and Burt Lake band descendants.

This proposed finding does not answer the interpretive question of whether a historical identification of a Burt Lake group or Indian settlement that contained no Vincent descendants constitutes an identification of a petitioning group in which Burt Lake descendants are outnumbered by Vincent descendants, because whichever way this question is resolved the result is that the petitioner fails to meet the requirements of criterion (a). If historical identifications of a historical Burt Lake Indian entity are rejected as identifications of the current petitioner, because that historical entity is significantly different in composition from the petitioning entity, then the petitioner has not been identified on a substantially continuous basis. The available evidence does not demonstrate that both components of the petitioner's membership were identified as constituting a single Indian entity, or separate Indian entities that amalgamated, from 1900 to 1978. Alternatively, if historical identifications of a historical Burt Lake settlement are accepted as identifications of the current petitioner, because a substantial portion of the

petitioning group has connections to that historical settlement, then the petitioner has not been identified on a substantially continuous basis because of the lack of such identifications between 1917 and 1931 and between 1956 and 1978.

The BLB petitioner does not meet criterion 83.7(b), which requires that a predominant portion of the petitioning group comprises a distinct community from historical times until the present. The current membership divides into two main groups of descendants, that have never formed a single social community nor did they form two separate communities that amalgamated. Evidence shows that the descendants of the Cheboygan band lived in an exclusive Indian Village on Burt Lake until the burnout of 1900, when they established a settlement on Indian Road, which remained exclusively Indian until as recently as 1938. Its residents primarily married Indians within a regional marriage system, attended a Roman Catholic Indian mission, buried their dead in its cemetery, and socialized with one another. Since WWII, most of the descendants of Indian Road have lived elsewhere, in regional centers and downstate cities. Descendants of Indian Road continued to identify with the historical Indian Village and Indian Road settlement, and maintained a Burt Lake identity. The evidence does not demonstrate that younger generations, born away from Indian Road, maintained social ties to each other and to the residents of the tiny settlement remaining on Indian Road.

The second main group of descendants consists of John B. Vincent's descendants through two of his children. The available evidence shows that their family's history is different from and unrelated to the history of the Indians living at Burt Lake. No evidence demonstrates that these two groups of descendants ever socialized at any time before 1984, as a distinct social community, or that the Vincents participated in an Indian community at any time before 1984. Since 1984, the evidence shows that only a tiny portion of the petitioner's membership descending from John B. Vincent has ever attended a BLB event. The evidence does not demonstrate that the petitioner formed a distinct community at present.

The petitioner does not meet criterion 83.7(c), which requires that it has maintained political influence or authority over its members as an autonomous entity from historical times until the present. Acknowledgment precedent accepts that group political

influence and authority were maintained within historical Indian villages, such as the Indian Village on Burt Lake before it was burned in 1900. From 1900 to 1977, individuals associated with the Indian Road settlement made political representations for various groups, but the political connection of those named individual(s) to any Burt Lake political entity, and the composition of any group they represented, was almost always ambiguous. The existing record contains only a few examples of a bilateral political relationship, such as in letters from 1911 and 1914. It was not demonstrated that in the 1930's, groups which possibly took opposing views on the Indian Reorganization Act, represented a Burt Lake entity or faction of a Burt Lake entity. Oral history recounts that "gatherings" of men met at Indian Road to discuss political issues, but this information is too general to be useful in showing the internal political processes of a Burt Lake entity. In 1977, when former Indian Road resident Margaret Martell began to formally organize the petitioner, she recruited family and close friends tied to Indian Road. The group sought retribution for the destruction of the historical village, an issue of personal significance to older members. A small core group, raised in the Indian Road settlement, served on the board of directors, until 1984, when Donald Moore, a descendant of John B. Vincent, joined the group and immediately became its chairman.

There is no evidence in the record that the ancestors of John B. Vincent ever participated in political activity with Indians at Burt Lake until Moore became chairman in 1984. Nor is there any evidence that they were part of another Indian entity that exercised political influence and amalgamated with a Burt Lake entity to form a single political entity before 1984. In 1991, Carl L. Frazier, another descendant of John B. Vincent, became chairman. Immediately, a group of Burt Lake descendants initiated an unsuccessful recall of the Vincents from the group's board, after which participation by Burt Lake descendants diminished. Since Congress recognized Little Traverse Bay Band (LTBB) in 1994, 174 Burt Lake descendants, 1/4 of its members, including past leaders and long-term members descending from Burt Lake joined LTBB, which recognizes its ancestors on the Durant Roll as qualifying ancestors for membership. With the exception of about five members of the Vincent families, including the chairman and two board

members, the part of the petitioner descending from John Vincent otherwise has extremely low participation rates. No other evidence shows them influencing or being influenced by other Burt Lake members or leaders. The two groups of descendants together do not participate in a common political process, and thus, the petitioner does not exercise political influence or authority over its members at present. Therefore, the petitioner does not meet criterion 83.7(c).

The BLB petitioner meets criterion 83.7(d), which requires the petitioner to submit its governing document including its membership criteria. The petitioner's current membership by-laws require members to document their descent from an Indian appearing (1) in Special Agent Horace B. Durant's 1908 field notes for the "Burt Lake" band, identifying descendants of the 33 family heads of the Joseph Way-bway-dum band as listed on page 31 of the 1870 annuity list for Ottawa and Chippewa Indians of Michigan; or (2) as recipients of the Cheboiganing/Burt Lake Band's land allotments or homesteads pursuant to the 1855 Treaty of Detroit; or, (3) as residents enumerated on the 1910 Indian population schedule of the Federal Census of Burt Township, Cheboygan County, Michigan.

The BLB petitioner does not meet criterion 83.7(e), which requires that the petitioner's members descend from a historical Indian tribe or from tribes that combined and functioned as a single autonomous political entity. This criterion further requires that the petitioner submit an official membership list of all known current members, and that the governing body provide a separate certification of that membership list. The official membership list of December 23, 2002, contained 861 entries, but only 490 individuals on that list were alive, had submitted signed application forms, and had not submitted written relinquishment forms.

About 46 percent of those 490 current members descend from historical individuals identified as members of the band under chief Joseph Way-bway-dum in the 1870 annuity list of the Ottawa and Chippewa Indians of Michigan that was termed the "Burt Lake Band" by Special Agent Horace B. Durant in 1908. By acknowledgment precedent, this level of descent from the historical tribe is not sufficient to meet the requirements of the criterion.

About 48 percent of the 490 current members descend from one historical individual, John B. Vincent (1816-1903), who in 1873 sold his interest in an allotment patented to him in 1875

located in the reserve set aside for the Cheboygan band by the 1855 Treaty of Detroit. However, John B. Vincent did not participate in the band's allotment selections of 1857 and 1864, and the petitioner did not provide any documentation demonstrating that John B. Vincent descended from the Cheboygan band. John B. Vincent did not appear on any Ottawa and Chippewa annuity list furnished by the petitioner. Since individuals from Ottawa and Chippewa bands other than Cheboygan obtained allotments in 1875 in the Cheboygan reserve, the 1875 list of allottees in that reserve is not a list of members of the Cheboygan band. Earlier allotment selection records of 1857 and 1864 contain band affiliation information, are deemed reliable evidence of Cheboygan members, and do not include John B. Vincent.

The BLB petitioner meets criterion 83.7(f), which requires that a petitioning group be composed principally of persons who are not members of any acknowledged North American Indian tribe. Enrollment of some of the petitioner's members in federally recognized tribes has occurred since at least 1994, the first year in which written relinquishments gave the reason as "enrollment at Little Traverse Bay Bands."

Fifty of the 490 current members of the BLB petitioner are also members of the federally acknowledged LTBB or the Sault Ste. Marie Band of Chippewa Indians without having formally relinquished their membership in the petitioner. As 90 percent of the group is not enrolled elsewhere, the petitioner meets this criterion.

The BLB petitioner meets criterion 83.7(g), because there is no evidence in the record that the petitioner or its members have been explicitly terminated or forbidden a Federal relationship by an act of Congress.

Based on this preliminary factual determination, the Department proposes not to extend Federal Acknowledgment under 25 CFR part 83 to the petitioner known as the Burt Lake Band of Ottawa and Chippewa Indians, Inc.

As provided by 25 CFR 83.10(h) of the regulations, a report summarizing the evidence, reasoning, and analyses that are the basis for the proposed decision will be provided to the petitioner and interested parties, and is available to other parties upon written request.

Comments on the proposed finding and/or requests for a copy of the report of evidence should be addressed to the Office of the Assistant Secretary—Indian Affairs, 1951 Constitution Avenue, NW., Washington, DC 20240,

Attention: Office of Federal Acknowledgment, Mail Stop 34B-SIB.

Comments on the proposed finding should be submitted within 180 calendar days from the date of publication of this notice. The period for comment on a proposed finding may be extended for up to an additional-180 days at the AS-IA's discretion upon a finding of good cause (83.10(i)). Comments by interested and informed parties must be provided to the petitioner as well as to the Federal government (83.10(h)). After the close of the 180-day comment period, and any extensions, the petitioner has 60 calendar days to respond to third-party comments (83.10(k)). This period may be extended at the AS-IA's discretion, if warranted by the extent and nature of the comments.

After the expiration of the comment and response periods described above, the Department will consult with the petitioner concerning establishment of a schedule for preparation of the final determination. After consideration of the written arguments and evidence rebutting the proposed finding and within 60 days after beginning preparation of the final determination, the AS-IA will publish the final determination of the petitioner's status in the **Federal Register** as provided in 25 CFR 83.10(1).

Dated: April 5, 2004.

Aurene M. Martin,

Principal Deputy Assistant Secretary—Indian Affairs.

[FR Doc. 04-8599 Filed 4-14-04; 8:45 am]

BILLING CODE 4310-4J-P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[MT-069-1310-DB-034E]

Notice of Intent To Conduct Scoping and Prepare an Environmental Impact Statement (EIS) for the Blackleaf Project, Teton County, MT

AGENCIES: Bureau of Land Management, Interior.

ACTION: Notice of intent.

SUMMARY: Startech Energy, Inc. (Operator of the Blackleaf Unit, a Federal Oil and Gas Unit), hereinafter referred to as "Startech" has submitted to the Bureau of Land Management (BLM) Applications for Permit to Drill for natural gas on lease, MTM 24615. This lease is located on BLM managed land, in Teton County along the Rocky Mountain Front. The proposed drilling location is within the Montana Thrust-

Belt, approximately 75 miles northwest of Great Falls, Montana.

Under provisions of section 102(2)(C) of the National Environmental Policy Act (NEPA) and pertinent Federal regulations, the BLM announces its intention to prepare an EIS, and to solicit public comments regarding issues, concerns and resource information pertaining to this proposed project.

Comments, including names and street addresses of respondents, will be available for public review at the BLM Lewistown Field Office during regular business hours 7:45 a.m. to 4:30 p.m., Monday through Friday, except holidays, and may be published as part of the EIS. Individual respondents may request confidentiality. If you wish to withhold your name or street address from public review or from disclosure under the Freedom of Information Act, you must state this prominently at the beginning of your written comments. Such requests will be honored to the extent allowed by law. Anonymous comments will not be accepted. All submissions from organizations and businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, will be available for public inspection in their entirety.

DATES: This Notice initiates the public scoping process. The BLM can best determine the scope of this EIS if issues/concerns are submitted within 45 days of the publication of this Notice. Scoping meeting dates and locations will be announced in local newspapers, on local radio stations, by mail and on the BLM Lewistown Field Office Web page (<http://www.mt.blm.gov/ldo/index.html>). Public scoping meeting announcements will be made at least 15 days prior to the meetings. All comments received at the public meetings or submitted in writing by mail or electronically via the internet will aid the BLM in identifying issues, developing a range of alternatives, and analyzing environmental impacts. The BLM will provide additional opportunities for public participation throughout the preparation of the EIS.

ADDRESSES: Comments should be submitted in writing to: Field Manager, Bureau of Land Management, Lewistown Field Office, P.O. Box 1160, Lewistown, Montana 59457, Attn: Blackleaf Project EIS Team Lead; via electronic submittal, the e-mail address is mt_blackleaf_eis@blm.gov.

FOR FURTHER INFORMATION CONTACT: Lynn Ricci, Blackleaf Project EIS Team Lead, BLM, Lewistown Field Office,

P.O. Box 1160, Lewistown, Montana 59457, 406/538-1922.

SUPPLEMENTARY INFORMATION: Startech proposes to drill a total of three wells from one location within the existing Blackleaf Exploration Unit at T. 25 N., R. 8 W., section 6. The proposed exploratory/development well would offset a Known Geologic Structure that was tested for natural gas from an exploratory well in Muddy Creek drilled in 1959. The surface location of Startech's proposed drill site is located within BLM's Blind Horse Outstanding Natural Area. In addition to public land managed by the BLM, the proposed action involves privately owned surface estate and land managed by the Montana Department of Fish, Wildlife and Parks.

The first well would be drilled vertically to approximately 6,500 feet, and the next two wells would be drilled directionally from the same drill site to fully develop the natural gas reservoir. Approximately four acres would be disturbed in order to construct a well pad (400 feet by 400 feet) to accommodate the drilling rig and subsequent production equipment. Existing roads and pipelines would be utilized to minimize impacts to the area, though portions of the road system would need to be upgraded. Approximately 200 feet of new road would be constructed from the existing road to the proposed well site. Approximately eight miles of new pipeline would be constructed from the well site to the existing production facility located in T. 26 N., R. 8 W., section 8.

In order to minimize activity at the well site following the drilling and completion of the wells, Startech proposes to produce full well stream fluids to the existing production facility that would be upgraded, located in section 8. Produced fluids would be compressed at this production facility, and then transferred by pipeline to a distant gas processing facility. At the gas plant, hydrocarbon condensate (oil) and water would be separated and recovered. The gas would be sweetened to remove approximately 0.5% hydrogen sulfide (H₂S) contaminant, and then processed to place it into marketable condition for sale into an existing natural gas pipeline approximately 25 miles north east of the project area. Two shut-in wells, from previous drilling and production activity in the Blackleaf Unit in the 1980s, would be returned to production upon successful completion of the proposed wells.

The EIS will analyze the applicant's proposal and the reasonable foreseeable development scenario (RFD) expected during the life of this project, which includes an additional eight potential locations. The gas processing plant is also a reasonable foreseeable action and therefore, expected impacts would be evaluated but not to the same degree as for the proposed action.

Issues that will be analyzed in the EIS include: cultural heritage resources; visual resource management; social and economic conditions; threatened and endangered species, and sensitive species of wildlife and plants and their habitats; air quality; water quality; recreation; noxious weeds; and reasonable foreseeable future actions.

Dated: April 6, 2004.

David L. Mari,

Lewistown Field Manager.

[FR Doc. 04-8218 Filed 4-14-04; 8:45 am]

BILLING CODE 4310-SS-P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NV-055-5853-EU]

Notice of Realty Actions: Competitive Sale of Public Lands in Clark County, NV; Termination of Recreation and Public Purposes Classification and Segregation; Withdrawal of the Formerly Classified Lands by the Southern Nevada Public Land Management Act

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: The Bureau of Land Management (BLM) proposes to sell federally owned parcels of land in Clark County, Nevada, aggregating approximately 2,532.01 acres. All sales will be conducted on June 2, 2004, in accordance with competitive bidding procedures. The BLM also is terminating the R&PP classification of other lands in Clark County that are withdrawn by the Southern Nevada Public Land Management Act.

DATES: Comments regarding the proposed sale must be received by BLM on or before June 1, 2004.

Sealed bids must be received by BLM not later than 4:30 p.m., p.d.t., May 26, 2004.

All parcels of land proposed for sale are to be put up for purchase and sale, at public auction, beginning at 10 a.m., p.d.t., June 2, 2004. Registration for oral bidding will begin at 8 a.m., p.d.t., June 2, 2004. The public auction will begin at 10 a.m., p.d.t., June 2, 2004.

Other deadline dates for the receipt of payments, and arranging for certain payments to be made by electronic transfer, are specified in the proposed terms and conditions of sale, as stated herein.

ADDRESSES: Comments regarding the proposed sale, as well as sealed bids to be submitted to BLM, should be addressed to: Field Manager, Las Vegas Field Office, Bureau of Land Management, 4701 N. Torrey Pines Drive, Las Vegas, Nevada 89130.

More detailed information regarding the proposed sale and the lands involved may be reviewed during normal business hours (7:30 a.m. to 4:30 p.m.) at the Las Vegas Field Office (LVFO).

The address for oral bidding registration, and for where the public auction will be held, is: Sam's Town Hotel and Casino, 5111 Boulder Highway, Las Vegas, Nevada.

The auction will take place at Sam's Town Live, located within the Sam's Town Hotel and Casino.

FOR FURTHER INFORMATION CONTACT: You may contact Judy Fry, Program, SALES at (702) 515-5081 or by e-mail at jfry@nv.blm.gov. You may also call (702) 515-5000 and ask to have your call directed to a member of the Sales Team.

SUPPLEMENTARY INFORMATION: The following lands have been authorized and designated for disposal under the Southern Nevada Public Land Management Act of 1998 (112 Stat. 2343), as amended by the Clark County Conservation of Public Land and Natural Resources Act of 2002 (116 Stat. 1994), (hereinafter "SNPLMA"). These lands are proposed to be put up for purchase and sale by competitive auction on June 2, 2004, at an oral auction to be held in accordance with the applicable provisions of section 203 and section 209 of the Federal Land Policy and Management Act of 1976 (FLPMA) (43 U.S.C. 1713 and 1719), respectively, and its implementing regulations, 43 CFR part 2710, at not less than the fair market value (FMV) of each parcel, as determined by the authorized officer after an appraisal.

Lands Proposed for Sale

Mount Diablo Meridian, Nevada

T.19 S, R. 59 E.,

Sec. 2, W $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$,

E $\frac{1}{2}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$;

Sec. 25, SE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$.

T.19 S, R. 60 E.,

Sec. 18, Lots 13 and 14,

E $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$;

Sec. 29, NE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,

SE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$;

Sec. 31, NE $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$,

NE $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,

SE $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,

NW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
SW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
NE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$,
SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 32, NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$,
NW $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$.
T. 20 S, R. 60 E.,
Sec. 6, Lots 40 through 49,
SE $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$,
NE $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$,
SE $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$,
Sec. 22, N $\frac{1}{2}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$,
Sec. 33, Lots 60 and 61.
T. 21 S, R. 60 E.,
Sec. 3, Lots 88, 89 and 90;
Sec. 24, S $\frac{1}{2}$ SE $\frac{1}{4}$;
Sec. 28, N $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
S $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
NW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
SW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$.
T. 22 S, R. 60 E.,
Sec. 15, NW $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
E $\frac{1}{2}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
NE $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 16, W $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
S $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$,
W $\frac{1}{2}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$,
W $\frac{1}{2}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 17, E $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$,
W $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 21, NW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$,
NW $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
N $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
NW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$,
NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$;
Sec. 22, E $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$;
Sec. 23, SW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$;
Sec. 24, NW $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$,
SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
NW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$,
SW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$,
NW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$,
SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$,
NW $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$;
Sec. 26, W $\frac{1}{2}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$.
T. 22 S, R. 61 E.,
Sec. 28, Lots 37 and 48;
Sec. 29, NW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 30, SW $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{2}$,
W $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{2}$;
Sec. 33, Lots 85 through 88.
T. 23 S, R. 61 E.,
Sec. 7, Lots 1 and 2, NE $\frac{1}{4}$, E $\frac{1}{2}$ NW $\frac{1}{4}$,
NE $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 11, S $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
E $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$, S $\frac{1}{2}$ S $\frac{1}{2}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$,
SW $\frac{1}{4}$ SE $\frac{1}{4}$, W $\frac{1}{2}$ W $\frac{1}{2}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 14, W $\frac{1}{2}$ W $\frac{1}{2}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$,
SE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$, W $\frac{1}{2}$ NE $\frac{1}{4}$,
W $\frac{1}{2}$ E $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$, W $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$,
E $\frac{1}{2}$ E $\frac{1}{2}$ NW $\frac{1}{4}$, E $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
NE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
S $\frac{1}{2}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$,
NE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$,
S $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$,
SW $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$, S $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$,
SE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$;
Sec. 15, SW $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$,
SW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$, SW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$,
NE $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$,
S $\frac{1}{2}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$, S $\frac{1}{2}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$,
S $\frac{1}{2}$ SE $\frac{1}{4}$;
Sec. 22, E $\frac{1}{2}$, SW $\frac{1}{4}$;
Sec. 23, All;

Sec. 24, SW $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$,
SW $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$,
SW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$,
SE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
W $\frac{1}{2}$ E $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$, W $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
E $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,
W $\frac{1}{2}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$, W $\frac{1}{2}$ E $\frac{1}{2}$ SW $\frac{1}{4}$,
W $\frac{1}{2}$ SW $\frac{1}{4}$, W $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$,
SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$

Consisting of 71 Parcels Containing 2,532.01 Acres, More or Less

The proposed sale will include nine (9) parcels that have been identified for sale at previous auctions, but did not sell because either they did not receive any bids, or the sales were cancelled due to default. These nine (9) parcels identified as N-75200, N-77032, N-77040, N-77054, N-77055, N-77057 and N-77065, N-76385 and N-76400 contain 1,966.25 acres, more or less. The nine (9) resale parcels will be auctioned under the terms and conditions of this NORA.

If a parcel of land is sold, the locatable mineral interests therein will be sold simultaneously as part of the sale. The lands identified for sale have no known locatable mineral value. An offer to purchase any parcel at auction will constitute an application for conveyance of the locatable mineral interests. In conjunction with the final payment, the applicant will be required to pay a \$50.00 non-refundable filing fee for processing the conveyance of the locatable mineral interests.

Terms and Conditions of Sale

The terms and conditions applicable to this sale are as follows: All parcels are subject to the following:

1. All discretionary leaseable and saleable mineral deposits are reserved; but permittees, licensees, and lessees retain the right to prosper for, mine, and remove such minerals owned by the United States under applicable law and any regulations that the Secretary of the Interior may prescribe, including all necessary access and exit rights.

2. A right-of-way is reserved for ditches and canals constructed by authority of the United States under the Act of August 30, 1890 (42 U.S.C. 945).

3. All parcels are subject to valid existing rights. Parcels may also be subject to applications received prior to publication of this notice if processing the application would have no adverse affect on the federally approved Fair Market Value (FMV). Encumbrances of record, appearing in the BLM public files for the parcels proposed for sale, are available for review during business hours, 7:30 a.m. p.d.t. to 4:30 p.m. f.d.t., Monday through Friday, at the BLM LVFO.

4. All parcels are subject to reservations for roads, public utilities and flood control purposes, both existing and proposed, in accordance with the local governing entities' Transportation Plans.

5. No warranty of any kind, express or implied, is given by the United States as to the title, physical condition or potential uses of the parcels of land proposed for sale; and the conveyance of any such parcel will not be on a contingency basis. However, to the extent required by law, all such parcels are subject to the requirements of section 120(h) of the Comprehensive Environmental Response Compensation and Liability Act, as amended (CERCLA) (42 U.S.C. 9620(h)).

6. All purchases/patentees, by accepting a patent, agree to indemnify, defend, and hold the United States harmless from any costs, damages, claims, causes of action, penalties, fines, liabilities, and judgment of any kind or nature arising from the past, present, and future acts or omissions of the patentees or their employees, agents, contractors, or lessees, or any third-party, arising out of or in connection with the patentees' use, occupancy, or operations on the patented real property. This indemnification and hold harmless agreement includes, but is not limited to, acts and omissions of the patentees and their employees, agents, contractors, or lessees, or any third party, arising out of or in connection with the use and/or occupancy of the patented real property which has already resulted or does hereafter result in: (1) Violations of Federal, State, and local laws and regulations that are now or may in the future become, applicable to the real property; (2) judgments, claims or demands of any kind assessed against the United States; (3) costs, expenses, or damages of any kind incurred by the United States; (4) other releases or threatened releases of solid or a hazardous waste(s) and/or hazardous substance(s), as defined by Federal or State environmental laws, off, on, into or under land, property and other interests of the United States; (5) other activities by which solids or hazardous substances or wastes, as defined by Federal and State environmental laws are generated, released, stored, used or otherwise disposed of on the patented real property, and any clean up response, remedial action or other actions related in any manner to said solid or hazardous substances or wastes; or (6) natural resource damages as defined by Federal and State law. This covenant shall be construed as running with the parcels of land patented or otherwise

conveyed by the United States, and may be enforced by the United States in court of competent jurisdiction.

7. Maps delineating the individual proposed sale parcels are available for public review at the BLM LVFO. Current appraisals for each parcel will be available for public review at the LVFO on or about April 5, 2004.

8. (a) bids may be received by sealed bid for all parcels (with the exception of N-75200 and N-77125), or orally for all parcels at auction. Because of the Memorial Day holiday, all sealed bids must be received at the BLM LVFO, no later than 4:30 p.m. P.d.t., May 26, 2004. Sealed bid envelopes must be marked on the lower front left corner with the BLM Serial Number for the parcel and the sale date. Bids must be for not less than the federally approved FMV and a separate bid must be submitted for each parcel.

8. (b) Each sealed bid shall be accompanied by a certified check, money order, bank draft, or cashier's check made payable to the order of the Bureau of Land Management, for not less than 10 percent or more than 30 percent of the amount bid. The highest qualified sealed bid for each parcel will become the starting bid at the oral auction. If no sealed bids are received, oral bidding will begin at the FMV, as determined by the authorized officer.

9. All parcels will be put up for competitive sale by oral auction beginning at 10 a.m., P.d.t., June 2, 2004, at Sam's Town Live located inside of Sam's Town Hotel and Casino, 5111 Boulder Highway, Las Vegas, Nevada. Sam's Town Live is located near the box office and close to the movie theatres within Sam's Town Hotel and Casino. Interested parties who will not be bidding are not required to register and may proceed directly to Sam's Town Live. If you are at the auction to conduct business with the high bidders or are there to observe the process, should seating become limited, you may be asked to relinquish your seat in order to provide seating for all bidders before the auction begins. We will try to provide an audio/visual transmission outside the hall for your convenience.

10. All oral bidders are required to register. Registration for oral bidding will begin at 8 a.m. P.d.t. on the day of the sale and will end at 10 a.m. P.d.t. You may pre-register by mail or fax by completing the form located in the sale folder and also available at the BLM LVFO.

11. Prior to receiving a bidder number on the day of the sale, all registered bidders must submit a certified check, bank draft, or cashier's check in the amount of \$10,000. The check must list

as individual (and not joint) payees both the Bureau of Land Management and your name or company name separated by the word "or". On the day of the sale, pre-registered bidders may go to the Express Registration Desk, present a Photo Identification Card, the required \$10,000 check, and receive a bidder number. All other bidders must go to the standard Registration Line where additional information will be requested along with your Photo Identification Card and the required \$10,000 check. Upon completion of registration you will be given a bidder number. If you are a successful bidder, the \$10,000 will be applied to your required 20% deposit. For parcels N-75200 and N-77125, arrangements may be made for Electronic Fund Transfer (EFT) of the 20% deposit by notifying BLM no later than May 14, 2004 of your intent to use EFT.

12. If you purchase one or more parcels and default on any single parcel, the default will be against all of your parcels. BLM will retain your \$10,000 and the sale of all parcels to you will be canceled. Following the auction, checks will be returned to the unsuccessful bidders upon presentation of photo identification at the Registration Area.

13. The highest qualifying bid for any parcel, whether sealed or oral, will be declared the high bid. The apparent high bidder, if an oral bidder, must submit the full deposit amount by 4:30 p.m. P.d.t. on the day of the sale in the form of cash, personal check, bank draft, cashier's check, money order or any combination thereof, made payable to the Bureau of Land Management, for not less than 20 percent of the amount of the successful bid. If not paid by close of the auction, funds must be delivered no later than 4:30 a.m. P.d.t. the day of the sale to the BLM Collection Officers at Sam's Town Live.

14. The remainder of the full bid price, whether sealed or oral, must be paid within 180 calendar days of the competitive sale date in the form of a certified check, money order, bank draft, or cashier's check made payable to the Bureau of Land Management. Personal checks will no longer be accepted. Arrangements for Electronic Fund Transfer (EFT) to BLM for the balance which is due on or before November 29, 2004, should be made a minimum of two weeks prior to the date you wish to make payment. Failure to pay the full price within the 180 days will disqualify the apparent high bidder and cause the entire bid deposit to be forfeited to the BLM.

15. Parcels N-75200 and N-77125 will only be put up for sale at the oral auction. Sealed bids for these parcels

will not be accepted. If these parcels are not sold at the oral auction, they will not be sold on the Online Internet Auction.

16. Oral bids will be considered only if received at the place of sale and made at least for the FMV as determined by the authorized officer. For parcels designated Serial Numbers N-75200 and N-77125 specifically, each prospective bidder will be required to present a certified check, postal money order, bank draft or cashier's check made payable to the order of (individually and not jointly) the Bureau of Land Management or (insert your name or company name here) for an amount of money which shall be no less than 20% of the federally approved FMV of the designated parcels. Serial Numbers N-75200 and N-77125, in order to be eligible to bid on each respective parcel. In order to bid on both designated parcels listed, a separate certified check, postal money order, bank draft or cashier's check for an amount of money which shall be no less than 20% of the federally approved FMV for each designated parcel will be required. The check(s) must list both the Bureau of Land Management and your name or company name separated by the word "or".

17. *Additional Information:* The BLM may accept or reject any or all offers, or withdraw any parcel of land or interest therein from sale, if, in the opinion of the authorized officer, consummation of the sale would not be fully consistent with FLPMA or other applicable laws or are determined to not be in the public interest. If not sold, any parcel described above in this notice may be identified for sale at a later date without further legal notice. Unsold parcels, with the exception of parcels N-75200 and N-77125, may be put up for sale on the Internet. Internet auction procedures will be available at www.auctionrnp.com. If unsold on the Internet, parcels may be put up for sale at future auctions without additional legal notice. Upon publication of this notice and until the completion of the sale, the BLM is no longer accepting land use applications affecting any parcel identified for sale, including parcels that have been published in a previous notice of realty action. However, land use applications may be considered after completion of the sale for parcels that are not sold through sealed, oral, or online Internet auction procedures provided the authorization will not adversely affect the marketability or value of the parcel.

Federal law requires bidders to be U.S. citizens 18 years of age or older; a corporation subject to the laws of any State or of the United States; a State,

State Instrumentality, or political subdivision authorized to hold property, or an entity including, but not limited to, associations or partnerships capable of holding property or interests therein under the laws of the State of Nevada. Certification of qualification, including citizenship or corporation or partnership, must accompany the bid deposit.

In order to determine the value, through appraisal, of the parcels of land proposed to be sold, certain extraordinary assumptions may have been made of the attributes and limitations of the lands and potential effects of local regulations and policies on potential future land uses. Through publication of this NORA, the Bureau of Land Management gives notice that these assumptions may not be endorsed or approved by units of local government. It is the buyer's responsibility to be aware of all applicable local government policies, laws, and regulations that would affect the subject lands, including any required dedication of lands for public uses. It is also the buyer's responsibility to be aware of existing or projected use of nearby property. When conveyed out of Federal ownership, the lands will be subject to any applicable reviews and approvals by the respective unit of local government for proposed future uses, and any such reviews and approvals will be the responsibility of the buyer. Any land lacking access from a public road or highway will be conveyed as such, and future access acquisition will be the responsibility of the buyer.

Detailed information concerning the sale, including the reservations, sale procedures and conditions, CERCLA and other environmental documents is available for review at the BLM LVFO, or by calling (702) 515-5114. This information will also be available on the Internet at <http://propertydisposal.gsa.gov>. Click on NV for Nevada. It will also be available on the Internet at <http://www.nv.blm.gov>. Click on Southern Nevada Public Land Management Act and go to Land Sales.

Public Comments

The general public and interested parties may submit comments regarding the proposed sale and purchase to the Field Manager, BLM LVFO, up to 45 days after publication of this notice in the *Federal Register*. Any adverse comments will be reviewed by the Nevada BLM State Director, who may sustain, vacate, or modify this realty action in whole or in part. In the absence of any adverse comments, this realty action will become the final determination of the Department of

Interior. Any comments received during this process, as well as the commentor's name and address, will be available to the public in the administrative record and/or pursuant to a Freedom of Information Act request. You may indicate for the record that you do not wish to have your name and/or address made available to the public. Any determination by the Bureau of Land Management to release or withhold the names and/or addresses of those who comment will be made on a case-by-case basis. A request from a commentor to have their name and/or address withheld from public release will be honored to the extent permissible by law.

Termination of R&PP Classification—SNPLMA Withdrawal

Additionally, the following leases granted under the Recreation and Public Purposes (R&PP) Act, 43 U.S.C. 869 *et. seq.*, have relinquished: N-37113 (98FR5515), N-63113 (64FR50527-50528), and N-66077 (65FR3245-3246). This notice officially terminates the R&PP classification and segregation of the parcels, but does not serve as an opening order because those parcels are within the disposal boundary set by Congress in SNPLMA. Pursuant to section 4(c) of SNPLMA, these parcels are withdraw, subject to valid existing rights, from entry and appropriation under the public land laws, location and entry under the mining laws and from operation under the mineral leasing and geothermal leasing laws, until such time as the Secretary of Interior terminates the withdrawal or the lands are patented.

Dated: April 1, 2004.

Mark T. Morse,
Field Manager.

[FR Doc. 04-8535 Filed 4-14-04; 8:45 am]
BILLING CODE 4310-HC-M

DEPARTMENT OF THE INTERIOR

Minerals Management Service

Outer Continental Shelf (OCS) Cook Inlet Alaska, Oil and Gas Lease Sale 191

AGENCY: Minerals Management Service (MMS), Interior.

ACTION: Final notice of Sale 191, Cook Inlet.

SUMMARY: The MMS will hold Sale 191 on May 19, 2004, in accordance with provisions of the OCS Lands Act (43 U.S.C. 1331-1356, as amended) and the implementing regulations (30 CFR part 256).

DATES: Sale 191 is scheduled to be held on Wednesday, May 19, 2004, at the Wilda Marston Theatre, Z. J. Loussac Public Library, 3600 Denali Street, Anchorage, Alaska. Public opening and reading will begin at approximately 10 a.m. immediately following the planned State of Alaska Cook Inlet and Northslope Foothills Areawide Sales at the same location. All times referred to in this document are local Anchorage, Alaska, times, unless otherwise specified.

ADDRESSES: The "Notice of Sale Package" contains detailed information essential to potential bidders. Interested parties can obtain the package by writing or calling the: Alaska OCS Region, Information Resource Center, Minerals Management Service, 949 East 36th Avenue, Room 330, Anchorage, Alaska 99508-4302; telephone: (907) 271-6438 or 1-800-764-2627.

These documents may be viewed and downloaded from the MMS Web site at www.mms.gov/alaska. Please note: This Internet site may be temporarily unavailable; if so, please contact the Information Resource Center at the address and phone number above regarding the potential restoration of this site or the availability of a temporary alternative site.

Filing of Bids: Bidders will be required to submit bids to MMS at the Alaska OCS Region Office, 949 East 36th Avenue, Third Floor, Anchorage, Alaska 99508 by 10 a.m. on the day before the sale, Tuesday, May 18, 2004. If bids are mailed, the envelope containing all of the sealed bids must be marked as follows: "Attention: Mr. Tom Warren, Contains Sealed Bids for Sale 191." If bids are received later than the time and date specified, they will be returned unopened to the bidders. Bidders may not modify or withdraw their bids unless the Regional Director, Alaska OCS Region, receives a written modification or written withdrawal request prior to 10 a.m., Tuesday, May 18, 2004.

Proposed Sale Area: The MMS is offering for bid in this sale all of the unleased acreage in the area of Cook Inlet identified on the map included as part of this notice. A detailed listing of the blocks and hectares can be obtained by request at the address given above or on the MMS Web site above.

Lease Terms and Conditions: For leases resulting from this sale the following terms and conditions apply:

Initial Period: Eight years.

Minimum Bonus Bid Amount: \$25 per hectare or fraction thereof for all blocks.

Rental: \$5 per hectare or fraction thereof, to be paid on or before the first

day of each lease year until a discovery of oil or gas, then at the rate of \$13 per hectare or fraction thereof payable on or before the last day of each lease year in any full lease year in which royalties on production are not due. This provision is applicable to all leases included in an approved unit where one or more of the unitized leases has a discovery.

Royalty Rates: A 12½ percent royalty rate will apply for all blocks.

Minimum Royalty: \$13 per hectare or fraction thereof per year, to be paid at the expiration of each lease year which commences after oil and gas is produced

and on which royalties are due. If the actual royalty paid in a lease year exceeds the minimum royalty requirement, then no minimum royalty payment is due. In those lease years in which the actual royalty is less than the prescribed minimum royalty, the difference between the prescribed minimum royalty (\$13 per hectare per year) and actual royalty must be paid.

Royalty Suspension Areas: A royalty suspension volume (RSV) of 30 million barrels of oil equivalent (30 MMBOE) will apply to first oil and gas production from each lease. Oil and gas production

are combined in the RSV allowance. Gas RSV is calculated on a volume basis (30 MMbbl = 168.6 Bcf). Royalty suspensions for oil are subject to price thresholds which apply to all leases. The following price thresholds (both floor and ceiling) apply to production for each lease issued. Price thresholds do not apply to gas. The price thresholds have been revised from the proposed NOS to be consistent with both current and expected future market oil prices. The price thresholds are:

Product	Price thresholds	
	Floor (not adjusted for inflation)	Ceiling—2004\$ (adjusted for inflation)
Oil (per bbl)	\$21.00	\$39.00
Gas (per MMBtu)	Not Applicable	Not Applicable

The RSV is discussed in more detail in the Leasing Activities Information document titled "Royalty Suspension Provisions for Oil and Gas Production Cook Inlet Oil and Gas Lease Sale 191" included in the Notice of Sale Package. This document provides specific details regarding royalty suspension eligibility, price thresholds (floors and ceilings) and implementation.

Stipulations and Information to Lessees: The document entitled "Lease Stipulations and Information to Lessees for Oil and Gas Lease Sale 191" contains the text of the Stipulations and the Information to Lessees that apply to this sale. This document is included in the Notice of Sale 191 Package.

Method of Bidding: For each block bid upon, a bidder must submit a separate signed bid in a sealed envelope labeled "Sealed Bid for Oil and Gas Lease Sale 191, not to be opened until 10 a.m., Wednesday, May 19, 2004." The total amount of the bid must be in whole dollars; any cent amount above the whole dollar will be ignored by MMS. Details of the information required on the bid(s) and the bid envelope(s) are specified in the document "Bid Form and Envelope" contained in the Notice of Sale Package.

The MMS published a list of restricted joint bidders, which applies to this sale, in the *Federal Register* at 68 FR 58705 on October 10, 2003. Bidders submitting joint bids must state on the bid form the proportionate interest of each participating bidder, in percent to a maximum of five decimal places, e.g. 33.33333 percent. The MMS may require bidders to submit other documents in accordance with 30 CFR 256.46. The MMS warns bidders against violation of 18 U.S.C. 1860 prohibiting

unlawful combination or intimidation of bidders. Bidders must execute all documents in conformance with signatory authorizations on file in the Alaska OCS Region. Partnerships also must submit or have on file a list of signatories authorized to bind the partnership. Bidders are advised that MMS considers the signed bid to be a legally binding obligation on the part of the bidder(s) to comply with all applicable regulations, including paying the one-fifth bonus bid amount on all high bids. A statement to this effect must be included on each bid as specified in the document "Bid Form and Envelope" contained in the Notice of Sale Package.

Bonus Bid Deposit: Each bidder submitting an apparent high bid must submit a bonus bid deposit to MMS equal to one-fifth of the bonus bid amount for each such bid submitted for Sale 191. Under the authority granted by 30 CFR 256.46(b), MMS requires bidders to use electronic funds transfer (EFT) procedures for payment of the one-fifth bonus bid deposits. Such payment will be due by 1 p.m. eastern time on the day following bid reading. Such a deposit does not constitute and shall not be construed as acceptance of any bid on behalf of the United States. If a lease is awarded, MMS requests that only one transaction be used for payment of the four-fifths bonus bid amount and the first year's rental.

In addition, certain bid submitters (i.e., those that do not currently own or operate an OCS mineral lease OR those that have ever defaulted on a one-fifth bonus payment (EFT or otherwise)) will be required to guarantee (secure) their one-fifth bonus payment prior to the submission of bids. The detailed bid

deposit EFT procedures, including options for those submitters required to secure the EFT one-fifth bonus bid amount, are specified under "Instructions for Making EFT Bonus Payments" in the Notice of Sale 191 Package.

Withdrawal of Blocks: The United States reserves the right to withdraw any block from this sale prior to issuance of a written acceptance of a bid for the block.

Acceptance, Rejection, or Return of Bids: The United States reserves the right to reject any and all bids. In any case, no bid will be accepted, and no lease for any block will be awarded to any bidder, unless the bidder has complied with all requirements of this Notice, including the documents contained in the associated Notice of Sale 191 Package and applicable regulations; the bid is the highest valid bid; and the amount of the bid has been determined to be adequate by the authorized officer. The Attorney General of the United States may also review the results of the lease sale prior to the acceptance of bids and issuance of leases. Any bid submitted which does not conform to the requirements of this notice, the OCS Lands Act, as amended, and other applicable regulations may be returned to the person submitting that bid by the Regional Director and not considered for acceptance. To ensure that the Government receives a fair return for the conveyance of lease rights for this sale, high bids will be evaluated in accordance with MMS bid adequacy procedures.

Successful Bidders: As required by MMS, each company that has been awarded a lease must execute all copies of the lease (Form MMS-2005 (March

1986) as amended), pay by EFT the balance of the bonus bid amount and the first year's rental for each lease issued in accordance with the requirements of 30 CFR 218.155, and satisfy the bonding requirements of 30 CFR part 256, subpart I. Each bidder who is a successful high bidder must have on file in the Alaska OCS Region a currently valid certification (Debarment Certification Form) certifying that the bidder is not excluded from participation in primary covered transactions under Federal non-procurement programs and activities. A certification previously provided to that office remains currently valid until new or revised information applicable to that certification become available. In the event of new or revised applicable information, MMS will require a subsequent certification before lease issuance can occur. Persons submitting such certification should review the requirements of 43 CFR part 12, subpart D. A copy of the Debarment

Certification Form is contained in the Notice of Sale Package.

Affirmative Action: The MMS requests that, prior to bidding, Equal Opportunity Affirmative Action Representation Form MMS 2032 (June 1985) and Equal Opportunity Compliance Report Certification Form MMS 2033 (June 1985) be on file in the Alaska OCS Region. This certification is required by 41 CFR 60 and Executive Order No. 11246 of September 24, 1965, as amended by Executive Order No. 11375 of October 13, 1967. In any event, prior to the execution of any lease contract, both forms are required to be on file in the Alaska OCS Region.

Notice of Bidding Systems: Section 8(a)(8) of the OCS Lands Act (43 U.S.C. 1337(a)(8)) requires that, at least 30 days before any lease sale, a notice be submitted to Congress and published in the **Federal Register**. This Notice of Bidding Systems is for Sale 191, Cook Inlet, scheduled to be held on May 19, 2004.

In Sale 191, all blocks are being offered under a bidding system that uses

a cash bonus and a fixed royalty of 12½ percent with a royalty suspension of up to 30 MMBOE. Oil and gas would be combined in determining the use of the RSV. This bidding system is authorized under 30 CFR 260.110(a)(7), which allows use of a cash bonus bid with a royalty rate of not less than 12½ percent and with suspension of royalties for a period, volume, or value of production, and an annual rental. Analysis performed by MMS indicates that use of this system provides an incentive for development of this area while ensuring that a fair sharing of revenues will result if major discoveries are made and produced.


Specific royalty suspension provisions for Sale 191 are contained in the document "Royalty Suspension Provisions for Oil and Gas Production Cook Inlet Oil and Gas Lease Sale 191" included in the Notice of Sale Package.

Dated: April 7, 2004.

R.M. "Johnnie" Burton,

Director, Minerals Management Service.

BILLING CODE 4310-MR-P



February 17, 2004

[FR Doc. 04-8518 Filed 4-14-04; 8:45 am]
BILLING CODE 4310-MR-C

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation

Glen Canyon Dam Adaptive Management Work Group (AMWG), Notice of Meeting

AGENCY: Bureau of Reclamation, Interior.

ACTION: Notice of public meeting.

SUMMARY: The Adaptive Management Program (AMP) was implemented as a result of the Record of Decision on the Operation of Glen Canyon Dam Final Environmental Impact Statement to comply with consultation requirements of the Grand Canyon Protection Act (Pub. L. 102-575) of 1992. The AMP provides an organization and process to ensure the use of scientific information in decision making concerning Glen Canyon Dam operations and protection of the affected resources consistent with the Grand Canyon Protection Act. The AMP has been organized and includes a federal advisory committee (AMWG), a technical work group (TWG), a monitoring and research center, and independent review panels. The TWG is a subcommittee of the AMWG and provides technical advice and information for the AMWG to act upon.

Date and Location: The TWG will conduct the following public meeting:

Phoenix, Arizona—May 3 and 4, 2004. The meeting will begin at 9:30 a.m. and conclude at 5 p.m. on the first day and will begin at 8 a.m. and conclude at noon on the second day. The meeting will be held at the Bureau of Indian Affairs-Western Regional Office, 2 Arizona Center, 400 N. 5th Street, Conference Rooms A (12th Floor), Phoenix, Arizona.

Agenda: The purpose of the meeting will be to begin development of the long-term experimental plan, and discuss the TWG Operating Procedures, ad hoc group updates, environmental compliance, and other administrative and resource issues pertaining to the AMP.

To allow full consideration of information by the TWG members, written notice must be provided to Dennis Kubly, Bureau of Reclamation, Upper Colorado Regional Office, 125 South State Street, Room 6107, Salt Lake City, Utah, 84138; telephone (801) 524-3715; faxogram (801) 524-3858; e-mail at dkubly@uc.usbr.gov (5) days prior to the meeting. Any written comments received will be provided to

the AMWG and TWG members prior to the meeting.

FOR FURTHER INFORMATION CONTACT: Dennis Kubly, telephone (801) 524-3715; faxogram (801) 524-3858; or via e-mail at dkubly@uc.usbr.gov.

Dated: April 6, 2004.

Dennis Kubly,
Chief, Adaptive Management Group,
Environmental Resources Division, Upper
Colorado Regional Office.

[FR Doc. 04-8548 Filed 4-14-04; 8:45 am]

BILLING CODE 4310-MN-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 731-TA-1070 (Preliminary)]

Certain Tissue Paper Products and Crepe Paper Products From China

Determination

On the basis of the record¹ developed in the subject investigation, the United States International Trade Commission (Commission) determines, pursuant to section 733(a) of the Tariff Act of 1930 (19 U.S.C. 1673b(a)) (the Act), that there is a reasonable indication that an industry in the United States is materially injured by reason of imports from China of certain tissue paper products and that an industry in the United States is materially injured by reason of imports from China of crepe paper products that are alleged to be sold in the United States at less than fair value (LTFV). The tissue paper products and crepe paper products subject to this investigation do not have specific classification numbers assigned to them under the Harmonized Tariff Schedule of the United States (HTS) and appear to be imported under one or more of several different residual or "basket" categories, including but not necessarily limited to the following subheadings: 4802.30; 4802.54; 4802.61; 4802.62; 4802.69; 4804.39; 4806.40; 4808.30; 4808.90; 4811.90; 4823.90; and 9505.90.40.

Commencement of Final Phase Investigation

Pursuant to section 207.18 of the Commission's rules, the Commission also gives notice of the commencement of the final phase of its investigation. The Commission will issue a final phase notice of scheduling, which will be published in the FR as provided in section 207.21 of the Commission's

¹ The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

rules, upon notice from the Department of Commerce (Commerce) of an affirmative preliminary determination in the investigation under section 733(b) of the Act, or, if the preliminary determination is negative, upon notice of an affirmative final determination in that investigation under section 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigation need not enter a separate appearance for the final phase of the investigation. Industrial users, and, if the merchandise under investigation is sold at the retail level, representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigation.

Background

On February 17, 2004, a petition was filed with the Commission and Commerce by Seaman Paper Company of Massachusetts, Inc. (Otter River, MA), American Crepe Corporation (Montoursville, PA), Eagle Tissue LLC (South Windsor, CT), Flower City Tissue Mills Co. (Rochester, NY), Garlock Printing & Converting, Inc. (Gardner, MA), Paper Service Ltd. (Hinsdale, NH), Putney Paper Co., Ltd. (Putney, VT), and the Paper, Allied-Industrial, Chemical and Energy Workers International Union AFL-CIO, CLC, alleging that industries in the United States are materially injured by reason of LTFV imports of certain tissue paper products and crepe paper products from China. Accordingly, effective February 17, 2004, the Commission instituted antidumping duty investigation No. 731-TA-1070 (Preliminary).

Notice of the institution of the Commission's investigation and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the FR of February 23, 2004 (69 FR 8232). The conference was held in Washington, DC, on March 9, 2004, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission transmitted its determination in this investigation to the Secretary of Commerce on April 2, 2004. The views of the Commission are contained in USITC Publication 3682 (April 2004), entitled Certain Tissue Paper Products and Crepe Paper

Products from China: Investigation No. 731-TA-1070 (Preliminary).

By order of the Commission.

Issued: April 9, 2004.

Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. 04-8579 Filed 4-14-04; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Bureau of Alcohol, Tobacco, Firearms and Explosives

Agency Information Collection Activities: Proposed Collection; Comments Requested

ACTION: 60-Day notice of information collection under review: Special Agent Medical Preplacement.

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for "sixty days" until June 14, 2004. This process is conducted in accordance with 5 CFR 1320.10.

If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Eddie Trejo, Recruitment Branch, 6333 3rd Street, NW., Suite 600, Washington, DC 20001.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who

are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *Title of the Form/Collection:* Special Agent Medical Preplacement.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 2300.10. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Individuals or households. Other: None. The form is used by a special agent who is applying for a position has specific medical standards. The information collected is used to determine the medical suitability to qualify for a position that has specific medical standards and physical requirements. The information will also be used to make a recommendation on either hiring or not hiring an applicant.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that 300 respondents will complete a 45-minute form.

(6) *An estimate of the total public burden (in hours) associated with the collection:* There are an estimated 225 annual total burden hours associated with this collection.

If additional information is required contact: Brenda E. Dyer, Deputy Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530.

Dated: April 9, 2004.

Brenda E. Dyer,

Deputy Clearance Officer, PRA, Department of Justice.

[FR Doc. 04-8524 Filed 4-14-04; 8:45 am]

BILLING CODE 4410-FY-P

DEPARTMENT OF JUSTICE

Bureau of Alcohol, Tobacco, Firearms and Explosives

Agency Information Collection Activities: Proposed Collection; Comments Requested

ACTION: 60-Day Notice of Information Collection Under Review: Application for Federal Firearms License (Collector of Curios and Relics).

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for "sixty days" until June 14, 2004. This process is conducted in accordance with 5 CFR 1320.10.

If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Craig Sabo, Firearms, Explosives and Arson Services Division, Room 5100, 650 Massachusetts Avenue, NW., Washington, DC 20226.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *Title of the Form/Collection:* Application for Federal Firearms License (Collector of Curios and Relics).

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 7CR (5310.16). Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Individuals or households. Other: None. The form is used to determine the eligibility of the applicant to engage in certain operations (firearms classified as curios or relics to facilitate a personal collection), to determine location and extent of operations and to determine whether the operations will be in conformity with Federal laws and regulations. The form has been revised to include the option to pay the fee for the license by credit card.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that 7,300 respondents will complete a 15 minute form.

(6) *An estimate of the total public burden (in hours) associated with the collection:* There are an estimated 1,825 annual total burden hours associated with this collection.

If additional information is required contact: Brenda E. Dyer, Deputy Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530.

Dated: April 9, 2004.

Brenda E. Dyer,

Deputy Clearance Officer, PRA, Department of Justice.

[FR Doc. 04-8525 Filed 4-14-04; 8:45 am]

BILLING CODE 4410-FY-P

DEPARTMENT OF LABOR

Office of the Secretary

Submission for OMB Review; Comment Request

April 8, 2004.

The Department of Labor (DOL) has submitted the following public information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chapter 35). A copy of each

ICR, with applicable supporting documentation, may be obtained by contacting the Department of Labor (DOL). To obtain documentation, contact Ira Mills on 202-693-4122 (this is not a toll-free number) or e-mail: mills.ira@dol.gov.

Comments should be sent to Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL, Office of Management and Budget, Room 10235, Washington, DC 20503, 202-395-7316 (this is not a toll-free number), within 30 days from the date of this publication in the **Federal Register**.

The OMB is particularly interested in comments which:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Agency: Employment Standards Administration.

Type of Review: Extension of a currently approved collection.

Title: Claim for Reimbursement-Assisted Reemployment.

OMB Number: 1215-0178.

Frequency: Quarterly.

Affected Public: Business or other for-profit; not for-profit institutions.

Number of Respondents: 20.

Number of Annual Responses: 80.

Estimated Time Per Response: 30 minutes.

Burden Hours Total: 40.

Total annualized capital/startup costs: \$0.

Total annual costs (operating/maintaining systems or purchasing services): \$0.

Description: The information collected on Form CA-2231 provides the Office of Workers' Compensation Programs (OWCP) with the necessary remittance information for the employer to document the hours of work, certify the payment of wages to the claimant for which reimbursement is sought, and

summarize the nature and costs of the wage reimbursement program for a prompt decision by OWCP.

Ira L. Mills,

Departmental Clearance Officer.

[FR Doc. 04-8556 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-28-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Employee Benefits Security Administration, Labor.

ACTION: Notice of approval.

SUMMARY: The Employee Benefits Security Administration (EBSA) is announcing that a revision to the information collection included in Prohibited Transaction Exemption 81-6 (PTE 81-6), Loans of Securities by Employee Benefit Plans to Certain Broker-Dealers and Banks has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520). This notice announces the OMB approval number and expiration date.

FOR FURTHER INFORMATION CONTACT: Gerald B. Lindrew, U.S. Department of Labor, Employee Benefits Security Administration, 200 Constitution Avenue, NW., Room N-5647, Washington, DC 20210. Telephone: (202) 693-8410. This telephone number is not toll-free.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 23, 2003 (68 FR 60715), because of changes to Prohibited Transaction Exemption 81-6 (PTE 81-6), Loans of Securities by Employee Benefit Plans to Certain Broker-Dealers and Banks, the Agency published its intent to request approval by OMB of the Information Collection Request (ICR) included in the revised exemption. The revision was the result of amending PTE 81-6, currently approved under OMB Number 1210-0065, and combining it with a restated Prohibited Transaction Exemption 82-63, currently approved under OMB Number 1210-0062. The Department combined the two exemptions to facilitate their use and understanding by the public. In accordance with the PRA, OMB has approved the information collections in both exemptions under OMB control number 1210-0065; OMB control number 1210-0062 will no

longer be used. The approval expires on December 31, 2006. Under 5 CFR 1320.5(b), an Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection displays a valid control number.

Dated: March 31, 2004.

Gerald B. Lindrew,

Deputy Director, Office of Policy and Research, Employee Benefits Security Administration.

[FR Doc. 04-8551 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-29-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

Agency Information Collection Activities; Announcement of OMB approval

AGENCY: Employee Benefits Security Administration, Labor.

ACTION: Notice of approval.

SUMMARY: The Employee Benefits Security Administration (EBSA) is announcing that a collection of information in connection with Prohibited Transaction Exemption 88-59, permitting, under certain conditions, an employee benefit plan to provide mortgage financing to purchasers of residential dwelling units, has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520). This notice announces the OMB approval number and expiration date.

FOR FURTHER INFORMATION CONTACT: Gerald B. Lindrew, U.S. Department of Labor, Employee Benefits Security Administration, 200 Constitution Avenue, NW., Room N-5647, Washington, DC 20210. Telephone: (202) 693-8410. This telephone number is not toll-free.

SUPPLEMENTARY INFORMATION: In the *Federal Register* of November 5, 2003 (68 FR 62620), EBSA announced its intent to request renewal of its current OMB approval for the information collection in connection with Prohibited Transaction Exemption 88-59. In accordance with the PRA, OMB has renewed its approval for the information collection under OMB control number 1210-0095. The approval expires on March 31, 2007. Under 5 CFR 1320.5(b), an Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the

collection displays a valid control number.

Dated: March 31, 2004.

Gerald B. Lindrew,

Deputy Director, Office of Policy and Research, Employee Benefits Security Administration.

[FR Doc. 04-8552 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-29-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Employee Benefits Security Administration, Labor.

ACTION: Notice.

SUMMARY: The Employee Benefits Security Administration (EBSA) is announcing that a collection of information in connection with Prohibited Transaction Exemption 80-83, involving purchases of securities where issuer may use proceeds to reduce indebtedness to parties in interest has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520). This notice announces the OMB approval number and expiration date.

FOR FURTHER INFORMATION CONTACT: Gerald B. Lindrew, U.S. Department of Labor, Employee Benefits Security Administration, 200 Constitution Avenue, NW., Room N-5647, Washington, DC, 20210. Telephone: (202) 693-8410. This telephone number is not toll-free.

SUPPLEMENTARY INFORMATION: In the *Federal Register* of October 28, 2003 (68 FR 64168), EBSA announced its intent to request renewal of its current OMB approval for the information collection in connection with Prohibited Transaction Exemption 80-83. In accordance with the PRA, OMB has renewed its approval for the information collection under OMB control number 1210-0064. The approval expires on March 31, 2007. Under 5 CFR 1320.5(b), an Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection displays a valid control number.

Dated: March 31, 2004.

Gerald B. Lindrew,

Deputy Director, Office of Policy and Research, Employee Benefits Security Administration.

[FR Doc. 04-8553 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-29-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Employee Benefits Security Administration, Labor.

ACTION: Notice of approval.

SUMMARY: The Employee Benefits Security Administration (EBSA) is announcing that a collection of information included in a regulation pertaining to filing a petition under Section 3(40) of the Employee Retirement Income Security Act of 1974 (ERISA) for a determination by the Secretary of Labor as to whether a particular employee benefit plan is established or maintained under or pursuant to one or more collective bargaining agreements has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520). This document notice the OMB approval number and expiration date.

FOR FURTHER INFORMATION CONTACT: Gerald B. Lindrew, U.S. Department of Labor, Employee Benefits Security Administration, 200 Constitution Avenue, NW., Room N-5647, Washington, DC 20210. Telephone: (202) 693-8410. This telephone number is not toll-free.

SUPPLEMENTARY INFORMATION: In the *Federal Register* of November 12, 2003 (68 FR 64127), the EBSA announced its intent to request renewal of its current OMB approval for the Information Collection Request (ICR) contained in the regulation pertaining to filing a Petition for a Finding under Section 3(40) of ERISA. In accordance with the PRA, OMB has renewed its approval for the information collection under OMB control number 1210-0119. The approval expires on March 31, 2007. Under 5 CFR 1320.5(b), an Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection displays a valid control number.

Dated: March 31, 2004.

Gerald B. Lindrew,

Deputy Director, Office of Policy and Research, Employee Benefits Security Administration.

[FR Doc. 04-8554 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-29-P

DEPARTMENT OF LABOR

Employment and Training Administration

Proposed Information Collection; Comments: Services to Migrant and Seasonal Farm Workers Report, ETA Form 5148 and the Employment Service Complaint Referral Record, ETA Form 8429

ACTION: Notice.

SUMMARY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a pre-clearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(2)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Employment and Training Administration (ETA) is soliciting comments concerning the proposed two-year extension of the Services to Migrant and Seasonal Farm Workers Report, ETA Form 5148, and the Employment Service Complaint Referral Record, ETA Form 8429, from the current end date of June 30, 2004, to the new end date of June 30, 2006.

DATES: Submit comments on or before June 14, 2004.

ADDRESSES: Send comments to: Anthony Dais, U.S. Department of Labor/Employment and Training Administration, Office of Workforce Investment, Room S-4321, 200 Constitution Avenue, NW., Washington, DC 20210, (202) 693-2784—not a toll free number, fax: (202) 693-3015 and e-mail address: dais.anthony@dol.gov.

FOR FURTHER INFORMATION CONTACT: Erik Land, U.S. Department of Labor/Employment and Training Administration, Office of Workforce Investment, Room S-4321, 200 Constitution Avenue, NW., Washington,

DC 20210, (202) 693-2916—not a toll free number and e-mail address: lang.erik@dol.gov.

SUPPLEMENTARY INFORMATION:

I. Background

ETA regulations at 20 CFR parts 651, 653, and 658 under the Wagner-Peyser Act, as amended by the Workforce Investment Act of 1998, set forth requirements to ensure that Migrant and Seasonal Farmworkers (MSFWs) receive services that are qualitatively equivalent and quantitatively proportionate to the services provided to non-MSFWs. In compliance with 20 CFR 653.109, the Department established record-keeping requirements to allow for the efficient and effective monitoring of State Workforce Agencies' (SWAs) regulatory compliance. The ETA Form 5148, Services to Migrant and Seasonal Farm Workers Report, is used to collect data which are primarily used to monitor and measure the extent and effectiveness of SWA service delivery to MSFWs. The ETA Form 8429, Employment Service Compliant Referral Record, is used to collect and document all individual complaints filed under the complaint system.

II. Desired Focus of Comments

Currently, ETA is soliciting comments concerning the proposed two-year extension of the Services to Migrant and Seasonal Farm Workers Report, ETA Form 5148, and the Employment Service Complaint Referral Record, ETA Form 8429, from the current end date of June 30, 2004, to the new end date of June 30, 2006, including focusing on the following:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond by including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

A copy of the proposed information collection request can be obtained by contacting the office listed above in the **ADDRESSES** section of this notice.

III. Current Actions

This is a request for Office of Management and Budget (OMB) approval under the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)) to extend the collection of the Services to Migrant and Seasonal Farm Workers Report, ETA Form 5148, and the Employment Service Complaint Referral Record, ETA Form 8429, from the current end date of June 30, 2004, to new end date of June 30, 2006.

Type of Review: Extension (without change).

Agency: Employment and Training Administration.

Title: ETA Form 5148, Services to Migrant and Seasonal Farm Workers Report, and ETA Form 8429, Employment Service Complaint Referral Record.

OMB Number: 1205-0039.

Complaint Log Maintenance

1. Recordkeeping:
 - Number of record-keepers:* 168.
 - Annual hours per record:* 6.3
 - Record-keeper hours:* 1,058.
2. Processing ETA FORM 8429:
 - Annual number of forms:* 2,520.
 - Minutes per form:* 8.
 - Processing hours:* 336.

Outreach Log

1. Recordkeeping:
 - Number of record-keepers:* 150.
 - Annual hours per record-keeper:* 26.
 - Record-keepers hours:* 3,900
2. Data Collection/Reporting ETA FORM 5148:
 - Number of Respondents:* 52.
 - Annual number of reports:* 4.
 - Total number of reports:* 208.
 - Minutes per report:* 70.
 - Record keeping hours:* 243.
 - Estimated Total Burden Hours:* 5,537.
 - Total Burden Cost (operating/maintaining):* \$0.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of the information collection request; they will also become a matter of public record.

Dated: April 9, 2004.

Emily Stover DeRocco,
Assistant Secretary for Employment and Training.

[FR Doc. 04-8555 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-30-M

DEPARTMENT OF LABOR**Veterans' Employment and Training Service****Solicitation for Grant Application for Veterans' Workforce Investment Program (VWIP) Supplementary Grants for Program Year 2003**

Announcement Type: Initial Announcement.

Funding Opportunity Number: 04-02. *Catalog of Federal Domestic Assistance (CFDA) Number:* 17.802.

Key Dates: Applications are to be submitted by no later than May 17, 2004.

Delivery Address: U.S. Department of Labor, Procurement Services Center, Attention: Cassandra Mitchell, Reference SGA 04-02, Room N5416, 200 Constitution Ave., NW., Washington, DC 20210.

Executive Summary: The U.S. Department of Labor, Veterans' Employment and Training Service (VETS) announces a competition for the balance of the Veterans' Workforce Investment Program (VWIP) grant funds for Program Year (PY) 2003 as authorized under section 168 of the Workforce Investment Act of 1998. This notice contains all of the necessary information and forms needed to apply for grant funding. Selected programs will assist eligible veterans by providing employment, training, support services, credentialing, networking information, and/or other assistance. Under this solicitation for grant applications (SGA), VETS anticipates that up to \$400,000 in PY 2003 funds will be available for grant awards. The awards will be in the form of 12-month grants. The VWIP programs are designed to be flexible in addressing the universal as well as local or regional problems that may have had a negative impact on veterans reentering the workforce, including lack of coordinating information between local service providers. VETS, through this SGA, is seeking applications that take one of two approaches—either providing direct services to veterans, or providing outreach and public information activities that result in job and job training opportunities for veterans.

I. Funding Opportunity Description

Section 168 of the Workforce Investment Act of 1998 (WIA) amended the training programs made available to veterans. See sec. 168, Public Law 105-220, 112 Stat. 1027 (29 U.S.C. 2913). Section 168 authorizes the Department of Labor to make grants to meet the needs for workforce investment

activities of veterans with service-connected disabilities, veterans who have significant barriers to employment, veterans who served on active duty in the armed forces during a war or in a campaign or expedition for which a campaign badge has been authorized, and recently separated veterans within 48 months of discharge. The Department of Labor is authorized to make grants to public agencies, and private non-profit organizations, and community-based organizations (including faith-based organizations) that are determined to have an understanding of the unemployment problems of veterans, familiarity with the area to be served, and the capability to administer a program of workforce investment activities for such veterans effectively.

The VWIP grants under section 168 of the Workforce Investment Act of 1998 are intended to address one or more of three objectives:

- To provide new and creative service delivery systems that address the complex employment problems facing veterans; or
- To provide services to assist in integrating veterans into meaningful employment within the labor force; or
- To provide outreach efforts such as communication strategies or conferences designed to address systemic problems with diverse agencies sharing information or to sponsor conferences designed to bring systemic change in skills development recognition that are barriers to veterans entering the workforce.

This SGA seeks to fund programs that are flexible, creative, innovative, and non-duplicative in addressing local or regional problems that have had a negative impact on keeping veterans from the workforce and improving the employment and retention of veterans.

The project design may provide for one of the following two options:

1. Employment and training services such as basic skills instruction, remedial education activities, job search activities including job search workshops, job counseling, job preparatory training including résumé writing and interviewing skills, subsidized trial employment, on-the-job training, classroom training, placement follow-up services, and other services provided under WIA.
2. Outreach activities such as local or regional newsletters or other communications devices that convey important information to all entities involved in providing employment and training services to veterans, or regional or national conferences. For example, conferences might bring together interested parties from within and

outside the public labor exchange system in order to share important information on strategies for removing credentialing barriers facing veterans with viable but unrecognized skills.

No model is mandatory but the applicant must design a program that is responsive to local, regional, or national needs, is unique, creative, innovative and non-duplicative, and will carry out the objectives of the program to successfully integrate eligible veterans into the workforce. Under the Government Performance and Results Act, Public Law 103-62, 107 Stat. 285 (31 U.S.C. 1101 *et seq.*), Congress and the public are looking for program results rather than program processes.

If the grantee contemplates training and placement activity, coordination with the Disabled Veterans Employment Program Specialists (DVOP's) and Local Veterans Employment Representatives (LVER's) in the jurisdiction is required. Additionally, wherever possible, DVOP and LVER staff should be utilized for job development and placement activities for veterans who are ready to enter employment or who are in need of intensive case management services. Many of these staff members have received training in case management at the National Veterans Training Institute and have a priority of focus on assisting those most at a disadvantage in the labor market. VETS urges working hand-in-hand with DVOP/LVER staff to achieve economies of resources.

II. Award Information

Awards will be made in the form of 12-month grants. Up to five grant awards are anticipated. The total amount of funds available for this solicitation is \$400,000. Awards are expected to range from \$75,000 to a maximum of \$250,000. The Department of Labor reserves the right to negotiate the amounts to be awarded under this competition. Requests exceeding \$250,000 will be considered non-responsive.

The period of performance will be for twelve (12) months from the date of award unless modified. It is expected that successful applicants will commence program operations under this solicitation not later than June 30, 2004. Program funds must be obligated within 12 months of the grant award. However, funds may be reserved for limited activities including follow-up and grant closeout.

III. Eligibility Information

1. *Eligible Applicants.* Under section 168(a)(2) of the Workforce Investment Act, grants may be made to public agencies, private non-profit

organizations, and community based organizations (including faith-based organizations) that DOL determines have familiarity with the area and population to be served and can administer an effective program. Entities that have already received PY 2003 grants are not eligible to be awarded funds under this SGA. Eligible applicants will fall into one of the following categories:

- State and Local Workforce Investment Boards established under sections 111 and 117 of the Workforce Investment Act.

- States and State agencies. A State agency may propose in its application to serve one or more of the political subdivisions in its State. As noted below, this does not preclude a city or county agency from submitting an application to serve its own jurisdiction.

- Local public agencies, meaning any public agency of a general purpose political subdivision of a State that has the power to levy taxes and spend funds, as well as general corporate and police powers. (This typically refers to cities and counties.)

- Private non-profit organizations, including faith-based and community organizations, that have a capacity to manage grants and have or will provide the necessary linkages with other service providers. Entities organized under section 501(c)(4) of the Internal Revenue Code that engage in lobbying activities are not eligible to receive funds under this announcement. Section 18 of the Lobbying Disclosure Act of 1995, Public Law 104-65, 109 Stat. 691 (2 U.S.C. 1611) prohibits instituting an award, grant, or loan of Federal funds to 501(c)(4) entities that engage in lobbying.

- Applicants for VWIP must satisfy a "responsibility review" that demonstrates an ability to administer Federal funds. See 20 CFR 667.170.

In accordance with 29 CFR part 98, entities that are debarred or suspended shall be excluded from Federal financial assistance and are ineligible to receive a VWIP grant.

2. *Cost Sharing or Matching.* Although VETS encourages applicants to use cost sharing and matching funds, Veterans Workforce Investment Grants do not require grantees to share costs or provide matching funds.

3. *Other Eligibility Criteria.* To be eligible for participation in a training program administered under VWIP, an individual must be a veteran fitting one of the following categories:

"* * * veterans with service-connected disabilities, veterans who have significant barriers to employment, veterans who served on active duty in

the armed forces during a war or in a campaign or expedition for which a campaign badge has been authorized, and recently separated veterans [those within 48 months of discharge]." See section 168 (a)(1) of the Workforce Investment Act.

IV. Application and Submission Information

1. *Address to Request Application Package.* Applications announcements or forms will not be mailed. The **Federal Register** may be obtained from your nearest government office or library. This SGA, together with its attachments, includes all information needed to apply. Additional application packages may be obtained from the VETS Web site at <http://www.dol.gov/vets> and at <http://www.fedgrants.gov>. If additional copies of the standard forms are needed, they can be downloaded from http://www.whitehouse.gov/omb/grants/grants_forms.html. To receive any amendments to this solicitation (please reference SGA 04-02), all applicants must register their name and address in writing with the Grant Officer at the following address: U.S. Department of Labor, Procurement Services Center, Room N-5416, 200 Constitution Ave., NW., Washington, DC 20210.

2. *Content and Format of Application Submission.* Applicants must submit a cover letter and an original and two (2) copies of each part of this proposal. The proposal consists of two separate and distinct parts, Part 1 is the technical proposal and Part 2 is the cost proposal. The information provided in these two parts is essential in gaining an understanding of the programmatic and fiscal contents of the grant application.

Part 1—*The Technical Proposal* consists of a narrative proposal that demonstrates: the need for this particular grant program; the services and activities proposed to obtain successful outcomes for the veterans served; and the applicant's capability to accomplish the expected outcomes of the proposed project design. Applicants must be responsive to the Rating Criteria contained in section V (1) and address all of the rating factors as thoroughly as possible in the narrative.

The technical proposal narrative must not exceed fifteen (15) pages double-spaced, font size no less than 11 pt., and typewritten on one side of the paper only. [The applicant also must complete the forms, *i.e.*, the Technical Performance Goals chart provided in the SGA, or some other matrix designed to show performance goals. See Appendix D.]. Required forms and appendices/ attachments are not included in the page count.

In order to facilitate the review process, the following format for the technical proposal is strongly recommended:

- *Need for the program.* The applicant must identify the geographic area to be served; estimate the number of eligible veterans and their needs; indicate poverty, and unemployment rates in the area; and identify the gaps in the local community infrastructure that contribute to the employment and other barriers faced by the targeted veterans. Include Labor Market Information (LMI) on the outlook for job opportunities in the service area. In the case of outreach activities, the need for communications strategies such as Web sites, newsletters or conferences must be fully explained.

- *Approach or strategy to obtain successful outcomes for veterans.* The applicant must identify which of the two approaches it proposes to take to produce positive outcomes for veterans—direct services or outreach and public information activities. This section of the proposal should discuss how direct services to veterans will meet the needs of eligible veterans identified, or how the outreach effort will implement the communications strategies described in the "need for the program" section. Regardless of which approach proposed, this section should include identification of how the applicants proposed approach or strategy will increase or solidify cooperation, coordination, sharing of information between agencies in the community, the region, or in the nation.

- *An indication that the applicant has the capability and knowledge to accomplish the goals in the application.*

Part 2—*Cost Proposal.* The cost proposal consists of a completed Standard Form (SF) 424 "Application for Federal Assistance", SF 424A "Budget Information Sheet", a detailed cost breakdown of each line item on the SF 424A, and supporting materials. Copies of all required forms, with instructions for completion, are included as appendices to this SGA. Applicants can expect that the cost proposal will be reviewed for allowability, how the money is allocated, and reasonableness of placement and enrollment costs. VETS reserves the right to have a State representative review and verify all data. The cost proposal must include the following items:

(i) The Standard Form (SF) 424, "Application for Federal Assistance" (original signed in blue-ink). Please note that, beginning October 1, 2003, all applicants for Federal grant and funding opportunities are required to include a

Dun and Bradstreet (DUNS) number with their application. See OMB Notice of Final Policy Issuance, 68 Fed. Reg. 38402 (June 27, 2003). The DUNS number is a nine-digit identification number that uniquely identifies business entities. There is no charge for obtaining a DUNS number (although it may take 14–30 days).

To obtain a DUNS number, access the following Web site: <http://www.dunandbradstreet.com> or call 1-866-705-5711. Requests for exemption from the DUNS number requirement must be made to OMB. The Dun and Bradstreet Number of the applicant should be entered in the "Organizational Unit" section of block 5 of SF 424. The Catalog of Federal Domestic Assistance number for this program is 17.802. It must be entered on the SF 424, Block 10.

(ii) Standard Form (SF) 424A "Budget Information Sheet" in Appendix B,

(iii) A detailed cost breakout of each line item on the Budget Information Sheet, which should be labeled as "Budget Narrative." Please ensure that costs reported on the SF 424A correspond accurately with the Budget Narrative. The budget narrative must include the following information at a minimum:

- A breakout of all personnel costs by position, title, salary rates, and percent of time of each position to be devoted to the proposed project (including sub-awardees);

- An explanation and breakout of extraordinary fringe benefit rates and associated charges (*i.e.*, rates exceeding 35% of salaries and wages);

- An explanation of the purpose and composition of, and method used to derive the costs, of each of the following: travel, equipment, supplies, sub-awards/contracts, and any other costs. The applicant must include costs of any required travel described in this solicitation. Mileage charges may not exceed 36 cents per mile;

- A description/specification of and justification for equipment purchases, if any. Tangible, non-expendable personal property having a useful life of more than one year and a unit acquisition cost of \$5,000 or more per unit must be specifically identified.

- Matching funds, leveraged funds, and in-kind services are not required for VWIP grants. However, if matching funds, leveraged funds or in-kind services are to be used, an identification of all sources of leveraged or matching funds and an explanation of the derivation of the value of matching/in-kind services must be provided. When resources such as matching funds, leveraged funds and/or the value of in-

kind contributions are made available, please show in section B of the Budget Information Sheet.

(iv) Assurance and Certification signature page, Appendix C.

(v) All applicants must submit evidence of satisfactory financial management capability, which must include recent financial and/or audit statements.

(vi) All applicants must include, as a separate appendix, a list of all employment and training grants and contracts that it has had in the past three (3) years, including grant/contract officer contact information.

(vii) Documentation of indirect cost rates, as described in section IV (5) below.

(viii) A copy of the applicant's most recent (within 12 months) audited financial statement.

(ix) Direct Cost Descriptions for Applicants and Sub-Applicants (See Appendix E.)

(x) Survey on Ensuring Equal Opportunity for Applicants (See Appendix F.)

3. Submission Dates and Times

The grant application package must be received at the designated location by the date and time specified or it will not be considered. Any application received at the Office of Procurement Services after 4:45 p.m. ET, May 17, 2004 will not be considered unless it is received before the award is made and:

- It is determined by the Government that the late receipt was due solely to mishandling by the Government after receipt at the U.S. Department of Labor at the address indicated;

- It was sent by registered or certified mail not later than the fifth calendar day before the closing date of this announcement; or

- It was sent by U.S. Postal Service Express Mail Next Day Service-Post Office to Addressee, not later than 5 p.m. at the location of mailing two (2) working days, excluding weekends and Federal holidays, prior to the closing date of this announcement. The only acceptable evidence to establish the date of mailing of a late application sent by registered or certified mail is the U.S. Postal Service postmark on the envelope or wrapper and on the original receipt from the U.S. Postal Service. If the postmark is not legible, an application received after the above closing time and date shall be processed as if mailed late. "Postmark" means a printed, stamped or otherwise placed impression (not a postage meter machine impression) that is readily identifiable without further action as having been applied and affixed by an employee of

the U.S. Postal Service on the date of mailing. Therefore applicants should request that the postal clerk place a legible hand cancellation "bull's-eye" postmark on both the receipt and the envelope or wrapper.

The only acceptable evidence to establish the date of mailing of a late application sent by U.S. Postal Service Express Mail Next Day Service-Post Office to Addressee is the date entered by the Post Office clerk on the "Express Mail Next Day Service-Post Office to Addressee" label and the postmark on the envelope or wrapper and on the original receipt from the U.S. Postal Service.

"Postmark" has the same meaning as defined above. Therefore, applicants should request that the postal clerk place a legible hand cancellation "bull's-eye" postmark on both the receipt and the envelope or wrapper.

The only acceptable evidence to establish the time of receipt at the U.S. Department of Labor is the date/time stamp of the Procurement Services Center on the application wrapper or other documentary evidence of receipt maintained by that office.

Applications sent by other delivery services, such as Federal Express, UPS, etc., will also be accepted.

All applicants are advised that U.S. mail delivery in the Washington, DC area has been erratic due to security. All applicants must take this into consideration when preparing to meet the application deadline, as you assume the risk for ensuring a timely submission.

4. *Intergovernmental Review.* This funding opportunity is not subject to Executive Order 12372.

"Intergovernmental Review of Federal Programs."

5. *Funding Restrictions.* Rules relating to allowable costs are addressed in 20 CFR 667.200 through 667.220. Under 20 CFR 667.210(b), limits on administrative costs will be negotiated with the grantee and identified in the grant award documents. Construction costs (as opposed to maintenance and/or repair costs) are generally not allowed under WIA. While there are no specific limits on indirect costs, the amount of indirect cost charged to the grant is subject to the overall limitation on administrative costs as negotiated in the grant agreement.

Indirect costs claimed by the applicant must be based on a federally approved rate. A copy of the negotiated approved and signed indirect cost negotiation agreement must be submitted with the application. If the applicant does not presently have an approved indirect cost rate, a proposed

rate with justification may be submitted. Successful applicants will be required to negotiate an acceptable and allowable rate with the appropriate DOL Regional Office of Cost Determination or cognizant agency within 90 days of grant award. (See <http://www.whitehouse.gov/omb/grants/attach.html>.) Rates that can be tracked through the State Workforce Agency's Cost Accounting System represent an acceptable means of allocating costs to DOL and, therefore, can be approved for use in grants to State Workforce Agencies.

6. Other Submission Requirements. Applications may be submitted by registered or certified mail, U.S. Postal Service Express Mail Next Day Service-Post Office to Addressee, U.S. Postal Service First Class Mail, other delivery services (UPS, FEDEX, etc.), or hand delivery in accordance with the submission instructions under section IV (2) above. Applications cannot be accepted by e-mail or facsimile machine.

V. Application Review Information

1. Panel Review Criteria

Applications will be reviewed based upon the following criteria, up to a maximum of 100 points:

A. Need for the Project: 30 points

Applications will be scored on the documented extent of need for this project, as demonstrated by: (i) The potential number or concentration of veterans in the proposed project area relative to other similar areas of jurisdiction; (ii) the high rates of poverty and/or unemployment in the proposed project area as determined by the census or other surveys; (iii) the extent of gaps in the local infrastructure that create employment barriers that hinder the target population; (iv) the number of service members separating from the armed forces at local military bases; (v) problems with coordination between service providers; and (vi) identification of credentialing barriers which need to be addressed.

B. Overall Strategy To Enhance Services Provided to Veterans, To Initiate Actions To Provide Workforce Investment Activities for Veterans Not Otherwise Served, or To Provide Outreach and Public Information Activities To Develop and Promote Maximum Job and Job Training Opportunities for Eligible Veterans: 40 points

The application must include a description of the proposed approach to address one of the permissible

strategies—either to provide workforce investment activities or to provide outreach and public information activities. Applicants should demonstrate how the activities will be tailored or will be responsive to the needs of veterans, and the employers seeking to hire veterans. Applications will be scored on the extent to which they demonstrate the following:

In the case of an application describing direct services to veterans:

(i) Is the project Unique—Has any other service provider tried the same approach;

(ii) Is the project Creative—What will this project do that other projects won't do or haven't done;

(iii) Is the project Innovative—Are any changes made to traditional service delivery programs to make them more effective?

As part of its service proposal, has the grantee planned to provide appropriate awareness, information sharing, and orientation activities on veterans and their needs to the following: Federal, State, and local entitlement services such as the Social Security Administration (SSA), Department of Veterans Affairs (DVA), State Workforce Agencies (SWAs) and their local job service offices or one-stop-centers including service programs such as Disabled Veterans Outreach Program (DVOP) Specialists, Local Veterans' Employment Representatives (LVERS) (which integrate WIA, labor exchange, and other employment and social services), detoxification facilities, etc.; civic and private groups and especially veterans' service organizations such as The American Legion, Disabled American Veterans, Veterans of Foreign Wars, and American Veterans (AMVETS); Family Service Centers on local military bases and local managers of Transition Assistance Program classes (this might be accomplished by the publication of an assistance guide or other periodical with information about these services); and faith and community based organizations?

In the case of an outreach program:

(i) Is the project Unique—Has any other service provider tried the same approach;

(ii) Is the project Creative—What will this project do that other projects won't do or haven't done;

(iii) Is the project Innovative—Are any changes made to traditional outreach programs to make them more effective?

In its proposal for outreach, has the grantee planned to provide appropriate awareness, information sharing, and orientation activities on veterans and their needs to the following: Federal, State, and local entitlement services

such as the Social Security Administration (SSA), Department of Veterans Affairs (DVA), State Workforce Agencies (SWAs) and their local job service offices or one-stop-centers including service programs such as Disabled Veterans Outreach Program (DVOP) Specialists, Local Veterans' Employment Representatives (LVERS) (which integrate WIA, labor exchange, and other employment and social services), detoxification facilities, etc.; civic and private groups and especially veterans' service organizations such as The American Legion, Disabled American Veterans, Veterans of Foreign Wars, and American Veterans (AMVETS); Family Service Centers on local military bases and local managers of Transition Assistance Program classes (this might be accomplished by the publication of an assistance guide or other periodical with information about these services); and faith and community based organizations?

Additionally, where the project design focuses on improved coordination/cooperation, community outreach, conferences and public information, has the narrative described a comprehensive plan for meeting the challenges and solving the problems associated with getting disparate groups talking to each other and/or getting relevant information to eligible veterans in a cogent, logical, and efficient manner on a regular basis.

C. Demonstrated Capability in Providing Required Program Services: 30 points

The applicant must describe its relevant prior experience in either operating a public information or community outreach effort or operating employment and training programs and providing services to participants similar to those which are proposed under this solicitation. Specific outcomes of the applicant's prior experience must be described, including costs per enrollment and cost per entered employment or, in the case of outreach activities, number of relevant parties reached or conferences attended. The applicant must also address its capability and ability for timely startup of the program. The applicant should delineate its staff capability and ability to manage the financial aspects of a grant program, including a recent (within the last 12 months) financial statement or audit if available. Final or most recent technical reports for other relevant programs must be submitted if applicable and will not be scored against the page count. Because prior grant experience is not a requirement for this grant, some applicants may not have any technical reports to submit.

2. Review and Selection Process

The Grant Officer, with the assistance of VETS staff, will conduct an initial screening to determine responsiveness, timeliness, completeness, and eligibility of the applicant. Following the initial screening, the review panel using the point scoring system specified above in V(1) will review those applications determined to meet these criteria. Applications will be ranked based on the score assigned by the panel after careful evaluation by each panel member. The ranking will be the primary basis to identify applicants as potential grantees. Although the Government reserves the right to award on the basis of the initial proposal submissions, the Government may establish a competitive range, based upon the proposal evaluation, for the purpose of selecting qualified applicants. The panel's conclusions are advisory in nature and not binding on the Grant Officer. The Government reserves the right to ask for clarification or hold discussions, but is not obligated to do so. The Government further reserves the right to select applicants out of rank order if such a selection would, in its opinion, result in the most effective and appropriate combination of funding, program and administrative costs e.g., cost per enrollment and placement, demonstration models, and geographic service areas. While points will not be awarded for cost issues, cost per entered employment will be given serious consideration in the selection of awardees. The Grant Officer's determination for award under SGA 04-02 is the final agency action. The submission of the same proposal from any prior year Homeless Veterans' Reintegration Project or VWIP competition does not guarantee an award under this solicitation.

VI. Award Administration

1. Award Notices

The Grant Officer will notify successful applicants of their awards. The notification letter will contain instructions on when performance under the terms of the award may begin. No activity associated with a grant application is authorized prior to official notification of an award by the Grant Officer. Before the actual grant award, the Grant Officer, in consultation with VETS staff, may enter into negotiations concerning such items as program components, funding levels, and administrative systems. If the negotiations do not result in an acceptable submittal, the Grant Officer reserves the right to terminate the

negotiation and decline to fund the proposal.

2. Administrative and National Policy Requirements

Grantees must comply with the provisions of WIA and its regulations, as applicable. All grants will also be subject to the following administrative standards and provisions, if applicable to the particular grantees:

- 20 CFR Part 667—Administrative provisions for programs including VWIP, under Title I of WIA.
- 29 CFR Part 93—Lobbying.
- 29 CFR Part 95—Uniform Administrative Requirements for Grants and Agreements with Institutions of Higher Education, Hospitals, and Other Non-profit Organizations, and with Commercial Organizations.
- 29 CFR Part 96—Federal Standards for Audit of Federally Funded Grants, Contracts and Agreements.
- 29 CFR Part 97—Uniform Administrative Requirements for Grants and Cooperative Agreements to State and local Governments.
- 29 CFR Part 98—Federal Standards for Government-wide Debarment and Suspension (Non-procurement) and Government-wide Requirements for Drug-Free Workplace (Grants).
- 29 CFR Part 99—Audit of States, Local Governments, and Non-profit Organizations.
- 29 CFR Parts 30, 31, 32, 33, 36, and 37—Equal Employment Opportunity in Apprenticeship and Training; Nondiscrimination in Federally Assisted Programs of the Department of Labor, Effectuation of Title VI of the Civil Rights Act of 1964; Nondiscrimination on the Basis of Handicap in Programs and Activities; and Nondiscrimination on the Basis of Sex in Education Programs Receiving Federal Financial Assistance; and Implementation of the Nondiscrimination and Equal Opportunity Provisions of the Workforce Investment Act of 1988.
- In accordance with WIA section 195(6), programs funded under this SGA may not involve political activities. Additionally, in accordance with section 18 of the Lobbying Disclosure Act of 1995, Public Law 104-65 (2 U.S.C. 1611), non profit entities incorporated under 501(c)(4) that engage in lobbying activities are not eligible to receive Federal funds and grants.

3. *Reporting Requirements.* The grantees will be required to submit the reports and documents listed below:

A. Financial Reports

The grantee must report outlays, program income, and other financial

information on a quarterly basis using SF 269A, Financial Status Report, Short Form. This form will cite the assigned grant number and be submitted to the appropriate State Director for Veterans' Employment and Training (DVET) no later than 30 days after the ending date of each Federal fiscal quarter (i.e., reports are due October 30, January 30, April 30 and July 30) during the grant period.

B. Program Reports

Grantees must electronically submit a Quarterly Technical Performance Report 30 days after the end of each Federal fiscal quarter (i.e., reports are due October 30, January 30, April 30 and July 30) to the appropriate State Director of Veterans Employment and Training that contains the following:

- A comparison of actual accomplishments to established goals for the reporting period and any findings related to monitoring efforts;
- An explanation for variances of plus or minus 15% of planned program and/or expenditure goals, to include: (i) identification of corrective action, which will be taken to meet the planned goals, if required by the Grant Officer's Technical Representative; and (ii) a timetable for accomplishment of the corrective action.

C. Three (3) Month Follow-Up Report

Not later than 120 days after the grant expiration date, the grantee must submit a report showing/assessing program results at the 90-day mark. The report should also contain the following:

- Financial Status Report (SF269A) (copy to be provided following grant awards); and
- Technical Performance Report (Program Goals).

D. Six (6) Month Follow-Up Report—Close Out

No later than 210 days after the grant performance period ends, the grantee must submit a follow-up report containing the following:

- Final Financial Status Report (SF269A); and
- Final Narrative Report identifying—(a) the total combined (directed/assisted) number of veterans placed during the entire grant period; (b) the number of veterans still employed during follow up; (c) whether the veterans are still employed at the same or similar job, and if not what are the reasons; (d) whether the training received was applicable to jobs held; (e) wages at placement and during follow-up period; (f) an explanation regarding why those veterans placed during the grant but not employed at the end of the

follow-up period are not so employed; and (g) any recommendations to improve the program. Reporting requirements under D. above will not apply to programs involving outreach and public information activities that do not involve the direct training and placement of eligible veterans.

VII. Agency Contacts

For answers to questions or help with problems while the funding period is open contact Cassandra Willis, U.S. Department of Labor, Procurement Services Center, telephone (202) 693-4570.

VIII. Other Information

Unless specifically provided in the grant agreement, DOL's acceptance of a proposal and an award of Federal funds to sponsor any program(s) do not provide a waiver of any grant

requirements and/or procedures. For example, the OMB circulars require and an entity's procurement procedures must provide that all procurement transactions will be conducted, as practical, to provide open and free competition. If a proposal identifies a specific entity to provide the services, the DOL award does not provide the justification or basis to sole-source the procurement, *i.e.*, avoid competition.

FOR FURTHER INFORMATION CONTACT: It is recommended that you confirm receipt of your application by contacting Cassandra Mitchell, U.S. Department of Labor, Procurement Services Center, telephone (202) 693-4570, prior to the closing deadline. [This is not a toll-free number.]

All applicants are advised that U.S. mail delivery in the Washington, DC area has been erratic due to security concerns. All applicants must take this

into consideration when preparing to meet the application deadline.

Signed at Washington, DC this 7th day of April, 2004.

Lisa Harvey,
Acting Grant Officer.

Appendices

Appendix A: Application for Federal Assistance SF 424
Appendix B: Budget Information Sheet SF 424A
Appendix C: Assurances and Certifications Signature Page
Appendix D: Technical Performance Goals Form
Appendix E: Direct Cost Descriptions for Applicants and Sub-Applicants
Appendix F: Survey on Ensuring Equal Opportunity for Applicants
Appendix G: The Glossary of Terms
Appendix H: Legal Rules Applying to Faith Based Organizations

BILLING CODE 4510-79-P

**APPLICATION FOR
FEDERAL ASSISTANCE**

1. TYPE OF SUBMISSION: Application <input type="checkbox"/> Construction <input type="checkbox"/> Non-Construction Preapplication <input type="checkbox"/> Construction <input type="checkbox"/> Non-Construction		2. DATE SUBMITTED	Applicant Identifier
		3. DATE RECEIVED BY STATE	State Application Identifier
		4. DATE RECEIVED BY FEDERAL AGENCY	Federal Identifier
5. APPLICANT INFORMATION			
Legal Name:		Organizational Unit:	
Address (give city, county, State, and zip code):		Name and telephone number of person to be contacted on matters involving this application (give area code)	
6. EMPLOYER IDENTIFICATION NUMBER (EIN): [] [] - [] [] [] [] [] [] [] []		7. TYPE OF APPLICANT: (enter appropriate letter in box) <input type="checkbox"/>	
8. TYPE OF APPLICATION: <input type="checkbox"/> New <input type="checkbox"/> Continuation <input type="checkbox"/> Revision If Revision, enter appropriate letter(s) in box(es) [] [] A. Increase Award B. Decrease Award C. Increase Duration D. Decrease Duration Other(specify): _____		A. State H. Independent School Dist. B. County I. State Controlled Institution of Higher Learning C. Municipal J. Private University D. Township K. Indian Tribe E. Interstate L. Individual F. Intermunicipal M. Profit Organization G. Special District N. Other (Specify) _____	
10. CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER: [] [] - [] [] [] [] TITLE: _____		9. NAME OF FEDERAL AGENCY:	
12. AREAS AFFECTED BY PROJECT (Cities, Counties, States, etc.):		11. DESCRIPTIVE TITLE OF APPLICANT'S PROJECT:	
13. PROPOSED PROJECT		14. CONGRESSIONAL DISTRICTS OF:	
Start Date	Ending Date	a. Applicant	b. Project
15. ESTIMATED FUNDING:		16. IS APPLICATION SUBJECT TO REVIEW BY STATE EXECUTIVE ORDER 12372 PROCESS?	
a. Federal	\$ _____ ⁰⁰	a. YES. THIS PREAPPLICATION/APPLICATION WAS MADE AVAILABLE TO THE STATE EXECUTIVE ORDER 12372 PROCESS FOR REVIEW ON: DATE _____	
b. Applicant	\$ _____ ⁰⁰	b. No. <input type="checkbox"/> PROGRAM IS NOT COVERED BY E. O. 12372 <input type="checkbox"/> OR PROGRAM HAS NOT BEEN SELECTED BY STATE FOR REVIEW	
c. State	\$ _____ ⁰⁰	17. IS THE APPLICANT DELINQUENT ON ANY FEDERAL DEBT? <input type="checkbox"/> Yes If "Yes," attach an explanation. <input type="checkbox"/> No	
d. Local	\$ _____ ⁰⁰		
e. Other	\$ _____ ⁰⁰		
f. Program Income	\$ _____ ⁰⁰		
g. TOTAL	\$ _____ ⁰⁰		
18. TO THE BEST OF MY KNOWLEDGE AND BELIEF, ALL DATA IN THIS APPLICATION/PREAPPLICATION ARE TRUE AND CORRECT, THE DOCUMENT HAS BEEN DULY AUTHORIZED BY THE GOVERNING BODY OF THE APPLICANT AND THE APPLICANT WILL COMPLY WITH THE ATTACHED ASSURANCES IF THE ASSISTANCE IS AWARDED.			
a. Type Name of Authorized Representative		b. Title	c. Telephone Number
d. Signature of Authorized Representative		e. Date Signed	

INSTRUCTIONS FOR THE SF-424

Public reporting burden for this collection of information is estimated to average 45 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0043), Washington, DC 20503.

PLEASE DO NOT RETURN YOUR COMPLETED FORM TO THE OFFICE OF MANAGEMENT AND BUDGET. SEND IT TO THE ADDRESS PROVIDED BY THE SPONSORING AGENCY.

This is a standard form used by applicants as a required facesheet for preapplications and applications submitted for Federal assistance. It will be used by Federal agencies to obtain applicant certification that States which have established a review and comment procedure in response to Executive Order 12372 and have selected the program to be included in their process, have been given an opportunity to review the applicant's submission.

- | Item: | Entry: | Item: | Entry: |
|-------|---|-------|--|
| 1. | Self-explanatory. | 12. | List only the largest political entities affected (e.g., State, counties, cities). |
| 2. | Date application submitted to Federal agency (or State if applicable) and applicant's control number (if applicable). | 13. | Self-explanatory. |
| 3. | State use only (if applicable). | 14. | List the applicant's Congressional District and any District(s) affected by the program or project. |
| 4. | If this application is to continue or revise an existing award, enter present Federal identifier number. If for a new project, leave blank. | 15. | Amount requested or to be contributed during the first funding/budget period by each contributor. Value of in-kind contributions should be included on appropriate lines as applicable. If the action will result in a dollar change to an existing award, indicate <i>only</i> the amount of the change. For decreases, enclose the amounts in parentheses. If both basic and supplemental amounts are included, show breakdown on an attached sheet. For multiple program funding, use totals and show breakdown using same categories as item 15. |
| 5. | Legal name of applicant, name of primary organizational unit which will undertake the assistance activity, complete address of the applicant, and name and telephone number of the person to contact on matters related to this application. | 16. | Applicants should contact the State Single Point of Contact (SPOC) for Federal Executive Order 12372 to determine whether the application is subject to the State intergovernmental review process. |
| 6. | Enter Employer Identification Number (EIN) as assigned by the Internal Revenue Service. | 17. | This question applies to the applicant organization, not the person who signs as the authorized representative. Categories of debt include delinquent audit disallowances, loans and taxes. |
| 7. | Enter the appropriate letter in the space provided. | 18. | To be signed by the authorized representative of the applicant. A copy of the governing body's authorization for you to sign this application as official representative must be on file in the applicant's office. (Certain Federal agencies may require that this authorization be submitted as part of the application.) |
| 8. | Check appropriate box and enter appropriate letter(s) in the space(s) provided:

-- "New" means a new assistance award.

-- "Continuation" means an extension for an additional funding/budget period for a project with a projected completion date.

-- "Revision" means any change in the Federal Government's financial obligation or contingent liability from an existing obligation. | | |
| 9. | Name of Federal agency from which assistance is being requested with this application. | | |
| 10. | Use the Catalog of Federal Domestic Assistance number and title of the program under which assistance is requested. | | |
| 11. | Enter a brief descriptive title of the project. If more than one program is involved, you should append an explanation on a separate sheet. If appropriate (e.g., construction or real property projects), attach a map showing project location. For preapplications, use a separate sheet to provide a summary description of this project. | | |

OMB Approval No. 0348-0044

BUDGET INFORMATION - Non-Construction Programs
SECTION A - BUDGET SUMMARY

Grant Program Function or Activity (a)	Catalog of Federal Domestic Assistance Number (b)	Estimated Unobligated Funds		New or Revised Budget		Total (g)
		Federal (c)	Non-Federal (d)	Federal (e)	Non-Federal (f)	
1.		\$		\$		\$
2.						
3.						
4.						
5. Totals		\$	\$	\$	\$	\$
SECTION B - BUDGET CATEGORIES						
GRANT PROGRAM, FUNCTION OR ACTIVITY						
6. Object Class Categories	(1)	(2)	(3)	(4)	(5)	Total (5)
a. Personnel	\$	\$	\$	\$		\$
b. Fringe Benefits						
c. Travel						
d. Equipment						
e. Supplies						
f. Contractual						
g. Construction						
h. Other						
i. Total Direct Charges (sum of 6a-6h)						
j. Indirect Charges						
k. TOTALS (sum of 6i and 6j)	\$	\$	\$	\$	\$	\$
7. Program Income						
	\$	\$	\$	\$	\$	\$

Standard Form 424A (Rev. 7-97)
 Prescribed by OMB Circular A-102

Authorized for Local Reproduction

Previous Edition Usable

SECTION C - NON-FEDERAL RESOURCES					(e) TOTALS
(a) Grant Program	(b) Applicant	(c) State	(d) Other Sources		
8.	\$	\$	\$	\$	\$
9.					
10.					
11.					
12. TOTAL (sum of lines 8-11)	\$	\$	\$	\$	\$
SECTION D - FORECASTED CASH NEEDS					4th Quarter
Total for 1st Year	1st Quarter	2nd Quarter	3rd Quarter		
13. Federal	\$	\$	\$	\$	\$
14. Non-Federal					
15. TOTAL (sum of lines 13 and 14)	\$	\$	\$	\$	\$
SECTION E - BUDGET ESTIMATES OF FEDERAL FUNDS NEEDED FOR BALANCE OF THE PROJECT					(e) Fourth
(a) Grant Program	FUTURE FUNDING PERIODS (Years)				
	(b) First	(c) Second	(d) Third		
16.	\$	\$	\$	\$	\$
17.					
18.					
19.					
20. TOTAL (sum of lines 16-19)	\$	\$	\$	\$	\$
SECTION F - OTHER BUDGET INFORMATION					
21. Direct Charges:	22. Indirect Charges:				
23. Remarks:					

INSTRUCTIONS FOR THE SF-424A

Public reporting burden for this collection of information is estimated to average 180 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0044), Washington, DC 20503.

PLEASE DO NOT RETURN YOUR COMPLETED FORM TO THE OFFICE OF MANAGEMENT AND BUDGET. SEND IT TO THE ADDRESS PROVIDED BY THE SPONSORING AGENCY.

General Instructions

This form is designed so that application can be made for funds from one or more grant programs. In preparing the budget, adhere to any existing Federal grantor agency guidelines which prescribe how and whether budgeted amounts should be separately shown for different functions or activities within the program. For some programs, grantor agencies may require budgets to be separately shown by function or activity. For other programs, grantor agencies may require a breakdown by function or activity. Sections A, B, C, and D should include budget estimates for the whole project except when applying for assistance which requires Federal authorization in annual or other funding period increments. In the latter case, Sections A, B, C, and D should provide the budget for the first budget period (usually a year) and Section E should present the need for Federal assistance in the subsequent budget periods. All applications should contain a breakdown by the object class categories shown in Lines a-k of Section B.

Section A. Budget Summary Lines 1-4 Columns (a) and (b)

For applications pertaining to a *single* Federal grant program (Federal Domestic Assistance Catalog number) and *not requiring* a functional or activity breakdown, enter on Line 1 under Column (a) the Catalog program title and the Catalog number in Column (b).

For applications pertaining to a *single* program *requiring* budget amounts by multiple functions or activities, enter the name of each activity or function on each line in Column (a), and enter the Catalog number in Column (b). For applications pertaining to multiple programs where none of the programs require a breakdown by function or activity, enter the Catalog program title on each line in Column (a) and the respective Catalog number on each line in Column (b).

For applications pertaining to *multiple* programs where one or more programs *require* a breakdown by function or activity, prepare a separate sheet for each program requiring the breakdown. Additional sheets should be used when one form does not provide adequate space for all breakdown of data required. However, when more than one sheet is used, the first page should provide the summary totals by programs.

Lines 1-4, Columns (c) through (g)

For *new* applications, leave Column (c) and (d) blank. For each line entry in Columns (a) and (b), enter in Columns (e), (f), and (g) the appropriate amounts of funds needed to support the project for the first funding period (usually a year).

For *continuing grant program applications*, submit these forms before the end of each funding period as required by the grantor agency. Enter in Columns (c) and (d) the estimated amounts of funds which will remain unobligated at the end of the grant funding period only if the Federal grantor agency instructions provide for this. Otherwise, leave these columns blank. Enter in columns (e) and (f) the amounts of funds needed for the upcoming period. The amount(s) in Column (g) should be the sum of amounts in Columns (e) and (f).

For *supplemental grants and changes* to existing grants, do not use Columns (c) and (d). Enter in Column (e) the amount of the increase or decrease of Federal funds and enter in Column (f) the amount of the increase or decrease of non-Federal funds. In Column (g) enter the new total budgeted amount (Federal and non-Federal) which includes the total previous authorized budgeted amounts plus or minus, as appropriate, the amounts shown in Columns (e) and (f). The amount(s) in Column (g) should not equal the sum of amounts in Columns (e) and (f).

Line 5 - Show the totals for all columns used.

Section B Budget Categories

In the column headings (1) through (4), enter the titles of the same programs, functions, and activities shown on Lines 1-4, Column (a), Section A. When additional sheets are prepared for Section A, provide similar column headings on each sheet. For each program, function or activity, fill in the total requirements for funds (both Federal and non-Federal) by object class categories.

Line 6a-l - Show the totals of Lines 6a to 6h in each column.

Line 6j - Show the amount of indirect cost.

Line 6k - Enter the total of amounts on Lines 6i and 6j. For all applications for new grants and continuation grants the total amount in column (5). Line 6k, should be the same as the total amount shown in Section A, Column (g), Line 5. For supplemental grants and changes to grants, the total amount of the increase or decrease as shown in Columns (1)-(4), Line 6k should be the same as the sum of the amounts in Section A, Columns (e) and (f) on Line 5.

Line 7 - Enter the estimated amount of income, if any, expected to be generated from this project. Do not add or subtract this amount from the total project amount. Show under the program

INSTRUCTIONS FOR THE SF-424A (continued)

narrative statement the nature and source of income. The estimated amount of program income may be considered by the Federal grantor agency in determining the total amount of the grant.

Section C. Non-Federal Resources

Lines 8-11 Enter amounts of non-Federal resources that will be used on the grant. If in-kind contributions are included, provide a brief explanation on a separate sheet.

Column (a) - Enter the program titles identical to Column (a), Section A. A breakdown by function or activity is not necessary.

Column (b) - Enter the contribution to be made by the applicant.

Column (c) - Enter the amount of the State's cash and in-kind contribution if the applicant is not a State or State agency. Applicants which are a State or State agencies should leave this column blank.

Column (d) - Enter the amount of cash and in-kind contributions to be made from all other sources.

Column (e) - Enter totals of Columns (b), (c), and (d).

Line 12 - Enter the total for each of Columns (b)-(e). The amount in Column (e) should be equal to the amount on Line 5, Column (f), Section A.

Section D. Forecasted Cash Needs

Line 13 - Enter the amount of cash needed by quarter from the grantor agency during the first year.

Line 14 - Enter the amount of cash from all other sources needed by quarter during the first year.

Line 15 - Enter the totals of amounts on Lines 13 and 14.

Section E. Budget Estimates of Federal Funds Needed for Balance of the Project

Lines 16-19 - Enter in Column (a) the same grant program titles shown in Column (a), Section A. A breakdown by function or activity is not necessary. For new applications and continuation grant applications, enter in the proper columns amounts of Federal funds which will be needed to complete the program or project over the succeeding funding periods (usually in years). This section need not be completed for revisions (amendments, changes, or supplements) to funds for the current year of existing grants.

If more than four lines are needed to list the program titles, submit additional schedules as necessary.

Line 20 - Enter the total for each of the Columns (b)-(e). When additional schedules are prepared for this Section, annotate accordingly and show the overall totals on this line.

Section F. Other Budget Information

Line 21 - Use this space to explain amounts for individual direct object class cost categories that may appear to be out of the ordinary or to explain the details as required by the Federal grantor agency.

Line 22 - Enter the type of indirect rate (provisional, predetermined, final or fixed) that will be in effect during the funding period, the estimated amount of the base to which the rate is applied, and the total indirect expense.

Line 23 - Provide any other explanations or comments deemed necessary.

CERTIFICATIONS AND ASSURANCES

ASSURANCES AND CERTIFICATIONS SIGNATURE PAGE

The Department of Labor will not award a grant or agreement where the grantee/recipient has failed to accept the ASSURANCES AND CERTIFICATIONS contained in this section. By signing and returning this signature page, the grantee/recipient is providing the certifications set forth below:

- A. Certification Regarding Lobbying, Debarment, Suspension, Other Responsibility Matters - Primary Covered Transactions and Certifications Regarding Drug-Free/Tobacco-Free Workplace,
- B. Certification of Release of Information
- C. Assurances - Non-Construction Programs
- D. Applicant is not a 501(c)(4) organization

APPLICANT NAME and LEGAL ADDRESS:

If there is any reason why one of the assurances or certifications listed cannot be signed, please explain. Applicant need only submit and return this signature page with the grant application. All other instruction shall be kept on file by the applicant.

SIGNATURE OF AUTHORIZED CERTIFYING OFFICIAL

TITLE

APPLICANT ORGANIZATION

DATE SUBMITTED

Please Note: This signature page and any pertinent attachments which may be required by these assurances and certifications shall be attached to the applicant's Cost Proposal.

Quarterly Performance and Enrollment Goals

(Enter all data cumulatively)

Grant Number:
Performance Goals

Program Year:

	Quarters			
	1	2	3	4
Assessments				
Participants/Enrollments				
Employment Development Plans				
Job Placement Services				
Follow-up services at 90 days				
Placements/Entered Employments				
Terminations				

Core Training

	Quarters			
	1	2	3	4
Classroom Training				
On-the-job training				
Remedial education				
Literacy and bilingual training				
Institutional skills training				
Occupational skills training				
On-site industry-specific training				
Customized training				
Apprenticeship training				
Upgrading and retraining				
Supportive Services				
Other (specify)				
Total Individuals				

Ancillary Services

	Quarters			
	1	2	3	4
Counseling and/or Vocational Guidance				
Job Search Assistance				
Case Management				
Job Club				
Work Experience				
Tools/Fees/etc.				
Other (specify)				

Enrollment Goals by Eligibility Groups (do not double count)

	Quarters			
	1	2	3	4
Campaign/Wartime veteran				
Service-Connected Disabled veteran				
Recently-separated veteran				

Enrollment Plan by Eligibility Subgroups (from above, as applicable, include here)

	Quarters			
	1	2	3	4
Youth veterans (20-24 years of age)				
Economically Disadvantaged veterans				
Welfare and/or Public Assistance recipient veterans				
Female veterans				
Homeless veterans				
African-American veterans				
Hispanic veterans				
Native American veterans				
Other minority veterans				

Benchmarks

	Quarters			
	1	2	3	4
Average Wage at Placement				
Placement Rate				

Direct Cost Descriptions For Applicants and Sub-Applicants*

Position Title(s)	Annual Salary/Wage Rate	% of Time Charged to Grant	Proposed Administration Costs **	Proposed Program Costs

Sub-Total

Administration Program

Fringe Benefits For All Positions

Contractual

Travel

Indirect Costs

Equipment

Supplies

Total Costs -----

Administration Program

** Administrative costs are associated with the supervision and management of the program and do not directly or immediately affect participants.

* Direct costs for all funded positions for both applicant and sub-applicant(s) must be provided.

U.S. Department of Labor
Veterans' Employment and Training Service

GLOSSARY OF TERMS

Adequate Employment – See Unsubsidized Employment.

Administrative Costs - Administrative costs shall consist of all direct and indirect costs associated with the supervision and management of the program. These costs shall include the administrative costs, both direct and indirect, of sub-recipients and contractors.

Adult Basic Education - Education for adults whose inability to speak, read, or write the English language or to effectively reason mathematically, constitutes a substantial impairment of their ability to get or retain employment commensurate with their real ability, which is designed to help eliminate such inability and raise the level, of education of such individuals with a view to making them less likely to become dependent on others, to improve their ability to benefit from occupational training and otherwise increase their opportunities for more productive and profitable employment, and to make them better able to meet their adult responsibilities.

Ancillary Services – Employment and training related activities other than core training that may enhance a participant's employability.

Apprenticeship Training – A formal occupational training program that combines on-the-job training and related instruction and in which workers learn the practical and conceptual skills required for a skilled occupation, craft, or trade. It may be registered or unregistered.

Assessment/Intake - A process for screening individual applicants for program eligibility making the level of need determinations; making an initial determination what services or programs can best benefit the applicants; providing information about services, program eligibility, and the availability of those services, and the routing or selecting individual applicants for particular service delivery or program participation.

Assisted Placements Into Unsubsidized Employment - Assisted placements into unsubsidized employment should be recorded where the definition for placement with unsubsidized employment above is met, but the placement was arranged by an agency to which the homeless veteran was referred to.

Average Hourly Wage At Placement - The average hourly wage at placement is the average hourly wage rates at placement of all assisted placements plus direct placements.

Assurance and Certifications - The act of signifying intent to comply with applicable federal and State laws and regulations as a condition for receiving and expanding USDOL grant funds.

Barriers to Employment - Characteristics that may hinder an individual's hiring promotion or participation in the labor force. Identification of these barriers will vary by location and labor market. Some examples of individuals who may face barriers to employment include: single parents, women, displaced homemakers, youth, public assistance recipients, older workers, substance abusers, teenage parents, certain veterans, ethnic minorities, and those with limited English speaking ability or a criminal record or with a lack of education, work experience, credential, child care arrangements, transportation or alternative working parents.

Campaign Badge veteran - A veteran who served on active duty during the war (e.g., WWII), action (e.g., Korea, Vietnam), in a campaign, or an expedition for which a campaign badge of an expeditionary medal has been authorized (e.g. Bosnia, Grenada, Haiti, Panama, Southeast Asia, and Somalia).

Case Management - A client centered approach in the delivery of intensive services, designed to prepare and coordinate comprehensive employment plans for participants, to assure access to the necessary training and supportive services, and to provide support during program participation and after job placement.

Case Manager - One who coordinates, facilitates or provides direct services to a client or trainee from application through placement, post placement follow-up, or other case closing, exclusively, through periodic contact and the provision of appropriate assistance.

Classroom Training - Any training of the type normally conducted in an institutional setting, including vocational education, which is designed to provide individuals with the technical skills and information required to perform a specific job or group of jobs. It may also include training designed to enhance the employability of individuals by upgrading basic skills, throughout the provision of courses such as remedial education, training in the primary language of persons with limited English language proficiency, or English as a second language training.

Close Out - Grant close out is the process by which the Federal grantor agency (in the case of VETS grants, Department of Labor) determines that all applicable administrative actions and all required work of the grant have been completed by the grantee and the grantor.

Cognizant Federal Agency - The federal agency that is assigned audit or indirect cost rate approval responsibility for a particular recipient organization by the Office of Management and Budget (OMB Circular A-87 and A-102 [20 CFR, Part 97]).

Community Based Organization - means a private non-profit organization that is representative of a community or a significant segment of a community and that has demonstrated expertise and effectiveness in the field of workforce investment. Faith-Based organizations are considered a subset.

Cost Per Placement - The cost per placement into unsubsidized employment is obtained by dividing the total funds expended by the total of direct placements plus assisted placements.

Counseling - A form of assistance which provides guidance in the development of a participant's vocational goals and the means to achieve those goals; and/or assist a participant with the solution to one or more individual problems which may pose a barrier (s) to sustained employment.

Counselor - (Employment/Vocational): A trained and qualified professional authorized to provide direct assistance (beyond advising and informing) through planning, testing, training and otherwise readying an individual for sustained employment.

Customized Training - A training program designed to meet the special requirements of an employer who has entered into an agreement with a Service Delivery Area to hire individuals who are trained to the employer's specifications. The training may occur at the employer's site or may be provided by a training vendor able to meet the employer's requirements. Such training usually requires a commitment from the employer to hire a specified number of trainees who satisfactorily complete the training.

Direct Placements Into Unsubsidized Employment - A direct placement into unsubsidized employment must be a placement made directly by staff with an established employer who covers all employment costs for 20 or more hours per week at or above the minimum wage. Day labor and other very short-term placements should not be recorded as placements into unsubsidized employment.

Disabled Veteran - A veteran who is entitled to compensation under laws administered by the Veterans Administration; or an individual who was medically discharged or otherwise released from active duty, due to service-connected disability.

Disallowed Costs - Disallowed costs are those charges to a grant that the grantor agency (or its representative) determines to be unallowable in accordance with the applicable Federal Cost Principles or other conditions in the grant.

Disabled Veterans' Outreach Program (DVOP) - A program of Federal assistance through grants to States to staff and support in accordance with 38 U.S.C. 4103A, appointed to perform a number of duties chief among which are direct employer contact, particularly with Federal contractors, Federal employers using individualized job development techniques, and with veterans (particularly with disabled veterans) using a case management approach to client-centered services.

Economically Disadvantaged - An individual who (a) receives, or is a member of a family which receives, cash welfare payments under a Federal, state, or local welfare program; (b) has, or is a member of a family which has, received a total family income for the six-month period prior to application for the program involved (exclusive of unemployment compensation, child support payments, and welfare payments) which, in relation to family size, was not in excess of the higher of (i) the official poverty line (as defined by the Office of Management and Budget, and revised annually in accordance with section 673 (2) of the Omnibus Budget Reconciliation Act of 1981 (42 U.S.C. 9902(2)), or (ii) 70 percent of the lower living standard income level; (c) is receiving (or has been determined within the 6-month period prior to the application for

program involved to be eligible to receive) food stamps pursuant to the Food Stamp Act of 1977; (d) qualifies as a homeless individual under section 103 of the Stewart B. McKinney Homeless Assistance Act; (e) is a foster child on behalf of whom state or local government payments are made or (f) in cases permitted by regulations of the Secretary, is an individual with a disability whose income meets the requirements of clause (a) or (b), but who is a member of a family whose income does not meet such requirements.

Eligible - Meeting the minimum requisite qualifications to be considered for the provision of services or entry into a position under a funded program or as required by law.

Employability Development Services (EDS) - This includes services and activities that will develop or increase the employability of the participant. Generally, this includes vocational counseling, classroom and on-the-job training, pre-employment services (such as job seeking skills and job search workshops), temporary or trial employment, sheltered work environments and other related services and activities. Planned services should assist the participant in addressing specific barriers to employment and finding a job. These activities may be provided by the applicant or by a Sub-grantee, contractor or another source such as the local Workforce Investment Act program or the DVOP personnel or LVERs. Such services are not mandatory but entries should reflect the services described in the application and the expected number of participants receiving or enrolled in such services during each quarter. Participants may be recorded more than once if they receive more than one service.

Employment Development Plan (EDP) - An individualized written plan or intervention strategy for serving an individual which, as a result of an assessment of the veteran's economic needs, vocational interests, aptitudes, work history, etc., defines a reasonable vocational or employment goal and the developmental services or steps required to reach the goal and which documents the accomplishments made by the individual.

Employment Service - the state level organization or public labor exchange system affiliated with the Department of Labor's United States Employment Service.

Enlistments - Individuals who have expressed an interest, signed up for a workshop or enrollment in the program.

Entered Employment - Applicants for service who were placed in jobs or otherwise obtained employment as a result of services used or received.

Entered Employment Rate - This is a method used to determine the percentage of participants who become employed. The percentage is calculated by dividing the number of total participants who were enrolled in the program by the number of participants who were placed or entered employment through the program.

Enrolled Veteran - Shall be synonymous with the term participant. A veteran who has been determined eligible for services at intake and who is receiving or scheduled to receive core training.

Faith-Based Organization – see “community-based organization”.

Follow-up - The tracking of clients for a period of time up to 180 days after initial placement, last referral date for services or completion of training programs to determine current status, outcome or whether to offer additional services (such as additional referral, job retention advisement, etc.).

Full-Time Equivalent (FTE) – a personnel charge to the grant equal to 2,080 hours per year.

FY - Fiscal Year. For federal government purposes, any twelve month period beginning on October 1 and ending on September 30.

General Equivalency Diploma (GED) – A high school equivalency diploma that is obtained by passing the General Educational Diploma Equivalency Test that measures the application of skills and knowledge generally associated with four (4) years of traditional high school instruction.

Grant Officer's Technical Representative (GOTR) - An individual (usually the DVET) serving on behalf of the Grant Officer who maintains and ensures the integrity of the approved grant agreement by reviewing and making recommendations regarding technical matters not involving a change in scope, cost, or conditions.

Homeless or homeless individual – includes persons who lack a fixed, regular, and adequate nighttime residence. It also includes persons whose primary nighttime residence is either supervised public or private shelter designed to provide temporary living accommodations; an institution that provides a temporary residence for individuals intended to be institutionalized; or a private place not designed for, or ordinarily used as, a regular sleeping accommodation for human beings. [Reference 42 U.S.C., Section 11302 (a)].

Indirect cost - A cost that is incurred for a common or joint purpose benefiting more than one cost objective and that is not readily assignable to the cost objective specifically benefited.

In-kind Services – Property or services which benefit federally assisted project or program and which are contributed without charge to the grantee.

Institutional Skills Training – training conducted in an institutional setting and designed to ensure that individuals acquire the skills, knowledge, and abilities necessary to perform a job or group of jobs in an occupation for which there is a demand.

Intake – A process for screening individual applicants for eligibility; making an initial determination whether the program can benefit the applicants; providing information about the program, its services and the availability of those services; and selecting individual applicants for participation in the program.

Intensive Services - The provision of concentrated staff services to clients who indicate the need for facilitation or interventions to secure lasting employment. The case management approach to service delivery is a viable model for successfully providing such services and obtaining the clients goals.

Job Club Activities - A form of job search assistance provided in a group setting. Usually job clubs provide instruction and assistance in completing job applications and developing resumes and focus on maximizing employment opportunities in the labor market and developing job leads. Many job clubs use telephone banks and provide group support to participants before and after they interview for job openings.

Job Development - The process of marketing a program participant to employers, including informing employers about what the participant can do and soliciting a job interview for that individual with the employer (targeted job development); and the development of one or more job openings or training opportunities with one or more employers using a variety of techniques and means of contact.

Job Placement Services - Job placement services are geared towards placing participants in jobs and may involve activities such as job search assistance, training, or job development. These services are initiated to enhance and expedite participants' transition from training to employment.

Job Search Assistance - An activity, which focuses on building practical skills and knowledge to identify and initiate employer contact and conduct successful interview with employers. Various approaches may be used to include participation in a job club, receive instruction in identifying personal strengths and goals, resume application preparation, learn interview techniques, and receive labor market information. Job search assistance is often self-service activity in which individuals obtain information about specific job openings or general jobs or occupational information.

Labor Exchange - Refers to the services provided to job seekers and employers by the State Employment Services Agencies, or other designated entities. Preparatory services to job seekers may include assessment, testing, counseling, provision of labor market information, targeted job development, resulting in job referral and follow-up with former applicants and prospective employers. Employer-oriented services may include accepting job orders, screening applicants, referring qualified applicants and providing follow-up to foster job retention and develop additional job openings or training opportunities.

Labor Exchange Delivery System (LEDS) - Describes the system of matching jobs and training opportunities with applicants operating with Federal employment and job training funds.

Labor Force - The sum of all civilians classified as employed and unemployed and members of the Armed Forces stationed in the United States. [Bureau of Labor Statistics Bulletin 2175].

Labor Market Area – an economically integrated geographic area within which individuals can reside and find employment within a reasonable distance or can readily change employment without changing their place of residence.

Literacy and Bilingual Training – See Adult Basic Education.

Local Veterans' Employment Representative (LVER) Program - A program of Federal assistance through grants to States to staff in accordance with 38 U.S.C.4104 to perform a number of duties, chief among which are the provision of intensive (case management) services to targeted eligible veterans with emphasis on VA, VR&E, and to functionally supervise without necessarily exercising line supervisor authority over the provision of services to veterans by SDP staff.

Minimum Economic Need – the level of wages paid to a program participant that will enable that participant to become economically self-sufficient.

Minority Veterans – for the purposes of the HVRP and VWIP programs, veterans who are Workforce Investment Act (WIA) eligible and are members of the following ethnic categories: African American, Hispanic, American Indian or Alaskan Native, Asian or Pacific Islander.

National Veterans' Training Institute (NVTI) - An agency contracted with USDOL/VETS to develop and provide skills development and enhancement training to individuals who are determined by the Assistant Secretary for Veterans' Employment and Training and who deliver or monitor the provision of employment and training services to veterans (38 U.S.C. 4109).

Number Retaining Job for 90 Days -To be counted as retaining a job for 90 days, continuous employment with one or more employers for at least 90 days must be verified and the definition for either direct placement or assisted placement into unsubsidized employment above is met. This allows clients who have moved into a position with a different employer to be recorded as retaining the job for 90 days as long as the client has been steadily employed for that length of time.

Number Retaining Job For 180 Days - To be counted as retaining a job for 180 days, continuous employment with one or more employers for at least 180 days must be verified, and the definition for either placement or assisted placement into unsubsidized employment above is met. This allows clients who have moved into a position with a different employer to be recorded as retaining the job for 180 days as long as the client has been steadily employed for that length of time.

Occupational Skills Training – Includes both (1) vocational education which is designed to provide individuals with the technical skills and information required to perform a specific job or group of jobs, and (2) on-the-job training.

Offender – Any adult or juvenile who has been subject to any stage of the criminal justice process for whom services under this program may be beneficial or who requires assistance in overcoming artificial barriers to employment resulting from a record of arrest or conviction.

On-the-Job Training (OJT) – means training by an employer that is provided to a paid participant while engaged in productive work in a job that: (a) provides knowledge or skill essential to the full and adequate performance of the job; (b) provides reimbursement to the employer of up to 50 percent of the wage rate of the participant, for the extraordinary costs of providing the training and additional supervision related to the participant is being trained, taking into account the content of the training, the prior work experience of the participant, and the service strategy of the participant, as appropriate. Usually in the OJT agreement, there is a promise on the part of the employer to hire the trainee upon successful completion of the training.

On-Site Industry-Specific Training – This is training which is specifically tailored to the needs of a particular employer and/or industry. Participants may be trained according to specifications developed by an employer for an occupation or group of occupations at a job site. Such training is usually presented to a group of participants in an environment or job site representative of the actual job/occupation, and there is often an obligation on the part of the employer to hire a certain number of participants who successfully complete the training.

Outreach - An active effort by program staff to encourage individuals in the designated service delivery area to avail themselves of program services.

Outside Funds – Resources pledged to the grant program that have a quantified dollar value. Such resources may include training funds from programs such as WIA Title I that are put aside for the exclusive use by participants enrolled in a program. Outside funds do not include in-kind services.

Participant – means an individual who has been determined to be eligible to participate in and who is receiving services (except follow-up services) under the program. Participation shall be deemed to commence on the first day, following determination of eligibility, on which the individual began receiving subsidized employment, training, or other services provided under the program. An individual who receives only outreach and/or intake assessment services does not meet this definition.

Participants Enrolled - A client should be recorded as having been enrolled when an intake form has been completed, and services, referral, and/or employment has been received through the program. This should be an unduplicated count over the year, i.e., each participant is recorded only once, regardless of the number of times she or he receives assistance.

Participants Services - This cost includes supportive, training, or social rehabilitation services, which will assist in stabilizing the participant. This category should reflect all costs other than administrative.

Placed Into Transitional Or Permanent Housing - A placement into transitional or permanent housing should be recorded when a veteran served by the program upgrades his/her housing situation during the reporting period from shelter/streets to transitional housing or permanent housing or from transitional housing to permanent housing. Placements resulting from referrals by staff shall be counted. This item is however an unduplicated count over the year, except that a participant may be counted once upon entering transitional housing and again upon obtaining permanent housing.

Placement - the act of securing unsubsidized employment for or by a participant.

Placement Rate - This is a method used to determine the percentage of participants who become employed. The figure is calculated by dividing the number of total participants who were registered for services or enrolled in the program by the number of applicants or program participants who were placed or otherwise entered employment.

Pre-apprenticeship Training - Any training designed to increase or upgrade specific academic, or cognitive, or physical skills required as a prerequisite for entry into a specific trade or occupation.

Pre-enrollment Assessment - The process of determining the employability and training needs of individuals before enrolling them into the program. Individual factors usually addressed during pre-enrollment assessment include: an evaluation and/or measurement of vocational interests and aptitudes, present abilities, previous education and work experience, income requirements, and personal circumstances.

Preference - The application of priorities in the consideration and selection through appointment or assignment of staff to funded positions, or in the provision of direct services and order of referral to listed openings in the order designated by statute regulation, and grant agreement.

Program Resources - Includes the total of both program or grant and outside funds.

Program Year (PY) - The 12-month period beginning July 1 in the fiscal year for which the appropriation is made, and ending on the following June 30.

Qualified - An individual who has been determined to possess the requisite knowledge, skills, and abilities for positions within the context of the selection process used to identify and rank persons possessing those attributes.

Rate of Placement Into Unsubsidized Employment - The rate of placement into unsubsidized employment is obtained by dividing the number placed into unsubsidized employment, plus the number of assisted placements into unsubsidized employment by the number of clients enrolled.

Recently Separated Veteran - Refers to an individual who applies for program participation or assistance within 48 months of separation from active U.S. military service [29 U.S.C. 1503 (27) (c)].

Remedial Education – Education instruction, particularly in basic skills, to raise an individual's general competency level in order to succeed in vocational education or skill training programs, or employment.

Service Connected Disabled - Refers to (1) a veteran who is entitled to compensation under laws administered by the Department of Veterans' Affairs, or (2) an individual who was discharged or released from active duty because of a service-connected disability (38 U.S.C. 4211 (3); 29 U.S.C., Chapter 19, section 1503 (27) (C))

Service Delivery Point (SDP) - Includes offices of the public employment delivery system operated directly or by contract with the State Workforce Agency as grantee within a State and may include One –Stop Career Centers, local employment service offices, and any satellite or itinerant offices at which labor exchange services are available.

Solicitation for Grant Applications (SGA) - A document which provides the requirements and instructions for the submission by eligible applicants identified in the document's text of requests for Federal domestic assistance (funds) for one or more programs or grants-in-aid.

State Workforce Agency (SWA) - The State level organization, as affiliated with the former United States Employment Service.

Subgrant – An award of financial assistance in the form of money, or property in lieu of money, made under a grant by a grantee to an eligible subgrantee.

Subgrantee – The government or other legal entity to which a subgrant is awarded and which is accountable to the grantee for the use of the funds provided.

Suitable Employment – See "Unsubsidized Employment".

Substance Abuser – An individual dependent on alcohol or drugs, especially narcotics, whose dependency constitutes or results in a substantial barrier to employment.

Supportive Services – means services which are necessary to enable an individual eligible for training, but who cannot afford to pay for such services, to participate in a training program funded under the grant. Such supportive services may include transportation, health care, financial assistance (except as a post-termination service), drug and alcohol abuse counseling and referral, individual and family counseling, special services and materials for individuals with disabilities, job coaches, child care and dependent care, temporary shelter, financial counseling, and other reasonable expenses required for participation in the training program and may be provided in-kind or through cash assistance.

Targeted Job Development - The identification and marketing of a group of qualified applicants with similar occupations or employment barriers requiring personal visitation/phone contact with those employers likely to employ these individuals.

Total Planned Expenditures - Identified forecasted financial needs to accomplish programmatic objectives broken down into fiscal quarters.

Unsubsidized Employment - Employment not financed from funds provided under the grant. In the grant program the term "adequate" or "suitable" employment is also used to mean placement in unsubsidized employment which pays an income adequate to accommodate the participants' minimum economic needs.

Upgrading or Retraining - Training given to an individual who needs such training to advance above an entry level or dead-end position. This training shall include assisting veterans in acquiring needed state certification to be employed in the same field as they were trained in the military (i.e., Commercial Truck Driving License (CDL), Emergency Medical Technician (EMT), Airframe & Power Plant (A&P), Teaching Certificate, etc.)

Veteran - An individual who served in the United States active military, naval, or air service, and who was discharged or released there from under conditions other than dishonorable (29 U.S.C. Chapter 19, section 1503 (27) (A) [for WIA, Section 168 (VWIP) and WIA, Title I training/services]).

Veterans' Workforce Investment Program (VWIP) - Competitively awarded employment and training grants to meet the needs of veterans with significant barriers to employment; with service-connected disabilities; who served on active duty in the armed forces during a campaign or expedition for which a campaign badge has been authorized; and recently separated veterans. The U.S. Department of Labor, Veterans' Employment and Training Service awards VWIP grants as authorized under the Workforce Investment Act (WIA), Section 168.

Vocational Exploration Training - Through assessments such as interest inventories and/or counseling, a process of identifying occupations or occupational areas in which a person may find satisfaction and potential, and for which his or her aptitudes and other qualifications may be appropriate.

Vocational Guidance - The provision of information, suggestions, and advice through discussion with individuals who are considering a geographical or vocational choice or change, relating to their career decision.

Wartime Veteran - See "campaign veteran above."

Welfare and/or Public Assistance recipient - An individual who, during the course of the program year, receives or is a member of a family who receives cash welfare or public assistance payments under a Federal, state, or local welfare program.

Workforce Investment Act (WIA) – The purpose of this Act is to establish programs to prepare youth and unskilled adults for entry into the labor force and to afford job training to those economically disadvantaged individuals and other individuals, including veterans, who face serious barriers to employment and who are in need of such training to obtain prospective employment. The Act requires the Assistant Secretary for Veterans' Employment and Training to consult with the Secretary of the Department of Veterans Affairs to ensure that programs funded under VWIP of this Act meet the employment and training needs of service-connected disabled, Campaign, and recently separated veterans and are coordinated, to the maximum extent feasible, with related programs and activities.

Work Experience – A temporary activity (six months or less) which provides an individual with the opportunity to acquire the skills and knowledge necessary to perform a job, including appropriate work habits and behaviors, and which may be combined with classroom or other training. When wages are paid to a participant on work experience and when such wages are wholly paid for under WIA, the participant may not receive this training under a private, for profit employer.

Youth – An individual between 20 and 24 years of age.



SURVEY ON ENSURING EQUAL OPPORTUNITY FOR APPLICANTS

Federal Agency Use Only

OMB No. 1225-0083 Exp. 02/28/2006

NOTE: Please place survey form directly behind the Standard Application for Federal Assistance (SF 424) fact sheet.

Purpose: This form is for applicants that are private nonprofit organizations (not including private universities). Please complete it to assist the federal government in ensuring that all qualified applicants, small or large, non-religious or faith-based, have an equal opportunity to compete for federal funding. Information provided on this form will not be considered in any way in making funding decisions and will not be included in the federal grants database.

1. Does the applicant have 501(c)(3) status?

 Yes No

2. How many full-time equivalent employees does the applicant have? (Check only one box.)

 3 or Fewer 15-50

 4-5 51-100

 6-14 over 100

3. What is the size of the applicant's annual budget? (Check only one box.)

 Less Than \$150,000

 \$150,000 - \$299,999

 \$300,000 - \$499,999

 \$500,000 - \$999,999

 \$1,000,000 - \$4,999,999

 \$5,000,000 or more

4. Is the applicant a faith-based/religious organization?

 Yes No

5. Is the applicant a non-religious community-based organization?

 Yes No

6. Is the applicant an intermediary that will manage the grant on behalf of other organizations?

 Yes No

7. Has the applicant ever received a government grant or contract (Federal, State, or local)?

 Yes No

8. Is the applicant a local affiliate of a national organization?

 Yes No

Survey Instructions on Ensuring Equal Opportunity for Applicants

1. 501(c)(3) status is a legal designation provided on application to the Internal Revenue Service by eligible organizations. Some grant programs may require nonprofit applicants to have 501(c)(3) status. Other grant programs do not.
2. For example, two part-time employees who each work half-time equal one full-time equivalent employee. If the applicant is a local affiliate of a national organization, the responses to survey questions 2 and 3 should reflect the staff and budget size of the local affiliate.
3. Annual budget means the amount of money your organization spends each year on all of its activities.
4. Self-identify.
5. An organization is considered a community-based organization if its headquarters/service location shares the same zip code as the clients you serve.
6. An "intermediary" is an organization that enables a group of small organizations to receive and manage government funds by administering the grant on their behalf.
7. Self-explanatory.
8. Self-explanatory

Paperwork Burden Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. The valid OMB control number for this information collection is **1225-0083**. The time required to complete this information collection is estimated to average five (5) minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. **If you have any comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: Departmental Clearance Officer, U.S. Department of Labor, 200 Constitution Avenue NW, Room N-1301, Washington, D.C. 20210. If you have comments or concerns regarding the status of your individual submission of this form, write directly to: Joyce I. Mays, Application Control Center, U.S. Department of Labor, 200 Constitution Avenue, NW, Washington, DC 20210.**

Legal Rules that Apply to Faith-based Organizations that Receive Government Funds

The government is prohibited from directly funding religious activity.* These grants may not be used for religious instruction, worship, prayer, proselytizing or other inherently religious practices. Neutral, secular criteria that neither favor nor disfavor religion must be employed in the selection of grant and sub-grant recipients. In addition, under the WIA and DOL regulations implementing the Workforce Investment Act, a recipient may not train a participant in religious activities, or permit participants to construct, operate, or maintain any part of a facility that is primarily used or devoted to religious instruction or worship. Under WIA, "no individual shall be excluded from participation in, denied the benefits of, subjected to discrimination under, or denied employment in the administration of or in connection with, any such program or activity because of race, color, religion, sex (except as otherwise permitted under Title IX of the Education Amendments of 1972), national origin, age, disability, or political affiliation or belief."

**The term "direct" funding is used to describe funds that are provided "directly" by a governmental entity or an intermediate organization with the same duties as a governmental entity, as opposed to funds that an organization receives as the result of the genuine and independent private choice of a beneficiary. In other contexts, the term "direct" funding may be used to refer to those funds that an organization receives directly from the Federal government (also known as "discretionary" funding) as opposed to funding that it receives from a State or local government (also known as "indirect" or "block grant" funding). In this SGA, the term "direct" has the former meaning.*

[FR Doc. 04-8557 Filed 4-14-04; 8:45 am]

BILLING CODE 4510-79-C

NUCLEAR REGULATORY COMMISSION

[Docket No. 72-3]

Progress Energy Carolinas, Inc.; Notice of Docketing, Notice of Proposed Action, and Notice of Opportunity for a Hearing for Renewal of Materials License SNM-2502 for the H. B. Robinson, Unit 2, Independent Spent Fuel Storage Installation**ACTION:** Notice of license renewal, and opportunity to request a hearing.**DATES:** A request for hearing and/or petition for leave to intervene must be filed by June 14, 2004.**FOR FURTHER INFORMATION CONTACT:** Christopher M. Regan, Project Manager, Spent Fuel Project Office, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555. Telephone: (301) 415-1179; fax number: (301) 415-1179; e-mail: cmr1@nrc.gov.**SUPPLEMENTARY INFORMATION:****I. Introduction**

The U.S. Nuclear Regulatory Commission (NRC or Commission) is considering an application dated February 27, 2004, from Progress Energy Carolinas, Inc. (applicant or PEC) for the renewal of materials license SNM-2502, under the provisions of 10 CFR part 72, for the receipt, possession, storage and transfer of spent fuel, reactor-related Greater than Class C (GTCC) waste and other radioactive materials associated with spent fuel storage at the H. B. Robinson, Unit 2, Independent Spent Fuel Storage Installation (ISFSI), located at the H. B. Robinson Steam Electric Plant, Unit 2, site in Darlington County, South Carolina. If granted, the renewed license will authorize the applicant to continue to store spent fuel in a dry cask storage system at the applicant's H. B. Robinson, Unit 2, ISFSI. Pursuant to the provisions of 10 CFR part 72, the renewal term of the license for the ISFSI would be twenty (20) years; however, the applicant has submitted a separate exemption request with the license renewal application, which, if granted, would allow the license to be renewed for 40 years. This application was docketed under 10 CFR part 72; the ISFSI Docket No. is 72-3.

An NRC administrative review, documented in a letter to PEC dated April 7, 2004, found that the application contains sufficient information for the

NRC staff to begin its technical review. Prior to issuance of the requested license, the Commission will have made the findings required by the Atomic Energy Act of 1954, as amended (the Act), and the Commission's regulations. These findings will be documented in a Safety Evaluation Report. The issuance of the renewed materials license will not be approved until the NRC has reviewed the application and has concluded that renewal of the license will not be inimical to the common defense and security and will not constitute an unreasonable risk to the health and safety of the public. The NRC will complete an environmental evaluation, in accordance with 10 CFR part 51, to determine if the preparation of an environmental impact statement is warranted or if an environmental assessment and finding of no significant impact are appropriate. This action will be the subject of a subsequent notice in the **Federal Register**.

II. Opportunity To Request a Hearing

In accordance with the general requirements in subpart C of 10 CFR part 2, "Rules of General Applicability; Hearing Requests, Petitions to Intervene, Availability of Documents, Selection of Specific Hearing Procedures, Presiding Officer Powers, and General Hearing Management for NRC Adjudicatory Hearings,"¹ any person whose interest may be affected by a proceeding and who desires to participate as a party must file a written request for hearing or petition for leave to intervene ("request for hearing") and a specification of the contentions which the person seeks to have litigated in the hearing.

In accordance with 10 CFR 2.302(a), a request for hearing must be filed with the Commission either by:

1. First class mail addressed to: Office of the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff;

2. Courier, express mail, and expedited delivery services: Office of the Secretary, Sixteenth Floor, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852, Attention: Rulemakings and Adjudications Staff, between 7:45 a.m. and 4:15 p.m., Federal workdays;

3. E-mail addressed to the Office of the Secretary, U.S. Nuclear Regulatory Commission, hearingdocket@nrc.gov; or

4. By facsimile transmission addressed to the Office of the Secretary, U.S. Nuclear Regulatory Commission,

Washington, DC, Attention: Rulemakings and Adjudications Staff, at (301) 415-1101; verification number is (301) 415-1966.

In accordance with 10 CFR 2.302(b), all documents offered for filing must be accompanied by proof of service on all parties to the proceeding or their attorneys of record as required by law or by rule or order of the Commission, including:

1. Mr. J. W. Moyer, Vice-President—HBRSEP, Unit 2, Progress Energy Carolinas, Inc., H. B. Robinson Nuclear Plant, 3851 West Entrance Road, Hartsville, SC 29550.

2. The NRC staff, by delivery to the Office of the General Counsel, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852, or by mail addressed to the Office of the General Counsel, U.S. Nuclear Regulatory Commission, Washington DC 20555-0001. Hearing requests should also be transmitted to the Office of the General Counsel, either by means of facsimile transmission to (301) 415-3725, or by e-mail to ogcmailcenter@nrc.gov.

The formal requirements for documents are contained in 10 CFR 2.304(b), (c), (d), and (e). In accordance with 10 CFR 2.304(f), a document filed by electronic mail or facsimile transmission need not comply with the formal requirements of 10 CFR 2.304(b), (c), and (d), as long as an original and two (2) copies otherwise complying with all of the requirements of 10 CFR 2.304(b), (c), and (d) are mailed within two (2) days thereafter to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff.

In accordance with 10 CFR 2.309(b), a request for a hearing must be filed by June 14, 2004.

In addition to meeting other applicable requirements of 10 CFR 2.309, a request for hearing must state:

1. The name, address, and telephone number of the requestor;

2. The nature of the requestor's right under the Act to be made a party to the proceeding;

3. The nature and extent of the requestor's property, financial or other interest in the proceeding;

4. The possible effect of any decision or order that may be issued in the proceeding on the requestor's interest; and

5. The circumstances establishing that the request for a hearing is timely in accordance with 10 CFR 2.309(b). Nontimely requests will not be entertained absent a determination by the Commission, the presiding officer or the Atomic Safety and Licensing Board designated to rule on the request and

¹ The references to 10 CFR part 2 in this notice refer to the amendments to the NRC Rules of Practice, 69 FR 2182 (January 14, 2004).

contentions that the request should be granted and the contentions should be admitted based upon a balancing of the factors specified in 10 CFR 2.309(c).

In accordance with 10 CFR 2.309(f)(1), a request for hearing must set forth with particularity the contentions sought to be raised. For each contention, the request must:

1. Provide a specific statement of the issue of law or fact to be raised or controverted;
2. Provide a brief explanation of the basis for the contention;
3. Demonstrate that the issue raised in the contention is within the scope of the proceeding;
4. Demonstrate that the issue raised in the contention is material to the findings that the NRC must make to support the action that is involved in the proceeding;
5. Provide a concise statement of the alleged facts or expert opinions which support the requestor's position on the issue and on which the requestor intends to rely at hearing, together with references to the specific sources and documents on which the requestor intends to rely to support its position on the issue; and
6. Provide sufficient information to show that a genuine dispute exists with the applicant on a material issue of law or fact. This information must include references to specific portions of the application (including the applicant's environmental report and safety report) that the requestor disputes and the supporting reasons for each dispute, or, if the requestor believes the application fails to contain information on a relevant matter as required by law, the identification of each failure and the supporting reasons for the requestor's belief.

In addition, in accordance with 10 CFR 2.309(f)(2), contentions must be based on documents or other information available at the time the petition is to be filed, such as the application, supporting safety analysis report, environmental report or other supporting document filed by the applicant, or otherwise available to the petitioner. On issues arising under the National Environmental Policy Act, the requestor shall file contentions based on the applicant's environmental report. The requestor may amend those contentions or file new contentions if there are data or conclusions in the NRC draft, or final environmental impact statement, environmental assessment, or any supplements relating thereto, that differ significantly from the data or conclusions in the applicant's documents. Contentions may be amended or new contentions filed after

the initial filing only with leave of the presiding officer upon making the showings specified in 10 CFR 2.309(f)(2).

Each contention shall be given a separate numeric or alpha designation within one of the following groups:

1. Technical—primarily concerns issues relating to matters discussed or referenced in the Safety Analysis Report for the proposed action.
2. Environmental—primarily concerns issues relating to matters discussed or referenced in the Environmental Report for the proposed action.
3. Emergency Planning—primarily concerns issues relating to matters discussed or referenced in the Emergency Plan as it relates to the proposed action.
4. Physical Security—primarily concerns issues relating to matters discussed or referenced in the Physical Security Plan as it relates to the proposed action.
5. Miscellaneous—does not fall into one of the categories outlined above. If the requestor believes a contention raises issues that cannot be classified as primarily falling into one of these categories, the requestor must set forth the contention and supporting bases, in full, separately for each category into which the requestor asserts the contention belongs with a separate designation for that category.

Requestors should, when possible, consult with each other in preparing contentions and combine similar subject matter concerns into a joint contention, for which one of the co-sponsoring requestors is designated the lead representative. Further, in accordance with 10 CFR 2.309(f)(3), any requestor that wishes to adopt a contention proposed by another requestor must do so in writing within ten days of the date the contention is filed, and designate a representative who shall have the authority to act for the requestor.

In accordance with 10 CFR 2.309(g), a request for hearing may also address the selection of hearing procedures, taking into account the provisions of 10 CFR 2.310. The Commission hereby provides notice that this is a proceeding on an application for a license amendment falling within the scope of section 134 of the Nuclear Waste Policy Act of 1982 (NWPAA), 42 U.S.C. 10154. Under section 134 of NWPAA, the Commission, at the request of any party to the proceeding, shall use hybrid hearing procedures with respect to any matter which the Commission determines to be in controversy among the parties. The hybrid procedures in section 134 provide for oral argument on matters in controversy, preceded by

discovery under the Commission's rules. Following oral argument, those factual issues that involve a genuine and substantial dispute, together with any remaining questions of law, shall be designated for resolution in an adjudicatory hearing. Adjudicatory hearings are to be held on only those issues found to meet the criteria of section 134 and set for hearing after oral argument.

The Commission's rules implementing section 134 of NWPAA are found in 10 CFR part 2, subpart K, "Hybrid Hearing Procedures for Expansion of Spent Fuel Storage Capacity at Civilian Nuclear Power Reactors," (as revised at 69 FR 2182, 2266-2267; January 14, 2004). Under those rules, any party may invoke the hybrid hearing procedures by requesting an oral argument in a request for hearing filed in accordance with 10 CFR 2.309, or in the applicant's or the NRC staff's response to a request for hearing. If it is determined that a hearing will be held, the presiding officer shall grant a timely request for oral argument. The presiding officer may grant an untimely request for oral argument only upon a showing of good cause by the requesting party for the failure to file on time and after providing the other parties an opportunity to respond to the untimely request. If the presiding officer grants a request for oral argument, any hearing held on the application must be conducted in accordance with the hybrid hearing procedures. If no party to the proceeding requests oral argument, or if all untimely requests for oral argument are denied, the presiding officer shall conduct the proceeding in accordance with the subpart under which the proceeding was initially conducted as determined in accordance with 10 CFR 2.310.

III. Further Information

In accordance with 10 CFR 2.390 of NRC's "Rules of Practice," final NRC records and documents regarding this proposed action, including the application for license renewal dated February 27, 2004, and supporting documentation, are publicly available in the records component of NRC's Agencywide Documents Access and Management System (ADAMS). These documents may be inspected at NRC's Public Electronic Reading Room at <http://www.nrc.gov/reading-rm/adams.html> under Accession No. ML040690774. These documents may also be viewed electronically on the public computers located at the NRC's Public Document Room (PDR), O1F21, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852. The PDR

reproduction contractor will copy documents for a fee. Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at 1-800-397-4209 or (301) 415-4737, or by e-mail to pdr@nrc.gov.

Dated at Rockville, Maryland, this 7th day of April, 2004.

For the Nuclear Regulatory Commission.

Christopher M. Regan,

*Project Manager, Spent Fuel Project Office,
Office of Nuclear Material Safety and
Safeguards.*

[FR Doc. 04-8549 Filed 4-14-04; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

U.S. Armed Forces: Environmental Assessment and Final Finding of No Significant Impact, Exemption to the Requirements in 10 CFR 20.1801, 20.1802 and 20.2201

I. Summary

The U.S. Nuclear Regulatory Commission (NRC) has performed an Environmental Assessment (EA) to evaluate a license amendment that would add a license condition exempting the U.S. Armed Forces (Armed Forces) from certain requirements involving the use and storage of radioactive sealed source devices used for monitoring and detecting chemical warfare agents during military exercises and maneuvers. During these times, the Armed Forces would be specifically exempt from requirements contained in: (1) 10 CFR 20.1801, "Security of stored material," when the Armed Forces store authorized radioactive sealed source devices that are used for monitoring and detecting chemical warfare agents during military exercises or maneuvers on U.S. Government-controlled property;¹ (2) 10 CFR 20.1802, "Control of material not in storage," when the Armed Forces employ these devices during exercises or maneuvers on U.S. Government-controlled property; and (3) 10 CFR 20.2201, "Reports of theft or loss of licensed byproduct material," when these devices are lost when they are stored or used during military exercises or maneuvers on U.S. Government-controlled property. The conclusion of the EA is a Finding of No

Significant Impact (FONSI) for the proposed licensing action.

II. Environmental Assessment

1.0 Introduction

1.1 Background

U.S. Department of the Army reported a number of lost licensed radioactive sealed source devices that are used for monitoring and detecting chemical warfare agents. In response to this, NRC performed a reactive inspection (Report No. 030-35349/2002-001). In an "Exercise of Enforcement Discretion" letter dated October 3, 2003, to the Director, Integrated Material Management Center, U.S. Department of the Army (Army), NRC stated that the NRC plans to amend the Army's license to exempt the licensee from the requirements in 10 CFR 20.1801, 20.1802, and 20.2201 when the licensee is storing or using devices intended to monitor and detect chemical warfare agents during military exercises or maneuvers on U.S. Government-controlled property. The U.S. Navy and U.S. Air Force have also acquired these types of devices and are using them under Master Materials Licenses issued by the NRC. Thus, NRC plans to grant them the same license amendment.

NRC staff has evaluated the environmental impacts of a license amendment that would exempt the Armed Forces from the requirement in: (1) 10 CFR 20.1801, "Security of stored material," when the Armed Forces store authorized radioactive sealed source devices that are used for monitoring and detecting chemical warfare agents during military exercises or maneuvers on U.S. Government-controlled property; (2) 10 CFR 20.1802, "Control of material not in storage," when the Armed Forces employ these devices during exercises or maneuvers on U.S. Government-controlled property; and (3) 10 CFR 20.2201, "Reports of theft or loss of licensed byproduct material," when these devices are lost when they are stored or used during military exercises or maneuvers on U.S. Government-controlled property.

This EA has been prepared pursuant to the NRC regulations in 10 CFR part 51, which implement the requirements of the National Environmental Policy Act (NEPA) of 1969. The purpose of this document is to assess the environmental consequences of the proposed action and the alternatives to the proposed action.

1.2 Review Scope

In accordance with part 51, this EA: (1) Presents information and analysis for determining whether to issue a FONSI

or to prepare an Environmental Impact Statement (EIS); (2) fulfills NRC's compliance with NEPA when no EIS is necessary; and (3) facilitates preparation of an EIS if one is necessary. Should NRC issue a FONSI, no EIS would be prepared and NRC would issue a license condition to the Armed Forces exempting them from meeting the requirements in 10 CFR 20.1801, 20.1802, and 20.2201, when the Armed Forces use authorized radioactive sealed source devices for monitoring and detecting chemical warfare agents during planned military exercises or maneuvers on U.S. Government-controlled property located in the United States, as described herein. This EA applies to consideration of amendments to licenses held by the Army, Navy and Air Force as discussed hereafter.

The Army holds NRC Byproduct Material License No. 12-00722-16, (Ref. 2) (previously License No. 19-30563-01), pursuant to 10 CFR part 30, which authorizes the possession and use of chemical agent detectors or chemical agent monitors containing small amounts of radioactive sealed source material.

NRC has established a license category known as a Master Materials License (MML). An MML can be issued only to a Federal organization that successfully meets the criteria stated in 10 CFR 30.33 (and 10 CFR 40.32 or 10 CFR 70.31, as appropriate), and can demonstrate to NRC, through its diverse licensing activities, experience of complex radiation-program centralized management, inspection, education, qualification, training, and experience as outlined in NRC NUREG-1556 Volume 10, (Ref. 4) that it is able to administer effectively a licensing program.

The U.S. Navy (Navy) holds MML No. 45-23645-01NA, (Ref. 3) from NRC, that allows the Navy to possess and use sealed sources as required. The Navy and Marine Corps use the Navy's license for chemical agent detectors in their possession. NRC issued MML No. 42-23539-01AF, (Ref. 1) to the U.S. Air Force (Air Force) for byproduct, source, and special nuclear material, as needed. The Air Force has acquired and uses chemical detectors under this license.

Armed Forces licenses authorize possession and use of devices containing up to 300 microcuries of Americium-241 (Am-241) or up to 30 millicuries of Nickel-63 (Ni-63). The U.S. Armed Forces use these chemical detecting and monitoring devices on Department of Defense (DOD) installations and temporary job sites, where NRC has jurisdiction.

¹ Government-controlled property refers to property that is permanently maintained by the U.S. Federal Government for planned training exercises or maneuvers by individual units, commands, and inter-commands of the U.S. Armed Forces, including friendly foreign military elements.

A chemical detector typically consists of a detector cell; electronic circuitry; a power source; an air pump (air or vapor sample ingress is much smaller than the human finger); a heater; and a robust outside case. The detector cells contain a radioactive source that is normally coiled into a cylindrical shape, with the radioactive side inward. Am-241 is extracted from Plutonium-241 generated during normal operations of nuclear reactors. The Ni-63 sources are made by electroplating the nickel onto a metallic foil, which then can be formed into a cylindrical source. NRC regulations require that generally licensed devices be tamper-resistant. Normally, tamper-resistant screws are used to restrict unauthorized human access to the radioactive source or sources installed in the generally and exempt licensed chemical detector. There is a wide variety of devices; numerous U.S. and foreign-based organizations manufacture them.

Devices that the Armed Forces acquire are intended for the soldiers to use in training and in the battlefield to monitor and detect chemical warfare agents. NRC regulations require that the manufactures, distributors, or maintenance providers of devices using radioactive sealed sources have a specific license. The regulations allow general licensees to use certain tamper-proofed certified radioactive sealed source devices. Individuals who would be responsible for conducting any maintenance on generally licensed sealed source devices that requires opening the device casing, housing, or modules must have a specific license. In real-time battlefield-simulated military exercises, the Armed Forces may have to conduct *insitu* maintenance. For dual specific-general licenses to be used within the various branches of the Armed Forces, specific licenses would be necessary for maintenance activities, and replacement of radioactive sources and source safety features.

The NRC staff believes that the current regulations addressing the accountability, tracking, and loss of control of these devices are not appropriate when the detectors are used during military exercises and maneuvers on U.S. Government-controlled property, because these areas are generally remote areas, with restricted or no access to the public or the private sector. Furthermore, the radioactive sealed sources used for the above activities are solid metallic fixed forms of radioactive material that are housed in robust structures; therefore, loss of control of these devices does not result in a release of radioactive material. The radiation dose rates

associated with these devices are very low. Comparable devices with similar designs have been authorized by the NRC as exempt devices and distributed to public end users exempt from the loss, loss of control and security requirements mentioned herein. Because of the restricted access, harsh and hazardous environments associated with the military exercises, it is difficult for the Armed Forces to effectively enforce the regulations addressing the accountability, tracking and loss of control of these devices during maneuvers and exercises. However, the radiological and security risks associated with the use of these devices during Armed Forces maneuvers and exercises were evaluated in determining whether an exemption should be granted, so as to arrive at a balanced decision, without impacting the safety of the Armed Forces personnel or the members of the public.

Currently, the Armed Forces possess approximately 65,000 of these detection and monitoring devices. The Army has reported a loss of 3 to 4 devices per year, per 10,000 devices. Because the Armed Forces use detectors in both wartime and simulated military battlefield exercises, and ordered maneuvers, in the air, on land, and at sea, it is anticipated that the loss of these devices will continue at the current rate, or increase a small amount because of the increased deployment warranted by the current world political situation, and the associated widespread deployment of the Armed Forces.

1.3 Proposed Action

Given the circumstances described above, the staff is considering granting a license amendment exempting the Armed Forces from certain control and reporting requirements during military exercises and maneuvers. During these times, the Armed Forces would be specifically exempt from requirements contained in: (1) 10 CFR 20.1801, "Security of stored material," when the Armed Forces store these authorized radioactive sealed source devices for monitoring and detecting chemical warfare agents during military exercises or maneuvers on U.S. Government-controlled property; (2) 10 CFR 20.1802, "Control of material not in storage," when the Armed Forces employ these devices during exercises or maneuvers on U.S. Government-controlled property; and (3) 10 CFR 20.2201, "Reports of theft or loss of licensed byproduct material," when these devices are lost when they are stored or used during military exercises or

maneuvers on U.S. Government-controlled property.

The exemption would not apply to: (1) Devices stored or used at other times, or lost under other conditions; (2) theft of the devices; or (3) devices lost in the U.S. public domain. Additionally, the Armed Forces licensees would continue to implement their established existing programs for tracking military assets and storage records of these devices. The Armed Forces would be required to keep records onsite of losses and loss of control of these devices and on request, make them available for review by the NRC Inspection staff.

1.4 Need for Proposed Action

NRC has closely reviewed the Armed Forces control and tracking procedures.

Although the Armed Forces have established an effective tracking and control program for these devices, losses have occurred and losses could still reasonably occur because of the unique circumstances associated with the use of such devices by the Armed Forces. The use of these detectors is critical for the safety of Armed Forces personnel, and, indirectly, critical to the safety of U.S. citizens. In addition, the use of these detectors (*i.e.*, for military exercises and maneuvers to prepare soldiers for battlefield conditions) is outside the scenarios envisioned when NRC regulations and policies on the accountability, tracking, and loss of control of radioactive sealed sources were developed.

Given the scope and nature of the U.S. military exercises, constant control and surveillance over such devices during military exercises and maneuvers may not always be possible or practical. For example, during these exercises and maneuvers, the devices are deliberately camouflaged to avoid detection by the enemy, and deployed manually or remotely from the air. To ensure constant control could be hazardous and may put some military personnel in harm's way. According to the Armed Forces reports, the majority of the losses have occurred during combat exercises and, with some exceptions, on U.S. Government-controlled property. Additionally, current requirements to report each separate loss of a device or devices may interfere with, and may even hinder, smooth military maneuvers and exercises, since the current regulations may trigger reactive or augmented team inspections by NRC after the repeated reported losses of detection and monitoring devices.

1.5 Alternatives

Available alternatives to NRC are:

1. Continue the current mode of operations to ensure compliance with referenced NRC regulations at all times (See section 1.2 for details of the current mode of operations). This is a no-action alternative.

2. Grant the exemption to the Armed Forces for the devices by issuing a license amendment (See section 1.3 for more details). This is the staff's preferred alternative.

3. Modify regulatory provisions applicable to these devices through the rulemaking process. The effect of this alternative would be to grant the same exemptions discussed for the proposed action. This type of action takes about 2 to 3 years.

2.0 Affected Environment

The affected environment for Alternatives 1, 2, and 3 is considered to be the immediate vicinity of the deployment of a device primarily on federally-controlled facilities and properties. Loss or loss of control of a device or devices would not lead to a release of radioactive material to the environment because the protective features (shielding and containment), as described in section 1.2, are robust and remain functional. Further, these devices contain small quantities of radioactive sealed sources (up to 300 microcuries of Americium-241 or up to 30 millicuries of Nickel-63).

These devices are normally tracked from central locations under the supervision of the licensee's staff and are issued on request to armed services units that may be stationed throughout the world. However, this exemption is only applicable to devices used or stored during military exercises or maneuvers on U.S. Government-controlled property, e.g., DOD installations throughout the United States of America. The Armed Forces currently inform NRC of lost devices that occur both in the U.S. and overseas, including some losses that occur in areas outside NRC's jurisdiction.

3.0 Environmental Impacts of Proposed Action and Alternatives

3.1 Public Health

Because of their portability (hand-held or capable of swift setup and dismantling in field) and potential radiological risk (if devices are taken apart), isolated lapses in control and accountability of these devices have continued to concern the Commission. However, the U.S. Armed Forces have established a safe operational record with these low-dose, robust radioactive devices, even when extensively deployed. Thus, taking into account the

military's safety record with these devices and their need for these devices, the staff is assessing the need for this license amendment and its impact on public health.

The three alternatives described in Section 1.5 represent the approaches that could be used in addressing the exemption request. The staff evaluated the three alternatives and their individual impact on public health. The impact of implementing any of these alternatives on public health will be the same because the alternatives address procedural and device loss, loss of control and accountability issues. Alternative 2 is being proposed since this alternative was found to be more efficient and practical compared to the other two alternatives. Also, this alternative reduces unnecessary regulatory burden on the licensees.

Alternative 1 (No action): The impact of this alternative would be similar to the proposed action. NRC believes that these very low-risk detection devices are currently over-regulated for the uses discussed in this EA. Based on the review of the circumstances surrounding the loss of the detectors, NRC believes that both the burden to the licensee of frequent reporting and the expenditure of NRC and MMLs resources performing reactive inspections after reports of loss of control of these devices, do not enhance the safe use of these devices. In fact, continued application of the current approach requiring reporting of loss of control events could inadvertently provide information to United States adversaries and could adversely impact the purpose or the intended outcome of a military exercise.

Alternative 2 (Proposed action): The principal users of chemical agent detectors and monitors are the Armed Forces. The devices are used to protect personnel when entering areas where the use of chemical warfare agents is likely. Other users could also include Federal, State, or local government agencies that support Emergency First Responders. These devices are portable (hand-held or able to be swiftly set up and dismantled in the field) and used by trained personnel, making them operable under dynamic or stressful situations and, at times, under very trying circumstances.

NRC performed analysis to support and verify the allowed use of exempt radioactive quantities of Americium-241 and Nickel-63 in chemical monitoring. The model, computer codes used, and assumptions made in the exemption analysis for chemical monitoring devices are presented in section 2.15.5 of NUREG-1717 (Ref. 5). The analysis

estimated maximum individual doses from chemical detectors containing 160 microcuries of Americium-241 and 10 millicuries of Nickel-63 and compared them to the regulatory limits (shown in Table 2.15.6 and Table 2.15.7 of NUREG-1717). The results of the NRC analysis indicate very small radiation doses which are an order of magnitude below the specified dose limits contained in 10 CFR sections 32.27 and 32.28.

Armed Forces licenses authorize possession and use of devices containing up to 300 microcuries of Americium-241 (Am-241) or up to 30 millicuries of Nickel-63 (Ni-63), which are two to three times higher than the radioactive source strength considered in NUREG-1717. However, the maximum doses associated with devices used by the U.S. Armed Forces would still be below the regulatory limits. Also, the radiation dose to a member of the public from a loss of control of a device would be extremely small. This is due, in part, to the fact that the U.S. Armed Forces use these chemical detection and monitoring devices on remote DOD installations and temporary job sites that are great distances from each other, and the time spent by individuals near or close to a lost device is estimated to be about one hour. It is expected that the individual dose from normal use or the potential dose from a loss of control, a temporarily displaced device, or a lost device, would not result in radiation exposure to the workers or the public significantly above the background radiation.

Although the Armed Forces have established an effective tracking and control program, losses could still reasonably occur because of the unique circumstances associated with the use of such devices. This use is critical for the safety of U.S. Armed Forces personnel, and is certainly outside the scenarios envisioned when NRC regulations and policies on the loss of sources were developed. Given the scope and nature of military activities, constant control and surveillance over such devices may not always be practical or possible. According to the Armed Forces reports, the majority of the losses have occurred during combat exercises and, with one exception, on U.S. Government-controlled property (one loss occurred when a device, which was believed to be in use on U.S. Government-controlled property, was later discovered in the U.S. public domain).

We conclude that no significant impacts on the public health under normal and accident conditions are expected as a result of granting this exemption to the Armed Forces.

Further, implementation of this alternative will reduce unnecessary burden on the Armed Forces and enable them to more efficiently use these devices when conducting exercises and maneuvers. Additionally, this license exemption should improve staff efficiency and effectiveness by reducing the work load of NRC and MMLs inspectors, who are required to conduct a reactive inspection each time a device is reported lost.

Alternative 3 (Rulemaking): It is expected that the impact from the rulemaking alternative would be similar to the impact of the proposed action; however, a lengthy time frame and large expenditures of resources are associated with the rulemaking process. A long-term reliable impact assessment that would support a rulemaking may not be available for more than five years. A rulemaking would not, in this case, provide a timely response to the current need. By the time a rule making could be completed, the Armed Forces may have shifted to using non-radioactive detection devices or other emerging technologies. NRC anticipates that, with the passage of time, the use of sealed sources in detection and monitoring devices for chemical agents is likely to diminish.

3.2 Water, Geology, Soils, Air Quality, Demography, Biota, and Cultural and Historic Resources

The NRC staff has determined that the proposed licensing exemption (Alternative 2) will not impact the quality of water resources, since the radioactive source quantities are very small and are not soluble in water. The staff has determined that the proposed exemption will not significantly impact geology, soils, air quality, demography, biota, and cultural and historic resources, under normal and accident use scenarios. NRC staff has reviewed the historical performance of this type of detection device and the potential for future deployment and concluded that no significant cumulative impacts are anticipated.

NRC staff has determined that the proposed action will not affect listed or proposed threatened or endangered species or critical habitat. NRC staff has determined that the proposed action is not the type that has the potential to cause effects on historic properties. Therefore, no further consultation with the regulatory authority responsible for overseeing section 106 of the National Historic Preservation Act was found necessary.

Impacts on water, geology, soils, air quality, demography, biota, and historic resources of implementing Alternatives

1 and 3 (described in section 1.5) are expected to be similar to those in the proposed action. As discussed in section 3.1, Alternative 2 is being proposed because it is the more efficient and practical alternative, and reduces unnecessary regulatory burden on the concerned licensees.

4.0 Conclusion

The NRC staff has determined that granting of this exemption will have no significant adverse effect on the public health and safety, or the environment. Based on its review, the NRC staff has determined that the environmental impacts associated with the proposed action do not warrant the preparation of an EIS.

5.0 Agencies and Persons Contacted

NRC contacted the U.S. Navy and U.S. Air Force MML National Radiation Program Oversight Committees and the Appropriate U.S. Army Commands. The need to contact State government officials was considered; however, it was concluded that such consultation was not necessary, since the proposed limited exemption is limited to federally-controlled facilities and properties.

6.0 References

1. U.S. Air Force Master Materials License No. 42-23539-01AF.
2. U.S. Department of Army License No. 12-00722-16.
3. U.S. Navy Master Materials License No. 45-23645-01NA.
4. U.S. Nuclear Regulatory Commission, Program-Specific Guidance About Master Materials Licenses, December 2000, NUREG-1556, Vol. 10.
5. U.S. Nuclear Regulatory Commission, Systematic Radiological Assessment of Exemptions for Source and Byproduct Materials, June 2001, NUREG-1717.

III. Finding of No Significant Impact

The action that NRC is considering is to issue an exemption to the Armed Forces in the form of a license condition that would exempt them from the requirements contained in: (1) 10 CFR 20.1801, "Security of stored material," when the Armed Forces store these authorized radioactive sealed source devices for monitoring and detecting chemical warfare agents during military exercises or maneuvers on U.S. Government-controlled property; (2) 10 CFR 20.1802, "Control of material not in storage," when the Armed Forces employ these devices during exercises or maneuvers on U.S. Government-controlled property; and (3) 10 CFR

20.2201, "Reports of theft or loss of licensed byproduct material," when these devices are lost when they are stored or used during military exercises or maneuvers on U.S. Government-controlled property.

The exemption would not apply to: (1) Devices stored or used at other times, or lost under other conditions; (2) theft of the devices; or (3) devices lost in the U.S. public domain. Additionally, under this exemption, the Armed Forces licensees would continue to implement their established existing programs for tracking and controlling these devices, and would be required to keep records of losses and loss of control available onsite for review by the NRC Inspectors.

The Commission has prepared this EA in light of the proposed action. In the assessment, the Commission has concluded that environmental impacts associated with the proposed action would not be significant and do not warrant the preparation of an EIS. Accordingly, based on the environment impacts described in section II, the Commission is issuing a FONSI for this licensing action.

IV. Further Information

Any questions about this action can be directed to Ujagar S. Bhachu at (301) 415-7894, or by e-mail at usb@nrc.gov.

Dated at Rockville, Maryland, this 8th day of April, 2004.

For the Nuclear Regulatory Commission.

Thomas H. Essig,

Chief, Materials Safety and Inspection Branch, Division of Industrial and Medical Nuclear Safety, NMSS.

[FR Doc. 04-8550 Filed 4-14-04; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR WASTE TECHNICAL REVIEW BOARD

Notice of Meeting

Board Meeting: May 18-19, 2004—Washington, DC: The U.S. Nuclear Waste Technical Review will meet with the DOE and interested parties to discuss the potential for localized corrosion during periods of above boiling temperatures in a repository planned for Yucca Mountain in Nevada.

Pursuant to its authority under section 5051 of Public Law 100-203, Nuclear Waste Policy Amendments Act of 1987, on Tuesday and Wednesday, May 18 and 19, 2004, the U.S. Nuclear Waste Technical Review Board (Board) will hold its spring meeting in Washington, DC. The Board has invited the U.S. Department of Energy (DOE) and several other interested parties—including the Nuclear Regulatory

Commission (NRC), the Electric Power Research Institute (EPRI), and the State of Nevada—to present their research and views on the potential for corrosion of waste packages during the “thermal pulse,” the period of approximately 1,000 years after closure when temperatures would be above boiling inside a repository for high-level radioactive waste planned for Yucca Mountain in Nevada. In a letter and a report to the DOE last fall, the Board concluded that, based on analyses of DOE and other data, all the conditions necessary for localized corrosion of waste packages will likely be present in repository tunnels during the thermal pulse.

The Board meeting will be held at the Embassy Suites Hotel; 1250 22nd Street, NW., Washington, DC 20037. The telephone number is 202-857-3388, and the fax number is 202-293-3173. The meeting is open to the public, and opportunities for public comment will be provided. The meeting sessions will begin at 8 a.m. on both days.

Tuesday’s session will begin with overviews of the status of program activities related to the Yucca Mountain project and updates on activities related to basic science, seismicity, and transportation of spent nuclear fuel and high-level radioactive waste. On Tuesday afternoon, representatives of the NRC, EPRI, and the State of Nevada will present their views and relevant research on the potential for corrosion on waste packages during the thermal pulse.

Most of the meeting on Wednesday will be devoted to presentations by the DOE and to discussion of DOE views, research, and analyses related to repository tunnel environments and the potential for localized corrosion during the thermal pulse. Meeting participants will have an opportunity to make brief wrap-up comments at the end of the day on Wednesday.

The meeting agenda will include time for public comment before adjournment on both days. Those wanting to speak during the public comment periods are encouraged to sign the “Public Comment Register” at the check-in table. A time limit may have to be set on individual remarks, but written comments of any length may be submitted for the record.

An agenda will be available approximately one week before the meeting. Copies of the agenda can be requested by telephone or obtained from the Board’s Web site: www.nwtrb.gov. Beginning on June 21, 2004, transcripts of the meeting will be available on the Board’s Web site, via e-mail, on computer disk, and on a library-loan

basis in paper format from Davonya Barnes of the Board staff.

A block of rooms has been reserved at the Embassy Suites Hotel. A meeting rate is available for reservations made by April 19, 2004. When making a reservation, please state that you are attending the Nuclear Waste Technical Review Board meeting. For more information, contact the NWTRB; Karyn Severson, External Affairs; 2300 Clarendon Boulevard, Suite 1300; Arlington, VA 22201-3367; (tel) 703-235-4473; (fax) 703-235-4495.

The Board was created by Congress in the Nuclear Waste Policy Amendments Act of 1987. The Board’s purpose is to evaluate the technical and scientific validity of activities undertaken by the Secretary of Energy related to managing the disposal of the nation’s spent nuclear fuel and high-level radioactive waste. In the same legislation, Congress directed the DOE to characterize the Yucca Mountain site to determine its suitability as the location of a potential repository for the permanent disposal of spent nuclear fuel and high-level radioactive waste.

Dated: April 5, 2004.

William D. Barnard,
Executive Director, Nuclear Waste Technical Review Board.

[FR Doc. 04-8532 Filed 4-14-04; 8:45 am]

BILLING CODE 6820-AM-M

COMMISSION ON OCEAN POLICY

Preliminary Report

ACTION: Notice of public availability and comment period.

SUMMARY: The U.S. Commission on Ocean Policy was established pursuant to the Oceans Act of 2000 to make recommendations to the President and Congress for a coordinated and comprehensive national ocean policy. The preliminary draft of the final report is being made available to the nation’s Governors and other interested parties for their review and comment.

DATES: The preliminary report will be available for public review on April 20, 2004. Comments on the report must be received in the Commission office no later than the close of business on May 21, 2004, e.t.

ADDRESSES: Send electronic comments (e-mail) to: comments@oceancommission.gov. Comments may also be mailed to: U.S. Commission on Ocean Policy, 1120 20th Street, NW., Suite 200 North, Washington, DC 20036. Comments may be sent by facsimile to: 202-418-3475.

FOR FURTHER INFORMATION CONTACT:

Michael Kearns, U.S. Commission on Ocean Policy, 1120 20th Street, NW., Washington, DC 20036, 202-418-3442, kearns@oceancommission.gov.

SUPPLEMENTARY INFORMATION: This notice is being issued pursuant to the Oceans Act 2000 (Pub. L. 106-256, sec. 3(g)(1)(A)). The report and detailed instructions for submitting comments will be available at the Commission’s Web site, www.oceancommission.gov, on April 20, 2004, when the report is released to the public. The report is also available for public review at the Commission’s office at 1120 20th Street, NW., Suite 200 North, Washington, DC 20036, from 2 p.m.–5 p.m. e.t. on April 20th and thereafter from 9 a.m.–5 p.m. e.t., Monday through Friday, during the remainder of the comment period. Comments sent by facsimile should include the words “Public Comment on Preliminary Report” on the coversheet. All public comments must include the individual’s name, institutional affiliation (optional), address, telephone number, and e-mail address. Comments should contain no attachments. All public comments received will be reviewed by the Commission and will become part of the official record of its work. Only comments received electronically will be acknowledged. Public comments will not be posted to the Web site. Sufficient time will be allowed for any needed changes to the report as a result of gubernatorial or other stakeholder comments. When such changes are made and the final report is approved by the Commission, it will be transmitted to the President and Congress.

Dated: April 9, 2004.

Thomas R. Kitsos,
Executive Director.

[FR Doc. 04-8546 Filed 4-14-04; 8:45 am]

BILLING CODE 6820-WM-P

PENSION BENEFIT GUARANTY CORPORATION

Required Interest Rate Assumption for Determining Variable-Rate Premium; Interest on Late Premium Payments; Interest on Underpayments and Overpayments of Single-Employer Plan Termination Liability and Multiemployer Withdrawal Liability; Interest Assumptions for Multiemployer Plan Valuations Following Mass Withdrawal

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Notice of interest rates and assumptions.

SUMMARY: This notice informs the public of the interest rates and assumptions to be used under certain Pension Benefit Guaranty Corporation regulations. These rates and assumptions are published elsewhere (or can be derived from rates published elsewhere), but are collected and published in this notice for the convenience of the public. Interest rates are also published on the PBGC's Web site (<http://www.pbgc.gov>).

The PBGC notes that the provisions of the Job Creation and Worker Assistance Act of 2002 that temporarily increased the required interest rate to be used to determine the PBGC's variable-rate premium to 100% (from 85%) of the annual yield on 30-year Treasury securities expired at the end of 2003. The Pension Funding Equity Act of 2004, which was signed into law by the President on April 10, 2004, changes the rules for determining the required interest rate for plan years beginning in 2004 or 2005. The PBGC intends shortly to publish a **Federal Register** notice reflecting the new required interest rates and post the changes on the PBGC's Web site.

DATES: The interest assumptions for performing multiemployer plan valuations following mass withdrawal under part 4281 apply to valuation dates occurring in May 2004. The interest rates for late premium payments under part 4007 and for underpayments and overpayments of single-employer plan termination liability under part 4062 and multiemployer withdrawal liability under part 4219 apply to interest accruing during the second quarter (April through June) of 2004.

FOR FURTHER INFORMATION CONTACT: Harold J. Ashner, Assistant General Counsel, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street, NW., Washington, DC 20005, 202-326-4024. (TTY/TDD users may call the Federal relay service toll-free at 1-800-877-8339 and ask to be connected to 202-326-4024.)

SUPPLEMENTARY INFORMATION:

Variable-Rate Premiums

Section 4006(a)(3)(E)(iii)(II) of the Employee Retirement Income Security Act of 1974 (ERISA) and § 4006.4(b)(1) of the PBGC's regulation on Premium Rates (29 CFR part 4006) prescribe use of an assumed interest rate (the "required interest rate") in determining a single-employer plan's variable-rate premium.

The PBGC notes that the provisions of the Job Creation and Worker Assistance

Act of 2002 that temporarily increased the required interest rate to be used to determine the PBGC's variable-rate premium to 100% (from 85%) of the annual yield on 30-year Treasury securities expired at the end of 2003. The Pension Funding Equity Act of 2004, which was signed into law by the President on April 10, 2004, changes the rules for determining the required interest rate for plan years beginning in 2004 or 2005. The PBGC intends shortly to publish a **Federal Register** notice reflecting the new required interest rates and post the changes on the PBGC's Web site.

Late Premium Payments; Underpayments and Overpayments of Single-Employer Plan Termination Liability

Section 4007(b) of ERISA and § 4007.7(a) of the PBGC's regulation on Payment of Premiums (29 CFR part 4007) require the payment of interest on late premium payments at the rate established under section 6601 of the Internal Revenue Code. Similarly, § 4062.7 of the PBGC's regulation on Liability for Termination of Single-Employer Plans (29 CFR part 4062) requires that interest be charged or credited at the section 6601 rate on underpayments and overpayments of employer liability under section 4062 of ERISA. The section 6601 rate is established periodically (currently quarterly) by the Internal Revenue Service. The rate applicable to the second quarter (April through June) of 2004, as announced by the IRS, is 5 percent.

The following table lists the late payment interest rates for premiums and employer liability for the specified time periods:

From—	Through—	Interest rate (percent)
4/1/98	12/31/98	8
1/1/99	3/31/99	7
4/1/99	3/31/00	8
4/1/00	3/31/01	9
4/1/01	6/30/01	8
7/1/01	12/31/01	7
1/1/02	12/31/02	6
1/1/03	9/30/03	5
10/1/03	3/31/04	4
4/1/04	6/30/04	5

Underpayments and Overpayments of Multiemployer Withdrawal Liability

Section 4219.32(b) of the PBGC's regulation on Notice, Collection, and Redetermination of Withdrawal Liability (29 CFR part 4219) specifies the rate at which a multiemployer plan is to charge or credit interest on underpayments and overpayments of

withdrawal liability under section 4219 of ERISA unless an applicable plan provision provides otherwise. For interest accruing during any calendar quarter, the specified rate is the average quoted prime rate on short-term commercial loans for the fifteenth day (or the next business day if the fifteenth day is not a business day) of the month preceding the beginning of the quarter, as reported by the Board of Governors of the Federal Reserve System in Statistical Release H.15 ("Selected Interest Rates"). The rate for the second quarter (April through June) of 2004 (i.e., the rate reported for March 15, 2004) is 4.00 percent.

The following table lists the withdrawal liability underpayment and overpayment interest rates for the specified time periods:

From	Through	Interest rate (percent)
7/1/97	12/31/98	8.50
1/1/99	9/30/99	7.75
10/1/99	12/31/99	8.25
1/1/00	3/31/00	8.50
4/1/00	6/30/00	8.75
7/1/00	3/31/01	9.50
4/1/01	6/30/01	8.50
7/1/01	9/30/01	7.00
10/1/01	12/31/01	6.50
1/1/02	12/31/02	4.75
1/1/03	9/30/03	4.25
10/1/03	6/30/04	4.00

Multiemployer Plan Valuations Following Mass Withdrawal

The PBGC's regulation on Duties of Plan Sponsor Following Mass Withdrawal (29 CFR part 4281) prescribes the use of interest assumptions under the PBGC's regulation on Allocation of Assets in Single-Employer Plans (29 CFR part 4044). The interest assumptions applicable to valuation dates in May 2004 under part 4044 are contained in an amendment to part 4044 published elsewhere in today's **Federal Register**. Tables showing the assumptions applicable to prior periods are codified in appendix B to 29 CFR part 4044.

Issued in Washington, DC, on this 12th day of April 2004.

Joseph H. Grant,

Deputy Executive Director and Chief Operating Officer, Pension Benefit Guaranty Corporation.

[FR Doc. 04-8589 Filed 4-14-04; 8:45 am]

BILLING CODE 7708-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. IC-26416; File No. 812-12942]

ING USA Annuity & Life Insurance Company, et al. April 9, 2004.**AGENCY:** The Securities and Exchange Commission ("SEC" or "Commission").**ACTION:** Notice of application for an order pursuant to section 26(c) of the Investment Company Act of 1940, as amended, (the "Act") approving certain substitutions of securities and for an order of exemption pursuant to section 17(b) of the Act.

APPLICANTS: ING USA Annuity & Life Insurance Company ("ING USA"), Separate Account B of ING USA Annuity & Life Insurance Company ("Account B"), Separate Account EQ of ING USA Annuity & Life Insurance Company ("Account EQ"), ING Life Insurance and Annuity Company ("ING Life"), Variable Annuity Account C of ING Life Insurance & Annuity Company ("ING VA C Account"), Variable Life Account C of ING Life Insurance & Annuity Company ("ING C Account"), ReliaStar Life Insurance Company ("ReliaStar"), ReliaStar Select Variable Account of ReliaStar Life Insurance Company ("RLS Select VA"), ReliaStar Select Life Variable Account of ReliaStar Life Insurance Company, ("RLS Select LVA"), ReliaStar Life Insurance Company of New York ("ReliaStar New York"), ReliaStar Life Insurance Company of New York—Separate Account NY-B ("RLNY Separate Account B"); Variable Life Separate Account I of ReliaStar Life Insurance Company of New York ("RLNY VL Separate Account I"), Variable Annuity Separate Account II of ReliaStar Life Insurance Company of New York ("RLNY VA II"), Security Life of Denver Insurance Company ("Security Life"), Security Life Separate Account A1 ("Security Life A1"), Security Life Separate Account L1 ("Security Life L1"), Southland Life Insurance Company ("Southland"), Southland Separate Account A1 ("Southland A1"), Southland Separate Account L1 ("Southland L1") and ING Investors Trust (the "Trust") (together, the "Applicants"). Prior to May 1, 2003, ING Investors Trust was known as The GCG Trust. Effective May 1, 2003, the name of The GCG Trust was changed to ING Investors Trust. At the same time, the name of each portfolio of The GCG Trust also was changed.

SUMMARY: The Applicants have submitted an application for an order of the Securities and Exchange

Commission (the "Commission"), pursuant to section 26(c) of the Investment Company Act of 1940, as amended (the "1940 Act"), permitting the substitutions of securities issued by certain registered investment companies held by Account B, Account EQ, ING VA C Account, ING C Account, RLS Select VA, RLS Select LVA, RLNY Separate Account B, RLNY VL Separate Account I, RLNY VA II, Security Life A1, Security Life L1, Southland A1 and Southland L1 (each, an "Account" and together, the "Accounts") to support certain in force variable life insurance policies and variable annuity contracts (collectively, the "Contracts") issued by ING USA, ING Life, ReliaStar, ReliaStar New York, Security Life and Southland (each a "Company" and together, the "Companies"). More particularly, the Applicants propose to substitute shares of certain investment management companies (each a "Management Company") currently held by sub-accounts of the various Accounts for shares of certain series of the Trust as follows: (1) Shares of Fidelity Variable Insurance Products—Money Market Portfolio (Initial Class) (the "Fidelity Money Fund") for Institutional Class shares of the ING Liquid Asset Portfolio of the Trust, formerly known as the Liquid Asset Portfolio (the "Liquid Asset Portfolio" or the "New Money Market Fund"); (2) Class O shares of The Alger American Fund—Alger American Small Capitalization Portfolio (the "Alger Fund") for Institutional Class shares of the ING J. P. Morgan Fleming Small Cap Equity Portfolio of the Trust (the "Small Cap Portfolio"); (3) Initial Class shares of Fidelity Variable Insurance Products—Index 500 Portfolio (the "Fidelity VIP Fund") for Institutional Class shares of the ING Stock Index Portfolio of the Trust (the "ING Index Portfolio"); (4) shares of Fund for Life Series of the Trust (the "Fund for Life") for Service Class shares of the ING T. Rowe Price Capital Appreciation Portfolio of the Trust, formerly the Fully Managed Portfolio (the "Fully Managed Portfolio"); (5) shares of Institutional Class shares of Janus Aspen Series—Growth Portfolio (the "Janus Institutional Fund") and Service Class Shares of Janus Aspen Series—Growth Portfolio (the "Janus Service Fund") for Institutional Class shares of the ING Van Kampen Equity Growth Portfolio of the Trust, formerly the Equity Growth Portfolio (the "Equity Growth Portfolio"); (6) shares of Neuberger Berman Advisers Management Trust—Partners Portfolio (the "Neuberger Fund") for Institutional Class Shares of the ING Mercury Focus Value Portfolio

of the Trust (the "Focus Value Portfolio"); and (7) Administrative Class shares of PIMCO Variable Insurance Trust—High Yield Bond Portfolio (the "PIMCO Fund") for Service Class shares of the ING PIMCO High Yield Bond Portfolio of the Trust (the "High Yield Portfolio"). Applicants also seek an order of exemption pursuant to section 17(b) of the 1940 Act to permit certain in-kind redemptions and purchases in connection with the substitution.

FILING DATE: The application was filed on March 12, 2003. The application was amended and restated on October 29, 2003, amended and restated on March 24, 2004 and amended and restated on March 31, 2004. Applicants represent that they will file an amendment to the application during the notice period to conform the representations set forth herein.

HEARING OR NOTIFICATION OF HEARING: An order granting the Application will be issued unless the Commission orders a hearing. Interested persons may request a hearing by writing to the Secretary of the Commission and serving Applicants with a copy of the request, personally or by mail. Hearing requests should be received by the Commission by 5:30 p.m. on April 30, 2004, and should be accompanied by proof of service on Applicants, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Secretary of the Commission.

ADDRESSES: For the Commission: Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549. For Applicants, Terrence O. Davis, Esquire, ING Americas U.S. Legal Services, 1475 Dunwoody Drive, West Chester, Pennsylvania 19380.

FOR FURTHER INFORMATION CONTACT: Curtis A. Young, Senior Counsel, or Lorna J. MacLeod, Branch Chief, Office of Insurance Products, Division of Investment Management, at (202) 942-0670.

SUPPLEMENTARY INFORMATION: The following is a summary of the amended and restated application. The complete amended and restated application is available for a fee from the SEC's Public Reference Branch, 450 Fifth Street, NW., Washington, DC 20549-0102 (tel. (202) 942-8090).

I. The Proposed Substitution

The Applicants have requested that the Commission issue an order to permit the substitution ("Substitution") of certain shares of various portfolios for shares of similar portfolios offered by the Trust. More particularly, the Applicants propose to substitute shares of certain investment management companies currently held by sub-accounts of the various Accounts for shares of certain series of the Trust as follows: (1) Shares of the Fidelity Money Fund for Institutional Class shares of the Liquid Asset Portfolio; (2) Class O shares of The Alger Fund for Institutional Class shares of the Small Cap Portfolio; (3) Initial Class shares of the Fidelity VIP Fund for Institutional Class shares of the ING Index Portfolio; (4) shares of Fund for Life for Service Class shares of the Fully Managed Portfolio; (5) shares of the Janus Institutional Fund and the Janus Service Fund for Institutional Class shares of the Equity Growth Portfolio; (6) shares of the Neuberger Fund for Institutional Class Shares of the Focus Value Portfolio; and (7) Administrative Class shares of the PIMCO Fund for Service class shares of the High Yield Portfolio.

II. Applicants' Representations

A. Each of the Companies listed below is a direct or indirect subsidiary of ING Groep, N.V. ("ING"). ING is a global financial services holding company based in The Netherlands which is active in the field of insurance, banking and asset management in more than 60 countries. As a result each of the Companies likely would be deemed to be an affiliate of each other.

1. *ING USA*. ING USA is an Iowa stock life insurance company which originally was organized under the insurance laws of Minnesota. Prior to January 1, 2004, ING USA was known as Golden American Life Insurance Company ("Golden"). Effective on January 1, 2004, Equitable Life Insurance Company of Iowa ("Equitable"), along with several other affiliated companies, was merged with and into Golden and the name of Golden changed to ING USA. Prior to the merger, Golden primarily was engaged primarily in the issuance of variable annuity and variable life insurance products. Subsequent to the merger, ING USA succeeded to business of Golden and became the sponsor and depositor of Account B along with Account EQ.

2. *ING Life*. ING Life is a stock life insurance company organized under the insurance laws of the State of

Connecticut in 1976 and an indirect wholly-owned subsidiary of ING. Through a merger, ING Life succeeded to the business of Aetna Variable Annuity Life Insurance Company (formerly Participating Annuity Life Insurance Company, an Arkansas life insurance company organized in 1954). Prior to May 1, 2002, the ING Life was known as Aetna Life Insurance and Annuity Company. ING Life principally is engaged in the business of issuing life insurance policies and variable annuity contracts. ING Life also is registered as an investment adviser under the Investment Advisers Act of 1940, as amended, and, as such, is the investment adviser for ING Partners, Inc. (prior to May 1, 2002 known as Portfolio Partners, Inc.) ING Life is the depositor of ING VA C Account and ING C Account, each of which is a separate account of ING Life and is registered with the Commission as a unit investment trust.

3. *ReliaStar*. ReliaStar is a stock life insurance company organized in 1885 and incorporated under the laws of the State of Minnesota. ReliaStar is an indirect, wholly-owned subsidiary of ING which principally offers individual life insurance and annuities, employee benefits and retirement contracts.

4. *ReliaStar New York*. ReliaStar New York is a stock life insurance company that was incorporated under the laws of the State of New York in 1917. ReliaStar New York is an indirect, wholly-owned subsidiary of ReliaStar Financial, an indirect, wholly owned subsidiary of ING. ReliaStar New York principally offers individual life insurance and annuities.

5. *Security Life*. Security Life is a stock life insurance company organized under the laws of the State of Colorado in 1929. Security Life is a wholly owned indirect subsidiary of ING and principally is engaged in the business of issuing life insurance policies and annuity contracts.

6. *Southland Life*. Southland Life is a stock life insurance company organized under the laws of the State of Texas in 1908. Southland Life principally is engaged in the business of issuing life insurance policies and annuity contracts.

7. Each of the Accounts is a segregated asset account of the applicable Company, and is registered under the 1940 Act as a unit investment trust. Each of the respective Accounts is used by the Company of which it is a part to support the Contracts that it issues.

8. Each Account is administered and accounted for as part of the general business of the Company of which it is

a part. The assets of each Account attributable to the Contracts issued through it are owned by each Company but are held separately from all other assets of that Company for the benefit of the owners of, and persons entitled to benefits under such Contracts. Pursuant to applicable state insurance law, such assets are not chargeable with liabilities arising out of any other business that each Company may conduct. Income, if any, gains and losses, realized or unrealized, from each Account are credited to or charged against the assets of that Account, without regard to other income, gains or losses of its Company or any of its other segregated asset accounts. Each Account is a "separate account" as defined by Rule 0-1(e) under the 1940 Act.

9. Each Account is divided into subaccounts. Each Account has subaccounts, each of which invests exclusively in shares of one investment company portfolio of the Trust, a Replaced Fund or another mutual fund. Each investment company portfolio has its own distinct investment objective(s) and policies. Income, gains and losses, realized or unrealized, of a portfolio are credited to or charged against the corresponding subaccount of each Account without regard to any other income, gains or losses of the applicable Company. Assets equal to the reserves and other contract liabilities with respect to each are not chargeable with liabilities arising out of any other business of the applicable Company.

10. The Contracts are flexible premium variable annuity and variable life insurance contracts. The variable annuity Contracts provide for the accumulation of values on a variable basis, fixed basis, or both, during the accumulation period, and provide settlement or annuity payment options on a variable or fixed basis. The variable life insurance Contracts provide for the accumulation of values on a variable basis, fixed basis, or both throughout the insured's life and for a death benefit, upon the death of the insured. Under each of the Contracts, each Company reserves the right to substitute shares of one fund or portfolio for shares of another.

11. A Contract owner may transfer all or any part of the Contract value from one subaccount to any other subaccount or a fixed account as long as the Contract remains in effect for variable life insurance contracts, and at any time up to 30 days before the due date of the first annuity payment for variable annuity contracts. For many of the variable annuity contracts, the Company issuing the Contract reserves the right to

limit the number of transfers during a specified period.

12. Each Company, on behalf of itself and their Accounts propose a series of substitutions of shares held in the

applicable Accounts. The table below summarizes the proposed substitutions.

Replaced fund	Class of shares (if applicable)	Substitute trust portfolio	Substitute trust portfolio class	Account(s) holding replaced money market fund(s)
Replaced Money Market Funds				
Fidelity Money Fund	Initial	Liquid Asset Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Security Life A1. Southland A1. Southland L1. Security Life L1.
Non-Money Market Funds				
Alger Fund	Class O	Small Cap Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Security Life A1. Security Life L1. Southland A1. Southland A2. Southland L1. RLNY VA II. RLS Select VA. RLS Select LVA. RLNY VL I. Security Life A1. Security Life L1. Southland A1. Southland L1. ING Acct. C. RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Southland A1. Southland L1. Southland A1. Southland L1. Security Life L1. Account B.
Fidelity VIP	Initial	ING Index Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VL I. Security Life A1. Security Life L1. Southland A1. Southland L1. RLNY VA II. RLS Select VA. RLS Select LVA. RLNY VL I. Security Life A1. Security Life L1. Southland A1. Southland L1. Southland A1. Southland L1. Security Life L1. Account B.
Janus Fund	Institutional	Equity Growth Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Southland A1. Southland L1. Southland A1. Southland L1. Security Life L1. Account B.
Janus Fund	Service	Equity Growth Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Southland A1. Southland L1. Southland A1. Southland L1. Security Life L1. Account B.
Fund for Life	N/A	Fully Managed Portfolio	Service	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Security Life A1. Security Life L1.
Neuberger Fund	N/A	Focus Value Portfolio	Institutional	RLS Select VA. RLS Select LVA. RLNY VA II. RLNY VL I. Security Life A1. Security Life L1.
PIMCO Fund	Administrative	High Yield Portfolio	Service	Account B. Account EQ. RLNY Separate. Account B.

13. Applicants believe that for each proposed substitution, the investment objectives and policies of the replacing Fund(s) or Portfolio(s) are sufficiently similar to those of the replaced Fund(s) or Portfolio(s) that Contract owners will have reasonable continuity in investment expectations. Applicants also believe that the proposed substitutions will better serve the interests of Contract owners because, in each case, the replacing Fund or

Portfolio has either the same or lower fees or expenses.

14. Each Management Company is registered as an open-end management investment company under the Act. Further, each is a series investment company as defined by Rule 18f-2 under the Act and issues separate series of shares of stock (for corporations) or of beneficial interest (for business trusts) in connection with each Fund or Portfolio. The shares of each Fund or

Portfolio are registered under the 1933 Act on Form N-1A.

15. The investment objective of the Fidelity Money Fund is substantially identical to the investment objective of the Liquid Asset Portfolio. More particularly, the investment objective of the Fidelity Money Fund is to seek as a high a level of current income as is consistent with the preservation of capital and liquidity. On the other hand, the investment objective of the Liquid Asset Portfolio is to seek a high level of

current income consistent with the preservation of capital and liquidity. Similarly, the investment policies of the Fidelity Money Fund are substantially similar to the policies of the Liquid Asset Portfolio. Both the Fidelity Money Fund and the Liquid Asset Portfolio have elected to use the amortized cost method to value their respective portfolio securities. As a result, both the Fidelity Money Fund and the Liquid Asset Portfolio are subject to the requirements of Rule 2a-7 adopted under the 1940 Act. Among other features, Rule 2a-7 sets forth certain requirements concerning issuer creditworthiness and diversification standards which must be complied with by money market funds seeking to use the amortized cost method. Thus, the Fidelity Money Fund and the Liquid Asset Portfolio are required to follow substantially identical policies as prescribed by Rule 2a-7.

16. The Alger Fund and the Small Cap Portfolio share the same investment objective. More particularly, both the Alger Fund and the Small Cap Portfolio each seek to achieve long term capital appreciation. Furthermore, both the Alger Fund and the Small Cap Portfolio (each a "Small Cap Fund") have substantially identical policies. Each Small Cap Fund principally invests in stocks of companies included on the Russell 2000 Growth Index or the S&P SmallCap 600 Index.

17. The investment objective of the Fidelity VIP Fund and the ING Index Portfolio (each an "Index Fund") are identical. More specifically, each Index Fund seeks to achieve investment results that correspond to the total return of common stocks publicly traded in the United States, as represented by the S&P 500 Index.

Furthermore, each Index Fund has substantially identical investment policies as the other Index Fund. Each Index Fund invests substantially all of its assets in securities of companies included on the S&P 500 Index.

18. The Janus Fund and the Equity Growth Portfolio have substantially

identical investment objectives. The investment objective of the Janus Fund is to seek long-term growth of capital in a manner consistent with the preservation of capital. While the investment objective of the Equity Growth Portfolio is to achieve long-term capital appreciation. Both the Janus Fund and the Equity Growth Portfolio seek to achieve growth in their investment portfolios over the longer term. Further both the Janus Fund and the Equity Growth Portfolio pursue their respective investment objectives by investing principally in U.S. companies and foreign companies listed on securities exchanges in the United States with larger market capitalizations. The investment policies of the Janus Fund and the Equity Growth Portfolio are nearly identical. Both the Janus Fund and the Equity Growth Portfolio are permitted to invest in a wide range of securities, but each invests the majority of its assets in equity securities.

19. The investment objective of the Neuberger Fund and the Focus Value Portfolio are substantially identical. Both the Neuberger Fund and the Focus Value Portfolio seek growth of capital. However, the Focus Value Portfolio seeks to achieve the growth of capital over the long term. While the language of the investment objective of may not be articulated the same, each fund pursues its respective investment objective by investing in the same types of issuers. More particularly, both the Neuberger Fund and the Focus Value Portfolio seek to find issuers whose stock prices are believed to be undervalued. Furthermore, each fund has the ability to invest in a range of securities in pursuit of its investment objective, including junk bonds.

20. Both the PIMCO Fund and the High Yield Portfolio (each a "Bond Fund") have the same investment objective. More specifically, each Bond Fund seeks maximum total return, consistent with preservation of capital and prudent investment management. The High Yield Portfolio is modeled

after the PIMCO Fund. As a result, the investment objectives and policies of each Bond Fund nearly are identical. Furthermore, it is anticipated that PIMCO will manage the High Yield Portfolio after the Substitution in substantially the same manner as PIMCO manages the PIMCO Fund.

21. While the Fully Managed Portfolio is not a "fund of funds," there is no substitution alternative available among the investment portfolios of the ING Investors Trust for the Fund For Life's structure as a "fund of funds." Both the Fully Managed Portfolio and the Fund For Life share the primary objective of high total investment return. The Fully Managed Portfolio also has the same investment strategy as the Fund For Life, of allocating assets among equity and bond classes of investments, with the majority invested in equity investments. In addition, the Fund For Life is authorized to allocate 10% of its assets to mutual funds investing in international equity securities; the Fully Managed Portfolio is authorized to invest 20% of its net assets in equity securities of foreign issuers. Golden American has, therefore, concluded that the overall investment objectives of the Fund For Life and the Fully Managed Portfolio are sufficiently similar to be appropriate for substitution.

22. A significant difference in the configuration of the funds is how the fees are structured by each portfolio together with the fact that the overall expenses are lower or comparable under the Trust Portfolio fee structure. Each Trust Portfolio is part of the unified fee structure of the Trust, under which DSI, which receives a fixed management fee, pays almost all of the operating expenses incurred by each Trust Portfolio. In contrast, each Replaced Fund pays both a management or advisory fee and all of its own operating expenses. The following tables compare the expenses of each Replaced Fund with the expenses of the corresponding Trust Portfolio (as a percentage of average daily net assets):

REPLACED MONEY MARKET FUND VS. LIQUID ASSET PORTFOLIO
(In percent)

Replaced fund Fidelity money fund (Initial class)	Expenses	Trust portfolio Liquid asset portfolio (Instit. class)
Management Fee	0.20	0.27
Other Expenses, 12b-1 Fees	0.10	0.01
Total Expenses	0.30	0.28

NON-MONEY MARKET REPLACED FUNDS VS. CORRESPONDING TRUST PORTFOLIO
[In percent]

	Replaced fund Alger Fund	Trust portfolio Small cap port- folio (Institutional class)
Management Fee	0.85	0.90
Other Expenses	0.11	0.0
12b-1 Fees		
Total Expenses	0.96	0.90
	Fidelity VIP (Initial class)	ING Index Portfolio (Institutional class)
Management Fee	0.24	0.27
Other Expenses	0.10	0.01
12b-1 Fees		
Total Expenses	0.34	0.28
	Fund for Life	Fully Managed Portfolio (Service class)
Management Fee	0.10	0.68
Other Expenses	2.95	0.25
12b-1 Fees		0.01
Total Expenses	13.05	0.94
	Janus Fund (Institutional class)	Equity Growth Portfolio (Institutional class)
Management Fee	0.65	0.65
Other Expenses	0.02	0.02
12b-1 Fees		
Total Expenses	0.67	0.67
	Janus Fund (Service class)	Equity Growth Portfolio (Institutional class)
Management Fee	0.65	0.65
Other Expenses	0.02	0.02
12b-1 Fees	0.25	
Total Expenses	0.92	0.67
	Neuberger Fund	Focus Value Fund (Institutional Class)
Management Fee	0.82	0.80
Other Expenses	0.13	0.00
12b-1 Fees		
Total Expenses	0.95	0.80
	PIMCO Fund (Administrative class)	High Yield Portfolio (Service class)
Management Fee	0.25	0.49
Other Expenses	0.25	0.01
12b-1 Fees	0.25	0.25
Total Expenses	0.75	0.75

NON-MONEY MARKET REPLACED FUNDS VS. CORRESPONDING TRUST PORTFOLIO—Continued
[In percent]

	Replaced fund Alger Fund	Trust portfolio Small cap portfolio (Institutional class)
Total Net Expenses	0.75	0.75

¹ DSI has agreed to waive and/or assume 0.55% of the annual expenses of the Fund for Life.

23. The accompanying chart shows the approximate year-end size (in net assets), expense ratio (ratio of operating expenses as a percentage of average net assets), and annual total returns for the past year for each of the Funds and Portfolios involved in the proposed substitutions.

COMPARISON OF THE REPLACED FUNDS TO THE TRUST PORTFOLIOS

Replaced fund	As of	Net assets	Expense ratio	Total return
Replaced Money Market Fund				
Fidelity Money Fund	Dec. 31, 2003	\$1,817,439,610	0.29%	1.00%
Trust Portfolio				
Liquid Asset Portfolio (Institutional Class) ²				
Non-Money Market Funds				
Alger Fund	Dec. 31, 2003	\$469,076,000	0.97%	42.34%
Trust Portfolio				
Small Cap Portfolio (Institutional Class) ³				
Fidelity VIP (Initial Class)	Dec. 31, 2003	\$3,031,540,423	0.34%	28.41%
Trust Portfolio				
ING Index Portfolio ⁴				

² As of the date of this Application, the Institutional Class shares of the Liquid Asset Portfolio had not yet commenced operation.

³ As of the date of this Application, the Institutional Class shares of the Small Cap Portfolio had not yet commenced operation.

⁴ As noted above, the ING Index Portfolio is being created in anticipation of the substitutions contemplated by this Application. Thus, there is no operating history to report for this Trust Portfolio.

Replaced fund	As of	Net assets	Expense ratio	Total return
Janus Fund	Dec. 31, 2003	\$1,666,317,000	0.67%	31.73%
Trust Portfolio				
Equity Growth Portfolio ⁵ (Institutional Class)				
Janus Fund	Dec. 31, 2003	\$211,100,000	0.92%	31.49%
Trust Portfolio				
Equity Growth Portfolio ⁶ (Institutional Class)				
Neuberger Fund	Dec. 31, 2003	\$669,639,353	0.91%	35.09%

Replaced fund	As of	Net assets	Expense ratio	Total return
Trust Portfolio				
Focus Value Portfolio ⁷ (Institutional Class)				
PIMCO Fund	Dec. 31, 2003	\$955,599,000	0.75%	22.85%
Trust Portfolio				
High Yield Portfolio ⁸ (Service)				
Fund for Life	Dec. 31, 2003	\$108,405	3.05%	18.40%
New Portfolio				
Fully Managed (Service)	Dec. 31, 2003	\$1,413,027,000	0.94%	25.23%

⁵ The Equity Growth Portfolio has not yet commenced operations.

⁶ *Id.*

⁷ The Focus Value Portfolio has not yet commenced operations.

⁸ The High Yield Portfolio has not yet commenced operations.

24. Applicants propose to rationalize and consolidate their underlying investment portfolio and fund offerings among the Contracts. The rationalization and consolidation effort and resulting proposed substitutions arise from two factors. First, as a consequence of several acquisitions and/or mergers over the past several years involving ING and one or more of the Companies, there are several asset management divisions/groups being offered by each of the various Companies. Second, contemporaneously, the various Companies conducted a reevaluation of the array of investment options offered within each Contract. The goal of the reevaluation was to identify and establish an updated, current array of investment options for the Contracts and respond to distributor feedback regarding offerings in various variable annuity and life insurance contracts.

25. As a result of the review process described above, the Applicants determined that maintaining and servicing such a large array of often redundant investment options unnecessarily uses resources which could be better directed elsewhere, including the servicing of existing Contracts. Furthermore, Applicants believe that such a large array of underlying fund options is inefficient and not necessary in light of the investment options offered by the Trust which have investment objectives and policies that, in most cases, are substantially identical to those of the Replaced Fund. Thus, a plan was developed to realign some of the underlying fund/portfolio offerings and/or to rationalize such offerings of which

the proposed substitutions are an essential component.

26. The Trust, in anticipation of the proposed consolidation formed several new Portfolios, including the Equity Growth Portfolio, Focus Value Portfolio and ING Index Portfolio. In addition, the Companies began adding several new options to the certain Contracts this past May 1 and, where possible, closed off the proposed Replaced Fund to new investments as of that date. The Applicants believe that Contract owners will benefit from these efforts in several respects.

27. Apart from the substitution of the underlying mutual funds, the rights of affected Contract owners and the obligations of the Companies under the Contracts would not be altered by the Substitutions. Affected Contract owners will not incur any additional tax liability or any additional fees or expenses as a result of the Substitutions.

28. The Substitutions will take place at relative net asset value (in accordance with Rule 22c-1 under the 1940 Act) with no change in the amount of any affected Contract owner's accumulation value or death benefit or in dollar value of his or her investment in the Accounts. Affected Contract owners will not incur any fees or charges as a result of the Substitutions nor will their rights or the Companies' obligations under the affected Contracts be altered in any way. The Companies or their affiliates will pay all other expenses incurred with the Substitutions, including legal, accounting, and other fees and expenses. In addition, the Substitutions will not impose any tax liability on affected Contract owners. The Substitutions will not cause the affected Contract fees and charges currently

being paid by affected Contract owners to be greater after the Substitutions than before the Substitutions. In addition, while the Companies do not anticipate increasing Contract fees and/or charges paid by any current Contract owners, the Companies have agreed not to increase the Contract fees and charges currently being assessed by the Contracts for a period of at least two years following the Substitutions.

29. Affected Contract owners will have the right to surrender their affected Contracts or reallocate accumulation value of each Replaced Fund in accordance with the terms and conditions of their Contract prior to (and after) the Effective Date.

30. Each affected Contract owner will receive a copy of (i) a supplement informing shareholders of the proposed substitution; (ii) a prospectus for the appropriate Trust portfolio, and (iii) a second supplement setting forth the Effective Date and advising affected Contract owners of their right to reconsider the Substitutions and, if they so choose, any time prior to the Effective Date, they may withdraw or reallocate accumulation value under the affected Contract or otherwise terminate their interest thereof in accordance with the terms and conditions of their Contract; and (iv) within five business days of the Effective Date, a Post-Substitution Notice. If affected Contract owners reallocate accumulation value prior to the Effective Date, or within 30 days after the Effective Date, there will be no charge for the initial reallocation of accumulated value from each Affected Subaccount and the initial reallocation will not be counted toward the total number of reallocations made

within the Contract year for purposes of determining whether the number of reallocations which may be made without incurring administrative or transfer fees, if any, under the relevant Contract has been exceeded. The Companies will not exercise any right they may have under the Contracts to impose additional restrictions or fees on transfers from the Replaced Funds under the Contracts for a period of at least thirty days following the proposed substitutions.

III. Applicant's Legal Analysis

1. Section 26(c) of the Act requires the depositor of a registered unit investment trust holding the securities of a single issuer to receive Commission approval before substituting the securities held by the trust. Each of the Contracts expressly reserved to the Companies the right, subject to compliance with applicable law, to substitute shares of another open-end management investment company for shares of an open-end management investment company held by a subaccount of an Account. The prospectuses for the Contracts and the Accounts contain appropriate disclosure of this right.

2. The Companies reserved this right of substitution both to protect themselves and their Contract owners in situations where either might be harmed or disadvantaged by circumstances surrounding the issuer of the shares held by one or more of its separate accounts and to afford the opportunity to replace such shares where to do so could benefit the Contract owners and Companies.

3. Applicants maintain that Contract owners will be better served by the proposed substitutions. Applicants anticipate that the replacement of certain unpopular Portfolios or Funds will result in a Contract that is administered and managed more efficiently, and one that is more competitive with other variable products in both wholesale and retail markets. Applicants state that for all of the proposed substitutions, the new Portfolios or Funds are either substantially the same or more conservative in their investment objective(s) or strategies or both, than the Portfolios or Funds that they would replace. Likewise, Applicants believe that a majority of the new Portfolios or Funds have a substantially similar or lower investment risk profile than the Portfolios or Funds each would replace.

4. In addition to the foregoing, Applicants generally submit that the proposed substitutions meet the standards that the Commission and its staff have applied to similar

substitutions that have been approved in the past.

5. Applicants anticipate that Contract owners will be at least as well off with the proposed array of subaccounts to be offered after the proposed substitutions as they have been with the array of subaccounts offered before the substitutions. The proposed substitutions retain for Contract owners the investment flexibility that is a central feature of the Contracts. If the proposed substitutions are carried out, all Contract owners will be permitted to allocate purchase payments and transfer accumulated values and contract values between and among the remaining subaccounts as they could before the proposed substitutions.

6. Applicants assert that each of the proposed substitutions is not the type of substitution that Section 26(c) was designed to prevent. Unlike traditional unit investment trusts where a depositor could only substitute an investment security in a manner which permanently affected all the investors in the trust, the Contracts provide each Contract owner with the right to exercise his or her own judgment and transfer accumulation and contract values into other subaccounts. Moreover, the Contracts will offer Contract owners the opportunity to transfer amounts out of the affected subaccounts into any of the remaining subaccounts without cost or other disadvantage. The proposed substitutions, therefore, will not result in the type of costly forced redemption that Section 26(c) was designed to prevent.

7. Applicants maintain that the proposed substitutions also are unlike the type of substitution that Section 26(c) was designed to prevent in that by purchasing a Contract, Contract owners select much more than a particular investment company in which to invest their account values. They also select the specific types of insurance coverages offered by the various Companies under the Contracts as well as numerous other rights and privileges set forth in each Contract. Contract owners may also have considered the size, financial condition, type, and reputation of ING and the various Companies. These factors will not change because of the proposed substitutions.

8. Applicants submit that, for all the reasons stated above, the proposed substitutions are consistent with the protection of investors and the purposes fairly intended by the policy and provisions of the Act.

9. Section 17(a)(1) of the Act, in relevant part, prohibits any affiliated person of a registered investment

company, or any affiliated person of such person, acting as principal, from knowingly selling any security or other property to that company. Section 17(a)(2) of the Act generally prohibits the persons described above, acting as principals, from knowingly purchasing any security or other property from the registered investment company. Section 17(b) of the Act provides that the Commission may, upon application, grant an order exempting any transaction from the prohibitions of Section 17(a) if the evidence establishes that: (1) The terms of the proposed transaction, including the consideration to be paid or received, are reasonable and fair and do not involve overreaching on the part of any person concerned; (2) the proposed transaction is consistent with the policy of each registered investment company concerned, as recited in its registration statement and records filed under the Act; and (3) the proposed transaction is consistent with the general purposes of the Act.

10. Applicants maintain that the terms of the proposed transactions, including the consideration to be paid and received by each Portfolio or Fund involved, are reasonable, fair and do not involve overreaching principally because the transactions do not cause owners' interests under a Contract to be diluted and because the transactions will conform with the principal conditions enumerated in Rule 17a-7. The proposed transactions will take place at relative net asset value with no change in the amount of any Contract owner's Contract or cash value or death benefit or in the dollar value of his or her investment in any of the Accounts. Even though the Applicants may not rely on Rule 17a-7, Applicants believe that the Rule's conditions outline the type of safeguards that result in transactions that are fair and reasonable to registered investment company participants and preclude overreaching in connection with an investment company by its affiliated persons.

11. Applicants submit that the Substitutions by the Companies are consistent with the policies of each Portfolio and each Replaced Fund, as recited in the current registration statements and reports filed by each under the 1940 Act. Finally, Applicants submit that the Substitutions are consistent with the general purposes of the 1940 Act.

12. The boards of trustees or directors, as applicable of each Replaced Fund and the Trust have adopted procedures, as required by paragraph (e)(1) of Rule 17a-7, pursuant to which the portfolios or funds of each may purchase and sell

securities to and from their affiliates. The Companies and the investment advisers will carry out the Substitutions in conformity with the principal conditions of Rule 17a-7 and each Replaced Fund's and the Trust's procedures thereunder. Although the transaction may not be entirely for cash, with the exception of the substitution involving the PIMCO Fund and the High Yield Portfolio as described below, it will be effected based upon (i) the independent market price of the portfolio securities valued as specified in paragraph (b) of Rule 17a-7, and (ii) the net asset value per share of each Portfolio and the corresponding Replaced Fund valued in accordance with the procedures disclosed in the registration statements for each Fund and as required by Rule 22c-1 under the 1940 Act. No brokerage commission, fee, or other remuneration will be paid to any party in connection with the proposed transactions. In addition, the Trust Board will subsequently review the Substitutions and make the determinations required by paragraph (e)(3) of Rule 17a-7.

13. With regard to the substitution involving the PIMCO Fund and the High Yield Portfolio, DSI and the investment adviser to the PIMCO Fund and the investment sub-adviser to the High Yield Portfolio, PIMCO, intend to value securities selected for transfer between the two funds in a manner that is consistent with the current methodology used to calculate the daily net asset value of the PIMCO Fund. Currently, PIMCO employs certain third party, independent pricing services to value securities held by the PIMCO Fund ("vendor pricing"). DSI and PIMCO intend to employ vendor pricing to value securities held by the PIMCO Fund that are selected for transfer to the High-Yield Portfolio. Securities will be selected for transfer to the High Yield Portfolio on a pro-rata basis.

14. After the assets have been contributed to the Trust, responsibility for valuation of the securities held by the High Yield Portfolio will shift to the valuation committee of the Board of the Trust. At the end of the first trading following the transfer, the valuation agent and custodian for the Trust, the Bank of New York, will value the securities held by the High-Yield Portfolio. The foregoing notwithstanding, the Board of the Trust will retain ultimate responsibility for the valuation of the securities held by the High Yield Portfolio.

15. DSI and PIMCO believe that the use of neutral, third party vendor prices will ensure that both portfolios utilize unbiased evaluations in determining

respective security and, ultimately, portfolio market values. In the event that independent pricing services do not provide valuations for a specific security selected for transfer, DSI and PIMCO, in accordance with paragraph (b)(4) of Rule 17a-7 under the 40 Act, will rely on the "average of highest current independent bid and lowest current independent offer determined on the basis of reasonable inquiry * * *" in valuing such security.

16. The Substitutions are consistent with the general purposes of the 1940 Act, as enunciated in the Findings and Declaration of Policy in Section 1 of the 1940 Act. The proposed transactions do not present any of the issues or abuses that the 1940 Act is designed to prevent. Moreover, the proposed transactions will be effected in a manner consistent with the public interest and the protection of investors, as required by Section 6(c) of the 1940 Act. Contract owners will be fully informed of the terms of the Substitutions through the supplements and the Post-Substitution Notice and will have an opportunity to withdraw from the Replaced Fund through reallocation to another subaccount or otherwise terminate their interest thereof in accordance with the terms and conditions of their Contract prior to the Effective Date.

IV. Applicant's Conditions

For purposes of the approval sought pursuant to Section 26(c) of the Act, the substitutions described in the amended and restated application will not be completed, unless all of the following conditions are met:

1. The Commission shall have issued an order (i) approving the Substitutions under Section 26(c) of the 1940 Act; and (ii) exempting the in-kind redemptions from the provisions of Section 17(a) of the 1940 Act as necessary to carry out the transactions described in this Application.

2. Each affected Contract owner will have been sent a copy of (i) a supplement informing shareholders of this Application; (ii) a prospectus for the appropriate Trust Portfolio, and (iii) a second supplement setting forth the Effective Date and advising affected Contract owners of their right to reconsider the Substitutions and, if they so choose, any time prior to the Effective Date, they may reallocate or withdraw amounts under their affected Contract or otherwise terminate their interest thereof in accordance with the terms and conditions of their Contract. If affected Contract owners reallocate accumulation value prior to the Effective Date, or within 30 days after the Effective Date, there will be no

charge for the initial reallocation of accumulated value from each affected Subaccount and the initial reallocation will not be counted toward the total number of reallocations made within the Contract year for purposes of determining whether the number of reallocations which may be made without incurring administrative or transfer fees, if any, under the relevant Contract has been exceeded. The Companies will not exercise any right they may have under the Contracts to impose additional restrictions or fees on transfers from the Replaced Funds under the Contracts for a period of at least thirty days following the proposed substitutions.

3. The Companies shall have satisfied themselves, that (a) the Contracts allow the substitution of investment company shares in the manner contemplated by the Substitutions and related transactions described herein; (b) the transactions can be consummated as described in this Application under applicable insurance laws; and (c) that any regulatory requirements in each jurisdiction where the Contracts are qualified for sale, have been complied with to the extent necessary to complete the transactions.

Within five business days of the Effective Date of the Substitutions, the Applicants will forward to affected Contract owners a Post-Substitution Notice.

V. Conclusion

Applicants assert that, for the reasons summarized above, the requested order approving the Substitution and related transactions involving redemptions should be granted.

For the Commission, by the Division of Investment Management, pursuant to delegated authority.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 04-8567 Filed 4-14-04; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-49548; File No. SR-Amex-2004-02]

Self Regulatory Organizations; Order Granting Approval to Proposed Rule Change and Amendment No. 1 by the American Stock Exchange LLC Relating to the Listing and Trading of Notes Linked to the Performance of the Select Utility Index

April 9, 2004.

On January 8, 2004, the American Stock Exchange LLC ("Amex" or

"Exchange"), filed with the Securities and Exchange Commission ("Commission"), pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² a proposed rule change to list and trade notes, the return on which is based upon a modified market capitalization-weighted portfolio of 20 dividend paying common stocks selected from the Standard & Poor's ("S&P") Utilities Sector, as reconstituted from time to time in the manner set forth in the Amex's proposal (the "Select Utility Index"). On February 12, 2004, the Exchange filed Amendment No. 1 to the proposed rule change.³

The proposed rule change was published for comment in the *Federal Register* on February 23, 2004.⁴ The Commission received no comments on the proposal.

Based on the description of the Notes, the Select Utility Index methodology, and the listing and trading criteria set forth in the Notice, the Commission finds that the proposed rule change, as amended, is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange⁵ and, in particular, the requirements of section 6 of the Act⁶ and the rules and regulations thereunder. The Commission finds specifically that the proposed rule change is consistent with section 6(b)(5) of the Act,⁷ which requires, among other things, that the rules of an exchange be designed to facilitate transactions in securities, to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and in general to protect investors and the public interest. The Commission believes that the Amex's proposal to list

and trade notes based on the Select Utility Index gives investors exposure to the dividend paying stocks in the S&P Utilities Sector and the ability to make additional unique investment choices in a manner consistent with the requirements of section 6(b)(5)⁸ of the Act.

As described in the Notice, at maturity, the holder of a Note will receive an amount based upon the percentage change of the Select Utility Index. The Notes will not have a minimum principal amount that will be repaid and, accordingly, payments on the Notes prior to or at maturity may be less than the original issue price of the Notes. The Notes are cash-settled in U.S. dollars and do not give the holders any right to receive a portfolio security or any other ownership right or interest in the portfolio of securities comprising the Select Utility Index. As described in the Notice, the Select Utility Index is initially constituted and reconstituted in a manner to reduce market impact and provide a better process for the Issuer to hedge its market risk in connection with the Notes. While the Exchange states that there will be limited change in the component stocks of the Select Utility Index, there may be significant changes in the weightings because the market capitalization weighting is adjusted so that no one component exceeds 10%. However, the Commission finds that this initial constitution and the quarterly reconstitutions are disclosed, and the process of constitutions and reconstitutions should help to alleviate both market impact and Issuer risk.

Subject to the criteria in the Prospectus for the Notes, the Amex has sole discretion regarding changes to the Select Utility Index due to reconstitutions and adjustments to the Index and the multipliers of the individual components. Thus, the Amex is determining, calculating, and selecting the component stocks of Index based on the 20 highest combined dividends scores on the relevant determination date. Amex represents that it maintains and enforces appropriate policies and trading restrictions that address the use of non-public information by its employees, such as non-public knowledge derived in the component selection and maintenance of the Select Utilities Index.

As of April 8, 2004, the market capitalization of the securities included in the Index ranged from a high of \$22 billion to a low of \$1 billion. The average daily trading volume for these same securities for the last six (6)

months ranged from a high of 564,568 shares to a low of 124,400 shares.⁹ Given that large trading volume and capitalization of the component securities underlying the Index, the Commission believes that the listing and trading of the Notes that are linked to the Select Utility Index should not unduly impact the market for the underlying securities or raise manipulative concerns. Moreover, the issuers of the underlying securities comprising the Select Utility Index, are subject to reporting requirements under the Act, and all of the component stocks are either listing or traded on, or traded through the facilities of, U.S. securities markets. In addition, the Exchange's equity margin and trading rules will apply to the Notes. The Commission also believes that the Exchange has appropriate surveillance procedures in place to detect and deter potential manipulation for similar index-lined products. By applying these procedures to the Notes, the Commission believes that the potential for manipulation of the underlying securities is minimal, thereby protecting investors and the public interest.

Furthermore, the Commission notes that the Notes are dependant upon the individual credit of the issuer, Merrill Lynch. To some extent this credit risk is minimized by the Exchange's listing standards in Section 107A of the Company Guide which provide that only issuers satisfying substantial asset and equity requirements may issue securities such as the Notes. In any event, financial information regarding Merrill Lynch, in addition to the information on the component stocks comprising the Index, will be publicly available.¹⁰

The Commission also has a systemic concern, however, that a broker-dealer such as Merrill Lynch, or a subsidiary providing a hedge for the issuer, will incur position exposure. However, as the Commission has concluded in previous approval orders for other hybrid instruments issued by broker-dealers,¹¹ the Commission believes that this concern is minimal given the size of the Notes issued in relation to the net worth of Merrill Lynch.

Finally, the Commission notes that the value of the Index will be

⁹ Telephone Conversation between Jeffrey P. Burns, Associate General Counsel, Amex, and Florence Harmon, Senior Special Counsel, Division, Commission, on April 8, 2004.

¹⁰ The Commission notes that the component stocks that comprise the Index are reporting companies under the Act, and the Notes will be registered under Section 12 of the Act.

¹¹ See Securities Exchange Act Release No. 47983 (June 4, 2003), 68 FR 5032 (June 11, 2003).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ See Letter from Jeffrey P. Burns, Associate General Counsel, Amex, to Nancy Sanow, Assistant Director, Division of Market Regulation ("Division"), Commission, dated February 11, 2004 ("Amendment No. 1"). In Amendment No. 1, the Amex clarified its earlier comparison of the Select Utility Index proposed herein with an existing index, the Select Sector Utilities Index. The Amex also included a representation that the Exchange would consult with the Commission in the event that the number of Index components falls to ten (10) or fewer stocks.

⁴ See Securities Exchange Act Release No. 49239 (February 12, 2004), 69 FR 8245 (February 23, 2004) ("Notice").

⁵ In approving this proposed rule change, the Commission notes that it has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

⁶ 15 U.S.C. 78f.

⁷ 15 U.S.C. 78f(b)(5).

⁸ *Id.*

disseminated at least once every fifteen seconds throughout the trading day. The Commission believes that providing access to the value of the Index at least once every fifteen seconds throughout the trading day is extremely important and will provide benefits to investors in the products.

It is therefore ordered, pursuant to section 19(b)(2) of the Act,¹² that the proposed rule change (File No. SR-Amex-2004-02), as amended, be, and it hereby is, approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.¹³

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 04-8521 Filed 4-14-04; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-49547; File No. SR-NASD-2004-046]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change and Amendment No. 1 thereto by National Association of Securities Dealers, Inc. Regarding SuperMontage Postable Auto-Ex Orders

April 9, 2004.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on March 16, 2004, the National Association of Securities Dealers, Inc. ("NASD"), through its subsidiary, The Nasdaq Stock Market, Inc. ("Nasdaq"), filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been prepared by Nasdaq. On April 2, 2004, Nasdaq filed Amendment No. 1 to the proposal.³ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

¹² 15 U.S.C. 78s(b)(2).

¹³ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ See letter from John M. Yetter, Associate General Counsel, Nasdaq, to, Katherine England, Assistant Director, Division of Market Regulation ("Division"), Commission, dated April 1, 2004 ("Amendment No. 1"). In Amendment No. 1, Nasdaq clarified certain aspects of the description, proposed implementation date, and the rule text of the proposed rule change.

I. Self-Regulatory Organization's Statement of the Terms of the Substance of the Proposed Rule Change

Nasdaq proposes to modify the Auto-Ex Order of the Nasdaq National Market Execution System ("NNMS" or "SuperMontage"). Pursuant to section 19(b)(3)(A) of the Act⁴ and Rule 19b-4(f)(6) thereunder,⁵ Nasdaq has designated the proposed rule change as non-controversial. Nasdaq intends to implement the proposed rule change on or about May 17, 2004,⁶ and will inform market participants of the exact implementation date via a Head Trader Alert on <http://www.nasdaqtrader.com>.

The text of the proposed rule change is below. Proposed new language is italicized; proposed deletions are in brackets.⁷

4700. NASDAQ NATIONAL MARKET EXECUTION SYSTEM (NNMS)

4701. Definitions

Unless stated otherwise, the terms described below shall have the following meaning:

(a)-(jj) No change.

(kk) The term "Auto-Ex" shall mean, for orders in Nasdaq listed securities so designated, an order that (*except when it is displayed or interacts with a displayed Discretionary Order at a price in its discretionary price range*) will execute solely against the Quotes/Orders of NNMS Participants that participate in the automatic execution functionality of the NNMS and that do not charge a separate quote access fee to NNMS Participants accessing their Quotes/Orders through the NNMS. *An Auto-Ex Order may be designated as "Immediate or Cancel" (an "IOC Auto-Ex Order") or "Day" or "GTC" (a "Postable Auto-Ex Order"). An NNMS Participant entering a Postable Auto-Ex Order may (but is not required to) specify that the order will utilize the functionality associated with Discretionary Orders.*

(ll)-(nn) No change.

⁴ 15 U.S.C. 78s(b)(3)(A).

⁵ 17 C.F.R. 240.19b-4(f)(6).

⁶ See Amendment No. 1, *supra* note 3.

⁷ The text of the proposed rule change is shown as marked against the text of the SuperMontage rules as published in Exhibit A to Securities Exchange Act Release No. 49349 (March 2, 2004), 69 FR 10775 (March 8, 2004) (SR-NASD-2004-149). It should be noted, however, that such Exhibit A contained a minor technical error, in that it did not accurately reflect the text of Amendment Nos. 2 and 3 to SR-NASD-2003-143, as approved by the Commission in Securities Exchange Act Release No. 49020 (January 5, 2004), 69 FR 1769 (January 12, 2004) (SR-NASD-2003-143). Accordingly, this proposed rule change includes several additions and deletions to restore changes made through Amendment Nos. 2 and 3 to SR-NASD-2003-143. See Amendment No. 1, *supra* note 3.

(oo) Reserved.

(pp)-(uu) No change.

* * * * *

4706. Order Entry Parameters

(a) Non-Directed Orders—

(1) General. The following requirements shall apply to Non-Directed Orders Entered by NNMS [Market] Participants:

(A)-(B) No change.

(1)-(3) No change.

(4) Starting at 7:30 a.m., until the 4 p.m. market close, IOC and Day Non-Directed Orders may be entered into NNMS (or previously entered orders cancelled), but such orders entered prior to market open will not become available for execution until 9:30 a.m. Eastern Time. GTC orders may be entered (or previously entered GTC orders cancelled) between the hours 7:30 a.m. to 6:30 p.m. Eastern Time, but such orders entered prior to market open, or GTC orders carried over from previous trading days, will not become available for execution until 9:30 a.m. Eastern Time. Exception: For Nasdaq listed securities only, Non-Directed Day (other than Pegged, *Postable Auto-Ex*, and Discretionary Orders) and GTC orders (*other than Postable Auto-Ex Orders*) may be executed prior to market open if required under Rule 4710(b)(3)(B).

(5) [f] For Nasdaq listed securities, an order may be designated as "Auto-Ex," in which case the order *may* [will also automatically] be designated as IOC[,], Day or GTC. [An Auto-Ex Order will execute solely against the Quotes/Orders of NNMS Participants at the best bid/best offer that participate in the automatic execution functionality of the NNMS and that do not charge a separate quote-access fee to NNMS Participants accessing their Quotes/Orders through the NNMS.] *If an NNMS Participant entering a Postable Auto-Ex Order specifies that the order will utilize the functionality associated with Discretionary Orders, the order will automatically be designated as Day.*

(6)-(12) No change.

(C)-(E) No change.

(F) An NNMS [Market] Participant may enter a Non-Directed

Order that is either a market order or a limit order prior to the market's open. Market orders and limit orders designated as Immediate or Cancel, [and] limit orders designated as Total Immediate or Cancel, *Auto-Ex Orders*, and Discretionary Orders whose displayed price or discretionary price range would lock or cross another Quote/Order if they were displayed orders shall be held in a time-priority queue that will begin to be processed by

NNMS at market open. If an Immediate or Cancel limit order is unmarketable at the time it reaches the front of the time-priority processing queue, it will be returned to the entering market participant. Limit orders that are not designated as Immediate or Cancel orders shall be retained by NNMS for potential display in conformity with Rule 4707(b) and/or potential execution in conformity with Rule 4710(b)(1)(B).

(2) Entry of Non-Directed Orders by NNMS Order Entry Firms—In addition to the requirements in paragraph (a)(1) of this rule, the following conditions shall apply to Non-Directed Orders entered by NNMS Order Entry Firms:

(A) (i) All Non-Directed orders in Nasdaq listed securities shall be designated as Immediate or Cancel, GTC or Day but shall be required to be entered as Non-Attributable if not entered as IOC. NNMS Order Entry Firms may designate orders as "Pegged" or "Discretionary," in which case the order will also automatically be designated as Day. NNMS Order Entry Firms may also designate orders as "Auto-Ex," in which case the order may be designated as IOC, Day or GTC. If an NNMS Order Entry Firm entering a Postable Auto-Ex Order specifies that the order will utilize the functionality associated with Discretionary Orders, the order will automatically be designated as Day. For IOC orders, if after entry into the NNMS of a Non-Directed Order that is marketable, the order (or the unexecuted portion thereof) becomes non-marketable, the system will return the order (or unexecuted portion thereof) to the entering participant.

(ii) No change.

(B) A Non-Directed Order that is either a market or limit order may be entered prior to the market's open. Limit and market orders designated as Immediate or Cancel or, in the case of ITS Securities, IOX, Auto-Ex Orders, and Discretionary Orders [or, in the case of ITS Securities, IOX,] whose displayed price or discretionary price range would lock or cross another Quote/Order if they were displayed will be held in a time-priority queue that will begin to be processed at market open. A limit order that is designated as IOC or, in the case of ITS Securities, IOX, and that is not marketable at the time it reaches the front of the time-priority processing queue will be returned to the entering participant.

(b)-(e) No change.

* * * * *

4710. Participant Obligations in NNMS

(a) No change.

(b) Non-Directed Orders

(1) No change.

(A) No change.

(B) No change.

(i) No change.

(ii) Exceptions—The following exceptions shall apply to the above execution parameters:

a.-c. No change.

[(d)] d. An Auto-Ex O[O]rder in a Nasdaq listed security that is designated IOC will [execute] interact solely [against] with the Quotes/Orders of NNMS Participants [at the best bid/best offer] that participate in the automatic execution functionality of the NNMS and that do not charge a separate quote-access fee to NNMS Participants accessing their Quotes/Orders through the NNMS ("Auto-Ex Eligible Participants"). An IOC Auto-Ex Order will not interact with the Quote/Order of an Auto-Ex Eligible Participant if the Quote/Order of an NNMS Participant that is not an Auto-Ex Eligible Participant is priced better than the Quote/Order of any Auto-Ex Eligible Participant at that time. An IOC Auto-Ex O[O]rder (or an unexecuted portion thereof) will be cancelled if it cannot be immediately executed.

Upon entry into the NNMS, a Postable Auto-Ex Order will be processed in the same manner as an IOC Auto-Ex Order; provided, however, that if the Postable Auto-Ex Order includes discretionary prices, the order will be processed in the same manner as a Discretionary Order, but will interact solely with the Quotes/Orders of Auto-Ex Eligible Participants and will not interact with the Quote/Order of an Auto-Ex Eligible Participant if the Quote/Order of an NNMS Participant that is not an Auto-Ex Eligible Participant is priced better than the Quote/Order of any Auto-Ex Eligible Participant at that time. Any portion of a Postable Auto-Ex Order that cannot be immediately executed will be displayed, unless it would lock or cross the Quote/Order of an NNMS Participant that is not an Auto-Ex Eligible Participant, in which case the Postable Auto-Ex Order (or any unexecuted portion thereof) will be cancelled. Depending on the functionality specified by the NNMS Participant entering the order, a Postable Auto-Ex Order that is displayed will have the same characteristics and be subject to the same rules as a regular limit order or a Discretionary Order.

For purposes of this subclause d., any displayed Discretionary Order that may be executed against (or delivered to) an Auto-Ex Order at a price in the Discretionary Order's discretionary price range will be deemed to have been entered by an Auto-Ex Eligible Participant.

e. No change.

(C)-(D) No change.

(2)-(8) No change.

(c)-(e) No change.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, Nasdaq included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. Nasdaq has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Commission recently approved a new SuperMontage order type, known as the Auto-Ex Order,⁸ which executes solely against the Quotes/Orders of SuperMontage participants that participate in the system's automatic execution functionality and that do not charge a separate quote-access fee to participants accessing their Quotes/Orders through SuperMontage ("Auto-Ex Eligible Participants"). Auto-Ex Orders access liquidity available at multiple price levels, but do not "trade through" the Quote/Order of an Order-Delivery ECN (or an auto-ex ECN that charges an access fee). Thus, an Auto-Ex Order is now automatically designated Immediate or Cancel ("IOC"), and the order (or any unexecuted portion thereof) is cancelled whenever the best price available through SuperMontage solely reflects the Quote/Order of a market participant that is not eligible to receive the Auto-Ex Order.

Nasdaq is proposing to provide market participants with the option of designating Auto-Ex Orders as "Day" or "Good-till-Cancelled" orders ("Postable Auto-Ex Orders"). A Postable Auto-Ex Order would initially be processed in the same manner as an IOC Auto-Ex Order. Once all liquidity available from Auto-Ex Eligible Participants has been accessed, the order may then be eligible for display. However, the order will be cancelled, rather than displayed, if its price would lock or cross the Quote/Order of a market participant that is not an Auto-Ex Eligible Participant. For

⁸ See Securities Exchange Act Release No. 49020 (January 5, 2004), 69 FR 1769 (January 12, 2004) (SR-NASD-2003-143).

example, if the best offer in Nasdaq was \$20.05 and a market participant entered a Day Auto-Ex Order to buy at \$20.05, the order would access all liquidity offered by Auto-Ex Eligible Participants at \$20.05, and if there was no offer at that price level from a market participant that was not an Auto-Ex Eligible Participant, the order (or unexecuted portion thereof) would be displayed at \$20.05. However, if an Order-Delivery ECN (or an auto-ex ECN that charges an access fee) had an offer at \$20.05 displayed in SuperMontage, the Postable Auto-Ex Order (or unexecuted portion thereof) would be cancelled, because it would lock the ECN's offer if it were displayed. Once a Postable Auto-Ex Order is displayed as a Quote/Order, it may interact with trading interest entered by any NNMS Participant, including participants that are not Auto-Ex Eligible Participants.

Postable Auto-Ex Orders may be entered (but not displayed or executed) prior to market open. Such orders will be held in a time-priority queue (along with IOC orders and executable Discretionary Orders) and processed by the NNMS at 9:30. Nasdaq believes that this limitation on the use of Postable Auto-Ex Order functionality in the period before the market open is logical, since automatic executions are not available before 9:29:30 in any event. If Postable Auto-Ex Orders entered before this time were not queued, they would, in almost all circumstances, be processed like regular Day or Good-Till-Cancelled orders; accordingly, Nasdaq expects that there would be little use of the order type prior to 9:30 if the order were displayable in the period before the market open.⁹ By queuing Postable Auto-Ex Orders entered before 9:30, Nasdaq will allow market participants to obtain rapid executions at market open, followed by the immediate cancellation or posting of size that cannot be immediately executed.

The Postable Auto-Ex Order can be combined with the functionality associated with Discretionary Orders. Such an order will be processed like a regular Discretionary Order prior to posting, except that it will not be delivered to the Quotes/Orders of Order-Delivery ECNs (or access-fee charging ECNs). Like a regular Auto-Ex Order, however, the order may not execute at a price worse than a price available from an Order-Delivery (or access fee-charging) ECN, and would cancel if it could not be posted without locking or crossing such an ECN. Accordingly, since a Discretionary Order seeks to execute at multiple prices before

posting, a Postable Auto-Ex Order with discretionary prices would be more likely to cancel prior to posting than a Postable Auto-Ex Order with a single price. If, however, the order can be posted, it will be subject to the same terms and conditions as any other Discretionary Order after it is posted.

The filing also clarifies the manner in which an Auto-Ex Order may interact with a displayed Discretionary Order. Specifically, because a displayed Discretionary Order that is executable at a price in its discretionary price range is executed automatically or delivered based on the status of its potential contra party, rather than the status of the participant that entered the order, the Discretionary Order may execute against (or be delivered to) an incoming Auto-Ex Order even if the Discretionary Order was not posted by an Auto-Ex Eligible Participant. By contrast, if the Auto-Ex Order is executable against a Discretionary Order at its displayed price, the extent to which the orders may interact depends on whether the participant that entered the Discretionary Order is an Auto-Ex Eligible Participant.

2. Statutory Basis

Nasdaq believes that the proposed rule change is consistent with the provisions of section 15A of the Act,¹⁰ in general, and with section 15A(b)(6) of the Act,¹¹ in particular, in that it is designed to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. The proposed rule change will provide market participants with a voluntary tool that will allow them to access liquidity available through SuperMontage quickly and at a low cost and subsequently to offer liquidity.

B. Self-Regulatory Organization's Statement on Burden on Competition

Nasdaq does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act, as amended.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing of Commission Action

The foregoing rule change has become effective pursuant to section 19(b)(3)(A) of the Act,¹² and subparagraph (f)(6) of Rule 19b-4,¹³ thereunder because it does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate. At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.¹⁴

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549-0609. Comments should be submitted electronically at the following e-mail address: rule-comments@sec.gov. All comment letters should refer to File No. SR-NASD-2004-046. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, comments should be sent in hard copy or by e-mail but not by both methods. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the

¹⁰ 15 U.S.C. 78o-3.

¹¹ 15 U.S.C. 78o-3(b)(6).

¹² 15 U.S.C. 78s(b)(3)(A).

¹³ 17 CFR 240.19b-4(f)(6).

¹⁴ For the purposes of calculating the 60-day abrogation period, the Commission considers the proposed rule change to have been filed on April 2, 2004, the date Nasdaq filed Amendment No. 1.

⁹ See Amendment No. 1, *supra* note 3.

public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refer to File No. SR-NASD-2004-046 and should be submitted by May 6, 2004.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority,¹⁵

Margaret H. McFarland,
Deputy Secretary.

[FR Doc. 04-8520 Filed 4-14-04; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-49550; File No. SR-PCX-2004-24]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Pacific Exchange, Inc. Relating to Exchange Fees and Charges

April 9, 2004.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on March 26, 2004, the Pacific Exchange, Inc. ("PCX" or "Exchange") filed with the Securities and Exchange Commission ("SEC" or "Commission") the proposed rule change as described in items I, II, and III below, which items have been prepared by PCX. PCX filed the proposed rule change pursuant to section 19(b)(3)(A) of the Act³ and Rule 19b-4(f)(2) thereunder,⁴ which renders the proposal effective upon filing with the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

PCX, through its wholly owned subsidiary, PCX Equities, Inc. ("PCXE"), is proposing to amend its PCXE Schedule of Fees and Charges ("Schedule") in order to amend the statutory disqualification application fee. The text of the proposed rule change is available at the principal

office of the PCX and at the Commission.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, PCX included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in item IV below. PCX has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

PCX is proposing to amend the PCXE statutory disqualification fee. On December 12, 2003, the Exchange filed a proposal with the Commission to amend the PCX statutory disqualification application fee for its Options Members, which became effective upon filing.⁵ In that rule proposal, the Exchange proposed to amend the PCX statutory disqualification fee to \$2,000 for all applications resulting in statutory disqualification proceedings. PCX previously assessed \$250 to process applications for approved status despite grounds for statutory disqualification. In order to bring this fee up to the competitive levels of other SROs, PCX proposed to increase the fee to \$2,000 and assess the fee for all applications resulting in statutory disqualification proceedings.⁶ Hence, the fee would not be assessed unless the review of the application reveals that such a proceeding is necessary. The Exchange now proposes to amend the equivalent statutory disqualification application fee for PCXE, as the application procedures are identical for its PCX Members and PCXE ETP Holders.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with section 6(b) of the Act,⁷ in general, and section 6(b)(4) of the Act,⁸ in particular, in that it provides for the equitable

allocation of reasonable dues, fee, and other charges among its members.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange has neither solicited nor received written comments on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to section 19(b)(3)(A)(ii) of the Act⁹ and Rule 19b-4(f)(2) thereunder because it establishes or changes a due, fee or other charge imposed by the Exchange. At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate the rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549-0609. Comments should be submitted electronically at the following e-mail address: rule-comments@sec.gov. All comment letters should refer to File No. SR-PCX-2004-24. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, comments should be sent in hard copy or by e-mail but not by both methods. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than

⁵ See Release No. 34-48971 (Dec. 22, 2003), 68 FR 75307 (Dec. 30, 2003) (SR-PCX-2003-69).

⁶ See Chicago Board Options Exchange, Inc. ("CBOE") Fee Schedule, Appendix A. The CBOE assesses a \$2,700 fee for applications resulting in statutory disqualification proceedings.

⁷ 15 U.S.C. 78f(b).

⁸ 15 U.S.C. 78f(b)(4).

⁹ 15 U.S.C. 78s(b)(3)(A)(ii).

¹⁵ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ 15 U.S.C. 78s(b)(3)(A).

⁴ 17 CFR 240.19b-4(f)(2).

those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the PCX. All submissions should refer to File No. SR-PCX-2004-24 and should be submitted by May 6, 2004.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.¹⁰

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 04-8566 Filed 4-14-04; 8:45 am]

BILLING CODE 8010-01-P

DEPARTMENT OF STATE

[Public Notice 4687]

Bureau of Educational and Cultural Affairs Request for Grant Proposals: Africa Workforce Development

SUMMARY: The Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs (ECA), United States Department of State, announces an open competition for grants to support a series of exchange and partnership development programs promoting "Africa Workforce Development." U.S. public and private non-profit organizations meeting the provisions described in Internal Revenue Code section 26 U.S.C. 501(c)(3) may submit proposals to develop and implement exchanges involving participants from Sub-Saharan Africa. These U.S. organizations should demonstrate relevant expertise on Sub-Saharan Africa and be able to show the commitment of a partner in that region for development of the program design as well as its implementation. The FY-2004 Consolidated Appropriations Act (PL 108-199) earmarks \$400,000 to support Africa Workforce Development Exchanges. ECA anticipates awarding up to three grants of approximately \$133,000 each under this competition. Based upon the results of a similar competition conducted in FY-2002, it is anticipated that this will be an intense competition. In FY-2002, two grants totaling approximately \$300,000 were awarded to support this initiative out of a total of 16 proposals reviewed. Proposals that clearly demonstrate significant cost sharing—with 20% of the amount requested from ECA as the preferred minimum target—will be

judged more competitive. Deadline for post marking submissions is Friday, May 28, 2004.

Important Note: This Request for Grant Proposals contains language in the "Shipment and Deadline for Proposals" section that is significantly different from that used in the past. Please pay special attention to procedural changes as outlined.

Program Information

Overview: The Bureau seeks both to promote workforce development in Africa and mutual understanding between Africans and Americans through exchange programs linking U.S. specialists on workforce development with African counterparts seeking to upgrade the African workforce. A U.S.-African partnership approach is requested to emphasize benefits for both sides and to promote sustainability of effort. Proposals should show learning and contribution on both sides, and there should be roughly equal numbers of persons traveling to and from the U.S. The partnership approach should also help to build a network of counterpart institutions in the U.S. and Africa which invigorate and inform each other, enable collaborations and joint projects, and promote the exchange of information and resources.

The Bureau encourages applicants to consider carefully the choice of target countries. In order to prevent duplication of effort, applicants should research the work of development agencies (such as USAID and UN agencies) on the target themes, and select countries for which there has been limited investment on the issue. Applicants are welcome to contact the Public Affairs Sections (PAS) in U.S. Embassies in Africa, and the Office of Citizen Exchanges in Washington, DC, to discuss proposed activities and their relevance to mission priorities.

Applicants may design single-country or multiple-country projects; however proposals should focus on one or two countries rather than a large group so as to maximize impact with a definable population. The Bureau offers the following programming ideas and suggestions.

Africa Workforce Development: The purpose of this program is to enhance workforce development efforts in Sub-Saharan Africa through professional exchanges that also build mutual understanding between Africans and Americans. Proposals should plan to pursue all of the following purposes: (a) Conduct an analysis of workforce needs in a specified population, (b) develop a strategy to address some of those needs, and (c) carry out enough activities in the strategy to assess its value and (d) lead

to refinements and sustainability. In developing and carrying out such a program, we encourage the use of electronic information technologies both as a vehicle for correspondence and training and as a workforce skill to be taught.

The Office realizes that there are many different conceptions of and approaches to workforce development and realizes that the challenge of workforce development is not likely to be addressed fully in rather small exchange programs such as anticipated here. Thus, it will be important for each grant proposal to present a vision for workforce development for a defined population, but then stipulate a specific and manageable set of objectives to be pursued, the activities to be conducted in that pursuit, and performance indicators to be used in measuring progress. While ECA is open to considering a wide variety of program plans, the Bureau will give priority to proposals that do the following:

- Assist citizens in making the transition from academic studies to participation in the workforce;
- Assist citizens in learning skills and attitudes which make them more employable;
- Guide citizens in seeking jobs and in carrying them out satisfactorily;
- Provide training in information technology;
- Develop programs which can be delivered online as well as in person;
- Develop programs which are adaptable to local and individual needs;
- Develop programs which are easily portable and can be replicated in different venues; and
- Develop programs which will attract and maintain the attention of citizens, encouraging their initiative and commitment.

While all of Sub-Saharan Africa is eligible in this solicitation, proposals should focus on one or two countries rather than a large group so as to maximize impact in an observable manner.

In order to assess the capability and long-term commitment of African partners, applicants should consider the possibility of selecting their partners through a competitive process.

Project Guidelines

The Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs (ECA) consults with and supports American public and private nonprofit organizations in developing and implementing multi-phased, often multi-year, exchanges of professionals, community leaders, scholars, public policy advocates, etc. These exchanges

¹⁰ 17 CFR 200.30-3(a)(12).

address issues of critical importance to both the United States and to the countries with which the exchanges will be conducted. They encourage substantive and cooperative interaction among counterparts, and they entail both theoretical and experiential learning for all participants. An important goal is the development of sustained, international institutional and individual linkages. In addition to providing a context for professional development and collaborative problem solving, these projects are intended to introduce participants to one another's political, social, and economic structures, facilitating improved communication and enhancing mutual understanding.

Applicants should state expected goals and objectives in the proposal narrative and describe a clear and convincing plan for carrying out a coherent sequence of activities to fulfill them. The Office is particularly interested in grantees measuring and evaluating achievement of goals and objectives. This purpose is described in greater detail in the Review Criteria section of this RFGP.

Suggested activities might include:

1. (If necessary) Initial travel by American organizers for needs assessment, orientation, planning or training to develop contacts and relationships with both American diplomatic mission officers and counterpart organizations/individuals through which the exchange activities will be conducted, and to provide initial consultation and training for African participants.
2. First program session in the African target country (may coincide with needs assessment). American professionals and African partners extend their planning and analysis of needs and conduct (perhaps) training sessions on the subject of their exchange project, and select African participants for further consultation in the U.S.
3. A U.S.-based program, including orientation for African participants to program purposes and to U.S. society, discussions on U.S. approaches and strategy, site visits, additional training of trainers, or limited internships or job shadowing opportunities. This phase might also develop specific action plans to be pursued in the next phase.
4. A return visit by American specialists to collaborate with African participants from the U.S.-based program in conducting additional workshops, seminars, on-site training or other activities.
5. Planning and training programs carried out in the African target country on Workforce Development led by the

Africans who have received training in the U.S.

6. Distance learning techniques using appropriate technology and activities meant to bridge the digital divide are also encouraged to the extent possible.

This program is *not* primarily academic in nature; it should explain, set and carry out practical activities in pursuit of workforce development. The Office of Citizen Exchanges encourages applicants to be creative and innovative in planning projects. Activities may combine elements of skill enrichment, theoretical orientation, and experiential, community-based initiatives designed to achieve objectives. Activities should provide participants an opportunity to experience each other's culture and may include activities or events hosted by local institutions and home stays with community members.

Eligibility: U.S. public and private non-profit organizations meeting the provisions described in IRS regulation 26 CFR 1.501(c)(3) are eligible to apply. All proposals will receive equal consideration.

Selection of Participants: Proposals should include a description of an open, merit-based participant selection process for all program components requiring selection of individual participants. A draft application form and a sample announcement used for recruitment advertising should be included. For travel to the U.S., priority should be given to participants who have not previously traveled to the United States.

Public Affairs Section Involvement: The Public Affairs Section (PAS) of U.S. Embassies in participating African countries will play an important role in project implementation. These posts will evaluate project proposals, monitor planning between the grantee organization and in-country partners, facilitate in-country activities, nominate participants and vet grantee nominations, observe in-country activities when feasible, debrief participants, and evaluate project impact. Applicants should expect to work closely with the PAS in the target country in selecting participants, and all African exchange participants traveling to the U.S. must be approved by the Embassies. The Embassies retain the right to nominate participants and to advise the grantee regarding participants recommended by other entities.

Embassies will work with grantee organizations to assist Africans nominated for international travel in obtaining the necessary J-1 visas for entry into the United States. Although project design, administration and implementation are the responsibility of

the grantee, the grantee is expected to inform the Embassies of its operations and procedures and to coordinate with and involve PAS officers in the development of project activities. The PAS should be consulted regarding country priorities, political and cultural sensitivities, current security concerns, scheduling, and related logistic and programmatic issues.

Adherence to All Regulations Governing the J Visa

In compliance with the terms of 22 CFR 62, which covers the administration of the Exchange Visitor Program (J visa program), the Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs will be the official program sponsor of exchange programs resulting from this solicitation, and an employee of the Bureau will be the "Responsible Officer" for the program. Under the terms of 22 CFR part 62, organizations receiving grants under this RFGP will be third parties "cooperating with or assisting the sponsor in the conduct of the sponsor's program." The actions of grantee program organizations shall be "imputed to the sponsor in evaluating the sponsor's compliance with" 22 CFR part 62. Therefore, the Bureau expects that any organization receiving a grant under this competition will render all assistance necessary to enable the Bureau to fully comply with 22 CFR part 62 *et seq.* The Bureau of Educational and Cultural Affairs places great emphasis on the secure and proper administration of Exchange Visitor (J visa) Programs and adherence by grantee program organizations and program participants to all regulations governing J visa programs. Therefore, proposals should state that the applicant is prepared to assist the Bureau in meeting all requirements governing the administration of Exchange Visitor Programs as set forth in 22 CFR part 62. If the applicant has experience as a designated Exchange Visitor Program Sponsor, the applicant should discuss its record of compliance with 22 CFR part 62 *et seq.*, including oversight of their Responsible Officers and Alternate Responsible Officers, screening and selection of program participants, provision of pre-arrival information and orientation to participants, monitoring of participants, proper maintenance and security of forms, record-keeping, reporting and other requirements. The Office of Citizen Exchanges of ECA will be responsible for issuing the DS-2019 forms to participants in this program. A copy of the complete regulations governing the administration of Exchange Visitor (J) programs is

available at <http://exchanges.state.gov> or from: United States Department of State, Office of Exchange Coordination and Designation, ECA/EC/ECD—SA—44, Room 734, 301 Fourth Street, SW., Washington, DC 20547, Telephone: (202) 401-9810, FAX: (202) 401-9809.

Budget Guidelines

The Bureau expects to award up to three grants, not exceeding \$133,000 each, to support program and administrative costs required to implement exchange programs under this competition. Applicants must submit a comprehensive line-item budget based on guidance provided in the Proposal Submission Instructions (PSI) of the Solicitation Package. Grants awarded to organizations with less than four years of experience in conducting international exchange programs will be limited to \$60,000. Proposals which clearly demonstrate a significant cost-sharing—with 20% of the amount requested from ECA as the preferred minimum target—will be judged more competitive. For example, an organization requesting \$133,000 would be more competitive if the proposal presents at least \$26,600 in allowable cost sharing, so that the total program value would be at least \$159,600.

Allowable costs include the following:

(1) Direct Program Expenses (including general program expenses, such as orientation and program-related supplies, educational materials, consultants, interpreters, room rental, and evaluation; and participant program expenses, such as medical screening, domestic and international travel and per diem)

(2) Administrative Expenses, including indirect costs (*i.e.*, salaries, telephone/fax, and other direct administrative costs)

(3) Travel costs for visa processing purposes: All foreign participants funded by any grant agreement resulting from this competition must travel on J-1 visas. Failure to secure a J-1 visa for the foreign participant will preclude charging the participant's cost to the grant agreement. Participants will apply for J-1 visas only after the Office of Citizen Exchanges and the mission Public Affairs Section or consulate have approved their participation in this program. The Office of Citizen Exchanges will issue DS-2019 forms and deliver to foreign program participants through the mission Public Affairs Section. All J visas for African program visitors must be issued by the consular offices in the target country, so proposals should include costs for potential participants to travel to those

offices to pick up DS-2019 forms and for visa interviews and processing.

Please refer to the Solicitation Package for complete budget guidelines and formatting instructions. Instructions for downloading the Solicitation Package are provided below.

Announcement Title and Number

All correspondence with the Bureau concerning this RFGP should reference the above title and number: ECA/PE/C/NEA-AF-04-57.

To Download a Solicitation Package Via Internet

The entire Solicitation Package (Request for Grant Proposal and Proposal Submission Instructions), may be downloaded from the Bureau's Web site: <http://exchanges.state.gov/education/rfgps>.

Please read all information before downloading. If you are unable to download the Solicitation Package from the Department of State ECA Web site, you may request a copy, which contains required application forms, specific budget instructions, and standard guidelines for proposal preparation, from the Office of Citizen Exchanges.

New OMB Requirement

An OMB policy directive published in the **Federal Register** on Friday, June 27, 2003, requires that all organizations applying for Federal grants or cooperative agreements must provide a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number when applying on or after October 1, 2003. The complete OMB policy directive can be referenced at http://www.whitehouse.gov/omb/fedreg/062703_grant_identifier.pdf. Please also visit the ECA Web site at <http://exchanges.state.gov/education/rfgps/menu.htm> for additional information on how to comply with this new directive.

FOR FURTHER INFORMATION CONTACT: The Office of Citizen Exchanges, ECA/PE/C/NEA-AF, U.S. Department of State, 301 Fourth St., SW., Room 216, Washington, DC 20547, Attention: Jim Ogul; Telephone number: 202/205-0535; fax number: 202/619-4350; Internet e-mail address: ogulje@state.gov.

Organizations planning to submit proposals are encouraged to contact the program office for consultation. Before doing so, applicants should read the complete **Federal Register** announcement and be prepared to discuss concrete matters specific to the guidelines set forth in this request for grant proposals (RFGP). Once the RFGP deadline has passed, Bureau staff may not discuss this competition with

applicants until the proposal review process has been completed.

Shipment and Deadline for Proposals

Important Note: The deadline for postmarking proposals in this competition is Friday, May 28, 2004. In light of recent events and heightened security measures, proposal submissions must be made via a nationally recognized overnight delivery service (*i.e.*, DHL, Federal Express, UPS, Airborne Express, or U.S. Postal Service Express Overnight Mail, *etc.*) and be shipped no later than the above deadline.

The delivery services used by applicants must have in-place, centralized shipping identification and tracking systems that may be accessed via the Internet and delivery people who are identifiable by commonly recognized uniforms and delivery vehicles. Proposals shipped on or before the above deadline but received at ECA more than seven days after the deadline will be ineligible for further consideration under this competition. Proposals shipped after the established deadline will be ineligible for consideration under this competition. It is each applicant's responsibility to ensure that each package is marked with a legible tracking number and to monitor and confirm delivery to ECA. Delivery of proposal packages may not be made via local courier service or in person for this competition. Faxed documents will not be accepted at any time. Only proposals submitted as stated above will be considered.

Applicants must follow all instructions in the Solicitation Package. The original and 9 copies of the proposal should be sent to: U.S. Department of State, SA-44, Bureau of Educational and Cultural Affairs, Ref.: ECA/PE/C/NEA-AF-04-57, Program Management, ECA/EX/PM, Room 534, 301 Fourth St., SW., Washington, DC 20547. Applicants must also submit the "Executive Summary," "Proposal Narrative," and "Budget" sections of the proposal in text (.txt) format on a PC-formatted disk. ECA will transmit these files electronically to the Public Affairs Sections of the relevant U.S. Embassies for review.

Diversity, Freedom and Democracy Guidelines

Pursuant to ECA's authorizing legislation, programs must maintain a non-political character and should be balanced and representative of the diversity of American political, social, and cultural life. "Diversity" should be interpreted in the broadest sense and encompass differences including, but not limited to ethnicity, race, gender, religion, geographic location, socio-

economic status, and physical challenges. Applicants are strongly encouraged to adhere to the advancement of this principle both in program administration and in program content. Please refer to the review criteria under the "Support for Diversity" section for specific suggestions on incorporating diversity into the total proposal. Public Law 104-319 provides that "in carrying out programs of educational and cultural exchange in countries whose people do not fully enjoy freedom and democracy," the Bureau "shall take appropriate steps to provide opportunities for participation in such programs to human rights and democracy leaders of such countries." Public Law 106-113 requires that the governments of the countries described above do not have inappropriate influence in the selection process. Proposals should reflect advancement of these goals in their program contents, to the full extent deemed feasible.

Review Process

The Bureau will acknowledge receipt of all proposals and will review them for technical eligibility. Proposals will be deemed ineligible if they do not fully adhere to the guidelines stated herein and in the Solicitation Package. All eligible proposals will be reviewed by the Program Office, as well as by Public Affairs Sections from target countries in Sub-Saharan Africa, and the State Department's Africa Area Public Diplomacy office. Eligible proposals will be forwarded to panels of State Department officers for advisory review. Proposals may also be reviewed by the Office of the Legal Advisor or by other Department elements. Final funding decisions are at the discretion of the Department of State's Assistant Secretary for Educational and Cultural Affairs. Final technical authority for assistance awards (grants or cooperative agreements) resides with the Bureau's Grants Officer.

Review Criteria

Technically eligible applications will be competitively reviewed according to the criteria stated below. These criteria are not rank-ordered and all carry equal weight in proposal evaluation.

1. *Quality of Program Idea:* Proposals should be substantive, coherent, focused on issues of demonstrable relevance to proposed participants and objectives, and responsive to the program suggestions and guidelines described above. Specific goals and subsidiary objectives should be delineated which are achievable and relevant to African workforce development. Both workforce

development in Africa and mutual understanding between Americans and Africans should be pursued.

2. *Implementation Plan and Ability to Achieve Objectives:* A detailed implementation plan should establish a clear and logical connection between the interest, the expertise, and the logistic capacity of the applicant and the objectives to be achieved. In order to facilitate program planning and later evaluation, each objective delineated should be specifically linked to a program goal, should be attainable in a specified time frame, and should be observable directly or indirectly. The proposal should explain, in concrete terms, how the institution plans to achieve the objectives. Institutional resources—including personnel—assigned to the project should be adequate and appropriate. The substance of workshops and site visits should be spelled out, and the responsibilities of U.S. participants and in-country partners should be clearly described. There should be roughly equal numbers of Americans going to Africa and Africans coming to the U.S. in this program.

3. *Multiplier Effect/Impact:* Proposed programs should show an expansion of impact from direct participants to a wider population, strengthen long-term mutual understanding, and advance maximum sharing of information and establishment of sustainable institutional and individual linkages.

4. *Institution's Record/Ability:* Proposals should include an institutional record of successful exchange programs, with reference to responsible fiscal management and full compliance with reporting requirements.

5. *Cost Effectiveness:* Administrative costs should be kept to a minimum, and all budgetary line items should be reasonable and allowable.

6. *Cost Sharing:* Proposals which clearly demonstrate significant cost sharing—with 20% of the amount requested from ECA as the preferred minimum target—will be judged more competitive. Cost sharing may be provided through in-cash and in-kind contributions from the U.S. and partner organization(s).

7. *Program Evaluation:* The Office of Citizen Exchanges is giving greater attention to program evaluation than before in order to better determine program impact and to help in selecting future program designs for support. Proposals should spell out a plan to evaluate both implementation and outcome of the proposed program, and we urge the employment of an independent, expert evaluator. There

should be an assessment of each major activity or phase of the program and a summary evaluation of impact conducted six months or more after the end of other program activities.

Successful evaluation depends heavily on setting clear goals and objectives at the outset of a program. The more that objectives are "smart" (specific, measurable, attainable, results-oriented, and placed in a reasonable time frame), the easier it will be to track and assess impact. In addition at the outset, a standard or target of acceptable performance should be proposed for each objective.

Although some exchange program goals and objectives may be difficult to quantify, we urge applicants to identify indicators and observational techniques to associate with all objectives so that program progress and outcome can be observed. Evaluation should distinguish between program outputs (*i.e.*, the number of activities or participants that are supported) and program outcomes or results (*e.g.*, changes in knowledge, skill, behavior, policies, *etc.*, which result from the program).

For evaluating results, one approach might be to state objectives in behavioral terms with outcome measured by behavioral changes. Another approach might assess changes in knowledge and skill and attitude through comparison of test results at the beginning and at the end of a set of program activities. Yet another approach might compare the knowledge, behavior, or attitudes of participants in the program with a similar group that did not participate in it. Overall, an evaluation plan will be judged more satisfactory the more that it specifies (a) a distinct population with which to work, (b) a manageable set of workforce development objectives and time line for that population, (c) clear descriptions of performance indicators for each objective, (d) measurement tools for collecting data, (e) a methodology for aggregating observations, and (f) inference strategies for interpreting data. We recommend providing draft evaluation instruments such as questionnaires.

8. *Support of Diversity:* Proposals should demonstrate an understanding and support of ECA's policy on diversity. Program content (orientation, evaluation, program sessions, resource materials, follow-on activities) and program administration (selection process, orientation, evaluation) should address diversity in a comprehensive and relevant manner. A program may be designed for a narrowly defined audience (*e.g.*, rural women with no more than primary education) if there is

a rationale in choosing such targeting and a program plan which respects the Bureau's policy on diversity. Applicants should refer to ECA's Diversity, Freedom and Democracy Guidelines on page four of the Proposal Submission Instructions (PSI).

Authority

Overall grant-making authority for this program is contained in the Mutual Educational and Cultural Exchange Act of 1961, Public Law 87-256, as amended, also known as the Fulbright-Hays Act. The purpose of the Act is "to enable the Government of the United States to increase mutual understanding between the people of the United States and the people of other countries; to strengthen the ties which unite us with other nations by demonstrating the educational and cultural interests, developments, and achievements of the people of the United States and other nations and thus to assist in the development of friendly, sympathetic and peaceful relations between the United States and other countries of the world."

Notice

The terms and conditions published in this RFGP are binding and may not be modified by any Bureau representative. Explanatory information provided by the Bureau or program officers that contradicts published language will not be binding. Issuance of the RFGP does not constitute an award commitment on the part of the U.S. Government. The Bureau reserves the right to reduce, revise, or increase proposal budgets in accordance with the needs of the program and the availability of funds. Awards made will be subject to periodic reporting and evaluation requirements. Organizations will be expected to cooperate with the Bureau in evaluating their programs under the principles of the Government Performance and Results Act (GPRA) of 1993, which requires federal agencies to measure and report on the results of their programs and activities.

Notification

Final awards cannot be made until funds have been appropriated by Congress, allocated and committed through internal Bureau procedures.

Dated: April 6, 2004.

C. Miller Crouch,

Principal Deputy Assistant Secretary, Bureau of Educational and Cultural Affairs, Department of State.

[FR Doc. 04-8466 Filed 4-14-04; 8:45 am]

BILLING CODE 4710-05-P

DEPARTMENT OF STATE

[Public Notice 4688]

Bureau of Educational and Cultural Affairs Request for Grant Proposals (RFGP): Tibet Professional, Educational and Cultural Exchange Projects

SUMMARY: The Office of Citizen Exchanges welcomes proposals in an open competition for Tibet Professional, Educational and Cultural Exchange Projects that focus on the themes of Cultural Preservation and Economic Self-sufficiency. Approximately \$500,000 is available to support projects under this competition in Fiscal Year 2004.

Public and private non-profit organizations meeting the provisions described in Internal Revenue Code section 26 U.S.C. 501(c)(3) may submit proposals to promote understanding between the people of the United States and Tibetan people living in Tibetan communities in China through professional, educational and cultural projects.

Applicants should ensure that their proposals comply with the Tibet Policy Act of 2002, particularly that their projects promote in all stages the active participation of Tibetans (see section 611 of the Foreign Relations Authorization Act, 2003 (Pub. L. 107-228), section 616(d), Tibet Project Principles).

Interested applicants should read this complete **Federal Register** announcement before addressing inquiries to the Office of Citizen Exchanges but are encouraged to contact the Program Manager to discuss their ideas before submitting a full proposal. Once the RFGP deadline has passed, Bureau staff may not discuss this competition with applicants until the proposal review process has been completed.

Important Note: This Request for Grant Proposals contains language in the "Shipment and Deadline for Proposals" section that is significantly different from that used in the past. Please pay special attention to the procedural changes outlined.

Announcement Name and Number

All correspondence with the Bureau concerning this RFGP should reference the "Open Competition for Tibet Professional, Educational and Cultural Exchange Projects" and reference number ECA/PE/C/WHAEP-04-54. Please refer to title and number in all correspondence or telephone calls to the Office of Citizen Exchanges.

FOR FURTHER INFORMATION CONTACT: Interested organizations and institutions

may contact the Office of Citizen Exchanges, Room 216, SA-44, U.S. Department of State, 301 4th Street, SW., Washington, DC 20547, telephone number 202/260-5485, fax number 202/260-0440, or mcnealdb@state.gov to request a Solicitation Package. The Solicitation Package contains detailed award criteria, required application forms, specific budget instructions, and standard guidelines for proposal preparation. Please specify Program Manager Douglas McNeal on all other inquiries and correspondence.

To Download a Solicitation Package via Internet

The entire Solicitation Package also may be downloaded from the Bureau's Web site at <http://exchanges.state.gov/education/RFGPs>. Please read all information before downloading.

Program Information

Overview

The Office of Citizen Exchanges welcomes proposals that focus on the themes of Cultural Preservation and Economic Self-sufficiency under this competition for FY-2004 Tibet Professional, Educational and Cultural Exchange Projects. Approximately \$500,000 is expected to be available for such projects from the Bureau's FY-2004 appropriation. Grant awards will not exceed \$150,000; grants awarded to organizations with less than four years' experience in conducting international exchange programs will be limited to \$60,000.

Cultural Preservation

Projects under this theme should aim to assist Tibetans in preserving their cultural heritage through activities designed to reduce the pillage of irreplaceable cultural heritage and to create opportunities to develop long-term strategies for preserving cultural property through training and conservation, museum development, and public education. Projects might include supporting the preservation of cultural sites; objects in a site, museum or similar institution; or forms of traditional cultural expression. The proposals may encompass topics such as museum needs, historic buildings, collections, archaeological sites, rare manuscripts, language, or traditional arts, crafts, or music.

Economic Self-Sufficiency

Vocational Education

Proposals are sought which emphasize vocational training or administration and development of vocational schools targeted towards the

practical needs of Tibetan communities. Discussion of how to integrate education with economic planning, how to diversify revenue sources, and how to recruit, train and retain strong faculty would all contribute towards increased emphasis on vocational education and its importance to both Americans and Tibetans in a modern and changing economy. Vocational education may include practical training of entrepreneurs, development of Tibetan-language educational materials (such as Tibetan-English teaching guides or Tibetan-language public health education materials), or development of distance-learning technology solutions for remote rural schools. English-language training projects that are held in China are preferred over ones that would bring Tibetans to the U.S. for training.

Developing Entrepreneurship

Projects under this theme may focus on the skills Tibetans, many of whom come from rural backgrounds with rudimentary economies, need to function effectively in a modern economy (e.g., finance, accounting, and language skills). Projects will be favored that explore ways in which both the government and the private sector can help promote sustainable entrepreneurship, including access to credit, ecologically conscious tourism policies and investment, or English language training for trade or tourism purposes. Programs that train budding entrepreneurs and develop micro-finance programs for them are welcome.

Sustainable Growth and Eco-Tourism

Exchanges funded under this theme would help American and Tibetan conservationists, tourism planners, and economic planners share their experience in managing tourism resources and development projects, particularly in ecologically fragile areas, and would contribute to better understanding of conservation and concepts essential to responsible economic growth. Local community projects are invited in fields such as eco-tourism, renewable energy, or poverty alleviation projects, including farm technology, animal husbandry, or agricultural marketing.

Guidelines

The Office seeks proposals that train and assist Tibetans living in Tibetan communities in China by providing professional experience and exposure to American life and culture through internships, workshops and other learning and sharing experiences hosted by local U.S. institutions. The

experiences also will provide Americans the opportunity to learn about Tibetan culture and the social and economic challenges Tibetans face today. These two-way exchanges should not be simply academic in nature but should provide practical, hands-on experience in U.S. public or private sector settings that may be adapted to an individual's institution upon return home. Proposals may combine elements of professional enrichment, job shadowing and internships appropriate to the language ability and interests of the participants.

General Program Guidelines

Applicants must identify the local organizations and individuals in the counterpart country with whom they are proposing to collaborate and describe in detail previous cooperative programming or contacts. Specific information about the counterpart organizations' activities and accomplishments is required and must be included in the section on Institutional Capacity. All proposals must contain letters of support tailored to the project being proposed from all foreign-country partner organizations or will be declared ineligible.

Exchanges and training programs supported by institutional grants from the Bureau should operate at two levels: they should enhance institutional partnerships, and they should offer practical information and experience to individuals and groups to assist them with their professional responsibilities. Strong proposals usually have the following characteristics:

- A proven track record of working in the proposed issue area;
- An experienced staff with language facility and a commitment by the staff to monitor projects locally to improve accountability;
- A clear, convincing plan showing how permanent results will be accomplished as a result of the activity funded by the grant; and a follow-on plan beyond the scope of the Bureau grant.

Proposal narratives must demonstrate an organization's willingness to consult closely with the Public Affairs Section and other officers at the U.S. Embassy in Beijing and at the U.S. Consulate General in Chengdu. Proposal narratives must commit to invite representatives of the Embassy or Consulate to participate in all program sessions and site visits as well as confirm that materials developed for the project will all acknowledge USG funding for the program. Please note that this will be a formal requirement in final grant awards.

Suggested Program Designs

Bureau-supported exchanges may include internships; study tours; short-term, non-technical experiential learning; extended and intensive workshops; and seminars convened in the United States or overseas. Examples of possible program activities include:

1. A U.S.-based program that includes: orientation to program purposes and to U.S. society, study tour and site visits, professional internships or placements, interaction and dialogue, hands-on training, professional development, and action plan development.

2. Capacity-building or training-of-trainer (ToT) workshops to help participants to identify priorities, create work plans, strengthen professional and volunteer skills, share their experience with committed people within each country, and become active in a practical and valuable way.

3. Seed or small grants to indigenous non-profit organizations to support community-based educational projects that build upon exchange activities and that address issues of local concern. Proposals may include a component for a Seed or Small Grants Competition (often referred to as 'sub-grants' or 'secondary grants'). This requires a detailed plan for recruitment and advertising, description of the proposal review and award mechanism, a plan for how the grantee would monitor and evaluate small-grant activity, and a proposed sum for an average grant. The small grants should be directly linked to exchange activities. Small or seed grants may not be used for micro-credit or re-lending. Small or seed grants may not exceed 10% of the total value of the grant sought from ECA.

4. Site visits by U.S. facilitators or experts to monitor projects in the region and to provide additional training and consultation as needed.

5. Content-based Internet training or cyber-training to encourage citizen participation in workshops, fora, chats, or discussions via the Internet that will stimulate communication and information sharing among key opinion leaders on priority topics. Proposals that include Internet utilization must reflect knowledge of the opportunities and obstacles that exist for use of information technology in the target country or countries, and, if needed, provide hardware, software and servers, preferably as a form of cost sharing.

Selection of Participants

All grant proposals should clearly describe the type of persons who will participate in the program as well as the

process by which participants will be selected. It is recommended that for programs including U.S. internships, grant applicants submit letters tentatively committing host institutions to support the internships. In the selection of Tibetan participants, the Department, the U.S. Embassy in Beijing and the U.S. Consulate General in Chengdu retain the right to review all participant nominations and to accept or reject participants recommended by grantee institutions. The grantee institution will also provide to the Office of Citizen Exchanges for information purposes the names of American participants and brief (two-page) biographical data on each. Priority in two-way exchange proposals will be given to foreign participants who have not previously traveled to the United States.

Diversity, Freedom and Democracy Guidelines

Pursuant to the Bureau's authorizing legislation, programs must maintain a non-political character and should be balanced and representative of the diversity of American political, social, and cultural life. "Diversity" should be interpreted in the broadest sense and encompass differences including, but not limited to ethnicity, race, sex, religion, geographic location, socioeconomic status, and disabilities. Applicants are strongly encouraged to adhere to the advancement of this principle both in program administration and in program content. Please refer to the 'Support of Diversity' section of the review criteria (below) for specific suggestions on incorporating diversity into the total proposal. Public Law 104-319 provides that "in carrying out programs of educational and cultural exchange in countries whose people do not fully enjoy freedom and democracy," the Bureau "shall take appropriate steps to provide opportunities for participation in such programs to human rights and democracy leaders of such countries." Public Law 106-113 requires that the governments of the countries described above not have inappropriate influence in the selection process. Proposals should reflect advancement of these goals in their program content, to the extent deemed feasible.

Adherence to All Regulations Governing the J Visa

The Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs is the official program sponsor of the exchange program covered by this grant invitation, and an employee of the Bureau will be the "Responsible Officer"

for the program under the terms of 22 CFR part 62, which covers the administration of the Exchange Visitor Program (J-visa program). Under the terms of 22 CFR part 62, organizations receiving grants under this program will be third parties "cooperating with or assisting the sponsor in the conduct of the sponsor's program." The actions of grantee program organizations shall be "imputed to the sponsor in evaluating the sponsor's compliance with" 22 CFR part 62. Therefore, the Bureau expects that any organization receiving a grant under this competition will render all assistance necessary to enable the Bureau fully to comply with 22 CFR part 62 *et seq.* The Bureau of Educational and Cultural Affairs places great emphasis on the secure and proper administration of Exchange Visitor (J-visa) Programs and adherence by grantee program organizations and program participants to all regulations governing the J-visa program status. Therefore, proposals should state explicitly in writing that the applicant is prepared to assist the Bureau in meeting all requirements governing the administration of Exchange Visitor Programs as set forth in 22 CFR part 62. If the applicant has experience as a designated Exchange Visitor Program Sponsor, the application should discuss the record of compliance with 22 CFR part 62 *et seq.*, including the oversight of Responsible Officers and Alternate Responsible Officers, screening and selection of program participants, provision of pre-arrival information and orientation to participants, monitoring of participants, proper maintenance and security of forms, record-keeping, reporting and other requirements.

The Office of Citizen Exchanges of ECA will be responsible for issuing DS-2019 forms to participants in this program.

A copy of the complete regulations governing the administration of Exchange Visitor (J) programs is available at <http://exchanges.state.gov> or from: United States Department of State, Office of Exchange Coordination and Designation, ECA/EC/ECD-SA-44, Room 734, 301 4th Street, SW., Washington, DC 20547, Telephone: (202) 401-9810, Fax: (202) 401-9809.

New OMB Requirement

An OMB policy directive published in the *Federal Register* on June 27, 2003, requires that all organizations applying for Federal grants or cooperative agreements must provide a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number when applying for any Federal grants or cooperative agreements on or after

October 1, 2003. The complete OMB policy directive can be referenced at http://www.whitehouse.gov/omb/fedreg/062703_grant_identifier.pdf. Please also visit the ECA Web site at <http://exchanges.state.gov/education/rfgps/menu.htm> for additional information on how to comply with this new directive.

The Solicitation Package offers specifics about the program as well as certain requirements that accompany Federal assistance awards. Compliance with those requirements is mandatory. Complete applications are essential to facilitating the review and award process. Please refer to the Technical Format and Instructions page in the Proposal Submission Instructions.

Shipment and Deadline for Proposals

Your complete proposal package (the original proposal, ten copies and one extra copy of the application cover sheet) must be postmarked by Thursday, May 27, 2004, and sent to: U.S. Department of State, SA-44, Bureau of Educational and Cultural Affairs, Reference: ECA/PE/C/WHA/EAP-04-54, Program Management, ECA/EX/PM, Room 534, 301 4th St., SW., Washington, DC 20547-0002.

Important Note: The deadline for this submission is Thursday, May 27, 2004. In light of recent events and heightened security measures, proposal submissions must be sent via a nationally recognized overnight delivery service (*i.e.*, Airborne Express, DHL, Federal Express, UPS, or U.S. Postal Service Express Overnight Mail, *etc.*) and be shipped no later than May 27. The delivery services used by applicants must have in-place, centralized shipping identification and tracking systems that may be accessed via the Internet and delivery people who are identifiable by commonly recognized uniforms and delivery vehicles. It is each applicant's responsibility to ensure that each package is marked with a legible tracking number and to monitor and confirm delivery via the Internet. Neither faxed documents nor documents postmarked after the above deadline will be accepted.

Please also submit the Executive Summary, Proposal Narrative, and Budget sections of the proposal as e-mail attachments in Microsoft Word and Excel to the program manager at mcnealdb@state.gov. The Bureau will transmit these files electronically to the Public Affairs sections at the U.S. Embassy in Beijing and the Consulate General in Chengdu for their review, with the goal of reducing the time it takes to get embassy comments for the Bureau's review process.

Budget Guidelines

Applicants must submit a comprehensive budget for the entire program, including a summary budget

as well as breakdowns reflecting both administrative and program costs. Applicants may provide separate sub-budgets for each program component, phase, location or activity. Grant awards will not exceed \$150,000; grants awarded to organizations with less than four years' experience in conducting international exchange programs will be limited to \$60,000.

Since Bureau grant assistance is to constitute only a portion of total project funding, proposals should list and provide evidence of other anticipated sources of financial and in-kind support. To be eligible for consideration under this competition, proposals must provide a minimum of 30 percent cost sharing of the amount of grant funds sought from ECA, although proposals with higher cost-sharing levels are welcome.

Example: A proposal requests \$125,000 in grant funds from ECA, for a project with a total budget of \$500,000. The required minimum cost sharing offered would be \$37,500. In this case, the cost sharing far exceeds the minimum, since actual cost sharing is \$375,000.

When cost sharing is offered, it is understood and agreed that the applicant must provide the minimum amount of cost sharing as stipulated in this RFGP and later included in an approved grant agreement. Cost sharing may be in the form of allowable direct or indirect costs. For accountability, you must maintain written records to support all costs which are claimed as your contribution, as well as costs to be paid by the Federal government. Such records are subject to audit. The basis for determining the value of cash and in-kind contributions must be in accordance with OMB Circular A-110, (Revised), Subpart C.23—Cost Sharing and Matching. In the event you do not provide the minimum amount of cost sharing as stipulated in the approved budget, ECA's contribution will be reduced in like proportion.

The following project costs are eligible for consideration for funding:

1. Travel costs. International and domestic airfare, visas, transit costs, and ground transportation costs. Please note that all air travel must be in compliance with the Fly America Act. There is no charge for J-1 visas for participants in Bureau-sponsored programs.

2. Per Diem. For the U.S. program, organizations have the option of using a flat \$160/day for program participants or the published U.S. Federal per diem rates for individual American cities. For activities outside the U.S., the published Federal per diem rates must be used. **Note:** U.S. escorting staff must use the

published Federal per diem rates, not the flat rate. Per diem rates may be accessed at <http://www.policyworks.gov/>.

3. Interpreters. If needed, interpreters for the U.S. program are available through the Language Services Division of the U.S. Department of State. Typically, a pair of simultaneous interpreters is provided for every four visitors who need interpretation. Bureau grants do not pay for foreign interpreters to accompany delegations from their home country. Grant proposal budgets should contain a flat \$160/day per diem for each Department of State interpreter, as well as home-program-home air transportation of \$400 per interpreter plus any U.S. travel expenses during the program. Salary expenses are covered centrally and should not be part of an applicant's proposed budget. Locally arranged interpreters with adequate skills and experience may be used by the grantee in lieu of State Department interpreters, with the same 1:4 ratio of interpreters to participants. However, the cost of hiring such interpreters may not exceed the rate for U.S. Department of State interpreters.

4. Book and cultural allowance. Foreign participants are entitled to and escorts are reimbursed for a one-time cultural allowance of \$150 per person, plus a participant book allowance of \$50. U.S. program staff members are not eligible to receive these benefits.

5. Consultants. Consultants may be used to provide specialized expertise, design or manage growth projects, or to make presentations. Honoraria generally do not exceed \$250 per day. Subcontracting organizations may also be used, in which case the written agreement between the prospective grantee and subcontractor should be included in the proposal. Subcontracts should be itemized in the budget.

6. Room rental. Room rental may not exceed \$250 per day.

7. Materials development. Proposals may contain costs to purchase, develop, and translate materials for participants.

8. Equipment. Proposals may contain limited costs to purchase equipment crucial to the success of the program, such as computers, fax machines and copy machines. However, equipment costs must be kept to a minimum, and costs for furniture are not allowed.

9. Working Meal. The grant budget may provide for only one working meal during the program. Per-capita costs may not exceed \$5-8 for a lunch and \$14-20 for a dinner, excluding room rental. The number of invited guests may not exceed participants by more than a factor of two-to-one. Interpreters must be included as participants.

10. Return travel allowance. A return travel allowance of \$70 for each foreign participant may be included in the budget. This may be used for incidental expenses incurred during international travel.

11. Health Insurance. Foreign participants will be covered under the terms of a U.S. Department of State-sponsored health insurance policy. The premium is paid by the U.S. Department of State directly to the insurance company. Applicants are permitted to include in the budget costs for travel insurance for U.S. participants.

12. Administrative Costs. Costs necessary for the effective administration of the program may include salaries for grant organization employees, benefits, and other direct or indirect costs per detailed instructions in the Solicitation Package.

Please refer to the Solicitation Package for complete budget guidelines and formatting instructions.

Review Process

The program office, the Public Diplomacy section and other elements at the U.S. Embassy in Beijing, and officials at the U.S. Consulate in Chengdu will review all eligible proposals. Eligible proposals, which must comply with Federal and Bureau regulations and guidelines, will be submitted to Bureau advisory panels for review. Proposals may also be reviewed by the Office of the Legal Adviser or by other Department elements. Final funding decisions are at the discretion of the Department of State's Assistant Secretary for Educational and Cultural Affairs. Final technical authority for grants resides with the Bureau's Grants Officer.

Review Criteria

Technically eligible applications will be competitively reviewed according to the criteria stated below.

1. Institutional Capacity/Record/Ability: Proposed personnel and institutional resources should be adequate and appropriate to achieve the program or project's goals. For technical projects, foreign experts and their local partners will be required to have the necessary education, training and experience for the work to be undertaken, in addition to language skills where applicable. Proposals should demonstrate an institutional record of successful development of exchange programs, including responsible fiscal management and full compliance with all reporting requirements for past Bureau grants as determined by Bureau Grant Staff. The Bureau will consider the past

performance of prior recipients and the demonstrated potential of new applicants. Applicants should have a multiyear track record of successful work in Tibetan regions of China or other remote parts of Asia.

2. Program planning to achieve program objectives: Proposals should clearly demonstrate how the institution plans to achieve the program's objectives. Objectives should be reasonable, feasible, and flexible. The proposal should contain a detailed agenda and relevant work plan that demonstrates substantive undertakings and logistical capacity. Agenda and plan should adhere to the program overview and guidelines described above.

3. Multiplier effect/impact: Proposed programs should strengthen long-term mutual understanding, including maximum sharing of information and establishment of long-term institutional and individual linkages.

4. Follow-on Activities: Proposals should provide a plan for continued follow-on activity to ensure that Bureau-supported programs not be isolated events.

5. Support of Diversity: Proposals should demonstrate substantive support of the Bureau's policy on diversity. Achievable and relevant features should be cited in both program administration (selection of participants, program venue and program evaluation) and program content (orientation and wrap-up sessions, program meetings, resource materials and follow-up activities).

6. Monitoring and Project Evaluation Plan: Proposals should provide a detailed plan for monitoring and evaluating the program. The evaluation plan should identify anticipated outcomes and performance requirements clearly related to program objectives and activities and include procedures for ongoing monitoring and corrective action when necessary. The identification of best practices relating to project administration is also encouraged, as is the discussion of unforeseen difficulties.

7. Cost-effectiveness/Cost-sharing: The overhead and administrative components of the proposal, including salaries and honoraria, should be kept as low as possible. All other items should be necessary and appropriate. Proposals must provide 30% cost sharing (of the amount of grant funds requested from ECA) through other private sector support as well as institutional direct funding contributions.

Authority

Overall grant-making authority for this program is contained in the Mutual

Educational and Cultural Exchange Act of 1961, Public Law 87-256, as amended, also known as the Fulbright-Hays Act. The purpose of the Act is "to enable the Government of the United States to increase mutual understanding between the people of the United States and the people of other countries . . . ; to strengthen the ties which unite us with other nations by demonstrating the educational and cultural interests, developments, and achievements of the people of the United States and other nations * * * and thus to assist in the development of friendly, sympathetic and peaceful relations between the United States and the other countries of the world."

Notice

The terms and conditions published in this RFGP are binding and may not be modified by any Bureau representative. Explanatory information provided by the Bureau that contradicts published language will not be binding. Issuance of this RFGP does not constitute a commitment on the part of the Government. The Bureau reserves the right to reduce, revise, or increase proposal budgets in accordance with the needs of the program and the availability of funds. Awards made will be subject to periodic reporting and evaluation requirements.

Notification

Final awards cannot be made until funds have been appropriated by Congress, allocated, and committed through internal Bureau procedures.

Dated: April 7, 2004.

C. Miller Crouch,

Principal Deputy Assistant Secretary, Bureau of Educational and Cultural Affairs, Department of State.

[FR Doc. 04-8467 Filed 4-14-04; 8:45 am]

BILLING CODE 4710-05-P

DEPARTMENT OF STATE

[Public Notice 4691]

Bureau of Educational and Cultural Affairs Request for Grant Proposals: Professional Exchange Programs in Turkey

SUMMARY: The Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs announces an open competition for Professional Exchange Programs in Turkey. The Bureau anticipates awarding three to five grants under this competition. Projects should target one of the following themes: Human rights law, media internships and women's leadership. Public and private non-profit organizations meeting

the provisions described in Internal Revenue Code section 26 U.S.C. 501(c)(3) may submit proposals to support international projects in the United States and Turkey involving current or potential leaders.

Important Note: This Request for Grant Proposals contains language in the "Shipment and Deadline for Proposals" section that is significantly different from that used in the past. Please pay special attention to procedural changes as outlined.

Announcement Title and Number: All correspondence with the Bureau concerning this RFGP should reference the "Professional Exchange Programs in Turkey" and number ECA/PE/C/EUR-04-68.

FOR FURTHER INFORMATION CONTACT:

Interested organizations/institutions may contact the Office of Citizen Exchanges, Room 220, SA-44, U.S. Department of State, 301 4th Street, SW., Washington, DC 20547, Attention: Professional Exchange Programs in Turkey, telephone number (202) 260-6230, fax number (202) 619-4350 to request a Solicitation Package. The Solicitation Package, which includes the Request for Grant Proposals (RFGP), the Proposal Submission Instructions (PSI) and the diversity statement, contains detailed award criteria, required application forms, specific budget instructions, and standard guidelines for proposal preparation.

For specific inquiries, please contact Chris Miner by phone or email at (202) 401-7342 (minercx@state.gov).

To Download a Solicitation Package Via Internet: The entire Solicitation Package may be downloaded from the Bureau's Web site at <http://exchanges.state.gov/education/RFGPs>. Please read all information before downloading.

Please read the complete **Federal Register** announcement before sending inquiries or submitting proposals. Once the RFGP deadline has passed, Bureau staff may not discuss this competition with applicants until the proposal review process has been completed.

General Program Guidelines: This competition is based on the premise that people-to-people exchanges encourage and strengthen democratic initiatives and nurture the social, political and economic development of societies. Exchanges and training programs supported by institutional grants from the Bureau should operate at two levels: they should enhance institutional partnerships, and they should offer practical information and experience to individuals and groups to assist them with their professional responsibilities.

Strong proposals usually have the following characteristics:

- A proven track record of working in the proposed issue area and country;
- Experienced staff with language facility and a commitment by the staff to monitor projects locally to ensure implementation;
- A clear, convincing plan showing how permanent results will be accomplished as a result of the activity funded by the grant;
- A post-grant plan that includes activities that will take place after the Bureau-funded grant has concluded. (See Review Criterion #5 below for more information on post-grant activities.) and;
- A detailed discussion of project needs and feasibility. Proposals that include costs or time for a needs assessment may be deemed less competitive.

Applicants should identify the local organizations and individuals in Turkey with whom they are proposing to collaborate and describe in detail previous cooperative programming and/or contacts. Specific information about the counterpart organizations' activities and accomplishments should be included in the section under "Institutional Capacity." (See Review Criterion #2 below.) Proposals should contain letters of support tailored to the proposed project from partner organizations in Turkey. Applicants should clearly outline in the narrative the foreign partner's role and responsibilities in project management and implementation.

Proposal narratives must clearly demonstrate an organization's commitment to consult closely with the designated program officer at Bureau of Educational and Cultural Affairs, and with Public Affairs Section at the U.S. Embassy in Ankara, Turkey. Proposal narratives must confirm that all materials developed for the project will acknowledge Bureau funding for the program as well as a commitment to invite representatives of Embassy Ankara to participate in various program sessions/site visits. Please note that this will be a formal requirement in all final grant awards.

Suggested Program Designs

Bureau-supported exchanges may include internships; study tours; short-term, non-technical experiential learning; extended and intensive workshops; and seminars taking place in the United States or overseas. Examples of program activities include:

1. A U.S.-based program that includes: orientation to program purposes and to U.S. society; study

tour/site visits; professional internships/placements; interaction and dialogue; hands-on training; professional development; and action plan development. Proposals that include U.S.-based training will receive the highest priority.

2. Capacity-building/training-of-trainer (TOT) workshops to help participants to identify priorities, create work plans; strengthen professional and volunteer skills; share their experience with committed people within each country; and become active in a practical and valuable way.

3. Site visits by U.S. facilitators/experts to monitor projects in the region and to provide additional training and consultations as needed.

Activities ineligible for support: The Office does not support proposals limited to conferences or seminars (*i.e.*, one to fourteen-day programs with plenary sessions, main speakers, panels, and a passive audience). It will support conferences only when they are a small part of a larger project in duration that is receiving Bureau funding from this competition. No funding is available exclusively to send U.S. citizens to conferences or conference-type seminars overseas; nor is funding available for bringing foreign nationals to conferences or to routine professional association meetings in the United States.

Selection of Participants: All grant proposals should clearly describe the type of persons that will participate in the program as well as the participant selection process. For programs that include U.S. internships, applicants should submit letters of support from host institutions. In the selection of foreign participants, the Bureau and U.S. Embassies retain the right to review all participant nominations and to accept or refuse participants recommended by grantee institutions. When American participants are selected, grantee institutions must provide their names and brief biographical data to the Office of Citizen Exchanges. Priority in two-way exchange proposals will be given to foreign participants who have not previously traveled to the United States.

Programs must comply with J-1 visa regulations. Please refer to "Adherence with J-1 Visa Regulations" below.

Program Data Requirements: Organizations awarded grants will be required to maintain specific data on program participants and activities in an electronically accessible database format that can be shared with the Bureau as required. At a minimum, the data must include the following:

- (1) Name, address, contact information and biographic sketch of all persons who travel internationally on funds provided by the grant or who benefit from the grant funding but do not travel.

- (2) Itineraries of international and domestic travel, providing dates of travel and cities in which any exchange experiences take place.

Adherence to All Regulations Governing the J Visa

The Office of Citizen Exchanges of the Bureau of Educational and Cultural Affairs is the official program sponsor of the exchange program covered by this RFGP, and an employee of the Bureau will be the "Responsible Officer" for the program under the terms of 22 CFR part 62, which covers the administration of the Exchange Visitor Program (J visa program). Under the terms of 22 CFR part 62, organizations receiving grants under this RFGP will be third parties "cooperating with or assisting the sponsor in the conduct of the sponsor's program." The actions of grantee program organizations shall be "imputed to the sponsor in evaluating the sponsor's compliance with" 22 CFR part 62. Therefore, the Bureau expects that any organization receiving a grant under this competition will render all assistance necessary to enable the Bureau to fully comply with 22 CFR part 62 *et seq.*

The Bureau of Educational and Cultural Affairs places great emphasis on the secure and proper administration of Exchange Visitor (J visa) Programs and adherence by grantee program organizations and program participants to all regulations governing the J visa program status. Therefore, proposals should explicitly state in writing that the applicant is prepared to assist the Bureau in meeting all requirements governing the administration of Exchange Visitor Programs as set forth in 22 CFR part 62. If your organization has experience as a designated Exchange Visitor Program Sponsor, the applicant should discuss its record of compliance with 22 CFR part 62 *et seq.*, including the oversight of their Responsible Officers and Alternate Responsible Officers, screening and selection of program participants, provision of pre-arrival information and orientation to participants, monitoring of participants, proper maintenance and security of forms, record-keeping, reporting and other requirements.

The Office of Citizen Exchanges will be responsible for issuing DS-2019 forms to participants in this program.

A copy of the complete regulations governing the administration of

Exchange Visitor (J) programs is available at <http://exchanges.state.gov> or from: United States Department of State, Office of Exchange Coordination and Designation, ECA/EC/ECD—SA—44, Room 734, 301 4th Street, SW., Washington, DC 20547, Telephone: (202) 401-9810. FAX: (202) 401-9809.

Evaluation: In general, evaluation should occur throughout the project. The evaluation should incorporate an assessment of the program from a variety of perspectives. Specifically, project assessment efforts will focus on: (a) Determining if objectives are being met or have been met, (b) identifying any other related training needs, and (c) assessing if the project has effectively identified resources, advocates, and financial support for the sustainability of future projects. Informal evaluation through discussions and other sources of feedback will be carried out throughout the duration of the project. Formal evaluation must be conducted at the end of each component, should measure the impact of the activities and should obtain participants' feedback on the program content and administration. A detailed evaluation will be conducted at the conclusion of the project and a report will be submitted to the Department of State Bureau of Educational and Cultural Affairs. When possible, the evaluation should be conducted by an independent evaluator.

Program Information: Overview: The Bureau welcomes proposals that respond directly to the themes listed below. Given budgetary considerations, projects in countries and for themes other than those listed will not be eligible for consideration and will be ruled technically ineligible. The themes listed below are important to the Office of Citizen Exchanges, but no guarantee is made or implied that grants will be awarded in all categories.

In order to prevent duplication of effort, proposals should reflect an understanding of the work of international and USG agencies so that projects complement other exchange or assistance programs.

Proposals that include two-way exchanges will be considered more competitive than those that propose exchanges in one direction. Applicants should carefully review the following information in formulating proposals in Turkey.

Proposal narratives should provide detailed information on major program activities to be undertaken, including agendas for both U.S. and in-country activities, a clear explanation of participant recruitment and selection strategies and letters of commitment from any outside partners. Proposals

should also take into account the need for ongoing sharing of information, training and concrete plans for self-sustainability.

Applicants are strongly encouraged to consult with the Public Affairs Section at the U.S. Embassy in Ankara regarding program content and partner organizations before submitting proposals. Applicants must demonstrate their administrative and programmatic ability to carry out in-country activities without the assistance of the Public Affairs Sections in Ankara and Istanbul. Award-receiving applicants will be expected to work very closely with the Office of Citizen Exchanges and the Embassy in Ankara on all aspects of the program.

To be eligible for a grant award under this competition, the proposed professional training and exchange projects in Turkey must address one of the following specific themes.

- Judicial Reform
- Media
- Women's Leadership

Judicial Reform

Turkey is engaged in a comprehensive reform effort aimed at advancing its European Union candidacy, an objective that is strongly supported by the Mission. The Turkish Parliament has adopted a wide range of human rights-related reform legislation over the past two years. Implementation of the reforms has, however, been slow in some areas, including the judicial field. For example, prosecutors still open cases against individuals for non-violent expression, although such cases normally end in acquittal. All detainees have the right to immediate attorney access, but the police often fail to inform detainees of this right. An estimated five percent of detainees consult with attorneys. Prosecutors are charged with supervising the police during the investigation phase, but lack the resources to do so.

Trials are often lengthy, with overworked felony courts typically holding one hearing per month.

The Bureau welcomes proposals for a legal exchange project between Turkey and the U.S. that focuses on the topics of freedom of expression, police conduct, and trial alternatives. The project should include activities that develop measures and procedures that will improve the way judicial and police professionals handle these important issues. The Bureau expects that the selected grantee will work closely with the Turkish Ministry of Justice and the Turkish Constitutional Court throughout the project. Objectives

for each topic are briefly outlined below:

Freedom of expression. The project should aim to create a judicial directive that would establish the official Turkish position on freedom of expression standards, as established by the European Court of Human Rights.

Police conduct. This initiative should establish a network of legal institutions to address police misconduct in Turkey. Such a network would include an independent oversight body, a mechanism for judicial oversight, and internal police disciplinary and training bodies.

Trial alternatives. In order to reduce the caseload of Turkish prosecutors, project activities should support the design and implementation of a strategy for trial alternatives.

Primary Turkish participants should include judges and prosecutors from the State Security Courts, Felony Courts, and Courts of Cassation (appeals courts). Judges and prosecutors from other sectors, along with defense lawyers, academics, NGOs and others involved in Turkey's judicial system, could also be considered for participation.

Project activities should include exchanges in both the U.S. and Turkey. In the U.S., seminars, workshops, site visits and shadowing or internship opportunities may be arranged. Turkish judges and prosecutors would meet with their U.S. counterparts and other experts in human rights law, visit university law schools with relevant programs, observe court proceedings, and consult on the development of materials.

It is anticipated that three separate programs in the United States would be undertaken. In Turkey, U.S. participants should conduct workshops, seminars, and consultations on mechanisms in our two legal systems to protect freedom of expression, among other topics. It is expected that the in-country activities would include a component to reach out to a wider audience so that the project is not limited only to participants in the U.S. program. In addition, the program in Turkey would include the design and development of a mid-career professional training module for judges and prosecutors to be administered by the training department at the Ministry of Justice.

Project funding: The total funding available for this project is approximately \$400,000. The Bureau anticipates awarding one grant for this project.

Media Internships

Turkey's ongoing process of democratization has brought about

tremendous change in the country's media. Prior to the 1980 military coup, the Turkish media was tightly controlled by the state. Since the reestablishment of civilian authority in 1983, Turkey has seen an enormous expansion in freedom of the press. Given the power of the media in Turkey to set the political agenda and shape public opinion, including views of the United States, it is in our interest to work with Turkish media personnel. This exchange program should provide an opportunity for Turkish and U.S. media professionals to exchange views on a wide range of issues.

The Bureau is seeking proposals for a media exchange project between Turkey and the U.S. It would be a two-part exchange of Turkish media professionals traveling to the U.S. and would also include visits to Turkey by American counterparts.

The first stage would be a visit to the U.S. for eight to ten relatively high-level news editors from major newspapers and at broadcast outlets for a two-week introduction to the U.S. media. The two-week program would consist of a seminar at a university or media-related foundation, job-shadowing placements in U.S. newspapers and broadcast outlets, site visits and a one-day debriefing. The seminar and placements would provide an opportunity to exchange views and information on the media environment and the journalism profession in Turkey and the U.S. Topics could include, but would not be limited to, the role of the editor in the news process and the challenges and responsibilities of a free and independent media.

The second stage would be for eight to ten young journalists from the print and electronic media. It would begin with a similar seminar at a university or media-related foundation, and be followed by three-week placements at appropriate newspapers and broadcast media outlets that would provide an opportunity for orientation, observation, and practical hands-on experience. The program would conclude with a two-day debriefing.

Both U.S. visits would be followed by visits to Turkey by one or more U.S. media experts (editors, correspondents, academics) to conduct seminars and workshops for a wider audience and to visit the newspapers and broadcast outlets where the Turkish visitors to the U.S. are employed. A more senior media professional(s) from the U.S. would follow up the visit of the first group, while a correspondingly more junior U.S. professional(s) would come to Turkey after the visit of the second group.

Projects should include both English-speaking and non-English speaking participants. Proposals should clearly describe what provisions will be made for non-English speakers.

A list of media establishments willing to host the participants and tentative letters of commitment should be included in the proposal, as should information pertinent to the university or media-related foundation that would conduct the seminar.

Please note that the winning applicant must coordinate closely with the Public Affairs Section of the U.S. Embassy in Ankara on program development and implementation. Embassy Ankara will nominate all participants for the program.

Project funding: The total funding available for this project is approximately \$185,000. The Bureau anticipates awarding one grant for this project.

Women's Leadership and Democracy Building Project

Over the past decade, women's organizations in Turkey have emerged as an important force for social change, economic development, and democratic governance. However, the low number of active women leaders in many fields, ranging from politics to business to civil society, indicates that there remains significant progress to achieve in obtaining equal status and opportunity for women, particularly in rural areas and small cities outside Ankara and Istanbul. That said, women in Turkey have had far greater success in and opportunities for fulfilling leadership roles than have their counterparts in neighboring countries.

The Bureau seeks proposals that would simultaneously achieve two related objectives. The first objective is to enhance women's leadership roles in civil society and democratic governance. The second goal is to provide training to Turkish women's NGOs that would equip them with the organizational capacity to share expertise with their counterparts in neighboring countries and establish ongoing institutional relationships and dialogue between NGOs from Turkey and NGOs from other countries.

Turkish participants should include women leaders and aspiring leaders who are active in local or national governance and in civil society NGOs. Participants should be recruited from outlying cities and towns, in-addition to Ankara and Istanbul.

Projects will include both English-speaking and non-English-speaking participants, with the latter predominating. Projects should clearly

describe what provisions will be made for non-English speakers.

Programs would focus on developing management skills for organizational efficiency, increasing visibility and effectiveness in the political and civil society spheres, influencing decisions at the local and national levels of government, and building NGO networks and coalitions within Turkey and with counterparts in neighboring countries. Program activity may take place in Turkey and the United States; there must be a component that is conducted in Turkey. Applicants should consult closely with the Public Affairs Section in Ankara in the selection of an in-country partner or partners, which would handle all activities based in Turkey, including participant recruitment and selection and workshop and consultation logistics.

Project funding: The total funding available for this project is approximately \$185,000. The Bureau anticipates awarding one grant for this project.

The proposal submitted by your organization must demonstrate how the above-listed goals will be met. Your proposal narrative should also provide detailed information on major program activities to be undertaken, including agendas for both U.S. and in-country activities, a clear explanation of participant recruitment and selection strategies and letters of commitment from any outside partners. Proposals should also take into account the need for ongoing sharing of information, training and concrete plans for self-sustainability.

Budget Guidelines: Grants awarded to eligible organizations with less than four years of experience in conducting international exchange programs will be limited to an award of \$60,000. Applicants must submit a comprehensive budget for the entire program and must provide a summary budget as well as breakdowns reflecting both administrative and program budgets in the proposal. Applicants may provide separate sub-budgets for each program component, phase, location, or activity to provide clarification. Please refer to the Proposal Submission Instructions (PSI) for complete budget guidelines and formatting instructions.

Since Bureau grant assistance constitutes only a portion of total project funding, proposals should provide evidence of other anticipated sources of financial and in-kind support. Applicants are strongly encouraged to provide cost sharing to the fullest extent possible. State Department Review Panels will consider proposals that offer little or no cost

sharing less competitive under the criterion, "Cost Effectiveness and Cost Sharing".

Applicants must submit a comprehensive budget for the entire program.

The following are deemed allowable program costs:

1. Travel. International and domestic airfare (per the "Fly America Act"), ground transportation, and visas for U.S. participants. (J-1 visas for Bureau-supported participants from Turkey to travel to the U.S. are issued at no charge.)

2. Per Diem. For U.S.-based programming, organizations should use the published Federal per diem rates for individual U.S. cities. For activities in Turkey, the Bureau strongly encourages applicants to budget realistic costs that reflect the local economy. Domestic per diem rates may be accessed at: <http://policyworks.gov/org/main/mt/homepage/mtt/perdiem/perd03d.html>. Foreign per diem rates can be accessed at: <http://www.state.gov/m/a/als/prdm/>.

3. Interpreters. For U.S.-based activities, ECA strongly encourages applicants to hire their own locally-based interpreters or may ask the Bureau to assign U.S. Department of State interpreters. Typically, one interpreter is provided for every four visitors that require interpreting. When an applicant proposes to use State Department interpreters, the following expenses should be included in the budget: Published Federal per diem rates (both "lodging" and "M&IE"); "home-program-home" transportation in the amount of \$400 per interpreter; reimbursement for taxi fares; and cell phone usage at \$10 per week. If the applicant uses State Department interpreters, salary expenses will be covered by the Bureau and should not be part of an applicant's proposed budget. Bureau funds cannot support interpreters who accompany delegations from their home country or travel internationally.

4. Book and cultural allowance. Foreign participants are entitled to a one-time cultural allowance of \$150 per person, plus a book allowance of \$50. Interpreters should be reimbursed up to \$150 for expenses when they escort participants to cultural events. U.S. program staff, trainers or participants are not eligible to receive these benefits.

5. Consultants. Consultants may be used to provide specialized expertise or to make presentations. Daily honoraria cannot exceed \$250 per day. Subcontracting organizations may also be used, in which case the written agreement between the prospective grantee and subcontractor should be

included in the proposal. Such subcontracts should detail the division of responsibilities and proposed costs. Subcontracts should be itemized in the budget.

6. Room rental. Room rental may not exceed \$250 per day.

7. Materials development. Proposals may contain costs to purchase, develop and translate materials for participants.

The Bureau strongly discourages the use of automatic translation software for the preparation of training materials or any information distributed to the group of participants or network of organizations. Costs for high-quality translation of materials should be anticipated and included in the budget. Grantee organizations should expect to submit a copy of all program materials to the Bureau.

8. Equipment. Proposals may include limited costs to purchase equipment for Turkey-based programming such as computers, fax machines and copy machines. Costs for furniture are not allowed. Equipment costs must be kept to a minimum.

9. Working meal. Only one working meal may be provided during the program. Per capita costs may not exceed \$5-8 for a lunch and \$14-20 for a dinner, excluding room rental. The number of invited guests may not exceed participants by more than a factor of two-to-one. Interpreters must be included as participants.

10. Return travel allowance. A return travel allowance of \$70 for each foreign participant may be included in the budget. The allowance may be used for incidental expenses incurred during international travel.

11. Health Insurance. Foreign participants will be covered under the terms of a Bureau-sponsored health insurance policy. The premium is paid by the Bureau directly to the insurance company. Applicants are permitted to include costs for travel insurance for U.S. participants in the budget.

12. Wire transfer fees. When necessary, applicants may include costs to transfer funds to partner organizations overseas. Grantees are urged to research applicable taxes that may be imposed by host governments on these transfers.

13. In-country travel costs for visa processing purposes. Given the new requirements associated with obtaining J-1 visas for Bureau-supported participants, applicants should include costs for participant and/or in-country partner travel and shipping to U.S. embassies or consulates for visa processing purposes, such as interviews and delivery/pick up of DS-2019 forms.

14. Administrative Costs. Costs necessary for the effective administration of the program may include salaries for grantee organization employees, benefits, and other direct and indirect costs per detailed instructions in the Application Package. While there is no rigid ratio of administrative to program costs, priority will be given to proposals whose administrative costs are less than twenty-five (25) percent of the total requested from the Bureau. Proposals should show strong administrative cost-sharing contributions from the applicant, the in-country partner and other sources.

Please refer to the Solicitation Package for complete budget guidelines and formatting instructions.

New OMB Requirement

An OMB policy directive published in the Federal Register on Friday, June 27, 2003, requires that all organizations applying for Federal grants or cooperative agreements must provide a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number when applying for all Federal grants or cooperative agreements on or after October 1, 2003. The complete OMB policy directive can be referenced at http://www.whitehouse.gov/omb/fedreg/062703_grant_identifier.pdf. Please also visit the ECA Web site at <http://exchanges.state.gov/education/rfgps/menu.htm> for additional information on how to comply with this new directive.

Shipment and Deadline for Proposals:
Important Note: The deadline for this competition is Thursday, June 10, 2004. In light of recent events and heightened security measures, proposal submissions must be sent via a nationally recognized overnight delivery service (*i.e.*, DHL, Federal Express, UPS, Airborne Express, or U.S. Postal Service Express Overnight Mail, etc.) and be shipped no later than the above deadline. The delivery services used by applicants must have in-place, centralized shipping identification and tracking systems that may be accessed via the Internet and delivery people who are identifiable by commonly recognized uniforms and delivery vehicles. Proposals shipped on or before the above deadline but received at ECA more than seven days after the deadline will be ineligible for further consideration under this competition. Proposals shipped after the established deadlines are ineligible for consideration under this competition. It is each applicant's responsibility to ensure that each package is marked with a legible tracking number and to

monitor/confirm delivery to ECA via the Internet. Delivery of proposal packages may not be made via local courier service or in person for this competition. Faxed documents will not be accepted at any time. Only proposals submitted as stated above will be considered.

Applicants must follow all instructions in the Solicitation Package. The original and eight copies of the application should be sent to: U.S. Department of State, SA-44, Bureau of Educational and Cultural Affairs, Ref.: ECA/PE/C/EUR-04-68, Program Management, ECA/EX/PM, Room 534, 301 4th Street, SW., Washington, DC 20547.

Applicants must also submit the "Executive Summary" and "Proposal Narrative" sections of the proposal in text (.txt) format on a PC-formatted disk. The Bureau will provide these files electronically to the Public Affairs Section at the U.S. embassy for its review.

Diversity, Freedom and Democracy Guidelines

Pursuant to the Bureau's authorizing legislation, programs must maintain a non-political character and should be balanced and representative of the diversity of American political, social, and cultural life. "Diversity" should be interpreted in the broadest sense and encompass differences including, but not limited to ethnicity, race, gender, religion, geographic location, socio-economic status, and disabilities. Applicants are strongly encouraged to adhere to the advancement of this principle both in program administration and in program content. Please refer to the review criteria under the "Support for Diversity" section for specific suggestions on incorporating diversity into the total proposal. Public Law 104-319 provides that "in carrying out programs of educational and cultural exchange in countries whose people do not fully enjoy freedom and democracy," the Bureau "shall take appropriate steps to provide opportunities for participation in such programs to human rights and democracy leaders of such countries." Public Law 106-113 requires that the governments of the countries described above do not have inappropriate influence in the selection process. Proposals should reflect advancement of these goals in their program contents, to the full extent deemed feasible.

Review Process

Technically eligible applications will be competitively reviewed according to the criteria stated below. These criteria

are not rank ordered and all carry equal weight in the proposal evaluation:

1. Program Planning and Ability to Achieve Program Objectives: Program objectives should be stated clearly and should reflect the applicant's expertise in the subject area and region. Objectives should respond to the priority topics in this announcement and should relate to the current conditions in the target countries. A detailed agenda and relevant work plan should explain how objectives will be achieved and should include a timetable for completion of major tasks. The substance of workshops, internships, seminars and/or consulting should be described in detail. Sample training schedules should be outlined. Responsibilities of in-country partners should be clearly described.

2. Institutional Capacity: The proposal should include (1) the U.S. institution's mission and date of establishment; (2) detailed information about the in-country partner institution's capacity and the history of the U.S. and in-country partnership; (3) an outline of prior awards—U.S. government and private support received for the target theme/region; and (4) descriptions of experienced staff members who will implement the program. Proposed personnel and institutional resources should be adequate and appropriate to achieve the program's goals. The proposal should reflect the institution's expertise in the subject area and knowledge of the conditions in the target country. Proposals should demonstrate an institutional record of successful exchange programs, including responsible fiscal management and full compliance with all reporting requirements for past Bureau grants as determined by Bureau Grant Staff. The Bureau will consider the past performance of prior recipients and the demonstrated potential of new applicants.

3. Cost Effectiveness and Cost Sharing: Overhead and administrative costs in the proposal budget, including salaries, honoraria and subcontracts for services, should be kept to a minimum. Under this review criterion proposals whose administrative costs are less than twenty-five (25) percent of the total funds requested from the Bureau will be considered more competitive. Applicants are strongly encouraged to cost share a portion of overhead and administrative expenses. Cost-sharing, including contributions from the applicant, the in-country partner, and other sources should be included in the budget request. Proposal budgets that do

not provide cost-sharing will be deemed not competitive in this category.

4. Support of Diversity: Proposals should demonstrate substantive support of the Bureau's policy on diversity. Achievable and relevant features should be cited in both program administration (selection of participants, program venues and program evaluation) and program content (orientation and wrap-up sessions, program meetings, resource materials and follow-up activities). Applicants should refer to the Bureau's Diversity, Freedom and Democracy Guidelines in the Proposal Submission Instructions (PSI).

5. Evaluation: Proposals should include a detailed plan to monitor and evaluate the program. A draft survey questionnaire plus a description of a methodology that will link outcomes to original project objectives should be provided. Successful applicants will be expected to submit intermediate reports after each project component concludes or on a quarterly basis, whichever is less frequent.

6. Post-Grant Activities: Applicants should provide a plan to conduct activities after the Bureau-funded project has concluded in order to ensure that Bureau-supported programs are not isolated events. Funds for all post-grant activities must be in the form of contributions from the applicant or sources outside of the Bureau. Costs for these activities should not appear in the proposal budget, but should be outlined in the narrative.

Authority

Overall grant making authority for this program is contained in the Mutual Educational and Cultural Exchange Act of 1961, Public Law 87-256, as amended, also known as the Fulbright-Hays Act. The purpose of the Act is "to enable the Government of the United States to increase mutual understanding between the people of the United States and the people of other countries * * *; to strengthen the ties which unite us with other nations by demonstrating the educational and cultural interests, developments, and achievements of the people of the United States and other nations * * * and thus to assist in the development of friendly, sympathetic and peaceful relations between the United States and the other countries of the world." The funding authority for the program above is provided through Fulbright-Hays legislation.

Notice

The terms and conditions published in this RFGP are binding and may not be modified by any Bureau representative. Explanatory information

provided by the Bureau that contradicts published language will not be binding.

Issuance of the RFGP does not constitute an award commitment on the part of the Government. The Bureau reserves the right to reduce, revise, or increase proposal budgets in accordance with the needs of the program and the availability of funds. Awards made will be subject to periodic reporting and evaluation requirements.

Notification

Final awards cannot be made until funds have been appropriated by Congress, allocated and committed through internal Bureau procedures.

Dated: April 9, 2004.

C. Miller Crouch,

Principal Deputy Assistant Secretary, Bureau of Educational and Cultural Affairs, Department of State.

[FR Doc. 04-8584 Filed 4-14-04; 8:45 am]

BILLING CODE 4710-05-P

DEPARTMENT OF STATE

[Public Notice 4657]

Public Meeting of Advisory Committee for the Study of Eastern Europe and the Independent States of the Former Soviet Union (Title VIII)

The Department of State announces that the Advisory Committee for the Study of Eastern Europe and the Independent States of the Former Soviet Union (Title VIII) will convene on Thursday, May 27, 2004, beginning at 10 a.m. in Room 1107, U.S. Department of State, Harry S Truman Building, 2201 C Street, NW., Washington, DC.

The Advisory Committee will recommend grant recipients for the FY 2004 competition of the Program for the Study of Eastern Europe and the Independent States of the Former Soviet Union in connection with the "Research and Training for Eastern Europe and the Independent States of the Former Soviet Union Act of 1983, as amended." The agenda will include opening statements by the Chairman and members of the committee, and, within the committee, discussion, approval, and recommendation that the Department of State negotiate grant agreements with certain "national organizations with an interest and expertise in conducting research and training concerning the countries of Eastern Europe and the Independent States of the Former Soviet Union," based on the guidelines contained in the call for applications published in the *Federal Register* on February 3, 2004. Following committee deliberation, interested members of the

public may make oral statements concerning the Title VIII program in general.

This meeting will be open to the public; however, attendance will be limited to the seating available. Entry into the Harry S Truman building is controlled and must be arranged in advance of the meeting. Those planning to attend should notify Susan Nelson, INR/RES, U.S. Department of State, (202) 736-4610 by Monday, May 24, 2004, providing their Full Name, Date of Birth, Social Security Number, Citizenship, and any requirements for special needs. All attendees must use the 2201 C Street, NW., entrance to the building. Visitors who arrive without prior notification and without photo identification will not be admitted.

Dated: April 6, 2004.

Kenneth E. Roberts,

Executive Director, Program for Study of Eastern Europe and Independent States of the Former Soviet Union, Department of State.

[FR Doc. 04-8574 Filed 4-14-04; 8:45 am]

BILLING CODE 4710-32-P

DEPARTMENT OF TRANSPORTATION

Office of the Secretary

Transportation Labor-Management Board Meeting

AGENCY: Department of Transportation, Office of the Secretary.

ACTION: Notice of meeting.

SUMMARY: The U.S. Department of Transportation (DOT) announces a meeting of the Transportation Labor-Management Board (Board). Notice of the meeting is required under the Federal Advisory Committee Act.

Time and Place: The Board will meet on Friday, April 30, 2004, at 10 a.m., at the U.S. Department of Transportation, Nassif Building, room 3246a, 400 Seventh Street, SW., Washington, DC 20590. The room is located on the 3rd floor.

Type of Meeting: The meeting is open to the public. Please note that visitors without a government identification badge should enter the Nassif Building at the Southwest lobby, for clearance at the Visitor's Desk. Seating will be available on a first-come, first-served basis. Handicapped individuals wishing to attend should contact DOT to obtain appropriate accommodations.

Point of Contact: Stephen Gomez, Executive Secretary, Transportation Labor-Management Board, U.S. Department of Transportation, Nassif Building, 400 Seventh Street, SW., room

7411, Washington, DC 20590, (202) 366-9455 or 4088.

SUPPLEMENTARY INFORMATION: The Board will be briefed on DOT's personnel and payroll migration to the Department of Interior's Federal Personnel and Payroll System (FPPS), the DOT Learning Management System, the results of the DOT Labor Relations Climate Survey, and the administration of OPM's 2004 human capital survey.

Public Participation: We invite interested persons and organizations to submit comments. Mail or deliver your comments or recommendations to Stephen Gomez at the address shown above. Comments should be received by April 23, 2004, in order to be considered at the April 30th meeting.

Issued in Washington, DC, on April 7, 2004.

For the U.S. Department of Transportation.

Linda Moody,

Associate Director, Workforce Environment and Pay Division.

[FR Doc. 04-8501 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-62-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Notice of Submission Deadline for International Slots for the Winter 2004-2005 Scheduling Season

AGENCY: Department of Transportation, FAA.

ACTION: Notice of submission deadline.

SUMMARY: On October 1, 1999, the FAA amended the regulations governing takeoff and landing slots and slot allocation procedures at certain High Density Traffic Airports as a result of the "Open Transborder" Agreement between the Government of the United States and the Government of Canada. One element of this final rule established that the deadline for submission of requests for international slots will be published in a *Federal Register* notice for each scheduling season. The purpose of the amendment is for the FAA deadline for international slots requests to coincide with the International Air Transport Association deadline for submission of international requests. In accordance with this amendment, the FAA announces in this notice that the deadline for submitting requests for international slots for allocation under 14 CFR 93.217 is May 17, 2004.

DATES: Requests for international slots must be submitted no later than May 17, 2004.

ADDRESSES: Requests may be submitted by mail to Slot Administration Office, AGC-220 Office of the Chief Counsel, 800 Independence Ave., SW., Washington, DC 20591; facsimile: 202-267-7277; ARINC: DCAYAXD; e-mail address: 7-AWA-slotadmin@faa.gov.

FOR FURTHER INFORMATION CONTACT: Lorelei Peter, Air Traffic and Operations Law Branch, Regulations Division, Office of the Chief Counsel, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone number: 202-267-3073.

Issued in Washington, DC, on April 4, 2004.

Andrew B. Steinberg,
Chief Counsel.

[FR Doc. 04-8511 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Summary Notice No. PE-2004-26]

Petitions for Exemption; Dispositions of Petitions Issued

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of dispositions of prior petitions.

SUMMARY: Pursuant to FAA's rulemaking provisions governing the application, processing, and disposition of petitions for exemption part 11 of title 14, Code of Federal Regulations (14 CFR), this notice contains a summary of certain dispositions of certain petitions previously received. The purpose of this notice is to improve the public's awareness of, and participation in, this aspect of FAA's regulatory activities.

FOR FURTHER INFORMATION CONTACT: Tim Adams (202) 267-8033, or Sandy Buchanan-Sumter (202) 267-7271, Office of Rulemaking (ARM-1), Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591.

This notice is published pursuant to 14 CFR 11.85 and 11.91.

Issued in Washington, DC, on April 9, 2004.

Donald P. Byrne,
Assistant Chief Counsel for Regulations.

Dispositions of Petitions

Docket No.: FAA-2002-12751.
Petitioner: F.S. Air Service, Inc.
Section of 14 CFR Affected: 14 CFR 135.143(c)(2).

Description of Relief Sought/Disposition: To permit F.S. Air Service,

Inc., to operate certain aircraft under part 135 without a TSO-C112 (Mode S) transponder installed on those aircraft. **Grant, 4/1/2004, Exemption No. 7845A**

Docket No.: FAA-2002-11509.

Petitioner: Atlantic Southeast Airlines, Inc.

Section of 14 CFR Affected: 14 CFR 121.434(c)(1)(ii).

Description of Relief Sought/Disposition: To permit Atlantic Southeast Airlines, Inc., to substitute a qualified and authorized check airman in place of a Federal Aviation Administration inspector to observe a qualifying pilot in command (PIC) while that PIC is performing prescribed duties during at least one flight leg that includes a takeoff and a landing when completing initial or upgrade training as specified in § 121.424. **Grant, 3/31/2004, Exemption No. 7135B**

Docket No.: FAA-2002-12416.

Petitioner: Air Transport Association of America.

Section of 14 CFR Affected: 14 CFR 121.309(f)(2).

Description of Relief Sought/Disposition: To permit Atlantic Transport Association of America member airlines to locate the aft megaphone at door 4-left on their Boeing 747 aircraft. **Grant, 4/1/2004, Exemption No. 6140E**

Docket No.: FAA-2002-11495.

Petitioner: Mountain Air Cargo.

Section of 14 CFR Affected: 14 CFR 121.345(c)(2).

Description of Relief Sought/Disposition: To permit Mountain Air Cargo to operate certain aircraft under part 121 without a TSO-C112 (Mode S) transponder installed on those aircraft. **Grant, 4/6/2004, Exemption No. 7801A**

Docket No.: FAA-2002-11424.

Petitioner: Empire Airlines.

Section of 14 CFR Affected: 14 CFR 121.345(c).

Description of Relief Sought/Disposition: To permit Empire Airlines to operate certain aircraft under part 121 without a TSO-C112 (Mode S) transponder installed on those aircraft. **Grant, 4/6/2004, Exemption No. 7800A**

Docket No.: FAA-2002-11564.

Petitioner: Cedar Rapids Police Department, Air Support Division.

Section of 14 CFR Affected: 14 CFR 91.209(a) and (b).

Description of Relief Sought/Disposition: To permit the Cedar Rapids Police Department, Air Support Division, to conduct air operations without lighted position and anticollision lights required by § 91.209. **Grant, 4/5/2004, Exemption No. 6780C**

Docket No.: FAA-2004-17352.

Petitioner: Mr. Don M. Newman.
Section of 14 CFR Affected: 14 CFR 91.109(a) and (b)(3).

Description of Relief Sought/Disposition: To permit Mr. Don M. Newman to conduct certain flight training and to provide simulated instrument flight experience in certain Beech airplanes that are equipped with a functioning throw-over control wheel. **Grant, 4/5/2004, Exemption No. 8287**

Docket No.: FAA-2002-12253.

Petitioner: Continental Airlines, Inc.

Section of 14 CFR Affected: 14 CFR 121.440(a) and SFAR 58, paragraph 6(b)(3)(ii)(A).

Description of Relief Sought/Disposition: To permit Continental Airlines, Inc., to meet line check requirements using an alternative line check program. **Grant, 4/5/2004, Exemption No. 7861B**

Docket No.: FAA-2002-11930.

Petitioner: High Adventure Air Charter, Guides & Outfitters, Inc.

Section of 14 CFR Affected: 14 CFR 135.143(c)(2).

Description of Relief Sought/Disposition: To permit High Adventure Air Charter, Guides & Outfitters, Inc., to operate certain aircraft under part 135 without a TSO-C112 (Mode S) transponder installed on those aircraft. **Grant, 3/29/2004, Exemption No. 7288B**

Docket No.: FAA-2004-17381.

Petitioner: Golden Gate Helicopters, LLC.

Section of 14 CFR Affected: 14 CFR 135.143(c)(2).

Description of Relief Sought/Disposition: To permit Golden Gate Helicopters, LLC, to operate certain aircraft under part 135 without a TSO-C112 (Mode S) transponder installed on those aircraft. **Grant, 3/31/2004, Exemption No. 8286**

Docket No.: FAA-2001-9940.

Petitioner: Peninsula Airways, Inc., d.b.a. PenAir.

Section of 14 CFR Affected: 14 CFR 121.574(a)(1) and (3).

Description of Relief Sought/Disposition: To permit Peninsula Airways, Inc., d.b.a. PenAir, to carry and operate oxygen storage and dispensing equipment for medical use by patients requiring emergency or continuing medical attention while onboard an aircraft operated by PenAir when the equipment is furnished and maintained by a hospital treating the patient. **Grant, 3/29/2004, Exemption No. 6523D**

Docket No.: FAA-2002-11578.

Petitioner: Northwest Seaplanes, Inc.
Section of 14 CFR Affected: 14 CFR 135.203(a)(1).

Description of Relief Sought/Disposition: To permit Northwest

Seaplanes, Inc., to conduct operations outside controlled airspace, over water, at an altitude below 500 feet above the surface but not less than 200 feet above the surface. *Grant, 3/29/2004, Exemption No. 6461E*

[FR Doc. 04-8502 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2004-17049]

Notice of Request for Comments on Renewing the Approval for an Information Collection: Motor Carrier Safety Assistance Program

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice and request for comments.

SUMMARY: This action informs the public that FMCSA intends to request the Office of Management and Budget (OMB) to renew approval for the information collection required by the Motor Carrier Safety Assistance Program (MCSAP). That information consists of grant application preparation, quarterly reports and electronic data documenting the results of driver/vehicle inspections performed by the States. This notice is required by the Paperwork Reduction Act.

DATES: You must submit comments by June 14, 2004.

ADDRESSES: Mail or hand deliver comments to the U. S. Department of Transportation, Dockets Management Facility, Room PL-401, 400 Seventh Street, SW., Washington, DC 20590, or submit electronically at <http://dmses.dot.gov/submit>. Be sure to include the docket number appearing in the heading of this document on your comment. All comments received will be available for examination and copying at the above address from 9 a.m. to 5 p.m., e.t., Monday through Friday, except Federal holidays. If you would like to be notified when your comment is received, you must include a self-addressed, stamped postcard or you may print the acknowledgment page that appears after submitting comments electronically.

FOR FURTHER INFORMATION CONTACT: James D. McCauley, (202) 366-0133, Office of Safety Programs, Federal Motor Carrier Safety Administration, Department of Transportation, 400 Seventh Street, SW., Washington, DC 20590. Office hours are from 7:30 a.m.

to 4 p.m., e.t., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Title: Motor Carrier Safety Assistance Program.

OMB Number: 2126-0010.

Background: Sections 401-404 of the Surface Transportation Assistance Act of 1982 (STAA) established a program of financial assistance to States for the purpose of implementing programs to enforce: (a) Federal rules, regulations, standards and orders applicable to commercial motor vehicle safety; and (b) compatible State rules, regulations, standards and orders. This grant-in-aid program is known as the Motor Carrier Safety Assistance Program. The Intermodal Surface Transportation Efficiency Act of 1991 (ISTEA) added programs, such as drug interdiction, traffic enforcement and size and weight activities to the core program established by the STAA.

The Transportation Equity Act for the 21st Century (TEA-21) further revised the MCSAP by broadening its purpose beyond enforcement activities and programs by requiring participating States to assume greater responsibility for improving motor carrier safety. The TEA-21 required States to develop performance-based plans reflecting national priorities and performance goals, revised the MCSAP funding distribution formula and created a new incentive funding program. As a result, States are given greater flexibility in designing programs to address national and State goals for reducing the number and severity of commercial motor vehicle (CMV) accidents. The implementing regulations were published in the *Federal Register* on March 21, 2000 (65 FR 15092).

In order to qualify for a grant, participating States must submit a Commercial Vehicle Safety Plan (CVSP). After the grant is awarded, States must submit inspection data and quarterly reports explaining work activities and accomplishments. The FMCSA monitors and evaluates a State's progress under its approved CVSP. The agency also determines whether a change in the State's level of effort is required to meet the intended objectives of the CVSP. If a State fails to operate within the guidelines of the approved CVSP or does not remedy any identified deficiencies or incompatibilities in a timely manner, the FMCSA may cease participation in that State's CVSP. This information collection provides the basis for these responsibilities and decisions.

States submit the CVSP in hard copy. The quarterly report and inspection data

continue to be collected electronically. The estimated annual burden for this collection increases slightly due to a growing number of driver/vehicle inspections.

Respondents: State and local MCSAP lead agencies.

Estimated Total Annual Burden: 11,854 hours (Grant application preparation: 848 hours; quarterly report preparation: 339 hours; and inspection data upload: 10,667 hours). The above figures reflect 20 percent of the total estimated hours to perform the activities listed since MCSAP reimburses up to 80 percent of the eligible costs incurred in the administration of an approved plan as set forth in 49 CFR 350.303, 350.309 and 350.311.

Public Comments Invited: We invite you to comment on any aspect of this information collection, including, but not limited to: (1) Whether the collection of information is necessary for the proper performance of the functions of the FMCSA, including whether the information has practical utility; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the collected information; and (4) ways to minimize the collection burden without reducing the quality of the information collected.

Electronic Access and Filing: You may submit or retrieve comments online through the Docket Management System (DMS) at <http://dmses.dot.gov/submit>. Acceptable formats include: MS Word (versions 95 to 97), MS Word for Mac (versions 6 to 8), Rich Text File (RTF), American Standard Code Information Interchange (ASCII)(TXT), Portable Document Format (PDF), and WordPerfect (versions 7 to 8). The DMS is available 24 hours each day, 365 days each year. Electronic submission and retrieval help and guidelines are available under the help section of the Web site. You may also download an electronic copy of this document from the DOT Docket Management System on the Internet at <http://dms.dot.gov/search.htm>. Please include the docket number appearing in the heading of this document.

Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. chapter 35, as amended; and 49 CFR 1.73.

Issued on: April 7, 2004.

Annette M. Sandberg,
Administrator.

[FR Doc. 04-8499 Filed 4-14-04; 8:45 am]

BILLING CODE 4910-EX-P

DEPARTMENT OF TRANSPORTATION**National Highway Traffic Safety Administration**

[Docket No. NHTSA 2001-11041, Notice 2]

Toyota Motor Corporation, Denial of Application for Decision of Inconsequential Noncompliance

Toyota Motor Corporation (TMC) has determined that certain 2000-2001 Model Year (MY) Celicas are equipped with daytime running lamps (DRLs) whose location fails to comply with the spacing requirements of Federal Motor Vehicle Safety Standard (FMVSS) No. 108, "Lamps, Reflective Devices and Associated Equipment." Toyota has filed an appropriate report pursuant to 49 CFR part 573, "Defect and Noncompliance Reports." Toyota has also applied to be exempted from the notification and remedy requirements of 49 U.S.C chapter 301—"Motor Vehicle Safety" on the basis that the noncompliance is inconsequential to motor vehicle safety.

Notice of receipt of the application was published in the *Federal Register* (67 FR 1270) on January 9, 2002. Opportunity was afforded for public comment until February 8, 2002. One comment was received from Koito Manufacturing Co., LTD. (Koito), a lighting manufacturer, and two comments were received from individuals, Steve Johnson and Margaret Coleman.

Paragraph S5.5.11 (a)(4) of FMVSS No. 108 states that " * * * if not optically combined with a turn signal lamp, [the DRL] is located so that the distance from its lighted edge to the optical center of the nearest turn signal lamp is not less than 100mm, unless * * * the luminous intensity of the DRL is not more than 2,600 candela at any location in the beam * * * "

Between May 7, 1999 and June 18, 2001, Toyota produced 92,794 MY 2000-2001 Celicas with DRLs that do not meet the FMVSS No. 108 minimum spacing requirements relating to turn signals. As stated above, unless the maximum luminous intensity of the DRL is not more than 2,600 candela (cd) at any location in the beam, the optical center of the turn signal must be at least 100 millimeters (mm) from the lighted edge of the DRL. The peak intensity of the Celica DRLs is 5,880 cd and the distance between the optical center of the turn signal and the lighted edge of the DRL is 45.6 mm. Thus, the spacing is too close and the DRL peak intensity is too high.

Toyota supports its application for inconsequential noncompliance with the following:

Toyota conducted subjective evaluations of turn signal visibility using 20 contractors for the subject vehicles under various conditions, and confirmed that visibility for the subject vehicles is substantially better than vehicles that were modified to meet the minimum turn signal/maximum DRL luminous intensity permitted by the

standard. According to Toyota's evaluation, the flashing of the subject turn signals can be readily discerned by a driver in an oncoming vehicle at a distance of 300 feet, and much more so than vehicles with modified signals/DRLs. The assessment distance of 300 feet is the same used in NHTSA's own evaluation of turn signal masking, as described in the final rule published in the Monday, January 11, 1993, *Federal Register* (58 FR 3500).


In addition to the subjective measures, [Toyota also provides] the following technical factors which contribute to good visibility of the turn signal lamps:

The turn signal lighted area is 45.1 cm², two times larger than the 22 cm² required by FMVSS 108.

The luminous intensity of the subject vehicle's turn signal lamps [is] 568 cd, or 2.8 times the minimum value of 200 cd.

The substantial distance from the turn signal optical center (bulb filament axes) to the DRL's lighted edge is 82 mm, exceeding 80% of the requirements. In this case, the "substantial" distance refers to the distance from the turn signal's optical center to the actual lighted edge "A" [as shown in the figure below], although the theoretical lighted edge is point "C" (45.6mm). In [the figure below], the lighted range from A to C of the reflector emits only light which is parallel to the axis of the DRL, which can only be seen by drivers in oncoming vehicles that are looking along the optical axis of the DRL. However, as one moves off center, this light is no longer visible. Therefore the perceptible DRL's lighted area, except for the unique case where the eye-point is on the optical axis of the DRL, is actually from A to B (as shown in the figure).

BILLING CODE 4910-59-P

**BILLING CODE 4910-59-C**

The subject vehicles meet all of the requirements of [Canadian Motor Vehicle Safety Standard (CMVSS)] 108 and the identical DRL requirements [that] are found in FMVSS 108 prior to October 1, 1995.

Finally, although Toyota has sold approximately 100,000 of the subject vehicles since the summer of 1999 in the USA and Canada, it has not received any customer complaints [or] accident reports that alleged problems with turn signal visibility or masking.

As stated above, three public comments were received. The first comment was from Koito. It supported Toyota's position that the noncompliance is inconsequential to safety. Koito stated that the

requirements for DRL/turn signal spacing and maximum intensity contain two points that are "contradictory and controversial in terms of motor vehicle safety." Regarding the situation when the turn signal lamp is located less than 100 mm from the lighted edge of the DRL, CMVSS No. 108, the Canadian standard, requires that the DRL have an intensity of 2,600 cd or less or that the front turn signal lamp have its minimum luminous intensities multiplied by a factor of 2.5. FMVSS No. 108 requires these two conditions to be met concurrently. Koito states that this "difference generates some controversial difficulties in designing a

DRL for [the] U.S. and Canadian market because a design could be a violation of [law] while it is fully supported by the requirement of the other country."

Regarding the luminous intensity requirements, Koito points out that FMVSS No. 108 does not require any limitation of luminous intensity when a DRL is optically combined with a lower beam headlamp, provided that a turn signal located within 100 mm of the DRL has its minimum required luminous intensities multiplied by 2.5. Koito states that there are many examples of lower beam headlamps that have a luminous intensity of 2,600 cd or higher because Figure 15 in FMVSS No.

108 allows a lower beam headlamp to have an intensity of up to 5,000 cd at test point H-V. In summation, Koito stated that the current wording of FMVSS No. 108 does not fully explain its technical legitimacy.

The second comment was from Mr. Steve Johnson, an individual. Mr. Johnson is in favor of denying the petition due to the large margin of noncompliance. He also stated that, when he encountered one of the subject vehicles making a turn about 240 feet away from him, he could not see the turn signal due to the glare from the DRL. When the vehicle had begun to make the turn and the DRL was pointed away from his line of sight, he could then see the turn signal.

The third comment was from Ms. Margaret Coleman, also an individual. Ms. Coleman stated her dislike for DRLs and recommended that the DRLs on the subject vehicles be disconnected. She did not comment on the merits of Toyota's rationale for granting its petition.

The reason for specifying a spacing relationship is to lessen the likelihood of motor vehicle crashes, deaths, and injuries, by ensuring visibility of a vehicle's turn signal lamps in daylight. In this case, Toyota claimed that, although the DRLs on the Celica do not meet the spacing requirements, the visibility of the vehicles is substantially better than vehicles that comply with the permissible spacing requirements. Toyota measured the distance from the DRL's lighted edge to the optical center of the nearest turn signal lamp as 45.6 mm, not the required minimum of 100 mm. Also, the DRL emits more than twice the maximum luminous intensity specified in the standard for being located closer than 100 mm from the turn signal's optical center. However, Toyota found in subjective testing that the turn signals could be readily discerned by a driver in an oncoming vehicle at a distance of 300 feet. It believes that this is better performance than vehicles with compliant DRL/turn signal spacing.

The agency has reviewed Toyota's rationale for granting the petition and does not agree. Toyota produced almost 100,000 vehicles on which the required spacing between the DRL and turn signal is approximately 55 percent below the minimum required distance. The agency notes that the noncompliance would not have occurred if the DRL had an intensity of 2,600 cd or less. However, Toyota chose not to do this.

Toyota based part of its rationale for granting the petition on the subjective evaluations of 20 contractors. We do not

find this type of subjective evaluation persuasive, particularly when noncompliances are far from minimum required levels.

Toyota also discussed an alternative method of measuring the distance between the DRL's lighted edge and the optical center of the turn signal. The above figure outlines these two spacing measurements. Toyota stated that the spacing of 45.6 mm between the DRL's lighted edge and the turn signal's optical center (line C to the optical center) would only be seen when looking along the optical axis of the DRL. In other positions, the DRL's lighted edge (line A) would be seen by observers as being 82 mm from the turn signal's optical center. The agency does not find merit in this rationale. First, the distance measured from line A is 18 mm less than the minimum requirement. This is still a significant difference. Second, although the distance from line C to the turn signal's optical center (45.6 mm) may not best represent the DRL's lighted edge in all conditions, it does represent a worst-case scenario. The intent of the standard is to account for all possible viewing locations. Certainly, there will be situations where opposing drivers will be looking along the optical axis of the subject vehicles' DRL. For example, if a vehicle is attempting to make a left turn in front of oncoming traffic, drivers of the oncoming vehicles may be in a position where the turn signal is not visible. Mr. Johnson described a similar situation in his comments.

In its comments on the petition, Koito stated that the FMVSS No. 108 requirements for DRL/turn signal spacing and intensity are not the same as those in the Canadian standard. It referred to "difficulties in designing a DRL for [the] U.S. and Canadian market." While it is true that, in this case, FMVSS No. 108 is more stringent than CMVSS No. 108, we note that it is still possible to build a vehicle having DRLs that meets both standards albeit using a different type of DRL configuration. In any event, vehicles sold in the United States are required to meet United States standards.

Finally, Koito stated that "the current wording of FMVSS No. 108 does not fully explain its technical legitimacy." Explanation of the rationale for a requirement is not contained in the regulatory language in the standard. Generally, it is found in the preambles to the notice of proposed rulemaking and the final rule in the *Federal Register*. The final rule amending FMVSS No. 108 to add the current spacing requirements was published on December 16, 1993 (58 FR 65673).

In consideration of the foregoing, NHTSA has decided that Toyota has not met its burden of persuasion that the noncompliance it describes is inconsequential to motor vehicle safety, and that it should not be exempted from the notification and remedy requirements of the statute. Accordingly, its application is hereby denied and it must proceed to notify and remedy as required by statute, at no cost to the consumer.

Authority: (49 U.S.C. 30118(d) and 30120(h); delegations of authority at 49 CFR 1.50 and 501.8).

Issued on: April 8, 2004.

Roger A. Saul,

Director, Office of Crashworthiness Standards.

[FR Doc. 04-8500 Filed 4-14-04; 8:45 am]
BILLING CODE 4910-59-P

DEPARTMENT OF THE TREASURY

Submission for OMB Review; Comment Request

April 8, 2004.

The Department of the Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104-13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 11000, 1750 Pennsylvania Avenue, NW., Washington, DC 20220.

DATES: Written comments should be received on or before May 17, 2004, to be assured of consideration.

Bureau of the Public Debt (PD)

OMB Number: 1535-0094.

Form Number: None.

Type of Review: Extension.

Title: Regulations Governing Payments by the Authorized Clearing House Method on Account of United States Securities.

Description: The information is needed in order to make payments to investors in United States Securities by the Automated Clearing House (ACH) method.

Respondents: State, local or tribal government.

Estimated Number of Respondents: 1.

Estimated Burden Hours Per

Respondent: 1 hour.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 1 hour.

OMB Number: 1535-0095.

Form Number: None.

Type of Review: Extension.

Title: Regulations Governing United States Savings Bonds Series E/EE and H/HH.

Description: The regulations mandate the payment of H/HH interest by Direct Deposit (ACH method).

Respondents: Individuals or households, business or other for-profit, not-for-profit institutions, State, local or tribal government.

Estimated Number of Respondents: 1.

Estimated Burden Hours Per Respondent: 1 hour.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 1 hour.

OMB Number: 1535-0121.

Form Number: PD F 5376 and PD F 5377.

Type of Review: Extension.

Title: PD F 5376: U.S. Treasury Securities State and Local Government Series Change Request; and PD F 5377: U.S. Treasury Securities State and Local Government Series Early Redemption Request.

Description: These forms are used for accounts maintenance changes and early redemption of State and local government series securities.

Respondents: State, local or tribal government.

Estimated Number of Respondents: 3,350.

Estimated Burden Hours Per Respondent:

PD F 5376: 30 min.

PD F 5377: 30 min.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 1,675 hours.

OMB Number: 1535-0130.

Form Number: PD F 5387.

Type of Review: Extension.

Title: Request for Reissue of Series I United States Savings Bonds.

Description: This form is used to request reissue to add coowner or beneficiary, correct error, show change of name.

Respondents: Individuals or households.

Estimated Number of Respondents: 3,000.

Estimated Burden Hours Per Respondent: 30 minutes.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 1,500 hours.

OMB Number: 1535-0131.

Form Number: PD F 5394.

Type of Review: Extension.

Title: Application for Disposition of Series I Savings Bonds after the Death of the Registered Owner(s).

Description: This form is used to distribute Series I savings bonds after the death of the registered owner(s).

Respondents: Individuals or households.

Estimated Number of Respondents: 1,000.

Estimated Burden Hours Per Respondent: 45 minutes.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 750 hours.

OMB Number: 1535-0132.

Form Number: PD F 5386.

Type of Review: Extension.

Title: Request for Reissue of Series I Savings Bonds by the Representative of the Estate of an Incompetent or Minor.

Description: This form is used by court-appointed or other authorized individual to request reissue on behalf of an incompetent, minor, or other person under a legal disability.

Respondents: Individuals or households.

Estimated Number of Respondents: 1,000.

Estimated Burden Hours Per Respondent: 20 minutes.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 330 hours.

OMB Number: 1535-0133.

Form Number: PD F 5385.

Type of Review: Extension.

Title: Request for Payment of Series I Savings Bonds By The representative of the Estate of an Incompetent or Minor.

Description: This form is used by court-appointed or other authorized individual to request payment on behalf of an incompetent, minor, or other person under a legal disability.

Respondents: Individuals or households.

Estimated Number of Respondents: 1,000.

Estimated Burden Hours Per Respondent: 20 minutes.

Frequency of Response: On occasion.

Estimated Total Reporting Burden Hours: 330 hours.

Clearance Officer: Vicki S. Thorpe, (304) 480-6553, Bureau of the Public Debt, 200 Third Street, Parkersburg, West VA 26106-1328.

OMB Reviewer: Joseph F. Lackey, Jr., (202) 395-7316, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

Lois K. Holland,

Treasury, PRA Clearance Officer.

[FR Doc. 04-8565 Filed 4-14-04; 8:45 am]

BILLING CODE 4810-39-P

DEPARTMENT OF VETERANS AFFAIRS

Office of Research and Development; Government Owned Invention Available for Licensing

AGENCY: Office of Research and Development.

ACTION: Notice of government owned invention available for licensing.

SUMMARY: The invention listed below is owned by the U.S. Government as represented by the Department of Veterans Affairs, and is available for licensing in accordance with 35 U.S.C. 207 and 37 CFR part 404 and/or CRADA Collaboration under 15 U.S.C. 3710a to achieve expeditious commercialization of results of federally funded research and development. Foreign patents are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Technical and licensing information on the invention may be obtained by writing to: Robert W. Potts, Department of Veterans Affairs, Director Technology Transfer Program, Office of Research and Development (12TT), 810 Vermont Avenue, NW., Washington, DC 20420; fax: 202-254-0473; e-mail at bob.potts@hq.med.va.gov. Any request for information should include the Number and Title for the relevant invention as indicated below. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

SUPPLEMENTARY INFORMATION: The invention available for licensing is: U.S. Provisional Patent Application No. 60/532,889 "Macrophage Migration Inhibitory Factor: A Central Mediator of Inflammation in the Pelvic Viscera".

Dated: April 8, 2004.

Anthony J. Principi,

Secretary, Department of Veterans Affairs.

[FR Doc. 04-8562 Filed 4-14-04; 8:45 am]

BILLING CODE 8320-01-P

DEPARTMENT OF VETERANS AFFAIRS

Office of Research and Development; Government Owned Invention Available for Licensing and/or Cooperative Research and Development Agreement (CRADA) Collaboration

AGENCY: Office of Research and Development.

ACTION: Notice of government owned invention available for licensing.

SUMMARY: The invention listed below is owned by the U.S. Government as represented by the Department of Veterans Affairs, and is available for licensing in accordance with 35 U.S.C. 207 and 37 CFR part 404 and/or CRADA collaboration under 15 U.S.C. 3710a to achieve expeditious commercialization of results of federally funded research and development. Foreign patents are filed on selected inventions to extend

market coverage for U.S. companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Technical and licensing information on the invention may be obtained by writing to: Robert W. Potts, Department of Veterans Affairs, Director Technology Transfer Program, Office of Research and Development (12TT), 810 Vermont Avenue, NW., Washington, DC 20420; fax: 202-254-0473; e-mail at bob.potts@hq.med.va.gov. Any request for information should include the Number and Title for the relevant invention as indicated below. Issued

patents and published applications may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

SUPPLEMENTARY INFORMATION: The invention available for licensing is: VHA Docket No. 04-033 entitled "Mutations in PKCy are the Cause for Spinocerebellar Ataxia."

Dated: April 8, 2004.

Anthony J. Principi,
Secretary, Department of Veterans Affairs.

[FR Doc. 04-8563 Filed 4-14-04; 8:45 am]

BILLING CODE 8320-01-P



Federal Register

Thursday,
April 15, 2004

Part II

Department of Veterans Affairs

Reasonable Charges for Medical Care or
Services; 2004 Calendar Year Update;
Notice

**DEPARTMENT OF VETERANS
AFFAIRS**

**Reasonable Charges for Medical Care
or Services; 2004 Calendar Year
Update**

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: Section 17.101 of Title 38 of the Code of Federal Regulations sets forth the Department of Veterans Affairs (VA) medical regulations concerning "reasonable charges" for medical care or services provided or furnished by VA to a veteran:

- For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract;
- For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or
- For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

The regulations include methodologies for establishing billed amounts for the following types of charges: Acute inpatient facility charges; skilled nursing facility/sub-acute inpatient facility charges; partial hospitalization facility charges; outpatient facility charges; physician and other professional charges, including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by Healthcare Common Procedure Coding System (HCPCS) Level II codes. The regulations also provide that data for calculating actual charge amounts at individual VA facilities based on these

methodologies will either be published in a notice in the **Federal Register** or will be posted on the Internet site of the Veterans Health Administration Chief Business Office, currently at <http://www.va.gov/cbo>, under "Charge Data." Some of these charges are hereby updated as described in the **SUPPLEMENTARY INFORMATION** section of this notice. These changes are effective April 15, 2004.

When charges for medical care or services, provided or furnished at VA expense by either VA or non-VA providers, have not been established under other provisions of the regulations, the method for determining VA's charges is set forth at 38 CFR 17.101(a)(8).

This notice also includes a correction to Table G, Physician and Other Professional Services Relative Value Units (RVUS) by CPT/HCPCS Code.

FOR FURTHER INFORMATION CONTACT: Romona Greene, Chief Business Office (168), Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 254-0361. (This is not a toll free number.)

SUPPLEMENTARY INFORMATION: Of the charge types listed in the Summary section of this notice, acute inpatient facility charges and skilled nursing facility/sub-acute inpatient facility charges are not being changed. Acute inpatient facility charges remain the same as set forth in a notice published in the **Federal Register** on December 19, 2003 (68 FR 70867). Skilled nursing facility/sub-acute inpatient facility charges remain the same as set forth in a notice published in the **Federal Register** on October 2, 2003 (68 FR 56892).

Based on the methodologies set forth in 38 CFR 17.101, this document provides an update to charges for 2004 HCPCS Level II and Current Procedural Technology (CPT) codes. Charges are also being updated based on more recent versions of data sources for the following charge types: Partial hospitalization facility charges; outpatient facility charges; physician and other professional charges,

including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes. These updated charges are effective April 15, 2004.

In this update, we are retaining the table designations used in the notice published in the **Federal Register** on October 2, 2003 (68 FR 56892). Accordingly, the tables identified as being updated by this notice correspond to the applicable tables published in the October 2 notice, beginning with Table C. Table G is not being updated but is being republished in this notice to reflect a correction to the data in columns titled Facility Practice Expense RVU's and Non-Facility Practice Expense RVU's which were inadvertently reversed in the October 2, 2003 **Federal Register** Notice.

We have updated the list of data sources presented in Supplementary Table 1 to reflect the updated data sources used to establish the updated charges described in this notice.

As a reminder, in Supplementary Table 3 published in the **Federal Register** dated December 19, 2003, we set forth the list of VA medical facility locations, which includes their three-digit Zip Codes and provider-based/non-provider-based designations. In accordance with the final rule, subsequent updates to Supplementary Table 3 will be posted on the Internet site of the Veterans Health Administration Chief Business Office.

Consistent with the regulations, the updated data tables and supplementary tables containing the changes described are published with this notice and will be effective until changed by a subsequent **Federal Register** notice.

Approved: March 22, 2004.

Anthony J. Principi,
Secretary of Veterans Affairs.

BILLING CODE 8320-01-P

TABLE C. — OBSERVATION CARE FACILITY NATIONWIDE BASE AND HOURLY CHARGES

Description	Base Charge	Hourly Charge
Observation Facility Care	\$188.39	\$38.40

TABLE D. — PARTIAL HOSPITALIZATION FACILITY NATIONWIDE PER DIEM CHARGE

Description	All-Inclusive Per Diem Charge
Partial Hospitalization Facility	\$454.05

TABLE E. — AMBULANCE AND OTHER EMERGENCY TRANSPORTATION CHARGES BY HCPCS CODE

HCPCS Code	Description	Charge
A0380	Basic Life Support Mileage (Per Mile)	\$10.46
A0390	Advanced Life Support Mileage (Per Mile)	\$9.66
A0425	Ground Mileage, Per Statute Mile	\$10.64
A0426	Ambulance Service, Advanced Life Support, Non-Emergency Transport, Level 1 (ALS 1)	\$668.15
A0427	Ambulance Service, Advanced Life Support, Emergency Transport, Level 1 (ALS1-Emergency)	\$732.06
A0428	Ambulance Service, Basic Life Support, Non-Emergency Transport, (BLS)	\$435.75
A0429	Ambulance Service, Basic Life Support, Emergency Transport (BLS-Emergency)	\$488.04
A0430	Ambulance Service, Conventional Air Services, Transport, One Way (Fixed Wing)	\$4,706.56
A0431	Ambulance Service; Conventional Air Services, Transport, One Way (Rotary Wing)	\$5,625.24
A0435	Fixed Wing Air Mileage, Per Statute Mile	\$44.16
A0436	Rotary Wing Air Mileage, Per Statute Mile	\$67.61

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 1 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
10021	Fna w/o image		+	\$219.01	
10022	Fna w/image		+	\$411.06	
10040	Acne surgery		+	\$175.61	
10060	Drainage of skin abscess		+	\$447.81	
10061	Drainage of skin abscess		+	\$447.81	
10080	Drainage of pilonidal cyst		+	\$447.81	
10081	Drainage of pilonidal cyst		+	\$3,188.56	
10120	Remove foreign body		+	\$447.81	
10121	Remove foreign body		+	\$3,862.11	
10140	Drainage of hematoma/fluid		+	\$3,188.56	
10160	Puncture drainage of lesion		+	\$248.71	
10180	Complex drainage, wound		+	\$3,188.56	
11000	Debride infected skin		+	\$432.27	
11001	Debride infected skin add-on		+	\$206.25	
11010	Debride skin, fx		+	\$1,068.77	
11011	Debride skin/muscle, fx		+	\$1,068.77	
11012	Debride skin/muscle/bone, fx		+	\$1,068.77	
11040	Debride skin, partial		+	\$432.27	
11041	Debride skin, full		+	\$432.27	
11042	Debride skin/tissue		+	\$696.76	
11043	Debride tissue/muscle		+	\$696.76	
11044	Debride tissue/muscle/bone		+	\$2,181.43	
11055	Trim skin lesion		+	\$206.25	
11056	Trim skin lesions, 2 to 4		+	\$206.25	
11057	Trim skin lesions, over 4		+	\$303.14	
11100	Biopsy, skin lesion		+	\$248.71	
11101	Biopsy, skin add-on		+	\$248.71	
11200	Removal of skin tags		+	\$303.14	
11201	Remove skin tags add-on		+	\$432.27	
11300	Shave skin lesion		+	\$206.25	
11301	Shave skin lesion		+	\$206.25	
11302	Shave skin lesion		+	\$206.25	
11303	Shave skin lesion		+	\$432.27	
11305	Shave skin lesion		+	\$303.14	
11306	Shave skin lesion		+	\$303.14	
11307	Shave skin lesion		+	\$303.14	
11308	Shave skin lesion		+	\$303.14	
11310	Shave skin lesion		+	\$303.14	
11311	Shave skin lesion		+	\$303.14	
11312	Shave skin lesion		+	\$303.14	
11313	Shave skin lesion		+	\$696.76	
11400	Removal of skin lesion		+	\$1,068.77	
11401	Removal of skin lesion		+	\$1,068.77	
11402	Removal of skin lesion		+	\$1,068.77	
11403	Removal of skin lesion		+	\$1,917.62	
11404	Removal of skin lesion		+	\$3,862.11	
11406	Removal of skin lesion		+	\$3,862.11	
11420	Removal of skin lesion		+	\$1,917.62	
11421	Removal of skin lesion		+	\$1,917.62	
11422	Removal of skin lesion		+	\$1,917.62	
11423	Removal of skin lesion		+	\$1,917.62	
11424	Removal of skin lesion		+	\$3,862.11	
11426	Removal of skin lesion		+	\$5,085.32	
11440	Removal of skin lesion		+	\$1,068.77	
11441	Removal of skin lesion		+	\$1,068.77	
11442	Removal of skin lesion		+	\$1,917.62	
11443	Removal of skin lesion		+	\$1,917.62	
11444	Removal of skin lesion		+	\$1,917.62	
11446	Removal of skin lesion		+	\$5,085.32	
11450	Removal, sweat gland lesion		+	\$5,085.32	
11451	Removal, sweat gland lesion		+	\$5,085.32	
11462	Removal, sweat gland lesion		+	\$5,085.32	
11463	Removal, sweat gland lesion		+	\$5,085.32	
11470	Removal, sweat gland lesion		+	\$5,085.32	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 2 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
11471	Removal, sweat gland lesion		+	\$5,085.32	
11600	Removal of skin lesion		+	\$1,068.77	
11601	Removal of skin lesion		+	\$1,068.77	
11602	Removal of skin lesion		+	\$1,068.77	
11603	Removal of skin lesion		+	\$1,917.62	
11604	Removal of skin lesion		+	\$1,917.62	
11606	Removal of skin lesion		+	\$3,862.11	
11620	Removal of skin lesion		+	\$1,917.62	
11621	Removal of skin lesion		+	\$1,068.77	
11622	Removal of skin lesion		+	\$1,917.62	
11623	Removal of skin lesion		+	\$3,862.11	
11624	Removal of skin lesion		+	\$3,862.11	
11626	Removal of skin lesion		+	\$5,085.32	
11640	Removal of skin lesion		+	\$1,917.62	
11641	Removal of skin lesion		+	\$1,917.62	
11642	Removal of skin lesion		+	\$1,917.62	
11643	Removal of skin lesion		+	\$1,917.62	
11644	Removal of skin lesion		+	\$3,862.11	
11646	Removal of skin lesion		+	\$5,085.32	
11719	Trim nail(s)		+	\$180.03	
11720	Debride nail, 1-5		+	\$180.03	
11721	Debride nail, 6 or more		+	\$180.03	
11730	Removal of nail plate		+	\$303.14	
11732	Remove nail plate, add-on		+	\$206.25	
11740	Drain blood from under nail		+	\$180.03	
11750	Removal of nail bed		+	\$1,068.77	
11752	Remove nail bed/finger tip		+	\$5,085.32	
11755	Biopsy, nail unit		+	\$1,068.77	
11760	Repair of nail bed		+	\$453.09	
11762	Reconstruction of nail bed		+	\$453.09	
11765	Excision of nail fold, toe		+	\$432.27	
11770	Removal of pilonidal lesion		+	\$5,085.32	
11771	Removal of pilonidal lesion		+	\$5,085.32	
11772	Removal of pilonidal lesion		+	\$5,085.32	
11900	Injection into skin lesions		+	\$206.25	
11901	Added skin lesions injection		+	\$206.25	
11920	Correct skin color defects		+	\$453.09	
11921	Correct skin color defects		+	\$453.09	
11922	Correct skin color defects		+	\$453.09	
11950	Therapy for contour defects		+	\$453.09	
11951	Therapy for contour defects		+	\$453.09	
11952	Therapy for contour defects		+	\$453.09	
11954	Therapy for contour defects		+	\$453.09	
11960	Insert tissue expander(s)		+	\$4,298.81	
11970	Replace tissue expander		+	\$4,298.81	
11971	Remove tissue expander(s)		+	\$5,085.32	
11976	Removal of contraceptive cap		+	\$1,068.77	
11980	Implant hormone pellet(s)			\$170.98	
11981	Insert drug implant device			\$170.98	
11982	Remove drug implant device			\$170.98	
11983	Remove/insert drug implant			\$170.98	
12001	Repair superficial wound(s)		+	\$453.09	
12002	Repair superficial wound(s)		+	\$453.09	
12004	Repair superficial wound(s)		+	\$453.09	
12005	Repair superficial wound(s)		+	\$453.09	
12006	Repair superficial wound(s)		+	\$453.09	
12007	Repair superficial wound(s)		+	\$453.09	
12011	Repair superficial wound(s)		+	\$453.09	
12013	Repair superficial wound(s)		+	\$453.09	
12014	Repair superficial wound(s)		+	\$453.09	
12015	Repair superficial wound(s)		+	\$453.09	
12016	Repair superficial wound(s)		+	\$453.09	
12017	Repair superficial wound(s)		+	\$453.09	
12018	Repair superficial wound(s)		+	\$453.09	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association All rights reserved

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 3 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
12020	Closure of split wound		+	\$453.09	
12021	Closure of split wound		+	\$453.09	
12031	Layer closure of wound(s)		+	\$453.09	
12032	Layer closure of wound(s)		+	\$453.09	
12034	Layer closure of wound(s)		+	\$453.09	
12035	Layer closure of wound(s)		+	\$453.09	
12036	Layer closure of wound(s)		+	\$453.09	
12037	Layer closure of wound(s)		+	\$1,401.69	
12041	Layer closure of wound(s)		+	\$453.09	
12042	Layer closure of wound(s)		+	\$453.09	
12044	Layer closure of wound(s)		+	\$453.09	
12045	Layer closure of wound(s)		+	\$453.09	
12046	Layer closure of wound(s)		+	\$453.09	
12047	Layer closure of wound(s)		+	\$1,401.69	
12051	Layer closure of wound(s)		+	\$453.09	
12052	Layer closure of wound(s)		+	\$453.09	
12053	Layer closure of wound(s)		+	\$453.09	
12054	Layer closure of wound(s)		+	\$453.09	
12055	Layer closure of wound(s)		+	\$453.09	
12056	Layer closure of wound(s)		+	\$453.09	
12057	Layer closure of wound(s)		+	\$1,401.69	
13100	Repair of wound or lesion		+	\$1,401.69	
13101	Repair of wound or lesion		+	\$1,401.69	
13102	Repair wound/lesion add-on		+	\$453.09	
13120	Repair of wound or lesion		+	\$453.09	
13121	Repair of wound or lesion		+	\$453.09	
13122	Repair wound/lesion add-on		+	\$453.09	
13131	Repair of wound or lesion		+	\$453.09	
13132	Repair of wound or lesion		+	\$453.09	
13133	Repair wound/lesion add-on		+	\$453.09	
13150	Repair of wound or lesion		+	\$1,401.69	
13151	Repair of wound or lesion		+	\$453.09	
13152	Repair of wound or lesion		+	\$1,401.69	
13153	Repair wound/lesion add-on		+	\$453.09	
13160	Late closure of wound		+	\$4,298.81	
14000	Skin tissue rearrangement		+	\$4,298.81	
14001	Skin tissue rearrangement		+	\$4,298.81	
14020	Skin tissue rearrangement		+	\$4,298.81	
14021	Skin tissue rearrangement		+	\$4,298.81	
14040	Skin tissue rearrangement		+	\$4,298.81	
14041	Skin tissue rearrangement		+	\$4,298.81	
14060	Skin tissue rearrangement		+	\$4,298.81	
14061	Skin tissue rearrangement		+	\$4,298.81	
14300	Skin tissue rearrangement		+	\$4,298.81	
14350	Skin tissue rearrangement		+	\$4,298.81	
15000	Skin graft		+	\$1,401.69	
15001	Skin graft add-on		+	\$1,401.69	
15050	Skin pinch graft		+	\$1,401.69	
15100	Skin split graft		+	\$4,298.81	
15101	Skin split graft add-on		+	\$4,298.81	
15120	Skin split graft		+	\$4,298.81	
15121	Skin split graft add-on		+	\$4,298.81	
15200	Skin full graft		+	\$4,298.81	
15201	Skin full graft add-on		+	\$1,401.69	
15220	Skin full graft		+	\$4,298.81	
15221	Skin full graft add-on		+	\$1,401.69	
15240	Skin full graft		+	\$4,298.81	
15241	Skin full graft add-on		+	\$1,401.69	
15260	Skin full graft		+	\$4,298.81	
15261	Skin full graft add-on		+	\$1,401.69	
15342	Cultured skin graft, 25 cm		+	\$453.09	
15343	Culture skin graft addl 25 cm		+	\$453.09	
15350	Skin homograft		+	\$2,147.31	
15351	Skin homograft add-on		+	\$4,298.81	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 4 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
15400	Skin heterograft		+	\$1,401.69	
15401	Skin heterograft add-on		+	\$1,401.69	
15570	Form skin pedicle flap		+	\$4,298.81	
15572	Form skin pedicle flap		+	\$4,298.81	
15574	Form skin pedicle flap		+	\$4,298.81	
15576	Form skin pedicle flap		+	\$4,298.81	
15600	Skin graft		+	\$4,298.81	
15610	Skin graft		+	\$4,298.81	
15620	Skin graft		+	\$4,298.81	
15630	Skin graft		+	\$4,298.81	
15650	Transfer skin pedicle flap		+	\$4,298.81	
15732	Muscle-skin graft, head/neck		+	\$4,298.81	
15734	Muscle-skin graft, trunk		+	\$4,298.81	
15736	Muscle-skin graft, arm		+	\$4,298.81	
15738	Muscle-skin graft, leg		+	\$4,298.81	
15740	Island pedicle flap graft		+	\$4,298.81	
15750	Neurovascular pedicle graft		+	\$4,298.81	
15760	Composite skin graft		+	\$4,298.81	
15770	Derma-fat-fascia graft		+	\$4,298.81	
15775	Hair transplant punch grafts		+	\$1,401.69	
15776	Hair transplant punch grafts		+	\$1,401.69	
15780	Abrasion treatment of skin		+	\$5,085.32	
15781	Abrasion treatment of skin		+	\$1,068.77	
15782	Dressing change not for burn		+	\$1,068.77	
15783	Abrasion treatment of skin		+	\$696.76	
15786	Abrasion, lesion, single		+	\$206.25	
15787	Abrasion, lesions, add-on		+	\$303.14	
15788	Chemical peel, face, epiderm		+	\$206.25	
15789	Chemical peel, face, dermal		+	\$432.27	
15792	Chemical peel, nonfacial		+	\$206.25	
15793	Chemical peel, nonfacial		+	\$206.25	
15810	Salabrasion		+	\$696.76	
15811	Salabrasion		+	\$696.76	
15819	Plastic surgery, neck		+	\$1,401.69	
15820	Revision of lower eyelid		+	\$4,298.81	
15821	Revision of lower eyelid		+	\$4,298.81	
15822	Revision of upper eyelid		+	\$4,298.81	
15823	Revision of upper eyelid		+	\$4,298.81	
15824	Removal of forehead wrinkles		+	\$4,298.81	
15825	Removal of neck wrinkles		+	\$4,298.81	
15826	Removal of brow wrinkles		+	\$4,298.81	
15828	Removal of face wrinkles		+	\$4,298.81	
15829	Removal of skin wrinkles		+	\$4,298.81	
15831	Excise excessive skin tissue		+	\$5,085.32	
15832	Excise excessive skin tissue		+	\$5,085.32	
15833	Excise excessive skin tissue		+	\$5,085.32	
15834	Excise excessive skin tissue		+	\$5,085.32	
15835	Excise excessive skin tissue		+	\$1,401.69	
15836	Excise excessive skin tissue		+	\$3,862.11	
15837	Excise excessive skin tissue		+	\$3,862.11	
15838	Excise excessive skin tissue		+	\$3,862.11	
15839	Excise excessive skin tissue		+	\$3,862.11	
15840	Graft for face nerve palsy		+	\$4,298.81	
15841	Graft for face nerve palsy		+	\$4,298.81	
15842	Flap for face nerve palsy		+	\$4,298.81	
15845	Skin and muscle repair, face		+	\$4,298.81	
15850	Removal of sutures		+	\$696.76	
15851	Removal of sutures		+	\$696.76	
15852	Dressing change not for burn			\$170.98	
15860	Test for blood flow in graft			\$109.96	
15876	Suction assisted lipectomy		+	\$4,298.81	
15877	Suction assisted lipectomy		+	\$4,298.81	
15878	Suction assisted lipectomy		+	\$4,298.81	
15879	Suction assisted lipectomy		+	\$4,298.81	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 5 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
15920	Removal of tail bone ulcer		+	\$1,068.77	
15922	Removal of tail bone ulcer		+	\$4,298.81	
15931	Remove sacrum pressure sore		+	\$5,085.32	
15933	Remove sacrum pressure sore		+	\$5,085.32	
15934	Remove sacrum pressure sore		+	\$4,298.81	
15935	Remove sacrum pressure sore		+	\$4,298.81	
15936	Remove sacrum pressure sore		+	\$4,298.81	
15937	Remove sacrum pressure sore		+	\$4,298.81	
15940	Remove hip pressure sore		+	\$5,085.32	
15941	Remove hip pressure sore		+	\$5,085.32	
15944	Remove hip pressure sore		+	\$4,298.81	
15945	Remove hip pressure sore		+	\$4,298.81	
15946	Remove hip pressure sore		+	\$4,298.81	
15950	Remove thigh pressure sore		+	\$5,085.32	
15951	Remove thigh pressure sore		+	\$5,085.32	
15952	Remove thigh pressure sore		+	\$4,298.81	
15953	Remove thigh pressure sore		+	\$4,298.81	
15956	Remove thigh pressure sore		+	\$4,298.81	
15958	Remove thigh pressure sore		+	\$4,298.81	
15999	Removal of pressure sore		+	\$5,085.32	
16000	Initial treatment of burn(s)		+	\$206.25	
16010	Treatment of burn(s)		+	\$696.76	
16015	Treatment of burn(s)		+	\$4,435.62	
16020	Treatment of burn(s)		+	\$303.14	
16025	Treatment of burn(s)		+	\$206.25	
16030	Treatment of burn(s)		+	\$432.27	
17000	Destroy benign/premalignant lesion		+	\$175.61	
17003	Destroy lesions, 2-14		+	\$175.61	
17004	Destroy lesions, 15 or more		+	\$602.01	
17106	Destruction of skin lesions		+	\$602.01	
17107	Destruction of skin lesions		+	\$602.01	
17108	Destruction of skin lesions		+	\$602.01	
17110	Destruct lesion, 1-14		+	\$175.61	
17111	Destruct lesion, 15 or more		+	\$175.61	
17250	Chemical cautery, tissue		+	\$303.14	
17260	Destruction of skin lesions		+	\$432.27	
17261	Destruction of skin lesions		+	\$432.27	
17262	Destruction of skin lesions		+	\$432.27	
17263	Destruction of skin lesions		+	\$432.27	
17264	Destruction of skin lesions		+	\$432.27	
17266	Destruction of skin lesions		+	\$696.76	
17270	Destruction of skin lesions		+	\$432.27	
17271	Destruction of skin lesions		+	\$303.14	
17272	Destruction of skin lesions		+	\$432.27	
17273	Destruction of skin lesions		+	\$432.27	
17274	Destruction of skin lesions		+	\$696.76	
17276	Destruction of skin lesions		+	\$696.76	
17280	Destruction of skin lesions		+	\$432.27	
17281	Destruction of skin lesions		+	\$432.27	
17282	Destruction of skin lesions		+	\$432.27	
17283	Destruction of skin lesions		+	\$432.27	
17284	Destruction of skin lesions		+	\$696.76	
17286	Destruction of skin lesions		+	\$432.27	
17304	Chemosurgery of skin lesion		+	\$806.17	
17305	2 stage mohs, up to 5 spec		+	\$806.17	
17306	3 stage mohs, up to 5 spec		+	\$806.17	
17307	Mohs addl stage up to 5 spec		+	\$806.17	
17310	Extensive skin chemosurgery		+	\$806.17	
17340	Cryotherapy of skin		+	\$206.25	
17360	Skin peel therapy		+	\$206.25	
17380	Hair removal by electrolysis		+	\$206.25	
17999	Skin tissue procedure		+	\$447.81	
19000	Drainage of breast lesion		+	\$430.33	
19001	Drain breast lesion add-on		+	\$430.33	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 6 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
19020	Incision of breast lesion		+	\$3,188.56	
19100	Bx breast percut w/o image		+	\$885.98	
19101	Biopsy of breast, open		+	\$4,760.63	
19102	Bx breast percut w/image		+	\$885.98	
19103	Bx breast percut w/device		+	\$1,511.43	
19110	nipple exploration		+	\$4,760.63	
19112	Excise breast duct fistula		+	\$4,760.63	
19120	Removal of breast lesion		+	\$4,760.63	
19125	Excision, breast lesion		+	\$4,760.63	
19126	Excision, addl breast lesion		+	\$4,760.63	
19140	Removal of breast tissue		+	\$4,760.63	
19160	Removal of breast tissue		+	\$4,760.63	
19162	Remove breast tissue, nodes		+	\$10,477.61	
19180	Removal of breast		+	\$8,101.09	
19182	Removal of breast		+	\$8,101.09	
19240	Removal of breast		+	\$10,109.23	
19260	Removal of chest wall lesion		+	\$3,862.11	
19295	Place breast clip, percut			\$409.22	
19316	Suspension of breast		+	\$8,101.09	
19318	Reduction of large breast		+	\$10,477.61	
19324	Enlarge breast		+	\$10,477.61	
19325	Enlarge breast with implant		+	\$14,636.53	
19328	Removal of breast implant		+	\$8,101.09	
19330	Removal of implant material		+	\$8,101.09	
19340	Immediate breast prosthesis		+	\$10,109.23	
19342	Delayed breast prosthesis		+	\$14,636.53	
19350	Breast reconstruction		+	\$4,760.63	
19355	Correct inverted nipple(s)		+	\$8,101.09	
19357	Breast reconstruction		+	\$14,636.53	
19366	Breast reconstruction		+	\$8,101.09	
19370	Surgery of breast capsule		+	\$8,101.09	
19371	Removal of breast capsule		+	\$8,101.09	
19380	Revise breast reconstruction		+	\$10,109.23	
19396	Design custom breast implant		+	\$8,101.09	
19499	Breast surgery procedure		+	\$4,760.63	
20000	Incision of abscess		+	\$447.81	
20005	Incision of deep abscess		+	\$5,304.59	
20100	Explore wound, neck		+	\$762.52	
20101	Explore wound, chest		+	\$4,298.81	
20102	Explore wound, abdomen		+	\$4,298.81	
20103	Explore wound, extremity		+	\$762.52	
20150	Excise epiphyseal bar		+	\$9,287.20	
20200	Muscle biopsy		+	\$3,862.11	
20205	Deep muscle biopsy		+	\$3,862.11	
20206	Needle biopsy, muscle		+	\$885.98	
20220	Bone biopsy, trocar/needle		+	\$1,068.77	
20225	Bone biopsy, trocar/needle		+	\$1,917.62	
20240	Bone biopsy, excisional		+	\$5,085.32	
20245	Bone biopsy, excisional		+	\$5,085.32	
20250	Open bone biopsy		+	\$5,304.59	
20251	Open bone biopsy		+	\$5,304.59	
20500	Injection of sinus tract		+	\$484.51	
20520	Removal of foreign body		+	\$1,068.77	
20525	Removal of foreign body		+	\$5,085.32	
20526	Ther injection, carp tunnel		+	\$586.87	
20550	Inject tendon/ligament/cyst		+	\$586.87	
20551	Inj tendon origin/insertion		+	\$586.87	
20552	Inj trigger point, 1/2 muscl		+	\$586.87	
20553	Inject trigger points, > 3		+	\$586.87	
20600	Drain/inject, joint/bursa		+	\$586.87	
20605	Drain/inject, joint/bursa		+	\$586.87	
20610	Drain/inject, joint/bursa		+	\$586.87	
20612	Aspirate/inj ganglion cyst		+	\$586.87	
20615	Treatment of bone cyst		+	\$430.33	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 7 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
20650	Insert and remove bone pin		+	\$5,304.59	MDR
20660	Apply, rem fixation device			\$441.59	
20665	Removal of fixation device			\$170.98	
20670	Removal of support implant		+	\$3,862.11	
20680	Removal of support implant		+	\$5,085.32	
20690	Apply bone fixation device		+	\$6,722.37	
20692	Apply bone fixation device		+	\$6,722.37	
20693	Adjust bone fixation device		+	\$5,304.59	
20694	Remove bone fixation device		+	\$5,304.59	
20900	Removal of bone for graft		+	\$6,722.37	
20902	Removal of bone for graft		+	\$6,722.37	
20910	Remove cartilage for graft		+	\$4,298.81	
20912	Remove cartilage for graft		+	\$4,298.81	
20920	Removal of fascia for graft		+	\$4,298.81	
20922	Removal of fascia for graft		+	\$4,298.81	
20924	Removal of tendon for graft		+	\$6,722.37	
20926	Removal of tissue for graft		+	\$4,298.81	
20950	Fluid pressure, muscle		+	\$447.81	
20975	Electrical bone stimulation		+	\$5,304.59	
20982	Ablate, bone tumor(s) perq		+	\$8,136.98	
20999	Musculoskeletal surgery		+	\$5,304.59	
21010	Incision of jaw joint		+	\$5,907.64	
21015	Resection of facial tumor		+	\$4,123.29	
21025	Excision of bone, lower jaw		+	\$9,418.88	
21026	Excision of facial bone(s)		+	\$9,418.88	
21029	Contour of face bone lesion		+	\$9,418.88	
21030	Removal of face bone lesion		+	\$5,907.64	
21031	Remove exostosis, mandible		+	\$5,907.64	
21032	Remove exostosis, maxilla		+	\$5,907.64	
21034	Removal of face bone lesion		+	\$9,418.88	
21040	Removal of jaw bone lesion		+	\$5,907.64	
21044	Removal of jaw bone lesion		+	\$9,418.88	
21046	Remove mandible cyst complex		+	\$9,418.88	
21047	Excise lwr jaw cyst w/repair		+	\$9,418.88	
21048	Remove maxilla cyst complex		+	\$9,418.88	
21049	Excis uppr jaw cyst w/repair		+	\$9,418.88	
21050	Removal of jaw joint		+	\$9,418.88	
21060	Remove jaw joint cartilage		+	\$9,418.88	
21070	Remove coronoid process		+	\$9,418.88	
21076	Prepare face/oral prosthesis		+	\$5,907.64	
21077	Prepare face/oral prosthesis		+	\$9,418.88	
21079	Prepare face/oral prosthesis		+	\$9,418.88	
21080	Prepare face/oral prosthesis		+	\$9,418.88	
21081	Prepare face/oral prosthesis		+	\$9,418.88	
21082	Prepare face/oral prosthesis		+	\$9,418.88	
21083	Prepare face/oral prosthesis		+	\$9,418.88	
21084	Prepare face/oral prosthesis		+	\$9,418.88	
21085	Prepare face/oral prosthesis		+	\$4,123.29	
21086	Prepare face/oral prosthesis		+	\$9,418.88	
21087	Prepare face/oral prosthesis		+	\$9,418.88	
21088	Prepare face/oral prosthesis		+	\$9,418.88	
21089	Prepare face/oral prosthesis		+	\$4,123.29	
21100	Maxillofacial fixation		+	\$9,418.88	
21110	Interdental fixation		+	\$1,744.68	
21120	Reconstruction of chin		+	\$5,907.64	
21121	Reconstruction of chin		+	\$5,907.64	
21122	Reconstruction of chin		+	\$5,907.64	
21123	Reconstruction of chin		+	\$5,907.64	
21125	Augmentation, lower jaw bone		+	\$5,907.64	
21127	Augmentation, lower jaw bone		+	\$9,418.88	
21137	Reduction of forehead		+	\$5,907.64	
21138	Reduction of forehead		+	\$9,418.88	
21139	Reduction of forehead		+	\$9,418.88	
21181	Contour cranial bone lesion		+	\$5,907.64	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 8 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
21198	Reconstr lwr jaw segment		+	\$9,418.88	
21199	Reconstr lwr jaw w/advance		+	\$9,418.88	
21206	Reconstruct upper jaw bone		+	\$9,418.88	
21208	Augmentation of facial bones		+	\$9,418.88	
21209	Reduction of facial bones		+	\$9,418.88	
21210	Face bone graft		+	\$9,418.88	
21215	Lower jaw bone graft		+	\$9,418.88	
21230	Rib cartilage graft		+	\$9,418.88	
21235	Ear cartilage graft		+	\$5,907.64	
21240	Reconstruction of jaw joint		+	\$9,418.88	
21242	Reconstruction of jaw joint		+	\$9,418.88	
21243	Reconstruction of jaw joint		+	\$9,418.88	
21244	Reconstruction of lower jaw		+	\$9,418.88	
21245	Reconstruction of jaw		+	\$9,418.88	
21246	Reconstruction of jaw		+	\$9,418.88	
21248	Reconstruction of jaw		+	\$9,418.88	
21249	Reconstruction of jaw		+	\$9,418.88	
21260	Revise eye sockets		+	\$9,418.88	
21261	Revise eye sockets		+	\$9,418.88	
21263	Revise eye sockets		+	\$9,418.88	
21267	Revise eye sockets		+	\$9,418.88	
21270	Augmentation, cheek bone		+	\$9,418.88	
21275	Revision, orbitofacial bones		+	\$9,418.88	
21280	Revision of eyelid		+	\$9,418.88	
21282	Revision of eyelid		+	\$4,123.29	
21295	Revision of jaw muscle/bone		+	\$1,744.68	
21296	Revision of jaw muscle/bone		+	\$5,907.64	
21299	Cranio/maxillofacial surgery		+	\$4,123.29	
21300	Treatment of skull fracture		+	\$4,123.29	
21310	Treatment of nose fracture			\$170.98	
21315	Treatment of nose fracture			\$170.98	
21320	Treatment of nose fracture			\$170.98	
21325	Treatment of nose fracture		+	\$5,907.64	
21330	Treatment of nose fracture		+	\$5,907.64	
21335	Treatment of nose fracture		+	\$5,907.64	
21336	Treat nasal septal fracture		+	\$8,760.26	
21337	Treat nasal septal fracture		+	\$4,123.29	
21338	Treat nasoethmoid fracture		+	\$5,907.64	
21339	Treat nasoethmoid fracture		+	\$5,907.64	
21340	Treatment of nose fracture		+	\$9,418.88	
21345	Treat nose/jaw fracture		+	\$5,907.64	
21355	Treat cheek bone fracture		+	\$9,418.88	
21356	Treat cheek bone fracture			\$10,294.40	MDR
21365	Treat cheek bone fracture			\$12,353.29	MDR
21390	Treat eye socket fracture		+	\$9,418.88	
21400	Treat eye socket fracture		+	\$1,744.68	
21401	Treat eye socket fracture		+	\$4,123.29	
21406	Treat eye socket fracture		+	\$9,418.88	
21407	Treat eye socket fracture		+	\$9,418.88	
21421	Treat mouth roof fracture		+	\$5,907.64	
21440	Treat dental ridge fracture		+	\$5,907.64	
21445	Treat dental ridge fracture		+	\$5,907.64	
21450	Treat lower jaw fracture		+	\$484.51	
21451	Treat lower jaw fracture		+	\$1,744.68	
21452	Treat lower jaw fracture		+	\$4,123.29	
21453	Treat lower jaw fracture		+	\$9,418.88	
21454	Treat lower jaw fracture		+	\$5,907.64	
21461	Treat lower jaw fracture		+	\$9,418.88	
21462	Treat lower jaw fracture		+	\$9,418.88	
21465	Treat lower jaw fracture		+	\$9,418.88	
21470	Treat lower jaw fracture		+	\$9,418.88	
21480	Reset dislocated jaw		+	\$484.51	
21485	Reset dislocated jaw		+	\$4,123.29	
21490	Repair dislocated jaw		+	\$9,418.88	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 9 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
21493	Treat hyoid bone fracture		+	\$1,744.68	
21494	Treat hyoid bone fracture		+	\$1,744.68	
21497	Interdental wiring		+	\$4,123.29	
21499	Head surgery procedure		+	\$4,123.29	
21501	Drain neck/chest lesion		+	\$5,279.24	
21502	Drain chest lesion		+	\$5,304.59	
21550	Biopsy of neck/chest		+	\$3,862.11	
21555	Remove lesion, neck/chest		+	\$5,085.32	
21556	Remove lesion, neck/chest		+	\$5,085.32	
21600	Partial removal of rib		+	\$6,722.37	
21610	Partial removal of rib		+	\$6,722.37	
21685	Hyoid myotomy & suspension		+	\$1,744.68	
21700	Revision of neck muscle		+	\$5,304.59	
21720	Revision of neck muscle		+	\$5,304.59	
21725	Revision of neck muscle		+	\$447.81	
21742	Repair stern/nuss w/o scope		+	\$9,287.20	
21743	Repair sternum/nuss w/scope		+	\$9,287.20	
21800	Treatment of rib fracture		+	\$516.84	
21805	Treatment of rib fracture		+	\$8,760.26	
21820	Treat sternum fracture		+	\$516.84	
21899	Neck/chest surgery procedure		+	\$1,744.68	
21920	Biopsy soft tissue of back		+	\$1,917.62	
21925	Biopsy soft tissue of back		+	\$5,085.32	
21930	Remove lesion, back or flank		+	\$5,085.32	
21935	Remove tumor, back		+	\$5,085.32	
22100	Remove part of neck vertebra		+	\$10,808.50	
22101	Remove part, thorax vertebra		+	\$10,808.50	
22102	Remove part, lumbar vertebra		+	\$10,808.50	
22103	Remove extra spine segment		+	\$10,808.50	
22305	Treat spine process fracture		+	\$516.84	
22310	Treat spine fracture		+	\$516.84	
22315	Treat spine fracture		+	\$516.84	
22505	Manipulation of spine		+	\$3,640.96	
22520	Percut vertebroplasty thor		+	\$6,722.37	
22521	Percut vertebroplasty lumb		+	\$6,722.37	
22522	Percut vertebroplasty add'l		+	\$6,722.37	
22612	Lumbar spine fusion		+	\$10,808.50	
22614	Spine fusion, extra segment		+	\$10,808.50	
22899	Spine surgery procedure		+	\$516.84	
22900	Remove abdominal wall lesion		+	\$5,085.32	
22999	Abdomen surgery procedure		+	\$5,085.32	
23000	Removal of calcium deposits		+	\$3,862.11	
23020	Release shoulder joint		+	\$9,287.20	
23030	Drain shoulder lesion		+	\$5,279.24	
23031	Drain shoulder bursa		+	\$5,279.24	
23035	Drain shoulder bone lesion		+	\$5,304.59	
23040	Exploratory shoulder surgery		+	\$6,722.37	
23044	Exploratory shoulder surgery		+	\$6,722.37	
23065	Biopsy shoulder tissues		+	\$3,862.11	
23066	Biopsy shoulder tissues		+	\$5,085.32	
23075	Removal of shoulder lesion		+	\$3,862.11	
23076	Removal of shoulder lesion		+	\$5,085.32	
23077	Remove tumor of shoulder		+	\$5,085.32	
23100	Biopsy of shoulder joint		+	\$5,304.59	
23101	Shoulder joint surgery		+	\$6,722.37	
23105	Remove shoulder joint lining		+	\$6,722.37	
23106	Incision of collarbone joint		+	\$6,722.37	
23107	Explore treat shoulder joint		+	\$6,722.37	
23120	Partial removal, collar bone		+	\$9,287.20	
23125	Removal of collar bone		+	\$9,287.20	
23130	Remove shoulder bone, part		+	\$9,287.20	
23140	Removal of bone lesion		+	\$5,304.59	
23145	Removal of bone lesion		+	\$6,722.37	
23146	Removal of bone lesion		+	\$6,722.37	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 10 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
23150	Removal of humerus lesion		+	\$6,722.37	
23155	Removal of humerus lesion		+	\$6,722.37	
23156	Removal of humerus lesion		+	\$6,722.37	
23170	Remove collar bone lesion		+	\$6,722.37	
23172	Remove shoulder blade lesion		+	\$6,722.37	
23174	Remove humerus lesion		+	\$6,722.37	
23180	Remove collar bone lesion		+	\$6,722.37	
23182	Remove shoulder blade lesion		+	\$6,722.37	
23184	Remove humerus lesion		+	\$6,722.37	
23190	Partial removal of scapula		+	\$6,722.37	
23195	Removal of head of humerus		+	\$6,722.37	
23330	Remove shoulder foreign body		+	\$1,917.62	
23331	Remove shoulder foreign body		+	\$5,085.32	
23395	Muscle transfer, shoulder/arm		+	\$9,287.20	
23397	Muscle transfers		+	\$11,259.26	
23400	Fixation of shoulder blade		+	\$6,722.37	
23405	Incision of tendon & muscle		+	\$6,722.37	
23406	Incise tendon(s) & muscle(s)		+	\$6,722.37	
23410	Repair of tendon(s)		+	\$11,259.26	
23412	Repair rotator cuff, chronic		+	\$11,259.26	
23415	Release of shoulder ligament		+	\$9,287.20	
23420	Repair of shoulder		+	\$11,259.26	
23430	Repair biceps tendon		+	\$11,259.26	
23440	Remove/transplant tendon		+	\$11,259.26	
23450	Repair shoulder capsule		+	\$11,259.26	
23455	Repair shoulder capsule		+	\$11,259.26	
23460	Repair shoulder capsule		+	\$11,259.26	
23462	Repair shoulder capsule		+	\$11,259.26	
23465	Repair shoulder capsule		+	\$11,259.26	
23466	Repair shoulder capsule		+	\$11,259.26	
23470	Reconstruct shoulder joint		+	\$13,897.34	
23480	Revision of collar bone		+	\$9,287.20	
23485	Revision of collar bone		+	\$9,287.20	
23490	Reinforce clavicle		+	\$9,287.20	
23491	Reinforce shoulder bones		+	\$9,287.20	
23500	Treat clavicle fracture		+	\$516.84	
23505	Treat clavicle fracture		+	\$516.84	
23515	Treat clavicle fracture		+	\$8,760.26	
23520	Treat clavicle dislocation		+	\$516.84	
23525	Treat clavicle dislocation		+	\$516.84	
23530	Treat clavicle dislocation		+	\$8,760.26	
23532	Treat clavicle dislocation		+	\$8,760.26	
23540	Treat clavicle dislocation		+	\$516.84	
23545	Treat clavicle dislocation		+	\$516.84	
23550	Treat clavicle dislocation		+	\$8,760.26	
23552	Treat clavicle dislocation		+	\$8,760.26	
23570	Treat shoulder blade fx		+	\$516.84	
23575	Treat shoulder blade fx		+	\$516.84	
23585	Treat scapula fracture		+	\$8,760.26	
23600	Treat humerus fracture		+	\$516.84	
23605	Treat humerus fracture		+	\$516.84	
23615	Treat humerus fracture		+	\$8,760.26	
23616	Treat humerus fracture		+	\$8,760.26	
23620	Treat humerus fracture		+	\$516.84	
23625	Treat humerus fracture		+	\$516.84	
23630	Treat humerus fracture		+	\$8,760.26	
23650	Treat shoulder dislocation		+	\$516.84	
23655	Treat shoulder dislocation		+	\$3,640.96	
23660	Treat shoulder dislocation		+	\$8,760.26	
23665	Treat dislocation/fracture		+	\$516.84	
23670	Treat dislocation/fracture		+	\$8,760.26	
23675	Treat dislocation/fracture		+	\$516.84	
23680	Treat dislocation/fracture		+	\$8,760.26	
23700	Fixation of shoulder		+	\$3,640.96	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 11 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
23800	Fusion of shoulder joint		+	\$9,287.20	
23802	Fusion of shoulder joint		+	\$9,287.20	
23921	Amputation follow-up surgery		+	\$1,401.69	
23929	Shoulder surgery procedure		+	\$516.84	
23930	Drainage of arm lesion		+	\$5,279.24	
23931	Drainage of arm bursa		+	\$3,188.56	
23935	Drain arm/elbow bone lesion		+	\$5,304.59	
24000	Exploratory elbow surgery		+	\$6,722.37	
24006	Release elbow joint		+	\$6,722.37	
24065	Biopsy arm/elbow soft tissue		+	\$3,862.11	
24066	Biopsy arm/elbow soft tissue		+	\$3,862.11	
24075	Remove arm/elbow lesion		+	\$3,862.11	
24076	Remove arm/elbow lesion		+	\$5,085.32	
24077	Remove tumor of arm/elbow		+	\$5,085.32	
24100	Biopsy elbow joint lining		+	\$5,304.59	
24101	Explore/treat elbow joint		+	\$6,722.37	
24102	Remove elbow joint lining		+	\$6,722.37	
24105	Removal of elbow bursa		+	\$5,304.59	
24110	Remove humerus lesion		+	\$5,304.59	
24115	Remove/graft bone lesion		+	\$6,722.37	
24116	Remove/graft bone lesion		+	\$6,722.37	
24120	Remove elbow lesion		+	\$5,304.59	
24125	Remove/graft bone lesion		+	\$6,722.37	
24126	Remove/graft bone lesion		+	\$6,722.37	
24130	Removal of head of radius		+	\$6,722.37	
24134	Removal of arm bone lesion		+	\$6,722.37	
24136	Remove radius bone lesion		+	\$6,722.37	
24138	Remove elbow bone lesion		+	\$6,722.37	
24140	Partial removal of arm bone		+	\$6,722.37	
24145	Partial removal of radius		+	\$6,722.37	
24147	Partial removal of elbow		+	\$6,722.37	
24150	Extensive humerus surgery		+	\$11,259.26	
24151	Extensive humerus surgery		+	\$11,259.26	
24152	Extensive radius surgery		+	\$11,259.26	
24153	Extensive radius surgery		+	\$11,259.26	
24155	Removal of elbow joint		+	\$9,287.20	
24160	Remove elbow joint implant		+	\$6,722.37	
24164	Remove radius head implant		+	\$6,722.37	
24200	Removal of arm foreign body		+	\$1,068.77	
24201	Removal of arm foreign body		+	\$3,862.11	
24300	Manipulate elbow w/anesth		+	\$3,640.96	
24301	Muscle/tendon transfer		+	\$6,722.37	
24305	Arm tendon lengthening		+	\$6,722.37	
24310	Revision of arm tendon		+	\$5,304.59	
24320	Repair of arm tendon		+	\$9,287.20	
24330	Revision of arm muscles		+	\$9,287.20	
24331	Revision of arm muscles		+	\$9,287.20	
24332	Tenolysis, triceps		+	\$5,304.59	
24340	Repair of biceps tendon		+	\$9,287.20	
24341	Repair arm tendon/muscle		+	\$9,287.20	
24342	Repair of ruptured tendon		+	\$9,287.20	
24343	Repr elbow lat ligmnt w/tiss		+	\$6,722.37	
24344	Reconstruct elbow lat ligmnt		+	\$9,287.20	
24345	Repr elbow med ligmnt w/tissu		+	\$6,722.37	
24346	Reconstruct elbow med ligmnt		+	\$9,287.20	
24350	Repair of tennis elbow		+	\$6,722.37	
24351	Repair of tennis elbow		+	\$6,722.37	
24352	Repair of tennis elbow		+	\$6,722.37	
24354	Repair of tennis elbow		+	\$6,722.37	
24356	Revision of tennis elbow		+	\$6,722.37	
24360	Reconstruct elbow joint		+	\$8,104.84	
24361	Reconstruct elbow joint		+	\$13,897.34	
24362	Reconstruct elbow joint		+	\$13,897.34	
24363	Replace elbow joint		+	\$13,897.34	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 12 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
24365	Reconstruct head of radius		+	\$8,104.84	
24366	Reconstruct head of radius		+	\$13,897.34	
24400	Revision of humerus		+	\$6,722.37	
24410	Revision of humerus		+	\$6,722.37	
24420	Revision of humerus		+	\$9,287.20	
24430	Repair of humerus		+	\$9,287.20	
24435	Repair humerus with graft		+	\$9,287.20	
24470	Revision of elbow joint		+	\$9,287.20	
24495	Decompression of forearm		+	\$6,722.37	
24498	Reinforce humerus		+	\$9,287.20	
24500	Treat humerus fracture		+	\$516.84	
24505	Treat humerus fracture		+	\$516.84	
24515	Treat humerus fracture		+	\$8,760.26	
24516	Treat humerus fracture		+	\$8,760.26	
24530	Treat humerus fracture		+	\$516.84	
24535	Treat humerus fracture		+	\$516.84	
24538	Treat humerus fracture		+	\$8,760.26	
24545	Treat humerus fracture		+	\$8,760.26	
24546	Treat humerus fracture		+	\$8,760.26	
24560	Treat humerus fracture		+	\$516.84	
24565	Treat humerus fracture		+	\$516.84	
24566	Treat humerus fracture		+	\$8,760.26	
24575	Treat humerus fracture		+	\$8,760.26	
24576	Treat humerus fracture		+	\$516.84	
24577	Treat humerus fracture		+	\$516.84	
24579	Treat humerus fracture		+	\$8,760.26	
24582	Treat humerus fracture		+	\$8,760.26	
24586	Treat elbow fracture		+	\$8,760.26	
24587	Treat elbow fracture		+	\$8,760.26	
24600	Treat elbow dislocation		+	\$516.84	
24605	Treat elbow dislocation		+	\$3,640.96	
24615	Treat elbow dislocation		+	\$8,760.26	
24620	Treat elbow fracture		+	\$516.84	
24635	Treat elbow fracture		+	\$8,760.26	
24640	Treat elbow dislocation		+	\$516.84	
24650	Treat radius fracture		+	\$516.84	
24655	Treat radius fracture		+	\$516.84	
24665	Treat radius fracture		+	\$8,760.26	
24666	Treat radius fracture		+	\$8,760.26	
24670	Treat ulnar fracture		+	\$516.84	
24675	Treat ulnar fracture		+	\$516.84	
24685	Treat ulnar fracture		+	\$8,760.26	
24800	Fusion of elbow joint		+	\$9,287.20	
24802	Fusion/graft of elbow joint		+	\$9,287.20	
24925	Amputation follow-up surgery		+	\$5,304.59	
24935	Revision of amputation		+	\$11,259.26	
24999	Upper arm/elbow surgery		+	\$516.84	
25000	Incision of tendon sheath		+	\$5,304.59	
25001	Incise flexor carpi radialis		+	\$5,304.59	
25020	Decompress forearm 1 space		+	\$5,304.59	
25023	Decompress forearm 1 space		+	\$6,722.37	
25024	Decompress forearm 2 spaces		+	\$6,722.37	
25025	Decompress forearm 2 spaces		+	\$6,722.37	
25028	Drainage of forearm lesion		+	\$5,304.59	
25031	Drainage of forearm bursa		+	\$5,304.59	
25035	Treat forearm bone lesion		+	\$5,304.59	
25040	Explore/treat wrist joint		+	\$6,722.37	
25065	Biopsy forearm soft tissues		+	\$3,862.11	
25066	Biopsy forearm soft tissues		+	\$5,085.32	
25075	Remove forearm lesion subcu		+	\$3,862.11	
25076	Remove forearm lesion deep		+	\$5,085.32	
25077	Remove tumor, forearm/wrist		+	\$5,085.32	
25085	Incision of wrist capsule		+	\$5,304.59	
25100	Biopsy of wrist joint		+	\$5,304.59	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association All rights reserved

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 13 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
25101	Explore/treat wrist joint		+	\$6,722.37	
25105	Remove wrist joint lining		+	\$6,722.37	
25107	Remove wrist joint cartilage		+	\$6,722.37	
25110	Remove wrist tendon lesion		+	\$5,304.59	
25111	Remove wrist tendon lesion		+	\$4,027.45	
25112	Reremove wrist tendon lesion		+	\$4,027.45	
25115	Remove wrist/forearm lesion		+	\$5,304.59	
25116	Remove wrist/forearm lesion		+	\$5,304.59	
25118	Excise wrist tendon sheath		+	\$6,722.37	
25119	Partial removal of ulna		+	\$6,722.37	
25120	Removal of forearm lesion		+	\$6,722.37	
25125	Remove/graft forearm lesion		+	\$6,722.37	
25126	Remove/graft forearm lesion		+	\$6,722.37	
25130	Removal of wrist lesion		+	\$6,722.37	
25135	Remove & graft wrist lesion		+	\$6,722.37	
25136	Remove & graft wrist lesion		+	\$6,722.37	
25145	Remove forearm bone lesion		+	\$6,722.37	
25150	Partial removal of ulna		+	\$6,722.37	
25151	Partial removal of radius		+	\$6,722.37	
25170	Extensive forearm surgery		+	\$11,259.26	
25210	Removal of wrist bone		+	\$6,535.56	
25215	Removal of wrist bones		+	\$6,535.56	
25230	Partial removal of radius		+	\$6,722.37	
25240	Partial removal of ulna		+	\$6,722.37	
25248	Remove forearm foreign body		+	\$5,304.59	
25250	Removal of wrist prosthesis		+	\$6,722.37	
25251	Removal of wrist prosthesis		+	\$6,722.37	
25259	Manipulate wrist w/anesthes		+	\$516.84	
25260	Repair forearm tendon/muscle		+	\$6,722.37	
25263	Repair forearm tendon/muscle		+	\$6,722.37	
25265	Repair forearm tendon/muscle		+	\$6,722.37	
25270	Repair forearm tendon/muscle		+	\$6,722.37	
25272	Repair forearm tendon/muscle		+	\$6,722.37	
25274	Repair forearm tendon/muscle		+	\$6,722.37	
25275	Repair forearm tendon sheath		+	\$6,722.37	
25280	Revise wrist/forearm tendon		+	\$6,722.37	
25290	Incise wrist/forearm tendon		+	\$6,722.37	
25295	Release wrist/forearm tendon		+	\$5,304.59	
25300	Fusion of tendons at wrist		+	\$6,722.37	
25301	Fusion of tendons at wrist		+	\$6,722.37	
25310	Transplant forearm tendon		+	\$9,287.20	
25312	Transplant forearm tendon		+	\$9,287.20	
25315	Revise palsy hand tendon(s)		+	\$9,287.20	
25316	Revise palsy hand tendon(s)		+	\$9,287.20	
25320	Repair/revise wrist joint		+	\$9,287.20	
25332	Revise wrist joint		+	\$8,104.84	
25335	Realignment of hand		+	\$9,287.20	
25337	Reconstruct ulna/radioulnar		+	\$9,287.20	
25350	Revision of radius		+	\$9,287.20	
25355	Revision of radius		+	\$9,287.20	
25360	Revision of ulna		+	\$6,722.37	
25365	Revise radius & ulna		+	\$6,722.37	
25370	Revise radius or ulna		+	\$9,287.20	
25375	Revise radius & ulna		+	\$9,287.20	
25390	Shorten radius or ulna		+	\$6,722.37	
25391	Lengthen radius or ulna		+	\$9,287.20	
25392	Shorten radius & ulna		+	\$6,722.37	
25393	Lengthen radius & ulna		+	\$9,287.20	
25394	Repair carpal bone, shorten		+	\$4,027.45	
25400	Repair radius or ulna		+	\$6,722.37	
25405	Repair/graft radius or ulna		+	\$6,722.37	
25415	Repair radius & ulna		+	\$6,722.37	
25420	Repair/graft radius & ulna		+	\$9,287.20	
25425	Repair/graft radius or ulna		+	\$9,287.20	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 14 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
25426	Repair/graft radius & ulna		+	\$9,287.20	
25430	Vasc graft into carpal bone		+	\$6,535.56	
25431	Repair nonunion carpal bone		+	\$6,535.56	
25440	Repair/graft wrist bone		+	\$9,287.20	
25441	Reconstruct wrist joint		+	\$13,897.34	
25442	Reconstruct wrist joint		+	\$13,897.34	
25443	Reconstruct wrist joint		+	\$13,897.34	
25444	Reconstruct wrist joint		+	\$13,897.34	
25445	Reconstruct wrist joint		+	\$13,897.34	
25446	Wrist replacement		+	\$13,897.34	
25447	Repair wrist joint(s)		+	\$8,104.84	
25449	Remove wrist joint implant		+	\$8,104.84	
25450	Revision of wrist joint		+	\$9,287.20	
25455	Revision of wrist joint		+	\$9,287.20	
25490	Reinforce radius		+	\$9,287.20	
25491	Reinforce ulna		+	\$9,287.20	
25492	Reinforce radius and ulna		+	\$9,287.20	
25500	Treat fracture of radius		+	\$516.84	
25505	Treat fracture of radius		+	\$516.84	
25515	Treat fracture of radius		+	\$8,760.26	
25520	Treat fracture of radius		+	\$516.84	
25525	Treat fracture of radius		+	\$8,760.26	
25526	Treat fracture of radius		+	\$8,760.26	
25530	Treat fracture of ulna		+	\$516.84	
25535	Treat fracture of ulna		+	\$516.84	
25545	Treat fracture of ulna		+	\$8,760.26	
25560	Treat fracture radius & ulna		+	\$516.84	
25565	Treat fracture radius & ulna		+	\$516.84	
25574	Treat fracture radius & ulna		+	\$8,760.26	
25575	Treat fracture radius/ulna		+	\$8,760.26	
25600	Treat fracture radius/ulna		+	\$516.84	
25605	Treat fracture radius/ulna		+	\$516.84	
25611	Treat fracture radius/ulna		+	\$8,760.26	
25620	Treat fracture radius/ulna		+	\$8,760.26	
25622	Treat wrist bone fracture		+	\$516.84	
25624	Treat wrist bone fracture		+	\$516.84	
25628	Treat wrist bone fracture		+	\$8,760.26	
25630	Treat wrist bone fracture		+	\$516.84	
25635	Treat wrist bone fracture		+	\$516.84	
25645	Treat wrist bone fracture		+	\$8,760.26	
25650	Treat wrist bone fracture		+	\$516.84	
25651	Pin ulnar styloid fracture		+	\$8,760.26	
25652	Treat fracture ulnar styloid		+	\$8,760.26	
25660	Treat wrist dislocation		+	\$516.84	
25670	Treat wrist dislocation		+	\$8,760.26	
25671	Pin radioulnar dislocation		+	\$8,760.26	
25675	Treat wrist dislocation		+	\$516.84	
25676	Treat wrist dislocation		+	\$8,760.26	
25680	Treat wrist fracture		+	\$516.84	
25685	Treat wrist fracture		+	\$8,760.26	
25690	Treat wrist dislocation		+	\$516.84	
25695	Treat wrist dislocation		+	\$8,760.26	
25800	Fusion of wrist joint		+	\$9,287.20	
25805	Fusion/graft of wrist joint		+	\$9,287.20	
25810	Fusion/graft of wrist joint		+	\$9,287.20	
25820	Fusion of hand bones		+	\$4,027.45	
25825	Fuse hand bones with graft		+	\$6,535.56	
25830	Fusion, radioulnar jnt/ulna		+	\$9,287.20	
25907	Amputation follow-up surgery		+	\$5,304.59	
25922	Amputate hand at wrist		+	\$5,304.59	
25929	Amputation follow-up surgery		+	\$4,298.81	
25999	Forearm or wrist surgery		+	\$516.84	
26010	Drainage of finger abscess		+	\$447.81	
26011	Drainage of finger abscess		+	\$3,188.56	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 15 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
26020	Drain hand tendon sheath		+	\$4,027.45	
26025	Drainage of palm bursa		+	\$4,027.45	
26030	Drainage of palm bursa(s)		+	\$4,027.45	
26034	Treat hand bone lesion		+	\$4,027.45	
26035	Decompress fingers/hand		+	\$4,027.45	
26037	Decompress fingers/hand		+	\$4,027.45	
26040	Release palm contracture		+	\$6,535.56	
26045	Release palm contracture		+	\$6,535.56	
26055	Incise finger tendon sheath		+	\$4,027.45	
26060	Incision of finger tendon		+	\$4,027.45	
26070	Explore/treat hand joint		+	\$4,027.45	
26075	Explore/treat finger joint		+	\$4,027.45	
26080	Explore/treat finger joint		+	\$4,027.45	
26100	Biopsy hand joint lining		+	\$4,027.45	
26105	Biopsy finger joint lining		+	\$4,027.45	
26110	Biopsy finger joint lining		+	\$4,027.45	
26115	Removal hand lesion subcut		+	\$5,085.32	
26116	Removal hand lesion, deep		+	\$5,085.32	
26117	Remove tumor, hand/finger		+	\$5,085.32	
26121	Release palm contracture		+	\$6,535.56	
26123	Release palm contracture		+	\$6,535.56	
26125	Release palm contracture		+	\$6,535.56	
26130	Remove wrist joint lining		+	\$4,027.45	
26135	Revise finger joint, each		+	\$6,535.56	
26140	Revise finger joint, each		+	\$4,027.45	
26145	Tendon excision, palm/finger		+	\$4,027.45	
26160	Remove tendon sheath lesion		+	\$4,027.45	
26170	Removal of palm tendon, each		+	\$4,027.45	
26180	Removal of finger tendon		+	\$4,027.45	
26185	Remove finger bone		+	\$4,027.45	
26200	Remove hand bone lesion		+	\$4,027.45	
26205	Remove/graft bone lesion		+	\$6,535.56	
26210	Removal of finger lesion		+	\$4,027.45	
26215	Remove/graft finger lesion		+	\$4,027.45	
26230	Partial removal of hand bone		+	\$4,027.45	
26235	Partial removal, finger bone		+	\$4,027.45	
26236	Partial removal, finger bone		+	\$4,027.45	
26250	Extensive hand surgery		+	\$4,027.45	
26255	Extensive hand surgery		+	\$6,535.56	
26260	Extensive finger surgery		+	\$4,027.45	
26261	Extensive finger surgery		+	\$4,027.45	
26262	Partial removal of finger		+	\$4,027.45	
26320	Removal of implant from hand		+	\$3,862.11	
26340	Manipulate finger w/anesth		+	\$516.84	
26350	Repair finger/hand tendon		+	\$6,535.56	
26352	Repair/graft hand tendon		+	\$6,535.56	
26356	Repair finger/hand tendon		+	\$6,535.56	
26357	Repair finger/hand tendon		+	\$6,535.56	
26358	Repair/graft hand tendon		+	\$6,535.56	
26370	Repair finger/hand tendon		+	\$6,535.56	
26372	Repair/graft hand tendon		+	\$6,535.56	
26373	Repair finger/hand tendon		+	\$6,535.56	
26390	Revise hand/finger tendon		+	\$6,535.56	
26392	Repair/graft hand tendon		+	\$6,535.56	
26410	Repair hand tendon		+	\$4,027.45	
26412	Repair/graft hand tendon		+	\$6,535.56	
26415	Excision, hand/finger tendon		+	\$6,535.56	
26416	Graft hand or finger tendon		+	\$6,535.56	
26418	Repair finger tendon		+	\$4,027.45	
26420	Repair/graft finger tendon		+	\$6,535.56	
26426	Repair finger/hand tendon		+	\$6,535.56	
26428	Repair/graft finger tendon		+	\$6,535.56	
26432	Repair finger tendon		+	\$4,027.45	
26433	Repair finger tendon		+	\$4,027.45	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 16 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
26434	Repair/graft finger tendon		+	\$6,535.56	
26437	Realignment of tendons		+	\$4,027.45	
26440	Release palm/finger tendon		+	\$4,027.45	
26442	Release palm & finger tendon		+	\$6,535.56	
26445	Release hand/finger tendon		+	\$4,027.45	
26449	Release forearm/hand tendon		+	\$6,535.56	
26450	Incision of palm tendon		+	\$4,027.45	
26455	Incision of finger tendon		+	\$4,027.45	
26460	Incise hand/finger tendon		+	\$4,027.45	
26471	Fusion of finger tendons		+	\$4,027.45	
26474	Fusion of finger tendons		+	\$4,027.45	
26476	Tendon lengthening		+	\$4,027.45	
26477	Tendon shortening		+	\$4,027.45	
26478	Lengthening of hand tendon		+	\$4,027.45	
26479	Shortening of hand tendon		+	\$4,027.45	
26480	Transplant hand tendon		+	\$6,535.56	
26483	Transplant/graft hand tendon		+	\$6,535.56	
26485	Transplant palm tendon		+	\$6,535.56	
26489	Transplant/graft palm tendon		+	\$6,535.56	
26490	Revise thumb tendon		+	\$6,535.56	
26492	Tendon transfer with graft		+	\$6,535.56	
26494	Hand tendon/muscle transfer		+	\$6,535.56	
26496	Revise thumb tendon		+	\$6,535.56	
26497	Finger tendon transfer		+	\$6,535.56	
26498	Finger tendon transfer		+	\$6,535.56	
26499	Revision of finger		+	\$6,535.56	
26500	Hand tendon reconstruction		+	\$4,027.45	
26502	Hand tendon reconstruction		+	\$6,535.56	
26504	Hand tendon reconstruction		+	\$6,535.56	
26508	Release thumb contracture		+	\$4,027.45	
26510	Thumb tendon transfer		+	\$6,535.56	
26516	Fusion of knuckle joint		+	\$6,535.56	
26517	Fusion of knuckle joints		+	\$6,535.56	
26518	Fusion of knuckle joints		+	\$6,535.56	
26520	Release knuckle contracture		+	\$4,027.45	
26525	Release finger contracture		+	\$4,027.45	
26530	Revise knuckle joint		+	\$8,104.84	
26531	Revise knuckle with implant		+	\$13,897.34	
26535	Revise finger joint		+	\$8,104.84	
26536	Revise/implant finger joint		+	\$13,897.34	
26540	Repair hand joint		+	\$4,027.45	
26541	Repair hand joint with graft		+	\$6,535.56	
26542	Repair hand joint with graft		+	\$4,027.45	
26545	Reconstruct finger joint		+	\$6,535.56	
26546	Repair nonunion hand		+	\$6,535.56	
26548	Reconstruct finger joint		+	\$6,535.56	
26550	Construct thumb replacement		+	\$6,535.56	
26555	Positional change of finger		+	\$6,535.56	
26560	Repair of web finger		+	\$4,027.45	
26561	Repair of web finger		+	\$6,535.56	
26562	Repair of web finger		+	\$6,535.56	
26565	Correct metacarpal flaw		+	\$6,535.56	
26567	Correct finger deformity		+	\$6,535.56	
26568	Lengthen metacarpal/finger		+	\$6,535.56	
26580	Repair hand deformity		+	\$6,535.56	
26587	Reconstruct extra finger		+	\$4,027.45	
26590	Repair finger deformity		+	\$6,535.56	
26591	Repair muscles of hand		+	\$6,535.56	
26593	Release muscles of hand		+	\$4,027.45	
26596	Excision constricting tissue		+	\$6,535.56	
26600	Treat metacarpal fracture		+	\$516.84	
26605	Treat metacarpal fracture		+	\$516.84	
26607	Treat metacarpal fracture		+	\$516.84	
26608	Treat metacarpal fracture		+	\$8,760.26	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 17 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
26615	Treat metacarpal fracture		+	\$8,760.26	
26641	Treat thumb dislocation		+	\$516.84	
26645	Treat thumb fracture		+	\$516.84	
26650	Treat thumb fracture		+	\$8,760.26	
26665	Treat thumb fracture		+	\$8,760.26	
26670	Treat hand dislocation		+	\$516.84	
26675	Treat hand dislocation		+	\$516.84	
26676	Pin hand dislocation		+	\$8,760.26	
26685	Treat hand dislocation		+	\$8,760.26	
26686	Treat hand dislocation		+	\$8,760.26	
26700	Treat knuckle dislocation		+	\$516.84	
26705	Treat knuckle dislocation		+	\$516.84	
26706	Pin knuckle dislocation		+	\$516.84	
26715	Treat knuckle dislocation		+	\$8,760.26	
26720	Treat finger fracture, each		+	\$516.84	
26725	Treat finger fracture, each		+	\$516.84	
26727	Treat finger fracture, each		+	\$8,760.26	
26735	Treat finger fracture, each		+	\$8,760.26	
26740	Treat finger fracture, each		+	\$516.84	
26742	Treat finger fracture, each		+	\$516.84	
26746	Treat finger fracture, each		+	\$8,760.26	
26750	Treat finger fracture, each		+	\$516.84	
26755	Treat finger fracture, each		+	\$516.84	
26756	Pin finger fracture, each		+	\$8,760.26	
26765	Treat finger fracture, each		+	\$8,760.26	
26770	Treat finger dislocation		+	\$516.84	
26775	Treat finger dislocation		+	\$3,640.96	
26776	Pin finger dislocation		+	\$8,760.26	
26785	Treat finger dislocation		+	\$8,760.26	
26820	Thumb fusion with graft		+	\$6,535.56	
26841	Fusion of thumb		+	\$6,535.56	
26842	Thumb fusion with graft		+	\$6,535.56	
26843	Fusion of hand joint		+	\$6,535.56	
26844	Fusion/graft of hand joint		+	\$6,535.56	
26850	Fusion of knuckle		+	\$6,535.56	
26852	Fusion of knuckle with graft		+	\$6,535.56	
26860	Fusion of finger joint		+	\$6,535.56	
26861	Fusion of finger int, add-on		+	\$6,535.56	
26862	Fusion/graft of finger joint		+	\$6,535.56	
26863	Fuse/graft added joint		+	\$6,535.56	
26910	Amputate metacarpal bone		+	\$6,535.56	
26951	Amputation of finger/thumb		+	\$4,027.45	
26952	Amputation of finger/thumb		+	\$4,027.45	
26989	Hand/finger surgery		+	\$516.84	
26990	Drainage of pelvis lesion		+	\$5,304.59	
26991	Drainage of pelvis bursa		+	\$5,304.59	
27000	Incision of hip tendon		+	\$5,304.59	
27001	Incision of hip tendon		+	\$6,722.37	
27003	Incision of hip tendon		+	\$6,722.37	
27033	Exploration of hip joint		+	\$9,287.20	
27035	Deneration of hip joint		+	\$11,259.26	
27040	Biopsy of soft tissues		+	\$1,917.62	
27041	Biopsy of soft tissues		+	\$1,068.77	
27047	Remove hip/pelvis lesion		+	\$5,085.32	
27048	Remove hip/pelvis lesion		+	\$5,085.32	
27049	Remove tumor, hip/pelvis		+	\$5,085.32	
27050	Biopsy of sacroiliac joint		+	\$5,304.59	
27052	Biopsy of hip joint		+	\$5,304.59	
27060	Removal of ischial bursa		+	\$5,304.59	
27062	Remove femur lesion/bursa		+	\$5,304.59	
27065	Removal of hip bone lesion		+	\$5,304.59	
27066	Removal of hip bone lesion		+	\$6,722.37	
27067	Remove/graft hip bone lesion		+	\$6,722.37	
27080	Removal of tail bone		+	\$6,722.37	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 18 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27086	Remove hip foreign body		+	\$1,917.62	MDR
27087	Remove hip foreign body		+	\$5,304.59	
27096	Inject sacroiliac joint			\$1,012.30	
27097	Revision of hip tendon		+	\$6,722.37	
27098	Transfer tendon to pelvis		+	\$6,722.37	
27100	Transfer of abdominal muscle		+	\$9,287.20	
27105	Transfer of spinal muscle		+	\$9,287.20	
27110	Transfer of iliopsoas muscle		+	\$9,287.20	
27111	Transfer of iliopsoas muscle		+	\$9,287.20	
27193	Treat pelvic ring fracture		+	\$516.84	
27194	Treat pelvic ring fracture		+	\$3,640.96	
27200	Treat tail bone fracture		+	\$516.84	
27202	Treat tail bone fracture		+	\$8,760.26	
27216	Treat pelvic ring fracture		+	\$6,722.37	
27220	Treat hip socket fracture		+	\$516.84	
27230	Treat thigh fracture		+	\$516.84	
27235	Treat thigh fracture		+	\$6,722.37	
27238	Treat thigh fracture		+	\$516.84	
27246	Treat thigh fracture		+	\$516.84	
27250	Treat hip dislocation		+	\$516.84	
27252	Treat hip dislocation		+	\$3,640.96	
27256	Treat hip dislocation		+	\$516.84	
27257	Treat hip dislocation		+	\$3,640.96	
27265	Treat hip dislocation		+	\$516.84	
27266	Treat hip dislocation		+	\$3,640.96	
27275	Manipulation of hip joint		+	\$3,640.96	
27299	Pelvis/hip joint surgery		+	\$516.84	
27301	Drain thigh/knee lesion		+	\$5,279.24	
27305	Incise thigh tendon & fascia		+	\$5,304.59	
27306	Incision of thigh tendon		+	\$5,304.59	
27307	Incision of thigh tendons		+	\$5,304.59	
27310	Exploration of knee joint		+	\$6,722.37	
27315	Partial removal, thigh nerve		+	\$4,482.38	
27320	Partial removal, thigh nerve		+	\$4,482.38	
27323	Biopsy, thigh soft tissues		+	\$3,862.11	
27324	Biopsy, thigh soft tissues		+	\$5,085.32	
27327	Removal of thigh lesion		+	\$5,085.32	
27328	Removal of thigh lesion		+	\$5,085.32	
27329	Remove tumor, thigh/knee		+	\$5,085.32	
27330	Biopsy, knee joint lining		+	\$6,722.37	
27331	Explore/treat knee joint		+	\$6,722.37	
27332	Removal of knee cartilage		+	\$6,722.37	
27333	Removal of knee cartilage		+	\$6,722.37	
27334	Remove knee joint lining		+	\$6,722.37	
27335	Remove knee joint lining		+	\$6,722.37	
27340	Removal of kneecap bursa		+	\$5,304.59	
27345	Removal of knee cyst		+	\$5,304.59	
27347	Remove knee cyst		+	\$5,304.59	
27350	Removal of kneecap		+	\$6,722.37	
27355	Remove femur lesion		+	\$6,722.37	
27356	Remove femur lesion/graft		+	\$6,722.37	
27357	Remove femur lesion/graft		+	\$6,722.37	
27358	Remove femur lesion/fixation		+	\$6,722.37	
27360	Partial removal, leg bone(s)		+	\$6,722.37	
27372	Removal of foreign body		+	\$5,085.32	
27380	Repair of kneecap tendon		+	\$5,304.59	
27381	Repair/graft kneecap tendon		+	\$5,304.59	
27385	Repair of thigh muscle		+	\$5,304.59	
27386	Repair/graft of thigh muscle		+	\$5,304.59	
27390	Incision of thigh tendon		+	\$5,304.59	
27391	Incision of thigh tendons		+	\$5,304.59	
27392	Incision of thigh tendons		+	\$5,304.59	
27393	Lengthening of thigh tendon		+	\$6,722.37	
27394	Lengthening of thigh tendons		+	\$6,722.37	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 19 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27395	Lengthening of thigh tendons		+	\$9,287.20	
27396	Transplant of thigh tendon		+	\$6,722.37	
27397	Transplants of thigh tendons		+	\$9,287.20	
27400	Revise thigh muscles/tendons		+	\$9,287.20	
27403	Repair of knee cartilage		+	\$6,722.37	
27405	Repair of knee ligament		+	\$9,287.20	
27407	Repair of knee ligament		+	\$9,287.20	
27409	Repair of knee ligaments		+	\$9,287.20	
27418	Repair degenerated kneecap		+	\$9,287.20	
27420	Revision of unstable kneecap		+	\$9,287.20	
27422	Revision of unstable kneecap		+	\$9,287.20	
27424	Revision/removal of kneecap		+	\$9,287.20	
27425	Lateral retinacular release		+	\$6,722.37	
27427	Reconstruction, knee		+	\$11,259.26	
27428	Reconstruction, knee		+	\$11,259.26	
27429	Reconstruction, knee		+	\$11,259.26	
27430	Revision of thigh muscles		+	\$9,287.20	
27435	Incision of knee joint		+	\$9,287.20	
27437	Revise kneecap		+	\$8,104.84	
27438	Revise kneecap with implant		+	\$13,897.34	
27440	Revision of knee joint		+	\$8,104.84	
27441	Revision of knee joint		+	\$8,104.84	
27442	Revision of knee joint		+	\$8,104.84	
27443	Revision of knee joint		+	\$8,104.84	
27446	Revision of knee joint		+	\$21,932.65	
27496	Decompression of thigh/knee		+	\$5,304.59	
27497	Decompression of thigh/knee		+	\$5,304.59	
27498	Decompression of thigh/knee		+	\$5,304.59	
27499	Decompression of thigh/knee		+	\$5,304.59	
27500	Treatment of thigh fracture		+	\$516.84	
27501	Treatment of thigh fracture		+	\$516.84	
27502	Treatment of thigh fracture		+	\$516.84	
27503	Treatment of thigh fracture		+	\$516.84	
27508	Treatment of thigh fracture		+	\$516.84	
27509	Treatment of thigh fracture		+	\$8,760.26	
27510	Treatment of thigh fracture		+	\$516.84	
27516	Treat thigh fx growth plate		+	\$516.84	
27517	Treat thigh fx growth plate		+	\$516.84	
27520	Treat kneecap fracture		+	\$516.84	
27524	Treat kneecap fracture		+	\$8,760.26	
27530	Treat knee fracture		+	\$516.84	
27532	Treat knee fracture		+	\$516.84	
27535	Treat knee fracture		+	\$12,147.60	MDR
27538	Treat knee fracture(s)		+	\$516.84	
27550	Treat knee dislocation		+	\$516.84	
27552	Treat knee dislocation		+	\$3,640.96	
27560	Treat kneecap dislocation		+	\$516.84	
27562	Treat kneecap dislocation		+	\$3,640.96	
27566	Treat kneecap dislocation		+	\$8,760.26	
27570	Fixation of knee joint		+	\$3,640.96	
27594	Amputation follow-up surgery		+	\$5,304.59	
27599	Leg surgery procedure		+	\$516.84	
27600	Decompression of lower leg		+	\$5,304.59	
27601	Decompression of lower leg		+	\$5,304.59	
27602	Decompression of lower leg		+	\$5,304.59	
27603	Drain lower leg lesion		+	\$3,188.56	
27604	Drain lower leg bursa		+	\$5,304.59	
27605	Incision of achilles tendon		+	\$5,066.11	
27606	Incision of achilles tendon		+	\$5,304.59	
27607	Treat lower leg bone lesion		+	\$5,304.59	
27610	Explore/treat ankle joint		+	\$6,722.37	
27612	Exploration of ankle joint		+	\$6,722.37	
27613	Biopsy lower leg soft tissue		+	\$1,917.62	
27614	Biopsy lower leg soft tissue		+	\$5,085.32	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 20 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27615	Remove tumor, lower leg		+	\$8,760.26	
27618	Remove lower leg lesion		+	\$3,862.11	
27619	Remove lower leg lesion		+	\$5,085.32	
27620	Explore/treat ankle joint		+	\$6,722.37	
27625	Remove ankle joint lining		+	\$6,722.37	
27626	Remove ankle joint lining		+	\$6,722.37	
27630	Removal of tendon lesion		+	\$5,304.59	
27635	Remove lower leg bone lesion		+	\$6,722.37	
27637	Remove/graft leg bone lesion		+	\$6,722.37	
27638	Remove/graft leg bone lesion		+	\$6,722.37	
27640	Partial removal of tibia		+	\$9,287.20	
27641	Partial removal of fibula		+	\$6,722.37	
27647	Extensive ankle/heel surgery		+	\$9,287.20	
27650	Repair achilles tendon		+	\$9,287.20	
27652	Repair/graft achilles tendon		+	\$9,287.20	
27654	Repair of achilles tendon		+	\$9,287.20	
27656	Repair leg fascia defect		+	\$5,304.59	
27658	Repair of leg tendon, each		+	\$5,304.59	
27659	Repair of leg tendon, each		+	\$5,304.59	
27664	Repair of leg tendon, each		+	\$5,304.59	
27665	Repair of leg tendon, each		+	\$6,722.37	
27675	Repair lower leg tendons		+	\$5,304.59	
27676	Repair lower leg tendons		+	\$6,722.37	
27680	Release of lower leg tendon		+	\$6,722.37	
27681	Release of lower leg tendons		+	\$6,722.37	
27685	Revision of lower leg tendon		+	\$6,722.37	
27686	Revise lower leg tendons		+	\$6,722.37	
27687	Revision of calf tendon		+	\$6,722.37	
27690	Revise lower leg tendon		+	\$9,287.20	
27691	Revise lower leg tendon		+	\$9,287.20	
27692	Revise additional leg tendon		+	\$9,287.20	
27695	Repair of ankle ligament		+	\$6,722.37	
27696	Repair of ankle ligaments		+	\$6,722.37	
27698	Repair of ankle ligament		+	\$6,722.37	
27700	Revision of ankle joint		+	\$8,104.84	
27704	Removal of ankle implant		+	\$5,304.59	
27705	Incision of tibia		+	\$9,287.20	
27707	Incision of fibula		+	\$5,304.59	
27709	Incision of tibia & fibula		+	\$6,722.37	
27730	Repair of tibia epiphysis		+	\$6,722.37	
27732	Repair of fibula epiphysis		+	\$6,722.37	
27734	Repair lower leg epiphyses		+	\$6,722.37	
27740	Repair of leg epiphyses		+	\$6,722.37	
27742	Repair of leg epiphyses		+	\$9,287.20	
27745	Reinforce tibia		+	\$9,287.20	
27750	Treatment of tibia fracture		+	\$516.84	
27752	Treatment of tibia fracture		+	\$516.84	
27756	Treatment of tibia fracture		+	\$8,760.26	
27758	Treatment of tibia fracture		+	\$8,760.26	
27759	Treatment of tibia fracture		+	\$8,760.26	
27760	Treatment of ankle fracture		+	\$516.84	
27762	Treatment of ankle fracture		+	\$516.84	
27766	Treatment of ankle fracture		+	\$8,760.26	
27780	Treatment of fibula fracture		+	\$516.84	
27781	Treatment of fibula fracture		+	\$516.84	
27784	Treatment of fibula fracture		+	\$8,760.26	
27786	Treatment of ankle fracture		+	\$516.84	
27788	Treatment of ankle fracture		+	\$516.84	
27792	Treatment of ankle fracture		+	\$8,760.26	
27808	Treatment of ankle fracture		+	\$516.84	
27810	Treatment of ankle fracture		+	\$516.84	
27814	Treatment of ankle fracture		+	\$8,760.26	
27816	Treatment of ankle fracture		+	\$516.84	
27818	Treatment of ankle fracture		+	\$516.84	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 21 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27822	Treatment of ankle fracture		+	\$8,760.26	
27823	Treatment of ankle fracture		+	\$8,760.26	
27824	Treat lower leg fracture		+	\$516.84	
27825	Treat lower leg fracture		+	\$516.84	
27826	Treat lower leg fracture		+	\$8,760.26	
27827	Treat lower leg fracture		+	\$8,760.26	
27828	Treat lower leg fracture		+	\$8,760.26	
27829	Treat lower leg joint		+	\$8,760.26	
27830	Treat lower leg dislocation		+	\$516.84	
27831	Treat lower leg dislocation		+	\$516.84	
27832	Treat lower leg dislocation		+	\$8,760.26	
27840	Treat ankle dislocation		+	\$516.84	
27842	Treat ankle dislocation		+	\$3,640.96	
27846	Treat ankle dislocation		+	\$8,760.26	
27848	Treat ankle dislocation		+	\$8,760.26	
27860	Fixation of ankle joint		+	\$3,640.96	
27870	Fusion of ankle joint		+	\$9,287.20	
27871	Fusion of tibiofibular joint		+	\$9,287.20	
27884	Amputation follow-up surgery		+	\$5,304.59	
27889	Amputation of foot at ankle		+	\$6,722.37	
27892	Decompression of leg		+	\$5,304.59	
27893	Decompression of leg		+	\$5,304.59	
27894	Decompression of leg		+	\$5,304.59	
27899	Leg/ankle surgery procedure		+	\$516.84	
28001	Drainage of bursa of foot		+	\$3,188.56	
28002	Treatment of foot infection		+	\$5,304.59	
28003	Treatment of foot infection		+	\$5,304.59	
28005	Treat foot bone lesion		+	\$5,066.11	
28008	Incision of foot fascia		+	\$5,066.11	
28010	Incision of toe tendon		+	\$5,066.11	
28011	Incision of toe tendons		+	\$5,066.11	
28020	Exploration of foot joint		+	\$5,066.11	
28022	Exploration of foot joint		+	\$5,066.11	
28024	Exploration of toe joint		+	\$5,066.11	
28030	Removal of foot nerve		+	\$4,482.38	
28035	Decompression of tibia nerve		+	\$4,482.38	
28043	Excision of foot lesion		+	\$3,862.11	
28045	Excision of foot lesion		+	\$5,066.11	
28046	Resection of tumor, foot		+	\$5,066.11	
28050	Biopsy of foot joint lining		+	\$5,066.11	
28052	Biopsy of foot joint lining		+	\$5,066.11	
28054	Biopsy of toe joint lining		+	\$5,066.11	
28060	Partial removal, foot fascia		+	\$6,842.22	
28062	Removal of foot fascia		+	\$6,842.22	
28070	Removal of foot joint lining		+	\$6,842.22	
28072	Removal of foot joint lining		+	\$6,842.22	
28080	Removal of foot lesion		+	\$5,066.11	
28086	Excise foot tendon sheath		+	\$5,066.11	
28088	Excise foot tendon sheath		+	\$5,066.11	
28090	Removal of foot lesion		+	\$5,066.11	
28092	Removal of toe lesions		+	\$5,066.11	
28100	Removal of ankle/heel lesion		+	\$5,066.11	
28102	Remove/graft foot lesion		+	\$6,842.22	
28103	Remove/graft foot lesion		+	\$6,842.22	
28104	Removal of foot lesion		+	\$5,066.11	
28106	Remove/graft foot lesion		+	\$6,842.22	
28107	Remove/graft foot lesion		+	\$6,842.22	
28108	Removal of toe lesions		+	\$5,066.11	
28110	Part removal of metatarsal		+	\$6,842.22	
28111	Part removal of metatarsal		+	\$5,066.11	
28112	Part removal of metatarsal		+	\$5,066.11	
28113	Part removal of metatarsal		+	\$5,066.11	
28114	Removal of metatarsal heads		+	\$5,066.11	
28116	Revision of foot		+	\$5,066.11	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 22 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28118	Removal of heel bone		+	\$5,066.11	
28119	Removal of heel spur		+	\$5,066.11	
28120	Part removal of ankle/heel		+	\$5,066.11	
28122	Partial removal of foot bone		+	\$5,066.11	
28124	Partial removal of toe		+	\$5,066.11	
28126	Partial removal of toe		+	\$5,066.11	
28130	Removal of ankle bone		+	\$5,066.11	
28140	Removal of metatarsal		+	\$5,066.11	
28150	Removal of toe		+	\$5,066.11	
28153	Partial removal of toe		+	\$5,066.11	
28160	Partial removal of toe		+	\$5,066.11	
28171	Extensive foot surgery		+	\$5,066.11	
28173	Extensive foot surgery		+	\$5,066.11	
28175	Extensive foot surgery		+	\$5,066.11	
28190	Removal of foot foreign body		+	\$1,068.77	
28192	Removal of foot foreign body		+	\$3,862.11	
28193	Removal of foot foreign body		+	\$1,917.62	
28200	Repair of foot tendon		+	\$5,066.11	
28202	Repair/graft of foot tendon		+	\$6,842.22	
28208	Repair of foot tendon		+	\$5,066.11	
28210	Repair/graft of foot tendon		+	\$6,842.22	
28220	Release of foot tendon		+	\$5,066.11	
28222	Release of foot tendons		+	\$5,066.11	
28225	Release of foot tendon		+	\$5,066.11	
28226	Release of foot tendons		+	\$5,066.11	
28230	Incision of foot tendon(s)		+	\$5,066.11	
28232	Incision of toe tendon		+	\$5,066.11	
28234	Incision of foot tendon		+	\$5,066.11	
28238	Revision of foot tendon		+	\$6,842.22	
28240	Release of big toe		+	\$5,066.11	
28250	Revision of foot fascia		+	\$6,842.22	
28260	Release of midfoot joint		+	\$6,842.22	
28261	Revision of foot tendon		+	\$6,842.22	
28262	Revision of foot and ankle		+	\$6,842.22	
28264	Release of midfoot joint		+	\$6,842.22	
28270	Release of foot contracture		+	\$5,066.11	
28272	Release of toe joint, each		+	\$5,066.11	
28280	Fusion of toes		+	\$5,066.11	
28285	Repair of hammertoe		+	\$5,066.11	
28286	Repair of hammertoe		+	\$5,066.11	
28288	Partial removal of foot bone		+	\$6,842.22	
28289	Repair hallux rigidus		+	\$6,842.22	
28290	Correction of bunion		+	\$6,842.22	
28292	Correction of bunion		+	\$6,899.53	
28293	Correction of bunion		+	\$6,899.53	
28294	Correction of bunion		+	\$6,842.22	
28296	Correction of bunion		+	\$6,842.22	
28297	Correction of bunion		+	\$6,899.53	
28298	Correction of bunion		+	\$6,842.22	
28299	Correction of bunion		+	\$6,899.53	
28300	Incision of heel bone		+	\$6,842.22	
28302	Incision of ankle bone		+	\$6,842.22	
28304	Incision of midfoot bones		+	\$6,842.22	
28305	Incise/graft midfoot bones		+	\$6,842.22	
28306	Incision of metatarsal		+	\$6,842.22	
28307	Incision of metatarsal		+	\$6,842.22	
28308	Incision of metatarsal		+	\$6,842.22	
28309	Incision of metatarsals		+	\$6,842.22	
28310	Revision of big toe		+	\$5,066.11	
28312	Revision of toe		+	\$5,066.11	
28313	Repair deformity of toe		+	\$5,066.11	
28315	Removal of sesamoid bone		+	\$5,066.11	
28320	Repair of foot bones		+	\$6,842.22	
28322	Repair of metatarsals		+	\$6,842.22	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association All rights reserved Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 23 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28340	Resect enlarged toe tissue		+	\$5,066.11	
28341	Resect enlarged toe		+	\$5,066.11	
28344	Repair extra toe(s)		+	\$6,842.22	
28345	Repair webbed toe(s)		+	\$6,842.22	
28360	Reconstruct cleft foot		+	\$6,842.22	
28400	Treatment of heel fracture		+	\$516.84	
28405	Treatment of heel fracture		+	\$516.84	
28406	Treatment of heel fracture		+	\$8,760.26	
28415	Treat heel fracture		+	\$8,760.26	
28420	Treat/graft heel fracture		+	\$8,760.26	
28430	Treatment of ankle fracture		+	\$516.84	
28435	Treatment of ankle fracture		+	\$516.84	
28436	Treatment of ankle fracture		+	\$8,760.26	
28445	Treat ankle fracture		+	\$8,760.26	
28450	Treat midfoot fracture, each		+	\$516.84	
28455	Treat midfoot fracture, each		+	\$516.84	
28456	Treat midfoot fracture		+	\$8,760.26	
28465	Treat midfoot fracture, each		+	\$8,760.26	
28470	Treat metatarsal fracture		+	\$516.84	
28475	Treat metatarsal fracture		+	\$516.84	
28476	Treat metatarsal fracture		+	\$8,760.26	
28485	Treat metatarsal fracture		+	\$8,760.26	
28490	Treat big toe fracture		+	\$516.84	
28495	Treat big toe fracture		+	\$516.84	
28496	Treat big toe fracture		+	\$8,760.26	
28505	Treat big toe fracture		+	\$8,760.26	
28510	Treatment of toe fracture		+	\$516.84	
28515	Treatment of toe fracture		+	\$516.84	
28525	Treat toe fracture		+	\$8,760.26	
28530	Treat sesamoid bone fracture		+	\$516.84	
28531	Treat sesamoid bone fracture		+	\$8,760.26	
28540	Treat foot dislocation		+	\$516.84	
28545	Treat foot dislocation		+	\$3,640.96	
28546	Treat foot dislocation		+	\$8,760.26	
28555	Repair foot dislocation		+	\$8,760.26	
28570	Treat foot dislocation		+	\$516.84	
28575	Treat foot dislocation		+	\$516.84	
28576	Treat foot dislocation		+	\$8,760.26	
28585	Repair foot dislocation		+	\$8,760.26	
28600	Treat foot dislocation		+	\$516.84	
28605	Treat foot dislocation		+	\$516.84	
28606	Treat foot dislocation		+	\$8,760.26	
28615	Repair foot dislocation		+	\$8,760.26	
28630	Treat toe dislocation		+	\$516.84	
28635	Treat toe dislocation		+	\$3,640.96	
28636	Treat toe dislocation		+	\$8,760.26	
28645	Repair toe dislocation		+	\$8,760.26	
28660	Treat toe dislocation		+	\$516.84	
28665	Treat toe dislocation		+	\$3,640.96	
28666	Treat toe dislocation		+	\$8,760.26	
28675	Repair of toe dislocation		+	\$8,760.26	
28705	Fusion of foot bones		+	\$6,842.22	
28715	Fusion of foot bones		+	\$6,842.22	
28725	Fusion of foot bones		+	\$6,842.22	
28730	Fusion of foot bones		+	\$6,842.22	
28735	Fusion of foot bones		+	\$6,842.22	
28737	Revision of foot bones		+	\$6,842.22	
28740	Fusion of foot bones		+	\$6,842.22	
28750	Fusion of big toe joint		+	\$6,842.22	
28755	Fusion of big toe joint		+	\$5,066.11	
28760	Fusion of big toe joint		+	\$6,842.22	
28805	Amputation thru metatarsal			\$7,519.12	MDR
28810	Amputation toe & metatarsal		+	\$5,066.11	
28820	Amputation of toe		+	\$5,066.11	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 24 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28825	Partial amputation of toe		+	\$5,066.11	
28899	Foot/toes surgery procedure		+	\$516.84	
29000	Application of body cast			\$296.19	
29010	Application of body cast			\$296.19	
29015	Application of body cast			\$296.19	
29020	Application of body cast			\$296.19	
29025	Application of body cast			\$296.19	
29035	Application of body cast			\$296.19	
29040	Application of body cast			\$296.19	
29044	Application of body cast			\$296.19	
29046	Application of body cast			\$296.19	
29049	Application of figure eight			\$296.19	
29055	Application of shoulder cast			\$296.19	
29058	Application of shoulder cast			\$296.19	
29065	Application of long arm cast			\$296.19	
29075	Application of forearm cast			\$296.19	
29085	Apply hand/wrist cast			\$296.19	
29086	Apply finger cast			\$296.19	
29105	Apply long arm splint			\$296.19	
29125	Apply forearm splint			\$296.19	
29126	Apply forearm splint			\$296.19	
29130	Application of finger splint			\$296.19	
29131	Application of finger splint			\$296.19	
29200	Strapping of chest			\$296.19	
29220	Strapping of low back			\$296.19	
29240	Strapping of shoulder			\$296.19	
29260	Strapping of elbow or wrist			\$296.19	
29280	Strapping of hand or finger			\$296.19	
29305	Application of hip cast			\$296.19	
29325	Application of hip casts			\$296.19	
29345	Application of long leg cast			\$296.19	
29355	Application of long leg cast			\$296.19	
29358	Apply long leg cast brace			\$296.19	
29365	Application of long leg cast			\$296.19	
29405	Apply short leg cast			\$296.19	
29425	Apply short leg cast			\$296.19	
29435	Apply short leg cast			\$296.19	
29440	Addition of walker to cast			\$296.19	
29445	Apply rigid leg cast			\$296.19	
29450	Application of leg cast			\$296.19	
29505	Application, long leg splint			\$296.19	
29515	Application lower leg splint			\$296.19	
29520	Strapping of hip			\$296.19	
29530	Strapping of knee			\$296.19	
29540	Strapping of ankle			\$296.19	
29550	Strapping of toes			\$296.19	
29580	Application of paste boot			\$296.19	
29590	Application of foot splint			\$296.19	
29700	Removal/revision of cast			\$296.19	
29705	Removal/revision of cast			\$296.19	
29710	Removal/revision of cast			\$296.19	
29715	Removal/revision of cast			\$296.19	
29720	Repair of body cast			\$296.19	
29730	Windowing of cast			\$296.19	
29740	Wedging of cast			\$296.19	
29750	Wedging of clubfoot cast			\$296.19	
29799	CASTING/strapping procedure			\$296.19	
29800	Jaw arthroscopy/surgery		+	\$7,407.10	
29804	Jaw arthroscopy/surgery		+	\$7,407.10	
29805	Shoulder arthroscopy, dx		+	\$7,407.10	
29806	Shoulder arthroscopy/surgery		+	\$7,407.10	
29807	Shoulder arthroscopy/surgery		+	\$7,407.10	
29819	Shoulder arthroscopy/surgery		+	\$7,407.10	
29820	Shoulder arthroscopy/surgery		+	\$7,407.10	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 25 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
29821	Shoulder arthroscopy/surgery		+	\$7,407.10	
29822	Shoulder arthroscopy/surgery		+	\$7,407.10	
29823	Shoulder arthroscopy/surgery		+	\$7,407.10	
29824	Shoulder arthroscopy/surgery		+	\$7,407.10	
29825	Shoulder arthroscopy/surgery		+	\$7,407.10	
29826	Shoulder arthroscopy/surgery		+	\$11,654.95	
29827	Arthroscop rotator cuff repr		+	\$7,407.10	
29830	Elbow arthroscopy		+	\$7,407.10	
29834	Elbow arthroscopy/surgery		+	\$7,407.10	
29835	Elbow arthroscopy/surgery		+	\$11,654.95	
29836	Elbow arthroscopy/surgery		+	\$11,654.95	
29837	Elbow arthroscopy/surgery		+	\$7,407.10	
29838	Elbow arthroscopy/surgery		+	\$7,407.10	
29840	Wrist arthroscopy		+	\$7,407.10	
29843	Wrist arthroscopy/surgery		+	\$7,407.10	
29844	Wrist arthroscopy/surgery		+	\$7,407.10	
29845	Wrist arthroscopy/surgery		+	\$7,407.10	
29846	Wrist arthroscopy/surgery		+	\$7,407.10	
29847	Wrist arthroscopy/surgery		+	\$7,407.10	
29848	Wrist endoscopy/surgery		+	\$7,407.10	
29850	Knee arthroscopy/surgery		+	\$7,407.10	
29851	Knee arthroscopy/surgery		+	\$7,407.10	
29855	Tibial arthroscopy/surgery		+	\$11,654.95	
29856	Tibial arthroscopy/surgery		+	\$7,407.10	
29860	Hip arthroscopy, dx		+	\$7,407.10	
29861	Hip arthroscopy/surgery		+	\$7,407.10	
29862	Hip arthroscopy/surgery		+	\$11,654.95	
29863	Hip arthroscopy/surgery		+	\$11,654.95	
29870	Knee arthroscopy, dx		+	\$7,407.10	
29871	Knee arthroscopy/drainage		+	\$7,407.10	
29873	Knee arthroscopy/surgery		+	\$7,407.10	
29874	Knee arthroscopy/surgery		+	\$7,407.10	
29875	Knee arthroscopy/surgery		+	\$7,407.10	
29876	Knee arthroscopy/surgery		+	\$7,407.10	
29877	Knee arthroscopy/surgery		+	\$7,407.10	
29879	Knee arthroscopy/surgery		+	\$7,407.10	
29880	Knee arthroscopy/surgery		+	\$7,407.10	
29881	Knee arthroscopy/surgery		+	\$7,407.10	
29882	Knee arthroscopy/surgery		+	\$7,407.10	
29883	Knee arthroscopy/surgery		+	\$7,407.10	
29884	Knee arthroscopy/surgery		+	\$7,407.10	
29885	Knee arthroscopy/surgery		+	\$7,407.10	
29886	Knee arthroscopy/surgery		+	\$7,407.10	
29887	Knee arthroscopy/surgery		+	\$7,407.10	
29888	Knee arthroscopy/surgery		+	\$11,654.95	
29889	Knee arthroscopy/surgery		+	\$11,654.95	
29891	Ankle arthroscopy/surgery		+	\$7,407.10	
29892	Ankle arthroscopy/surgery		+	\$7,407.10	
29893	Scope, plantar fasciotomy		+	\$5,066.11	
29894	Ankle arthroscopy/surgery		+	\$7,407.10	
29895	Ankle arthroscopy/surgery		+	\$7,407.10	
29897	Ankle arthroscopy/surgery		+	\$7,407.10	
29898	Ankle arthroscopy/surgery		+	\$7,407.10	
29899	Ankle arthroscopy/surgery		+	\$7,407.10	
29900	Mcp joint arthroscopy, dx		+	\$4,027.45	
29901	Mcp joint arthroscopy, surg		+	\$4,027.45	
29902	Mcp joint arthroscopy, surg		+	\$4,027.45	
29999	Arthroscopy of joint		+	\$7,407.10	
30000	Drainage of nose lesion		+	\$484.51	
30020	Drainage of nose lesion		+	\$484.51	
30100	Intranasal biopsy		+	\$1,744.68	
30110	Removal of nose polyp(s)		+	\$4,123.29	
30115	Removal of nose polyp(s)		+	\$4,123.29	
30117	Removal of intranasal lesion		+	\$4,123.29	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 26 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
30118	Removal of intranasal lesion		+	\$5,907.64	
30120	Revision of nose		+	\$4,123.29	
30124	Removal of nose lesion		+	\$1,744.68	
30125	Removal of nose lesion		+	\$9,418.88	
30130	Removal of turbinate bones		+	\$4,123.29	
30140	Removal of turbinate bones		+	\$5,907.64	
30150	Partial removal of nose		+	\$9,418.88	
30160	Removal of nose		+	\$9,418.88	
30200	Injection treatment of nose		+	\$4,123.29	
30210	Nasal sinus therapy		+	\$1,744.68	
30220	Insert nasal septal button		+	\$1,744.68	
30300	Remove nasal foreign body			\$170.98	
30310	Remove nasal foreign body		+	\$4,123.29	
30320	Remove nasal foreign body		+	\$4,123.29	
30400	Reconstruction of nose		+	\$9,418.88	
30410	Reconstruction of nose		+	\$9,418.88	
30420	Reconstruction of nose		+	\$9,418.88	
30430	Revision of nose		+	\$5,907.64	
30435	Revision of nose		+	\$9,418.88	
30450	Revision of nose		+	\$9,418.88	
30460	Revision of nose		+	\$9,418.88	
30462	Revision of nose		+	\$9,418.88	
30465	Repair nasal stenosis		+	\$9,418.88	
30520	Repair of nasal septum		+	\$5,907.64	
30540	Repair nasal defect		+	\$9,418.88	
30545	Repair nasal defect		+	\$9,418.88	
30560	Release of nasal adhesions		+	\$484.51	
30580	Repair upper jaw fistula		+	\$9,418.88	
30600	Repair mouth/nose fistula		+	\$9,418.88	
30620	Intranasal reconstruction		+	\$9,418.88	
30630	Repair nasal septum defect		+	\$5,907.64	
30801	Cauterization, inner nose		+	\$1,744.68	
30802	Cauterization, inner nose		+	\$4,123.29	
30901	Control of nosebleed		+	\$392.22	
30903	Control of nosebleed		+	\$392.22	
30905	Control of nosebleed		+	\$392.22	
30906	Repeat control of nosebleed		+	\$392.22	
30915	Ligation, nasal sinus artery		+	\$7,767.55	
30920	Ligation, upper jaw artery		+	\$6,788.02	
30930	Therapy, fracture of nose		+	\$4,123.29	
30999	Nasal surgery procedure		+	\$484.51	
31000	Irrigation, maxillary sinus		+	\$484.51	
31002	Irrigation, sphenoid sinus		+	\$1,744.68	
31020	Exploration, maxillary sinus		+	\$5,907.64	
31030	Exploration, maxillary sinus		+	\$9,418.88	
31032	Explore sinus, remove polyps		+	\$9,418.88	
31040	Exploration behind upper jaw		+	\$5,907.64	
31050	Exploration, sphenoid sinus		+	\$9,418.88	
31051	Sphenoid sinus surgery		+	\$9,418.88	
31070	Exploration of frontal sinus		+	\$5,907.64	
31075	Exploration of frontal sinus		+	\$9,418.88	
31080	Removal of frontal sinus		+	\$9,418.88	
31081	Removal of frontal sinus		+	\$9,418.88	
31084	Removal of frontal sinus		+	\$9,418.88	
31085	Removal of frontal sinus		+	\$9,418.88	
31086	Removal of frontal sinus		+	\$9,418.88	
31087	Removal of frontal sinus		+	\$9,418.88	
31090	Exploration of sinuses		+	\$9,418.88	
31200	Removal of ethmoid sinus		+	\$9,418.88	
31201	Removal of ethmoid sinus		+	\$9,418.88	
31205	Removal of ethmoid sinus		+	\$9,418.88	
31225	Removal of upper jaw			\$7,756.02	MDR
31231	Nasal endoscopy, dx		+	\$230.90	
31233	Nasal/sinus endoscopy, dx		+	\$477.26	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 27 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
31235	Nasal/sinus endoscopy, dx		+	\$3,760.08	
31237	Nasal/sinus endoscopy, surg		+	\$5,522.69	
31238	Nasal/sinus endoscopy, surg		+	\$3,760.08	
31239	Nasal/sinus endoscopy, surg		+	\$5,522.69	
31240	Nasal/sinus endoscopy, surg		+	\$3,760.08	
31254	Revision of ethmoid sinus		+	\$5,522.69	
31255	Removal of ethmoid sinus		+	\$5,522.69	
31256	Exploration maxillary sinus		+	\$5,522.69	
31267	Endoscopy, maxillary sinus		+	\$5,522.69	
31276	Sinus endoscopy, surgical		+	\$5,522.69	
31287	Nasal/sinus endoscopy, surg		+	\$5,522.69	
31288	Nasal/sinus endoscopy, surg		+	\$5,522.69	
31299	Sinus surgery procedure		+	\$1,744.68	
31300	Removal of larynx lesion		+	\$5,907.64	
31320	Diagnostic incision, larynx		+	\$9,418.88	
31400	Revision of larynx		+	\$9,418.88	
31420	Removal of epiglottis		+	\$9,418.88	
31500	Insert emergency airway			\$822.37	
31502	Change of windpipe airway		+	\$569.80	
31505	Diagnostic laryngoscopy		+	\$230.90	
31510	Laryngoscopy with biopsy		+	\$3,760.08	
31511	Remove foreign body, larynx		+	\$477.26	
31512	Removal of larynx lesion		+	\$3,760.08	
31513	Injection into vocal cord		+	\$477.26	
31515	Laryngoscopy for aspiration		+	\$3,760.08	
31520	Diagnostic laryngoscopy		+	\$477.26	
31525	Diagnostic laryngoscopy		+	\$3,760.08	
31526	Diagnostic laryngoscopy		+	\$5,522.69	
31527	Laryngoscopy for treatment		+	\$5,522.69	
31528	Laryngoscopy and dilation		+	\$3,760.08	
31529	Laryngoscopy and dilation		+	\$3,760.08	
31530	Operative laryngoscopy		+	\$5,522.69	
31531	Operative laryngoscopy		+	\$5,522.69	
31535	Operative laryngoscopy		+	\$5,522.69	
31536	Operative laryngoscopy		+	\$5,522.69	
31540	Operative laryngoscopy		+	\$5,522.69	
31541	Operative laryngoscopy		+	\$5,522.69	
31560	Operative laryngoscopy		+	\$5,522.69	
31561	Operative laryngoscopy		+	\$5,522.69	
31570	Laryngoscopy with injection		+	\$3,760.08	
31571	Laryngoscopy with injection		+	\$5,522.69	
31575	Diagnostic laryngoscopy		+	\$477.26	
31576	Laryngoscopy with biopsy		+	\$5,522.69	
31577	Remove foreign body, larynx		+	\$935.94	
31578	Removal of larynx lesion		+	\$5,522.69	
31579	Diagnostic laryngoscopy		+	\$935.94	
31580	Revision of larynx		+	\$9,418.88	
31582	Revision of larynx		+	\$9,418.88	
31585	Treat larynx fracture		+	\$4,123.29	
31586	Treat larynx fracture		+	\$9,418.88	
31588	Revision of larynx		+	\$9,418.88	
31590	Reinnervate larynx		+	\$9,418.88	
31595	Larynx nerve surgery		+	\$9,418.88	
31599	Larynx surgery procedure		+	\$5,907.64	
31600	Incision of windpipe		+	\$5,907.64	
31601	Incision of windpipe		+	\$5,907.64	
31603	Incision of windpipe		+	\$1,744.68	
31605	Incision of windpipe		+	\$4,123.29	
31610	Incision of windpipe		+	\$5,907.64	
31611	Surgery/speech prosthesis		+	\$5,907.64	
31612	Puncture/clear windpipe		+	\$5,907.64	
31613	Repair windpipe opening		+	\$5,907.64	
31614	Repair windpipe opening		+	\$9,418.88	
31615	Visualization of windpipe		+	\$2,500.46	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 28 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
31622	Dx bronchoscope/wash		+	\$2,500.46	
31623	Dx bronchoscope/brush		+	\$2,500.46	
31624	Dx bronchoscope/lavage		+	\$2,500.46	
31625	Bronchoscopy w/biopsy(s)		+	\$2,500.46	
31628	Bronchoscopy/lung bx, each		+	\$2,500.46	
31629	Bronchoscopy/needle bx, each		+	\$2,500.46	
31630	Bronchoscopy dilate/fx repr		+	\$5,603.23	
31631	Bronchoscopy, dilate w/stent		+	\$5,603.23	
31632	Bronchoscopy/lung bx, add'l		+	\$2,500.46	
31633	Bronchoscopy/needle bx add'l		+	\$2,500.46	
31635	Bronchoscopy w/fb removal		+	\$2,500.46	
31640	Bronchoscopy w/tumor excise		+	\$5,603.23	
31641	Bronchoscopy, treat blockage		+	\$5,603.23	
31643	Diag bronchoscope/catheter		+	\$2,500.46	
31645	Bronchoscopy, clear airways		+	\$2,500.46	
31646	Bronchoscopy, reclear airway		+	\$2,500.46	
31656	Bronchoscopy, inj for x-ray		+	\$2,500.46	
31700	Insertion of airway catheter		+	\$477.26	
31717	Bronchial brush biopsy		+	\$935.94	
31720	Clearance of airways		+	\$230.90	
31730	Intro, windpipe wire/tube		+	\$935.94	
31750	Repair of windpipe		+	\$9,418.88	
31755	Repair of windpipe		+	\$9,418.88	
31785	Remove windpipe lesion		+	\$5,907.64	
31820	Closure of windpipe lesion		+	\$4,123.29	
31825	Repair of windpipe defect		+	\$5,907.64	
31830	Revise windpipe scar		+	\$5,907.64	
31899	Airways surgical procedure		+	\$2,500.46	
32000	Drainage of chest		+	\$831.91	
32002	Treatment of collapsed lung		+	\$831.91	
32005	Treat lung lining chemically		+	\$831.91	
32020	Insertion of chest tube		+	\$831.91	
32201	Drain, percut, lung lesion		+	\$831.91	
32400	Needle biopsy chest lining		+	\$885.98	
32405	Biopsy, lung or mediastinum		+	\$1,291.26	
32420	Puncture/clear lung		+	\$831.91	
32601	Thoracoscopy, diagnostic		+	\$7,841.49	
32602	Thoracoscopy, diagnostic		+	\$7,841.49	
32603	Thoracoscopy, diagnostic		+	\$7,841.49	
32604	Thoracoscopy, diagnostic		+	\$7,841.49	
32605	Thoracoscopy, diagnostic		+	\$7,841.49	
32606	Thoracoscopy, diagnostic		+	\$7,841.49	
32960	Therapeutic pneumothorax		+	\$831.91	
32999	Chest surgery procedure		+	\$831.91	
33010	Drainage of heart sac		+	\$831.91	
33011	Repeat drainage of heart sac		+	\$831.91	
33206	Insertion of heart pacemaker		+	\$23,189.53	
33207	Insertion of heart pacemaker		+	\$23,189.53	
33208	Insertion of heart pacemaker		+	\$23,348.60	
33210	Insertion of heart electrode		+	\$15,979.31	
33211	Insertion of heart electrode		+	\$15,979.31	
33212	Insertion of pulse generator		+	\$21,664.12	
33213	Insertion of pulse generator		+	\$22,980.41	
33214	Upgrade of pacemaker system		+	\$23,348.60	
33215	Reposition pacing-defib lead		+	\$5,192.99	
33216	Revise eltrd pacing-defib		+	\$15,979.31	
33217	Insert lead pace-defib, dual		+	\$15,979.31	
33218	Repair lead pace-defib, one		+	\$15,979.31	
33220	Repair lead pace-defib, dual		+	\$15,979.31	
33222	Revise pocket, pacemaker		+	\$4,298.81	
33223	Revise pocket, pacing-defib		+	\$4,298.81	
33224	Insert pacing lead & connect		+	\$3,738.61	
33225	L ventric pacing lead add-on		+	\$5,058.12	
33226	Reposition I ventric lead		+	\$5,192.99	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 29 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
33233	Removal of pacemaker system		+	\$5,192.99	
33234	Removal of pacemaker system		+	\$5,192.99	
33235	Removal pacemaker electrode		+	\$5,192.99	
33241	Remove pulse generator		+	\$5,192.99	
33244	Remove eltrd, transven		+	\$5,192.99	
33282	Implant pat-active ht record			\$17,018.73	
33284	Remove pat-active ht record		+	\$2,022.52	
33999	Cardiac surgery procedure		+	\$831.91	
34101	Removal of artery clot		+	\$9,360.98	
34111	Removal of arm artery clot		+	\$9,360.98	
34201	Removal of artery clot		+	\$9,360.98	
34203	Removal of leg artery clot		+	\$9,360.98	
34421	Removal of vein clot		+	\$9,360.98	
34471	Removal of vein clot		+	\$9,360.98	
34490	Removal of vein clot		+	\$9,360.98	
34501	Repair valve, femoral vein		+	\$9,360.98	
34510	Transposition of vein valve		+	\$9,360.98	
34520	Cross-over vein graft		+	\$9,360.98	
34530	Leg vein fusion		+	\$9,360.98	
35011	Repair defect of artery		+	\$8,008.57	
35180	Repair blood vessel lesion		+	\$5,677.10	
35184	Repair blood vessel lesion		+	\$5,677.10	
35188	Repair blood vessel lesion		+	\$9,360.98	
35190	Repair blood vessel lesion		+	\$5,677.10	
35201	Repair blood vessel lesion		+	\$5,677.10	
35206	Repair blood vessel lesion		+	\$5,677.10	
35207	Repair blood vessel lesion		+	\$9,360.98	
35226	Repair blood vessel lesion		+	\$5,677.10	
35231	Repair blood vessel lesion		+	\$5,677.10	
35236	Repair blood vessel lesion		+	\$5,677.10	
35256	Repair blood vessel lesion		+	\$5,677.10	
35261	Repair blood vessel lesion		+	\$8,008.57	
35266	Repair blood vessel lesion		+	\$8,008.57	
35286	Repair blood vessel lesion		+	\$8,008.57	
35321	Rechanneling of artery		+	\$5,677.10	
35458	Repair arterial blockage		+	\$9,478.00	
35459	Repair arterial blockage		+	\$9,478.00	
35460	Repair venous blockage		+	\$9,478.00	
35470	Repair arterial blockage		+	\$9,478.00	
35471	Repair arterial blockage		+	\$9,478.00	
35472	Repair arterial blockage		+	\$9,478.00	
35473	Repair arterial blockage		+	\$9,478.00	
35474	Repair arterial blockage		+	\$9,478.00	
35475	Repair arterial blockage		+	\$9,478.00	
35476	Repair venous blockage		+	\$9,478.00	
35484	Atherectomy, open		+	\$9,478.00	
35485	Atherectomy, open		+	\$9,478.00	
35490	Atherectomy, percutaneous		+	\$9,478.00	
35491	Atherectomy, percutaneous		+	\$9,478.00	
35492	Atherectomy, percutaneous		+	\$9,478.00	
35493	Atherectomy, percutaneous		+	\$9,478.00	
35494	Atherectomy, percutaneous		+	\$9,478.00	
35495	Atherectomy, percutaneous		+	\$9,478.00	
35500	Harvest vein for bypass		+	\$9,478.00	
35685	Bypass graft patency/patch		+	\$5,677.10	
35686	Bypass graft/av fist patency		+	\$5,677.10	
35761	Exploration of artery/vein		+	\$6,931.15	
35860	Explore limb vessels		+	\$5,677.10	
35875	Removal of clot in graft		+	\$9,360.98	
35876	Removal of clot in graft		+	\$9,360.98	
35879	Revise graft w/vein		+	\$9,360.98	
35881	Revise graft w/vein		+	\$9,360.98	
35903	Excision, graft, extremity		+	\$6,931.15	
36002	Pseudoaneurysm injection trt			\$654.62	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 30 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
36260	Insertion of infusion pump		+	\$23,486.79	
36261	Revision of infusion pump		+	\$6,256.99	
36262	Removal of infusion pump		+	\$6,256.99	
36415	Drawing blood			\$13.42	SAF
36420	Vein access cutdown < 1 yr		+	\$39.75	
36425	Vein access cutdown > 1 yr		+	\$39.75	
36430	Blood transfusion service			\$993.85	
36440	BI push transfuse, 2 yr or <			\$993.85	
36450	BI exchange/transfuse, nb			\$993.85	
36455	BI exchange/transfuse non-nb			\$993.85	
36460	Transfusion service, fetal			\$993.85	
36468	Injection(s), spider veins		+	\$290.73	
36469	Injection(s), spider veins		+	\$290.73	
36470	Injection therapy of vein		+	\$290.73	
36471	Injection therapy of veins		+	\$290.73	
36511	Apheresis wbc			\$3,569.11	
36512	Apheresis rbc			\$3,569.11	
36513	Apheresis platelets			\$3,569.11	
36514	Apheresis plasma			\$3,569.11	
36515	Apheresis, adsorp/reinfuse			\$10,183.73	
36516	Apheresis, selective			\$10,183.73	
36522	Photopheresis			\$10,183.73	
36550	Declot vascular device		+	\$588.14	
36555	Insert non-tunnel cv cath		+	\$3,108.06	
36556	Insert non-tunnel cv cath		+	\$3,108.06	
36557	Insert tunneled cv cath		+	\$3,108.06	
36558	Insert tunneled cv cath		+	\$3,108.06	
36560	Insert tunneled cv cath		+	\$6,931.15	
36561	Insert tunneled cv cath		+	\$6,931.15	
36563	Insert tunneled cv cath		+	\$6,931.15	
36565	Insert tunneled cv cath		+	\$6,931.15	
36566	Insert tunneled cv cath		+	\$20,750.00	
36568	Insert tunneled cv cath		+	\$3,108.06	
36569	Insert tunneled cv cath		+	\$3,108.06	
36570	Insert tunneled cv cath		+	\$3,108.06	
36571	Insert tunneled cv cath		+	\$3,108.06	
36575	Repair tunneled cv cath			\$1,292.17	
36576	Repair tunneled cv cath			\$1,292.17	
36578	Replace tunneled cv cath			\$1,292.17	
36580	Replace tunneled cv cath		+	\$3,108.06	
36581	Replace tunneled cv cath		+	\$3,108.06	
36582	Replace tunneled cv cath		+	\$6,931.15	
36583	Replace tunneled cv cath		+	\$6,931.15	
36584	Replace tunneled cv cath		+	\$3,108.06	
36585	Replace tunneled cv cath		+	\$3,108.06	
36589	Removal tunneled cv cath			\$1,292.17	
36590	Removal tunneled cv cath		+	\$2,022.52	
36595	Mech remov tunneled cv cath		+	\$1,099.59	
36596	Mech remov tunneled cv cath		+	\$1,099.59	
36597	Reposition venous catheter			\$1,292.17	
36640	Insertion catheter, artery		+	\$3,108.06	
36680	Insert needle, bone cavity		+	\$668.67	
36800	Insertion of cannula		+	\$6,931.15	
36810	Insertion of cannula		+	\$6,931.15	
36815	Insertion of cannula		+	\$6,931.15	
36819	Av fusion/uppr arm vein		+	\$9,360.98	
36820	Av fusion/forearm vein		+	\$9,360.98	
36821	Av fusion direct any site		+	\$9,360.98	
36825	Artery-vein autograft		+	\$9,360.98	
36830	Artery-vein graft		+	\$9,360.98	
36831	Open thrombect av fistula		+	\$9,360.98	
36832	Av fistula revision, open		+	\$9,360.98	
36833	Av fistula revision		+	\$9,360.98	
36834	Repair A-V aneurysm		+	\$9,360.98	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 31 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
36835	Artery to vein shunt		+	\$6,931.15	
36838	Dist revas ligation, hemo		+	\$9,360.98	
36860	External cannula declotting		+	\$3,148.66	
36861	Cannula declotting		+	\$6,931.15	
36870	Percut thrombect av fistula		+	\$8,008.57	
37200	Transcatheter biopsy		+	\$1,291.26	
37201	Transcatheter therapy infuse		+	\$845.29	
37202	Transcatheter therapy infuse		+	\$588.14	
37203	Transcatheter retrieval		+	\$3,148.66	
37204	Transcatheter occlusion		+	\$6,931.15	
37205	Transcatheter stent		+	\$16,796.96	
37206	Transcatheter stent add-on		+	\$16,796.96	
37207	Transcatheter stent		+	\$16,796.96	
37208	Transcatheter stent add-on		+	\$16,796.96	
37209	Exchange arterial catheter		+	\$3,148.66	
37250	Iv us first vessel add-on		+	\$8,568.20	
37251	Iv us each add vessel add-on		+	\$8,568.20	
37500	Endoscopy ligate perf veins		+	\$6,788.02	
37501	Vascular endoscopy procedure		+	\$6,788.02	
37565	Ligation of neck vein		+	\$5,677.10	
37600	Ligation of neck artery		+	\$5,677.10	
37605	Ligation of neck artery		+	\$7,767.55	
37606	Ligation of neck artery		+	\$7,767.55	
37607	Ligation of a-v fistula		+	\$6,788.02	
37609	Temporal artery procedure		+	\$3,862.11	
37615	Ligation of neck artery		+	\$7,767.55	
37620	Revision of major vein		+	\$7,767.55	
37650	Revision of major vein		+	\$7,767.55	
37700	Revise leg vein		+	\$7,767.55	
37720	Removal of leg vein		+	\$6,788.02	
37730	Removal of leg veins		+	\$6,788.02	
37735	Removal of leg veins/lesion		+	\$6,788.02	
37760	Revision of leg veins		+	\$7,767.55	
37765	Phleb veins - extrem - to 20		+	\$7,767.55	
37766	Phleb veins - extrem 20+		+	\$7,767.55	
37780	Revision of leg vein		+	\$7,767.55	
37785	Ligate/divide/excise vein		+	\$7,767.55	
37790	Penile venous occlusion		+	\$7,972.25	
37799	Vascular surgery procedure		+	\$39.75	
38120	Laparoscopy, splenectomy		+	\$10,937.84	
38129	Laparoscope proc, spleen		+	\$8,821.92	
38205	Harvest allogenic stem cells		+	\$3,569.11	
38206	Harvest auto stem cells		+	\$3,569.11	
38220	Bone marrow aspiration		+	\$613.12	
38221	Bone marrow biopsy		+	\$613.12	
38230	Bone marrow collection		+	\$3,569.11	
38240	Bone marrow/stem transplant		+	\$1,666.38	
38241	Bone marrow/stem transplant		+	\$1,666.38	
38242	Lymphocyte infuse transplant		+	\$3,569.11	
38300	Drainage, lymph node lesion		+	\$5,279.24	
38305	Drainage, lymph node lesion		+	\$5,279.24	
38308	Incision of lymph channels		+	\$5,393.49	
38500	Biopsy/removal, lymph nodes		+	\$5,393.49	
38505	Needle biopsy, lymph nodes		+	\$885.98	
38510	Biopsy/removal, lymph nodes		+	\$5,393.49	
38520	Biopsy/removal, lymph nodes		+	\$5,393.49	
38525	Biopsy/removal, lymph nodes		+	\$5,393.49	
38530	Biopsy/removal, lymph nodes		+	\$5,393.49	
38542	Explore deep node(s), neck		+	\$9,977.17	
38550	Removal, neck/ampit lesion		+	\$5,393.49	
38555	Removal, neck/ampit lesion		+	\$5,393.49	
38570	Laparoscopy, lymph node biop		+	\$10,937.84	
38571	Laparoscopy, lymphadenectomy		+	\$15,016.18	
38572	Laparoscopy, lymphadenectomy		+	\$10,937.84	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 32 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
38589	Laparoscope proc. lymphatic		+	\$8,821.92	
38700	Removal of lymph nodes, neck		+	\$5,393.49	
38720	Removal of lymph nodes, neck		+	\$5,393.49	
38740	Remove armpit lymph nodes		+	\$9,977.17	
38745	Remove armpit lymph nodes		+	\$9,977.17	
38760	Remove groin lymph nodes		+	\$5,393.49	
38999	Blood/lymph system procedure			\$993.85	
39400	Visualization of chest		+	\$7,841.49	
40490	Biopsy of lip		+	\$484.51	
40500	Partial excision of lip		+	\$4,123.29	
40510	Partial excision of lip		+	\$5,907.64	
40520	Partial excision of lip		+	\$4,123.29	
40525	Reconstruct lip with flap		+	\$5,907.64	
40527	Reconstruct lip with flap		+	\$5,907.64	
40530	Partial removal of lip		+	\$5,907.64	
40650	Repair lip		+	\$1,744.68	
40652	Repair lip		+	\$1,744.68	
40654	Repair lip		+	\$1,744.68	
40700	Repair cleft lip/nasal		+	\$9,418.88	
40701	Repair cleft lip/nasal		+	\$9,418.88	
40702	Repair cleft lip/nasal		+	\$9,418.88	
40720	Repair cleft lip/nasal		+	\$9,418.88	
40761	Repair cleft lip/nasal		+	\$9,418.88	
40799	Lip surgery procedure		+	\$4,123.29	
40800	Drainage of mouth lesion		+	\$484.51	
40801	Drainage of mouth lesion		+	\$1,744.68	
40804	Removal, foreign body, mouth			\$170.98	
40805	Removal, foreign body, mouth		+	\$1,744.68	
40806	Incision of lip fold		+	\$484.51	
40808	Biopsy of mouth lesion		+	\$484.51	
40810	Excision of mouth lesion		+	\$4,123.29	
40812	Excise/repair mouth lesion		+	\$4,123.29	
40814	Excise/repair mouth lesion		+	\$4,123.29	
40816	Excision of mouth lesion		+	\$5,907.64	
40818	Excise oral mucosa for graft		+	\$484.51	
40819	Excise lip or cheek fold		+	\$1,744.68	
40820	Treatment of mouth lesion		+	\$4,123.29	
40830	Repair mouth laceration		+	\$484.51	
40831	Repair mouth laceration		+	\$1,744.68	
40840	Reconstruction of mouth		+	\$5,907.64	
40842	Reconstruction of mouth		+	\$5,907.64	
40843	Reconstruction of mouth		+	\$5,907.64	
40844	Reconstruction of mouth		+	\$9,418.88	
40845	Reconstruction of mouth		+	\$9,418.88	
40899	Mouth surgery procedure		+	\$1,744.68	
41000	Drainage of mouth lesion		+	\$4,123.29	
41005	Drainage of mouth lesion		+	\$484.51	
41006	Drainage of mouth lesion		+	\$5,907.64	
41007	Drainage of mouth lesion		+	\$4,123.29	
41008	Drainage of mouth lesion		+	\$4,123.29	
41009	Drainage of mouth lesion		+	\$484.51	
41010	Incision of tongue fold		+	\$4,123.29	
41015	Drainage of mouth lesion		+	\$484.51	
41016	Drainage of mouth lesion		+	\$1,744.68	
41017	Drainage of mouth lesion		+	\$1,744.68	
41018	Drainage of mouth lesion		+	\$1,744.68	
41100	Biopsy of tongue		+	\$1,744.68	
41105	Biopsy of tongue		+	\$4,123.29	
41108	Biopsy of floor of mouth		+	\$1,744.68	
41110	Excision of tongue lesion		+	\$4,123.29	
41112	Excision of tongue lesion		+	\$4,123.29	
41113	Excision of tongue lesion		+	\$4,123.29	
41114	Excision of tongue lesion		+	\$5,907.64	
41115	Excision of tongue fold		+	\$1,744.68	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 33 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
41116	Excision of mouth lesion		+	\$4,123.29	
41120	Partial removal of tongue		+	\$5,907.64	
41250	Repair tongue laceration		+	\$484.51	
41251	Repair tongue laceration		+	\$484.51	
41252	Repair tongue laceration		+	\$1,744.68	
41500	Fixation of tongue		+	\$5,907.64	
41510	Tongue to lip surgery		+	\$4,123.29	
41520	Reconstruction, tongue fold		+	\$1,744.68	
41599	Tongue and mouth surgery		+	\$484.51	
41800	Drainage of gum lesion		+	\$484.51	
41805	Removal foreign body, gum		+	\$5,907.64	
41806	Removal foreign body, jawbone		+	\$4,123.29	
41820	Excision, gum, each quadrant		+	\$1,744.68	
41821	Excision of gum flap		+	\$1,744.68	
41822	Excision of gum lesion		+	\$4,123.29	
41823	Excision of gum lesion		+	\$5,907.64	
41825	Excision of gum lesion		+	\$4,123.29	
41826	Excision of gum lesion		+	\$4,123.29	
41827	Excision of gum lesion		+	\$5,907.64	
41828	Excision of gum lesion		+	\$4,123.29	
41830	Removal of gum tissue		+	\$4,123.29	
41850	Treatment of gum lesion		+	\$4,123.29	
41870	Gum graft		+	\$5,907.64	
41872	Repair gum		+	\$4,123.29	
41874	Repair tooth socket		+	\$5,907.64	
41899	Dental surgery procedure		+	\$4,123.29	
42000	Drainage mouth roof lesion		+	\$484.51	
42100	Biopsy roof of mouth		+	\$1,744.68	
42104	Excision lesion, mouth roof		+	\$4,123.29	
42106	Excision lesion, mouth roof		+	\$4,123.29	
42107	Excision lesion, mouth roof		+	\$5,907.64	
42120	Remove palate/lesion		+	\$9,418.88	
42140	Excision of uvula		+	\$1,744.68	
42145	Repair palate, pharynx/uvula		+	\$5,907.64	
42160	Treatment mouth roof lesion		+	\$4,123.29	
42180	Repair palate		+	\$484.51	
42182	Repair palate		+	\$9,418.88	
42200	Reconstruct cleft palate		+	\$9,418.88	
42205	Reconstruct cleft palate		+	\$9,418.88	
42210	Reconstruct cleft palate		+	\$9,418.88	
42215	Reconstruct cleft palate		+	\$9,418.88	
42220	Reconstruct cleft palate		+	\$9,418.88	
42225	Reconstruct cleft palate		+	\$9,418.88	
42226	Lengthening of palate		+	\$9,418.88	
42227	Lengthening of palate		+	\$9,418.88	
42235	Repair palate		+	\$4,123.29	
42260	Repair nose to lip fistula		+	\$5,907.64	
42280	Preparation, palate mold		+	\$484.51	
42281	Insertion, palate prosthesis		+	\$4,123.29	
42299	Palate/uvula surgery		+	\$484.51	
42300	Drainage of salivary gland		+	\$4,123.29	
42305	Drainage of salivary gland		+	\$4,123.29	
42310	Drainage of salivary gland		+	\$484.51	
42320	Drainage of salivary gland		+	\$484.51	
42325	Create salivary cyst drain		+	\$484.51	
42326	Create salivary cyst drain		+	\$1,744.68	
42330	Removal of salivary stone		+	\$4,123.29	
42335	Removal of salivary stone		+	\$4,123.29	
42340	Removal of salivary stone		+	\$4,123.29	
42400	Biopsy of salivary gland		+	\$885.98	
42405	Biopsy of salivary gland		+	\$4,123.29	
42408	Excision of salivary cyst		+	\$4,123.29	
42409	Drainage of salivary cyst		+	\$4,123.29	
42410	Excise parotid gland/lesion		+	\$9,418.88	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 34 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
42415	Excise parotid gland/lesion		+	\$9,418.88	
42420	Excise parotid gland/lesion		+	\$9,418.88	
42425	Excise parotid gland/lesion		+	\$9,418.88	
42440	Excise submaxillary gland		+	\$9,418.88	
42450	Excise sublingual gland		+	\$5,907.64	
42500	Repair salivary duct		+	\$5,907.64	
42505	Repair salivary duct		+	\$9,418.88	
42507	Parotid duct diversion		+	\$9,418.88	
42508	Parotid duct diversion		+	\$9,418.88	
42509	Parotid duct diversion		+	\$9,418.88	
42510	Parotid duct diversion		+	\$9,418.88	
42600	Closure of salivary fistula		+	\$4,123.29	
42650	Dilation of salivary duct		+	\$1,744.68	
42660	Dilation of salivary duct		+	\$484.51	
42665	Ligation of salivary duct		+	\$5,907.64	
42699	Salivary surgery procedure		+	\$4,123.29	
42700	Drainage of tonsil abscess		+	\$484.51	
42720	Drainage of throat abscess		+	\$4,123.29	
42725	Drainage of throat abscess		+	\$9,418.88	
42800	Biopsy of throat		+	\$4,123.29	
42802	Biopsy of throat		+	\$4,123.29	
42804	Biopsy of upper nose/throat		+	\$4,123.29	
42806	Biopsy of upper nose/throat		+	\$5,907.64	
42808	Excise pharynx lesion		+	\$4,123.29	
42809	Remove pharynx foreign body			\$170.98	
42810	Excision of neck cyst		+	\$5,907.64	
42815	Excision of neck cyst		+	\$9,418.88	
42820	Remove tonsils and adenoids		+	\$5,589.04	
42821	Remove tonsils and adenoids		+	\$5,589.04	
42825	Removal of tonsils		+	\$5,589.04	
42826	Removal of tonsils		+	\$5,589.04	
42830	Removal of adenoids		+	\$5,589.04	
42831	Removal of adenoids		+	\$5,589.04	
42835	Removal of adenoids		+	\$5,589.04	
42836	Removal of adenoids		+	\$5,589.04	
42842	Extensive surgery of throat		+	\$5,907.64	
42844	Extensive surgery of throat		+	\$9,418.88	
42860	Excision of tonsil tags		+	\$5,589.04	
42870	Excision of lingual tonsil		+	\$5,589.04	
42890	Partial removal of pharynx		+	\$9,418.88	
42892	Revision of pharyngeal walls		+	\$9,418.88	
42900	Repair throat wound		+	\$1,744.68	
42950	Reconstruction of throat		+	\$5,907.64	
42955	Surgical opening of throat		+	\$5,907.64	
42960	Control throat bleeding		+	\$392.22	
42962	Control throat bleeding		+	\$9,418.88	
42970	Control nose/throat bleeding		+	\$392.22	
42972	Control nose/throat bleeding		+	\$4,123.29	
42999	Throat surgery procedure		+	\$1,744.68	
43020	Incision of esophagus		+	\$1,744.68	
43030	Throat muscle surgery		+	\$4,123.29	
43130	Removal of esophagus pouch		+	\$5,907.64	
43200	Esophagus endoscopy		+	\$2,214.25	
43201	Esoph scope w/submucous inj		+	\$2,214.25	
43202	Esophagus endoscopy, biopsy		+	\$2,214.25	
43204	Esoph scope w/sclerosis inj		+	\$2,214.25	
43205	Esophagus endoscopy/ligation		+	\$2,214.25	
43215	Esophagus endoscopy		+	\$2,214.25	
43216	Esophagus endoscopy/lesion		+	\$2,214.25	
43217	Esophagus endoscopy		+	\$2,214.25	
43219	Esophagus endoscopy		+	\$9,885.06	
43220	Esoph endoscopy, dilation		+	\$2,214.25	
43226	Esoph endoscopy, dilation		+	\$2,214.25	
43227	Esoph endoscopy, repair		+	\$2,214.25	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 35 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
43228	Esoph endoscopy, ablation		+	\$2,214.25	
43231	Esoph endoscopy w/us exam		+	\$2,214.25	
43232	Esoph endoscopy w/us fn bx		+	\$2,214.25	
43234	Upper GI endoscopy, exam		+	\$2,214.25	
43235	Uppr gi endoscopy, diagnosis		+	\$2,214.25	
43236	Uppr gi scope w/submuc inj		+	\$2,214.25	
43237	Endoscopic us exam, esoph		+	\$2,214.25	
43238	Uppr gi endoscopy w/us fn bx		+	\$2,214.25	
43239	Upper GI endoscopy, biopsy		+	\$2,214.25	
43240	Esoph endoscope w/drain cyst		+	\$2,214.25	
43241	Upper GI endoscopy with tube		+	\$2,214.25	
43242	Uppr gi endoscopy w/us fn bx		+	\$2,214.25	
43243	Upper gi endoscopy & inject		+	\$2,214.25	
43244	Upper GI endoscopy/ligation		+	\$2,214.25	
43245	Uppr gi scope dilate strict		+	\$2,214.25	
43246	Place gastrostomy tube		+	\$2,214.25	
43247	Operative upper GI endoscopy		+	\$2,214.25	
43248	Uppr gi endoscopy/guide wire		+	\$2,214.25	
43249	Esoph endoscopy, dilation		+	\$2,214.25	
43250	Upper GI endoscopy/tumor		+	\$2,214.25	
43251	Operative upper GI endoscopy		+	\$2,214.25	
43255	Operative upper GI endoscopy		+	\$2,214.25	
43256	Uppr gi endoscopy w stent		+	\$9,885.06	
43258	Operative upper GI endoscopy		+	\$2,214.25	
43259	Endoscopic ultrasound exam		+	\$2,214.25	
43260	Endo cholangiopancreatograph		+	\$4,837.27	
43261	Endo cholangiopancreatograph		+	\$4,837.27	
43262	Endo cholangiopancreatograph		+	\$4,837.27	
43263	Endo cholangiopancreatograph		+	\$4,837.27	
43264	Endo cholangiopancreatograph		+	\$4,837.27	
43265	Endo cholangiopancreatograph		+	\$4,837.27	
43267	Endo cholangiopancreatograph		+	\$4,837.27	
43268	Endo cholangiopancreatograph		+	\$9,885.06	
43269	Endo cholangiopancreatograph		+	\$9,885.06	
43271	Endo cholangiopancreatograph		+	\$4,837.27	
43272	Endo cholangiopancreatograph		+	\$4,837.27	
43280	Laparoscopy, fundoplasty		+	\$15,016.18	
43289	Laparoscope proc, esoph		+	\$8,821.92	
43450	Dilate esophagus		+	\$1,736.89	
43453	Dilate esophagus		+	\$1,736.89	
43456	Dilate esophagus		+	\$1,736.89	
43458	Dilate esophagus		+	\$1,736.89	
43499	Esophagus surgery procedure		+	\$2,214.25	
43600	Biopsy of stomach		+	\$2,214.25	
43651	Laparoscopy, vagus nerve		+	\$15,016.18	
43652	Laparoscopy, vagus nerve		+	\$15,016.18	
43653	Laparoscopy, gastrostomy		+	\$10,937.84	
43659	Laparoscope proc, stom		+	\$8,821.92	
43750	Place gastrostomy tube		+	\$2,214.25	
43752	Nasal/orogastric w/stent		+	\$569.80	
43760	Change gastrostomy tube		+	\$569.80	
43761	Reposition gastrostomy tube		+	\$569.80	
43830	Place gastrostomy tube		+	\$2,214.25	
43831	Place gastrostomy tube		+	\$2,214.25	
43870	Repair stomach opening		+	\$2,214.25	
43999	Stomach surgery procedure		+	\$2,214.25	
44100	Biopsy of bowel		+	\$2,214.25	
44200	Laparoscopy, enterolysis		+	\$10,937.84	
44201	Laparoscopy, jejunostomy		+	\$10,937.84	
44206	Lap part colectomy w/stoma		+	\$15,016.18	
44207	L colectomy/coloproctostomy		+	\$15,016.18	
44208	L colectomy/coloproctostomy		+	\$15,016.18	
44238	Laparoscope proc, intestine		+	\$8,821.92	
44239	Laparoscope proc, rectum		+	\$8,821.92	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 36 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
44312	Revision of ileostomy		+	\$4,298.81	
44340	Revision of colostomy		+	\$4,298.81	
44360	Small bowel endoscopy		+	\$2,383.36	
44361	Small bowel endoscopy/biopsy		+	\$2,383.36	
44363	Small bowel endoscopy		+	\$2,383.36	
44364	Small bowel endoscopy		+	\$2,383.36	
44365	Small bowel endoscopy		+	\$2,383.36	
44366	Small bowel endoscopy		+	\$2,383.36	
44369	Small bowel endoscopy		+	\$2,383.36	
44370	Small bowel endoscopy/stent		+	\$9,885.06	
44372	Small bowel endoscopy		+	\$2,383.36	
44373	Small bowel endoscopy		+	\$2,383.36	
44376	Small bowel endoscopy		+	\$2,383.36	
44377	Small bowel endoscopy/biopsy		+	\$2,383.36	
44378	Small bowel endoscopy		+	\$2,383.36	
44379	S bowel endoscope w/stent		+	\$9,885.06	
44380	Small bowel endoscopy		+	\$2,383.36	
44382	Small bowel endoscopy		+	\$2,383.36	
44383	Ileoscopy w/stent		+	\$9,885.06	
44385	Endoscopy of bowel pouch		+	\$2,107.50	
44386	Endoscopy, bowel pouch/biop		+	\$2,107.50	
44388	Colonoscopy		+	\$2,107.50	
44389	Colonoscopy with biopsy		+	\$2,107.50	
44390	Colonoscopy for foreign body		+	\$2,107.50	
44391	Colonoscopy for bleeding		+	\$2,107.50	
44392	Colonoscopy & polypectomy		+	\$2,107.50	
44393	Colonoscopy, lesion removal		+	\$2,107.50	
44394	Colonoscopy w/snare		+	\$2,107.50	
44397	Colonoscopy w/stent		+	\$9,885.06	
44500	Intro, gastrointestinal tube		+	\$569.80	
44799	Unlisted procedure intestine		+	\$2,383.36	
44950	Appendectomy			\$6,801.38	MedStat
44970	Laparoscopy, appendectomy		+	\$8,821.92	
44979	Laparoscopy proc. app		+	\$8,821.92	
45000	Drainage of pelvic abscess		+	\$1,038.35	
45005	Drainage of rectal abscess		+	\$1,038.35	
45020	Drainage of rectal abscess		+	\$1,038.35	
45100	Biopsy of rectum		+	\$4,634.46	
45108	Removal of anorectal lesion		+	\$5,911.49	
45150	Excision of rectal stricture		+	\$4,634.46	
45160	Excision of rectal lesion		+	\$5,911.49	
45170	Excision of rectal lesion		+	\$5,911.49	
45190	Destruction, rectal tumor		+	\$5,911.49	
45300	Proctosigmoidoscopy dx		+	\$1,072.97	
45303	Proctosigmoidoscopy dilate		+	\$1,072.97	
45305	Proctosigmoidoscopy w/bx		+	\$1,072.97	
45307	Proctosigmoidoscopy fb		+	\$1,072.97	
45308	Proctosigmoidoscopy removal		+	\$2,079.64	
45309	Proctosigmoidoscopy removal		+	\$2,079.64	
45315	Proctosigmoidoscopy removal		+	\$2,079.64	
45317	Proctosigmoidoscopy bleed		+	\$2,079.64	
45320	Proctosigmoidoscopy ablate		+	\$2,079.64	
45321	Proctosigmoidoscopy volvul		+	\$2,079.64	
45327	Proctosigmoidoscopy w/stent		+	\$9,885.06	
45330	Diagnostic sigmoidoscopy		+	\$1,072.97	
45331	Sigmoidoscopy and biopsy		+	\$1,072.97	
45332	Sigmoidoscopy w/fb removal		+	\$1,072.97	
45333	Sigmoidoscopy & polypectomy		+	\$2,079.64	
45334	Sigmoidoscopy for bleeding		+	\$2,079.64	
45335	Sigmoidoscopy w/submuc inj		+	\$2,079.64	
45337	Sigmoidoscopy & decompress		+	\$2,079.64	
45338	Sigmoidoscopy w/tumr remove		+	\$2,079.64	
45339	Sigmoidoscopy w/ablate tumr		+	\$2,079.64	
45340	Sig w/balloon dilation		+	\$2,079.64	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 37 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
45341	Sigmoidoscopy w/ultrasound		+	\$2,079.64	
45342	Sigmoidoscopy w/us guide bx		+	\$2,079.64	
45345	Sigmoidoscopy w/stent		+	\$9,885.06	
45355	Surgical colonoscopy		+	\$2,107.50	
45378	Diagnostic colonoscopy		+	\$2,107.50	
45379	Colonoscopy w/fb removal		+	\$2,107.50	
45380	Colonoscopy and biopsy		+	\$2,107.50	
45381	Colonoscopy, submucous inj		+	\$2,107.50	
45382	Colonoscopy/control bleeding		+	\$2,107.50	
45383	Lesion removal colonoscopy		+	\$2,107.50	
45384	Lesion remove colonoscopy		+	\$2,107.50	
45385	Lesion removal colonoscopy		+	\$2,107.50	
45386	Colonoscopy dilate stricture		+	\$2,107.50	
45387	Colonoscopy w/stent		+	\$9,885.06	
45500	Repair of rectum		+	\$4,634.46	
45505	Repair of rectum		+	\$5,911.49	
45520	Treatment of rectal prolapse		+	\$290.73	
45560	Repair of rectocele		+	\$5,911.49	
45900	Reduction of rectal prolapse		+	\$1,038.35	
45905	Dilation of anal sphincter		+	\$4,634.46	
45910	Dilation of rectal narrowing		+	\$4,634.46	
45915	Remove rectal obstruction		+	\$1,038.35	
45999	Rectum surgery procedure		+	\$1,038.35	
46020	Placement of seton		+	\$1,038.35	
46030	Removal of rectal marker		+	\$1,038.35	
46040	Incision of rectal abscess		+	\$4,634.46	
46045	Incision of rectal abscess		+	\$5,911.49	
46050	Incision of anal abscess		+	\$1,038.35	
46060	Incision of rectal abscess		+	\$5,911.49	
46070	Incision of anal septum		+	\$2,731.55	
46080	Incision of anal sphincter		+	\$4,634.46	
46083	Incise external hemorrhoid		+	\$1,038.35	
46200	Removal of anal fissure		+	\$5,911.49	
46210	Removal of anal crypt		+	\$4,634.46	
46211	Removal of anal crypts		+	\$5,911.49	
46220	Removal of anal tag		+	\$4,634.46	
46221	Ligation of hemorrhoid(s)		+	\$1,038.35	
46230	Removal of anal tags		+	\$4,634.46	
46250	Hemorrhoidectomy		+	\$5,911.49	
46255	Hemorrhoidectomy		+	\$5,911.49	
46257	Remove hemorrhoids & fissure		+	\$5,911.49	
46258	Remove hemorrhoids & fistula		+	\$5,911.49	
46260	Hemorrhoidectomy		+	\$5,911.49	
46261	Remove hemorrhoids & fissure		+	\$5,911.49	
46262	Remove hemorrhoids & fistula		+	\$5,911.49	
46270	Removal of anal fistula		+	\$5,911.49	
46275	Removal of anal fistula		+	\$5,911.49	
46280	Removal of anal fistula		+	\$5,911.49	
46285	Removal of anal fistula		+	\$5,911.49	
46288	Repair anal fistula		+	\$5,911.49	
46320	Removal of hemorrhoid clot		+	\$1,038.35	
46500	Injection into hemorrhoid(s)		+	\$2,731.55	
46600	Diagnostic anoscopy			\$170.98	
46604	Anoscopy and dilation		+	\$2,079.64	
46606	Anoscopy and biopsy		+	\$2,079.64	
46608	Anoscopy, remove for body		+	\$2,079.64	
46610	Anoscopy, remove lesion		+	\$2,079.64	
46611	Anoscopy		+	\$2,079.64	
46612	Anoscopy, remove lesions		+	\$2,079.64	
46614	Anoscopy, control bleeding		+	\$2,079.64	
46615	Anoscopy		+	\$2,079.64	
46700	Repair of anal stricture		+	\$5,911.49	
46706	Repr of anal fistula w/glue		+	\$1,038.35	
46750	Repair of anal sphincter		+	\$5,911.49	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 38 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
46753	Reconstruction of anus		+	\$5,911.49	
46754	Removal of suture from anus		+	\$4,634.46	
46760	Repair of anal sphincter		+	\$5,911.49	
46761	Repair of anal sphincter		+	\$5,911.49	
46762	Implant artificial sphincter		+	\$5,911.49	
46900	Destruction, anal lesion(s)		+	\$696.76	
46910	Destruction, anal lesion(s)		+	\$4,435.62	
46916	Cryosurgery, anal lesion(s)		+	\$303.14	
46917	Laser surgery, anal lesions		+	\$5,198.44	
46922	Excision of anal lesion(s)		+	\$5,198.44	
46924	Destruction, anal lesion(s)		+	\$5,198.44	
46934	Destruction of hemorrhoids		+	\$2,731.55	
46935	Destruction of hemorrhoids		+	\$2,731.55	
46936	Destruction of hemorrhoids		+	\$4,634.46	
46937	Cryotherapy of rectal lesion		+	\$4,634.46	
46938	Cryotherapy of rectal lesion		+	\$5,911.49	
46940	Treatment of anal fissure		+	\$4,634.46	
46942	Treatment of anal fissure		+	\$1,038.35	
46945	Ligation of hemorrhoids		+	\$2,731.55	
46946	Ligation of hemorrhoids		+	\$2,731.55	
46999	Anus surgery procedure		+	\$1,038.35	
47000	Needle biopsy of liver		+	\$1,291.26	
47011	Percut drain, liver lesion		+	\$2,680.39	
47100	Wedge biopsy of liver			\$7,470.94	MDR
47370	Laparo ablate liver tumor rf		+	\$10,937.84	
47371	Laparo ablate liver cryosurg		+	\$10,937.84	
47379	Laparoscopy procedure, liver		+	\$8,821.92	
47382	Percut ablate liver rf		+	\$8,136.98	
47399	Liver surgery procedure		+	\$2,680.39	
47490	Incision of gallbladder		+	\$2,280.27	
47510	Insert catheter, bile duct		+	\$2,280.27	
47511	Insert bile duct drain		+	\$2,280.27	
47525	Change bile duct catheter		+	\$2,359.48	
47530	Revise/reinsert bile tube		+	\$2,359.48	
47552	Biliary endoscopy thru skin		+	\$2,280.27	
47553	Biliary endoscopy thru skin		+	\$2,280.27	
47554	Biliary endoscopy thru skin		+	\$2,280.27	
47555	Biliary endoscopy thru skin		+	\$2,280.27	
47556	Biliary endoscopy thru skin		+	\$2,280.27	
47560	Laparoscopy w/choleangio		+	\$8,821.92	
47561	Laparo w/choleangio/biopsy		+	\$8,821.92	
47562	Laparoscopic cholecystectomy		+	\$10,937.84	
47563	Laparo cholecystectomy/graph		+	\$10,937.84	
47564	Laparo cholecystectomy/explr		+	\$10,937.84	
47579	Laparoscopy proc, biliary		+	\$8,821.92	
47630	Remove bile duct stone		+	\$2,280.27	
47999	Bile tract surgery procedure		+	\$2,280.27	
48102	Needle biopsy, pancreas		+	\$1,291.26	
48511	Drain pancreatic pseudocyst		+	\$2,680.39	
48999	Pancreas surgery procedure		+	\$885.98	
49000	Exploration of abdomen			\$5,686.60	MedStat
49020	Drain abdominal abscess			\$9,961.25	MDR
49021	Drain abdominal abscess			\$6,640.84	MDR
49060	Drain, open, retro abscess			\$8,301.05	MDR
49080	Puncture, peritoneal cavity		+	\$831.91	
49081	Removal of abdominal fluid		+	\$831.91	
49085	Remove abdomen foreign body		+	\$5,612.38	
49180	Biopsy, abdominal mass		+	\$1,291.26	
49200	Removal of abdominal lesion		+	\$8,821.92	
49250	Excision of umbilicus		+	\$5,612.38	
49320	Diag laparo separate proc		+	\$8,821.92	
49321	Laparoscopy, biopsy		+	\$8,821.92	
49322	Laparoscopy, aspiration		+	\$8,821.92	
49323	Laparo drain lymphocele		+	\$8,821.92	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 39 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
49329	Laparo proc, abdrm/per/oment		+	\$8,821.92	
49419	Insrt abdom cath for chemobx		+	\$23,486.79	
49420	Insert abdom drain, temp		+	\$7,279.88	
49421	Insert abdom drain, perm		+	\$7,279.88	
49422	Remove perm cannula/catheter		+	\$5,192.99	
49423	Exchange drainage catheter		+	\$2,280.27	
49426	Revise abdomen-venous shunt		+	\$5,612.38	
49429	Removal of shunt		+	\$5,192.99	
49491	Rpr hem preemie reduc		+	\$7,273.67	
49492	Rpr ing hem premie, blocked		+	\$7,273.67	
49495	Rpr ing hernia baby, reduc		+	\$7,273.67	
49496	Rpr ing hernia baby, blocked		+	\$7,273.67	
49500	Rpr ing hernia, init, reduce		+	\$7,273.67	
49501	Rpr ing hernia, init blocked		+	\$7,273.67	
49505	Prp i/hem init reduc>5 yr		+	\$7,273.67	
49507	Prp i/hem init block>5 yr		+	\$7,273.67	
49520	Rerepair ing hernia, reduce		+	\$7,273.67	
49521	Rerepair ing hernia, blocked		+	\$7,273.67	
49525	Repair ing hernia, sliding		+	\$7,273.67	
49540	Repair lumbar hernia		+	\$7,273.67	
49550	Rpr rem hernia, init, reduce		+	\$7,273.67	
49553	Rpr fem hernia, init blocked		+	\$7,273.67	
49555	Rerepair fem hernia, reduce		+	\$7,273.67	
49557	Rerepair fem hernia, blocked		+	\$7,273.67	
49560	Rpr ventral hern init, reduc		+	\$7,273.67	
49561	Rpr ventral hern init, block		+	\$7,273.67	
49565	Rerepair ventrl hern, reduce		+	\$7,273.67	
49566	Rerepair ventrl hern, block		+	\$7,273.67	
49568	Hernia repair w/mesh		+	\$7,273.67	
49570	Rpr epigastric hern, reduce		+	\$7,273.67	
49572	Rpr epigastric hern, blocked		+	\$7,273.67	
49580	Rpr umbil hern, reduc < 5 yr		+	\$7,273.67	
49582	Rpr umbil hern, block < 5 yr		+	\$7,273.67	
49585	Rpr umbil hern, reduc > 5 yr		+	\$7,273.67	
49587	Rpr umbil hern, block > 5 yr		+	\$7,273.67	
49590	Repair spigilian hernia		+	\$7,273.67	
49600	Repair umbilical lesion		+	\$7,273.67	
49650	Laparo hernia repair initial		+	\$10,937.84	
49651	Laparo hernia repair recur		+	\$10,937.84	
49659	Laparo proc, hernia repair		+	\$10,937.84	
49900	Repair of abdominal wall			\$9,961.25	MDR
49999	Abdomen surgery procedure		+	\$5,612.38	
50021	Renal abscess, percut drain		+	\$2,680.39	
50080	Removal of kidney stone		+	\$9,018.20	
50081	Removal of kidney stone		+	\$9,018.20	
50200	Biopsy of kidney		+	\$1,291.26	
50390	Drainage of kidney lesion		+	\$1,291.26	
50392	Insert kidney drain		+	\$4,553.63	
50393	Insert ureteral tube		+	\$4,553.63	
50395	Create passage to kidney		+	\$4,553.63	
50396	Measure kidney pressure		+	\$310.82	
50398	Change kidney tube		+	\$2,359.48	
50541	Laparo ablate renal cyst		+	\$8,821.92	
50542	Laparo ablate renal mass		+	\$10,937.84	
50543	Laparo partial nephrectomy		+	\$10,937.84	
50544	Laparoscopy, pyeloplasty		+	\$8,821.92	
50549	Laparoscope proc, renal		+	\$8,821.92	
50551	Kidney endoscopy		+	\$1,860.91	
50553	Kidney endoscopy		+	\$4,553.63	
50555	Kidney endoscopy & biopsy		+	\$1,860.91	
50557	Kidney endoscopy & treatment		+	\$5,914.93	
50559	Renal endoscopy/radiotracer		+	\$1,860.91	
50561	Kidney endoscopy & treatment		+	\$4,553.63	
50562	Renal scope w/tumor resect		+	\$1,860.91	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 40 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
50575	Kidney endoscopy			\$6,781.24	MDR
50590	Fragmenting of kidney stone		+	\$12,218.17	
50686	Measure ureter pressure		+	\$310.82	
50688	Change of ureter tube		+	\$2,359.48	
50945	Laparoscopy ureterolithotomy		+	\$10,937.84	
50947	Laparo new ureter/bladder		+	\$10,937.84	
50948	Laparo new ureter/bladder		+	\$10,937.84	
50949	Laparoscope proc, ureter		+	\$8,821.92	
50951	Endoscopy of ureter		+	\$1,860.91	
50953	Endoscopy of ureter		+	\$1,860.91	
50955	Ureter endoscopy & biopsy		+	\$4,553.63	
50957	Ureter endoscopy & treatment		+	\$4,553.63	
50959	Ureter endoscopy & tracer		+	\$4,553.63	
50961	Ureter endoscopy & treatment		+	\$4,553.63	
50970	Ureter endoscopy		+	\$1,860.91	
50972	Ureter endoscopy & catheter		+	\$1,860.91	
50974	Ureter endoscopy & biopsy		+	\$4,553.63	
50976	Ureter endoscopy & treatment		+	\$4,553.63	
50978	Ureter endoscopy & tracer		+	\$4,553.63	
50980	Ureter endoscopy & treatment		+	\$4,553.63	
51000	Drainage of bladder		+	\$310.82	
51005	Drainage of bladder		+	\$310.82	
51010	Drainage of bladder		+	\$3,978.77	
51020	Incise & treat bladder		+	\$5,914.93	
51030	Incise & treat bladder		+	\$5,914.93	
51040	Incise & drain bladder		+	\$5,914.93	
51045	Incise bladder/drain ureter		+	\$1,860.91	
51050	Removal of bladder stone		+	\$5,914.93	
51065	Remove ureter calculus		+	\$5,914.93	
51080	Drainage of bladder abscess		+	\$3,188.56	
51500	Removal of bladder cyst		+	\$7,273.67	
51520	Removal of bladder lesion		+	\$5,914.93	
51700	Irrigation of bladder		+	\$310.82	
51705	Change of bladder tube		+	\$569.80	
51710	Change of bladder tube		+	\$2,359.48	
51715	Endoscopic injection/implant		+	\$8,110.71	
51720	Treatment of bladder lesion		+	\$670.55	
51725	Simple cystometrogram	b	+	\$670.55	
51726	Complex cystometrogram	b	+	\$670.55	
51736	Urine flow measurement	b	+	\$310.82	
51741	Electro-uroflowmetry, first	b	+	\$310.82	
51772	Urethra pressure profile	b	+	\$310.82	
51784	Anal/urinary muscle study	b	+	\$310.82	
51785	Anal/urinary muscle study	b	+	\$310.82	
51792	Urinary reflex study	b	+	\$310.82	
51795	Urine voiding pressure study	b	+	\$310.82	
51797	Intraabdominal pressure test	b	+	\$310.82	
51798	Us urine capacity measure			\$170.98	
51880	Repair of bladder opening		+	\$5,914.93	
51990	Laparo urethral suspension		+	\$10,937.84	
51992	Laparo sling operation		+	\$15,016.18	
52000	Cystoscopy		+	\$1,860.91	
52001	Cystoscopy, removal of clots		+	\$1,860.91	
52005	Cystoscopy & ureter catheter		+	\$4,553.63	
52007	Cystoscopy and biopsy		+	\$4,553.63	
52010	Cystoscopy & duct catheter		+	\$1,860.91	
52204	Cystoscopy		+	\$4,553.63	
52214	Cystoscopy and treatment		+	\$5,914.93	
52224	Cystoscopy and treatment		+	\$5,914.93	
52234	Cystoscopy and treatment		+	\$5,914.93	
52235	Cystoscopy and treatment		+	\$5,914.93	
52240	Cystoscopy and treatment		+	\$5,914.93	
52250	Cystoscopy and radiotracer		+	\$5,914.93	
52260	Cystoscopy and treatment		+	\$4,553.63	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 41 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
52265	Cystoscopy and treatment		+	\$1,860.91	
52270	Cystoscopy & revise urethra		+	\$4,553.63	
52275	Cystoscopy & revise urethra		+	\$4,553.63	
52276	Cystoscopy and treatment		+	\$4,553.63	
52277	Cystoscopy and treatment		+	\$5,914.93	
52281	Cystoscopy and treatment		+	\$4,553.63	
52282	Cystoscopy, implant stent			\$17,536.39	
52283	Cystoscopy and treatment		+	\$4,553.63	
52285	Cystoscopy and treatment		+	\$4,553.63	
52290	Cystoscopy and treatment		+	\$4,553.63	
52300	Cystoscopy and treatment		+	\$4,553.63	
52301	Cystoscopy and treatment		+	\$4,553.63	
52305	Cystoscopy and treatment		+	\$4,553.63	
52310	Cystoscopy and treatment		+	\$1,860.91	
52315	Cystoscopy and treatment		+	\$4,553.63	
52317	Remove bladder stone		+	\$5,914.93	
52318	Remove bladder stone		+	\$5,914.93	
52320	Cystoscopy and treatment		+	\$5,914.93	
52325	Cystoscopy, stone removal		+	\$5,914.93	
52327	Cystoscopy, inject material		+	\$5,914.93	
52330	Cystoscopy and treatment		+	\$5,914.93	
52332	Cystoscopy and treatment		+	\$5,914.93	
52334	Create passage to kidney		+	\$5,914.93	
52341	Cysto w/ureter stricture tx		+	\$5,914.93	
52342	Cysto w/up stricture tx		+	\$5,914.93	
52343	Cysto w/renal stricture tx		+	\$5,914.93	
52344	Cysto/uretero, stone remove		+	\$5,914.93	
52345	Cysto/uretero w/up stricture		+	\$5,914.93	
52346	Cystouretero w/renal strict		+	\$5,914.93	
52347	Cystoscopy, resect ducts		+	\$4,553.63	
52351	Cystouretero & or pyeloscope		+	\$4,553.63	
52352	Cystouretero w/stone remove		+	\$5,914.93	
52353	Cystouretero w/lithotripsy		+	\$9,018.20	
52354	Cystouretero w/biopsy		+	\$5,914.93	
52355	Cystouretero w/excise tumor		+	\$5,914.93	
52400	Cystouretero w/congen repr		+	\$5,914.93	
52450	Incision of prostate		+	\$5,914.93	
52500	Revision of bladder neck		+	\$5,914.93	
52510	Dilation prostatic urethra		+	\$4,553.63	
52601	Prostatectomy (TURP)		+	\$9,018.20	
52606	Control postop bleeding		+	\$5,914.93	
52612	Prostatectomy, first stage		+	\$9,018.20	
52614	Prostatectomy, second stage		+	\$9,018.20	
52620	Remove residual prostate		+	\$9,018.20	
52630	Remove prostate regrowth		+	\$9,018.20	
52640	Relieve bladder contracture		+	\$5,914.93	
52647	Laser surgery of prostate		+	\$9,018.20	
52648	Laser surgery of prostate		+	\$9,018.20	
52700	Drainage of prostate abscess		+	\$5,914.93	
53000	Incision of urethra		+	\$4,549.99	
53010	Incision of urethra		+	\$4,549.99	
53020	Incision of urethra		+	\$4,549.99	
53025	Incision of urethra		+	\$4,549.99	
53040	Drainage of urethra abscess		+	\$8,110.71	
53060	Drainage of urethra abscess		+	\$4,549.99	
53080	Drainage of urinary leakage		+	\$4,549.99	
53200	Biopsy of urethra		+	\$4,549.99	
53210	Removal of urethra		+	\$7,761.48	
53215	Removal of urethra		+	\$4,549.99	
53220	Treatment of urethra lesion		+	\$7,761.48	
53230	Removal of urethra lesion		+	\$7,761.48	
53235	Removal of urethra lesion		+	\$4,549.99	
53240	Surgery for urethra pouch		+	\$7,761.48	
53250	Removal of urethra gland		+	\$4,549.99	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 42 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
53260	Treatment of urethra lesion		+	\$4,549.99	
53265	Treatment of urethra lesion		+	\$4,549.99	
53270	Removal of urethra gland		+	\$8,110.71	
53275	Repair of urethra defect		+	\$4,549.99	
53400	Revise urethra, stage 1		+	\$7,761.48	
53405	Revise urethra, stage 2		+	\$7,761.48	
53410	Reconstruction of urethra		+	\$7,761.48	
53420	Reconstruct urethra, stage 1		+	\$7,761.48	
53425	Reconstruct urethra, stage 2		+	\$7,761.48	
53430	Reconstruction of urethra		+	\$7,761.48	
53431	Reconstruct urethra/bladder		+	\$7,761.48	
53440	Correct bladder function			\$17,536.39	
53442	Remove penile prosthesis		+	\$8,110.71	
53444	Insert tandem cuff			\$17,536.39	
53445	Insert urolves nck sphincter			\$22,979.92	
53446	Remove uro sphincter		+	\$7,761.48	
53447	Remove/replace ur sphincter			\$22,979.92	
53449	Repair uro sphincter		+	\$7,761.48	
53450	Revision of urethra		+	\$7,761.48	
53460	Revision of urethra		+	\$4,549.99	
53500	Urethry, transvag w/ scope		+	\$7,761.48	
53502	Repair of urethra injury		+	\$4,549.99	
53505	Repair of urethra injury		+	\$8,110.71	
53510	Repair of urethra injury		+	\$4,549.99	
53515	Repair of urethra injury		+	\$7,761.48	
53520	Repair of urethra defect		+	\$7,761.48	
53600	Dilate urethra stricture		+	\$670.55	
53601	Dilate urethra stricture		+	\$310.82	
53605	Dilate urethra stricture		+	\$4,553.63	
53620	Dilate urethra stricture		+	\$3,978.77	
53621	Dilate urethra stricture		+	\$310.82	
53660	Dilation of urethra		+	\$310.82	
53661	Dilation of urethra		+	\$310.82	
53665	Dilation of urethra		+	\$4,549.99	
53850	Prostatic microwave thermobx		+	\$13,334.51	
53852	Prostatic rf thermobx		+	\$13,334.51	
53853	Prostatic water thermother		+	\$5,058.12	
53899	Urology surgery procedure		+	\$310.82	
54000	Slitting of prepuce		+	\$4,549.99	
54001	Slitting of prepuce		+	\$4,549.99	
54015	Drain penis lesion		+	\$3,188.56	
54050	Destruction, penis lesion(s)		+	\$303.14	
54055	Destruction, penis lesion(s)		+	\$4,435.62	
54056	Cryosurgery, penis lesion(s)		+	\$206.25	
54057	Laser surg, penis lesion(s)		+	\$4,435.62	
54060	Excision of penis lesion(s)		+	\$4,435.62	
54065	Destruction, penis lesion(s)		+	\$5,198.44	
54100	Biopsy of penis		+	\$3,862.11	
54105	Biopsy of penis		+	\$5,085.32	
54110	Treatment of penis lesion		+	\$7,972.25	
54111	Treat penis lesion, graft		+	\$7,972.25	
54112	Treat penis lesion, graft		+	\$7,972.25	
54115	Treatment of penis lesion		+	\$5,279.24	
54120	Partial removal of penis		+	\$7,972.25	
54150	Circumcision		+	\$5,027.77	
54152	Circumcision		+	\$5,027.77	
54160	Circumcision		+	\$5,027.77	
54161	Circumcision		+	\$5,027.77	
54162	Lysis penil circumc lesion		+	\$5,027.77	
54163	Repair of circumcision		+	\$5,027.77	
54164	Frenulotomy of penis		+	\$5,027.77	
54200	Treatment of penis lesion		+	\$670.55	
54205	Treatment of penis lesion		+	\$7,972.25	
54220	Treatment of penis lesion		+	\$670.55	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 43 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
54231	Dynamic cavernosometry		+	\$3,978.77	
54235	Penile injection		+	\$310.82	
54240	Penis study	b	+	\$310.82	
54250	Penis study	b	+	\$310.82	
54300	Revision of penis		+	\$7,972.25	
54304	Revision of penis		+	\$7,972.25	
54308	Reconstruction of urethra		+	\$7,972.25	
54312	Reconstruction of urethra		+	\$7,972.25	
54316	Reconstruction of urethra		+	\$7,972.25	
54318	Reconstruction of urethra		+	\$7,972.25	
54322	Reconstruction of urethra		+	\$7,972.25	
54324	Reconstruction of urethra		+	\$7,972.25	
54326	Reconstruction of urethra		+	\$7,972.25	
54328	Revise penis/urethra		+	\$7,972.25	
54340	Secondary urethral surgery		+	\$7,972.25	
54344	Secondary urethral surgery		+	\$7,972.25	
54348	Secondary urethral surgery		+	\$7,972.25	
54352	Reconstruct urethra/penis		+	\$7,972.25	
54360	Penis plastic surgery		+	\$7,972.25	
54380	Repair penis		+	\$7,972.25	
54385	Repair penis		+	\$7,972.25	
54400	Insert semi-rigid prosthesis			\$17,536.39	
54401	Insert self-contd prosthesis			\$22,979.92	
54405	Insert multi-comp penis pros			\$22,979.92	
54406	Remove multi-comp penis pros		+	\$7,972.25	
54408	Repair multi-comp penis pros		+	\$7,972.25	
54410	Remove/replace penis prosth			\$22,979.92	
54415	Remove self-contd penis pros		+	\$7,972.25	
54416	Remv/repl penis contain pros			\$17,536.39	
54420	Revision of penis		+	\$7,972.25	
54435	Revision of penis		+	\$7,972.25	
54440	Repair of penis		+	\$7,972.25	
54450	Preputial stretching		+	\$670.55	
54500	Biopsy of testis		+	\$2,680.39	
54505	Biopsy of testis		+	\$5,848.20	
54512	Excise lesion testis		+	\$5,848.20	
54520	Removal of testis		+	\$5,848.20	
54522	Orchiectomy, partial		+	\$5,848.20	
54530	Removal of testis		+	\$7,273.67	
54550	Exploration for testis		+	\$7,273.67	
54600	Reduce testis torsion		+	\$5,848.20	
54620	Suspension of testis		+	\$5,848.20	
54640	Suspension of testis		+	\$7,273.67	
54660	Revision of testis		+	\$5,848.20	
54670	Repair testis injury		+	\$5,848.20	
54680	Relocation of testis(es)		+	\$5,848.20	
54690	Laparoscopy, orchiectomy		+	\$10,937.84	
54692	Laparoscopy, orchiopexy		+	\$15,016.18	
54699	Laparoscope proc, testis		+	\$8,821.92	
54700	Drainage of scrotum		+	\$5,848.20	
54800	Biopsy of epididymis		+	\$430.33	
54820	Exploration of epididymis		+	\$5,848.20	
54830	Remove epididymis lesion		+	\$5,848.20	
54840	Remove epididymis lesion		+	\$5,848.20	
54860	Removal of epididymis		+	\$5,848.20	
54861	Removal of epididymis		+	\$5,848.20	
54900	Fusion of spermatic ducts		+	\$5,848.20	
54901	Fusion of spermatic ducts		+	\$5,848.20	
55000	Drainage of hydrocele		+	\$430.33	
55040	Removal of hydrocele		+	\$7,273.67	
55041	Removal of hydrocele		+	\$7,273.67	
55060	Repair of hydrocele		+	\$5,848.20	
55100	Drainage of scrotum abscess		+	\$3,188.56	
55110	Explore scrotum		+	\$5,848.20	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 44 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
55120	Removal of scrotum lesion		+	\$5,848.20	
55150	Removal of scrotum		+	\$5,848.20	
55175	Revision of scrotum		+	\$5,848.20	
55180	Revision of scrotum		+	\$5,848.20	
55200	Incision of sperm duct		+	\$5,848.20	
55250	Removal of sperm duct(s)		+	\$5,848.20	
55400	Repair of sperm duct		+	\$5,848.20	
55450	Ligation of sperm duct		+	\$5,848.20	
55500	Removal of hydrocele		+	\$5,848.20	
55520	Removal of sperm cord lesion		+	\$5,848.20	
55530	Revise spermatic cord veins		+	\$5,848.20	
55535	Revise spermatic cord veins		+	\$7,273.67	
55540	Revise hernia & sperm veins		+	\$7,273.67	
55550	Laparo ligate spermatic vein		+	\$10,937.84	
55559	Laparo proc, spermatic cord		+	\$8,821.92	
55680	Remove sperm pouch lesion		+	\$5,848.20	
55700	Biopsy of prostate		+	\$1,053.25	
55705	Biopsy of prostate		+	\$1,053.25	
55720	Drainage of prostate abscess		+	\$5,914.93	
55725	Drainage of prostate abscess		+	\$5,914.93	
55859	Percut/needle insert, pros		+	\$9,018.20	
55860	Surgical exposure, prostate		+	\$3,978.77	
55870	Electroejaculation		+	\$1,308.21	
55873	Cryoablate prostate		+	\$23,291.86	
55899	Genital surgery procedure		+	\$310.82	
56405	I & D of vulva/perineum		+	\$734.86	
56420	Drainage of gland abscess		+	\$734.86	
56440	Surgery for vulva lesion		+	\$4,993.48	
56441	Lysis of labial lesion(s)		+	\$4,076.76	
56501	Destroy, vulva lesions, sim		+	\$4,435.62	
56515	Destroy vulva lesion/s compl		+	\$5,198.44	
56605	Biopsy of vulva/perineum		+	\$1,068.77	
56606	Biopsy of vulva/perineum		+	\$1,068.77	
56620	Partial removal of vulva		+	\$6,685.13	
56625	Complete removal of vulva		+	\$6,685.13	
56700	Partial removal of hymen		+	\$4,993.48	
56720	Incision of hymen		+	\$4,076.76	
56740	Remove vagina gland lesion		+	\$4,993.48	
56800	Repair of vagina		+	\$4,993.48	
56805	Repair clitoris		+	\$4,993.48	
56810	Repair of perineum		+	\$4,993.48	
56820	Exam of vulva w/scope		+	\$307.96	
56821	Exam/biopsy of vulva w/scope		+	\$385.63	
57000	Exploration of vagina		+	\$4,993.48	
57010	Drainage of pelvic abscess		+	\$4,993.48	
57020	Drainage of pelvic fluid		+	\$734.86	
57022	I & d vaginal hematoma, pp		+	\$3,188.56	
57023	I & d vag hematoma, non-ob		+	\$3,188.56	
57061	Destroy vag lesions, simple		+	\$4,993.48	
57065	Destroy vag lesions, complex		+	\$4,993.48	
57100	Biopsy of vagina		+	\$734.86	
57105	Biopsy of vagina		+	\$4,993.48	
57106	Remove vagina wall, partial		+	\$4,993.48	
57107	Remove vagina tissue, part		+	\$6,685.13	
57109	Vaginectomy partial w/nodes		+	\$6,685.13	
57120	Closure of vagina		+	\$6,685.13	
57130	Remove vagina lesion		+	\$4,993.48	
57135	Remove vagina lesion		+	\$4,993.48	
57150	Treat vagina infection		+	\$56.28	
57155	Insert uteri tandems/ovoids		+	\$4,076.76	
57160	Insert pessary/other device		+	\$307.96	
57170	Fitting of diaphragm/cap		+	\$56.28	
57180	Treat vaginal bleeding		+	\$734.86	
57200	Repair of vagina		+	\$4,993.48	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 45 OF 84

CPT/ HCPSC Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
57210	Repair vagina/perineum		+	\$4,993.48	
57220	Revision of urethra		+	\$6,685.13	
57230	Repair of urethral lesion		+	\$6,685.13	
57240	Repair bladder & vagina		+	\$6,685.13	
57250	Repair rectum & vagina		+	\$6,685.13	
57260	Repair of vagina		+	\$6,685.13	
57265	Extensive repair of vagina		+	\$6,685.13	
57268	Repair of bowel bulge		+	\$6,685.13	
57284	Repair paravaginal defect		+	\$6,685.13	
57287	Revise/remove sling repair		+	\$10,431.03	
57288	Repair bladder defect		+	\$10,431.03	
57289	Repair bladder & vagina		+	\$6,685.13	
57291	Construction of vagina		+	\$6,685.13	
57300	Repair rectum-vagina fistula		+	\$6,685.13	
57310	Repair urethrovaginal lesion		+	\$6,685.13	
57320	Repair bladder-vagina lesion		+	\$6,685.13	
57330	Repair bladder-vagina lesion		+	\$6,685.13	
57400	Dilation of vagina		+	\$4,993.48	
57410	Pelvic examination		+	\$4,993.48	
57415	Remove vaginal foreign body		+	\$4,993.48	
57420	Exam of vagina w/scope		+	\$734.86	
57421	Exam/biopsy of vag w/scope		+	\$734.86	
57425	Laparoscopy, surg, colpopexy		+	\$8,821.92	
57452	Examination of vagina		+	\$385.63	
57454	Vagina examination & biopsy		+	\$734.86	
57455	Biopsy of cervix w/scope		+	\$734.86	
57456	Endocerv curettage w/scope		+	\$734.86	
57460	Cervix excision		+	\$4,076.76	
57461	Conz of cervix w/scope, leep		+	\$4,993.48	
57500	Biopsy of cervix		+	\$734.86	
57505	Endocervical curettage		+	\$734.86	
57510	Cauterization of cervix		+	\$4,076.76	
57511	Cryocautery of cervix		+	\$385.63	
57513	Laser surgery of cervix		+	\$4,076.76	
57520	Conization of cervix		+	\$4,993.48	
57522	Conization of cervix		+	\$6,685.13	
57530	Removal of cervix		+	\$6,685.13	
57550	Removal of residual cervix		+	\$6,685.13	
57555	Remove cervix/repair vagina		+	\$6,685.13	
57556	Remove cervix, repair bowel		+	\$6,685.13	
57700	Revision of cervix		+	\$4,993.48	
57720	Revision of cervix		+	\$4,993.48	
57800	Dilation of cervical canal		+	\$4,076.76	
57820	D & c of residual cervix		+	\$4,368.48	
58100	Biopsy of uterus lining		+	\$307.96	
58120	Dilation and curettage		+	\$4,368.48	
58145	Myomectomy vag method		+	\$6,685.13	
58300	Insert intrauterine device			\$728.05	MDR
58301	Remove intrauterine device		+	\$385.63	
58321	Artificial insemination		+	\$1,308.21	
58322	Artificial insemination		+	\$1,308.21	
58323	Sperm washing		+	\$1,308.21	
58345	Reopen fallopian tube		+	\$4,993.48	
58346	Insert heyman uten capsule		+	\$4,076.76	
58350	Reopen fallopian tube		+	\$4,993.48	
58353	Endometr ablate, thermal		+	\$6,685.13	
58545	Laparoscopic myomectomy		+	\$8,821.92	
58546	Laparo-myomectomy, complex		+	\$10,937.84	
58550	Laparo-asst vag hysterectomy		+	\$15,016.18	
58552	Laparo-vag hyst incl t/o		+	\$10,937.84	
58553	Laparo-vag hyst, complex		+	\$10,937.84	
58554	Laparo-vag hyst w/t/o, compl		+	\$10,937.84	
58555	Hysteroscopy, dx, sep proc		+	\$5,335.91	
58558	Hysteroscopy, biopsy		+	\$5,335.91	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 46 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
58559	Hysteroscopy, lysis		+	\$5,335.91	
58560	Hysteroscopy, resect septum		+	\$7,627.09	
58561	Hysteroscopy, remove myoma		+	\$7,627.09	
58562	Hysteroscopy, remove fb		+	\$5,335.91	
58563	Hysteroscopy, ablation		+	\$7,627.09	
58578	Laparo proc, uterus		+	\$8,821.92	
58579	Hysteroscope procedure		+	\$5,335.91	
58600	Division of fallopian tube		+	\$6,685.13	
58615	Occlude fallopian tube(s)		+	\$4,993.48	
58660	Laparoscopy, lysis		+	\$10,937.84	
58661	Laparoscopy, remove adnexa		+	\$10,937.84	
58662	Laparoscopy, excise lesions		+	\$10,937.84	
58670	Laparoscopy, tubal cautery		+	\$10,937.84	
58671	Laparoscopy, tubal block		+	\$10,937.84	
58672	Laparoscopy, fimbrioplasty		+	\$10,937.84	
58673	Laparoscopy, salpingostomy		+	\$10,937.84	
58679	Laparo proc, oviduct-ovary		+	\$8,821.92	
58720	Removal of ovary/tube(s)		+	\$9,305.68	MedStat
58800	Drainage of ovarian cyst(s)		+	\$4,076.76	
58820	Drain ovary abscess, open		+	\$6,685.13	
58823	Drain pelvic abscess, percut		+	\$4,076.76	
58900	Biopsy of ovary(s)		+	\$4,076.76	
58920	Partial removal of ovary(s)		+	\$6,685.13	
58925	Removal of ovarian cyst(s)		+	\$6,685.13	
58970	Retrieval of oocyte		+	\$4,993.48	
58974	Transfer of embryo		+	\$1,308.21	
58976	Transfer of embryo		+	\$1,308.21	
58999	Genital surgery procedure		+	\$56.28	
59000	Amniocentesis, diagnostic		+	\$257.12	
59001	Amniocentesis, therapeutic		+	\$257.12	
59012	Fetal cord puncture, prenatal		+	\$257.12	
59015	Chorion biopsy		+	\$257.12	
59020	Fetal contract stress test	b	+	\$257.12	
59025	Fetal non-stress test	b	+	\$257.12	
59030	Fetal scalp blood sample		+	\$257.12	
59070	Transabdom amnioinfus w/ us		+	\$257.12	
59072	Umbilical cord occlud w/ us		+	\$257.12	
59074	Fetal fluid drainage w/ us		+	\$257.12	
59076	Fetal shunt placement, w/ us		+	\$257.12	
59150	Treat ectopic pregnancy		+	\$10,937.84	
59151	Treat ectopic pregnancy		+	\$10,937.84	
59160	D & c after delivery		+	\$4,368.48	
59200	Insert cervical dilator		+	\$385.63	
59300	Episiotomy or vaginal repair		+	\$4,076.76	
59320	Revision of cervix		+	\$4,993.48	
59409	Obstetrical care		+	\$4,147.57	
59412	Antepartum manipulation		+	\$583.31	
59414	Deliver placenta		+	\$4,147.57	
59612	Vbac delivery only		+	\$4,147.57	
59812	Treatment of miscarriage		+	\$4,047.51	
59820	Care of miscarriage		+	\$4,047.51	
59821	Treatment of miscarriage		+	\$4,047.51	
59840	Abortion		+	\$4,317.70	
59841	Abortion		+	\$4,317.70	
59866	Abortion (mpr)		+	\$257.12	
59870	Evacuate mole of uterus		+	\$4,047.51	
59871	Remove cerclage suture		+	\$4,993.48	
59897	Fetal invas px w/ us		+	\$257.12	
59898	Laparo proc, ob care/deliver		+	\$8,821.92	
59899	Maternity care procedure		+	\$257.12	
60000	Drain thyroid/tongue cyst		+	\$1,744.68	
60001	Aspirate/inject thyroid cyst		+	\$430.33	
60100	Biopsy of thyroid		+	\$430.33	
60200	Remove thyroid lesion		+	\$9,977.17	

NOTES CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 47 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
60210	Partial thyroid excision		+	\$9,977.17	
60212	Partial thyroid excision		+	\$9,977.17	
60220	Partial removal of thyroid		+	\$9,977.17	
60225	Partial removal of thyroid		+	\$9,977.17	
60240	Removal of thyroid		+	\$9,977.17	
60252	Removal of thyroid		+	\$9,418.88	
60260	Repeat thyroid surgery		+	\$9,418.88	
60280	Remove thyroid duct lesion		+	\$9,977.17	
60281	Remove thyroid duct lesion		+	\$9,977.17	
60500	Explore parathyroid glands		+	\$9,418.88	
60512	Autotransplant parathyroid		+	\$5,085.32	
60659	Laparo proc, endocrine		+	\$8,821.92	
60699	Endocrine surgery procedure		+	\$9,977.17	
61000	Remove cranial cavity fluid		+	\$805.83	
61001	Remove cranial cavity fluid		+	\$805.83	
61020	Remove brain cavity fluid		+	\$805.83	
61026	Injection into brain canal		+	\$805.83	
61050	Remove brain canal fluid		+	\$805.83	
61055	Injection into brain canal		+	\$805.83	
61070	Brain canal shunt procedure		+	\$805.83	
61215	Insert brain-fluid device		+	\$8,373.86	
61330	Decompress eye socket		+	\$9,418.88	
61623	Endovasc temporary vessel occl		+	\$7,257.31	
61624	Occlusion/embolization cath		+	\$9,561.41	MDR
61626	Transcath occlusion, non-cns		+	\$9,478.00	
61790	Treat trigeminal nerve		+	\$4,482.38	
61791	Treat trigeminal tract		+	\$586.87	
61795	Brain surgery using computer		+	\$1,714.36	
61880	Revise/remove neuroelectrode		+	\$5,538.93	
61885	Implant neurostim one array		+	\$25,664.04	
61886	Implant neurostim arrays		+	\$25,338.40	
61888	Revise/remove neuroreceiver		+	\$12,561.86	
62194	Replace/irrigate catheter		+	\$569.80	
62225	Replace/irrigate catheter		+	\$2,359.48	
62230	Replace/revise brain shunt		+	\$8,373.86	
62252	Csf shunt reprogram	b	+	\$760.48	
62263	Lysis epidural adhesions		+	\$3,139.10	
62264	Epidural lysis on single day		+	\$3,139.10	
62268	Drain spinal cord cyst		+	\$805.83	
62269	Needle biopsy, spinal cord		+	\$885.98	
62270	Spinal fluid tap, diagnostic		+	\$1,392.68	
62272	Drain cerebro spinal fluid		+	\$1,392.68	
62273	Treat epidural spine lesion		+	\$1,392.68	
62280	Treat spinal cord lesion		+	\$1,748.02	
62281	Treat spinal cord lesion		+	\$1,748.02	
62282	Treat spinal canal lesion		+	\$1,748.02	
62287	Percutaneous diskectomy		+	\$4,482.38	
62292	Injection into disk lesion		+	\$805.83	
62294	Injection into spinal artery		+	\$805.83	
62310	Inject spine c/t		+	\$1,392.68	
62311	Inject spine l/s (cd)		+	\$1,392.68	
62318	Inject spine w/cath, c/t		+	\$1,392.68	
62319	Inject spine w/cath l/s (cd)		+	\$1,392.68	
62350	Implant spinal canal cath		+	\$6,857.12	
62351	Implant spinal canal cath		+	\$10,808.50	
62355	Remove spinal canal catheter		+	\$3,139.10	
62360	Insert spine infusion device		+	\$22,661.95	
62361	Implant spine infusion pump		+	\$22,288.88	
62362	Implant spine infusion pump		+	\$22,288.88	
62365	Remove spine infusion device		+	\$3,139.10	
62367	Analyze spine infusion pump	b		\$760.48	
62368	Analyze spine infusion pump	b		\$760.48	
63001	Removal of spinal lamina		+	\$10,808.50	
63003	Removal of spinal lamina		+	\$10,808.50	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 48 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
63005	Removal of spinal lamina		+	\$10,808.50	
63011	Removal of spinal lamina		+	\$10,808.50	
63012	Removal of spinal lamina		+	\$10,808.50	
63015	Removal of spinal lamina		+	\$10,808.50	
63016	Removal of spinal lamina		+	\$10,808.50	
63017	Removal of spinal lamina		+	\$10,808.50	
63020	Neck spine disk surgery		+	\$10,808.50	
63030	Low back disk surgery		+	\$10,808.50	
63035	Spinal disk surgery add-on		+	\$10,808.50	
63040	Laminotomy, single cervical		+	\$10,808.50	
63042	Laminotomy, single lumbar		+	\$10,808.50	
63045	Removal of spinal lamina		+	\$10,808.50	
63046	Removal of spinal lamina		+	\$10,808.50	
63047	Removal of spinal lamina		+	\$10,808.50	
63048	Remove spinal lamina add-on		+	\$10,808.50	
63055	Decompress spinal cord		+	\$10,808.50	
63056	Decompress spinal cord		+	\$10,808.50	
63057	Decompress spine cord add-on		+	\$10,808.50	
63064	Decompress spinal cord		+	\$10,808.50	
63066	Decompress spine cord add-on		+	\$10,808.50	
63600	Remove spinal cord lesion		+	\$4,482.38	
63610	Stimulation of spinal cord		+	\$4,482.38	
63615	Remove lesion of spinal cord		+	\$4,482.38	
63650	Implant neuroelectrodes			\$14,117.31	
63655	Implant neuroelectrodes			\$22,479.50	
63660	Revise/remove neuroelectrode		+	\$5,538.93	
63685	Implant neuroreceiver		+	\$25,338.40	
63688	Revise/remove neuroreceiver		+	\$12,561.86	
63741	Install spinal shunt		+	\$14,168.21	
63744	Revision of spinal shunt		+	\$14,168.21	
63746	Removal of spinal shunt		+	\$2,022.52	
64400	N block inj, trigeminal		+	\$586.87	
64402	N block inj, facial		+	\$586.87	
64405	N block inj, occipital		+	\$586.87	
64408	N block inj, vagus		+	\$586.87	
64410	N block inj, phrenic		+	\$586.87	
64412	N block inj, spinal accessor		+	\$586.87	
64413	N block inj, cervical plexus		+	\$586.87	
64415	Injection for nerve block		+	\$586.87	
64416	N block cont infuse, b plex		+	\$586.87	
64417	N block inj, axillary		+	\$586.87	
64418	N block inj, suprascapular		+	\$586.87	
64420	N block inj, intercost, sng		+	\$1,748.02	
64421	N block inj, intercost, mlt		+	\$1,748.02	
64425	N block inj ilio-ing/hypogi		+	\$586.87	
64430	N block inj, pudendal		+	\$586.87	
64435	N block inj, paracervical		+	\$586.87	
64445	Injection for nerve block		+	\$586.87	
64446	N blk inj, sciatic, cont inf		+	\$586.87	
64447	N block inj fem, single		+	\$586.87	
64448	N block inj fem, cont inf		+	\$586.87	
64449	N block inj, lumbar plexus		+	\$586.87	
64450	N block, other peripheral		+	\$586.87	
64470	Inj paravertebral c/t		+	\$1,748.02	
64472	Inj paravertebral c/t add-on		+	\$1,748.02	
64475	Inj paravertebral l/s		+	\$1,748.02	
64476	Inj paravertebral l/s add-on		+	\$1,748.02	
64479	Inj foramen epidural c/t		+	\$1,748.02	
64480	Inj foramen epidural add-on		+	\$1,748.02	
64483	Inj foramen epidural l/s		+	\$1,748.02	
64484	Inj foramen epidural add-on		+	\$1,748.02	
64505	N block, sphenopalatine gangl		+	\$586.87	
64508	N block, carotid sinus s/p		+	\$586.87	
64510	N block, stellate ganglion		+	\$1,748.02	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 49 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
64517	N block inj, hypogag plxs		+	\$586.87	MDR
64520	N block, lumbar/thoracic		+	\$1,748.02	
64530	N block inj, celiac pelus		+	\$1,748.02	
64550	Apply neurostimulator			\$309.86	
64553	Implant neuroelectrodes			\$22,479.50	
64555	Implant neuroelectrodes			\$14,117.31	
64560	Implant neuroelectrodes			\$14,117.31	
64561	Implant neuroelectrodes			\$14,117.31	
64565	Implant neuroelectrodes			\$14,117.31	
64573	Implant neuroelectrodes			\$22,479.50	
64575	Implant neuroelectrodes			\$14,117.31	
64577	Implant neuroelectrodes			\$22,479.50	
64580	Implant neuroelectrodes			\$22,479.50	
64581	Implant neuroelectrodes			\$14,117.31	
64585	Revise/remove neuroelectrode		+	\$5,538.93	
64590	Implant neuroreceiver		+	\$25,338.40	
64595	Revise/remove neuroreceiver		+	\$12,561.86	
64600	Injection treatment of nerve		+	\$3,139.10	
64605	Injection treatment of nerve		+	\$3,139.10	
64610	Injection treatment of nerve		+	\$3,139.10	
64612	Destroy nerve, face muscle		+	\$586.87	
64613	Destroy nerve, spine muscle		+	\$586.87	
64614	Destroy nerve, extrem musc		+	\$586.87	
64620	Injection treatment of nerve		+	\$3,139.10	
64622	Destr paravertebrl nerve l/s		+	\$3,139.10	
64623	Destr paravertebral n add-on		+	\$3,139.10	
64626	Destr paravertebrl nerve c/t		+	\$3,139.10	
64627	Destr paravertebral n add-on		+	\$3,139.10	
64630	Injection treatment of nerve		+	\$1,748.02	
64640	Injection treatment of nerve		+	\$1,748.02	
64680	Injection treatment of nerve		+	\$3,139.10	
64681	Injection treatment of nerve		+	\$3,139.10	
64702	Revise finger/toe nerve		+	\$4,482.38	
64704	Revise hand/foot nerve		+	\$4,482.38	
64708	Revise arm/leg nerve		+	\$4,482.38	
64712	Revision of sciatic nerve		+	\$4,482.38	
64713	Revision of arm nerve(s)		+	\$4,482.38	
64714	Revise low back nerve(s)		+	\$4,482.38	
64716	Revision of cranial nerve		+	\$4,482.38	
64718	Revise ulnar nerve at elbow		+	\$4,482.38	
64719	Revise ulnar nerve at wrist		+	\$4,482.38	
64721	Carpal tunnel surgery		+	\$4,482.38	
64722	Relieve pressure on nerve(s)		+	\$4,482.38	
64726	Release foot/toe nerve		+	\$4,482.38	
64727	Internal nerve revision		+	\$4,482.38	
64732	Incision of brow nerve		+	\$4,482.38	
64734	Incision of cheek nerve		+	\$4,482.38	
64736	Incision of chin nerve		+	\$4,482.38	
64738	Incision of jaw nerve		+	\$4,482.38	
64740	Incision of tongue nerve		+	\$4,482.38	
64742	Incision of facial nerve		+	\$4,482.38	
64744	Incise nerve, back of head		+	\$4,482.38	
64746	Incise diaphragm nerve		+	\$4,482.38	
64761	Incision of pelvis nerve		+	\$4,482.38	
64771	Sever cranial nerve		+	\$4,482.38	
64772	Incision of spinal nerve		+	\$4,482.38	
64774	Remove skin nerve lesion		+	\$4,482.38	
64776	Remove digit nerve lesion		+	\$4,482.38	
64778	Digit nerve surgery add-on		+	\$4,482.38	
64782	Remove limb nerve lesion		+	\$4,482.38	
64783	Limb nerve surgery add-on		+	\$4,482.38	
64784	Remove nerve lesion		+	\$4,482.38	
64786	Remove sciatic nerve lesion		+	\$6,743.64	
64787	Implant nerve end		+	\$4,482.38	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 50 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
64788	Remove skin nerve lesion		+	\$4,482.38	
64790	Removal of nerve lesion		+	\$4,482.38	
64792	Removal of nerve lesion		+	\$6,743.64	
64795	Biopsy of nerve		+	\$4,482.38	
64802	Remove sympathetic nerves		+	\$4,482.38	
64820	Remove sympathetic nerves		+	\$4,482.38	
64821	Remove sympathetic nerves		+	\$6,535.56	
64822	Remove sympathetic nerves		+	\$6,535.56	
64823	Remove sympathetic nerves		+	\$6,535.56	
64831	Repair of digit nerve		+	\$6,743.64	
64832	Repair nerve add-on		+	\$6,743.64	
64834	Repair of hand or foot nerve		+	\$6,743.64	
64835	Repair of hand or foot nerve		+	\$6,743.64	
64836	Repair of hand or foot nerve		+	\$6,743.64	
64837	Repair nerve add-on		+	\$6,743.64	
64840	Repair of leg nerve		+	\$6,743.64	
64856	Repair/transpose nerve		+	\$6,743.64	
64857	Repair arm/leg nerve		+	\$6,743.64	
64858	Repair sciatic nerve		+	\$6,743.64	
64859	Nerve surgery		+	\$6,743.64	
64861	Repair of arm nerves		+	\$6,743.64	
64862	Repair of low back nerves		+	\$6,743.64	
64864	Repair of facial nerve		+	\$6,743.64	
64865	Repair of facial nerve		+	\$6,743.64	
64870	Fusion of facial/other nerve		+	\$6,743.64	
64872	Subsequent repair of nerve		+	\$6,743.64	
64874	Repair & revise nerve add-on		+	\$6,743.64	
64876	Repair nerve/shorten bone		+	\$6,743.64	
64885	Nerve graft, head or neck		+	\$6,743.64	
64886	Nerve graft, head or neck		+	\$6,743.64	
64890	Nerve graft, hand or foot		+	\$6,743.64	
64891	Nerve graft, hand or foot		+	\$6,743.64	
64892	Nerve graft, arm or leg		+	\$6,743.64	
64893	Nerve graft, arm or leg		+	\$6,743.64	
64895	Nerve graft, hand or foot		+	\$6,743.64	
64896	Nerve graft, hand or foot		+	\$6,743.64	
64897	Nerve graft, arm or leg		+	\$6,743.64	
64898	Nerve graft, arm or leg		+	\$6,743.64	
64901	Nerve graft add-on		+	\$6,743.64	
64902	Nerve graft add-on		+	\$6,743.64	
64905	Nerve pedicle transfer		+	\$6,743.64	
64907	Nerve pedicle transfer		+	\$6,743.64	
64999	Nervous system surgery		+	\$586.87	
65091	Revise eye		+	\$7,915.51	
65093	Revise eye with implant		+	\$6,014.60	
65101	Removal of eye		+	\$7,915.51	
65103	Remove eye/insert implant		+	\$7,915.51	
65105	Remove eye/attach implant		+	\$7,915.51	
65110	Removal of eye		+	\$7,915.51	
65112	Remove eye/revise socket		+	\$7,915.51	
65114	Remove eye/revise socket		+	\$7,915.51	
65125	Revise ocular implant		+	\$4,721.50	
65130	Insert ocular implant		+	\$6,014.60	
65135	Insert ocular implant		+	\$6,014.60	
65140	Attach ocular implant		+	\$7,915.51	
65150	Revise ocular implant		+	\$6,014.60	
65155	Reinsert ocular implant		+	\$7,915.51	
65175	Removal of ocular implant		+	\$4,721.50	
65205	Remove foreign body from eye			\$230.34	
65210	Remove foreign body from eye			\$592.97	
65220	Remove foreign body from eye			\$592.97	
65222	Remove foreign body from eye			\$592.97	
65235	Remove foreign body from eye		+	\$3,887.88	
65260	Remove foreign body from eye		+	\$5,042.21	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 51 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
65265	Remove foreign body from eye		+	\$5,042.21	
65270	Repair of eye wound		+	\$4,721.50	
65272	Repair of eye wound		+	\$3,887.88	
65275	Repair of eye wound		+	\$3,887.88	
65280	Repair of eye wound		+	\$5,804.09	
65285	Repair of eye wound		+	\$5,804.09	
65286	Repair of eye wound		+	\$3,887.88	
65290	Repair of eye socket wound		+	\$5,888.70	
65400	Removal of eye lesion		+	\$3,887.88	
65410	Blopsy of cornea		+	\$3,887.88	
65420	Removal of eye lesion		+	\$3,887.88	
65426	Removal of eye lesion		+	\$5,804.09	
65430	Corneal smear			\$182.84	
65435	Curette/treat cornea		+	\$1,661.86	
65436	Curette/treat cornea		+	\$3,887.88	
65450	Treatment of corneal lesion			\$592.97	
65600	Revision of cornea		+	\$4,721.50	
65710	Corneal transplant		+	\$10,161.47	
65730	Corneal transplant		+	\$10,161.47	
65750	Corneal transplant		+	\$10,161.47	
65755	Corneal transplant		+	\$10,161.47	
65770	Revise cornea with implant		+	\$10,161.47	
65771	Radial keratotomy			\$2,345.87	MDR
65772	Correction of astigmatism		+	\$3,887.88	
65775	Correction of astigmatism		+	\$3,887.88	
65780	Ocular reconst, transplant		+	\$10,161.47	
65781	Ocular reconst, transplant		+	\$10,161.47	
65782	Ocular reconst, transplant		+	\$10,161.47	
65800	Drainage of eye		+	\$3,887.88	
65805	Drainage of eye		+	\$3,887.88	
65810	Drainage of eye		+	\$5,804.09	
65815	Drainage of eye		+	\$5,804.09	
65820	Relieve inner eye pressure		+	\$1,333.29	
65850	Incision of eye		+	\$5,804.09	
65855	Laser surgery of eye		+	\$1,340.44	
65860	Incise inner eye adhesions		+	\$1,340.44	
65865	Incise inner eye adhesions		+	\$3,887.88	
65870	Incise inner eye adhesions		+	\$5,804.09	
65875	Incise inner eye adhesions		+	\$5,804.09	
65880	Incise inner eye adhesions		+	\$3,887.88	
65900	Remove eye lesion		+	\$3,887.88	
65920	Remove implant of eye		+	\$3,887.88	
65930	Remove blood clot from eye		+	\$5,804.09	
66020	Injection treatment of eye		+	\$3,887.88	
66030	Injection treatment of eye		+	\$3,887.88	
66130	Remove eye lesion		+	\$5,804.09	
66150	Glaucoma surgery		+	\$3,887.88	
66155	Glaucoma surgery		+	\$5,804.09	
66160	Glaucoma surgery		+	\$5,804.09	
66165	Glaucoma surgery		+	\$5,804.09	
66170	Glaucoma surgery		+	\$5,804.09	
66172	Incision of eye		+	\$7,256.36	
66180	Implant eye shunt		+	\$7,256.36	
66185	Revise eye shunt		+	\$7,256.36	
66220	Repair eye lesion		+	\$5,042.21	
66225	Repair/graft eye lesion		+	\$7,256.36	
66250	Follow-up surgery of eye		+	\$3,887.88	
66500	Incision of iris		+	\$1,333.29	
66505	Incision of iris		+	\$1,333.29	
66600	Remove iris and lesion		+	\$3,887.88	
66605	Removal of iris		+	\$5,804.09	
66625	Removal of iris		+	\$3,887.88	
66630	Removal of iris		+	\$3,887.88	
66635	Removal of iris		+	\$5,804.09	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 52 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
66680	Repair iris & ciliary body		+	\$5,804.09	
66682	Repair iris & ciliary body		+	\$5,804.09	
66700	Destruction, ciliary body		+	\$3,887.88	
66710	Destruction, ciliary body		+	\$3,887.88	
66720	Destruction, ciliary body		+	\$3,887.88	
66740	Destruction, ciliary body		+	\$3,887.88	
66761	Revision of iris		+	\$1,340.44	
66762	Revision of iris		+	\$1,340.44	
66770	Removal of inner eye lesion		+	\$1,340.44	
66820	Incision, secondary cataract		+	\$1,333.29	
66821	After cataract laser surgery		+	\$1,340.44	
66825	Reposition intraocular lens		+	\$5,804.09	
66830	Removal of lens lesion		+	\$1,333.29	
66840	Removal of lens material		+	\$3,332.12	
66850	Removal of lens material		+	\$7,516.69	
66852	Removal of lens material		+	\$7,516.69	
66920	Extraction of lens		+	\$7,516.69	
66930	Extraction of lens		+	\$7,516.69	
66940	Extraction of lens		+	\$3,332.12	
66982	Cataract surgery, complex		+	\$5,348.45	
66983	Cataract surg w/iol, 1 stage		+	\$5,348.45	
66984	Cataract surg w/iol, 1 stage		+	\$5,348.45	
66985	Insert lens prosthesis		+	\$5,348.45	
66986	Exchange lens prosthesis		+	\$5,348.45	
66999	Eye surgery procedure		+	\$1,333.29	
67005	Partial removal of eye fluid		+	\$9,245.45	
67010	Partial removal of eye fluid		+	\$9,245.45	
67015	Release of eye fluid		+	\$9,245.45	
67025	Replace eye fluid		+	\$5,042.21	
67027	Implant eye drug system		+	\$9,245.45	
67028	Injection eye drug		+	\$1,375.11	
67030	Incise inner eye strands		+	\$5,042.21	
67031	Laser surgery, eye strands		+	\$1,340.44	
67036	Removal of inner eye fluid		+	\$9,245.45	
67038	Strip retinal membrane		+	\$9,245.45	
67039	Laser treatment of retina		+	\$9,245.45	
67040	Laser treatment of retina		+	\$10,533.75	
67101	Repair detached retina		+	\$1,375.11	
67105	Repair detached retina		+	\$1,306.67	
67107	Repair detached retina		+	\$10,533.75	
67108	Repair detached retina		+	\$10,533.75	
67110	Repair detached retina		+	\$5,042.21	
67112	Rerepair detached retina		+	\$10,533.75	
67115	Release encircling material		+	\$5,042.21	
67120	Remove eye implant material		+	\$5,042.21	
67121	Remove eye implant material		+	\$9,245.45	
67141	Treatment of retina		+	\$1,375.11	
67145	Treatment of retina		+	\$1,306.67	
67208	Treatment of retinal lesion		+	\$1,375.11	
67210	Treatment of retinal lesion		+	\$1,306.67	
67218	Treatment of retinal lesion		+	\$5,042.21	
67220	Treatment of choroid lesion		+	\$1,375.11	
67221	Ocular photodynamic ther		+	\$1,375.11	
67225	Eye photodynamic ther add-on		+	\$1,375.11	
67227	Treatment of retinal lesion		+	\$1,375.11	
67228	Treatment of retinal lesion		+	\$1,306.67	
67250	Reinforce eye wall		+	\$4,721.50	
67255	Reinforce/graft eye wall		+	\$9,245.45	
67299	Eye surgery procedure		+	\$1,375.11	
67311	Revise eye muscle		+	\$5,888.70	
67312	Revise two eye muscles		+	\$5,888.70	
67314	Revise eye muscle		+	\$5,888.70	
67316	Revise two eye muscles		+	\$5,888.70	
67318	Revise eye muscle(s)		+	\$5,888.70	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 53 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
67320	Revise eye muscle(s) add-on		+	\$5,888.70	
67331	Eye surgery follow-up add-on		+	\$5,888.70	
67332	Rerevise eye muscles add-on		+	\$5,888.70	
67334	Revise eye muscle w/suture		+	\$5,888.70	
67335	Eye suture during surgery		+	\$5,888.70	
67340	Revise eye muscle add-on		+	\$5,888.70	
67343	Release eye tissue		+	\$5,888.70	
67345	Destroy nerve of eye muscle		+	\$865.82	
67350	Biopsy eye muscle		+	\$604.35	
67399	Eye muscle surgery procedure		+	\$5,888.70	
67400	Explore/biopsy eye socket		+	\$6,014.60	
67405	Explore/drain eye socket		+	\$6,014.60	
67412	Explore/treat eye socket		+	\$6,014.60	
67413	Explore/treat eye socket		+	\$6,014.60	
67414	Explr/decompress eye socket		+	\$7,915.51	
67415	Aspiration, orbital contents		+	\$1,661.86	
67420	Explore/treat eye socket		+	\$7,915.51	
67430	Explore/treat eye socket		+	\$7,915.51	
67440	Explore/drain eye socket		+	\$7,915.51	
67445	Explr/decompress eye socket		+	\$7,915.51	
67450	Explore/biopsy eye socket		+	\$7,915.51	
67500	Inject/treat eye socket			\$592.97	
67505	Inject/treat eye socket		+	\$865.82	
67515	Inject/treat eye socket		+	\$1,661.86	
67550	Insert eye socket implant		+	\$7,915.51	
67560	Revise eye socket implant		+	\$6,014.60	
67570	Decompress optic nerve		+	\$7,915.51	
67599	Orbit surgery procedure		+	\$1,661.86	
67700	Drainage of eyelid abscess		+	\$865.82	
67710	Incision of eyelid		+	\$1,661.86	
67715	Incision of eyelid fold		+	\$4,721.50	
67800	Remove eyelid lesion		+	\$865.82	
67801	Remove eyelid lesions		+	\$1,661.86	
67805	Remove eyelid lesions		+	\$865.82	
67808	Remove eyelid lesion(s)		+	\$4,721.50	
67810	Biopsy of eyelid		+	\$865.82	
67820	Revise eyelashes			\$230.34	
67825	Revise eyelashes		+	\$865.82	
67830	Revise eyelashes		+	\$1,661.86	
67835	Revise eyelashes		+	\$4,721.50	
67840	Remove eyelid lesion		+	\$1,661.86	
67850	Treat eyelid lesion		+	\$1,661.86	
67875	Closure of eyelid by suture		+	\$1,661.86	
67880	Revision of eyelid		+	\$3,887.88	
67882	Revision of eyelid		+	\$4,721.50	
67900	Repair brow defect		+	\$4,721.50	
67901	Repair eyelid defect		+	\$4,721.50	
67902	Repair eyelid defect		+	\$4,721.50	
67903	Repair eyelid defect		+	\$4,721.50	
67904	Repair eyelid defect		+	\$4,721.50	
67906	Repair eyelid defect		+	\$4,721.50	
67908	Repair eyelid defect		+	\$4,721.50	
67909	Revise eyelid defect		+	\$4,721.50	
67911	Revise eyelid defect		+	\$4,721.50	
67912	Correction eyelid w/ implant		+	\$1,661.86	
67914	Repair eyelid defect		+	\$4,721.50	
67915	Repair eyelid defect		+	\$1,661.86	
67916	Repair eyelid defect		+	\$4,721.50	
67917	Repair eyelid defect		+	\$4,721.50	
67921	Repair eyelid defect		+	\$4,721.50	
67922	Repair eyelid defect		+	\$4,721.50	
67923	Repair eyelid defect		+	\$4,721.50	
67924	Repair eyelid defect		+	\$4,721.50	
67930	Repair eyelid wound		+	\$4,721.50	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 54 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
67935	Repair eyelid wound		+	\$4,721.50	
67938	Remove eyelid foreign body			\$230.34	
67950	Revision of eyelid		+	\$4,721.50	
67961	Revision of eyelid		+	\$4,721.50	
67966	Revision of eyelid		+	\$4,721.50	
67971	Reconstruction of eyelid		+	\$6,014.60	
67973	Reconstruction of eyelid		+	\$6,014.60	
67974	Reconstruction of eyelid		+	\$6,014.60	
67975	Reconstruction of eyelid		+	\$4,721.50	
67999	Revision of eyelid		+	\$4,721.50	
68020	Incise/drain eyelid lining		+	\$4,721.50	
68040	Treatment of eyelid lesions			\$230.34	
68100	Biopsy of eyelid lining		+	\$1,333.29	
68110	Remove eyelid lining lesion		+	\$604.35	
68115	Remove eyelid lining lesion		+	\$1,661.86	
68130	Remove eyelid lining lesion		+	\$3,887.88	
68135	Remove eyelid lining lesion		+	\$1,661.86	
68200	Treat eyelid by injection			\$230.34	
68320	Revise/graft eyelid lining		+	\$4,721.50	
68325	Revise/graft eyelid lining		+	\$7,915.51	
68326	Revise/graft eyelid lining		+	\$6,014.60	
68328	Revise/graft eyelid lining		+	\$6,014.60	
68330	Revise eyelid lining		+	\$3,887.88	
68335	Revise/graft eyelid lining		+	\$6,014.60	
68340	Separate eyelid adhesions		+	\$4,721.50	
68360	Revise eyelid lining		+	\$5,804.09	
68362	Revise eyelid lining		+	\$5,804.09	
68371	Harvest eye tissue, alograft		+	\$3,887.88	
68399	Eyelid lining surgery		+	\$1,661.86	
68400	Incise/drain tear gland		+	\$865.82	
68420	Incise/drain tear sac		+	\$4,721.50	
68440	Incise tear duct opening		+	\$865.82	
68500	Removal of tear gland		+	\$6,014.60	
68505	Partial removal, tear gland		+	\$6,014.60	
68510	Biopsy of tear gland		+	\$4,721.50	
68520	Removal of tear sac		+	\$6,014.60	
68525	Biopsy of tear sac		+	\$4,721.50	
68530	Clearance of tear duct		+	\$4,721.50	
68540	Remove tear gland lesion		+	\$6,014.60	
68550	Remove tear gland lesion		+	\$7,915.51	
68700	Repair tear ducts		+	\$6,014.60	
68705	Revise tear duct opening		+	\$865.82	
68720	Create tear sac drain		+	\$7,915.51	
68745	Create tear duct drain		+	\$6,014.60	
68750	Create tear duct drain		+	\$7,915.51	
68760	Close tear duct opening			\$230.34	
68761	Close tear duct opening			\$592.97	
68770	Close tear system fistula		+	\$4,721.50	
68801	Dilate tear duct opening			\$592.97	
68810	Probe nasolacrimal duct		+	\$604.35	
68811	Probe nasolacrimal duct		+	\$4,721.50	
68815	Probe nasolacrimal duct		+	\$4,721.50	
68840	Explore/irrigate tear ducts		+	\$604.35	
68899	Tear duct system surgery		+	\$604.35	
69000	Drain external ear lesion		+	\$447.81	
69005	Drain external ear lesion		+	\$3,188.56	
69020	Drain outer ear canal lesion		+	\$447.81	
69100	Biopsy of external ear		+	\$1,068.77	
69105	Biopsy of external ear canal		+	\$4,123.29	
69110	Remove external ear, partial		+	\$3,862.11	
69120	Removal of external ear		+	\$5,907.64	
69140	Remove ear canal lesion(s)		+	\$5,907.64	
69145	Remove ear canal lesion(s)		+	\$3,862.11	
69150	Extensive ear canal surgery		+	\$1,744.68	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 55 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
69200	Clear outer ear canal			\$170.98	
69205	Clear outer ear canal		+	\$5,085.32	
69210	Remove impacted ear wax			\$170.98	
69220	Clean out mastoid cavity		+	\$206.25	
69222	Clean out mastoid cavity		+	\$4,123.29	
69300	Revise external ear		+	\$5,907.64	
69310	Rebuild outer ear canal		+	\$9,418.88	
69320	Rebuild outer ear canal		+	\$9,418.88	
69399	Outer ear surgery procedure		+	\$484.51	
69400	Inflate middle ear canal		+	\$484.51	
69401	Inflate middle ear canal		+	\$484.51	
69405	Catheterize middle ear canal		+	\$1,744.68	
69410	Inset middle ear (baffle)		+	\$484.51	
69420	Incision of eardrum		+	\$1,744.68	
69421	Incision of eardrum		+	\$4,123.29	
69424	Remove ventilating tube		+	\$1,744.68	
69433	Create eardrum opening		+	\$1,744.68	
69436	Create eardrum opening		+	\$4,123.29	
69440	Exploration of middle ear		+	\$5,907.64	
69450	Eardrum revision		+	\$9,418.88	
69501	Mastoidectomy		+	\$9,418.88	
69502	Mastoidectomy		+	\$5,907.64	
69505	Remove mastoid structures		+	\$9,418.88	
69511	Extensive mastoid surgery		+	\$9,418.88	
69530	Extensive mastoid surgery		+	\$9,418.88	
69540	Remove ear lesion		+	\$4,123.29	
69550	Remove ear lesion		+	\$9,418.88	
69552	Remove ear lesion		+	\$9,418.88	
69601	Mastoid surgery revision		+	\$9,418.88	
69602	Mastoid surgery revision		+	\$9,418.88	
69603	Mastoid surgery revision		+	\$9,418.88	
69604	Mastoid surgery revision		+	\$9,418.88	
69605	Mastoid surgery revision		+	\$9,418.88	
69610	Repair of eardrum		+	\$5,907.64	
69620	Repair of eardrum		+	\$5,907.64	
69631	Repair eardrum structures		+	\$9,418.88	
69632	Rebuild eardrum structures		+	\$9,418.88	
69633	Rebuild eardrum structures		+	\$9,418.88	
69635	Repair eardrum structures		+	\$9,418.88	
69636	Rebuild eardrum structures		+	\$9,418.88	
69637	Rebuild eardrum structures		+	\$9,418.88	
69641	Revise middle ear & mastoid		+	\$9,418.88	
69642	Revise middle ear & mastoid		+	\$9,418.88	
69643	Revise middle ear & mastoid		+	\$9,418.88	
69644	Revise middle ear & mastoid		+	\$9,418.88	
69645	Revise middle ear & mastoid		+	\$9,418.88	
69646	Revise middle ear & mastoid		+	\$9,418.88	
69650	Release middle ear bone		+	\$5,907.64	
69660	Revise middle ear bone		+	\$9,418.88	
69661	Revise middle ear bone		+	\$9,418.88	
69662	Revise middle ear bone		+	\$9,418.88	
69666	Repair middle ear structures		+	\$9,418.88	
69667	Repair middle ear structures		+	\$9,418.88	
69670	Remove mastoid air cells		+	\$9,418.88	
69676	Remove middle ear nerve		+	\$9,418.88	
69700	Close mastoid fistula		+	\$9,418.88	
69711	Remove/repair hearing aid		+	\$9,418.88	
69714	Implant temple bone w/stimulat		+	\$9,418.88	
69715	Temple bone implnt w/stimulat		+	\$9,418.88	
69717	Temple bone implant revision		+	\$9,418.88	
69718	Revise temple bone implant		+	\$9,418.88	
69720	Release facial nerve		+	\$9,418.88	
69725	Release facial nerve		+	\$9,418.88	
69740	Repair facial nerve		+	\$9,418.88	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 56 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
69745	Repair facial nerve		+	\$9,418.88	
69799	Middle ear surgery procedure		+	\$4,123.29	
69801	Incise inner ear		+	\$9,418.88	
69802	Incise inner ear		+	\$9,418.88	
69805	Explore inner ear		+	\$9,418.88	
69806	Explore inner ear		+	\$9,418.88	
69820	Establish inner ear window		+	\$9,418.88	
69840	Revise inner ear window		+	\$9,418.88	
69905	Remove inner ear		+	\$9,418.88	
69910	Remove inner ear & mastoid		+	\$9,418.88	
69915	Incise inner ear nerve		+	\$9,418.88	
69930	Implant cochlear device		+	\$42,869.90	
69949	Inner ear surgery procedure		+	\$4,123.29	
69955	Release facial nerve		+	\$9,418.88	
69960	Release inner ear canal		+	\$9,418.88	
69979	Temporal bone surgery		+	\$484.51	
70010	Contrast x-ray of brain	b		\$1,040.79	
70015	Contrast x-ray of brain	b		\$1,040.79	
70030	X-ray eye for foreign body	b		\$208.01	
70100	X-ray exam of jaw	b		\$208.01	
70110	X-ray exam of jaw	b		\$208.01	
70120	X-ray exam of mastoids	b		\$208.01	
70130	X-ray exam of mastoids	b		\$208.01	
70134	X-ray exam of middle ear	b		\$380.44	
70140	X-ray exam of facial bones	b		\$208.01	
70150	X-ray exam of facial bones	b		\$208.01	
70160	X-ray exam of nasal bones	b		\$208.01	
70170	X-ray exam of tear duct	b		\$638.02	
70190	X-ray exam of eye sockets	b		\$208.01	
70200	X-ray exam of eye sockets	b		\$208.01	
70210	X-ray exam of sinuses	b		\$208.01	
70220	X-ray exam of sinuses	b		\$208.01	
70240	X-ray exam, pituitary saddle	b		\$208.01	
70250	X-ray exam of skull	b		\$208.01	
70260	X-ray exam of skull	b		\$380.44	
70300	X-ray exam of teeth	b		\$220.00	
70310	X-ray exam of teeth	b		\$220.00	
70320	Full mouth x-ray of teeth	b		\$220.00	
70328	X-ray exam of jaw joint	b		\$208.01	
70330	X-ray exam of jaw joints	b		\$208.01	
70332	X-ray exam of jaw joint	b		\$956.24	
70336	Magnetic image, jaw joint	b		\$1,852.70	
70350	X-ray head for orthodontia	b		\$208.01	
70355	Panoramic x-ray of jaws	b		\$208.01	
70360	X-ray exam of neck	b		\$208.01	
70370	Throat x-ray & fluoroscopy	b		\$413.01	
70371	Speech evaluation, complex	b		\$413.01	
70373	Contrast x-ray of larynx	b		\$638.02	
70380	X-ray exam of salivary gland	b		\$208.01	
70390	X-ray exam of salivary duct	b		\$878.93	
70450	Ct head/brain w/o dye	b		\$1,189.62	
70460	Ct head/brain w/dye	b		\$1,591.00	
70470	Ct head/brain w/o & w/ dye	b		\$1,887.00	
70480	Ct orbit/ear/fossa w/o dye	b		\$1,189.62	
70481	Ct orbit/ear/fossa w/dye	b		\$1,591.00	
70482	Ct orbit/ear/fossa w/o&w dye	b		\$1,887.00	
70486	Ct maxillofacial w/o dye	b		\$1,189.62	
70487	Ct maxillofacial w/dye	b		\$1,591.00	
70488	Ct maxillofacial w/o & w dye	b		\$1,887.00	
70490	Ct soft tissue neck w/o dye	b		\$1,189.62	
70491	Ct soft tissue neck w/dye	b		\$1,591.00	
70492	Ct soft tissue neck w/o & w/dye	b		\$1,887.00	
70496	Ct angiography, head	b		\$1,714.68	
70498	Ct angiography, neck	b		\$1,714.68	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 57 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
70540	Mri orbit/face/neck w/o dye	b		\$1,987.98	
70542	Mri orbit/face/neck w/dye	b		\$2,076.33	
70543	Mri orbit/face/neck w/o & w dye	b		\$2,998.23	
70544	Mr angiography head w/o dye	b		\$1,987.98	
70545	Mr angiography head w/dye	b		\$2,076.33	
70546	Mr angiograph head w/o&w dye	b		\$2,998.23	
70547	Mr angiography neck w/o dye	b		\$1,987.98	
70548	Mr angiography neck w/dye	b		\$2,076.33	
70549	Mr angiograph neck w/o&w dye	b		\$2,998.23	
70551	Mri brain w/o dye	b		\$1,987.98	
70552	Mri brain w/ dye	b		\$2,076.33	
70553	Mri brain w/o & w/ dye	b		\$2,998.23	
70557	Mri brain w/o dye	b		\$1,987.98	
70558	Mri brain w/ dye	b		\$2,076.33	
70559	Mri brain w/o & w/ dye	b		\$2,998.23	
71010	Chest x-ray	b		\$208.01	
71015	Chest x-ray	b		\$208.01	
71020	Chest x-ray	b		\$208.01	
71021	Chest x-ray	b		\$208.01	
71022	Chest x-ray	b		\$208.01	
71023	Chest x-ray and fluoroscopy	b		\$413.01	
71030	Chest x-ray	b		\$208.01	
71034	Chest x-ray and fluoroscopy	b		\$413.01	
71035	Chest x-ray	b		\$208.01	
71040	Contrast x-ray of bronchi	b		\$638.02	
71060	Contrast x-ray of bronchi	b		\$878.93	
71090	X-ray & pacemaker insertion	b		\$413.01	
71100	X-ray exam of ribs	b		\$208.01	
71101	X-ray exam of ribs/chest	b		\$208.01	
71110	X-ray exam of ribs	b		\$208.01	
71111	X-ray exam of ribs/ chest	b		\$380.44	
71120	X-ray exam of breastbone	b		\$208.01	
71130	X-ray exam of breastbone	b		\$208.01	
71250	Ct thorax w/o dye	b		\$1,189.62	
71260	Ct thorax w/dye	b		\$1,591.00	
71270	Ct thorax w/o & w/ dye	b		\$1,887.00	
71275	Ct angiography, chest	b		\$1,714.68	
71550	Mri chest w/o dye	b		\$1,987.98	
71551	Mri chest w/dye	b		\$2,076.33	
71552	Mri chest w/o & w/dye	b		\$2,998.23	
71555	Mri angio chest w or w/o dye	b		\$3,185.28	MDR
72010	X-ray exam of spine	b		\$380.44	
72020	X-ray exam of spine	b		\$208.01	
72040	X-ray exam of neck spine	b		\$208.01	
72050	X-ray exam of neck spine	b		\$380.44	
72052	X-ray exam of neck spine	b		\$380.44	
72069	X-ray exam of trunk spine	b		\$208.01	
72070	X-ray exam of thoracic spine	b		\$208.01	
72072	X-ray exam of thoracic spine	b		\$208.01	
72074	X-ray exam of thoracic spine	b		\$208.01	
72080	X-ray exam of trunk spine	b		\$208.01	
72090	X-ray exam of trunk spine	b		\$380.44	
72100	X-ray exam of lower spine	b		\$208.01	
72110	X-ray exam of lower spine	b		\$380.44	
72114	X-ray exam of lower spine	b		\$380.44	
72120	X-ray exam of lower spine	b		\$208.01	
72125	Ct neck spine w/o dye	b		\$1,189.62	
72126	Ct neck spine w/dye	b		\$1,591.00	
72127	Ct neck spine w/o & w/dye	b		\$1,887.00	
72128	Ct chest spine w/o dye	b		\$1,189.62	
72129	Ct chest spine w/dye	b		\$1,591.00	
72130	Ct chest spine w/o & w/dye	b		\$1,887.00	
72131	Ct lumbar spine w/o dye	b		\$1,189.62	
72132	Ct lumbar spine w/dye	b		\$1,591.00	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 58 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
72133	Ct lumbar spine w/o & w/dye	b		\$1,887.00	
72141	Mri neck spine w/o dye	b		\$1,987.98	
72142	Mri neck spine w/dye	b		\$2,076.33	
72146	Mri chest spine w/o dye	b		\$1,987.98	
72147	Mri chest spine w/dye	b		\$2,076.33	
72148	Mri lumbar spine w/o dye	b		\$1,987.98	
72149	Mri lumbar spine w/dye	b		\$2,076.33	
72156	Mri neck spine w/o & w/dye	b		\$2,998.23	
72157	Mri chest spine w/o & w/dye	b		\$2,998.23	
72158	Mri lumbar spine w/o & w/dye	b		\$2,998.23	
72159	Mr angio spine w/o&w/dye	b		\$3,313.72	MDR
72170	X-ray exam of pelvis	b		\$208.01	
72190	X-ray exam of pelvis	b		\$208.01	
72191	Ct angiograph pelv w/o&w/dye	b		\$1,714.68	
72192	Ct pelvis w/o dye	b		\$1,189.62	
72193	Ct pelvis w/dye	b		\$1,591.00	
72194	Ct pelvis w/o & w/dye	b		\$1,887.00	
72195	Mri pelvis w/o dye	b		\$1,987.98	
72196	Mri pelvis w/dye	b		\$2,076.33	
72197	Mri pelvis w/o & w/dye	b		\$2,998.23	
72198	Mr angio pelvis w/o & w/dye	b		\$3,107.96	MDR
72200	X-ray exam sacroiliac joints	b		\$208.01	
72202	X-ray exam sacroiliac joints	b		\$208.01	
72220	X-ray exam tailbone	b		\$208.01	
72240	Contrast x-ray of neck spine	b		\$1,040.79	
72255	Contrast x-ray, thorax spine	b		\$1,040.79	
72265	Contrast x-ray, lower spine	b		\$1,040.79	
72270	Contrast x-ray, spine	b		\$1,040.79	
72275	Epidurography	b		\$1,040.79	
72285	X-ray c/t spine disk	b		\$3,388.37	
72295	X-ray of lower spine disk	b		\$3,388.37	
73000	X-ray exam of collar bone	b		\$208.01	
73010	X-ray exam of shoulder blade	b		\$208.01	
73020	X-ray exam of shoulder	b		\$208.01	
73030	X-ray exam of shoulder	b		\$208.01	
73040	Contrast x-ray of shoulder	b		\$956.24	
73050	X-ray exam of shoulders	b		\$208.01	
73060	X-ray exam of humerus	b		\$208.01	
73070	X-ray exam of elbow	b		\$208.01	
73080	X-ray exam of elbow	b		\$208.01	
73085	Contrast x-ray of elbow	b		\$956.24	
73090	X-ray exam of forearm	b		\$208.01	
73092	X-ray exam of arm, infant	b		\$208.01	
73100	X-ray exam of wrist	b		\$208.01	
73110	X-ray exam of wrist	b		\$208.01	
73115	Contrast x-ray of wrist	b		\$956.24	
73120	X-ray exam of hand	b		\$208.01	
73130	X-ray exam of hand	b		\$208.01	
73140	X-ray exam of finger(s)	b		\$208.01	
73200	Ct upper extremity w/o dye	b		\$1,189.62	
73201	Ct upper extremity w/dye	b		\$1,591.00	
73202	Ct uppr extremity w/o&w/dye	b		\$1,887.00	
73206	Ct angio upr extrm w/o&w/dye	b		\$1,714.68	
73218	Mri upper extremity w/o dye	b		\$1,987.98	
73219	Mri upper extremity w/dye	b		\$2,076.33	
73220	Mri uppr extremity w/o&w/dye	b		\$2,998.23	
73221	Mri joint upr extrem w/o dye	b		\$1,987.98	
73222	Mri joint upr extrem w/dye	b		\$2,076.33	
73223	Mri joint upr extr w/o&w/dye	b		\$2,998.23	
73225	Mr angio upr extr w/o&w/dye	b		\$2,197.79	MDR
73500	X-ray exam of hip	b		\$208.01	
73510	X-ray exam of hip	b		\$208.01	
73520	X-ray exam of hips	b		\$208.01	
73525	Contrast x-ray of hip	b		\$956.24	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 59 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
73530	X-ray exam of hip	b		\$380.44	
73540	X-ray exam of pelvis & hips	b		\$208.01	
73542	X-ray exam, sacroiliac joint	b		\$956.24	
73550	X-ray exam of thigh	b		\$208.01	
73560	X-ray exam of knee, 1 or 2	b		\$208.01	
73562	X-ray exam of knee, 3	b		\$208.01	
73564	X-ray exam, knee, 4 or more	b		\$208.01	
73565	X-ray exam of knees	b		\$208.01	
73580	Contrast x-ray of knee joint	b		\$956.24	
73590	X-ray exam of lower leg	b		\$208.01	
73592	X-ray exam of leg, infant	b		\$208.01	
73600	X-ray exam of ankle	b		\$208.01	
73610	X-ray exam of ankle	b		\$208.01	
73615	Contrast x-ray of ankle	b		\$956.24	
73620	X-ray exam of foot	b		\$208.01	
73630	X-ray exam of foot	b		\$208.01	
73650	X-ray exam of heel	b		\$208.01	
73660	X-ray exam of toe(s)	b		\$208.01	
73700	Ct lower extremity w/o dye	b		\$1,189.62	
73701	Ct lower extremity w/dye	b		\$1,591.00	
73702	Ct lwr extremity w/o&w/dye	b		\$1,887.00	
73706	Ct angio lwr extr w/o&w/dye	b		\$1,714.68	
73718	Mri lower extremity w/o dye	b		\$1,987.98	
73719	Mri lower extremity w/dye	b		\$2,076.33	
73720	Mri lwr extremity w/o&w/dye	b		\$2,998.23	
73721	Mri jint of lwr extre w/o dye	b		\$1,987.98	
73722	Mri joint of lwr extr w/dye	b		\$2,076.33	
73723	Mri joint lwr extr w/o&w/dye	b		\$2,998.23	
73725	Mr ang lwr ext w or w/o dye	b		\$2,182.33	MDR
74000	X-ray exam of abdomen	b		\$208.01	
74010	X-ray exam of abdomen	b		\$208.01	
74020	X-ray exam of abdomen	b		\$208.01	
74022	X-ray exam series, abdomen	b		\$380.44	
74150	Ct abdomen w/o dye	b		\$1,189.62	
74160	Ct abdomen w/dye	b		\$1,591.00	
74170	Ct abdomen w/o & w/dye	b		\$1,887.00	
74175	Ct angio abdom w/o & w/dye	b		\$1,714.68	
74181	Mri abdomen w/o dye	b		\$1,987.98	
74182	Mri abdomen w/dye	b		\$2,076.33	
74183	Mri abdomen w/o & w/dye	b		\$2,998.23	
74185	Mri angio, abdom w or w/o dye	b		\$3,662.25	MDR
74190	X-ray exam of pentoneum	b		\$638.02	
74210	Contrst x-ray exam of throat	b		\$485.24	
74220	Contrast x-ray, esophagus	b		\$485.24	
74230	Cine/vid x-ray, throat/esoph	b		\$485.24	
74235	Remove esophagus obstruction	b		\$835.49	
74240	X-ray exam, upper gi tract	b		\$485.24	
74241	X-ray exam, upper gi tract	b		\$485.24	
74245	X-ray exam, upper gi tract	b		\$712.97	
74246	Contrst x-ray uppr gi tract	b		\$485.24	
74247	Contrst x-ray uppr gi tract	b		\$485.24	
74249	Contrst x-ray uppr gi tract	b		\$712.97	
74250	X-ray exam of small bowel	b		\$485.24	
74251	X-ray exam of small bowel	b		\$712.97	
74260	X-ray exam of small bowel	b		\$712.97	
74270	Contrast x-ray exam of colon	b		\$485.24	
74280	Contrast x-ray exam of colon	b		\$712.97	
74283	Contrast x-ray exam of colon	b		\$485.24	
74290	Contrast x-ray, gallbladder	b		\$485.24	
74291	Contrast x-rays, gallbladder	b		\$485.24	
74300	X-ray bile ducts/pancreas	b		\$638.02	
74301	X-rays at surgery add-on	b		\$638.02	
74305	X-ray bile ducts/pancreas	b		\$638.02	
74320	Contrast x-ray of bile ducts	b		\$878.93	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 60 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
74327	X-ray bile stone removal	b		\$835.49	
74340	X-ray guide for GI tube	b		\$413.01	
74350	X-ray guide, stomach tube	b		\$638.02	
74355	X-ray guide, intestinal tube	b		\$638.02	
74360	X-ray guide, GI dilation	b		\$835.49	
74363	X-ray, bile duct dilation	b		\$2,250.82	
74400	Contrst x-ray, urinary tract	b		\$787.43	
74410	Contrst x-ray, urinary tract	b		\$787.43	
74415	Contrst x-ray, urinary tract	b		\$787.43	
74420	Contrst x-ray, urinary tract	b		\$787.43	
74425	Contrst x-ray, urinary tract	b		\$787.43	
74430	Contrast x-ray, bladder	b		\$787.43	
74440	X-ray, male genital tract	b		\$787.43	
74445	X-ray exam of penis	b		\$787.43	
74450	X-ray, urethra/bladder	b		\$787.43	
74455	X-ray, urethra/bladder	b		\$787.43	
74470	X-ray exam of kidney lesion	b		\$878.93	
74475	X-ray control, cath insert	b		\$2,250.82	
74480	X-ray control, cath insert	b		\$835.49	
74485	X-ray guide, GU dilation	b		\$835.49	
74710	X-ray measurement of pelvis	b		\$208.01	
74740	X-ray, female genital tract	b		\$878.93	
74742	X-ray, fallopian tube	b		\$638.02	
74775	X-ray exam of perineum	b		\$787.43	
75552	Heart mri for morph w/o dye	b		\$1,987.98	
75553	Heart mri for morph w/dye	b		\$2,076.33	
75554	Cardiac MRI/function	b		\$1,852.70	
75555	Cardiac MRI/limited study	b		\$1,852.70	
75600	Contrast x-ray exam of aorta	b		\$5,532.96	
75605	Contrast x-ray exam of aorta	b		\$5,532.96	
75625	Contrast x-ray exam of aorta	b		\$5,532.96	
75630	X-ray aorta, leg arteries	b		\$5,532.96	
75635	Ct angio abdominal arteries	b		\$1,714.68	
75650	Artery x-rays, head & neck	b		\$5,532.96	
75658	Artery x-rays, arm	b		\$5,532.96	
75660	Artery x-rays, head & neck	b		\$3,124.01	
75662	Artery x-rays, head & neck	b		\$3,124.01	
75665	Artery x-rays, head & neck	b		\$5,532.96	
75671	Artery x-rays, head & neck	b		\$5,532.96	
75676	Artery x-rays, neck	b		\$5,532.96	
75680	Artery x-rays, neck	b		\$5,532.96	
75685	Artery x-rays, spine	b		\$3,124.01	
75705	Artery x-rays, spine	b		\$3,124.01	
75710	Artery x-rays, arm/leg	b		\$5,532.96	
75716	Artery x-rays, arms/legs	b		\$5,532.96	
75722	Artery x-rays, kidney	b		\$5,532.96	
75724	Artery x-rays, kidneys	b		\$5,532.96	
75726	Artery x-rays, abdomen	b		\$5,532.96	
75731	Artery x-rays, adrenal gland	b		\$5,532.96	
75733	Artery x-rays, adrenals	b		\$5,532.96	
75736	Artery x-rays, pelvis	b		\$5,532.96	
75741	Artery x-rays, lung	b		\$3,124.01	
75743	Artery x-rays, lungs	b		\$5,532.96	
75746	Artery x-rays, lung	b		\$3,124.01	
75756	Artery x-rays, chest	b		\$3,124.01	
75774	Artery x-ray, each vessel	b		\$2,995.24	
75790	Visualize A-V shunt	b		\$1,926.04	
75801	Lymph vessel x-ray, arm/leg	b		\$878.93	
75803	Lymph vessel x-ray, arms/legs	b		\$878.93	
75805	Lymph vessel x-ray, trunk	b		\$878.93	
75807	Lymph vessel x-ray, trunk	b		\$878.93	
75809	Nonvascular shunt, x-ray	b		\$638.02	
75810	Vein x-ray, spleen/liver	b		\$3,124.01	
75820	Vein x-ray, arm/leg	b		\$1,926.04	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 61 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
75822	Vein x-ray, arms/legs	b		\$1,926.04	
75825	Vein x-ray, trunk	b		\$3,124.01	
75827	Vein x-ray, chest	b		\$3,124.01	
75831	Vein x-ray, kidney	b		\$1,894.25	
75833	Vein x-ray, kidneys	b		\$3,124.01	
75840	Vein x-ray, adrenal gland	b		\$1,894.25	
75842	Vein x-ray, adrenal glands	b		\$1,894.25	
75860	Vein x-ray, neck	b		\$1,894.25	
75870	Vein x-ray, skull	b		\$1,894.25	
75872	Vein x-ray, skull	b		\$1,894.25	
75880	Vein x-ray, eye socket	b		\$1,894.25	
75885	Vein x-ray, liver	b		\$3,124.01	
75887	Vein x-ray, liver	b		\$5,532.96	
75889	Vein x-ray, liver	b		\$3,124.01	
75891	Vein x-ray, liver	b		\$3,124.01	
75894	X-rays, transcath therapy	b		\$2,250.82	
75896	X-rays, transcath therapy	b		\$2,250.82	
75898	Follow-up angiography	b		\$878.93	
75900	Arterial catheter exchange	b		\$1,187.56	MDR
75901	Remove cva device obstruct	b		\$878.93	
75902	Remove cva lumen obstruct	b		\$638.02	
75940	X-ray placement, vein filter	b		\$1,292.17	
75945	Intravascular us	b		\$654.62	
75946	Intravascular us add-on	b		\$654.62	
75952	Endovasc repair abdom aorta	b		\$3,855.87	MDR
75960	Transcatheter intro, stent	b		\$5,532.96	
75961	Retrieval, broken catheter	b		\$5,532.96	
75962	Repair arterial blockage	b		\$5,532.96	
75964	Repair artery blockage, each	b		\$5,532.96	
75966	Repair arterial blockage	b		\$5,532.96	
75968	Repair artery blockage, each	b		\$5,532.96	
75970	Vascular biopsy	b		\$5,532.96	
75978	Repair venous blockage	b		\$2,995.24	
75980	Contrast xray exam bile duct	b		\$835.49	
75982	Contrast xray exam bile duct	b		\$2,250.82	
75984	Xray control catheter change	b		\$878.93	
75992	Atherectomy, x-ray exam	b		\$5,532.96	
75993	Atherectomy, x-ray exam	b		\$5,532.96	
75994	Atherectomy, x-ray exam	b		\$5,532.96	
75995	Atherectomy, x-ray exam	b		\$5,532.96	
75996	Atherectomy, x-ray exam	b		\$5,532.96	
76000	Fluoroscope examination	b		\$413.01	
76006	X-ray stress view	b		\$208.01	
76010	X-ray, nose to rectum	b		\$208.01	
76012	Percut vertebroplasty fluor	b		\$1,040.79	
76013	Percut vertebroplasty, ct	b		\$1,040.79	
76020	X-rays for bone age	b		\$208.01	
76040	X-rays, bone evaluation	b		\$208.01	
76061	X-rays, bone survey	b		\$380.44	
76062	X-rays, bone survey	b		\$380.44	
76065	X-rays, bone evaluation	b		\$380.44	
76066	Joint survey, single view	b		\$208.01	
76070	CT scan, bone density study	b		\$339.90	
76071	Ct bone density, peripheral	b		\$594.25	
76075	Dexa, axial skeleton study	b		\$339.90	
76076	Dexa, peripheral study	b		\$211.71	
76078	Radiographic absorptiometry	b		\$380.44	
76080	X-ray exam of fistula	b		\$638.02	
76082	Computer mammogram add-on	b		\$44.44	
76086	X-ray of mammary duct	b		\$638.02	
76088	X-ray of mammary ducts	b		\$638.02	
76090	Mammogram, one breast	b		\$183.08	
76091	Mammogram, both breasts	b		\$183.08	
76093	Magnetic image, breast	b		\$3,711.35	MDR

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 62 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
76094	Magnetic image, both breasts	b		\$4,875.35	MDR
76095	Stereotactic breast biopsy	b		\$1,292.17	
76096	X-ray of needle wire, breast	b		\$1,018.27	
76098	X-ray exam, breast specimen	b		\$208.01	
76100	X-ray exam of body section	b		\$380.44	
76101	Complex body section x-ray	b		\$878.93	
76102	Complex body section x-rays	b		\$878.93	
76120	Cine/video x-rays	b		\$413.01	
76125	Cine/video x-rays add-on	b		\$208.01	
76150	X-ray exam, dry process	e		\$208.01	
76355	Ct scan for localization	b		\$1,591.00	
76360	Ct scan for needle biopsy	b		\$1,591.00	
76362	Ct guide for tissue ablation	b		\$1,189.62	
76370	Ct scan for therapy guide	b		\$594.25	
76375	3d/holograph reconstr add-on	b		\$594.25	
76380	CAT scan follow-up study	b		\$594.25	
76390	Mr spectroscopy	b		\$1,505.95	SAF
76393	Mr guidance for needle place	b		\$1,852.70	
76394	Mri for tissue ablation	b		\$1,852.70	
76400	Magnetic image, bone marrow	b		\$1,852.70	
76496	Fluoroscopic procedure			\$413.01	
76497	Ct procedure			\$594.25	
76498	Mri procedure			\$1,852.70	
76499	Radiographic procedure			\$208.01	
76506	Echo exam of head	b		\$560.10	
76511	Echo exam of eye	b		\$560.10	
76512	Echo exam of eye	b		\$560.10	
76513	Echo exam of eye, water bath	b		\$364.05	
76514	Echo exam of eye, thickness	b		\$364.05	
76516	Echo exam of eye	b		\$560.10	
76519	Echo exam of eye	b		\$560.10	
76529	Echo exam of eye	b		\$364.05	
76536	Us exam of head and neck	b		\$560.10	
76604	Us exam, chest, b-scan	b		\$560.10	
76645	Us exam, breast(s)	b		\$364.05	
76700	Us exam, abdom, complete	b		\$560.10	
76705	Echo exam of abdomen	b		\$560.10	
76770	Us exam abdo back wall, comp	b		\$560.10	
76775	Us exam abdo back wall, lim	b		\$560.10	
76778	Us exam kidney transplant	b		\$560.10	
76800	Us exam, spinal canal	b		\$560.10	
76801	Ob us < 14 wks, single fetus	b		\$364.05	
76802	Ob us < 14 wks, add'l fetus	b		\$364.05	
76805	Us exam, pg uterus, compl	b		\$560.10	
76810	Us exam, pg uterus, mult	b		\$364.05	
76811	Ob.us, detailed, snl fetus	b		\$654.62	
76812	Ob us, detailed, add'l fetus	b		\$560.10	
76815	Us exam, pg uterus limit	b		\$364.05	
76816	Us exam pg uterus repeat	b		\$364.05	
76817	Transvaginal us, obstetric	b		\$364.05	
76818	Fetal biophys profil w/nst	b		\$560.10	
76819	Fetal biophys profil w/o nst	b		\$560.10	
76825	Echo exam of fetal heart	b		\$450.38	
76826	Echo exam of fetal heart	b		\$394.57	
76827	Echo exam of fetal heart	b		\$450.38	
76828	Echo exam of fetal heart	b		\$394.57	
76830	Transvaginal us, non-ob	b		\$560.10	
76831	Echo exam, uterus	b		\$560.10	
76856	Us exam, pelvic, complete	b		\$560.10	
76857	Us exam, pelvic, limited	b		\$364.05	
76870	Us exam, scrotum	b		\$560.10	
76872	Us, transrectal	b		\$560.10	
76873	Ethograp trans r, pros study	b		\$560.10	
76880	Us exam, extremity	b		\$560.10	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 63 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
76885	Us exam infant hips, dynamic	b		\$560.10	
76886	Us exam infant hips, static	b		\$560.10	
76930	Echo guide, cardiocentesis	b		\$381.26	
76932	Echo guide for heart biopsy	b		\$381.26	
76936	Echo guide for artery repair	b		\$381.26	
76940	Us guide, tissue ablation	b		\$381.26	
76941	Echo guide for transfusion	b		\$381.26	
76942	Echo guide for biopsy	b		\$381.26	
76945	Echo guide, villus sampling	b		\$381.26	
76946	Echo guide for amniocentesis	b		\$381.26	
76948	Echo guide, ova aspiration	b		\$381.26	
76950	Echo guidance radiotherapy	b		\$381.26	
76965	Echo guidance radiotherapy	b		\$381.26	
76970	Ultrasound exam follow-up	b		\$364.05	
76975	GI endoscopic ultrasound	b		\$560.10	
76977	Us bone density measure	b		\$170.98	
76986	Ultrasound guide intraoper	b		\$560.10	
76999	Echo examination procedure			\$364.05	
77280	Set radiation therapy field	b		\$432.89	
77285	Set radiation therapy field	b		\$1,025.38	
77290	Set radiation therapy field	b		\$1,025.38	
77295	Set radiation therapy field	b		\$4,002.02	
77300	Radiation therapy dose plan	b		\$432.89	
77301	Radiotherapy dose plan, imrt	b		\$3,738.61	
77305	Teletx isodose plan simple	b		\$432.89	
77310	Teletx isodose plan intermed	b		\$432.89	
77315	Teletx isodose plan complex	b		\$1,025.38	
77321	Special teletx port plan	b		\$1,025.38	
77326	Radiation therapy dose plan	b		\$1,025.38	
77327	Brachytx isodose calc interm	b		\$1,025.38	
77328	Brachytx isodose plan compl	b		\$1,025.38	
77331	Special radiation dosimetry	b		\$432.89	
77332	Radiation treatment aid(s)	b		\$766.36	
77333	Radiation treatment aid(s)	b		\$766.36	
77334	Radiation treatment aid(s)	b		\$766.36	
77336	Radiation physics consult	e		\$432.89	
77370	Radiation physics consult	e		\$1,025.38	
77399	External radiation dosimetry	e		\$432.89	
77401	Radiation treatment delivery	e		\$378.48	
77402	Radiation treatment delivery	e		\$378.48	
77403	Radiation treatment delivery	e		\$378.48	
77404	Radiation treatment delivery	e		\$378.48	
77406	Radiation treatment delivery	e		\$378.48	
77407	Radiation treatment delivery	e		\$378.48	
77408	Radiation treatment delivery	e		\$378.48	
77409	Radiation treatment delivery	e		\$378.48	
77411	Radiation treatment delivery	e		\$378.48	
77412	Radiation treatment delivery	e		\$553.63	
77413	Radiation treatment delivery	e		\$553.63	
77414	Radiation treatment delivery	e		\$553.63	
77416	Radiation treatment delivery	e		\$553.63	
77417	Radiology port film(s)	e		\$208.01	
77418	Radiation tx delivery, imrt	e		\$1,572.75	
77470	Special radiation treatment	b		\$1,681.09	
77520	Proton trmt, simple w/o comp	e		\$2,838.72	
77522	Proton trmt, simple w/comp	e		\$2,838.72	
77523	Proton trmt, intermediate	c		\$4,178.45	
77525	Proton treatment, complex	c		\$4,178.45	
77600	Hyperthermia treatment	b		\$1,343.29	
77605	Hyperthermia treatment	b		\$1,343.29	
77610	Hyperthermia treatment	b		\$1,343.29	
77615	Hyperthermia treatment	b		\$1,343.29	
77620	Hyperthermia treatment	b		\$1,343.29	
77750	Infuse radioactive materials	b		\$378.48	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 64 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
77761	Apply intrcav radiat simple	b		\$1,068.97	
77762	Apply intrcav radiat interm	b		\$1,068.97	
77763	Apply intrcav radiat compl	b		\$1,068.97	
77776	Apply interstit radiat simpl	b		\$1,068.97	
77777	Apply interstit radiat inter	b		\$1,068.97	
77778	Apply interstit radiat compl	b		\$2,985.19	
77781	High intensity brachytherapy	b		\$4,028.49	
77782	High intensity brachytherapy	b		\$4,028.49	
77783	High intensity brachytherapy	b		\$4,028.49	
77784	High intensity brachytherapy	b		\$4,028.49	
77789	Apply surface radiation	b		\$378.48	
77799	Radium/radioisotope therapy			\$4,028.49	
78000	Thyroid, single uptake	b		\$476.41	
78001	Thyroid, multiple uptakes	b		\$476.41	
78003	Thyroid suppress/stimul	b		\$476.41	
78006	Thyroid imaging with uptake	b		\$814.21	
78007	Thyroid image, mult uptakes	b		\$932.39	
78010	Thyroid imaging	b		\$814.21	
78011	Thyroid imaging with flow	b		\$814.21	
78015	Thyroid met imaging	b		\$1,282.44	
78016	Thyroid met imaging/studies	b		\$1,282.44	
78018	Thyroid met imaging, body	b		\$1,282.44	
78020	Thyroid met uptake	b		\$539.43	
78070	Parathyroid nuclear imaging	b		\$932.39	
78075	Adrenal nuclear imaging	b		\$932.39	
78099	Endocrine nuclear procedure			\$814.21	
78102	Bone marrow imaging, ltd	b		\$1,109.65	
78103	Bone marrow imaging, mult	b		\$1,109.65	
78104	Bone marrow imaging, body	b		\$1,109.65	
78110	Plasma volume, single	b		\$1,294.10	
78111	Plasma volume, multiple	b		\$1,294.10	
78120	Red cell mass, single	b		\$1,294.10	
78121	Red cell mass, multiple	b		\$1,294.10	
78122	Blood volume	b		\$1,294.10	
78130	Red cell survival study	b		\$1,294.10	
78135	Red cell survival kinetics	b		\$1,294.10	
78140	Red cell sequestration	b		\$1,294.10	
78160	Plasma iron turnover	b		\$1,294.10	
78162	Radioiron absorption exam	b		\$1,294.10	
78170	Red cell iron utilization	b		\$1,294.10	
78172	Total body iron estimation	b		\$1,294.10	
78185	Spleen imaging	b		\$1,109.65	
78190	Platelet survival, kinetics	b		\$476.41	
78191	Platelet survival	b		\$476.41	
78195	Lymph system imaging	b		\$1,109.65	
78199	Blood/lymph nuclear exam			\$1,109.65	
78201	Liver imaging	b		\$1,275.43	
78202	Liver imaging with flow	b		\$1,275.43	
78205	Liver imaging (3D)	b		\$1,275.43	
78206	Liver image (3d) with flow	b		\$1,275.43	
78215	Liver and spleen imaging	b		\$1,275.43	
78216	Liver & spleen image/flow	b		\$1,275.43	
78220	Liver function study	b		\$1,275.43	
78223	Hepatobiliary imaging	b		\$1,275.43	
78230	Salivary gland imaging	b		\$1,152.67	
78231	Serial salivary imaging	b		\$1,152.67	
78232	Salivary gland function exam	b		\$1,152.67	
78258	Esophageal motility study	b		\$1,152.67	
78261	Gastric mucosa imaging	b		\$1,152.67	
78262	Gastroesophageal reflux exam	b		\$1,152.67	
78264	Gastric emptying study	b		\$1,152.67	
78270	Vit B-12 absorption exam	b		\$476.41	
78271	Vit b-12 absrp exam, int fac	b		\$476.41	
78272	Vit B-12 absorp, combined	b		\$476.41	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 65 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
78278	Acute GI blood loss imaging	b		\$1,152.67	
78282	GI protein loss exam	b		\$1,152.67	
78290	Meckel's divert exam	b		\$1,152.67	
78291	Leveen/shunt patency exam	b		\$1,152.67	
78299	GI nuclear procedure	b		\$1,152.67	
78300	Bone imaging, limited area	b		\$1,152.66	
78305	Bone imaging, multiple areas	b		\$1,152.66	
78306	Bone imaging, whole body	b		\$1,152.66	
78315	Bone imaging, 3 phase	b		\$1,152.66	
78320	Bone imaging (3D)	b		\$1,152.66	
78350	Bone mineral, single photon	b		\$380.44	
78351	Bone mineral, dual photon	b		\$550.42	MDR
78399	Musculoskeletal nuclear exam	b		\$1,152.66	
78414	Non-imaging heart function	b		\$1,315.59	
78428	Cardiac shunt imaging	b		\$1,315.59	
78445	Vascular flow imaging	b		\$647.21	
78455	Venous thrombosis study	b		\$647.21	
78456	Acute venous thrombus image	b		\$647.21	
78457	Venous thrombosis imaging	b		\$647.21	
78458	Ven thrombosis images, bilat	b		\$647.21	
78459	Heart muscle imaging (PET)	b		\$4,128.70	
78460	Heart muscle blood, single	b		\$1,315.59	
78461	Heart muscle blood, multiple	b		\$2,048.07	
78464	Heart image (3d), single	b		\$1,315.59	
78465	Heart image (3d), multiple	b		\$2,048.07	
78466	Heart infarct image	b		\$1,315.59	
78468	Heart infarct image (ef)	b		\$1,315.59	
78469	Heart infarct image (3D)	b		\$1,315.59	
78472	Gated heart, planar, single	b		\$1,315.59	
78473	Gated heart, multiple	b		\$1,298.64	
78478	Heart wall motion add-on	b		\$539.43	
78480	Heart function add-on	b		\$539.43	
78481	Heart first pass, single	b		\$1,315.59	
78483	Heart first pass, multiple	b		\$1,298.64	
78494	Heart image, spect	b		\$1,315.59	
78496	Heart first pass add-on	b		\$539.43	
78499	Cardiovascular nuclear exam	b		\$1,349.27	MedStat
78580	Lung perfusion imaging	b		\$984.31	
78584	Lung V/Q image single breath	b		\$1,600.40	
78585	Lung V/Q imaging	b		\$1,600.40	
78586	Aerosol lung image, single	b		\$984.31	
78587	Aerosol lung image, multiple	b		\$984.31	
78588	Perfusion lung image	b		\$1,600.40	
78591	Vent image, 1 breath, 1 proj	b		\$984.31	
78593	Vent image, 1 proj, gas	b		\$984.31	
78594	Vent image, mult proj, gas	b		\$984.31	
78596	Lung differential function	b		\$1,600.40	
78599	Respiratory nuclear exam	b		\$984.31	
78600	Brain imaging, ltd static	b		\$1,577.35	
78601	Brain imaging, ltd w/flow	b		\$1,577.35	
78605	Brain imaging, complete	b		\$1,577.35	
78606	Brain imaging, compl w/flow	b		\$1,577.35	
78607	Brain imaging (3D)	b		\$1,577.35	
78610	Brain flow imaging only	b		\$1,577.35	
78615	Cerebral vascular flow image	b		\$1,577.35	
78630	Cerebrospinal fluid scan	b		\$1,102.38	
78635	CSF ventriculography	b		\$1,102.38	
78645	CSF shunt evaluation	b		\$1,102.38	
78647	Cerebrospinal fluid scan	b		\$1,102.38	
78650	CSF leakage imaging	b		\$1,102.38	
78660	Nuclear exam of tear flow	b		\$1,102.38	
78699	Nervous system nuclear exam	b		\$1,577.35	
78700	Kidney imaging, static	b		\$1,088.38	
78701	Kidney imaging with flow	b		\$1,088.38	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 66 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
78704	Imaging renogram	b		\$1,088.38	
78707	Kidney flow/function image	b		\$1,088.38	
78708	Kidney flow/function image	b		\$1,267.20	
78709	Kidney flow/function image	b		\$1,267.20	
78710	Kidney imaging (3D)	b		\$1,088.38	
78715	Renal vascular flow exam	b		\$1,088.38	
78725	Kidney function study	b		\$476.41	
78730	Urinary bladder retention	b		\$1,088.38	
78740	Ureteral reflux study	b		\$1,088.38	
78760	Testicular imaging	b		\$1,088.38	
78761	Testicular imaging/flow	b		\$1,088.38	
78799	Genitourinary nuclear exam	b		\$1,088.38	
78800	Tumor imaging, limited area	b		\$1,282.44	
78801	Tumor imaging, mult areas	b		\$1,282.44	
78802	Tumor imaging, whole body	b		\$1,282.44	
78803	Tumor imaging (3D)	b		\$1,282.44	
78804	Tumor imaging, whole body	b		\$2,858.94	
78805	Abscess imaging, ltd area	b		\$1,282.44	
78806	Abscess imaging, whole body	b		\$1,282.44	
78807	Nuclear localization/abscess	b		\$1,282.44	
78810	Tumor imaging (PET)	b		\$4,350.53	SAF
78999	Nuclear diagnostic exam			\$476.41	
79000	Init hyperthyroid therapy	b		\$1,043.37	
79001	Repeat hyperthyroid therapy	b		\$1,043.37	
79020	Thyroid ablation	b		\$1,043.37	
79030	Thyroid ablation, carcinoma	b		\$1,043.37	
79035	Thyroid metastatic therapy	b		\$1,043.37	
79100	Hematopoietic nuclear therapy	b		\$1,043.37	
79200	Intracavitary nuclear trmt	b		\$1,043.37	
79300	Interstitial nuclear therapy	b		\$1,043.37	
79400	Nonhemato nuclear therapy	b		\$1,043.37	
79403	Hematopoietic nuclear therapy	b		\$2,419.10	
79420	Intravascular nuclear ther	b		\$1,043.37	
79440	Nuclear joint therapy	b		\$1,043.37	
79999	Nuclear medicine therapy			\$1,043.37	
80050	General health panel			\$298.72	MDR
80500	Lab pathology consultation			\$125.22	
80502	Lab pathology consultation			\$76.22	
85060	Blood smear interpretation			\$76.22	
85097	Bone marrow interpretation			\$125.22	
86485	Skin test, candida			\$41.47	
86490	Coccidioidomycosis skin test	e		\$41.47	
86510	Histoplasmosis skin test	e		\$41.47	
86580	TB intradermal test	e		\$41.47	
86585	TB tine test	e		\$41.47	
86586	Skin test, unlisted			\$41.47	
86850	RBC antibody screen			\$79.73	
86860	RBC antibody elution			\$119.57	
86870	RBC antibody identification			\$119.57	
86880	Coombs test, direct			\$49.12	
86885	Coombs test, indirect, qual			\$49.12	
86886	Coombs test, indirect, titer			\$49.12	
86890	Autologous blood process			\$291.85	
86891	Autologous blood, op salvage			\$79.73	
86900	Blood typing, ABO			\$49.12	
86901	Blood typing, Rh (D)			\$49.12	
86903	Blood typing, antigen screen			\$79.73	
86904	Blood typing, patient serum			\$79.73	
86905	Blood typing, RBC antigens			\$79.73	
86906	Blood typing, Rh phenotype			\$79.73	
86911	Blood typing, antigen system			\$78.98	MDR
86920	Compatibility test			\$119.57	
86921	Compatibility test			\$79.73	
86922	Compatibility test			\$119.57	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 67 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
86927	Plasma, fresh frozen			\$119.57	
86930	Frozen blood prep			\$291.85	
86931	Frozen blood thaw			\$291.85	
86932	Frozen blood freeze/thaw			\$291.85	
86945	Blood product/irradiation			\$119.57	
86950	Leukocyte transfusion			\$291.85	
86965	Pooling blood platelets			\$119.57	
86970	RBC pretreatment			\$79.73	
86971	RBC pretreatment			\$79.73	
86972	RBC pretreatment			\$79.73	
86975	RBC pretreatment, serum			\$79.73	
86976	RBC pretreatment, serum			\$79.73	
86977	RBC pretreatment, serum			\$79.73	
86978	RBC pretreatment, serum			\$79.73	
86985	Split blood or products			\$291.85	
86999	Transfusion procedure			\$79.73	
88104	Cytopathology, fluids	b		\$125.22	
88106	Cytopathology, fluids	b		\$125.22	
88107	Cytopathology, fluids	b		\$125.22	
88108	Cytopath, concentrate tech	b		\$125.22	
88112	Cytopath, cell enhance tech	b		\$125.22	
88125	Forensic cytopathology	b		\$76.22	
88160	Cytopath smear, other source	b		\$76.22	
88161	Cytopath smear, other source	b		\$125.22	
88162	Cytopath smear, other source	b		\$125.22	
88172	Cytopathology eval of fna	b		\$125.22	
88173	Cytopath eval, fna, report	b		\$125.22	
88180	Cell marker study	b		\$125.22	
88182	Cell marker study	b		\$191.04	
88299	Cytogenetic study			\$76.22	
88300	Surgical path, gross	b		\$76.22	
88302	Tissue exam by pathologist	b		\$76.22	
88304	Tissue exam by pathologist	b		\$125.22	
88305	Tissue exam by pathologist	b		\$125.22	
88307	Tissue exam by pathologist	b		\$191.04	
88309	Tissue exam by pathologist	b		\$191.04	
88311	Decalcify tissue	b		\$76.22	
88312	Special stains	b		\$76.22	
88313	Special stains	b		\$76.22	
88314	Histochemical stain	b		\$76.22	
88318	Chemical histochemistry	b		\$76.22	
88319	Enzyme histochemistry	b		\$76.22	
88321	Microslide consultation			\$76.22	
88323	Microslide consultation	b		\$125.22	
88325	Comprehensive review of data			\$191.04	
88329	Path consult introp			\$76.22	
88331	Path consult intraop, 1 bloc	b		\$125.22	
88332	Path consult intraop, add'l	b		\$76.22	
88342	Immunohistochemistry	b		\$191.04	
88346	Immunofluorescent study	b		\$125.22	
88347	Immunofluorescent study	b		\$191.04	
88348	Electron microscopy	b		\$989.39	
88349	Scanning electron microscopy	b		\$989.39	
88355	Analysis, skeletal muscle	b		\$191.04	
88356	Analysis, nerve	b		\$191.04	
88358	Analysis, tumor	b		\$191.04	
88361	Immunohistochemistry, tumor	b		\$191.04	
88362	Nerve teasing preparations	b		\$191.04	
88365	Tissue hybridization	b		\$191.04	
89100	Sample intestinal contents			\$415.47	
89105	Sample intestinal contents			\$415.47	
89130	Sample stomach contents			\$415.47	
89132	Sample stomach contents			\$415.47	
89135	Sample stomach contents			\$415.47	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 68 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
89136	Sample stomach contents			\$415.47	
89140	Sample stomach contents			\$415.47	
89141	Sample stomach contents			\$415.47	
89220	Sputum specimen collection			\$125.22	
89230	Collect sweat for test			\$191.04	
89250	Cultr oocyte/embryo <4 days			\$248.88	
89251	Cultr oocyte/embryo <4 days			\$248.88	
89253	Embryo hatching			\$248.88	
89254	Oocyte identification			\$248.88	
89255	Prepare embryo for transfer			\$248.88	
89257	Sperm identification			\$248.88	
89258	Cryopreservation; embryo(s)			\$248.88	
89259	Cryopreservation, sperm			\$248.88	
89260	Sperm isolation, simple			\$248.88	
89261	Sperm isolation, complex			\$248.88	
89264	Identify sperm tissue			\$248.88	
89268	Insemination of oocytes			\$248.88	
89272	Extended culture of oocytes			\$248.88	
89280	Assist oocyte fertilization			\$248.88	
89281	Assist oocyte fertilization			\$248.88	
89290	Biopsy, oocyte polar body			\$248.88	
89291	Biopsy, oocyte polar body			\$248.88	
89335	Cryopreserve testicular tiss			\$248.88	
89342	Storage/year; embryo(s)			\$248.88	
89343	Storage/year; sperm/semen			\$248.88	
89344	Storage/year; reprod tissue			\$248.88	
89346	Storage/year; oocyte			\$248.88	
89352	Thawing cryopresrvd; embryo			\$248.88	
89353	Thawing cryopresrvd; sperm			\$248.88	
89354	Thaw cryoprsrvd; reprod tiss			\$248.88	
89356	Thawing cryopresrvd; oocyte			\$248.88	
90375	Rabies ig, im/sc			\$199.02	
90376	Rabies ig, heat treated			\$199.02	
90379	Rsv ig, iv			\$199.02	
90385	Rh ig, minidose, im			\$199.02	
90393	Vaccina ig, im			\$199.02	
90396	Vancella-zoster ig, im			\$199.02	
90586	Bcg vaccine, intravesical			\$199.02	
90636	Hep a/hep b vacc, adult im			\$71.28	
90655	Flu vaccine, 6-35 mo, im			\$18.64	
90657	Flu vaccine, 6-35 mo, im			\$18.64	SAF
90658	Flu vaccine, 3 yrs, im			\$17.43	SAF
90675	Rabies vaccine, im			\$199.02	
90676	Rabies vaccine, id			\$199.02	
90693	Typhoid vaccine, akd, sc			\$199.02	
90716	Chicken pox vaccine, sc			\$71.28	
90723	Dtap-hep b-ipv vaccine, im			\$199.02	
90725	Cholera vaccine, injectable			\$71.28	
90732	Pneumococcal vaccine			\$36.32	SAF
90740	Hepb vacc, ill pat 3 dose im			\$199.02	
90743	Hep b vacc, adol, 2 dose, im			\$199.02	
90744	Hepb vacc ped/adol 3 dose im			\$199.02	
90746	Hep b vaccine, adult, im			\$199.02	
90747	Hepb vacc, ill pat 4 dose im			\$199.02	
90748	Hep b/hib vaccine, im			\$71.28	
90780	IV infusion therapy, 1 hour			\$3,432.50	MedStat
90781	IV infusion, additional hour			\$95.28	SAF
90782	Injection, sc/im			\$85.47	
90783	Injection, ia			\$204.65	
90784	Injection, iv			\$204.65	
90788	Injection of antibiotic			\$204.65	
90799	Ther/prophylactic/dx inject			\$30.71	
90801	Psy dx interview			\$170.92	
90802	Intac psy dx interview			\$170.92	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 69 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
90804	Psytx, office, 20-30 min			\$198.11	
90805	Psytx, off, 20-30 min w/e&m			\$198.11	
90806	Psytx, off, 45-50 min			\$170.92	
90807	Psytx, off, 45-50 min w/e&m			\$170.92	
90808	Psytx, office, 75-80 min			\$170.92	
90809	Psytx, off, 75-80, w/e&m			\$170.92	
90810	Intac psytx, off, 20-30 min			\$198.11	
90811	Intac psytx, 20-30, w/e&m			\$198.11	
90812	Intac psytx, off, 45-50 min			\$170.92	
90813	Intac psytx, 45-50 min w/e&m			\$170.92	
90814	Intac psytx, off, 75-80 min			\$170.92	
90815	Intac psytx, 75-80 w/e&m			\$170.92	
90816	Psytx, hosp, 20-30 min			\$198.11	
90817	Psytx, hosp, 20-30 min w/e&m			\$198.11	
90818	Psytx, hosp, 45-50 min			\$170.92	
90819	Psytx, hosp, 45-50 min w/e&m			\$170.92	
90821	Psytx, hosp, 75-80 min			\$170.92	
90822	Psytx, hosp, 75-80 min w/e&m			\$170.92	
90823	Intac psytx, hosp, 20-30 min			\$198.11	
90824	Intac psytx, hsp 20-30 w/e&m			\$198.11	
90826	Intac psytx, hosp, 45-50 min			\$170.92	
90827	Intac psytx, hsp 45-50 w/e&m			\$170.92	
90828	Intac psytx, hosp, 75-80 min			\$170.92	
90829	Intac psytx, hsp 75-80 w/e&m			\$170.92	
90845	Psychoanalysis			\$170.92	
90846	Family psytx w/o patient			\$259.09	
90847	Family psytx w/patient			\$259.09	
90849	Multiple family group psytx			\$154.13	
90853	Group psychotherapy			\$154.13	
90857	Intac group psytx			\$154.13	
90862	Medication management			\$102.26	
90865	Narcosynthesis			\$170.92	
90870	Electroconvulsive therapy			\$562.21	
90871	Electroconvulsive therapy			\$924.11	MDR
90875	Psychophysiological therapy			\$65.07	SAF
90880	Hypnotherapy			\$170.92	
90899	Psychiatric service/therapy			\$198.11	
90901	Biofeedback train, any meth			\$156.30	MDR
90911	Biofeedback peni/uro/rectal			\$355.56	
90925	Esrd related services, day			\$722.29	MDR
90935	Hemodialysis, one evaluation			\$1,430.93	MDR
90937	Hemodialysis, repeated eval			\$407.23	MDR
90945	Dialysis, one evaluation			\$1,430.93	
90947	Dialysis, repeated eval			\$92.89	MDR
90989	Dialysis training, complete			\$419.37	SAF
90993	Dialysis training, incompl			\$357.92	MDR
90999	Dialysis procedure			\$334.52	SAF
91000	Esophageal intubation	b		\$850.56	
91010	Esophagus motility study	b		\$850.56	
91011	Esophagus motility study	b		\$850.56	
91012	Esophagus motility study	b		\$850.56	
91020	Gastric motility	b		\$850.56	
91030	Acid perfusion of esophagus	b		\$850.56	
91032	Esophagus, acid reflux test	b		\$850.56	
91033	Prolonged acid reflux test	b		\$850.56	
91052	Gastric analysis test	b		\$850.56	
91055	Gastric intubation for smear	b		\$415.47	
91060	Gastric saline load test	b		\$415.47	
91065	Breath hydrogen test	b		\$415.47	
91100	Pass intestine bleeding tube			\$415.47	
91105	Gastric intubation treatment			\$415.47	
91110	Gi tract capsule endoscopy	b		\$2,858.94	
91122	Anal pressure record	b	+	\$670.55	
91132	Electrogastrography	b		\$415.47	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 70 OF 84

CPT/ HCPSC Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
91133	Electrogastrography w/test	b		\$415.47	
91299	Gastroenterology procedure			\$415.47	
92002	Eye exam, new patient			\$88.95	
92004	Eye exam, new patient			\$151.44	
92012	Eye exam established pat			\$93.03	
92014	Eye exam & treatment			\$151.44	
92015	Refraction			\$33.81	SAF
92018	New eye exam & treatment		+	\$604.35	
92019	Eye exam & treatment		+	\$604.35	
92020	Special eye evaluation			\$182.84	
92060	Special eye evaluation	b		\$182.84	
92065	Orthoptic/pleoptic training	b		\$182.84	
92081	Visual field examination(s)	b		\$182.84	
92082	Visual field examination(s)	b		\$230.34	
92083	Visual field examination(s)	b		\$230.34	
92120	Tonography & eye evaluation			\$182.84	
92130	Water provocation tonography			\$230.34	
92135	Ophthalmic dx imaging	b		\$182.84	
92136	Ophthalmic biometry	b		\$182.84	
92140	Glaucoma provocative tests			\$230.34	
92225	Special eye exam, initial			\$230.34	
92226	Special eye exam, subsequent			\$230.34	
92230	Eye exam with photos		+	\$604.35	
92235	Eye exam with photos	b	+	\$604.35	
92240	Icg angiography	b		\$592.97	
92250	Eye exam with photos	b		\$182.84	
92260	Ophthalmoscopy/dynamometry			\$182.84	
92265	Eye muscle evaluation	b		\$592.97	
92270	Electro-oculography	b		\$230.34	
92275	Electroretinography	b		\$592.97	
92283	Color vision examination	b		\$182.84	
92284	Dark adaptation eye exam	b		\$230.34	
92285	Eye photography	b		\$182.84	
92286	Internal eye photography	b		\$230.34	
92287	Internal eye photography	b		\$592.97	
92311	Contact lens fitting			\$647.57	
92312	Contact lens fitting			\$647.57	
92313	Contact lens fitting			\$647.57	
92315	Prescription of contact lens			\$647.57	
92316	Prescription of contact lens			\$647.57	
92317	Prescription of contact lens			\$647.57	
92325	Modification of contact lens			\$647.57	
92326	Replacement of contact lens			\$647.57	
92330	Fitting of artificial eye			\$182.84	
92352	Special spectacles fitting			\$647.57	
92353	Special spectacles fitting			\$647.57	
92354	Special spectacles fitting			\$647.57	
92355	Special spectacles fitting			\$647.57	
92358	Eye prosthesis service			\$647.57	
92371	Repair & adjust spectacles			\$647.57	
92499	Eye service or procedure			\$182.84	
92502	Ear and throat examination		+	\$484.51	
92511	Nasopharyngoscopy		+	\$230.90	
92512	Nasal function studies			\$207.38	
92516	Facial nerve function test			\$416.44	
92520	Laryngeal function studies			\$416.44	
92541	Spontaneous nystagmus test	b		\$207.38	
92542	Positional nystagmus test	b		\$207.38	
92543	Caloric vestibular test	b		\$207.38	
92544	Optokinetic nystagmus test	b		\$207.38	
92545	Oscillating tracking test	b		\$207.38	
92546	Sinusoidal rotational test	b		\$416.44	
92547	Supplemental electrical test	e		\$207.38	
92548	Posturography	b		\$416.44	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 71 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
92552	Pure tone audiometry, air	e		\$107.01	
92553	Audiometry, air & bone	e		\$291.13	
92555	Speech threshold audiometry	e		\$107.01	
92556	Speech audiometry, complete	e		\$107.01	
92557	Comprehensive hearing test	e		\$291.13	
92561	Bekesy audiometry, diagnosis	e		\$291.13	
92562	Loudness balance test	e		\$107.01	
92563	Tone decay hearing test	e		\$107.01	
92564	Sisi hearing test	e		\$107.01	
92565	Stenger test, pure tone	e		\$107.01	
92567	Tympanometry	e		\$107.01	
92568	Acoustic reflex testing	e		\$107.01	
92569	Acoustic reflex decay test	e		\$107.01	
92571	Filtered speech hearing test	e		\$107.01	
92572	Staggered spondaic word test	e		\$107.01	
92573	Lombard test	e		\$107.01	
92575	Sensorineural acuity test	e		\$291.13	
92576	Synthetic sentence test	e		\$107.01	
92577	Stenger test, speech	e		\$291.13	
92579	Visual audiometry (vra)	e		\$291.13	
92582	Conditioning play audiometry	e		\$291.13	
92583	Select picture audiometry	e		\$107.01	
92584	Electrocochleography	e		\$416.44	
92585	Auditor evoke potent, compre	b		\$684.78	
92586	Auditor evoke potent, limit	e		\$273.67	
92587	Evoked auditory test	b		\$207.38	
92588	Evoked auditory test	b		\$207.38	
92589	Auditory function test(s)	e		\$107.01	
92590	Hearing aid exam, one ear			\$174.30	SAF
92591	Hearing aid exam, both ears			\$206.84	SAF
92592	Hearing aid check, one ear			\$97.61	SAF
92593	Hearing aid check, both ears			\$102.62	SAF
92596	Ear protector evaluation	e		\$291.13	
92601	Cochlear implt f/up exam < 7			\$291.13	
92602	Reprogram cochlear implt < 7			\$291.13	
92603	Cochlear implt f/up exam 7 >			\$291.13	
92604	Reprogram cochlear implt 7 >			\$291.13	
92700	Ent procedure/service			\$107.01	
92950	Heart/lung resuscitation cpr			\$822.37	
92953	Temporary external pacing			\$822.37	
92960	Cardioversion electric, ext			\$1,703.62	
92961	Cardioversion, electric, int	b		\$1,703.62	
92973	Percut coronary thrombectomy		+	\$1,099.59	
92974	Cath place, cardio brachytx		+	\$9,896.33	
92977	Dissolve clot, heart vessel		+	\$845.29	
92978	Intravasc us, heart add-on	b		\$8,568.20	
92979	Intravasc us, heart add-on	b		\$8,568.20	
92980	Insert intracoronary stent		+	\$20,191.42	
92981	Insert intracoronary stent		+	\$20,191.42	
92982	Coronary artery dilation		+	\$15,799.79	
92984	Coronary artery dilation		+	\$15,799.79	
92986	Revision of aortic valve		+	\$15,799.79	
92987	Revision of mitral valve		+	\$15,799.79	
92990	Revision of pulmonary valve		+	\$15,799.79	
92995	Coronary atherectomy		+	\$22,842.01	
92996	Coronary atherectomy add-on		+	\$22,842.01	
92997	Pul art balloon repr, percut		+	\$9,478.00	
92998	Pul art balloon repr, percut		+	\$9,478.00	
93005	Electrocardiogram, tracing	e		\$129.54	
93017	Cardiovascular stress test	e		\$559.82	
93024	Cardiac drug stress test	b		\$559.82	
93025	Microvolt t-wave assess	e		\$559.82	
93041	Rhythm ECG, tracing	e		\$129.54	
93225	ECG monitor/record, 24 hrs	e		\$376.22	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 72 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
93226	ECG monitor/report, 24 hrs	e		\$376.22	
93231	ECG monitor/record, 24 hrs	e		\$376.22	
93236	ECG monitor/report, 24 hrs	e		\$376.22	
93270	ECG recording	e		\$376.22	
93271	ECG/monitoring and analysis	e		\$376.22	
93278	ECG/signal-averaged	b		\$129.54	
93303	Echo transthoracic	b		\$857.65	
93304	Echo transthoracic	b		\$394.57	
93307	Echo exam of heart	b		\$857.65	
93308	Echo exam of heart	b		\$394.57	
93312	Echo transesophageal	b		\$1,821.90	
93313	Echo transesophageal	b		\$1,821.90	
93315	Echo transesophageal	b		\$1,821.90	
93316	Echo transesophageal	b		\$1,821.90	
93318	Echo transesophageal intraop	b		\$1,821.90	
93320	Doppler echo exam, heart	b		\$450.38	
93321	Doppler echo exam, heart	b		\$394.57	
93325	Doppler color flow add-on	b		\$394.57	
93350	Echo transthoracic	b		\$857.65	
93501	Right heart catheterization	b	+	\$9,721.69	
93503	Insert/place heart catheter	b	+	\$3,148.66	
93505	Biopsy of heart lining	b	+	\$3,148.66	
93508	Cath placement, angiography	b	+	\$9,721.69	
93510	Left heart catheterization	b	+	\$9,721.69	
93511	Left heart catheterization	b	+	\$9,721.69	
93514	Left heart catheterization	b	+	\$9,721.69	
93524	Left heart catheterization	b	+	\$9,721.69	
93526	Rt & Lt heart catheters	b	+	\$9,721.69	
93527	Rt & Lt heart catheters	b	+	\$9,721.69	
93528	Rt & Lt heart catheters	b	+	\$9,721.69	
93529	Rt, Lt heart catheterization	b	+	\$9,721.69	
93530	Rt heart cath, congenital	b	+	\$9,721.69	
93531	R & l heart cath, congenital	b	+	\$9,721.69	
93532	R & l heart cath, congenital	b	+	\$9,721.69	
93533	R & l heart cath, congenital	b	+	\$9,721.69	
93580	Transcath closure of asd	b	+	\$9,896.33	
93581	Transcath closure of vsd	b	+	\$9,896.33	
93600	Bundle of His recording	b	+	\$12,016.13	
93602	Intra-atrial recording	b	+	\$12,016.13	
93603	Right ventricular recording	b	+	\$12,016.13	
93609	Map tachycardia, add-on	b	+	\$12,016.13	
93610	Intra-atrial pacing	b	+	\$12,016.13	
93612	Intraventricular pacing	b	+	\$12,016.13	
93613	Electrophys map 3d, add-on	b	+	\$12,016.13	
93615	Esophageal recording	b	+	\$12,016.13	
93616	Esophageal recording	b	+	\$12,016.13	
93618	Heart rhythm pacing	b	+	\$12,016.13	
93619	Electrophysiology evaluation	b	+	\$10,865.72	
93620	Electrophysiology evaluation	b	+	\$10,865.72	
93621	Electrophysiology evaluation	b	+	\$10,865.72	
93622	Electrophysiology evaluation	b	+	\$10,865.72	
93623	Stimulation, pacing heart	b	+	\$12,016.13	
93624	Electrophysiologic study	b	+	\$3,283.13	
93631	Heart pacing, mapping	b	+	\$12,016.13	
93640	Evaluation heart device	b		\$3,283.13	
93641	Electrophysiology evaluation	b		\$3,283.13	
93642	Electrophysiology evaluation	b		\$3,283.13	
93650	Ablate heart dysrhythm focus	b	+	\$13,252.95	
93651	Ablate heart dysrhythm focus	b	+	\$13,252.95	
93652	Ablate heart dysrhythm focus	b	+	\$13,252.95	
93660	Tilt table evaluation	b		\$1,374.76	
93662	Intracardiac ecg (ice)	b		\$8,568.20	
93668	Peripheral vascular rehab	b		\$820.41	
93701	Bioimpedance, thoracic	b		\$129.54	

MDR

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 73 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
93721	Plethysmography tracing	e		\$290.52	
93724	Analyze pacemaker system	b		\$117.93	
93727	Analyze ilr system			\$117.93	
93731	Analyze pacemaker system	b		\$117.93	
93732	Analyze pacemaker system	b		\$117.93	
93733	Telephone analy, pacemaker	b		\$117.93	
93734	Analyze pacemaker system	b		\$117.93	
93735	Analyze pacemaker system	b		\$117.93	
93736	Telephonic analy, pacemaker	b		\$117.93	
93740	Temperature gradient studies	b		\$177.57	
93741	Analyze ht pace device sngl	b		\$172.47	
93742	Analyze ht pace device sngl	b		\$172.47	
93743	Analyze ht pace device dual	b		\$172.47	
93744	Analyze ht pace device dual	b		\$172.47	
93760	Cephalic thermogram	b		\$781.76	MDR
93786	Ambulatory BP recording	e		\$376.22	
93788	Ambulatory BP analysis	e		\$804.00	MDR
93797	Cardiac rehab			\$131.58	
93798	Cardiac rehab/monitor			\$131.58	
93799	Cardiovascular procedure			\$474.22	
93875	Extracranial study	b		\$474.22	
93880	Extracranial study	b		\$654.62	
93882	Extracranial study	b		\$654.62	
93886	Intracranial study	b		\$654.62	
93888	Intracranial study	b		\$560.10	
93922	Extremity study	b		\$474.22	
93923	Extremity study	b		\$474.22	
93924	Extremity study	b		\$474.22	
93925	Lower extremity study	b		\$654.62	
93926	Lower extremity study	b		\$654.62	
93930	Upper extremity study	b		\$654.62	
93931	Upper extremity study	b		\$560.10	
93965	Extremity study	b		\$474.22	
93970	Extremity study	b		\$654.62	
93971	Extremity study	b		\$654.62	
93975	Vascular study	b		\$654.62	
93976	Vascular study	b		\$654.62	
93978	Vascular study	b		\$654.62	
93979	Vascular study	b		\$654.62	
93980	Penile vascular study	b		\$654.62	
93981	Penile vascular study	b		\$654.62	
93990	Doppler flow testing	b		\$654.62	
94010	Breathing capacity test	b		\$290.52	
94014	Patient recorded spirometry			\$177.57	
94015	Patient recorded spirometry	e		\$599.59	
94060	Evaluation of wheezing	b		\$290.52	
94070	Evaluation of wheezing	b		\$599.59	
94150	Vital capacity test	b		\$177.57	
94200	Lung function test (MBC/MVV)	b		\$177.57	
94240	Residual lung capacity	b		\$290.52	
94250	Expired gas collection	b		\$177.57	
94260	Thoracic gas volume	b		\$290.52	
94350	Lung nitrogen washout curve	b		\$290.52	
94360	Measure airflow resistance	b		\$177.57	
94370	Breath airway closing volume	b		\$177.57	
94375	Respiratory flow volume loop	b		\$177.57	
94400	CO2 breathing response curve	b		\$177.57	
94450	Hypoxia response curve	b		\$177.57	
94620	Pulmonary stress test/simple	b		\$290.52	
94621	Pulm stress test/complex	b		\$599.59	
94640	Airway inhalation treatment			\$67.29	
94642	Aerosol inhalation treatment			\$190.01	
94656	Initial ventilator mgmt			\$515.80	
94657	Continued ventilator mgmt			\$515.80	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 74 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
94660	Pos airway pressure, CPAP			\$252.12	
94662	Neg press ventilation, cnp			\$515.80	
94664	Aerosol or vapor inhalations			\$67.29	
94667	Chest wall manipulation			\$67.29	
94668	Chest wall manipulation			\$67.29	
94680	Exhaled air analysis, o2	b		\$177.57	
94681	Exhaled air analysis, o2/co2	b		\$290.52	
94690	Exhaled air analysis	b		\$177.57	
94720	Monoxide diffusing capacity	b		\$290.52	
94725	Membrane diffusion capacity	b		\$290.52	
94750	Pulmonary compliance study	b		\$177.57	
94770	Exhaled carbon dioxide test	b		\$177.57	
94772	Breath recording, infant			\$599.59	
94799	Pulmonary service/procedure			\$177.57	
95004	Percut allergy skin tests			\$238.12	
95010	Percut allergy titrate test			\$238.12	
95015	Id allergy titrate-drug/bug			\$238.12	
95024	Id allergy test, drug/bug			\$238.12	
95027	Skin end point titration	e		\$238.12	
95028	Id allergy test-delayed type	e		\$238.12	
95044	Allergy patch tests			\$238.12	
95052	Photo patch test			\$238.12	
95056	Photosensitivity tests			\$238.12	
95060	Eye allergy tests	e		\$238.12	
95065	Nose allergy test	e		\$238.12	
95070	Bronchial allergy tests	e		\$599.59	
95071	Bronchial allergy tests	e		\$599.59	
95075	Ingestion challenge test			\$850.56	
95078	Provocative testing	e		\$238.12	
95115	Immunotherapy, one injection			\$30.71	
95117	Immunotherapy injections			\$85.47	
95125	Immunotherapy, many antigens			\$158.00	SAF
95144	Antigen therapy services			\$106.44	
95145	Antigen therapy services			\$106.44	
95146	Antigen therapy services			\$106.44	
95147	Antigen therapy services			\$106.44	
95148	Antigen therapy services			\$106.44	
95149	Antigen therapy services			\$106.44	
95165	Antigen therapy services			\$106.44	
95170	Antigen therapy services			\$106.44	
95180	Rapid desensitization			\$238.12	
95199	Allergy immunology services			\$238.12	
95250	Glucose monitoring, cont	e	+	\$659.76	
95805	Multiple sleep latency test	b		\$2,769.46	
95806	Sleep study, unattended	b		\$697.27	
95807	Sleep study, attended	b		\$2,769.46	
95808	Polysomnography, 1-3	b		\$2,769.46	
95810	Polysomnography, 4 or more	b		\$2,769.46	
95811	Polysomnography w/cpap	b		\$2,769.46	
95812	Electroencephalogram (EEG)	b		\$697.27	
95813	Eeg, over 1 hour	b		\$697.27	
95816	Electroencephalogram (EEG)	b		\$531.58	
95819	Electroencephalogram (EEG)	b		\$531.58	
95822	Sleep electroencephalogram	b		\$531.58	
95824	Eeg, cerebral death only	b		\$531.58	
95827	night electroencephalogram	b		\$2,769.46	
95829	Surgery electrocorticogram	b		\$531.58	
95857	Tensilon test			\$273.67	
95858	Tensilon test & myogram	b		\$129.70	
95860	Muscle test, one limb	b		\$273.67	
95861	Muscle test, 2 limbs	b		\$273.67	
95863	Muscle test, 3 limbs	b		\$273.67	
95864	Muscle test, 4 limbs	b		\$273.67	
95867	Muscle test, head or neck	b		\$273.67	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 75 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
95868	Muscle test cran nerve bilat	b		\$273.67	
95869	Muscle test, thor paraspinal	b		\$129.70	
95870	Muscle test, nonparaspinal	b		\$129.70	
95872	Muscle test, one fiber	b		\$273.67	
95875	Limb exercise test	b		\$129.70	
95900	Motor nerve conduction test	b		\$129.70	
95903	Motor nerve conduction test	b		\$129.70	
95904	Sense nerve conduction test	b		\$129.70	
95920	Intraop nerve test add-on	b		\$684.78	
95921	Autonomic nerv function test	b		\$273.67	
95922	Autonomic nerv function test	b		\$273.67	
95923	Autonomic nerv function test	b		\$129.70	
95925	Somatosensory testing	b		\$684.78	
95926	Somatosensory testing	b		\$684.78	
95927	Somatosensory testing	b		\$684.78	
95930	Visual evoked potential test	b		\$273.67	
95933	Blink reflex test	b		\$129.70	
95934	H-reflex test	b		\$129.70	
95936	H-reflex test	b		\$129.70	
95937	Neuromuscular junction test	b		\$273.67	
95950	Ambulatory eeg monitoring	b		\$697.27	
95951	EEG monitoring/videorecord	b		\$2,769.46	
95953	EEG monitoring/computer	b		\$2,769.46	
95954	EEG monitoring/giving drugs	b		\$531.58	
95955	EEG during surgery	b		\$697.27	
95956	Eeg monitoring, cable/radio	b		\$531.58	
95957	EEG digital analysis	b		\$531.58	
95958	EEG monitoring/function test	b		\$697.27	
95961	Electrode stimulation, brain	b		\$684.78	
95962	Electrode stim, brain add-on	b		\$684.78	
95965	Meg, spontaneous	b		\$21,750.00	
95966	Meg, evoked, single	b		\$6,377.63	
95967	Meg, evoked, each add'l	b		\$4,178.45	
95970	Analyze neurostim, no prog			\$265.35	
95971	Analyze neurostim, simple			\$265.35	
95972	Analyze neurostim, complex			\$265.35	
95973	Analyze neurostim, complex			\$265.35	
95974	Cranial neurostim, complex			\$265.35	
95975	Cranial neurostim, complex			\$265.35	
95990	Spin/brain pump refill & main		+	\$518.48	
95991	Spin/brain pump refill & main		+	\$518.48	
95999	Neurological procedure			\$129.70	
96000	Motion analysis, video/3d			\$659.76	
96001	Motion test w/ft press meas			\$659.76	
96002	Dynamic surface emg			\$659.76	
96003	Dynamic fine wire emg			\$659.76	
96100	Psychological testing			\$558.86	
96105	Assessment of aphasia			\$123.96	SAF
96110	Developmental test, lim			\$558.86	
96111	Developmental test, extend			\$558.86	
96115	Neurobehavior status exam			\$558.86	
96117	Neuropsych test battery			\$558.86	
96150	Assess hlth/behav, init			\$198.11	
96151	Assess hlth/behav, subseq			\$198.11	
96152	Intervene hlth/behav, indiv			\$198.11	
96153	Intervene hlth/behav, group			\$198.11	
96154	Interv hlth/behav, fam w/pt			\$198.11	
96155	Interv hlth/behav fam no pt			\$198.11	
96520	Port pump refill & main		+	\$518.48	
96530	Pump refilling, maintenance		+	\$518.48	
96545	Provide chemotherapy agent			\$77.39	SAF
96567	Photodynamic tx, skin		+	\$659.76	
96570	Photodynamic tx, 30 min		+	\$1,099.59	
96571	Photodynamic tx, addl 15 min		+	\$1,099.59	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 76 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
96900	Ultraviolet light therapy			\$101.69	
96910	Photochemotherapy with UV-B			\$101.69	
96912	Photochemotherapy with UV-A			\$101.69	
96913	Photochemotherapy, UV-A or B			\$371.71	
96920	Laser tx, skin < 250 sq cm		+	\$206.25	
96921	Laser tx, skin 250-500 sq cm		+	\$206.25	
96922	Laser tx, skin > 500 sq cm		+	\$303.14	
96999	Dermatological procedure		+	\$175.61	
97014	Electric stimulation therapy			\$58.91	MDR
98925	Osteopathic manipulation			\$66.90	
98926	Osteopathic manipulation			\$66.90	
98927	Osteopathic manipulation			\$66.90	
98928	Osteopathic manipulation			\$66.90	
98929	Osteopathic manipulation			\$66.90	
98940	Chiropractic manipulation			\$66.90	
98941	Chiropractic manipulation			\$66.90	
98942	Chiropractic manipulation			\$66.90	
99000	Specimen handling			\$30.31	MDR
99001	Specimen handling			\$26.57	MDR
99002	Device handling			\$135.95	SAF
99050	Medical services after hrs			\$174.30	SAF
99058	Office emergency care			\$46.88	MedStat
99170	Anogenital exam, child		+	\$56.28	
99172	Ocular function screen	b		\$191.00	MDR
99183	Hyperbaric oxygen therapy			\$2,836.24	MedStat
99195	Phlebotomy			\$134.09	
99199	Special service/proc/report			\$539.12	MedStat
99201	Office/outpatient visit, new	a		\$93.03	
99202	Office/outpatient visit, new	a		\$93.03	
99203	Office/outpatient visit, new	a		\$88.95	
99204	Office/outpatient visit, new	a		\$151.44	
99205	Office/outpatient visit, new	a		\$151.44	
99211	Office/outpatient visit, est	a		\$93.03	
99212	Office/outpatient visit, est	a		\$93.03	
99213	Office/outpatient visit, est	a		\$88.95	
99214	Office/outpatient visit, est	a		\$151.44	
99215	Office/outpatient visit, est	a		\$151.44	
99241	Office consultation			\$93.03	
99242	Office consultation			\$93.03	
99243	Office consultation			\$88.95	
99244	Office consultation			\$151.44	
99245	Office consultation			\$151.44	
99271	Confirmatory consultation			\$93.03	
99272	Confirmatory consultation			\$93.03	
99273	Confirmatory consultation			\$88.95	
99274	Confirmatory consultation			\$151.44	
99275	Confirmatory consultation			\$151.44	
99281	Emergency dept visit	f		\$215.41	
99282	Emergency dept visit	f		\$215.41	
99283	Emergency dept visit	f		\$443.59	
99284	Emergency dept visit	f		\$704.98	
99285	Emergency dept visit	f		\$704.98	
99291	Critical care, first hour			\$2,155.61	
99385	Prev visit, new, age 18-39			\$147.97	MedStat
99386	Prev visit, new, age 40-64			\$84.59	MedStat
99387	Prev visit, new, 65 & over			\$152.69	SAF
99391	Prev visit, est, infant			\$193.38	MedStat
99395	Prev visit, est, age 18-39			\$178.73	MedStat
99396	Prev visit, est, age 40-64			\$128.92	MedStat
99397	Prev visit, est, 65 & over			\$88.25	MDR
99401	Preventive counseling, indiv			\$72.17	MDR
99402	Preventive counseling, indiv			\$191.73	SAF
99404	Preventive counseling, indiv			\$190.45	MedStat
99412	Preventive counseling, group			\$133.32	MedStat

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 77 OF 84

CPT/ HCPSC Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
99431	Initial care, normal newborn			\$93.03	
99440	Newborn resuscitation			\$822.37	
99499	Unlisted e&m service			\$2,519.00	MedStat
0003T	Cervicography			\$109.96	
0009T	Endometrial cryoablation		+	\$8,136.98	
0012T	Osteochondral knee autograft		+	\$7,407.10	
0013T	Osteochondral knee allograft		+	\$7,407.10	
0014T	Meniscal transplant, knee		+	\$7,407.10	
0016T	Thermtx choroid vasc lesion		+	\$1,375.11	
0018T	Transcranial magnetic stim			\$129.70	
0027T	Endoscopic epidural lysis		+	\$3,738.61	
0046T	Cath lavage, mammary duct(s)		+	\$248.71	
0047T	Cath lavage, mammary duct(s)		+	\$248.71	
0058T	Cryopreservation, ovary tiss			\$248.88	
0059T	Cryopreservation, oocyte			\$248.88	
A4209	5+ CC sterile syringe&needle			\$4.07	SAF
A4221	Maint drug infus cath per wk			\$55.25	SAF
A4222	Drug infusion pump supplies			\$81.34	SAF
A4232	Syringe w/needle insulin 3cc			\$0.49	SAF
A4253	Blood glucose/reagent strips			\$5.81	SAF
A4259	Lancets per box			\$2.91	SAF
A4550	Surgical trays			\$124.92	SAF
A4554	Disposable underpads			\$2.61	SAF
A4556	Electrodes, pair			\$23.24	SAF
A4590	Special casting material			\$44.16	SAF
A4624	Tracheal suction tube			\$6.48	SAF
A4628	Oropharyngeal suction cath			\$10.81	SAF
A4642	Satumomab pendetide per dose			\$7,882.22	
A7000	Disposable canister for pump			\$48.51	SAF
A7002	Tubing used w suction pump			\$27.89	SAF
A7015	Aerosol mask used w nebulize			\$1.81	SAF
A9270	Non-covered item or service			\$87.15	SAF
A9300	Exercise equipment			\$17.43	SAF
A9500	Technetium TC 99m sestamibi			\$379.00	
A9502	Technetium TC99M tetrofosmin			\$3,557.59	
A9505	Thallous chloride TL 201/mci			\$118.89	
A9507	Indium/111 capromab pendetid			\$10,858.64	
A9508	lobenguane sulfate I-131, per 0.5 mCi			\$886.72	
A9511	Technetium TC 99m depreotide			\$3,764.64	
A9517	Th I131 so iodide cap millic			\$29.30	
A9521	Technetiumtc-99m exametazine			\$4,411.69	
A9524	Iodinated I-131 serumalbumin, per 5uci			\$259.76	
A9528	Dx I131 so iodide cap millic			\$29.30	
A9529	Dx I131 so iodide sol millic			\$34.71	
A9530	Th I131 so iodide sol millic			\$34.71	
A9600	Strontium-89 chloride			\$4,772.27	
A9605	Samarium sm153 lexidronamm			\$2,641.09	
C1079	CO 57/58 per 0.5 uCi			\$894.99	
C1091	IN111 oxyquinoline,per0.5mCi			\$854.58	
C1092	IN 111 pentetate per 0.5 mCi			\$904.36	
C1122	Tc 99M ARCITUMOMAB PER VIAL			\$4,354.35	
C1178	BUSULFAN IV, 6 Mg			\$106.09	
C1200	TC 99M Sodlum Glucoheptonat			\$115.25	
C1201	TC 99M SUCCIMER, PER Vial			\$478.31	
C1300	HYPERBARIC Oxygen			\$447.84	
C1305	Apligraf			\$5,273.64	
C1775	FDG, per dose (4-40 mCi/ml)			\$1,427.18	
C8900	MRA w/cont, abd			\$2,076.33	
C8901	MRA w/o cont, abd			\$1,987.98	
C8902	MRA w/o fol w/cont, abd			\$2,998.23	
C8903	MRI w/cont, breast, uni			\$2,076.33	
C8904	MRI w/o cont, breast, uni			\$1,987.98	
C8905	MRI w/o fol w/cont, brst, un			\$2,998.23	
C8906	MRI w/cont, breast, bi			\$2,076.33	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 78 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
C8907	MRI w/o cont, breast, bi			\$1,987.98	
C8908	MRI w/o fol w/cont, breast,			\$2,998.23	
C8909	MRA w/cont, chest			\$2,076.33	
C8910	MRA w/o cont, chest			\$1,987.98	
C8911	MRA w/o fol w/cont, chest			\$2,998.23	
C8912	MRA w/cont, lwr ext			\$2,076.33	
C8913	MRA w/o cont, lwr ext			\$1,987.98	
C8914	MRA w/o fol w/cont, lwr ext			\$2,998.23	
C8918	MRA w/cont, pelvis			\$2,076.33	
C8919	MRA w/o cont, pelvis			\$1,987.98	
C8920	MRA w/o fol w/cont, pelvis			\$2,998.23	
C9003	Palivizumab, per 50 mg			\$2,688.45	
C9008	Baclofen Refill Kit-500mcg			\$281.36	
C9009	Baclofen Refill Kit-2000mcg			\$179.98	
C9013	Co 57 cobaltous chloride			\$215.70	
C9105	Hep B imm glob, per 1 ml			\$239.64	
C9109	Tirofiban hcl, 6.25 mg			\$831.01	
C9112	Perflutren lipid micro, 2ml			\$522.52	
C9113	Inj pantoprazole sodium, via			\$88.42	
C9121	Injection, argatroban			\$55.69	
C9123	Transcyte, per 247 sq cm			\$2,625.47	
C9200	Orcel, per 36 cm2			\$4,002.65	
C9201	Dermagraft, per 37.5 sq cm			\$2,036.50	
C9202	Octafluoropropane			\$522.52	
C9203	Perflhexane lipid micro			\$485.30	
C9205	Oxaliplatin			\$32.16	
C9211	Inj, alefacept, IV			\$2,264.72	
C9212	Inj, alefacept, IM			\$1,609.59	
C9701	Stretta System		+	\$8,136.98	
C9703	Bard Endoscopic Suturing Sys		+	\$7,257.31	
C9704	Inj inert subs upper GI		+	\$7,697.14	
D0150	Comprehensive oral evaluation			\$137.89	
D0240	Intraoral occlusal film			\$137.89	
D0250	Extraoral first film			\$137.89	
D0260	Extraoral ea additional film			\$137.89	
D0270	Dental bitewing single film			\$137.89	
D0272	Dental bitewings two films			\$137.89	
D0274	Dental bitewings four films			\$137.89	
D0277	Vert bitewings-sev to eight			\$137.89	
D0460	Pulp vitality test			\$137.89	
D0472	Gross exam, prep & report			\$137.89	
D0473	Micro exam, prep & report			\$137.89	
D0474	Micro w exam of surg margins			\$137.89	
D0480	Cytopath smear prep & report			\$137.89	
D0502	Other oral pathology procedu			\$137.89	
D0999	Unspecified diagnostic proce			\$137.89	
D1510	Space maintainer fxd unilat			\$137.89	
D1515	Fixed bilat space maintainer			\$137.89	
D1520	Remove unilat space maintain			\$137.89	
D1525	Remove bilat space maintain			\$137.89	
D1550	Recement space maintainer			\$137.89	
D2970	Temporary- fractured tooth			\$137.89	
D2999	Dental unspec restorative pr			\$137.89	
D3460	Endodontic endosseous implan			\$137.89	
D3999	Endodontic procedure			\$137.89	
D4260	Osseous surgery per quadrant			\$137.89	
D4263	Bone replce graft first site			\$137.89	
D4264	Bone replce graft each add			\$137.89	
D4268	Surgical revision procedure			\$137.89	
D4270	Pedicle soft tissue graft pr			\$137.89	
D4271	Free soft tissue graft proc			\$137.89	
D4273	Subepithelial tissue graft			\$137.89	
D4355	Full mouth debridement			\$137.89	
D4381	Localized chemo delivery			\$137.89	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 79 OF 84

CPT/ HCPSCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
D5911	Facial moulage sectional			\$137.89	
D5912	Facial moulage complete			\$137.89	
D5983	Radiation applicator			\$137.89	
D5984	Radiation shield			\$137.89	
D5985	Radiation cone locator			\$137.89	
D5987	Commissure splint			\$137.89	
D6920	Dental connector bar			\$137.89	
D7111	Coronal remnants deciduous t			\$137.89	
D7140	Extraction erupted tooth/exr			\$137.89	
D7210	Rem imp tooth w mucoper flap			\$137.89	
D7220	Impact tooth remov soft tiss			\$137.89	
D7230	Impact tooth remov part bony			\$137.89	
D7240	Impact tooth remov comp bony			\$137.89	
D7241	Impact tooth rem bony w/comp			\$137.89	
D7250	Tooth root removal			\$137.89	
D7260	Oral antral fistula closure			\$137.89	
D7261	Primary closure sinus perf			\$137.89	
D7291	Transseptal fibrotomy			\$137.89	
D7940	Reshaping bone orthognathic			\$137.89	
D9630	Other drugs/medications			\$137.89	
D9930	Treatment of complications			\$137.89	
D9940	Dental occlusal guard			\$137.89	
D9950	Occlusion analysis			\$137.89	
D9951	Limited occlusal adjustment			\$137.89	
D9952	Complete occlusal adjustment			\$137.89	
G0008	Admin influenza virus vac			\$16.12	MedStat
G0009	Admin pneumococcal vaccine			\$17.43	SAF
G0010	Admin hepatitis b vaccine			\$71.28	
G0030	PET imaging prev PET single	c		\$4,128.70	
G0031	PET imaging prev PET multiple	c		\$4,128.70	
G0032	PET follow SPECT 78464 singl	c		\$4,128.70	
G0033	PET follow SPECT 78464 mult	c		\$4,128.70	
G0034	PET follow SPECT 78865 singl	c		\$4,128.70	
G0035	PET follow SPECT 78465 mult	c		\$4,128.70	
G0036	PET follow comry angio sing	c		\$4,128.70	
G0037	PET follow comry angio mult	c		\$4,128.70	
G0038	PET follow myocard perf sing	c		\$4,128.70	
G0039	PET follow myocard perf mult	c		\$4,128.70	
G0040	PET follow stress echo singl	c		\$4,128.70	
G0041	PET follow stress echo mult	c		\$4,128.70	
G0042	PET follow ventriculogm sing	c		\$4,128.70	
G0043	PET follow ventriculogm mult	c		\$4,128.70	
G0044	PET following rest ECG singl	c		\$4,128.70	
G0045	PET following rest ECG mult	b		\$4,128.70	
G0046	PET follow stress ECG singl	c		\$4,128.70	
G0047	PET follow stress ECG mult	c		\$4,128.70	
G0101	CA screen;pelvic/breast exam			\$93.03	
G0104	CA screen;flexi sigmoidoscope			\$753.93	
G0105	Colorectal scrn; hi risk ind		+	\$2,010.85	
G0106	Colon CA screen;barium enema	b		\$696.17	
G0117	Glaucoma scrn hgh risk direc			\$182.84	
G0118	Glaucoma scrn hgh risk direc			\$182.84	
G0120	Colon ca scrn; barium enema	b		\$696.17	
G0121	Colon ca scrn not hi rsk ind		+	\$2,010.85	
G0125	PET img WhBD sgl pulm ring	b		\$6,377.63	
G0127	Trim nail(s)		+	\$180.03	
G0128	CORF skilled nursing service			\$34.86	SAF
G0130	Single energy x-ray study	b		\$208.01	
G0166	Extrnl counterpulse, per tx		+	\$495.78	
G0168	Wound closure by adhesive			\$170.98	
G0173	Stereo radioisurgery,complete			\$21,750.00	
G0175	OPPS Service,sched team conf			\$151.44	
G0179	MD recertification HHA PT			\$87.15	SAF
G0186	Dstry eye lesn,ldr vsst tech		+	\$1,375.11	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 80 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
G0204	Diagnostic mammography digital	b		\$262.83	
G0206	Diagnostic mammography digital	b		\$262.83	
G0210	PET img wholebody dx lung	b		\$6,377.63	
G0211	PET img whbd ring init lung	b		\$6,377.63	
G0212	PET img whbd ring restag lun	b		\$6,377.63	
G0213	PET img wholebody dx	b		\$6,377.63	
G0214	PET img wholebod init	b		\$6,377.63	
G0215	PETimg wholebod restag	b		\$6,377.63	
G0216	PET img whbd ring dx melanom	b		\$6,377.63	
G0217	PET img whbd ring init melan	b		\$6,377.63	
G0218	PET img whbd ring restag mel	b		\$6,377.63	
G0220	PET img whbd ring dx lymphom	b		\$6,377.63	
G0221	PET img whbd ring init lymph	b		\$6,377.63	
G0222	PET img whbd ring resta lymph	b		\$6,377.63	
G0223	PET img whbd ring dx hea	c		\$6,377.63	
G0224	PETimg whbd ring ini hea	b		\$6,377.63	
G0225	PET img whbd ring restag hea	b		\$6,377.63	
G0226	PET img whbd dx esophag	c		\$6,377.63	
G0227	PET img whbd ring ini esopha	b		\$6,377.63	
G0228	PET img whbd ring restg esop	b		\$6,377.63	
G0229	PET img metabolic brain ring	b		\$6,377.63	
G0230	PET myocard viability post	c		\$6,377.63	
G0231	PET WhBD colorec; gamma cam	c		\$6,377.63	
G0232	PET whbd lymphoma; gamma cam	c		\$6,377.63	
G0233	PET whbd melanoma; gamma cam	c		\$6,377.63	
G0234	PET WhBD pulm nod; gamma cam	c		\$6,377.63	
G0237	Therapeutic procd strg endur			\$104.81	
G0238	Oth resp proc, indiv			\$104.81	
G0239	Oth resp proc, group			\$104.81	
G0242	Multisource photon ster plan			\$6,377.63	
G0243	Multisour photon stero treat			\$21,750.00	
G0244	Observ care by facility topt			\$1,557.98	
G0245	Initial Foot Exam PTLOPS			\$93.03	
G0246	Followup eval of foot pt lop			\$93.03	
G0247	Routine footcare pt w lops		+	\$180.03	
G0248	Demonstrate use home inr mon	e		\$659.76	
G0249	Provide test material, equipm	e		\$659.76	
G0251	Linear acc based stero radio			\$5,058.12	
G0252	PET imaging initial dx	c		\$6,377.63	
G0253	PET image brst dection recur	b		\$6,377.63	
G0254	PET image brst eval to bx	c		\$6,377.63	
G0257	Unsched dialysis ESRD pt hos			\$1,430.93	
G0260	inj for sacroiliac jt anesth		+	\$586.87	
G0264	Assmt otr CHF, CP, asthma			\$93.03	
G0267	Bone marrow or psc harvest			\$993.85	
G0268	Removal of impacted wax md			\$170.98	
G0288	Recon, CTA for pre & post sug	e		\$1,979.27	
G0290	Drug-eluting stents, single		+	\$22,382.73	
G0291	Drug-eluting stents, each add		+	\$22,382.73	
G0292	Adm exp drugs, clinical trial			\$659.76	
G0293	Non-cov surg proc, clin trial			\$1,539.43	
G0294	Non-cov proc, clinical trial			\$329.88	
G0296	PET img restag thyrod cance	c		\$6,377.63	
G0297	Insert single chamber/cd		+	\$36,788.34	
G0298	Insert dual chamber/cd		+	\$36,788.34	
G0299	Insert/repos single icd+leads		+	\$49,399.48	
G0300	Insert reposit lead dual+gen		+	\$49,399.48	
G0302	Pre-op service LVRS complete			\$3,298.78	
G0303	Pre-op service LVRS 10-15dos			\$2,419.10	
G0304	Pre-op service LVRS 1-9 dos			\$1,099.59	
G0305	Post op service LVRS min 6			\$1,099.59	
G0338	Linear accelerator stero pln			\$6,377.63	
G0339	Robot lin-radsurg com, first			\$21,750.00	
G0340	Robt lin-radsurg fractx 2-5			\$16,493.88	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 81 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
G3001	Admin + supply, tositumomab			\$9,896.33	
J0130	Abciximab injection			\$1,808.80	
J0150	Injection adenosine 6 MG			\$73.70	
J0152	Adenosine injection			\$215.65	
J0205	Alglucerase injection			\$141.33	
J0207	Amifostine			\$1,597.07	
J0256	Alpha 1 proteinase inhibitor			\$13.06	
J0287	Amphotericin b lipid complex			\$79.40	
J0288	Ampho b cholesteryl sulfate			\$79.40	
J0289	Amphotericin b liposome inj			\$79.40	
J0350	Injection anistreplase 30 u			\$9,497.77	
J0583	Bivalirudin			\$6.13	
J0585	Botulinum toxin a per unit			\$8.13	
J0587	Botulinum toxin type B			\$30.98	
J0637	Caspofungin acetate			\$116.16	
J0850	Cytomegalovirus imm IV /vial			\$2,510.62	
J1190	Dexrazoxane HCl injection			\$428.13	
J1245	Dipyridamole injection			\$52.45	
J1327	Eptifibatid Injection			\$45.22	
J1335	Ertapenem injection			\$83.70	
J1438	Etanercept injection			\$547.07	
J1440	Filgrastim 300 mcg injection			\$655.43	
J1441	Filgrastim 480 mcg injection			\$1,107.34	
J1563	IV immune globulin			\$180.33	
J1564	Immune globulin 10 mg			\$1.58	
J1565	RSV-ivig			\$62.99	
J1570	Ganciclovir sodium injection			\$122.90	
J1626	Granisetron HCl injection			\$59.44	
J1745	Infliximab injection			\$120.69	
J1785	Injection imiglucerase /unit			\$4.71	
J1825	Interferon beta-1a			\$471.09	
J1830	Interferon beta-1b / .25 MG			\$255.86	
J1950	Leuprolide acetate /3.75 MG			\$1,823.97	
J2020	Linezolid injection			\$129.76	
J2260	Inj milnnone lactate / 5 MG			\$39.00	
J2324	Nesiritide			\$534.59	
J2353	Octreotide injection, depot			\$280.22	
J2354	Octreotide inj, non-depot			\$15.01	
J2355	Oprelvekin injection			\$944.56	
J2430	Pamidronate disodjum /30 MG			\$465.61	
J2505	Injection, pegfilgrastim 6mg			\$9,881.02	
J2545	Pentamidine isethionate/300mg			\$281.20	
J2788	Rho d immune globulin 50 mcg			\$122.59	SAF
J2790	Rho d immune globulin inj			\$353.71	
J2792	Rho(D) immune globulin h, sd			\$72.45	
J2820	Sargramostim injection			\$102.46	
J2941	Somatropin injection			\$1,133.47	
J2993	Retepase injection			\$4,810.72	
J2995	Inj streptokinase /250000 IU			\$326.73	
J2997	Alteplase recombinant			\$55.66	
J3100	Tenecteplase injection			\$9,487.45	
J3240	Thyrotropin injection			\$2,177.17	
J3245	Tirofiban hydrochloride			\$1,662.02	
J3305	Inj trimetrexate glucuronate			\$502.42	
J3315	Triptorelin pamoate			\$1,357.54	
J3365	Urokinase 250,000 IU inj			\$786.14	
J3395	Verteporfin injection			\$5,141.48	
J3486	Ziprasidone mesylate			\$70.80	
J3487	Zoledronic acid			\$803.38	
J7190	Factor viii			\$0.51	
J7191	Factor VIII (porcine)			\$7.20	
J7192	Factor viii recombinant			\$2.33	
J7193	Factor IX non-recombinant			\$1.94	
J7194	Factor ix complex			\$0.68	

NOTES. CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 82 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
J7195	Factor IX recombinant			\$1.05	
J7198	Anti-inhibitor			\$1.70	
J7310	Ganciclovir long act implant			\$329.39	
J7317	Sodium hyaluronate injection			\$255.65	
J7320	Hylan G-F 20 injection			\$822.03	
J7502	Cyclosporine oral 100 mg			\$7.50	
J7504	Lymphocyte immune globulin			\$982.64	
J7505	Monoclonal antibodies			\$2,837.64	
J7507	Tacrolimus oral per 1 MG			\$4.23	
J7511	Antithymocyte globulin rabbit			\$1,260.75	
J7513	Daclizumab, parenteral			\$1,498.82	
J7517	Mycophenolate mofetil oral			\$3.39	
J7520	Sirolimus, oral			\$9.97	
J7525	Tacrolimus injection			\$418.85	
J7618	Albuterol Inh sol con			\$4.30	SAF
J7619	Albuterol inh sol u d			\$9.88	SAF
J7643	Glycopyrrolate inhal sol u d			\$22.08	SAF
J7644	Ipratropium brom inh sol u d			\$13.05	SAF
J7699	Inhalation solution for DME			\$82.64	SAF
J7799	Non-inhalation drug for DME			\$43.69	SAF
J8499	Oral prescrip drug non chemo			\$5.81	SAF
J8510	Oral busulfan			\$7.34	
J8520	Capecitabine, oral, 150 mg			\$11.96	
J8521	Capecitabine, oral, 500 mg			\$14.84	SAF
J8560	Etoposide oral 50 MG			\$83.41	
J8700	Temozolomide			\$25.93	
J9000	Doxorubic hcl 10 MG vi chemo			\$16.33	
J9001	Doxorubicin hcl liposome inj			\$1,387.33	
J9010	Alemtuzumab injection			\$2,060.95	
J9015	Aldesleukin/single use vial			\$2,589.58	
J9017	Arsenic trioxide			\$130.63	
J9020	Asparaginase injection			\$137.97	
J9031	Bcg live intravesical vac			\$295.13	
J9040	Bleomycin sulfate injection			\$295.74	
J9045	Carboplatin injection			\$524.46	
J9060	Cisplatin 10 MG injection			\$29.41	
J9065	Inj cladribine per 1 MG			\$94.55	
J9070	Cyclophosphamide 100 MG inj			\$10.56	
J9093	Cyclophosphamide lyophilized			\$8.64	
J9096	Cyclophosphamide lyophilized			\$358.93	MedStat
J9098	Cytarabine liposome			\$1,309.65	
J9100	Cytarabine hcl 100 MG inj			\$5.88	
J9130	Dacarbazine 100 mg inj			\$20.21	
J9150	Daunorubicin			\$136.81	
J9151	Daunorubicin citrate liposom			\$245.88	
J9160	Denileukin difitox, 300 mcg			\$4,692.65	
J9170	Docetaxel			\$1,261.89	
J9178	Inj, epirubicin hcl, 2 mg			\$97.44	
J9181	Etoposide 10 MG inj			\$3.15	
J9182	Etoposide 100 MG inj			\$285.85	SAF
J9185	Fludarabine phosphate inj			\$1,255.43	
J9200	Floxuridine injection			\$252.13	
J9201	Gemcitabine HCl			\$426.66	
J9202	Goserelin acetate implant			\$1,574.23	
J9206	Innotecan injection			\$513.85	
J9208	Ifosfomide injection			\$277.15	
J9209	Mesna injection			\$67.22	
J9211	Idarubicin hcl injection			\$678.31	
J9213	Interferon alfa-2a inj			\$122.99	
J9214	Interferon alfa-2b inj			\$52.45	
J9215	Interferon alfa-n3 inj			\$31.10	
J9216	Interferon gamma 1-b inj			\$1,106.47	
J9217	Leuprolide acetate suspnsion			\$2,194.19	
J9218	Leuprolide acetate injection			\$55.12	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 83 OF 84

CPT/ HCPSC Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
J9219	Leuprolide acetate implant			\$19,038.55	
J9245	Inj melphalan hydrochl 50 MG			\$1,481.18	
J9260	Methotrexate sodium inj			\$24.40	SAF
J9265	Paclitaxel injection			\$300.84	
J9268	Pentostatin injection			\$6,792.78	
J9270	Plicamycin (mithramycin) inj			\$330.73	
J9280	Mitomycin 5 MG inj			\$117.66	
J9293	Mitoxantrone hydrochl / 5 MG			\$1,258.07	
J9300	Gemtuzumab ozogamicin			\$7,699.66	
J9310	Rituximab cancer treatment			\$1,757.26	
J9320	Streptozocin injection			\$498.81	
J9340	Thiotepa injection			\$172.46	
J9350	Topotecan			\$2,815.86	
J9355	Trastuzumab			\$204.96	
J9357	Valrubicin, 200 mg			\$1,856.96	
J9390	Vinorelbine tartrate/10 mg			\$384.32	
J9395	Injection, Fulvestrant			\$298.26	
J9600	Porfimer sodium			\$9,076.76	
M0064	Visit for drug monitoring			\$102.26	
P3001	Screening pap smear by phys			\$221.22	MedStat
P9010	Whole blood for transfusion			\$386.75	
P9011	Blood split unit			\$182.27	
P9012	Cryoprecipitate each unit			\$128.92	
P9016	RBC leukocytes reduced			\$523.56	
P9017	Plasma 1 donor frz w/in 8 hr			\$413.61	
P9019	Platelets, each unit			\$182.27	
P9020	Platelet rich plasma unit			\$235.58	
P9021	Red blood cells unit			\$378.91	
P9022	Washed red blood cells unit			\$706.77	
P9023	Frozen plasma, pooled, sd			\$546.76	
P9031	Platelets leukocytes reduced			\$199.07	
P9032	Platelets, irradiated			\$328.95	
P9033	Platelets leukoreduced irrad			\$523.56	
P9034	Platelets, pheresis			\$1,789.77	
P9035	Platelet pheres leukoreduced			\$1,789.77	
P9036	Platelet pheresis irradiated			\$1,951.47	
P9037	Plate pheres leukoredu irrad			\$1,786.97	
P9038	RBC irradiated			\$477.88	
P9039	RBC deglycerolized			\$806.84	
P9040	RBC leukoreduced irradiated			\$806.84	
P9041	Albumin (human), 5%, 50ml			\$67.25	
P9043	Plasma protein fract, 5%, 50ml			\$408.96	
P9044	Cryoprecipitatereducedplasma			\$164.45	
P9045	Albumin (human), 5%, 250 ml			\$261.61	
P9046	Albumin (human), 25%, 20 ml			\$89.77	
P9047	Albumin (human), 25%, 50ml			\$201.57	
P9048	Plasmaprotein fract, 5%, 250ml			\$2,044.80	
P9050	Granulocytes, pheresis unit			\$5,492.07	
P9059	Plasma, frz between 8-24hour			\$413.61	
Q0035	Cardiokymography	b		\$559.82	
Q0081	Infusion ther other than che		+	\$668.67	
Q0083	Chemo by other than infusion	d		\$165.56	
Q0084	Chemotherapy by infusion	d		\$630.33	
Q0085	Chemo by both infusion and o	d		\$427.19	SAF
Q0091	Obtaining screen pap smear		+	\$56.28	
Q0136	Non esrd epoetin alpha inj			\$57.61	
Q0137	Darbepoetin alfa, non esrd			\$15.15	
Q0166	Granisetron HCl 1 mg oral			\$653.82	
Q0180	Dolasetron mesylate oral			\$580.00	
Q0187	Factor viia recombinant			\$5,691.47	
Q2003	Aprotinin, 10,000 kiu			\$63.02	
Q2005	Corticotrelin ovine triflutat			\$1,781.97	
Q2006	Digoxin immune fab (ovine)			\$8.49	
Q2007	Ethanolamine oleate 100 mg			\$318.85	

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 84 OF 84

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
Q2008	Fomepizole, 15 mg			\$50.60	
Q2009	Fosphenytoin, 50 mg			\$26.76	
Q2011	Hemin, per 1 mg			\$32.58	
Q2013	Pentastarch 10% solution			\$664.97	
Q2017	Teniposide, 50 mg			\$1,133.27	
Q2018	Urofollitropin, 75 iu			\$301.65	
Q2019	Basiliximab			\$6,771.71	
Q2022	VonWillebrandFactrCmplxperIU			\$2.19	
Q3000	Rubidium-Rb-82			\$869.66	
Q3002	Gallium ga 67			\$60.00	
Q3003	Technetium tc99m bicisate			\$2,101.19	
Q3005	Technetium tc99m mertiatide			\$7,257.31	
Q3007	Sodium phosphate p32			\$292.22	
Q3008	Indium 111-in pentetretotide			\$5,031.73	
Q3011	Chromic phosphate p32			\$357.45	
Q3012	Cyanocobalamin cobalt co57			\$208.39	
Q3025	IM inj interferon beta 1-a			\$50.86	
Q4051	Splint supplies misc			\$68.56	SAF

Key to Status/Usage Indicators:

- a Cannot be billed by VA non-provider-based clinics, because the charge is included in the associated professional charge.
- b Cannot be billed by VA non-provider-based clinics, because a technical component charge from the professional charge table applies.
- c Can be billed by VA non-provider-based clinics.
- d Cannot be billed by VA non-provider-based clinics, because a different code is used for professional billing.
- e Cannot be billed by VA non-provider-based clinics, because a stand-alone charge from the professional charge table applies.
- f Can be billed for patients who are subsequently admitted to the hospital.
- All other procedures cannot be billed by VA non-provider-based clinics, (because the service is generally considered facility only, or else the facility charge is included in the professional non-facility practice expense units).

Charge Methodology:

No entry: RVUs obtained from the Medicare APC Fee Schedule.
 All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.1.

NOTES: CPT Codes and descriptions only copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 CDT-4 Codes copyright American Dental Association. All rights reserved

¹ See end of table.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 1 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
10021		Fna w/o image	Surgery		1.27	0.54	2.20		
10022		Fna w/image	Surgery		1.27	0.42	2.61		
10040		Acne surgery	Surgery		1.18	0.68	1.02		
10060		Drainage of skin abscess	Surgery		1.17	0.94	1.20		
10061		Drainage of skin abscess	Surgery		2.40	1.51	1.81		
10080		Drainage of pilonidal cyst	Surgery		1.17	1.14	3.13		
10081		Drainage of pilonidal cyst	Surgery		2.45	1.51	4.11		
10120		Remove foreign body	Surgery		1.22	0.41	1.46		
10121		Remove foreign body	Surgery		2.69	1.88	3.33		
10140		Drainage of hematoma/fluid	Surgery		1.53	0.91	1.51		
10160		Puncture drainage of lesion	Surgery		1.20	0.46	0.73		
10180		Complex drainage, wound	Surgery		2.25	2.08	3.25		
11000		Debride infected skin	Surgery		0.60	0.22	0.57		
11001		Debride infected skin add-on	Surgery		0.30	0.11	0.23		
11010		Debride skin, fx	Surgery		4.19	2.33	6.74		
11011		Debride skin, fx	Surgery		4.94	2.37	8.03		
11012		Debride skin/muscle, fx	Surgery		6.87	3.86	12.01		
11040		Debride skin/muscle/bone, fx	Surgery		0.50	0.21	0.51		
11041		Debride skin, partial	Surgery		0.82	0.33	0.65		
11042		Debride skin, full	Surgery		1.12	0.45	0.97		
11043		Debride skin/tissue	Surgery		2.38	2.61	3.41		
11044		Debride tissue/muscle	Surgery		3.06	3.77	4.50		
11055		Debride tissue/muscle/bone	Surgery		0.43	0.17	0.55		
11056		Trim skin lesion	Surgery		0.61	0.24	0.63		
11057		Trim skin lesions, 2 to 4	Surgery		0.79	0.31	0.73		
11100		Trim skin lesions, over 4	Surgery		0.81	0.37	1.26		
11101		Biopsy of skin lesion	Surgery		0.41	0.19	0.34		
11200		Biopsy, skin add-on	Surgery		0.77	0.77	1.06		
11201		Removal of skin tags	Surgery		0.29	0.12	0.16		
11300		Remove skin tags add-on	Surgery		0.51	0.22	1.00		
11301		Shave skin lesion	Surgery		0.85	0.37	1.12		
11302		Shave skin lesion	Surgery		1.05	0.46	1.31		
11303		Shave skin lesion	Surgery		1.24	0.52	1.59		
11305		Shave skin lesion	Surgery		0.67	0.27	0.84		
11306		Shave skin lesion	Surgery		0.99	0.41	1.11		
11307		Shave skin lesion	Surgery		1.14	0.49	1.29		
11308		Shave skin lesion	Surgery		1.41	0.59	1.45		
11310		Shave skin lesion	Surgery		0.73	0.33	1.12		
11311		Shave skin lesion	Surgery		1.05	0.48	1.24		
11312		Shave skin lesion	Surgery		1.20	0.55	1.44		
11313		Shave skin lesion	Surgery		1.62	0.72	1.82		
11401		Exc tr-ext b9+marg 0.5 < cm	Surgery		0.85	0.89	2.00		
11402		Exc tr-ext b9+marg 0.6-1 cm	Surgery		1.23	1.03	2.07		
11403		Exc tr-ext b9+marg 1.1-2 cm	Surgery		1.51	1.10	2.25		
11404		Exc tr-ext b9+marg 2.1-3 cm	Surgery		1.79	1.33	2.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 2 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
11404		Exc tr-ext b9+marg 3.1-4 cm	Surgery		2.06	1.41	2.73		
11406		Exc tr-ext b9+marg > 4.0 cm	Surgery		2.76	1.67	3.10		
11420		Exc h-f-nk-sp b9+marg 0.5 <	Surgery		0.98	0.94	1.77		
11421		Exc h-f-nk-sp b9+marg 0.6-1	Surgery		1.42	1.12	2.08		
11422		Exc h-f-nk-sp b9+marg 1.1-2	Surgery		1.63	1.34	2.27		
11423		Exc h-f-nk-sp b9+marg 2.1-3	Surgery		2.01	1.46	2.61		
11424		Exc h-f-nk-sp b9+marg 3.1-4	Surgery		2.43	1.61	2.82		
11426		Exc h-f-nk-sp b9+marg > 4 cm	Surgery		3.77	2.11	3.52		
11440		Exc face-mm b9+marg 0.5 < cm	Surgery		1.06	1.33	2.28		
11441		Exc face-mm b9+marg 0.6-1 cm	Surgery		1.48	1.51	2.40		
11442		Exc face-mm b9+marg 1.1-2 cm	Surgery		1.72	1.56	2.59		
11443		Exc face-mm b9+marg 2.1-3 cm	Surgery		2.29	1.83	2.97		
11444		Exc face-mm b9+marg 3.1-4 cm	Surgery		3.14	2.19	3.54		
11446		Exc face-mm b9+marg > 4 cm	Surgery		4.48	2.78	4.11		
11450		Removal, sweat gland lesion	Surgery		2.73	2.03	5.11		
11451		Removal, sweat gland lesion	Surgery		3.94	2.56	6.74		
11462		Removal, sweat gland lesion	Surgery		2.51	2.02	5.20		
11463		Removal, sweat gland lesion	Surgery		3.94	2.69	6.96		
11470		Removal, sweat gland lesion	Surgery		3.25	2.27	5.14		
11471		Removal, sweat gland lesion	Surgery		4.40	2.78	6.85		
11600		Exc tr-ext mlg+marg 0.5 < cm	Surgery		1.31	0.98	2.65		
11601		Exc tr-ext mlg+marg 0.6-1 cm	Surgery		1.80	1.23	2.72		
11602		Exc tr-ext mlg+marg 1.1-2 cm	Surgery		1.95	1.27	2.86		
11603		Exc tr-ext mlg+marg 2.1-3 cm	Surgery		2.19	1.33	3.11		
11604		Exc tr-ext mlg+marg 3.1-4 cm	Surgery		2.40	1.40	3.41		
11606		Exc tr-ext mlg+marg > 4 cm	Surgery		3.42	1.75	4.11		
11620		Exc h-f-nk-sp mlg+marg 0.5 <	Surgery		1.19	0.96	2.62		
11621		Exc h-f-nk-sp mlg+marg 0.6-1	Surgery		1.76	1.25	2.73		
11622		Exc h-f-nk-sp mlg+marg 1.1-2	Surgery		2.09	1.39	3.00		
11623		Exc h-f-nk-sp mlg+marg 2.1-3	Surgery		2.61	1.59	3.36		
11624		Exc h-f-nk-sp mlg+marg 3.1-4	Surgery		3.06	1.78	3.79		
11626		Exc h-f-nk-sp mlg+marg > 4 cm	Surgery		4.29	2.40	4.70		
11640		Exc face-mm mlig+marg 0.5 <	Surgery		1.35	1.12	2.69		
11641		Exc face-mm mlig+marg 0.6-1	Surgery		2.16	1.54	3.06		
11642		Exc face-mm mlig+marg 1.1-2	Surgery		2.59	1.73	3.44		
11643		Exc face-mm mlig+marg 2.1-3	Surgery		3.10	1.96	3.85		
11644		Exc face-mm mlig+marg 3.1-4	Surgery		4.02	2.47	4.74		
11646		Exc face-mm mlig+marg > 4 cm	Surgery		5.94	3.49	5.81		
11719		Trim nail(s)	Surgery		0.17	0.07	0.25		
11720		Debride nail, 1-5	Surgery		0.32	0.13	0.34		
11721		Debride nail, 6 or more	Surgery		0.54	0.21	0.43		
11730		Removal of nail plate	Surgery		1.13	0.43	1.02		
11732		Remove nail plate, add-on	Surgery		0.57	0.22	0.43		
11740		Drain blood from under nail	Surgery		0.37	0.14	0.85		
11750		Removal of nail bed	Surgery		1.86	1.72	2.13		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 3 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
11752		Remove nail bed/finger tip	Surgery		2.67	2.95	2.95		
11755		Biopsy, nail unit	Surgery		1.31	0.54	1.10		
11760		Repair of nail bed	Surgery		1.58	1.21	1.84		
11762		Reconstruction of nail bed	Surgery		2.89	1.83	2.27		
11765		Excision of nail fold, toe	Surgery		0.69	0.52	1.14		
11770		Removal of pilonidal lesion	Surgery		2.61	1.51	3.52		
11771		Removal of pilonidal lesion	Surgery		5.73	3.33	5.70		
11772		Removal of pilonidal lesion	Surgery		6.97	3.87	7.17		
11800		Injection into skin lesions	Surgery		0.52	0.22	0.65		
11901		Added skin lesions injection	Surgery		0.80	0.38	0.66		
11920		Correct skin color defects	Surgery		1.61	0.78	1.99		
11921		Correct skin color defects	Surgery		1.93	0.98	2.36		
11922		Correct skin color defects	Surgery		0.49	0.25	0.37		
11950		Therapy for contour defects	Surgery		0.84	0.40	1.15		
11951		Therapy for contour defects	Surgery		1.19	0.51	1.50		
11952		Therapy for contour defects	Surgery		1.69	0.68	1.87		
11954		Therapy for contour defects	Surgery		1.85	0.91	2.44		
11960		Insert tissue expander(s)	Surgery		9.07	10.52	10.52		
11970		Replace tissue expander(s)	Surgery		7.05	6.10	6.10		
11971		Remove tissue expander(s)	Surgery		2.13	4.76	7.10		
11975		Insert contraceptive cap	Surgery		1.48	0.57	1.42		
11976		Removal of contraceptive cap	Surgery		1.78	0.68	1.70		
11977		Removal/reinsert contra cap	Surgery		3.30	1.26	2.27		
11980		Implant hormone pellet(s)	Surgery		1.48	0.54	1.10		
11981		Insert drug implant device	Surgery		1.48	0.68	1.74		
11982		Remove drug implant device	Surgery		1.78	0.84	1.97		
11983		Remove/insert drug implant	Surgery		3.30	1.47	2.32		
12001		Repair superficial wound(s)	Surgery		1.70	0.49	2.00		
12002		Repair superficial wound(s)	Surgery		1.86	0.93	2.06		
12004		Repair superficial wound(s)	Surgery		2.24	1.05	2.36		
12005		Repair superficial wound(s)	Surgery		2.86	1.23	2.85		
12006		Repair superficial wound(s)	Surgery		3.66	1.54	3.43		
12007		Repair superficial wound(s)	Surgery		4.11	1.84	3.86		
12011		Repair superficial wound(s)	Surgery		1.76	0.50	2.16		
12013		Repair superficial wound(s)	Surgery		1.99	0.97	2.31		
12014		Repair superficial wound(s)	Surgery		2.46	1.09	2.61		
12015		Repair superficial wound(s)	Surgery		3.19	1.28	3.19		
12016		Repair superficial wound(s)	Surgery		3.92	1.56	3.60		
12017		Repair superficial wound(s)	Surgery		4.70	1.91	1.91		
12018		Repair superficial wound(s)	Surgery		5.52	2.27	2.27		
12020		Closure of split wound	Surgery		2.62	1.75	2.65		
12021		Closure of split wound	Surgery		1.84	1.41	1.74		
12031		Layer closure of wound(s)	Surgery		2.15	0.81	2.31		
12032		Layer closure of wound(s)	Surgery		2.47	1.84	3.88		
12034		Layer closure of wound(s)	Surgery		2.92	1.41	3.17		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 4 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
12035		Layer closure of wound(s)	Surgery		3.42	2.18	5.26		
12036		Layer closure of wound(s)	Surgery		4.04	2.38	5.36		
12037		Layer closure of wound(s)	Surgery		4.66	2.78	6.41		
12041		Layer closure of wound(s)	Surgery		2.37	0.87	2.47		
12042		Layer closure of wound(s)	Surgery		2.74	1.37	3.21		
12044		Layer closure of wound(s)	Surgery		3.14	1.56	3.20		
12045		Layer closure of wound(s)	Surgery		3.63	2.17	3.67		
12046		Layer closure of wound(s)	Surgery		4.24	2.76	6.57		
12047		Layer closure of wound(s)	Surgery		4.64	3.10	6.42		
12051		Layer closure of wound(s)	Surgery		2.47	1.36	3.23		
12052		Layer closure of wound(s)	Surgery		2.77	1.34	3.17		
12053		Layer closure of wound(s)	Surgery		3.12	1.50	3.22		
12054		Layer closure of wound(s)	Surgery		3.45	1.60	3.54		
12055		Layer closure of wound(s)	Surgery		4.42	2.14	6.76		
12056		Layer closure of wound(s)	Surgery		5.23	3.07	6.10		
12057		Layer closure of wound(s)	Surgery		5.95	3.76	6.10		
13100		Repair of wound or lesion	Surgery		3.12	1.78	3.51		
13101		Repair of wound or lesion	Surgery		3.91	2.22	3.75		
13102		Repair of wound or lesion	Surgery		1.24	0.57	0.74		
13120		Repair of wound or lesion	Surgery		3.30	1.82	3.61		
13121		Repair of wound or lesion	Surgery		4.32	2.32	3.97		
13122		Repair of wound or lesion	Surgery		1.44	0.63	0.87		
13131		Repair of wound or lesion	Surgery		3.78	2.14	3.88		
13132		Repair of wound or lesion	Surgery		5.94	3.17	4.68		
13133		Repair of wound or lesion	Surgery		2.19	1.03	1.19		
13150		Repair of wound or lesion	Surgery		3.80	2.61	5.50		
13151		Repair of wound or lesion	Surgery		4.44	3.03	5.40		
13152		Repair of wound or lesion	Surgery		6.32	3.93	6.08		
13153		Repair of wound or lesion	Surgery		2.38	1.14	1.34		
13160		Late closure of wound	Surgery		10.46	7.14	7.14		
14000		Skin tissue rearrangement	Surgery		5.88	5.12	8.52		
14001		Skin tissue rearrangement	Surgery		8.46	6.59	9.94		
14020		Skin tissue rearrangement	Surgery		6.58	5.99	9.17		
14021		Skin tissue rearrangement	Surgery		10.04	7.74	10.45		
14040		Skin tissue rearrangement	Surgery		7.86	6.86	8.25		
14041		Skin tissue rearrangement	Surgery		11.47	8.68	10.64		
14060		Skin tissue rearrangement	Surgery		8.49	7.69	9.08		
14061		Skin tissue rearrangement	Surgery		12.27	9.51	11.66		
14300		Skin tissue rearrangement	Surgery		11.74	9.17	11.19		
14350		Skin tissue rearrangement	Surgery		9.60	7.12	7.12		
15000		Skin graft	Surgery		3.99	2.20	3.81		
15001		Skin graft add-on	Surgery		1.00	0.41	1.36		
15050		Skin pinch graft	Surgery		4.29	4.74	5.97		
15100		Skin split graft	Surgery		9.04	7.80	12.63		
15101		Skin split graft add-on	Surgery		1.72	1.66	3.83		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. --- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 5 OF 179

CPT/ HCP/PCS Code	Modifier	CPT/HCP/PCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
15120		Skin split graft			9.82	7.77	10.78		
15121		Skin split graft add-on			2.67	1.87	4.58		
15200		Skin full graft			8.02	6.00	10.71		
15201		Skin full graft add-on			1.32	0.62	1.04		
15220		Skin full graft			7.86	6.43	10.59		
15221		Skin full graft add-on			1.19	0.56	0.91		
15240		Skin full graft			9.03	7.65	10.15		
15241		Skin full graft add-on			1.86	0.92	1.45		
15260		Skin full graft			10.04	8.60	9.88		
15261		Skin full graft add-on			2.23	1.42	2.72		
15342		Cultured skin graft, 25 cm			1.00	0.55	1.83		
15343		Culture skin graft addl 25 cm			0.25	0.10	0.27		
15350		Skin homograft			3.99	4.83	8.22		
15351		Skin homograft add-on			1.00	0.39	0.94		
15400		Skin heterograft			3.99	4.10	4.18		
15401		Skin heterograft add-on			1.00	0.44	1.22		
15570		Form skin pedicle flap			9.20	6.68	9.17		
15572		Form skin pedicle flap			9.26	6.25	8.38		
15574		Form skin pedicle flap			8.68	6.95	8.79		
15576		Form skin pedicle flap			1.91	2.70	7.04		
15600		Skin graft			2.42	3.03	3.73		
15610		Skin graft			2.94	3.67	7.46		
15620		Skin graft			3.27	3.93	6.84		
15630		Skin graft			3.96	4.02	6.70		
15650		Transfer skin pedicle flap			17.81	12.22	18.05		
15732		Muscle-skin graft, head/neck			17.76	12.34	17.84		
15734		Muscle-skin graft, trunk			16.25	11.22	18.16		
15736		Muscle-skin graft, arm			17.89	11.74	17.93		
15738		Muscle-skin graft, leg			10.23	7.88	9.81		
15740		Island pedicle flap graft			11.39	5.04	9.04		
15750		Neurovascular pedicle graft			35.18	20.69	20.69		
15756		Free myo/skin flap microvasc			35.18	21.73	21.73		
15757		Free skin flap, microvasc			35.05	21.72	21.72		
15758		Free fascial flap, microvasc			8.73	7.02	9.71		
15760		Composite skin graft			7.51	6.69	6.69		
15770		Dermat-fat-fascia graft			3.95	1.32	2.78		
15775		Hair transplant punch grafts			5.53	2.81	5.39		
15776		Hair transplant punch grafts			7.28	7.07	7.07		
15780		Abrasion treatment of skin			4.84	5.35	5.35		
15781		Abrasion treatment of skin			4.31	4.30	4.30		
15782		Abrasion treatment of skin			4.28	4.17	4.92		
15783		Abrasion treatment of skin			2.03	1.27	1.63		
15786		Abrasion, lesion, single			0.33	0.16	0.32		
15787		Abrasion, lesions, add-on			2.09	2.27	3.34		
15788		Chemical peel, face, epiderm							

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 6 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
15789		Chemical peel, face, dermal	Surgery		4.91	4.91	6.39		
15792		Chemical peel, nonfacial	Surgery		1.86	2.76	3.16		
15793		Chemical peel, nonfacial	Surgery		3.73	4.14	4.14		
15810		Salabrasion	Surgery		4.73	3.87	3.87		
15811		Salabrasion	Surgery		5.38	5.52	6.31		
15819		Plastic surgery, neck	Surgery		9.37	7.20	7.20		
15820		Revision of lower eyelid	Surgery		5.14	5.34	6.85		
15821		Revision of lower eyelid	Surgery		5.71	5.23	7.23		
15822		Revision of upper eyelid	Surgery		4.44	4.36	5.80		
15823		Revision of upper eyelid	Surgery		7.04	6.24	7.79		
15824		Removal of forehead wrinkles	Surgery					17.87	MDR
15825		Removal of neck wrinkles	Surgery					20.42	MDR
15826		Removal of brow wrinkles	Surgery					17.87	MDR
15828		Removal of face wrinkles	Surgery					47.23	MDR
15829		Removal of skin wrinkles	Surgery					52.34	MDR
15831		Excise excessive skin tissue	Surgery						
15832		Excise excessive skin tissue	Surgery		12.38	8.22	8.22		
15833		Excise excessive skin tissue	Surgery		11.57	8.38	8.38		
15834		Excise excessive skin tissue	Surgery		10.62	6.24	6.24		
15835		Excise excessive skin tissue	Surgery		10.83	7.71	7.71		
15836		Excise excessive skin tissue	Surgery		11.65	7.63	11.40		
15837		Excise excessive skin tissue	Surgery		9.33	6.81	6.81		
15838		Excise excessive skin tissue	Surgery		8.42	7.00	7.80		
15839		Excise excessive skin tissue	Surgery		7.12	6.09	6.09		
15840		Graft for face nerve palsy	Surgery		9.37	6.21	7.84		
15841		Graft for face nerve palsy	Surgery		13.24	10.05	10.05		
15842		Flap for face nerve palsy	Surgery		23.23	15.08	15.08		
15845		Skin and muscle repair, face	Surgery		37.90	23.01	23.01		
15850		Removal of sutures	Surgery		12.55	9.36	9.36		
15851		Removal of sutures	Surgery		0.78	0.30	1.58		
15852		Dressing change, not for burn	Surgery		0.86	0.34	1.72		
15860		Test for blood flow in graft	Surgery		0.86	0.36	1.87		
15876		Suction assisted lipectomy	Surgery		1.95	0.79	1.28		
15877		Suction assisted lipectomy	Surgery						
15878		Suction assisted lipectomy	Surgery						
15879		Suction assisted lipectomy	Surgery						
15920		Removal of tail bone ulcer	Surgery		7.94	5.61	5.61		PHCS
15922		Removal of tail bone ulcer	Surgery		9.89	7.31	7.31		PHCS
15931		Remove sacrum pressure sore	Surgery		9.23	5.75	5.75		PHCS
15933		Remove sacrum pressure sore	Surgery		10.83	7.94	7.94		
15934		Remove sacrum pressure sore	Surgery		12.67	8.15	8.15		
15935		Remove sacrum pressure sore	Surgery		14.55	10.40	10.40		
15936		Remove sacrum pressure sore	Surgery		12.36	8.36	8.36		
15937		Remove sacrum pressure sore	Surgery		14.19	9.96	9.96		
15940		Remove hip pressure sore	Surgery		9.33	6.23	6.23		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 7 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
15941		Remove hip pressure sore	Surgery		11.41	9.58	9.58	9.58	Misc.
15944		Remove hip pressure sore	Surgery		11.44	8.70	8.70	8.70	
15945		Remove hip pressure sore	Surgery		12.67	9.74	9.74	9.74	
15946		Remove hip pressure sore	Surgery		21.54	14.41	14.41	14.41	
15950		Remove thigh pressure sore	Surgery		7.53	5.47	5.47	5.47	
15951		Remove thigh pressure sore	Surgery		10.70	7.95	7.95	7.95	
15952		Remove thigh pressure sore	Surgery		11.37	7.83	7.83	7.83	
15953		Remove thigh pressure sore	Surgery		12.61	9.07	9.07	9.07	
15956		Remove thigh pressure sore	Surgery		15.50	10.85	10.85	10.85	
15958		Remove thigh pressure sore	Surgery		15.46	11.13	11.13	11.13	
15989		Removal of pressure sore	Surgery						
16000		Initial treatment of burn(s)	Surgery		0.89	0.27	0.86	0.86	
16010		Treatment of burn(s)	Surgery		0.87	0.63	0.66	0.66	
16015		Treatment of burn(s)	Surgery		2.35	1.15	1.15	1.15	
16020		Treatment of burn(s)	Surgery		0.80	0.61	1.31	1.31	
16025		Treatment of burn(s)	Surgery		1.85	0.97	1.79	1.79	
16030		Treatment of burn(s)	Surgery		2.08	1.12	2.20	2.20	
16035		Incision of burn scab, initi	Surgery		3.74	1.47	1.47	1.47	
16036		Inclise burn scab, add incis	Surgery		1.50	0.60	0.60	0.60	
17000		Destroy benign/premigl lesion	Surgery		0.60	0.32	0.98	0.98	
17003		Destroy lesions, 2-14	Surgery		0.15	0.07	0.11	0.11	
17004		Destroy lesions, 15 or more	Surgery		2.79	1.29	2.32	2.32	
17106		Destruction of skin lesions	Surgery		4.58	3.34	4.87	4.87	
17107		Destruction of skin lesions	Surgery		9.15	5.45	7.52	7.52	
17108		Destruction of skin lesions	Surgery		13.18	7.68	9.65	9.65	
17110		Destruct lesion, 1-14	Surgery		0.65	0.49	1.83	1.83	
17111		Destruct lesion, 15 or more	Surgery		0.92	0.59	1.68	1.68	
17250		Chemical cautery, tissue	Surgery		0.50	0.35	1.23	1.23	
17260		Destruction of skin lesions	Surgery		0.91	0.44	1.28	1.28	
17261		Destruction of skin lesions	Surgery		1.17	0.59	1.62	1.62	
17262		Destruction of skin lesions	Surgery		1.56	0.78	1.89	1.89	
17263		Destruction of skin lesions	Surgery		1.79	0.88	2.07	2.07	
17264		Destruction of skin lesions	Surgery		1.94	0.89	2.23	2.23	
17266		Destruction of skin lesions	Surgery		2.34	0.99	2.53	2.53	
17270		Destruction of skin lesions	Surgery		1.32	0.64	1.71	1.71	
17271		Destruction of skin lesions	Surgery		1.49	0.74	1.79	1.79	
17272		Destruction of skin lesions	Surgery		1.77	0.88	2.00	2.00	
17273		Destruction of skin lesions	Surgery		2.05	0.99	2.21	2.21	
17274		Destruction of skin lesions	Surgery		2.59	1.20	2.58	2.58	
17276		Destruction of skin lesions	Surgery		3.20	1.44	2.97	2.97	
17280		Destruction of skin lesions	Surgery		1.17	0.57	1.62	1.62	
17281		Destruction of skin lesions	Surgery		1.72	0.86	1.91	1.91	
17282		Destruction of skin lesions	Surgery		2.04	1.01	2.17	2.17	
17283		Destruction of skin lesions	Surgery		2.64	1.25	2.56	2.56	
17284		Destruction of skin lesions	Surgery		3.21	1.52	2.94	2.94	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 8 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
17286		Destruction of skin lesions	Surgery		4.43	2.19	3.71		
17304		1 stage mohs, up to 5 spec	Surgery		7.59	3.57	8.09		
17305		2 stage mohs, up to 5 spec	Surgery		2.85	1.34	3.81		
17306		3 stage mohs, up to 5 spec	Surgery		2.85	1.35	3.83		
17307		Mohs addl stage up to 5 spec	Surgery		2.85	1.37	3.78		
17310		Mohs any stage > 5 spec each	Surgery		0.95	0.46	1.65		
17340		Cryotherapy of skin	Surgery		0.76	0.31	0.37		
17360		Skin peel therapy	Surgery		1.43	0.75	1.46		
17380		Hair removal by electrolysis	Surgery					0.76	MDR
17999		Skin tissue procedure	Surgery					1.74	Misc.
19000		Drainage of breast lesion	Surgery		0.84	0.36	2.03		
19001		Drain breast lesion add-on	Surgery		0.42	0.14	0.79		
19002		Incision of breast lesion	Surgery		3.56	2.77	6.00		
19030		Injection for breast x-ray	Surgery		1.53	0.50	3.37		
19100		Bx breast percut w/o image	Surgery		1.27	0.42	2.15		
19101		Bx breast percut w/image	Surgery		3.18	1.68	4.69		
19102		Bx breast percut w/device	Surgery		2.00	0.65	3.98		
19103		Nipple exploration	Surgery		3.69	1.23	12.07		
19110		Excise breast duct fistula	Surgery		4.29	3.06	5.82		
19112		Removal of breast lesion	Surgery		3.66	2.68	5.80		
19120		Excision, breast lesion	Surgery		5.55	3.08	4.58		
19125		Excision, addl breast lesion	Surgery		6.05	3.30	4.83		
19126		Removal of breast tissue	Surgery		2.93	1.01	1.01		
19140		Removal of breast tissue	Surgery		5.13	3.42	7.29		
19160		Remove breast tissue, nodes	Surgery		5.98	3.45	3.45		
19162		Removal of breast	Surgery		13.51	6.38	6.38		
19180		Removal of breast	Surgery		8.79	5.06	5.06		
19182		Removal of breast	Surgery		7.72	4.81	4.81		
19200		Removal of breast	Surgery		15.47	8.04	8.04		
19220		Removal of breast	Surgery		15.70	8.30	8.30		
19240		Removal of chest wall lesion	Surgery		15.98	8.28	8.28		
19260		Revision of chest wall	Surgery		15.42	11.30	11.30		
19271		Extensive chest wall surgery	Surgery		18.87	18.23	18.23		
19272		Place needle wire, breast	Surgery		21.52	19.18	19.18		
19290		Place needle wire, breast	Surgery		1.27	0.41	3.01		
19291		Place breast clip, percut	Surgery		0.63	0.21	1.75		
19295		Suspension of breast	Surgery		0.00	2.77	2.77		
19316		Reduction of large breast	Surgery		10.67	7.59	7.59		
19318		Enlarge breast	Surgery		15.60	11.20	11.20		
19324		Enlarge breast with implant	Surgery		5.84	4.92	4.92		
19325		Removal of breast implant	Surgery		8.44	6.59	6.59		
19328		Removal of implant material	Surgery		5.67	5.07	5.07		
19330		Immediate breast prosthesis	Surgery		7.58	6.07	6.07		
19340		Delayed breast prosthesis	Surgery		6.32	3.12	3.12		
19342			Surgery		11.18	8.97	8.97		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 9 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
19350		Breast reconstruction	Surgery		8.91	7.11	14.20		
19355		Correct inverted nipple(s)	Surgery		7.56	5.00	12.80		
19357		Breast reconstruction	Surgery		18.13	13.85	13.85		
19361		Breast reconstruction	Surgery		19.23	11.78	11.78		
19364		Breast reconstruction	Surgery		40.94	23.64	23.64		
19366		Breast reconstruction	Surgery		21.25	11.23	11.23		
19367		Breast reconstruction	Surgery		25.69	16.57	16.57		
19368		Breast reconstruction	Surgery		32.37	20.26	20.26		
19369		Breast reconstruction	Surgery		29.78	19.79	19.79		
19370		Surgery of breast capsule	Surgery		9.34	6.95	6.95		
19371		Removal of breast capsule	Surgery		9.13	7.87	7.87		
19380		Revise breast reconstruction	Surgery		2.17	7.76	7.76		
19396		Design custom breast implant	Surgery			0.99	5.78	8.77	Misc.
19499		Breast surgery procedure	Surgery						
20000		Incision of abscess	Surgery		2.12	1.61	2.36		
20005		Incision of deep abscess	Surgery		3.41	2.42	3.34		
20100		Explore wound, neck	Surgery		10.06	4.38	5.79		
20101		Explore wound, chest	Surgery		3.22	1.61	2.96		
20102		Explore wound, abdomen	Surgery		3.93	1.80	3.51		
20103		Explore wound, extremity	Surgery		5.29	3.23	4.14		
20150		Excise epiphyseal bar	Surgery		13.67	7.21	7.21		
20200		Muscle biopsy	Surgery		1.46	0.78	3.19		
20205		Deep muscle biopsy	Surgery		2.35	1.21	4.14		
20206		Needle biopsy, muscle	Surgery		0.99	0.35	3.17		
20220		Bone biopsy, trocar/needle	Surgery		1.27	2.89	4.73		
20225		Bone biopsy, excisional	Surgery		1.87	2.96	4.92		
20240		Bone biopsy, excisional	Surgery		3.23	2.60	2.80		
20245		Bone biopsy, excisional	Surgery		7.77	6.36	6.36		
20250		Open bone biopsy	Surgery		5.02	4.54	4.54		
20251		Open bone biopsy	Surgery		5.55	5.17	5.17		
20500		Injection of sinus tract	Surgery		1.23	3.89	5.88		
20501		Injection of sinus tract for x-ray	Surgery		0.76	0.25	3.03		
20520		Removal of foreign body	Surgery		1.85	1.81	2.25		
20525		Removal of foreign body	Surgery		3.49	2.66	3.43		
20526		Removal of foreign body	Surgery		0.94	0.51	0.97		
20550		Ther injection, carp tunnel	Surgery		0.75	0.24	0.71		
20551		inj tendon sheath/ligament	Surgery		0.75	0.34	0.68		
20552		inject tendon origin/insert	Surgery		0.66	0.21	0.73		
20553		inject trigger point, 1 or 2	Surgery		0.75	0.23	0.84		
20600		inject trigger points, =/> 3	Surgery		0.68	0.36	0.64		
20605		Drain/inject, joint/bursa	Surgery		0.88	0.37	0.75		
20610		Drain/inject, joint/bursa	Surgery		0.79	0.41	0.94		
20612		Aspirate/inj ganglion cyst	Surgery		0.70	0.34	0.71		
20815		Treatment of bone cyst	Surgery		2.28	1.83	2.54		
20850		Insert and remove bone pin	Surgery		2.23	1.94	2.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 10 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
20660		Apply, rem fixation device	Surgery		2.51	1.70	3.07		
20661		Application of head brace	Surgery		4.88	4.95	4.95		
20662		Application of pelvis brace	Surgery		6.06	5.43	5.43		
20663		Application of thigh brace	Surgery		5.42	4.76	4.76		
20664		Halo brace application	Surgery		8.05	7.03	7.03		
20665		Removal of fixation device	Surgery		1.31	1.30	2.05		
20670		Removal of support implant	Surgery		1.74	3.93	6.69		
20680		Removal of support implant	Surgery		3.34	3.22	3.22		
20690		Apply bone fixation device	Surgery		3.51	2.47	2.47		
20692		Apply bone fixation device	Surgery		6.40	3.73	3.73		
20693		Adjust bone fixation device	Surgery		5.85	5.54	5.54		
20694		Remove bone fixation device	Surgery		4.15	4.49	6.86		
20802		Replantation, arm, complete	Surgery		41.09	21.40	21.40		
20805		Replant forearm, complete	Surgery		49.93	35.06	35.06		
20808		Replantation hand, complete	Surgery		61.56	43.43	43.43		
20816		Replantation digit, complete	Surgery		30.89	39.17	39.17		
20822		Replantation digit, complete	Surgery		25.55	35.90	35.90		
20824		Replantation thumb, complete	Surgery		30.89	38.12	38.12		
20827		Replantation thumb, complete	Surgery		26.37	37.95	37.95		
20838		Replantation foot, complete	Surgery		41.35	22.70	22.70		
20900		Removal of bone for graft	Surgery		5.57	5.79	7.31		
20902		Remove cartilage for graft	Surgery		7.54	6.86	6.86		
20910		Remove cartilage for graft	Surgery		5.33	5.44	7.11		
20912		Remove of fascia for graft	Surgery		6.34	6.09	6.09		
20920		Removal of fascia for graft	Surgery		5.30	4.37	4.37		
20922		Removal of tendon for graft	Surgery		6.60	5.06	6.73		
20924		Removal of tendon for graft	Surgery		6.47	5.92	5.92		
20926		Removal of tissue for graft	Surgery		5.52	4.93	4.93		
20930		Spinal bone allograft	Surgery					3.65	MDR
20931		Spinal bone allograft	Surgery		1.81	0.93	0.93		
20936		Spinal bone autograft	Surgery		2.79	1.46	1.46		
20937		Spinal bone autograft	Surgery		3.02	1.56	1.56		
20938		Spinal bone autograft	Surgery		1.26	1.01	1.36		
20950		Fluid pressure, muscle	Surgery		39.15	25.01	25.01		
20955		Fibula bone graft, microvasc	Surgery		24.86	24.86	24.86		
20956		Iliac bone graft, microvasc	Surgery		19.08	19.08	19.08		
20957		Mt bone graft, microvasc	Surgery		39.21	26.41	26.41		
20962		Other bone graft, microvasc	Surgery		43.85	27.48	27.48		
20969		Bone/skin graft, microvasc	Surgery		43.00	25.84	25.84		
20970		Bone/skin graft, iliac crest	Surgery		42.93	20.14	21.79		
20972		Bone/skin graft, metatarsal	Surgery		45.69	25.29	25.29		
20973		Bone/skin graft, great toe	Surgery		0.62	0.65	0.62		
20974		Electrical bone stimulation	Surgery		2.60	1.73	1.73		
20975		Electrical bone stimulation	Surgery		0.62	0.34	0.34		
20979		Us bone stimulation	Surgery		0.62	0.34	0.77		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 11 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
20982		Ablate, bone tumor(s) perq			7.27	2.99	105.35	1.41	Misc.
20999		Musculoskeletal surgery							
21010		Incision of jaw joint			10.12	7.25	7.25		
21015		Resection of facial tumor			5.28	5.53	7.25		
21025		Excision of bone, lower jaw			10.04	8.21	10.20		
21026		Excision of facial bone(s)			4.84	5.53	6.94		
21029		Contour of face bone lesion			7.70	6.27	8.60		
21030		Excise max/zygoma b9 tumor			4.49	4.31	6.84		
21031		Remove exostosis, mandible			3.24	3.14	4.58		
21032		Remove exostosis, maxilla			3.24	3.25	4.63		
21034		Excise max/zygoma m1g tumor			16.15	11.32	13.56		
21040		Excise mandible lesion			4.49	4.14	6.87		
21044		Removal of jaw bone lesion			11.84	8.68	8.68		
21045		Extensive jaw surgery			16.15	11.43	11.43		
21046		Remove mandible cyst complex			12.98	12.69	12.69		
21047		Excise tr jaw cyst w/repair			18.72	13.44	13.44		
21048		Remove maxilla cyst complex			13.48	12.97	12.97		
21049		Excis upper jaw cyst w/repair			17.97	13.03	13.03		
21050		Removal of jaw joint			10.75	10.26	10.26		
21060		Remove jaw joint cartilage			10.21	9.80	9.80		
21070		Remove coronoid process			8.19	7.03	7.03		
21076		Prepare facel/oral prosthesis			13.40	10.17	12.71		
21077		Prepare facel/oral prosthesis			33.70	26.20	32.20		
21079		Prepare facel/oral prosthesis			22.31	17.49	22.21		
21080		Prepare facel/oral prosthesis			25.06	19.77	25.22		
21081		Prepare facel/oral prosthesis			22.85	17.79	22.95		
21082		Prepare facel/oral prosthesis			20.84	15.99	19.88		
21083		Prepare facel/oral prosthesis			19.27	14.73	19.35		
21084		Prepare facel/oral prosthesis			22.48	17.68	22.71		
21085		Prepare facel/oral prosthesis			8.99	6.88	8.52		
21086		Prepare facel/oral prosthesis			24.88	19.60	24.30		
21087		Prepare facel/oral prosthesis			24.88	19.41	23.89		
21088		Prepare facel/oral prosthesis						10.85	PHCS
21089		Prepare facel/oral prosthesis						16.97	Misc.
21100		Maxillofacial fixation							
21110		Interdental fixation			4.21	4.62	5.62		
21116		Infection, jaw joint x-ray			5.20	5.66	7.02		
21120		Reconstruction of chin			0.81	0.34	7.32		
21121		Reconstruction of chin			4.32	5.30	8.63		
21122		Reconstruction of chin			7.63	6.65	10.43		
21123		Reconstruction of chin			8.51	7.08	7.08		
21125		Augmentation, lower jaw bone			11.14	8.26	8.26		
21127		Augmentation, lower jaw bone			10.60	8.28	11.82		
21137		Reduction of forehead			11.10	9.11	14.52		
21138		Reduction of forehead			9.61	7.44	7.44		
					12.17	9.31	9.31		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 12 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
21139		Reduction of forehead			14.59	9.78	9.78	9.78	
21141		Reconstruct midface, left			18.07	13.88	13.88	13.88	
21142		Reconstruct midface, left			18.78	13.08	13.08	13.08	
21143		Reconstruct midface, left			19.55	14.09	14.09	14.09	
21144		Reconstruct midface, left			19.91	14.15	14.15	14.15	
21147		Reconstruct midface, left			20.68	15.59	15.59	15.59	
21150		Reconstruct midface, left			21.74	15.29	15.29	15.29	
21151		Reconstruct midface, left			25.20	14.12	14.12	14.12	
21154		Reconstruct midface, left			28.26	17.92	17.92	17.92	
21155		Reconstruct midface, left			30.47	20.18	20.18	20.18	
21159		Reconstruct midface, left			34.40	22.30	22.30	22.30	
21160		Reconstruct midface, left			42.32	24.47	24.47	24.47	
21172		Reconstruct orbit/forehead			46.37	24.41	24.41	24.41	
21175		Reconstruct orbit/forehead			27.76	14.07	14.07	14.07	
21179		Reconstruct entire forehead			33.12	18.31	18.31	18.31	
21180		Reconstruct entire forehead			22.22	14.86	14.86	14.86	
21181		Reconstruct entire forehead			25.15	16.07	16.07	16.07	
21182		Contour cranial bone lesion			9.89	7.81	7.81	7.81	
21183		Reconstruct cranial bone			32.14	19.66	19.66	19.66	
21184		Reconstruct cranial bone			35.26	21.36	21.36	21.36	
21188		Reconstruct cranial bone			38.18	22.55	22.55	22.55	
21193		Reconstruction of midface			22.43	15.18	15.18	15.18	
21194		Reconst lwr jaw w/o graft			17.12	12.97	12.97	12.97	
21195		Reconst lwr jaw w/graft			19.81	14.06	14.06	14.06	
21198		Reconst lwr jaw w/o fixation			17.21	13.26	13.26	13.26	
21199		Reconst lwr jaw w/fixation			18.88	13.88	13.88	13.88	
21206		Reconst lwr jaw segment			14.14	10.90	10.90	10.90	
21208		Reconst lwr jaw w/advance			15.98	9.19	9.19	9.19	
21209		Reconstruct upper jaw bone			14.08	10.81	10.81	10.81	
21210		Augmentation of facial bones			10.21	9.28	9.28	9.28	
21215		Face bone graft			6.71	7.23	7.23	7.23	
21230		Lower jaw bone graft			10.21	11.89	11.89	11.89	
21235		Rib cartilage graft			10.21	9.41	9.41	9.41	
21240		Ear cartilage graft			10.75	9.61	9.61	9.61	
21242		Reconstruction of jaw joint			10.75	8.57	8.57	8.57	
21243		Reconstruction of jaw joint			6.71	7.10	7.10	7.10	
21244		Reconstruction of jaw joint			14.03	12.70	12.70	12.70	
21245		Reconstruction of lower jaw			12.93	12.21	12.21	12.21	
21246		Reconstruction of lower jaw			20.76	17.87	17.87	17.87	
21247		Reconstruction of jaw			11.84	10.06	10.06	10.06	
21248		Reconstruction of jaw			11.84	9.73	9.73	9.73	
21249		Reconstruct lower jaw bone			12.45	9.65	9.65	9.65	
21249		Reconstruction of jaw			22.60	17.93	17.93	17.93	
21249		Reconstruction of jaw			11.46	9.31	9.31	9.31	
21255		Reconstruct lower jaw bone			17.49	12.66	12.66	12.66	
21255		Reconstruct lower jaw bone			16.69	12.78	12.78	12.78	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 13 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
21256		Reconstruction of orbit	Surgery		16.17	12.17	12.17		
21260		Revise eye sockets	Surgery		16.50	8.96	8.96		
21261		Revise eye sockets	Surgery		31.44	19.21	19.21		
21263		Revise eye sockets	Surgery		28.38	12.86	12.86		
21267		Revise eye sockets	Surgery		18.87	13.22	13.22		
21268		Revise eye sockets	Surgery		24.44	15.32	15.32		
21270		Augmentation, cheek bone	Surgery		10.21	8.10	11.90		
21275		Revision, orbitofacial bones	Surgery		11.22	8.74	8.74		
21280		Revision of eyelid	Surgery		6.02	6.07	6.07		
21282		Revision of eyelid	Surgery		3.48	4.68	4.68		
21295		Revision of jaw muscle/bone	Surgery		1.53	2.82	2.82		
21296		Revision of jaw muscle/bone	Surgery		4.24	4.43	4.43		
21299		Cranio/maxillofacial surgery	Surgery					20.01	Misc.
21300		Treatment of skull fracture	Surgery		0.72	0.26	2.38		
21310		Treatment of nose fracture	Surgery		0.58	0.15	2.34		
21315		Treatment of nose fracture	Surgery		1.51	1.27	3.03		
21320		Treatment of nose fracture	Surgery		1.85	1.84	4.25		
21325		Treatment of nose fracture	Surgery		3.76	3.75	3.75		
21330		Treatment of nose fracture	Surgery		5.37	5.28	5.28		
21335		Treatment of nose fracture	Surgery		8.60	6.81	6.81		
21336		Treat nasal septal fracture	Surgery		5.71	6.07	6.07		
21337		Treat nasal septal fracture	Surgery		2.70	3.69	5.11		
21338		Treat nasoethmoid fracture	Surgery		6.45	5.99	5.99		
21339		Treat nasoethmoid fracture	Surgery		8.08	6.75	6.75		
21340		Treatment of nose fracture	Surgery		10.75	8.70	8.70		
21343		Treatment of sinus fracture	Surgery		12.93	10.14	10.14		
21344		Treatment of sinus fracture	Surgery		19.69	13.71	13.71		
21345		Treat nose/law fracture	Surgery		8.15	7.90	11.54		
21346		Treat nose/law fracture	Surgery		10.59	9.03	13.18		
21347		Treat nose/law fracture	Surgery		12.67	9.77	9.77		
21348		Treat nose/law fracture	Surgery		16.66	11.31	11.31		
21355		Treat cheek bone fracture	Surgery		3.76	2.37	4.70		
21356		Treat cheek bone fracture	Surgery		4.14	3.22	11.67		
21360		Treat cheek bone fracture	Surgery		6.45	6.19	13.89		
21365		Treat cheek bone fracture	Surgery		14.93	11.77	11.77		
21366		Treat cheek bone fracture	Surgery		17.74	11.64	11.64		
21385		Treat eye socket fracture	Surgery		9.15	7.07	7.07		
21386		Treat eye socket fracture	Surgery		9.15	7.48	7.48		
21387		Treat eye socket fracture	Surgery		9.69	7.54	7.54		
21390		Treat eye socket fracture	Surgery		10.11	8.01	8.01		
21395		Treat eye socket fracture	Surgery		12.66	9.32	9.32		
21400		Treat eye socket fracture	Surgery		1.40	2.10	3.72		
21401		Treat eye socket fracture	Surgery		3.26	3.87	5.05		
21406		Treat eye socket fracture	Surgery		7.00	6.35	6.35		
21407		Treat eye socket fracture	Surgery		8.60	7.14	7.14		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 14 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUS	Facility Practice Expense RVUS	Non-Facility Practice Expense RVUS	Total Expense RVUS	Charge Methodology
21408		Treat eye socket fracture	Surgery		12.36	9.21	9.21		
21421		Treat mouth roof fracture	Surgery		5.13	6.16	9.92		
21422		Treat mouth roof fracture	Surgery		8.31	7.10	11.28		
21423		Treat mouth roof fracture	Surgery		10.38	8.49	8.49		
21431		Treat craniofacial fracture	Surgery		7.04	6.84	10.66		
21432		Treat craniofacial fracture	Surgery		8.60	6.19	6.19		
21433		Treat craniofacial fracture	Surgery		25.31	16.83	16.83		
21435		Treat craniofacial fracture	Surgery		17.22	12.96	12.96		
21436		Treat craniofacial fracture	Surgery		28.00	18.42	18.42		
21440		Treat dental ridge fracture	Surgery		2.70	4.11	8.05		
21445		Treat dental ridge fracture	Surgery		5.37	6.28	10.45		
21450		Treat lower jaw fracture	Surgery		2.97	3.76	10.65		
21451		Treat lower jaw fracture	Surgery		4.86	5.76	8.77		
21452		Treat lower jaw fracture	Surgery		1.98	3.56	7.65		
21453		Treat lower jaw fracture	Surgery		5.53	6.83	10.50		
21454		Treat lower jaw fracture	Surgery		6.45	6.54	6.54		
21461		Treat lower jaw fracture	Surgery		8.08	8.30	12.52		
21462		Treat lower jaw fracture	Surgery		9.78	9.02	14.06		
21465		Treat lower jaw fracture	Surgery		11.89	10.05	10.05		
21470		Treat lower jaw fracture	Surgery		15.32	12.24	12.24		
21480		Reset dislocated jaw	Surgery		0.61	0.19	1.95		
21485		Repair dislocated jaw	Surgery		3.98	4.80	5.94		
21490		Repair dislocated jaw	Surgery		11.84	9.90	9.90		
21493		Treat hyoid bone fracture	Surgery		1.27	2.84	2.84		
21494		Treat hyoid bone fracture	Surgery		6.27	5.70	5.70		
21495		Treat hyoid bone fracture	Surgery		5.68	5.99	5.99		
21497		Interdental wiring	Surgery		3.85	5.01	6.54		
21499		Head surgery procedure	Surgery					7.51	Misc.
21501		Drain neck/chest lesion	Surgery		3.80	3.95	4.70		
21502		Drain chest lesion	Surgery		7.11	5.70	5.70		
21510		Drainage of bone lesion	Surgery		5.73	5.72	5.72		
21550		Blopsy of neck/chest	Surgery		2.06	1.74	3.64		
21555		Remove lesion, neck/chest	Surgery		4.34	3.17	5.06		
21556		Remove lesion, neck/chest	Surgery		5.56	4.11	4.11		
21557		Remove tumor, neck/chest	Surgery		8.87	5.44	5.44		
21600		Partial removal of rib	Surgery		5.80	5.80	5.80		
21610		Partial removal of rib	Surgery		14.59	9.04	9.04		
21615		Removal of rib	Surgery		9.86	6.73	6.73		
21616		Removal of rib and nerves	Surgery		12.02	8.05	8.05		
21620		Partial removal of sternum	Surgery		6.78	6.07	6.07		
21627		Sternal debridement	Surgery		6.80	6.46	6.46		
21630		Extensive sternum surgery	Surgery		17.35	11.99	11.99		
21632		Extensive sternum surgery	Surgery		18.11	11.18	11.18		
21685		Hyoid myotomy & suspension	Surgery		12.98	10.09	10.09		
21700		Revision of neck muscle	Surgery		6.18	4.86	6.08		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 15 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
21705		Revision of neck muscle/rib	Surgery		9.59	5.63	5.63		
21720		Revision of neck muscle	Surgery		5.67	4.64	5.67		
21725		Revision of neck muscle	Surgery		6.98	5.52	5.52		
21740		Reconstruction of sternum	Surgery		16.48	8.60	8.60	25.36	MDR
21742		Repair sternum/nuss w/o scope	Surgery					33.37	MDR
21743		Repair sternum/nuss w/scope	Surgery		10.75	6.14	6.14		
21750		Repair of sternum separation	Surgery		0.96	1.40	2.10		
21800		Treatment of rib fracture	Surgery		2.75	3.35	3.35		
21805		Treatment of rib fracture(s)	Surgery		6.85	5.03	5.03		
21810		Treatment of rib fracture(s)	Surgery		1.28	1.83	2.63		
21820		Treat sternum fracture	Surgery		7.40	6.69	6.69		
21825		Treat sternum fracture	Surgery						
21899		Neck/chest surgery procedure	Surgery		2.06	1.49	3.28		
21920		Biopsy soft tissue of back	Surgery		4.48	3.35	6.63		
21925		Biopsy soft tissue of back	Surgery		4.99	3.46	5.48		
21930		Remove lesion, back or flank	Surgery		17.93	10.20	10.20		
21935		Remove tumor, back	Surgery		9.72	7.63	7.63		
22100		Remove part of neck vertebra	Surgery		9.80	7.87	7.87		
22101		Remove part, thorax vertebra	Surgery		9.80	8.08	8.08		
22102		Remove part, lumbar vertebra	Surgery		2.34	1.21	1.21		
22103		Remove extra spine segment	Surgery		12.72	9.27	9.27		
22110		Remove part of neck vertebra	Surgery		12.79	9.33	9.33		
22112		Remove part, thorax vertebra	Surgery		12.79	9.31	9.31		
22114		Remove part, lumbar vertebra	Surgery		2.32	1.17	1.17		
22116		Remove extra spine segment	Surgery		23.78	15.51	15.51		
22210		Revision of neck spine	Surgery		19.39	13.27	13.27		
22212		Revision of thorax spine	Surgery		19.42	13.78	13.78		
22214		Revision of lumbar spine	Surgery		6.03	3.14	3.14		
22216		Revise, extra spine segment	Surgery		21.34	13.79	13.79		
22220		Revision of neck spine	Surgery		21.49	11.61	11.61		
22222		Revision of thorax spine	Surgery		21.49	14.24	14.24		
22224		Revision of lumbar spine	Surgery		6.03	3.11	3.11		
22226		Revise, extra spine segment	Surgery		2.05	2.39	3.19		
22305		Treat spine process fracture	Surgery		2.61	4.11	4.88		
22310		Treat spine fracture	Surgery		8.83	7.53	13.42		
22315		Treat spine fracture	Surgery		21.47	13.52	13.52		
22318		Treat odontoid fx w/o graft	Surgery		23.96	14.90	14.90		
22319		Treat odontoid fx w/graft	Surgery		18.27	12.15	12.15		
22325		Treat spine fracture	Surgery		19.56	12.83	12.83		
22326		Treat neck spine fracture	Surgery		19.17	12.44	12.44		
22327		Treat thorax spine fracture	Surgery		4.60	2.28	2.28		
22328		Treat each add spine fx	Surgery		1.87	0.94	0.94		
22505		Manipulation of spine	Surgery		8.90	4.34	101.62		
22520		Percut vertebroplasty thor	Surgery		8.33	4.18	89.47		
22521		Percut vertebroplasty lumb	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 16 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
22522		Percut vertebroplasty addl	Surgery		4.30	1.69	1.69		
22532		Lat thorax spine fusion	Surgery		23.96	14.82	14.82		
22533		Lat lumbar spine fusion	Surgery		23.09	13.48	13.48		
22534		Lat thor/lumb, add'l seg	Surgery		5.99	3.04	3.04		
22548		Neck spine fusion	Surgery		25.78	15.83	15.83		
22554		Neck spine fusion	Surgery		18.59	12.32	12.32		
22556		Neck spine fusion	Surgery		23.42	14.68	14.68		
22558		Thorax spine fusion	Surgery		22.25	13.24	13.24		
22558		Lumbar spine fusion	Surgery		5.52	2.80	2.80		
22585		Additional spinal fusion	Surgery		20.48	13.29	13.29		
22590		Spine & skull spinal fusion	Surgery		19.36	12.80	12.80		
22595		Neck spinal fusion	Surgery		16.12	11.14	11.14		
22600		Neck spine fusion	Surgery		16.00	11.32	11.32		
22610		Thorax spine fusion	Surgery		20.97	14.09	14.09		
22612		Lumbar spine fusion	Surgery		6.43	3.36	3.36		
22614		Spine fusion, extra segment	Surgery		20.81	13.55	13.55		
22630		Lumbar spine fusion	Surgery		5.22	2.67	2.67		
22632		Spine fusion, extra segment	Surgery		18.22	12.64	12.64		
22800		Fusion of spine	Surgery		30.63	19.48	19.48		
22802		Fusion of spine	Surgery		36.22	22.58	22.58		
22804		Fusion of spine	Surgery		26.23	16.25	16.25		
22810		Fusion of spine	Surgery		30.22	18.29	18.29		
22812		Fusion of spine	Surgery		32.65	19.95	19.95		
22818		Fusion of spine	Surgery		31.78	18.86	18.86		
22819		Kyphectomy, 1-2 segments	Surgery		36.39	20.03	20.03		
22830		Kyphectomy, 3 or more	Surgery		10.53	7.89	7.89		MDR
22840		Exploration of spinal fusion	Surgery		12.52	6.51	6.51	9.26	
22841		Insert spine fixation device	Surgery		12.56	6.53	6.53		
22842		Insert spine fixation device	Surgery		13.44	6.63	6.63		
22843		Insert spine fixation device	Surgery		16.42	8.78	8.78		
22844		Insert spine fixation device	Surgery		11.94	6.11	6.11		
22845		Insert spine fixation device	Surgery		12.40	6.36	6.36		
22846		Insert spine fixation device	Surgery		13.78	7.06	7.06		
22847		Insert spine fixation device	Surgery		5.99	3.20	3.20		
22848		Insert pelv fixation device	Surgery		11.76	6.11	6.11		
22849		Reinsert spinal fixation	Surgery		18.48	11.76	11.76		
22850		Remove spine fixation device	Surgery		9.51	7.00	7.00		
22851		Apply spine prosth device	Surgery		6.70	3.37	3.37		
22852		Remove spine fixation device	Surgery		9.00	6.79	6.79		
22855		Remove spine fixation device	Surgery		15.11	9.72	9.72		Misc.
22899		Spine surgery procedure	Surgery		5.79	3.28	3.28	19.09	
22900		Remove abdominal wall lesion	Surgery						Misc.
22999		Abdomen surgery procedure	Surgery		4.35	4.16	4.16	9.07	
23000		Removal of calcium deposits	Surgery		8.92	7.58	7.58		
23020		Release shoulder joint	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 17 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
23030		Drain shoulder lesion	Surgery		3.42	2.93	3.01		
23031		Drain shoulder bursa	Surgery		2.74	2.69	2.69		
23035		Drain shoulder bone lesion	Surgery		6.60	8.51	8.51		
23040		Exploratory shoulder surgery	Surgery		9.19	7.85	7.85		
23044		Exploratory shoulder surgery	Surgery		7.11	6.50	6.50		
23065		Biopsy shoulder tissues	Surgery		2.27	1.54	2.81		
23066		Biopsy shoulder tissues	Surgery		4.15	4.07	5.10		
23075		Removal of shoulder lesion	Surgery		2.39	1.82	2.24		
23076		Removal of shoulder lesion	Surgery		7.82	5.78	5.78		
23077		Remove tumor of shoulder	Surgery		16.07	10.76	10.76		
23100		Biopsy of shoulder joint	Surgery		6.02	5.69	5.69		
23101		Shoulder joint surgery	Surgery		5.57	5.39	5.39		
23105		Remove shoulder joint lining	Surgery		8.22	7.17	7.17		
23106		Incision of collarbone joint	Surgery		5.95	5.77	5.77		
23107		Explore treat shoulder joint	Surgery		8.61	7.39	7.39		
23120		Partial removal, collar bone	Surgery		7.10	6.48	6.48		
23125		Removal of collar bone	Surgery		9.38	7.63	7.63		
23130		Remove shoulder bone, part	Surgery		7.54	7.10	7.10		
23140		Removal of bone lesion	Surgery		6.88	5.41	5.41		
23145		Removal of bone lesion	Surgery		9.08	7.58	7.58		
23146		Removal of bone lesion	Surgery		7.82	7.13	7.13		
23150		Removal of humerus lesion	Surgery		8.47	6.97	6.97		
23155		Removal of humerus lesion	Surgery		10.33	8.46	8.46		
23156		Removal of humerus lesion	Surgery		8.67	7.38	7.38		
23170		Remove collar bone lesion	Surgery		6.85	6.36	6.36		
23172		Remove shoulder blade lesion	Surgery		6.89	6.41	6.41		
23174		Remove humerus lesion	Surgery		9.50	8.37	8.37		
23180		Remove collar bone lesion	Surgery		8.52	9.21	9.21		
23182		Remove shoulder blade lesion	Surgery		8.14	8.89	8.89		
23184		Remove humerus lesion	Surgery		9.37	9.54	9.54		
23190		Partial removal of scapula	Surgery		7.23	6.23	6.23		
23195		Removal of head of humerus	Surgery		9.80	7.76	7.76		
23200		Removal of collar bone	Surgery		12.06	8.97	8.97		
23210		Removal of shoulder blade	Surgery		12.47	9.30	9.30		
23220		Partial removal of humerus	Surgery		14.54	10.87	10.87		
23221		Partial removal of humerus	Surgery		17.71	11.84	11.84		
23222		Partial removal of humerus	Surgery		23.88	15.85	15.85		
23330		Remove shoulder foreign body	Surgery		1.85	1.91	1.98		
23331		Remove shoulder foreign body	Surgery		7.37	6.79	6.79		
23332		Remove shoulder foreign body	Surgery		11.60	9.31	9.31		
23350		Injection for shoulder x-ray	Surgery		1.00	0.33	3.85		
23395		Muscle transfer, shoulder/arm	Surgery		16.82	12.74	12.74		
23397		Muscle transfers	Surgery		16.11	11.40	11.40		
23400		Fixation of shoulder blade	Surgery		13.52	10.16	10.16		
23405		Incision of tendon & muscle	Surgery		8.36	7.01	7.01		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 18 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
23406		Incise tendon(s) & muscle(s)	Surgery		10.77	8.41	8.41		
23410		Repair rotator cuff, acute	Surgery		12.43	9.40	9.40		
23412		Repair rotator cuff, chronic	Surgery		13.29	9.90	9.90		
23415		Release of shoulder ligament	Surgery		9.96	7.97	7.97		
23420		Repair of shoulder	Surgery		13.28	10.78	10.78		
23430		Repair biceps tendon	Surgery		9.97	8.11	8.11		
23440		Remove/transplant tendon	Surgery		10.46	8.29	8.29		
23450		Repair shoulder capsule	Surgery		13.38	9.87	9.87		
23455		Repair shoulder capsule	Surgery		14.35	10.45	10.45		
23460		Repair shoulder capsule	Surgery		15.35	11.37	11.37		
23462		Repair shoulder capsule	Surgery		15.28	10.78	10.78		
23465		Repair shoulder capsule	Surgery		15.83	11.30	11.30		
23466		Repair shoulder capsule	Surgery		14.20	11.27	11.27		
23470		Reconstruct shoulder joint	Surgery		17.12	12.13	12.13		
23472		Reconstruct shoulder joint	Surgery		21.07	14.27	14.27		
23480		Revision of collar bone	Surgery		11.16	8.77	8.77		
23485		Revision of collar bone	Surgery		13.41	9.91	9.91		
23490		Reinforce clavicle	Surgery		11.84	8.81	8.81		
23491		Reinforce shoulder bones	Surgery		14.19	10.70	10.70		
23500		Treat clavicle fracture	Surgery		2.08	2.57	3.66		
23505		Treat clavicle fracture	Surgery		3.68	3.76	5.33		
23515		Treat clavicle fracture	Surgery		7.40	6.52	6.52		
23520		Treat clavicle dislocation	Surgery		2.16	2.71	3.65		
23525		Treat clavicle dislocation	Surgery		3.59	3.88	5.27		
23530		Treat clavicle dislocation	Surgery		7.30	6.03	6.03		
23532		Treat clavicle dislocation	Surgery		8.00	6.92	6.92		
23540		Treat clavicle dislocation	Surgery		2.23	2.46	4.26		
23545		Treat clavicle dislocation	Surgery		3.25	3.38	4.50		
23550		Treat clavicle dislocation	Surgery		7.23	6.38	6.38		
23552		Treat clavicle dislocation	Surgery		8.44	7.26	7.26		
23570		Treat shoulder blade fx	Surgery		2.23	2.87	3.67		
23575		Treat shoulder blade fx	Surgery		4.05	4.24	5.76		
23585		Treat scapula fracture	Surgery		8.95	7.50	7.60		
23600		Treat humerus fracture	Surgery		2.93	3.82	5.73		
23605		Treat humerus fracture	Surgery		4.86	4.96	6.59		
23615		Treat humerus fracture	Surgery		9.34	8.69	8.69		
23616		Treat humerus fracture	Surgery		21.24	14.13	14.13		
23620		Treat humerus fracture	Surgery		2.40	3.23	5.20		
23625		Treat humerus fracture	Surgery		3.92	4.56	6.33		
23630		Treat humerus fracture	Surgery		7.34	6.59	6.59		
23650		Treat shoulder dislocation	Surgery		3.38	2.88	4.69		
23650		Treat shoulder dislocation	Surgery		4.56	4.16	4.16		
23655		Treat shoulder dislocation	Surgery		7.48	6.36	6.36		
23660		Treat shoulder dislocation	Surgery		4.46	4.93	6.58		
23665		Treat dislocation/fracture	Surgery		7.89	6.82	6.82		
23670		Treat dislocation/fracture	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 19 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
23675		Treat dislocation/fracture	Surgery		6.04	6.06	7.56		
23680		Treat dislocation/fracture	Surgery		10.04	8.09	8.09		
23700		Fixation of shoulder	Surgery		2.52	2.30	2.30		
23800		Fusion of shoulder joint	Surgery		14.14	10.46	10.46		
23802		Fusion of shoulder joint	Surgery		16.58	10.23	10.23		
23900		Amputation of arm & girdle	Surgery		19.69	11.91	11.91		
23920		Amputation at shoulder joint	Surgery		14.59	10.09	10.09		
23921		Amputation follow-up surgery	Surgery		5.48	5.16	5.16		
23929		Shoulder surgery procedure	Surgery						Misc.
23930		Drainage of arm lesion	Surgery		2.94	2.35	2.71		
23931		Drainage of arm bursa	Surgery		1.79	2.19	2.43		
23935		Drain arm/elbow bone lesion	Surgery		6.08	6.13	6.13		
24000		Exploratory elbow surgery	Surgery		5.81	5.36	5.36		
24006		Release elbow joint	Surgery		9.30	7.99	7.69		
24065		Biopsy arm/elbow soft tissue	Surgery		2.08	1.78	2.10		
24066		Biopsy arm/elbow soft tissue	Surgery		5.20	4.27	5.76		
24075		Remove arm/elbow lesion	Surgery		3.91	3.67	5.05		
24076		Remove arm/elbow lesion	Surgery		6.29	5.09	5.09		
24077		Remove tumor of arm/elbow	Surgery		11.74	8.65	8.65		
24100		Biopsy elbow joint lining	Surgery		4.92	4.49	4.49		
24101		Explore/treat elbow joint	Surgery		6.12	5.86	5.86		
24102		Remove elbow joint lining	Surgery		8.02	6.83	6.83		
24105		Removal of elbow bursa	Surgery		3.60	4.35	4.35		
24110		Remove humerus lesion	Surgery		7.38	6.71	6.71		
24115		Remove/graft bone lesion	Surgery		9.62	7.35	7.35		
24116		Remove/graft bone lesion	Surgery		11.79	9.11	9.11		
24120		Remove elbow lesion	Surgery		6.64	5.88	5.88		
24125		Remove/graft bone lesion	Surgery		7.88	6.18	6.18		
24126		Remove/graft bone lesion	Surgery		8.30	6.97	6.97		
24130		Removal of head of radius	Surgery		6.24	5.95	5.95		
24134		Removal of arm bone lesion	Surgery		9.72	9.18	9.18		
24136		Remove radius bone lesion	Surgery		7.98	7.41	7.41		
24138		Remove elbow bone lesion	Surgery		8.04	7.67	7.67		
24140		Partial removal of arm bone	Surgery		9.17	9.49	9.49		
24145		Partial removal of radius	Surgery		7.57	8.15	8.15		
24147		Partial removal of elbow	Surgery		7.53	8.64	8.64		
24149		Radical resection of elbow	Surgery		14.18	11.41	11.41		
24150		Extensive humerus surgery	Surgery		13.25	10.10	10.10		
24151		Extensive humerus surgery	Surgery		15.56	11.67	11.67		
24152		Extensive radius surgery	Surgery		10.04	7.85	7.85		
24153		Extensive radius surgery	Surgery		11.52	5.83	5.83		
24155		Removal of elbow joint	Surgery		11.71	8.41	8.41		
24160		Remove elbow joint implant	Surgery		7.82	6.77	6.77		
24164		Remove radius head implant	Surgery		6.22	5.66	5.66		
24200		Removal of arm foreign body	Surgery		1.76	1.87	1.97		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 20 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
24201		Removal of arm foreign body			4.55	4.34	5.68		
24220		Injection for elbow x-ray			1.31	0.44	10.32		
24300		Manipulate elbow w/anesth			3.74	5.48	5.48		
24301		Muscle/tendon transfer			10.18	8.18	8.18		
24305		Arm tendon lengthening			7.44	6.68	6.68		
24310		Revision of arm tendon			5.97	5.72	5.72		
24320		Repair of arm tendon			10.54	7.74	7.74		
24330		Revision of arm muscles			9.59	7.86	7.86		
24331		Revision of arm muscles			10.63	8.60	8.60		
24332		Tenolysis, triceps			7.44	6.58	6.58		
24340		Repair of biceps tendon			7.88	6.91	6.91		
24341		Repair arm tendon/muscle			7.75	7.75	7.75		
24342		Repair of ruptured tendon			10.60	8.46	8.46		
24343		Repr elbow lat ligmnt w/issu			8.64	7.93	7.93		
24344		Reconstruct elbow lat ligmnt			13.98	11.31	11.31		
24345		Repr elbow med ligmnt w/issu			8.64	7.93	7.93		
24346		Reconstruct elbow med ligmnt			13.98	11.31	11.31		
24350		Repair of tennis elbow			11.17	7.83	7.83		
24351		Repair of tennis elbow			13.98	11.17	11.17		
24352		Repair of tennis elbow			5.24	5.52	5.52		
24354		Repair of tennis elbow			5.90	5.86	5.86		
24355		Revision of tennis elbow			6.42	6.12	6.12		
24356		Revision of tennis elbow			6.47	6.08	6.08		
24360		Reconstruct elbow joint			6.67	6.26	6.26		
24361		Reconstruct elbow joint			12.32	9.35	9.35		
24362		Reconstruct elbow joint			14.06	10.44	10.44		
24363		Replace elbow joint			14.97	9.97	9.97		
24365		Reconstruct head of radius			18.46	13.53	13.53		
24366		Reconstruct head of radius			8.38	7.09	7.09		
24400		Revision of humerus			9.12	7.43	7.43		
24410		Revision of humerus			11.04	8.91	8.91		
24420		Revision of humerus			14.80	10.43	10.43		
24430		Repair of humerus			13.42	10.66	10.66		
24435		Repair of humerus with graft			12.79	9.75	9.75		
24470		Revision of elbow joint			13.15	10.83	10.83		
24495		Decompression of forearm			8.73	7.62	7.62		
24498		Reinforce humerus			11.90	9.05	9.05		
24500		Treat humerus fracture			9.28	3.21	3.61		
24505		Treat humerus fracture			5.16	5.28	7.29		
24515		Treat humerus fracture			11.63	9.34	9.34		
24516		Treat humerus fracture			11.63	9.11	9.11		
24530		Treat humerus fracture			3.49	3.94	5.39		
24535		Treat humerus fracture			6.86	6.40	8.39		
24538		Treat humerus fracture			9.42	8.69	8.69		
24545		Treat humerus fracture			10.44	8.42	8.42		
24546		Treat humerus fracture			15.67	11.31	11.31		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 21 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
24560		Treat humerus fracture	Surgery		2.80	3.21	5.07		
24565		Treat humerus fracture	Surgery		5.55	5.40	7.28		
24566		Treat humerus fracture	Surgery		7.78	8.11	8.11		
24575		Treat humerus fracture	Surgery		10.64	8.30	8.30		
24576		Treat humerus fracture	Surgery		2.86	3.99	4.94		
24577		Treat humerus fracture	Surgery		5.78	5.69	7.56		
24579		Treat humerus fracture	Surgery		11.58	8.83	8.83		
24582		Treat humerus fracture	Surgery		8.54	9.01	9.01		
24586		Treat elbow fracture	Surgery		15.19	11.11	11.11		
24587		Treat elbow fracture	Surgery		15.14	10.91	10.91		
24600		Treat elbow dislocation	Surgery		4.22	3.52	5.57		
24605		Treat elbow dislocation	Surgery		5.41	5.25	5.25		
24615		Treat elbow dislocation	Surgery		9.41	7.73	7.73		
24620		Treat elbow fracture	Surgery		6.97	6.11	6.11		
24635		Treat elbow fracture	Surgery		13.17	14.21	14.21		
24640		Treat elbow dislocation	Surgery		1.20	0.87	1.93		
24650		Treat radius fracture	Surgery		2.16	2.73	4.55		
24655		Treat radius fracture	Surgery		4.39	4.69	6.76		
24665		Treat radius fracture	Surgery		8.13	7.48	7.48		
24666		Treat radius fracture	Surgery		9.48	8.05	8.05		
24670		Treat ulnar fracture	Surgery		2.54	3.01	4.44		
24675		Treat ulnar fracture	Surgery		4.71	4.82	6.72		
24685		Treat ulnar fracture	Surgery		8.79	7.52	7.52		
24800		Fusion of elbow joint	Surgery		11.18	8.71	8.71		
24802		Fusion/graft of elbow joint	Surgery		13.67	10.32	10.32		
24900		Amputation of upper arm	Surgery		9.59	7.35	7.35		
24920		Amputation of upper arm	Surgery		9.53	7.52	7.52		
24925		Amputation follow-up surgery	Surgery		7.06	6.27	6.27		
24930		Amputation follow-up surgery	Surgery		10.23	7.52	7.52		
24931		Amputate upper arm & implant	Surgery		12.70	6.11	6.11		
24935		Revision of amputation	Surgery		15.54	8.42	8.42		MDR
24940		Revision of upper arm	Surgery					23.19	Misc.
24999		Upper arm/elbow surgery	Surgery					8.53	
25000		Incision of tendon sheath	Surgery		3.37	6.95	6.95		
25001		Incise flexor carpi radialis	Surgery		3.37	4.09	4.09		
25020		Decompress forearm 1 space	Surgery		5.91	9.94	9.94		
25023		Decompress forearm 1 space	Surgery		12.94	15.45	15.45		
25024		Decompress forearm 2 spaces	Surgery		9.49	7.52	7.52		
25025		Decompress forearm 2 spaces	Surgery		16.52	10.00	10.00		
25028		Drainage of forearm bursa	Surgery		5.24	8.48	8.48		
25031		Treat forearm bone lesion	Surgery		4.13	8.25	8.25		
25035		Explore/treat wrist joint	Surgery		7.35	14.03	14.03		
25040		Biopsy forearm soft tissues	Surgery		7.17	7.34	7.34		
25085		Biopsy forearm soft tissues	Surgery		1.99	2.79	2.79		
25066		Biopsy forearm soft tissues	Surgery		4.12	7.24	7.24		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 22 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
25075		Remove forearm lesion subcu	Surgery		3.73	6.13	6.13		
25076		Remove forearm lesion deep	Surgery		4.91	9.98	9.98		
25077		Remove tumor, forearm/wrist	Surgery		9.75	12.68	12.68		
25085		Incision of wrist capsule	Surgery		5.49	7.30	7.30		
25100		Biopsy of wrist joint	Surgery		3.89	5.41	5.41		
25101		Explore/treat wrist joint	Surgery		4.68	5.96	5.96		
25105		Remove wrist joint lining	Surgery		5.84	7.48	7.48		
25107		Remove wrist joint cartilage	Surgery		6.42	8.41	8.41		
25110		Remove wrist tendon lesion	Surgery		3.91	7.26	7.26		
25111		Remove wrist tendon lesion	Surgery		3.38	4.83	4.83		
25112		Remove wrist tendon lesion	Surgery		4.52	5.43	5.43		
25115		Remove wrist/forearm lesion	Surgery		8.81	14.44	14.44		
25116		Remove wrist/forearm lesion	Surgery		7.10	13.53	13.53		
25118		Excise wrist tendon sheath	Surgery		4.36	5.88	5.88		
25119		Partial removal of ulna	Surgery		6.03	7.77	7.77		
25120		Removal of forearm lesion	Surgery		6.09	12.44	12.44		
25125		Remove/graft forearm lesion	Surgery		7.47	13.21	13.21		
25126		Remove/graft forearm lesion	Surgery		7.54	13.31	13.31		
25130		Removal of wrist lesion	Surgery		5.25	6.51	6.51		
25135		Remove & graft wrist lesion	Surgery		6.88	7.53	7.53		
25136		Remove & graft wrist lesion	Surgery		5.96	6.68	6.68		
25145		Remove forearm bone lesion	Surgery		6.36	12.47	12.47		
25150		Partial removal of ulna	Surgery		7.08	8.41	8.41		
25151		Extensive forearm surgery	Surgery		7.38	13.08	13.08		
25170		Removal of wrist bone	Surgery		11.07	15.46	15.46		
25215		Removal of wrist bones	Surgery		5.94	6.90	6.90		
25230		Partial removal of radius	Surgery		7.88	8.89	8.89		
25240		Partial removal of ulna	Surgery		5.22	6.22	6.22		
25246		Injection for wrist x-ray	Surgery		5.16	7.09	7.09		
25248		Remove forearm foreign body	Surgery		1.45	0.48	0.05		
25250		Removal of wrist prosthesis	Surgery		5.13	8.75	8.75		
25251		Removal of wrist prosthesis	Surgery		6.59	6.00	6.00		
25259		Manipulate wrist w/anesth	Surgery		9.56	7.82	7.82		
25260		Repair forearm tendon/muscle	Surgery		3.74	5.48	5.48		
25263		Repair forearm tendon/muscle	Surgery		7.79	13.90	13.90		
25265		Repair forearm tendon/muscle	Surgery		7.81	13.81	13.81		
25270		Repair forearm tendon/muscle	Surgery		9.87	14.70	14.70		
25272		Repair forearm tendon/muscle	Surgery		5.99	12.60	12.60		
25274		Repair forearm tendon/muscle	Surgery		7.03	13.30	13.30		
25275		Repair forearm tendon sheath	Surgery		8.74	14.02	14.02		
25280		Revise wrist/forearm tendon	Surgery		8.49	7.47	7.47		
25290		Incise wrist/forearm tendon	Surgery		7.21	13.03	13.03		
25295		Release wrist/forearm tendon	Surgery		5.28	15.53	15.53		
25300		Fusion of tendons at wrist	Surgery		6.54	12.59	12.59		
					8.79	8.52	8.52		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 23 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
25301		Fusion of tendons at wrist	Surgery		8.39	8.16	8.16	8.16	
25310		Transplant forearm tendon	Surgery		8.13	13.44	13.44	13.44	
25312		Transplant forearm tendon	Surgery		9.56	14.32	14.32	14.32	
25315		Revise palsy hand tendon(s)	Surgery		10.18	14.89	14.89	14.89	
25316		Revise palsy hand tendon(s)	Surgery		12.31	16.66	16.66	16.66	
25320		Repair/revise wrist joint	Surgery		11.21	11.21	11.21	11.21	
25332		Revise wrist joint	Surgery		11.39	9.06	9.06	9.06	
25335		Realignment of hand	Surgery		12.86	11.72	11.72	11.72	
25337		Reconstruct ulna/radioulnar	Surgery		10.15	11.07	11.07	11.07	
25360		Revision of radius	Surgery		8.77	14.28	14.28	14.28	
25355		Revision of radius	Surgery		10.15	14.90	14.90	14.90	
25360		Revision of ulna	Surgery		8.42	14.17	14.17	14.17	
25365		Revise radius & ulna	Surgery		12.38	15.93	15.93	15.93	
25370		Revise radius or ulna	Surgery		13.34	16.30	16.30	16.30	
25375		Revise radius & ulna	Surgery		13.02	16.72	16.72	16.72	
25390		Shorten radius or ulna	Surgery		10.38	14.91	14.91	14.91	
25391		Lengthen radius or ulna	Surgery		13.63	16.87	16.87	16.87	
25392		Shorten radius & ulna	Surgery		13.93	16.24	16.24	16.24	
25393		Lengthen radius & ulna	Surgery		15.85	17.88	17.88	17.88	
25394		Repair carpal bone, shorten	Surgery		10.38	8.23	8.23	8.23	
25400		Repair radius or ulna	Surgery		10.90	15.49	15.49	15.49	
25405		Repair/graft radius or ulna	Surgery		14.36	17.58	17.58	17.58	
25415		Repair radius & ulna	Surgery		13.33	16.81	16.81	16.81	
25420		Repair/graft radius & ulna	Surgery		13.19	18.56	18.56	18.56	
25425		Repair/graft radius or ulna	Surgery		15.80	22.08	22.08	22.08	
25426		Repair/graft radius & ulna	Surgery		9.24	17.29	17.29	17.29	
25430		Vasc graft into carpal bone	Surgery		10.42	7.28	7.28	7.28	
25431		Repair nonunion carpal bone	Surgery		10.42	8.23	8.23	8.23	
25440		Repair/graft wrist bone	Surgery		10.42	9.41	9.41	9.41	
25441		Reconstruct wrist joint	Surgery		12.88	9.88	9.88	9.88	
25442		Reconstruct wrist joint	Surgery		10.83	8.77	8.77	8.77	
25443		Reconstruct wrist joint	Surgery		10.37	8.65	8.65	8.65	
25444		Reconstruct wrist joint	Surgery		11.13	9.07	9.07	9.07	
25445		Wrist replacement	Surgery		9.68	7.87	7.87	7.87	
25446		Repair wrist joint(s)	Surgery		16.53	11.81	11.81	11.81	
25447		Remove wrist joint implant	Surgery		10.35	8.54	8.54	8.54	
25449		Revision of wrist joint	Surgery		14.47	10.57	10.57	10.57	
25450		Revision of wrist joint	Surgery		7.86	10.41	10.41	10.41	
25455		Reinforce radius	Surgery		9.48	11.33	11.33	11.33	
25490		Reinforce ulna	Surgery		9.53	14.03	14.03	14.03	
25491		Reinforce radius and ulna	Surgery		9.95	14.79	14.79	14.79	
25492		Treat fracture of radius	Surgery		12.31	15.58	15.58	15.58	
25500		Treat fracture of radius	Surgery		2.45	2.71	2.71	2.71	
25505		Treat fracture of radius	Surgery		5.20	5.25	5.25	5.25	
25515		Treat fracture of radius	Surgery		9.17	7.47	7.47	7.47	

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 24 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
25520		Treat fracture of radius	Surgery		6.25	5.87	7.44		
25525		Treat fracture of radius	Surgery		12.22	9.94	9.94		
25526		Treat fracture of radius	Surgery		12.96	13.39	13.39		
25530		Treat fracture of ulna	Surgery		2.09	2.80	4.14		
25535		Treat fracture of ulna	Surgery		5.13	5.17	6.85		
25545		Treat fracture of ulna	Surgery		8.89	7.65	7.65		
25560		Treat fracture radius & ulna	Surgery		2.44	2.64	4.04		
25565		Treat fracture radius & ulna	Surgery		5.62	5.32	7.35		
25574		Treat fracture radius & ulna	Surgery		7.00	7.13	7.13		
25575		Treat fracture radius/ulna	Surgery		10.43	9.39	9.39		
25600		Treat fracture radius/ulna	Surgery		2.63	2.94	4.47		
25605		Treat fracture radius/ulna	Surgery		5.80	6.01	8.03		
25611		Treat fracture radius/ulna	Surgery		7.76	8.84	8.84		
25620		Treat fracture radius/ulna	Surgery		8.54	7.28	7.28		
25622		Treat wrist bone fracture	Surgery		2.61	3.12	4.64		
25624		Treat wrist bone fracture	Surgery		4.52	4.90	6.98		
25628		Treat wrist bone fracture	Surgery		8.42	7.81	7.81		
25630		Treat wrist bone fracture	Surgery		2.88	2.94	4.57		
25635		Treat wrist bone fracture	Surgery		4.38	3.89	6.75		
25645		Treat wrist bone fracture	Surgery		7.24	6.79	6.79		
25650		Treat wrist bone fracture	Surgery		3.05	3.22	4.83		
25651		Pin ulnar styloid fracture	Surgery		5.35	5.39	5.39		
25652		Treat fracture ulnar styloid	Surgery		7.59	6.85	6.85		
25660		Treat wrist dislocation	Surgery		4.75	4.66	4.66		
25670		Treat wrist dislocation	Surgery		7.91	7.08	7.08		
25671		Pin radioulnar dislocation	Surgery		5.98	5.98	5.98		
25675		Treat wrist dislocation	Surgery		4.66	4.61	6.49		
25676		Treat wrist dislocation	Surgery		8.03	7.32	7.32		
25680		Treat wrist fracture	Surgery		5.98	4.75	4.75		
25685		Treat wrist fracture	Surgery		9.77	7.87	7.87		
25690		Treat wrist dislocation	Surgery		5.49	5.39	5.39		
25695		Treat wrist dislocation	Surgery		8.33	7.19	7.19		
25800		Fusion of wrist joint	Surgery		9.75	9.10	9.10		
25805		Fusion/graft of wrist joint	Surgery		11.26	10.24	10.24		
25810		Fusion/graft of wrist joint	Surgery		10.55	9.88	9.88		
25820		Fusion of hand bones	Surgery		7.44	7.88	7.88		
25825		Fuse hand bones with graft	Surgery		9.26	9.22	9.22		
25830		Fusion, radioulnar int/ulna	Surgery		10.04	14.69	14.69		
25900		Amputation of forearm	Surgery		9.00	12.89	12.89		
25905		Amputation of forearm	Surgery		9.11	12.82	12.82		
25907		Amputation follow-up surgery	Surgery		7.79	12.21	12.21		
25909		Amputation follow-up surgery	Surgery		8.95	12.76	12.76		
25915		Amputation of forearm	Surgery		17.05	19.51	19.51		
25920		Amputate hand at wrist	Surgery		8.67	8.00	8.00		
25922		Amputate hand at wrist	Surgery		7.41	7.25	7.25		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 25 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUS	Facility Practice Expense RVUS	Non- Facility Practice Expense RVUS	Total Expense RVUS	Charge Method- ology
25924		Amputation follow-up surgery	Surgery		8.45	8.22	8.22	8.22	Misc.
25927		Amputation of hand	Surgery		8.79	12.15	12.15	12.15	
25929		Amputation follow-up surgery	Surgery		7.58	6.06	6.06	6.06	
25931		Amputation follow-up surgery	Surgery		7.80	12.06	12.06	12.06	
25999		Forearm or wrist surgery	Surgery						
26010		Drainage of finger abscess	Surgery		1.54	1.66	5.67	5.67	
26011		Drainage of finger abscess	Surgery		2.19	2.31	9.08	9.08	
26020		Drain hand tendon sheath	Surgery		4.66	5.57	5.57	5.57	
26025		Drainage of palm bursa	Surgery		4.81	5.36	5.36	5.36	
26030		Drainage of palm bursa(s)	Surgery		5.92	6.00	6.00	6.00	
26034		Treat hand bone lesion	Surgery		6.22	6.27	6.27	6.27	
26035		Decompress fingers/hand	Surgery		9.50	8.10	8.10	8.10	
26037		Decompress fingers/hand	Surgery		7.24	6.60	6.60	6.60	
26040		Release palm contracture	Surgery		3.33	3.99	3.99	3.99	
26045		Release palm contracture	Surgery		5.55	5.56	5.56	5.56	
26055		Incise finger tendon sheath	Surgery		2.69	3.85	14.54	14.54	
26060		Incision of finger tendon	Surgery		2.81	3.45	3.45	3.45	
26070		Explore/treat hand joint	Surgery		3.68	3.36	3.36	3.36	
26075		Explore/treat finger joint	Surgery		3.78	3.76	3.76	3.76	
26080		Explore/treat finger joint	Surgery		4.23	4.78	4.78	4.78	
26100		Biopsy hand joint lining	Surgery		3.66	4.10	4.10	4.10	
26105		Biopsy finger joint lining	Surgery		3.70	4.17	4.17	4.17	
26110		Biopsy finger joint lining	Surgery		3.52	3.98	3.98	3.98	
26115		Remove hand lesion subcut	Surgery		3.85	4.67	13.33	13.33	
26116		Remove hand lesion, deep	Surgery		5.52	5.92	5.92	5.92	
26117		Remove tumor, hand/finger	Surgery		8.54	7.03	7.03	7.03	
26121		Release palm contracture	Surgery		7.53	6.90	6.90	6.90	
26123		Release palm contracture	Surgery		9.28	8.74	8.74	8.74	
26125		Release palm contracture	Surgery		4.60	2.46	2.46	2.46	
26130		Remove wrist joint lining	Surgery		5.41	5.30	5.30	5.30	
26135		Revise finger joint, each	Surgery		6.95	6.39	6.39	6.39	
26140		Revise finger joint, each	Surgery		6.16	5.97	5.97	5.97	
26145		Tendon excision, palm/finger	Surgery		6.31	5.98	5.98	5.98	
26160		Remove tendon sheath lesion	Surgery		3.15	4.04	12.69	12.69	
26170		Removal of palm tendon, each	Surgery		4.76	4.88	4.88	4.88	
26180		Removal of finger tendon	Surgery		5.17	5.35	5.35	5.35	
26185		Remove finger bone	Surgery		5.24	5.91	5.91	5.91	
26200		Remove hand bone lesion	Surgery		5.50	5.29	5.29	5.29	
26205		Remove/graft bone lesion	Surgery		7.69	6.84	6.84	6.84	
26210		Removal of finger lesion	Surgery		5.14	5.36	5.36	5.36	
26215		Remove/graft finger lesion	Surgery		7.09	6.26	6.26	6.26	
26230		Partial removal of hand bone	Surgery		6.32	5.85	5.85	5.85	
26235		Partial removal, finger bone	Surgery		6.18	5.75	5.75	5.75	
26236		Partial removal, finger bone	Surgery		5.31	5.28	5.28	5.28	
26250		Extensive hand surgery	Surgery		7.54	6.38	6.38	6.38	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 28 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
26255		Extensive hand surgery	Surgery		12.41	9.35	9.35		
26260		Extensive finger surgery	Surgery		7.02	6.14	6.14		
26261		Extensive finger surgery	Surgery		9.08	6.23	6.23		
26262		Partial removal of finger	Surgery		5.66	5.29	5.29		
26320		Removal of implant from hand	Surgery		3.97	4.25	4.25		
26310		Manipulate finger, w/arth	Surgery		2.50	4.74	4.74		
26350		Repair finger/hand tendon	Surgery		5.98	15.49	15.49		
26352		Repair/graft hand tendon	Surgery		7.67	16.08	16.08		
26356		Repair finger/hand tendon	Surgery		8.06	18.91	18.91		
26357		Repair finger/hand tendon	Surgery		8.57	16.53	16.53		
26358		Repair/graft hand tendon	Surgery		9.13	17.43	17.43		
26370		Repair finger/hand tendon	Surgery		7.10	15.95	15.95		
26372		Repair/graft hand tendon	Surgery		8.75	17.32	17.32		
26373		Repair finger/hand tendon	Surgery		8.15	16.87	16.87		
26390		Revise hand/finger tendon	Surgery		9.18	13.92	13.92		
26392		Repair/graft hand tendon	Surgery		10.24	17.66	17.66		
26410		Repair hand tendon	Surgery		4.62	12.59	12.59		
26412		Repair/graft hand tendon	Surgery		6.30	13.92	13.92		
26415		Excision, hand/finger tendon	Surgery		8.33	12.28	12.28		
26416		Graft hand or finger tendon	Surgery		9.36	15.21	15.21		
26418		Repair finger tendon	Surgery		4.24	12.95	12.95		
26420		Repair/graft finger tendon	Surgery		6.76	14.26	14.26		
26425		Repair finger/hand tendon	Surgery		6.14	13.78	13.78		
26428		Repair/graft finger tendon	Surgery		7.20	14.58	14.58		
26432		Repair finger tendon	Surgery		4.01	10.69	10.69		
26433		Repair finger tendon	Surgery		4.55	11.37	11.37		
26434		Repair/graft finger tendon	Surgery		6.08	12.06	12.06		
26437		Realignment of tendons	Surgery		5.81	11.98	11.98		
26440		Release palm/finger tendon	Surgery		5.01	14.18	14.18		
26442		Release palm & finger tendon	Surgery		8.15	16.61	16.61		
26445		Release hand/finger tendon	Surgery		4.30	13.93	13.93		
26449		Release forearm/hand tendon	Surgery		6.99	16.39	16.39		
26450		Incision of palm tendon	Surgery		3.66	7.58	7.58		
26455		Incision of finger tendon	Surgery		3.63	7.50	7.50		
26460		Incise hand/finger tendon	Surgery		3.45	7.32	7.32		
26471		Fusion of finger tendons	Surgery		3.72	11.65	11.65		
26474		Fusion of finger tendons	Surgery		5.31	11.84	11.84		
26476		Tendon lengthening	Surgery		5.17	11.37	11.37		
26477		Tendon shortening	Surgery		5.14	11.54	11.54		
26478		Lengthening of hand tendon	Surgery		5.79	12.24	12.24		
26479		Shortening of hand tendon	Surgery		5.73	12.08	12.08		
26480		Transplant hand tendon	Surgery		6.66	15.68	15.68		
26483		Transplant/graft hand tendon	Surgery		8.28	16.12	16.12		
26485		Transplant palm tendon	Surgery		7.69	16.01	16.01		
26489		Transplant/graft palm tendon	Surgery		9.54	12.54	12.54		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 27 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
26490		Revise thumb tendon	Surgery		8.40	13.16	13.16	13.16	
26492		Tendon transfer with graft	Surgery		9.61	13.97	13.97	13.97	
26494		Hand tendon/muscle transfer	Surgery		8.46	13.61	13.61	13.61	
26496		Revise thumb tendon	Surgery		9.58	13.61	13.61	13.61	
26497		Finger tendon transfer	Surgery		9.56	13.96	13.96	13.96	
26498		Finger tendon transfer	Surgery		13.98	16.55	16.55	16.55	
26499		Revision of finger	Surgery		8.97	13.50	13.50	13.50	
26500		Hand tendon reconstruction	Surgery		5.95	12.12	12.12	12.12	
26502		Hand tendon reconstruction	Surgery		7.13	12.58	12.58	12.58	
26504		Hand tendon reconstruction	Surgery		7.46	13.01	13.01	13.01	
26508		Release thumb contracture	Surgery		6.00	12.11	12.11	12.11	
26510		Thumb tendon transfer	Surgery		5.42	11.79	11.79	11.79	
26516		Fusion of knuckle joint	Surgery		7.14	12.65	12.65	12.65	
26517		Fusion of knuckle joints	Surgery		8.82	13.96	13.96	13.96	
26518		Fusion of knuckle joints	Surgery		9.01	13.77	13.77	13.77	
26520		Release knuckle contracture	Surgery		5.29	14.63	14.63	14.63	
26525		Release finger contracture	Surgery		5.32	14.74	14.74	14.74	
26530		Revise knuckle joint	Surgery		6.88	6.02	6.02	6.02	
26531		Revise knuckle with implant	Surgery		7.90	6.99	6.99	6.99	
26535		Revise finger joint	Surgery		5.23	3.69	3.69	3.69	
26536		Revise/implant finger joint	Surgery		6.36	9.74	9.74	9.74	
26540		Repair hand joint	Surgery		6.42	12.35	12.35	12.35	
26541		Repair hand joint with graft	Surgery		8.61	13.83	13.83	13.83	
26542		Reconstruct finger joint	Surgery		6.77	12.39	12.39	12.39	
26545		Repair nonunion hand	Surgery		6.91	12.79	12.79	12.79	
26546		Reconstruct finger joint	Surgery		8.91	15.20	15.20	15.20	
26548		Construct thumb replacement	Surgery		8.02	13.39	13.39	13.39	
26550		Great toe-hand transfer	Surgery		21.21	18.16	18.16	18.16	
26551		Single transfer, toe-hand	Surgery		46.51	33.71	33.71	33.71	
26553		Double transfer, toe-hand	Surgery		46.20	23.22	23.22	23.22	
26554		Positional change of finger	Surgery		54.87	38.02	38.02	38.02	
26556		Toe joint transfer	Surgery		16.61	18.67	18.67	18.67	
26560		Repair of web finger	Surgery		47.19	34.50	34.50	34.50	
26561		Repair of web finger	Surgery		5.37	10.28	10.28	10.28	
26562		Repair of web finger	Surgery		10.90	12.93	12.93	12.93	
26565		Correct metacarpal flaw	Surgery		14.98	17.59	17.59	17.59	
26567		Correct finger deformity	Surgery		6.73	12.46	12.46	12.46	
26568		Lengthen metacarpal/finger	Surgery		6.81	12.39	12.39	12.39	
26580		Repair hand deformity	Surgery		9.07	16.09	16.09	16.09	
26587		Reconstruct extra finger	Surgery		18.15	13.98	13.98	13.98	
26590		Repair finger deformity	Surgery		14.03	9.05	9.05	9.05	
26591		Repair muscles of hand	Surgery		17.93	14.40	14.40	14.40	
26593		Release muscles of hand	Surgery		3.25	10.44	10.44	10.44	
26596		Excision constricting tissue	Surgery		5.30	11.51	11.51	11.51	
			Surgery		8.94	9.01	9.01	9.01	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 28 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
26600		Treat metacarpal fracture	Surgery		1.96	2.64	4.08		
26605		Treat metacarpal fracture	Surgery		2.85	3.58	5.25		
26607		Treat metacarpal fracture	Surgery		5.35	6.35	6.35		
26608		Treat metacarpal fracture	Surgery		5.35	6.35	6.35		
26615		Treat metacarpal fracture	Surgery		5.32	5.53	5.53		
26641		Treat thumb dislocation	Surgery		3.93	3.98	5.40		
26645		Treat thumb fracture	Surgery		4.40	4.17	6.10		
26650		Treat thumb fracture	Surgery		5.71	6.76	6.76		
26665		Treat thumb fracture	Surgery		7.59	6.80	6.80		
26670		Treat hand dislocation	Surgery		3.68	3.03	4.89		
26675		Treat hand dislocation	Surgery		4.63	4.41	6.23		
26676		Pin hand dislocation	Surgery		5.51	6.79	6.79		
26685		Treat hand dislocation	Surgery		6.97	6.26	6.26		
26686		Treat hand dislocation	Surgery		7.93	7.03	7.03		
26700		Treat knuckle dislocation	Surgery		3.68	2.96	4.65		
26705		Treat knuckle dislocation	Surgery		4.18	4.24	6.03		
26706		Pin knuckle dislocation	Surgery		5.11	5.09	5.09		
26715		Treat knuckle dislocation	Surgery		5.73	5.71	5.71		
26720		Treat finger fracture, each	Surgery		1.66	2.60	3.89		
26725		Treat finger fracture, each	Surgery		3.33	4.04	6.09		
26727		Treat finger fracture, each	Surgery		5.22	6.40	6.40		
26735		Treat finger fracture, each	Surgery		5.97	5.86	5.86		
26740		Treat finger fracture, each	Surgery		1.94	2.69	3.56		
26742		Treat finger fracture, each	Surgery		3.84	3.85	5.81		
26746		Treat finger fracture, each	Surgery		5.80	5.91	5.91		
26750		Treat finger fracture, each	Surgery		1.70	2.08	3.14		
26755		Treat finger fracture, each	Surgery		3.10	3.05	4.81		
26756		Pin finger fracture, each	Surgery		4.38	6.04	6.04		
26765		Treat finger fracture, each	Surgery		4.16	4.78	4.78		
26770		Treat finger dislocation	Surgery		3.02	2.55	4.40		
26775		Treat finger dislocation	Surgery		3.70	3.82	5.85		
26776		Pin finger dislocation	Surgery		4.79	6.21	6.21		
26785		Treat finger dislocation	Surgery		4.20	4.81	4.81		
26820		Thumb fusion with graft	Surgery		8.25	13.63	13.63		
26841		Fusion of thumb	Surgery		7.12	13.53	13.53		
26842		Thumb fusion with graft	Surgery		8.23	13.71	13.71		
26843		Fusion of hand joint	Surgery		7.60	12.68	12.68		
26844		Fusion/graft of hand joint	Surgery		8.72	13.68	13.68		
26850		Fusion of knuckle	Surgery		6.96	12.56	12.56		
26852		Fusion of knuckle with graft	Surgery		8.45	13.25	13.25		
26860		Fusion of finger joint	Surgery		4.68	11.55	11.55		
26861		Fusion of finger jnt, add-on	Surgery		1.74	0.93	0.93		
26862		Fusion/graft of finger joint	Surgery		7.36	12.75	12.75		
26863		Fuse/graft added joint	Surgery		3.89	2.12	2.12		
26910		Amputate metacarpal bone	Surgery		7.59	11.70	11.70		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 29 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
26951		Amputation of finger/thumb	Surgery		4.58	10.62	10.62	10.62	Misc.
26952		Amputation of finger/thumb	Surgery		6.30	12.23	12.23	12.23	
26989		Hand/finger surgery	Surgery		7.47	7.63	7.63	7.63	
26990		Drainage of pelvis lesion	Surgery		6.67	5.94	7.47	7.47	
26991		Drainage of bone lesion	Surgery		13.00	10.86	10.86	10.86	
26992		Incision of hip tendon	Surgery		6.93	5.29	5.29	5.29	
27000		Incision of hip tendon	Surgery		7.33	6.15	6.15	6.15	
27001		Incision of hip tendon	Surgery		9.65	6.55	6.55	6.55	
27003		Incision of hip tendon	Surgery		9.67	7.85	7.85	7.85	
27005		Incision of hip tendons	Surgery		11.14	7.99	7.99	7.99	
27006		Incision of hip tendons	Surgery		11.14	8.60	8.60	8.60	
27025		Drainage of hip joint	Surgery		12.99	9.66	9.66	9.66	
27030		Exploration of hip joint	Surgery		13.37	9.93	9.93	9.93	
27033		Denervation of hip joint	Surgery		16.66	12.33	12.33	12.33	
27035		Excision of hip joint	Surgery		12.86	10.03	10.03	10.03	
27036		Excision of hip joint/muscle	Surgery		2.87	2.05	2.05	2.05	
27040		Biopsy of soft tissues	Surgery		9.88	6.73	6.73	6.73	
27041		Biopsy of soft tissues	Surgery		7.44	4.99	4.99	4.99	
27047		Remove hip/pelvis lesion	Surgery		6.24	5.04	5.04	5.04	
27048		Remove hip/pelvis lesion	Surgery		13.64	8.81	8.81	8.81	
27049		Remove tumor, hip/pelvis	Surgery		4.35	4.48	4.48	4.48	
27050		Biopsy of sacroiliac joint	Surgery		6.22	5.89	5.89	5.89	
27052		Biopsy of hip joint	Surgery		8.53	7.36	7.36	7.36	
27054		Removal of hip joint lining	Surgery		5.42	4.84	4.84	4.84	
27060		Removal of ischial bursa	Surgery		5.36	5.22	5.22	5.22	
27062		Remove femur lesion/bursa	Surgery		5.89	5.54	5.54	5.54	
27065		Removal of hip bone lesion	Surgery		10.31	8.51	8.51	8.51	
27066		Removal of hip bone lesion	Surgery		13.81	10.67	10.67	10.67	
27067		Remove/graft hip bone lesion	Surgery		10.70	9.78	9.78	9.78	
27070		Partial removal of hip bone	Surgery		11.44	10.75	10.75	10.75	
27071		Partial removal of hip bone	Surgery		34.95	19.68	19.68	19.68	
27075		Extensive hip surgery	Surgery		22.09	14.79	14.79	14.79	
27076		Extensive hip surgery	Surgery		39.94	23.10	23.10	23.10	
27077		Extensive hip surgery	Surgery		13.42	10.43	10.43	10.43	
27078		Extensive hip surgery	Surgery		13.73	10.09	10.09	10.09	
27079		Extensive hip surgery	Surgery		6.38	5.08	5.08	5.08	
27080		Removal of tail bone	Surgery		1.87	1.87	1.87	1.87	
27086		Remove hip foreign body	Surgery		8.53	6.71	6.71	6.71	
27087		Remove hip foreign body	Surgery		11.13	8.65	8.65	8.65	
27090		Removal of hip prosthesis	Surgery		22.11	13.86	13.86	13.86	
27091		Removal of hip prosthesis	Surgery		1.30	0.48	0.48	0.48	
27093		Injection for hip x-ray	Surgery		1.50	0.52	0.52	0.52	
27095		Injection for hip x-ray	Surgery		1.40	0.33	0.33	0.33	
27096		Infect sacroiliac joint	Surgery		8.79	6.47	6.47	6.47	
27097		Revision of hip tendon	Surgery						

NOTE: CPT Codes and descriptions only. are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 30 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
27098		Transfer tendon to pelvis	Surgery		8.82	7.10	7.10		
27100		Transfer of abdominal muscle	Surgery		11.06	8.73	8.73		
27105		Transfer of spinal muscle	Surgery		11.75	9.20	9.20		
27110		Transfer of iliopsoas muscle	Surgery		13.24	9.33	9.33		
27111		Transfer of iliopectus muscle	Surgery		12.13	9.18	9.18		
27120		Reconstruction of hip socket	Surgery		17.98	11.74	11.74		
27122		Reconstruction of hip socket	Surgery		14.96	10.91	10.91		
27125		Partial hip replacement	Surgery		14.67	10.49	10.49		
27130		Total hip arthroplasty	Surgery		20.09	13.21	13.21		
27132		Total hip arthroplasty	Surgery		23.27	15.48	15.48		
27134		Revise hip joint replacement	Surgery		28.48	17.69	17.69		
27137		Revise hip joint replacement	Surgery		21.14	13.82	13.82		
27138		Revise hip joint replacement	Surgery		22.14	14.28	14.28		
27140		Transplant femur ridge	Surgery		12.22	9.41	9.41		
27146		Incision of hip bone	Surgery		17.40	12.27	12.27		
27147		Revision of hip bone	Surgery		20.55	13.34	13.34		
27151		Incision of hip bones	Surgery		22.48	8.21	8.21		
27156		Revision of hip bones	Surgery		24.59	16.10	16.10		
27158		Revision of pelvis	Surgery		19.71	11.24	11.24		
27161		Incision of neck of femur	Surgery		16.68	12.09	12.09		
27165		Incision/fixation of femur	Surgery		17.88	12.85	12.85		
27170		Repair/graft femur head/neck	Surgery		16.05	11.30	11.30		
27175		Treat slipped epiphysis	Surgery		8.45	6.58	6.58		
27176		Treat slipped epiphysis	Surgery		12.03	8.98	8.98		
27177		Treat slipped epiphysis	Surgery		15.06	10.83	10.83		
27178		Treat slipped epiphysis	Surgery		11.97	8.40	8.40		
27179		Revise head/neck of femur	Surgery		12.96	9.92	9.92		
27181		Treat slipped epiphysis	Surgery		14.66	10.15	10.15		
27185		Revision of femur epiphysis	Surgery		9.17	7.58	7.58		
27187		Reinforce hip bones	Surgery		13.52	10.33	10.33		
27193		Treat pelvic ring fracture	Surgery		5.55	5.74	7.10		
27194		Treat pelvic ring fracture	Surgery		9.64	7.50	8.75		
27200		Treat tail bone fracture	Surgery		1.84	2.17	3.04		
27202		Treat tail bone fracture	Surgery		7.03	17.65	17.65		
27215		Treat pelvic fracture(s)	Surgery		10.03	7.17	7.17		
27216		Treat pelvic ring fracture	Surgery		15.17	9.72	9.72		
27217		Treat pelvic ring fracture	Surgery		14.09	10.15	10.15		
27218		Treat pelvic ring fracture	Surgery		20.12	11.50	11.50		
27220		Treat hip socket fracture	Surgery		6.17	5.51	7.06		
27222		Treat hip socket fracture	Surgery		12.68	9.88	9.88		
27226		Treat hip wall fracture	Surgery		14.89	7.92	7.92		
27227		Treat hip fracture(s)	Surgery		23.41	15.35	15.35		
27228		Treat hip fracture(s)	Surgery		27.12	17.57	17.57		
27230		Treat thigh fracture	Surgery		5.49	5.04	5.04		
27232		Treat thigh fracture	Surgery		10.66	7.18	7.18		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 31 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
27235		Treat thigh fracture	Surgery		12.14	9.39	9.39		
27236		Treat thigh fracture	Surgery		15.58	10.93	10.93		
27238		Treat thigh fracture	Surgery		5.51	5.09	5.09		
27240		Treat thigh fracture	Surgery		12.48	9.37	9.37		
27244		Treat thigh fracture	Surgery		15.92	11.26	11.26		
27245		Treat thigh fracture	Surgery		20.28	13.70	13.70		
27246		Treat thigh fracture	Surgery		4.70	4.41	5.66		
27248		Treat thigh fracture	Surgery		10.43	8.19	8.19		
27250		Treat hip dislocation	Surgery		6.94	4.77	4.77		
27252		Treat hip dislocation	Surgery		10.37	7.39	7.39		
27253		Treat hip dislocation	Surgery		12.90	9.72	9.72		
27254		Treat hip dislocation	Surgery		18.23	12.03	12.03		
27256		Treat hip dislocation	Surgery		4.11	2.09	3.43		
27257		Treat hip dislocation	Surgery		5.21	2.88	2.88		
27258		Treat hip dislocation	Surgery		15.41	10.91	10.91		
27259		Treat hip dislocation	Surgery		21.52	14.16	14.16		
27265		Treat hip dislocation	Surgery		5.04	4.76	4.76		
27266		Treat hip dislocation	Surgery		7.48	6.27	6.27		
27275		Manipulation of hip joint	Surgery		2.27	2.13	2.13		
27280		Fusion of sacroiliac joint	Surgery		13.37	10.30	10.30		
27282		Fusion of pubic bones	Surgery		11.32	8.23	8.23		
27284		Fusion of hip joint	Surgery		23.41	14.83	14.83		
27286		Fusion of hip joint	Surgery		23.41	15.81	15.81		
27290		Amputation of leg at hip	Surgery		23.25	14.16	14.16		
27295		Pelvis/hip joint surgery	Surgery		18.62	11.54	11.54	33.30	Misc.
27299		Drain thigh/knee lesion	Surgery		6.48	5.88	7.34		
27301		Drain thigh/knee lesion	Surgery		8.27	7.24	7.24		
27303		Drainage of bone lesion	Surgery		5.91	5.36	5.36		
27305		Incise thigh tendon & fascia	Surgery		4.61	4.80	4.80		
27306		Incision of thigh tendon	Surgery		5.79	5.52	5.52		
27307		Incision of thigh tendons	Surgery		9.26	7.54	7.54		
27310		Exploration of knee joint	Surgery		6.96	4.83	4.83		
27315		Partial removal, thigh nerve	Surgery		6.29	5.12	5.12		
27320		Biopsy, thigh soft tissues	Surgery		2.28	1.92	2.19		
27323		Biopsy, thigh soft tissues	Surgery		4.89	4.35	4.35		
27324		Biopsy, thigh soft tissues	Surgery		4.46	3.91	5.34		
27327		Removal of thigh lesion	Surgery		5.56	4.57	4.57		
27328		Removal of thigh lesion	Surgery		14.12	9.51	9.51		
27329		Remove tumor, thigh/knee	Surgery		4.96	4.61	4.61		
27330		Biopsy, knee joint lining	Surgery		5.87	5.51	5.51		
27331		Explore/treat knee joint	Surgery		8.26	7.08	7.08		
27332		Removal of knee cartilage	Surgery		7.29	6.60	6.60		
27333		Removal of knee cartilage	Surgery		8.69	7.38	7.38		
27334		Remove knee joint lining	Surgery		9.99	8.18	8.18		
27335		Remove knee joint lining	Surgery						

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 32 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
27340		Removal of kneecap bursa	Surgery		4.17	4.53	4.53		
27345		Removal of knee cyst	Surgery		5.91	5.61	5.61		
27347		Remove knee cyst	Surgery		5.77	5.42	5.42		
27350		Removal of kneecap	Surgery		8.16	7.19	7.19		
27355		Remove femur lesion	Surgery		7.64	6.81	6.81		
27356		Remove femur lesion/graft	Surgery		9.47	7.88	7.88		
27357		Remove femur lesion/graft	Surgery		10.51	8.70	8.70		
27358		Remove femur lesion/fixation	Surgery		4.73	2.54	2.54		
27360		Partial removal, leg bone(s)	Surgery		10.48	9.95	9.95		
27365		Extensive leg surgery	Surgery		16.25	11.67	11.67		
27370		Injection for knee x-ray	Surgery		0.96	0.32	12.01		
27372		Removal of foreign body	Surgery		5.06	4.69	6.00		
27372		Repair of kneecap tendon	Surgery		7.15	7.25	7.25		
27380		Repair/graft kneecap tendon	Surgery		10.32	9.05	9.05		
27381		Repair of thigh muscle	Surgery		7.75	7.59	7.59		
27386		Repair/graft of thigh muscle	Surgery		10.54	9.46	9.46		
27390		Incision of thigh tendon	Surgery		5.32	5.26	5.26		
27391		Incision of thigh tendons	Surgery		7.19	6.63	6.63		
27392		Incision of thigh tendons	Surgery		9.19	7.72	7.72		
27393		Lengthening of thigh tendon	Surgery		6.38	5.85	5.85		
27394		Lengthening of thigh tendons	Surgery		8.49	7.28	7.28		
27395		Lengthening of thigh tendons	Surgery		11.71	9.38	9.38		
27396		Transplant of thigh tendon	Surgery		7.85	7.07	7.07		
27397		Transplants of thigh tendons	Surgery		11.26	9.03	9.03		
27400		Revise thigh muscles/tendons	Surgery		9.01	7.34	7.34		
27403		Repair of knee cartilage	Surgery		8.32	7.14	7.14		
27405		Repair of knee ligament	Surgery		8.64	7.46	7.46		
27407		Repair of knee ligament	Surgery		10.26	8.30	8.30		
27409		Repair of knee ligaments	Surgery		12.88	9.91	9.91		
27418		Repair degenerated kneecap	Surgery		10.83	8.85	8.85		
27420		Revision of unstable kneecap	Surgery		9.82	8.05	8.05		
27422		Revision of unstable kneecap	Surgery		9.77	8.07	8.07		
27424		Revision/removal of kneecap	Surgery		9.80	8.04	8.04		
27425		Lateral release release open	Surgery		5.21	5.49	5.49		
27427		Reconstruction, knee	Surgery		9.35	7.74	7.74		
27428		Reconstruction, knee	Surgery		13.98	11.10	11.10		
27429		Reconstruction, knee	Surgery		15.50	12.34	12.34		
27430		Revision of thigh muscles	Surgery		9.66	7.96	7.96		
27435		Incision of knee joint	Surgery		9.48	8.36	8.36		
27437		Revise kneecap	Surgery		8.45	7.11	7.11		
27438		Revise kneecap with implant	Surgery		11.21	8.43	8.43		
27440		Revision of knee joint	Surgery		10.41	5.97	5.97		
27441		Revision of knee joint	Surgery		10.80	6.65	6.65		
27442		Revision of knee joint	Surgery		11.87	8.80	8.80		
27443		Revision of knee joint	Surgery		10.91	8.59	8.59		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 33 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
27445		Revision of knee joint	Surgery		17.65	12.23	12.23		
27446		Revision of knee joint	Surgery		15.82	11.15	11.15		
27447		Total knee arthroplasty	Surgery		21.45	14.46	14.46		
27448		Incision of thigh	Surgery		11.04	8.65	8.65		
27450		Reassignment of thigh bone	Surgery		13.96	10.59	10.59		
27454		Realignment of knee	Surgery		17.53	12.50	12.50		
27455		Realignment of knee	Surgery		12.80	9.87	9.87		
27457		Shortening of thigh bone	Surgery		13.43	9.91	9.91		
27465		Lengthening of thigh bone	Surgery		13.85	10.34	10.34		
27466		Shorten/lengthen thighs	Surgery		16.31	11.87	11.87		
27468		Repair of thigh	Surgery		18.94	12.45	12.45		
27470		Repair/graft of thigh	Surgery		16.05	11.83	11.83		
27472		Surgery to stop leg growth	Surgery		17.69	12.72	12.72		
27475		Surgery to stop leg growth	Surgery		8.63	7.22	7.22		
27477		Surgery to stop leg growth	Surgery		8.84	7.73	7.73		
27479		Surgery to stop leg growth	Surgery		12.78	9.86	9.86		
27485		Surgery to stop leg growth	Surgery		8.83	7.38	7.38		
27486		Reviser/replace knee joint	Surgery		19.24	13.34	13.34		
27487		Reviser/replace knee joint	Surgery		25.23	16.41	16.41		
27488		Removal of knee prosthesis	Surgery		15.72	11.54	11.54		
27495		Reinforce thigh	Surgery		15.53	11.47	11.47		
27496		Decompression of thigh/knee	Surgery		6.10	5.72	5.72		
27497		Decompression of thigh/knee	Surgery		7.16	5.66	5.66		
27498		Decompression of thigh/knee	Surgery		7.98	6.11	6.11		
27499		Decompression of thigh/knee	Surgery		8.99	6.99	6.99		
27500		Treatment of thigh fracture	Surgery		5.91	4.99	7.01		
27501		Treatment of thigh fracture	Surgery		5.91	5.66	7.57		
27502		Treatment of thigh fracture	Surgery		10.56	8.10	8.10		
27503		Treatment of thigh fracture	Surgery		10.56	8.26	8.26		
27506		Treatment of thigh fracture	Surgery		17.42	12.70	12.70		
27507		Treatment of thigh fracture	Surgery		13.97	9.88	9.88		
27508		Treatment of thigh fracture	Surgery		5.82	5.32	6.97		
27509		Treatment of thigh fracture	Surgery		7.70	7.90	7.90		
27510		Treatment of thigh fracture	Surgery		9.12	7.17	7.17		
27511		Treatment of thigh fracture	Surgery		13.62	11.19	11.19		
27513		Treatment of thigh fracture	Surgery		17.89	13.83	13.83		
27514		Treat thigh fx growth plate	Surgery		17.27	13.29	13.29		
27516		Treat thigh fx growth plate	Surgery		5.36	5.38	7.27		
27517		Treat thigh fx growth plate	Surgery		8.77	7.35	8.89		
27519		Treat thigh fx growth plate	Surgery		15.00	11.61	11.61		
27520		Treat kneecap fracture	Surgery		2.86	3.41	5.22		
27524		Treat kneecap fracture	Surgery		9.99	8.14	8.14		
27530		Treat knee fracture	Surgery		3.77	4.26	5.88		
27532		Treat knee fracture	Surgery		7.29	6.26	7.82		
27535		Treat knee fracture	Surgery		11.48	10.09	10.09		

NOTE. CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE

PAGE 34 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
27536		Treat knee fracture			15.63	11.48	11.48	11.48	
27538		Treat knee fracture(s)			4.86	5.08	7.07	7.07	
27540		Treat knee fracture			13.08	9.46	9.46	9.46	
27550		Treat knee dislocation			5.75	4.92	6.57	6.57	
27552		Treat knee dislocation			7.89	6.86	6.86	6.86	
27556		Treat knee dislocation			14.39	11.66	11.66	11.66	
27557		Treat knee dislocation			16.74	13.12	13.12	13.12	
27558		Treat knee dislocation			17.69	13.08	13.08	13.08	
27560		Treat kneecap dislocation			3.81	3.29	5.58	5.58	
27562		Treat kneecap dislocation			5.78	4.79	4.79	4.79	
27566		Treat kneecap dislocation			12.21	9.26	9.26	9.26	
27570		Fixation of knee joint			1.74	1.81	1.81	1.81	
27580		Fusion of knee			19.34	14.75	14.75	14.75	
27590		Amputate leg at thigh			12.01	7.10	7.10	7.10	
27591		Amputate leg at thigh			12.66	8.87	8.87	8.87	
27592		Amputate leg at thigh			10.00	6.59	6.59	6.59	
27594		Amputation follow-up surgery			6.91	5.45	5.45	5.45	
27596		Amputation follow-up surgery			10.58	7.22	7.22	7.22	
27598		Amputate lower leg at knee			10.51	7.32	7.32	7.32	
27599		Leg surgery procedure							
27600		Decompression of lower leg			5.64	4.75	4.75	4.75	
27601		Decompression of lower leg			5.63	5.04	5.04	5.04	
27602		Decompression of lower leg			7.34	5.33	5.33	5.33	
27603		Decompression of lower leg			4.93	4.85	10.64	10.64	
27604		Drain lower leg bursa			4.46	4.53	8.58	8.58	
27605		Incision of achilles tendon			2.87	2.34	8.80	8.80	
27606		Incision of achilles tendon			4.13	3.40	10.03	10.03	
27607		Treat lower leg bone lesion			7.96	6.58	6.58	6.58	
27610		Explore/treat ankle joint			8.33	7.06	7.06	7.06	
27612		Exploration of ankle joint			7.32	6.12	6.12	6.12	
27613		Biopsy lower leg soft tissue			2.17	1.76	3.77	3.77	
27614		Biopsy lower leg soft tissue			5.65	4.63	8.78	8.78	
27615		Remove tumor, lower leg			12.54	10.56	10.56	10.56	
27618		Remove lower leg lesion			5.08	4.21	9.10	9.10	
27619		Remove lower leg lesion			8.39	6.17	10.62	10.62	
27620		Explore/treat ankle joint			5.97	5.50	5.50	5.50	
27625		Remove ankle joint lining			8.29	6.54	6.54	6.54	
27628		Remove ankle joint lining			8.90	7.00	7.00	7.00	
27630		Removal of tendon lesion			4.79	4.46	8.99	8.99	
27635		Remove lower leg bone lesion			7.77	6.84	6.84	6.84	
27637		Remove/graft leg bone lesion			9.84	8.35	8.35	8.35	
27638		Remove/graft leg bone lesion			10.55	8.39	8.39	8.39	
27640		Partial removal of tibia			11.35	10.81	10.81	10.81	
27641		Partial removal of fibula			9.23	8.83	8.83	8.83	
27645		Extensive lower leg surgery			14.15	12.34	12.34	12.34	
								19.68	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 35 OF 179

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
27646		Extensive lower leg surgery	Surgery		12.64	11.34	11.34		
27647		Extensive ankle/heel surgery	Surgery		12.22	7.85	7.85		
27648		Injection for ankle x-ray	Surgery		0.96	0.33	0.33		
27650		Repair achilles tendon	Surgery		9.68	7.51	7.51		
27652		Repair/graft achilles tendon	Surgery		10.31	8.01	8.01		
27654		Repair of achilles tendon	Surgery		10.00	7.23	7.23		
27656		Repair leg fascia defect	Surgery		4.56	4.01	4.01		
27658		Repair of leg tendon, each	Surgery		4.97	4.77	4.77		
27659		Repair of leg tendon, each	Surgery		6.80	5.80	5.80		
27664		Repair of leg tendon, each	Surgery		4.58	4.74	4.74		
27665		Repair of leg tendon, each	Surgery		5.39	5.18	5.18		
27675		Repair lower leg tendons	Surgery		7.17	5.79	5.79		
27676		Repair lower leg tendons	Surgery		8.41	6.77	6.77		
27680		Release of lower leg tendons	Surgery		5.73	5.19	5.19		
27681		Release of lower leg tendons	Surgery		6.81	5.96	5.96		
27685		Revision of lower leg tendon	Surgery		6.49	5.51	5.51		
27686		Revision of lower leg tendons	Surgery		7.45	6.59	6.59		
27687		Revision of calf tendon	Surgery		6.23	5.42	5.42		
27690		Revise lower leg tendon	Surgery		8.70	6.45	6.45		
27691		Revise lower leg tendon	Surgery		9.95	7.81	7.81		
27692		Revise additional leg tendon	Surgery		1.87	0.93	0.93		
27695		Repair of ankle ligament	Surgery		6.50	5.92	5.92		
27696		Repair of ankle ligaments	Surgery		8.26	6.50	6.50		
27698		Repair of ankle ligament	Surgery		9.35	6.98	6.98		
27700		Revision of ankle joint	Surgery		9.28	5.62	5.62		
27702		Reconstruct ankle joint	Surgery		13.65	10.32	10.32		
27703		Reconstruction, ankle joint	Surgery		15.85	11.09	11.09		
27704		Removal of ankle implant	Surgery		7.61	5.52	5.52		
27705		Incision of tibia	Surgery		10.36	8.23	8.23		
27707		Incision of fibula	Surgery		4.36	5.01	5.01		
27709		Incision of tibia & fibula	Surgery		9.94	8.16	8.16		
27712		Realignment of lower leg	Surgery		14.23	10.72	10.72		
27715		Revision of lower leg	Surgery		14.37	10.84	10.84		
27720		Repair of tibia	Surgery		11.77	9.45	9.45		
27722		Repair/graft of tibia	Surgery		11.80	9.21	9.21		
27724		Repair/graft of tibia	Surgery		18.17	12.45	12.45		
27725		Repair of lower leg	Surgery		15.57	11.88	11.88		
27727		Repair of lower leg	Surgery		13.99	10.41	10.41		
27730		Repair of tibia epiphysis	Surgery		7.40	6.45	6.45		
27732		Repair of tibia epiphysis	Surgery		5.31	5.00	5.00		
27734		Repair lower leg epiphyses	Surgery		8.47	6.42	6.42		
27740		Repair of leg epiphyses	Surgery		9.29	7.93	7.93		
27742		Repair of leg epiphyses	Surgery		10.28	7.26	7.26		
27745		Reinforce tibia	Surgery		10.05	8.21	8.21		
27750		Treatment of tibia fracture	Surgery		3.19	3.77	3.77		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply
See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 36 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
27752		Treatment of tibia fracture	Surgery		5.83	5.49	7.38		
27756		Treatment of tibia fracture	Surgery		6.77	6.52	6.52		
27758		Treatment of tibia fracture	Surgery		11.65	9.19	9.19		
27759		Treatment of tibia fracture	Surgery		13.74	10.32	10.32		
27760		Treatment of ankle fracture	Surgery		3.01	3.53	5.25		
27762		Treatment of ankle fracture	Surgery		5.24	5.16	7.12		
27766		Treatment of ankle fracture	Surgery		8.35	7.16	7.16		
27780		Treatment of fibula fracture	Surgery		2.65	3.21	4.92		
27781		Treatment of fibula fracture	Surgery		4.39	4.49	6.35		
27784		Treatment of fibula fracture	Surgery		7.10	6.45	6.45		
27786		Treatment of ankle fracture	Surgery		2.84	3.33	5.09		
27788		Treatment of ankle fracture	Surgery		4.44	4.50	6.46		
27792		Treatment of ankle fracture	Surgery		7.65	6.90	6.90		
27808		Treatment of ankle fracture	Surgery		2.83	3.60	5.68		
27810		Treatment of ankle fracture	Surgery		5.12	4.99	6.95		
27814		Treatment of ankle fracture	Surgery		10.66	8.55	8.55		
27816		Treatment of ankle fracture	Surgery		2.89	3.40	4.99		
27818		Treatment of ankle fracture	Surgery		5.49	5.04	7.06		
27822		Treatment of ankle fracture	Surgery		10.98	10.63	10.63		
27823		Treatment of ankle fracture	Surgery		12.98	11.49	11.49		
27824		Treat lower leg fracture	Surgery		2.89	3.74	5.56		
27825		Treat lower leg fracture	Surgery		6.18	5.86	8.19		
27826		Treat lower leg fracture	Surgery		8.53	8.87	8.87		
27827		Treat lower leg fracture	Surgery		14.04	12.71	12.71		
27828		Treat lower leg fracture	Surgery		16.21	13.85	13.85		
27829		Treat lower leg joint	Surgery		5.48	6.77	6.77		
27830		Treat lower leg dislocation	Surgery		3.78	3.83	5.12		
27831		Treat lower leg dislocation	Surgery		4.55	4.43	4.43		
27832		Treat lower leg dislocation	Surgery		6.48	6.16	6.16		
27840		Treat ankle dislocation	Surgery		4.57	3.89	3.89		
27842		Treat ankle dislocation	Surgery		6.20	5.08	5.08		
27846		Treat ankle dislocation	Surgery		9.78	7.91	7.91		
27848		Treat ankle dislocation	Surgery		11.18	9.71	9.71		
27860		Fixation of ankle joint	Surgery		2.34	2.01	2.01		
27870		Fusion of ankle joint, open	Surgery		13.89	10.50	10.50		
27871		Fusion of tibiofibular joint	Surgery		9.16	7.62	7.62		
27880		Amputation of lower leg	Surgery		11.83	7.46	7.46		
27881		Amputation of lower leg	Surgery		12.32	9.01	9.01		
27882		Amputation of lower leg	Surgery		8.93	6.93	6.93		
27884		Amputation follow-up surgery	Surgery		8.20	6.10	6.10		
27886		Amputation follow-up surgery	Surgery		9.31	6.82	6.82		
27888		Amputation of foot at ankle	Surgery		9.66	7.60	7.60		
27889		Amputation of foot at ankle	Surgery		9.97	6.74	6.74		
27892		Decompression of leg	Surgery		7.38	5.85	5.85		
27893		Decompression of leg	Surgery		7.34	5.74	5.74		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 37 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
27804		Decompression of leg	Surgery		10.47	7.93	7.93	11.65	Misc.
27899		Leg/ankle surgery procedure	Surgery						
28001		Drainage of bursa of foot	Surgery		2.73	3.51	5.82		
28002		Treatment of foot infection	Surgery		4.61	4.64	7.22		
28003		Treatment of foot infection	Surgery		8.40	6.04	7.68		
28005		Treat foot bone lesion	Surgery		8.67	6.36	6.36		
28008		Incision of foot fascia	Surgery		4.44	3.55	5.68		
28010		Incision of toe tendon	Surgery		2.84	2.91	5.53		
28011		Incision of toe tendons	Surgery		4.13	4.24	7.42		
28020		Exploration of foot joint	Surgery		5.00	4.20	7.07		
28022		Exploration of foot joint	Surgery		4.66	3.93	6.09		
28024		Exploration of toe joint	Surgery		4.37	3.99	6.20		
28030		Removal of foot nerve	Surgery		6.14	3.58	3.58		
28035		Decompression of tibia nerve	Surgery		6.08	4.03	5.54		
28043		Excision of foot lesion	Surgery		3.53	3.28	5.79		
28045		Excision of foot lesion	Surgery		4.71	3.71	6.12		
28046		Resection of tumor, foot	Surgery		10.16	7.34	9.42		
28050		Biopsy of foot joint lining	Surgery		4.24	3.66	5.78		
28052		Biopsy of foot joint lining	Surgery		3.93	3.56	5.97		
28054		Biopsy of toe joint lining	Surgery		3.44	3.36	5.82		
28060		Partial removal, foot fascia	Surgery		5.22	4.03	6.39		
28062		Removal of foot fascia	Surgery		6.51	4.19	7.13		
28070		Removal of foot joint lining	Surgery		5.09	3.89	5.96		
28072		Removal of foot joint lining	Surgery		4.57	4.32	6.43		
28080		Removal of foot lesion	Surgery		3.57	3.70	5.93		
28086		Excise foot tendon sheath	Surgery		4.77	4.69	9.50		
28088		Excise foot tendon sheath	Surgery		3.85	4.00	7.04		
28090		Removal of foot lesion	Surgery		4.40	3.55	6.02		
28092		Removal of toe lesions	Surgery		3.63	3.61	6.33		
28100		Removal of ankle/heel lesion	Surgery		5.65	4.81	9.21		
28102		Remove/graft foot lesion	Surgery		7.72	6.05	6.05		
28103		Remove/graft foot lesion	Surgery		6.49	4.76	8.41		
28104		Removal of foot lesion	Surgery		5.11	4.05	6.35		
28106		Remove/graft foot lesion	Surgery		7.15	4.59	4.59		
28107		Remove/graft foot lesion	Surgery		5.55	4.32	7.24		
28108		Removal of toe lesions	Surgery		4.15	3.36	5.44		
28110		Part removal of metatarsal	Surgery		4.07	3.68	6.03		
28111		Part removal of metatarsal	Surgery		5.00	4.18	7.18		
28112		Part removal of metatarsal	Surgery		4.48	4.06	6.69		
28113		Part removal of metatarsal	Surgery		4.78	4.65	6.81		
28114		Revision of foot	Surgery		9.78	8.52	11.93		
28116		Removal of heel bone	Surgery		7.74	5.22	7.20		
28118		Removal of heel spur	Surgery		5.95	4.53	7.13		
28119		Part removal of ankle/heel	Surgery		5.38	3.87	6.21		
28120		Part removal of ankle/heel	Surgery		5.39	5.07	8.67		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 38 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
28122		Partial removal of foot bone			7.28	5.69	7.89		
28124		Partial removal of toe			4.80	4.06	6.08		
28126		Partial removal of toe			3.51	3.51	5.34		
28130		Removal of ankle bone			8.10	6.70	6.70		
28140		Removal of metatarsal			6.90	5.00	8.26		
28150		Removal of toe			4.08	3.78	5.98		
28153		Partial removal of toe			3.65	3.08	5.40		
28160		Partial removal of toe			3.73	3.83	5.68		
28171		Extensive foot surgery			9.59	5.69	5.69		
28173		Extensive foot surgery			8.79	5.64	8.26		
28175		Extensive foot surgery			6.04	4.10	6.68		
28190		Removal of foot foreign body			1.96	3.47	6.51		
28192		Removal of foot foreign body			4.63	3.72	6.43		
28193		Removal of foot foreign body			5.72	4.11	6.35		
28200		Repair of foot tendon			4.59	3.71	5.94		
28202		Repair/graft of foot tendon			6.83	4.63	8.16		
28208		Repair of foot tendon			4.36	3.46	5.72		
28210		Repair/graft of foot tendon			6.34	4.19	7.12		
28220		Release of foot tendon			4.52	3.56	5.56		
28222		Release of foot tendons			5.61	4.23	5.95		
28225		Release of foot tendon			3.65	3.07	5.26		
28226		Release of foot tendons			4.52	3.85	5.61		
28230		Incision of foot tendon(s)			4.23	3.61	5.62		
28232		Incision of toe tendon			3.36	3.44	5.66		
28234		Incision of foot tendon			3.72	3.47	5.81		
28238		Revision of foot tendon			7.72	5.07	7.97		
28240		Release of big toe			4.35	3.63	5.59		
28250		Revision of foot fascia			5.91	4.25	6.53		
28260		Release of midfoot joint			7.95	5.14	7.09		
28261		Revision of foot tendon			11.71	7.34	8.91		
28262		Revision of foot and ankle			15.81	11.44	14.32		
28264		Release of midfoot joint			10.33	7.82	8.51		
28270		Release of foot contracture			4.75	4.19	5.90		
28272		Release of toe joint, each			3.79	3.04	5.14		
28280		Fusion of toes			5.18	4.52	7.25		
28285		Repair of hammer toe			4.58	3.85	5.96		
28286		Repair of hammer toe			4.55	3.67	5.74		
28288		Partial removal of foot bone			4.73	5.30	6.69		
28289		Repair hallux rigidus			7.03	6.21	8.97		
28290		Correction of bunion			5.65	5.28	7.02		
28292		Correction of bunion			7.03	5.75	7.80		
28293		Correction of bunion			9.14	6.01	10.84		
28294		Correction of bunion			8.55	5.08	7.64		
28296		Correction of bunion			9.17	5.80	8.14		
28297		Correction of bunion			9.17	6.74	9.11		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 39 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
28298		Correction of bunion	Surgery		7.93	5.40	7.31		
28299		Correction of bunion	Surgery		10.56	6.41	8.71		
28300		Incision of heel bone	Surgery		9.53	7.07	13.10		
28302		Incision of ankle bone	Surgery		9.54	6.95	13.11		
28304		Incision of midfoot bones	Surgery		9.15	5.80	8.16		
28305		Incise/graft midfoot bones	Surgery		10.48	6.80	10.90		
28306		Incision of metatarsal	Surgery		5.85	4.25	7.19		
28307		Incision of metatarsal	Surgery		6.32	5.33	11.59		
28308		Incision of metatarsal	Surgery		5.28	3.76	6.07		
28309		Incision of metatarsals	Surgery		12.76	8.05	8.05		
28310		Revision of big toe	Surgery		5.42	3.96	6.24		
28312		Revision of toe	Surgery		4.54	4.11	5.98		
28313		Repair deformity of toe	Surgery		5.00	5.45	6.43		
28315		Removal of sesamoid bone	Surgery		4.85	3.67	5.82		
28320		Repair of foot bones	Surgery		9.17	6.76	6.76		
28322		Repair of metatarsals	Surgery		8.33	6.33	10.13		
28340		Resect enlarged toe tissue	Surgery		6.97	4.41	7.06		
28341		Resect enlarged toe	Surgery		8.40	4.95	7.23		
28344		Repair extra toe(s)	Surgery		4.25	3.69	6.78		
28345		Repair webbed toe(s)	Surgery		5.91	4.79	6.99		
28360		Reconstruct cleft foot	Surgery		13.32	10.50	10.50		
28400		Treatment of heel fracture	Surgery		2.16	2.98	4.28		
28405		Treatment of heel fracture	Surgery		4.56	4.53	5.51		
28406		Treatment of heel fracture	Surgery		6.30	6.80	6.80		
28415		Treat heel fracture	Surgery		15.95	13.24	13.24		
28420		Treat/graft heel fracture	Surgery		16.62	12.97	12.97		
28430		Treatment of ankle fracture	Surgery		2.09	2.61	4.07		
28435		Treatment of ankle fracture	Surgery		3.39	3.63	4.49		
28436		Treatment of ankle fracture	Surgery		4.70	5.90	5.90		
28445		Treat ankle fracture	Surgery		15.60	11.02	11.02		
28450		Treat midfoot fracture, each	Surgery		1.90	2.52	4.07		
28455		Treat midfoot fracture, each	Surgery		3.09	3.41	3.97		
28456		Treat midfoot fracture	Surgery		2.68	4.21	4.21		
28465		Treat midfoot fracture, each	Surgery		7.00	6.37	6.37		
28470		Treat metatarsal fracture	Surgery		1.99	2.48	3.87		
28475		Treat metatarsal fracture	Surgery		2.97	3.19	4.05		
28476		Treat metatarsal fracture	Surgery		3.37	4.99	4.99		
28485		Treat metatarsal fracture	Surgery		5.70	5.55	5.55		
28490		Treat big toe fracture	Surgery		1.09	1.73	2.21		
28495		Treat big toe fracture	Surgery		1.58	2.06	2.50		
28496		Treat big toe fracture	Surgery		2.33	3.63	9.72		
28505		Treat big toe fracture	Surgery		3.80	4.70	9.71		
28510		Treatment of toe fracture	Surgery		1.09	1.69	1.98		
28515		Treatment of toe fracture	Surgery		1.46	1.99	2.33		
28525		Treat toe fracture	Surgery		3.32	4.25	9.30		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 40 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
28530		Treat sesamoid bone fracture	Surgery		1.06	1.46	2.08		
28531		Treat sesamoid bone fracture	Surgery		2.35	2.51	8.98		
28540		Treat foot dislocation	Surgery		2.04	2.67	2.87		
28545		Treat foot dislocation	Surgery		2.45	2.86	2.86		
28546		Treat foot dislocation	Surgery		3.20	4.84	7.89		
28555		Repair foot dislocation	Surgery		6.29	6.54	11.49		
28570		Treat foot dislocation	Surgery		1.66	2.29	2.89		
28575		Treat foot dislocation	Surgery		3.31	4.03	4.37		
28576		Treat foot dislocation	Surgery		4.16	5.51	10.15		
28585		Repair foot dislocation	Surgery		7.98	6.53	8.14		
28600		Treat foot dislocation	Surgery		1.89	2.66	3.29		
28605		Treat foot dislocation	Surgery		2.71	3.61	3.74		
28606		Treat foot dislocation	Surgery		4.89	6.01	16.02		
28615		Repair foot dislocation	Surgery		7.76	7.98	7.98		
28630		Treat toe dislocation	Surgery		1.70	1.12	1.22		
28635		Treat toe dislocation	Surgery		1.91	1.49	1.66		
28636		Treat toe dislocation	Surgery		2.77	3.07	6.14		
28645		Repair toe dislocation	Surgery		4.21	3.50	5.66		
28660		Treat toe dislocation	Surgery		1.23	1.16	1.61		
28665		Treat toe dislocation	Surgery		1.82	1.63	1.65		
28666		Treat toe dislocation	Surgery		2.66	2.24	5.93		
28675		Repair of toe dislocation	Surgery		2.92	3.77	8.81		
28705		Fusion of foot bones	Surgery		18.77	12.43	12.43		
28715		Fusion of foot bones	Surgery		13.08	9.74	9.74		
28725		Fusion of foot bones	Surgery		11.59	8.30	8.30		
28730		Fusion of foot bones	Surgery		10.74	8.47	8.47		
28735		Fusion of foot bones	Surgery		10.83	7.86	7.86		
28737		Revision of foot bones	Surgery		9.63	6.87	6.87		
28740		Fusion of foot bones	Surgery		8.01	6.43	11.59		
28750		Fusion of big toe joint	Surgery		7.29	6.59	12.97		
28755		Fusion of big toe joint	Surgery		4.73	3.86	6.83		
28760		Fusion of big toe joint	Surgery		7.74	5.62	8.04		
28800		Amputation of midfoot	Surgery		8.20	6.04	6.04		
28805		Amputation thru metatarsal	Surgery		8.38	5.90	5.90		
28810		Amputation toe & metatarsal	Surgery		6.20	4.76	4.76		
28820		Amputation of toe	Surgery		4.40	4.10	8.50		
28825		Partial amputation of toe	Surgery		3.58	3.79	7.91		
28899		Foot/toes surgery procedure	Surgery						Misc.
29000		Application of body cast	Surgery		2.25	1.72	3.09	9.04	
29010		Application of body cast	Surgery		2.06	1.73	3.30		
29015		Application of body cast	Surgery		2.41	1.58	3.01		
29020		Application of body cast	Surgery		2.11	1.41	3.30		
29025		Application of body cast	Surgery		2.40	1.83	3.22		
29035		Application of body cast	Surgery		1.77	1.54	3.45		
29040		Application of body cast	Surgery		2.22	1.51	2.57		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 41 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
29044		Application of body cast	Surgery		2.12	1.85	3.80		
29046		Application of body cast	Surgery		2.41	2.02	3.27		
29049		Application of figure eight	Surgery		0.89	0.54	1.24		
29055		Application of shoulder cast	Surgery		1.78	1.43	2.81		
29058		Application of shoulder cast	Surgery		1.31	0.73	1.50		
29065		Application of long arm cast	Surgery		0.87	0.74	1.26		
29075		Application of forearm cast	Surgery		0.77	0.67	1.20		
29085		Apply hand/wrist cast	Surgery		0.87	0.63	1.23		
29086		Apply finger cast	Surgery		0.62	0.51	0.93		
29105		Apply long arm splint	Surgery		0.87	0.52	1.18		
29125		Apply forearm splint	Surgery		0.59	0.40	0.99		
29126		Apply forearm splint	Surgery		0.77	0.46	1.19		
29130		Application of finger splint	Surgery		0.50	0.17	0.45		
29131		Application of finger splint	Surgery		0.55	0.24	0.73		
29200		Strapping of chest	Surgery		0.65	0.36	0.75		
29220		Strapping of low back	Surgery		0.64	0.39	0.72		
29240		Strapping of shoulder	Surgery		0.71	0.37	0.86		
29260		Strapping of elbow or wrist	Surgery		0.55	0.34	0.75		
29280		Strapping of hand or finger	Surgery		0.51	0.34	0.81		
29305		Application of hip cast	Surgery		2.03	1.71	3.19		
29325		Application of hip casts	Surgery		2.32	1.89	3.37		
29345		Application of long leg cast	Surgery		1.40	1.04	1.69		
29355		Application of long leg cast	Surgery		1.53	1.10	1.65		
29358		Apply long leg cast brace	Surgery		1.43	1.07	1.96		
29365		Application of long leg cast	Surgery		1.18	0.93	1.58		
29405		Apply short leg cast	Surgery		0.86	0.70	1.17		
29425		Apply short leg cast	Surgery		1.01	0.72	1.18		
29435		Apply short leg cast	Surgery		1.18	0.91	1.49		
29440		Addition of walker to cast	Surgery		0.57	0.28	0.67		
29445		Apply rigid leg cast	Surgery		1.78	0.96	1.75		
29450		Application of leg cast	Surgery		2.08	1.10	1.45		
29505		Application, long leg splint	Surgery		0.69	0.46	1.15		
29515		Application, lower leg splint	Surgery		0.73	0.47	0.85		
29520		Strapping of hip	Surgery		0.54	0.45	0.87		
29530		Strapping of knee	Surgery		0.57	0.35	0.80		
29540		Strapping of ankle and/or ft	Surgery		0.51	0.32	0.41		
29550		Strapping of toes	Surgery		0.47	0.28	0.41		
29560		Application of paste boot	Surgery		0.57	0.36	0.65		
29590		Application of foot splint	Surgery		0.76	0.30	0.50		
29700		Removal/revision of cast	Surgery		0.57	0.28	0.88		
29705		Removal/revision of cast	Surgery		0.76	0.38	0.79		
29710		Removal/revision of cast	Surgery		1.34	0.70	1.49		
29715		Removal/revision of cast	Surgery		0.94	0.40	1.14		
29720		Repair of body cast	Surgery		0.68	0.38	1.10		
29730		Windowing of cast	Surgery		0.75	0.36	0.78		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 42 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
29740		Wedging of cast			1.12	0.49	1.12		
29750		Wedging of clubfoot cast			1.26	0.58	1.04		Misc.
29799		Casting/strapping procedure						1.43	
29800		Jaw arthroscopy/surgery			6.42	7.12	7.12		
29804		Jaw arthroscopy/surgery			8.13	8.41	8.41		
29805		Shoulder arthroscopy, dx			5.88	5.65	5.65		
29806		Shoulder arthroscopy/surgery			14.35	10.94	10.94		
29807		Shoulder arthroscopy/surgery			13.88	10.78	10.78		
29819		Shoulder arthroscopy/surgery			7.61	6.66	6.66		
29820		Shoulder arthroscopy/surgery			7.06	6.12	6.12		
29821		Shoulder arthroscopy/surgery			7.71	6.68	6.68		
29822		Shoulder arthroscopy/surgery			7.42	6.58	6.58		
29823		Shoulder arthroscopy/surgery			8.16	7.09	7.09		
29824		Shoulder arthroscopy/surgery			8.24	7.33	7.33		
29825		Shoulder arthroscopy/surgery			7.61	6.64	6.64		
29826		Shoulder arthroscopy/surgery			8.98	7.41	7.41		
29827		Shoulder arthroscopy/surgery			15.34	11.32	11.32		
29830		Arthroscop rotator cuff repr			5.25	5.25	5.25		
29834		Elbow arthroscopy			6.27	5.72	5.72		
29835		Elbow arthroscopy/surgery			6.47	5.77	5.77		
29836		Elbow arthroscopy/surgery			7.54	6.66	6.66		
29837		Elbow arthroscopy/surgery			6.86	6.02	6.02		
29838		Elbow arthroscopy/surgery			7.70	6.76	6.76		
29840		Elbow arthroscopy/surgery			5.53	5.24	5.24		
29843		Wrist arthroscopy			6.00	5.54	5.54		
29844		Wrist arthroscopy/surgery			6.36	5.71	5.71		
29845		Wrist arthroscopy/surgery			7.51	6.38	6.38		
29846		Wrist arthroscopy/surgery			6.74	5.95	5.95		
29847		Wrist arthroscopy/surgery			7.07	6.10	6.10		
29848		Wrist arthroscopy/surgery			5.43	5.49	5.49		
29850		Knee arthroscopy/surgery			8.18	5.04	5.04		
29851		Knee arthroscopy/surgery			13.08	9.66	9.66		
29855		Tibial arthroscopy/surgery			10.60	8.60	8.60		
29856		Tibial arthroscopy/surgery			14.12	10.51	10.51		
29860		Hip arthroscopy, dx			8.04	6.82	6.82		
29861		Hip arthroscopy/surgery			9.14	7.22	7.22		
29862		Hip arthroscopy/surgery			9.89	8.39	8.39		
29863		Hip arthroscopy/surgery			9.89	8.34	8.34		
29870		Knee arthroscopy, dx			5.06	4.80	4.80		
29871		Knee arthroscopy/drainage			6.54	5.76	5.76		
29873		Knee arthroscopy/surgery			5.99	6.37	6.37		
29874		Knee arthroscopy/surgery			7.04	5.97	5.97		
29875		Knee arthroscopy/surgery			6.30	5.74	5.74		
29876		Knee arthroscopy/surgery			7.91	6.88	6.88		
29877		Knee arthroscopy/surgery			7.34	6.59	6.59		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 43 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
29879		Knee arthroscopy/surgery	Surgery		8.03	6.97	6.97		
29880		Knee arthroscopy/surgery	Surgery		8.49	7.21	7.21		
29881		Knee arthroscopy/surgery	Surgery		7.75	6.82	6.82		
29882		Knee arthroscopy/surgery	Surgery		6.64	7.10	7.10		
29883		Knee arthroscopy/surgery	Surgery		11.03	8.90	8.90		
29884		Knee arthroscopy/surgery	Surgery		7.32	6.55	6.55		
29885		Knee arthroscopy/surgery	Surgery		9.08	7.81	7.81		
29886		Knee arthroscopy/surgery	Surgery		7.53	6.70	6.70		
29887		Knee arthroscopy/surgery	Surgery		9.03	7.78	7.78		
29888		Knee arthroscopy/surgery	Surgery		13.88	10.09	10.09		
29889		Knee arthroscopy/surgery	Surgery		15.98	12.23	12.23		
29891		Ankle arthroscopy/surgery	Surgery		8.39	7.35	7.35		
29892		Ankle arthroscopy/surgery	Surgery		8.99	7.59	7.59		
29893		Ankle arthroscopy/surgery	Surgery		6.14	3.92	3.92		
29894		Scope, plantar fasciomy	Surgery		7.20	5.39	5.39		
29895		Ankle arthroscopy/surgery	Surgery		6.98	5.39	5.39		
29897		Ankle arthroscopy/surgery	Surgery		7.17	5.78	5.78		
29898		Ankle arthroscopy/surgery	Surgery		8.31	6.11	6.11		
29899		Ankle arthroscopy/surgery	Surgery		13.89	9.84	9.84		
29900		Mcp joint arthroscopy, dx	Surgery		5.41	5.69	5.69		
29901		Mcp joint arthroscopy, surg	Surgery		6.12	6.09	6.09		
29902		Mcp joint arthroscopy, surg	Surgery		6.69	6.37	6.37		
29999		Arthroscopy of joint	Surgery					14.57	Misc.
30000		Drainage of nose lesion	Surgery		1.43	1.41	1.41		
30020		Drainage of nose lesion	Surgery		1.43	1.48	1.48		
30100		Intranasal biopsy	Surgery		0.94	0.82	0.82		
30110		Removal of nose polyp(s)	Surgery		1.63	1.58	1.58		
30115		Removal of nose polyp(s)	Surgery		4.34	4.02	4.02		
30117		Removal of intranasal lesion	Surgery		3.16	3.25	3.25		
30118		Removal of intranasal lesion	Surgery		9.68	7.27	7.27		
30120		Revision of nose	Surgery		5.26	5.48	5.48		
30124		Removal of nose lesion	Surgery		3.10	3.03	3.03		
30125		Removal of nose lesion	Surgery		7.15	5.92	5.92		
30130		Removal of turbinate bones	Surgery		3.37	3.51	3.51		
30140		Removal of turbinate bones	Surgery		3.42	3.97	3.97		
30150		Partial removal of nose	Surgery		9.13	7.66	7.66		
30160		Removal of nose	Surgery		9.57	7.65	7.65		
30200		Injection treatment of nose	Surgery		0.78	0.77	0.77		
30210		Nasal sinus therapy	Surgery		1.08	1.32	1.32		
30220		Insert nasal septal bulion	Surgery		1.54	1.54	1.54		
30300		Remove nasal foreign body	Surgery		1.04	1.96	1.96		
30310		Remove nasal foreign body	Surgery		1.96	3.20	3.20		
30320		Remove nasal foreign body	Surgery		4.51	4.49	4.49		
30400		Reconstruction of nose	Surgery		9.82	9.16	9.16		
30410		Reconstruction of nose	Surgery		12.96	10.94	10.94		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 44 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
30420		Reconstruction of nose			15.86	12.42	12.42	12.42	
30430		Revision of nose			7.20	8.10	8.10	8.10	
30435		Revision of nose			11.69	10.62	10.62	10.62	
30450		Revision of nose			18.62	14.10	14.10	14.10	
30460		Revision of nose			9.95	7.75	7.75	7.75	
30462		Revision of nose			19.54	13.67	13.67	13.67	
30465		Repair nasal stenosis			11.82	7.67	7.67	7.67	
30520		Repair of nasal septum			5.69	5.15	5.15	5.15	
30540		Repair nasal defect			7.74	5.62	5.62	5.62	
30545		Repair nasal defect			11.36	8.64	8.64	8.64	
30560		Release of nasal adhesions			1.26	2.16	2.16	2.16	
30580		Repair upper jaw fistula			6.68	6.12	6.12	6.12	
30600		Repair mouth/nose fistula			6.01	5.52	5.52	5.52	
30620		Intranasal reconstruction			5.96	5.78	5.78	5.78	
30630		Repair nasal septum defect			7.11	6.18	6.18	6.18	
30801		Cauterization, inner nose			1.09	2.07	2.07	2.07	
30802		Cauterization, inner nose			2.03	2.58	2.58	2.58	
30901		Control of nosebleed			1.21	0.33	0.33	0.33	
30903		Control of nosebleed			1.54	0.50	0.50	0.50	
30905		Control of nosebleed			1.87	0.76	0.76	0.76	
30906		Repeat control of nosebleed			2.45	1.20	1.20	1.20	
30915		Ligation, nasal sinus artery			7.19	5.82	5.82	5.82	
30920		Ligation, upper jaw artery			9.82	7.49	7.49	7.49	
30930		Therapy, fracture of nose			1.26	1.65	1.65	1.65	Misc.
30999		Nasal surgery procedure							
31000		Irrigation, maxillary sinus							
31002		Irrigation, sphenoid sinus			1.15	1.41	1.41	1.41	
31020		Exploration, maxillary sinus			1.91	3.29	3.29	3.29	
31030		Exploration, maxillary sinus			2.94	3.51	3.51	3.51	
31032		Explore sinus, remove polyps			5.91	4.81	4.81	4.81	
31040		Exploration behind upper jaw			6.56	5.60	5.60	5.60	
31050		Exploration, sphenoid sinus			9.41	6.27	6.27	6.27	
31051		Sphenoid sinus surgery			5.27	4.50	4.50	4.50	
31070		Exploration of frontal sinus			7.10	5.86	5.86	5.86	
31075		Exploration of frontal sinus			4.27	4.20	4.20	4.20	
31080		Removal of frontal sinus			9.15	7.21	7.21	7.21	
31081		Removal of frontal sinus			11.40	8.44	8.44	8.44	
31084		Removal of frontal sinus			12.73	9.46	9.46	9.46	
31085		Removal of frontal sinus			13.49	10.04	10.04	10.04	
31086		Removal of frontal sinus			14.18	10.41	10.41	10.41	
31087		Removal of frontal sinus			12.84	9.86	9.86	9.86	
31090		Exploration of sinuses			13.08	9.79	9.79	9.79	
31200		Removal of ethmoid sinus			9.52	8.59	8.59	8.59	
31201		Removal of ethmoid sinus			4.96	5.02	5.02	5.02	
31205		Removal of ethmoid sinus			8.36	6.82	6.82	6.82	
		Removal of ethmoid sinus			10.22	7.63	7.63	7.63	
								6.88	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 45 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
31225		Removal of upper jaw	Surgery		19.20	13.74	13.74		
31230		Removal of upper jaw	Surgery		21.91	15.12	15.12		
31231		Nasal endoscopy, dx	Surgery		1.10	0.92	3.55		
31233		Nasal/sinus endoscopy, dx	Surgery		2.18	1.51	4.49		
31235		Nasal/sinus endoscopy, dx	Surgery		2.64	1.76	5.10		
31237		Nasal/sinus endoscopy, surg	Surgery		2.98	1.91	5.40		
31238		Nasal/sinus endoscopy, surg	Surgery		3.26	2.12	5.45		
31239		Nasal/sinus endoscopy, surg	Surgery		8.69	8.28	8.28		
31240		Nasal/sinus endoscopy, surg	Surgery		2.61	1.76	1.76		
31254		Revision of ethmoid sinus	Surgery		4.84	2.89	2.89		
31255		Removal of ethmoid sinus	Surgery		6.95	4.15	4.15		
31256		Exploration, maxillary sinus	Surgery		3.29	2.14	2.14		
31267		Endoscopy, maxillary sinus	Surgery		5.45	3.34	3.34		
31276		Sinus endoscopy, surgical	Surgery		8.84	5.17	5.17		
31287		Nasal/sinus endoscopy, surg	Surgery		3.91	2.49	2.49		
31288		Nasal/sinus endoscopy, surg	Surgery		4.57	2.85	2.85		
31290		Nasal/sinus endoscopy, surg	Surgery		17.21	12.15	12.15		
31291		Nasal/sinus endoscopy, surg	Surgery		18.16	12.55	12.55		
31292		Nasal/sinus endoscopy, surg	Surgery		14.74	10.71	10.71		
31293		Nasal/sinus endoscopy, surg	Surgery		16.19	11.52	11.52		
31294		Nasal/sinus endoscopy, surg	Surgery		19.03	13.00	13.00		
31299		Sinus surgery procedure	Surgery					5.43	Misc.
31300		Removal of larynx lesion	Surgery		14.27	12.03	12.03		
31320		Diagnostic incision, larynx	Surgery		5.25	7.24	7.24		
31360		Removal of larynx	Surgery		17.05	13.95	13.95		
31365		Partial removal of larynx	Surgery		24.12	17.63	17.63		
31367		Partial removal of larynx	Surgery		21.83	17.41	17.41		
31368		Partial removal of larynx	Surgery		27.05	21.00	21.00		
31370		Partial removal of larynx	Surgery		21.35	17.05	17.05		
31375		Partial removal of larynx	Surgery		20.18	15.35	15.35		
31380		Partial removal of larynx	Surgery		20.18	15.31	15.31		
31382		Removal of larynx & pharynx	Surgery		20.49	16.56	16.56		
31390		Reconstruct larynx & pharynx	Surgery		27.49	21.24	21.24		
31395		Revision of larynx	Surgery		31.04	25.13	25.13		
31400		Removal of epiglottitis	Surgery		10.29	10.00	10.00		
31420		Insert emergency airway	Surgery		2.33	0.55	0.55		
31500		Change of windpipe airway	Surgery		0.65	0.26	1.49		
31502		Diagnostic laryngoscopy	Surgery		0.61	0.64	1.57		
31505		Laryngoscopy with biopsy	Surgery		1.92	1.28	3.42		
31510		Remove foreign body, larynx	Surgery		2.16	1.11	3.25		
31511		Removal of larynx lesion	Surgery		2.07	1.39	3.34		
31512		Injection into vocal cord	Surgery		2.10	1.49	1.49		
31513		Laryngoscopy for aspiration	Surgery		1.80	1.10	3.71		
31515		Diagnostic laryngoscopy	Surgery		2.56	1.60	1.60		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 46 OF 179

CPT/HCP/PCS Code	Modifier	CPT/HCP/PCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
31525		Diagnostic laryngoscopy	Surgery		2.63	1.70	3.86		
31526		Diagnostic laryngoscopy	Surgery		2.57	1.75	1.75		
31527		Laryngoscopy for treatment	Surgery		3.27	1.90	1.90		
31528		Laryngoscopy and dilation	Surgery		2.37	1.45	1.45		
31529		Laryngoscopy and dilation	Surgery		2.68	1.72	1.72		
31530		Operative laryngoscopy	Surgery		3.38	1.98	1.98		
31531		Operative laryngoscopy	Surgery		3.58	2.31	2.31		
31535		Operative laryngoscopy	Surgery		3.16	2.02	2.02		
31536		Operative laryngoscopy	Surgery		3.55	2.29	2.29		
31540		Operative laryngoscopy	Surgery		4.12	2.59	2.59		
31541		Operative laryngoscopy	Surgery		4.52	2.81	2.81		
31560		Operative laryngoscopy	Surgery		5.45	3.17	3.17		
31561		Operative laryngoscopy	Surgery		5.99	3.38	3.38		
31570		Laryngoscopy with injection	Surgery		3.86	2.42	5.74		
31571		Laryngoscopy with injection	Surgery		4.26	2.63	2.63		
31575		Diagnostic laryngoscopy	Surgery		1.10	0.91	1.88		
31576		Laryngoscopy with biopsy	Surgery		1.97	1.31	3.62		
31577		Remove foreign body, larynx	Surgery		2.47	1.57	3.74		
31578		Removal of larynx lesion	Surgery		2.84	1.56	4.25		
31579		Diagnostic laryngoscopy	Surgery		2.26	1.52	3.80		
31580		Revision of larynx	Surgery		12.36	11.12	11.12		
31582		Revision of larynx	Surgery		21.59	17.42	17.42		
31584		Treat larynx fracture	Surgery		19.61	14.58	14.58		
31585		Treat larynx fracture	Surgery		4.63	5.59	5.59		
31586		Treat larynx fracture	Surgery		8.02	8.36	8.36		
31587		Revision of larynx	Surgery		11.97	10.05	10.05		
31588		Revision of larynx	Surgery		13.09	13.10	13.10		
31590		Reinnervate larynx	Surgery		6.96	8.81	8.81		
31595		Larynx nerve surgery	Surgery		8.33	7.65	7.65		Misc.
31599		Larynx surgery procedure	Surgery					2.88	
31600		Incision of windpipe	Surgery		7.17	3.20	3.20		
31601		Incision of windpipe	Surgery		4.44	2.41	2.41		
31603		Incision of windpipe	Surgery		4.14	1.72	1.72		
31605		Incision of windpipe	Surgery		3.57	1.19	1.19		
31610		Incision of windpipe	Surgery		8.75	7.45	7.45		
31611		Surgery/speech prosthesis	Surgery		5.63	5.95	5.95		
31612		Puncture/clear windpipe	Surgery		0.91	0.36	1.12		
31613		Repair windpipe opening	Surgery		4.58	5.42	5.42		
31614		Repair windpipe opening	Surgery		7.11	7.81	7.81		
31615		Visualization of windpipe	Surgery		2.09	1.20	2.63		
31622		Dx bronchoscope/wash	Surgery		2.78	0.69	4.17		
31623		Dx bronchoscope/brush	Surgery		2.88	0.89	5.05		
31624		Dx bronchoscope/lavage	Surgery		2.88	0.90	4.28		
31625		Bronchoscopy w/biopsy(s)	Surgery		3.36	1.26	5.37		
31628		Bronchoscopy/lung bx, each	Surgery		3.80	1.34	5.53		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 47 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
31629		Bronchoscopy/needle bx, each			3.36	1.22	1.22		
31630		Bronchoscopy dilate/fix repr			3.81	2.00	2.00		
31631		Bronchoscopy, dilate w/stent			4.36	2.02	2.02		
31632		Bronchoscopy/needle bx, add'l			1.03	0.32	0.76		
31633		Bronchoscopy/lung bx, add'l			1.32	0.40	0.91		
31635		Bronchoscopy/needle bx add'l			3.67	1.67	1.67		
31640		Bronchoscopy w/tumor excise			4.93	2.35	2.35		
31641		Bronchoscopy, treat blockage			5.02	2.12	2.12		
31643		Diag bronchoscope/catheter			3.49	1.31	1.31		
31645		Bronchoscopy, clear airways			3.16	1.20	1.20		
31646		Bronchoscopy, reclear airway			2.72	1.08	1.08		
31856		Bronchoscopy, inj for x-ray			2.17	0.93	0.93		
31700		Insertion of airway catheter			1.34	0.69	2.05		
31708		Instill airway contrast dye			1.41	0.58	0.58		
31710		Insertion of airway catheter			1.30	0.71	0.71		
31715		Injection for bronchus x-ray			1.11	0.59	0.59		
31717		Bronchial brush biopsy			2.12	0.87	2.96		
31720		Clearance of airways			1.06	0.33	1.45		
31725		Clearance of airways			1.96	0.56	1.87		
31730		Intro, windpipe wire/tube			2.85	1.09	2.22		
31750		Repair of windpipe			13.00	11.57	11.57		
31755		Repair of windpipe			15.91	14.20	14.20		
31760		Repair of windpipe			22.32	10.82	10.82		
31766		Reconstruction of windpipe			30.38	13.76	13.76		
31770		Repair/graft of bronchus			22.48	10.34	10.34		
31775		Reconstruct bronchus			23.50	11.89	11.89		
31780		Reconstruct windpipe			17.69	11.14	11.14		
31781		Reconstruct windpipe			23.49	12.22	12.22		
31785		Remove windpipe lesion			17.20	10.26	10.26		
31786		Remove windpipe lesion			23.94	13.20	13.20		
31800		Repair of windpipe injury			7.42	4.88	4.88		
31805		Repair of windpipe injury			13.11	7.29	7.29		
31820		Closure of windpipe lesion			4.48	4.93	5.52		
31825		Repair of windpipe defect			6.80	7.05	7.61		
31830		Revise windpipe scar			4.49	5.30	5.68		Misc.
31899		Anyways surgical procedure						4.39	
32000		Drainage of chest			1.54	0.48	3.13		
32002		Treatment of collapsed lung			2.19	0.84	3.32		
32005		Treat lung lining chemically			2.19	0.70	6.58		
32020		Insertion of chest tube			3.97	1.45	1.45		
32035		Exploration of chest			8.66	5.91	5.91		
32036		Exploration of chest			9.67	6.49	6.49		
32095		Biopsy through chest wall			8.35	5.42	5.42		
32100		Exploration/biopsy of chest			15.22	7.88	7.88		
32110		Explore/repair chest			22.97	10.81	10.81		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 48 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
32120		Re-exploration of chest	Surgery		11.52	7.13	7.13		
32124		Explore chest free adhesions	Surgery		12.70	7.27	7.27		
32140		Removal of lung lesion(s)	Surgery		13.91	7.75	7.75		
32141		Remove/treat lung lesions	Surgery		13.98	7.62	7.62		
32150		Removal of lung lesion(s)	Surgery		14.13	7.68	7.68		
32151		Remove lung foreign body	Surgery		14.19	8.07	8.07		
32160		Open chest heart massage	Surgery		9.29	5.32	5.32		
32200		Drain, open, lung lesion	Surgery		15.27	8.66	8.66		
32201		Drain, percut, lung lesion	Surgery		3.99	1.30	1.30		
32215		Treat chest lining	Surgery		11.31	6.96	6.96		
32220		Release of lung	Surgery		23.96	13.02	13.02		
32225		Partial release of lung	Surgery		13.94	7.72	7.72		
32310		Removal of chest lining	Surgery		13.42	7.46	7.46		
32320		Free/remove chest lining	Surgery		23.96	12.22	12.22		
32400		Needle biopsy chest lining	Surgery		1.76	0.55	0.55		
32402		Open biopsy chest lining	Surgery		7.55	5.17	5.17		
32405		Biopsy, lung or mediastinum	Surgery		1.93	0.63	0.63		
32420		Puncture/clear lung	Surgery		2.18	0.83	0.83		
32440		Removal of lung	Surgery		24.96	12.96	12.96		
32442		Sleeve pneumonectomy	Surgery		26.20	14.82	14.82		
32445		Removal of lung	Surgery		25.05	14.13	14.13		
32480		Partial removal of lung	Surgery		23.71	12.12	12.12		
32482		Bilobectomy	Surgery		24.96	12.97	12.97		
32484		Segmentectomy	Surgery		20.66	11.44	11.44		
32486		Sleeve lobectomy	Surgery		23.88	13.30	13.30		
32488		Completion pneumonectomy	Surgery		25.67	13.84	13.84		
32491		Lung volume reduction	Surgery		21.22	12.68	12.68		
32500		Partial removal of lung	Surgery		21.97	12.40	12.40		
32501		Repair bronchus add-on	Surgery		4.68	1.54	1.54		
32520		Remove lung & revise chest	Surgery		21.65	11.36	11.36		
32522		Remove lung & revise chest	Surgery		24.16	12.17	12.17		
32523		Remove lung & revise chest	Surgery		26.46	12.86	12.86		
32540		Removal of lung lesion	Surgery		14.62	9.68	9.68		
32601		Thoracoscopy, diagnostic	Surgery		5.45	2.42	2.42		
32602		Thoracoscopy, diagnostic	Surgery		5.95	2.58	2.58		
32604		Thoracoscopy, diagnostic	Surgery		7.80	3.09	3.09		
32605		Thoracoscopy, diagnostic	Surgery		8.77	3.53	3.53		
32606		Thoracoscopy, diagnostic	Surgery		6.92	2.97	2.97		
32650		Thoracoscopy, diagnostic	Surgery		8.39	3.39	3.39		
32651		Thoracoscopy, surgical	Surgery		10.73	6.80	6.80		
32652		Thoracoscopy, surgical	Surgery		12.89	7.26	7.26		
32653		Thoracoscopy, surgical	Surgery		18.63	10.19	10.19		
32654		Thoracoscopy, surgical	Surgery		12.85	7.01	7.01		
32655		Thoracoscopy, surgical	Surgery		18.42	7.57	7.57		
32655		Thoracoscopy, surgical	Surgery		13.08	7.27	7.27		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 49 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
32656		Thoracoscopy, surgical	Surgery		12.89	7.97	7.97		
32657		Thoracoscopy, surgical	Surgery		13.63	7.72	7.72		
32658		Thoracoscopy, surgical	Surgery		11.61	7.38	7.38		
32659		Thoracoscopy, surgical	Surgery		11.57	7.49	7.49		
32660		Thoracoscopy, surgical	Surgery		17.40	9.52	9.52		
32661		Thoracoscopy, surgical	Surgery		13.23	7.83	7.83		
32662		Thoracoscopy, surgical	Surgery		16.42	8.85	8.85		
32663		Thoracoscopy, surgical	Surgery		18.44	10.81	10.81		
32664		Thoracoscopy, surgical	Surgery		14.18	7.67	7.67		
32665		Thoracoscopy, surgical	Surgery		15.52	8.17	8.17		
32800		Repair lung hernia	Surgery		13.67	7.49	7.49		
32810		Close chest after drainage	Surgery		13.03	7.59	7.59		
32815		Close bronchial fistula	Surgery		23.12	11.04	11.04		
32820		Reconstruct injured chest	Surgery		21.45	12.29	12.29		
32851		Lung transplant, single	Surgery		38.57	27.97	27.97		
32852		Lung transplant with bypass	Surgery		41.74	33.35	33.35		
32853		Lung transplant, double	Surgery		47.74	31.96	31.96		
32854		Lung transplant with bypass	Surgery		50.90	34.97	34.97		
32900		Removal of rib(s)	Surgery		20.24	9.95	9.95		
32905		Revise & repair chest wall	Surgery		20.72	10.19	10.19		
32906		Revise & repair chest wall	Surgery		26.73	12.14	12.14		
32940		Revision of lung	Surgery		19.40	9.53	9.53		
32960		Therapeutic pneumothorax	Surgery		1.84	0.57	1.76		
32957		Total lung lavage	Surgery		5.99	1.91	1.91		
32999		Chest surgery procedure	Surgery					5.42	Misc.
33010		Drainage of heart sac	Surgery		2.24	0.96	0.96		
33011		Repeat drainage of heart sac	Surgery		2.24	1.00	1.00		
33015		Incision of heart sac	Surgery		6.79	4.99	4.98		
33020		Incision of heart sac	Surgery		12.59	6.84	6.84		
33025		Incision of heart sac	Surgery		12.07	6.39	6.39		
33030		Partial removal of heart sac	Surgery		18.68	9.59	9.59		
33031		Partial removal of heart sac	Surgery		21.76	10.10	10.10		
33050		Removal of heart sac lesion	Surgery		14.34	7.90	7.90		
33120		Removal of heart lesion	Surgery		24.52	11.68	11.68		
33130		Removal of heart lesion	Surgery		21.36	10.18	10.18		
33140		Heart revascularize (tmr)	Surgery		19.97	10.94	10.94		
33141		Heart tmr w/other procedure	Surgery		4.83	1.59	1.59		
33200		Insertion of heart pacemaker	Surgery		12.46	6.98	6.98		
33201		Insertion of heart pacemaker	Surgery		10.16	6.73	6.73		
33206		Insertion of heart pacemaker	Surgery		6.66	4.57	4.57		
33207		Insertion of heart pacemaker	Surgery		8.03	4.76	4.76		
33208		Insertion of heart pacemaker	Surgery		8.12	4.86	4.86		
33210		Insertion of heart electrode	Surgery		3.30	1.25	1.25		
33211		Insertion of heart electrode	Surgery		3.39	1.32	1.32		
33212		Insertion of pulse generator	Surgery		5.51	3.42	3.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 50 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
33213		Insertion of pulse generator	Surgery		6.36	3.78	3.78		
33214		Upgrade of pacemaker system	Surgery		7.74	4.99	4.99		
33215		Reposition pacing-defib lead	Surgery		4.75	3.18	3.18		
33216		Insert lead pace-defib, one	Surgery		5.77	4.30	4.30		
33217		Insert lead pace-defib, dual	Surgery		5.74	4.33	4.33		
33218		Repair lead pace-defib, one	Surgery		5.43	4.37	4.37		
33220		Repair lead pace-defib, dual	Surgery		5.51	4.34	4.34		
33222		Revise pocket, pacemaker	Surgery		4.95	4.36	4.36		
33223		Revise pocket, pacing-defib	Surgery		6.45	4.64	4.64		
33224		Insert pacing lead & connect	Surgery		9.04	4.02	4.02		
33225		L ventric pacing lead add-on	Surgery		8.33	3.23	3.23		
33226		Reposition I ventric lead	Surgery		8.68	3.88	3.88		
33233		Removal of pacemaker system	Surgery		3.29	3.31	3.31		
33234		Removal of pacemaker system	Surgery		7.81	4.95	4.95		
33235		Removal pacemaker electrode	Surgery		9.39	6.86	6.86		
33236		Remove electrode/thoracotomy	Surgery		12.58	7.48	7.48		
33237		Remove electrode/thoracotomy	Surgery		13.69	7.84	7.84		
33238		Remove electrode/thoracotomy	Surgery		15.20	8.26	8.26		
33240		Insert pulse generator	Surgery		7.59	4.66	4.66		
33241		Remove pulse generator	Surgery		3.24	2.99	2.99		
33243		Remove eltrd/thoracotomy	Surgery		22.61	11.50	11.50		
33244		Remove eltrd, transven	Surgery		13.74	8.96	8.96		
33245		Insert epic eltrd pace-defib	Surgery		14.28	8.03	8.03		
33246		Insert epic eltrd/pacemaker	Surgery		20.68	10.41	10.41		
33249		Eltrd/insert pace-defib	Surgery		14.21	8.49	8.49		
33250		Ablate heart dysrhythm focus	Surgery		21.82	11.13	11.13		
33251		Ablate heart dysrhythm focus	Surgery		24.84	11.74	11.74		
33253		Reconstruct atria	Surgery		31.01	13.91	13.91		
33261		Ablate heart dysrhythm focus	Surgery		24.84	11.85	11.85		
33262		Implant pal-active ht record	Surgery		4.16	4.11	4.11		
33284		Remove pal-active ht record	Surgery		2.50	3.58	3.58		
33300		Repair of heart wound	Surgery		17.89	9.31	9.31		
33305		Repair of heart wound	Surgery		21.41	10.70	10.70		
33310		Exploratory heart surgery	Surgery		18.48	9.65	9.65		
33315		Exploratory heart surgery	Surgery		22.34	10.95	10.95		
33320		Repair major blood vessel(s)	Surgery		16.76	8.30	8.30		
33321		Repair major vessel	Surgery		20.17	9.86	9.86		
33322		Repair major blood vessel(s)	Surgery		20.59	10.44	10.44		
33330		Insert major vessel graft	Surgery		21.40	10.35	10.35		
33332		Insert major vessel graft	Surgery		23.92	10.59	10.59		
33335		Insert major vessel graft	Surgery		29.96	13.42	13.42		
33400		Repair of aortic valve	Surgery		28.46	15.73	15.73		
33401		Valvuloplasty, open	Surgery		23.87	13.57	13.57		
33403		Valvuloplasty, w/cp bypass	Surgery		24.85	14.37	14.37		
33404		Prepare heart-aorta conduit	Surgery		28.50	14.58	14.58		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 51 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- Method- ology
33405		Replacement of aortic valve	Surgery		34.95	18.36	18.36	18.36	
33406		Replacement of aortic valve	Surgery		37.44	19.20	19.20	19.20	
33410		Replacement of aortic valve	Surgery		32.41	16.66	16.66	16.66	
33411		Replacement of aortic valve	Surgery		36.20	18.83	18.83	18.83	
33412		Replacement of aortic valve	Surgery		41.94	20.50	20.50	20.50	
33413		Replacement of aortic valve	Surgery		43.43	20.91	20.91	20.91	
33414		Repair of aortic valve	Surgery		30.30	14.23	14.23	14.23	
33415		Revision, subvalvular tissue	Surgery		27.11	12.11	12.11	12.11	
33416		Revised ventricle muscle	Surgery		30.30	13.59	13.59	13.59	
33417		Repair of aortic valve	Surgery		28.49	13.71	13.71	13.71	
33420		Revision of mitral valve	Surgery		22.67	9.66	9.66	9.66	
33422		Revision of mitral valve	Surgery		25.90	13.71	13.71	13.71	
33425		Repair of mitral valve	Surgery		26.96	13.10	13.10	13.10	
33426		Repair of mitral valve	Surgery		32.95	17.21	17.21	17.21	
33427		Repair of mitral valve	Surgery		39.94	19.44	19.44	19.44	
33430		Replacement of mitral valve	Surgery		33.45	17.37	17.37	17.37	
33460		Revision of tricuspid valve	Surgery		23.56	11.38	11.38	11.38	
33463		Valvuloplasty, tricuspid	Surgery		25.58	12.99	12.99	12.99	
33464		Valvuloplasty, tricuspid	Surgery		27.29	13.60	13.60	13.60	
33465		Replace tricuspid valve	Surgery		28.75	13.05	13.05	13.05	
33468		Revision of tricuspid valve	Surgery		30.07	13.76	13.76	13.76	
33470		Revision of pulmonary valve	Surgery		20.78	10.78	10.78	10.78	
33471		Valvotomy, pulmonary valve	Surgery		22.22	9.82	9.82	9.82	
33472		Revision of pulmonary valve	Surgery		22.22	11.97	11.97	11.97	
33474		Revision of pulmonary valve	Surgery		23.01	10.95	10.95	10.95	
33475		Replacement, pulmonary valve	Surgery		32.95	15.48	15.48	15.48	
33476		Revision of heart chamber	Surgery		25.73	12.03	12.03	12.03	
33478		Revision of heart chamber	Surgery		26.70	13.13	13.13	13.13	
33496		Repair, prosth valve clot	Surgery		27.21	12.83	12.83	12.83	
33500		Repair heart vessel fistula	Surgery		25.51	11.54	11.54	11.54	
33501		Repair heart vessel fistula	Surgery		17.75	8.34	8.34	8.34	
33502		Coronary artery correction	Surgery		21.01	11.15	11.15	11.15	
33503		Coronary artery graft	Surgery		21.75	9.83	9.83	9.83	
33504		Coronary artery graft	Surgery		24.62	11.91	11.91	11.91	
33505		Repair artery w/funnel	Surgery		26.80	13.02	13.02	13.02	
33506		Repair artery, translocation	Surgery		35.45	14.66	14.66	14.66	
33508		Endoscopic vein harvest	Surgery		0.31	0.10	0.10	0.10	
33510		CABG, vein, single	Surgery		28.96	16.41	16.41	16.41	
33511		CABG, vein, two	Surgery		29.96	17.15	17.15	17.15	
33512		CABG, vein, three	Surgery		31.75	17.68	17.68	17.68	
33513		CABG, vein, four	Surgery		31.95	17.86	17.86	17.86	
33514		CABG, vein, five	Surgery		32.70	18.14	18.14	18.14	
33516		CABG, vein, six or more	Surgery		34.95	18.88	18.88	18.88	
33517		CABG, artery-vein, single	Surgery		2.57	0.84	0.84	0.84	
33518		CABG, artery-vein, two	Surgery		4.84	1.59	1.59	1.59	

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 52 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
33519		CABG, artery-vein, three	Surgery		7.11	2.33	2.33		
33521		CABG, artery-vein, four	Surgery		9.39	3.08	3.08		
33522		CABG, artery-vein, five	Surgery		11.65	3.82	3.82		
33523		Cabg, art-vein, six or more	Surgery		13.93	4.55	4.55		
33530		Coronary artery, bypass/reop	Surgery		5.85	1.91	1.91		
33533		CABG, arterial, single	Surgery		29.96	16.54	16.54		
33534		CABG, arterial, two	Surgery		32.15	17.79	17.79		
33535		CABG, arterial, three	Surgery		34.45	18.22	18.22		
33536		Cabg, arterial, four or more	Surgery		37.44	18.38	18.38		
33542		Removal of heart lesion	Surgery		28.81	13.08	13.08		
33545		Repair of heart damage	Surgery		36.72	15.73	15.73		
33572		Open coronary endarterectomy	Surgery		4.44	1.46	1.46		
33600		Closure of valve	Surgery		29.47	12.62	12.62		
33602		Anastomosis/artery-aorta	Surgery		28.50	12.54	12.54		
33606		Repair anomaly w/conduit	Surgery		30.69	13.75	13.75		
33608		Repair by enlargement	Surgery		31.04	14.19	14.19		
33610		Repair double ventricle	Surgery		30.56	14.20	14.20		
33611		Repair double ventricle	Surgery		33.95	14.23	14.23		
33612		Repair, modified fontan	Surgery		34.95	15.25	15.25		
33615		Repair, single ventricle	Surgery		33.95	15.14	15.14		
33617		Repair single ventricle	Surgery		36.94	16.11	16.11		
33619		Repair heart septum defect	Surgery		44.93	20.94	20.94		
33641		Revision of heart veins	Surgery		21.36	9.64	9.64		
33645		Repair heart septum defects	Surgery		24.78	11.84	11.84		
33647		Repair heart septum defects	Surgery		28.69	13.86	13.86		
33660		Repair of heart defects	Surgery		29.96	13.58	13.58		
33665		Repair of heart defects	Surgery		28.56	13.91	13.91		
33670		Repair of heart chambers	Surgery		34.95	13.39	13.39		
33681		Repair heart septum defect	Surgery		30.56	14.77	14.77		
33684		Repair heart septum defect	Surgery		29.61	13.71	13.71		
33688		Repair heart septum defect	Surgery		30.57	10.58	10.58		
33690		Reinforce pulmonary artery	Surgery		19.52	10.32	10.32		
33692		Repair of heart defects	Surgery		30.70	14.02	14.02		
33694		Repair of heart defects	Surgery		33.95	14.32	14.32		
33697		Repair of heart defects	Surgery		35.95	14.95	14.95		
33702		Repair of heart defects	Surgery		26.50	12.65	12.65		
33710		Repair of heart defects	Surgery		29.67	14.08	14.08		
33720		Repair of heart defect	Surgery		26.52	12.36	12.36		
33722		Repair of heart defect	Surgery		28.37	13.94	13.94		
33730		Repair heart-vein defect(s)	Surgery		34.20	14.23	14.23		
33732		Revision of heart chamber	Surgery		28.12	13.50	13.50		
33735		Revision of heart chamber	Surgery		21.36	10.08	10.08		
33736		Revision of heart chamber	Surgery		23.48	11.95	11.95		
33737		Revision of heart chamber	Surgery		21.73	11.02	11.02		
33750		Major vessel shunt	Surgery		21.38	10.31	10.31		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSC CODE
PAGE 53 OF 179

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
33755		Major vessel shunt	Surgery		21.76	8.86	8.86		
33762		Major vessel shunt	Surgery		21.76	10.24	10.24		
33764		Major vessel shunt & graft	Surgery		21.76	10.31	10.31		
33766		Major vessel shunt	Surgery		22.73	11.73	11.73		
33767		Major vessel shunt	Surgery		24.46	11.81	11.81		
33770		Repair great vessels defect	Surgery		36.94	14.77	14.77		
33771		Repair great vessels defect	Surgery		34.60	12.48	12.48		
33774		Repair great vessels defect	Surgery		30.93	14.23	14.23		
33775		Repair great vessels defect	Surgery		32.15	14.28	14.28		
33776		Repair great vessels defect	Surgery		33.99	15.88	15.88		
33777		Repair great vessels defect	Surgery		33.41	14.95	14.95		
33778		Repair great vessels defect	Surgery		39.94	16.98	16.98		
33779		Repair great vessels defect	Surgery		36.16	15.49	15.49		
33780		Repair great vessels defect	Surgery		41.69	19.13	19.13		
33781		Repair great vessels defect	Surgery		36.40	13.56	13.56		
33786		Repair arterial trunk	Surgery		38.94	16.79	16.79		
33788		Revision of pulmonary artery	Surgery		26.58	12.03	12.03		
33800		Aortic suspension	Surgery		16.22	8.21	8.21		
33802		Repair vessel defect	Surgery		17.63	9.30	9.30		
33803		Repair vessel defect	Surgery		19.57	9.84	9.84		
33813		Repair septal defect	Surgery		20.62	10.99	10.99		
33814		Repair septal defect	Surgery		25.73	12.73	12.73		
33820		Revise major vessel	Surgery		16.27	8.39	8.39		
33822		Revise major vessel	Surgery		17.29	9.03	9.03		
33824		Revise major vessel	Surgery		19.49	10.06	10.06		
33840		Remove aorta constriction	Surgery		20.60	10.36	10.36		
33845		Remove aorta constriction	Surgery		22.09	11.42	11.42		
33851		Remove aorta constriction	Surgery		21.24	10.78	10.78		
33852		Repair septal defect	Surgery		23.67	11.45	11.45		
33853		Repair septal defect	Surgery		31.67	14.92	14.92		
33860		Ascending aortic graft	Surgery		37.94	16.55	16.55		
33861		Ascending aortic graft	Surgery		41.94	17.81	17.81		
33863		Ascending aortic graft	Surgery		44.93	18.80	18.80		
33870		Transverse aortic arch graft	Surgery		43.93	18.49	18.49		
33875		Thoracic aortic graft	Surgery		33.01	14.18	14.18		
33877		Thoracoabdominal graft	Surgery		42.54	16.43	16.43		
33910		Remove lung artery emboli	Surgery		24.55	11.52	11.52		
33915		Remove lung artery emboli	Surgery		20.99	9.68	9.68		
33916		Surgery of great vessel	Surgery		25.79	11.43	11.43		
33917		Repair pulmonary artery	Surgery		24.46	12.27	12.27		
33918		Repair pulmonary atresia	Surgery		26.41	12.19	12.19		
33919		Repair pulmonary atresia	Surgery		39.94	17.62	17.62		
33920		Repair pulmonary atresia	Surgery		31.90	13.92	13.92		
33922		Transect pulmonary artery	Surgery		23.48	10.96	10.96		
33924		Remove pulmonary shunt	Surgery		5.49	1.85	1.85		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 54 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
33935		Transplantation, heart/lung	Surgery		60.87	29.07	29.07	46.15	PHCS
33940		Removal of donor heart	Surgery		42.04	21.66	21.66		
33945		Transplantation of heart	Surgery		19.33	4.93	4.93		
33960		External circulation assist	Surgery		10.91	3.63	3.63		
33961		External circulation assist	Surgery		4.84	1.85	1.85		
33967		Insert ia percut device	Surgery		0.64	0.23	0.23		
33968		Remove aortic assist device	Surgery		6.74	2.29	2.29		
33970		Aortic circulation assist	Surgery		9.68	6.07	6.07		
33971		Aortic circulation assist	Surgery		9.75	3.32	3.32		
33973		Insert balloon device	Surgery		14.39	7.95	7.95		
33974		Remove intra-aortic balloon	Surgery		20.97	6.31	6.31		
33975		Implant ventricular device	Surgery		22.97	7.58	7.58		
33976		Implant ventricular device	Surgery		19.26	11.13	11.13		
33977		Remove ventricular device	Surgery		21.70	11.80	11.80		
33978		Remove ventricular device	Surgery		45.93	14.97	14.97		
33979		Insert intracorporeal device	Surgery		56.17	25.52	25.52		
33980		Remove intracorporeal device	Surgery						
33999		Cardiac surgery procedure	Surgery						
34001		Removal of artery clot	Surgery		12.89	6.75	6.75		Misc.
34051		Removal of artery clot	Surgery		15.19	7.82	7.82		
34101		Removal of artery clot	Surgery		9.99	5.38	5.38		
34111		Removal of arm artery clot	Surgery		9.99	5.38	5.38		
34151		Removal of artery clot	Surgery		24.96	10.45	10.45		
34201		Removal of artery clot	Surgery		10.01	5.45	5.45		
34203		Removal of leg artery clot	Surgery		16.48	8.09	8.09		
34401		Removal of vein clot	Surgery		24.96	10.72	10.72		
34421		Removal of vein clot	Surgery		11.98	6.33	6.33		
34451		Removal of vein clot	Surgery		26.96	11.49	11.49		
34471		Removal of vein clot	Surgery		10.16	5.35	5.35		
34490		Removal of vein clot	Surgery		9.85	5.46	5.46		
34501		Repair valve, femoral vein	Surgery		15.98	8.55	8.55		
34502		Repair valve, femoral vein	Surgery		26.91	12.34	12.34		
34510		Reconstruct vena cava	Surgery		16.92	9.46	9.46		
34520		Transposition of vein valve	Surgery		17.92	8.72	8.72		
34530		Cross-over vein graft	Surgery		16.62	8.65	8.65		
34800		Leg vein fusion	Surgery		20.72	9.21	9.21		
34802		Endovasc abdo repair w/tube	Surgery		22.97	9.83	9.83		
34804		Endovasc abdo repr wide/vein	Surgery		22.97	9.84	9.84		
34805		Endovasc abdo repr w/pros	Surgery		21.85	9.46	9.46		
34808		Endovasc abdo occlud device	Surgery		4.12	1.38	1.38		
34812		Xpose for endoprosth, femori	Surgery		6.74	2.24	2.24		
34813		Femoral endovasc graft add-on	Surgery		4.79	1.58	1.58		
34820		Xpose for endoprosth, iliac	Surgery		9.74	3.25	3.25		
34825		Endovasc extend prosth, init	Surgery		11.98	6.17	6.17		
34826		Endovasc exten prosth, addl	Surgery		4.12	1.38	1.38		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 55 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
34830		Open aortic tube prosth repr	Surgery		32.54	13.76	13.76		
34831		Open aortiliac prosth repr	Surgery		35.29	11.80	11.80		
34832		Open aortofemor prosth repr	Surgery		35.29	14.68	14.68		
34833		Xoose for endoprosth, iliac	Surgery		11.98	4.51	4.51		
34834		Xoose, endoprosth, brachial	Surgery		5.34	2.23	2.23		
34800		Endovasc iliac repr w/graft	Surgery		16.36	7.82	7.82		
35001		Repair defect of artery	Surgery		19.61	9.59	9.59		
35002		Repair artery rupture, neck	Surgery		20.97	9.74	9.74		
35005		Repair defect of artery	Surgery		18.09	8.89	8.89		
35011		Repair defect of artery	Surgery		17.97	8.02	8.02		
35013		Repair artery rupture, arm	Surgery		21.97	9.73	9.73		
35021		Repair defect of artery	Surgery		19.62	9.50	9.50		
35022		Repair artery rupture, chest	Surgery		23.15	10.10	10.10		
35045		Repair defect of arm artery	Surgery		17.34	7.58	7.58		
35081		Repair defect of artery	Surgery		27.97	11.51	11.51		
35082		Repair artery rupture, aorta	Surgery		38.44	15.35	15.35		
35091		Repair defect of artery	Surgery		35.35	13.63	13.63		
35092		Repair artery rupture, aorta	Surgery		44.93	17.70	17.70		
35102		Repair defect of artery	Surgery		30.71	12.41	12.41		
35103		Repair artery rupture, groin	Surgery		40.44	15.92	15.92		
35111		Repair defect of artery	Surgery		24.96	10.51	10.51		
35112		Repair artery rupture spleen	Surgery		29.96	12.01	12.01		
35121		Repair defect of artery	Surgery		29.96	12.42	12.42		
35122		Repair artery rupture, belly	Surgery		34.95	13.86	13.86		
35131		Repair defect of artery	Surgery		24.96	10.80	10.80		
35132		Repair artery rupture, groin	Surgery		29.96	12.42	12.42		
35141		Repair defect of artery	Surgery		19.97	8.95	8.95		
35142		Repair artery rupture, thigh	Surgery		23.27	10.40	10.40		
35151		Repair defect of artery	Surgery		22.61	10.04	10.04		
35152		Repair artery rupture, knee	Surgery		25.58	11.43	11.43		
35161		Repair defect of artery	Surgery		18.73	9.19	9.19		
35162		Repair artery rupture	Surgery		19.75	9.61	9.61		
35180		Repair blood vessel lesion	Surgery		13.60	6.98	6.98		
35182		Repair blood vessel lesion	Surgery		29.96	12.85	12.85		
35184		Repair blood vessel lesion	Surgery		17.97	8.34	8.34		
35188		Repair blood vessel lesion	Surgery		14.26	7.67	7.67		
35189		Repair blood vessel lesion	Surgery		27.96	12.00	12.00		
35190		Repair blood vessel lesion	Surgery		12.73	6.50	6.50		
35201		Repair blood vessel lesion	Surgery		16.12	8.02	8.02		
35208		Repair blood vessel lesion	Surgery		13.23	6.61	6.61		
35209		Repair blood vessel lesion	Surgery		10.13	7.51	7.51		
35211		Repair blood vessel lesion	Surgery		22.09	10.70	10.70		
35216		Repair blood vessel lesion	Surgery		18.72	9.04	9.04		
35221		Repair blood vessel lesion	Surgery		24.35	9.98	9.98		
35226		Repair blood vessel lesion	Surgery		14.48	7.52	7.52		

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE

PAGE 56 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
35231		Repair blood vessel lesion			19.97	9.81	9.81		
35236		Repair blood vessel lesion			17.08	7.95	7.95		
35241		Repair blood vessel lesion			23.09	11.20	11.20		
35246		Repair blood vessel lesion			26.41	11.51	11.51		
35251		Repair blood vessel lesion			30.15	11.84	11.84		
35256		Repair blood vessel lesion			18.33	8.43	8.43		
35261		Repair blood vessel lesion			17.77	8.05	8.05		
35266		Repair blood vessel lesion			14.89	7.06	7.06		
35271		Repair blood vessel lesion			22.09	10.59	10.59		
35276		Repair blood vessel lesion			24.21	11.28	11.28		
35281		Repair blood vessel lesion			27.96	11.75	11.75		
35286		Repair blood vessel lesion			16.14	8.12	8.12		
35301		Rechanneling of artery			18.67	8.50	8.50		
35311		Rechanneling of artery			26.96	11.79	11.79		
35321		Rechanneling of artery			15.98	7.41	7.41		
35331		Rechanneling of artery			26.16	11.28	11.28		
35341		Rechanneling of artery			25.07	10.91	10.91		
35351		Rechanneling of artery			22.97	9.64	9.64		
35355		Rechanneling of artery			18.47	8.12	8.12		
35361		Rechanneling of artery			28.16	11.75	11.75		
35363		Rechanneling of artery			30.15	12.63	12.63		
35371		Rechanneling of artery			14.70	6.99	6.99		
35381		Rechanneling of artery			17.97	8.08	8.08		
35390		Reoperation, carotid add-on			15.79	7.85	7.85		
35400		Angioscopy			3.19	1.07	1.07		
35450		Repair arterial blockage			3.00	1.12	1.12		
35452		Repair arterial blockage			10.05	4.04	4.04		
35454		Repair arterial blockage			6.90	3.17	3.17		
35456		Repair arterial blockage			6.03	2.84	2.84		
35458		Repair arterial blockage			7.34	3.29	3.29		
35459		Repair arterial blockage			9.48	4.01	4.01		
35460		Repair arterial blockage			8.62	3.64	3.64		
35470		Repair venous blockage			6.03	2.68	2.68		
35471		Repair arterial blockage			8.62	3.85	3.85		
35472		Repair arterial blockage			10.05	4.45	4.45		
35473		Repair arterial blockage			6.90	3.24	3.24		
35474		Repair arterial blockage			7.03	2.92	2.92		
35475		Repair arterial blockage			7.35	2.88	2.88		
35476		Repair venous blockage			9.46	4.06	4.06		
35480		Atherectomy, open			6.03	2.85	2.85		
35481		Atherectomy, open			11.06	4.51	4.51		
35482		Atherectomy, open			7.60	3.48	3.48		
35483		Atherectomy, open			6.64	3.09	3.09		
35484		Atherectomy, open			8.09	3.54	3.54		
					10.42	4.23	4.23		

NOTE: CPT Codes and descriptions only are copyright © 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 57 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
35485		Atherectomy, open	Surgery		9.48	4.06	4.06		
35490		Atherectomy, percutaneous	Surgery		11.06	4.71	4.71		
35491		Atherectomy, percutaneous	Surgery		7.60	3.30	3.30		
35492		Atherectomy, percutaneous	Surgery		6.64	3.19	3.19		
35493		Atherectomy, percutaneous	Surgery		8.09	3.81	3.81		
35494		Atherectomy, percutaneous	Surgery		10.42	4.40	4.40		
35495		Atherectomy, percutaneous	Surgery		9.48	4.39	4.39		
35500		Harvest vein for bypass	Surgery		6.44	2.03	2.03		
35501		Artery bypass graft	Surgery		19.16	8.51	8.51		
35506		Artery bypass graft	Surgery		19.64	9.51	9.51		
35507		Artery bypass graft	Surgery		19.64	9.51	9.51		
35508		Artery bypass graft	Surgery		19.64	9.46	9.46		
35509		Artery bypass graft	Surgery		18.62	9.48	9.48		
35510		Artery bypass graft	Surgery		18.04	8.80	8.80		
35511		Artery bypass graft	Surgery		22.97	10.17	10.17		
35512		Artery bypass graft	Surgery		21.17	9.39	9.39		
35515		Artery bypass graft	Surgery		22.47	10.00	10.00		
35516		Artery bypass graft	Surgery		18.82	9.33	9.33		
35518		Artery bypass graft	Surgery		16.30	6.84	6.84		
35521		Artery bypass graft	Surgery		21.17	9.02	9.02		
35522		Artery bypass graft	Surgery		22.17	9.87	9.87		
35525		Artery bypass graft	Surgery		21.73	9.74	9.74		
35526		Artery bypass graft	Surgery		20.60	9.35	9.35		
35531		Artery bypass graft	Surgery		29.91	12.56	12.56		
35533		Artery bypass graft	Surgery		36.15	14.54	14.54		
35536		Artery bypass graft	Surgery		27.96	11.77	11.77		
35541		Artery bypass graft	Surgery		31.65	13.00	13.00		
35546		Artery bypass graft	Surgery		25.76	11.25	11.25		
35548		Artery bypass graft	Surgery		25.50	10.91	10.91		
35549		Artery bypass graft	Surgery		21.54	9.46	9.46		
35551		Artery bypass graft	Surgery		23.31	10.42	10.42		
35556		Artery bypass graft	Surgery		26.63	11.56	11.56		
35558		Artery bypass graft	Surgery		21.73	9.77	9.77		
35560		Artery bypass graft	Surgery		21.17	9.59	9.59		
35563		Artery bypass graft	Surgery		31.95	13.37	13.37		
35565		Artery bypass graft	Surgery		24.16	10.57	10.57		
35566		Artery bypass graft	Surgery		23.17	10.17	10.17		
35571		Artery bypass graft	Surgery		26.88	11.45	11.45		
35572		Harvest femoropopliteal vein	Surgery		24.02	10.91	10.91		
35582		Vein bypass graft	Surgery		6.81	2.34	2.34		
35583		Vein bypass graft	Surgery		27.09	11.62	11.62		
35585		Vein bypass graft	Surgery		22.34	10.21	10.21		
35587		Vein bypass graft	Surgery		28.35	12.32	12.32		
35600		Harvest artery for cabg	Surgery		24.71	11.54	11.54		
35601		Artery bypass graft	Surgery		4.94	1.63	1.63		
					17.47	8.66	8.66		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 58 OF 179

CPT/ HCPSC Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
35606		Artery bypass graft	Surgery		18.68	9.06	9.06		
35612		Artery bypass graft	Surgery		15.74	7.92	7.92		
35616		Artery bypass graft	Surgery		15.68	8.14	8.14		
35621		Artery bypass graft	Surgery		19.97	8.71	8.71		
35623		Artery bypass graft	Surgery		23.96	10.54	10.54		
35626		Bypass graft, not vein	Surgery		27.71	12.03	12.03		
35631		Artery bypass graft	Surgery		33.95	13.88	13.88		
35636		Artery bypass graft	Surgery		29.46	12.35	12.35		
35641		Artery bypass graft	Surgery		24.53	11.11	11.11		
35642		Artery bypass graft	Surgery		17.95	8.72	8.72		
35645		Artery bypass graft	Surgery		17.44	8.31	8.31		
35646		Artery bypass graft	Surgery		30.95	13.15	13.15		
35647		Artery bypass graft	Surgery		27.96	11.82	11.82		
35650		Artery bypass graft	Surgery		18.97	8.40	8.40		
35651		Artery bypass graft	Surgery		25.00	10.89	10.89		
35654		Artery bypass graft	Surgery		24.96	10.70	10.70		
35656		Artery bypass graft	Surgery		19.50	8.64	8.64		
35661		Artery bypass graft	Surgery		18.97	8.96	8.96		
35663		Artery bypass graft	Surgery		21.97	10.02	10.02		
35665		Artery bypass graft	Surgery		20.97	9.48	9.48		
35666		Artery bypass graft	Surgery		22.16	10.72	10.72		
35671		Artery bypass graft	Surgery		19.30	9.43	9.43		
35681		Composite bypass graft	Surgery		1.60	0.53	0.53		
35682		Composite bypass graft	Surgery		7.19	2.40	2.40		
35683		Composite bypass graft	Surgery		8.49	2.83	2.83		
35685		Bypass graft patency/patch	Surgery		4.04	1.35	1.35		
35686		Bypass graft/av fist patency	Surgery		3.34	1.13	1.13		
35691		Arterial transposition	Surgery		18.02	8.45	8.45		
35693		Arterial transposition	Surgery		15.34	7.76	7.76		
35694		Arterial transposition	Surgery		19.13	8.64	8.64		
35695		Arterial transposition	Surgery		19.13	8.60	8.60		
35697		Reimplant artery each	Surgery		3.00	1.03	1.03		
35700		Reoperation, bypass graft	Surgery		3.08	1.03	1.03		
35701		Exploration, carotid artery	Surgery		8.49	5.18	5.18		
35721		Exploration, femoral artery	Surgery		7.17	4.48	4.48		
35741		Exploration popliteal artery	Surgery		7.99	4.71	4.71		
35761		Exploration of artery/vein	Surgery		5.36	4.07	4.07		
35800		Explore neck vessels	Surgery		7.01	4.68	4.68		
35820		Explore chest vessels	Surgery		12.86	7.20	7.20		
35840		Explore abdominal vessels	Surgery		9.76	5.31	5.31		
35860		Explore limb vessels	Surgery		5.54	4.06	4.06		
35870		Repair vessel graft defect	Surgery		22.14	9.81	9.81		
35875		Removal of clot in graft	Surgery		10.11	5.24	5.24		
35876		Removal of clot in graft	Surgery		16.97	7.59	7.59		
35879		Revise graft w/vein	Surgery		15.98	7.75	7.75		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 59 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
35881		Revise graft w/vein			17.97	8.75	8.75		
35901		Excision, graft, neck			8.18	5.36	5.36		
35903		Excision, graft, extremity			9.38	6.01	6.01		
35905		Excision, graft, thorax			31.20	13.26	13.26		
35907		Excision, graft, abdomen			34.95	14.11	14.11		
36000		Place needle in vein			0.18	0.05	0.60		
36002		Pseudoaneurysm injection tr			1.96	0.99	2.91		
36005		Injection ext venography			0.95	0.32	8.47		
36010		Place catheter in vein			2.43	0.79	0.79		
36011		Place catheter in vein			3.14	1.03	1.03		
36012		Place catheter in vein			3.51	1.15	1.15		
36013		Place catheter in vein			2.52	0.66	0.66		
36014		Place catheter in artery			3.02	0.99	0.99		
36015		Place catheter in artery			3.51	1.15	1.15		
36100		Place catheter in artery			3.02	1.10	1.10		
36120		Establish access to artery			2.01	0.65	0.65		
36140		Establish access to artery			2.01	0.66	0.64		
36145		Artery to vein shunt			2.01	0.66	0.66		
36160		Establish access to aorta			2.52	0.85	0.85		
36200		Place catheter in aorta			3.02	1.02	1.02		
36215		Place catheter in artery			4.67	1.58	1.58		
36216		Place catheter in artery			5.27	1.76	1.76		
36217		Place catheter in artery			6.29	2.14	2.14		
36218		Place catheter in artery			1.01	0.35	0.35		
36245		Place catheter in artery			4.67	1.65	1.65		
36246		Place catheter in artery			5.27	1.79	1.79		
36247		Place catheter in artery			6.29	2.10	2.10		
36248		Place catheter in artery			1.01	0.35	0.35		
36280		Insertion of infusion pump			9.70	4.90	4.90		
36281		Revision of infusion pump			5.44	3.66	3.66		
36282		Removal of infusion pump			4.01	2.77	2.77	4.04	Misc.
36299		Vessel injection procedure			0.39	0.09	0.29		
36400		BI draw < 3 yrs fem/ulnar			0.31	0.08	0.27		
36405		BI draw < 3 yrs scalp vein			0.18	0.05	0.30		
36406		BI draw < 3 yrs other vein			0.18	0.05	0.30		
36410		Non-routine BI draw > 3 yrs							
36415		Routine venipuncture	Miscellaneous Medical	b					
36416		Capillary blood draw	Miscellaneous Medical	b					
36420		Vein access cutdown < 1 yr			1.01	0.28	3.06		MDR
36425		Vein access cutdown > 1 yr			0.76	0.22	0.22		MDR
36430		Blood transfusion service			0.00	1.01	1.01		
36440		BI push transfuse, 2 yr or <			1.03	0.30	0.30		
36450		BI exchange/transfuse, nb			2.23	0.71	0.71		
36455		BI exchange/transfuse non-nb			2.43	1.02	1.02		
36460		Transfusion service, fetal			6.56	2.25	2.25		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 60 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
36468		Injection(s), spider veins	Surgery					1.97	SAF
36469		Injection(s), spider veins	Surgery		1.09	0.44	2.72	2.10	PHCS
36470		Injection therapy of vein	Surgery		1.57	0.60	3.07		
36471		Injection therapy of veins	Surgery		6.98	2.73	7.91		
36481		Insertion of catheter, vein	Surgery		3.51	1.37	1.37		
36500		Insertion of catheter, vein	Surgery		1.09	0.61	3.74		
36510		Insertion of catheter, vein	Surgery		1.74	0.71	0.71		
36511		Apheresis wbc	Surgery		1.74	0.71	0.71		
36512		Apheresis rbc	Surgery		1.74	0.71	0.71		
36513		Apheresis platelets	Surgery		1.74	0.71	0.71		
36514		Apheresis plasma	Surgery		1.74	0.73	0.73		
36515		Apheresis, adsorp/reinfuse	Surgery		1.22	0.51	0.51		
36516		Apheresis, selective	Surgery		1.67	1.13	30.33		MDR
36522		Photopheresis	Surgery						
36540		Collect blood venous device	Surgery		0.00	0.39	0.39		
36550		Decub vascular device	Surgery		2.68	0.82	6.00		
36555		Insert non-tunnel cv cath	Surgery		2.50	0.74	5.85		
36556		Insert non-tunnel cv cath	Surgery		5.09	2.58	13.56		
36557		Insert tunneled cv cath	Surgery		4.79	2.47	13.45		
36558		Insert tunneled cv cath	Surgery		6.24	2.96	29.19		
36560		Insert tunneled cv cath	Surgery		5.99	2.87	29.11		
36561		Insert tunneled cv cath	Surgery		6.19	2.98	38.09		
36563		Insert tunneled cv cath	Surgery		5.99	2.87	22.15		
36565		Insert tunneled cv cath	Surgery		6.49	3.04	22.95		
36566		Insert tunneled cv cath	Surgery		1.92	0.59	8.19		
36568		Insert tunneled cv cath	Surgery		1.82	0.57	7.39		
36569		Insert tunneled cv cath	Surgery		5.31	2.64	40.27		
36570		Insert tunneled cv cath	Surgery		5.29	2.63	35.64		
36571		Insert tunneled cv cath	Surgery		0.67	0.26	3.35		
36575		Repair tunneled cv cath	Surgery		3.19	1.76	7.71		
36576		Repair tunneled cv cath	Surgery		3.49	2.20	10.54		
36578		Replace tunneled cv cath	Surgery		1.31	0.41	6.76		
36580		Replace tunneled cv cath	Surgery		3.43	1.84	13.27		
36581		Replace tunneled cv cath	Surgery		5.19	2.76	26.63		
36582		Replace tunneled cv cath	Surgery		5.24	2.77	13.13		
36583		Replace tunneled cv cath	Surgery		1.20	0.54	7.23		
36584		Replace tunneled cv cath	Surgery		4.79	2.62	35.46		
36585		Replace tunneled cv cath	Surgery		2.27	1.41	2.20		
36589		Removal tunneled cv cath	Surgery		3.30	1.64	6.41		
36590		Removal tunneled cv cath	Surgery		3.59	1.46	19.71		
36595		Mech remov tunneled cv cath	Surgery		0.75	0.49	4.39		
36596		Reposition venous catheter	Surgery		1.21	0.43	3.18		
36597		Withdrawal of arterial blood	Surgery		0.32	0.09	0.48		
36600		Insertion catheter, artery	Surgery		1.15	0.24	0.24		
36620									

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 61 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
36625		Insertion catheter, artery	Surgery		2.11	0.52	0.52		
36640		Insertion catheter, artery	Surgery		2.10	1.05	1.05		
36660		Insertion catheter, artery	Surgery		1.40	0.44	0.44		
36680		Insert needle, bone cavity	Surgery		1.20	0.49	0.49		
36800		Insertion of cannula	Surgery		2.43	1.81	1.81		
36810		Insertion of cannula	Surgery		3.96	1.69	1.69		
36815		Insertion of cannula	Surgery		2.62	1.17	1.17		
36819		Av fusion/upper arm vein	Surgery		13.98	6.40	6.40		
36820		Av fusion/forearm vein	Surgery		13.98	6.40	6.40		
36821		Av fusion direct any site	Surgery		8.92	4.71	4.71		
36822		Insertion of cannula(s)	Surgery		5.41	4.49	4.49		
36823		Insertion of cannula(s)	Surgery		20.97	9.48	9.48		
36825		Artery-vein autograft	Surgery		9.83	5.14	5.14		
36830		Artery-vein nonautograft	Surgery		11.98	5.30	5.30		
36831		Open thrombect av fistula	Surgery		7.99	3.97	3.97		
36832		Av fistula revision, open	Surgery		10.48	4.79	4.79		
36833		Av fistula revision	Surgery		11.93	5.25	5.25		
36834		Repair A-V aneurysm	Surgery		9.92	4.81	4.81		
36835		Artery to vein shunt	Surgery		7.14	4.39	4.39		
36838		Dist revas ligation, hemo	Surgery		20.60	9.36	9.36		
36860		External cannula dectlotting	Surgery		2.01	1.35	1.35		
36861		Cannula dectlotting	Surgery		2.52	1.48	1.48		
36870		Percut thrombect av fistula	Surgery		5.15	3.14	3.14		
37140		Revision of circulation	Surgery		23.56	10.50	10.50		
37145		Revision of circulation	Surgery		24.57	10.93	10.93		
37160		Revision of circulation	Surgery		21.57	9.30	9.30		
37180		Revision of circulation	Surgery		24.57	10.35	10.35		
37181		Splice spleen/kidney veins	Surgery		26.64	11.06	11.06		
37182		Insert hepatic shunt (tips)	Surgery		16.97	6.27	6.27		
37183		Remove hepatic shunt (tips)	Surgery		7.99	3.08	3.08		
37195		Thrombolytic therapy, stroke	Surgery		0.00	8.08	8.08		
37200		Transcatheter biopsy	Surgery		4.55	1.50	1.50		
37201		Transcatheter therapy infuse	Surgery		4.99	2.52	2.52		
37202		Transcatheter therapy infuse	Surgery		5.87	3.03	3.03		
37203		Transcatheter retrieval	Surgery		5.02	2.53	2.53		
37204		Transcatheter occlusion	Surgery		18.11	5.93	5.93		
37205		Transcatheter stent	Surgery		4.12	3.74	3.74		
37206		Transcatheter stent add-on	Surgery		4.12	1.44	1.44		
37207		Transcatheter stent	Surgery		8.27	3.17	3.17		
37208		Transcatheter stent add-on	Surgery		4.12	1.39	1.39		
37209		Exchange arterial catheter	Surgery		2.27	0.75	0.75		
37250		Iv us first vessel add-on	Surgery		2.10	0.75	0.75		
37251		Iv us each add vessel add-on	Surgery		1.60	0.55	0.55		
37500		Endoscopy ligate perf veins	Surgery		10.98	7.12	7.12		
37501		Vascular endoscopy procedure	Surgery					18.10	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 62 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
37565		Ligation of neck vein	Surgery		10.86	5.65	5.65		
37600		Ligation of neck artery	Surgery		11.23	6.67	6.67		
37605		Ligation of neck artery	Surgery		13.09	6.94	6.94		
37606		Ligation of neck artery	Surgery		6.27	4.59	4.59		
37607		Ligation of a-v fistula	Surgery		6.15	3.59	3.59		
37608		Temporal artery procedure	Surgery		3.00	1.98	1.98		
37615		Ligation of neck artery	Surgery		5.72	4.12	4.12		
37616		Ligation of chest artery	Surgery		16.47	8.15	8.15		
37617		Ligation of abdomen artery	Surgery		22.03	9.22	9.22		
37618		Ligation of extremity artery	Surgery		4.83	3.59	3.59		
37620		Revision of major vein	Surgery		10.54	5.72	5.72		
37650		Revision of major vein	Surgery		7.79	4.72	4.72		
37660		Revision of major vein	Surgery		20.97	9.10	9.10		
37700		Revise leg vein	Surgery		3.72	2.81	2.81		
37720		Removal of leg vein	Surgery		5.65	3.73	3.73		
37730		Removal of leg veins/flexion	Surgery		7.32	4.28	4.28		
37735		Ligation, leg veins, open	Surgery		10.51	5.54	5.54		
37760		Phleb veins - extrem - to 20	Surgery		10.45	5.38	5.38		
37765		Phleb veins - extrem 20+	Surgery		7.34	4.55	4.55		
37780		Revision of leg vein	Surgery		9.29	5.26	5.26		
37785		Revise secondary varicosity	Surgery		3.83	2.88	2.88		
37788		Revascularization, penis	Surgery		3.83	2.64	2.64		
37790		Penile venous occlusion	Surgery		21.98	9.29	9.29		Misc.
37799		Vascular surgery procedure	Surgery		8.33	4.53	4.53	0.11	
38100		Removal of spleen, total	Surgery		14.48	6.23	6.23		
38101		Removal of spleen, partial	Surgery		15.29	6.58	6.58		
38102		Removal of spleen, total	Surgery		4.79	1.65	1.65		
38115		Repair of ruptured spleen	Surgery		15.80	6.70	6.70		
38120		Laparoscopy, splenectomy	Surgery		16.97	7.43	7.43		Misc.
38129		Laparoscopy proc, spleen	Surgery						
38200		Injection for spleen x-ray	Surgery		2.64	0.89	0.89		
38205		Harvest allogenic stem cells	Surgery		1.50	0.67	0.67		
38206		Harvest auto stem cells	Surgery						
38207		Cryopreserve stem cells	Surgery						
38208		Thaw preserved stem cells	Surgery						
38209		Wash harvest stem cells	Surgery						
38210		T-cell depletion of harvest	Surgery						
38211		Tumor cell depletion of harvest	Surgery						
38212		Rbc depletion of harvest	Surgery						
38213		Platelet depletion of harvest	Surgery						
38214		Volume depletion of harvest	Surgery						
38215		Harvest stem cell concentrate	Surgery						
38220		Bone marrow aspiration	Surgery		1.08	0.52	0.52		
38221		Bone marrow biopsy	Surgery		1.37	0.65	0.65		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 63 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
38230		Bone marrow collection	Surgery		4.53	3.08	3.08		
38240		Bone marrow/stern transplant	Surgery		2.24	1.03	1.03		
38241		Bone marrow/infuse transplant	Surgery		2.24	1.04	1.04		
38242		Lymphocyte infuse transplant	Surgery		1.71	0.77	0.77		
38300		Drainage, lymph node lesion	Surgery		1.99	2.07	4.42		
38305		Drainage, lymph node lesion	Surgery		5.99	4.38	5.98		
38308		Incision of lymph channels	Surgery		6.44	3.75	5.71		
38380		Thoracic duct procedure	Surgery		7.45	5.71	5.71		
38381		Thoracic duct procedure	Surgery		12.86	6.94	6.94		
38382		Thoracic duct procedure	Surgery		10.05	5.83	5.83		
38500		Biopsy/removal, lymph nodes	Surgery		3.74	2.10	3.78		
38505		Needle biopsy, lymph nodes	Surgery		1.14	2.13	2.13		
38510		Biopsy/removal, lymph nodes	Surgery		6.42	3.51	5.65		
38520		Biopsy/removal, lymph nodes	Surgery		6.66	4.11	4.11		
38525		Biopsy/removal, lymph nodes	Surgery		6.06	3.36	3.36		
38530		Biopsy/removal, lymph nodes	Surgery		7.97	4.46	4.46		
38542		Explore deep node(s), neck	Surgery		5.90	4.51	4.51		
38550		Removal, neck/arm/pt lesion	Surgery		6.91	3.99	3.99		
38555		Removal, neck/arm/pt lesion	Surgery		14.12	8.62	8.62		
38562		Removal, pelvic lymph nodes	Surgery		10.47	5.83	5.83		
38564		Removal, abdomen lymph nodes	Surgery		10.81	5.30	5.30		
38570		Laparoscopy, lymph node biop	Surgery		9.24	3.94	3.94		
38571		Laparoscopy, lymphadenectomy	Surgery		14.66	5.60	5.60		
38572		Laparoscopy, lymphadenectomy	Surgery		16.57	7.04	7.04		Misc.
38589		Laparoscopy proc, lymphatic	Surgery		8.23	8.09	8.09		
38700		Removal of lymph nodes, neck	Surgery		13.59	11.07	11.07		
38720		Removal of lymph nodes, neck	Surgery		14.52	11.57	11.57		
38724		Removal of lymph nodes, neck	Surgery		10.01	5.01	5.01		
38740		Remove armpit lymph nodes	Surgery		13.08	6.19	6.19		
38745		Remove armpit lymph nodes	Surgery		4.88	1.62	1.62		
38748		Remove thoracic lymph nodes	Surgery		4.88	1.68	1.68		
38747		Remove abdominal lymph nodes	Surgery		12.93	6.20	6.20		
38760		Remove groin lymph nodes	Surgery		19.95	8.92	8.92		
38765		Remove groin lymph nodes	Surgery		13.21	5.81	5.81		
38770		Remove pelvis lymph nodes	Surgery		16.57	8.27	8.27		
38780		Remove abdomen lymph nodes	Surgery		1.29	0.79	11.24		
38790		Inject for lymphatic x-ray	Surgery		0.52	0.44	0.44		
38792		Identify sentinel node	Surgery		4.44	3.40	3.40		Misc.
38794		Access thoracic lymph duct	Surgery		6.09	4.70	4.70		
38999		Blood/lymph system procedure	Surgery		11.77	6.67	6.67		
39000		Exploration of chest	Surgery		13.60	6.82	6.82		
39010		Exploration of chest	Surgery		17.39	8.55	8.55		
39200		Removal chest lesion	Surgery		5.60	4.87	4.87		
39220		Removal chest lesion	Surgery						
39400		Visualization of chest	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 64 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
39499		Chest procedure			13.17	6.52	6.52	10.47	Misc.
39501		Repair diaphragm laceration	Surgery		16.31	7.20	7.20		
39502		Repair paraesophageal hernia	Surgery		94.86	33.56	33.56		
39503		Repair of diaphragm hernia	Surgery		16.08	8.11	8.11		
39520		Repair of diaphragm hernia	Surgery		15.39	7.20	7.20		
39530		Repair of diaphragm hernia	Surgery		16.40	7.45	7.45		
39531		Repair of diaphragm hernia	Surgery		13.30	6.29	6.29		
39540		Repair of diaphragm hernia	Surgery		14.39	6.65	6.65		
39541		Repair of diaphragm hernia	Surgery		13.35	7.62	7.62		
39545		Revision of diaphragm	Surgery		11.98	6.35	6.35		
39560		Resect diaphragm, simple	Surgery		17.47	9.40	9.40		
39561		Resect diaphragm, complex	Surgery						
39599		Diaphragm surgery procedure	Surgery						
40490		Biopsy of lip	Surgery		1.22	0.61	0.61	21.04	Misc.
40500		Partial excision of lip	Surgery		4.27	4.90	4.90		
40510		Partial excision of lip	Surgery		4.69	4.79	4.79		
40520		Partial excision of lip	Surgery		4.66	5.03	5.03		
40525		Reconstruct lip with flap	Surgery		7.54	6.90	6.90		
40527		Reconstruct lip with flap	Surgery		9.12	7.85	7.85		
40530		Partial removal of lip	Surgery		5.39	5.19	5.19		
40650		Repair lip	Surgery		3.63	3.80	3.80		
40652		Repair lip	Surgery		4.25	5.23	5.23		
40654		Repair lip	Surgery		5.30	5.96	5.96		
40700		Repair cleft lip/nasal	Surgery		12.77	9.51	9.51		
40701		Repair cleft lip/nasal	Surgery		15.83	11.79	11.79		
40702		Repair cleft lip/nasal	Surgery		13.02	8.47	8.47		
40720		Repair cleft lip/nasal	Surgery		13.53	10.50	10.50		
40761		Repair cleft lip/nasal	Surgery		14.70	10.82	10.82		
40799		Lip surgery procedure	Surgery		1.17	1.14	1.14		
40800		Drainage of mouth lesion	Surgery		2.53	2.03	2.03		
40801		Drainage of mouth lesion	Surgery		1.24	1.12	1.12		
40804		Removal, foreign body, mouth	Surgery		2.69	1.98	1.98		
40805		Removal, foreign body, mouth	Surgery		0.31	0.95	0.95		
40806		Incision of lip fold	Surgery		0.96	1.08	1.08		
40808		Excision of mouth lesion	Surgery		1.31	1.21	1.21		
40810		Excise/repair mouth lesion	Surgery		2.31	1.78	1.78		
40812		Excise/repair mouth lesion	Surgery		3.41	3.29	3.29		
40814		Excise/repair mouth lesion	Surgery		3.66	3.39	3.39		
40816		Excise oral mucosa for graft	Surgery		2.41	3.53	3.53		
40818		Excise lip or cheek fold	Surgery		2.41	2.92	2.92		
40819		Treatment of mouth lesion	Surgery		1.28	2.35	2.35		
40820		Repair mouth laceration	Surgery		1.76	2.51	2.51		
40830		Repair mouth laceration	Surgery		2.46	3.08	3.08		
40831		Repair mouth laceration	Surgery		8.72	7.36	7.36		
40840		Reconstruction of mouth	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 65 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
40842		Reconstruction of mouth	Surgery		8.72	7.10	8.68		
40843		Reconstruction of mouth	Surgery		12.08	8.61	10.87		
40844		Reconstruction of mouth	Surgery		15.99	11.75	13.82		
40845		Reconstruction of mouth	Surgery		18.55	13.55	15.82		
40889		Mouth surgery procedure	Surgery						
41000		Drainage of mouth lesion	Surgery		1.30	1.40	2.47		
41005		Drainage of mouth lesion	Surgery		1.26	1.62	2.67		
41006		Drainage of mouth lesion	Surgery		3.24	3.44	4.38		
41007		Drainage of mouth lesion	Surgery		3.10	3.31	4.16		
41008		Drainage of mouth lesion	Surgery		3.36	3.49	4.53		
41009		Drainage of mouth lesion	Surgery		3.58	3.85	4.86		
41010		Incision of tongue fold	Surgery		1.06	3.46	3.46		
41015		Drainage of mouth lesion	Surgery		3.95	4.06	5.36		
41016		Drainage of mouth lesion	Surgery		4.06	4.07	5.45		
41017		Drainage of mouth lesion	Surgery		5.09	4.25	5.80		
41018		Drainage of mouth lesion	Surgery		1.63	1.42	2.56		
41100		Biopsy of tongue	Surgery		1.42	1.31	2.46		
41105		Biopsy of floor of mouth	Surgery		1.05	1.12	2.20		
41108		Excision of tongue lesion	Surgery		1.51	1.33	2.52		
41110		Excision of tongue lesion	Surgery		2.73	2.71	4.25		
41112		Excision of tongue lesion	Surgery		3.19	2.98	4.60		
41113		Excision of tongue lesion	Surgery		8.46	6.31	8.75		
41114		Excision of tongue lesion	Surgery		1.74	2.57	3.43		
41115		Excision of tongue fold	Surgery		2.44	2.77	4.22		
41116		Excision of mouth lesion	Surgery		9.75	7.58	7.58		
41120		Partial removal of tongue	Surgery		11.13	8.36	8.36		
41130		Partial removal of tongue	Surgery		23.06	14.83	14.83		
41135		Tongue and neck surgery	Surgery		25.46	16.06	16.06		
41140		Removal of tongue	Surgery		30.01	19.18	19.18		
41145		Tongue removal, neck surgery	Surgery		23.01	15.49	15.49		
41150		Tongue, mouth, jaw surgery	Surgery		23.73	15.96	15.96		
41153		Tongue, mouth, neck surgery	Surgery		27.68	17.99	17.99		
41155		Tongue, jaw, & neck surgery	Surgery		1.91	1.62	3.07		
41250		Repair tongue laceration	Surgery		2.27	1.93	3.58		
41251		Repair tongue laceration	Surgery		2.97	2.28	4.16		
41252		Repair tongue laceration	Surgery		3.70	3.63	3.63		
41500		Fixation of tongue	Surgery		3.41	3.10	3.10		
41510		Tongue to lip surgery	Surgery		2.73	3.22	4.07		
41520		Reconstruction, tongue fold	Surgery						
41599		Tongue and mouth surgery	Surgery						
41800		Drainage of gum lesion	Surgery						
41805		Removal foreign body, gum	Surgery		1.17	1.44	2.66		Misc.
41806		Removal foreign body, jawbone	Surgery		1.24	2.33	2.73		Misc.
41820		Excision, gum, each quadrant	Surgery		2.69	3.14	3.62		Misc.
41821		Excision of gum flap	Surgery					4.52	Misc.
								4.89	MDR
								1.10	MDR

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 66 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
41822		Excision of gum lesion	Surgery		2.31	1.33	4.09		
41823		Excision of gum lesion	Surgery		3.30	4.10	5.82		
41825		Excision of gum lesion	Surgery		1.31	2.35	3.27		
41826		Excision of gum lesion	Surgery		2.31	2.89	3.85		
41827		Excision of gum lesion	Surgery		3.41	3.84	5.61		
41828		Excision of gum lesion	Surgery		3.09	3.35	4.38		
41830		Removal of gum tissue	Surgery		3.34	3.57	4.91		
41850		Treatment of gum lesion	Surgery					2.45	MDR
41870		Gum graft	Surgery					6.12	MDR
41872		Repair gum	Surgery		2.59	3.53	4.63		
41874		Repair tooth socket	Surgery		3.09	3.29	4.68		
41899		Dental surgery procedure	Surgery						
42000		Drainage mouth roof lesion	Surgery		1.23	1.25	2.72		
42100		Biopsy roof of mouth	Surgery		1.31	1.36	2.27		
42104		Excision lesion, mouth roof	Surgery		1.64	1.55	2.76		
42106		Excision lesion, mouth roof	Surgery		2.10	2.81	3.72		
42107		Excision lesion, mouth roof	Surgery		4.43	4.18	6.07		
42120		Remove palate/lesion	Surgery		6.16	5.56	5.56		
42140		Excision of uvula	Surgery		1.62	2.37	2.48		
42145		Repair palate, pharynx/uvula	Surgery		8.04	6.61	6.61		
42160		Treatment mouth roof lesion	Surgery		1.80	2.65	3.59		
42180		Repair palate	Surgery		2.50	2.12	3.38		
42182		Repair palate	Surgery		3.82	3.06	4.23		
42200		Reconstruct cleft palate	Surgery		11.98	9.01	9.01		
42205		Reconstruct cleft palate	Surgery		13.27	9.35	9.35		
42210		Reconstruct cleft palate	Surgery		14.48	10.52	10.52		
42215		Reconstruct cleft palate	Surgery		8.81	7.55	7.55		
42220		Reconstruct cleft palate	Surgery		7.01	5.64	5.64		
42225		Reconstruct cleft palate	Surgery		9.53	7.66	7.66		
42226		Lengthening of palate	Surgery		9.99	7.88	7.88		
42227		Lengthening of palate	Surgery		9.51	7.34	7.34		
42235		Repair palate	Surgery		7.86	5.35	5.35		
42260		Repair nose to lip fistula	Surgery		9.79	7.44	9.23		
42280		Preparation, palate mold	Surgery		1.54	0.88	2.00		
42281		Insertion, palate prosthesis	Surgery		1.93	1.88	2.92		
42299		Palate/uvula surgery	Surgery		1.93	1.83	2.95		
42300		Drainage of salivary gland	Surgery		6.06	4.95	4.95		
42305		Drainage of salivary gland	Surgery		1.56	1.54	2.34		
42310		Drainage of salivary gland	Surgery		2.35	2.11	3.52		
42320		Drainage of salivary gland	Surgery		2.75	2.23	3.54		
42325		Create salivary cyst drain	Surgery		3.77	3.10	4.54		
42326		Create salivary cyst drain	Surgery		2.21	1.86	3.30		
42330		Removal of salivary stone	Surgery		3.31	3.36	3.90		
42335		Removal of salivary stone	Surgery		4.59	4.27	5.14		
42340		Removal of salivary stone	Surgery					14.65	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 67 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
42400		Biopsy of salivary gland			0.78	0.72	1.75		
42405		Blepharoplasty			3.29	2.48	4.17		
42408		Excision of salivary gland			4.53	4.06	5.05		
42409		Drainage of salivary cyst			2.81	3.09	3.55		
42410		Excise parotid gland/lesion			9.33	6.64	6.64		
42415		Excise parotid gland/lesion			16.86	11.26	11.26		
42420		Excise parotid gland/lesion			19.56	12.77	12.77		
42425		Excise parotid gland/lesion			13.00	9.07	9.07		
42426		Excise parotid gland/lesion			21.23	13.43	13.43		
42440		Excise sublingual gland			6.96	5.06	5.06		
42450		Excise sublingual gland			4.61	4.24	5.66		
42500		Repair salivary duct			4.29	4.18	5.46		
42505		Repair salivary duct			6.17	5.36	6.90		
42507		Parotid duct diversion			6.10	5.20	5.20		
42508		Parotid duct diversion			9.09	7.02	7.02		
42509		Parotid duct diversion			11.52	8.42	8.42		
42510		Parotid duct diversion			8.14	6.11	6.11		
42550		Injection for salivary x-ray			1.25	0.41	13.05		
42600		Closure of salivary fistula			4.81	4.52	5.83		
42650		Dilation of salivary duct			0.77	0.71	1.17		
42660		Dilation of salivary duct			1.13	0.84	1.48		
42665		Ligation of salivary duct			2.53	2.96	3.56		
42699		Salivary surgery procedure			1.62	1.73	2.74		Misc.
42700		Drainage of tonsil abscess			5.41	3.82	5.04		
42720		Drainage of throat abscess			10.70	8.00	8.00		
42725		Drainage of throat abscess			1.39	1.40	2.23		
42800		Biopsy of throat			1.54	1.94	4.38		
42802		Biopsy of throat			1.24	1.79	3.97		
42804		Biopsy of upper nose/throat			1.58	1.92	4.11		
42806		Excise pharynx lesion			2.30	1.93	3.17		
42809		Remove pharynx foreign body			1.81	1.36	2.36		
42810		Excision of neck cyst			3.25	3.37	4.84		
42815		Excision of neck cyst			7.06	5.42	5.42		
42820		Remove tonsils and adenoids			3.90	3.47	3.47		
42821		Remove tonsils and adenoids			4.28	3.68	3.68		
42825		Removal of tonsils			3.41	3.32	3.32		
42826		Removal of tonsils			3.37	3.21	3.21		
42830		Removal of adenoids			2.57	2.62	2.62		
42831		Removal of adenoids			2.71	2.86	2.86		
42835		Removal of adenoids			2.30	2.62	2.62		
42836		Removal of adenoids			3.18	3.14	3.14		
42842		Extensive surgery of throat			8.75	6.74	6.74		
42844		Extensive surgery of throat			14.29	10.03	10.03		
42845		Extensive surgery of throat			24.25	16.11	16.11		
								12.02	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 68 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
42860		Excision of tonsil tags	Surgery		2.22	2.58	2.58	2.58	
42870		Excision of lingual tonsil	Surgery		5.39	4.79	4.79	4.79	
42880		Partial removal of pharynx	Surgery		12.92	9.34	9.34	9.34	
42892		Revision of pharyngeal walls	Surgery		15.81	10.89	10.89	10.89	
42894		Revision of pharyngeal walls	Surgery		22.85	15.07	15.07	15.07	
42900		Repair throat wound	Surgery		5.24	3.70	3.70	3.70	
42950		Reconstruction of throat	Surgery		8.09	6.60	6.60	6.60	
42953		Repair throat, esophagus	Surgery		8.95	7.53	7.53	7.53	
42955		Surgical opening of throat	Surgery		7.38	5.58	5.58	5.58	
42960		Control throat bleeding	Surgery		2.33	2.00	2.00	2.00	
42961		Control throat bleeding	Surgery		5.58	4.85	4.85	4.85	
42962		Control throat bleeding	Surgery		7.13	5.73	5.73	5.73	
42970		Control nose/throat bleeding	Surgery		5.42	3.61	3.61	3.61	
42971		Control nose/throat bleeding	Surgery		6.20	4.97	4.97	4.97	
42972		Control nose/throat bleeding	Surgery		7.19	5.47	5.47	5.47	
42999		Throat surgery procedure	Surgery					7.37	Misc.
43020		Incision of esophagus	Surgery		8.08	5.70	5.70	5.70	
43030		Throat muscle surgery	Surgery		7.68	5.82	5.82	5.82	
43045		Incision of esophagus	Surgery		20.09	10.76	10.76	10.76	
43100		Excision of esophagus lesion	Surgery		9.18	6.27	6.27	6.27	
43101		Excision of esophagus lesion	Surgery		16.22	7.94	7.94	7.94	
43107		Removal of esophagus	Surgery		39.94	17.14	17.14	17.14	
43108		Removal of esophagus	Surgery		34.14	14.30	14.30	14.30	
43112		Removal of esophagus	Surgery		43.43	18.24	18.24	18.24	
43113		Removal of esophagus	Surgery		35.22	15.20	15.20	15.20	
43116		Partial removal of esophagus	Surgery		31.17	16.81	16.81	16.81	
43117		Partial removal of esophagus	Surgery		39.94	16.38	16.38	16.38	
43118		Partial removal of esophagus	Surgery		33.15	13.87	13.87	13.87	
43121		Partial removal of esophagus	Surgery		29.15	12.75	12.75	12.75	
43122		Partial removal of esophagus	Surgery		39.94	16.49	16.49	16.49	
43123		Partial removal of esophagus	Surgery		33.15	14.18	14.18	14.18	
43124		Removal of esophagus	Surgery		27.28	13.16	13.16	13.16	
43130		Removal of esophagus pouch	Surgery		11.73	7.62	7.62	7.62	
43135		Removal of esophagus pouch	Surgery		16.08	8.16	8.16	8.16	
43200		Esophagus endoscopy	Surgery		1.59	1.10	1.10	1.10	
43201		Esoph scope w/submucous inj	Surgery		2.09	1.27	1.27	1.27	
43202		Esophagus endoscopy, biopsy	Surgery		1.89	0.96	0.96	0.96	
43204		Esoph scope w/sclerostis inj	Surgery		3.76	1.54	1.54	1.54	
43205		Esophagus endoscopy/ligation	Surgery		3.78	1.55	1.55	1.55	
43215		Esophagus endoscopy	Surgery		2.60	1.22	1.22	1.22	
43216		Esophagus endoscopy/lesion	Surgery		2.40	1.18	1.18	1.18	
43217		Esophagus endoscopy	Surgery		2.90	1.21	1.21	1.21	
43219		Esophagus endoscopy	Surgery		2.80	1.37	1.37	1.37	
43220		Esoph endoscopy, dilation	Surgery		2.10	0.99	0.99	0.99	
43226		Esoph endoscopy, dilation	Surgery		2.34	1.06	1.06	1.06	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 69 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
43227		Esoph endoscopy, repair	Surgery		3.59	1.47	1.47		
43228		Esoph endoscopy, ablation	Surgery		3.76	1.58	1.58		
43231		Esoph endoscopy w/us exam	Surgery		3.19	1.33	1.33		
43232		Esoph endoscopy w/us fn bx	Surgery		4.47	1.84	1.84		
43234		Upper GI endoscopy, exam	Surgery		2.01	0.90	0.90		
43235		Upper GI endoscopy, diagnosis	Surgery		2.39	1.07	1.07		
43236		Upper GI scope w/submuc inl	Surgery		2.92	1.26	1.26		
43237		Endoscopic us exam, esoph	Surgery		3.98	1.61	1.61		
43238		Upper GI endoscopy w/us fn bx	Surgery		5.02	1.97	1.97		
43239		Upper GI endoscopy, biopsy	Surgery		2.87	1.23	1.23		
43240		Esoph endoscope w/drain cyst	Surgery		6.95	2.65	2.65		
43241		Upper GI endoscopy with tube	Surgery		2.59	1.14	1.14		
43242		Upper GI endoscopy w/us fn bx	Surgery		7.30	2.78	2.78		
43243		Upper GI endoscopy & inject	Surgery		4.56	1.84	1.84		
43244		Upper GI endoscopy/ligation	Surgery		5.04	2.01	2.01		
43245		Upper GI scope dilate strict	Surgery		3.18	1.34	1.34		
43246		Place gastrostomy tube	Surgery		4.32	1.74	1.74		
43247		Operative upper GI endoscopy	Surgery		3.38	1.42	1.42		
43248		Upper GI endoscopy/guide wire	Surgery		3.15	1.35	1.35		
43249		Esoph endoscopy, dilation	Surgery		2.90	1.25	1.25		
43250		Upper GI endoscopy/tumor	Surgery		3.20	1.35	1.35		
43251		Operative upper GI endoscopy	Surgery		3.69	1.53	1.53		
43255		Operative upper GI endoscopy	Surgery		4.81	1.92	1.92		
43256		Upper GI endoscopy w stent	Surgery		4.34	1.77	1.77		
43258		Operative upper GI endoscopy	Surgery		4.54	1.84	1.84		
43259		Endoscopic ultrasound exam	Surgery		5.19	2.04	2.04		
43260		Endo cholangiopancreatograph	Surgery		5.95	2.31	2.31		
43261		Endo cholangiopancreatograph	Surgery		6.26	2.42	2.42		
43262		Endo cholangiopancreatograph	Surgery		7.38	2.81	2.81		
43263		Endo cholangiopancreatograph	Surgery		7.28	2.78	2.78		
43264		Endo cholangiopancreatograph	Surgery		8.89	3.35	3.35		
43265		Endo cholangiopancreatograph	Surgery		10.00	3.73	3.73		
43267		Endo cholangiopancreatograph	Surgery		7.38	2.80	2.80		
43268		Endo cholangiopancreatograph	Surgery		7.38	2.90	2.90		
43271		Endo cholangiopancreatograph	Surgery		8.20	3.10	3.10		
43272		Endo cholangiopancreatograph	Surgery		7.38	2.80	2.80		
43280		Laparoscopy, fundoplasty	Surgery		7.38	2.81	2.81		
43288		Laparoscopy proc, esoph	Surgery		17.22	7.33	7.33	24.55	Misc.
43300		Repair of esophagus	Surgery		9.13	6.51	6.51		
43305		Repair esophagus and fistula	Surgery		17.96	10.78	10.78		
43310		Repair of esophagus	Surgery		25.35	11.15	11.15		
43312		Repair esophagus and fistula	Surgery		28.38	12.00	12.00		
43313		Esophagoplasty congenital	Surgery		45.21	20.15	20.15		
43314		Tracheo-esophagoplasty cong	Surgery		50.19	22.05	22.05		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 70 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
43320		Fuse esophagus & stomach	Surgery		19.90	9.27	9.27	9.27	
43324		Revise esophagus & stomach	Surgery		20.54	8.82	8.82	8.82	
43325		Revise esophagus & stomach	Surgery		20.03	8.84	8.84	8.84	
43326		Revise esophagus & stomach	Surgery		19.71	9.34	9.34	9.34	
43330		Repair of esophagus	Surgery		20.10	8.59	8.59	8.59	
43331		Repair of esophagus	Surgery		19.58	9.03	9.03	9.03	
43340		Fuse esophagus & intestine	Surgery		20.82	10.06	10.06	10.06	
43341		Fuse esophagus & intestine	Surgery		15.76	8.50	8.50	8.50	
43350		Surgical opening, esophagus	Surgery		18.32	9.85	9.85	9.85	
43351		Surgical opening, esophagus	Surgery		15.24	8.45	8.45	8.45	
43352		Surgical opening, esophagus	Surgery		35.65	15.15	15.15	15.15	
43360		Gastrointestinal repair	Surgery		40.44	16.98	16.98	16.98	
43361		Gastrointestinal repair	Surgery		21.17	9.43	9.43	9.43	
43400		Ligate esophagus veins	Surgery		22.06	9.56	9.56	9.56	
43401		Esophagus surgery for veins	Surgery		19.98	9.62	9.62	9.62	
43405		Ligate/staple esophagus	Surgery		13.45	7.69	7.69	7.69	
43410		Repair esophagus wound	Surgery		24.96	11.80	11.80	11.80	
43415		Repair esophagus wound	Surgery		14.33	7.48	7.48	7.48	
43420		Repair esophagus opening	Surgery		21.00	10.03	10.03	10.03	
43425		Repair esophagus opening	Surgery		1.38	0.73	0.73	0.73	
43450		Dilate esophagus	Surgery		1.51	0.78	0.78	0.78	
43453		Dilate esophagus	Surgery		2.57	1.15	1.15	1.15	
43455		Dilate esophagus	Surgery		3.06	1.33	1.33	1.33	
43458		Dilate esophagus	Surgery		3.79	1.49	1.49	1.49	
43460		Pressure treatment esophagus	Surgery					4.58	Misc.
43499		Esophagus surgery procedure	Surgery		11.03	5.00	5.00	5.00	
43500		Surgical opening of stomach	Surgery		20.01	8.36	8.36	8.36	
43501		Surgical repair of stomach	Surgery		23.10	9.51	9.51	9.51	
43502		Surgical repair of stomach	Surgery		13.06	6.59	6.59	6.59	
43510		Surgical opening of stomach	Surgery		9.98	5.30	5.30	5.30	
43520		Incision of pyloric muscle	Surgery		1.91	1.03	1.03	1.03	
43600		Biopsy of stomach	Surgery		11.96	5.32	5.32	5.32	
43605		Biopsy of stomach	Surgery		14.58	6.20	6.20	6.20	
43610		Excision of stomach lesion	Surgery		17.81	7.61	7.61	7.61	
43611		Excision of stomach lesion	Surgery		29.99	11.87	11.87	11.87	
43620		Removal of stomach	Surgery		30.68	12.06	12.06	12.06	
43621		Removal of stomach	Surgery		32.48	12.66	12.66	12.66	
43622		Removal of stomach	Surgery		22.56	9.21	9.21	9.21	
43631		Removal of stomach, partial	Surgery		22.56	9.21	9.21	9.21	
43632		Removal of stomach, partial	Surgery		23.07	9.37	9.37	9.37	
43633		Removal of stomach, partial	Surgery		25.08	10.14	10.14	10.14	
43634		Removal of stomach, partial	Surgery		2.06	0.70	0.70	0.70	
43635		Removal of stomach, partial	Surgery		28.96	11.94	11.94	11.94	
43638		Removal of stomach, partial	Surgery		29.61	11.74	11.74	11.74	
43639		Removal of stomach, partial	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 71 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
43640		Vagotomy & pylorus repair	Surgery		16.99	7.30	7.30		
43641		Vagotomy & pylorus repair	Surgery		17.24	7.41	7.41		
43651		Laparoscopy, vagus nerve	Surgery		10.13	4.80	4.80		
43652		Laparoscopy, vagus nerve	Surgery		12.13	5.40	5.40		
43653		Laparoscopy, gastrostomy	Surgery		7.72	4.22	4.22		
43659		Laparoscopy, proc. stom	Surgery					14.93	Misc.
43750		Place gastrostomy tube	Surgery		4.48	2.72	2.72		
43752		Nasal/orogastric w/lient	Surgery		0.68	0.26	0.26		
43760		Change gastrostomy tube	Surgery		1.10	0.45	0.45		
43761		Reposition gastrostomy tube	Surgery		2.01	0.79	0.79		
43800		Reconstruction of pylorus	Surgery		13.67	5.94	5.94		
43810		Fusion of stomach and bowel	Surgery		14.63	6.23	6.23		
43820		Fusion of stomach and bowel	Surgery		15.35	6.45	6.45		
43825		Fusion of stomach and bowel	Surgery		19.19	8.06	8.06		
43830		Place gastrostomy tube	Surgery		9.52	4.88	4.88		
43831		Place gastrostomy tube	Surgery		7.83	4.54	4.54		
43832		Place gastrostomy tube	Surgery		15.58	6.90	6.90		
43840		Repair of stomach lesion	Surgery		15.54	6.81	6.81		
43842		Gastroplasty for obesity	Surgery		18.44	8.15	8.15		
43843		Gastroplasty for obesity	Surgery		18.62	8.12	8.12		
43846		Gastric bypass for obesity	Surgery		24.01	10.37	10.37		
43847		Gastric bypass for obesity	Surgery		26.88	11.32	11.32		
43848		Revision gastroplasty	Surgery		29.35	12.25	12.25		
43850		Revise stomach-bowel fusion	Surgery		24.68	9.87	9.87		
43855		Revise stomach-bowel fusion	Surgery		26.12	10.38	10.38		
43860		Revise stomach-bowel fusion	Surgery		24.96	10.03	10.03		
43865		Revise stomach-bowel fusion	Surgery		26.48	10.56	10.56		
43870		Repair stomach opening	Surgery		9.68	4.55	4.55		
43880		Repair stomach-bowel fistula	Surgery		24.61	9.97	9.97		
43999		Stomach surgery procedure	Surgery					21.80	Misc.
44005		Freeding of bowel adhesion	Surgery		16.21	6.77	6.77		
44010		Incision of small bowel	Surgery		12.50	5.50	5.50		
44015		Insert needle cath bowel	Surgery		2.62	0.89	0.89		
44020		Explore small intestine	Surgery		13.97	5.98	5.98		
44021		Decompress small bowel	Surgery		14.06	6.02	6.02		
44025		Incision of large bowel	Surgery		14.26	6.07	6.07		
44050		Reduce bowel obstruction	Surgery		14.01	6.00	6.00		
44055		Correct malrotation of bowel	Surgery		21.97	8.78	8.78		
44100		Blopsy of bowel	Surgery		2.01	1.10	1.10		
44110		Excise intestine lesion(s)	Surgery		11.79	5.27	5.27		
44111		Excision of bowel lesion(s)	Surgery		14.27	6.17	6.17		
44120		Removal of small intestine	Surgery		16.97	7.12	7.12		
44121		Removal of small intestine	Surgery		4.44	1.53	1.53		
44125		Removal of small intestine	Surgery		17.51	7.31	7.31		
44126		Enterectomy w/o taper, cong	Surgery		35.45	14.16	14.16		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 72 OF 179

CPT/ HCP/PCS Code	Modifier	CPT/HCP/PCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
44127		Enterectomy w/taper, cong	Surgery		40.94	15.79	15.79		
44128		Enterectomy cong, add-on	Surgery		4.44	1.54	1.54		
44130		Bowel to bowel fusion	Surgery		14.47	6.26	6.26		
44139		Mobilization of colon	Surgery		2.23	0.76	0.76		
44140		Partial removal of colon	Surgery		20.97	8.69	8.69		
44141		Partial removal of colon	Surgery		19.48	10.15	10.15		
44143		Partial removal of colon	Surgery		22.96	10.80	10.80		
44144		Partial removal of colon	Surgery		21.50	9.69	9.69		
44145		Partial removal of colon	Surgery		26.38	10.87	10.87		
44146		Partial removal of colon	Surgery		27.50	12.98	12.98		
44147		Partial removal of colon	Surgery		20.68	8.74	8.74		
44150		Removal of colon	Surgery		23.91	12.16	12.16		
44151		Removal of colon/ileostomy	Surgery		26.84	13.54	13.54		
44152		Removal of colon/ileostomy	Surgery		27.79	11.68	11.68		
44153		Removal of colon/ileostomy	Surgery		30.54	14.56	14.56		
44155		Removal of colon/ileostomy	Surgery		27.82	13.44	13.44		
44156		Removal of colon/ileostomy	Surgery		30.74	15.20	15.20		
44160		Removal of colon	Surgery		18.59	7.80	7.80		
44200		Laparoscopy, enterolysis	Surgery		14.42	6.23	6.23		
44201		Laparoscopy, jejunostomy	Surgery		9.77	4.70	4.70		
44202		Lap resect s/intestine singl	Surgery		22.01	8.98	8.98		
44203		Lap resect s/intestine, addl	Surgery		4.44	1.50	1.50		
44204		Laparo partial colectomy	Surgery		25.04	10.00	10.00		
44205		Lap colectomy part w/ileum	Surgery		22.20	8.88	8.88		
44206		Lap part colectomy w/stoma	Surgery		26.96	11.37	11.37		
44207		L colectomy/coloproctostomy	Surgery		29.96	11.59	11.59		
44208		L colectomy/coloproctostomy	Surgery		31.95	13.27	13.27		
44210		Laparo total proctocolectomy	Surgery		27.96	12.03	12.03		
44211		Laparo total proctocolectomy	Surgery		34.95	14.74	14.74		
44212		Laparo total proctocolectomy	Surgery		32.45	13.88	13.88		
44238		Laparoscope proc, intestine	Surgery						Misc.
44239		Laparoscope proc, rectum	Surgery					20.65	Misc.
44300		Open bowel to skin	Surgery		12.09	5.53	5.53		
44310		Ileostomy/jejunostomy	Surgery		15.93	6.73	6.73		
44312		Revision of ileostomy	Surgery		8.01	4.03	4.03		
44314		Revision of ileostomy	Surgery		15.03	6.60	6.60		
44316		Devise bowel pouch	Surgery		21.06	8.60	8.60		
44320		Colostomy	Surgery		17.61	7.71	7.71		
44322		Colostomy with biopsies	Surgery		11.96	6.70	6.70		
44340		Revision of colostomy	Surgery		7.71	4.31	4.31		
44345		Revision of colostomy	Surgery		15.41	6.93	6.93		
44346		Revision of colostomy	Surgery		16.96	7.43	7.43		
44360		Small bowel endoscopy	Surgery		2.59	1.12	1.12		
44361		Small bowel endoscopy/biopsy	Surgery		2.87	1.21	1.21		
44363		Small bowel endoscopy	Surgery		3.49	1.40	1.40		
								20.65	Misc.
								49.69	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 73 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
44364		Small bowel endoscopy	Surgery		3.73	1.52	1.52		
44365		Small bowel endoscopy	Surgery		3.31	1.38	1.38		
44366		Small bowel endoscopy	Surgery		4.40	1.76	1.76		
44369		Small bowel endoscopy	Surgery		4.51	1.76	1.76		
44370		Small bowel endoscopy/stent	Surgery		4.79	1.99	1.99		
44372		Small bowel endoscopy	Surgery		4.40	1.75	1.75		
44373		Small bowel endoscopy	Surgery		3.49	1.45	1.45		
44376		Small bowel endoscopy	Surgery		5.25	2.04	2.04		
44377		Small bowel endoscopy/biopsy	Surgery		5.52	2.15	2.15		
44378		Small bowel endoscopy	Surgery		7.12	2.71	2.71		
44379		S bowel endoscope w/stent	Surgery		7.46	2.93	2.93		
44380		Small bowel endoscopy	Surgery		1.05	0.56	0.56		
44382		Small bowel endoscopy	Surgery		1.27	0.65	0.65		
44383		ileoscopy w/stent	Surgery		2.94	1.28	1.28		
44385		Endoscopy of bowel pouch	Surgery		1.82	0.96	0.96		
44386		Endoscopy, bowel pouch/biops	Surgery		2.12	1.12	1.12		
44388		Colon endoscopy	Surgery		2.82	1.16	1.16		
44389		Colonoscopy with biopsy	Surgery		3.13	1.28	1.28		
44390		Colonoscopy for foreign body	Surgery		3.82	1.51	1.51		
44391		Colonoscopy for bleeding	Surgery		4.31	1.72	1.72		
44392		Colonoscopy & polypectomy	Surgery		3.81	1.52	1.52		
44393		Colonoscopy, lesion removal	Surgery		4.83	1.88	1.88		
44394		Colonoscopy w/snare	Surgery		4.42	1.75	1.75		
44397		Colonoscopy w/stent	Surgery		4.70	2.06	2.06		
44500		Intro, gastrointestinal tube	Surgery		0.49	0.36	0.36		
44602		Suture, small intestine	Surgery		16.01	6.42	6.42		
44603		Suture, small intestine	Surgery		18.63	7.31	7.31		
44604		Suture, large intestine	Surgery		16.01	6.49	6.49		
44605		Repair of bowel lesion	Surgery		19.50	8.46	8.46		
44615		Intestinal stricturoplasty	Surgery		15.91	6.72	6.72		
44620		Repair bowel opening	Surgery		12.18	5.36	5.36		
44625		Repair bowel opening	Surgery		15.03	6.35	6.35		
44626		Repair bowel opening	Surgery		25.32	9.87	9.87		
44640		Repair bowel-skin fistula	Surgery		21.62	8.62	8.62		
44650		Repair bowel fistula	Surgery		22.54	8.93	8.93		
44660		Repair bowel-bladder fistula	Surgery		21.33	8.40	8.40		
44661		Repair bowel-bladder fistula	Surgery		24.77	9.60	9.60		
44680		Surgical revision, intestine	Surgery		15.38	6.48	6.48		
44700		Suspend bowel w/prosthesis	Surgery		16.09	6.69	6.69		
44701		Intraop colon lavage add-on	Surgery		3.10	1.06	1.06		Misc.
44799		Intestine surgery procedure	Surgery		11.21	5.43	5.43	24.09	
44800		Excision of bowel pouch	Surgery		12.07	5.53	5.53		Misc.
44820		Excision of mesentery lesion	Surgery		10.72	5.04	5.04		
44850		Repair of mesentery	Surgery						
44899		Bowel surgery procedure	Surgery					16.64	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 74 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
44900		Drain abscess, open	Surgery		10.12	4.74	4.74		
44901		Drain abscess, percut	Surgery		3.37	1.12	1.12		
44950		Appendectomy	Surgery		9.99	4.35	4.35		
44955		Appendectomy add-on	Surgery		1.53	0.53	0.53		
44960		Appendectomy	Surgery		12.32	5.38	5.38		
44970		Laparoscopy, appendectomy	Surgery		8.69	4.23	4.23		
44979		Laparoscopy, appendectomy	Surgery						
45000		Drainage of pelvic abscess	Surgery		4.51	2.98	2.98		Misc.
45005		Drainage of rectal abscess	Surgery		1.99	1.69	1.69		
45020		Drainage of rectal abscess	Surgery		4.71	3.31	3.31		
45100		Biopsy of rectum	Surgery		3.67	2.39	2.39		
45108		Removal of anorectal lesion	Surgery		4.75	2.91	2.91		
45110		Removal of rectum	Surgery		27.96	12.50	12.50		
45111		Partial removal of rectum	Surgery		16.46	7.21	7.21		
45112		Removal of rectum	Surgery		30.49	11.82	11.82		
45113		Partial proctectomy	Surgery		30.53	12.69	12.69		
45114		Partial removal of rectum	Surgery		27.28	11.01	11.01		
45116		Partial removal of rectum	Surgery		24.54	10.08	10.08		
45119		Remove rectum w/reservoir	Surgery		30.79	12.54	12.54		
45120		Removal of rectum	Surgery		24.56	10.19	10.19		
45121		Removal of rectum and colon	Surgery		27.00	11.18	11.18		
45123		Partial proctectomy	Surgery		16.68	6.90	6.90		
45126		Pelvic exenteration	Surgery		45.09	19.38	19.38		
45130		Excision of rectal prolapse	Surgery		16.42	6.80	6.80		
45135		Excision of rectal prolapse	Surgery		19.25	8.48	8.48		
45136		Excise ileoanal reservoir	Surgery		27.26	12.52	12.52		
45150		Excision of rectal stricture	Surgery		5.66	2.98	2.98		
45160		Excision of rectal lesion	Surgery		15.30	6.68	6.68		
45170		Excision of rectal lesion	Surgery		11.47	5.27	5.27		
45190		Destruction, rectal tumor	Surgery		9.73	4.68	4.68		
45300		Proctosigmoidoscopy dx	Surgery		0.38	0.31	0.31		
45303		Proctosigmoidoscopy dilate	Surgery		0.44	0.35	0.35		
45305		Proctosigmoidoscopy w/bx	Surgery		1.01	0.52	0.52		
45307		Proctosigmoidoscopy fb	Surgery		0.94	0.50	0.50		
45308		Proctosigmoidoscopy removal	Surgery		0.83	0.46	0.46		
45309		Proctosigmoidoscopy removal	Surgery		2.01	0.86	0.86		
45315		Proctosigmoidoscopy removal	Surgery		1.40	0.65	0.65		
45317		Proctosigmoidoscopy bleed	Surgery		1.50	0.68	0.68		
45320		Proctosigmoidoscopy ablate	Surgery		1.58	0.73	0.73		
45321		Proctosigmoidoscopy volvul	Surgery		1.17	0.56	0.56		
45327		Proctosigmoidoscopy w/rent	Surgery		1.65	0.70	0.70		
45330		Diagnostic sigmoidoscopy	Surgery		0.96	0.52	0.52		
45331		Sigmoidoscopy and biopsy	Surgery		1.15	0.63	0.63		
45332		Sigmoidoscopy w/bx removal	Surgery		1.79	0.85	0.85		
45333		Sigmoidoscopy & polypectomy	Surgery		1.79	0.85	0.85		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 75 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
45334		Sigmoidoscopy for bleeding	Surgery		2.73	1.18	1.18		
45335		Sigmoidoscopy w/submuc inj	Surgery		1.46	0.68	3.44		
45337		Sigmoidoscopy & decompress	Surgery		2.36	1.05	1.05		
45338		Sigmoidoscopy w/lumr remove	Surgery		2.34	1.05	5.03		
45339		Sigmoidoscopy w/ablate tumr	Surgery		3.14	1.32	3.34		
45340		Sig w/balloon dilation	Surgery		1.89	0.83	6.72		
45341		Sigmoidoscopy w/ultrasound	Surgery		2.60	1.12	1.12		
45342		Sigmoidoscopy w/us guide bx	Surgery		4.05	1.60	1.60		
45345		Sigmoidoscopy w/stent	Surgery		2.92	1.20	1.20		
45355		Surgical colonoscopy	Surgery		3.51	1.40	1.40		
45378		Diagnostic colonoscopy	Surgery		3.69	1.58	6.04		
45379		Colonoscopy w/bi removal	Surgery		4.68	1.86	7.56		
45380		Colonoscopy and biopsy	Surgery		4.43	1.78	7.07		
45381		Colonoscopy, submucous inj	Surgery		4.19	1.69	8.14		
45382		Colonoscopy/control bleeding	Surgery		5.68	2.23	9.72		
45383		Lesion removal colonoscopy	Surgery		5.86	2.27	7.65		
45384		Lesion removal colonoscopy	Surgery		4.69	1.87	6.69		
45385		Lesion removal colonoscopy	Surgery		5.30	2.08	7.69		
45386		Colonoscopy dilate stricture	Surgery		4.57	1.83	13.65		
45387		Colonoscopy w/stent	Surgery		5.90	2.35	2.35		
45500		Repair of rectum	Surgery		7.28	3.59	3.59		
45505		Treatment of rectal prolapse	Surgery		7.57	3.87	3.87		
45520		Correct rectal prolapse	Surgery		0.55	0.19	0.85		
45540		Correct rectal prolapse	Surgery		16.25	6.86	6.86		
45541		Repair rectum/remove sigmoid	Surgery		13.38	6.00	6.00		
45560		Repair of rectocele	Surgery		22.97	9.29	9.29		
45562		Exploration/repair of rectum	Surgery		10.56	5.12	5.12		
45563		Exploration/repair of rectum	Surgery		15.36	7.05	7.05		
45800		Repair rectibulbar fistula	Surgery		23.43	10.61	10.61		
45805		Repair fistula w/colostomy	Surgery		17.74	7.50	7.50		
45820		Repair rectourethral fistula	Surgery		20.75	9.60	9.60		
45825		Repair fistula w/colostomy	Surgery		18.45	7.70	7.70		
45900		Reduction of tctal prolapse	Surgery		21.22	9.91	9.91		
45905		Dilation of anal sphincter	Surgery		2.61	1.52	1.52		
45910		Dilation of rectal narrowing	Surgery		2.30	1.43	1.43		
45915		Remove rectal obstruction	Surgery		2.80	1.66	1.66		
45999		Rectum surgery procedure	Surgery		3.14	1.17	4.73		Misc.
46020		Placement of seton	Surgery		2.90	1.86	2.28	5.83	
46030		Removal of rectal marker	Surgery		1.23	0.71	1.35		
46040		Incision of rectal abscess	Surgery		4.95	3.17	5.30		
46045		Incision of rectal abscess	Surgery		2.92	2.92	2.92		
46050		Incision of anal abscess	Surgery		1.19	0.86	2.57		
46060		Incision of anal abscess	Surgery		5.68	3.30	3.30		
46070		Incision of rectal abscess	Surgery		2.71	1.88	1.88		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 76 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
46080		Incision of anal sphincter	Surgery		2.49	1.13	2.39		
46083		Incise external hemorrhoid	Surgery		1.40	0.95	2.50		
46200		Removal of anal fissure	Surgery		3.41	2.43	3.64		
46210		Removal of anal crypt	Surgery		2.67	2.14	4.81		
46211		Removal of anal crypts	Surgery		4.24	2.85	5.08		
46220		Removal of anal tag	Surgery		1.56	0.94	2.27		
46221		Ligation of hemorrhoid(s)	Surgery		2.04	1.12	1.62		
46230		Removal of anal tags	Surgery		2.57	1.28	3.04		
46250		Hemorrhoidectomy	Surgery		3.88	2.46	4.86		
46255		Hemorrhoidectomy	Surgery		4.59	2.67	5.40		
46257		Remove hemorrhoids & fissure	Surgery		5.39	2.91	2.91		
46258		Remove hemorrhoids & fistula	Surgery		5.72	3.31	3.31		
46260		Hemorrhoidectomy	Surgery		6.36	3.26	3.26		
46261		Remove hemorrhoids & fissure	Surgery		7.07	3.66	3.66		
46262		Remove hemorrhoids & fistula	Surgery		7.49	3.79	3.79		
46270		Removal of anal fistula	Surgery		3.71	2.38	4.66		
46275		Removal of anal fistula	Surgery		4.55	2.57	4.36		
46280		Removal of anal fistula	Surgery		5.97	3.31	3.31		
46285		Removal of anal fistula	Surgery		4.08	2.35	3.59		
46288		Repair anal fistula	Surgery		7.12	3.72	3.72		
46320		Removal of hemorrhoid clot	Surgery		1.61	0.85	2.12		
46500		Injection into hemorrhoid(s)	Surgery		1.61	0.62	2.79		
46600		Diagnostic anoscopy	Surgery		0.50	0.38	1.58		
46604		Anoscopy and dilation	Surgery		1.31	0.64	9.30		
46606		Anoscopy and biopsy	Surgery		0.81	0.44	3.83		
46608		Anoscopy, remove for body	Surgery		1.51	0.68	4.42		
46610		Anoscopy, remove lesion	Surgery		1.32	0.63	4.08		
46611		Anoscopy	Surgery		1.81	0.80	3.35		
46612		Anoscopy, remove lesions	Surgery		2.34	1.00	5.19		
46614		Anoscopy, control bleeding	Surgery		2.01	0.87	2.28		
46615		Anoscopy	Surgery		2.68	1.10	2.52		
46700		Repair of anal stricture	Surgery		9.12	4.24	4.24		
46705		Repr of anal fistula w/glue	Surgery		6.89	3.75	3.75		
46706		Repr of anal fistula w/glue	Surgery		2.39	1.24	1.24		
46715		Repair of anovaginal fistula	Surgery		7.19	3.64	3.64		
46716		Repair of anovaginal fistula	Surgery		15.05	7.98	7.98		
46730		Construction of absent anus	Surgery		26.71	12.04	12.04		
46735		Construction of absent anus	Surgery		32.12	13.58	13.58		
46740		Construction of absent anus	Surgery		29.96	13.21	13.21		
46742		Repair of imperforated anus	Surgery		35.75	17.54	17.54		
46744		Repair of cloacal anomaly	Surgery		52.55	21.17	21.17		
46746		Repair of cloacal anomaly	Surgery		58.13	25.20	25.20		
46748		Repair of cloacal anomaly	Surgery		64.11	23.81	23.81		
46750		Repair of anal sphincter	Surgery		10.23	5.10	5.10		
46751		Repair of anal sphincter	Surgery		8.76	5.51	5.51		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 77 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
46753		Reconstruction of anus	Surgery		8.28	3.88	3.88		
46754		Removal of suture from anus	Surgery		2.20	1.70	1.70		
46760		Repair of anal sphincter	Surgery		14.41	7.11	7.11		
46761		Repair of anal sphincter	Surgery		13.82	6.06	6.06		
46762		Implant artificial sphincter	Surgery		12.69	5.56	5.56		
46900		Destruction, anal lesion(s)	Surgery		1.91	0.79	0.79		
46910		Destruction, anal lesion(s)	Surgery		1.86	1.10	1.10		
46916		Cryosurgery, anal lesion(s)	Surgery		1.86	1.40	1.40		
46917		Laser surgery, anal lesions	Surgery		1.86	1.12	1.12		
46922		Excision of anal lesion(s)	Surgery		1.86	1.09	1.09		
46924		Destruction, anal lesion(s)	Surgery		2.76	1.36	1.36		
46934		Destruction of hemorrhoids	Surgery		3.50	2.70	2.70		
46935		Destruction of hemorrhoids	Surgery		2.43	1.21	1.21		
46936		Destruction of hemorrhoids	Surgery		3.68	2.26	2.26		
46937		Cryotherapy of rectal lesion	Surgery		2.69	1.22	1.22		
46938		Cryotherapy of rectal lesion	Surgery		4.65	2.70	2.70		
46940		Treatment of anal fissure	Surgery		2.32	1.09	1.09		
46942		Treatment of anal fissure	Surgery		2.04	1.02	1.02		
46945		Ligation of hemorrhoids	Surgery		1.84	1.88	1.88		
46948		Ligation of hemorrhoids	Surgery		2.58	1.85	1.85		
46999		Anus surgery procedure	Surgery		1.90	0.63	0.63		Misc.
47001		Needle biopsy of liver	Surgery		1.90	0.65	0.65		
47010		Open drainage, liver lesion	Surgery		15.99	8.55	8.55		
47011		Percut drain, liver lesion	Surgery		3.69	1.21	1.21		
47015		Inject/aspirate liver cyst	Surgery		15.09	7.56	7.56		
47100		Wedge biopsy of liver	Surgery		11.65	6.10	6.10		
47120		Partial removal of liver	Surgery		35.45	15.28	15.28		
47122		Extensive removal of liver	Surgery		55.05	21.62	21.62		
47125		Partial removal of liver	Surgery		49.12	19.67	19.67		
47130		Partial removal of liver	Surgery		53.27	21.14	21.14		
47135		Transplantation of liver	Surgery		81.40	32.07	32.07		
47136		Transplantation of liver	Surgery		68.50	27.50	27.50		
47140		Partial removal, donor liver	Surgery		54.92	22.74	22.74		
47141		Partial removal, donor liver	Surgery		67.40	27.39	27.39		
47142		Partial removal, donor liver	Surgery		74.89	29.97	29.97		
47300		Surgery for liver lesion	Surgery		15.06	7.29	7.29		
47350		Repair liver wound	Surgery		19.53	8.93	8.93		
47360		Repair liver wound	Surgery		26.88	11.67	11.67		
47361		Repair liver wound	Surgery		47.05	18.64	18.64		
47362		Repair liver wound	Surgery		18.48	8.80	8.80		
47370		Laparo ablate liver tumor rf	Surgery		19.66	8.18	8.18		
47371		Laparo ablate liver cryosurg	Surgery		19.66	8.19	8.19		
47379		Laparoscope procedure, liver	Surgery		22.97	9.39	9.39		
47380		Open ablate liver tumor rf	Surgery					27.85	Misc.

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 78 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
47381		Open ablate liver tumor cryo	Surgery		23.24	9.65	9.65		
47382		Percut ablate liver rf	Surgery		15.17	6.10	6.10	2.66	Misc.
47399		Liver surgery procedure	Surgery		32.44	13.55	13.55		
47400		Incision of liver duct	Surgery		19.85	8.82	8.82		
47420		Incision of bile duct	Surgery		19.80	8.87	8.87		
47425		Incision of bile duct	Surgery		18.01	8.42	8.42		
47460		Incise bile duct sphincter	Surgery		10.80	5.97	5.97		
47480		Incision of gallbladder	Surgery		7.22	5.83	5.83		
47490		Incision of gallbladder	Surgery		1.96	0.64	0.64		
47500		Injection for liver x-rays	Surgery		0.76	0.25	0.25		
47505		Injection for liver x-rays	Surgery		7.82	5.01	5.01		
47510		Insert catheter, bile duct	Surgery		10.48	5.09	5.09		
47511		Insert bile duct drain	Surgery		5.54	3.26	3.26		
47525		Change bile duct catheter	Surgery		5.84	4.32	4.32		
47530		Reviser/reinsert bile tube	Surgery		3.02	1.03	1.03		
47550		Bile duct endoscopy add-on	Surgery		6.03	2.40	2.40		
47552		Biliary endoscopy thru skin	Surgery		6.34	2.60	2.60		
47553		Biliary endoscopy thru skin	Surgery		9.05	3.38	3.38		
47554		Biliary endoscopy thru skin	Surgery		7.95	3.01	3.01		
47555		Biliary endoscopy thru skin	Surgery		8.55	3.33	3.33		
47556		Biliary endoscopy thru skin	Surgery		4.88	1.83	1.83		
47560		Laparoscopy w/choangiobiospy	Surgery		5.17	2.13	2.13		
47561		Laparoscopic cholecystectomy	Surgery		11.07	5.00	5.00		
47562		Laparo cholecystectomy/graph	Surgery		11.92	5.32	5.32		
47563		Laparo cholecystectomy/explr	Surgery		14.21	5.97	5.97		
47564		Laparo cholecystoenterostomy	Surgery		12.56	5.39	5.39	16.07	Misc.
47570		Laparoscopy proc. biliary	Surgery						
47579		Removal of gallbladder	Surgery		13.56	6.20	6.20		
47600		Removal of gallbladder	Surgery		14.67	6.55	6.55		
47605		Removal of gallbladder	Surgery		18.79	7.99	7.99		
47610		Removal of gallbladder	Surgery		18.75	7.94	7.94		
47612		Removal of gallbladder	Surgery		20.61	8.59	8.59		
47620		Remove bile duct stone	Surgery		9.10	4.80	4.80		
47630		Exploration of bile ducts	Surgery		15.60	7.48	7.48		
47700		Bile duct revision	Surgery		27.77	11.58	11.58		
47701		Excision of bile duct tumor	Surgery		23.00	10.01	10.01		
47711		Excision of bile duct tumor	Surgery		30.19	12.50	12.50		
47712		Excision of bile duct tumor	Surgery		18.77	8.49	8.49		
47715		Excision of bile duct cyst	Surgery		16.42	7.88	7.88		
47716		Fusion of bile duct cyst	Surgery		15.89	7.54	7.54		
47720		Fuse gallbladder & bowel	Surgery		19.09	8.63	8.63		
47721		Fuse upper gi structures	Surgery		18.45	8.45	8.45		
47740		Fuse gallbladder & bowel	Surgery		21.31	9.35	9.35		
47741		Fuse gallbladder & bowel	Surgery		25.81	10.92	10.92		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 78 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
47765		Fuse liver ducts & bowel	Surgery		24.84	10.89	10.89		
47780		Fuse bile ducts and bowel	Surgery		26.46	11.28	11.28		
47785		Fuse bile ducts and bowel	Surgery		31.13	13.01	13.01		
47800		Reconstruction of bile ducts	Surgery		23.27	10.13	10.13		
47801		Placement, bile duct support	Surgery		15.15	8.33	8.33		
47802		Fuse liver duct & intestine	Surgery		21.52	9.76	9.76		
47900		Suture bile duct injury	Surgery		19.87	8.93	8.93		Misc.
47999		Bile tract surgery procedure	Surgery					19.76	
48000		Drainage of abdomen	Surgery		28.03	11.58	11.58		
48001		Placement of drain, pancreas	Surgery		35.40	13.95	13.95		
48005		Resect/debride pancreas	Surgery		42.11	16.63	16.63		
48020		Removal of pancreatic stone	Surgery		15.68	7.35	7.35		
48100		Biopsy of pancreas, open	Surgery		12.21	5.65	5.65		
48102		Needle biopsy, pancreas	Surgery		4.67	2.45	2.45		
48120		Removal of pancreas lesion	Surgery		15.83	6.90	6.90		
48140		Partial removal of pancreas	Surgery		22.91	9.60	9.60		
48145		Partial removal of pancreas	Surgery		23.98	9.91	9.91		
48146		Pancreatectomy	Surgery		26.36	12.09	12.09		
48148		Removal of pancreatic duct	Surgery		17.31	7.68	7.68		
48150		Partial removal of pancreas	Surgery		47.93	19.65	19.65		
48152		Pancreatectomy	Surgery		43.68	18.35	18.35		
48153		Pancreatectomy	Surgery		47.82	19.74	19.74		
48154		Pancreatectomy	Surgery		44.03	18.38	18.38		
48155		Removal of pancreas	Surgery		24.60	11.82	11.82		MDR
48160		Pancreas removal/transplant	Surgery		24.68	10.22	10.22		
48180		Fuse pancreas and bowel	Surgery		1.95	0.64	0.64		
48400		Injection, intraop add-on	Surgery		15.26	7.40	7.40		
48500		Surgery of pancreatic cyst	Surgery		14.29	7.54	7.54		
48510		Drain pancreatic pseudocyst	Surgery		3.99	1.31	1.31		
48511		Drain pancreatic pseudocyst	Surgery		15.57	6.75	6.75		
48520		Fuse pancreas cyst and bowel	Surgery		19.69	8.16	8.16		
48540		Fuse pancreas cyst and bowel	Surgery		18.15	8.05	8.05		
48545		Pancreatolithaphy	Surgery		25.79	10.55	10.55		
48547		Duodenal exclusion	Surgery		34.12	17.32	17.32		
48554		Transpl allograft pancreas	Surgery		15.69	8.29	8.29		Misc.
48556		Removal, allograft pancreas	Surgery					34.90	
48999		Pancreas surgery procedure	Surgery		11.66	5.42	5.42		
49000		Exploration of abdomen	Surgery		10.47	5.07	5.07		
49002		Reopening of abdomen	Surgery		12.26	5.95	5.95		
49010		Exploration behind abdomen	Surgery		22.81	10.24	10.24		
49020		Drain abdominal abscess	Surgery		3.37	1.12	1.12		
49021		Drain abdominal abscess	Surgery		13.50	6.47	6.47		
49040		Drain, open, abdom abscess	Surgery		3.99	1.31	1.31		
49041		Drain, percut, abdom abscess	Surgery		15.84	7.48	7.48		
49060		Drain, open, retroper abscess	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 80 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
49061		Drain, percut, retroper absc			3.69	1.21	1.21		
49062		Drain to peritoneal cavity			11.34	5.50	5.50		
49080		Puncture, peritoneal cavity			1.35	0.45	0.45		
49081		Removal of abdominal fluid			1.26	0.57	0.57		
49085		Remove abdominal foreign body			12.12	5.56	5.56		
49180		Biopsy, abdominal mass			1.73	0.56	0.56		
49200		Removal of abdominal lesion			10.23	5.08	5.08		
49201		Remove abdom lesion, complex			14.82	7.10	7.10		
49215		Excise sacral spine tumor			33.45	14.09	14.09		
49220		Multiple surgery, abdomen			14.86	6.69	6.69		
49250		Excision of umbilicus			8.34	4.33	4.33		
49255		Removal of omentum			11.12	5.66	5.66		
49320		Diag laparo separate proc			5.09	2.64	2.64		
49321		Laparoscopy, biopsy			5.39	2.65	2.65		
49322		Laparoscopy, aspiration			5.69	2.99	2.99		
49323		Laparo drain lymphocele			9.47	4.52	4.52		
49329		Laparo proc, abdm/per/oment						7.73	Misc.
49400		Air injection into abdomen							
49419		insrt abdom cath for chemotx							
49420		insert abdom drain, temp							
49421		insert abdom drain, perm							
49422		Remove perm cannula/catheter			1.88	0.79	0.79		
49423		Exchange drainage catheter			6.64	3.56	3.56		
49424		Assess cyst, contrast inject			2.22	1.12	1.12		
49425		insert abdomen-venous drain			5.53	3.20	3.20		
49426		Revise abdomen-venous shunt			6.24	2.91	2.91		
49427		Injection, abdominal shunt			1.46	0.67	0.67		
49428		Ligation of shunt			0.76	0.44	0.44		
49429		Removal of shunt			11.35	5.65	5.65		
49491		Rpr hem preemie, blocked			9.62	4.82	4.82		
49492		Rpr ing hernia baby, reduc			0.89	0.48	0.48		
49495		Rpr ing hernia baby, blocked			6.05	3.29	3.29		
49496		Rpr ing hernia, init, reduce			7.39	3.44	3.44		
49500		Rpr ing hernia, init, blocked			11.11	5.07	5.07		
49501		Rpr l/hern init reduc>5 yr			14.01	6.14	6.14		
49505		Prp l/hern init block>5 yr			5.88	3.00	3.00		
49520		Rerepair ing hernia, reduce			8.78	4.37	4.37		
49521		Rerepair ing hernia, blocked			5.47	3.15	3.15		
49525		Repair ing hernia, sliding			8.87	4.24	4.24		
49540		Repair lumbar hernia			7.59	3.67	3.67		
49550		Rpr fem hernia, init, reduce			9.56	4.54	4.54		
49553		Rpr fem hernia, init blocked			9.62	4.49	4.49		
49555		Rerepair fem hernia, reduce			11.95	5.28	5.28		
49557		Rerepair fem hernia, blocked			8.56	4.13	4.13		
					10.37	4.91	4.91		
					3.62	4.16	4.16		
					9.43	4.46	4.46		
					9.02	4.32	4.32		
					11.13	5.03	5.03		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 81 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
49580		Rpr ventral hern init, reduc	Surgery		11.55	5.21	5.21		
49581		Rpr ventral hern init, block	Surgery		14.23	6.11	6.11		
49585		Rerepair ventrl hern, reduce	Surgery		11.55	5.28	5.28		
49586		Rerepair ventrl hern, block	Surgery		14.38	6.18	6.18		
49588		Hernia repair w/mesh	Surgery		4.88	1.68	1.68		
49570		Rpr epigastric hern, reduce	Surgery		5.68	3.20	3.20		
49572		Rpr epigastric hern, blocked	Surgery		6.72	3.50	3.50		
49560		Rpr umbil hern, reduc < 5 yr	Surgery		4.10	2.64	2.64		
49582		Rpr umbil hern, block < 5 yr	Surgery		6.64	3.53	3.53		
49585		Rpr umbil hern, reduc > 5 yr	Surgery		6.22	3.35	3.35		
49587		Rpr umbil hern, block > 5 yr	Surgery		7.55	3.78	3.78		
49590		Repair spigillian hernia	Surgery		8.53	4.13	4.13		
49600		Repair umbilical lesion	Surgery		10.94	5.39	5.39		
49605		Repair umbilical lesion	Surgery		75.89	28.65	28.65		
49606		Repair umbilical lesion	Surgery		18.57	7.77	7.77		
49610		Repair umbilical lesion	Surgery		10.48	5.26	5.26		
49611		Repair umbilical lesion	Surgery		8.91	7.25	7.25		
49650		Laparo hernia repair initial	Surgery		6.26	3.23	3.23		
49651		Laparo hernia repair recur	Surgery		8.23	4.09	4.09		
49659		Laparo proc, hernia repair	Surgery					9.49	Misc.
49900		Repair of abdominal wall	Surgery		12.26	6.28	6.28		
49904		Omental flap, extra-abdom	Surgery		19.97	15.52	15.52		
49905		Omental flap, intra-abdom	Surgery		6.54	2.30	2.30		
49999		Abdomen surgery procedure	Surgery					11.47	Misc.
50010		Exploration of kidney	Surgery		10.96	5.42	5.42		
50020		Renal abscess, open drain	Surgery		14.64	8.81	8.81		
50021		Renal abscess, percut drain	Surgery		3.37	1.11	1.11		
50040		Drainage of kidney	Surgery		14.92	8.42	8.42		
50045		Exploration of kidney	Surgery		15.44	6.80	6.80		
50060		Removal of kidney stone	Surgery		19.27	8.03	8.03		
50065		Incision of kidney	Surgery		20.76	6.24	6.24		
50070		Incision of kidney	Surgery		20.29	8.42	8.42		
50075		Removal of kidney stone	Surgery		25.30	10.19	10.19		
50080		Removal of kidney stone	Surgery		14.69	7.85	7.85		
50081		Removal of kidney stone	Surgery		21.77	10.35	10.35		
50100		Revis kidney blood vessels	Surgery		16.07	7.99	7.99		
50120		Exploration of kidney	Surgery		15.89	6.97	6.97		
50125		Explore and drain kidney	Surgery		16.50	7.12	7.12		
50130		Removal of kidney stone	Surgery		17.26	7.38	7.38		
50135		Exploration of kidney	Surgery		19.15	7.98	7.98		
50200		Bopsy of kidney	Surgery		2.63	0.90	0.90		
50205		Biopsy of kidney	Surgery		11.29	5.24	5.24		
50220		Remove kidney, open	Surgery		17.12	7.44	7.44		
50225		Remove kidney open, complex	Surgery		20.20	8.36	8.36		
50230		Remove kidney open, radical	Surgery		22.04	8.83	8.83		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 82 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
50234		Removal of kidney & ureter	Surgery		22.37	9.04	9.04		
50236		Removal of kidney & ureter	Surgery		24.82	11.41	11.41		
50240		Partial removal of kidney	Surgery		21.97	10.50	10.50		
50280		Removal of kidney lesion	Surgery		15.65	6.89	6.89		
50290		Removal of kidney lesion	Surgery		14.71	6.65	6.65		
50300		Removal of donor kidney	Surgery						
50320		Removal of donor kidney	Surgery						
50340		Removal of kidney	Surgery		22.18	9.96	9.96	26.89	MDR
50360		Transplantation of kidney	Surgery		12.13	6.93	6.93		
50365		Transplantation of kidney	Surgery		31.48	15.76	15.76		
50370		Remove transplanted kidney	Surgery		36.75	18.55	18.55		
50380		Reimplantation of kidney	Surgery		13.70	7.52	7.52		
50390		Drainage of kidney lesion	Surgery		20.73	13.26	13.26		
50392		Insert kidney drain	Surgery		1.96	0.64	0.64		
50393		Insert ureteral tube	Surgery		3.37	1.11	1.11		
50394		Injection for kidney x-ray	Surgery		4.15	1.35	1.35		
50395		Create passage to kidney	Surgery		0.76	0.25	0.25		
50396		Measure kidney pressure	Surgery		3.37	1.10	1.10		
50398		Change kidney tube	Surgery		2.09	0.86	0.86		
50400		Revision of kidney/ureter	Surgery		1.46	0.47	0.47		
50405		Revision of kidney/ureter	Surgery		19.47	7.72	7.72		
50500		Repair of kidney wound	Surgery		23.89	10.41	10.41		
50520		Close kidney-skin fistula	Surgery		19.54	8.77	8.77		
50525		Repair renal-abdomen fistula	Surgery		17.20	8.75	8.75		
50526		Repair renal-abdomen fistula	Surgery		22.24	10.16	10.16		
50540		Revision of horseshoe kidney	Surgery		23.98	10.88	10.88		
50541		Laparo ablate renal cyst	Surgery		19.90	8.55	8.55		
50542		Laparo ablate renal mass	Surgery		15.99	6.41	6.41		
50543		Laparo partial nephrectomy	Surgery		19.97	8.13	8.13		
50544		Laparoscopy, pyeloplasty	Surgery		25.46	10.27	10.27		
50545		Laparo radical nephrectomy	Surgery		22.37	8.47	8.47		
50546		Laparoscopic nephrectomy	Surgery		23.96	9.12	9.12		
50547		Laparo removal donor kidney	Surgery		20.45	8.30	8.30		
50548		Laparo remove k/ureter	Surgery		25.46	10.44	10.44		
50549		Laparoscopy proc, renal	Surgery		24.36	9.11	9.11	28.75	Misc.
50551		Kidney endoscopy	Surgery						
50553		Kidney endoscopy	Surgery						
50555		Kidney endoscopy & biopsy	Surgery		5.59	1.80	1.80		
50557		Kidney endoscopy & treatment	Surgery		5.98	1.95	1.95		
50559		Renal endoscopy/radiotracer	Surgery		6.52	2.11	2.11		
50561		Renal endoscopy & treatment	Surgery		6.61	2.12	2.12		
50562		Renal scope w/tumor resect	Surgery		6.77	2.19	2.19		
50570		Kidney endoscopy	Surgery		7.58	2.44	2.44		
50572		Kidney endoscopy	Surgery		10.90	3.84	3.84		
50574		Kidney endoscopy & biopsy	Surgery		9.53	3.06	3.06		
		Kidney endoscopy & biopsy	Surgery		10.33	3.33	3.33		
		Kidney endoscopy & biopsy	Surgery		11.00	3.57	3.57		

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 83 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
50575		Kidney endoscopy	Surgery		13.96	4.48	4.48		
50576		Kidney endoscopy & treatment	Surgery		10.97	3.51	3.51		
50578		Renal endoscopy/radiotracer	Surgery		11.33	3.64	3.64		
50580		Kidney endoscopy & treatment	Surgery		11.64	3.80	3.80		
50590		Fragmenting of kidney stone	Surgery		9.08	5.03	10.77		
50600		Exploration of ureter	Surgery		15.82	6.99	6.99		
50605		Insert ureteral support	Surgery		15.44	7.00	7.00		
50610		Removal of ureter stone	Surgery		15.90	7.24	7.24		
50620		Removal of ureter stone	Surgery		15.14	6.62	6.62		
50630		Removal of ureter stone	Surgery		14.92	6.56	6.56		
50650		Removal of ureter	Surgery		17.38	7.50	7.50		
50660		Removal of ureter	Surgery		19.52	8.24	8.24		
50684		Injection for ureter x-ray	Surgery		0.76	0.25	15.38		
50686		Measure ureter pressure	Surgery		1.51	0.65	4.56		
50688		Change of ureter tube	Surgery		1.17	1.75			
50690		Injection for ureter x-ray	Surgery		1.16	0.37	15.84		
50700		Revision of ureter	Surgery		15.19	7.30	7.30		
50715		Release of ureter	Surgery		18.87	9.03	9.03		
50722		Release/revise ureter	Surgery		16.33	8.03	8.03		
50727		Revise ureter	Surgery		18.46	8.31	8.31		
50728		Fusion of ureter & kidney	Surgery		8.17	5.20	5.20		
50740		Fusion of ureter & kidney	Surgery		18.39	7.96	7.96		
50750		Fusion of ureters	Surgery		19.48	8.27	8.27		
50760		Splicing of ureters	Surgery		18.39	7.95	7.95		
50770		Reimplant ureter in bladder	Surgery		19.48	8.25	8.25		
50780		Reimplant ureter in bladder	Surgery		16.33	7.86	7.86		
50782		Reimplant ureter in bladder	Surgery		19.51	9.83	9.83		
50783		Reimplant ureter in bladder	Surgery		20.52	9.35	9.35		
50785		Reimplant ureter in bladder	Surgery		20.49	8.58	8.58		
50800		Implant ureter in bowel	Surgery		14.50	6.99	6.99		
50810		Fusion of ureter & bowel	Surgery		20.02	9.57	9.57		
50815		Urine shunt to intestine	Surgery		19.90	8.93	8.93		
50820		Construct bowel bladder	Surgery		21.86	9.14	9.14		
50825		Construct bowel bladder	Surgery		28.14	11.65	11.65		
50830		Revise urine flow	Surgery		31.23	12.66	12.66		
50840		Replace ureter by bowel	Surgery		19.97	8.93	8.93		
50845		Appendico-vesicostomy	Surgery		20.66	8.87	8.87		
50860		Transplant ureter to skin	Surgery		15.34	6.89	6.89		
50900		Repair of ureter	Surgery		13.60	6.36	6.36		
50920		Closure ureter/skin fistula	Surgery		14.31	6.79	6.79		
50930		Closure ureter/bowel fistula	Surgery		18.69	8.19	8.19		
50940		Release of ureter	Surgery		14.49	6.63	6.63		
50945		Laparoscopy ureterolithotomy	Surgery		16.97	6.96	6.96		
50947		Laparoscopy new ureter/bladder	Surgery		24.46	9.66	9.66		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. --- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 84 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
50948		Laparo new ureter/bladder	Surgery		22.47	8.62	8.62	31.09	Misc.
50949		Laparoscopy proc, ureter	Surgery		5.83	1.87	5.34		
50951		Endoscopy of ureter	Surgery		6.23	2.00	18.61		
50953		Endoscopy of ureter	Surgery		6.74	2.22	20.51		
50955		Ureter endoscopy & biopsy	Surgery		6.78	2.18	18.26		
50957		Ureter endoscopy & treatment	Surgery		4.39	1.37	15.47		
50959		Ureter endoscopy & tracer	Surgery		6.04	1.94	25.47		
50961		Ureter endoscopy & treatment	Surgery		7.13	2.30	2.30		
50970		Ureter endoscopy	Surgery		6.88	2.27	2.27		
50972		Ureter endoscopy & catheter	Surgery		9.16	2.93	2.93		
50974		Ureter endoscopy & biopsy	Surgery		9.03	2.91	2.91		
50976		Ureter endoscopy & treatment	Surgery		5.09	1.67	1.67		
50978		Ureter endoscopy & tracer	Surgery		6.84	2.20	2.20		
50980		Ureter endoscopy & treatment	Surgery		0.78	0.24	1.98		
51000		Drainage of bladder	Surgery		1.02	0.34	4.80		
51005		Drainage of bladder	Surgery		3.52	1.89	5.74		
51010		Incise & treat bladder	Surgery		6.70	3.98	3.98		
51020		Incise & treat bladder	Surgery		6.76	4.09	4.09		
51030		Incise & drain bladder	Surgery		4.39	2.87	2.87		
51040		Incise bladder/drain ureter	Surgery		6.76	4.06	4.06		
51045		Removal of bladder stone	Surgery		6.91	3.75	3.75		
51050		Removal of ureter stone	Surgery		8.84	4.62	4.62		
51060		Remove ureter calculus	Surgery		8.84	4.47	4.47		
51065		Drainage of bladder abscess	Surgery		5.95	3.66	3.66		
51080		Removal of bladder cyst	Surgery		10.12	5.08	5.08		
51500		Removal of bladder lesion	Surgery		9.28	4.79	4.79		
51525		Removal of bladder lesion	Surgery		13.95	6.25	6.25		
51530		Repair of ureter lesion	Surgery		12.36	5.87	5.87		
51550		Partial removal of bladder	Surgery		12.55	6.23	6.23		
51555		Partial removal of bladder	Surgery		15.64	6.86	6.86		
51565		Revise bladder & ureter(s)	Surgery		21.20	8.81	8.81		
51570		Removal of bladder	Surgery		24.20	9.94	9.94		
51575		Removal of bladder & nodes	Surgery		30.40	12.26	12.26		
51580		Remove bladder/revise tract	Surgery		31.03	12.73	12.73		
51585		Remove bladder & nodes	Surgery		35.18	13.93	13.93		
51590		Remove bladder/revise tract	Surgery		32.61	12.84	12.84		
51595		Remove bladder/revise tract	Surgery		37.08	14.36	14.36		
51596		Remove bladder/create pouch	Surgery		39.46	15.47	15.47		
51597		Removal of pelvic structures	Surgery		38.29	15.07	15.07		
51600		Injection for bladder x-ray	Surgery		0.88	0.29	5.85		
51605		Preparation for bladder x-ray	Surgery		0.64	0.35	10.80		
51610		Injection for bladder x-ray	Surgery		1.05	0.60	1.72		
51700		Irrigation of bladder	Surgery		0.88	0.28	1.65		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 85 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
51701		Insert bladder catheter			0.50	0.19	1.64		
51702		Insert temp bladder cath			0.50	0.26			
51703		Insert bladder cath, complex			1.47	0.57	3.05		
51705		Change of bladder tube			1.02	0.61	2.34		
51710		Change of bladder tube			1.49	0.77	3.43		
51715		Endoscopic injection/implant			3.73	1.35	4.01		
51720		Treatment of bladder lesion			1.96	0.71	1.79		
51725	26	Simple cystometrogram			1.51	0.49	0.49		
51726	TC	Simple cystometrogram		a	0.00	5.28	5.28		
51726	TC	Complex cystometrogram		a	1.71	0.56	0.56		
51726	TC	Complex cystometrogram		a	0.00	7.28	7.28		
51736	26	Urine flow measurement			0.61	0.20	0.20		
51736	TC	Urine flow measurement		a	0.00	0.38	0.38		
51736	TC	Urine flow measurement		a	1.14	0.37	0.37		
51741	26	Electro-uroflowmetry, first			0.00	0.43	0.43		
51741	TC	Electro-uroflowmetry, first		a	1.61	0.55	0.55		
51772	26	Urethra pressure profile			0.00	5.23	5.23		
51772	TC	Urethra pressure profile		a	1.53	0.50	0.50		
51784	26	Anall/urinary muscle study			0.00	3.61	3.61		
51784	TC	Anall/urinary muscle study		a	1.53	0.50	0.50		
51785	26	Anall/urinary muscle study			0.00	4.12	4.12		
51785	TC	Anall/urinary muscle study		a	1.10	0.41	0.41		
51785	TC	Anall/urinary muscle study		a	0.00	5.57	5.57		
51792	26	Urinary reflex study			1.53	0.50	0.50		
51792	TC	Urinary reflex study		a	0.00	4.12	4.12		
51795	26	Urine voiding pressure study			1.10	0.41	0.41		
51795	TC	Urine voiding pressure study		a	0.00	5.57	5.57		
51795	TC	Urine voiding pressure study		a	1.60	0.52	0.52		
51797	26	Intraabdominal pressure test			0.00	5.43	5.43		
51797	TC	Intraabdominal pressure test		a	0.00	0.36	0.36		
51797	TC	Intraabdominal pressure test		a	17.39	7.69	7.69		
51798		Revision of bladder/urethra			17.86	8.46	8.46		
51800		Revision of urinary tract			10.89	5.57	5.57		
51820		Attach bladder/urethra			13.01	6.37	6.37		
51840		Attach bladder/urethra			9.72	4.87	4.87		
51841		Repair bladder neck			12.00	5.90	5.90		
51845		Repair of bladder wound			15.02	6.83	6.83		
51865		Repair of bladder wound			7.65	4.07	4.07		
51880		Repair of bladder/vagina lesion			12.95	6.22	6.22		
51900		Close bladder-uterus fistula			11.79	5.75	5.75		
51920		Hysterectomy/bladder repair			15.56	8.62	8.62		
51925		Correction of bladder defect			28.39	12.36	12.36		
51940		Revision of bladder & bowel			22.98	9.87	9.87		
51960		Construct bladder opening			11.34	5.49	5.49		
51980		Laparo urethral suspension			12.48	6.18	6.18		
51990		Laparo sling operation			13.99	6.24	6.24		
51992		Cystoscopy			2.01	0.76	0.76		
52000		Cystoscopy							

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 86 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
52001		Cystoscopy, removal of clots			5.44	1.87	5.18		
52005		Cystoscopy & ureter catheter			2.37	0.90	5.98		
52007		Cystoscopy and biopsy			3.02	1.15	1.15		
52010		Cystoscopy & duct catheter			3.02	1.13	1.13		
52024		Cystoscopy			3.02	0.91	3.63		
52214		Cystoscopy and treatment			3.70	1.33	1.33		
52224		Cystoscopy and treatment			3.14	1.15	1.15		
52234		Cystoscopy and treatment			4.62	1.63	1.63		
52235		Cystoscopy and treatment			5.44	1.90	1.90		
52240		Cystoscopy and treatment			9.71	3.30	3.30		
52250		Cystoscopy and radiotracer			4.49	1.66	1.66		
52260		Cystoscopy and treatment			3.91	1.43	1.43		
52265		Cystoscopy and treatment			2.94	1.12	3.75		
52270		Cystoscopy & revise urethra			3.36	1.25	1.25		
52275		Cystoscopy & revise urethra			4.69	1.67	1.67		
52276		Cystoscopy and treatment			4.99	1.79	1.79		
52277		Cystoscopy and treatment			6.16	2.26	2.26		
52281		Cystoscopy and treatment			2.80	1.08	7.43		
52282		Cystoscopy, implant stent			6.39	2.24	2.24		
52283		Cystoscopy and treatment			3.73	1.39	4.03		
52285		Cystoscopy and treatment			3.60	1.34	4.10		
52290		Cystoscopy and treatment			4.56	1.66	1.66		
52300		Cystoscopy and treatment			5.30	1.91	1.91		
52301		Cystoscopy and treatment			5.50	2.00	2.00		
52305		Cystoscopy and treatment			5.30	1.86	1.86		
52310		Cystoscopy and treatment			2.81	1.04	3.53		
52315		Cystoscopy and treatment			5.20	1.84	1.84		
52317		Remove bladder stone			6.71	2.28	2.28		
52318		Remove bladder stone			9.18	3.10	3.10		
52320		Cystoscopy and treatment			4.69	1.64	1.64		
52325		Cystoscopy, stone removal			6.15	2.11	2.11		
52327		Cystoscopy, inject material			5.18	1.83	1.83		
52330		Cystoscopy and treatment			5.03	1.76	1.76		
52332		Cystoscopy and treatment			2.83	1.06	1.06		
52334		Create passage to kidney			4.82	1.76	1.76		
52341		Cysto w/ureter stricture tx			5.99	2.22	2.22		
52342		Cysto w/up stricture tx			6.49	2.35	2.35		
52343		Cysto w/renal stricture tx			7.19	2.59	2.59		
52344		Cysto/uretero, stone remove			7.69	2.80	2.80		
52345		Cysto/uretero w/up stricture			8.19	2.96	2.96		
52346		Cystouretero w/renal strict			9.22	3.29	3.29		
52347		Cystoscopy, resect ducts			5.27	1.71	1.71		
52351		Cystouretero & or pyeloscopy			5.85	2.14	2.14		
52352		Cystouretero w/stone remove			6.87	2.51	2.51		
52353		Cystouretero w/lithotripsy			7.96	2.86	2.86		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 87 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
52354		Cystouretero w/biopsy	Surgery		7.33	2.67	2.67	2.67	
52355		Cystouretero w/excise tumor	Surgery		8.81	3.15	3.15	3.15	
52400		Cystouretero w/congen repr	Surgery		9.67	3.78	3.78	3.78	
52450		Incision of prostate	Surgery		7.63	3.71	3.71	3.71	
52600		Revision of bladder neck	Surgery		8.46	3.96	3.96	3.96	
52510		Dilation prostatic urethra	Surgery		6.71	3.14	3.14	3.14	
52601		Prostatectomy (TURP)	Surgery		12.35	5.15	5.15	5.15	
52606		Control postop bleeding	Surgery		8.12	3.58	3.58	3.58	
52612		Prostatectomy, first stage	Surgery		7.97	3.77	3.77	3.77	
52614		Prostatectomy, second stage	Surgery		6.83	3.38	3.38	3.38	
52620		Remove residual prostate	Surgery		6.60	3.01	3.01	3.01	
52630		Remove prostate regrowth	Surgery		7.25	3.22	3.22	3.22	
52640		Relieve bladder contracture	Surgery		6.61	2.98	2.98	2.98	
52647		Laser surgery of prostate	Surgery		10.34	4.57	4.57	4.57	
52648		Laser surgery of prostate	Surgery		11.19	4.84	4.84	4.84	
52700		Drainage of prostatic abscess	Surgery		3.21	3.21	3.21	3.21	
53000		Incision of urethra	Surgery		2.28	1.57	1.57	1.57	
53010		Incision of urethra	Surgery		3.63	3.02	3.02	3.02	
53020		Incision of urethra	Surgery		1.77	0.67	0.67	0.67	
53025		Incision of urethra	Surgery		1.13	0.51	0.51	0.51	
53040		Drainage of urethra abscess	Surgery		6.33	6.33	6.33	6.33	
53060		Drainage of urethra abscess	Surgery		2.63	1.45	1.45	1.45	
53080		Drainage of urinary leakage	Surgery		6.28	6.17	6.17	6.17	
53085		Drainage of urinary leakage	Surgery		10.25	7.63	7.63	7.63	
53200		Biopsy of urethra	Surgery		2.59	0.98	0.98	0.98	
53210		Removal of urethra	Surgery		12.55	5.98	5.98	5.98	
53215		Removal of urethra	Surgery		15.56	6.77	6.77	6.77	
53220		Treatment of urethra lesion	Surgery		6.99	3.84	3.84	3.84	
53230		Removal of urethra lesion	Surgery		9.57	4.84	4.84	4.84	
53235		Removal of urethra lesion	Surgery		10.12	5.02	5.02	5.02	
53240		Surgery for urethra pouch	Surgery		6.44	3.64	3.64	3.64	
53250		Removal of urethra gland	Surgery		5.88	3.38	3.38	3.38	
53255		Treatment of urethra lesion	Surgery		2.98	1.80	1.80	1.80	
53260		Removal of urethra gland	Surgery		3.12	1.84	1.84	1.84	
53270		Repair of urethra defect	Surgery		3.09	1.87	1.87	1.87	
53275		Revis urethra, stage 1	Surgery		4.52	2.28	2.28	2.28	
53400		Revis urethra, stage 2	Surgery		12.75	6.10	6.10	6.10	
53405		Reconstruction of urethra	Surgery		14.46	6.45	6.45	6.45	
53410		Reconstruction of urethra	Surgery		16.42	7.20	7.20	7.20	
53415		Reconstruct urethra, stage 1	Surgery		19.38	7.47	7.47	7.47	
53420		Reconstruct urethra, stage 2	Surgery		14.06	6.45	6.45	6.45	
53425		Reconstruct urethra, stage 2	Surgery		15.96	7.05	7.05	7.05	
53430		Reconstruction of urethra	Surgery		16.32	7.13	7.13	7.13	
53431		Reconstruct urethra/bladder	Surgery		19.86	8.17	8.17	8.17	
53440		Male sling procedure	Surgery		13.60	6.04	6.04	6.04	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 88 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
53442		Remove/revise male sling	Surgery		11.55	5.51	5.51		
53444		Insert landom cuff	Surgery		13.38	5.91	5.91		
53445		Insert uro/ves rck sphincter	Surgery		14.04	7.26	7.26		
53446		Remove uro sphincter	Surgery		10.21	5.27	5.27		
53447		Remove/replace ur sphincter	Surgery		13.47	6.48	6.48		
53448		Remov/replic ur sphinctr comp	Surgery		21.12	9.13	9.13		
53449		Repair uro sphincter	Surgery		9.69	4.85	4.85		
53450		Revision of urethra	Surgery		6.13	3.40	3.40		
53460		Revision of urethra	Surgery		7.11	3.82	3.82		
53500		Urethrys, transvag w/ scope	Surgery		12.19	6.19	6.19		
53502		Repair of urethra injury	Surgery		7.62	4.11	4.11		
53505		Repair of urethra injury	Surgery		7.62	3.99	3.99		
53510		Repair of urethra injury	Surgery		10.09	5.29	5.29		
53515		Repair of urethra injury	Surgery		13.29	6.05	6.05		
53520		Repair of urethra defect	Surgery		8.67	4.60	4.60		
53600		Dilate urethra stricture	Surgery		1.21	0.43	1.17		
53601		Dilate urethra stricture	Surgery		0.98	0.38	1.30		
53605		Dilate urethra stricture	Surgery		1.28	0.41	0.41		
53620		Dilate urethra stricture	Surgery		1.62	0.60	2.04		
53621		Dilate urethra stricture	Surgery		1.35	0.50	2.13		
53660		Dilation of urethra	Surgery		0.71	0.33	1.34		
53661		Dilation of urethra	Surgery		0.72	0.30	1.34		
53665		Dilation of urethra	Surgery		0.76	0.26	0.26		
53850		Prostatic microwave thermolx	Surgery		9.44	4.30	97.84		
53852		Prostatic rf thermolx	Surgery		9.87	4.69	93.04		
53853		Prostatic water thermolther	Surgery		5.23	3.18	57.88		Misc.
53899		Urology surgery procedure	Surgery					4.60	
54000		Slitting of prepuce	Surgery		1.54	1.33	1.33		
54001		Slitting of prepuce	Surgery		2.19	1.51	4.30		
54015		Drain penis lesion	Surgery		5.31	2.59	2.59		
54050		Destruction, penis lesion(s)	Surgery		1.24	1.05	1.69		
54055		Destruction, penis lesion(s)	Surgery		1.22	0.80	1.60		
54056		Cryosurgery, penis lesion(s)	Surgery		1.24	1.35	2.48		
54057		Laser surg, penis lesion(s)	Surgery		1.24	0.87	0.87		
54060		Excision of penis lesion(s)	Surgery		1.93	1.45	3.88		
54065		Destruction, penis lesion(s)	Surgery		2.42	1.72	1.72		
54100		Blopsy of penis	Surgery		1.90	0.82	2.87		
54105		Blopsy of penis	Surgery		3.49	1.96	1.96		
54110		Treatment of penis lesion	Surgery		10.11	5.64	5.64		
54111		Treat penis lesion, graft	Surgery		13.55	6.69	6.69		
54112		Treat penis lesion, graft	Surgery		15.84	7.69	7.69		
54115		Treatment of penis lesion	Surgery		6.14	4.47	8.53		
54120		Partial removal of penis	Surgery		9.96	5.80	5.80		
54125		Removal of penis	Surgery		13.51	6.75	6.75		
54130		Remove penis & nodes	Surgery		20.11	9.10	9.10		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 89 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
54135		Remove penis & nodes	Surgery		26.32	11.10	11.10		
54150		Circumcision	Surgery		1.81	0.97	0.97		
54152		Circumcision	Surgery		2.31	1.20	1.20		
54160		Circumcision	Surgery		2.48	1.11	1.11		
54161		Circumcision	Surgery		3.27	1.57	1.57		
54162		Lysis penil circumc lesion	Surgery		3.00	2.00	2.00		
54163		Repair of circumcision	Surgery		3.00	2.01	2.01		
54164		Frenulotomy of penis	Surgery		2.50	1.85	1.85		
54200		Treatment of penis lesion	Surgery		1.06	0.99	0.99		
54205		Treatment of penis lesion	Surgery		7.92	4.83	4.83		
54220		Treatment of penis lesion	Surgery		2.42	0.96	0.96		
54230		Prepare penis study	Surgery		1.34	0.87	0.87		
54231		Dynamic cavernosometry	Surgery		2.04	0.87	1.40		
54235		Penile injection	Surgery		1.19	0.58	0.98		
54240	TC	Penis study	Surgery		1.31	0.42	0.42		
54240	TC	Penis study	Surgery	a	0.00	0.59	0.59		
54250	TC	Penis study	Surgery		2.22	0.71	0.71		
54250	TC	Penis study	Surgery	a	0.00	0.22	0.22		
54300		Revision of penis	Surgery		10.39	5.75	5.75		
54304		Revision of penis	Surgery		12.47	6.54	6.54		
54312		Reconstruction of urethra	Surgery		11.81	6.17	6.17		
54308		Reconstruction of urethra	Surgery		13.55	7.20	7.20		
54316		Reconstruction of urethra	Surgery		16.79	8.15	8.15		
54318		Reconstruction of urethra	Surgery		11.23	6.00	6.00		
54322		Reconstruction of urethra	Surgery		12.99	6.63	6.63		
54326		Reconstruction of urethra	Surgery		16.29	8.22	8.22		
54324		Reconstruction of urethra	Surgery		15.70	8.00	8.00		
54328		Reconstruction of urethra	Surgery		15.63	7.45	7.45		
54326		Reconstruct urethra	Surgery		17.05	7.93	7.93		
54332		Revise penis/urethra	Surgery		20.01	10.71	10.71		
54336		Revise penis/urethra	Surgery		8.90	5.25	5.25		
54340		Secondary urethral surgery	Surgery		15.92	7.97	7.97		
54344		Secondary urethral surgery	Surgery		17.12	8.60	8.60		
54348		Reconstruct urethral/penis	Surgery		24.70	11.50	11.50		
54352		Penis plastic surgery	Surgery		11.91	6.19	6.19		
54360		Repair penis	Surgery		13.16	6.83	6.83		
54380		Repair penis	Surgery		15.37	8.49	8.49		
54385		Repair penis and bladder	Surgery		21.58	9.61	9.61		
54390		Insert semi-rigid prosthesis	Surgery		8.98	4.47	4.47		
54400		Insert self-conitd prosthesis	Surgery		10.26	5.83	5.83		
54401		Insert multi-comp penis pros	Surgery		13.41	6.06	6.06		
54405		Remove multi-comp penis pros	Surgery		12.08	5.46	5.46		
54406		Repair multi-comp penis pros	Surgery		12.73	5.77	5.77		
54408		Remove/replace penis prosth	Surgery		15.48	6.66	6.66		
54410		Remove/replace penis prosth	Surgery		15.98	7.09	7.09		
54411		Remove/repic penis pros, comp	Surgery						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 90 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
54415		Remove self-cont'd penis pros	Surgery		8.19	4.22	4.22		
54416		Remv/repl penis contain pros	Surgery		10.85	5.41	5.41		
54417		Remv/repl penis pros, compl	Surgery		14.17	6.21	6.21		
54420		Revision of penis	Surgery		11.40	5.71	5.71		
54430		Revision of penis	Surgery		10.13	5.25	5.25		
54435		Revision of penis	Surgery		6.11	3.73	3.73		
54440		Repair of penis	Surgery					14.95	MDR
54450		Preputial stretching	Surgery		1.12	0.47	0.47		
54500		Biopsy of testis	Surgery		1.31	0.56	0.56		
54505		Biopsy of testis	Surgery		3.45	1.93	1.93		
54512		Excise lesion testis	Surgery		8.57	4.15	4.15		
54520		Removal of testis	Surgery		5.22	2.85	2.85		
54522		Orchiectomy, partial	Surgery		9.49	4.91	4.91		
54530		Removal of testis	Surgery		8.57	4.31	4.31		
54535		Extensive testis surgery	Surgery		12.14	5.66	5.66		
54550		Exploration for testis	Surgery		7.77	3.90	3.90		
54560		Exploration for testis	Surgery		11.11	5.28	5.28		
54600		Reduce testis torsion	Surgery		7.00	3.61	3.61		
54620		Suspension of testis	Surgery		4.89	2.47	2.47		
54640		Suspension of testis	Surgery		6.89	3.80	3.80		
54650		Orchiopexy (Fowler-Stephens)	Surgery		11.43	5.52	5.52		
54660		Revision of testis	Surgery		5.10	3.05	3.05		
54670		Repair testis injury	Surgery		6.40	3.61	3.61		
54680		Relocation of testis(es)	Surgery		12.63	6.29	6.29		
54690		Laparoscopy, orchiectomy	Surgery		10.94	5.06	5.06		
54692		Laparoscopy, orchiopexy	Surgery		12.86	5.45	5.45		
54699		Laparoscopy proc, testis	Surgery					18.31	Misc.
54700		Drainage of scrotum	Surgery		3.42	1.95	1.95		
54800		Biopsy of epididymis	Surgery		2.33	0.90	0.90		
54820		Exploration of epididymis	Surgery		5.13	3.00	3.00		
54830		Remove epididymis lesion	Surgery		5.37	3.08	3.08		
54840		Remove epididymis lesion	Surgery		5.19	2.84	2.84		
54860		Removal of epididymis	Surgery		6.31	3.37	3.37		
54861		Removal of epididymis	Surgery		8.89	4.38	4.38		
54900		Fusion of spermatic ducts	Surgery		13.18	5.86	5.86		
54901		Fusion of spermatic ducts	Surgery		17.91	7.56	7.56		
55000		Drainage of hydrocele	Surgery		1.43	0.65	0.65		
55040		Removal of hydrocele	Surgery		5.35	2.96	2.96		
55041		Removal of hydrocele	Surgery		7.73	4.04	4.04		
55060		Repair of hydrocele	Surgery		5.51	3.13	3.13		
55100		Drainage of scrotum abscess	Surgery		2.13	1.59	1.59		
55110		Explore scrotum	Surgery		5.69	3.18	3.18		
55120		Removal of scrotum lesion	Surgery		5.08	2.98	2.98		
55150		Removal of scrotum	Surgery		7.21	3.96	3.96		
55175		Revision of scrotum	Surgery		5.23	3.06	3.06		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 91 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
55160		Revision of scrotum	Surgery		10.70	5.46	5.46		
55200		Incision of sperm duct	Surgery		4.23	2.41	5.53		
55250		Removal of sperm duct(s)	Surgery		3.29	2.78	9.07		
55300		Prepare, sperm duct x-ray	Surgery		3.50	1.31	1.31		
55400		Repair of sperm duct	Surgery		8.48	4.17	4.17		
55450		Ligation of sperm duct	Surgery		4.11	1.87	7.21		
55500		Removal of hydrocele	Surgery		5.58	3.15	3.15		
55520		Removal of sperm cord lesion	Surgery		6.02	3.31	3.31		
55530		Revise spermatic cord veins	Surgery		5.65	3.07	3.07		
55535		Revise spermatic cord veins	Surgery		6.55	3.45	3.45		
55540		Revise hernia & sperm veins	Surgery		7.66	3.86	3.86		
55550		Laparo ligate spermatic vein	Surgery		6.56	3.32	3.32		
55559		Laparo proc. spermatic cord	Surgery					9.88	Misc.
55600		Incise sperm duct pouch	Surgery		6.37	3.39	3.39		
55605		Incise sperm duct pouch	Surgery		7.95	4.36	4.36		
55650		Remove sperm duct pouch	Surgery		11.78	5.35	5.35		
55680		Remove sperm pouch lesion	Surgery		5.18	3.03	3.03		
55700		Biopsy of prostate	Surgery		1.57	0.71	4.33		
55705		Biopsy of prostate	Surgery		4.56	2.32	2.32		
55720		Drainage of prostate abscess	Surgery		7.63	3.95	3.95		
55725		Drainage of prostate abscess	Surgery		8.67	4.62	4.62		
55801		Removal of prostate	Surgery		17.77	7.38	7.38		
55810		Extensive prostate surgery	Surgery		22.55	8.71	8.71		
55812		Extensive prostate surgery	Surgery		27.47	11.14	11.14		
55815		Extensive prostate surgery	Surgery		30.41	12.07	12.07		
55821		Removal of prostate	Surgery		14.23	6.32	6.32		
55831		Removal of prostate	Surgery		15.60	6.77	6.77		
55840		Extensive prostate surgery	Surgery		22.66	9.44	9.44		
55842		Extensive prostate surgery	Surgery		24.34	10.01	10.01		
55845		Extensive prostate surgery	Surgery		28.51	11.11	11.11		
55859		Percut/needle insert, pros	Surgery		12.50	5.91	5.91		
55860		Surgical exposure, prostate	Surgery		14.43	6.44	6.44		
55862		Extensive prostate surgery	Surgery		18.36	7.96	7.96		
55865		Extensive prostate surgery	Surgery		22.84	9.38	9.38		
55866		Laparo radical prostatectomy	Surgery		30.69	11.81	11.81		
55870		Vag hyst w/enterocele repair	Surgery		2.58	1.09	1.54		
55873		Cryoablate prostate	Surgery		19.44	9.02	9.02		Misc.
55899		Genital surgery procedure	Surgery		1.44	1.15	1.33		
56405		I & D of vulva/perineum	Surgery		1.39	1.09	2.29		
56420		Drainage of gland abscess	Surgery		2.84	1.71	1.71		
56440		Surgery for vulva lesion	Surgery		1.97	1.42	1.83		
56441		Lysis of labial lesion(s)	Surgery		1.53	1.25	1.79		
56501		Destroy, vulva lesions, firm	Surgery		2.76	1.81	2.55		
56515		Destroy vulva lesion's compl	Surgery		1.10	0.46	1.09		
56605		Biopsy of vulva/perineum	Surgery					4.69	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 92 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
56605		Biopsy of vulva/perineum	Surgery		0.55	0.22	0.49		
56620		Partial removal of vulva	Surgery		7.46	4.84	4.84		
56625		Complete removal of vulva	Surgery		8.39	5.39	5.39		
56630		Extensive vulva surgery	Surgery		12.34	6.96	6.96		
56631		Extensive vulva surgery	Surgery		16.18	8.96	8.96		
56632		Extensive vulva surgery	Surgery		20.26	9.62	9.62		
56633		Extensive vulva surgery	Surgery		16.45	8.70	8.70		
56634		Extensive vulva surgery	Surgery		17.85	9.59	9.59		
56637		Extensive vulva surgery	Surgery		21.94	11.23	11.23		
56640		Extensive vulva surgery	Surgery		22.14	10.80	10.80		
56700		Partial removal of hymen	Surgery		2.52	1.73	1.73		
56720		Incision of hymen	Surgery		0.68	0.39	0.39		
56740		Remove vagina gland lesion	Surgery		4.56	2.47	2.47		
56800		Repair of vagina	Surgery		3.88	2.19	2.19		
56805		Repair clitoris	Surgery		18.83	9.43	9.43		
56810		Repair of perineum	Surgery		4.12	2.30	2.30		
56820		Exam of vulva w/scope	Surgery		1.50	0.63	0.63		
56821		Exam/biopsy of vulva w/scope	Surgery		2.05	0.90	0.90		
57000		Exploration of vagina	Surgery		2.97	1.73	1.73		
57010		Drainage of pelvic abscess	Surgery		6.02	3.85	3.85		
57020		Drainage of pelvic fluid	Surgery		1.50	0.59	0.59		
57022		I & d vaginal hematoma, pp	Surgery		2.56	1.50	1.50		
57023		I & d vag hematoma, non-ob	Surgery		4.74	2.59	2.59		
57061		Destroy vag lesions, simple	Surgery		1.25	1.12	1.12		
57065		Destroy vag lesions, complex	Surgery		2.61	1.66	1.66		
57100		Biopsy of vagina	Surgery		1.20	0.48	0.48		
57105		Biopsy of vagina	Surgery		1.69	1.32	1.32		
57106		Remove vagina wall, partial	Surgery		6.35	4.20	4.20		
57107		Remove vagina tissue, part	Surgery		22.97	10.50	10.50		
57109		Vaginectomy partial w/nodes	Surgery		26.96	11.34	11.34		
57110		Remove vagina wall, complete	Surgery		14.27	7.31	7.31		
57111		Remove vagina tissue, compl	Surgery		26.96	12.64	12.64		
57112		Vaginectomy w/nodes, compl	Surgery		28.96	12.19	12.19		
57120		Closure of vagina	Surgery		7.40	4.64	4.64		
57130		Remove vagina lesion	Surgery		2.43	1.55	1.55		
57135		Remove vagina lesion	Surgery		2.67	1.66	1.66		
57150		Treat vagina infection	Surgery		0.55	0.22	0.22		
57155		Insert uten tandemers/ovoids	Surgery		6.26	4.17	4.17		
57160		Insert pessary/other device	Surgery		0.89	0.38	0.38		
57170		Fitting of diaphragm/cap	Surgery		0.91	0.34	0.34		
57180		Treat vaginal bleeding	Surgery		1.58	1.29	1.29		
57200		Repair of vagina	Surgery		3.93	2.91	2.91		
57210		Repair vagina/perineum	Surgery		5.16	3.44	3.44		
57220		Revision of urethra	Surgery		4.30	3.12	3.12		
57230		Repair of urethral lesion	Surgery		5.63	3.42	3.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 93 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
57240		Repair bladder & vagina	Surgery		6.06	3.84	3.84		
57250		Repair rectum & vagina	Surgery		5.52	3.59	3.59		
57260		Repair of vagina	Surgery		8.26	4.86	4.86		
57265		Extensive repair of vagina	Surgery		11.32	6.06	6.06		
57268		Repair of bowel bulge	Surgery		6.75	4.21	4.21		
57270		Repair of bowel pouch	Surgery		12.09	6.28	6.28		
57280		Suspension of vagina	Surgery		15.02	7.39	7.39		
57282		Repair of vaginal prolapse	Surgery		8.85	5.32	5.32		
57284		Repair paravaginal defect	Surgery		12.68	7.17	7.17		
57287		Revise/remove sling repair	Surgery		10.69	5.52	5.52		
57288		Repair bladder defect	Surgery		13.00	5.95	5.95		
57289		Repair bladder & vagina	Surgery		11.56	6.07	6.07		
57291		Construction of vagina	Surgery		7.94	4.96	4.96		
57292		Construct vagina with graft	Surgery		13.07	6.98	6.98		
57300		Repair rectum-vagina fistula	Surgery		7.60	4.30	4.30		
57305		Repair rectum-vagina fistula	Surgery		13.75	6.30	6.30		
57307		Fistula repair & colostomy	Surgery		15.91	7.07	7.07		
57308		Fistula repair, transperine	Surgery		9.93	5.15	5.15		
57310		Repair urethrovaginal lesion	Surgery		6.77	3.90	3.90		
57311		Repair urethrovaginal lesion	Surgery		7.97	4.18	4.18		
57320		Repair bladder-vagina lesion	Surgery		8.00	4.43	4.43		
57330		Repair bladder-vagina lesion	Surgery		12.33	5.78	5.78		
57335		Repair vagina	Surgery		18.70	9.10	9.10		
57400		Dilation of vagina	Surgery		2.27	1.13	1.13		
57410		Pelvic examination	Surgery		1.75	0.89	0.89		
57415		Remove vaginal foreign body	Surgery		2.17	1.43	1.43		
57420		Exam of vagina w/scope	Surgery		1.60	0.67	0.67		
57421		Exam/biopsy of vag w/scope	Surgery		2.20	0.96	0.96		
57425		Laparoscopy, surg, colpopexy	Surgery		15.73	6.69	6.69		
57452		Exam of cervix w/scope	Surgery		1.50	0.63	0.63		
57454		Bx/curett of cervix w/scope	Surgery		2.33	1.00	1.00		
57455		Biopsy of cervix w/scope	Surgery		1.99	0.87	0.87		
57456		Endocerv curettage w/scope	Surgery		1.85	0.82	0.82		
57460		Bx of cervix w/scope,leep	Surgery		2.83	1.22	1.22		
57461		Conz of cervix w/scope,leep	Surgery		3.43	1.41	1.41		
57500		Biopsy of cervix	Surgery		0.97	0.47	0.47		
57505		Endocervical curettage	Surgery		1.14	1.10	1.10		
57510		Cauterization of cervix	Surgery		1.90	1.05	1.05		
57511		Cryocautery of cervix	Surgery		1.90	1.38	1.38		
57513		Laser surgery of cervix	Surgery		1.90	1.41	1.41		
57520		Conization of cervix	Surgery		4.03	2.77	2.77		
57522		Conization of cervix	Surgery		3.35	2.67	2.67		
57530		Removal of cervix	Surgery		4.78	3.43	3.43		
57531		Removal of cervix, radical	Surgery		27.96	13.23	13.23		
57540		Removal of residual cervix	Surgery		12.20	6.27	6.27		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 94 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
57545		Remove cervix/repair pelvis	Surgery		13.01	6.70	6.70		
57550		Removal of residual cervix	Surgery		5.52	3.86	3.86		
57555		Remove cervix/repair vagina	Surgery		8.94	5.14	5.14		
57556		Remove cervix, repair bowel	Surgery		8.36	4.88	4.88		
57700		Revision of cervix	Surgery		3.94	3.10	3.10		
57720		Revision of cervix	Surgery		4.12	3.15	3.15		
57800		Dilation of cervical canal	Surgery		0.77	0.47	0.76		
57820		D. & c of residual cervix	Surgery		1.67	1.14	1.49		
58100		Biopsy of uterus lining	Surgery		1.53	0.72	1.33		
58120		Dilation and curettage	Surgery		3.27	1.87	2.31		
58140		Myomectomy abdom method	Surgery		14.58	7.13	7.13		
58145		Myomectomy vag method	Surgery		8.03	4.84	4.84		
58146		Myomectomy abdom complex	Surgery		18.97	8.79	8.79		
58150		Total hysterectomy	Surgery		15.22	7.52	7.52		
58152		Total hysterectomy	Surgery		20.57	9.89	9.89		
58180		Partial hysterectomy	Surgery		15.27	7.49	7.49		
58200		Extensive hysterectomy	Surgery		21.56	10.05	10.05		
58210		Extensive hysterectomy	Surgery		26.81	13.27	13.27		
58240		Removal of pelvis contents	Surgery		38.33	17.72	17.72		
58260		Vaginal hysterectomy	Surgery		12.96	6.72	6.72		
58262		Vag hyst including t/o	Surgery		14.75	7.40	7.40		
58263		Vag hyst w/t/o & vag repair	Surgery		16.04	7.90	7.90		
58267		Vag hyst w/urinary repair	Surgery		17.01	8.42	8.42		
58270		Vag hyst w/enterocle repair	Surgery		14.24	7.10	7.10		
58275		Hysterectomy/revise vagina	Surgery		15.74	7.80	7.80		
58280		Hysterectomy/revise vagina	Surgery		16.98	8.28	8.28		
58285		Extensive hysterectomy	Surgery		22.23	10.02	10.02		
58290		Vag hyst complex	Surgery		18.97	8.92	8.92		
58291		Vag hyst incl t/o, complex	Surgery		20.76	9.89	9.89		
58292		Vag hyst t/o & repair, compl	Surgery		22.05	10.40	10.40		
58293		Vag hyst w/uro repair, compl	Surgery		23.03	10.91	10.91		
58294		Vag hyst w/enterocle, compl	Surgery		20.25	9.68	9.68		
58300		Insert intrauterine device	Surgery		1.01	0.38	1.42		
58301		Remove intrauterine device	Surgery		1.27	0.48	1.33		
58321		Artificial insemination	Surgery		0.92	0.37	1.15		
58322		Artificial insemination	Surgery		1.10	0.41	1.21		
58323		Sperm washing	Surgery		0.23	0.09	0.24		
58340		Catheter for hystero-graphy	Surgery		0.88	0.65	6.08		
58345		Reopen fallopian tube	Surgery		4.65	2.44	2.44		
58346		Insert heyman uter capsule	Surgery		6.74	3.93	3.93		
58350		Reopen fallopian tube	Surgery		1.01	0.93	1.50		
58353		Endometr ablate, thermal	Surgery		3.55	2.05	36.26		
58400		Suspension of uterus	Surgery		6.35	3.97	3.97		
58410		Suspension of uterus	Surgery		12.71	6.48	6.48		
58620		Repair of ruptured uterus	Surgery		11.90	6.07	6.07		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 95 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
58540		Revision of uterus			14.62	6.98	6.98		
58545		Laparoscopic myomectomy			14.58	7.19	7.19		
58546		Laparomyomectomy, complex			18.97	8.98	8.98		
58550		Laparo-assist vag hysterectomy			14.17	7.31	7.31		
58552		Laparo-vag hyst ind w/o			15.98	8.02	8.02		
58553		Laparo-vag hyst, complex			18.97	8.97	8.97		
58554		Laparo-vag hyst w/lo, compl			21.97	10.46	10.46		
58555		Hysteroscopy, dx, sep proc			3.33	1.46	2.10		
58558		Hysteroscopy, biopsy			4.74	2.06	2.06		
58559		Hysteroscopy, lysis			6.16	2.62	2.62		
58560		Hysteroscopy, resect septum			6.99	2.97	2.97		
58561		Hysteroscopy, remove myoma			9.99	4.18	4.18		
58562		Hysteroscopy, remove fb			5.20	2.21	2.21		
58563		Hysteroscopy, ablation			6.16	2.63	2.63		
58578		Laparo proc, uterus						21.48	Misc.
58579		Hysteroscope procedure			5.59	3.36	3.36	6.80	Misc.
58600		Division of fallopian tube			4.99	3.15	3.15		
58605		Division of fallopian tube			1.45	0.57	0.57		
58611		Ligate oviduct(s) add-on			3.89	2.72	2.72		
58615		Occlude fallopian tube(s)			11.27	5.28	5.28		
58660		Laparoscopy, lysis			11.03	5.14	5.14		
58661		Laparoscopy, remove adnexa			11.77	5.80	5.80		
58662		Laparoscopy, excise lesions			5.59	3.28	3.28		
58670		Laparoscopy, tubal cautery			5.59	3.30	3.30		
58671		Laparoscopy, tubal block			12.86	6.23	6.23		
58672		Laparoscopy, fimbrioplasty			13.72	6.63	6.63		
58673		Laparoscopy, salpingostomy							
58679		Laparo proc, oviduct-ovary						16.17	Misc.
58700		Removal of fallopian tube			12.03	6.01	6.01		
58720		Removal of ovary/tube(s)			11.34	5.81	5.81		
58740		Revise fallopian tube(s)			13.98	7.16	7.16		
58750		Repair oviduct			14.82	7.41	7.41		
58752		Revise ovarian tube(s)			14.82	6.99	6.99		
58760		Remove tubal obstruction			13.11	6.75	6.75		
58770		Create new tubal opening			13.95	6.95	6.95		
58800		Drainage of ovarian cyst(s)			4.13	2.99	4.49		
58805		Drainage of ovarian cyst(s)			5.87	3.55	3.55		
58820		Drain ovary abscess, open			4.21	3.34	3.34		
58822		Drain ovary abscess, percut			10.11	5.24	5.24		
58823		Drain pelvic abscess, percut			3.37	1.12	1.12		
58825		Transposition, ovary(s)			10.96	5.82	5.82		
58900		Biopsy of ovary(s)			5.98	3.61	3.61		
58920		Partial removal of ovary(s)			11.34	5.62	5.62		
58925		Removal of ovarian cyst(s)			11.34	5.71	5.71		
58940		Removal of ovary(s)			7.28	4.13	4.13		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 96 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
59943		Removal of ovary(s)	Surgery		18.40	8.75	8.75		
59950		Resect ovarian malignancy	Surgery		16.90	8.50	8.50		
59951		Resect ovarian malignancy	Surgery		22.35	10.55	10.55		
59952		Resect ovarian malignancy	Surgery		24.97	11.85	11.85		
59953		Tah, rad dissect for debulk	Surgery		31.95	14.61	14.61		
59954		Tah rad debulk/lymph remove	Surgery		34.95	15.77	15.77		
59960		Exploration of abdomen	Surgery		14.63	7.45	7.45		
59970		Retrieval of oocyte	Surgery		3.52	1.50	2.32		
59974		Transfer of embryo	Surgery					4.54	MDR
59976		Transfer of embryo	Surgery		3.82	1.83	2.64		
59999		Genital surgery procedure	Surgery						Misc.
59000		Amniocentesis, diagnostic	Maternity — Non-Deliveries		1.30	0.69	2.10		
59001		Amniocentesis, therapeutic	Maternity — Non-Deliveries		3.00	1.41	1.41		
59012		Fetal cord puncture, prenatal	Maternity — Non-Deliveries		3.44	1.56	1.56		
59015		Chorion biopsy	Maternity — Non-Deliveries		2.20	1.06	1.57		
59020	26	Fetal contract stress test	Maternity — Non-Deliveries		0.66	0.27	0.27		
59020	TC	Fetal contract stress test	Maternity — Non-Deliveries	a	0.00	0.52	0.52		
59025	26	Fetal non-stress test	Maternity — Non-Deliveries		0.53	0.21	0.21		
59025	TC	Fetal non-stress test	Maternity — Non-Deliveries	a	0.00	0.24	0.24		
59030		Fetal scalp blood sample	Maternity — Non-Deliveries		1.99	1.05	1.05		
59050		Fetal monitor w/report	Maternity — Non-Deliveries		0.89	0.36	0.36		
59051		Fetal monitor/interpret only	Maternity — Non-Deliveries		0.74	0.30	0.30		
59070		Transabdom amniocent w/ us	Maternity — Non-Deliveries		5.24	2.41	5.12		
59072		Umbilical cord occlud w/ us	Maternity — Non-Deliveries		8.99	3.13	3.13		
59074		Fetal fluid drainage w/ us	Maternity — Non-Deliveries		5.24	2.41	4.61		
59100		Fetal shunt placement, w/ us	Maternity — Non-Deliveries		8.99	3.13	3.13		
59100		Remove uterus lesion	Maternity — Non-Deliveries		12.33	6.48	6.48		
59120		Treat ectopic pregnancy	Maternity — Non-Deliveries		11.47	6.27	6.27		
59121		Treat ectopic pregnancy	Maternity — Non-Deliveries		11.65	6.35	6.35		
59130		Treat ectopic pregnancy	Maternity — Non-Deliveries		14.20	4.99	4.99		
59135		Treat ectopic pregnancy	Maternity — Non-Deliveries		13.86	7.25	7.25		
59136		Treat ectopic pregnancy	Maternity — Non-Deliveries		13.16	6.64	6.64		
59140		Treat ectopic pregnancy	Maternity — Non-Deliveries		5.45	3.59	5.20		
59150		Treat ectopic pregnancy	Maternity — Non-Deliveries		11.65	6.05	6.05		
59151		Treat ectopic pregnancy	Maternity — Non-Deliveries		11.47	6.09	6.09		
59160		Treat ectopic pregnancy	Maternity — Non-Deliveries		2.71	3.27	3.27		
59200		D & c after delivery	Maternity — Non-Deliveries		0.79	0.31	1.20		
59300		Episiotomy or vaginal repair	Maternity — Non-Deliveries		2.41	0.96	2.16		
59320		Revision of cervix	Maternity — Non-Deliveries		2.48	1.26	1.26		
59325		Revision of cervix	Maternity — Non-Deliveries		4.06	1.92	1.92		
59350		Repair of uterus	Maternity — Non-Deliveries		4.94	1.95	1.95		
59400		Obstetrical care	Maternity — Normal Deliveries		23.03	15.48	15.48		
59409		Obstetrical care	Maternity — Normal Deliveries		13.48	5.32	5.32		
59410		Obstetrical care	Maternity — Normal Deliveries		14.76	6.33	6.33		
59412		Antepartum manipulation	Maternity — Normal Deliveries		1.71	0.81	0.81		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFAKS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 97 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
59414		Deliver placenta	Maternity — Normal Deliveries		1.61	0.63	0.63		
59425		Antepartum care only	Maternity — Normal Deliveries		4.80	1.87	4.26		
59426		Antepartum care only	Maternity — Normal Deliveries		8.27	3.23	7.65		
59430		Care after delivery	Maternity — Normal Deliveries		2.13	0.94	1.24		
59510		Cesarean delivery	Maternity — Cesarean Deliveries		26.18	17.43	17.43		
59514		Cesarean delivery only	Maternity — Cesarean Deliveries		15.95	6.23	6.23		
59515		Cesarean delivery	Maternity — Cesarean Deliveries		17.34	7.87	7.87		
59525		Remove uterus after cesarean	Surgery		8.53	3.32	3.32		
59610		Vbac delivery	Maternity — Normal Deliveries		24.58	16.03	16.03		
59612		Vbac delivery only	Maternity — Normal Deliveries		15.04	6.07	6.07		
59614		Vbac care after delivery	Maternity — Normal Deliveries		16.32	6.96	6.96		
59618		Attempted vbac delivery	Maternity — Cesarean Deliveries		27.74	18.43	18.43		
59620		Attempted vbac delivery only	Maternity — Cesarean Deliveries		17.50	6.78	6.78		
59622		Attempted vbac after care	Maternity — Cesarean Deliveries		18.90	8.67	8.67		
59812		Treatment of miscarriage	Maternity — Non-Deliveries		4.00	2.56	2.56		
59820		Care of miscarriage	Maternity — Non-Deliveries		4.00	3.52	3.52		
59821		Treatment of miscarriage	Maternity — Non-Deliveries		4.46	3.45	3.45		
59830		Treat uterus infection	Maternity — Non-Deliveries		6.10	4.01	4.01		
59840		Abortion	Maternity — Non-Deliveries		3.01	2.13	2.13		
59841		Abortion	Maternity — Non-Deliveries		5.23	2.58	2.58		
59850		Abortion	Maternity — Non-Deliveries		5.90	3.27	3.27		
59851		Abortion	Maternity — Non-Deliveries		5.92	3.74	3.74		
59852		Abortion	Maternity — Non-Deliveries		8.23	5.06	5.06		
59855		Abortion	Maternity — Non-Deliveries		6.11	3.56	3.56		
59856		Abortion	Maternity — Non-Deliveries		7.47	4.07	4.07		
59857		Abortion	Maternity — Non-Deliveries		9.28	4.59	4.59		
59866		Abortion (mor)	Maternity — Non-Deliveries		3.99	1.83	1.83		
59870		Evacuate mole of uterus	Maternity — Non-Deliveries		6.00	4.43	4.43		
59871		Remove cerclage suture	Maternity — Non-Deliveries		2.13	1.13	1.13		Misc.
59897		Fetal invas px w/ us	Maternity — Non-Deliveries					0.98	Misc.
59898		Laparo proc, ob care/deliver	Maternity — Non-Deliveries					17.56	Misc.
59899		Maternity care procedure	Maternity — Non-Deliveries					20.51	Misc.
60000		Drain thyroid/tongue cyst	Surgery						
60001		Aspirate/inject thyroid cyst	Surgery						
60100		Biopsy of thyroid	Surgery		1.76	2.04	2.15		
60200		Remove thyroid lesion	Surgery		0.97	0.34	1.49		
60210		Partial thyroid excision	Surgery		1.56	0.53	1.42		
60212		Partial thyroid excision	Surgery		9.54	6.14	6.14		
60220		Partial removal of thyroid	Surgery		10.86	5.78	5.78		
60225		Partial removal of thyroid	Surgery		16.01	7.82	7.82		
60240		Removal of thyroid	Surgery		11.88	6.30	6.30		
60250		Removal of thyroid	Surgery		14.17	7.55	7.55		
60252		Removal of thyroid	Surgery		16.04	7.75	7.75		
60254		Extensive thyroid surgery	Surgery		20.54	10.29	10.29		
60260		Repeat thyroid surgery	Surgery		26.95	14.38	14.38		
60270		Removal of thyroid	Surgery		17.44	8.85	8.85		
					20.24	10.66	10.66		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 98 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
60271		Removal of thyroid	Surgery		16.80	8.78	8.78		
60280		Remove thyroid duct lesion	Surgery		5.86	4.83	4.83		
60281		Remove thyroid duct lesion	Surgery		8.52	5.99	5.99		
60500		Explore parathyroid glands	Surgery		16.21	7.53	7.53		
60502		Re-explore parathyroids	Surgery		20.32	9.49	9.49		
60505		Explore parathyroid glands	Surgery		21.46	11.12	11.12		
60512		Autotransplant parathyroid	Surgery		4.44	1.63	1.63		
60520		Removal of thymus gland	Surgery		16.78	8.38	8.38		
60521		Removal of thymus gland	Surgery		18.84	9.63	9.63		
60522		Removal of thymus gland	Surgery		23.06	11.35	11.35		
60540		Explore adrenal gland	Surgery		17.00	7.65	7.65		
60545		Explore adrenal gland	Surgery		19.85	8.61	8.61		
60600		Remove carotid body lesion	Surgery		17.90	10.90	10.90		
60605		Remove carotid body lesion	Surgery		20.21	12.79	12.79		
60650		Laparoscopy adrenalectomy	Surgery		19.97	7.99	7.99		
60659		Laparo proc, endocrine	Surgery					27.96	Misc.
60699		Endocrine surgery procedure	Surgery					18.18	Misc.
61000		Remove cranial cavity fluid	Surgery		1.58	0.96	0.96		
61001		Remove brain cavity fluid	Surgery		1.49	1.06	1.06		
61020		Remove brain cavity fluid	Surgery		1.51	1.35	1.35		
61026		Injection into brain canal	Surgery		1.69	1.41	1.41		
61050		Remove brain canal fluid	Surgery		1.51	1.26	1.26		
61055		Injection into brain canal	Surgery		2.10	1.42	1.42		
61070		Brain canal shunt procedure	Surgery		0.89	1.03	1.03		
61105		Twist drill hole	Surgery		5.13	3.95	3.95		
61107		Drill skull for implantation	Surgery		4.99	3.32	3.32		
61108		Drill skull for drainage	Surgery		10.17	7.14	7.14		
61120		Burr hole for puncture	Surgery		8.75	6.00	6.00		
61140		Pierce skull for biopsy	Surgery		15.88	9.91	9.91		
61150		Pierce skull for drainage	Surgery		17.54	10.41	10.41		
61151		Pierce skull for drainage	Surgery		12.40	7.85	7.85		
61154		Pierce skull & remove clot	Surgery		14.97	9.50	9.50		
61156		Pierce skull for drainage	Surgery		16.30	9.86	9.86		
61210		Pierce skull, implant device	Surgery		5.83	3.71	3.71		
61215		Insert brain-fluid device	Surgery		4.88	4.02	4.02		
61250		Pierce skull & explore	Surgery		10.40	6.87	6.87		
61253		Pierce skull & explore	Surgery		12.34	7.74	7.74		
61304		Open skull for exploration	Surgery		21.93	12.88	12.88		
61305		Open skull for exploration	Surgery		26.57	15.37	15.37		
61312		Open skull for drainage	Surgery		24.53	15.08	15.08		
61313		Open skull for drainage	Surgery		24.89	14.85	14.85		
61314		Open skull for drainage	Surgery		24.19	13.08	13.08		
61315		Open skull for drainage	Surgery		27.64	16.07	16.07		
61316		Implt cran bone flap to abdo	Surgery		1.39	0.57	0.57		
61320		Open skull for drainage	Surgery		25.58	14.80	14.80		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 99 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
61321		Open skull for drainage	Surgery		28.46	16.18	16.18	16.18	
61322		Decompressive craniotomy	Surgery		29.46	14.45	14.45	14.45	
61323		Decompressive lobectomy	Surgery		30.95	14.64	14.64	14.64	
61330		Decompress eye socket	Surgery		23.29	13.80	13.80	13.80	
61332		Explore/biopsy eye socket	Surgery		27.24	15.66	15.66	15.66	
61333		Explore orbit/remove lesion	Surgery		27.91	15.66	15.66	15.66	
61334		Explore orbit/remove object	Surgery		18.24	10.70	10.70	10.70	
61340		Subtemporal decompression	Surgery		18.63	11.16	11.16	11.16	
61343		Incise skull (press relief)	Surgery		29.73	16.88	16.88	16.88	
61345		Relieve cranial pressure	Surgery		27.16	15.47	15.47	15.47	
61440		Incise skull for surgery	Surgery		26.59	14.28	14.28	14.28	
61450		Incise skull for surgery	Surgery		25.91	14.35	14.35	14.35	
61458		Incise skull for brain wound	Surgery		27.25	15.58	15.58	15.58	
61460		Incise skull for surgery	Surgery		28.35	16.49	16.49	16.49	
61470		Incise skull for surgery	Surgery		26.02	13.91	13.91	13.91	
61480		Incise skull for surgery	Surgery		26.45	15.34	15.34	15.34	
61490		Incise skull for surgery	Surgery		25.62	14.39	14.39	14.39	
61500		Removal of skull lesion	Surgery		17.89	10.85	10.85	10.85	
61501		Remove infected skull bone	Surgery		14.82	9.25	9.25	9.25	
61510		Removal of brain lesion	Surgery		28.41	16.76	16.76	16.76	
61512		Remove brain lining lesion	Surgery		35.04	19.76	19.76	19.76	
61514		Removal of brain abscess	Surgery		25.22	14.50	14.50	14.50	
61516		Removal of brain lesion	Surgery		24.57	14.33	14.33	14.33	
61517		Implt brain chemox add-on	Surgery		1.38	0.57	0.57	0.57	
61518		Removal of brain lesion	Surgery		37.26	21.20	21.20	21.20	
61519		Remove brain lining lesion	Surgery		41.33	22.75	22.75	22.75	
61520		Removal of brain lesion	Surgery		54.76	30.46	30.46	30.46	
61521		Removal of brain lesion	Surgery		44.41	24.33	24.33	24.33	
61522		Removal of brain abscess	Surgery		29.41	16.49	16.49	16.49	
61524		Removal of brain lesion	Surgery		27.82	15.74	15.74	15.74	
61526		Removal of brain lesion	Surgery		52.09	29.62	29.62	29.62	
61530		Removal of brain lesion	Surgery		43.79	25.19	25.19	25.19	
61531		Implant brain electrodes	Surgery		14.61	9.17	9.17	9.17	
61533		Implant brain electrodes	Surgery		19.68	11.59	11.59	11.59	
61534		Removal of brain lesion	Surgery		20.94	12.15	12.15	12.15	
61535		Remove brain electrodes	Surgery		11.61	7.46	7.46	7.46	
61536		Removal of brain lesion	Surgery		35.47	19.87	19.87	19.87	
61537		Removal of brain tissue	Surgery		24.96	14.45	14.45	14.45	
61538		Removal of brain tissue	Surgery		26.77	15.38	15.38	15.38	
61539		Removal of brain tissue	Surgery		32.03	17.85	17.85	17.85	
61540		Removal of brain tissue	Surgery		29.96	17.48	17.48	17.48	
61541		Incision of brain tissue	Surgery		28.81	16.28	16.28	16.28	
61542		Removal of brain tissue	Surgery		30.97	17.91	17.91	17.91	
61543		Removal of brain tissue	Surgery		29.18	16.46	16.46	16.46	
61544		Remove & treat brain lesion	Surgery		25.46	13.90	13.90	13.90	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 100 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
61545		Excision of brain tumor	Surgery		43.73	24.33	24.33	24.33	
61546		Removal of pituitary gland	Surgery		31.25	17.58	17.58	17.58	
61548		Removal of pituitary gland	Surgery		21.50	12.85	12.85	12.85	
61550		Release of skull seams	Surgery		14.63	7.01	7.01	7.01	
61552		Release of skull seams	Surgery		19.53	9.20	9.20	9.20	
61556		Incise skull/sutures	Surgery		22.23	11.42	11.42	11.42	
61557		Incise skull/sutures	Surgery		22.35	13.68	13.68	13.68	
61558		Excision of skull/sutures	Surgery		25.54	14.25	14.25	14.25	
61559		Excision of skull/sutures	Surgery		32.74	19.39	19.39	19.39	
61563		Excision of skull tumor	Surgery		26.79	15.33	15.33	15.33	
61564		Excision of skull tumor	Surgery		33.78	18.37	18.37	18.37	
61566		Removal of brain tissue	Surgery		30.95	17.42	17.42	17.42	
61567		Incision of brain tissue	Surgery		35.45	20.73	20.73	20.73	
61570		Remove foreign body, brain	Surgery		24.56	13.97	13.97	13.97	
61571		Incise skull for brain wound	Surgery		26.35	15.21	15.21	15.21	
61575		Skull base/brainstem surgery	Surgery		34.31	19.74	19.74	19.74	
61576		Skull base/brainstem surgery	Surgery		52.35	29.68	29.68	29.68	
61580		Craniofacial approach, skull	Surgery		30.30	25.49	25.49	25.49	
61581		Craniofacial approach, skull	Surgery		34.55	23.05	23.05	23.05	
61582		Craniofacial approach, skull	Surgery		31.61	26.99	26.99	26.99	
61583		Craniofacial approach, skull	Surgery		36.16	25.01	25.01	25.01	
61584		Orbitocranial approach/skull	Surgery		34.60	24.41	24.41	24.41	
61585		Orbitocranial approach/skull	Surgery		38.55	26.46	26.46	26.46	
61586		Resect nasopharynx, skull	Surgery		25.06	22.35	22.35	22.35	
61590		Infratemporal approach/skull	Surgery		41.72	28.81	28.81	28.81	
61591		Infratemporal approach/skull	Surgery		43.61	29.71	29.71	29.71	
61592		Orbitocranial approach/skull	Surgery		39.58	26.60	26.60	26.60	
61595		Transmastoid approach/skull	Surgery		29.53	22.51	22.51	22.51	
61596		Transmastoid approach/skull	Surgery		35.58	24.59	24.59	24.59	
61597		Transcondylar approach/skull	Surgery		37.90	23.05	23.05	23.05	
61598		Transpetrosal approach/skull	Surgery		33.36	23.35	23.35	23.35	
61600		Resect/excise cranial lesion	Surgery		25.81	19.88	19.88	19.88	
61601		Resect/excise cranial lesion	Surgery		27.85	20.56	20.56	20.56	
61605		Resect/excise cranial lesion	Surgery		29.29	22.16	22.16	22.16	
61606		Resect/excise cranial lesion	Surgery		38.77	25.23	25.23	25.23	
61607		Resect/excise cranial lesion	Surgery		36.22	23.88	23.88	23.88	
61608		Resect/excise cranial lesion	Surgery		42.04	26.67	26.67	26.67	
61609		Transect artery, sinus	Surgery		9.88	4.87	4.87	4.87	
61610		Transect artery, sinus	Surgery		29.63	13.19	13.19	13.19	
61611		Transect artery, sinus	Surgery		7.41	3.84	3.84	3.84	
61612		Transect artery, sinus	Surgery		27.84	13.36	13.36	13.36	
61613		Remove aneurysm, sinus	Surgery		40.80	26.34	26.34	26.34	
61615		Resect/excise lesion, skull	Surgery		32.02	22.82	22.82	22.82	
61616		Resect/excise lesion, skull	Surgery		43.27	28.77	28.77	28.77	
61618		Repair dura	Surgery		16.96	10.51	10.51	10.51	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 101 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
61619		Repair dura			20.68	12.31	12.31		
61623		Endovasc temporary vessel occl			9.95	4.23	4.23		
61624		Transcath occlusion, cns			20.12	6.93	6.93		
61626		Transcath occlusion, non-cns			16.60	5.54	5.54		
61680		Intracranial vessel surgery			30.66	17.52	17.52		
61682		Intracranial vessel surgery			61.48	32.37	32.37		
61684		Intracranial vessel surgery			39.75	22.10	22.10		
61686		Intracranial vessel surgery			64.39	34.88	34.88		
61690		Intracranial vessel surgery			29.27	16.80	16.80		
61692		Intracranial vessel surgery			51.79	27.61	27.61		
61697		Brain aneurysm repr, complx			50.44	28.13	28.13		
61698		Brain aneurysm repr, simple			48.34	26.80	26.80		
61700		Brain aneurysm repr, simple			50.44	27.93	27.93		
61702		Inner skull vessel surgery			48.34	26.15	26.15		
61703		Clamp neck artery			17.44	10.52	10.52		
61705		Revise circulation to head			36.15	19.34	19.34		
61708		Revise circulation to head			35.25	15.20	15.20		
61710		Revise circulation to head			29.63	13.66	13.66		
61711		Fusion of skull arteries			36.28	19.90	19.90		
61720		Incise skull/brain surgery			16.74	10.03	10.03		
61735		Incise skull/brain surgery			20.40	12.22	12.22		
61750		Incise skull/brain surgery			18.17	10.67	10.67		
61751		Brain biopsy w/c/mr guide			17.59	10.86	10.86		
61760		Implant brain electrodes			22.24	8.77	8.77		
61770		Implant brain electrodes			21.41	12.31	12.31		
61790		Incise skull for treatment			10.84	5.95	5.95		
61791		Treat trigeminal nerve			14.59	8.96	8.96		
61793		Treat trigeminal tract			17.21	10.16	10.16		
61795		Focus radiation beam			4.03	2.04	2.04		
61850		Brain surgery using computer			12.37	7.71	7.71		
61860		Implant neuroelectrodes			20.84	12.13	12.13		
61863		Implant neuroelectrodes			18.97	9.21	9.21		
61864		Implant neuroelectrode, add'l			4.49	2.29	2.29		
61867		Implant neuroelectrode			31.29	13.81	13.81		
61868		Implant neuroelectrode, add'l			7.91	4.03	4.03		
61870		Implant neuroelectrodes			14.92	9.82	9.82		
61875		Implant neuroelectrodes			15.04	8.61	8.61		
61880		Revise/remove neuroelectrode			6.28	4.60	4.60		
61885		Implant neurostim one array			5.84	5.32	5.32		
61886		Implant neurostim arrays			7.99	6.36	6.36		
61888		Revise/remove neuroreveler			5.06	3.88	3.88		
62000		Treat skull fracture			12.51	5.55	5.55		
62005		Treat skull fracture			16.15	8.83	8.83		
62010		Treatment of head injury			19.78	11.75	11.75		
62100		Repair brain fluid leakage			22.00	12.85	12.85		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 102 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
62115		Reduction of skull defect	Surgery		21.63	11.69	11.69		
62116		Reduction of skull defect	Surgery		23.55	13.42	13.42		
62117		Reduction of skull defect	Surgery		26.56	15.44	15.44		
62120		Repair skull cavity lesion	Surgery		23.31	14.33	14.33		
62121		Incise skull repair	Surgery		21.55	12.75	12.75		
62140		Repair of skull defect	Surgery		13.49	8.36	8.36		
62141		Repair of skull defect	Surgery		14.89	9.10	9.10		
62142		Remove skull plate/flap	Surgery		10.77	7.03	7.03		
62143		Replace skull plate/flap	Surgery		13.03	8.08	8.08		
62145		Repair of skull & brain	Surgery		18.79	10.95	10.95		
62146		Repair of skull with graft	Surgery		16.10	9.68	9.68		
62147		Repair of skull with graft	Surgery		19.31	11.38	11.38		
62148		Retr bone flap to fix skull	Surgery		2.00	0.82	0.82		
62160		Neuroendoscopy add-on	Surgery		3.00	1.14	1.14		
62161		Dissect brain w/scope	Surgery		19.97	9.56	9.56		
62162		Remove colloid cyst w/scope	Surgery		25.21	11.69	11.69		
62163		Neuroendoscopy w/br removal	Surgery		15.48	7.85	7.85		
62164		Remove brain tumor w/scope	Surgery		27.46	12.90	12.90		
62165		Remove pituit tumor w/scope	Surgery		21.97	10.51	10.51		
62180		Establish brain cavity shunt	Surgery		21.03	12.34	12.34		
62190		Establish brain cavity shunt	Surgery		11.05	7.11	7.11		
62192		Establish brain cavity shunt	Surgery		12.23	7.66	7.66		
62194		Replace/irrigate catheter	Surgery		5.02	2.79	2.79		
62200		Establish brain cavity shunt	Surgery		16.29	10.89	10.89		
62201		Brain cavity shunt w/scope	Surgery		14.84	9.49	9.49		
62220		Establish brain cavity shunt	Surgery		12.98	8.02	8.02		
62223		Establish brain cavity shunt	Surgery		12.85	8.28	8.28		
62225		Replace/irrigate catheter	Surgery		5.40	4.11	4.11		
62230		Replace/revise brain shunt	Surgery		10.52	6.51	6.51		
62252	26	Csf shunt reprogram	Surgery		0.74	0.37	0.37		
62252	TC	Csf shunt reprogram	Surgery	a	0.00	1.11	1.11		
62256		Remove brain cavity shunt	Surgery		6.59	4.72	4.72		
62258		Replace brain cavity shunt	Surgery		14.52	8.74	8.74		
62263		Epidural lysis mult sessions	Surgery		6.13	2.39	2.39		
62264		Epidural lysis on single day	Surgery		4.42	1.40	1.40		
62268		Drain spinal cord cyst	Surgery		4.73	2.18	2.18		
62289		Needle biopsy, spinal cord	Surgery		5.01	2.01	2.01		
62270		Spinal fluid tap, diagnostic	Surgery		1.13	0.49	0.49		
62272		Drain cerebro spinal fluid	Surgery		1.35	0.64	0.64		
62273		Treat epidural spine lesion	Surgery		2.15	0.57	0.57		
62280		Treat spinal cord lesion	Surgery		2.63	0.88	0.88		
62281		Treat spinal cord lesion	Surgery		2.66	0.77	0.77		
62282		Treat spinal canal lesion	Surgery		2.33	0.79	0.79		
62284		Injection for myelogram	Surgery		1.54	0.60	0.60		
62287		Percutaneous disectomy	Surgery		8.07	5.52	5.52		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 103 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
62290		Inject for spine disk x-ray	Surgery		3.00	1.28	6.81		
62291		Inject for spine disk x-ray	Surgery		2.91	1.13	5.69		
62292		Injection into disk lesion	Surgery		7.85	4.50	4.50		
62294		Injection into spinal artery	Surgery		11.81	5.62	5.62		
62310		Inject spine c/t	Surgery		1.91	0.50	4.83		
62311		Inject spine l/s (cd)	Surgery		1.54	0.45	4.91		
62318		Inject spine w/cath, c/t	Surgery		2.04	0.51	5.51		
62319		Inject spine w/cath, l/s (cd)	Surgery		1.87	0.47	4.82		
62350		Implant spinal canal cath	Surgery		6.86	3.99	3.99		
62351		Implant spinal canal cath	Surgery		9.99	7.10	7.10		
62355		Remove spinal canal catheter	Surgery		5.44	3.20	3.20		
62360		Insert spine infusion device	Surgery		2.62	2.71	2.71		
62361		Implant spine infusion pump	Surgery		5.41	3.91	3.91		
62362		Implant spine infusion pump	Surgery		7.03	4.38	4.38		
62365		Remove spine infusion device	Surgery		5.41	3.60	3.60		
62367	26	Analyze spine infusion pump	Surgery		0.48	0.13	0.13		SAF
62367	TC	Analyze spine infusion pump	Surgery	a	0.75	0.19	0.19		SAF
62368	26	Analyze spine infusion pump	Surgery						
62368	TC	Analyze spine infusion pump	Surgery	a					
63001		Removal of spinal lamina	Surgery		15.80	9.52	9.52		
63003		Removal of spinal lamina	Surgery		15.93	9.86	9.86		
63005		Removal of spinal lamina	Surgery		14.90	9.93	9.93		
63011		Removal of spinal lamina	Surgery		14.50	8.26	8.26		
63012		Removal of spinal lamina	Surgery		15.38	10.09	10.09		
63015		Removal of spinal lamina	Surgery		19.32	11.89	11.89		
63016		Removal of spinal lamina	Surgery		19.17	11.79	11.79		
63017		Removal of spinal lamina	Surgery		15.92	10.36	10.36		
63020		Neck spine disk surgery	Surgery		14.79	9.67	9.67		
63030		Low back disk surgery	Surgery		11.98	8.39	8.39		
63035		Spinal disk surgery add-on	Surgery		3.15	1.59	1.59		
63040		Laminotomy, single cervical	Surgery		18.78	11.50	11.50		
63042		Laminotomy, single lumbar	Surgery		17.44	11.30	11.30		
63043		Laminotomy, addl cervical	Surgery						
63044		Laminotomy, addl lumbar	Surgery						
63045		Removal of spinal lamina	Surgery		16.48	10.35	10.35		
63046		Removal of spinal lamina	Surgery		15.78	10.16	10.16		
63047		Removal of spinal lamina	Surgery		14.59	9.85	9.85		
63048		Remove spinal lamina add-on	Surgery		3.26	1.67	1.67		
63055		Decompress spinal cord	Surgery		21.96	13.14	13.14		
63056		Decompress spinal cord	Surgery		20.33	12.54	12.54		
63057		Decompress spine cord add-on	Surgery		5.25	2.64	2.64		
63064		Decompress spinal cord	Surgery		24.57	14.45	14.45		
63066		Decompress spine cord add-on	Surgery		3.26	1.67	1.67		
63075		Neck, spine disk surgery	Surgery		19.38	12.08	12.08		MDR
63076		Neck, spine disk surgery	Surgery		4.04	2.06	2.06		MDR

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 104 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
63077		Spine disk surgery, thorax			21.41	12.76	12.76		
63078		Spine disk surgery, thorax			3.28	1.64	1.64		
63081		Removal of vertebral body			23.69	14.33	14.33		
63082		Remove vertebral body add-on			4.36	2.23	2.23		
63085		Removal of vertebral body			26.88	15.47	15.47		
63086		Remove vertebral body add-on			3.19	1.60	1.60		
63087		Removal of vertebral body			35.52	19.45	19.45		
63090		Remove vertebral body add-on			4.32	2.18	2.18		
63091		Removal of vertebral body			28.12	16.01	16.01		
63101		Remove vertebral body add-on			3.03	1.46	1.46		
63102		Removal of vertebral body			31.95	19.34	19.34		
63103		Remove vertebral body add-on			31.95	19.34	19.34		
63170		Incise spinal cord tract(s)			3.89	2.01	2.01		
63172		Drainage of spinal cyst			19.80	12.06	12.06		
63173		Drainage of spinal cyst			17.63	10.85	10.85		
63180		Revise spinal cord ligaments			21.96	13.03	13.03		
63182		Revise spinal cord ligaments			18.24	11.21	11.21		
63185		Incise spinal column/nerves			20.47	11.18	11.18		
63190		Incise spinal column/nerves			15.02	8.25	8.25		
63191		Incise spinal column/nerves			17.42	10.31	10.31		
63194		Incise spinal column & cord			17.51	10.68	10.68		
63195		Incise spinal column & cord			19.16	11.89	11.89		
63196		Incise spinal column & cord			18.81	11.24	11.24		
63197		Incise spinal column & cord			22.27	13.58	13.58		
63198		Incise spinal column & cord			21.08	12.39	12.39		
63199		Incise spinal column & cord			25.34	8.63	8.63		
63200		Release of spinal cord			26.85	15.24	15.24		
63251		Revise spinal cord vessels			19.15	11.48	11.48		
63252		Revise spinal cord vessels			40.70	20.03	20.03		
63265		Excise intraspinal lesion			41.14	22.69	22.69		
63266		Excise intraspinal lesion			41.13	22.33	22.33		
63267		Excise intraspinal lesion			21.53	12.81	12.81		
63268		Excise intraspinal lesion			22.27	13.22	13.22		
63270		Excise intraspinal lesion			17.92	11.09	11.09		
63271		Excise intraspinal lesion			18.49	10.42	10.42		
63272		Excise intraspinal lesion			26.76	15.52	15.52		
63273		Excise intraspinal lesion			26.88	15.63	15.63		
63275		Excise intraspinal lesion			25.28	14.73	14.73		
63276		Biopsy/excise spinal tumor			24.25	14.39	14.39		
63277		Biopsy/excise spinal tumor			23.64	13.83	13.83		
63278		Biopsy/excise spinal tumor			23.41	13.72	13.72		
63280		Biopsy/excise spinal tumor			20.80	12.54	12.54		
63281		Biopsy/excise spinal tumor			20.53	12.39	12.39		
63281		Biopsy/excise spinal tumor			28.31	16.37	16.37		
63281		Biopsy/excise spinal tumor			28.01	16.22	16.22		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 105 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
63282		Biopsy/excise spinal tumor	Surgery		26.35	15.38	15.38		
63283		Biopsy/excise spinal tumor	Surgery		24.96	14.71	14.71		
63285		Biopsy/excise spinal tumor	Surgery		35.95	20.01	20.01		
63286		Biopsy/excise spinal tumor	Surgery		35.58	19.97	19.97		
63287		Biopsy/excise spinal tumor	Surgery		36.64	20.53	20.53		
63290		Biopsy/excise spinal tumor	Surgery		37.32	20.66	20.66		
63300		Removal of vertebral body	Surgery		24.39	14.34	14.34		
63301		Removal of vertebral body	Surgery		27.56	15.58	15.58		
63302		Removal of vertebral body	Surgery		27.77	15.88	15.88		
63303		Removal of vertebral body	Surgery		30.45	16.92	16.92		
63304		Removal of vertebral body	Surgery		30.28	17.34	17.34		
63305		Removal of vertebral body	Surgery		31.98	18.06	18.06		
63306		Removal of vertebral body	Surgery		32.17	17.84	17.84		
63307		Removal of vertebral body	Surgery		31.58	16.82	16.82		
63308		Remove vertebral body add-on	Surgery		5.24	2.62	2.62		
63600		Remove spinal cord lesion	Surgery		14.00	5.44	5.44		
63610		Stimulation of spinal cord	Surgery		8.72	2.30	55.66		
63615		Remove lesion of spinal cord	Surgery		16.26	9.41	9.41		
63650		Implant neuroelectrodes	Surgery		6.73	3.22	3.22		
63655		Implant neuroelectrodes	Surgery		10.27	6.90	6.90		
63660		Revised/remove neuroelectrode	Surgery		6.15	3.63	3.63		
63665		Implant neuroreceiver	Surgery		7.03	4.16	4.16		
63688		Revised/remove neuroreceiver	Surgery		5.38	3.57	3.57		
63700		Repair of spinal herniation	Surgery		16.51	10.27	10.27		
63702		Repair of spinal herniation	Surgery		18.45	10.84	10.84		
63704		Repair of spinal herniation	Surgery		21.15	12.89	12.89		
63706		Repair of spinal herniation	Surgery		24.07	13.61	13.61		
63707		Repair spinal fluid leakage	Surgery		11.24	7.68	7.68		
63709		Repair spinal fluid leakage	Surgery		14.30	9.36	9.36		
63710		Graft repair of spine defect	Surgery		14.05	9.05	9.05		
63740		Install spinal shunt	Surgery		11.34	7.38	7.38		
63741		Install spinal shunt	Surgery		8.24	4.78	4.78		
63744		Revision of spinal shunt	Surgery		8.09	5.28	5.28		
63746		Removal of spinal shunt	Surgery		6.42	3.80	3.80		
64400		N block inj, trigeminal	Surgery		1.11	0.37	2.01		
64402		N block inj, facial	Surgery		1.25	0.53	1.74		
64405		N block inj, occipital	Surgery		1.32	0.39	1.52		
64408		N block inj, vagus	Surgery		1.41	0.66	1.56		
64410		N block inj, phrenic	Surgery		1.43	0.39	2.56		
64412		N block inj, spinal accessor	Surgery		1.18	0.37	2.71		
64413		N block inj, cervical plexus	Surgery		1.40	0.43	1.88		
64415		N block inj, brachial plexus	Surgery		1.48	0.39	2.84		
64416		N block cont infuse, b plex	Surgery		3.49	0.72	3.09		
64417		N block inj, axillary	Surgery		1.44	0.42	3.09		
64418		N block inj, suprascapular	Surgery		1.32	0.37	2.65		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 106 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
64420		N block inj, intercost, sng	Surgery		1.18	0.36	3.53		
64421		N block inj, intercost, mlt	Surgery		1.68	0.45	5.39		
64425		N block inj ilio-Ing/hypogi	Surgery		1.75	0.47	1.70		
64430		N block inj, pudendal	Surgery		1.46	0.49	2.59		
64435		N block inj, paracervical	Surgery		1.45	0.63	2.58		
64445		N block inj, sciatic, sng	Surgery		1.48	0.37	2.69		
64446		N blk inj, sciatic, cont lnt	Surgery		3.25	1.18	1.18		
64447		N block inj fem, single	Surgery		1.50	0.51	0.51		
64448		N block inj fem, cont inf	Surgery		3.00	1.03	1.03		
64449		N block inj, lumbar plexus	Surgery		3.00	0.97	0.97		
64450		N block, other peripheral	Surgery		1.27	0.41	1.26		
64470		inj paravertebral c/t	Surgery		1.85	0.56	4.86		
64472		inj paravertebral c/t add-on	Surgery		1.29	0.31	1.94		
64475		inj paravertebral l/s	Surgery		1.41	0.47	4.56		
64476		inj paravertebral l/s add-on	Surgery		0.98	0.25	1.82		
64479		inj foramen epidural c/t	Surgery		2.20	0.72	7.05		
64480		inj foramen epidural add-on	Surgery		1.54	0.46	2.41		
64483		inj foramen epidural l/s	Surgery		1.90	0.66	7.53		
64484		inj foramen epidural add-on	Surgery		1.33	0.37	2.80		
64505		N block, sphenopalatine gangl	Surgery		1.36	0.47	1.22		
64508		N block, carotid sinus s/p	Surgery		1.12	0.51	2.96		
64510		N block, stellate ganglion	Surgery		1.22	0.37	3.20		
64517		N block inj, hypogas plix	Surgery		2.20	0.87	2.70		
64520		N block, lumbar/thoracic	Surgery		1.35	0.41	4.56		
64530		N block inj, cellac pelus	Surgery		1.58	0.47	3.94		
64550		Apply neurostimulator	Surgery		0.18	0.05	0.30		
64553		Implant neuroelectrodes	Surgery		2.31	1.86	2.70		
64555		Implant neuroelectrodes	Surgery		2.27	1.20	3.09		
64560		Implant neuroelectrodes	Surgery		2.36	1.30	2.64		
64561		Implant neuroelectrodes	Surgery		6.73	3.16	3.16		
64565		Implant neuroelectrodes	Surgery		1.76	1.28	3.35		
64573		Implant neuroelectrodes	Surgery		7.49	5.23	5.23		
64575		Implant neuroelectrodes	Surgery		4.34	2.70	2.70		
64577		Implant neuroelectrodes	Surgery		4.61	3.32	3.32		
64580		Implant neuroelectrodes	Surgery		4.11	3.55	3.55		
64581		Revis/remove neuroelectrode	Surgery		13.48	5.41	5.41		
64385		Implant neuroreceiver	Surgery		2.06	1.71	11.57		
64590		Revis/remove neuroreceiver	Surgery		2.40	1.90	7.26		
64595		Injection treatment of nerve	Surgery		1.73	1.49	10.69		
64600		Injection treatment of nerve	Surgery		3.44	1.57	8.45		
64605		Injection treatment of nerve	Surgery		5.60	2.05	8.59		
64610		Injection treatment of nerve	Surgery		7.15	3.58	7.89		
64612		Destroy nerve, face muscle	Surgery		1.96	1.08	2.62		
64613		Destroy nerve, spine muscle	Surgery		1.96	0.99	2.97		
64614		Destroy nerve, extrem musc	Surgery		2.20	1.12	3.24		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 107 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
64620		Injection treatment of nerve			2.84	1.18	4.60		
64622		Destr paravertebral nerve l/s			3.00	1.23	7.62		
64623		Destr paravertebral n add-on			0.99	0.23	2.42		
64626		Destr paravertebral nerve c/t			3.28	1.85	6.67		
64627		Destr paravertebral n add-on			1.16	0.27	2.61		
64630		Injection treatment of nerve			3.00	1.28	2.73		
64640		Injection treatment of nerve			2.76	1.67	4.24		
64680		Injection treatment of nerve			2.62	1.28	5.97		
64681		Injection treatment of nerve			3.54	2.10	8.71		
64702		Revise finger/foot nerve			4.22	3.62	3.82		
64704		Revise hand/foot nerve			4.56	3.28	3.28		
64708		Revise arm/leg nerve			6.11	4.83	4.83		
64712		Revise sciatic nerve			7.74	4.99	4.99		
64713		Revision of arm nerve(s)			10.98	5.90	5.90		
64714		Revision low back nerve(s)			10.31	4.24	4.24		
64716		Revision of cranial nerve			6.30	5.26	5.26		
64718		Revise ulnar nerve at elbow			5.98	5.87	5.87		
64719		Revise ulnar nerve at wrist			4.84	4.46	4.46		
64721		Carpal tunnel surgery			4.28	4.95	4.95		
64722		Relieve pressure on nerve(s)			4.69	3.06	3.06		
64726		Release foot/leg nerve			4.17	2.76	2.76		
64727		Internal nerve revision			3.10	1.51	1.51		
64732		Incision of brow nerve			4.40	3.53	3.53		
64734		Incision of cheek nerve			4.91	4.06	4.06		
64736		Incision of chin nerve			4.59	4.03	4.03		
64738		Incision of jaw nerve			5.72	4.62	4.62		
64740		Incision of tongue nerve			5.58	4.39	4.39		
64742		Incision of facial nerve			6.24	4.74	4.74		
64744		Incise nerve, back of head			5.23	3.79	3.79		
64746		Incise diaphragm nerve			5.92	4.53	4.53		
64752		Incision of vagus nerve			7.05	4.31	4.31		
64755		Incision of stomach nerves			13.50	5.68	5.68		
64760		Incision of vagus nerve			6.95	3.52	3.52		
64761		Incision of pelvis nerve			6.40	3.56	3.56		
64763		Incise hip/thigh nerve			8.92	5.24	5.24		
64766		Incise hip/thigh nerve			8.66	5.26	5.26		
64771		Sever cranial nerve			7.34	5.58	5.58		
64772		Incision of spinal nerve			7.20	4.93	4.93		
64774		Remove skin nerve lesion			5.16	3.81	3.81		
64776		Remove digit nerve lesion			5.11	3.67	3.67		
64778		Digit nerve surgery add-on			3.11	1.50	1.50		
64782		Remove limb nerve lesion			6.22	3.75	3.75		
64783		Limb nerve surgery add-on			3.71	1.85	1.85		
64784		Remove nerve lesion			9.81	6.57	6.57		
64786		Remove sciatic nerve lesion			15.44	9.84	9.84		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 108 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
64787		Implant nerve end	Surgery		4.29	2.13	2.13		
64788		Remove skin nerve lesion	Surgery		4.60	3.47	3.47		
64790		Removal of nerve lesion	Surgery		11.29	7.19	7.19		
64792		Removal of nerve lesion	Surgery		14.90	8.84	8.84		
64795		Blopsy of nerve	Surgery		3.01	1.59	1.59		
64802		Remove sympathetic nerves	Surgery		9.14	5.17	5.17		
64804		Remove sympathetic nerves	Surgery		14.62	7.20	7.20		
64809		Remove sympathetic nerves	Surgery		13.65	5.80	5.80		
64818		Remove sympathetic nerves	Surgery		10.28	5.33	5.33		
64820		Remove sympathetic nerves	Surgery		10.35	7.11	7.11		
64821		Remove sympathetic nerves	Surgery		8.74	7.35	7.35		
64822		Remove sympathetic nerves	Surgery		8.74	7.27	7.27		
64823		Remove sympathetic nerves	Surgery		10.35	8.18	8.18		
64831		Repair of digit nerve	Surgery		9.43	7.05	7.05		
64832		Repair nerve add-on	Surgery		5.65	2.95	2.95		
64834		Repair of hand or foot nerve	Surgery		10.17	7.08	7.08		
64835		Repair of hand or foot nerve	Surgery		10.92	7.67	7.67		
64836		Repair of hand or foot nerve	Surgery		10.92	7.65	7.65		
64837		Repair nerve add-on	Surgery		6.25	3.25	3.25		
64840		Repair of leg nerve	Surgery		13.00	8.28	8.28		
64856		Repair/transpose nerve	Surgery		13.78	9.17	9.17		
64857		Repair arm/leg nerve	Surgery		14.47	9.62	9.62		
64858		Repair sciatic nerve	Surgery		16.47	10.74	10.74		
64859		Nerve surgery	Surgery		4.25	2.20	2.20		
64861		Repair of arm nerves	Surgery		19.21	11.83	11.83		
64862		Repair of low back nerves	Surgery		19.41	11.96	11.96		
64864		Repair of facial nerve	Surgery		12.53	8.10	8.10		
64865		Repair of facial nerve	Surgery		15.22	9.87	9.87		
64866		Fusion of facial/other nerve	Surgery		15.72	9.71	9.71		
64868		Fusion of facial/other nerve	Surgery		14.02	8.87	8.87		
64870		Fusion of facial/other nerve	Surgery		15.97	8.75	8.75		
64872		Subsequent repair of nerve	Surgery		1.98	1.09	1.09		
64874		Repair & revise nerve add-on	Surgery		2.98	1.54	1.54		
64876		Repair nerve/shorten bone	Surgery		3.37	1.28	1.28		
64885		Nerve graft, head or neck	Surgery		17.50	10.91	10.91		
64886		Nerve graft, head or neck	Surgery		20.72	12.75	12.75		
64890		Nerve graft, hand or foot	Surgery		15.13	9.99	9.99		
64891		Nerve graft, hand or foot	Surgery		16.12	7.63	7.63		
64892		Nerve graft, arm or leg	Surgery		14.63	8.86	8.86		
64893		Nerve graft, arm or leg	Surgery		15.58	9.89	9.89		
64895		Nerve graft, hand or foot	Surgery		19.22	9.67	9.67		
64896		Nerve graft, hand or foot	Surgery		20.46	11.01	11.01		
64897		Nerve graft, arm or leg	Surgery		18.21	10.72	10.72		
64898		Nerve graft, arm or leg	Surgery		19.47	11.81	11.81		
64901		Nerve graft add-on	Surgery		10.20	5.29	5.29		

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply.
See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 109 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
64902		Nerve graft add-on			11.81	5.99	5.99		
64905		Nerve pedicle transfer			14.00	8.56	8.56		
64907		Nerve pedicle transfer			18.80	12.50	12.50	8.64	Misc.
64999		Nervous system surgery							
65091		Revise eye			6.45	9.73	9.73		
65093		Revise eye with implant			6.86	10.09	10.09		
65101		Removal of eye			7.02	10.68	10.68		
65105		Remove eye/insert implant			7.56	10.87	10.87		
65106		Remove eye/attach implant			8.48	11.52	11.52		
65110		Removal of eye			13.93	14.61	14.61		
65112		Remove eye/revise socket			16.36	16.88	16.88		
65114		Remove eye/revise socket			17.50	17.10	17.10		
65125		Revise ocular implant			3.12	2.96	2.96		
65130		Insert ocular implant			7.14	10.24	10.24		
65135		Insert ocular implant			7.32	10.42	10.42		
65140		Attach ocular implant			8.01	10.87	10.87		
65150		Revise ocular implant			6.25	9.29	9.29		
65155		Reinsert ocular implant			6.65	11.59	11.59		
65175		Removal of ocular implant			6.27	9.65	9.65		
65205		Remove foreign body from eye			0.71	0.19	0.19		
65210		Remove foreign body from eye			0.84	0.30	0.74		
65220		Remove foreign body from eye			0.71	0.18	0.60		
65222		Remove foreign body from eye			0.93	0.27	0.76		
65235		Remove foreign body from eye			7.56	7.26	7.26		
65260		Remove foreign body from eye			10.94	11.43	11.43		
65265		Remove foreign body from eye			12.57	12.67	12.67		
65270		Repair of eye wound			1.90	2.24	3.83		
65272		Repair of eye wound			3.81	5.21	5.78		
65273		Repair of eye wound			4.35	5.63	5.63		
65275		Repair of eye wound			5.33	5.66	5.66		
65280		Repair of eye wound			7.65	8.17	8.17		
65285		Repair of eye wound			12.88	12.38	12.38		
65286		Repair of eye wound			5.50	7.52	8.42		
65290		Repair of eye socket wound			5.40	6.47	6.47		
65400		Removal of eye lesion			6.05	7.47	8.63		
65410		Blepharoplasty			1.47	0.65	1.72		
65420		Removal of eye lesion			4.16	6.74	7.53		
65426		Removal of eye lesion			5.24	6.54	7.49		
65430		Corneal smear			1.47	0.66	4.95		
65435		Curette/treat cornea			0.92	0.39	1.32		
65436		Curette/treat cornea			4.18	5.22	5.85		
65450		Treatment of corneal lesion			3.27	6.33	7.22		
65600		Revision of cornea			3.39	3.11	5.63		
65710		Corneal transplant			12.33	12.33	12.33		
65730		Corneal transplant			14.23	11.86	11.86		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 110 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
65750		Corneal transplant	Surgery		14.98	13.35	13.35		
65755		Corneal transplant	Surgery		14.87	13.26	13.26	30.91	MDR
65760		Revision of cornea	Surgery					35.86	MDR
65765		Revision of cornea	Surgery					33.39	MDR
65767		Corneal tissue transplant	Surgery						
65770		Revise cornea with implant	Surgery		17.53	14.31	14.31		
65771		Radial keratotomy	Surgery						
65772		Correction of astigmatism	Surgery		4.28	6.46	7.15		
65775		Correction of astigmatism	Surgery		5.78	7.35	7.35		
65780		Ocular reconst, transplant	Surgery		10.23	9.94	9.94		
65781		Ocular reconst, transplant	Surgery		17.64	13.31	13.31		
65782		Ocular reconst, transplant	Surgery		14.98	11.66	11.66		
65800		Drainage of eye	Surgery		1.91	1.17	2.27		
65805		Drainage of eye	Surgery		1.91	1.18	2.27		
65810		Drainage of eye	Surgery		4.86	8.05	8.05		
65815		Drainage of eye	Surgery		5.04	7.49	8.37		
65820		Relieve inner eye pressure	Surgery		8.12	10.65	10.65		
65850		Incision of eye	Surgery		10.50	9.38	9.38		
65855		Laser surgery of eye	Surgery		3.84	4.05	5.20		
65860		Incise inner eye adhesions	Surgery		3.54	3.26	3.90		
65865		Incise inner eye adhesions	Surgery		5.59	6.48	6.48		
65870		Incise inner eye adhesions	Surgery		6.26	7.14	7.14		
65875		Incise inner eye adhesions	Surgery		6.53	7.44	7.44		
65880		Incise inner eye adhesions	Surgery		7.08	7.69	7.69		
65900		Remove eye lesion	Surgery		10.91	11.51	11.51		
65920		Remove implant of eye	Surgery		8.39	8.70	8.70		
65930		Remove blood clot from eye	Surgery		7.43	7.74	7.74		
66020		Injection treatment of eye	Surgery		1.59	1.58	2.37		
66030		Injection treatment of eye	Surgery		1.25	1.42	2.21		
66130		Remove eye lesion	Surgery		7.68	6.92	7.48		
66150		Glaucoma surgery	Surgery		8.29	9.86	9.86		
66155		Glaucoma surgery	Surgery		8.28	9.80	9.80		
66160		Glaucoma surgery	Surgery		10.15	10.65	10.65		
66165		Glaucoma surgery	Surgery		8.00	9.69	9.69		
66170		Glaucoma surgery	Surgery		12.14	12.45	12.45		
66172		Incision of eye	Surgery		15.02	15.12	15.12		
66180		Implant eye shunt	Surgery		14.53	11.56	11.56		
66185		Revise eye shunt	Surgery		8.13	8.19	8.19		
66220		Repair eye lesion	Surgery		7.76	8.73	8.73		
66225		Repair/graft eye lesion	Surgery		11.03	9.32	9.32		
66250		Follow-up surgery of eye	Surgery		5.97	6.50	7.67		
66500		Incision of iris	Surgery		3.70	5.10	5.10		
66505		Incision of iris	Surgery		4.07	5.38	5.38		
66600		Remove iris and lesion	Surgery		8.67	8.91	8.91		
66605		Removal of iris	Surgery		12.77	11.26	11.26		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 111 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
66625		Removal of iris	Surgery		5.12	6.30	7.02		
66630		Removal of iris	Surgery		6.15	7.42	7.42		
66635		Removal of iris	Surgery		6.24	6.64	6.64		
66680		Repair iris & ciliary body	Surgery		5.43	6.04	6.04		
66700		Repair iris & ciliary body	Surgery		6.20	7.43	7.43		
66710		Destruction, ciliary body	Surgery		4.77	4.05	5.34		
66720		Destruction, ciliary body	Surgery		4.77	3.85	5.22		
66740		Destruction, ciliary body	Surgery		4.77	4.60	5.68		
66761		Revision of iris	Surgery		4.06	4.21	5.38		
66762		Revision of iris	Surgery		4.57	4.23	5.55		
66770		Removal of inner eye lesion	Surgery		4.57	4.22	5.62		
66820		Incision, secondary cataract	Surgery		5.17	4.73	6.05		
66821		After cataract laser surgery	Surgery		3.88	7.10	3.98		
66825		Reposition intraocular lens	Surgery		2.35	3.88	3.98		
66830		Removal of lens lesion	Surgery		8.22	10.08	10.08		
66840		Removal of lens material	Surgery		8.19	7.08	7.08		
66850		Removal of lens material	Surgery		7.90	6.99	6.99		
66852		Removal of lens material	Surgery		9.10	7.75	7.75		
66920		Extraction of lens	Surgery		9.96	8.20	8.20		
66930		Extraction of lens	Surgery		8.85	7.43	7.43		
66940		Extraction of lens	Surgery		10.16	8.57	8.57		
66982		Cataract surgery, complex	Surgery		8.92	8.01	8.01		
66983		Cataract surg w/obi, 1 stage	Surgery		13.48	9.92	9.92		
66984		Cataract surg w/obi, 1 stage	Surgery		8.98	6.20	6.20		
66985		Insert lens prosthesis	Surgery		10.21	7.63	7.63		
66986		Exchange lens prosthesis	Surgery		8.38	7.47	7.47		
66990		Ophthalmic endoscope add-on	Surgery		12.26	9.22	9.22		
66999		Eye surgery procedure	Surgery		1.51	0.69	0.69		
67005		Partial removal of eye fluid	Surgery		5.69	4.38	4.38		
67010		Partial removal of eye fluid	Surgery		6.86	4.93	4.93		
67015		Release of eye fluid	Surgery		6.91	7.73	7.73		
67025		Replace eye fluid	Surgery		6.83	7.51	14.23		
67027		Implant eye drug system	Surgery		10.83	8.79	12.78		
67028		Injection eye drug	Surgery		2.52	1.13	6.50		
67030		Incise inner eye strands	Surgery		4.83	6.81	6.81		
67031		Laser surgery, eye strands	Surgery		3.66	4.09	4.74		
67036		Removal of inner eye fluid	Surgery		11.87	9.35	9.35		
67038		Strip retinal membrane	Surgery		21.21	15.83	15.83		
67039		Laser treatment of retina	Surgery		14.50	12.54	12.54		
67040		Laser treatment of retina	Surgery		17.20	14.02	14.02		
67101		Repair detached retina	Surgery		7.52	8.11	9.85		
67105		Repair detached retina	Surgery		7.40	6.23	7.99		
67107		Repair detached retina	Surgery		14.82	12.82	12.82		
67108		Repair detached retina	Surgery		20.79	17.02	17.02		
								17.84	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 112 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
67110		Repair detached retina	Surgery		8.80	9.23	15.37		
67112		Rerepair detached retina	Surgery		16.83	14.59	14.59		
67115		Release encircling material	Surgery		4.98	7.09	7.09		
67120		Remove eye implant material	Surgery		5.97	6.93	12.30		
67121		Remove eye implant material	Surgery		10.65	11.17	11.17		
67141		Treatment of retina	Surgery		5.19	6.49	7.24		
67145		Treatment of retina	Surgery		5.36	4.94	5.76		
67208		Treatment of retinal lesion	Surgery		6.69	5.38	5.95		
67210		Treatment of retinal lesion	Surgery		8.81	5.79	6.25		
67218		Treatment of retinal lesion	Surgery		18.50	14.13	14.13		
67220		Treatment of choroid lesion	Surgery		13.11	8.83	9.84		
67221		Ocular photodynamic therapy	Surgery		4.00	1.81	4.69		
67225		Eye photodynamic therapy add-on	Surgery		0.47	0.22	0.26		
67227		Treatment of retinal lesion	Surgery		6.57	5.39	6.38		
67228		Treatment of retinal lesion	Surgery		12.72	8.42	10.83		
67250		Reinforce eye wall	Surgery		8.65	10.37	10.37		
67255		Reinforce/graft eye wall	Surgery		8.89	10.95	10.95		Misc.
67299		Eye surgery procedure	Surgery					21.22	
67311		Revise eye muscle	Surgery		6.64	6.42	6.42		
67312		Revise two eye muscles	Surgery		8.53	7.55	7.55		
67314		Revise eye muscle	Surgery		7.51	7.26	7.26		
67316		Revise two eye muscles	Surgery		9.65	8.22	8.22		
67318		Revise eye muscle(s)	Surgery		7.84	7.64	7.64		
67320		Revise eye muscle(s) add-on	Surgery		4.32	1.96	1.96		
67331		Eye surgery follow-up add-on	Surgery		4.05	1.91	1.91		
67332		Rerevise eye muscles add-on	Surgery		4.48	2.03	2.03		
67334		Revise eye muscle w/suture	Surgery		3.97	1.81	1.81		
67335		Eye suture during surgery	Surgery		2.49	1.12	1.12		
67340		Revise eye muscle add-on	Surgery		4.92	2.23	2.23		
67343		Release eye tissue	Surgery		7.34	7.34	7.34		
67345		Destroy nerve of eye muscle	Surgery		2.96	1.37	4.36		
67350		Biopsy eye muscle	Surgery		2.87	1.87	1.87		
67399		Eye muscle surgery procedure	Surgery					13.06	Misc.
67400		Explore/biopsy eye socket	Surgery						
67405		Explore/drain eye socket	Surgery		9.75	12.51	12.51		
67412		Explore/treat eye socket	Surgery		7.92	11.09	11.09		
67413		Explore/treat eye socket	Surgery		9.49	12.99	12.99		
67414		Expir/decompress eye socket	Surgery		9.99	12.14	12.14		
67415		Aspiration, orbital contents	Surgery		11.11	14.01	14.01		
67420		Explore/treat eye socket	Surgery		1.76	0.77	0.77		
67430		Explore/treat eye socket	Surgery		20.03	18.77	18.77		
67440		Explore/drain eye socket	Surgery		13.37	15.83	15.83		
67445		Expir/decompress eye socket	Surgery		13.07	15.47	15.47		
67450		Explore/biopsy eye socket	Surgery		14.40	15.70	15.70		
67500		Inject/treat eye socket	Surgery		13.49	15.82	15.82		
					0.79	0.19	0.82		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 113 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
67505		Inject/treat eye socket			0.82	0.21	0.92		
67515		Inject/treat eye socket			0.61	0.28	0.82		
67550		Insert eye socket implant			10.17	12.28	12.28		
67560		Revise eye socket implant			10.58	12.33	12.33		
67570		Decompress optic nerve			13.56	15.33	15.33		
67599		Orbit surgery procedure							
67700		Drainage of eyelid abscess			1.35	0.62	4.84		Misc.
67710		Incision of eyelid			1.02	0.53	4.99		
67715		Incision of eyelid fold			1.22	0.62	4.58		
67800		Remove eyelid lesion			1.38	0.69	2.50		
67801		Remove eyelid lesions			1.88	0.92	5.34		
67805		Remove eyelid lesions			2.22	1.08	5.49		
67808		Remove eyelid lesion(s)			3.79	5.23	5.23		
67810		Biopsy of eyelid			1.48	0.68	3.65		
67820		Revise eyelashes			0.89	0.37	1.11		
67825		Revise eyelashes			1.38	1.08	1.58		
67830		Revise eyelashes			1.70	1.95	7.48		
67835		Revise eyelashes			5.55	5.00	5.00		
67840		Remove eyelid lesion			2.04	1.00	5.32		
67850		Treat eyelid lesion			1.69	1.89	6.06		
67875		Closure of eyelid by suture			1.35	0.82	7.05		
67880		Revision of eyelid			3.79	4.29	9.66		
67882		Revision of eyelid			5.06	5.50	11.01		
67900		Repair brow defect			6.13	6.32	10.53		
67901		Repair eyelid defect			6.96	6.41	6.41		
67902		Repair eyelid defect			7.02	6.47	6.47		
67903		Repair eyelid defect			6.36	6.70	11.28		
67904		Repair eyelid defect			6.25	7.17	12.49		
67906		Repair eyelid defect			6.78	6.01	9.11		
67908		Repair eyelid defect			5.12	5.68	8.83		
67909		Revise eyelid defect			5.39	6.09	9.36		
67911		Revise eyelid defect			5.26	6.04	6.04		
67912		Correction eyelid w/ implant			5.67	5.27	20.38		
67914		Repair eyelid defect			3.67	3.95	9.30		
67915		Repair eyelid defect			3.18	2.58	7.90		
67916		Repair eyelid defect			5.30	5.69	11.78		
67917		Repair eyelid defect			6.01	6.15	9.71		
67921		Repair eyelid defect			3.39	3.75	9.11		
67922		Repair eyelid defect			3.06	3.49	7.86		
67923		Repair eyelid defect			5.87	5.90	11.35		
67924		Repair eyelid defect			5.78	5.65	9.10		
67930		Repair eyelid wound			3.60	2.95	8.42		
67935		Repair eyelid wound			6.21	5.95	11.36		
67938		Remove eyelid foreign body			1.33	0.56	5.81		
67950		Revision of eyelid			5.81	6.57	8.25		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 114 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
67961		Revision of eyelid	Surgery		5.68	5.70	10.20		
67966		Revision of eyelid	Surgery		6.56	5.66	6.33		
67971		Reconstruction of eyelid	Surgery		9.78	7.27	7.27		
67973		Reconstruction of eyelid	Surgery		12.85	9.24	9.24		
67974		Reconstruction of eyelid	Surgery		12.82	9.16	9.16		
67975		Reconstruction of eyelid	Surgery		9.12	6.95	6.95		
67998		Revision of eyelid	Surgery						Misc.
68020		Incise/drain eyelid lining	Surgery		1.37	0.68	5.69	4.70	
68040		Treatment of eyelid lesions	Surgery		0.85	0.37	4.82		
68100		Biopsy of eyelid lining	Surgery		1.35	0.61	5.01		
68110		Remove eyelid lining lesion	Surgery		1.77	1.40	6.06		
68115		Remove eyelid lining lesion	Surgery		2.36	1.13	5.56		
68130		Remove eyelid lining lesion	Surgery		4.92	4.28	8.14		
68135		Remove eyelid lining lesion	Surgery		1.84	0.90	5.32		
68200		Treat eyelid by injection	Surgery		0.49	0.23	0.72		
68320		Reverse/graft eyelid lining	Surgery		5.36	5.41	6.56		
68325		Reverse/graft eyelid lining	Surgery		7.35	6.39	6.39		
68326		Reverse/graft eyelid lining	Surgery		7.14	6.28	6.28		
68328		Reverse/graft eyelid lining	Surgery		8.17	7.03	7.03		
68330		Reverse eyelid lining	Surgery		4.82	6.05	7.24		
68335		Reverse/graft eyelid lining	Surgery		7.18	6.79	6.79		
68340		Separate eyelid adhesions	Surgery		4.16	4.77	10.80		
68360		Reverse eyelid lining	Surgery		4.36	5.58	6.60		
68362		Reverse eyelid lining	Surgery		7.33	7.72	7.72		
68371		Harvest eye tissue, allograft	Surgery		4.89	4.62	4.62		
68399		Eyelid lining surgery	Surgery					4.00	Misc.
68400		Incise/drain tear gland	Surgery		1.69	2.04	7.61		
68420		Incise/drain tear sac	Surgery		2.30	2.33	7.92		
68440		Incise tear duct opening	Surgery		0.94	0.49	4.93		
68500		Removal of tear gland	Surgery		11.00	10.16	10.16		
68505		Partial removal, tear gland	Surgery		10.92	11.17	11.17		
68510		Biopsy of tear gland	Surgery						
68520		Removal of tear sac	Surgery		4.60	2.10	8.42		
68525		Biopsy of tear sac	Surgery		7.50	7.78	7.78		
68530		Clearance of tear duct	Surgery		4.42	2.02	2.02		
68540		Remove tear gland lesion	Surgery		3.65	2.85	9.45		
68550		Remove tear gland lesion	Surgery		10.58	9.78	9.78		
68700		Repair tear ducts	Surgery		13.24	11.75	11.75		
68705		Reverse tear duct opening	Surgery		6.59	7.29	7.29		
68720		Create tear sac drain	Surgery		2.06	1.01	5.45		
68745		Create tear duct drain	Surgery		8.95	8.26	8.26		
68750		Create tear duct drain	Surgery		8.62	8.22	8.22		
68750		Create tear duct drain	Surgery		8.65	8.69	8.69		
68760		Close tear duct opening	Surgery		1.73	1.23	3.99		
68761		Close tear duct opening	Surgery		1.36	0.98	3.42		
68770		Close tear system fistula	Surgery		7.01	6.78	12.75		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 115 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
68801		Dilate tear duct opening	Surgery		0.94	0.60	0.94		
68810		Probe nasolacrimal duct	Surgery		1.90	0.92	2.32		
68811		Probe nasolacrimal duct	Surgery		2.35	2.36	2.36		
68815		Probe nasolacrimal duct	Surgery		3.20	2.68	8.16		
68840		Explore/irrigate tear ducts	Surgery		1.25	0.96	1.64		
68850		Injection for tear sac x-ray	Surgery		0.80	0.30	16.32	4.65	Misc.
68899		Tear duct system surgery	Surgery		1.45	1.39	2.95		
69000		Drain external ear lesion	Surgery		2.11	1.85	2.96		
69005		Drain external ear lesion	Surgery		1.48	2.03	3.92		
69020		Drain outer ear canal lesion	Surgery						
69080		Pierce earlobes	Surgery						
69100		Biopsy of external ear	Surgery		0.81	0.39	1.74		
69105		Remove external ear canal, partial	Surgery		0.85	0.77	2.31		
69110		Remove external ear	Surgery		3.43	3.03	4.07		
69120		Remove ear canal lesion(s)	Surgery		4.04	3.96	3.96		
69140		Remove ear canal lesion(s)	Surgery		7.96	6.69	6.69		
69145		Remove ear canal lesion(s)	Surgery		2.62	2.60	3.57		
69150		Extensive ear canal surgery	Surgery		13.41	14.47	9.90		
69155		Extensive ear/neck surgery	Surgery		20.77	14.47	14.47		
69200		Clear outer ear canal	Surgery		0.77	0.58	2.33		
69205		Clear outer ear canal	Surgery		1.20	1.35	1.35		
69210		Remove impacted ear wax	Surgery		0.61	0.24	0.63		
69220		Clean out mastoid cavity	Surgery		0.83	0.74	2.31		
69222		Clean out mastoid cavity	Surgery		1.40	2.02	3.78		
69300		Revise external ear	Surgery		6.35	4.23	4.23		
69310		Rebuild outer ear canal	Surgery		10.77	8.37	8.37		
69399		Outer ear surgery procedure	Surgery		16.93	12.09	12.09		
69400		Inflate middle ear canal	Surgery						
69401		Inflate middle ear canal	Surgery						
69405		Cathectize middle ear canal	Surgery						
69420		Incision of eardrum	Surgery						
69421		Incision of eardrum	Surgery		1.73	2.09	2.09		
69424		Remove ventilating tube	Surgery		0.85	0.88	2.14		
69433		Create eardrum opening	Surgery		1.52	1.66	3.09		
69436		Explore of middle ear	Surgery		1.96	2.22	2.22		
69440		Eardrum revision	Surgery		7.56	6.28	6.28		
69450		Mastoidectomy	Surgery		5.56	5.02	5.02		
69501		Remove mastoid structures	Surgery		9.06	7.06	7.06		
69502		Extensive mastoid surgery	Surgery		12.36	9.26	9.26		
69505		Extensive mastoid surgery	Surgery		12.97	9.51	9.51		
69511		Remove part of temporal bone	Surgery		13.50	9.85	9.85		
69530			Surgery		19.16	13.01	13.01		
69535			Surgery		36.09	22.36	22.36		
								1.21	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 116 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
69540		Remove ear lesion	Surgery		1.20	1.93	3.68		
69550		Remove ear lesion	Surgery		10.97	8.31	8.31		
69552		Remove ear lesion	Surgery		19.43	12.92	12.92		
69554		Remove ear lesion	Surgery		33.11	20.88	20.88		
69601		Mastoid surgery revision	Surgery		13.22	10.01	10.01		
69602		Mastoid surgery revision	Surgery		13.56	9.95	9.95		
69603		Mastoid surgery revision	Surgery		14.00	10.16	10.16		
69604		Mastoid surgery revision	Surgery		14.00	10.14	10.14		
69605		Mastoid surgery revision	Surgery		18.46	12.80	12.80		
69610		Repair of eardrum	Surgery		4.42	3.27	5.39		
69620		Repair of eardrum	Surgery		5.88	4.51	6.13		
69631		Repair eardrum structures	Surgery		9.85	7.85	7.85		
69632		Rebuild eardrum structures	Surgery		12.73	9.72	9.72		
69633		Rebuild eardrum structures	Surgery		12.08	9.38	9.38		
69635		Rebuild eardrum structures	Surgery		13.31	9.38	9.38		
69636		Rebuild eardrum structures	Surgery		15.20	11.15	11.15		
69637		Rebuild eardrum structures	Surgery		15.09	11.09	11.09		
69641		Revise middle ear & mastoid	Surgery		12.69	9.47	9.47		
69642		Revise middle ear & mastoid	Surgery		16.81	12.11	12.11		
69643		Revise middle ear & mastoid	Surgery		15.30	11.15	11.15		
69644		Revise middle ear & mastoid	Surgery		16.94	12.06	12.06		
69645		Revise middle ear & mastoid	Surgery		16.36	11.70	11.70		
69650		Release middle ear & mastoid	Surgery		17.96	12.63	12.63		
69660		Revise middle ear bone	Surgery		9.65	7.40	7.40		
69661		Revise middle ear bone	Surgery		11.88	8.60	8.60		
69662		Revise middle ear bone	Surgery		15.72	11.07	11.07		
69666		Revise middle ear bone	Surgery		15.42	10.79	10.79		
69667		Repair middle ear structures	Surgery		9.74	7.48	7.48		
69670		Repair middle ear structures	Surgery		9.75	7.46	7.46		
69676		Remove mastoid air cells	Surgery		11.49	8.63	8.63		
69700		Remove middle ear nerve	Surgery		9.51	7.60	7.60		
69710		Close mastoid fistula	Surgery		8.22	5.87	5.87		
69711		Implant/replace hearing aid	Surgery		10.42	8.06	8.06		
69714		Remove/repair hearing aid	Surgery		13.98	9.89	9.89		
69715		Implant temple bone w/stimul	Surgery		18.22	12.37	12.37		
69717		Temple bone implant w/stimul	Surgery		14.96	9.55	9.55		
69718		Temple bone implant revision	Surgery		18.47	12.27	12.27		
69720		Release facial nerve	Surgery		14.36	10.74	10.74		
69725		Release facial nerve	Surgery		25.34	16.83	16.83		
69740		Repair facial nerve	Surgery		15.94	10.35	10.35		
69745		Repair facial nerve	Surgery		16.66	11.34	11.34		
69799		Middle ear surgery procedure	Surgery						
69801		Incise inner ear	Surgery		8.85	6.81	6.81		
69802		Incise inner ear	Surgery		13.08	9.59	9.59		
								18.06	PHCS
									Misc.
								4.18	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 117 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
68805		Explore inner ear	Surgery		13.80	10.04	10.04		
68806		Explore inner ear	Surgery		12.33	9.17	9.17		
68820		Establish inner ear window	Surgery		10.32	7.83	7.83		
68840		Revise inner ear window	Surgery		11.08	8.30	8.30		
68905		Remove inner ear	Surgery		13.61	9.70	9.70		
68910		Remove inner ear & mastoid	Surgery		21.20	14.15	14.15		
68915		Incise inner ear nerve	Surgery		16.78	11.81	11.81		
68930		Implant cochlear device	Surgery						
68949		Inner ear surgery procedure	Surgery						
68955		Release facial nerve	Surgery		25.60	16.04	16.04		Misc.
68960		Release inner ear canal	Surgery		27.00	17.57	17.57		
68970		Remove inner ear lesion	Surgery		27.00	17.04	17.04		
68979		Temporal bone surgery	Surgery		29.99	18.32	18.32		
69950		Microsurgery add-on	Surgery		3.46	1.80	1.80		
70010	26	Contrast x-ray of brain	Radiology	a	1.19	0.39	0.39		
70015	TC	Contrast x-ray of brain	Radiology		0.00	4.34	4.34		
70015	26	Contrast x-ray of brain	Radiology	a	1.19	0.39	0.39		
70015	TC	Contrast x-ray of brain	Radiology		0.00	1.36	1.36		
70030	26	X-ray eye for foreign body	Radiology	a	0.17	0.06	0.06		
70030	TC	X-ray eye for foreign body	Radiology		0.00	0.41	0.41		
70100	26	X-ray exam of jaw	Radiology	a	0.18	0.06	0.06		
70100	TC	X-ray exam of jaw	Radiology		0.00	0.52	0.52		
70110	26	X-ray exam of jaw	Radiology	a	0.25	0.08	0.08		
70110	TC	X-ray exam of jaw	Radiology		0.00	0.62	0.62		
70120	26	X-ray exam of mastoids	Radiology	a	0.18	0.06	0.06		
70120	TC	X-ray exam of mastoids	Radiology		0.00	0.62	0.62		
70130	26	X-ray exam of mastoids	Radiology	a	0.34	0.11	0.11		
70130	TC	X-ray exam of mastoids	Radiology		0.00	0.79	0.79		
70134	26	X-ray exam of middle ear	Radiology	a	0.34	0.11	0.11		
70134	TC	X-ray exam of middle ear	Radiology		0.00	0.74	0.74		
70140	26	X-ray exam of facial bones	Radiology	a	0.19	0.06	0.06		
70140	TC	X-ray exam of facial bones	Radiology		0.00	0.62	0.62		
70150	26	X-ray exam of facial bones	Radiology	a	0.26	0.09	0.09		
70150	TC	X-ray exam of facial bones	Radiology		0.00	0.79	0.79		
70160	26	X-ray exam of nasal bones	Radiology	a	0.17	0.06	0.06		
70160	TC	X-ray exam of nasal bones	Radiology		0.00	0.52	0.52		
70170	26	X-ray exam of tear duct	Radiology	a	0.30	0.10	0.10		
70170	TC	X-ray exam of tear duct	Radiology		0.00	0.95	0.95		
70190	26	X-ray exam of eye sockets	Radiology	a	0.21	0.07	0.07		
70190	TC	X-ray exam of eye sockets	Radiology		0.00	0.62	0.62		
70200	26	X-ray exam of eye sockets	Radiology	a	0.28	0.09	0.09		
70200	TC	X-ray exam of eye sockets	Radiology		0.00	0.79	0.79		
70210	26	X-ray exam of sinuses	Radiology	a	0.17	0.06	0.06		
70210	TC	X-ray exam of sinuses	Radiology		0.00	0.62	0.62		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 118 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
70220	26	X-ray exam of sinuses	Radiology		0.25	0.08	0.08		
70220	TC	X-ray exam of sinuses	Radiology	a	0.00	0.79	0.08		
70240	26	X-ray exam, pituitary saddle	Radiology		0.19	0.06	0.06		
70240	TC	X-ray exam, pituitary saddle	Radiology	a	0.00	0.41	0.41		
70250	TC	X-ray exam of skull	Radiology		0.24	0.08	0.08		
70250	TC	X-ray exam of skull	Radiology	a	0.00	0.62	0.62		
70260	26	X-ray exam of skull	Radiology		0.34	0.11	0.11		
70260	TC	X-ray exam of skull	Radiology	a	0.00	0.89	0.89		
70300	26	X-ray exam of teeth	Radiology		0.10	0.05	0.05		
70300	TC	X-ray exam of teeth	Radiology	a	0.00	0.27	0.27		
70310	26	X-ray exam of teeth	Radiology		0.16	0.08	0.08		
70310	TC	X-ray exam of teeth	Radiology	a	0.00	0.41	0.41		
70320	26	Full mouth x-ray of teeth	Radiology		0.22	0.08	0.08		
70320	TC	Full mouth x-ray of teeth	Radiology	a	0.00	0.79	0.79		
70328	26	X-ray exam of jaw joint	Radiology		0.18	0.06	0.06		
70328	TC	X-ray exam of jaw joint	Radiology	a	0.00	0.49	0.49		
70330	26	X-ray exam of jaw joints	Radiology		0.24	0.08	0.08		
70330	TC	X-ray exam of jaw joints	Radiology	a	0.00	0.85	0.85		
70332	26	X-ray exam of jaw joint	Radiology		0.54	0.20	0.20		
70332	TC	X-ray exam of jaw joint	Radiology	a	0.00	2.10	2.10		
70336	26	Magnetic image, jaw joint	Radiology		1.48	0.48	0.48		
70336	TC	Magnetic image, jaw joint	Radiology	a	0.00	11.24	11.24		
70350	26	X-ray head for orthodontia	Radiology		0.17	0.07	0.07		
70350	TC	X-ray head for orthodontia	Radiology	a	0.00	0.37	0.37		
70355	26	Panoramic x-ray of jaws	Radiology		0.20	0.08	0.08		
70355	TC	Panoramic x-ray of jaws	Radiology	a	0.00	0.57	0.57		
70360	26	X-ray exam of neck	Radiology		0.17	0.06	0.06		
70360	TC	X-ray exam of neck	Radiology	a	0.00	0.41	0.41		
70370	26	Throat x-ray & fluoroscopy	Radiology		0.32	0.11	0.11		
70370	TC	Throat x-ray & fluoroscopy	Radiology	a	0.00	1.31	1.31		
70371	26	Speech evaluation, complex	Radiology		0.84	0.28	0.28		
70371	TC	Speech evaluation, complex	Radiology	a	0.00	2.10	2.10		
70373	26	Contrast x-ray of larynx	Radiology		0.44	0.15	0.15		
70373	TC	Contrast x-ray of larynx	Radiology	a	0.00	1.79	1.79		
70380	26	X-ray exam of salivary gland	Radiology		0.17	0.06	0.06		
70380	TC	X-ray exam of salivary gland	Radiology	a	0.00	0.67	0.67		
70390	26	X-ray exam of salivary duct	Radiology		0.38	0.13	0.13		
70390	TC	X-ray exam of salivary duct	Radiology	a	0.00	1.79	1.79		
70450	26	Ct head/brain w/o dye	Radiology		0.85	0.28	0.28		
70450	TC	Ct head/brain w/o dye	Radiology	a	0.00	4.74	4.74		
70460	26	Ct head/brain w/dye	Radiology		1.13	0.37	0.37		
70460	TC	Ct head/brain w/dye	Radiology	a	0.00	5.67	5.67		
70470	26	Ct head/brain w/o&w dye	Radiology		1.27	0.41	0.41		
70470	TC	Ct head/brain w/o&w dye	Radiology	a	0.00	7.10	7.10		
70480	26	Ct orbit/ear/fossa w/o dye	Radiology		1.28	0.42	0.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 119 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
70480	TC	Ct orbit/ear/fossa w/o dye	Radiology	a	0.00	4.74	4.74	4.74	
70481	26	Ct orbit/ear/fossa w/dye	Radiology		1.38	0.45	0.45	0.45	
70481	TC	Ct orbit/ear/fossa w/dye	Radiology	a	0.00	5.67	5.67	5.67	
70482	26	Ct orbit/ear/fossa w/o&w dye	Radiology		1.45	0.47	0.47	0.47	
70482	TC	Ct orbit/ear/fossa w/o&w dye	Radiology	a	0.00	7.10	7.10	7.10	
70486	26	Ct maxillofacial w/o dye	Radiology		1.14	0.37	0.37	0.37	
70486	TC	Ct maxillofacial w/o dye	Radiology	a	0.00	4.74	4.74	4.74	
70487	26	Ct maxillofacial w/dye	Radiology		1.30	0.42	0.42	0.42	
70487	TC	Ct maxillofacial w/dye	Radiology	a	0.00	5.67	5.67	5.67	
70488	26	Ct maxillofacial w/o&w dye	Radiology		1.42	0.46	0.46	0.46	
70488	TC	Ct maxillofacial w/o&w dye	Radiology	a	0.00	7.10	7.10	7.10	
70490	26	Ct soft tissue neck w/o dye	Radiology		1.28	0.42	0.42	0.42	
70490	TC	Ct soft tissue neck w/o dye	Radiology	a	0.00	4.74	4.74	4.74	
70491	26	Ct soft tissue neck w/dye	Radiology		1.38	0.45	0.45	0.45	
70491	TC	Ct soft tissue neck w/dye	Radiology	a	0.00	5.67	5.67	5.67	
70492	26	Ct soft tissue neck w/o & w/dye	Radiology		1.45	0.47	0.47	0.47	
70492	TC	Ct soft tissue neck w/o & w/dye	Radiology	a	0.00	7.10	7.10	7.10	
70496	26	Ct angiography, head	Radiology		1.75	0.57	0.57	0.57	
70496	TC	Ct angiography, head	Radiology	a	0.00	10.65	10.65	10.65	
70498	26	Ct angiography, neck	Radiology		1.75	0.57	0.57	0.57	
70498	TC	Ct angiography, neck	Radiology	a	0.00	10.65	10.65	10.65	
70540	26	Mri orbit/face/neck w/o dye	Radiology		1.35	0.44	0.44	0.44	
70540	TC	Mri orbit/face/neck w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
70542	26	Mri orbit/face/neck w/dye	Radiology		1.62	0.53	0.53	0.53	
70542	TC	Mri orbit/face/neck w/dye	Radiology	a	0.00	13.49	13.49	13.49	
70543	26	Mri orbit/face/neck w/o&w dye	Radiology		2.15	0.71	0.71	0.71	
70543	TC	Mri orbit/face/neck w/o&w dye	Radiology	a	0.00	24.98	24.98	24.98	
70544	26	Mri angiography head w/o dye	Radiology		1.20	0.39	0.39	0.39	
70544	TC	Mri angiography head w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
70545	26	Mri angiography head w/dye	Radiology		1.20	0.39	0.39	0.39	
70545	TC	Mri angiography head w/dye	Radiology	a	0.00	11.24	11.24	11.24	
70546	26	Mri angiography head w/o&w dye	Radiology		1.80	0.59	0.59	0.59	
70546	TC	Mri angiography head w/o&w dye	Radiology	a	0.00	22.49	22.49	22.49	
70547	26	Mri angiography neck w/o dye	Radiology		1.20	0.39	0.39	0.39	
70547	TC	Mri angiography neck w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
70548	26	Mri angiography neck w/dye	Radiology		1.20	0.39	0.39	0.39	
70548	TC	Mri angiography neck w/dye	Radiology	a	0.00	11.24	11.24	11.24	
70549	26	Mri angiography neck w/o&w dye	Radiology		1.80	0.59	0.59	0.59	
70549	TC	Mri angiography neck w/o&w dye	Radiology	a	0.00	22.49	22.49	22.49	
70551	26	Mri brain w/o dye	Radiology		1.48	0.49	0.49	0.49	
70551	TC	Mri brain w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
70552	26	Mri brain w/dye	Radiology		1.78	0.59	0.59	0.59	
70552	TC	Mri brain w/dye	Radiology	a	0.00	13.49	13.49	13.49	
70553	26	Mri brain w/o&w dye	Radiology		2.36	0.78	0.78	0.78	
70553	TC	Mri brain w/o&w dye	Radiology	a	0.00	24.98	24.98	24.98	

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 120 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
70557	26	Mri brain w/o dye	Radiology	a	2.90	0.98	0.98	15.52	SA
70557	TC	Mri brain w/o dye	Radiology						
70558	26	Mri brain w/ dye	Radiology	a	3.20	1.08	1.08	17.12	SA
70558	TC	Mri brain w/ dye	Radiology						
70559	26	Mri brain w/o & w/ dye	Radiology	a	3.20	1.08	1.08	17.12	SA
70559	TC	Mri brain w/o & w/ dye	Radiology						
71010	26	Chest x-ray	Radiology	a	0.18	0.06	0.06		
71010	TC	Chest x-ray	Radiology						
71015	26	Chest x-ray	Radiology	a	0.00	0.47	0.47		
71015	TC	Chest x-ray	Radiology						
71020	26	Chest x-ray	Radiology	a	0.00	0.21	0.07		
71020	TC	Chest x-ray	Radiology						
71021	26	Chest x-ray	Radiology	a	0.00	0.22	0.07		
71021	TC	Chest x-ray	Radiology						
71022	26	Chest x-ray	Radiology	a	0.00	0.62	0.62		
71022	TC	Chest x-ray	Radiology						
71023	26	Chest x-ray and fluoroscopy	Radiology	a	0.27	0.09	0.09		
71023	TC	Chest x-ray and fluoroscopy	Radiology						
71030	26	Chest x-ray	Radiology	a	0.00	0.74	0.74		
71030	TC	Chest x-ray	Radiology						
71034	26	Chest x-ray and fluoroscopy	Radiology	a	0.00	0.10	0.10		
71034	TC	Chest x-ray and fluoroscopy	Radiology						
71035	26	Chest x-ray	Radiology	a	0.00	0.74	0.74		
71035	TC	Chest x-ray	Radiology						
71040	26	Contrast x-ray of bronchi	Radiology	a	0.38	0.13	0.13		
71040	TC	Contrast x-ray of bronchi	Radiology						
71060	26	Contrast x-ray of bronchi	Radiology	a	0.00	0.79	0.79		
71060	TC	Contrast x-ray of bronchi	Radiology						
71090	26	X-ray & pacemaker insertion	Radiology	a	0.00	0.16	0.16		
71090	TC	X-ray & pacemaker insertion	Radiology						
71100	26	X-ray exam of ribs	Radiology	a	0.00	1.44	1.44		
71100	TC	X-ray exam of ribs	Radiology						
71101	26	X-ray exam of ribs/chest	Radiology	a	0.00	0.06	0.06		
71101	TC	X-ray exam of ribs/chest	Radiology						
71110	26	X-ray exam of ribs	Radiology	a	0.00	0.52	0.52		
71110	TC	X-ray exam of ribs	Radiology						
71111	26	X-ray exam of ribs/ chest	Radiology	a	0.00	0.19	0.19		
71111	TC	X-ray exam of ribs/ chest	Radiology						
71120	26	X-ray exam of breastbone	Radiology	a	0.00	1.46	1.46		
71120	TC	X-ray exam of breastbone	Radiology						
71130	26	X-ray exam of breastbone	Radiology	a	0.00	0.25	0.25		
71130	TC	X-ray exam of breastbone	Radiology						
71250	26	Ct thorax w/o dye	Radiology	a	0.00	2.21	2.21		
71250	TC	Ct thorax w/o dye	Radiology						
71260	26	Ct thorax w/dye	Radiology	a	0.54	0.21	0.21		
71260	TC	Ct thorax w/dye	Radiology						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 121 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
71260	TC	Ct thorax w/dye	Radiology	a	0.00	7.10	7.10	7.10	
71270	26	Ct thorax w/o&w dye	Radiology		1.38	0.45	0.45	0.45	
71270	TC	Ct thorax w/o&w dye	Radiology	a	0.00	8.88	8.88	8.88	
71275	26	Ct angiography, chest	Radiology		1.92	0.63	0.63	0.63	
71275	TC	Ct angiography, chest	Radiology	a	0.00	12.42	12.42	12.42	
71550	26	Mi chest w/o dye	Radiology		1.46	0.48	0.48	0.48	
71550	TC	Mi chest w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
71551	26	Mri chest w/dye	Radiology		1.73	0.57	0.57	0.57	
71551	TC	Mri chest w/dye	Radiology	a	0.00	13.49	13.49	13.49	
71552	26	Mi chest w/o&w/dye	Radiology		2.26	0.74	0.74	0.74	
71552	TC	Mi chest w/o&w/dye	Radiology	a	0.00	24.98	24.98	24.98	
71555	26	Mi angio chest w or w/o dye	Radiology		1.81	0.60	0.60	0.60	
71555	TC	Mi angio chest w or w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
72010	26	X-ray exam of spine	Radiology		0.45	0.15	0.15	0.15	
72010	TC	X-ray exam of spine	Radiology	a	0.00	1.03	1.03	1.03	
72020	26	X-ray exam of spine	Radiology		0.15	0.05	0.05	0.05	
72020	TC	X-ray exam of spine	Radiology	a	0.00	0.41	0.41	0.41	
72040	26	X-ray exam of neck spine	Radiology		0.22	0.07	0.07	0.07	
72040	TC	X-ray exam of neck spine	Radiology	a	0.00	0.60	0.60	0.60	
72050	26	X-ray exam of neck spine	Radiology		0.31	0.10	0.10	0.10	
72050	TC	X-ray exam of neck spine	Radiology	a	0.00	0.89	0.89	0.89	
72052	26	X-ray exam of trunk spine	Radiology		0.36	0.12	0.12	0.12	
72052	TC	X-ray exam of trunk spine	Radiology	a	0.00	1.13	1.13	1.13	
72069	26	X-ray exam of thoracic spine	Radiology		0.22	0.08	0.08	0.08	
72069	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.49	0.49	0.49	
72070	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07	0.07	
72070	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.65	0.65	0.65	
72072	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07	0.07	
72072	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.74	0.74	0.74	
72074	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07	0.07	
72074	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.91	0.91	0.91	
72080	26	X-ray exam of trunk spine	Radiology		0.22	0.07	0.07	0.07	
72080	TC	X-ray exam of trunk spine	Radiology	a	0.00	0.67	0.67	0.67	
72090	26	X-ray exam of trunk spine	Radiology		0.28	0.09	0.09	0.09	
72090	TC	X-ray exam of trunk spine	Radiology	a	0.00	0.67	0.67	0.67	
72100	26	X-ray exam of lower spine	Radiology		0.22	0.07	0.07	0.07	
72100	TC	X-ray exam of lower spine	Radiology	a	0.00	0.67	0.67	0.67	
72110	26	X-ray exam of lower spine	Radiology		0.31	0.10	0.10	0.10	
72110	TC	X-ray exam of lower spine	Radiology	a	0.00	0.91	0.91	0.91	
72114	26	X-ray exam of lower spine	Radiology		0.36	0.12	0.12	0.12	
72114	TC	X-ray exam of lower spine	Radiology	a	0.00	1.19	1.19	1.19	
72120	26	X-ray exam of lower spine	Radiology		0.22	0.07	0.07	0.07	
72120	TC	X-ray exam of lower spine	Radiology	a	0.00	0.89	0.89	0.89	
72125	26	Ct neck spine w/o dye	Radiology		1.16	0.38	0.38	0.38	
72125	TC	Ct neck spine w/o dye	Radiology	a	0.00	5.93	5.93	5.93	

NOTE: CPT Codes and descriptions only are copyright © 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 122 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
72126	26	Ct neck spine w/dye	Radiology		1.22	0.39	0.39		
72126	TC	Ct neck spine w/dye	Radiology	a	0.00	7.10	7.10		
72127	26	Ct neck spine w/o&w/dye	Radiology		1.27	0.41	0.41		
72127	TC	Ct neck spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72128	26	Ct chest spine w/o dye	Radiology		1.16	0.38	0.38		
72128	TC	Ct chest spine w/o dye	Radiology	a	0.00	5.93	5.93		
72129	26	Ct chest spine w/dye	Radiology		1.22	0.39	0.39		
72129	TC	Ct chest spine w/dye	Radiology	a	0.00	7.10	7.10		
72130	26	Ct chest spine w/o&w/dye	Radiology		1.27	0.41	0.41		
72130	TC	Ct chest spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72131	26	Ct lumbar spine w/o dye	Radiology		1.16	0.38	0.38		
72131	TC	Ct lumbar spine w/o dye	Radiology	a	0.00	5.93	5.93		
72132	26	Ct lumbar spine w/dye	Radiology		1.22	0.40	0.40		
72132	TC	Ct lumbar spine w/dye	Radiology	a	0.00	7.10	7.10		
72133	26	Ct lumbar spine w/o&w/dye	Radiology		1.27	0.42	0.42		
72133	TC	Ct lumbar spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72141	26	Mi neck spine w/o dye	Radiology		1.60	0.53	0.53		
72141	TC	Mi neck spine w/o dye	Radiology	a	0.00	11.24	11.24		
72142	26	Mi neck spine w/dye	Radiology		1.92	0.65	0.65		
72142	TC	Mi neck spine w/dye	Radiology	a	0.00	13.49	13.49		
72146	26	Mi chest spine w/o dye	Radiology		1.60	0.52	0.52		
72146	TC	Mi chest spine w/o dye	Radiology	a	0.00	12.48	12.48		
72147	26	Mi chest spine w/dye	Radiology		1.92	0.64	0.64		
72147	TC	Mi chest spine w/dye	Radiology	a	0.00	13.49	13.49		
72148	26	Mi lumbar spine w/o dye	Radiology		1.48	0.49	0.49		
72148	TC	Mi lumbar spine w/o dye	Radiology	a	0.00	12.48	12.48		
72149	26	Mi lumbar spine w/dye	Radiology		1.78	0.60	0.60		
72149	TC	Mi lumbar spine w/dye	Radiology	a	0.00	13.49	13.49		
72156	26	Mi neck spine w/o&w/dye	Radiology		2.57	0.85	0.85		
72156	TC	Mi neck spine w/o&w/dye	Radiology	a	0.00	24.98	24.98		
72157	26	Mi chest spine w/o&w/dye	Radiology		2.57	0.85	0.85		
72157	TC	Mi chest spine w/o&w/dye	Radiology	a	0.00	24.98	24.98		
72158	26	Mi lumbar spine w/o&w/dye	Radiology		2.36	0.78	0.78		
72158	TC	Mi lumbar spine w/o&w/dye	Radiology	a	0.00	24.98	24.98		
72159	26	Mi angio spine w/o&w/dye	Radiology		1.80	0.69	0.69		
72159	TC	Mi angio spine w/o&w/dye	Radiology	a	0.00	12.23	12.23		
72170	26	X-ray exam of pelvis	Radiology		0.17	0.06	0.06		
72170	TC	X-ray exam of pelvis	Radiology	a	0.00	0.52	0.52		
72190	26	X-ray exam of pelvis	Radiology		0.21	0.07	0.07		
72190	TC	X-ray exam of pelvis	Radiology	a	0.00	0.67	0.67		
72191	26	Ct angiograph pelv w/o&w/dye	Radiology		1.81	0.60	0.60		
72191	TC	Ct angiograph pelv w/o&w/dye	Radiology	a	0.00	12.07	12.07		
72192	26	Ct pelvis w/o dye	Radiology		1.09	0.36	0.36		
72192	TC	Ct pelvis w/o dye	Radiology	a	0.00	5.93	5.93		
72193	26	Ct pelvis w/dye	Radiology		1.16	0.38	0.38		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 123 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
72193	TC	Ct pelvis w/dye	Radiology	a	0.00	6.87	6.87	6.87	
72194	TC	Ct pelvis w/o&w/dye	Radiology	a	1.22	0.40	0.40	0.40	
72194	TC	Ct pelvis w/o&w/dye	Radiology	a	0.00	8.52	8.52	8.52	
72195	TC	Mri pelvis w/o dye	Radiology	a	1.46	0.48	0.48	0.48	
72195	TC	Mri pelvis w/o dye	Radiology	a	0.00	11.24	11.24	11.24	
72196	TC	Mri pelvis w/dye	Radiology	a	1.73	0.57	0.57	0.57	
72196	TC	Mri pelvis w/dye	Radiology	a	0.00	13.49	13.49	13.49	
72197	TC	Mri pelvis w/o & w/dye	Radiology	a	2.26	0.74	0.74	0.74	
72197	TC	Mri pelvis w/o & w/dye	Radiology	a	0.00	24.98	24.98	24.98	
72198	TC	Mri angio pelvis w/o&w/dye	Radiology	a	1.80	0.68	0.68	0.68	
72198	TC	Mri angio pelvis w/o&w/dye	Radiology	a	0.00	11.24	11.24	11.24	
72200	TC	X-ray exam sacroiliac joints	Radiology	a	0.17	0.06	0.06	0.06	
72200	TC	X-ray exam sacroiliac joints	Radiology	a	0.00	0.52	0.52	0.52	
72202	TC	X-ray exam sacroiliac joints	Radiology	a	0.19	0.06	0.06	0.06	
72202	TC	X-ray exam sacroiliac joints	Radiology	a	0.00	0.62	0.62	0.62	
72220	TC	X-ray exam of tailbone	Radiology	a	0.17	0.06	0.06	0.06	
72220	TC	X-ray exam of tailbone	Radiology	a	0.00	0.57	0.57	0.57	
72240	TC	Contrast x-ray of neck spine	Radiology	a	0.91	0.29	0.29	0.29	
72240	TC	Contrast x-ray of neck spine	Radiology	a	0.00	4.77	4.77	4.77	
72255	TC	Contrast x-ray, thorax spine	Radiology	a	0.91	0.28	0.28	0.28	
72255	TC	Contrast x-ray, thorax spine	Radiology	a	0.00	4.34	4.34	4.34	
72265	TC	Contrast x-ray, lower spine	Radiology	a	0.83	0.26	0.26	0.26	
72265	TC	Contrast x-ray, lower spine	Radiology	a	0.00	4.09	4.09	4.09	
72270	TC	Contrast x-ray of spine	Radiology	a	1.33	0.41	0.41	0.41	
72270	TC	Contrast x-ray of spine	Radiology	a	0.00	6.12	6.12	6.12	
72275	TC	Epidurography	Radiology	a	0.76	0.20	0.20	0.20	
72275	TC	Epidurography	Radiology	a	0.00	2.10	2.10	2.10	
72285	TC	X-ray c/t spine disk	Radiology	a	1.16	0.36	0.36	0.36	
72285	TC	X-ray c/t spine disk	Radiology	a	0.00	8.41	8.41	8.41	
72295	TC	X-ray of lower spine disk	Radiology	a	0.83	0.27	0.27	0.27	
72295	TC	X-ray of lower spine disk	Radiology	a	0.00	7.88	7.88	7.88	
73000	TC	X-ray exam of collar bone	Radiology	a	0.16	0.05	0.05	0.05	
73000	TC	X-ray exam of collar bone	Radiology	a	0.00	0.52	0.52	0.52	
73010	TC	X-ray exam of shoulder blade	Radiology	a	0.17	0.06	0.06	0.06	
73010	TC	X-ray exam of shoulder blade	Radiology	a	0.00	0.52	0.52	0.52	
73020	TC	X-ray exam of shoulder	Radiology	a	0.15	0.05	0.05	0.05	
73020	TC	X-ray exam of shoulder	Radiology	a	0.00	0.47	0.47	0.47	
73030	TC	X-ray exam of shoulder	Radiology	a	0.18	0.06	0.06	0.06	
73030	TC	X-ray exam of shoulder	Radiology	a	0.00	0.57	0.57	0.57	
73040	TC	Contrast x-ray of shoulder	Radiology	a	0.54	0.18	0.18	0.18	
73040	TC	Contrast x-ray of shoulder	Radiology	a	0.00	2.10	2.10	2.10	
73050	TC	X-ray exam of shoulders	Radiology	a	0.20	0.07	0.07	0.07	
73050	TC	X-ray exam of shoulders	Radiology	a	0.00	0.67	0.67	0.67	
73060	TC	X-ray exam of humerus	Radiology	a	0.17	0.06	0.06	0.06	
73060	TC	X-ray exam of humerus	Radiology	a	0.00	0.57	0.57	0.57	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 124 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
73070	26	X-ray exam of elbow	Radiology		0.15	0.05	0.05		
73070	TC	X-ray exam of elbow	Radiology	a	0.00	0.52	0.52		
73080	26	X-ray exam of elbow	Radiology		0.17	0.06	0.06		
73080	TC	X-ray exam of elbow	Radiology	a	0.00	0.57	0.57		
73085	26	Contrast x-ray of elbow	Radiology		0.54	0.19	0.19		
73085	TC	Contrast x-ray of elbow	Radiology	a	0.00	2.10	2.10		
73090	26	X-ray exam of forearm	Radiology		0.16	0.05	0.05		
73090	TC	X-ray exam of forearm	Radiology	a	0.00	0.52	0.52		
73092	26	X-ray exam of arm, infant	Radiology		0.16	0.05	0.05		
73092	TC	X-ray exam of arm, infant	Radiology	a	0.00	0.49	0.49		
73100	26	X-ray exam of wrist	Radiology		0.16	0.06	0.06		
73100	TC	X-ray exam of wrist	Radiology	a	0.00	0.49	0.49		
73110	26	X-ray exam of wrist	Radiology		0.17	0.06	0.06		
73110	TC	X-ray exam of wrist	Radiology	a	0.00	0.53	0.53		
73115	26	Contrast x-ray of wrist	Radiology		0.54	0.19	0.19		
73115	TC	Contrast x-ray of wrist	Radiology	a	0.00	1.58	1.58		
73120	26	X-ray exam of hand	Radiology		0.16	0.05	0.05		
73120	TC	X-ray exam of hand	Radiology	a	0.00	0.49	0.49		
73130	26	X-ray exam of hand	Radiology		0.17	0.06	0.06		
73130	TC	X-ray exam of hand	Radiology	a	0.00	0.53	0.53		
73140	26	X-ray exam of finger(s)	Radiology		0.13	0.04	0.04		
73140	TC	X-ray exam of finger(s)	Radiology	a	0.00	0.41	0.41		
73200	26	Ct upper extremity w/o dye	Radiology		1.09	0.36	0.36		
73200	TC	Ct upper extremity w/o dye	Radiology	a	0.00	4.97	4.97		
73201	26	Ct upper extremity w/dye	Radiology		1.16	0.38	0.38		
73201	TC	Ct upper extremity w/dye	Radiology	a	0.00	5.93	5.93		
73202	26	Ct upper extremity w/o&w/dye	Radiology		1.22	0.40	0.40		
73202	TC	Ct upper extremity w/o&w/dye	Radiology	a	0.00	7.45	7.45		
73206	26	Ct angio upr extrem w/o&w/dye	Radiology		1.81	0.59	0.59		
73206	TC	Ct angio upr extrem w/o&w/dye	Radiology	a	0.00	11.00	11.00		
73218	26	Mri upper extremity w/o dye	Radiology		1.35	0.44	0.44		
73218	TC	Mri upper extremity w/o dye	Radiology	a	0.00	11.24	11.24		
73219	26	Mri upper extremity w/dye	Radiology		1.62	0.53	0.53		
73219	TC	Mri upper extremity w/dye	Radiology	a	0.00	13.49	13.49		
73220	26	Mri upper extremity w/o&w/dye	Radiology		2.15	0.71	0.71		
73220	TC	Mri upper extremity w/o&w/dye	Radiology	a	0.00	24.98	24.98		
73221	26	Mri joint upr extrem w/o dye	Radiology		1.35	0.44	0.44		
73221	TC	Mri joint upr extrem w/o dye	Radiology	a	0.00	11.24	11.24		
73222	26	Mri joint upr extrem w/dye	Radiology		1.62	0.53	0.53		
73222	TC	Mri joint upr extrem w/dye	Radiology	a	0.00	13.49	13.49		
73223	26	Mri joint upr extr w/o&w/dye	Radiology		2.15	0.71	0.71		
73223	TC	Mri joint upr extr w/o&w/dye	Radiology	a	0.00	24.98	24.98		
73225	26	Mri angio upr extr w/o&w/dye	Radiology		1.73	0.67	0.67		
73225	TC	Mri angio upr extr w/o&w/dye	Radiology	a	0.00	11.01	11.01		
73500	26	X-ray exam of hip	Radiology		0.17	0.06	0.06		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 125 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
73500	TC	X-ray exam of hip	Radiology	a	0.00	0.47	0.47	0.47	
73510	26	X-ray exam of hip	Radiology	a	0.21	0.07	0.07	0.07	
73510	TC	X-ray exam of hip	Radiology	a	0.00	0.57	0.57	0.57	
73520	26	X-ray exam of hips	Radiology	a	0.26	0.09	0.09	0.09	
73520	TC	X-ray exam of hips	Radiology	a	0.00	0.67	0.67	0.67	
73525	26	Contrast x-ray of hip	Radiology	a	0.54	0.18	0.18	0.18	
73525	TC	Contrast x-ray of hip	Radiology	a	0.00	2.10	2.10	2.10	
73530	26	X-ray exam of hip	Radiology	a	0.29	0.10	0.10	0.10	
73530	TC	X-ray exam of hip	Radiology	a	0.00	0.52	0.52	0.52	
73540	26	X-ray exam of pelvis & hips	Radiology	a	0.20	0.07	0.07	0.07	
73540	TC	X-ray exam of pelvis & hips	Radiology	a	0.00	0.57	0.57	0.57	
73542	26	X-ray exam of pelvis & hips	Radiology	a	0.59	0.16	0.16	0.16	
73542	TC	X-ray exam, sacroiliac joint	Radiology	a	0.00	2.10	2.10	2.10	
73542	TC	X-ray exam, sacroiliac joint	Radiology	a	0.17	0.06	0.06	0.06	
73550	26	X-ray exam of thigh	Radiology	a	0.00	0.57	0.57	0.57	
73550	TC	X-ray exam of thigh	Radiology	a	0.00	0.52	0.52	0.52	
73560	26	X-ray exam of knee, 1 or 2	Radiology	a	0.18	0.06	0.06	0.06	
73560	TC	X-ray exam of knee, 1 or 2	Radiology	a	0.00	0.57	0.57	0.57	
73562	26	X-ray exam of knee, 3	Radiology	a	0.00	0.52	0.52	0.52	
73562	TC	X-ray exam of knee, 3	Radiology	a	0.00	0.06	0.06	0.06	
73564	26	X-ray exam, knee, 4 or more	Radiology	a	0.00	0.06	0.06	0.06	
73564	TC	X-ray exam, knee, 4 or more	Radiology	a	0.18	0.06	0.06	0.06	
73565	26	X-ray exam of knees	Radiology	a	0.00	0.57	0.57	0.57	
73565	TC	X-ray exam of knees	Radiology	a	0.22	0.08	0.08	0.08	
73580	26	Contrast x-ray of knee joint	Radiology	a	0.00	0.62	0.62	0.62	
73580	TC	Contrast x-ray of knee joint	Radiology	a	0.17	0.06	0.06	0.06	
73590	26	X-ray exam of lower leg	Radiology	a	0.00	0.49	0.49	0.49	
73590	TC	X-ray exam of lower leg	Radiology	a	0.54	0.18	0.18	0.18	
73592	26	X-ray exam of leg, infant	Radiology	a	0.00	2.62	2.62	2.62	
73592	TC	X-ray exam of leg, infant	Radiology	a	0.17	0.06	0.06	0.06	
73600	26	X-ray exam of ankle	Radiology	a	0.16	0.06	0.06	0.06	
73600	TC	X-ray exam of ankle	Radiology	a	0.00	0.49	0.49	0.49	
73610	26	X-ray exam of ankle	Radiology	a	0.16	0.05	0.05	0.05	
73610	TC	X-ray exam of ankle	Radiology	a	0.00	0.49	0.49	0.49	
73615	26	Contrast x-ray of ankle	Radiology	a	0.17	0.06	0.06	0.06	
73615	TC	Contrast x-ray of ankle	Radiology	a	0.00	0.53	0.53	0.53	
73620	26	X-ray exam of foot	Radiology	a	0.54	0.19	0.19	0.19	
73620	TC	X-ray exam of foot	Radiology	a	0.00	2.10	2.10	2.10	
73630	26	X-ray exam of foot	Radiology	a	0.16	0.05	0.05	0.05	
73630	TC	X-ray exam of foot	Radiology	a	0.00	0.49	0.49	0.49	
73650	26	X-ray exam of heel	Radiology	a	0.17	0.06	0.06	0.06	
73650	TC	X-ray exam of heel	Radiology	a	0.00	0.53	0.53	0.53	
73660	26	X-ray exam of toe(s)	Radiology	a	0.16	0.05	0.05	0.05	
73660	TC	X-ray exam of toe(s)	Radiology	a	0.00	0.47	0.47	0.47	
73680	26	X-ray exam of toe(s)	Radiology	a	0.13	0.04	0.04	0.04	
73700	TC	Ct lower extremity w/o dye	Radiology	a	0.00	0.41	0.41	0.41	
73700	TC	Ct lower extremity w/o dye	Radiology	a	1.09	0.36	0.36	0.36	
73700	TC	Ct lower extremity w/o dye	Radiology	a	0.00	4.97	4.97	4.97	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 126 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
73701	26	Ct lower extremity w/dye	Radiology	a	1.16	0.38	0.38		
73701	TC	Ct lower extremity w/dye	Radiology		0.00	5.93	5.93		
73702	26	Ct lwr extremity w/o&w/dye	Radiology	a	1.22	0.40	0.40		
73702	TC	Ct lwr extremity w/o&w/dye	Radiology		0.00	7.45	7.45		
73706	26	Ct angio lwr extr w/o&w/dye	Radiology	a	1.90	0.62	0.62		
73706	TC	Ct angio lwr extr w/o&w/dye	Radiology		0.00	11.00	11.00		
73718	26	Mri lower extremity w/o dye	Radiology	a	1.35	0.44	0.44		
73718	TC	Mri lower extremity w/o dye	Radiology		0.00	11.24	11.24		
73719	26	Mri lower extremity w/dye	Radiology	a	1.62	0.53	0.53		
73719	TC	Mri lower extremity w/dye	Radiology		0.00	13.49	13.49		
73720	26	Mri lwr extremity w/o&w/dye	Radiology	a	2.15	0.71	0.71		
73720	TC	Mri lwr extremity w/o&w/dye	Radiology		0.00	24.98	24.98		
73721	26	Mri int of lwr extre w/o dye	Radiology	a	1.35	0.44	0.44		
73721	TC	Mri int of lwr extre w/o dye	Radiology		0.00	11.24	11.24		
73722	26	Mri joint of lwr extr w/dye	Radiology	a	1.62	0.53	0.53		
73722	TC	Mri joint of lwr extr w/dye	Radiology		0.00	13.49	13.49		
73723	26	Mri joint lwr extr w/o&w/dye	Radiology	a	2.15	0.71	0.71		
73723	TC	Mri joint lwr extr w/o&w/dye	Radiology		0.00	24.98	24.98		
73725	26	Mri ang lwr ext w or w/o dye	Radiology	a	1.82	0.60	0.60		
73725	TC	Mri ang lwr ext w or w/o dye	Radiology		0.00	11.24	11.24		
74000	26	X-ray exam of abdomen	Radiology	a	0.18	0.06	0.06		
74000	TC	X-ray exam of abdomen	Radiology		0.00	0.52	0.52		
74010	26	X-ray exam of abdomen	Radiology	a	0.23	0.08	0.08		
74010	TC	X-ray exam of abdomen	Radiology		0.00	0.57	0.57		
74020	26	X-ray exam of abdomen	Radiology	a	0.27	0.09	0.09		
74020	TC	X-ray exam of abdomen	Radiology		0.00	0.62	0.62		
74022	26	X-ray exam series, abdomen	Radiology	a	0.32	0.11	0.11		
74022	TC	X-ray exam series, abdomen	Radiology		0.00	0.74	0.74		
74150	26	Ct abdomen w/o dye	Radiology	a	1.19	0.39	0.39		
74150	TC	Ct abdomen w/o dye	Radiology		0.00	5.67	5.67		
74160	26	Ct abdomen w/dye	Radiology	a	1.27	0.41	0.41		
74160	TC	Ct abdomen w/dye	Radiology		0.00	6.87	6.87		
74170	26	Ct abdomen w/o&w/dye	Radiology	a	1.40	0.45	0.45		
74170	TC	Ct abdomen w/o&w/dye	Radiology		0.00	8.52	8.52		
74175	26	Ct angio abdom w/o&w/dye	Radiology	a	1.90	0.62	0.62		
74175	TC	Ct angio abdom w/o&w/dye	Radiology		0.00	12.07	12.07		
74181	26	Mri abdomen w/o dye	Radiology	a	1.46	0.48	0.48		
74181	TC	Mri abdomen w/o dye	Radiology		0.00	11.24	11.24		
74182	26	Mri abdomen w/dye	Radiology	a	1.73	0.56	0.56		
74182	TC	Mri abdomen w/dye	Radiology		0.00	13.49	13.49		
74183	26	Mri abdomen w/o&w/dye	Radiology	a	2.26	0.74	0.74		
74183	TC	Mri abdomen w/o&w/dye	Radiology		0.00	24.98	24.98		
74185	26	Mri angio, abdom w or w/o dy	Radiology	a	1.80	0.59	0.59		
74185	TC	Mri angio, abdom w or w/o dy	Radiology		0.00	11.24	11.24		
74190	26	X-ray exam of pentoneum	Radiology	a	0.48	0.16	0.16		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 127 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
74190	TC	X-ray exam of peritoneum	Radiology	a	0.00	1.31	1.31		
74210	26	Contrast x-ray exam of throat	Radiology		0.36	0.12	0.12		
74210	TC	Contrast x-ray exam of throat	Radiology	a	0.00	1.19	1.19		
74220	26	Contrast x-ray, esophagus	Radiology		0.46	0.15	0.15		
74220	TC	Contrast x-ray, esophagus	Radiology	a	0.00	1.19	1.19		
74230	26	Cine/vid x-ray, throat/esoph	Radiology		0.53	0.18	0.18		
74230	TC	Cine/vid x-ray, throat/esoph	Radiology	a	0.00	1.31	1.31		
74235	26	Remove esophagus obstruction	Radiology		1.19	0.39	0.39		
74235	TC	Remove esophagus obstruction	Radiology	a	0.00	2.62	2.62		
74240	26	X-ray exam, upper gi tract	Radiology		0.69	0.23	0.23		
74240	TC	X-ray exam, upper gi tract	Radiology	a	0.00	1.46	1.46		
74241	26	X-ray exam, upper gi tract	Radiology		0.69	0.23	0.23		
74241	TC	X-ray exam, upper gi tract	Radiology	a	0.00	1.49	1.49		
74245	26	X-ray exam, upper gi tract	Radiology		0.91	0.30	0.30		
74245	TC	X-ray exam, upper gi tract	Radiology	a	0.00	2.39	2.39		
74246	26	Contrast x-ray upper gi tract	Radiology		0.69	0.23	0.23		
74246	TC	Contrast x-ray upper gi tract	Radiology	a	0.00	1.65	1.65		
74247	26	Contrast x-ray upper gi tract	Radiology		0.69	0.23	0.23		
74247	TC	Contrast x-ray upper gi tract	Radiology	a	0.00	1.69	1.69		
74249	26	Contrast x-ray upper gi tract	Radiology		0.91	0.30	0.30		
74249	TC	Contrast x-ray upper gi tract	Radiology	a	0.00	2.59	2.59		
74250	26	X-ray exam of small bowel	Radiology		0.47	0.16	0.16		
74250	TC	X-ray exam of small bowel	Radiology	a	0.00	1.31	1.31		
74251	26	X-ray exam of small bowel	Radiology		0.69	0.23	0.23		
74251	TC	X-ray exam of small bowel	Radiology	a	0.00	1.31	1.31		
74260	26	X-ray exam of small bowel	Radiology		0.50	0.17	0.17		
74260	TC	X-ray exam of small bowel	Radiology	a	0.00	1.49	1.49		
74270	26	Contrast x-ray exam of colon	Radiology		0.69	0.23	0.23		
74270	TC	Contrast x-ray exam of colon	Radiology	a	0.00	1.71	1.71		
74280	26	Contrast x-ray exam of colon	Radiology		0.99	0.33	0.33		
74280	TC	Contrast x-ray exam of colon	Radiology	a	0.00	2.24	2.24		
74283	26	Contrast x-ray exam of colon	Radiology		2.02	0.66	0.66		
74283	TC	Contrast x-ray exam of colon	Radiology	a	0.00	2.58	2.58		
74290	26	Contrast x-ray, gallbladder	Radiology		0.32	0.11	0.11		
74290	TC	Contrast x-ray, gallbladder	Radiology	a	0.00	0.74	0.74		
74291	26	Contrast x-rays, gallbladder	Radiology		0.20	0.07	0.07		
74291	TC	Contrast x-rays, gallbladder	Radiology	a	0.00	0.41	0.41		
74300	26	X-ray bile ducts/pancreas	Radiology		0.36	0.12	0.12		
74300	TC	X-ray bile ducts/pancreas	Radiology	a	0.00	0.12	0.12		
74301	26	X-rays at surgery add-on	Radiology		0.21	0.07	0.07		MDR
74301	TC	X-rays at surgery add-on	Radiology	a	0.00	0.07	0.07	1.20	MDR
74305	26	X-ray bile ducts/pancreas	Radiology		0.42	0.14	0.14		
74305	TC	X-ray bile ducts/pancreas	Radiology	a	0.00	0.79	0.79	0.14	
74320	26	Contrast x-ray of bile ducts	Radiology		0.54	0.18	0.18		
74320	TC	Contrast x-ray of bile ducts	Radiology	a	0.00	3.17	3.17	0.18	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 128 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
74327	26	X-ray bile stone removal	Radiology		0.70	0.23	0.23	0.23	
74327	TC	X-ray bile stone removal	Radiology	a	0.00	1.77	1.77	1.77	
74328	26	X-ray bile duct endoscopy	Radiology		0.70	0.23	0.23	0.23	
74328	TC	X-ray bile duct endoscopy	Radiology	a	0.00	3.17	3.17	3.17	
74329	26	X-ray for pancreas endoscopy	Radiology		0.70	0.23	0.23	0.23	
74329	TC	X-ray for pancreas endoscopy	Radiology	a	0.00	3.17	3.17	3.17	
74330	26	X-ray bile/panc endoscopy	Radiology		0.90	0.30	0.30	0.30	
74330	TC	X-ray bile/panc endoscopy	Radiology	a	0.00	3.17	3.17	3.17	
74340	26	X-ray guide for GI tube	Radiology		0.54	0.18	0.18	0.18	
74340	TC	X-ray guide for GI tube	Radiology	a	0.00	2.62	2.62	2.62	
74350	26	X-ray guide, stomach tube	Radiology		0.76	0.25	0.25	0.25	
74350	TC	X-ray guide, stomach tube	Radiology	a	0.00	3.17	3.17	3.17	
74355	26	X-ray guide, intestinal tube	Radiology		0.76	0.25	0.25	0.25	
74355	TC	X-ray guide, intestinal tube	Radiology	a	0.00	2.62	2.62	2.62	
74360	26	X-ray guide, GI dilation	Radiology		0.54	0.19	0.19	0.19	
74360	TC	X-ray guide, GI dilation	Radiology	a	0.00	3.17	3.17	3.17	
74363	26	X-ray, bile duct dilation	Radiology		0.88	0.29	0.29	0.29	
74363	TC	X-ray, bile duct dilation	Radiology	a	0.00	6.12	6.12	6.12	
74400	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16	0.16	
74400	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.69	1.69	1.69	
74410	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16	0.16	
74410	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.96	1.96	1.96	
74415	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16	0.16	
74415	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	2.12	2.12	2.12	
74420	26	Contrst x-ray, urinary tract	Radiology		0.36	0.12	0.12	0.12	
74420	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	2.62	2.62	2.62	
74425	26	Contrst x-ray, urinary tract	Radiology		0.36	0.12	0.12	0.12	
74425	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.31	1.31	1.31	
74430	26	Contrast x-ray, bladder	Radiology		0.32	0.11	0.11	0.11	
74430	TC	Contrast x-ray, bladder	Radiology	a	0.00	1.06	1.06	1.06	
74440	26	X-ray, male genital tract	Radiology		0.38	0.12	0.12	0.12	
74440	TC	X-ray, male genital tract	Radiology	a	0.00	1.13	1.13	1.13	
74445	26	X-ray exam of penis	Radiology		1.14	0.37	0.37	0.37	
74445	TC	X-ray exam of penis	Radiology	a	0.00	1.13	1.13	1.13	
74450	26	X-ray, urethra/bladder	Radiology		0.33	0.11	0.11	0.11	
74450	TC	X-ray, urethra/bladder	Radiology	a	0.00	1.46	1.46	1.46	
74455	26	X-ray, urethra/bladder	Radiology		0.33	0.11	0.11	0.11	
74455	TC	X-ray, urethra/bladder	Radiology	a	0.00	1.58	1.58	1.58	
74470	26	X-ray exam of kidney lesion	Radiology		0.54	0.18	0.18	0.18	
74470	TC	X-ray exam of kidney lesion	Radiology	a	0.00	1.25	1.25	1.25	
74475	26	X-ray control, cath insert	Radiology		0.54	0.18	0.18	0.18	
74475	TC	X-ray control, cath insert	Radiology	a	0.00	4.09	4.09	4.09	
74480	26	X-ray control, cath insert	Radiology		0.54	0.18	0.18	0.18	
74480	TC	X-ray control, cath insert	Radiology	a	0.00	4.09	4.09	4.09	
74485	26	X-ray guide, GU dilation	Radiology		0.54	0.18	0.18	0.18	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 129 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
74485	TC	X-ray guide, GU dilation	Radiology	a	0.00	3.17	3.17		
74710	26	X-ray measurement of pelvis	Radiology		0.34	0.11	0.11		
74710	TC	X-ray measurement of pelvis	Radiology	a	0.00	1.06	1.06		
74740	26	X-ray, female genital tract	Radiology		0.38	0.13	0.13		
74740	TC	X-ray, female genital tract	Radiology	a	0.00	1.31	1.31		
74742	26	X-ray, fallopian tube	Radiology		0.61	0.20	0.20		
74742	TC	X-ray, fallopian tube	Radiology	a	0.00	3.17	3.17		
74775	26	X-ray exam of perineum	Radiology		0.62	0.21	0.21		
74775	TC	X-ray exam of perineum	Radiology	a	0.00	1.46	1.46		
75552	26	Heart mri for morph w/o dye	Radiology		1.60	0.53	0.53		
75552	TC	Heart mri for morph w/o dye	Radiology	a	0.00	11.24	11.24		
75553	26	Heart mri for morph w/dye	Radiology		2.00	0.65	0.65		
75553	TC	Heart mri for morph w/dye	Radiology	a	0.00	11.24	11.24		
75554	26	Cardiac MRI/function	Radiology		1.83	0.64	0.64		
75554	TC	Cardiac MRI/function	Radiology	a	0.00	11.24	11.24		
75555	26	Cardiac MRI/limited study	Radiology		1.74	0.64	0.64		
75555	TC	Cardiac MRI/limited study	Radiology	a	0.00	11.24	11.24		
75556	26	Cardiac MRI/flow mapping	Radiology		0.49	0.19	0.19		
75556	TC	Cardiac MRI/flow mapping	Radiology	a	0.00	12.64	12.64		
75600	26	Contrast x-ray exam of aorta	Radiology		1.14	0.39	0.39		
75600	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	12.64	12.64		
75605	26	Contrast x-ray exam of aorta	Radiology		1.14	0.38	0.38		
75605	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	12.64	12.64		
75625	26	Contrast x-ray exam of aorta	Radiology		1.79	0.61	0.61		
75625	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	13.17	13.17		
75630	26	X-ray aorta, leg arteries	Radiology		2.40	0.80	0.80		
75630	TC	X-ray aorta, leg arteries	Radiology	a	0.00	15.97	15.97		
75635	26	Ct angio abdominal arteries	Radiology		0.00	0.49	0.49		
75635	TC	Ct angio abdominal arteries	Radiology	a	0.00	12.64	12.64		
75650	26	Artery x-rays, head & neck	Radiology		1.31	0.47	0.47		
75650	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75650	TC	Artery x-rays, head & neck	Radiology	a	1.49	0.49	0.49		
75658	26	Artery x-rays, arm	Radiology		1.66	0.59	0.59		
75658	TC	Artery x-rays, arm	Radiology	a	0.00	12.64	12.64		
75660	26	Artery x-rays, head & neck	Radiology		1.31	0.44	0.44		
75660	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75662	26	Artery x-rays, head & neck	Radiology		1.31	0.44	0.44		
75662	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75665	26	Artery x-rays, head & neck	Radiology		1.66	0.55	0.55		
75665	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75671	26	Artery x-rays, head & neck	Radiology		1.31	0.44	0.44		
75671	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75676	26	Artery x-rays, neck	Radiology		1.31	0.44	0.44		
75676	TC	Artery x-rays, neck	Radiology	a	0.00	12.64	12.64		
75680	26	Artery x-rays, neck	Radiology		1.66	0.55	0.55		
75680	TC	Artery x-rays, neck	Radiology	a	0.00	12.64	12.64		
75685	26	Artery x-rays, spine	Radiology		1.31	0.43	0.43		
75685	TC	Artery x-rays, spine	Radiology	a	0.00	12.64	12.64		
								12.37	PHCS

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 130 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
75685	TC	Artery x-rays, spine	Radiology	a	0.00	12.64	12.64	12.64	
75705	26	Artery x-rays, spine	Radiology		2.18	0.73	0.73	0.73	
75705	TC	Artery x-rays, spine	Radiology	a	0.00	12.64	12.64	12.64	
75710	TC	Artery x-rays, arm/leg	Radiology	a	0.00	0.38	0.38	0.38	
75710	TC	Artery x-rays, arm/leg	Radiology	a	1.14	12.64	12.64	12.64	
75716	26	Artery x-rays, arms/legs	Radiology		1.31	0.43	0.43	0.43	
75716	TC	Artery x-rays, arms/legs	Radiology	a	0.00	12.64	12.64	12.64	
75722	26	Artery x-rays, kidney	Radiology		1.14	0.40	0.40	0.40	
75722	TC	Artery x-rays, kidney	Radiology	a	0.00	12.64	12.64	12.64	
75724	26	Artery x-rays, kidneys	Radiology		1.49	0.56	0.56	0.56	
75724	TC	Artery x-rays, kidneys	Radiology	a	0.00	12.64	12.64	12.64	
75726	26	Artery x-rays, abdomen	Radiology		1.14	0.37	0.37	0.37	
75726	TC	Artery x-rays, abdomen	Radiology	a	0.00	12.64	12.64	12.64	
75731	26	Artery x-rays, adrenal gland	Radiology		1.14	0.37	0.37	0.37	
75731	TC	Artery x-rays, adrenal gland	Radiology	a	0.00	12.64	12.64	12.64	
75733	26	Artery x-rays, adrenals	Radiology		1.31	0.43	0.43	0.43	
75733	TC	Artery x-rays, adrenals	Radiology	a	0.00	12.64	12.64	12.64	
75736	26	Artery x-rays, pelvis	Radiology		1.14	0.37	0.37	0.37	
75736	TC	Artery x-rays, pelvis	Radiology	a	0.00	12.64	12.64	12.64	
75741	26	Artery x-rays, lung	Radiology		1.31	0.43	0.43	0.43	
75741	TC	Artery x-rays, lung	Radiology	a	0.00	12.64	12.64	12.64	
75743	26	Artery x-rays, lungs	Radiology		1.66	0.54	0.54	0.54	
75743	TC	Artery x-rays, lungs	Radiology	a	0.00	12.64	12.64	12.64	
75746	26	Artery x-rays, lung	Radiology		1.14	0.37	0.37	0.37	
75746	TC	Artery x-rays, lung	Radiology	a	0.00	12.64	12.64	12.64	
75756	26	Artery x-rays, chest	Radiology		1.14	0.44	0.44	0.44	
75756	TC	Artery x-rays, chest	Radiology	a	0.00	12.64	12.64	12.64	
75774	26	Artery x-ray, each vessel	Radiology		0.36	0.13	0.13	0.13	
75774	TC	Artery x-ray, each vessel	Radiology	a	0.00	12.64	12.64	12.64	
75790	26	Visualize A-V shunt	Radiology		1.84	0.60	0.60	0.60	
75790	TC	Visualize A-V shunt	Radiology	a	0.00	1.36	1.36	1.36	
75801	26	Lymph vessel x-ray, arm/leg	Radiology		0.81	0.27	0.27	0.27	
75801	TC	Lymph vessel x-ray, arm/leg	Radiology	a	0.00	5.44	5.44	5.44	
75803	26	Lymph vessel x-ray, arms/legs	Radiology		1.17	0.38	0.38	0.38	
75803	TC	Lymph vessel x-ray, arms/legs	Radiology	a	0.00	5.44	5.44	5.44	
75805	26	Lymph vessel x-ray, trunk	Radiology		0.81	0.27	0.27	0.27	
75805	TC	Lymph vessel x-ray, trunk	Radiology	a	0.00	6.12	6.12	6.12	
75807	26	Lymph vessel x-ray, trunk	Radiology		1.17	0.38	0.38	0.38	
75807	TC	Lymph vessel x-ray, trunk	Radiology	a	0.00	6.12	6.12	6.12	
75809	26	Nonvascular shunt, x-ray	Radiology		0.47	0.16	0.16	0.16	
75809	TC	Nonvascular shunt, x-ray	Radiology	a	0.00	0.79	0.79	0.79	
75810	26	Vein x-ray, spleen/liver	Radiology		1.14	0.37	0.37	0.37	
75810	TC	Vein x-ray, spleen/liver	Radiology	a	0.00	12.64	12.64	12.64	
75820	26	Vein x-ray, arm/leg	Radiology		0.70	0.23	0.23	0.23	
75820	TC	Vein x-ray, arm/leg	Radiology	a	0.00	0.95	0.95	0.95	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 131 OF 179

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
75822	26	Vein x-ray, arms/legs			1.06	0.35	0.35		
75822	TC	Vein x-ray, arms/legs		a	0.00	1.48	1.48		
75825	26	Vein x-ray, trunk			1.14	0.37	0.37		
75825	TC	Vein x-ray, trunk		a	0.00	12.64	12.64		
75827	26	Vein x-ray, chest			1.14	0.37	0.37		
75827	TC	Vein x-ray, chest		a	0.00	12.64	12.64		
75831	26	Vein x-ray, kidney			1.14	0.37	0.37		
75831	TC	Vein x-ray, kidney		a	0.00	12.64	12.64		
75833	26	Vein x-ray, kidneys			1.49	0.49	0.49		
75833	TC	Vein x-ray, kidneys		a	0.00	12.64	12.64		
75840	26	Vein x-ray, adrenal gland			1.14	0.37	0.37		
75840	TC	Vein x-ray, adrenal gland		a	0.00	12.64	12.64		
75842	26	Vein x-ray, adrenal glands			1.49	0.48	0.48		
75842	TC	Vein x-ray, adrenal glands		a	0.00	12.64	12.64		
75860	26	Vein x-ray, neck			1.14	0.39	0.39		
75860	TC	Vein x-ray, neck		a	0.00	12.64	12.64		
75870	26	Vein x-ray, skull			1.14	0.39	0.39		
75870	TC	Vein x-ray, skull		a	0.00	12.64	12.64		
75872	26	Vein x-ray, skull			1.14	0.37	0.37		
75872	TC	Vein x-ray, skull		a	0.00	12.64	12.64		
75880	26	Vein x-ray, eye socket			0.70	0.23	0.23		
75880	TC	Vein x-ray, eye socket		a	0.00	0.95	0.95		
75885	26	Vein x-ray, liver			1.44	0.47	0.47		
75885	TC	Vein x-ray, liver		a	0.00	12.64	12.64		
75887	26	Vein x-ray, liver			1.44	0.47	0.47		
75887	TC	Vein x-ray, liver		a	0.00	12.64	12.64		
75889	26	Vein x-ray, liver			1.14	0.37	0.37		
75889	TC	Vein x-ray, liver		a	0.00	12.64	12.64		
75891	26	Vein x-ray, liver			1.14	0.37	0.37		
75891	TC	Vein x-ray, liver		a	0.00	12.64	12.64		
75893	26	Venous sampling by catheter			0.54	0.18	0.18		
75893	TC	Venous sampling by catheter		a	0.00	12.64	12.64		
75894	26	X-rays, transcaath therapy			1.31	0.43	0.43		
75894	TC	X-rays, transcaath therapy		a	0.00	24.22	24.22		
75896	26	X-rays, transcaath therapy			1.31	0.45	0.45		
75896	TC	X-rays, transcaath therapy		a	0.00	21.06	21.06		
75898	26	Follow-up angiography			1.65	0.55	0.55		
75898	TC	Follow-up angiography		a	0.00	1.06	1.06		
75900	26	Arterial catheter exchange			0.49	0.16	0.16		
75900	TC	Arterial catheter exchange		a	0.00	21.04	21.04		
75901	26	Remove cva device obstruct			0.49	0.16	0.16		
75901	TC	Remove cva device obstruct		a	0.00	1.31	1.31		
75902	26	Remove cva lumen obstruct			0.39	0.13	0.13		
75902	TC	Remove cva lumen obstruct		a	0.00	1.31	1.31		
75940	26	X-ray placement, vein filter			0.54	0.18	0.18		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 132 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
75940	TC	X-ray placement, vein filter	Radiology	a	0.00	12.64	12.64		
75945	26	Intravascular us	Radiology	a	0.40	0.14	0.14		
75945	TC	Intravascular us	Radiology	a	0.00	4.58	4.58		
75946	26	Intravascular us add-on	Radiology	a	0.40	0.14	0.14		
75946	TC	Intravascular us add-on	Radiology	a	0.00	2.30	2.30		
75952	26	Endovasc repair abdom aorta	Radiology	a	4.49	1.50	1.50	23.49	MDR
75952	TC	Endovasc repair abdom aorta	Radiology	a	1.36	0.45	0.45		MDR
75953	26	Abdom aneurysm endovas rpr	Radiology	a	2.25	0.47	0.47	23.49	MDR
75953	TC	Abdom aneurysm endovas rpr	Radiology	a	0.82	0.29	0.29		
75954	26	Iliac aneurysm endovas rpr	Radiology	a	0.00	14.95	14.95		
75954	TC	Iliac aneurysm endovas rpr	Radiology	a	0.00	4.24	4.24		
75954	26	Transcatheter intro, stent	Radiology	a	0.00	10.54	10.54		
75954	TC	Transcatheter intro, stent	Radiology	a	0.54	0.19	0.19		
75960	26	Retrieval, broken catheter	Radiology	a	0.00	15.80	15.80		
75961	TC	Retrieval, broken catheter	Radiology	a	0.36	0.12	0.12		
75962	26	Repair arterial blockage	Radiology	a	0.00	8.42	8.42		
75962	TC	Repair arterial blockage	Radiology	a	1.31	0.46	0.46		
75964	26	Repair artery blockage, each	Radiology	a	0.00	15.80	15.80		
75964	TC	Repair artery blockage, each	Radiology	a	0.36	0.13	0.13		
75966	26	Repair arterial blockage	Radiology	a	0.00	8.42	8.42		
75966	TC	Repair arterial blockage	Radiology	a	0.63	0.29	0.29		
75968	26	Repair artery blockage, each	Radiology	a	0.00	11.59	11.59		
75968	TC	Repair artery blockage, each	Radiology	a	0.54	0.18	0.18		
75970	26	Vascular biopsy	Radiology	a	0.00	15.80	15.80		
75970	TC	Vascular biopsy	Radiology	a	1.44	0.47	0.47		
75976	26	Repair venous blockage	Radiology	a	0.00	5.44	5.44		
75976	TC	Repair venous blockage	Radiology	a	1.44	0.46	0.46		
75980	26	Contrast xray exam bile duct	Radiology	a	0.00	6.12	6.12		
75980	TC	Contrast xray exam bile duct	Radiology	a	0.72	0.24	0.24		
75982	26	Contrast xray exam bile duct	Radiology	a	0.00	1.96	1.96		
75982	TC	Contrast xray exam bile duct	Radiology	a	1.19	0.38	0.38		
75984	26	Xray control catheter change	Radiology	a	0.00	3.17	3.17		
75984	TC	Xray control catheter change	Radiology	a	0.54	0.19	0.19		
75988	26	Abscess drainage under x-ray	Radiology	a	0.00	15.80	15.80		
75988	TC	Abscess drainage under x-ray	Radiology	a	0.36	0.14	0.14		
75992	26	Atherectomy, x-ray exam	Radiology	a	0.00	8.42	8.42		
75992	TC	Atherectomy, x-ray exam	Radiology	a	1.31	0.46	0.46		
75993	26	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75993	TC	Atherectomy, x-ray exam	Radiology	a	1.31	0.47	0.47		
75994	26	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75994	TC	Atherectomy, x-ray exam	Radiology	a	1.31	0.47	0.47		
75995	26	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75995	TC	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75996	26	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75996	TC	Atherectomy, x-ray exam	Radiology	a	0.00	15.80	15.80		
75996	TC	Atherectomy, x-ray exam	Radiology	a	0.00	8.42	8.42		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 133 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
75998	26	Fluoroguide for vein device	Radiology		0.38	0.13	0.13		
75998	TC	Fluoroguide for vein device	Radiology	a	0.00	1.31	1.31		
76000	26	Fluoroscope examination	Radiology		0.17	0.05	0.05		
76000	TC	Fluoroscope examination	Radiology	a	0.00	1.31	1.31		
76001	26	Fluoroscope exam, extensive	Radiology		0.67	0.22	0.22		
76001	TC	Fluoroscope exam, extensive	Radiology	a	0.00	2.62	2.62		
76003	26	Needle localization by x-ray	Radiology		0.54	0.17	0.17		
76003	TC	Needle localization by x-ray	Radiology	a	0.00	1.31	1.31		
76005	26	Fluoroguide for spine inject	Radiology		0.80	0.16	0.16		
76005	TC	Fluoroguide for spine inject	Radiology	a	0.00	1.31	1.31		
76006	26	X-ray, stress view	Radiology		0.41	0.19	0.19		
76010	26	X-ray, nose to rectum	Radiology		0.18	0.06	0.06		
76010	TC	X-ray, nose to rectum	Radiology	a	0.00	0.52	0.52		MDR
76012	26	Percut vertebroplasty fluor	Radiology		1.31	0.46	0.46	5.38	
76012	TC	Percut vertebroplasty fluor	Radiology	a	0.00	0.47	0.47	7.77	MDR
76013	26	Percut vertebroplasty, ct	Radiology		0.00	0.06	0.06		
76013	TC	Percut vertebroplasty, ct	Radiology	a	0.00	0.52	0.52		
76020	26	X-rays for bone age	Radiology		1.31	0.46	0.46		
76020	TC	X-rays for bone age	Radiology	a	0.00	0.47	0.47		
76040	26	X-rays, bone evaluation	Radiology		0.19	0.06	0.06		
76040	TC	X-rays, bone evaluation	Radiology	a	0.00	0.52	0.52		
76061	26	X-rays, bone survey	Radiology		0.27	0.09	0.09		
76061	TC	X-rays, bone survey	Radiology	a	0.00	0.79	0.79		
76061	TC	X-rays, bone survey	Radiology	a	0.45	0.15	0.15		
76062	26	X-rays, bone survey	Radiology		0.00	1.00	1.00		
76062	TC	X-rays, bone survey	Radiology	a	0.54	0.18	0.18		
76065	26	X-rays, bone evaluation	Radiology		0.00	1.44	1.44		
76065	TC	X-rays, bone evaluation	Radiology	a	0.70	0.24	0.24		
76065	TC	X-rays, bone evaluation	Radiology	a	0.00	0.74	0.74		
76066	26	Joint survey, single view	Radiology		0.31	0.11	0.11		
76066	TC	Joint survey, single view	Radiology	a	0.00	1.12	1.12		
76070	26	Ct bone density, axial	Radiology		0.25	0.08	0.08		
76070	TC	Ct bone density, axial	Radiology	a	0.00	2.96	2.96		
76071	26	Ct bone density, peripheral	Radiology		0.22	0.07	0.07		
76071	TC	Ct bone density, peripheral	Radiology	a	0.00	2.96	2.96		
76075	26	Dexa, axial skeleton study	Radiology		0.30	0.10	0.10		
76075	TC	Dexa, axial skeleton study	Radiology	a	0.00	3.11	3.11		
76076	26	Dexa, peripheral study	Radiology		0.22	0.08	0.08		
76076	TC	Dexa, peripheral study	Radiology	a	0.00	0.76	0.76		
76078	26	Radiographic absorptiometry	Radiology		0.20	0.07	0.07		
76078	TC	Radiographic absorptiometry	Radiology	a	0.00	0.76	0.76		
76080	26	X-ray exam of fistula	Radiology		0.54	0.18	0.18		
76080	TC	X-ray exam of fistula	Radiology	a	0.00	1.06	1.06		
76080	TC	X-ray exam of fistula	Radiology	a	0.06	0.02	0.02		
76082	26	Computer mammogram add-on	Radiology		0.06	0.41	0.41		
76082	TC	Computer mammogram add-on	Radiology	a	0.00	0.02	0.02		
76083	26	Computer mammogram add-on	Radiology		0.06	0.41	0.41		
76083	TC	Computer mammogram add-on	Radiology	a	0.00	0.02	0.02		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 134 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
76086	26	X-ray of mammary duct	Radiology	a	0.36	0.12	0.12	0.60	
76086	TC	X-ray of mammary duct	Radiology		0.00	2.62	2.62	2.62	
76088	TC	X-ray of mammary ducts	Radiology	a	0.45	0.15	0.15	0.60	
76088	TC	X-ray of mammary ducts	Radiology		0.00	3.68	3.68	3.68	
76090	26	Mammogram, one breast	Radiology	a	0.70	0.23	0.23	0.93	
76090	TC	Mammogram, one breast	Radiology		0.00	1.06	1.06	1.06	
76091	26	Mammogram, both breasts	Radiology	a	0.87	0.29	0.29	1.16	
76091	TC	Mammogram, both breasts	Radiology		0.00	1.31	1.31	1.31	
76092	26	Mammogram, screening	Radiology	a	0.70	0.23	0.23	0.93	
76092	TC	Mammogram, screening	Radiology		0.00	1.23	1.23	1.23	
76093	26	Magnetic image, breast	Radiology	a	1.63	0.53	0.53	2.16	
76093	TC	Magnetic image, breast	Radiology		0.00	17.68	17.68	17.68	
76094	26	Magnetic image, both breasts	Radiology	a	1.63	0.53	0.53	2.16	
76094	TC	Magnetic image, both breasts	Radiology		0.00	23.99	23.99	23.99	
76095	26	Stereolactic breast biopsy	Radiology	a	1.59	0.52	0.52	2.11	
76095	TC	Stereolactic breast biopsy	Radiology		0.00	7.19	7.19	7.19	
76096	26	X-ray of needle wire, breast	Radiology	a	0.56	0.19	0.19	0.75	
76096	TC	X-ray of needle wire, breast	Radiology		0.00	1.31	1.31	1.31	
76096	26	X-ray exam, breast specimen	Radiology	a	0.16	0.05	0.05	0.21	
76096	TC	X-ray exam, breast specimen	Radiology		0.00	0.41	0.41	0.41	
76098	26	X-ray exam, breast specimen	Radiology	a	0.58	0.19	0.19	0.77	
76098	TC	X-ray exam, breast specimen	Radiology		0.00	1.25	1.25	1.25	
76100	26	X-ray exam of body section	Radiology	a	0.58	0.19	0.19	0.77	
76100	TC	X-ray exam of body section	Radiology		0.00	1.43	1.43	1.43	
76101	26	Complex body section x-ray	Radiology	a	0.58	0.20	0.20	0.78	
76101	TC	Complex body section x-ray	Radiology		0.00	1.74	1.74	1.74	
76102	26	Complex body section x-rays	Radiology	a	0.38	0.13	0.13	0.51	
76102	TC	Complex body section x-rays	Radiology		0.00	1.06	1.06	1.06	
76120	26	Cine/video x-rays	Radiology	a	0.27	0.09	0.09	0.36	
76120	TC	Cine/video x-rays	Radiology		0.00	0.79	0.79	0.79	
76125	26	Cine/video x-rays add-on	Radiology	a	0.00	0.00	0.00	0.00	SAF
76125	TC	Cine/video x-rays add-on	Radiology		0.00	0.00	0.00	0.00	MDR
76140	26	X-ray consultation	Radiology	a	0.00	0.41	0.41	0.41	MDR
76150	26	X-ray exam, dry process	Radiology	a	0.00	0.41	0.41	0.41	MDR
76350	26	Special x-ray contrast study	Radiology	a	1.21	0.40	0.40	1.61	
76350	TC	Special x-ray contrast study	Radiology		0.00	8.29	8.29	8.29	
76355	26	CAT scan for localization	Radiology	a	1.16	0.37	0.37	1.53	
76355	TC	CAT scan for localization	Radiology		0.00	8.29	8.29	8.29	
76360	26	CAT scan for needle biopsy	Radiology	a	3.99	1.30	1.30	5.29	
76360	TC	CAT scan for needle biopsy	Radiology		0.00	8.29	8.29	8.29	
76362	26	CAT scan for tissue ablation	Radiology	a	0.85	0.28	0.28	1.13	
76362	TC	CAT scan for tissue ablation	Radiology		0.00	2.96	2.96	2.96	
76370	26	CAT scan for therapy guide	Radiology	a	0.16	0.05	0.05	0.21	
76370	TC	CAT scan for therapy guide	Radiology		0.00	0.16	0.16	0.16	
76375	26	3d/holograph reconstr add-on	Radiology	a	0.00	0.00	0.00	0.00	
76375	TC	3d/holograph reconstr add-on	Radiology		0.00	3.55	3.55	3.55	
76380	26	CAT scan follow-up study	Radiology	a	0.98	0.33	0.33	1.31	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 135 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
76380	TC	CAT scan follow-up study	Radiology	a	0.00	3.51	3.51	3.51	
76390	26	Mr spectroscopy	Radiology		1.40	0.47	0.47	0.47	
76390	TC	Mr spectroscopy	Radiology	a	0.00	11.01	11.01	11.01	
76393	26	Mr guidance for needle place	Radiology		1.50	0.50	0.50	0.50	
76393	TC	Mr guidance for needle place	Radiology	a	0.00	11.24	11.24	11.24	
76394	26	Mr for tissue ablation	Radiology		4.24	1.39	1.39	1.39	
76394	TC	Mr for tissue ablation	Radiology	a	0.00	11.24	11.24	11.24	
76400	26	Magnetic image, bone marrow	Radiology		1.60	0.52	0.52	0.52	Misc.
76400	TC	Magnetic image, bone marrow	Radiology	a	0.00	11.24	11.24	11.24	Misc.
76496		Fluoroscopic procedure	Radiology					1.53	Misc.
76497		Ct procedure	Radiology					7.50	Misc.
76498		Mri procedure	Radiology					13.37	Misc.
76499		Radiographic procedure	Radiology					0.91	Misc.
76506	26	Echo exam of head	Radiology	a	0.63	0.25	0.25	0.25	
76506	TC	Echo exam of head	Radiology		0.00	1.43	1.43	1.43	
76511	26	Echo exam of eye	Radiology	a	0.00	1.43	1.43	1.43	
76511	TC	Echo exam of eye	Radiology		0.66	0.30	0.30	0.30	
76512	26	Echo exam of eye	Radiology	a	0.00	1.45	1.45	1.45	
76512	TC	Echo exam of eye	Radiology		0.66	0.30	0.30	0.30	
76513	26	Echo exam of eye, water bath	Radiology	a	0.00	1.54	1.54	1.54	
76513	TC	Echo exam of eye, water bath	Radiology		0.17	0.08	0.08	0.08	
76514	26	Echo exam of eye, thickness	Radiology	a	0.00	0.06	0.06	0.06	
76514	TC	Echo exam of eye, thickness	Radiology		0.54	0.25	0.25	0.25	
76516	26	Echo exam of eye	Radiology	a	0.00	1.20	1.20	1.20	
76516	TC	Echo exam of eye	Radiology		0.54	0.25	0.25	0.25	
76519	26	Echo exam of eye	Radiology	a	0.00	1.29	1.29	1.29	
76519	TC	Echo exam of eye	Radiology		0.57	0.25	0.25	0.25	
76529	26	Echo exam of eye	Radiology	a	0.00	1.15	1.15	1.15	
76529	TC	Echo exam of eye	Radiology		0.56	0.19	0.19	0.19	
76536	26	Us exam of head and neck	Radiology	a	0.00	1.43	1.43	1.43	
76536	TC	Us exam of head and neck	Radiology		0.55	0.18	0.18	0.18	
76604	26	Us exam, chest, b-scan	Radiology	a	0.00	1.31	1.31	1.31	
76604	TC	Us exam, chest, b-scan	Radiology		0.54	0.18	0.18	0.18	
76645	26	Us exam, breast(s)	Radiology	a	0.00	1.06	1.06	1.06	
76645	TC	Us exam, breast(s)	Radiology		0.81	0.27	0.27	0.27	
76700	26	Us exam, abdom, complete	Radiology	a	0.00	1.98	1.98	1.98	
76700	TC	Us exam, abdom, complete	Radiology		0.59	0.20	0.20	0.20	
76705	26	Echo exam of abdomen	Radiology	a	0.00	1.43	1.43	1.43	
76705	TC	Echo exam of abdomen	Radiology		0.74	0.25	0.25	0.25	
76770	26	Us exam abdo back wall, comp	Radiology	a	0.00	1.98	1.98	1.98	
76770	TC	Us exam abdo back wall, comp	Radiology		0.58	0.19	0.19	0.19	
76775	26	Us exam abdo back wall, lim	Radiology	a	0.00	1.43	1.43	1.43	
76775	TC	Us exam abdo back wall, lim	Radiology		0.00	1.43	1.43	1.43	
76778	26	Us exam kidney transplant	Radiology	a	0.00	0.74	0.74	0.74	
76778	TC	Us exam kidney transplant	Radiology		0.00	1.98	1.98	1.98	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 136 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
76800	26	Us exam, spinal canal	Radiology	a	1.13	0.35	0.35	0.35	
76800	TC	Us exam, spinal canal	Radiology		0.00	1.43	1.43	1.43	
76801	26	Ob us < 14 wks, single fetus	Radiology	a	0.99	0.35	0.35	0.35	
76801	TC	Ob us < 14 wks, single fetus	Radiology		0.00	2.10	2.10	2.10	
76802	26	Ob us < 14 wks, addl fetus	Radiology	a	0.83	0.29	0.29	0.29	
76802	TC	Ob us < 14 wks, addl fetus	Radiology		0.00	1.06	1.06	1.06	
76805	26	Ob us >= 14 wks, snl fetus	Radiology	a	0.99	0.35	0.35	0.35	
76805	TC	Ob us >= 14 wks, snl fetus	Radiology		0.00	2.10	2.10	2.10	
76810	26	Ob us >= 14 wks, addl fetus	Radiology	a	0.98	0.35	0.35	0.35	
76810	TC	Ob us >= 14 wks, addl fetus	Radiology		0.00	1.06	1.06	1.06	
76811	26	Ob us, detailed, snl fetus	Radiology	a	1.90	0.66	0.66	0.66	
76811	TC	Ob us, detailed, snl fetus	Radiology		0.00	3.54	3.54	3.54	
76812	26	Ob us, detailed, addl fetus	Radiology	a	1.78	0.63	0.63	0.63	
76812	TC	Ob us, detailed, addl fetus	Radiology		0.00	1.06	1.06	1.06	
76815	26	Ob us, limited, fetus(s)	Radiology	a	0.65	0.23	0.23	0.23	
76815	TC	Ob us, limited, fetus(s)	Radiology		0.00	1.43	1.43	1.43	
76816	26	Ob us, follow-up, par fetus	Radiology	a	0.85	0.32	0.32	0.32	
76816	TC	Ob us, follow-up, par fetus	Radiology		0.00	1.12	1.12	1.12	
76817	26	Transvaginal us, obstetric	Radiology	a	0.75	0.28	0.28	0.28	
76817	TC	Transvaginal us, obstetric	Radiology		0.00	1.52	1.52	1.52	
76818	26	Fetal biophys profile w/nst	Radiology	a	1.05	0.38	0.38	0.38	
76818	TC	Fetal biophys profile w/nst	Radiology		0.00	1.62	1.62	1.62	
76819	26	Fetal biophys profil w/o nst	Radiology	a	0.77	0.28	0.28	0.28	
76819	TC	Fetal biophys profil w/o nst	Radiology		0.00	1.62	1.62	1.62	
76825	26	Echo exam of fetal heart	Radiology	a	1.67	0.60	0.60	0.60	
76825	TC	Echo exam of fetal heart	Radiology		0.00	1.98	1.98	1.98	
76826	26	Echo exam of fetal heart	Radiology	a	0.83	0.29	0.29	0.29	
76826	TC	Echo exam of fetal heart	Radiology		0.00	0.71	0.71	0.71	
76827	26	Echo exam of fetal heart	Radiology	a	0.58	0.22	0.22	0.22	
76827	TC	Echo exam of fetal heart	Radiology		0.00	1.73	1.73	1.73	
76828	26	Echo exam of fetal heart	Radiology	a	0.56	0.22	0.22	0.22	
76828	TC	Echo exam of fetal heart	Radiology		0.00	1.12	1.12	1.12	
76830	26	Transvaginal us, non-ob	Radiology	a	0.69	0.23	0.23	0.23	
76830	TC	Transvaginal us, non-ob	Radiology		0.00	1.52	1.52	1.52	
76831	26	Echo exam, uterus	Radiology	a	0.72	0.26	0.26	0.26	
76831	TC	Echo exam, uterus	Radiology		0.00	1.52	1.52	1.52	
76856	26	Us exam, pelvic, complete	Radiology	a	0.69	0.23	0.23	0.23	
76856	TC	Us exam, pelvic, complete	Radiology		0.00	1.52	1.52	1.52	
76857	26	Us exam, pelvic, limited	Radiology	a	0.38	0.13	0.13	0.13	
76857	TC	Us exam, pelvic, limited	Radiology		0.00	1.57	1.57	1.57	
76870	26	Us exam, scrotum	Radiology	a	0.64	0.21	0.21	0.21	
76870	TC	Us exam, scrotum	Radiology		0.00	1.52	1.52	1.52	
76872	26	Echo exam, transrectal	Radiology	a	0.69	0.23	0.23	0.23	
76872	TC	Echo exam, transrectal	Radiology		0.00	1.86	1.86	1.86	
76873	26	Echograp trans r, pros study	Radiology	a	1.55	0.49	0.49	0.49	

NOTE. CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 137 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
76873	TC	Echograp trans r. pros study	Radiology	a	0.00	2.10	2.10		
76880	26	Us exam, extremity	Radiology		0.59	0.20	0.20		
76880	TC	Us exam, extremity	Radiology	a	0.00	1.43	1.43		
76885	26	Us exam infant hips, dynamic	Radiology		0.74	0.25	0.25		
76885	TC	Us exam infant hips, dynamic	Radiology	a	0.00	1.52	1.52		
76886	26	Us exam infant hips, static	Radiology		0.62	0.21	0.21		
76886	TC	Us exam infant hips, static	Radiology	a	0.00	1.43	1.43		
76930	26	Echo guide, cardiocentesis	Radiology		0.67	0.26	0.26		
76930	TC	Echo guide, cardiocentesis	Radiology	a	0.00	1.52	1.52		
76932	26	Echo guide for heart biopsy	Radiology		0.67	0.26	0.26		
76932	TC	Echo guide for heart biopsy	Radiology	a	0.00	1.52	1.52		
76936	26	Echo guide for artery repair	Radiology		1.99	0.66	0.66		
76936	TC	Echo guide for artery repair	Radiology	a	0.00	6.32	6.32		
76937	26	Us guide, vascular access	Radiology		0.30	0.10	0.10		
76937	TC	Us guide, vascular access	Radiology	a	0.00	0.37	0.37		
76940	26	Us guide, tissue ablation	Radiology		2.00	0.65	0.65		
76940	TC	Us guide, tissue ablation	Radiology	a	0.00	1.52	1.52		
76941	26	Echo guide for transfusion	Radiology		1.34	0.47	0.47		
76941	TC	Echo guide for transfusion	Radiology	a	0.00	1.53	1.53		
76942	26	Echo guide for biopsy	Radiology		0.67	0.22	0.22		
76942	TC	Echo guide for biopsy	Radiology	a	0.00	2.54	2.54		
76945	26	Echo guide, villus sampling	Radiology		0.67	0.23	0.23		
76945	TC	Echo guide, villus sampling	Radiology	a	0.00	1.53	1.53		
76946	26	Echo guide for amniocentesis	Radiology		0.38	0.14	0.14		
76946	TC	Echo guide for amniocentesis	Radiology	a	0.00	1.52	1.52		
76948	26	Echo guide, ova aspiration	Radiology		0.38	0.13	0.13		
76948	TC	Echo guide, ova aspiration	Radiology	a	0.00	1.52	1.52		
76950	26	Echo guidance radiotherapy	Radiology		0.58	0.19	0.19		
76950	TC	Echo guidance radiotherapy	Radiology	a	0.00	1.31	1.31		
76965	26	Echo guidance radiotherapy	Radiology		1.34	0.42	0.42		
76965	TC	Echo guidance radiotherapy	Radiology	a	0.00	5.59	5.59		
76970	26	Ultrasound exam follow-up	Radiology		0.40	0.13	0.13		
76970	TC	Ultrasound exam follow-up	Radiology	a	0.00	1.06	1.06		
76975	26	GI endoscopic ultrasound	Radiology		0.81	0.28	0.28		
76975	TC	GI endoscopic ultrasound	Radiology	a	0.00	1.52	1.52		
76977	26	Us bone density measure	Radiology		0.05	0.02	0.02		
76977	TC	Us bone density measure	Radiology	a	0.00	0.83	0.83		
76986	26	Ultrasound guide intraoper	Radiology		1.20	0.40	0.40		
76986	TC	Ultrasound guide intraoper	Radiology	a	0.00	2.62	2.62		
76986		Echo examination procedure	Radiology		1.39	0.51	0.51		
76986		Radiation therapy planning	Radiology		2.11	0.75	0.75		
77251		Radiation therapy planning	Radiology		3.14	1.12	1.12		
77262		Radiation therapy planning	Radiology		0.70	0.22	0.22		
77263		Set radiation therapy field	Radiology		0.00	3.48	3.48		
77280	26	Set radiation therapy field	Radiology	a					
77280	TC	Set radiation therapy field	Radiology						
								2.44	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 138 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
77285	26	Set radiation therapy field	Radiology	a	1.05	0.34	0.34	0.34	Misc.
77285	TC	Set radiation therapy field	Radiology		0.00	5.59	5.59	5.59	
77290	26	Set radiation therapy field	Radiology	a	1.56	0.49	0.49	0.49	
77290	TC	Set radiation therapy field	Radiology		0.00	6.53	6.53	6.53	
77295	26	Set radiation therapy field	Radiology	a	4.56	1.45	1.45	1.45	
77295	TC	Set radiation therapy field	Radiology		0.00	28.03	28.03	28.03	
77299		Radiation therapy planning	Radiology		0.62	0.20	0.20	0.20	
77300	26	Radiation therapy dose plan	Radiology	a	0.00	1.35	1.35	1.35	
77300	TC	Radiation therapy dose plan	Radiology		7.99	2.54	2.54	2.54	
77301	26	Radiotherapy dose plan, imrt	Radiology	a	0.00	28.03	28.03	28.03	
77301	TC	Radiotherapy dose plan, imrt	Radiology		0.70	0.23	0.23	0.23	
77305	26	Telex isodose plan simple	Radiology	a	0.00	1.87	1.87	1.87	
77305	TC	Telex isodose plan simple	Radiology		1.05	0.34	0.34	0.34	
77310	26	Telex isodose plan intermed	Radiology	a	0.00	2.34	2.34	2.34	
77310	TC	Telex isodose plan intermed	Radiology		1.56	0.49	0.49	0.49	
77315	26	Telex isodose plan complex	Radiology	a	0.00	2.66	2.66	2.66	
77315	TC	Telex isodose plan complex	Radiology		0.95	0.31	0.31	0.31	
77321	26	Special telex port plan	Radiology	a	0.00	4.06	4.06	4.06	
77321	TC	Special telex port plan	Radiology		0.93	0.30	0.30	0.30	
77326	26	Brachytx isodose calc simp	Radiology	a	0.00	2.37	2.37	2.37	
77326	TC	Brachytx isodose calc simp	Radiology		1.39	0.44	0.44	0.44	
77327	26	Brachytx isodose calc interm	Radiology	a	0.00	3.48	3.48	3.48	
77327	TC	Brachytx isodose calc interm	Radiology		2.09	0.66	0.66	0.66	
77328	26	Brachytx isodose plan compl	Radiology	a	0.00	4.97	4.97	4.97	
77328	TC	Brachytx isodose plan compl	Radiology		0.87	0.28	0.28	0.28	
77331	26	Special radiation dosimetry	Radiology	a	0.00	0.50	0.50	0.50	
77331	TC	Special radiation dosimetry	Radiology		0.54	0.17	0.17	0.17	
77332	26	Radiation treatment aid(s)	Radiology	a	0.00	1.35	1.35	1.35	
77332	TC	Radiation treatment aid(s)	Radiology		0.84	0.27	0.27	0.27	
77333	26	Radiation treatment aid(s)	Radiology	a	0.00	1.90	1.90	1.90	
77333	TC	Radiation treatment aid(s)	Radiology		1.24	0.39	0.39	0.39	
77334	26	Radiation treatment aid(s)	Radiology	a	0.00	3.26	3.26	3.26	
77334	TC	Radiation treatment aid(s)	Radiology		0.00	2.99	2.99	2.99	
77336		Radiation physics consult	Radiology	a	0.00	3.50	3.50	3.50	
77370		Radiation physics consult	Radiology	a	0.00				
77399		External radiation dosimetry	Radiology		0.00	1.78	1.78	1.78	
77401		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78	1.78	
77402		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78	1.78	
77403		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78	1.78	
77404		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78	1.78	
77406		Radiation treatment delivery	Radiology	a	0.00	2.09	2.09	2.09	
77407		Radiation treatment delivery	Radiology	a	0.00	2.09	2.09	2.09	
77408		Radiation treatment delivery	Radiology	a	0.00	2.09	2.09	2.09	
77409		Radiation treatment delivery	Radiology	a	0.00	2.09	2.09	2.09	
77411		Radiation treatment delivery	Radiology	a	0.00	2.09	2.09	2.09	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 139 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
77412		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77413		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77414		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77416		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77417		Radiation port film(s)	Radiology	a	0.00	0.59	0.59		
77418		Radiation tx delivery, inrt	Radiology	a	0.00	18.05	18.05		
77427		Radiation tx management, x5	Radiology		3.31	1.05	1.05		
77431		Radiation therapy management	Radiology		1.81	0.68	0.68		
77432		Stereotactic radiation trmt	Radiology		7.92	2.91	2.91		
77470		Special radiation treatment	Radiology		2.09	0.66	0.66		
77470		Special radiation treatment	Radiology	a	0.00	11.19	11.19		
77499		Radiation therapy management	Radiology					4.36	Misc.
77520	26	Proton trmt, simple w/o comp	Radiology	a				22.19	PHCS
77520	TC	Proton trmt, simple w/comp	Radiology	a				23.39	PHCS
77600	26	Hyperthermia treatment	Radiology		1.56	0.49	0.49		
77600	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77605	26	Hyperthermia treatment	Radiology		2.09	0.66	0.66		
77605	TC	Hyperthermia treatment	Radiology	a	0.00	4.08	4.08		
77610	26	Hyperthermia treatment	Radiology		1.56	0.50	0.50		
77610	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77615	26	Hyperthermia treatment	Radiology		2.09	0.66	0.66		
77615	TC	Hyperthermia treatment	Radiology	a	0.00	4.08	4.08		
77620	26	Hyperthermia treatment	Radiology		1.56	0.51	0.51		
77620	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77750	26	Infuse radioactive materials	Radiology		4.90	1.57	1.57		
77750	TC	Infuse radioactive materials	Radiology	a	0.00	1.34	1.34		
77761	26	Apply intrcav radiat simple	Radiology		3.80	1.10	1.10		
77761	TC	Apply intrcav radiat simple	Radiology	a	0.00	2.52	2.52		
77762	26	Apply intrcav radiat interm	Radiology		5.71	1.83	1.83		
77762	TC	Apply intrcav radiat interm	Radiology	a	0.00	3.62	3.62		
77763	26	Apply intrcav radiat compl	Radiology		8.56	2.72	2.72		
77763	TC	Apply intrcav radiat compl	Radiology	a	0.00	4.50	4.50		
77776	26	Apply interstit radiat simpl	Radiology		4.65	0.96	0.96		
77776	TC	Apply interstit radiat simpl	Radiology	a	0.00	2.18	2.18		
77777	26	Apply interstit radiat inter	Radiology		7.47	2.36	2.36		
77777	TC	Apply interstit radiat inter	Radiology	a	0.00	4.25	4.25		
77778	26	Apply interstit radiat compl	Radiology		11.17	3.54	3.54		
77778	TC	Apply interstit radiat compl	Radiology	a	0.00	5.15	5.15		
77781	26	High intensity brachytherapy	Radiology		1.66	0.53	0.53		
77781	TC	High intensity brachytherapy	Radiology	a	0.00	20.38	20.38		
77782	26	High intensity brachytherapy	Radiology		2.49	0.80	0.80		
77782	TC	High intensity brachytherapy	Radiology	a	0.00	20.38	20.38		
77783	26	High intensity brachytherapy	Radiology		3.72	1.18	1.18		
77783	TC	High intensity brachytherapy	Radiology	a	0.00	20.38	20.38		
77784	26	High intensity brachytherapy	Radiology		5.60	1.78	1.78		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. --- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 140 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
77784	TC	High intensity brachytherapy	Radiology	a	0.00	20.38	20.38		
77789	26	Apply surface radiation	Radiology	a	1.12	0.37	0.37		
77789	TC	Apply surface radiation	Radiology	a	0.00	0.45	0.45		
77790	26	Radiation handling	Radiology	a	1.05	0.34	0.34		
77790	TC	Radiation handling	Radiology	a	0.00	0.50	0.50		
77799		Radium/radiotope therapy	Radiology						Misc.
78000	26	Thyroid, single uptake	Radiology	a	0.19	0.07	0.07		
78000	TC	Thyroid, single uptake	Radiology	a	0.00	0.97	0.97		
78001	26	Thyroid, multiple uptakes	Radiology	a	0.26	0.09	0.09		
78001	TC	Thyroid, multiple uptakes	Radiology	a	0.00	1.31	1.31		
78003	26	Thyroid suppress/stimul	Radiology	a	0.33	0.11	0.11		
78003	TC	Thyroid suppress/stimul	Radiology	a	0.00	0.97	0.97		
78006	26	Thyroid imaging with uptake	Radiology	a	0.49	0.17	0.17		
78006	TC	Thyroid imaging with uptake	Radiology	a	0.00	2.39	2.39		
78007	26	Thyroid image, mult uptakes	Radiology	a	0.50	0.17	0.17		
78007	TC	Thyroid image, mult uptakes	Radiology	a	0.00	2.59	2.59		
78010	26	Thyroid imaging	Radiology	a	0.39	0.13	0.13		
78010	TC	Thyroid imaging	Radiology	a	0.00	1.83	1.83		
78011	26	Thyroid imaging with flow	Radiology	a	0.45	0.15	0.15		
78011	TC	Thyroid imaging with flow	Radiology	a	0.00	2.42	2.42		
78015	26	Thyroid met imaging	Radiology	a	0.67	0.23	0.23		
78015	TC	Thyroid met imaging	Radiology	a	0.00	2.59	2.59		
78016	26	Thyroid met imaging/studies	Radiology	a	0.82	0.29	0.29		
78016	TC	Thyroid met imaging/studies	Radiology	a	0.00	3.49	3.49		
78018	26	Thyroid met imaging, body	Radiology	a	0.86	0.30	0.30		
78018	TC	Thyroid met imaging, body	Radiology	a	0.00	5.45	5.45		
78020	26	Thyroid met uptake	Radiology	a	0.60	0.21	0.21		
78020	TC	Thyroid met uptake	Radiology	a	0.00	1.31	1.31		
78070	26	Parathyroid nuclear imaging	Radiology	a	0.82	0.28	0.28		
78070	TC	Parathyroid nuclear imaging	Radiology	a	0.00	1.83	1.83		
78075	26	Adrenal nuclear imaging	Radiology	a	0.74	0.27	0.27		
78075	TC	Adrenal nuclear imaging	Radiology	a	0.00	5.45	5.45		Misc.
78099		Endocrine nuclear procedure	Radiology						
78102	26	Bone marrow imaging, ltd	Radiology	a	0.55	0.20	0.20		
78102	TC	Bone marrow imaging, ltd	Radiology	a	0.00	2.04	2.04		
78103	26	Bone marrow imaging, mult	Radiology	a	0.75	0.26	0.26		
78103	TC	Bone marrow imaging, mult	Radiology	a	0.00	3.18	3.18		
78104	26	Bone marrow imaging, body	Radiology	a	0.60	0.27	0.27		
78104	TC	Bone marrow imaging, body	Radiology	a	0.00	4.09	4.09		
78110	26	Plasma volume, single	Radiology	a	0.19	0.07	0.07		
78110	TC	Plasma volume, single	Radiology	a	0.00	0.95	0.95		
78111	26	Plasma volume, multiple	Radiology	a	0.22	0.08	0.08		
78111	TC	Plasma volume, multiple	Radiology	a	0.00	2.59	2.59		
78120	26	Red cell mass, single	Radiology	a	0.23	0.08	0.08		
78120	TC	Red cell mass, single	Radiology	a	0.00	1.74	1.74		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 141 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
78121	26	Red cell mass, multiple	Radiology		0.32	0.11	0.11		
78121	TC	Red cell mass, multiple	Radiology	a	0.00	2.92	0.16		
78122	26	Blood volume	Radiology		0.45	0.16	0.16		
78122	TC	Blood volume	Radiology	a	0.00	4.62	4.62		
78130	26	Red cell survival study	Radiology		0.61	0.21	0.21		
78130	TC	Red cell survival study	Radiology	a	0.00	2.86	2.86		
78135	26	Red cell survival kinetics	Radiology		0.64	0.22	0.22		
78135	TC	Red cell survival kinetics	Radiology	a	0.00	4.89	4.89		
78140	26	Red cell sequestration	Radiology		0.61	0.20	0.20		
78140	TC	Red cell sequestration	Radiology	a	0.00	3.95	3.95		
78160	26	Plasma iron turnover	Radiology		0.33	0.12	0.12		
78160	TC	Plasma iron turnover	Radiology	a	0.00	3.68	3.68		
78162	26	Radioiron absorption exam	Radiology		0.00	0.19	0.19		
78162	TC	Radioiron absorption exam	Radiology	a	0.00	3.21	3.21		
78170	26	Radioiron absorption exam	Radiology		0.00	0.14	0.14		
78170	TC	Radioiron absorption exam	Radiology	a	0.00	5.33	5.33		
78172	26	Red cell iron utilization	Radiology		0.53	0.18	0.18		
78172	TC	Red cell iron utilization	Radiology	a	0.00	1.41	1.41		MDR
78172	TC	Total body iron estimation	Radiology		0.40	0.14	0.14		
78172	TC	Total body iron estimation	Radiology	a	0.00	2.37	2.37		
78185	26	Spleen imaging	Radiology		0.00	0.39	0.39		
78185	TC	Spleen imaging	Radiology	a	1.09	0.00	0.00		
78190	26	Platelet survival, kinetics	Radiology		0.00	5.73	5.73		
78190	TC	Platelet survival, kinetics	Radiology	a	0.00	0.20	0.20		
78191	26	Platelet survival	Radiology		0.61	0.00	0.00		
78191	TC	Platelet survival	Radiology	a	0.00	7.36	7.36		
78195	26	Lymph system imaging	Radiology		1.20	0.41	0.41		
78195	TC	Lymph system imaging	Radiology	a	0.00	4.09	4.09		
78199	26	Blood/lymph nuclear exam	Radiology		0.44	0.15	0.15		
78201	TC	Liver imaging	Radiology	a	0.00	2.37	2.37		
78201	TC	Liver imaging with flow	Radiology		0.51	0.16	0.16		
78202	26	Liver imaging with flow	Radiology		0.00	2.89	2.89		
78202	TC	Liver imaging with flow	Radiology	a	0.00	0.25	0.25		
78205	26	Liver imaging (3D)	Radiology		0.00	5.93	5.93		
78205	TC	Liver imaging (3D)	Radiology	a	0.96	0.34	0.34		
78206	26	Liver image (3d) with flow	Radiology		0.00	5.93	5.93		
78206	TC	Liver image (3d) with flow	Radiology	a	0.49	0.17	0.17		
78215	26	Liver and spleen imaging	Radiology		0.00	2.95	2.95		
78215	TC	Liver and spleen imaging	Radiology	a	0.00	0.20	0.20		
78216	26	Liver & spleen image/flow	Radiology		0.57	0.00	0.00		
78216	TC	Liver & spleen image/flow	Radiology	a	0.00	3.49	3.49		
78220	26	Liver function study	Radiology		0.49	0.17	0.17		
78220	TC	Liver function study	Radiology	a	0.00	3.74	3.74		
78223	26	Hepatobiliary imaging	Radiology		0.84	0.28	0.28		
78223	TC	Hepatobiliary imaging	Radiology	a	0.00	3.68	3.68		
78230	26	Salivary gland imaging	Radiology		0.45	0.15	0.15		
78230	TC	Salivary gland imaging	Radiology	a	0.00	2.18	2.18		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 142 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
78231	26	Serial salivary imaging	Radiology	a	0.52	0.19	0.19		
78231	TC	Serial salivary imaging	Radiology		0.00	3.18	3.18		
78232	26	Salivary gland function exam	Radiology	a	0.47	0.17	0.17		
78232	TC	Salivary gland function exam	Radiology		0.00	3.55	3.55		
78258	26	Esophageal motility study	Radiology	a	0.74	0.25	0.25		
78258	TC	Esophageal motility study	Radiology		0.00	2.89	2.89		
78261	26	Gastric mucosa imaging	Radiology	a	0.69	0.25	0.25		
78261	TC	Gastric mucosa imaging	Radiology		0.00	4.11	4.11		
78262	26	Gastroesophageal reflux exam	Radiology	a	0.68	0.24	0.24		
78262	TC	Gastroesophageal reflux exam	Radiology		0.00	4.27	4.27		
78264	26	Gastric emptying study	Radiology	a	0.78	0.27	0.27		
78264	TC	Gastric emptying study	Radiology		0.00	4.14	4.14		
78270	26	Vit B-12 absorption exam	Radiology	a	0.20	0.07	0.07		
78270	TC	Vit B-12 absorption exam	Radiology		0.00	1.55	1.55		
78271	26	Vit b-12 abstrp exam, int fac	Radiology	a	0.00	1.57	1.57		
78271	TC	Vit b-12 abstrp exam, int fac	Radiology		0.00	1.65	1.65		
78272	26	Vit B-12 absorp, combined	Radiology	a	0.27	0.10	0.10		
78272	TC	Vit B-12 absorp, combined	Radiology		0.00	2.33	2.33		
78278	26	Acute GI blood loss imaging	Radiology	a	0.99	0.34	0.34		
78278	TC	Acute GI blood loss imaging	Radiology		0.00	4.89	4.89		
78282	26	GI protein loss exam	Radiology	a	0.38	0.13	0.13		
78282	TC	GI protein loss exam	Radiology		0.68	0.23	0.23	2.89	MDR
78290	26	Meckel's divert exam	Radiology	a	0.00	3.06	3.06		
78290	TC	Meckel's divert exam	Radiology		0.88	0.30	0.30		
78291	26	Leveen/shunt patency exam	Radiology	a	0.00	3.08	3.08		
78291	TC	Leveen/shunt patency exam	Radiology		0.62	0.21	0.21	4.80	Misc.
78299	26	GI nuclear procedure	Radiology		0.00	2.50	2.50		
78300	TC	Bone imaging, limited area	Radiology	a	0.83	0.28	0.28		
78305	26	Bone imaging, multiple areas	Radiology	a	0.00	3.68	3.68		
78305	TC	Bone imaging, multiple areas	Radiology		0.86	0.29	0.29		
78306	26	Bone imaging, whole body	Radiology	a	0.00	4.29	4.29		
78306	TC	Bone imaging, whole body	Radiology		1.02	0.35	0.35		
78315	26	Bone imaging, 3 phase	Radiology	a	0.00	4.80	4.80		
78315	TC	Bone imaging, 3 phase	Radiology		1.04	0.37	0.37		
78320	26	Bone imaging (3D)	Radiology	a	0.00	5.93	5.93		
78320	TC	Bone imaging (3D)	Radiology		0.22	0.07	0.07		
78350	26	Bone mineral, single photon	Radiology	a	0.00	0.76	0.76		
78350	TC	Bone mineral, single photon	Radiology		0.45	0.16	0.16	0.58	PHCS
78351	26	Bone mineral, dual photon	Radiology	a				3.44	PHCS
78351	TC	Bone mineral, dual photon	Radiology					5.44	Misc.
78399	26	Musculoskeletal nuclear exam	Radiology						
78414	TC	Non-imaging heart function	Radiology	a					
78414	TC	Non-imaging heart function	Radiology		0.78	0.30	0.30	1.22	SAF
78428	26	Cardiac shunt imaging	Radiology						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 143 OF 179

CPT/ HCP/PCS Code	Modifier	CPT/HCP/PCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUS	Facility Practice Expense RVUS	Non- Facility Practice Expense RVUS	Total Expense RVUS	Charge Method- ology
78428	TC	Cardiac shunt imaging	Radiology	a	0.00	2.26	2.26	2.26	
78445	26	Vascular flow imaging	Radiology	a	0.49	0.17	0.17	0.17	
78445	TC	Vascular flow imaging	Radiology	a	0.00	1.87	1.87	1.87	
78455	26	Venous thrombosis study	Radiology	a	0.73	0.25	0.25	0.25	
78455	TC	Venous thrombosis study	Radiology	a	0.00	4.00	4.00	4.00	
78456	26	Acute venous thrombus image	Radiology	a	1.00	0.35	0.35	0.35	
78456	TC	Acute venous thrombus image	Radiology	a	0.00	4.00	4.00	4.00	
78457	26	Venous thrombosis imaging	Radiology	a	0.77	0.26	0.26	0.26	
78457	TC	Venous thrombosis imaging	Radiology	a	0.00	2.66	2.66	2.66	
78458	26	Ven thrombosis images, bilat	Radiology	a	0.90	0.33	0.33	0.33	
78458	TC	Ven thrombosis images, bilat	Radiology	a	0.00	4.04	4.04	4.04	
78459	26	Heart muscle imaging (PET)	Radiology	a	1.50	0.57	0.57	0.57	PHCS
78459	TC	Heart muscle imaging (PET)	Radiology	a	0.00	27.72	27.72	27.72	PHCS
78460	26	Heart muscle blood, single	Radiology	a	0.86	0.30	0.30	0.30	
78460	TC	Heart muscle blood, single	Radiology	a	0.00	2.37	2.37	2.37	
78461	26	Heart muscle blood, multiple	Radiology	a	1.23	0.43	0.43	0.43	
78461	TC	Heart muscle blood, multiple	Radiology	a	0.00	4.74	4.74	4.74	
78464	26	Heart image (3d), single	Radiology	a	1.09	0.38	0.38	0.38	
78464	TC	Heart image (3d), single	Radiology	a	0.00	7.10	7.10	7.10	
78465	26	Heart image (3d), multiple	Radiology	a	1.46	0.52	0.52	0.52	
78465	TC	Heart image (3d), multiple	Radiology	a	0.00	11.83	11.83	11.83	
78466	26	Heart infarct image	Radiology	a	0.69	0.25	0.25	0.25	
78466	TC	Heart infarct image	Radiology	a	0.00	2.62	2.62	2.62	
78468	26	Heart infarct image (et)	Radiology	a	0.80	0.28	0.28	0.28	
78468	TC	Heart infarct image (et)	Radiology	a	0.00	3.68	3.68	3.68	
78469	26	Heart infarct image (3D)	Radiology	a	0.92	0.32	0.32	0.32	
78469	TC	Heart infarct image (3D)	Radiology	a	0.00	5.24	5.24	5.24	
78472	26	Gated heart, planar, single	Radiology	a	0.98	0.35	0.35	0.35	
78472	TC	Gated heart, planar, single	Radiology	a	0.00	5.53	5.53	5.53	
78473	26	Gated heart, multiple	Radiology	a	1.47	0.51	0.51	0.51	
78473	TC	Gated heart, multiple	Radiology	a	0.00	8.29	8.29	8.29	
78478	26	Heart wall motion add-on	Radiology	a	0.62	0.23	0.23	0.23	
78478	TC	Heart wall motion add-on	Radiology	a	0.00	1.56	1.56	1.56	
78480	26	Heart function add-on	Radiology	a	0.62	0.23	0.23	0.23	
78480	TC	Heart function add-on	Radiology	a	0.00	1.56	1.56	1.56	
78481	26	Heart first pass, single	Radiology	a	0.98	0.37	0.37	0.37	
78481	TC	Heart first pass, single	Radiology	a	0.00	5.24	5.24	5.24	
78483	26	Heart first pass, multiple	Radiology	a	1.47	0.54	0.54	0.54	
78483	TC	Heart first pass, multiple	Radiology	a	0.00	7.89	7.89	7.89	
78491	26	Heart image (pet), single	Radiology	a	1.50	0.59	0.59	0.59	SA
78491	TC	Heart image (pet), single	Radiology	a	0.00	16.06	16.06	16.06	SA
78492	26	Heart image (pet), multiple	Radiology	a	1.87	0.74	0.74	0.74	PHCS
78492	TC	Heart image (pet), multiple	Radiology	a	0.00	20.04	20.04	20.04	PHCS
78494	26	Heart image (pet), spect	Radiology	a	1.19	0.41	0.41	0.41	
78494	TC	Heart image (pet), spect	Radiology	a	0.00	7.10	7.10	7.10	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE
PAGE 144 OF 179

CPT/ HCP/CS Code	Modifier	CPT/HCP/CS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
78496	26	Heart first pass add-on	Radiology	a	0.50	0.18	0.18	0.18	Misc.
78496	TC	Heart first pass add-on	Radiology		0.00	7.10	7.10	2.41	
78499	26	Cardiovascular nuclear exam	Radiology	a	0.74	0.25	0.25	0.25	Misc.
78580	TC	Lung perfusion imaging	Radiology		0.00	3.44	3.44	0.25	
78580	TC	Lung perfusion imaging	Radiology		0.99	0.33	0.33	0.33	Misc.
78584	TC	Lung V/Q image single breath	Radiology		0.00	3.21	3.21	0.33	
78584	TC	Lung V/Q image single breath	Radiology		1.09	0.37	0.37	0.37	Misc.
78585	26	Lung V/Q imaging	Radiology	a	0.40	0.13	0.13	0.13	
78585	TC	Lung V/Q imaging	Radiology		0.00	5.65	5.65	0.13	Misc.
78586	26	Aerosol lung image, single	Radiology	a	0.00	2.60	2.60	0.13	
78586	TC	Aerosol lung image, single	Radiology		0.49	0.17	0.17	0.17	Misc.
78587	26	Aerosol lung image, multiple	Radiology	a	0.00	2.81	2.81	0.17	
78587	TC	Aerosol lung image, multiple	Radiology		1.09	0.37	0.37	0.37	Misc.
78588	26	Perfusion lung image	Radiology	a	0.00	3.21	3.21	0.14	
78588	TC	Perfusion lung image	Radiology		0.40	0.14	0.14	0.14	Misc.
78591	26	Vent image, 1 breath, 1 proj	Radiology	a	0.00	2.86	2.86	0.15	
78591	TC	Vent image, 1 breath, 1 proj	Radiology		0.49	0.17	0.17	0.17	Misc.
78593	26	Vent image, 1 proj, gas	Radiology	a	0.00	3.46	3.46	0.18	
78593	TC	Vent image, 1 proj, gas	Radiology		0.53	0.18	0.18	0.18	Misc.
78594	26	Vent image, mult proj, gas	Radiology	a	0.00	4.99	4.99	0.42	
78594	TC	Vent image, mult proj, gas	Radiology		1.27	0.42	0.42	0.42	Misc.
78596	26	Lung differential function	Radiology	a	0.00	7.10	7.10	0.15	
78596	TC	Lung differential function	Radiology		0.44	0.15	0.15	0.15	Misc.
78599	26	Respiratory nuclear exam	Radiology	a	0.00	2.89	2.89	0.17	
78600	TC	Brain imaging, lid static	Radiology		0.51	0.17	0.17	0.17	Misc.
78601	26	Brain imaging, lid w/ flow	Radiology	a	0.00	3.41	3.41	0.19	
78601	TC	Brain imaging, lid w/ flow	Radiology		0.53	0.19	0.19	0.19	Misc.
78605	26	Brain imaging, complete	Radiology	a	0.00	3.41	3.41	0.22	
78605	TC	Brain imaging, complete	Radiology		0.64	0.22	0.22	0.22	Misc.
78606	26	Brain imaging, compl w/flow	Radiology	a	0.00	3.88	3.88	0.43	
78606	TC	Brain imaging, compl w/flow	Radiology		1.23	0.43	0.43	0.43	Misc.
78607	26	Brain imaging (3D)	Radiology	a	0.00	6.58	6.58	0.11	
78607	TC	Brain imaging (3D)	Radiology		0.30	0.11	0.11	0.11	PHCS PHCS
78608	26	Brain imaging (PET)	Radiology	a	0.00	1.58	1.58	0.16	
78608	TC	Brain imaging (PET)	Radiology		0.42	0.16	0.16	0.16	PHCS PHCS
78610	26	Brain flow imaging only	Radiology	a	0.00	3.86	3.86	0.23	
78610	TC	Brain flow imaging only	Radiology		0.68	0.23	0.23	0.23	PHCS PHCS
78615	26	Cerebral vascular flow image	Radiology	a	0.00	5.05	5.05	0.24	
78615	TC	Cerebral vascular flow image	Radiology		0.61	0.24	0.24	0.24	PHCS PHCS
78630	26	Cerebrospinal fluid scan	Radiology	a	0.00	2.56	2.56	0.20	
78630	TC	Cerebrospinal fluid scan	Radiology		0.57	0.20	0.20	0.20	PHCS PHCS
78635	26	CSF ventriculography	Radiology	a	0.00	2.56	2.56	0.20	
78635	TC	CSF ventriculography	Radiology		0.57	0.20	0.20	0.20	PHCS PHCS
78645	26	CSF shunt evaluation	Radiology	a	0.00	2.56	2.56	0.20	
78645	TC	CSF shunt evaluation	Radiology		0.57	0.20	0.20	0.20	PHCS PHCS

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 145 OF 179

CPT/HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
78645	TC	CSF shunt evaluation	Radiology	a	0.00	3.44	3.44		
78647	26	Cerebrospinal fluid scan	Radiology		0.90	0.32	0.32		
78647	TC	Cerebrospinal fluid scan	Radiology	a	0.00	5.93	5.93		
78650	26	CSF leakage imaging	Radiology		0.61	0.21	0.21		
78650	TC	CSF leakage imaging	Radiology	a	0.00	4.66	4.66		
78660	26	Nuclear exam of tear flow	Radiology		0.53	0.18	0.18		
78660	TC	Nuclear exam of tear flow	Radiology	a	0.00	2.12	2.12		
78699		Nervous system nuclear exam	Radiology					5.96	Misc.
78700	26	Kidney imaging, static	Radiology		0.45	0.15	0.15		
78700	TC	Kidney imaging, static	Radiology	a	0.00	3.06	3.06		
78701	26	Kidney imaging with flow	Radiology		0.49	0.17	0.17		
78701	TC	Kidney imaging with flow	Radiology	a	0.00	3.57	3.57		
78704	26	Imaging renogram	Radiology		0.74	0.25	0.25		
78704	TC	Imaging renogram	Radiology	a	0.00	3.97	3.97		
78707	26	Kidney flow/function image	Radiology		0.96	0.33	0.33		
78707	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78708	26	Kidney flow/function image	Radiology		1.21	0.41	0.41		
78708	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78709	26	Kidney flow/function image	Radiology		1.41	0.47	0.47		
78709	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78710	26	Kidney imaging (3D)	Radiology		0.66	0.22	0.22		
78710	TC	Kidney imaging (3D)	Radiology	a	0.00	5.93	5.93		
78715	26	Renal vascular flow exam	Radiology		0.30	0.11	0.11		
78715	TC	Renal vascular flow exam	Radiology	a	0.00	1.58	1.58		
78725	26	Kidney function study	Radiology		0.38	0.13	0.13		
78725	TC	Kidney function study	Radiology	a	0.00	1.79	1.79		
78730	26	Urinary bladder retention	Radiology		0.36	0.13	0.13		
78730	TC	Urinary bladder retention	Radiology	a	0.00	1.46	1.46		
78740	26	Ureteral reflux study	Radiology		0.57	0.19	0.19		
78740	TC	Ureteral reflux study	Radiology	a	0.00	2.12	2.12		
78760	26	Testicular imaging	Radiology		0.66	0.22	0.22		
78760	TC	Testicular imaging	Radiology	a	0.00	2.68	2.68		
78761	26	Testicular imaging/flow	Radiology		0.71	0.24	0.24		
78761	TC	Testicular imaging/flow	Radiology	a	0.00	3.21	3.21		
78799		Genitourinary nuclear exam	Radiology					5.77	Misc.
78800	26	Tumor imaging, limited area	Radiology		0.66	0.22	0.22		
78800	TC	Tumor imaging, limited area	Radiology	a	0.00	3.41	3.41		
78801	26	Tumor imaging, multi areas	Radiology		0.79	0.27	0.27		
78801	TC	Tumor imaging, multi areas	Radiology	a	0.00	4.24	4.24		
78802	26	Tumor imaging, whole body	Radiology		0.86	0.30	0.30		
78802	TC	Tumor imaging, whole body	Radiology	a	0.00	5.55	5.55		
78803	26	Tumor imaging (3D)	Radiology		1.09	0.38	0.38		
78803	TC	Tumor imaging (3D)	Radiology	a	0.00	6.58	6.58		
78804	26	Tumor imaging, whole body	Radiology		1.07	0.37	0.37		
78804	TC	Tumor imaging, whole body	Radiology	a	0.00	4.29	4.29		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 146 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
78805	26	Abscess imaging, lld area	Radiology	a	0.73	0.25	0.25		
78805	TC	Abscess imaging, lld area	Radiology		0.00	3.41	3.41		
78806	26	Abscess imaging, whole body	Radiology	a	0.86	0.30	0.30		
78806	TC	Abscess imaging, whole body	Radiology		0.00	6.45	6.45		
78807	26	Nuclear localization/abscess	Radiology	a	1.09	0.39	0.39		
78807	TC	Nuclear localization/abscess	Radiology		0.00	6.58	6.58		
78810	26	Tumor imaging (PET)	Radiology	a	1.93	0.74	0.74		PHCS
78810	TC	Tumor imaging (PET)	Radiology		0.05	0.02	0.02	31.42	
78890	26	Nuclear medicine data proc	Radiology	a	0.00	1.31	1.31		
78890	TC	Nuclear medicine data proc	Radiology		0.10	0.04	0.04		
78891	26	Nuclear med data proc	Radiology	a	0.00	2.62	2.62		
78891	TC	Nuclear med data proc	Radiology						
78990	26	Provide diag radionuclide(s)	Radiology	a	1.80	0.60	0.60		SAF Misc.
78999	26	Nuclear diagnostic exam	Radiology	a	0.00	2.62	2.62		
79000	TC	Init hyperthyroid therapy	Radiology		0.05	0.36	0.36		
79001	26	Repeat hyperthyroid therapy	Radiology	a	0.00	1.31	1.31		
79001	TC	Repeat hyperthyroid therapy	Radiology		1.81	0.60	0.60		
79020	26	Thyroid ablation	Radiology	a	0.00	2.62	2.62		
79020	TC	Thyroid ablation	Radiology		2.10	0.71	0.71		
79030	26	Thyroid ablation, carcinoma	Radiology	a	0.00	2.62	2.62		
79030	TC	Thyroid ablation, carcinoma	Radiology		2.52	0.88	0.88		
79035	26	Thyroid metastatic therapy	Radiology	a	0.00	2.62	2.62		
79035	TC	Thyroid metastatic therapy	Radiology		1.32	0.46	0.46		
79100	26	Hematopoietic nuclear therapy	Radiology	a	0.00	2.62	2.62		
79100	TC	Hematopoietic nuclear therapy	Radiology		1.99	0.69	0.69		
79200	26	Intracavitary nuclear trmt	Radiology	a	0.00	2.62	2.62		
79200	TC	Intracavitary nuclear trmt	Radiology		1.60	0.56	0.56	1.70	MDR
79300	26	Interstitial nuclear therapy	Radiology	a	1.96	0.67	0.67		
79300	TC	Interstitial nuclear therapy	Radiology		0.00	2.62	2.62		
79400	26	Nonhemato nuclear therapy	Radiology	a	2.25	0.90	0.90		
79400	TC	Nonhemato nuclear therapy	Radiology		0.00	4.29	4.29		
79403	26	Hematopoietic nuclear therapy	Radiology	a	1.51	0.49	0.49		SA
79403	TC	Hematopoietic nuclear therapy	Radiology		1.99	0.72	0.72	1.34	
79420	26	Intravascular nuclear ther	Radiology	a	0.00	2.62	2.62		
79420	TC	Intravascular nuclear ther	Radiology		0.00	2.62	2.62		
79440	26	Nuclear joint therapy	Radiology	a	0.00	2.62	2.62		
79440	TC	Nuclear joint therapy	Radiology		0.00	2.62	2.62		
79900	26	Provide ther radiopharm(s)	Radiology	a	0.37	0.16	0.16	0.73	SAF Misc.
79999	26	Nuclear medicine therapy	Radiology	a	1.33	0.58	0.58	5.02	
80500	26	Lab pathology consultation	Pathology		0.37	0.15	0.15		
80502	26	Lab pathology consultation	Pathology		0.37	0.15	0.15		
83020	26	Hemoglobin electrophoresis	Pathology		0.37	0.15	0.15		
83912	26	Genetic examination	Pathology		0.37	0.16	0.16		
84165	26	Assay of serum proteins	Pathology		0.37	0.16	0.16		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 147 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
84181	26	Western blot test	Pathology		0.37	0.14	0.14	0.14	
84182	26	Protein, western blot test	Pathology		0.37	0.16	0.17	0.17	
85060		Blood smear interpretation	Pathology		0.45	0.20	0.20	0.20	
85097		Bone marrow interpretation	Pathology		0.94	0.41	1.75	0.41	
85390	26	Fibrinolytics screen	Pathology		0.37	0.15	0.15	0.15	
85396		Clotting assay, whole blood	Pathology		0.37	0.17	0.17	0.17	
85578	26	Blood platelet aggregation	Pathology		0.37	0.16	0.17	0.17	
86077		Physician blood bank service	Pathology		0.94	0.41	0.46	0.46	
86078		Physician blood bank service	Pathology		0.94	0.40	0.49	0.49	
86079		Physician blood bank service	Pathology		0.94	0.41	0.41	0.41	
86255	26	Fluorescent antibody, screen	Pathology		0.37	0.16	0.17	0.17	
86256	26	Fluorescent antibody, titer	Pathology		0.37	0.16	0.16	0.16	
86320	26	Serum immunoelectrophoresis	Pathology		0.37	0.16	0.16	0.16	
86325	26	Other immunoelectrophoresis	Pathology		0.37	0.16	0.16	0.16	
86327	26	Immunoelectrophoresis assay	Pathology		0.42	0.19	0.18	0.18	
86334	26	Immunofixation procedure	Pathology		0.37	0.16	0.16	0.16	
86490		Coccidioidomycosis skin test	Pathology	a	0.00	0.29	0.29	0.29	
86510		Histoplasmosis skin test	Pathology	a	0.00	0.32	0.32	0.32	
86580		TB intradermal test	Pathology	a	0.00	0.26	0.26	0.26	
86585		TB tine test	Pathology	a	0.00	0.21	0.21	0.21	
86999		Transfusion procedure	Pathology					0.20	Misc.
87164	26	Dark field examination	Pathology		0.37	0.12	0.12	0.12	
87207	26	Smear, special stain	Pathology		0.37	0.16	0.17	0.17	
88104	26	Cytopathology, fluids	Pathology		0.56	0.25	0.25	0.25	
88104	TC	Cytopathology, fluids	Pathology	a	0.00	0.50	0.50	0.50	
88106	26	Cytopathology, fluids	Pathology		0.56	0.25	0.25	0.25	
88106	TC	Cytopathology, fluids	Pathology	a	0.00	0.37	0.37	0.37	
88107	26	Cytopathology, fluids	Pathology		0.76	0.34	0.34	0.34	
88107	TC	Cytopathology, fluids	Pathology	a	0.00	0.64	0.64	0.64	
88108	26	Cytopath, concentrate tech	Pathology		0.56	0.25	0.25	0.25	
88112	26	Cytopath, cell enhance tech	Pathology		0.00	0.56	0.56	0.56	
88112	TC	Cytopath, cell enhance tech	Pathology	a	1.18	0.51	0.51	0.51	
88125	26	Forensic cytopathology	Pathology		0.00	1.47	1.47	1.47	
88125	TC	Forensic cytopathology	Pathology	a	0.00	0.12	0.12	0.12	
88125	TC	Forensic cytopathology	Pathology	a	0.00	0.14	0.14	0.14	
88141	26	Cytopath, cv, interpret	Pathology		0.42	0.18	0.18	0.18	
88160	TC	Cytopath smear, other source	Pathology	a	0.50	0.22	0.22	0.22	
88160	TC	Cytopath smear, other source	Pathology	a	0.00	0.70	0.70	0.70	
88161	26	Cytopath smear, other source	Pathology		0.50	0.22	0.22	0.22	
88161	TC	Cytopath smear, other source	Pathology	a	0.00	0.66	0.66	0.66	
88162	26	Cytopath smear, other source	Pathology		0.76	0.34	0.34	0.34	
88162	TC	Cytopath smear, other source	Pathology	a	0.00	0.34	0.34	0.34	
88172	26	Cytopathology eval of fna	Pathology		0.60	0.27	0.27	0.27	
88172	TC	Cytopathology eval of fna	Pathology	a	0.00	0.39	0.39	0.39	
88173	26	Cytopath eval, fna, report	Pathology		1.39	0.60	0.60	0.60	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 148 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
88173	TC	Cytopath eval, fina, report	Pathology	a	0.00	1.15	1.15		
88180	26	Cell marker study	Pathology		0.36	0.16	0.16		
88180	TC	Cell marker study	Pathology	a	0.00	1.27	1.27		
88182	26	Cell marker study	Pathology		0.77	0.34	0.34		
88182	TC	Cell marker study	Pathology	a	0.00	1.25	1.25		
88291		Cytopathology procedure	Pathology						Misc.
88300	26	Cytomolecular report	Pathology		0.52	0.28	0.28		
88300	TC	Surgical path, gross	Pathology	a	0.08	0.04	0.04		
88302	26	Surgical path, gross	Pathology		0.00	0.24	0.24		
88302	TC	Tissue exam by pathologist	Pathology		0.13	0.06	0.06		
88304	26	Tissue exam by pathologist	Pathology	a	0.00	0.63	0.63		
88304	TC	Tissue exam by pathologist	Pathology		0.22	0.10	0.10		
88305	26	Tissue exam by pathologist	Pathology	a	0.00	0.77	0.77		
88305	TC	Tissue exam by pathologist	Pathology		0.75	0.34	0.34		
88307	26	Tissue exam by pathologist	Pathology	a	0.00	1.40	1.40		
88307	TC	Tissue exam by pathologist	Pathology		1.59	0.69	0.69		
88309	26	Tissue exam by pathologist	Pathology	a	0.00	1.96	1.96		
88309	TC	Tissue exam by pathologist	Pathology		2.28	1.00	1.00		
88311	26	Tissue exam by pathologist	Pathology	a	0.00	2.25	2.25		
88311	TC	Decalcify tissue	Pathology		0.24	0.11	0.11		
88312	26	Decalcify tissue	Pathology	a	0.00	0.09	0.09		
88312	TC	Special stains	Pathology		0.54	0.24	0.24		
88313	26	Special stains	Pathology	a	0.00	1.11	1.11		
88313	TC	Special stains	Pathology		0.24	0.11	0.11		
88314	26	Special stains	Pathology	a	0.00	0.98	0.98		
88314	TC	Histochemical stain	Pathology		0.45	0.20	0.20		
88318	26	Histochemical stain	Pathology	a	0.00	0.69	0.69		
88318	TC	Chemical histochemistry	Pathology		0.42	0.19	0.19		
88319	26	Chemical histochemistry	Pathology	a	0.00	0.61	0.61		
88319	TC	Enzyme histochemistry	Pathology		0.53	0.23	0.23		
88321	26	Enzyme histochemistry	Pathology	a	0.00	1.66	1.66		
88323	26	Microslide consultation	Pathology		1.30	0.56	0.56		
88323	TC	Microslide consultation	Pathology		1.35	0.59	0.59		
88325		Comprehensive review of data	Pathology	a	0.00	0.85	0.85		
88329		Path consult intraop	Pathology		2.22	0.97	2.90		
88331	26	Path consult intraop, 1 bloc	Pathology		0.67	0.30	0.63		
88331	TC	Path consult intraop, 1 bloc	Pathology	a	1.19	0.52	0.52		
88332	26	Path consult intraop, addl	Pathology		0.00	0.46	0.46		
88332	TC	Path consult intraop, addl	Pathology		0.59	0.26	0.26		
88342	26	Immunocytochemistry	Pathology	a	0.00	0.24	0.24		
88342	TC	Immunocytochemistry	Pathology		0.85	0.37	0.37		
88346	26	Immunofluorescent study	Pathology	a	0.00	0.98	0.98		
88346	TC	Immunofluorescent study	Pathology		0.86	0.37	0.37		
88347	26	Immunofluorescent study	Pathology	a	0.00	1.07	1.07		
88347			Pathology		0.86	0.36	0.36		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFARS apply.
See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 149 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
88347	TC	Immunofluorescent study	Pathology	a	0.00	1.40	1.40		
88348	26	Electron microscopy	Pathology		1.51	0.65	0.65		
88348	TC	Electron microscopy	Pathology	a	0.00	7.82	7.82		
88349	26	Scanning electron microscopy	Pathology	a	0.76	0.34	0.34		
88349	TC	Scanning electron microscopy	Pathology		0.00	9.65	9.65		
88355	26	Analysis, skeletal muscle	Pathology	a	1.85	0.80	0.80		
88355	TC	Analysis, skeletal muscle	Pathology		0.00	1.80	1.80		
88356	26	Analysis, nerve	Pathology	a	3.02	1.27	1.27		
88356	TC	Analysis, nerve	Pathology		0.00	1.60	1.60		
88356	26	Analysis, tumor	Pathology	a	0.95	1.23	1.23		
88356	TC	Analysis, tumor	Pathology		0.00	0.15	0.15		
88358	26	Immunohistochemistry, tumor	Pathology	a	0.94	0.41	0.41		
88361	TC	Immunohistochemistry, tumor	Pathology		0.00	2.18	2.18		
88361	26	Nerve teasing preparations	Pathology	a	2.17	0.93	0.93		
88362	TC	Nerve teasing preparations	Pathology		0.00	3.47	3.47		
88362	26	Tissue hybridization	Pathology	a	0.93	0.41	0.41		
88365	26	Tissue hybridization	Pathology		0.00	1.80	1.80		
88365	TC	Protein, western blot tissue	Pathology		0.37	0.13	0.13		
88371	26	Protein analysis w/probe	Pathology		0.37	0.17	0.17	2.49	Misc.
88372	26	Surgical pathology procedure	Pathology		0.37	0.16	0.16		
88399		Exam, synovial fluid crystals	Pathology		0.60	0.22	0.22		
88060	26	Sample intestinal contents	Pathology		0.50	0.17	0.17		
89100		Sample stomach contents	Pathology		0.45	0.13	0.13		
89105		Sample stomach contents	Pathology		0.19	0.06	0.06		
89130		Sample stomach contents	Pathology		0.79	0.25	0.25		
89132		Sample stomach contents	Pathology		0.21	0.09	0.09		
89135		Sample stomach contents	Pathology		0.94	0.28	0.28		
89136		Sample stomach contents	Pathology		0.85	0.34	0.34		
89140		Sample stomach contents	Pathology		0.00	0.40	0.40		
89141		Sputum specimen collection	Pathology		0.00	0.44	0.44		
89220		Collect sweat for test	Pathology						
90281		Human ig, im	Therapeutic Injections					0.77	PHCS
90283		Human ig, iv	Therapeutic Injections					2.16	PHCS
90287		Botulinum antitoxin	Therapeutic Injections					0.55	PHCS
90371		Hep b ig, im	Therapeutic Injections					4.56	SAF
90375		Rabies ig, im/sc	Therapeutic Injections					5.22	MDR
90376		Rabies ig, heat treated	Therapeutic Injections					4.98	MDR
90378		Rsv ig, im, 50mg	Therapeutic Injections					22.71	PHCS
90379		Rsv ig, iv	Therapeutic Injections					27.49	PHCS
90384		Rh ig, full-dose, im	Therapeutic Injections					3.10	PHCS
90385		Rh ig, mid-dose, im	Therapeutic Injections					1.73	MDR
90389		Rh ig, iv	Therapeutic Injections					6.95	SAF
90396		Tetanus ig, im	Therapeutic Injections					3.85	MDR
90396		Varicella-zoster ig, im	Therapeutic Injections					2.75	PHCS
90399		Immune globulin	Therapeutic Injections					4.56	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 150 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
90471		Immunization admin	Immunizations		0.00	0.21	0.21	0.36	MDR
90472		Immunization admin, each add	Immunizations		0.00	0.14	0.14	0.36	MDR
90473		Immune admin oral/nasal	Immunizations					1.05	PHCS
90474		Immune admin oral/nasal addl	Immunizations					0.41	PHCS
90475		Adenovirus vaccine, type 4	Immunizations					2.97	MDR
90477		Adenovirus vaccine, type 7	Immunizations					4.00	PHCS
90581		Anthrax vaccine, sc	Immunizations					3.19	PHCS
90585		Bcg vaccine, intravesical	Immunizations					1.21	PHCS
90586		Bcg vaccine, percut	Immunizations					0.96	PHCS
90632		Hep a vaccine, adult im	Immunizations					0.96	PHCS
90633		Hep a vacc, ped/adol, 2 dose	Immunizations					0.96	PHCS
90634		Hep a vacc, ped/adol, 3 dose	Immunizations					1.73	PHCS
90636		Hep a/hep b vacc, adult im	Immunizations					0.57	PHCS
90645		Hib vaccine, hboc, im	Immunizations					0.61	PHCS
90646		Hib vaccine, prp-d, im	Immunizations					0.57	PHCS
90647		Hib vaccine, prp-omp, im	Immunizations					0.64	PHCS
90648		Hib vaccine, prp-l, im	Immunizations					0.25	PHCS
90657		Flu vaccine, 6-35 mo, im	Immunizations					0.25	PHCS
90658		Flu vaccine, 3 yrs, im	Immunizations					0.34	PHCS
90660		Flu vaccine, nasal	Immunizations					1.41	MDR
90665		Lyme disease vaccine, im	Immunizations					1.27	PHCS
90669		Pneumococcal vacc, ped <5	Immunizations					2.80	PHCS
90675		Rabies vaccine, im	Immunizations					2.75	PHCS
90676		Rabies vaccine, id	Immunizations					0.76	PHCS
90680		Rotovirus vaccine, oral	Immunizations					0.78	PHCS
90690		Typhoid vaccine, oral	Immunizations					0.93	PHCS
90691		Typhoid vaccine, im	Immunizations					0.85	PHCS
90692		Typhoid vaccine, h-p, sc/id	Immunizations					0.76	PHCS
90693		Typhoid vaccine, akd, sc	Immunizations					0.61	PHCS
90700		Diap vaccine, im	Immunizations					0.51	PHCS
90701		Dip vaccine, im	Immunizations					0.32	PHCS
90702		Dt vaccine < 7, im	Immunizations					0.32	PHCS
90703		Tetanus vaccine, im	Immunizations					0.57	PHCS
90704		Mumps vaccine, sc	Immunizations					0.51	PHCS
90705		Measles vaccine, sc	Immunizations					0.51	PHCS
90706		Rubella vaccine, sc	Immunizations					0.83	PHCS
90707		Mmr vaccine, sc	Immunizations					0.70	PHCS
90708		Measles-rubella vaccine, sc	Immunizations					0.99	PHCS
90710		Mmr vaccine, sc	Immunizations					0.47	MDR
90712		Oral poliovirus vaccine	Immunizations					0.57	PHCS
90713		Poliovirus, ipv, sc	Immunizations					1.10	PHCS
90716		Chicken pox vaccine, sc	Immunizations					1.27	PHCS
90717		Yellow fever vaccine, sc	Immunizations					0.33	PHCS
90718		Td vaccine > 7, im	Immunizations					0.32	PHCS
90719		Diphtheria vaccine, im	Immunizations						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 151 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
90720		Dtp/hib vaccine, im	Immunizations					0.89	PHCS
90721		Dtap/hib vaccine, im	Immunizations					0.96	PHCS
90723		Dtap-hep b-ipv vaccine, im	Immunizations					1.47	PHCS
90725		Cholera vaccine, injectable	Immunizations					0.40	PHCS
90727		Plague vaccine, im	Immunizations					0.38	PHCS
90732		Pneumococcal vaccine	Immunizations					0.41	PHCS
90733		Meningococcal vaccine, sc	Immunizations					1.34	PHCS
90735		Encephalitis vaccine, sc	Immunizations					1.53	PHCS
90740		Hepb vacc, ill pat 3 dose im	Immunizations					5.05	PHCS
90743		Hep b vacc, adol, 2 dose, im	Immunizations					1.02	PHCS
90744		Hepb vacc ped/adol 3 dose im	Immunizations					0.76	PHCS
90746		Hep b vaccine, adult, im	Immunizations					1.15	PHCS
90747		Hepb vacc, ill pat 4 dose im	Immunizations					4.31	PHCS
90748		Hep b/hib vaccine, im	Immunizations					1.07	PHCS
90749		Vaccine toxoid	Immunizations					0.61	Misc.
90780		IV infusion therapy, 1 hour	Therapeutic Injections		0.17	2.15	2.15		
90781		IV infusion, additional hour	Therapeutic Injections		0.17	0.46	0.46		
90782		Injection, sc/im	Therapeutic Injections		0.17	0.32	0.32		
90783		Injection, ia	Therapeutic Injections		0.17	0.32	0.32		
90784		Injection, iv	Therapeutic Injections		0.17	0.80	0.80		
90788		Injection of antibiotic	Therapeutic Injections		0.17	0.27	0.27		
90799		Therapeutic injections	Therapeutic Injections						
90801		Psy dx interview	OP Psych./Alc. & Drug Abuse		2.80	0.94	1.17	0.49	Misc.
90802		Intac psy dx interview	OP Psych./Alc. & Drug Abuse		3.01	0.98	1.20		
90804		Psydx, office, 20-30 min	OP Psych./Alc. & Drug Abuse		1.21	0.38	0.49		
90805		Psydx, off, 20-30 min w/e&m	OP Psych./Alc. & Drug Abuse		1.37	0.42	0.50		
90806		Psydx, off, 45-50 min	OP Psych./Alc. & Drug Abuse		1.86	0.60	0.70		
90807		Psydx, off, 45-50 min w/e&m	OP Psych./Alc. & Drug Abuse		2.02	0.63	0.70		
90808		Psydx, office, 75-80 min	OP Psych./Alc. & Drug Abuse		2.79	0.91	1.03		
90809		Psydx, off, 75-80, w/e&m	OP Psych./Alc. & Drug Abuse		2.95	0.92	1.00		
90810		Intac psydx, off, 20-30 min	OP Psych./Alc. & Drug Abuse		1.32	0.42	0.50		
90811		Intac psydx, 20-30, w/e&m	OP Psych./Alc. & Drug Abuse		1.48	0.46	0.57		
90812		Intac psydx, off, 45-50 min	OP Psych./Alc. & Drug Abuse		1.97	0.84	0.79		
90813		Intac psydx, 45-50 min w/e&m	OP Psych./Alc. & Drug Abuse		2.13	0.67	0.77		
90814		Intac psydx, off, 75-80 min	OP Psych./Alc. & Drug Abuse		2.90	0.99	1.11		
90815		Intac psydx, 75-80 w/e&m	OP Psych./Alc. & Drug Abuse		3.06	0.95	1.05		
90816		Psydx, hosp, 20-30 min	OP Psych./Alc. & Drug Abuse		1.25	0.46	0.46		
90817		Psydx, hosp, 20-30 min w/e&m	OP Psych./Alc. & Drug Abuse		1.41	0.45	0.45		
90818		Psydx, hosp, 45-50 min	OP Psych./Alc. & Drug Abuse		1.89	0.69	0.69		
90819		Psydx, hosp, 45-50 min w/e&m	OP Psych./Alc. & Drug Abuse		2.05	0.65	0.65		
90821		Psydx, hosp, 75-80 min	OP Psych./Alc. & Drug Abuse		2.83	1.01	1.01		
90822		Psydx, hosp, 75-80 min w/e&m	OP Psych./Alc. & Drug Abuse		2.99	0.95	0.95		
90823		Intac psydx, hosp, 20-30 min	OP Psych./Alc. & Drug Abuse		1.36	0.48	0.48		
90824		Intac psydx, hsp 20-30 w/e&m	OP Psych./Alc. & Drug Abuse		1.52	0.49	0.49		
90826		Intac psydx, hosp, 45-50 min	OP Psych./Alc. & Drug Abuse		2.01	0.73	0.73		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 152 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
90827		Intac psyx, hsp 45-50 w/e&m	OP Psych./Alc. & Drug Abuse		2.16	0.69	0.69		
90828		Intac psyx, hosp, 75-80 min	OP Psych./Alc. & Drug Abuse		2.94	1.07	1.07		
90829		Intac psyx, hsp 75-80 w/e&m	OP Psych./Alc. & Drug Abuse		3.10	0.99	0.99		
90845		Psychoanalysis	OP Psych./Alc. & Drug Abuse		1.79	0.55	0.58		
90846		Family psyx w/o patient	OP Psych./Alc. & Drug Abuse		1.83	0.65	0.65		
90847		Family psyx w/patient	OP Psych./Alc. & Drug Abuse		2.21	0.76	0.82		
90849		Multiple family group psyx	OP Psych./Alc. & Drug Abuse		0.59	0.24	0.27		
90853		Group psychotherapy	OP Psych./Alc. & Drug Abuse		0.59	0.23	0.25		
90857		Intac group psyx	OP Psych./Alc. & Drug Abuse		0.63	0.26	0.30		
90862		Medication management	OP Psych./Alc. & Drug Abuse		0.95	0.32	0.40		
90865		Narcosisynthesis	OP Psych./Alc. & Drug Abuse		2.84	0.89	1.59		
90870		Electroconvulsive therapy	OP Psych./Alc. & Drug Abuse		1.88	0.79	0.79		
90871		Electroconvulsive therapy	OP Psych./Alc. & Drug Abuse		2.72	1.07	1.07		
90875		Psychophysiological therapy	OP Psych./Alc. & Drug Abuse		1.20	0.46	0.90		
90876		Psychophysiological therapy	OP Psych./Alc. & Drug Abuse		1.90	0.73	1.16		MDR
90880		Hypnotherapy	OP Psych./Alc. & Drug Abuse		2.19	0.69	1.04	3.32	MDR
90882		Environmental manipulation	OP Psych./Alc. & Drug Abuse		0.97	0.37	0.37		
90885		Psy evaluation of records	OP Psych./Alc. & Drug Abuse		1.48	0.56	0.82	2.86	MDR
90887		Consultation with family	OP Psych./Alc. & Drug Abuse					2.56	Misc.
90889		Preparation of report	OP Psych./Alc. & Drug Abuse						
90899		Psychiatric service/therapy	OP Psych./Alc. & Drug Abuse						
90901		Biological train, any meth	Miscellaneous Medical		0.41	0.14	0.66		
90911		Biological feedback peni/uro/rectal	Miscellaneous Medical		0.89	0.31	1.61		
90918		ESRD related services, month	Miscellaneous Medical		11.16	7.34	7.34		
90919		ESRD related services, month	Miscellaneous Medical		8.53	4.07	4.07		
90920		ESRD related services, month	Miscellaneous Medical		7.26	3.81	3.81		
90921		ESRD related services, month	Miscellaneous Medical		4.46	2.48	2.48		
90922		ESRD related services, day	Miscellaneous Medical		0.37	0.22	0.22		
90923		ESRD related services, day	Miscellaneous Medical		0.28	0.13	0.13		
90924		ESRD related services, day	Miscellaneous Medical		0.24	0.12	0.12		
90925		ESRD related services, day	Miscellaneous Medical		0.15	0.08	0.08		
90935		Hemodialysis, one evaluation	Miscellaneous Medical		1.22	0.67	0.67		
90937		Hemodialysis, repeated eval	Miscellaneous Medical		2.11	0.98	0.98		
90939	26	Hemodialysis study, transcut	Miscellaneous Medical					0.92	MDR
90939	TC	Hemodialysis study, transcut	Miscellaneous Medical	a				1.37	MDR
90940	26	Hemodialysis access study	Miscellaneous Medical					0.92	MDR
90940	TC	Hemodialysis access study	Miscellaneous Medical	a				1.37	MDR
90945		Dialysis, one evaluation	Miscellaneous Medical						
90947		Dialysis, repeated eval	Miscellaneous Medical		1.28	0.70	0.70		
90969		Dialysis training, complete	Miscellaneous Medical		2.16	1.01	1.01	14.95	MDR
90993		Dialysis training, incompl	Miscellaneous Medical					2.52	MDR
90997		Hemoperfusion	Miscellaneous Medical		1.84	1.41	1.41		
90999		Dialysis procedure	Miscellaneous Medical		0.73	0.25	0.25	3.09	Misc.
91000	26	Esophageal intubation	Miscellaneous Medical	a	0.00	0.08	0.08		
91000	TC	Esophageal intubation	Miscellaneous Medical						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 153 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
91010	26	Esophagus motility study	Miscellaneous Medical	a	1.25	0.43	0.43	0.43	PHCS
91010	TC	Esophagus motility study	Miscellaneous Medical		0.00	2.28	2.28	2.04	
91011	26	Esophagus motility study	Miscellaneous Medical	a	1.50	0.53	0.53	0.38	
91011	TC	Esophagus motility study	Miscellaneous Medical		0.00	2.67	2.67	0.38	
91012	26	Esophagus motility study	Miscellaneous Medical	a	1.46	0.51	0.51	0.24	
91012	TC	Esophagus motility study	Miscellaneous Medical		0.00	2.83	2.83	0.49	
91020	26	Gastric motility	Miscellaneous Medical	a	1.44	0.48	0.48	3.96	
91020	TC	Gastric motility	Miscellaneous Medical		0.00	2.45	2.45		
91030	26	Acid perfusion of esophagus	Miscellaneous Medical	a	0.91	0.33	0.33		
91030	TC	Acid perfusion of esophagus	Miscellaneous Medical		0.00	2.07	2.07		
91032	26	Esophagus, acid reflux test	Miscellaneous Medical	a	1.21	0.41	0.41		
91032	TC	Esophagus, acid reflux test	Miscellaneous Medical		0.00	3.69	3.69		
91033	26	Prolonged acid reflux test	Miscellaneous Medical	a	1.30	0.45	0.45		
91033	TC	Prolonged acid reflux test	Miscellaneous Medical		0.00	3.71	3.71		
91052	26	Gastric analysis test	Miscellaneous Medical	a	0.79	0.28	0.28		
91052	TC	Gastric analysis test	Miscellaneous Medical		0.00	1.91	1.91		
91055	26	Gastric intubation for smear	Miscellaneous Medical	a	0.94	0.27	0.27		
91055	TC	Gastric intubation for smear	Miscellaneous Medical		0.00	2.10	2.10		
91060	26	Gastric saline load test	Miscellaneous Medical	a	0.45	0.14	0.14		
91060	TC	Gastric saline load test	Miscellaneous Medical		0.00	0.16	0.16		
91065	26	Breath hydrogen test	Miscellaneous Medical	a	0.20	0.07	0.07		
91065	TC	Breath hydrogen test	Miscellaneous Medical		0.00	1.89	1.89		
91100	26	Pass intestine bleeding tube	Miscellaneous Medical	a	1.08	0.29	0.29		
91100	TC	Pass intestine bleeding tube	Miscellaneous Medical		0.37	0.09	0.09		
91110	26	Gastric intubation treatment	Miscellaneous Medical	a	3.64	1.30	1.30		
91110	TC	Gastric intubation treatment	Miscellaneous Medical		0.00	19.83	19.83		
91122	26	GI tract capsule endoscopy	Miscellaneous Medical	a	1.77	0.60	0.60		
91122	TC	GI tract capsule endoscopy	Miscellaneous Medical		0.00	5.46	5.46		
91123	26	Anal pressure record	Miscellaneous Medical	a	0.52	0.19	0.19		
91123	TC	Anal pressure record	Miscellaneous Medical		0.66	0.24	0.24		
91132	26	Irigate fecal impaction	Miscellaneous Medical	a	0.88	0.35	0.35		
91132	TC	Irigate fecal impaction	Miscellaneous Medical		1.67	0.68	0.68		
91133	26	Electrogastrography	Miscellaneous Medical	a	0.67	0.29	0.29		
91133	TC	Electrogastrography	Miscellaneous Medical		1.10	0.46	0.46		
91133	TC	Electrogastrography w/test	Miscellaneous Medical	a	0.38	0.15	0.15		
91133	TC	Electrogastrography w/test	Miscellaneous Medical		2.50	1.08	1.08		
91299		Gastroenterology procedure	Miscellaneous Medical		1.31	0.56	0.56		
92002		Eye exam, new patient	Vision Exams		0.37	0.16	0.16		
92004		Eye exam, new patient	Vision Exams		0.69	0.29	0.29		
92012		Eye exam established pat	Vision Exams		0.00	0.43	0.43		
92014		Eye exam & treatment	Vision Exams		0.37	0.16	0.16		
92015		Refraction	Miscellaneous Medical		0.00	0.43	0.43		
92018		New eye exam & treatment	Miscellaneous Medical		0.37	0.16	0.16		
92019		Eye exam & treatment	Miscellaneous Medical		0.69	0.29	0.29		
92020		Special eye evaluation	Miscellaneous Medical		0.00	0.43	0.43		
92060	26	Special eye evaluation	Miscellaneous Medical	a	0.00	0.37	0.37		
92060	TC	Special eye evaluation	Miscellaneous Medical		0.00	0.43	0.43		
92065	26	Orthoptic/pleoptic training	Miscellaneous Medical	a	0.37	0.16	0.16		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 154 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
92065	TC	Orthoptic/pleoptic training	Miscellaneous Medical	a	0.00	0.39	0.39		
92070		Fitting of contact lens	Miscellaneous Medical		0.70	0.32	1.08		
92081	26	Visual field examination(s)	Miscellaneous Medical		0.36	0.15	0.15		
92081	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	0.70	0.70		
92082	26	Visual field examination(s)	Miscellaneous Medical		0.44	0.19	0.19		
92082	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	0.96	0.96		
92083	26	Visual field examination(s)	Miscellaneous Medical		0.50	0.22	0.22		
92083	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	1.11	1.11		
92100		Serial tonometry exam(s)	Miscellaneous Medical		0.92	0.37	1.26		
92120		Tonography & eye evaluation	Miscellaneous Medical		0.81	0.32	1.04		
92130		Water provocation tonography	Miscellaneous Medical		0.81	0.37	1.23		
92135	26	Ophthalmic dx imaging	Miscellaneous Medical		0.35	0.16	0.16		
92135	TC	Ophthalmic dx imaging	Miscellaneous Medical	a	0.00	0.62	0.62		
92136	26	Ophthalmic biometry	Miscellaneous Medical		0.54	0.25	0.25		
92136	TC	Ophthalmic biometry	Miscellaneous Medical	a	0.00	1.50	1.50		
92140		Glaucoma provocative tests	Miscellaneous Medical		0.50	0.21	0.94		
92225		Special eye exam, initial	Miscellaneous Medical		0.38	0.16	0.22		
92226		Special eye exam, subsequent	Miscellaneous Medical		0.33	0.15	0.21		
92230		Eye exam with photos	Miscellaneous Medical		0.60	0.20	1.67		
92235	26	Eye exam with photos	Miscellaneous Medical		0.81	0.37	0.37		
92235	TC	Eye exam with photos	Miscellaneous Medical	a	0.00	2.95	2.95		
92240	26	log angiography	Miscellaneous Medical		1.10	0.49	0.49		
92240	TC	log angiography	Miscellaneous Medical	a	0.00	6.54	6.54		
92250	26	Eye exam with photos	Miscellaneous Medical		0.44	0.20	0.20		
92250	TC	Eye exam with photos	Miscellaneous Medical	a	0.00	1.53	1.53		
92260		Ophthalmoscopy/dynamometry	Miscellaneous Medical		0.20	0.09	0.29		
92265	26	Eye muscle evaluation	Miscellaneous Medical		0.81	0.28	0.28		
92265	TC	Eye muscle evaluation	Miscellaneous Medical	a	0.00	1.60	1.60		
92270	26	Electro-oculography	Miscellaneous Medical		0.81	0.34	0.34		
92270	TC	Electro-oculography	Miscellaneous Medical	a	0.00	1.22	1.22		
92275	26	Electroretinography	Miscellaneous Medical		1.01	0.42	0.42		
92275	TC	Electroretinography	Miscellaneous Medical	a	0.00	1.51	1.51		
92283	26	Color vision examination	Miscellaneous Medical		0.17	0.07	0.07		
92283	TC	Color vision examination	Miscellaneous Medical	a	0.00	0.76	0.76		
92284	26	Dark adaptation eye exam	Miscellaneous Medical		0.24	0.09	0.09		
92284	TC	Dark adaptation eye exam	Miscellaneous Medical	a	0.00	2.22	2.22		
92285	26	Eye photography	Miscellaneous Medical		0.20	0.09	0.09		
92285	TC	Eye photography	Miscellaneous Medical	a	0.00	0.98	0.98		
92286	26	Internal eye photography	Miscellaneous Medical		0.66	0.30	0.30		
92286	TC	Internal eye photography	Miscellaneous Medical	a	0.00	3.07	3.07		MDR
92287	26	Internal eye photography	Miscellaneous Medical		1.17	0.45	1.12		MDR
92287	TC	Internal eye photography	Miscellaneous Medical	a	1.08	0.35	1.18		MDR
92310		Contact lens fitting	Vision Exams		1.26	0.49	1.16		
92311		Contact lens fitting	Miscellaneous Medical					1.50	
92312		Contact lens fitting	Miscellaneous Medical					2.00	

NOTE: CPT Codes and descriptions only are copyright, 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 155 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
92313		Contact lens fitting	Miscellaneous Medical		0.92	0.29	1.16		
92314		Prescription of contact lens	Vision Exams		0.69	0.27	0.94		
92315		Prescription of contact lens	Miscellaneous Medical		0.45	0.16	0.95		
92316		Prescription of contact lens	Miscellaneous Medical		0.68	0.30	1.00		
92317		Prescription of contact lens	Miscellaneous Medical		0.45	0.15	1.05		
92325		Modification of contact lens	Vision Exams		0.00	0.39	0.39		
92326		Replacement of contact lens	Vision Exams		0.00	1.64	1.64		
92330		Fitting of artificial eye	Miscellaneous Medical		1.08	0.33	1.08		
92335		Fitting of artificial eye	Miscellaneous Medical		0.45	0.17	1.01		
92340		Fitting of spectacles	Vision Exams		0.37	0.14	0.70		
92341		Fitting of spectacles	Vision Exams		0.47	0.18	0.74		
92342		Fitting of spectacles	Vision Exams		0.53	0.21	0.76		
92352		Special spectacles fitting	Vision Exams		0.37	0.14	0.73		
92353		Special spectacles fitting	Miscellaneous Medical		0.50	0.19	0.78		
92354		Special spectacles fitting	Miscellaneous Medical		0.00	8.89	8.89		
92355		Special spectacles fitting	Miscellaneous Medical		0.00	4.34	4.34		
92358		Eye prosthesis service	Miscellaneous Medical		0.00	0.97	0.97		
92370		Repair & adjust spectacles	Vision Exams		0.32	0.13	0.55		
92371		Repair & adjust spectacles	Miscellaneous Medical		0.00	0.62	0.62	5.04	SAF
92390		Supply of spectacles	Vision Exams					2.88	SAF
92391		Supply of contact lenses	Vision Exams		0.00	3.79	3.79		
92392		Supply of contact lenses	Vision Exams		0.00	11.76	11.76		
92393		Supply of low vision aids	Miscellaneous Medical		0.00	1.28	1.28		
92395		Supply of artificial eye	Miscellaneous Medical		0.00	2.16	2.16		
92396		Supply of spectacles	Miscellaneous Medical		0.00			1.15	Misc.
92499		Supply of contact lenses	Miscellaneous Medical		0.00				
92502		Eye service or procedure	Miscellaneous Medical		1.51	1.13	1.13		
92504		Ear and throat examination	Miscellaneous Medical		0.18	0.09	0.49		
92506		Ear microscopy examination	Miscellaneous Medical		0.86	0.40	2.61		
92507		Speech/hearing evaluation	Hearing/Speech Exams		0.52	0.24	1.13		
92508		Speech/hearing therapy	Hearing/Speech Exams		0.26	0.12	0.52		
92510		Speech/hearing therapy	Hearing/Speech Exams		1.50	0.82	2.08		
92511		Rehab for ear implant	Hearing/Speech Exams		0.84	0.79	3.14		
92512		Nasopharyngoscopy	Miscellaneous Medical		0.55	0.16	1.08		
92516		Nasal function test	Miscellaneous Medical		0.43	0.22	0.89		
92520		Facial nerve function test	Miscellaneous Medical		0.76	0.38	0.50		
92526		Laryngeal function studies	Miscellaneous Medical		0.55	0.20	1.66		
92531		Oral function therapy	Miscellaneous Medical					0.64	MDR
92532		Spontaneous nystagmus study	Miscellaneous Medical					0.75	MDR
92533		Positional nystagmus test	Miscellaneous Medical					1.20	MDR
92534		Caloric vestibular test	Miscellaneous Medical					0.53	MDR
92541	26	Optokinetic nystagmus test	Miscellaneous Medical		0.40	0.19	0.19		
92542	TC	Spontaneous nystagmus test	Miscellaneous Medical	a	0.00	0.78	0.78		
92543	TC	Positional nystagmus test	Miscellaneous Medical		0.33	0.16	0.16		
92544	TC	Positional nystagmus test	Miscellaneous Medical	a	0.00	0.90	0.90		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 156 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
92543	26	Caloric vestibular test	Miscellaneous Medical	a	0.10	0.05	0.05	0.20	
92543	TC	Caloric vestibular test	Miscellaneous Medical		0.00	0.48	0.48	0.48	
92544	26	Opiokinetic nystagmus test	Miscellaneous Medical	a	0.26	0.12	0.12	0.38	
92544	TC	Opiokinetic nystagmus test	Miscellaneous Medical		0.00	0.72	0.72	0.72	
92545	26	Oscillating tracking test	Miscellaneous Medical	a	0.23	0.11	0.11	0.34	
92545	TC	Oscillating tracking test	Miscellaneous Medical		0.00	0.68	0.68	0.68	
92546	26	Sinusoidal rotational test	Miscellaneous Medical	a	0.29	0.13	0.13	0.42	
92546	TC	Sinusoidal rotational test	Miscellaneous Medical		0.00	1.67	1.67	1.67	
92547	26	Sinusoidal rotational test	Miscellaneous Medical	a	0.00	1.15	1.15	1.15	
92547	TC	Supplemental electrical test	Miscellaneous Medical		0.50	0.26	0.26	0.76	
92548	26	Posturography	Miscellaneous Medical	a	0.00	2.93	2.93	2.93	
92548	TC	Posturography	Miscellaneous Medical		0.00	0.44	0.44	0.44	MDR
92551	26	Pure tone hearing test, air	Hearing/Speech Exams	a	0.00	0.66	0.66	0.66	
92551	TC	Pure tone hearing test, air	Hearing/Speech Exams		0.00	0.37	0.37	0.37	
92552	26	Pure tone audiometry, air	Hearing/Speech Exams	a	0.00	0.57	0.57	0.57	
92552	TC	Audiometry, air & bone	Hearing/Speech Exams		0.00	1.19	1.19	1.19	
92553	26	Speech threshold audiometry	Hearing/Speech Exams	a	0.00	0.72	0.72	0.72	
92555	26	Speech audiometry, complete	Hearing/Speech Exams	a	0.00	0.40	0.40	0.40	
92556	26	Comprehensive hearing test	Hearing/Speech Exams	a	0.00	0.47	0.47	0.47	
92557	26	Group audiometric testing	Hearing/Speech Exams	a	0.00	0.39	0.39	0.39	
92559	26	Bekeesy audiometry, screen	Hearing/Speech Exams	a	0.00	0.52	0.52	0.52	
92560	26	Bekeesy audiometry, diagnosis	Hearing/Speech Exams	a	0.00	0.37	0.37	0.37	
92561	26	Loudness balance test	Hearing/Speech Exams	a	0.00	0.40	0.40	0.40	
92562	26	Tone decay hearing test	Hearing/Speech Exams	a	0.00	0.38	0.38	0.38	
92563	26	Sisi hearing test	Hearing/Speech Exams	a	0.00	0.09	0.09	0.09	
92564	26	Stenger test, pure tone	Hearing/Speech Exams	a	0.00	0.35	0.35	0.35	
92565	26	Tympanometry	Hearing/Speech Exams	a	0.00	0.30	0.30	0.30	
92567	26	Acoustic reflex testing	Hearing/Speech Exams	a	0.00	0.44	0.44	0.44	
92568	26	Acoustic reflex decay test	Hearing/Speech Exams	a	0.00	0.72	0.72	0.72	
92569	26	Filtered speech hearing test	Hearing/Speech Exams	a	0.00	0.40	0.40	0.40	
92571	26	Staggered spondaic word test	Hearing/Speech Exams	a	0.00	0.38	0.38	0.38	
92572	26	Lombard test	Hearing/Speech Exams	a	0.00	0.09	0.09	0.09	
92573	26	Sensorineural acuity test	Hearing/Speech Exams	a	0.00	0.35	0.35	0.35	
92575	26	Synthetic sentence test	Hearing/Speech Exams	a	0.00	0.30	0.30	0.30	
92576	26	Stenger test, speech	Hearing/Speech Exams	a	0.00	0.44	0.44	0.44	
92577	26	Visual audiometry (vra)	Hearing/Speech Exams	a	0.00	0.72	0.72	0.72	
92579	26	Conditioning play audiometry	Hearing/Speech Exams	a	0.00	0.73	0.73	0.73	
92582	26	Select picture audiometry	Hearing/Speech Exams	a	0.00	0.89	0.89	0.89	
92583	26	Electrocochleography	Hearing/Speech Exams	a	0.00	2.49	2.49	2.49	
92584	26	Auditor evoke potent, compre	Hearing/Speech Exams	a	0.00	0.22	0.22	0.22	
92585	TC	Auditor evoke potent, compre	Hearing/Speech Exams		0.50	1.86	1.86	2.36	
92585	26	Auditor evoke potent, limit	Hearing/Speech Exams	a	0.00	1.86	1.86	1.86	
92586	26	Evoked auditory test	Hearing/Speech Exams	a	0.00	0.07	0.07	0.07	
92587	TC	Evoked auditory test	Hearing/Speech Exams		0.13	1.31	1.31	1.44	
92587	26	Evoked auditory test	Hearing/Speech Exams	a	0.00	0.36	0.36	0.36	
92588	TC	Evoked auditory test	Hearing/Speech Exams		0.00	1.47	1.47	1.47	
92588	26	Auditory function test(s)	Hearing/Speech Exams	a	0.00	0.53	0.53	0.53	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 157 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
92590		Hearing aid exam, one ear	Hearing/Speech Exams					1.51	MDR
92591		Hearing aid exam, both ears	Hearing/Speech Exams					2.26	MDR
92592		Hearing aid check, one ear	Hearing/Speech Exams					0.66	MDR
92593		Hearing aid check, both ears	Hearing/Speech Exams					0.99	MDR
92594		Electro hearing aid test, one	Hearing/Speech Exams					0.72	MDR
92595		Electro hearing aid test, both	Hearing/Speech Exams					1.08	MDR
92596		Ear protector evaluation	Hearing/Speech Exams	a	0.00	0.59	0.59		
92597		Oral speech device eval	Hearing/Speech Exams		0.86	0.45	1.69		
92601		Cochlear implant /up exam < 7	Miscellaneous Medical		0.00	3.41	3.41		
92602		Reprogram cochlear implant < 7	Miscellaneous Medical		0.00	2.36	2.36		
92603		Cochlear implant /up exam 7 >	Miscellaneous Medical		0.00	2.23	2.23		
92604		Reprogram cochlear implant 7 >	Miscellaneous Medical		0.00	1.47	1.47		
92607		Ex for speech device rx, 1hr	Miscellaneous Medical		0.00	3.22	3.22		
92608		Ex for speech device rx addl	Miscellaneous Medical		0.00	0.67	0.67		
92609		Use of speech device service	Miscellaneous Medical		0.00	1.60	1.60		
92610		Evaluate swallowing function	Miscellaneous Medical		0.00	3.44	3.44		
92611		Motion fluoroscopy/swallow	Miscellaneous Medical		0.00	3.44	3.44		
92612		Endoscopy swallow 1st (fees)	Miscellaneous Medical		1.27	0.67	2.71		
92613		Endoscopy swallow 1st (fees)	Miscellaneous Medical		0.71	0.39	0.39		
92614		Laryngoscopic sensory test	Miscellaneous Medical		1.27	0.61	2.41		
92615		Eval laryngoscopy sense test	Miscellaneous Medical		0.63	0.36	0.36		
92616		Fees w/laryngeal sense test	Miscellaneous Medical		1.88	0.97	3.29		
92617		Intemp fees/laryngeal test	Miscellaneous Medical		0.79	0.44	0.44	0.46	Misc.
92700		Ent procedure/service	Miscellaneous Medical						
92950		Heart/lung resuscitation cpr	Cardiovascular		3.79	0.98	0.98		
92953		Temporary external pacing	Cardiovascular		0.23	0.23	0.23		
92960		Cardioversion electric, ext	Cardiovascular		2.25	1.17	6.66		
92961	26	Cardioversion, electric, int	Cardiovascular						
92961	TC	Cardioversion, electric, int	Cardiovascular	a					
92970		Cardioassist, internal	Cardiovascular						
92971		Cardioassist, external	Cardiovascular						
92973		Percut coronary thrombectomy	Surgery		3.51	1.07	1.07		
92974		Cath place, cardio brachytx	Surgery		1.77	0.85	0.85		
92975		Dissolve clot, heart vessel	Surgery		3.28	1.29	1.29		
92977		Dissolve clot, heart vessel	Cardiovascular		3.00	1.18	1.18		
92978	26	Intravasc us, heart add-on	Cardiovascular		7.24	2.81	2.81		
92978	TC	Intravasc us, heart add-on	Cardiovascular	a	0.00	8.08	8.08		
92979	26	Intravasc us, heart add-on	Cardiovascular		1.80	0.71	0.71		
92979	TC	Intravasc us, heart add-on	Cardiovascular	a	0.00	4.58	4.58		
92980		Insert intracoronary stent	Cardiovascular		1.44	0.56	0.56		
92981		Insert intracoronary stent	Cardiovascular		0.00	2.30	2.30		
92982		Coronary artery dilation	Surgery		14.82	6.07	6.07		
92984		Revision of aortic valve	Surgery		4.16	1.64	1.64		
92986		Revision of mitral valve	Surgery		10.96	4.55	4.55		
92987			Surgery		2.97	1.16	1.16		
			Surgery		21.77	11.62	11.62		
			Surgery		22.67	12.01	12.01		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 158 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
92990		Revision of pulmonary valve	Surgery		17.31	9.63	9.63	36.93	MDR
92992		Revision of heart chamber	Surgery			4.98	4.98	25.88	MDR
92993		Revision of heart chamber	Surgery		12.07	1.28	1.28		
92995		Coronary atherectomy	Surgery		3.26	4.85	4.85		
92996		Coronary atherectomy add-on	Surgery		11.98	2.21	2.21		
92897		Pul art balloon repr. percut	Surgery	a	5.99	0.51	0.51		
92998		Pul art balloon repr. percut	Surgery	a	0.17	0.45	0.45		
93000		Electrocardiogram, complete	Cardiovascular		0.00	0.06	0.06		
93005		Electrocardiogram, tracing	Cardiovascular		0.17	0.06	0.06		
93010		Electrocardiogram report	Cardiovascular		0.00	6.04	6.04		
93012		Transmission of ecg	Cardiovascular		0.52	0.19	0.19		
93014		Report on transmitted ecg	Cardiovascular		0.75	1.98	1.98		
93015		Cardiovascular stress test	Cardiovascular	a	0.45	0.17	0.17		
93016		Cardiovascular stress test	Cardiovascular	a	0.00	1.69	1.69		
93017		Cardiovascular stress test	Cardiovascular	a	0.30	0.12	0.12		
93018		Cardiovascular stress test	Cardiovascular	a	1.17	0.45	0.45		
93024		Cardiac drug stress test	Cardiovascular		0.00	1.12	1.12		
93024	26	Cardiac drug stress test	Cardiovascular	a	0.00	0.29	0.29		
93024	TC	Cardiac drug stress test	Cardiovascular	a	0.00	7.89	7.89		
93025	26	Microvolt t-wave assess	Cardiovascular	a	0.16	0.20	0.20		
93025	TC	Microvolt t-wave assess	Cardiovascular	a	0.00	0.15	0.15		
93040		Rhythm ECG with report	Cardiovascular		0.16	0.05	0.05		
93041		Rhythm ECG, tracing	Cardiovascular		0.52	3.63	3.63		
93042		Rhythm ECG, report	Cardiovascular		0.00	1.24	1.24		
93224		ECG monitor/report, 24 hrs	Cardiovascular		0.00	2.19	2.19		
93225		ECG monitor/record, 24 hrs	Cardiovascular	a	0.52	0.20	0.20		
93226		ECG monitor/record, 24 hrs	Cardiovascular	a	0.52	3.90	3.90		
93227		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	1.52	1.52		
93230		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	2.18	2.18		
93231		ECG monitor/record, 24 hrs	Cardiovascular	a	0.52	0.20	0.20		
93232		ECG monitor/report, 24 hrs	Cardiovascular	a	2.79	2.79	2.79		
93233		ECG monitor/report, 24 hrs	Cardiovascular	a	0.45	2.62	2.62		
93235		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	0.17	0.17		
93236		ECG monitor/report, 24 hrs	Cardiovascular	a	0.45	0.52	0.52		
93237		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	1.24	1.24		
93268		ECG record/review	Cardiovascular		0.00	6.04	6.04		
93270		ECG recording	Cardiovascular		0.00	0.19	0.19		
93271		Ecg monitoring and analysis	Cardiovascular		0.52	0.10	0.10		
93272		Ecg/review, interpret only	Cardiovascular		0.25	0.10	0.10		
93278	26	ECG/signal-averaged	Cardiovascular	a	1.30	0.48	0.48		
93278	TC	ECG/signal-averaged	Cardiovascular	a	0.00	3.87	3.87		
93303	26	Echo transthoracic	Cardiovascular	a	0.00	0.28	0.28		
93303	TC	Echo transthoracic	Cardiovascular	a	0.00	1.95	1.95		
93303	26	Echo transthoracic	Cardiovascular	a	0.00	0.92	0.92		
93304	26	Echo transthoracic	Cardiovascular	a					
93304	TC	Echo transthoracic	Cardiovascular						
93307	26	Echo exam of heart	Cardiovascular						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 159 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
93307	TC	Echo exam of heart	Cardiovascular	a	0.00	3.87	3.87		
93308	TC	Echo exam of heart	Cardiovascular	a	0.53	0.21	0.21		
93312	TC	Echo transesophageal	Cardiovascular	a	0.00	1.95	1.95		
93313	TC	Echo transesophageal	Cardiovascular	a	2.20	0.79	0.79		
93314	TC	Echo transesophageal	Cardiovascular	a	0.00	3.79	3.79		
93315	TC	Echo transesophageal	Cardiovascular	a	0.95	0.21	0.21		
93316	TC	Echo transesophageal	Cardiovascular	a	1.25	0.47	0.47		
93317	TC	Echo transesophageal	Cardiovascular	a	0.00	3.79	3.79		
93318	TC	Echo transesophageal intraop	Cardiovascular	a	2.78	1.02	1.02		MDR
93320	TC	Doppler echo exam, heart	Cardiovascular	a	0.95	0.24	0.24		MDR
93321	TC	Doppler echo exam, heart	Cardiovascular	a	1.83	0.67	0.67		MDR
93322	TC	Doppler echo exam, heart	Cardiovascular	a	2.20	0.47	0.47		MDR
93325	TC	Doppler color flow add-on	Cardiovascular	a	0.38	0.15	0.15		
93326	TC	Doppler color flow add-on	Cardiovascular	a	0.00	1.72	1.72		
93350	TC	Echo transthoracic	Cardiovascular	a	0.15	0.06	0.06		
93501	TC	Right heart catheterization	Cardiovascular	a	0.00	1.12	1.12		
93503	TC	Insert/place heart catheter	Cardiovascular	a	0.07	0.03	0.03		
93505	TC	Biopsy of heart lining	Cardiovascular	a	0.00	2.91	2.91		
93508	TC	Cath placement, angiography	Cardiovascular	a	1.48	0.57	0.57		
93510	TC	Left heart catheterization	Cardiovascular	a	0.00	1.77	1.77		
93511	TC	Left heart catheterization	Cardiovascular	a	3.02	1.15	1.15		
93514	TC	Left heart catheterization	Cardiovascular	a	0.00	16.96	16.96		
93524	TC	Left heart catheterization	Cardiovascular	a	2.91	0.68	0.68		
93526	TC	Rt & Lt heart catheters	Cardiovascular	a	4.37	1.69	1.69		
93527	TC	Rt & Lt heart catheters	Cardiovascular	a	0.00	1.99	1.99		
93528	TC	Rt & Lt heart catheters	Cardiovascular	a	4.09	2.09	2.09		
93529	TC	Rt, Lt heart catheterization	Cardiovascular	a	0.00	12.64	12.64		
					4.32	2.18	2.18		
					0.00	37.08	37.08		
					5.02	2.45	2.45		
					0.00	36.10	36.10		
					7.04	3.14	3.14		
					0.00	36.10	36.10		
					6.94	3.19	3.19		
					0.00	47.17	47.17		
					5.98	2.82	2.82		
					0.00	48.46	48.46		
					7.27	3.33	3.33		
					0.00	47.17	47.17		
					8.99	4.05	4.05		
					0.00	47.17	47.17		
					4.79	2.29	2.29		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 160 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
93529	TC	Rt, lt heart catheterization	Surgery	a	0.00	47.17	47.17	47.17	
93530	26	Rt heart cath, congenital	Surgery		4.22	1.94	1.94	1.94	
93530	TC	Rt heart cath, congenital	Surgery	a	0.00	16.96	16.96	16.96	
93531	26	R & l heart cath, congenital	Surgery		3.34	3.59	3.59	3.59	
93531	TC	R & l heart cath, congenital	Surgery	a	0.00	48.46	48.46	48.46	
93532	26	R & l heart cath, congenital	Surgery		9.99	4.27	4.27	4.27	
93532	TC	R & l heart cath, congenital	Surgery	a	0.00	47.17	47.17	47.17	
93533	26	R & l heart cath, congenital	Surgery		6.69	2.81	2.81	2.81	
93533	TC	R & l heart cath, congenital	Surgery	a	0.00	47.17	47.17	47.17	
93539		Injection, cardiac cath	Cardiovascular		0.40	0.16	0.16	0.16	
93540		Injection, cardiac cath	Cardiovascular		0.43	0.17	0.17	0.17	
93541		Injection for lung angiogram	Cardiovascular		0.29	0.11	0.11	0.11	
93542		Injection for heart x-rays	Cardiovascular		0.29	0.11	0.11	0.11	
93543		Injection for heart x-rays	Cardiovascular		0.29	0.12	0.12	0.12	
93544		Injection for aortography	Cardiovascular		0.25	0.10	0.10	0.10	
93545		Inject for coronary x-rays	Cardiovascular		0.40	0.16	0.16	0.16	
93555	26	Imaging, cardiac cath	Cardiovascular		0.81	0.32	0.32	0.32	
93555	TC	Imaging, cardiac cath	Cardiovascular	a	0.00	6.30	6.30	6.30	
93556	26	Imaging, cardiac cath	Cardiovascular		0.83	0.33	0.33	0.33	
93556	TC	Imaging, cardiac cath	Cardiovascular	a	0.00	9.93	9.93	9.93	
93561	26	Cardiac output measurement	Surgery		0.50	0.16	0.16	0.16	
93561	TC	Cardiac output measurement	Surgery	a	0.00	0.52	0.52	0.52	
93562	26	Cardiac output measurement	Surgery		0.16	0.05	0.05	0.05	
93562	TC	Cardiac output measurement	Surgery	a	0.00	0.32	0.32	0.32	
93571	26	Heart flow reserve measure	Surgery		1.80	0.68	0.68	0.68	
93571	TC	Heart flow reserve measure	Surgery	a	0.00	4.58	4.58	4.58	
93572	26	Heart flow reserve measure	Surgery		1.44	0.50	0.50	0.50	
93572	TC	Heart flow reserve measure	Surgery	a	0.00	2.30	2.30	2.30	
93580		Transcath closure of asd	Surgery		17.97	7.21	7.21	7.21	
93581		Transcath closure of vsd	Surgery		24.39	9.66	9.66	9.66	
93600	26	Bundle of His recording	Cardiovascular		2.12	0.83	0.83	0.83	
93600	TC	Bundle of His recording	Cardiovascular	a	0.00	1.96	1.96	1.96	
93602	26	Intra-atrial recording	Cardiovascular		2.12	0.83	0.83	0.83	
93602	TC	Intra-atrial recording	Cardiovascular	a	0.00	1.12	1.12	1.12	
93603	26	Right ventricular recording	Cardiovascular		2.12	0.82	0.82	0.82	
93603	TC	Right ventricular recording	Cardiovascular	a	0.00	1.69	1.69	1.69	
93609	26	Map tachycardia, add-on	Cardiovascular		4.99	1.95	1.95	1.95	
93609	TC	Map tachycardia, add-on	Cardiovascular	a	0.00	2.72	2.72	2.72	
93610	26	Intra-atrial pacing	Cardiovascular		3.02	1.16	1.16	1.16	
93610	TC	Intra-atrial pacing	Cardiovascular	a	0.00	1.36	1.36	1.36	
93612	26	Intraventricular pacing	Cardiovascular		3.02	1.16	1.16	1.16	
93612	TC	Intraventricular pacing	Cardiovascular	a	0.00	1.62	1.62	1.62	
93613	26	Electrophys map 3d, add-on	Cardiovascular		0.00				
93613	TC	Electrophys map 3d, add-on	Cardiovascular	a	0.00				
93613	TC	Electrophys map 3d, add-on	Cardiovascular						
93615	26	Esophageal recording	Cardiovascular		0.99	0.27	0.27	0.27	
								5.36	SA
								0.98	SAF

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 161 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
93615	TC	Esophageal recording	Cardiovascular	a	0.00	0.32	0.32		
93616	26	Esophageal recording	Cardiovascular		1.49	0.42	0.42		
93616	TC	Esophageal recording	Cardiovascular	a	0.00	0.32	0.32		
93618	26	Heart rhythm pacing	Cardiovascular		4.25	1.68	1.68		
93618	TC	Heart rhythm pacing	Cardiovascular	a	0.00	3.98	3.98		
93619	26	Electrophysiology evaluation	Cardiovascular		7.31	3.20	3.20		
93619	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	7.74	7.74		
93620	26	Electrophysiology evaluation	Cardiovascular		11.57	4.86	4.86		
93620	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	11.57	11.57		SAF
93621	26	Electrophysiology evaluation	Cardiovascular		2.10	0.82	0.82		
93621	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	2.10	2.10		MDR
93622	26	Electrophysiology evaluation	Cardiovascular		3.10	1.21	1.21		
93622	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	3.10	3.10		MDR
93623	26	Stimulation, pacing heart	Cardiovascular		2.85	1.12	1.12		
93623	TC	Stimulation, pacing heart	Cardiovascular	a	0.00	2.85	2.85		MDR
93624	26	Electrophysiologic study	Cardiovascular		4.80	2.20	2.20		
93624	TC	Electrophysiologic study	Cardiovascular	a	0.00	4.80	4.80		MDR
93631	26	Heart pacing, mapping	Cardiovascular		0.00	1.99	1.99		
93631	TC	Heart pacing, mapping	Cardiovascular	a	0.00	1.99	1.99		
93640	26	Evaluation heart device	Cardiovascular		3.51	1.36	1.36		
93640	TC	Evaluation heart device	Cardiovascular	a	0.00	3.51	3.51		
93641	26	Electrophysiology evaluation	Cardiovascular		5.92	2.32	2.32		
93641	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	5.92	5.92		
93642	26	Electrophysiology evaluation	Cardiovascular		4.88	2.22	2.22		
93642	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	4.88	4.88		
93650	26	Ablate heart dysrhythm focus	Cardiovascular		10.49	4.45	4.45		
93651	26	Ablate heart dysrhythm focus	Cardiovascular		16.23	6.35	6.35		
93652	26	Ablate heart dysrhythm focus	Cardiovascular		17.65	6.91	6.91		
93660	26	Tilt table evaluation	Cardiovascular		1.89	0.74	0.74		
93660	TC	Tilt table evaluation	Cardiovascular	a	0.00	1.89	1.89		
93662	26	Intracardiac eeg (ice)	Cardiovascular		2.80	1.11	1.11		
93662	TC	Intracardiac eeg (ice)	Cardiovascular	a	0.00	2.80	2.80		
93668	26	Peripheral vascular rehab	Cardiovascular		0.17	0.07	0.07		PHCS
93701	26	Bioimpedance, thoracic	Cardiovascular		0.00	0.95	0.95		MDR
93701	TC	Bioimpedance, thoracic	Cardiovascular	a	0.00	0.95	0.95		
93720	26	Total body plethysmography	Cardiovascular		0.00	0.71	0.71		SAF
93720	TC	Total body plethysmography	Cardiovascular	a	0.00	0.71	0.71		SAF
93721	26	Plethysmography tracing	Cardiovascular		4.88	1.92	1.92		
93721	TC	Plethysmography tracing	Cardiovascular	a	0.00	4.88	4.88		
93722	26	Analyze pacemaker system	Cardiovascular		0.52	0.20	0.20		
93724	26	Analyze pacemaker system	Cardiovascular		0.45	0.18	0.18		
93724	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.45	0.45		
93727	26	Analyze lir system	Cardiovascular		0.00	0.49	0.49		
93727	TC	Analyze lir system	Cardiovascular	a	0.00	0.49	0.49		
93731	26	Analyze pacemaker system	Cardiovascular		0.00	0.36	0.36		
93731	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.36	0.36		
93732	26	Analyze pacemaker system	Cardiovascular		0.92	0.36	0.36		
93732	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.92	0.92		

NOTE: CPT Codes and descriptions only. are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 162 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
93732	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.51	0.51		
93733	26	Telephone analy, pacemaker	Cardiovascular		0.17	0.07	0.07		
93733	TC	Telephone analy, pacemaker	Cardiovascular	a	0.00	0.73	0.73		
93734	26	Analyze pacemaker system	Cardiovascular		0.38	0.15	0.15		
93734	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.35	0.35		
93735	26	Analyze pacemaker system	Cardiovascular		0.74	0.29	0.29		
93735	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.44	0.44		
93736	26	Telephone analy, pacemaker	Cardiovascular		0.15	0.06	0.06		
93736	TC	Telephone analy, pacemaker	Cardiovascular	a	0.00	0.63	0.63		
93740	26	Temperature gradient studies	Cardiovascular		0.16	0.04	0.04		
93740	TC	Temperature gradient studies	Cardiovascular	a	0.00	0.16	0.16		
93741	26	Analyze ht pace device snl	Cardiovascular		0.80	0.32	0.32		
93741	TC	Analyze ht pace device snl	Cardiovascular	a	0.00	0.67	0.67		
93742	26	Analyze ht pace device snl	Cardiovascular		0.91	0.36	0.36		
93742	TC	Analyze ht pace device snl	Cardiovascular	a	0.00	0.67	0.67		
93743	26	Analyze ht pace device dual	Cardiovascular		1.03	0.40	0.40		
93743	TC	Analyze ht pace device dual	Cardiovascular	a	0.00	0.74	0.74		
93744	26	Analyze ht pace device dual	Cardiovascular		1.18	0.46	0.46		
93744	TC	Analyze ht pace device dual	Cardiovascular	a	0.00	0.67	0.67		
93760	26	Cephalic thermogram	Cardiovascular					0.44	MDR
93760	TC	Cephalic thermogram	Cardiovascular	a				1.74	MDR
93762	26	Peripheral thermogram	Cardiovascular					0.64	MDR
93762	TC	Peripheral thermogram	Cardiovascular	a				2.56	MDR
93770	26	Measure venous pressure	Cardiovascular		0.16	0.05	0.05		
93770	TC	Measure venous pressure	Cardiovascular	a	0.00	0.03	0.03		
93784	26	Ambulatory BP monitoring	Cardiovascular		0.38	1.55	1.55		
93786	26	Ambulatory BP recording	Cardiovascular		0.00	0.91	0.91		
93788	26	Ambulatory BP analysis	Cardiovascular		0.00	0.51	0.51		
93790	26	Review/report BP recording	Cardiovascular		0.38	0.13	0.13		
93797	26	Cardiac rehab	Cardiovascular		0.18	0.97	0.97		
93798	26	Cardiac rehab/monitor	Cardiovascular		0.28	0.11	0.49		
93799	26	Cardiovascular procedure	Cardiovascular		0.22	0.08	0.08		
93799	TC	Cardiovascular procedure	Miscellaneous Medical		0.00	1.58	1.58		
93875	26	Extracranial study	Miscellaneous Medical	a	0.60	0.21	0.21		
93875	TC	Extracranial study	Miscellaneous Medical		0.00	3.97	3.97		
93880	26	Extracranial study	Miscellaneous Medical		0.40	0.14	0.14		
93880	TC	Extracranial study	Miscellaneous Medical	a	0.00	2.87	2.87		
93882	26	Extracranial study	Miscellaneous Medical		0.94	0.37	0.37		
93882	TC	Extracranial study	Miscellaneous Medical	a	0.00	4.10	4.10		
93886	26	Intracranial study	Miscellaneous Medical		0.62	0.23	0.23		
93886	TC	Intracranial study	Miscellaneous Medical	a	0.00	2.79	2.79		
93888	26	Intracranial study	Miscellaneous Medical		0.25	0.09	0.09		
93888	TC	Intracranial study	Miscellaneous Medical	a	0.00	1.84	1.84		
93922	26	Extremity study	Miscellaneous Medical		0.00	0.15	0.15		
93922	TC	Extremity study	Miscellaneous Medical	a	0.45	0.15	0.15		
93923	26	Extremity study	Miscellaneous Medical						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARSDFAARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 163 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
93923	TC	Extremity study	Miscellaneous Medical	a	0.00	2.85	2.85	2.85	
93924	26	Extremity study	Miscellaneous Medical	a	0.50	0.17	0.17	0.67	
93924	TC	Extremity study	Miscellaneous Medical	a	0.00	3.59	3.59	3.59	
93925	26	Lower extremity study	Miscellaneous Medical	a	0.58	0.20	0.20	0.78	
93925	TC	Lower extremity study	Miscellaneous Medical	a	0.00	4.67	4.67	4.67	
93926	26	Lower extremity study	Miscellaneous Medical	a	0.39	0.13	0.13	0.52	
93926	TC	Lower extremity study	Miscellaneous Medical	a	0.00	3.36	3.36	3.36	
93930	26	Upper extremity study	Miscellaneous Medical	a	0.46	0.16	0.16	0.62	
93930	TC	Upper extremity study	Miscellaneous Medical	a	0.00	3.69	3.69	3.69	
93931	26	Upper extremity study	Miscellaneous Medical	a	0.31	0.11	0.11	0.42	
93931	TC	Upper extremity study	Miscellaneous Medical	a	0.00	2.71	2.71	2.71	
93965	26	Extremity study	Miscellaneous Medical	a	0.00	2.71	2.71	2.71	
93965	TC	Extremity study	Miscellaneous Medical	a	0.35	0.12	0.12	0.47	
93970	26	Extremity study	Miscellaneous Medical	a	0.00	1.74	1.74	1.74	
93970	TC	Extremity study	Miscellaneous Medical	a	0.68	0.23	0.23	0.91	
93971	26	Extremity study	Miscellaneous Medical	a	0.00	3.74	3.74	3.74	
93971	TC	Extremity study	Miscellaneous Medical	a	0.45	0.15	0.15	0.60	
93975	26	Vascular study	Miscellaneous Medical	a	1.80	0.60	0.60	2.40	
93975	TC	Vascular study	Miscellaneous Medical	a	0.00	5.22	5.22	5.22	
93976	26	Vascular study	Miscellaneous Medical	a	1.21	0.40	0.40	1.61	
93976	TC	Vascular study	Miscellaneous Medical	a	0.00	3.06	3.06	3.06	
93976	TC	Vascular study	Miscellaneous Medical	a	0.65	0.22	0.22	0.87	
93978	26	Vascular study	Miscellaneous Medical	a	0.00	3.36	3.36	3.36	
93978	TC	Vascular study	Miscellaneous Medical	a	0.44	0.15	0.15	0.59	
93979	26	Vascular study	Miscellaneous Medical	a	0.00	2.50	2.50	2.50	
93979	TC	Vascular study	Miscellaneous Medical	a	1.25	0.41	0.41	1.66	
93980	26	Penile vascular study	Miscellaneous Medical	a	0.00	4.37	4.37	4.37	
93980	TC	Penile vascular study	Miscellaneous Medical	a	0.00	0.15	0.15	0.15	
93981	26	Penile vascular study	Miscellaneous Medical	a	0.00	4.46	4.46	4.46	
93981	TC	Penile vascular study	Miscellaneous Medical	a	0.25	0.09	0.09	0.34	
93990	26	Doppler flow testing	Miscellaneous Medical	a	0.00	3.33	3.33	3.33	
93990	TC	Doppler flow testing	Miscellaneous Medical	a	0.17	0.05	0.05	0.22	
94010	26	Breathing capacity test	Miscellaneous Medical	a	0.00	0.62	0.62	0.62	
94010	TC	Breathing capacity test	Miscellaneous Medical	a	0.00	0.77	0.77	0.77	
94014		Patient recorded spirometry	Miscellaneous Medical	a	0.52	0.52	0.52	1.04	
94015		Patient recorded spirometry	Miscellaneous Medical	a	0.00	0.31	0.31	0.31	
94016	26	Review patient spirometry	Miscellaneous Medical	a	0.00	1.02	1.02	1.02	
94060	26	Evaluation of wheezing	Miscellaneous Medical	a	0.80	0.19	0.19	0.99	
94060	TC	Evaluation of wheezing	Miscellaneous Medical	a	0.00	2.80	2.80	2.80	
94070	26	Evaluation of wheezing	Miscellaneous Medical	a	0.07	0.03	0.03	0.10	
94070	TC	Evaluation of wheezing	Miscellaneous Medical	a	0.00	0.45	0.45	0.45	
94150	26	Vital capacity test	Miscellaneous Medical	a	0.00	0.11	0.11	0.11	
94150	TC	Vital capacity test	Miscellaneous Medical	a	0.00	0.41	0.41	0.41	
94200	26	Lung function test (MBC/IMVV)	Miscellaneous Medical	a	0.00	0.08	0.08	0.08	
94200	TC	Lung function test (MBC/IMVV)	Miscellaneous Medical	a	0.00	0.41	0.41	0.41	
94240	26	Residual lung capacity	Miscellaneous Medical	a	0.26	0.08	0.08	0.34	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 164 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
94240	TC	Residual lung capacity	Miscellaneous Medical	a	0.00	0.62	0.62		
94250	26	Expired gas collection	Miscellaneous Medical		0.11	0.03	0.03		
94250	TC	Expired gas collection	Miscellaneous Medical	a	0.00	0.62	0.62		
94260	26	Thoracic gas volume	Miscellaneous Medical		0.13	0.04	0.04		
94260	TC	Thoracic gas volume	Miscellaneous Medical	a	0.00	0.53	0.53		
94350	26	Lung nitrogen washout curve	Miscellaneous Medical		0.26	0.08	0.08		
94350	TC	Lung nitrogen washout curve	Miscellaneous Medical	a	0.00	0.67	0.67		
94360	26	Measure airflow resistance	Miscellaneous Medical		0.26	0.08	0.08		
94360	TC	Measure airflow resistance	Miscellaneous Medical	a	0.00	0.61	0.61		
94370	26	Breath airflow closing volume	Miscellaneous Medical		0.26	0.08	0.08		
94370	TC	Breath airflow closing volume	Miscellaneous Medical	a	0.00	0.64	0.64		
94375	26	Breath airflow closing volume	Miscellaneous Medical		0.31	0.10	0.10		
94375	TC	Breath airflow closing volume	Miscellaneous Medical	a	0.00	0.51	0.51		
94375	TC	Respiratory flow volume loop	Miscellaneous Medical		0.40	0.12	0.12		
94400	26	Respiratory flow volume loop	Miscellaneous Medical		0.00	0.72	0.72		
94400	TC	CO2 breathing response curve	Miscellaneous Medical	a	0.00	0.12	0.12		
94400	TC	CO2 breathing response curve	Miscellaneous Medical		0.40	0.12	0.12		
94450	26	Hypoxia response curve	Miscellaneous Medical		0.00	0.56	0.56		
94450	TC	Hypoxia response curve	Miscellaneous Medical	a	0.00	0.64	0.64		
94620	26	Pulmonary stress test/simple	Miscellaneous Medical		0.64	0.20	0.20		
94620	TC	Pulmonary stress test/simple	Miscellaneous Medical	a	0.00	2.22	2.22		
94621	26	Pulmonary stress test/complex	Miscellaneous Medical		1.42	0.43	0.43		
94621	TC	Pulmonary stress test/complex	Miscellaneous Medical	a	0.00	1.63	1.63		
94640	26	Pulm stress test/complex	Miscellaneous Medical		0.00	0.32	0.32		
94640	TC	Pulm stress test/complex	Miscellaneous Medical	a	0.00	0.32	0.32	2.30	MDR
94642		Airway inhalation treatment	Miscellaneous Medical		1.22	0.32	0.32		
94656		Aerosol inhalation treatment	Miscellaneous Medical		0.83	0.25	0.25		
94657		Initial ventilator mgmt	Miscellaneous Medical		0.76	0.24	0.24		
94657		Continued ventilator mgmt	Miscellaneous Medical		0.76	0.24	0.24		
94660		Pos airway pressure, CPAP	Miscellaneous Medical		0.00	0.32	0.32		
94662		Neg press ventilation, cnp	Miscellaneous Medical		0.00	0.54	0.54		
94664		Evaluate pt use of inhaler	Miscellaneous Medical		0.00	0.46	0.46		
94667		Chest wall manipulation	Miscellaneous Medical		0.00	0.08	0.08		
94668		Chest wall manipulation	Miscellaneous Medical		0.26	0.08	0.08		
94680	26	Exhaled air analysis, o2	Miscellaneous Medical		0.00	1.81	1.81		
94680	TC	Exhaled air analysis, o2	Miscellaneous Medical	a	0.00	0.07	0.07		
94681	26	Exhaled air analysis, o2/co2	Miscellaneous Medical		0.20	1.81	1.81		
94681	TC	Exhaled air analysis, o2/co2	Miscellaneous Medical	a	0.00	0.25	0.25		
94681	TC	Exhaled air analysis, o2/co2	Miscellaneous Medical		0.07	0.02	0.02		
94690	26	Exhaled air analysis	Miscellaneous Medical		0.00	1.95	1.95		
94690	TC	Exhaled air analysis	Miscellaneous Medical	a	0.00	0.08	0.08		
94690	TC	Exhaled air analysis	Miscellaneous Medical		0.26	0.08	0.08		
94720	26	Monoxide diffusing capacity	Miscellaneous Medical		0.00	0.92	0.92		
94720	TC	Monoxide diffusing capacity	Miscellaneous Medical	a	0.00	0.08	0.08		
94725	26	Membrane diffusion capacity	Miscellaneous Medical		0.26	0.08	0.08		
94725	TC	Membrane diffusion capacity	Miscellaneous Medical	a	0.00	2.84	2.84		
94750	26	Membrane diffusion capacity	Miscellaneous Medical		0.00	0.07	0.07		
94750	TC	Membrane diffusion capacity	Miscellaneous Medical	a	0.23	0.07	0.07		
94750	TC	Pulmonary compliance study	Miscellaneous Medical		0.00	1.28	1.28		
94750	TC	Pulmonary compliance study	Miscellaneous Medical	a	0.00	0.04	0.04		
94760		Measure blood oxygen level	Miscellaneous Medical		0.00	0.07	0.07		
94761		Measure blood oxygen level	Miscellaneous Medical		0.00	0.07	0.07		
94762		Measure blood oxygen level	Miscellaneous Medical		0.00	0.40	0.40		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 165 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
94770	26	Exhaled carbon dioxide test	Miscellaneous Medical		0.15	0.04	0.04		
94770	TC	Exhaled carbon dioxide test	Miscellaneous Medical	a	0.00	1.63	1.63	0.55	Misc.
94799		Pulmonary service/procedure	Miscellaneous Medical		0.00	0.10	0.10		
95004		Percut allergy skin tests	Allergy Testing		0.15	0.06	0.33		
95010		Percut allergy titrate test	Allergy Testing		0.00	0.15	0.15		
95015		Id allergy titrate-drug/bug	Allergy Testing		0.00	0.15	0.15		
95024		Id allergy test, drug/bug	Allergy Testing	a	0.00	0.15	0.15		
95027		Id allergy titrate-airborne	Allergy Testing	a	0.00	0.24	0.24		
95028		Id allergy test-delayed type	Allergy Testing		0.00	0.21	0.21		
95044		Allergy patch tests	Allergy Testing		0.00	0.26	0.26		
95052		Photo patch test	Allergy Testing		0.00	0.18	0.18		
95056		Photosensitivity tests	Allergy Testing	a	0.00	0.35	0.35		
95060		Eye allergy tests	Allergy Testing	a	0.00	0.21	0.21		
95065		Nose allergy test	Allergy Testing	a	0.00	2.29	2.29		
95070		Bronchial allergy tests	Allergy Testing	a	0.00	2.93	2.93		
95071		Bronchial allergy tests	Allergy Testing	a	0.95	0.38	0.83		
95075		Ingestion challenge test	Allergy Testing	a	0.00	0.26	0.26		
95078		Provocative testing	Allergy Testing	a	0.00	0.38	0.38		
95115		Immunotherapy, one injection	Allergy immunotherapy		0.00	0.50	0.50		
95117		Immunotherapy injections	Allergy immunotherapy					0.54	MDR
95120		Immunotherapy, one injection	Allergy immunotherapy					0.66	MDR
95125		Immunotherapy, many antigens	Allergy immunotherapy					0.93	MDR
95130		Immunotherapy, insect venom	Allergy immunotherapy					1.18	MDR
95131		Immunotherapy, insect venom	Allergy immunotherapy					1.43	MDR
95132		Immunotherapy, insect venoms	Allergy immunotherapy					1.72	MDR
95133		Immunotherapy, insect venoms	Allergy immunotherapy					2.07	MDR
95134		Immunotherapy, insect venoms	Allergy immunotherapy						
95144		Antigen therapy services	Allergy immunotherapy		0.06	0.02	0.15		
95145		Antigen therapy services	Allergy immunotherapy		0.06	0.06	0.33		
95146		Antigen therapy services	Allergy immunotherapy		0.06	0.03	0.44		
95147		Antigen therapy services	Allergy immunotherapy		0.06	0.02	0.42		
95148		Antigen therapy services	Allergy immunotherapy		0.06	0.03	0.58		
95149		Antigen therapy services	Allergy immunotherapy		0.06	0.03	0.81		
95165		Antigen therapy services	Allergy immunotherapy		0.06	0.02	0.20		
95170		Antigen therapy services	Allergy immunotherapy		0.06	0.02	0.14		
95180		Rapid desensitization	Allergy immunotherapy		2.01	0.82	1.52		
95199		Allergy immunology services	Allergy immunotherapy					0.26	Misc.
95250		Glucose monitoring, cont	Miscellaneous Medical	a	0.00	3.82	3.82		
95805	26	Multiple sleep latency test	Miscellaneous Medical		1.88	0.66	0.66		
95805	TC	Multiple sleep latency test	Miscellaneous Medical	a	0.00	15.60	15.60		
95806	26	Sleep study, unattended	Miscellaneous Medical		1.66	0.53	0.53		
95806	TC	Sleep study, unattended	Miscellaneous Medical	a	0.00	3.28	3.28		
95807	26	Sleep study, attended	Miscellaneous Medical		1.66	0.53	0.53		
95807	TC	Sleep study, attended	Miscellaneous Medical	a	0.00	11.14	11.14		
95808	26	Polysomnography, 1-3	Miscellaneous Medical		2.65	0.93	0.93		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 166 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
95808	TC	Polysomnography, 1-3	Miscellaneous Medical	a	0.00	11.98	11.98		
95810	26	Polysomnography, 4 or more	Miscellaneous Medical		3.52	1.18	1.18		
95810	TC	Polysomnography, 4 or more	Miscellaneous Medical	a	0.00	15.84	15.84		
95811	26	Polysomnography w/cpap	Miscellaneous Medical		3.79	1.27	1.27		
95811	TC	Polysomnography w/cpap	Miscellaneous Medical	a	0.00	17.18	17.18		
95812	26	Eeg, 41-60 minutes	Miscellaneous Medical		1.08	0.45	0.45		
95812	TC	Eeg, 41-60 minutes	Miscellaneous Medical	a	0.00	3.46	3.46		
95813	26	Eeg, over 1 hour	Miscellaneous Medical		1.73	0.70	0.70		
95813	TC	Eeg, over 1 hour	Miscellaneous Medical	a	0.00	4.23	4.23		
95816	26	Eeg, awake and drowsy	Miscellaneous Medical		0.00	0.46	0.46		
95816	TC	Eeg, awake and drowsy	Miscellaneous Medical	a	0.00	2.68	2.68		
95819	26	Eeg, awake and asleep	Miscellaneous Medical		1.08	0.46	0.46		
95819	TC	Eeg, awake and asleep	Miscellaneous Medical	a	0.00	3.23	3.23		
95822	26	Eeg, coma or sleep only	Miscellaneous Medical		1.08	0.45	0.45		
95822	TC	Eeg, coma or sleep only	Miscellaneous Medical	a	0.00	3.90	3.90		
95824	26	Eeg, cerebral death only	Miscellaneous Medical		0.74	0.32	0.32		
95824	TC	Eeg, cerebral death only	Miscellaneous Medical	a	0.00	0.40	0.40		PHCS
95827	26	Eeg, all night recording	Miscellaneous Medical		1.08	0.40	0.40		
95827	TC	Eeg, all night recording	Miscellaneous Medical	a	0.00	2.30	2.30		
95829	26	Surgery electrocorticogram	Miscellaneous Medical		6.20	2.33	2.33		
95829	TC	Surgery electrocorticogram	Miscellaneous Medical	a	0.00	28.97	28.97		
95830	TC	Insert electrodes for EEG	Miscellaneous Medical		1.70	0.73	0.73		
95831		Limb muscle testing, manual	Miscellaneous Medical		0.28	0.13	0.34		
95832		Hand muscle testing, manual	Miscellaneous Medical		0.29	0.12	0.25		
95833		Body muscle testing, manual	Miscellaneous Medical		0.47	0.23	0.45		
95834		Body muscle testing, manual	Miscellaneous Medical		0.60	0.28	0.50		
95851		Range of motion measurements	Miscellaneous Medical		0.16	0.08	0.37		
95852		Range of motion measurements	Miscellaneous Medical		0.11	0.05	0.26		
95857		Tension test	Miscellaneous Medical		0.53	0.23	0.61		
95857	26	Tension test & myogram	Miscellaneous Medical		1.56	0.67	0.67		
95858		Tension test & myogram	Miscellaneous Medical	a	0.00	0.39	0.39		
95858	TC	Muscle test, one limb	Miscellaneous Medical		0.96	0.42	0.42		
95860	26	Muscle test, one limb	Miscellaneous Medical	a	0.00	1.03	1.03		
95860	TC	Muscle test, one limb	Miscellaneous Medical	a	0.00	0.68	0.68		
95861	26	Muscle test, 2 limbs	Miscellaneous Medical		1.54	0.74	0.74		
95861	TC	Muscle test, 2 limbs	Miscellaneous Medical	a	0.00	0.81	0.81		
95863	26	Muscle test, 3 limbs	Miscellaneous Medical		1.87	0.94	0.94		
95863	TC	Muscle test, 3 limbs	Miscellaneous Medical	a	0.00	0.87	0.87		
95864	26	Muscle test, 4 limbs	Miscellaneous Medical		1.99	1.79	1.79		
95864	TC	Muscle test, 4 limbs	Miscellaneous Medical	a	0.00	0.22	0.22		
95867	26	Muscle test cran nerve unilat	Miscellaneous Medical		0.79	0.35	0.35		
95867	TC	Muscle test cran nerve unilat	Miscellaneous Medical	a	0.00	0.58	0.58		
95868	26	Muscle test cran nerve bilat	Miscellaneous Medical		1.18	0.51	0.51		
95868	TC	Muscle test cran nerve bilat	Miscellaneous Medical	a	0.00	0.70	0.70		
95869	26	Muscle test, thor paraspinal	Miscellaneous Medical		0.37	0.16	0.16		
95869	TC	Muscle test, thor paraspinal	Miscellaneous Medical	a	0.00	0.22	0.22		

NOTE: CPT Codes and descriptions only, are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 167 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
95870	26	Muscle test, nonparaspinal	Miscellaneous Medical	a	0.37	0.16	0.16	0.16	
95870	TC	Muscle test, nonparaspinal	Miscellaneous Medical		0.00	0.22	0.22	0.22	
95872	26	Muscle test, one fiber	Miscellaneous Medical	a	1.50	0.63	0.63	0.63	
95872	TC	Muscle test, one fiber	Miscellaneous Medical		0.00	0.60	0.60	0.60	
95875	26	Limb exercise test	Miscellaneous Medical	a	1.10	0.46	0.46	0.46	
95875	TC	Limb exercise test	Miscellaneous Medical		0.00	1.00	1.00	1.00	
95900	26	Motor nerve conduction test	Miscellaneous Medical	a	0.42	0.19	0.19	0.19	
95900	TC	Motor nerve conduction test	Miscellaneous Medical		0.00	1.10	1.10	1.10	
95903	26	Motor nerve conduction test	Miscellaneous Medical	a	0.60	0.26	0.26	0.26	
95903	TC	Motor nerve conduction test	Miscellaneous Medical		0.00	0.95	0.95	0.95	
95904	26	Sense nerve conduction test	Miscellaneous Medical	a	0.34	0.15	0.15	0.15	
95904	TC	Sense nerve conduction test	Miscellaneous Medical		0.00	0.96	0.96	0.96	
95920	26	Intraop nerve test add-on	Miscellaneous Medical	a	2.11	0.94	0.94	0.94	
95920	TC	Intraop nerve test add-on	Miscellaneous Medical		0.00	1.31	1.31	1.31	
95921	26	Autonomic nerve function test	Miscellaneous Medical	a	0.90	0.33	0.33	0.33	
95921	TC	Autonomic nerve function test	Miscellaneous Medical		0.00	0.37	0.37	0.37	
95922	26	Autonomic nerve function test	Miscellaneous Medical	a	0.96	0.40	0.40	0.40	
95922	TC	Autonomic nerve function test	Miscellaneous Medical		0.00	0.37	0.37	0.37	
95923	26	Autonomic nerve function test	Miscellaneous Medical	a	0.90	0.37	0.37	0.37	
95923	TC	Autonomic nerve function test	Miscellaneous Medical		0.00	1.71	1.71	1.71	
95925	26	Somatosensory testing	Miscellaneous Medical	a	0.54	0.23	0.23	0.23	
95925	TC	Somatosensory testing	Miscellaneous Medical		0.00	0.91	0.91	0.91	
95926	26	Somatosensory testing	Miscellaneous Medical	a	0.54	0.24	0.24	0.24	
95926	TC	Somatosensory testing	Miscellaneous Medical		0.00	0.91	0.91	0.91	
95927	26	Somatosensory testing	Miscellaneous Medical	a	0.54	0.25	0.25	0.25	
95927	TC	Somatosensory testing	Miscellaneous Medical		0.00	0.91	0.91	0.91	
95930	26	Visual evoked potential test	Miscellaneous Medical	a	0.35	0.15	0.15	0.15	
95930	TC	Visual evoked potential test	Miscellaneous Medical		0.00	1.28	1.28	1.28	
95933	26	Blink reflex test	Miscellaneous Medical	a	0.59	0.24	0.24	0.24	
95933	TC	Blink reflex test	Miscellaneous Medical		0.00	0.79	0.79	0.79	
95934	26	H-reflex test	Miscellaneous Medical	a	0.51	0.22	0.22	0.22	
95934	TC	H-reflex test	Miscellaneous Medical		0.00	0.22	0.22	0.22	
95936	26	H-reflex test	Miscellaneous Medical	a	0.55	0.24	0.24	0.24	
95936	TC	H-reflex test	Miscellaneous Medical		0.00	0.22	0.22	0.22	
95937	26	Neuromuscular junction test	Miscellaneous Medical	a	0.65	0.27	0.27	0.27	
95937	TC	Neuromuscular junction test	Miscellaneous Medical		0.00	0.34	0.34	0.34	
95950	26	Ambulatory eeg monitoring	Miscellaneous Medical	a	1.51	0.64	0.64	0.64	
95950	TC	Ambulatory eeg monitoring	Miscellaneous Medical		0.00	3.83	3.83	3.83	
95951	26	EEG monitoring/videorecord	Miscellaneous Medical	a	5.99	2.57	2.57	2.57	
95951	TC	EEG monitoring/videorecord	Miscellaneous Medical		0.00	6.12	6.12	6.12	MDR
95953	26	EEG monitoring/computer	Miscellaneous Medical	a	3.08	1.29	1.29	1.29	
95953	TC	EEG monitoring/computer	Miscellaneous Medical		0.00	6.35	6.35	6.35	
95954	26	EEG monitoring/giving drugs	Miscellaneous Medical	a	2.45	1.05	1.05	1.05	
95954	TC	EEG monitoring/giving drugs	Miscellaneous Medical		0.00	3.24	3.24	3.24	
95955	26	EEG monitoring/giving drugs	Miscellaneous Medical	a	1.01	0.36	0.36	0.36	
95955	TC	EEG monitoring/giving drugs	Miscellaneous Medical		0.00	0.36	0.36	0.36	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCP/PCS CODE

PAGE 168 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
95955	TC	EEG during surgery	Miscellaneous Medical	a	0.00	1.97	1.97		
95956	26	Eeg monitoring, cable/radio	Miscellaneous Medical		3.08	1.30	1.30		
95956	TC	Eeg monitoring, cable/radio	Miscellaneous Medical	a	0.00	12.84	12.84		
95957	26	EEG digital analysis	Miscellaneous Medical		1.98	0.85	0.85		
95957	TC	EEG digital analysis	Miscellaneous Medical	a	0.00	1.71	1.71		
95958	26	EEG monitoring/function test	Miscellaneous Medical		4.24	1.75	1.75		
95958	TC	EEG monitoring/function test	Miscellaneous Medical	a	0.00	1.75	1.75		
95961	26	Electrode stimulation, brain	Miscellaneous Medical		2.97	1.32	1.32		
95961	TC	Electrode stimulation, brain	Miscellaneous Medical	a	0.00	1.31	1.31		
95962	26	Electrode stim, brain add-on	Miscellaneous Medical		3.21	1.39	1.39		
95962	TC	Electrode stim, brain add-on	Miscellaneous Medical	a	0.00	1.31	1.31		
95965	26	Meg, spontaneous	Miscellaneous Medical		7.99	3.42	3.42		
95965	TC	Meg, spontaneous	Miscellaneous Medical	a	3.99	1.73	1.73	45.64	SA
95966	26	Meg, evoked, single	Miscellaneous Medical		3.49	1.33	1.33		
95966	TC	Meg, evoked, single	Miscellaneous Medical	a	0.45	0.15	0.17	22.88	SA
95967	26	Meg, evoked, each addl	Miscellaneous Medical		1.50	0.23	0.28		
95967	TC	Meg, evoked, each addl	Miscellaneous Medical	a	0.92	0.49	0.59	19.28	SA
95970		Analyze neurostim, no prog	Miscellaneous Medical		3.00	1.29	1.29		
95971		Analyze neurostim, simple	Miscellaneous Medical		1.70	0.73	0.73		
95972		Analyze neurostim, complex	Miscellaneous Medical		0.00	1.50	1.50		
95973		Analyze neurostim, complex	Miscellaneous Medical		0.77	0.19	1.43		
95974		Cranial neurostim, complex	Miscellaneous Medical		1.80	0.55	0.55		
95975		Cranial neurostim, complex	Miscellaneous Medical		2.15	0.66	0.66		
95990		Spin/brain pump refl & main	Miscellaneous Medical		0.41	0.15	0.15		
95991		Spin/brain pump refl & main	Miscellaneous Medical		0.37	0.14	0.14		
95999		Neurological procedure	Miscellaneous Medical		2.14	0.95	0.95		
96000		Motion analysis, video/3d	Miscellaneous Medical		0.00	1.77	1.77		
96001		Motion test w/ft press meas	Miscellaneous Medical		0.00	1.77	1.77		
96002		Dynamic surface emg	Miscellaneous Medical		0.00	1.77	1.77		
96003		Dynamic fine wire emg	Miscellaneous Medical		0.00	1.77	1.77		
96004		Phys review of motion tests	Miscellaneous Medical		0.00	1.77	1.77		
96100		Psychological testing	Miscellaneous Medical		0.00	1.77	1.77		
96105		Assessment of aphasia	Miscellaneous Medical		0.00	1.77	1.77		
96110		Developmental test, lim	Miscellaneous Medical		2.80	1.07	1.07		
96111		Developmental test, extend	Miscellaneous Medical		0.00	1.77	1.77		
96115		Neurobehavior status exam	Miscellaneous Medical		0.00	1.77	1.77		
96117		Neuropsych test battery	Miscellaneous Medical		0.50	0.18	0.19		
96150		Assess lith/behav, init	Miscellaneous Medical		0.48	0.17	0.18		
96151		Assess lith/behav, subseq	Miscellaneous Medical		0.46	0.16	0.17		
96152		Intervene lith/behav, indiv	Miscellaneous Medical		0.10	0.04	0.04		
96153		Intervene lith/behav, group	Miscellaneous Medical		0.45	0.16	0.17		
96154		Interv lith/behav, fam w/pt	Miscellaneous Medical		0.44	0.17	0.18		
96155		Interv lith/behav fam no pt	Miscellaneous Medical		0.17	1.12	1.12		
96400		Chemotherapy, sc/im	Miscellaneous Medical		0.52	0.24	0.24		
96405		Intralestial chemo admin	Miscellaneous Medical					1.81	Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 169 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
96406		Intraleisional chemo admin	Miscellaneous Medical		0.80	0.30	3.10		
96408		Chemotherapy, push technique	Miscellaneous Medical		0.17	2.91	2.91		
96410		Chemotherapy, infusion method	Miscellaneous Medical		0.17	4.16	4.16		
96412		Chemo, infuse method add-on	Miscellaneous Medical		0.17	0.98	0.98		
96414		Chemo, infuse method add-on	Miscellaneous Medical		0.17	5.22	5.22		
96420		Chemotherapy, push technique	Miscellaneous Medical		0.17	2.81	2.81		
96422		Chemotherapy, infusion method	Miscellaneous Medical		0.17	5.19	5.19		
96425		Chemo, infuse method add-on	Miscellaneous Medical		0.17	1.96	1.96		
96440		Chemotherapy, intracavitary	Miscellaneous Medical		0.17	4.73	4.73		
96445		Chemotherapy, into CNS	Miscellaneous Medical		2.37	1.24	8.42		
96450		Port pump refill & main	Miscellaneous Medical		2.20	1.19	8.54		
96520		Syst pump refill & main	Miscellaneous Medical		1.89	1.10	7.32		
96530		Chemotherapy injection	Miscellaneous Medical		0.17	3.94	3.94		
96542		Provide chemotherapy agent	Miscellaneous Medical		0.17	2.86	2.86		
96545		Chemotherapy, unspecified	Miscellaneous Medical		1.42	0.66	4.43		SAF
96549		Photodynamic tx, skin	Miscellaneous Medical		0.00	0.98	0.98		Misc.
96570		Photodynamic tx, 30 min	Miscellaneous Medical		1.10	0.37	0.37		
96571		Photodynamic tx, addl 15 min	Miscellaneous Medical		0.55	0.20	0.20		
96900		Ultraviolet light therapy	Miscellaneous Medical		0.00	0.48	0.48		
96902		Trichogram	Miscellaneous Medical		0.41	0.16	0.25		
96910		Photochemotherapy with UV-B	Miscellaneous Medical		0.00	1.07	1.07		
96912		Photochemotherapy with UV-A	Miscellaneous Medical		0.00	1.34	1.34		
96913		Photochemotherapy, UV-A or B	Miscellaneous Medical		0.00	1.78	1.78		
96920		Laser tx, skin < 250 sq cm	Miscellaneous Medical		1.15	0.56	7.67		
96921		Laser tx, skin 250-500 sq cm	Miscellaneous Medical		1.17	0.57	7.74		
96922		Laser tx, skin > 500 sq cm	Miscellaneous Medical		2.10	1.04	8.48		
96999		Dermatological procedure	Miscellaneous Medical					1.07	Misc.
97001		Pt evaluation	Physical Medicine		1.20	0.45	0.73		
97002		Pt re-evaluation	Physical Medicine		0.60	0.24	0.43		
97003		Ot evaluation	Physical Medicine		1.20	0.40	0.86		
97004		Ot re-evaluation	Physical Medicine		0.60	0.20	0.60		
97005		Athletic train eval	Physical Medicine						MDR
97006		Athletic train reeval	Physical Medicine						MDR
97010		Hot or cold packs therapy	Physical Medicine		0.06	0.05	0.05		
97012		Mechanical traction therapy	Physical Medicine		0.25	0.14	0.14		
97014		Electric stimulation therapy	Physical Medicine		0.18	0.19	0.19		
97016		Vasopneumatic device therapy	Physical Medicine		0.18	0.19	0.19		
97018		Paraffin bath therapy	Physical Medicine		0.06	0.11	0.11		
97020		Microwave therapy	Physical Medicine		0.06	0.06	0.06		
97022		Whirlpool therapy	Physical Medicine		0.17	0.22	0.22		
97024		Diathermy treatment	Physical Medicine		0.06	0.09	0.09		
97026		Infrared therapy	Physical Medicine		0.06	0.06	0.06		
97028		Ultraviolet therapy	Physical Medicine		0.08	0.07	0.07		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 170 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
97032		Electrical stimulation	Physical Medicine		0.25	0.16	0.16		
97033		Electric current therapy	Physical Medicine		0.26	0.28	0.28		
97034		Contrast bath therapy	Physical Medicine		0.21	0.16	0.16		
97035		Ultrasound therapy	Physical Medicine		0.21	0.11	0.11		
97036		Hydrotherapy	Physical Medicine		0.28	0.33	0.33		
97039		Physical therapy treatment	Physical Medicine		0.20	0.10	0.10		
97110		Therapeutic exercises	Physical Medicine		0.45	0.28	0.28		
97112		Neuromuscular reeducation	Physical Medicine		0.45	0.30	0.30		
97113		Aquatic therapy/exercises	Physical Medicine		0.44	0.40	0.40		
97116		Gait training therapy	Physical Medicine		0.40	0.24	0.24		
97124		Massage therapy	Physical Medicine		0.35	0.23	0.23		
97139		Physical medicine procedure	Physical Medicine		0.21	0.20	0.20		
97140		Manual therapy	Physical Medicine		0.43	0.26	0.26		
97150		Group therapeutic procedures	Physical Medicine		0.27	0.18	0.18		
97504		Orthotic training	Physical Medicine		0.45	0.33	0.33		
97520		Prosthetic training	Physical Medicine		0.45	0.28	0.28		
97530		Therapeutic activities	Physical Medicine		0.44	0.32	0.32		
97532		Cognitive skills development	Physical Medicine		0.44	0.21	0.21		
97533		Sensory integration	Physical Medicine		0.44	0.24	0.24		
97535		Self care mgmt training	Physical Medicine		0.45	0.33	0.33		
97537		Community/work reintegration	Physical Medicine		0.45	0.27	0.27		
97542		Wheelchair mgmt training	Physical Medicine		0.45	0.28	0.28		MDR
97545		Work hardening	Physical Medicine					2.68	MDR
97546		Work hardening add-on	Physical Medicine		0.50	0.49	0.49	1.07	MDR
97601		Wound(s) care, selective	Physical Medicine					0.39	MDR
97602		Wound(s) care non-selective	Physical Medicine		0.25	0.41	0.41		
97703		Prosthetic checkout	Physical Medicine		0.45	0.30	0.30		
97750		Physical performance test	Physical Medicine		0.62	0.29	0.29		
97755		Assistive technology assess	Physical Medicine					0.96	MDR
97780		Acupuncture w/ stim	Physical Medicine					1.20	MDR
97781		Acupuncture w/ stim	Physical Medicine					0.76	Misc.
97799		Physical medicine procedure	Physical Medicine		0.00	0.47	0.47		
97802		Medical nutrition, indiv, in	Miscellaneous Medical		0.00	0.47	0.47		
97803		Med nutrition, indiv, subseq	Miscellaneous Medical		0.00	0.19	0.19		
97804		Medical nutrition, group	Miscellaneous Medical		0.00	0.14	0.14		
98925		Osteopathic manipulation	Physical Medicine		0.45	0.25	0.25		
98926		Osteopathic manipulation	Physical Medicine		0.65	0.42	0.42		
98927		Osteopathic manipulation	Physical Medicine		0.87	0.30	0.30		
98928		Osteopathic manipulation	Physical Medicine		1.03	0.35	0.35		
98929		Osteopathic manipulation	Physical Medicine		1.19	0.37	0.37		
98940		Chiropractic manipulation	Chiropractor		0.45	0.12	0.12		
98941		Chiropractic manipulation	Chiropractor		0.65	0.18	0.18		
98942		Chiropractic manipulation	Chiropractor		0.87	0.24	0.24		
98943		Chiropractic manipulation	Chiropractor		0.40	0.16	0.16		
99000		Specimen handling	Miscellaneous Medical					0.22	MDR

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 171 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
99001		Specimen handling	Miscellaneous Medical					0.25	MDR
99002		Device handling	Miscellaneous Medical					0.37	MDR
99026		In-hospital on call service	Miscellaneous Medical					2.10	PHCS
99050		Medical services after hrs	Miscellaneous Medical					0.69	MDR
99052		Medical services at night	Miscellaneous Medical					0.69	MDR
99054		Medical servcs, unusual hrs	Miscellaneous Medical					0.69	MDR
99056		Non-office medical services	Miscellaneous Medical					0.90	MDR
99058		Office emergency care	Miscellaneous Medical					0.93	MDR
99075		Medical testimony	Miscellaneous Medical					5.27	PHCS
99078		Group health education	Miscellaneous Medical					0.90	PHCS
99080		Special reports or forms	Miscellaneous Medical					0.72	PHCS
99082		Unusual physician travel	Miscellaneous Medical					0.47	PHCS
99090		Computer data analysis	Miscellaneous Medical					1.50	PHCS
99091		Collect/review data from pt	Miscellaneous Medical					1.50	PHCS
99100		Special anesthesia service	Miscellaneous Medical					0.08	PHCS
99116		Anesthesia with hypothermia	Surgery					0.50	PHCS
99135		Special anesthesia procedure	Surgery		0.80	0.38	1.92	0.63	PHCS
99140		Emergency anesthesia	Surgery		0.60	0.31	0.99	0.39	PHCS
99141		Sedation, iv/inf or inhalant	Surgery		1.75	0.52	1.72		PHCS
99142		Sedation, oral/rectal/nasal	Surgery						PHCS
99170		Anogenital exam, child	Miscellaneous Medical						PHCS
99172	26	Ocular function screen	Vision Exams						PHCS
99173	TC	Ocular function screen	Vision Exams	a					MDR
99175		Visual acuity screen	Vision Exams		0.00	1.40	1.40	0.28	MDR
99177		Induction of vomiting	Miscellaneous Medical		2.34	0.72	4.75	1.10	MDR
99183		Hyperbaric oxygen therapy	Miscellaneous Medical					0.69	MDR
99185	26	Regional hypothermia	Miscellaneous Medical						MDR
99185	TC	Regional hypothermia	Miscellaneous Medical	a					MDR
99186	26	Total body hypothermia	Miscellaneous Medical					0.25	MDR
99186	TC	Total body hypothermia	Miscellaneous Medical	a				0.39	MDR
99190		Special pump services	Miscellaneous Medical					1.19	MDR
99191		Special pump services	Miscellaneous Medical					1.78	MDR
99192		Special pump services	Miscellaneous Medical					14.50	MDR
99195		Phlebotomy	Miscellaneous Medical		0.00	0.44	0.44	10.87	MDR
99199		Special services/procr/report	Miscellaneous Medical					7.25	MDR
99201		Office/outpatient visit, new	Office/Home Visits/Urgent Care Visits		0.45	0.16	0.50	0.32	Misc.
99202		Office/outpatient visit, new	Office/Home Visits/Urgent Care Visits		0.88	0.32	0.79	0.32	
99203		Office/outpatient visit, new	Office/Home Visits/Urgent Care Visits		1.34	0.48	1.13	0.71	
99204		Office/outpatient visit, new	Office/Home Visits/Urgent Care Visits		2.00	0.71	1.51	0.71	
99205		Office/outpatient visit, new	Office/Home Visits/Urgent Care Visits		2.67	0.95	1.80	0.95	
99211		Office/outpatient visit, est	Office/Home Visits/Urgent Care Visits		0.17	0.06	0.39	0.17	
99212		Office/outpatient visit, est	Office/Home Visits/Urgent Care Visits		0.45	0.16	0.54	0.45	
99213		Office/outpatient visit, est	Office/Home Visits/Urgent Care Visits		0.67	0.24	0.70	0.67	
99214		Office/outpatient visit, est	Office/Home Visits/Urgent Care Visits		1.10	0.40	1.05	1.10	
99215		Office/outpatient visit, est	Office/Home Visits/Urgent Care Visits		1.77	0.65	1.34	1.77	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 172 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
99217		Observation care discharge	Emergency Room Visits		1.28	0.53	0.53		
99218		Observation care	Emergency Room Visits		1.28	0.43	0.43		
99219		Observation care	Emergency Room Visits		2.14	0.72	0.72		
99220		Observation care	Emergency Room Visits		2.99	1.03	1.03		
99221		Initial hospital care	Inpatient Visits		1.28	0.45	0.45		
99222		Initial hospital care	Inpatient Visits		2.14	0.74	0.74		
99223		Initial hospital care	Inpatient Visits		2.99	1.04	1.04		
99231		Subsequent hospital care	Inpatient Visits		0.64	0.23	0.23		
99232		Subsequent hospital care	Inpatient Visits		1.06	0.37	0.37		
99233		Subsequent hospital care	Inpatient Visits		1.51	0.52	0.52		
99234		Observ/hosp same date	Inpatient Visits		2.56	1.00	1.00		
99235		Observ/hosp same date	Inpatient Visits		3.41	1.29	1.29		
99236		Observ/hosp same date	Inpatient Visits		4.26	1.59	1.59		
99238		Hospital discharge day	Inpatient Visits		1.28	0.54	0.54		
99239		Hospital discharge day	Inpatient Visits		1.75	0.74	0.74		
99241		Office consultation	Consults		0.64	0.22	0.22		
99242		Office consultation	Consults		1.29	0.46	0.46		
99243		Office consultation	Consults		1.72	0.63	0.63		
99244		Office consultation	Consults		2.58	0.92	0.92		
99245		Office consultation	Consults		3.42	1.24	1.24		
99251		Initial inpatient consult	Consults		0.66	0.25	0.25		
99252		Initial inpatient consult	Consults		1.32	0.50	0.50		
99253		Initial inpatient consult	Consults		1.82	0.68	0.68		
99254		Initial inpatient consult	Consults		2.64	0.99	0.99		
99255		Follow-up inpatient consult	Consults		3.64	1.35	1.35		
99261		Follow-up inpatient consult	Consults		0.42	0.16	0.16		
99262		Follow-up inpatient consult	Consults		0.85	0.31	0.31		
99263		Follow-up inpatient consult	Consults		1.27	0.45	0.45		
99271		Confirmatory consultation	Consults		0.45	0.16	0.16		
99272		Confirmatory consultation	Consults		0.84	0.31	0.31		
99273		Confirmatory consultation	Consults		1.19	0.44	0.44		
99274		Confirmatory consultation	Consults		1.73	0.64	0.64		
99275		Confirmatory consultation	Consults		2.31	0.84	0.84		
99281		Emergency dept visit	Emergency Room Visits		0.33	0.09	0.09		
99282		Emergency dept visit	Emergency Room Visits		0.55	0.15	0.15		
99283		Emergency dept visit	Emergency Room Visits		1.24	0.31	0.31		
99284		Emergency dept visit	Emergency Room Visits		1.95	0.47	0.47		
99285		Direct advanced life support	Emergency Room Visits		3.06	0.72	0.72		SAF
99288		Ped crit care transport	Emergency Room Visits					1.26	
99289		Ped crit care transport addl	Inpatient Visits		4.79	1.91	1.91		
99290		Critical care, first hour	Inpatient Visits		2.40	0.83	0.83		
99291		Critical care, addl 30 min	Inpatient Visits		3.99	1.28	1.28		
99292		Ped critical care, initial	Inpatient Visits		2.00	0.64	0.64		
99293		Ped critical care, initial	Inpatient Visits		15.98	4.96	4.96		
99294		Ped critical care, subseq	Inpatient Visits		7.99	2.49	2.49		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 173 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
99295		Neonate crit care, initial	Inpatient Visits		18.46	5.39	5.39		
99296		Neonate critical care subseq	Inpatient Visits		7.99	2.55	2.55		
99298		ic for lbw infant < 1500 gm	Inpatient Visits		2.75	0.93	0.93		
99299		ic, lbw infant 1500-2500 gm	Inpatient Visits		2.50	0.95	0.95		
99301		Nursing facility care	Inpatient Visits		1.20	0.40	0.67		
99302		Nursing facility care	Inpatient Visits		1.61	0.54	0.95		
99303		Nursing facility care	Inpatient Visits		2.01	0.67	1.16		
99311		Nursing fac care, subseq	Inpatient Visits		0.60	0.20	0.47		
99312		Nursing fac care, subseq	Inpatient Visits		1.00	0.34	0.65		
99313		Nursing fac care, subseq	Inpatient Visits		1.42	0.47	0.84		
99315		Nursing fac discharge day	Inpatient Visits		1.13	0.37	0.70		
99316		Nursing fac discharge day	Inpatient Visits		1.50	0.51	0.90		
99321		Rest home visit, new patient	Office/Home Visits/Urgent Care Visits		0.71	0.35	0.35		
99322		Rest home visit, new patient	Office/Home Visits/Urgent Care Visits		1.01	0.46	0.46		
99323		Rest home visit, new patient	Office/Home Visits/Urgent Care Visits		1.28	0.55	0.55		
99331		Rest home visit, est pat	Office/Home Visits/Urgent Care Visits		0.60	0.32	0.32		
99332		Rest home visit, est pat	Office/Home Visits/Urgent Care Visits		0.80	0.38	0.38		
99333		Rest home visit, est pat	Office/Home Visits/Urgent Care Visits		1.00	0.45	0.45		
99341		Home visit, new patient	Office/Home Visits/Urgent Care Visits		1.01	0.48	0.48		
99342		Home visit, new patient	Office/Home Visits/Urgent Care Visits		1.52	0.68	0.68		
99343		Home visit, new patient	Office/Home Visits/Urgent Care Visits		2.27	0.95	0.95		
99344		Home visit, new patient	Office/Home Visits/Urgent Care Visits		3.03	1.18	1.18		
99345		Home visit, new patient	Office/Home Visits/Urgent Care Visits		3.78	1.44	1.44		
99347		Home visit, est patient	Office/Home Visits/Urgent Care Visits		0.76	0.39	0.39		
99348		Home visit, est patient	Office/Home Visits/Urgent Care Visits		1.26	0.71	0.71		
99349		Home visit, est patient	Office/Home Visits/Urgent Care Visits		2.02	1.04	1.04		
99350		Home visit, est patient	Office/Home Visits/Urgent Care Visits		3.03	1.40	1.40		
99354		Prolonged service, office	Office/Home Visits/Urgent Care Visits		1.77	0.66	0.75		
99355		Prolonged service, office	Office/Home Visits/Urgent Care Visits		1.71	0.62	0.73		
99356		Prolonged service, inpatient	Inpatient Visits		1.71	0.63	0.63		
99357		Prolonged service, inpatient	Inpatient Visits						MDR
99358		Prolonged serv, w/o contact	Office/Home Visits/Urgent Care Visits					4.36	MDR
99359		Prolonged serv, w/o contact	Office/Home Visits/Urgent Care Visits					2.18	MDR
99360		Physician standby services	Miscellaneous Medical					2.02	MDR
99374		Home health care supervision	Office/Home Visits/Urgent Care Visits						
99375		Home health care supervision	Office/Home Visits/Urgent Care Visits						
99377		Hospice care supervision	Office/Home Visits/Urgent Care Visits		1.10	0.41	0.70		
99378		Hospice care supervision	Office/Home Visits/Urgent Care Visits		1.73	1.55	1.55		
99379		Nursing fac care supervision	Office/Home Visits/Urgent Care Visits		1.10	0.41	0.70		
99380		Nursing fac care supervision	Office/Home Visits/Urgent Care Visits		1.73	1.94	1.94		
99381		Prev visit, new, infant	Office/Home Visits/Urgent Care Visits		1.73	1.00	1.00		
99382		Prev visit, new, age 1-4	Well, Baby Exams		1.19	0.45	1.50		
99383		Prev visit, new, age 5-11	Physical Exams		1.36	0.52	1.54		
99384		Prev visit, new, age 12-17	Physical Exams		1.36	0.52	1.48		
99385		Prev visit, new, age 18-39	Physical Exams		1.53	0.59	1.55		

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 174 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
99386		Prev visit, new, age 40-64	Physical Exams		1.88	0.72	1.74	1.83	PHCS
99387		Prev visit, new, 65 & over	Physical Exams		2.06	0.79	1.87	2.46	Misc.
99391		Prev visit, est, Infant	Well Baby Exams		1.02	0.39	1.02		
99392		Prev visit, est, age 1-4	Physical Exams		1.19	0.45	1.09		
99393		Prev visit, est, age 5-11	Physical Exams		1.36	0.52	1.13		
99394		Prev visit, est, age 12-17	Physical Exams		1.36	0.52	1.16		
99395		Prev visit, est, age 18-39	Physical Exams		1.53	0.59	1.25		
99396		Prev visit, est, age 40-64	Physical Exams		1.71	0.66	1.36		
99397		Prev visit, est, 65 & over	Physical Exams		0.48	0.19	0.62		
99401		Preventive counseling, indiv	Physical Exams		0.98	0.37	0.87		
99402		Preventive counseling, indiv	Physical Exams		1.46	0.55	1.09		
99403		Preventive counseling, indiv	Physical Exams		1.95	0.75	1.32		
99404		Preventive counseling, group	Physical Exams		0.15	0.06	0.18		
99411		Preventive counseling, group	Physical Exams		0.25	0.10	0.25		
99412		Health risk assessment test	Physical Exams						
99420		Unlisted preventive service	Physical Exams						
99429		Initial care, normal newborn	Inpatient Visits		1.17	0.38	0.38		
99431		Newborn care, not in hosp	Well Baby Exams		1.26	0.40	0.90		
99432		Normal newborn care/hospital	Inpatient Visits		0.62	0.20	0.20		
99433		Newborn discharge day hosp	Inpatient Visits		1.50	0.50	0.50		
99435		Attendance, birth	Inpatient Visits		1.50	0.46	0.46		
99436		Newborn resuscitation	Inpatient Visits		2.93	0.94	0.94		
99440		Life/disability evaluation	Office/Home Visits/Urgent Care Visits						PHCS
99450		Disability examination	Office/Home Visits/Urgent Care Visits						SAF
99455		Disability examination	Office/Home Visits/Urgent Care Visits						PHCS
99456		Unlisted e&m service	Office/Home Visits/Urgent Care Visits						Misc.
99499		Home visit, prenatal	Office/Home Visits/Urgent Care Visits						PHCS
99500		Home visit, postnatal	Office/Home Visits/Urgent Care Visits						PHCS
99501		Home visit, nb care	Office/Home Visits/Urgent Care Visits						PHCS
99502		Home visit, resp therapy	Office/Home Visits/Urgent Care Visits						PHCS
99503		Home visit mech ventilator	Office/Home Visits/Urgent Care Visits						PHCS
99504		Home visit, stoma care	Office/Home Visits/Urgent Care Visits						PHCS
99505		Home visit, im injection	Office/Home Visits/Urgent Care Visits						PHCS
99506		Home visit, cath maintain	Office/Home Visits/Urgent Care Visits						PHCS
99507		Home visit day life activity	Office/Home Visits/Urgent Care Visits						PHCS
99509		Home visit, fecal/enema mgmt	Office/Home Visits/Urgent Care Visits						PHCS
99511		Home visit, hemodialysis	Office/Home Visits/Urgent Care Visits						PHCS
99512		Home visit nos	Office/Home Visits/Urgent Care Visits						PHCS
99600		Home infusion/visit, 2 hrs	Immunizations						Misc.
99601		Admin influenza virus vac	Immunizations						PHCS
G0008		Admin pneumococcal vaccine	Immunizations						PHCS
G0009		Admin hepatitis b vaccine	Immunizations						PHCS
G0010		PET imaging prev PET single	Radiology						PHCS
G0030	26	PET imaging prev PET multiple	Radiology		1.50	0.58	0.58		PHCS
G0031	26				1.87	0.72	0.72		Misc.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 175 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
G0032	26	PET follow SPECT 78464 singl	Radiology		1.50	0.54	0.54		
G0033	26	PET follow SPECT 78464 mult	Radiology		1.87	0.74	0.74		
G0034	26	PET follow SPECT 78665 singl	Radiology		1.50	0.57	0.57		
G0035	26	PET follow SPECT 78465 mult	Radiology		1.87	0.73	0.73		
G0036	26	PET follow comry angio sing	Radiology		1.50	0.56	0.56		
G0037	26	PET follow comry angio mult	Radiology		1.87	0.71	0.71		
G0038	26	PET follow myocard perf sing	Radiology		1.50	0.52	0.52		
G0039	26	PET follow myocard perf mult	Radiology		1.87	0.71	0.71		
G0040	26	PET follow stress echo singl	Radiology		1.50	0.59	0.59		
G0041	26	PET follow stress echo mult	Radiology		1.87	0.73	0.73		
G0042	26	PET follow ventriculogram sing	Radiology		1.50	0.61	0.61		
G0043	26	PET follow ventriculogram mult	Radiology		1.87	0.75	0.75		
G0044	26	PET following rest ECG singl	Radiology		1.50	0.59	0.59		
G0045	26	PET following rest ECG mult	Radiology		1.87	0.72	0.72		
G0046	TC	PET following rest ECG singl	Radiology	a	1.50	0.59	0.59	14.35	SAF
G0047	26	PET follow stress ECG mult	Radiology		1.87	0.72	0.72		
G0101		CA screen;pelvic/breast exam	Physical Exams						
G0102		Prostate ca screening; dre	Physical Exams						
G0104		CA screen;flex sigmoidoscope	Surgery		1.50	0.59	0.59		
G0105		Colorectal scm; hi risk ind	Surgery		1.87	0.73	0.73		
G0106	26	Colon CA screen;barium enema	Surgery		0.45	0.17	0.52		
G0108	TC	Colon CA screen;barium enema	Surgery		0.17	0.06	0.39		
G0109		Diab manage tm; per; indiv	Surgery		0.96	0.52	2.20		
G0110		Diab manage tm; ind;group	Surgery		3.69	1.58	6.04		
G0111		Nett pulm-rehab educ; ind	Miscellaneous Medical		0.00	0.00	0.00		
G0112		Nett pulm-rehab educ; group	Miscellaneous Medical		0.99	0.33	2.24		
G0113		Nett;nutrition guid; initial	Miscellaneous Medical	a	0.00	2.24	2.24		
G0114		Nett;nutrition guid; subseopt	Miscellaneous Medical		1.72	0.66	1.20		
G0115		Nett;psychosocial consult	Miscellaneous Medical		1.29	0.41	0.83		
G0116		Nett;psychosocial testing	Miscellaneous Medical		1.20	0.37	0.49		
G0117		Nett;psychosocial counsel	Miscellaneous Medical		1.11	0.34	1.01		
G0118		Glaucoma scm high risk direc	Miscellaneous Medical		0.45	0.19	0.71		
G0120	26	Colon ca scm; barium enema	Miscellaneous Medical		0.17	0.07	0.52		
G0121	TC	Colon ca scm; barium enema	Miscellaneous Medical	a	0.00	0.33	2.24		
G0122		Colon ca scm; barium enema	Miscellaneous Medical		0.00	2.24	2.24		
G0124	26	Screen cv; thin layer by MD	Pathology		3.69	1.58	6.04		
G0125	TC	PET image pulmonary nodule	Radiology		0.99	0.38	0.98		
G0127		PET image pulmonary nodule	Radiology		0.00	2.19	2.19		
G0128		Trim nail(s)	Radiology		0.42	0.18	0.18		
G0130	26	CORF skilled nursing service Single energy x-ray study	Miscellaneous Medical	a	1.50	0.52	0.52	34.15	SAF

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 176 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
G0130	TC	Single energy x-ray study	Radiology	a	0.00	0.81	0.81		
G0141		Ser c/v cyto,autosis and rnd	Pathology		0.42	0.18	0.18		
G0166		Extrnl counterpulse, per tx	Miscellaneous Medical		0.07	0.03	3.58		
G0168		Wound closure by adhesive	Surgery		0.45	0.16	1.92		
G0179		MD recertification HHA PT	Office/Home Visits/Urgent Care Visits		0.45	1.07	1.07		
G0180		MD certification HHA patient	Office/Home Visits/Urgent Care Visits		0.67	1.29	1.29		
G0181		Home health care supervision	Office/Home Visits/Urgent Care Visits		1.73	1.52	1.52		
G0182		Hospice care supervision	Office/Home Visits/Urgent Care Visits		1.73	1.71	1.71	18.47	SAF
G0186		Dstry eye lesn,ldr, vsnl tech	Miscellaneous Medical						
G0202	26	Screen mammography film digital	Radiology		0.70	0.23	0.23		
G0202	TC	Screen mammography film digital	Radiology	a	0.00	2.56	2.56		
G0204	26	Diagnostic mammography digital	Radiology		0.87	0.29	0.29		
G0204	TC	Diagnostic mammography digital	Radiology	a	0.00	2.52	2.52		
G0206	26	Diagnostic mammography digital	Radiology		0.70	0.23	0.23		
G0206	TC	Diagnostic mammography digital	Radiology	a	0.00	2.02	2.02		
G0210	26	PET img wholebody dx/lung	Radiology		1.50	0.51	0.51		
G0210	TC	PET img wholebody dx/lung	Radiology	a				34.16	SAF
G0211	26	PET img wholebody int/lung	Radiology		1.50	0.51	0.51		
G0211	TC	PET img wholebody int/lung	Radiology	a				34.62	SAF
G0212	26	PET img wholebod restag lung	Radiology		1.50	0.51	0.51		
G0212	TC	PET img wholebod restag lung	Radiology	a				33.62	SAF
G0213	26	PET img wholebody dx	Radiology		1.50	0.51	0.51		
G0213	TC	PET img wholebody dx	Radiology	a				30.50	SAF
G0214	26	PET img wholebod int/l	Radiology		1.50	0.51	0.51		
G0214	TC	PET img wholebod int/l	Radiology	a				34.62	SAF
G0215	26	PETimg wholebod restag	Radiology		1.50	0.51	0.51		
G0215	TC	PETimg wholebod restag	Radiology	a				34.62	SAF
G0216	26	PET img wholebod dx melanoma	Radiology		1.50	0.51	0.51		
G0216	TC	PET img wholebod dx melanoma	Radiology	a				29.31	SAF
G0217	26	PET img wholebod int/melan	Radiology		1.50	0.51	0.51		
G0217	TC	PET img wholebod int/melan	Radiology	a				34.62	SAF
G0218	26	PET img wholebod restag mel	Radiology		1.50	0.51	0.51		
G0218	TC	PET img wholebod restag mel	Radiology	a				34.62	SAF
G0220	26	PET img wholebod dx lymphoma	Radiology		1.50	0.51	0.51		
G0220	TC	PET img wholebod dx lymphoma	Radiology	a				34.61	SAF
G0221	26	PET imag wholebod int lympho	Radiology		1.50	0.51	0.51		
G0221	TC	PET imag wholebod int lympho	Radiology	a				32.33	SAF
G0222	26	PET imag wholebod resta lymph	Radiology		1.50	0.52	0.52		
G0222	TC	PET imag wholebod resta lymph	Radiology	a				34.62	SAF
G0223	26	PET imag wholebod reg dx head	Radiology		1.50	0.51	0.51		
G0223	TC	PET imag wholebod reg dx head	Radiology	a				34.61	SAF
G0224	26	PET imag wholebod reg int/hea	Radiology		1.50	0.51	0.51		
G0224	TC	PET imag wholebod reg int/hea	Radiology	a				36.29	SAF
G0225	26	PET whol restag headneckonly	Radiology		1.50	0.52	0.52		
G0225	TC	PET whol restag headneckonly	Radiology	a				30.03	SAF
G0226	26	PET img wholebody dx esophagi	Radiology		1.50	0.53	0.53		
G0226	TC	PET img wholebody dx esophagi	Radiology	a				30.03	SAF

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPSCS CODE
PAGE 177 OF 179

CPT/ HCPSCS Code	Modifier	CPT/HCPSCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUS	Facility Practice Expense RVUS	Non- Facility Practice Expense RVUS	Total Expense RVUS	Charge Method- ology
G0227	26	PET img wholebody ini esophage	Radiology		1.50	0.52	0.52	30.03	SAF
G0227	TC	PET img wholebody ini esophage	Radiology	a	1.50	0.51	0.51	30.96	SAF
G0228	26	PET img wholebody restg esopha	Radiology	a	1.50	0.51	0.51	37.93	SAF
G0228	TC	PET img wholebody restg esopha	Radiology						
G0229	26	PET img metaboloc brain pres	Radiology		1.50	0.53	0.53		
G0229	TC	PET img metaboloc brain pres	Radiology		1.50	0.51	0.51		
G0230	26	PET myocardi viability post	Radiology		1.50	0.52	0.52		
G0230	TC	PET myocardi viability post	Radiology		1.50	0.52	0.52		
G0231	26	PET whdb lymphoma; gamma cam	Radiology		1.50	0.52	0.52		
G0231	TC	PET whdb lymphoma; gamma cam	Radiology		1.50	0.52	0.52		
G0232	26	PET whdb melanoma; gamma cam	Radiology		1.50	0.52	0.52		
G0232	TC	PET whdb melanoma; gamma cam	Radiology		1.50	0.52	0.52		
G0233	26	PET WHBD pulm nod; gamma cam	Radiology		1.50	0.52	0.52		
G0233	TC	PET WHBD pulm nod; gamma cam	Radiology		1.50	0.52	0.52		
G0234	26	Therapeutic proced strg endur	Miscellaneous Medical		0.00	0.47	0.47	0.20	SAF
G0237		Oth resp proc; indiv	Miscellaneous Medical					0.38	SAF
G0238		Oth resp proc; group	Miscellaneous Medical						
G0239		Initial foot exam pt lops	Office/Home Visits/Urgent Care Visits		0.88	0.32	0.79		
G0245		Followup eval of foot pt lops	Office/Home Visits/Urgent Care Visits		0.45	0.16	0.54		
G0246		Routine footcare pt w lops	Office/Home Visits/Urgent Care Visits		0.50	0.21	0.51		
G0247		Demonstrate use home inr mon	Office/Home Visits/Urgent Care Visits	a	0.00	6.75	6.75		
G0248		Provide test material;equipm	Cardiovascular	a	0.00	3.91	3.91		
G0249		MD review interpret of test	Cardiovascular		0.00	0.06	0.06		
G0250		PET imaging initial dx	Radiology		1.50	0.60	0.60		
G0252	26	PET image brst decton recur	Radiology	a	1.87	0.71	0.71	34.05	SAF
G0253	26	PET image brst decton recur	Radiology		1.87	0.71	0.71		
G0253	TC	PET image brst decton recur	Radiology		0.61	0.25	0.63		
G0254	26	PET image brst eval to bx	Surgery		0.00	0.47	0.47		
G0258		Removal of impacted wax md	Miscellaneous Medical		0.00	0.19	0.19		
G0268		MNT subs bx for change dx	Miscellaneous Medical		0.25	0.10	0.10		
G0270		Group MNT 2 or more 30 mins	Radiology		0.25	0.10	0.10		
G0271		Renal angio, cardiac cath	Radiology		0.18	0.11	0.11		
G0275		Iliac art angio, cardiac cath	Physical Medicine		0.18	0.11	0.11		
G0278		Elec stim unattend for press	Physical Medicine		0.00	10.66	10.66		
G0281		Elec stim other than wound	Radiology	a	1.48	0.56	0.56		
G0283		Recon, CTA for surg plan	Radiology		1.87	0.71	0.71		
G0288		Arthro, loose body + chondro	Surgery		1.48	0.71	0.71		
G0289	26	PET img restag thyroid cance	Radiology		12.74	8.54	8.54		
G0296		ESRD related svc 4+mo<2yrs	Miscellaneous Medical		10.61	7.10	7.10		
G0300		ESRD related svc 2-3mo<2yrs	Miscellaneous Medical		9.73	4.72	4.72		
G0309		ESRD related svc 1 visit<2yr	Miscellaneous Medical		8.11	3.92	3.92		
G0310		ESRD related svcs 4+mo 2-11yr	Miscellaneous Medical		6.49	3.14	3.14		
G0311		ESRD relate svcs 2-3 mo 2-11y	Miscellaneous Medical		8.28	4.42	4.42		
G0312		ESRD related svcs 1 mon 2-11y	Miscellaneous Medical		6.90	3.67	3.67		
G0313		ESRD related svcs 4+ mo 12-19	Miscellaneous Medical		5.52	2.86	2.86		
G0314		ESRD related svcs 2-3mo 12-19	Miscellaneous Medical		5.09	2.86	2.86		
G0315		ESRD relate svcs 1 vist 12-19	Miscellaneous Medical		4.24	2.38	2.38		
G0316		ESRD related svcs 4+mo 20+ yrs	Miscellaneous Medical						
G0317		ESRD related svcs 2-3 mo 20+y	Miscellaneous Medical						
G0318		ESRD related svcs 2-3 mo 20+y	Miscellaneous Medical						

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 178 OF 179

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology
G0319		ESRD related svs 1 visit 20+	Miscellaneous Medical		3.39	1.90	1.90	1.79	SAF
G0320		ESRD related svs home under2	Miscellaneous Medical		10.61	7.10	7.10	2.13	SAF
G0321		ESRD related svs home mo<2yrs	Miscellaneous Medical		6.90	3.67	3.67	2.69	SAF
G0322		ESRD relate svs home mo 12-19	Miscellaneous Medical		8.11	3.92	3.92	2.41	SAF
G0323		ESRD related svs home mo 20+	Miscellaneous Medical		4.24	2.38	2.38	3.19	SAF
G0324		ESRD relate svs home/dy<2y	Miscellaneous Medical		0.35	0.24	0.24	0.32	SAF
G0325		ESRD relate home/dy 2-11 yr	Miscellaneous Medical		0.23	0.12	0.12	0.47	SAF
G0326		ESRD relate home/dy 12-19yr	Miscellaneous Medical		0.27	0.13	0.13	0.51	SAF
G0327		ESRD relate home/dy 20+ yrs	Miscellaneous Medical		0.14	0.08	0.08	0.41	SAF
G9001		MCCD, initial rate	Miscellaneous Medical					2.08	SAF
G9002		MCCD,maintenance rate	Miscellaneous Medical					0.94	SAF
G9003		MCCD, risk adj hi, initial	Miscellaneous Medical					0.48	MDR
G9004		MCCD, risk adj lo, initial	Miscellaneous Medical					1.41	MDR
G9005		MCCD, risk adj, maintenance	Miscellaneous Medical					2.02	MDR
G9008		Mccd,phys coor-care oversight	Miscellaneous Medical					3.03	SAF
G9009		MCCD, risk adj, level 3	Miscellaneous Medical					0.93	SAF
H0004		Alcohol and/or drug services	Miscellaneous Medical					1.35	SAF
H0020		Alcohol and/or drug services	Miscellaneous Medical					3.20	SAF
M0064		Visit for drug monitoring	OP Psych./Aic. & Drug Abuse		0.37	0.12	0.34	4.36	SAF
M0076		Prolotherapy	OP Psych./Aic. & Drug Abuse					0.77	SAF
P3001		IV chelationtherapy	Miscellaneous Medical					3.20	SAF
P7001		Screening pap smear by phys	Cardiovascular					0.58	MDR
P9010		Culture bacterial urine	Pathology		0.42	0.18	0.18	0.77	MDR
P9011		Whole blood for transfusion	Miscellaneous Medical					1.35	SAF
P9015		Blood split unit	Miscellaneous Medical					3.20	SAF
P9019		RBC leukocytes reduced	Miscellaneous Medical					4.36	SAF
P9020		Platelets, each unit	Miscellaneous Medical					0.58	MDR
P9021		Platelet rich plasma unit	Miscellaneous Medical					1.35	SAF
P9022		Red blood cells unit	Miscellaneous Medical					3.20	SAF
P9041		Washed red blood cells unit	Miscellaneous Medical					0.77	MDR
P9043		Albumin (human),5%, 50ml	Miscellaneous Medical					1.35	SAF
P9045		Plasma protein fract.5%,50ml	Miscellaneous Medical					3.20	SAF
P9046		Albumin (human), 5%, 250 ml	Miscellaneous Medical					0.58	MDR
P9047		Albumin (human), 25%, 20 ml	Miscellaneous Medical					1.35	MDR
P9048		Albumin (human), 25%, 50ml	Miscellaneous Medical					0.73	MDR
P9603		Plasma protein fract.5%,250ml	Miscellaneous Medical					1.35	MDR
P9604		One-way allow prorated miles	Miscellaneous Medical					1.69	MDR
Q0035		One-way allow prorated trip	Miscellaneous Medical					0.01	SAF
Q0035	26	Cardiokymography	Miscellaneous Medical		0.17	0.07	0.07	0.11	MDR
Q0035	TC	Cardiokymography	Radiology	a	0.00	0.07	0.07	0.07	MDR
Q0091		Obtaining screen pap smear	Pathology		0.37	0.14	0.38	0.38	SAF
Q0092		Set up port xray equipment	Radiology		0.00	0.32	0.66	0.66	SAF

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage indicators and Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE
PAGE 179 OF 179

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
-----------------------	----------	----------------------------	---------------------------------------	-------------------------------	-------------------------	---	---	--------------------------	----------------------------

Key to Status/Usage Indicators:

- a Cannot be billed by VA Hospital Outpatients and Provider-Based Clinics (because the service is separately priced as outpatient facility charges — see Table F).
 - b Cannot be billed by VA Hospital Outpatients and Provider-Based Clinics (because a different code is used for facility billing).
- No entry: Can be billed at all VA locations.

Charge Methodology:

Misc: RVUs obtained using the methodology for unlisted procedures.
No entry: RVUs obtained from the Medicare Physician Fee Schedule.
All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.0.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE

PAGE 1 OF 4

CPT Code	CPT Code Description	Base Units
00100	Anes-Proc Salivary Glands Incl Bx	5.0
00102	Anes-Proc Plastic Repair Cleft Lip	6.0
00103	Anes-Reconstructive Proc Eyelid	5.0
00104	Anes-Electroconvulsive Therapy	4.0
00120	Anes-Ext Mid&Innr Ear W/Bx; Nos	5.0
00124	Anes-Ext Mid&Innr Ear W/Bx; Otscopy	4.0
00126	Anes-Ext Mid&Innr Ear W/Bx; Tympanot	4.0
00140	Anesthesia Procedures On Eye; Nos	5.0
00142	Anesthesia Proc Eye; Lens Surgery	4.0
00144	Anes-Proc Eye; Corneal Transplant	6.0
00145	Anes-Proc Eye; Vitreoretinal Surg	6.0
00147	Anesthesia Proc Eye; Inlectomy	4.0
00148	Anesthesia Proc Eye; Ophthalmoscopy	4.0
00160	Anes-Proc Nose&Access Sinuses; Nos	5.0
00162	Anes-Nse&Acsc Sinuses; Radl Surg	7.0
00164	Anes-Nse&Acsc Sinuses; Bx Sft Tiss	4.0
00170	Anes-Intraoral Including Bx; Nos	5.0
00172	Anes-Intraoral W/Bx; Repr Cit Palate	6.0
00174	Anes-Intraoral W/Bx; Exc Tumor	6.0
00176	Anes-Intraoral Incl Bx; Radl Surgery	7.0
00190	Anes-Proc Facial Bones/Skull; Nos	5.0
00192	Anes-Proc Fce Bns/Skull; Radl Surg	7.0
00210	Anes-Intracran; Nos	11.0
00212	Anes-Intracran; Subdural Taps	5.0
00214	Anes-Cran; Burr Holes-Ventricrph	9.0
00215	Anes-Intracran;Elev Skl Fx-Xtradurl	9.0
00216	Anes-Intracran; Vascular Procedures	15.0
00218	Anes-Intracran; Proc Sitting Pstn	13.0
00220	Anes-Intracran;Cerebrosp Fl Shnting	10.0
00222	Anes-Intracran;Elec-Coag Cran Nerv	6.0
00300	Anes-Integ-Musc&Nerv-Head-Trunk;Nos	5.0
00320	Anes-Esoph Thyrd Trachea;Nos 1 Yr/>	6.0
00322	Anes-Esoph Thyroid Trach;Bx Thyroid	3.0
00326	Anes-Larynx&Trach Chld < 1 Yr Age	7.0
00350	Anes-Proc Major Vessels Neck; Nos	10.0
00352	Anes-Proc Maj Ves Neck; Simple Lig	5.0
00400	Anes-Integ Extrem Trnk Perin; Nos	3.0
00402	Anes-Integ Extrem Trnk; Brst Recon	5.0
00404	Anes-Integ Trunk; Radl Breast Proc	5.0
00406	Anes-Integ;Radl Brst W/Node Dissect	13.0
00410	Anes-Integ Extm Trnk;Convrt Arryth	4.0
00450	Anes-Proc Clavicle&Scapula; Nos	5.0
00452	Anes-Proc Clav&Scapula; Radl Surg	6.0
00454	Anes-Proc Clav&Scapula; Bx Clav	3.0
00470	Anes-Partial Rib Resection; Nos	6.0
00472	Anes-Part Rib Res; Thoracoplasty	10.0
00474	Anes-Part Rib Resection; Radl Proc	13.0
00500	Anes-On Esophagus	15.0
00520	Anes-Closed Chest; Nos	6.0
00522	Anes-Closed Chest; Needle Bx Pleura	4.0
00524	Anes-Closed Chest; Pneumocentesis	4.0
00528	Anes-Clo Chst;Mediastnscp No 1 Lung	8.0
00529	Anes-Clos Chst; Mediastnscpy 1 Lung	11.0
00530	Anes-Perm Trns Pacemkr Insertion	4.0
00532	Anes-Access Cntrl Venous Circ	4.0
00534	Anes-Trns Insr/Repl Pacing Defib	7.0
00537	Anes-Card Eps Incl Radiofreq Ablat	7.0
00539	Anes-Tracheobronchial Reconstruct	18.0
00540	Anes-Thoracot; Nos	12.0
00541	Anes-Thoracot; Util 1 Lung Vent	15.0
00542	Anes-Thoracot; Decortication	15.0
00546	Anes-Thoracot Lungs;Thoracoplasty	15.0
00548	Anes-Thoracot Lungs;Intrathor Trach	17.0
00550	Anesthesia For Sternal Debridement	10.0
00560	Anes-Hrt Pericard Sac; W/O Oxygntr	15.0
00562	Anes-Hrt Pericard Sac; W/Oxygntr	20.0
00563	Anes-Hrt Percard Sac;Oxygntr&Arst	25.0
00566	Anes-Direct Cabq W/O Pump Oxygenatr	25.0

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE

PAGE 2 OF 4

CPT Code	CPT Code Description	Base Units
00580	Anes-Hrt Tplnt/Hrt/Lung Tplnt	20.0
00600	Anesthesia Proc C-Spine&Cord; Nos	10.0
00604	Anes-Cerv Spine&Cord; Pt Sit Pstr	13.0
00620	Anesthesia Proc T-Spine&Cord; Nos	10.0
00622	Anes-Thoracic;Thoracolum Sympathect	13.0
00630	Anesthesia Proc Lumbar Region; Nos	8.0
00632	Anes-Proc Lumb Rgn; Lumb Sympathect	7.0
00634	Anes-Lumb Rgn; Chemonucleolysis	10.0
00635	Anes-Lumb Rgn; Dx/Tx Lumb Punct	4.0
00640	Anes-Manip Sprn/Clos Proc Sprn	3.0
00670	Anes-Exten Spine & Spinal Cord	13.0
00700	Anes-Proc Upper Ant Abd Wall; Nos	4.0
00702	Anes-Up Ant Abd Wall; Perq Livr Bx	4.0
00730	Anes-Proc Upper Posterior Abd Wall	5.0
00740	Anes-Ugi Endoscopy-Intro Prox Duod	5.0
00750	Anes-Hernia Repairs Upper Abd; Nos	4.0
00752	Anes-Hernia Repr Up Abd; &/Dehis	6.0
00754	Anes-Hem Repr Up Abd; Ormphalocele	7.0
00756	Anes-Hernia Repr Up Abd;Transabd	7.0
00770	Anes-On Major Abd Blood Vessels	15.0
00790	Anes-Intraper Up Abd W/Lap;Nos	7.0
00792	Anes-Intraper Up Abd W/Lap;Hepatec	13.0
00794	Anes-Intraper Up W/Lap;Pancreatect	8.0
00796	Anes-Intraper Up W/Lap;Liver Tplnt	30.0
00797	Anes-Intraper W/Lap; Gastr Restirct	8.0
00800	Anes-Proc Lower Ant Abd Wall; Nos	4.0
00802	Anes-Lw Ant Abd Wall; Panniculect	5.0
00810	Anes-Low Intest Endo-Dist To Duod	5.0
00820	Anes-Proc Lower Posterior Abd Wall	5.0
00830	Anes-Hernia Repairs Lower Abd; Nos	4.0
00832	Anes-Hern Rep ; Ventral&Inci Hern S	6.0
00834	Anes-Hern Repr Nos Under 1 Yr Age	5.0
00836	Anes-Hem Nos<37Wk Brth &<50Wk Surg	6.0
00840	Anes-Intraper W/Laparscpy; Nos	6.0
00842	Anes-Intraper W/Laparscpy; Amnio	4.0
00844	Anes-Intraper;Abd-Perinl Resection	7.0
00846	Anes-Intraper Low W/Lap;Radl Hyst	8.0
00848	Anes-Intraper W/Lap;Pelv Exentratn	8.0
00851	Anes-Intraper W/Lap; Tubal Lig	6.0
00860	Anes-Xtraper W/Urn Tract; Nos	6.0
00862	Anes-Xtraper;Up 1/3 Ureter/Nephrect	7.0
00864	Anes-Xtraper Low Abd;Tot Cystect	8.0
00865	Anes-Xtraper Low;Radl Prostactect	7.0
00866	Anes-Xtraper Low Abd;Adrenalectomy	10.0
00868	Anes-Xtraper Low Abd;Renal Trsplnt	10.0
00870	Anes-Xtraper Low Abd;Cystolithotomy	5.0
00872	Anes-Lith Etracorp;W/Water Bath	7.0
00873	Anes-Lith Xtracorp;W/O Water Bath	5.0
00880	Anes-Proc Major Lower Abd Ves; Nos	15.0
00882	Anes-Maj Ves; Inf Vena Cava Lig	10.0
00902	Anesthesia For; Anorectal Procedure	5.0
00904	Anes-For; Radical Perineal Proc	7.0
00906	Anesthesia For; Vulvectomy	4.0
00908	Anes-For; Perineal Prostatectomy	6.0
00910	Anes-Transurethral; Nos	3.0
00912	Anes-Tmsureth;Resect Bladder Tumor	5.0
00914	Anes-Transurethral ; Turp	5.0
00916	Anes-Tmsureth;Post Resection Bleed	5.0
00918	Anes-Tmsureth;W/Manip&/Remv Calcu	5.0
00920	Anesthesia Proc Male Genitalia; Nos	3.0
00921	Anes-Male Gnt; Vasect Unilat/Bilat	3.0
00922	Anes-Proc Male Gnt; Seminl Vesicles	6.0
00924	Anes-Male;Undescend Testis Uni/Bil	4.0
00926	Anes-Male Gnt; Radl Orchest Ing	4.0
00928	Anes-Male Gnt; Radl Orchest Abd	6.0
00930	Anes-Male Genit;Orchiopexy Uni/Bil	4.0
00932	Anes-Proc Male Gnt; Cmpl Amp Penis	4.0
00934	Anes-Male;Radl Amp Penis-Ing Lymph	6.0

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE

PAGE 3 OF 4

CPT Code	CPT Code Description	Base Units
00936	Anes Male;Radl Amp Penis-Ing&Iliac	8.0
00938	Anes-Male Genit;Insrnt Penile Prosth	4.0
00940	Anes-Vag; Not Otherwise Specified	3.0
00942	Anes-Vag; Colpot Vaginect&Opn Ureth	4.0
00944	Anes-Vag; Vaginal Hysterectomy	6.0
00948	Anes-Vag; Cervical Cerclage	4.0
00950	Anes-Vag ; Culdoscopy	5.0
00952	Anes-Vag;Hysteroscopy&/Salpingraphy	4.0
01112	Anes-Bn Marrow Asp&/Bx Iliac Crest	5.0
01120	Anesthesia Procedures Bony Pelvis	6.0
01130	Anes-Body Cast Application/Rev	3.0
01140	Anesthesia Interpelviabd Amputation	15.0
01150	Anes-Radl Tumor Pelv No Hndqtr Amp	10.0
01160	Anes-Clos Proc Invlv Pubis/Si Jnt	4.0
01170	Anes-Open Proc Invlv Pubis/Si Jnt	8.0
01173	Anes-Opn Rep Fx Pelv/Column Acetab	12.0
01180	Anes-Obtur Neurectomy; Extrapelvic	3.0
01190	Anes-Obtur Neurectomy; Intrapelvic	4.0
01200	Anes-All Clos Proc Invlv Hip Joint	4.0
01202	Anes-Arthroscopic Proc Hip Joint	4.0
01210	Anes-Open Proc Invlv Hip Joint; Nos	6.0
01212	Anes-Open Proc Invlv Hip;Disartic	10.0
01214	Anes-Open Hip Jnt; Tot Hip Arthplsty	8.0
01215	Anes-Open Invlv Hip;Total Hip Rev	10.0
01220	Anes-All Clos Proc Invlv Up 2/3 Fem	4.0
01230	Anes-Open Invlv Upper 2/3 Femur;Nos	6.0
01232	Anes-Open Invlv Upper 2/3 Femur;Amp	5.0
01234	Anes-Open Upper 2/3 Femur;Radl Res	8.0
01250	Anes-All Nerv Musc Tend Fasc Up Leg	4.0
01260	Anes-Invlv Vns Upper Leg Incl Expl	3.0
01270	Anes-Invlv Artery Up Leg W/Gft;Nos	8.0
01272	Anes-Invlv Art Up Leg W/Gft;Fem Lig	4.0
01274	Anes-Invlv Art Up Leg W/Gft;Fem Emb	6.0
01320	Anes-Nerv Musc Fasc Burs Knee&/Pop	4.0
01340	Anes-All Clos Proc Lower 1/3 Femur	4.0
01360	Anes-All Open Proc Lower 1/3 Femur	5.0
01380	Anes-All Closed Proc Knee Joint	3.0
01382	Anes-Dx Arthroscopic Proc Knee Jnt	3.0
01390	Anes-All Clos Up Ends Tib Fib&/Pat	3.0
01392	Anes-All Open Up Ends Tib Fib&/Pat	4.0
01400	Anes-Open/Scope Proc Knee Jnt; Nos	4.0
01402	Anes-Open/Scope Knee Jnt; Tot Plsty	7.0
01404	Anes-Open/Scope Knee Jnt; Disartic	5.0
01420	Anes-All Cast Applic/Repr W/Knee	3.0
01430	Anes-Proc Veins Knee&Pop Area; Nos	3.0
01432	Anes-Vns Knee&Pop Area; Av Fist	6.0
01440	Anes-Proc Art Knee&Pop Area; Nos	8.0
01442	Anes-Art Knee;Pop Thrombendartect	8.0
01444	Anes-Art Knee;Pop Exc Occl/Aneur	8.0
01462	Anes-All Clos Proc Low Leg Ank&Foot	3.0
01464	Anes-Arthroscopic Proc Ank &Or Foot	3.0
01470	Anes-Nerv Musc Fasc Leg Ank&Ft;Nos	3.0
01472	Anes-Nerv Musc Leg&Ft;Repr Achilles	5.0
01474	Anes-Nrv Musc Leg&Ft;Gastroc Recess	5.0
01480	Anes-Open Bones Low Leg Ank&Ft;Nos	3.0
01482	Anes-Open Bones Lw Leg;Radl Res/Amp	4.0
01484	Anes-Open Bns Lw Leg;Osteot Tib Fib	4.0
01486	Anes-Open Bones Lw Leg;Tot Ank Repl	7.0
01490	Anes-Lw Leg Cast Applic Removl/Repr	3.0
01500	Anes-Art Lw Leg W/Byps Gft; Nos	8.0
01502	Anes-Art Low Leg W/Gft;Embolectomy	6.0
01520	Anes-Proc Veins Lower Leg; Nos	3.0
01522	Anes-Veins Lw Leg;Thrombect Direct	5.0
01610	Anes-Nerv Musc Tend Fasc Burs Shldr	5.0
01620	Anes-All Clos Hum Sc Ac&Shldr Jnt	4.0
01622	Anes-Dx Arthroscopic Proc Shldr Jnt	4.0
01630	Anes-Open/Scope Hum Sc Ac&Shldr;Nos	5.0
01632	Anes-Opn/Scope Hum Sc&Shldr;Rad Res	6.0

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE

PAGE 4 OF 4

CPT Code	CPT Code Description	Base Units
01634	Anes-Opn/Scope Hum Sc&Shldr;Disartc	9.0
01636	Anes-Opn/Scope Hum Sc Ac&Shldr; Amp	15.0
01638	Anes-Open/Scope Hum Ac&Shldr; Repl	10.0
01650	Anes-Proc Art Shoulder&Axilla; Nos	6.0
01652	Anes-Art Shldr&Ax; Ax-Brach Aneur	10.0
01654	Anes-Proc Art Shldr&Ax; Byps Graft	8.0
01656	Anes-Art Shldr&Ax; Ax-Fem Byps Gft	10.0
01670	Anes-On Veins Of Shoulder&Axilla	4.0
01680	Anes-Shldr Cast Applic/Remv/Repr;Nos	3.0
01682	Anes-Shldr Cast Applic/Remv;Soica	4.0
01710	Anes-Nrv Musc Burs Up Arm&Elb;Nos	3.0
01712	Anes-Nrv Musc Burs Up Arm&Elb;Tenot	5.0
01714	Anes-Nrv Musc Up Arm&Elb;Tenoplasty	5.0
01716	Anes-Nrv Musc Up Arm&Elb;Tenodesis	5.0
01730	Anes-All Closed Proc Humerus&Elbow	3.0
01732	Anes-Dx Arthroscopic Proc Elb Joint	3.0
01740	Anes-Open/Surg Scope Proc Elb; Nos	4.0
01742	Anes-Open/Scope Proc Elb;Osteot Hum	5.0
01744	Anes-Open/Scope Elb;Rep Non/Mal Hum	5.0
01756	Anes-Open/Scope Proc Elb; Radl Proc	6.0
01758	Anes-Opn/Scope Elb;Exc Cyst/Tum Hum	5.0
01760	Anes-Open/Scope Elb; Tot Elb Repl	7.0
01770	Anes-Proc Art Upper Arm&Elbow; Nos	6.0
01772	Anes-Proc Art Upper Arm&Elb; Embo	6.0
01780	Anes-Proc Veins Upper Arm&Elb; Nos	3.0
01782	Anes-Proc Vns Up Arm&Elb; Phleborr	4.0
01810	Anes-All Nerv Musc Forarm Wrst&Hnd	3.0
01820	Anes-Clos Radius Ulna Wrst/Hnd Bone	3.0
01829	Anes-Dx Arthroscopic Proc Wrist	3.0
01830	Anes-Opn/Scope/Endo Wrst/Hnd; Nos	3.0
01832	Anes-Open/Scope/Endo Wrst/Hnd; Tot	6.0
01840	Anes-Proc Art Forarm Wrst&Hand; Nos	6.0
01842	Anes-Proc Art Forarm Wrst&Hand; Embo	6.0
01844	Anes-Vasc Shnt/Shnt Rev Any Type	6.0
01850	Anes-Proc Vns Forarm Wrst&Hand; Nos	3.0
01852	Anes-Vns Forarm Wrst&Hnd; Phleborr	4.0
01860	Anes-Forarm/Hand Cast Applic/Remv	3.0
01905	Anes-Myelgrph Diskgrph Vertplsty	5.0
01916	Anes-Diagnostic Artrgrph/Venography	6.0
01920	Anes-Card Cath Cor Angio&Ventricgrph	7.0
01922	Anes-Non-Invasive Imaging/Rad Tx	7.0
01924	Anes-Tx Intrvn Rad Art Sys; Nos	5.0
01925	Anes-Tx Intrvn Rad Art; Carotid/Cor	7.0
01926	Anes-Tx Rad Art;Intrcran -Card/Aort	8.0
01930	Anes-Tx Intrvn Rad Venus/Lymph; Nos	5.0
01931	Anes-Tx Rad Venus; Intrahep/Portal	7.0
01932	Anes-Tx Rad Venus; Intrahep/Jugular	6.0
01933	Anes-Tx Rad Venus/Lymph; Intracran	7.0
01951	Anes-2&3 Deg Bm Exc/Debrid; < 4%	3.0
01952	Anes-2&3 Deg Bm Exc/Debrid; 4-9%	5.0
01953	Anes-2-3 Deg Exc/Debrid;Ea Add 9%	1.0
01958	Anes-External Cephalic Version Proc	5.0
01960	Anesthesia Vaginal Delivery Only	5.0
01961	Anesthesia Cesarean Delivery Only	7.0
01962	Anes-Urgent Hyst Follow Deliv	8.0
01963	Anes-C/S Hyst W/O Labr Analg/Anes	8.0
01964	Anesthesia For Abortion Procedures	4.0
01967	Neurax Labr Anlg/Anes-Plan Vag Del	5.0
01968	Anes-Cd Flw Neurax Labr Analg/Anes	2.0
01969	Anes-C/S Hyst Flw Neurax Labr Analg	5.0
01990	Physiolog Supp-Harv Org-Brain Dead	7.0
01991	Anes-Dx/Tx Nrv Blks&Inj; Not Prone	3.0
01992	Anes-Dx/Tx Nrv Blks&Inj; Prone Pstn	5.0
01995	Rgn Iv Admn Loc Anes Agt/Oth Med	5.0
01996	Daily Hos Epidurl/Subarach Cont Rx	3.0
01999	Unlisted Anesthesia Procedure	5.0

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 1 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D0120	Periodic oral evaluation	\$37.67	I
D0140	Limit oral eval problm focus	\$57.69	I
D0150	Comprehensive oral evaluation	\$63.44	I
D0160	Extensv oral eval prob focus	\$136.55	I
D0170	Re-eval,est pt,problem focus	\$51.83	I
D0180	Comp periodontal evaluation	\$73.31	I
D0210	Intraor complete film series	\$103.25	I
D0220	Intraoral periapical first f	\$21.71	I
D0230	Intraoral periapical ea add	\$17.48	I
D0240	Intraoral occlusal film	\$31.66	I
D0250	Extraoral first film	\$44.78	I
D0260	Extraoral ea additional film	\$40.05	I
D0270	Dental bitewing single film	\$21.73	I
D0272	Dental bitewings two films	\$34.01	I
D0274	Dental bitewings four films	\$49.19	I
D0277	Vert bitewings-sev to eight	\$73.81	I
D0290	Dental film skull/facial bon	\$112.11	I
D0310	Dental salivography	\$310.92	I
D0320	Dental tmj arthrogram incl i	\$502.13	I
D0321	Dental other tmj films	\$171.50	I
D0322	Dental tomographic survey	\$417.72	I
D0330	Dental panoramic film	\$88.25	I
D0340	Dental cephalometric film	\$99.50	I
D0350	Oral/facial images	\$51.28	I
D0415	Bacteriologic study	\$27.04	I
D0425	Caries susceptibility test	\$24.71	I
D0460	Pulp vitality test	\$42.43	I
D0470	Diagnostic casts	\$86.96	I
D0472	Gross exam, prep & report	\$73.12	I
D0473	Micro exam, prep & report	\$119.05	I
D0474	Micro w exam of surg margins	\$137.51	I
D0480	Cytopath smear prep & report	\$112.52	I
D0502	Other oral pathology procedu	\$133.44	I
D0999	Unspecified diagnostic proce	\$1,118.51	I
D1110	Dental prophylaxis adult	\$72.16	I
D1120	Dental prophylaxis child	\$52.44	I
D1201	Topical fluor w prophy child	\$75.54	I
D1203	Topical fluor w/o prophy chi	\$29.89	I
D1204	Topical fluor w/o prophy adu	\$29.15	I
D1205	Topical fluoride w/ prophy a	\$88.18	I
D1310	Nutri counsel-control caries	\$44.29	I
D1320	Tobacco counseling	\$52.08	I
D1330	Oral hygiene instruction	\$46.75	I
D1351	Dental sealant per tooth	\$42.16	I
D1510	Space maintainer fxd unilat	\$267.02	II
D1515	Fixed bilat space maintainer	\$378.34	II
D1520	Remove unilat space maintain	\$337.41	II
D1525	Remove bilat space maintain	\$447.29	II
D1550	Recement space maintainer	\$60.41	II
D2140	Amalgam one surface permanen	\$103.22	II
D2150	Amalgam two surfaces permane	\$129.99	II
D2160	Amalgam three surfaces perma	\$157.41	II
D2161	Amalgam 4 or > surfaces perm	\$190.50	II
D2330	Resin one surface-anterior	\$119.16	II
D2331	Resin two surfaces-anterior	\$147.84	II
D2332	Resin three surfaces-anterio	\$181.74	II
D2335	Resin 4/> surf or w incis an	\$217.79	II
D2390	Ant resin-based cmpst crown	\$275.34	II
D2391	Post 1 srfc resinbased cmpst	\$132.70	II
D2392	Post 2 srfc resinbased cmpst	\$177.26	II
D2393	Post 3 srfc resinbased cmpst	\$219.07	II
D2394	Post >=4srfc resinbase cmpst	\$258.01	II
D2410	Dental gold foil one surface	\$177.78	III
D2420	Dental gold foil two surface	\$431.45	III
D2430	Dental gold foil three surfa	\$781.11	III
D2510	Dental inlay metallic 1 surf	\$647.44	III
D2520	Dental inlay metallic 2 surf	\$729.13	III

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 2 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D2530	Dental inlay metl 3/more sur	\$803.11	III
D2542	Dental onlay metallic 2 surf	\$798.45	III
D2543	Dental onlay metallic 3 surf	\$838.09	III
D2544	Dental onlay metl 4/more sur	\$869.18	III
D2610	Inlay porcelain/ceramic 1 su	\$722.21	III
D2620	Inlay porcelain/ceramic 2 su	\$772.38	III
D2630	Dental onlay porc 3/more sur	\$812.10	III
D2642	Dental onlay porcelin 2 surf	\$820.57	III
D2643	Dental onlay porcelin 3 surf	\$850.77	III
D2644	Dental onlay porc 4/more sur	\$889.76	III
D2650	Inlay composite/resin one su	\$582.85	III
D2651	Inlay composite/resin two su	\$659.08	III
D2652	Dental inlay resin 3/mre sur	\$701.10	III
D2662	Dental onlay resin 2 surface	\$701.09	III
D2663	Dental onlay resin 3 surface	\$738.77	III
D2664	Dental onlay resin 4/mre sur	\$773.95	III
D2710	Crown resin laboratory	\$478.00	III
D2720	Crown resin w/ high noble me	\$869.99	III
D2721	Crown resin w/ base metal	\$759.92	III
D2722	Crown resin w/ noble metal	\$800.35	III
D2740	Crown porcelain/ceramic subs	\$904.19	III
D2750	Crown porcelain w/ h noble m	\$865.23	III
D2751	Crown porcelain fused base m	\$790.75	III
D2752	Crown porcelain w/ noble met	\$824.96	III
D2780	Crown 3/4 cast hi noble met	\$866.31	III
D2781	Crown 3/4 cast base metal	\$821.19	III
D2782	Crown 3/4 cast noble metal	\$832.88	III
D2783	Crown 3/4 porcelain/ceramic	\$883.10	III
D2790	Crown full cast high noble m	\$848.34	III
D2791	Crown full cast base metal	\$791.34	III
D2792	Crown full cast noble metal	\$814.32	III
D2799	Provisional crown	\$327.19	III
D2910	Dental recement inlay	\$81.24	III
D2920	Dental recement crown	\$81.25	III
D2930	Prefab stnlss steel crwn pri	\$211.11	III
D2931	Prefab stnlss steel crown pe	\$242.82	III
D2932	Prefabricated resin crown	\$265.38	III
D2933	Prefab stainless steel crown	\$283.77	III
D2940	Dental sedative filling	\$85.07	III
D2950	Core build-up incl any pins	\$210.63	III
D2951	Tooth pin retention	\$46.57	III
D2952	Post and core cast + crown	\$332.00	III
D2953	Each addnl cast post	\$198.01	III
D2954	Prefab post/core + crown	\$266.10	III
D2955	Post removal	\$230.26	III
D2957	Each addnl prefab pcst	\$140.94	III
D2960	Laminate labial veneer	\$532.55	III
D2961	Lab labial veneer resin	\$770.57	III
D2962	Lab labial veneer porcelain	\$847.03	III
D2970	Temporary- fractured tooth	\$222.98	III
D2980	Crown repair	\$216.29	III
D2999	Dental unspec restorative pr	\$1,132.22	III
D3110	Pulp cap direct	\$61.55	II
D3120	Pulp cap indirect	\$55.08	II
D3220	Therapeutic pulpotomy	\$141.20	II
D3221	Gross pulpal debridement	\$160.15	II
D3230	Pulpal therapy anterior prim	\$181.30	II
D3240	Pulpal therapy posterior pri	\$204.25	II
D3310	Anterior	\$582.63	II
D3320	Root canal therapy 2 canals	\$694.13	II
D3330	Root canal therapy 3 canals	\$872.65	II
D3331	Non-surg tx root canal obs	\$277.19	II
D3332	Incomplete endodontic tx	\$377.29	II
D3333	Internal root repair	\$198.75	II
D3346	Retreat root canal anterior	\$747.35	II
D3347	Retreat root canal bicuspid	\$858.77	II
D3348	Retreat root canal molar	\$1,023.35	II

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 3 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D3351	Apexification/recalc initial	\$301.25	II
D3352	Apexification/recalc interim	\$168.73	II
D3353	Apexification/recalc final	\$490.05	II
D3410	Apicoect/periad surg anter	\$637.17	II
D3421	Root surgery bicuspid	\$692.81	II
D3425	Root surgery molar	\$788.20	II
D3426	Root surgery ea add root	\$286.31	II
D3430	Retrograde filling	\$209.04	II
D3450	Root amputation	\$420.72	II
D3460	Endodontic endosseous implan	\$1,600.26	II
D3470	Intentional replantation	\$745.71	II
D3910	Isolation- tooth w rubb dam	\$157.73	II
D3920	Tooth splitting	\$344.13	II
D3950	Canal prep/fitting of dowel	\$158.98	II
D3999	Endodontic procedure	\$1,157.52	II
D4210	Gingivectomy/plasty per quad	\$516.74	II
D4211	Gingivectomy/plasty per tooth	\$196.00	II
D4240	Gingival flap proc w/ planin	\$630.96	II
D4241	Gngvl flap w rootplan 1-3 th	\$418.86	II
D4245	Apically positioned flap	\$559.88	II
D4249	Crown lengthen hard tissue	\$697.88	II
D4260	Osseous surgery per quadrant	\$943.45	II
D4261	Osseous surgl-3teethperquad	\$684.67	II
D4263	Bone replce graft first site	\$424.03	II
D4264	Bone replce graft each add	\$179.95	II
D4265	Bio mtrls to aid soft/os reg	\$396.03	II
D4266	Guided tiss regen resorb	\$504.28	II
D4267	Guided tiss regen nonresorb	\$604.23	II
D4268	Surgical revision procedure	\$594.55	II
D4270	Pedicle soft tissue graft pr	\$725.51	II
D4271	Free soft tissue graft proc	\$775.38	II
D4273	Subepithelial tissue graft	\$868.53	II
D4274	Distal/proximal wedge proc	\$393.04	II
D4275	Soft tissue allograft	\$640.50	II
D4276	Con tissue w dble ped graft	\$893.75	II
D4320	Provision splnt intracoronal	\$367.77	II
D4321	Provisional splint extracoro	\$323.21	II
D4341	Periodontal scaling & root	\$202.06	II
D4342	Periodontal scaling 1-3teeth	\$131.03	II
D4355	Full mouth debridement	\$136.30	II
D4381	Localized chemo delivery	\$109.49	II
D4910	Periodontal maint procedures	\$112.76	II
D4920	Unscheduled dressing change	\$90.43	II
D4999	Unspecified periodontal proc	\$1,059.48	II
D5110	Dentures complete maxillary	\$1,176.08	III
D5120	Dentures complete mandible	\$1,172.08	III
D5130	Dentures immediat maxillary	\$1,287.21	III
D5140	Dentures immediat mandible	\$1,273.76	III
D5211	Dentures maxill part resin	\$940.42	III
D5212	Dentures mand part resin	\$1,024.32	III
D5213	Dentures maxill part metal	\$1,291.42	III
D5214	Dentures mandibl part metal	\$1,301.42	III
D5281	Removable partial denture	\$730.98	III
D5410	Dentures adjust cmplt maxil	\$66.86	III
D5411	Dentures adjust cmplt mand	\$66.51	III
D5421	Dentures adjust part maxill	\$66.86	III
D5422	Dentures adjust part mandibl	\$66.86	III
D5510	Dentur repr broken compl bas	\$145.23	III
D5520	Replace denture teeth complt	\$123.70	III
D5610	Dentures repair resin base	\$145.86	III
D5620	Rep part denture cast frame	\$184.19	III
D5630	Rep partial denture clasp	\$188.15	III
D5640	Replace part denture teeth	\$130.23	III
D5650	Add tooth to partial denture	\$162.59	III
D5660	Add clasp to partial denture	\$195.21	III
D5670	Repic tth&acric on mtl frmwk	\$480.34	III
D5671	Repic tth&acric mandibular	\$504.94	III

CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 4 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D5710	Dentures rebase cmplt maxil	\$444.49	III
D5711	Dentures rebase cmplt mand	\$437.71	III
D5720	Dentures rebase part maxill	\$428.52	III
D5721	Dentures rebase part mandbl	\$432.42	III
D5730	Denture rein cmplt maxil ch	\$273.98	III
D5731	Denture rein cmplt mand chr	\$273.98	III
D5740	Denture rein part maxil chr	\$261.01	III
D5741	Denture rein part mand chr	\$260.98	III
D5750	Denture rein cmplt max lab	\$355.23	III
D5751	Denture rein cmplt mand lab	\$353.83	III
D5760	Denture rein part maxil lab	\$353.89	III
D5761	Denture rein part mand lab	\$353.89	III
D5810	Denture Intern cmplt maxill	\$576.48	III
D5811	Denture Intern cmplt mandbl	\$598.83	III
D5820	Denture Intern part maxill	\$478.86	III
D5821	Denture Intern part mandbl	\$491.91	III
D5850	Denture tiss conditn maxill	\$129.69	III
D5851	Denture tiss conditn mandbl	\$131.10	III
D5860	Overdenture complete	\$1,812.54	III
D5861	Overdenture partial	\$1,571.30	III
D5862	Precision attachment	\$488.34	III
D5867	Replacement of precision att	\$180.94	III
D5875	Prosthesis modification	\$348.71	III
D5899	Removable prosthodontic proc	\$1,058.42	III
D5911	Facial moulage sectional	\$565.23	III
D5912	Facial moulage complete	\$565.23	III
D5913	Nasal prosthesis	\$3,402.04	III
D5914	Auricular prosthesis	\$3,402.04	III
D5915	Orbital prosthesis	\$4,454.15	III
D5916	Ocular prosthesis	\$1,498.79	III
D5919	Facial prosthesis	\$847.58	III
D5922	Nasal septal prosthesis	\$847.58	III
D5923	Ocular prosthesis interim	\$847.58	III
D5924	Cranial prosthesis	\$985.68	III
D5925	Facial augmentation implant	\$207.68	III
D5926	Replacement nasal prosthesis	\$847.58	III
D5927	Auricular replacement	\$847.58	III
D5928	Orbital replacement	\$847.58	III
D5929	Facial replacement	\$847.58	III
D5931	Surgical obturator	\$2,027.39	III
D5932	Postsurgical obturator	\$3,422.90	III
D5933	Refitting of obturator	\$847.58	III
D5934	Mandibular flange prosthesis	\$3,157.33	III
D5935	Mandibular denture prosth	\$2,802.22	III
D5936	Temp obturator prosthesis	\$3,095.27	III
D5937	Trismus appliance	\$560.52	III
D5951	Feeding aid	\$860.30	III
D5952	Pediatric speech aid	\$1,841.18	III
D5953	Adult speech aid	\$3,115.62	III
D5954	Superimposed prosthesis	\$2,918.22	III
D5955	Palatal lift prosthesis	\$2,731.00	III
D5958	Intraoral con def inter plt	\$847.58	III
D5959	Intraoral con def mod palat	\$847.58	III
D5960	Modify speech aid prosthesis	\$305.72	III
D5982	Surgical stent	\$422.17	III
D5983	Radiation applicator	\$1,095.35	III
D5984	Radiation shield	\$1,095.35	III
D5985	Radiation cone locator	\$1,095.35	III
D5986	Fluoride applicator	\$144.58	III
D5987	Commissure splint	\$1,431.64	III
D5988	Surgical splint	\$558.43	III
D5999	Maxillofacial prosthesis	\$847.58	III
D6010	Odontics endosteal implant	\$1,784.10	III
D6020	Odontics abutment placement	\$307.94	III
D6040	Odontics eposteal implant	\$7,736.74	III
D6050	Odontics transosteal implt	\$5,009.76	III
D6053	Impln/abtmnt sprt rmv dnt	\$1,793.27	III

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 5 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D6054	Implnt/abtmnt spprt remvprtl	\$1,643.33	III
D6055	Implant connecting bar	\$605.54	III
D6056	Prefabricated abutment	\$603.59	III
D6057	Custom abutment	\$783.01	III
D6058	Abutment supported crown	\$1,165.17	III
D6059	Abutment supported mtl crown	\$1,175.67	III
D6060	Abutment supported mtl crown	\$1,035.20	III
D6061	Abutment supported mtl crown	\$1,106.20	III
D6062	Abutment supported mtl crown	\$1,129.51	III
D6063	Abutment supported mtl crown	\$1,122.82	III
D6064	Abutment supported mtl crown	\$1,137.03	III
D6065	Implant supported crown	\$1,242.90	III
D6066	Implant supported mtl crown	\$1,218.72	III
D6067	Implant supported mtl crown	\$1,173.97	III
D6068	Abutment supported retainer	\$1,126.54	III
D6069	Abutment supported retainer	\$1,142.33	III
D6070	Abutment supported retainer	\$912.68	III
D6071	Abutment supported retainer	\$1,150.01	III
D6072	Abutment supported retainer	\$1,177.13	III
D6073	Abutment supported retainer	\$1,033.14	III
D6074	Abutment supported retainer	\$1,063.56	III
D6075	Implant supported retainer	\$1,242.35	III
D6076	Implant supported retainer	\$1,163.58	III
D6077	Implant supported retainer	\$1,208.34	III
D6078	Implnt/abut suprtid fixd dent	\$4,461.10	III
D6079	Implnt/abut suprtid fixd dent	\$2,143.45	III
D6080	Implant maintenance	\$99.46	III
D6090	Repair Implant	\$428.28	III
D6095	Odontics repr abutment	\$475.28	III
D6100	Removal of implant	\$573.35	III
D6199	Implant procedure	\$1,151.20	III
D6210	Prosthodont high noble metal	\$841.10	III
D6211	Bridge base metal cast	\$773.58	III
D6212	Bridge noble metal cast	\$801.88	III
D6240	Bridge porcelain high noble	\$853.93	III
D6241	Bridge porcelain base metal	\$772.51	III
D6242	Bridge porcelain noble metal	\$815.95	III
D6245	Bridge porcelain/ceramic	\$867.58	III
D6250	Bridge resin w/high noble	\$839.61	III
D6251	Bridge resin base metal	\$770.19	III
D6252	Bridge resin w/noble metal	\$794.97	III
D6253	Provisional pontic	\$311.47	III
D6545	Dental retainr cast metl	\$458.24	III
D6548	Porcelain/ceramic retainer	\$560.28	III
D6600	Porcelain/ceramic inlay 2srf	\$739.98	III
D6601	Porc/ceram inlay >= 3 surfac	\$803.95	III
D6602	Cst hgh nble mtl inlay 2 srf	\$776.70	III
D6603	Cst hgh nble mtl inlay >=3sr	\$815.28	III
D6604	Cst bse mtl Inlay 2 surfac	\$760.98	III
D6605	Cst bse mtl inlay >= 3 surfa	\$911.10	III
D6606	Cast noble metal inlay 2 sur	\$732.98	III
D6607	Cst noble mtl Inlay >=3 surf	\$921.08	III
D6608	Onlay porc/crmc 2 surfac	\$788.35	III
D6609	Onlay porc/crmc >=3 surfac	\$897.37	III
D6610	Onlay cst hgh nbl mtl 2 srfc	\$833.25	III
D6611	Onlay cst hgh nbl mtl >=3srf	\$933.81	III
D6612	Onlay cst base mtl 2 surface	\$900.74	III
D6613	Onlay cst base mtl >=3 surfa	\$973.71	III
D6614	Onlay cst nbl mtl 2 surfac	\$923.43	III
D6615	Onlay cst nbl mtl >=3 surfac	\$988.40	III
D6720	Retain crown resin w hi nble	\$872.56	III
D6721	Crown resin w/base metal	\$790.51	III
D6722	Crown resin w/noble metal	\$859.54	III
D6740	Crown porcelain/ceramic	\$920.37	III
D6750	Crown porcelain high noble	\$892.15	III
D6751	Crown porcelain base metal	\$809.41	III
D6752	Crown porcelain noble metal	\$849.96	III

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 6 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D6780	Crown 3/4 high noble metal	\$865.20	III
D6781	Crown 3/4 cast based metal	\$837.30	III
D6782	Crown 3/4 cast noble metal	\$801.79	III
D6783	Crown 3/4 porcelain/ceramic	\$882.63	III
D6790	Crown full high noble metal	\$865.22	III
D6791	Crown full base metal cast	\$807.21	III
D6792	Crown full noble metal cast	\$838.45	III
D6793	Provisional retainer crown	\$332.29	III
D6920	Dental connector bar	\$154.90	III
D6930	Dental recement bridge	\$117.22	III
D6940	Stress breaker	\$281.29	III
D6950	Precision attachment	\$490.22	III
D6970	Post & core plus retainer	\$326.50	III
D6971	Cast post bridge retainer	\$297.72	III
D6972	Prefab post & core plus reta	\$254.62	III
D6973	Core build up for retainer	\$205.39	III
D6975	Coping metal	\$566.44	III
D6976	Each addnl cast post	\$171.32	III
D6977	Each addtl prefab post	\$124.83	III
D6980	Bridge repair	\$279.32	III
D6985	Pediatric partial denture fx	\$590.95	III
D6999	Fixed prosthodontic proc	\$1,058.42	III
D7111	Coronal remnants deciduous t	\$101.26	II
D7140	Extraction erupted tooth/exr	\$119.40	II
D7210	Rem Imp tooth w mucoper flap	\$211.26	II
D7220	Impact tooth remov soft tiss	\$254.36	II
D7230	Impact tooth remov part bony	\$328.14	II
D7240	Impact tooth remov comp bony	\$389.80	II
D7241	Impact tooth rem bony w/comp	\$469.45	II
D7250	Tooth root removal	\$231.95	II
D7260	Oral antral fistula closure	\$1,709.05	II
D7261	Primary closure sinus perf	\$580.45	II
D7270	Tooth reimplantation	\$417.40	II
D7272	Tooth transplantation	\$557.25	II
D7280	Exposure impact tooth orthod	\$458.89	II
D7281	Exposure tooth aid eruption	\$386.85	II
D7282	Mobilize erupted/malpos toot	\$165.81	II
D7285	Biopsy of oral tissue hard	\$551.30	II
D7286	Biopsy of oral tissue soft	\$292.48	II
D7287	Cytology sample collection	\$116.02	II
D7290	Repositioning of teeth	\$381.84	II
D7291	Transseptal fiberotomy	\$170.28	II
D7310	Alveoplasty w/ extraction	\$224.66	II
D7320	Alveoplasty w/o extraction	\$382.34	II
D7340	Vestibuloplasty ridge extens	\$1,303.36	II
D7350	Vestibuloplasty exten graft	\$2,033.66	II
D7410	Rad exc lesion up to 1.25 cm	\$489.07	II
D7411	Excision benign lesion>1.25c	\$528.76	II
D7412	Excision benign lesion compl	\$630.80	II
D7413	Excision malig lesion<=1.25c	\$848.03	II
D7414	Excision malig lesion>1.25cm	\$1,092.45	II
D7415	Excision malig les complicat	\$1,185.21	II
D7440	Malig tumor exc to 1.25 cm	\$585.97	II
D7441	Malig tumor > 1.25 cm	\$863.83	II
D7450	Rem odontogen cyst to 1.25cm	\$534.91	II
D7451	Rem odontogen cyst > 1.25 cm	\$855.01	II
D7460	Rem nonodonto cyst to 1.25cm	\$523.87	II
D7461	Rem nonodonto cyst > 1.25 cm	\$869.66	II
D7465	Lesion destruction	\$327.62	II
D7471	Rem exostosis any site	\$612.92	II
D7472	Removal of torus palatinus	\$732.77	II
D7473	Remove torus mandibularis	\$689.50	II
D7485	Surg reduct osseoustuberosit	\$604.85	II
D7490	Mandible resection	\$6,531.38	II
D7510	I&d abscc intraoral soft tiss	\$195.46	II
D7520	I&d abscess extraoral	\$890.01	II
D7530	Removal fb skin/areolar tiss	\$304.33	II

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 7 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D7540	Removal of fb reaction	\$443.10	II
D7550	Removal of sloughed off bone	\$318.06	II
D7560	Maxillary sinusotomy	\$1,512.49	II
D7610	Maxilla open reduct simple	\$3,417.82	II
D7620	Clsd reduct simpl maxilla fx	\$2,348.30	II
D7630	Open red simpl mandible fx	\$4,133.99	II
D7640	Clsd red simpl mandible fx	\$2,675.37	II
D7650	Open red simp malar/zygom fx	\$2,099.55	II
D7660	Clsd red simp malar/zygom fx	\$1,161.75	II
D7670	Closed rductn splint alveolus	\$1,075.71	II
D7671	Alveolus open reduction	\$832.00	II
D7680	Reduct simple facial bone fx	\$5,766.48	II
D7710	Maxilla open reduct compound	\$3,708.36	II
D7720	Clsd reduct compd maxilla fx	\$2,157.19	II
D7730	Open reduct compd mandible fx	\$4,744.95	II
D7740	Clsd reduct compd mandible fx	\$2,804.38	II
D7750	Open red comp malar/zygma fx	\$3,419.93	II
D7760	Clsd red comp malar/zygma fx	\$1,263.52	II
D7770	Open reduct compd alveolus fx	\$1,810.27	II
D7771	Alveolus clsd reduct stblz te	\$1,281.17	II
D7780	Reduct compnd facial bone fx	\$7,881.81	II
D7810	Tmj open reduct-dislocation	\$3,523.05	II
D7820	Closed tmp manipulation	\$529.18	II
D7830	Tmj manipulation under anest	\$439.77	II
D7840	Removal of tmj condyle	\$4,654.45	II
D7850	Tmj meniscectomy	\$4,346.32	II
D7852	Tmj repair of joint disc	\$4,719.33	II
D7854	Tmj excisn of joint membrane	\$4,806.59	II
D7856	Tmj cutting of a muscle	\$3,206.01	II
D7858	Tmj reconstruction	\$5,726.47	II
D7860	Tmj cutting into joint	\$2,753.22	II
D7865	Tmj reshaping components	\$4,103.82	II
D7870	Tmj aspiration joint fluid	\$271.05	II
D7871	Lysis + lavage w catheters	\$779.74	II
D7872	Tmj diagnostic arthroscopy	\$1,799.98	II
D7873	Tmj arthroscopy lysis adhesn	\$2,056.19	II
D7874	Tmj arthroscopy disc reposit	\$2,712.82	II
D7875	Tmj arthroscopy synovectomy	\$2,919.93	II
D7876	Tmj arthroscopy discectomy	\$3,105.57	II
D7877	Tmj arthroscopy debridement	\$2,804.87	II
D7880	Occlusal orthotic appliance	\$682.88	II
D7899	Tmj unspecified therapy	\$1,089.00	II
D7910	Dent suture recent wnd to 5cm	\$258.85	II
D7911	Dental suture wound to 5 cm	\$563.35	II
D7912	Suture complicate wnd > 5 cm	\$1,065.29	II
D7920	Dental skin graft	\$2,197.52	II
D7940	Reshaping bone orthognathic	\$2,309.77	II
D7941	Bone cutting ramus closed	\$7,266.97	II
D7943	Cutting ramus open w/graft	\$7,532.81	II
D7944	Bone cutting segmented	\$6,239.01	II
D7945	Bone cutting body mandible	\$6,454.04	II
D7946	Reconstruction maxilla total	\$7,776.95	II
D7947	Reconstruct maxilla segment	\$7,189.37	II
D7948	Reconstruct midface no graft	\$10,337.63	II
D7949	Reconstruct midface w/graft	\$13,385.62	II
D7950	Mandible graft	\$2,037.09	II
D7955	Repair maxillofacial defects	\$2,016.10	II
D7960	Frenulectomy/frenulotomy	\$417.73	II
D7970	Excision hyperplastic tissue	\$435.48	II
D7971	Excision pericoronar gingiva	\$172.09	II
D7972	Surg reduct fibrous tuberosit	\$555.99	II
D7980	Sialolithotomy	\$608.43	II
D7981	Excision of salivary gland	\$416.41	II
D7982	Sialodochoplasty	\$1,435.87	II
D7983	Closure of salivary fistula	\$1,323.23	II
D7990	Emergency tracheotomy	\$1,270.77	II
D7991	Dental coronoidectomy	\$3,660.19	II

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE
PAGE 8 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D7995	Synthetic graft facial bones	\$382.68	II
D7996	Implant mandible for augment	\$1,622.43	II
D7997	Appliance removal	\$212.90	II
D7999	Oral surgery procedure	\$1,089.00	II
D8010	Limited dental tx primary	\$1,324.04	III
D8020	Limited dental tx transition	\$1,464.54	III
D8030	Limited dental tx adolescent	\$1,573.54	III
D8040	Limited dental tx adult	\$1,661.04	III
D8050	Intercep dental tx primary	\$1,652.04	III
D8060	Intercep dental tx transiti	\$1,800.54	III
D8070	Compre dental tx transition	\$2,832.54	III
D8080	Compre dental tx adolescent	\$2,875.04	III
D8090	Compre dental tx adult	\$2,995.04	III
D8210	Orthodontic rem appliance tx	\$907.54	III
D8220	Fixed appliance therapy habt	\$958.54	III
D8660	Preorthodontic tx visit	\$146.89	III
D8670	Periodic orthodontic tx visit	\$173.89	III
D8680	Orthodontic retention	\$424.74	III
D8690	Orthodontic treatment	\$185.46	III
D8691	Repair ortho appliance	\$128.23	III
D8692	Replacement retainer	\$226.95	III
D8999	Orthodontic procedure	\$1,110.08	III
D9110	Tx dental pain minor proc	\$90.40	II
D9210	Dent anesthesia w/o surgery	\$25.70	II
D9211	Regional block anesthesia	\$28.80	II
D9212	Trigeminal block anesthesia	\$62.34	II
D9215	Local anesthesia	\$24.11	II
D9220	General anesthesia	\$314.21	II
D9221	General anesthesia ea ad 15m	\$128.24	II
D9230	Analgesia	\$48.38	II
D9241	Intravenous sedation	\$294.90	II
D9242	IV sedation ea ad 30 m	\$112.61	II
D9248	Sedation (non-iv)	\$66.65	II
D9310	Dental consultation	\$122.06	I
D9410	Dental house call	\$204.14	I
D9420	Hospital call	\$258.11	I
D9430	Office visit during hours	\$59.52	I
D9440	Office visit after hours	\$116.65	I
D9450	Case presentation tx plan	\$52.49	I
D9610	Dent therapeutic drug inject	\$66.72	III
D9630	Other drugs/medicaments	\$38.31	III
D9910	Dent appl desensitizing med	\$41.14	III
D9911	Appl desensitizing resin	\$56.60	III
D9920	Behavior management	\$111.21	III
D9930	Treatment of complications	\$93.53	III
D9940	Dental occlusal guard	\$496.60	III
D9941	Fabrication athletic guard	\$154.03	III
D9950	Occlusion analysis	\$237.72	III
D9951	Limited occlusal adjustment	\$115.68	III
D9952	Complete occlusal adjustment	\$561.42	III
D9970	Enamel microabrasion	\$43.54	III
D9971	Odontoplasty 1-2 teeth	\$57.69	III
D9972	Extrnl bleaching per arch	\$270.34	III
D9973	Extrnl bleaching per tooth	\$35.17	III
D9974	Intnl bleaching per tooth	\$219.22	III
D9999	Adjunctive procedure	\$1,054.21	III

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 1 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
78267	Breath tst attain/anal c-14	Pathology	0.37	
78268	Breath test analysis, c-14	Pathology	3.14	
80048	Basic melabolic panel	Pathology	0.40	
80050	General health panel	Pathology	1.42	MDR
80051	Electrolyte panel	Pathology	0.33	
80053	Comprehen metabolic panel	Pathology	0.49	
80055	Obstetric panel	Pathology	1.29	MDR
80061	Lipid panel	Pathology	0.63	
80069	Renal function panel	Pathology	0.41	
80074	Acute hepatitis panel	Pathology	2.22	
80076	Hepatic function panel	Pathology	0.38	
80100	Drug screen, qualitate/multi	Pathology	0.68	
80101	Drug screen, single	Pathology	0.64	
80102	Drug confirmation	Pathology	0.62	
80103	Drug analysis, tissue prep	Pathology	0.44	MDR
80150	Assay of amikacin	Pathology	0.70	
80152	Assay of amitriptyline	Pathology	0.84	
80154	Assay of benzodiazepines	Pathology	0.86	
80156	Assay, carbamazepine, total	Pathology	0.68	
80157	Assay, carbamazepine, free	Pathology	0.62	
80158	Assay of cyclosporine	Pathology	0.84	
80160	Assay of desipramine	Pathology	0.80	
80162	Assay of digoxin	Pathology	0.62	
80164	Assay, dipropylacetic acid	Pathology	0.63	
80166	Assay of doxepin	Pathology	0.72	
80168	Assay of ethosuximide	Pathology	0.76	
80170	Assay of gentamicin	Pathology	0.76	
80172	Assay of gold	Pathology	0.76	
80173	Assay of haloperidol	Pathology	0.68	
80174	Assay of imipramine	Pathology	0.80	
80176	Assay of lidocaine	Pathology	0.69	
80178	Assay of lithium	Pathology	0.31	
80182	Assay of nortriptyline	Pathology	0.63	
80184	Assay of phenobarbital	Pathology	0.53	
80185	Assay of phenytoin, total	Pathology	0.62	
80186	Assay of phenytoin, free	Pathology	0.64	
80188	Assay of pnmidone	Pathology	0.77	
80190	Assay of procainamide	Pathology	0.78	
80192	Assay of procainamide	Pathology	0.78	
80194	Assay of quinidine	Pathology	0.68	
80196	Assay of salicylate	Pathology	0.33	
80197	Assay of tacrolimus	Pathology	0.64	
80198	Assay of theophylline	Pathology	0.66	
80200	Assay of tobramycin	Pathology	0.75	
80201	Assay of topiramate	Pathology	0.56	
80202	Assay of vancomycin	Pathology	0.63	
80299	Quantitative assay, drug	Pathology	0.64	
80400	Acth stimulation panel	Pathology	1.52	
80402	Acth stimulation panel	Pathology	4.06	
80406	Acth stimulation panel	Pathology	3.65	
80408	Aldosterone suppression eval	Pathology	5.86	
80410	Calcitonin stimul panel	Pathology	3.75	
80412	CRH stimulation panel	Pathology	15.38	
80414	Testosterone response	Pathology	2.41	
80415	Estradiol response panel	Pathology	2.61	
80416	Renin stimulation panel	Pathology	6.16	
80417	Renin stimulation panel	Pathology	2.05	
80418	Pituitary evaluation panel	Pathology	27.05	
80420	Dexamethasone panel	Pathology	3.36	
80422	Glucagon tolerance panel	Pathology	2.15	
80424	Glucagon tolerance panel	Pathology	2.36	
80426	Gonadotropin hormone panel	Pathology	6.93	
80428	Growth hormone panel	Pathology	3.11	
80430	Growth hormone panel	Pathology	3.66	
80432	Insulin suppression panel	Pathology	6.30	
80434	Insulin tolerance panel	Pathology	4.72	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 2 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
80435	Insulin tolerance panel	Pathology	4.81	
80436	Metyrapone panel	Pathology	4.25	
80438	TRH stimulation panel	Pathology	2.35	
80439	TRH stimulation panel	Pathology	3.14	
80440	TRH stimulation panel	Pathology	2.71	
81000	Unnalysis, nonauto w/scope	Pathology	0.15	
81001	Urinalysis, auto w/scope	Pathology	0.15	
81002	Urinalysis nonauto w/o scope	Pathology	0.12	
81003	Urinalysis, auto, w/o scope	Pathology	0.10	
81005	Unnalysis	Pathology	0.10	
81007	Urine screen for bacteria	Pathology	0.12	
81015	Microscopic exam of urine	Pathology	0.14	
81020	Urinalysis, glass test	Pathology	0.17	
81025	Urine pregnancy test	Pathology	0.30	
81050	Urinalysis, volume measure	Pathology	0.14	
81099	Urinalysis test procedure	Pathology	0.15	Unlisted
82000	Assay of blood acetaldehyde	Pathology	0.58	
82003	Assay of acetaminophen	Pathology	0.94	
82009	Test for acetone/ketones	Pathology	0.21	
82010	Acetone assay	Pathology	0.38	
82013	Acetylcholinesterase assay	Pathology	0.52	
82016	Acylcamitines, qual	Pathology	0.65	
82017	Acylcamitines, quant	Pathology	0.79	
82024	Assay of acth	Pathology	1.80	
82030	Assay of adp & amp	Pathology	1.20	
82040	Assay of serum albumin	Pathology	0.23	
82042	Assay of unne albumin	Pathology	0.24	
82043	Microalbumin, quantitative	Pathology	0.27	
82044	Microalbumin, semiquant	Pathology	0.21	
82055	Assay of ethanol	Pathology	0.50	
82075	Assay of breath ethanol	Pathology	0.56	
82085	Assay of aldolase	Pathology	0.45	
82088	Assay of aldosterone	Pathology	1.90	
82101	Assay of urine alkaloids	Pathology	1.40	
82103	Alpha-1-antitrypsin, total	Pathology	0.63	
82104	Alpha-1-antitrypsin, pheno	Pathology	0.67	
82105	Alpha-fetoprotein, serum	Pathology	0.78	
82106	Alpha-fetoprotein, amniotic	Pathology	0.78	
82108	Assay of aluminum	Pathology	1.19	
82120	Amines, vaginal fluid qual	Pathology	0.18	
82127	Amino acid, single qual	Pathology	0.65	
82128	Amino acids, mult qual	Pathology	0.65	
82131	Amino acids, single quant	Pathology	0.79	
82135	Assay, aminolevulinic acid	Pathology	0.77	
82136	Amino acids, quant, 2-5	Pathology	0.79	
82139	Amino acids, quan, 6 or more	Pathology	0.79	
82140	Assay of ammonia	Pathology	0.68	
82143	Amniotic fluid scan	Pathology	0.32	
82145	Assay of amphetamines	Pathology	0.73	
82150	Assay of amylase	Pathology	0.30	
82154	Androstanediol glucuronide	Pathology	1.35	
82157	Assay of androstenedione	Pathology	1.37	
82160	Assay of androsterone	Pathology	1.17	
82163	Assay of angiotensin II	Pathology	0.96	
82164	Angiotensin I enzyme test	Pathology	0.68	
82172	Assay of apolipoprotein	Pathology	0.72	
82175	Assay of arsenic	Pathology	0.89	
82180	Assay of ascorbic acid	Pathology	0.46	
82190	Atomic absorption	Pathology	0.70	
82205	Assay of barbiturates	Pathology	0.53	
82232	Assay of beta-2 protein	Pathology	0.76	
82239	Bile acids, total	Pathology	0.80	
82240	Bile acids, cholyglycine	Pathology	1.24	
82247	Bilirubin, total	Pathology	0.23	
82248	Bilirubin, direct	Pathology	0.23	
82252	Fecal bilirubin test	Pathology	0.21	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 3 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
82261	Assay of biotinidase	Pathology	0.79	
82270	Test for blood, feces	Pathology	0.15	
82273	Test for blood, other source	Pathology	0.15	
82274	Assay test for blood, fecal	Pathology	0.60	
82286	Assay of bradykinin	Pathology	0.32	
82300	Assay of cadmium	Pathology	1.08	
82306	Assay of vitamin D	Pathology	1.38	
82307	Assay of vitamin D	Pathology	1.50	
82308	Assay of calcitonin	Pathology	1.25	
82310	Assay of calcium	Pathology	0.24	
82330	Assay of calcium	Pathology	0.64	
82331	Calcium infusion test	Pathology	0.24	
82340	Assay of calcium in urine	Pathology	0.28	
82355	Calculus analysis, qual	Pathology	0.54	
82360	Calculus assay, quant	Pathology	0.60	
82365	Calculus spectroscopy	Pathology	0.60	
82370	X-ray assay, calculus	Pathology	0.58	
82373	Assay, c-d transfer measure	Pathology	0.84	
82374	Assay, blood carbon dioxide	Pathology	0.23	
82375	Assay, blood carbon monoxide	Pathology	0.58	
82376	Test for carbon monoxide	Pathology	0.28	
82378	Carcinoembryonic antigen	Pathology	0.89	
82379	Assay of carnitine	Pathology	0.79	
82380	Assay of carotene	Pathology	0.43	
82382	Assay, urine catecholamines	Pathology	0.80	
82383	Assay, blood catecholamines	Pathology	1.17	
82384	Assay, three catecholamines	Pathology	1.18	
82387	Assay of cathepsin-d	Pathology	0.97	
82390	Assay of ceruloplasmin	Pathology	0.50	
82397	Chemiluminescent assay	Pathology	0.66	
82415	Assay of chloramphenicol	Pathology	0.59	
82435	Assay of blood chloride	Pathology	0.21	
82436	Assay of urine chloride	Pathology	0.23	
82438	Assay, other fluid chlorides	Pathology	0.23	
82441	Test for chlorohydrocarbons	Pathology	0.28	
82465	Assay, bld/serum cholesterol	Pathology	0.20	
82480	Assay, serum cholinesterase	Pathology	0.37	
82482	Assay, rbc cholinesterase	Pathology	0.36	
82485	Assay, chondroitin sulfate	Pathology	0.96	
82486	Gas/liquid chromatography	Pathology	0.84	
82487	Paper chromatography	Pathology	0.74	
82488	Paper chromatography	Pathology	1.00	
82489	Thin layer chromatography	Pathology	0.86	
82491	Chromatography, quant, sing	Pathology	0.84	
82492	Chromatography, quant, mult	Pathology	0.84	
82495	Assay of chromium	Pathology	0.95	
82507	Assay of citrate	Pathology	1.30	
82520	Assay of cocaine	Pathology	0.71	
82523	Collagen crosslinks	Pathology	0.87	
82525	Assay of copper	Pathology	0.58	
82528	Assay of corticosterone	Pathology	1.05	
82530	Cortisol, free	Pathology	0.78	
82533	Total cortisol	Pathology	0.76	
82540	Assay of creatine	Pathology	0.22	
82541	Column chromatography, qual	Pathology	0.84	
82542	Column chromatography, quant	Pathology	0.84	
82543	Column chromatograph/isotope	Pathology	0.84	
82544	Column chromatograph/isotope	Pathology	0.84	
82550	Assay of ck (cpk)	Pathology	0.30	
82552	Assay of cpk in blood	Pathology	0.63	
82553	Creatine, MB fraction	Pathology	0.54	
82554	Creatine, isoforms	Pathology	0.55	
82565	Assay of creatinine	Pathology	0.24	
82570	Assay of urine creatinine	Pathology	0.24	
82575	Creatinine clearance test	Pathology	0.44	
82585	Assay of cryofibrinogen	Pathology	0.40	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 4 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
82595	Assay of cryoglobulin	Pathology	0.30	
82600	Assay of cyanide	Pathology	0.91	
82607	Vitamin B-12	Pathology	0.70	
82608	B-12 binding capacity	Pathology	0.67	
82615	Test for urine cystines	Pathology	0.38	
82626	Dehydroepiandrosterone	Pathology	1.18	
82627	Dehydroepiandrosterone	Pathology	1.04	
82633	Desoxycorticosterone	Pathology	1.45	
82634	Deoxycortisol	Pathology	1.37	
82638	Assay of dibucaine number	Pathology	0.57	
82646	Assay of dihydrocodeinone	Pathology	0.96	
82649	Assay of dihydromorphinone	Pathology	1.20	
82651	Assay of dihydrotestosterone	Pathology	1.20	
82652	Assay of dihydroxyvitamin d	Pathology	1.80	
82654	Assay of dimethadione	Pathology	0.65	
82657	Enzyme cell activity	Pathology	0.84	
82658	Enzyme cell activity, ra	Pathology	0.84	
82664	Electrophoretic test	Pathology	1.60	
82666	Assay of epiandrosterone	Pathology	1.00	
82668	Assay of erythropoietin	Pathology	0.88	
82670	Assay of estradiol	Pathology	1.30	
82671	Assay of estrogens	Pathology	1.51	
82672	Assay of estrogen	Pathology	1.01	
82677	Assay of estriol	Pathology	1.13	
82679	Assay of estrone	Pathology	1.17	
82690	Assay of ethchlorvynol	Pathology	0.81	
82693	Assay of ethylene glycol	Pathology	0.70	
82696	Assay of etiocholanolone	Pathology	1.10	
82705	Fats/lipids, feces, qual	Pathology	0.24	
82710	Fats/lipids, feces, quant	Pathology	0.78	
82715	Assay of fecal fat	Pathology	0.80	
82725	Assay of blood fatty acids	Pathology	0.62	
82726	Long chain fatty acids	Pathology	0.84	
82728	Assay of ferritin	Pathology	0.64	
82731	Assay of fetal fibronectin	Pathology	3.01	
82735	Assay of fluoride	Pathology	0.87	
82742	Assay of flurazepam	Pathology	0.92	
82746	Blood folic acid serum	Pathology	0.69	
82747	Assay of folic acid, rbc	Pathology	0.81	
82757	Assay of semen fructose	Pathology	0.81	
82759	Assay of rbc galactokinase	Pathology	1.00	
82760	Assay of galactose	Pathology	0.52	
82775	Assay galactose transferase	Pathology	0.98	
82776	Galactose transferase test	Pathology	0.39	
82784	Assay of gammaglobulin igm	Pathology	0.43	
82785	Assay of gammaglobulin ige	Pathology	0.77	
82787	Igg 1, 2, 3 or 4, each	Pathology	0.37	
82800	Blood pH	Pathology	0.40	
82803	Blood gases: pH, pO2 & pCO2	Pathology	0.90	
82805	Blood gases W/O2 saturation	Pathology	1.32	
82810	Blood gases, O2 sat only	Pathology	0.41	
82820	Hemoglobin-oxygen affinity	Pathology	0.47	
82926	Assay of gastric acid	Pathology	0.25	
82928	Assay of gastric acid	Pathology	0.31	
82938	Gastrin test	Pathology	0.83	
82941	Assay of gastrin	Pathology	0.82	
82943	Assay of glucagon	Pathology	0.67	
82945	Glucose other fluid	Pathology	0.18	
82946	Glucagon tolerance test	Pathology	0.70	
82947	Assay, glucose, blood quant	Pathology	0.18	
82948	Reagent strip/blood glucose	Pathology	0.15	
82950	Glucose test	Pathology	0.22	
82951	Glucose tolerance test (GTT)	Pathology	0.60	
82952	GTT-added samples	Pathology	0.18	
82953	Glucose-tolbutamide test	Pathology	0.71	
82955	Assay of g6pd enzyme	Pathology	0.45	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 5 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
82960	Test for G6PD enzyme	Pathology	0.28	
82962	Glucose blood test	Pathology	0.11	
82963	Assay of glucosidase	Pathology	1.00	
82965	Assay of gdh enzyme	Pathology	0.36	
82975	Assay of glutamine	Pathology	0.74	
82977	Assay of GGT	Pathology	0.34	
82978	Assay of glutathione	Pathology	0.67	
82979	Assay, rbc glutathione	Pathology	0.32	
82980	Assay of glutethimide	Pathology	0.86	
82985	Glycated protein	Pathology	0.70	
83001	Gonadotropin (FSH)	Pathology	0.87	
83002	Gonadotropin (LH)	Pathology	0.86	
83003	Assay, growth hormone (hgh)	Pathology	0.78	
83008	Assay of guanosine	Pathology	0.78	
83010	Assay of haptoglobin, quant	Pathology	0.59	
83012	Assay of haptoglobins	Pathology	0.80	
83013	H pylori analysis	Pathology	3.14	
83014	H pylori drug admin/collect	Pathology	0.37	
83015	Heavy metal screen	Pathology	0.88	
83018	Quantitative screen, metals	Pathology	1.02	
83020	Hemoglobin electrophoresis	Pathology	0.60	
83021	Hemoglobin chromatography	Pathology	0.84	
83026	Hemoglobin, copper sulfate	Pathology	0.11	
83030	Fetal hemoglobin, chemical	Pathology	0.39	
83033	Fetal hemoglobin assay, qual	Pathology	0.28	
83036	Glycated hemoglobin test	Pathology	0.45	
83045	Blood methemoglobin test	Pathology	0.23	
83050	Blood methemoglobin assay	Pathology	0.34	
83051	Assay of plasma hemoglobin	Pathology	0.34	
83055	Blood sulfhemoglobin test	Pathology	0.23	
83060	Blood sulfhemoglobin assay	Pathology	0.39	
83065	Assay of hemoglobin heat	Pathology	0.32	
83068	Hemoglobin stability screen	Pathology	0.40	
83069	Assay of urine hemoglobin	Pathology	0.18	
83070	Assay of hemosiderin, qual	Pathology	0.22	
83071	Assay of hemosiderin, quant	Pathology	0.32	
83080	Assay of b hexosaminidase	Pathology	0.79	
83088	Assay of histamine	Pathology	1.38	
83090	Assay of homocystine	Pathology	0.79	
83150	Assay of for hva	Pathology	0.90	
83491	Assay of corticosteroids	Pathology	0.82	
83497	Assay of 5-hiaa	Pathology	0.60	
83498	Assay of progesterone	Pathology	1.27	
83499	Assay of progesterone	Pathology	1.18	
83500	Assay, free hydroxyproline	Pathology	1.06	
83505	Assay, total hydroxyproline	Pathology	1.13	
83516	Immunoassay, nonantibody	Pathology	0.54	
83518	Immunoassay, dipstick	Pathology	0.40	
83519	Immunoassay, nonantibody	Pathology	0.63	
83520	Immunoassay, RIA	Pathology	0.60	
83525	Assay of insulin	Pathology	0.53	
83527	Assay of insulin	Pathology	0.60	
83528	Assay of intrinsic factor	Pathology	0.74	
83540	Assay of iron	Pathology	0.30	
83550	Iron binding test	Pathology	0.41	
83570	Assay of idh enzyme	Pathology	0.41	
83582	Assay of ketogenic steroids	Pathology	0.66	
83586	Assay 17- ketosteroids	Pathology	0.60	
83593	Fractionation, ketosteroids	Pathology	1.23	
83605	Assay of lactic acid	Pathology	0.50	
83615	Lactate (LD) (LDH) enzyme	Pathology	0.28	
83625	Assay of ldh enzymes	Pathology	0.60	
83632	Placental lactogen	Pathology	0.94	
83633	Test urine for lactose	Pathology	0.26	
83634	Assay of urine for lactose	Pathology	0.54	
83655	Assay of lead	Pathology	0.56	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 6 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
83661	L/s ratio, fetal lung	Pathology	1.03	
83662	Foam stability, fetal lung	Pathology	0.88	
83663	Fluoro polarize, fetal lung	Pathology	0.88	
83664	Lamellar bdy, fetal lung	Pathology	0.88	
83670	Assay of lap enzyme	Pathology	0.43	
83690	Assay of lipase	Pathology	0.32	
83715	Assay of blood lipoproteins	Pathology	0.53	
83716	Assay of blood lipoproteins	Pathology	1.16	
83718	Assay of lipoprotein	Pathology	0.38	
83719	Assay of blood lipoprotein	Pathology	0.54	
83721	Assay of blood lipoprotein	Pathology	0.45	
83727	Assay of lrh hormone	Pathology	0.80	
83735	Assay of magnesium	Pathology	0.31	
83775	Assay of md enzyme	Pathology	0.34	
83785	Assay of manganese	Pathology	1.15	
83788	Mass spectrometry qual	Pathology	0.84	
83789	Mass spectrometry quant	Pathology	0.84	
83805	Assay of meprobamate	Pathology	0.82	
83825	Assay of mercury	Pathology	0.76	
83835	Assay of metanephrines	Pathology	0.79	
83840	Assay of methadone	Pathology	0.76	
83857	Assay of methalbumin	Pathology	0.50	
83858	Assay of methsuximide	Pathology	0.69	
83864	Mucopolysaccharides	Pathology	0.93	
83866	Mucopolysaccharides screen	Pathology	0.46	
83872	Assay synovial fluid mucin	Pathology	0.27	
83873	Assay of csf protein	Pathology	0.80	
83874	Assay of myoglobin	Pathology	0.60	
83880	Natriuretic peptide	Pathology	1.58	
83883	Assay, nephelometry not spec	Pathology	0.63	
83885	Assay of nickel	Pathology	1.14	
83887	Assay of nicotine	Pathology	1.11	
83890	Molecule isolate	Pathology	0.19	
83891	Molecule isolate nucleic	Pathology	0.19	
83892	Molecular diagnostics	Pathology	0.19	
83893	Molecule dot/slot/blot	Pathology	0.19	
83894	Molecule gel electrophor	Pathology	0.19	
83896	Molecular diagnostics	Pathology	0.19	
83897	Molecule nucleic transfer	Pathology	0.19	
83898	Molecule nucleic ampli	Pathology	0.78	
83901	Molecule nucleic ampli	Pathology	0.78	
83902	Molecular diagnostics	Pathology	0.66	
83903	Molecule mutation scan	Pathology	0.78	
83904	Molecule mutation identify	Pathology	0.78	
83905	Molecule mutation identify	Pathology	0.78	
83906	Molecule mutation identify	Pathology	0.78	
83912	Genetic examination	Pathology	0.19	
83915	Assay of nucleotidase	Pathology	0.52	
83916	Oligoctional bands	Pathology	0.94	
83918	Organic acids, total, quant	Pathology	0.77	
83919	Organic acids, qual, each	Pathology	0.77	
83921	Organic acid, single, quant	Pathology	0.77	
83925	Assay of opiates	Pathology	0.91	
83930	Assay of blood osmolality	Pathology	0.31	
83935	Assay of urine osmolality	Pathology	0.32	
83937	Assay of osteocalcin	Pathology	1.39	
83945	Assay of oxalate	Pathology	0.60	
83950	Oncoprotein, her-2/neu	Pathology	3.01	
83970	Assay of parathormone	Pathology	1.93	
83986	Assay of body fluid acidity	Pathology	0.17	
83992	Assay for phenacyclidine	Pathology	0.69	
84022	Assay of phenothiazine	Pathology	0.73	
84030	Assay of blood pku	Pathology	0.26	
84035	Assay of phenylketones	Pathology	0.17	
84060	Assay acid phosphatase	Pathology	0.34	
84061	Phosphatase, forensic exam	Pathology	0.37	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 7 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
84066	Assay prostate phosphatase	Pathology	0.45	
84075	Assay alkaline phosphatase	Pathology	0.24	
84078	Assay alkaline phosphatase	Pathology	0.34	
84080	Assay alkaline phosphatases	Pathology	0.69	
84081	Amniotic fluid enzyme test	Pathology	0.77	
84085	Assay of rbc pg6d enzyme	Pathology	0.31	
84087	Assay phosphohexose enzymes	Pathology	0.48	
84100	Assay of phosphorus	Pathology	0.22	
84105	Assay of urine phosphorus	Pathology	0.24	
84106	Test for porphobilinogen	Pathology	0.20	
84110	Assay of porphobilinogen	Pathology	0.39	
84119	Test urine for porphyrins	Pathology	0.40	
84120	Assay of urine porphyrins	Pathology	0.69	
84126	Assay of feces porphyrins	Pathology	1.19	
84127	Assay of feces porphyrins	Pathology	0.54	
84132	Assay of serum potassium	Pathology	0.21	
84133	Assay of urine potassium	Pathology	0.20	
84134	Assay of prealbumin	Pathology	0.68	
84135	Assay of pregnenediol	Pathology	0.89	
84138	Assay of pregnanetriol	Pathology	0.88	
84140	Assay of pregnenolone	Pathology	0.97	
84143	Assay of 17-hydroxypregne	Pathology	1.07	
84144	Assay of progesterone	Pathology	0.97	
84146	Assay of prolactin	Pathology	0.90	
84150	Assay of prostaglandin	Pathology	1.17	
84152	Assay of psa, complexed	Pathology	0.86	
84153	Assay of psa, total	Pathology	0.86	
84154	Assay of psa, free	Pathology	0.86	
84155	Assay of protein	Pathology	0.17	
84156	Assay of protein, urine	Pathology	0.17	
84157	Assay of protein, other	Pathology	0.17	
84160	Assay of serum protein	Pathology	0.24	
84165	Assay of serum proteins	Pathology	0.50	
84181	Western blot test	Pathology	0.80	
84182	Protein, western blot test	Pathology	0.84	
84202	Assay RBC protoporphyrin	Pathology	0.67	
84203	Test RBC protoporphyrin	Pathology	0.40	
84206	Assay of proinsulin	Pathology	0.83	
84207	Assay of vitamin b-6	Pathology	1.31	
84210	Assay of pyruvate	Pathology	0.51	
84220	Assay of pyruvate kinase	Pathology	0.44	
84228	Assay of quinine	Pathology	0.54	
84233	Assay of estrogen	Pathology	3.01	
84234	Assay of progesterone	Pathology	3.03	
84235	Assay of endocrine hormone	Pathology	2.44	
84238	Assay, nonendocrine receptor	Pathology	1.71	
84244	Assay of renin	Pathology	1.03	
84252	Assay of vitamin b-2	Pathology	0.94	
84255	Assay of selenium	Pathology	1.19	
84260	Assay of serotonin	Pathology	1.45	
84270	Assay of sex hormone globul	Pathology	1.01	
84275	Assay of sialic acid	Pathology	0.63	
84285	Assay of silica	Pathology	1.10	
84295	Assay of serum sodium	Pathology	0.22	
84300	Assay of urine sodium	Pathology	0.23	
84302	Assay of sweat sodium	Pathology	0.23	
84305	Assay of somatomedin	Pathology	0.99	
84307	Assay of somatostatin	Pathology	0.85	
84311	Spectrophotometry	Pathology	0.33	
84315	Body fluid specific gravity	Pathology	0.12	
84375	Chromatogram assay, sugars	Pathology	0.91	
84376	Sugars, single, qual	Pathology	0.26	
84377	Sugars, multiple, qual	Pathology	0.26	
84378	Sugars single quant	Pathology	0.54	
84379	Sugars multiple quant	Pathology	0.54	
84392	Assay of urine sulfate	Pathology	0.22	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 8 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category.	Total RVUs	Charge Method- ology
84402	Assay of testosterone	Pathology	1.19	
84403	Assay of total testosterone	Pathology	1.21	
84425	Assay of vitamin b-1	Pathology	0.99	
84430	Assay of thiocyanate	Pathology	0.54	
84432	Assay of thyroglobulin	Pathology	0.75	
84436	Assay of total thyroxine	Pathology	0.32	
84437	Assay of neonatal thyroxine	Pathology	0.30	
84439	Assay of free thyroxine	Pathology	0.42	
84442	Assay of thyroid activity	Pathology	0.69	
84443	Assay thyroid stim hormone	Pathology	0.78	
84445	Assay of tsi	Pathology	2.37	
84446	Assay of vitamin e	Pathology	0.66	
84449	Assay of transcortin	Pathology	0.84	
84450	Transferase (AST) (SGOT)	Pathology	0.24	
84460	Alanine amino (ALT) (SGPT)	Pathology	0.25	
84466	Assay of transferrin	Pathology	0.60	
84478	Assay of triglycerides	Pathology	0.27	
84479	Assay of thyroid (t3 or t4)	Pathology	0.30	
84480	Assay, triiodothyronine (t3)	Pathology	0.66	
84481	Free assay (FT-3)	Pathology	0.79	
84482	T3 reverse	Pathology	0.74	
84484	Assay of troponin, quant	Pathology	0.46	
84485	Assay duodenal fluid trypsin	Pathology	0.35	
84488	Test feces for trypsin	Pathology	0.34	
84490	Assay of feces for trypsin	Pathology	0.36	
84510	Assay of tyrosine	Pathology	0.49	
84512	Assay of troponin, qual	Pathology	0.36	
84520	Assay of urea nitrogen	Pathology	0.18	
84525	Urea nitrogen semi-quant	Pathology	0.18	
84540	Assay of urine/urea-n	Pathology	0.22	
84545	Urea-N clearance test	Pathology	0.31	
84550	Assay of blood/uric acid	Pathology	0.21	
84560	Assay of urine/uric acid	Pathology	0.22	
84577	Assay of feces/urobilinogen	Pathology	0.58	
84578	Test urine urobilinogen	Pathology	0.15	
84580	Assay of urine urobilinogen	Pathology	0.33	
84583	Assay of urine urobilinogen	Pathology	0.23	
84585	Assay of urine vma	Pathology	0.72	
84586	Assay of vip	Pathology	1.65	
84588	Assay of vasopressin	Pathology	1.58	
84590	Assay of vitamin a	Pathology	0.54	
84591	Assay of nos vitamin	Pathology	0.54	
84597	Assay of vitamin k	Pathology	0.64	
84600	Assay of volatiles	Pathology	0.75	
84620	Xylose tolerance test	Pathology	0.55	
84630	Assay of zinc	Pathology	0.53	
84681	Assay of c-peptide	Pathology	0.97	
84702	Chorionic gonadotropin test	Pathology	0.70	
84703	Chorionic gonadotropin assay	Pathology	0.35	
84830	Ovulation tests	Pathology	0.47	
84999	Clinical chemistry test	Pathology	0.24	Unlisted
85002	Bleeding time test	Pathology	0.21	
85004	Automated diff wbc count	Pathology	0.30	
85007	Bi smear w/diff wbc count	Pathology	0.16	
85008	Bi smear w/o diff wbc count	Pathology	0.16	
85009	Manual diff wbc count b-coat	Pathology	0.17	
85013	Spun microhematocrit	Pathology	0.11	
85014	Hematocrit	Pathology	0.11	
85018	Hemoglobin	Pathology	0.11	
85025	Complete cbc w/auto diff wbc	Pathology	0.36	
85027	Complete cbc, automated	Pathology	0.30	
85032	Manual cell count, each	Pathology	0.20	
85041	Automated rbc count	Pathology	0.14	
85044	Manual reticulocyte count	Pathology	0.20	
85045	Automated reticulocyte count	Pathology	0.19	
85046	Reticyte/hgb concentrate	Pathology	0.26	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 9 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
85048	Automated leukocyte count	Pathology	0.12	
85049	Automated platelet count	Pathology	0.21	
85055	Reticulated platelet assay	Pathology	1.25	
85130	Chromogenic substrate assay	Pathology	0.56	
85170	Blood clot retraction	Pathology	0.17	
85175	Blood clot lysis time	Pathology	0.21	
85210	Blood clot factor II test	Pathology	0.61	
85220	Blood clot factor V test	Pathology	0.82	
85230	Blood clot factor VII test	Pathology	0.84	
85240	Blood clot factor VIII test	Pathology	0.84	
85244	Blood clot factor VIII test	Pathology	0.95	
85245	Blood clot factor VIII test	Pathology	1.07	
85246	Blood clot factor VIII test	Pathology	1.07	
85247	Blood clot factor VIII test	Pathology	1.07	
85250	Blood clot factor IX test	Pathology	0.89	
85260	Blood clot factor X test	Pathology	0.84	
85270	Blood clot factor XI test	Pathology	0.84	
85280	Blood clot factor XII test	Pathology	0.90	
85290	Blood clot factor XIII test	Pathology	0.76	
85291	Blood clot factor XIII test	Pathology	0.41	
85292	Blood clot factor assay	Pathology	0.88	
85293	Blood clot factor assay	Pathology	0.88	
85300	Antithrombin III test	Pathology	0.55	
85301	Antithrombin III test	Pathology	0.50	
85302	Blood clot inhibitor antigen	Pathology	0.56	
85303	Blood clot inhibitor test	Pathology	0.65	
85305	Blood clot inhibitor assay	Pathology	0.54	
85306	Blood clot inhibitor test	Pathology	0.72	
85307	Assay activated protein c	Pathology	0.72	
85335	Factor inhibitor test	Pathology	0.60	
85337	Thrombomodulin	Pathology	0.49	
85345	Coagulation time	Pathology	0.20	
85347	Coagulation time	Pathology	0.20	
85348	Coagulation time	Pathology	0.17	
85360	Euglobulin lysis	Pathology	0.39	
85362	Fibrin degradation products	Pathology	0.32	
85366	Fibrinogen test	Pathology	0.40	
85370	Fibrinogen test	Pathology	0.53	
85378	Fibrin degrade, semiquant	Pathology	0.33	
85379	Fibrin degradation, quant	Pathology	0.48	
85380	Fibrin degradation, vte	Pathology	0.48	
85384	Fibrinogen	Pathology	0.40	
85385	Fibrinogen	Pathology	0.40	
85390	Fibrinolysins screen	Pathology	0.24	
85400	Fibrinolytic plasmin	Pathology	0.41	
85410	Fibrinolytic antiplasmin	Pathology	0.36	
85415	Fibrinolytic plasminogen	Pathology	0.80	
85420	Fibrinolytic plasminogen	Pathology	0.30	
85421	Fibrinolytic plasminogen	Pathology	0.48	
85441	Heinz bodies, direct	Pathology	0.20	
85445	Heinz bodies, induced	Pathology	0.32	
85460	Hemoglobin, fetal	Pathology	0.36	
85461	Hemoglobin, fetal	Pathology	0.31	
85475	Hemolysin	Pathology	0.41	
85520	Heparin assay	Pathology	0.61	
85525	Heparin neutralization	Pathology	0.55	
85530	Heparin-protamine tolerance	Pathology	0.66	
85536	Iron stain peripheral blood	Pathology	0.30	
85540	Wbc alkaline phosphatase	Pathology	0.40	
85547	RBC mechanical fragility	Pathology	0.40	
85549	Muramidase	Pathology	0.88	
85555	RBC osmotic fragility	Pathology	0.31	
85557	RBC osmotic fragility	Pathology	0.62	
85576	Blood platelet aggregation	Pathology	1.00	
85597	Platelet neutralization	Pathology	0.84	
85610	Prothrombin time	Pathology	0.18	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 10 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
85611	Prothrombin test	Pathology	0.18	
85612	Viper venom prothrombin time	Pathology	0.45	
85613	Russell viper venom, diluted	Pathology	0.45	
85635	Reptilase test	Pathology	0.46	
85651	Rbc sed rate, nonautomated	Pathology	0.17	
85652	Rbc sed rate, automated	Pathology	0.13	
85660	RBC sickle cell test	Pathology	0.26	
85670	Thrombin time, plasma	Pathology	0.27	
85675	Thrombin time, titer	Pathology	0.32	
85705	Thromboplastin inhibition	Pathology	0.45	
85730	Thromboplastin time, partial	Pathology	0.28	
85732	Thromboplastin time, partial	Pathology	0.30	
85810	Blood viscosity examination	Pathology	0.55	
85999	Hematology procedure	Pathology	0.30	Unlisted
86000	Agglutinins, febrile	Pathology	0.33	
86001	Allergen specific ige	Pathology	0.24	
86003	Allergen specific IgE	Pathology	0.24	
86005	Allergen specific IgE	Pathology	0.37	
86021	WBC antibody identification	Pathology	0.70	
86022	Platelet antibodies	Pathology	0.86	
86023	Immunoglobulin assay	Pathology	0.58	
86038	Antinuclear antibodies	Pathology	0.56	
86039	Antinuclear antibodies (ANA)	Pathology	0.52	
86060	Antistreptolysin o, titer	Pathology	0.34	
86063	Antistreptolysin o, screen	Pathology	0.27	
86140	C-reactive protein	Pathology	0.24	
86141	C-reactive protein, hs	Pathology	0.60	
86146	Glycoprotein antibody	Pathology	1.19	
86147	Cardiolipin antibody	Pathology	1.19	
86148	Phospholipid antibody	Pathology	0.75	
86155	Chemotaxis assay	Pathology	0.75	
86156	Cold agglutinin, screen	Pathology	0.31	
86157	Cold agglutinin, titer	Pathology	0.38	
86160	Complement, antigen	Pathology	0.56	
86161	Complement/function activity	Pathology	0.56	
86162	Complement, total (CH50)	Pathology	0.95	
86171	Complement fixation, each	Pathology	0.47	
86185	Counterimmunoelectrophoresis	Pathology	0.42	
86215	Deoxyribonuclease, antibody	Pathology	0.62	
86225	DNA antibody	Pathology	0.64	
86226	DNA antibody, single strand	Pathology	0.57	
86235	Nuclear antigen antibody	Pathology	0.84	
86243	Fc receptor	Pathology	0.96	
86255	Fluorescent antibody, screen	Pathology	0.56	
86256	Fluorescent antibody, titer	Pathology	0.56	
86277	Growth hormone antibody	Pathology	0.73	
86280	Hemagglutination inhibition	Pathology	0.38	
86294	Immunoassay, tumor qual	Pathology	0.92	
86300	Immunoassay, tumor ca 15-3	Pathology	0.97	
86301	Immunoassay, tumor ca 19-9	Pathology	0.97	
86304	Immunoassay, tumor, ca 125	Pathology	0.97	
86308	Heterophile antibodies	Pathology	0.24	
86309	Heterophile antibodies	Pathology	0.30	
86310	Heterophile antibodies	Pathology	0.34	
86316	Immunoassay, tumor other	Pathology	0.97	
86317	Immunoassay, infectious agent	Pathology	0.70	
86318	Immunoassay, infectious agent	Pathology	0.60	
86320	Serum immunoelectrophoresis	Pathology	1.05	
86325	Other immunoelectrophoresis	Pathology	1.04	
86327	Immunoelectrophoresis assay	Pathology	1.06	
86329	Immunodiffusion	Pathology	0.66	
86331	Immunodiffusion ouchterlony	Pathology	0.56	
86332	Immune complex assay	Pathology	1.14	
86334	Immunofixation procedure	Pathology	1.04	
86336	Inhibin A	Pathology	0.73	
86337	Insulin antibodies	Pathology	1.00	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 11 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
86340	Intrinsic factor antibody	Pathology	0.70	
86341	Islet cell antibody	Pathology	0.92	
86343	Leukocyte histamine release	Pathology	0.58	
86344	Leukocyte phagocytosis	Pathology	0.37	
86353	Lymphocyte transformation	Pathology	2.29	
86359	T cells, total count	Pathology	1.76	
86360	T cell, absolute count/ratio	Pathology	2.19	
86361	T cell, absolute count	Pathology	1.25	
86376	Microsomal antibody	Pathology	0.68	
86378	Migration inhibitory factor	Pathology	0.92	
86382	Neutralization test, viral	Pathology	0.79	
86384	Nitroblue tetrazolium dye	Pathology	0.53	
86403	Particle agglutination test	Pathology	0.48	
86406	Particle agglutination test	Pathology	0.50	
86430	Rheumatoid factor test	Pathology	0.26	
86431	Rheumatoid factor, quant	Pathology	0.26	
86485	Skin test, candida	Pathology	0.28	
86586	Skin test, unlisted	Pathology	0.26	MDR Unlisted
86590	Streptokinase, antibody	Pathology	0.51	
86592	Blood serology, qualitative	Pathology	0.20	
86593	Blood serology, quantitative	Pathology	0.21	
86602	Antinomyces antibody	Pathology	0.48	
86603	Adenovirus antibody	Pathology	0.60	
86606	Aspergillus antibody	Pathology	0.70	
86609	Bacterium antibody	Pathology	0.60	
86611	Bartonella antibody	Pathology	0.48	
86612	Blastomyces antibody	Pathology	0.60	
86615	Bordetella antibody	Pathology	0.62	
86617	Lyme disease antibody	Pathology	0.72	
86618	Lyme disease antibody	Pathology	0.80	
86619	Borrelia antibody	Pathology	0.62	
86622	Brucella antibody	Pathology	0.42	
86625	Campylobacter antibody	Pathology	0.61	
86628	Candida antibody	Pathology	0.56	
86631	Chlamydia antibody	Pathology	0.55	
86632	Chlamydia igm antibody	Pathology	0.59	
86635	Coccidioides antibody	Pathology	0.54	
86638	Q fever antibody	Pathology	0.57	
86641	Cryptococcus antibody	Pathology	0.67	
86644	CMV antibody	Pathology	0.67	
86645	CMV antibody, IgM	Pathology	0.79	
86648	Diphtheria antibody	Pathology	0.71	
86651	Encephalitis antibody	Pathology	0.62	
86652	Encephalitis antibody	Pathology	0.62	
86653	Encephalitis antibody	Pathology	0.62	
86654	Encephalitis antibody	Pathology	0.62	
86658	Enterovirus antibody	Pathology	0.61	
86663	Epstein-barr antibody	Pathology	0.61	
86664	Epstein-barr antibody	Pathology	0.71	
86665	Epstein-barr antibody	Pathology	0.85	
86666	Ehrlichia antibody	Pathology	0.48	
86668	Francisella tularensis	Pathology	0.49	
86671	Fungus antibody	Pathology	0.57	
86674	Giardia lamblia antibody	Pathology	0.69	
86677	Helicobacter pylori	Pathology	0.68	
86682	Helminth antibody	Pathology	0.61	
86684	Hemophilus influenza	Pathology	0.74	
86687	Htlv-i antibody	Pathology	0.39	
86688	Htlv-ii antibody	Pathology	0.65	
86689	HTLV/HIV confirmatory test	Pathology	0.90	
86692	Hepatitis, delta agent	Pathology	0.80	
86694	Herpes simplex test	Pathology	0.67	
86695	Herpes simplex test	Pathology	0.62	
86696	Herpes simplex type 2	Pathology	0.90	
86698	Histoplasma	Pathology	0.58	
86701	HIV-1	Pathology	0.41	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 12 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
86702	HIV-2	Pathology	0.63	
86703	HIV-1/HIV-2, single assay	Pathology	0.64	
86704	Hep b core antibody, total	Pathology	0.56	
86705	Hep b core antibody, igm	Pathology	0.55	
86706	Hep b surface antibody	Pathology	0.50	
86707	Hep be antibody	Pathology	0.54	
86708	Hep a antibody, total	Pathology	0.58	
86709	Hep a antibody, igm	Pathology	0.53	
86710	Influenza virus antibody	Pathology	0.63	
86713	Legionella antibody	Pathology	0.71	
86717	Leishmania antibody	Pathology	0.57	
86720	Leptospira antibody	Pathology	0.62	
86723	Listeria monocytogenes ab	Pathology	0.62	
86727	Lymph choriomeningitis ab	Pathology	0.60	
86729	Lympho venereum antibody	Pathology	0.56	
86732	Mucormycosis antibody	Pathology	0.62	
86735	Mumps antibody	Pathology	0.61	
86738	Mycoplasma antibody	Pathology	0.62	
86741	Neisseria meningitidis	Pathology	0.62	
86744	Nocardia antibody	Pathology	0.62	
86747	Parvovirus antibody	Pathology	0.70	
86750	Malaria antibody	Pathology	0.62	
86753	Protozoa antibody nos	Pathology	0.58	
86756	Respiratory virus antibody	Pathology	0.60	
86757	Rickettsia antibody	Pathology	0.90	
86759	Rotavirus antibody	Pathology	0.62	
86762	Rubella antibody	Pathology	0.67	
86765	Rubeola antibody	Pathology	0.60	
86768	Salmonella antibody	Pathology	0.62	
86771	Shigella antibody	Pathology	0.62	
86774	Tetanus antibody	Pathology	0.69	
86777	Toxoplasma antibody	Pathology	0.67	
86778	Toxoplasma antibody, igm	Pathology	0.67	
86781	Treponema pallidum, confirm	Pathology	0.62	
86784	Trichinella antibody	Pathology	0.59	
86787	Varicella-zoster antibody	Pathology	0.60	
86790	Virus antibody nos	Pathology	0.60	
86793	Yersinia antibody	Pathology	0.62	
86800	Thyroglobulin antibody	Pathology	0.74	
86803	Hepatitis c ab test	Pathology	0.67	
86804	Hep c ab test, confirm	Pathology	0.72	
86805	Lymphocytotoxicity assay	Pathology	2.44	
86806	Lymphocytotoxicity assay	Pathology	2.22	
86807	Cytotoxic antibody screening	Pathology	1.85	
86808	Cytotoxic antibody screening	Pathology	1.39	
86812	HLA typing, A, B, or C	Pathology	1.20	
86813	HLA typing, A, B, or C	Pathology	2.71	
86816	HLA typing, DR/DQ	Pathology	1.30	
86817	HLA typing, DR/DQ	Pathology	3.00	
86821	Lymphocyte culture, mixed	Pathology	2.64	
86822	Lymphocyte culture, primed	Pathology	1.71	
86849	Immunology procedure	Pathology	0.48	Unlisted
86850	RBC antibody screen	Pathology	0.41	MDR
86860	RBC antibody elution	Pathology	0.41	MDR
86870	RBC antibody identification	Pathology	0.71	MDR
86880	Coombs test, direct	Pathology	0.25	
86885	Coombs test, indirect, qual	Pathology	0.27	
86886	Coombs test, indirect, titer	Pathology	0.24	
86890	Autologous blood process	Pathology	1.63	MDR
86891	Autologous blood, op salvage	Pathology	2.55	MDR
86900	Blood typing, ABO	Pathology	0.14	
86901	Blood typing, Rh (D)	Pathology	0.20	MDR
86903	Blood typing, antigen screen	Pathology	0.44	
86904	Blood typing, patient serum	Pathology	0.44	
86905	Blood typing, RBC antigens	Pathology	0.18	
86906	Blood typing, Rh phenotype	Pathology	0.36	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of table for note regarding Charge Methodology

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 13 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
86910	Blood typing, paternity test	Pathology	0.45	MDR
86911	Blood typing, antigen system	Pathology	0.35	MDR
86920	Compatibility test	Pathology	0.45	MDR
86921	Compatibility test	Pathology	0.41	MDR
86922	Compatibility test	Pathology	0.25	MDR
86927	Plasma, fresh frozen	Pathology	0.22	MDR
86930	Frozen blood prep	Pathology	2.04	MDR
86931	Frozen blood thaw	Pathology	2.25	MDR
86932	Frozen blood freeze/thaw	Pathology	2.45	MDR
86940	Hemolysins/agglutinins, auto	Pathology	0.38	
86941	Hemolysins/agglutinins	Pathology	0.57	
86945	Blood product/irradiation	Pathology	0.61	MDR
86950	Leukocyte transfusion	Pathology	1.12	MDR
86965	Pooling blood platelets	Pathology	0.29	MDR
86970	RBC pretreatment	Pathology	0.33	MDR
86971	RBC pretreatment	Pathology	0.33	MDR
86972	RBC pretreatment	Pathology	0.31	MDR
86975	RBC pretreatment, serum	Pathology	0.20	MDR
86976	RBC pretreatment, serum	Pathology	0.16	MDR
86977	RBC pretreatment, serum	Pathology	0.20	MDR
86978	RBC pretreatment, serum	Pathology	0.45	MDR
86985	Split blood or products	Pathology	0.43	MDR
87001	Small animal inoculation	Pathology	0.62	
87003	Small animal inoculation	Pathology	0.79	
87015	Specimen concentration	Pathology	0.31	
87040	Blood culture for bacteria	Pathology	0.48	
87045	Feces culture, bacteria	Pathology	0.44	
87046	Stool cult, bacteria, each	Pathology	0.44	
87070	Culture, bacteria, other	Pathology	0.40	
87071	Culture bacter aerobic othr	Pathology	0.44	
87073	Culture bacteria anaerobic	Pathology	0.44	
87075	Culture bacteria anaerobic	Pathology	0.44	
87076	Culture anaerobe ident, each	Pathology	0.38	
87077	Culture aerobic identify	Pathology	0.38	
87081	Culture screen only	Pathology	0.31	
87084	Culture of specimen by kit	Pathology	0.40	
87086	Urine culture/colony count	Pathology	0.38	
87088	Urine bacteria culture	Pathology	0.38	
87101	Skin fungi culture	Pathology	0.36	
87102	Fungus isolation culture	Pathology	0.39	
87103	Blood fungus culture	Pathology	0.42	
87106	Fungi identification, yeast	Pathology	0.48	
87107	Fungi identification, mold	Pathology	0.48	
87109	Mycoplasma	Pathology	0.72	
87110	Chlamydia culture	Pathology	0.91	
87116	Mycobacteria culture	Pathology	0.50	
87118	Mycobactenc identification	Pathology	0.51	
87140	Culture type immunofluoresc	Pathology	0.26	
87143	Culture typing, gic/hplc	Pathology	0.58	
87147	Culture type, immunologic	Pathology	0.24	
87149	Culture type, nucleic acid	Pathology	0.94	
87152	Culture type pulse field gel	Pathology	0.24	
87158	Culture typing, added method	Pathology	0.24	
87164	Dark field examination	Pathology	0.50	
87166	Dark field examination	Pathology	0.53	
87168	Macroscopic exam arthropod	Pathology	0.20	
87169	Macroscopic exam parasite	Pathology	0.20	
87172	Pinworm exam	Pathology	0.20	
87176	Tissue homogenization, cult	Pathology	0.27	
87177	Ova and parasites smears	Pathology	0.42	
87181	Microbe susceptible, diffuse	Pathology	0.22	
87184	Microbe susceptible, disk	Pathology	0.32	
87185	Microbe susceptible, enzyme	Pathology	0.22	
87186	Microbe susceptible, mic	Pathology	0.40	
87187	Microbe susceptible, mlc	Pathology	0.48	
87188	Microbe suscept, macrobroth	Pathology	0.31	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 14 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
87190	Microbe suscept, mycobacteri	Pathology	0.26	
87197	Bactericidal level, serum	Pathology	0.70	
87205	Smear, gram stain	Pathology	0.20	
87206	Smear, fluorescent/acid stai	Pathology	0.25	
87207	Smear, special stain	Pathology	0.28	
87210	Smear, wet mount, saline/ink	Pathology	0.20	
87220	Tissue exam for fungi	Pathology	0.20	
87230	Assay, toxin or antitoxin	Pathology	0.92	
87250	Virus inoculate, eggs/animal	Pathology	0.91	
87252	Virus inoculation, tissue	Pathology	1.22	
87253	Virus inoculate tissue, addl	Pathology	0.94	
87254	Virus inoculation, shell via	Pathology	0.91	
87255	Genet virus isolate, hsv	Pathology	1.58	
87260	Adenovirus ag, if	Pathology	0.56	
87265	Pertussis ag, if	Pathology	0.56	
87267	Enterovirus antibody, dfa	Pathology	0.56	
87269	Giardia ag, if	Pathology	0.56	
87270	Chlamydia trachomatis ag, if	Pathology	0.56	
87271	Cryptosporidium/gardia ag, if	Pathology	0.56	
87272	Cryptosporidium/gardia ag, if	Pathology	0.56	
87273	Herpes simplex 2, ag, if	Pathology	0.56	
87274	Herpes simplex 1, ag, if	Pathology	0.56	
87275	Influenza b, ag, if	Pathology	0.56	
87276	Influenza a, ag, if	Pathology	0.56	
87277	Legionella micdadei, ag, if	Pathology	0.56	
87278	Legion pneumophilia ag, if	Pathology	0.56	
87279	Parainfluenza, ag, if	Pathology	0.56	
87280	Respiratory syncytial ag, if	Pathology	0.56	
87281	Pneumocystis carinii, ag, if	Pathology	0.56	
87283	Rubeola, ag, if	Pathology	0.56	
87285	Treponema pallidum, ag, if	Pathology	0.56	
87290	Varicella zoster, ag, if	Pathology	0.56	
87299	Antibody detection, nos, if	Pathology	0.56	
87300	Ag detection, polyval, if	Pathology	0.56	
87301	Adenovirus ag, eia	Pathology	0.56	
87320	Chylmd trach ag, eia	Pathology	0.56	
87324	Clostridium ag, eia	Pathology	0.56	
87327	Cryptococcus neoform ag, eia	Pathology	0.56	
87328	Cryptospor ag, eia	Pathology	0.56	
87329	Giardia ag, eia	Pathology	0.56	
87332	Cytomegalovirus ag, eia	Pathology	0.56	
87335	E coli 0157 ag, eia	Pathology	0.56	
87336	Entamoeb hist dispr, ag, eia	Pathology	0.56	
87337	Entamoeb hist group, ag, eia	Pathology	0.56	
87338	Hpylori, stool, eia	Pathology	0.67	
87339	H pylori ag, eia	Pathology	0.56	
87340	Hepatitis b surface ag, eia	Pathology	0.48	
87341	Hepatitis b surface, ag, eia	Pathology	0.48	
87350	Hepatitis be ag, eia	Pathology	0.54	
87380	Hepatitis delta ag, eia	Pathology	0.77	
87385	Histoplasma capsul ag, eia	Pathology	0.56	
87390	Hiv-1 ag, eia	Pathology	0.82	
87391	Hiv-2 ag, eia	Pathology	0.82	
87400	Influenza a/b, ag, eia	Pathology	0.56	
87420	Resp syncytial ag, eia	Pathology	0.56	
87425	Rotavirus ag, eia	Pathology	0.56	
87427	Shiga-like toxin ag, eia	Pathology	0.56	
87430	Strep a ag, eia	Pathology	0.56	
87449	Ag detect nos, eia, mult	Pathology	0.56	
87450	Ag detect nos, eia, single	Pathology	0.45	
87451	Ag detect polyval, eia, mult	Pathology	0.45	
87470	Bartonella, dna, dir probe	Pathology	0.94	
87471	Bartonella, dna, amp probe	Pathology	1.64	
87472	Bartonella, dna, quant	Pathology	2.00	
87475	Lyme dis, dna, dir probe	Pathology	0.94	
87476	Lyme dis, dna, amp probe	Pathology	1.64	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 15 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
87477	Lyme dis, dna, quant	Pathology	2.00	
87480	Candida, dna, dir probe	Pathology	0.94	
87481	Candida, dna, amp probe	Pathology	1.64	
87482	Candida, dna, quant	Pathology	1.95	
87485	Chylmd pneum, dna, dir probe	Pathology	0.94	
87486	Chylmd pneum, dna, amp probe	Pathology	1.64	
87487	Chylmd pneum, dna, quant	Pathology	2.00	
87490	Chylmd trach, dna, dir probe	Pathology	0.94	
87491	Chylmd trach, dna, amp probe	Pathology	1.64	
87492	Chylmd trach, dna, quant	Pathology	1.63	
87495	Cytomeg, dna, dir probe	Pathology	0.94	
87496	Cytomeg, dna, amp probe	Pathology	1.64	
87497	Cytomeg, dna, quant	Pathology	2.00	
87510	Gardner vag, dna, dir probe	Pathology	0.94	
87511	Gardner vag, dna, amp probe	Pathology	1.64	
87512	Gardner vag, dna, quant	Pathology	1.95	
87515	Hepatitis b, dna, dir probe	Pathology	0.94	
87516	Hepatitis b, dna, amp probe	Pathology	1.64	
87517	Hepatitis b, dna, quant	Pathology	2.00	
87520	Hepatitis c, rna, dir probe	Pathology	0.94	
87521	Hepatitis c, rna, amp probe	Pathology	1.64	
87522	Hepatitis c, rna, quant	Pathology	2.00	
87525	Hepatitis g, dna, dir probe	Pathology	0.94	
87526	Hepatitis g, dna, amp probe	Pathology	1.64	
87527	Hepatitis g, dna, quant	Pathology	1.95	
87528	Hsv, dna, dir probe	Pathology	0.94	
87529	Hsv, dna, amp probe	Pathology	1.64	
87530	Hsv, dna, quant	Pathology	2.00	
87531	Hhv-6, dna, dir probe	Pathology	0.94	
87532	Hhv-6, dna, amp probe	Pathology	1.64	
87533	Hhv-6, dna, quant	Pathology	1.95	
87534	Hiv-1, dna, dir probe	Pathology	0.94	
87535	Hiv-1, dna, amp probe	Pathology	1.64	
87536	Hiv-1, dna, quant	Pathology	3.97	
87537	Hiv-2, dna, dir probe	Pathology	0.94	
87538	Hiv-2, dna, amp probe	Pathology	1.64	
87539	Hiv-2, dna, quant	Pathology	2.00	
87540	Legion pneumo, dna, dir prob	Pathology	0.94	
87541	Legion pneumo, dna, amp prob	Pathology	1.64	
87542	Legion pneumo, dna, quant	Pathology	1.95	
87550	Mycobacteria, dna, dir probe	Pathology	0.94	
87551	Mycobacteria, dna, amp probe	Pathology	1.64	
87552	Mycobacteria, dna, quant	Pathology	2.00	
87555	M.tuberculo, dna, dir probe	Pathology	0.94	
87556	M.tuberculo, dna, amp probe	Pathology	1.64	
87557	M.tuberculo, dna, quant	Pathology	2.00	
87560	M.avium-intra, dna, dir prob	Pathology	0.94	
87561	M.avium-intra, dna, amp prob	Pathology	1.64	
87562	M.avium-intra, dna, quant	Pathology	2.00	
87580	M.pneumon, dna, dir probe	Pathology	0.94	
87581	M.pneumon, dna, amp probe	Pathology	1.64	
87582	M.pneumon, dna, quant	Pathology	1.95	
87590	N.gonorrhoeae, dna, dir prob	Pathology	0.94	
87591	N.gonorrhoeae, dna, amp prob	Pathology	1.64	
87592	N.gonorrhoeae, dna, quant	Pathology	2.00	
87620	Hpv, dna, dir probe	Pathology	0.94	
87621	Hpv, dna, amp probe	Pathology	1.64	
87622	Hpv, dna, quant	Pathology	1.95	
87650	Strep a, dna, dir probe	Pathology	0.94	
87651	Strep a, dna, amp probe	Pathology	1.64	
87652	Strep a, dna, quant	Pathology	1.95	
87660	Trichomonas vagin, dir probe	Pathology	0.94	
87797	Detect agent nos, dna, dir	Pathology	0.94	
87798	Detect agent nos, dna, amp	Pathology	1.64	
87799	Detect agent nos, dna, quant	Pathology	2.00	
87800	Detect agnt mult, dna, direc	Pathology	1.87	

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 16 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
87801	Detect agnt mult, dna, ampli	Pathology	3.28	
87802	Strep b assay w/optic	Pathology	0.56	
87803	Clostridium toxin a w/optic	Pathology	0.56	
87804	Influenza assay w/optic	Pathology	0.56	
87810	Chylmd trach assay w/optic	Pathology	0.56	
87850	N. gonorrhoeae assay w/optic	Pathology	0.56	
87880	Strep a assay w/optic	Pathology	0.56	
87899	Agent nos assay w/optic	Pathology	0.56	
87901	Genotype, dna, hiv reverse t	Pathology	12.02	
87902	Genotype, dna, hepatitis C	Pathology	12.02	
87903	Phenotype, dna hiv w/culture	Pathology	22.81	
87904	Phenotype, dna hiv w/clt add	Pathology	1.22	
87999	Microbiology procedure	Pathology	0.40	Unlisted
88000	Autopsy (necropsy), gross	Pathology	8.10	MDR
88005	Autopsy (necropsy), gross	Pathology	9.00	MDR
88007	Autopsy (necropsy), gross	Pathology	9.90	MDR
88012	Autopsy (necropsy), gross	Pathology	7.46	MDR
88014	Autopsy (necropsy), gross	Pathology	7.46	MDR
88016	Autopsy (necropsy), gross	Pathology	9.07	MDR
88020	Autopsy (necropsy), complete	Pathology	11.64	MDR
88025	Autopsy (necropsy), complete	Pathology	12.54	MDR
88027	Autopsy (necropsy), complete	Pathology	13.44	MDR
88028	Autopsy (necropsy), complete	Pathology	7.46	MDR
88029	Autopsy (necropsy), complete	Pathology	7.46	MDR
88036	Limited autopsy	Pathology	4.82	MDR
88037	Limited autopsy	Pathology	3.54	MDR
88040	Forensic autopsy (necropsy)	Pathology	19.29	MDR
88045	Coroner's autopsy (necropsy)	Pathology	1.61	MDR
88099	Necropsy (autopsy) procedure	Pathology	12.54	Unlisted
88130	Sex chromatin identification	Pathology	0.70	
88140	Sex chromatin identification	Pathology	0.37	
88142	Cytopath, c/v, thin layer	Pathology	0.95	
88143	Cytopath c/v thin layer redo	Pathology	0.95	
88147	Cytopath, c/v, automated	Pathology	0.53	
88148	Cytopath, c/v, auto rescreen	Pathology	0.71	
88150	Cytopath, c/v, manual	Pathology	0.49	
88152	Cytopath, c/v, auto redo	Pathology	0.49	
88153	Cytopath, c/v, redo	Pathology	0.49	
88154	Cytopath, c/v, select	Pathology	0.49	
88155	Cytopath, c/v, index add-on	Pathology	0.28	
88164	Cytopath tbs, c/v, manual	Pathology	0.49	
88165	Cytopath tbs, c/v, redo	Pathology	0.49	
88166	Cytopath tbs, c/v, auto redo	Pathology	0.49	
88167	Cytopath tbs, c/v, select	Pathology	0.49	
88174	Cytopath, c/v auto, in fluid	Pathology	1.00	
88175	Cytopath c/v auto fluid redo	Pathology	1.24	
88230	Tissue culture, lymphocyte	Pathology	5.44	
88233	Tissue culture, skin/biopsy	Pathology	6.57	
88235	Tissue culture, placenta	Pathology	6.87	
88237	Tissue culture, bone marrow	Pathology	5.90	
88239	Tissue culture, tumor	Pathology	6.89	
88240	Cell cryopreserve/storage	Pathology	0.47	
88241	Frozen cell preparation	Pathology	0.47	
88245	Chromosome analysis, 20-25	Pathology	6.95	
88248	Chromosome analysis, 50-100	Pathology	8.08	
88249	Chromosome analysis, 100	Pathology	8.08	
88261	Chromosome analysis, 5	Pathology	8.25	
88262	Chromosome analysis, 15-20	Pathology	5.82	
88263	Chromosome analysis, 45	Pathology	7.01	
88264	Chromosome analysis, 20-25	Pathology	5.82	
88267	Chromosome analys, placenta	Pathology	8.39	
88269	Chromosome analys, amniotic	Pathology	7.76	
88271	Cytogenetics, dna probe	Pathology	1.00	
88272	Cytogenetics, 3-5	Pathology	1.25	
88273	Cytogenetics, 10-30	Pathology	1.50	
88274	Cytogenetics, 25-99	Pathology	1.62	

NOTE. CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for note regarding Charge Methodology.

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 17 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology	
88275	Cytogenetics, 100-300	Pathology	1.87	Unlisted	
88280	Chromosome karyotype study	Pathology	1.17		
88283	Chromosome banding study	Pathology	3.20		
88285	Chromosome count, additional	Pathology	0.89		
88289	Chromosome study, additional	Pathology	1.61		
88299	Cytogenetic study	Pathology	5.82		
88371	Protein, western blot tissue	Pathology	1.04		
88372	Protein analysis w/probe	Pathology	1.06		
88400	Bilirubin total transcut	Pathology	0.23		
89050	Body fluid cell count	Pathology	0.22		
89051	Body fluid cell count	Pathology	0.26		
89055	Leukocyte count, fecal	Pathology	0.20		
89060	Exam, synovial fluid crystals	Pathology	0.33		
89125	Specimen fat stain	Pathology	0.20		
89160	Exam feces for meat fibers	Pathology	0.17		
89190	Nasal smear for eosinophils	Pathology	0.22		
89225	Starch granules, feces	Pathology	0.16		
89235	Water load test	Pathology	0.26		
89240	Pathology lab procedure	Pathology	0.26		Unlisted MDR
89250	Cultr oocyte/embryo <4 days	Pathology	14.03		
89300	Semen analysis w/huhner	Pathology	0.42		
89310	Semen analysis w/count	Pathology	0.40		
89320	Semen analysis, complete	Pathology	0.56		
89321	Semen analysis & motility	Pathology	0.56		
89325	Sperm antibody test	Pathology	0.50		
89329	Sperm evaluation test	Pathology	0.98		
89330	Evaluation, cervical mucus	Pathology	0.46		
G0001	Drawing blood for specimen	Pathology	0.10		
G0027	Semen analysis	Pathology	0.30		
G0103	Psa, total screening	Pathology	0.86		
G0107	CA screen; fecal blood test	Pathology	0.15		
G0123	Screen cerv/vag thin layer	Pathology	0.95		
G0143	Scr c/v cyto, thinlayer, resc	Pathology	0.95		
G0144	Scr c/v cyto, thinlayer, resc	Pathology	1.00		
G0145	Scr c/v cyto, thinlayer, resc	Pathology	1.24		
G0147	Scr c/v cyto, automated sys	Pathology	0.53		
G0148	Scr c/v cyto, autosys, resc	Pathology	0.71		
G0265	Cryopresevation Freeze+stora	Pathology	0.47		
G0266	Thawing + expansion froz cel	Pathology	0.47		
G0306	CBC/diffwbc w/o platelet	Pathology	0.36		
G0307	CBC without platelet	Pathology	0.30		
G0328	Fecal blood scm immunoassay	Pathology	0.60		
P2038	Blood mucoprotein	Pathology	0.23		
P3000	Screen pap by tech w md supv	Pathology	0.49		
P9612	Catheterize for urine spec	Pathology	0.10		
P9615	Urine specimen collect mult	Pathology	0.10		
Q0111	Wet mounts/ w preparations	Pathology	0.20		
Q0112	Potassium hydroxide preps	Pathology	0.20		
Q0113	Pinworm examinations	Pathology	0.25		
Q0114	Fem test	Pathology	0.33		
Q0115	Post-coital mucous exam	Pathology	0.46		

Charge Methodology:

Misc: RVUs obtained using the methodology for unlisted procedures.

No entry: RVUs based on Medicare Clinical Diagnostic Laboratory Fee Schedule.

All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.0.

NOTE: CPT Codes and descriptions only are copyright 2003 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of table for note regarding Charge Methodology.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 1 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
A4206		1 CC sterile syringe&needle		\$0.66	Non-Drug
A4207		2 CC sterile syringe&needle		\$0.66	Non-Drug
A4208		3 CC sterile syringe&needle		\$0.66	Non-Drug
A4209		5+ CC sterile syringe&needle	a	\$0.66	Non-Drug
A4210		Nonneedle injection device		\$1,642.49	Non-Drug
A4211		Supp for self-adm injections		\$0.84	Non-Drug
A4212		Non coring needle or stylet		\$15.84	Non-Drug
A4213		20+ CC syringe only		\$1.99	Non-Drug
A4215		Sterile needle		\$0.37	Non-Drug
A4216		Sterile water/saline, 10 ml		\$1.99	Non-Drug
A4217		Sterile water/saline, 500 ml		\$20.41	Non-Drug
A4220		Infusion pump refill kit		\$29.87	Non-Drug
A4221		Maint drug infus cath per wk	a	\$35.18	Non-Drug
A4222		Drug infusion pump supplies	a	\$71.97	Non-Drug
A4230		Infus insulin pump non needl		\$17.92	Non-Drug
A4231		Infusion insulin pump needle		\$9.79	Non-Drug
A4232		Syringe w/needle insulin 3cc	a	\$6.29	Non-Drug
A4244		Alcohol or peroxide per pint		\$1.99	Non-Drug
A4245		Alcohol wipes per box		\$5.31	Non-Drug
A4246		Betadine/phisohex solution		\$5.97	Non-Drug
A4247		Betadine/iodine swabs/wipes		\$9.29	Non-Drug
A4250		Urine reagent strips/tablets		\$33.46	Non-Drug
A4253		Blood glucose/reagent strips	a	\$57.14	Non-Drug
A4254	NU	Battery for glucose monitor		\$13.02	Non-Drug
A4254	RR	Battery for glucose monitor		\$2.70	Non-Drug
A4254	UE	Battery for glucose monitor		\$10.75	Non-Drug
A4255		Glucose monitor platforms		\$9.61	Non-Drug
A4256		Calibrator solution/chips		\$19.72	Non-Drug
A4257		Replace Lensshield Cartridge		\$21.53	Non-Drug
A4258		Lancet device each		\$28.84	Non-Drug
A4259		Lancets per box	a	\$21.52	Non-Drug
A4260		Levonorgestrel implant		\$705.14	Non-Drug
A4261		Cervical cap contraceptive		\$45.20	Non-Drug
A4262		Temporary tear duct plug		\$0.66	Non-Drug
A4263		Permanent tear duct plug		\$75.89	Non-Drug
A4265		Paraffin		\$5.09	Non-Drug
A4267		Male condom		\$0.66	Non-Drug
A4269		Spermicide		\$1.99	Non-Drug
A4270		Disposable endoscope sheath		\$32.16	Non-Drug
A4280		Brst prsths adhsv atthmnt		\$8.01	Non-Drug
A4284		Replcmnt breast pump shield		\$34.11	Non-Drug
A4285		Replcmnt breast pump bottle		\$6.79	Non-Drug
A4290		Sacral nerve stim test lead		\$206.95	Non-Drug
A4300		Cath impl vasc access portal		\$16.09	Non-Drug
A4301		Implantable access syst perc		\$72.58	Non-Drug
A4305		Drug delivery system >=50 ML		\$24.98	Non-Drug
A4306		Drug delivery system <=5 ML		\$34.77	Non-Drug
A4310		Insert tray w/o bag/cath		\$11.59	Non-Drug
A4311		Catheter w/o bag 2-way latex		\$22.12	Non-Drug
A4312		Cath w/o bag 2-way silicone		\$26.85	Non-Drug
A4313		Catheter w/bag 3-way		\$27.56	Non-Drug
A4314		Cath w/drainage 2-way latex		\$37.57	Non-Drug
A4315		Cath w/drainage 2-way silcne		\$39.19	Non-Drug
A4316		Cath w/drainage 3-way		\$42.18	Non-Drug
A4320		Irrigation tray		\$8.01	Non-Drug
A4321		Cath therapeutic irrig agent		\$2.58	Non-Drug
A4322		Irrigation syringe		\$4.56	Non-Drug
A4324		Male ext cath w/adh coating		\$2.93	Non-Drug
A4325		Male ext cath w/adh strip		\$2.43	Non-Drug
A4326		Male external catheter		\$16.13	Non-Drug
A4327		Fem urinary collect dev cup		\$66.17	Non-Drug
A4328		Fem uninary collect pouch		\$15.63	Non-Drug
A4330		Stool collection pouch		\$10.75	Non-Drug
A4331		Extension drainage tubing		\$4.78	Non-Drug
A4332		Lubricant for cath insertion		\$0.17	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 2 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
A4333		Urinary cath anchor device		\$2.97	Non-Drug
A4334		Urinary cath leg strap		\$6.64	Non-Drug
A4335		Incontinence supply		\$1.70	Non-Drug
A4338		Indwelling catheter latex		\$18.31	Non-Drug
A4340		Indwelling catheter special		\$47.13	Non-Drug
A4344		Cath indw foley 2 way silicon		\$23.87	Non-Drug
A4346		Cath indw foley 3 way		\$29.14	Non-Drug
A4347		Male external catheter		\$30.27	Non-Drug
A4348		Male ext cath extended wear		\$41.32	Non-Drug
A4351		Straight tip urine catheter		\$2.72	Non-Drug
A4352		Coude tip urinary catheter		\$9.64	Non-Drug
A4353		Intermittent urinary cath		\$10.53	Non-Drug
A4354		Cath insertion tray w/bag		\$17.63	Non-Drug
A4355		Bladder irrigation tubing		\$13.35	Non-Drug
A4356		Ext ureth clamp or compr dvc		\$67.66	Non-Drug
A4357		Bedside drainage bag		\$14.51	Non-Drug
A4358		Urinary leg or abdomen bag		\$9.97	Non-Drug
A4359		Urinary suspensory w/o leg b		\$45.47	Non-Drug
A4361		Ostomy face plate		\$27.35	Non-Drug
A4362		Solid skin barrier		\$5.20	Non-Drug
A4364		Adhesive, liquid or equal		\$3.95	Non-Drug
A4365		Adhesive remover wipes		\$16.92	Non-Drug
A4366		Ostomy vent		\$50.83	Non-Drug
A4367		Ostomy belt		\$11.03	Non-Drug
A4368		Ostomy filter		\$0.39	Non-Drug
A4369		Skin barrier liquid per oz		\$3.63	Non-Drug
A4371		Skin barrier powder per oz		\$5.49	Non-Drug
A4372		Skin barrier solid 4x4 equiv		\$6.29	Non-Drug
A4373		Skin barrier with flange		\$9.44	Non-Drug
A4375		Drainable plastic pch w fcpl		\$25.58	Non-Drug
A4376		Drainable rubber pch w fcpl		\$70.54	Non-Drug
A4377		Drainable plastic pch w/o fp		\$6.45	Non-Drug
A4378		Drainable rubber pch w/o fp		\$45.65	Non-Drug
A4379		Urinary plastic pouch w fcpl		\$22.39	Non-Drug
A4380		Urinary rubber pouch w fcpl		\$55.37	Non-Drug
A4381		Urinary plastic pouch w/o fp		\$6.93	Non-Drug
A4382		Urinary heavy plastic pch w/o fp		\$36.59	Non-Drug
A4383		Urinary rubber pouch w/o fp		\$41.86	Non-Drug
A4384		Ostomy faceplate/silicone ring		\$14.40	Non-Drug
A4385		Ostomy skin barrier solid ext wear		\$7.67	Non-Drug
A4387		Ostomy closed pouch w alt st barr		\$4.48	Non-Drug
A4388		Drainable pouch w ex wear barr		\$6.55	Non-Drug
A4389		Drainable pouch w st wear barr		\$9.35	Non-Drug
A4390		Drainable pouch ex wear convex		\$14.38	Non-Drug
A4391		Urinary pouch w ex wear barr		\$10.63	Non-Drug
A4392		Urinary pouch w st wear barr		\$12.27	Non-Drug
A4393		Urine pouch w ex wear bar conv		\$13.54	Non-Drug
A4394		Ostomy pouch liquid deodorant		\$3.87	Non-Drug
A4395		Ostomy pouch solid deodorant		\$0.07	Non-Drug
A4396		Peristomal hernia support belt		\$60.04	Non-Drug
A4397		Irrigation supply sleeve		\$7.20	Non-Drug
A4398		Ostomy irrigation bag		\$20.60	Non-Drug
A4399		Ostomy irrigation cone/cath w brs		\$18.31	Non-Drug
A4400		Ostomy irrigation set		\$72.45	Non-Drug
A4402		Lubricant per ounce		\$2.40	Non-Drug
A4404		Ostomy ring each		\$2.54	Non-Drug
A4405		Nonpectin based ostomy paste		\$5.11	Non-Drug
A4406		Pectin based ostomy paste		\$8.63	Non-Drug
A4407		Ext wear ostomy skin barrier <=4sq"		\$13.12	Non-Drug
A4408		Ext wear ostomy skin barrier >4sq"		\$14.77	Non-Drug
A4409		Ostomy skin barrier w flange <=4 sq"		\$9.35	Non-Drug
A4410		Ostomy skin barrier w flange >4sq"		\$13.54	Non-Drug
A4413		2 pc drainable ostomy pouch		\$8.27	Non-Drug
A4414		Ostomy skin barrier w flange <=4sq"		\$7.40	Non-Drug
A4415		Ostomy skin barrier w flange >4sq"		\$9.02	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 3 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
A4416		Ost pch clsd w barrier/filtr		\$3.71	Non-Drug
A4417		Ost pch w bar/bltinconv/filtr		\$5.02	Non-Drug
A4418		Ost pch clsd w/o bar w filtr		\$2.44	Non-Drug
A4419		Ost pch for bar w flange/flt		\$2.35	Non-Drug
A4420		Ost pch clsd for bar w lk fl		\$2.35	Non-Drug
A4421		Ostomy supply misc		\$0.57	Non-Drug
A4422		Ost pouch absorbent material		\$0.17	Non-Drug
A4423		Ost pch for bar w lk fl/filtr		\$2.35	Non-Drug
A4424		Ost pch drain w bar & filter		\$6.40	Non-Drug
A4425		Ost pch drain for barrier fl		\$4.83	Non-Drug
A4426		Ost pch drain 2 piece system		\$3.18	Non-Drug
A4427		Ost pch drain/barr lk flng/fl		\$4.83	Non-Drug
A4428		Urine ost pouch w faucet/tap		\$8.78	Non-Drug
A4429		Urine ost pouch w bltinconv		\$11.11	Non-Drug
A4430		Ost urine pch w b/bltin conv		\$11.48	Non-Drug
A4431		Ost pch urine w barrier/tapv		\$8.38	Non-Drug
A4432		Os pch urine w bar/fange/tap		\$4.84	Non-Drug
A4433		Urine ost pch bar w lock fln		\$4.50	Non-Drug
A4434		Ost pch unne w lock flng/flt		\$5.07	Non-Drug
A4450		Non-waterproof tape		\$0.13	Non-Drug
A4452		Waterproof tape		\$0.54	Non-Drug
A4455		Adhesive remover per ounce		\$2.15	Non-Drug
A4462		Abdmnl drssng holder/binder		\$4.95	Non-Drug
A4465		Non-elastic extremity binder		\$17.80	Non-Drug
A4470		Gravlee jet washer		\$11.92	Non-Drug
A4480		Vabra aspirator		\$9.95	Non-Drug
A4481		Tracheostoma filter		\$1.55	Non-Drug
A4483		Moisture exchanger		\$12.43	Non-Drug
A4490		Above knee surgical stocking		\$13.23	Non-Drug
A4495		Thigh length surg stocking		\$13.23	Non-Drug
A4500		Below knee surgical stocking		\$9.95	Non-Drug
A4510		Full length surg stocking		\$23.67	Non-Drug
A4521		Adult size diaper sm each		\$1.09	Non-Drug
A4522		Adult size diaper med each		\$1.09	Non-Drug
A4523		Adult size diaper lg each		\$1.92	Non-Drug
A4524		Adult size diaper xl each		\$1.92	Non-Drug
A4525		Adult size brief sm each		\$1.32	Non-Drug
A4526		Adult size bnef med each		\$1.99	Non-Drug
A4527		Adult size brief lg each		\$2.65	Non-Drug
A4528		Adult size brief xl each		\$1.32	Non-Drug
A4529		Child size diaper sm/med ea		\$1.09	Non-Drug
A4530		Child size diaper lg each		\$1.09	Non-Drug
A4531		Child size brief sm/med each		\$1.32	Non-Drug
A4532		Child size brief lg each		\$1.99	Non-Drug
A4533		Youth size diaper each		\$1.09	Non-Drug
A4534		Youth size brief each		\$1.32	Non-Drug
A4535		Disp incont liner/shield ea		\$0.66	Non-Drug
A4550		Surgical trays	a	\$56.31	Non-Drug
A4554		Disposable underpads	a	\$5.97	Non-Drug
A4556		Electrodes, pair	a	\$20.68	Non-Drug
A4557		Lead wires, pair		\$33.05	Non-Drug
A4558		Conductive paste or gel		\$11.45	Non-Drug
A4561		Pessary rubber, any type		\$33.82	Non-Drug
A4562		Pessary, non rubber,any type		\$83.88	Non-Drug
A4565		Slings		\$13.88	Non-Drug
A4570		Splint		\$32.81	Non-Drug
A4575		Hyperbaric o2 chamber disps		\$707.47	Non-Drug
A4580		Cast supplies (plaster)		\$30.11	Non-Drug
A4590		Special casting material	a	\$73.93	Non-Drug
A4595		TENS suppl 2 lead per month		\$43.70	Non-Drug
A4608		Transtracheal oxygen cath		\$89.82	Non-Drug
A4609		Trach suction cath clsd sys		\$23.67	Non-Drug
A4610		Trach sctn cath 72h clsdsys		\$34.76	Non-Drug
A4611	NU	Heavy duty battery		\$333.32	Non-Drug
A4611	RR	Heavy duty battery		\$32.05	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 4 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
A4611	UE	Heavy duty battery		\$247.58	Non-Drug
A4612	NU	Battery cables		\$129.93	Non-Drug
A4612	RR	Battery cables		\$15.17	Non-Drug
A4612	UE	Battery cables		\$96.79	Non-Drug
A4613	NU	Battery charger		\$242.13	Non-Drug
A4613	RR	Battery charger		\$23.84	Non-Drug
A4613	UE	Battery charger		\$172.44	Non-Drug
A4614		Hand-held PEFR meter		\$35.34	Non-Drug
A4615		Cannula nasal		\$3.35	Non-Drug
A4616		Tubing (oxygen) per foot		\$1.44	Non-Drug
A4617		Mouth piece		\$22.48	Non-Drug
A4618	NU	Breathing circuits		\$13.32	Non-Drug
A4618	RR	Breathing circuits		\$1.53	Non-Drug
A4618	UF	Breathing circuits		\$10.03	Non-Drug
A4619		Face tent		\$2.35	Non-Drug
A4620		Variable concentration mask		\$7.18	Non-Drug
A4623		Tracheostomy inner cannula		\$9.85	Non-Drug
A4624		Tracheal suction tube	a	\$7.57	Non-Drug
A4625		Trach care kit for new trach		\$10.42	Non-Drug
A4626		Tracheostomy cleaning brush		\$4.80	Non-Drug
A4627		Spacer bag/reservoir		\$34.35	Non-Drug
A4628	NU	Oropharyngeal suction cath	a	\$5.62	Non-Drug
A4629		Tracheostomy care kit		\$6.96	Non-Drug
A4630		Repl bat t.e.n.s. own by pt		\$12.56	Non-Drug
A4633		Uvi replacement bulb		\$62.04	Non-Drug
A4635	NU	Underarm crutch pad		\$11.00	Non-Drug
A4635	RR	Underarm crutch pad		\$2.78	Non-Drug
A4635	UE	Underarm crutch pad		\$8.61	Non-Drug
A4636	NU	Handgrip for cane etc		\$9.75	Non-Drug
A4636	RR	Handgrip for cane etc		\$1.75	Non-Drug
A4636	UE	Handgrip for cane etc		\$8.17	Non-Drug
A4637	NU	Repl tip cane/crutch/walker		\$6.87	Non-Drug
A4637	RR	Repl tip cane/crutch/walker		\$1.23	Non-Drug
A4637	UE	Repl tip cane/crutch/walker		\$6.15	Non-Drug
A4639		Infrared ht sys replmnt pad		\$491.74	Non-Drug
A4640	NU	Alternating pressure pad		\$100.93	Non-Drug
A4640	RR	Alternating pressure pad		\$12.84	Non-Drug
A4640	UE	Alternating pressure pad		\$68.70	Non-Drug
A4641		Diagnostic imaging agent		\$57.40	Non-Drug
A4642		Satumomab pendetide per dose	a	\$12.03	Non-Drug
A4643		High dose contrast MRI		\$12.02	Non-Drug
A4647		Supp- paramagnetic contr mat		\$143.16	Non-Drug
A4649		Surgical supplies		\$2.43	Non-Drug
A4651		Calibrated microcap tube		\$2.99	Non-Drug
A4652		Microcapillary tube sealant		\$4.48	Non-Drug
A4656		Needle any size		\$7.47	Non-Drug
A4657		Syringe w/wo needle		\$0.71	Non-Drug
A4660		Sphyg/bp app w cuff and stet		\$44.20	Non-Drug
A4663		Dialysis blood pressure cuff		\$49.44	Non-Drug
A4670		Automatic bp monitor, dial		\$119.64	Non-Drug
A4680		Activated carbon filter, ea		\$169.81	Non-Drug
A4690		Dialyzer, each		\$1,216.04	Non-Drug
A4706		Bicarbonate conc sol per gal		\$18.67	Non-Drug
A4707		Bicarbonate conc pow per pac		\$6.16	Non-Drug
A4708		Acetate conc sol per gallon		\$14.32	Non-Drug
A4709		Acid conc sol per gallon		\$14.32	Non-Drug
A4714		Treated water per gallon		\$19.43	Non-Drug
A4719		"Y set" tubing		\$12.75	Non-Drug
A4720		Dialysat sol fld vol > 249cc		\$17.73	Non-Drug
A4721		Dialysat sol fld vol > 999cc		\$35.47	Non-Drug
A4722		Dialys sol fld vol > 1999cc		\$42.97	Non-Drug
A4723		Dialys sol fld vol > 2999cc		\$43.53	Non-Drug
A4724		Dialys sol fld vol > 3999cc		\$43.60	Non-Drug
A4725		Dialys sol fld vol > 4999cc		\$46.16	Non-Drug
A4726		Dialys sol fld vol > 5999cc		\$51.29	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 5 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
A4730		Fistula cannulation set, ea		\$2.56	Non-Drug
A4736		Topical anesthetic, per gram		\$8.99	Non-Drug
A4737		Inj anesthetic per 10 ml		\$12.92	Non-Drug
A4740		Shunt accessory		\$1.49	Non-Drug
A4750		Art or venous blood tubing		\$17.95	Non-Drug
A4755		Comb art/venous blood tubing		\$26.96	Non-Drug
A4760		Dialysate sol test kit, each		\$37.37	Non-Drug
A4765		Dialysate conc pow per pack		\$11.96	Non-Drug
A4766		Dialysate conc sol add 10 ml		\$5.98	Non-Drug
A4770		Blood collection tube/vacuum		\$26.41	Non-Drug
A4772		Blood glucose test strips		\$41.22	Non-Drug
A4773		Occult blood test strips		\$28.26	Non-Drug
A4774		Ammonia test strips		\$14.95	Non-Drug
A4802		Protamine sulfate per 50 mg		\$8.85	Non-Drug
A4860		Disposable catheter tips		\$6.14	Non-Drug
A4870		Plumb/elec wk hm hemo equip		\$156.95	Non-Drug
A4890		Repair/maint cont hemo equip		\$156.95	Non-Drug
A4911		Drain bag/bottle		\$17.59	Non-Drug
A4913		Misc dialysis supplies noc		\$13.93	Non-Drug
A4918		Venous pressure clamp		\$1.49	Non-Drug
A4927		Non-sterile gloves		\$6.76	Non-Drug
A4928		Surgical mask		\$0.42	Non-Drug
A4929		Tourniquet for dialysis, ea		\$0.26	Non-Drug
A4930		Sterile, gloves per pair		\$1.58	Non-Drug
A5051		Pouch clsd w barr attached		\$3.10	Non-Drug
A5052		Clsd ostomy pouch w/o barr		\$2.24	Non-Drug
A5053		Clsd ostomy pouch faceplate		\$2.62	Non-Drug
A5054		Clsd ostomy pouch w/flange		\$2.69	Non-Drug
A5055		Stoma cap		\$2.16	Non-Drug
A5061		Pouch drainable w barrier at		\$5.28	Non-Drug
A5062		Drmbile ostomy pouch w/o barr		\$3.34	Non-Drug
A5063		Drain ostomy pouch w/flange		\$3.35	Non-Drug
A5071		Urinary pouch w/barrier		\$9.04	Non-Drug
A5072		Urinary pouch w/o barrier		\$5.28	Non-Drug
A5073		Urinary pouch on barr w/flng		\$4.78	Non-Drug
A5081		Continent stoma plug		\$4.96	Non-Drug
A5082		Continent stoma catheter		\$17.76	Non-Drug
A5093		Ostomy accessory convex inse		\$2.93	Non-Drug
A5102		Bedside drain btl w/wo tube		\$33.56	Non-Drug
A5105		Urinary suspensory		\$60.46	Non-Drug
A5112		Urinary leg bag		\$51.38	Non-Drug
A5113		Latex leg strap		\$7.07	Non-Drug
A5114		Foam/fabric leg strap		\$13.40	Non-Drug
A5119		Skin barrier wipes box pr 50		\$16.22	Non-Drug
A5121		Solid skin barrier 6x6		\$11.21	Non-Drug
A5122		Solid skin barrier 8x8		\$19.18	Non-Drug
A5126		Disk/foam pad +or- adhesive		\$1.99	Non-Drug
A5131		Appliance cleaner		\$23.62	Non-Drug
A5200		Percutaneous catheter anchor		\$16.89	Non-Drug
A5500		Diab shoe for density insert		\$97.91	Non-Drug
A5501		Diabetic custom molded shoe		\$291.29	Non-Drug
A5503		Diabetic shoe w/roller/rockr		\$52.61	Non-Drug
A5504		Diabetic shoe with wedge		\$46.82	Non-Drug
A5505		Diab shoe w/metatarsal bar		\$57.75	Non-Drug
A5506		Diabetic shoe w/off set heel		\$47.10	Non-Drug
A5507		Modification diabetic shoe		\$93.33	Non-Drug
A5508		Diabetic deluxe shoe		\$46.86	Non-Drug
A5509		Direct heat form shoe insert		\$46.38	Non-Drug
A5510		Compression form shoe insert		\$46.19	Non-Drug
A5511		Custom fab molded shoe inser		\$47.48	Non-Drug
A6000		Wound warming wound cover		\$33.25	Non-Drug
A6010		Collagen based wound filler		\$45.96	Non-Drug
A6011		Collagen gel/paste wound fil		\$3.43	Non-Drug
A6021		Collagen dressing <=16 sq in		\$31.26	Non-Drug
A6022		Collagen drsg>6<=48 sq in		\$31.26	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 6 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
A6023		Collagen dressing >48 sq in		\$281.62	Non-Drug
A6024		Collagen dsg wound filler		\$9.30	Non-Drug
A6025		Silicone gel sheet, each		\$46.52	Non-Drug
A6154		Wound pouch each		\$21.44	Non-Drug
A6196		Alginate dressing <=16 sq in		\$11.03	Non-Drug
A6197		Alginate drsg >16 <=48 sq in		\$24.49	Non-Drug
A6198		alginate dressing > 48 sq in		\$30.61	Non-Drug
A6199		Alginate drsg wound filler		\$7.95	Non-Drug
A6200		Compos drsg <=16 no border		\$14.22	Non-Drug
A6201		Compos drsg >16<=48 no bdr		\$30.94	Non-Drug
A6202		Compos drsg >48 no border		\$51.75	Non-Drug
A6203		Composite drsg <= 16 sq in		\$5.03	Non-Drug
A6204		Composite drsg >16<=48 sq in		\$9.36	Non-Drug
A6205		Composite drsg > 48 sq in		\$11.70	Non-Drug
A6206		Contact layer <= 16 sq in		\$8.62	Non-Drug
A6207		Contact layer >16<= 48 sq in		\$11.02	Non-Drug
A6208		Contact layer > 48 sq in		\$13.78	Non-Drug
A6209		Foam drsg <=16 sq in w/o bdr		\$11.24	Non-Drug
A6210		Foam drg >16<=48 sq in w/o b		\$29.63	Non-Drug
A6211		Foam drg > 48 sq in w/o bdr		\$43.61	Non-Drug
A6212		Foam drg <=16 sq in w/border		\$14.51	Non-Drug
A6213		Foam drg >16<=48 sq in w/bdr		\$15.39	Non-Drug
A6214		Foam drg > 48 sq in w/border		\$15.39	Non-Drug
A6216		Non-sterile gauze<=16 sq in		\$0.07	Non-Drug
A6217		Non-sterile gauze>16<=48 sq		\$0.66	Non-Drug
A6218		Non-sterile gauze > 48 sq in		\$0.66	Non-Drug
A6219		Gauze <= 16 sq in w/border		\$1.43	Non-Drug
A6220		Gauze >16 <=48 sq in w/bdr		\$3.87	Non-Drug
A6221		Gauze > 48 sq in w/border		\$4.84	Non-Drug
A6222		Gauze <=16 in no w/sal w/o b		\$3.19	Non-Drug
A6223		Gauze >16<=48 no w/sal w/o b		\$3.63	Non-Drug
A6224		Gauze > 48 in no w/sal w/o b		\$5.43	Non-Drug
A6228		Gauze <= 16 sq in water/sal		\$3.98	Non-Drug
A6229		Gauze >16<=48 sq in watr/sal		\$5.43	Non-Drug
A6230		Gauze > 48 sq in water/saline		\$5.97	Non-Drug
A6231		Hydrogel dsg<=16 sq in		\$7.04	Non-Drug
A6232		Hydrogel dsg>16<=48 sq in		\$10.33	Non-Drug
A6233		Hydrogel dressing >48 sq in		\$28.55	Non-Drug
A6234		Hydrocollid drg <=16 w/o bdr		\$9.83	Non-Drug
A6235		Hydrocollid drg >16<=48 w/o b		\$25.04	Non-Drug
A6236		Hydrocollid drg > 48 in w/o b		\$40.47	Non-Drug
A6237		Hydrocollid drg <=16 in w/bdr		\$11.88	Non-Drug
A6238		Hydrocollid drg >16<=48 w/bdr		\$33.88	Non-Drug
A6239		Hydrocollid drg > 48 in w/bdr		\$42.35	Non-Drug
A6240		Hydrocollid drg filler paste		\$18.28	Non-Drug
A6241		Hydrocolloid drg filler dry		\$3.86	Non-Drug
A6242		Hydrogel drg <=16 in w/o bdr		\$9.13	Non-Drug
A6243		Hydrogel drg >16<=48 w/o bdr		\$18.38	Non-Drug
A6244		Hydrogel drg >48 in w/o bdr		\$58.26	Non-Drug
A6245		Hydrogel drg <= 16 in w/bdr		\$10.92	Non-Drug
A6246		Hydrogel drg >16<=48 in w/b		\$14.84	Non-Drug
A6247		Hydrogel drg > 48 sq in w/b		\$35.34	Non-Drug
A6248		Hydrogel drsg gel filler		\$24.19	Non-Drug
A6250		Skin seal protect moisturizr		\$2.29	Non-Drug
A6251		Absorpt drg <=16 sq in w/o b		\$2.99	Non-Drug
A6252		Absorpt drg >16 <=48 w/o bdr		\$4.89	Non-Drug
A6253		Absorpt drg > 48 sq in w/o b		\$9.52	Non-Drug
A6254		Absorpt drg <=16 sq in w/bdr		\$1.82	Non-Drug
A6255		Absorpt drg >16<=48 in w/bdr		\$4.55	Non-Drug
A6256		Absorpt drg > 48 sq in w/bdr		\$5.68	Non-Drug
A6257		Transparent film <= 16 sq in		\$2.29	Non-Drug
A6258		Transparent film >16<=48 in		\$6.46	Non-Drug
A6259		Transparent film > 48 sq in		\$16.35	Non-Drug
A6260		Wound cleanser any type/size		\$1.99	Non-Drug
A6261		Wound filler gel/paste /oz		\$7.96	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 7 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
A6262		Wound filler dry form / gram		\$1.99	Non-Drug
A6266		Impreg gauze no h20/sal/yard		\$2.88	Non-Drug
A6402		Sterile gauze <= 16 sq in		\$0.17	Non-Drug
A6403		Sterile gauze>16 <= 48 sq in		\$0.65	Non-Drug
A6404		Sterile gauze > 48 sq in		\$1.32	Non-Drug
A6410		Sterile eye pad		\$0.59	Non-Drug
A6411		Non-sterile eye pad		\$0.66	Non-Drug
A6412		Occlusive eye patch		\$0.66	Non-Drug
A6550		Neg pres wound ther drsg set		\$41.78	Non-Drug
A6551		Neg press wound ther canistr		\$37.79	Non-Drug
A7000		Disposable canister for pump	a	\$17.10	Non-Drug
A7001		Nondisposable pump canister		\$49.57	Non-Drug
A7002		Tubing used w suction pump	a	\$9.22	Non-Drug
A7003		Nebulizer administration set		\$7.72	Non-Drug
A7004		Disposable nebulizer sml vol		\$6.42	Non-Drug
A7005		Nondisposable nebulizer set		\$46.48	Non-Drug
A7006		Filtered nebulizer admin set		\$17.10	Non-Drug
A7007		Lg vol nebulizer disposable		\$10.30	Non-Drug
A7008		Disposable nebulizer prefill		\$19.11	Non-Drug
A7009		Nebulizer reservoir bottle		\$63.78	Non-Drug
A7010		Disposable corrugated tubing		\$36.49	Non-Drug
A7011		Nondispos corrugated tubing		\$55.95	Non-Drug
A7012		Nebulizer water collec devic		\$9.15	Non-Drug
A7013		Disposable compressor filter		\$3.38	Non-Drug
A7014		Compressor nondispos filter		\$10.13	Non-Drug
A7015		Aerosol mask used w nebulize	a	\$6.53	Non-Drug
A7016		Nebulizer dome & mouthpiece		\$13.94	Non-Drug
A7017	NU	Nebulizer not used w oxygen		\$224.37	Non-Drug
A7017	RR	Nebulizer not used w oxygen		\$22.42	Non-Drug
A7017	UE	Nebulizer not used w oxygen		\$165.86	Non-Drug
A7018		Water distilled w/nebulizer		\$1.55	Non-Drug
A7025	NU	Replace chest compress vest		\$749.60	Non-Drug
A7026	NU	Replace chst cmprss sys hose		\$43.60	Non-Drug
A7030		CPAP full face mask		\$319.68	Non-Drug
A7031		Replacement facemask interfa		\$112.20	Non-Drug
A7032	NU	Replacement nasal cushion		\$61.15	Non-Drug
A7033	NU	Replacement nasal pillows		\$43.14	Non-Drug
A7034	NU	Nasal application device		\$195.75	Non-Drug
A7035	NU	Pos airway press headgear		\$59.78	Non-Drug
A7036	NU	Pos airway press chinstrap		\$29.05	Non-Drug
A7037	NU	Pos airway pressure tubing		\$62.00	Non-Drug
A7038	NU	Pos airway pressure filter		\$11.37	Non-Drug
A7039	NU	Filter, non disposable w pap		\$25.09	Non-Drug
A7042		Implanted pleural catheter		\$302.01	Non-Drug
A7043		Vacuum drainagebottle/tubing		\$43.39	Non-Drug
A7044	NU	PAP oral interface		\$201.46	Non-Drug
A7501		Tracheostoma valve w diaphra		\$155.51	Non-Drug
A7502		Replacement diaphragm/fplate		\$73.99	Non-Drug
A7503		HMES filter holder or cap		\$16.93	Non-Drug
A7504		Tracheostoma HMES filter		\$1.00	Non-Drug
A7505		HMES or trach valve housing		\$7.04	Non-Drug
A7506		HMES/trachvalve adhesivedisk		\$0.50	Non-Drug
A7507		Integrated filter & holder		\$3.74	Non-Drug
A7508		Housing & Integrated Adhesiv		\$4.31	Non-Drug
A7509		Heat & moisture exchange sys		\$2.12	Non-Drug
A7525		Tracheostomy mask		\$2.78	Non-Drug
A9150		Misc/exper non-prescript dru		\$9.48	Drug
A9270		Non-covered item or service	a	\$41.71	Non-Drug
A9300		Exercise equipment	a	\$5.33	Non-Drug
A9500		Technetium TC 99m sestamibi	a	\$144.13	Non-Drug
A9502		Technetium TC99M tetrofosmin	a	\$161.56	Non-Drug
A9503		Technetium TC 99m medronate		\$37.47	Non-Drug
A9504		Technetium tc 99m apotide		\$66.90	Non-Drug
A9505		Thallous chlonde TL 201/mci	a	\$63.25	Non-Drug
A9507		Indium/111 capromab pendetid	a	\$2,715.23	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 8 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
A9508		Iobenguane sulfate I-131	a	\$30.96	Non-Drug
A9510		Technetium TC99m Disofenin		\$107.33	Non-Drug
A9600		Strontium-89 chloride	a	\$989.18	Non-Drug
A9605		Samarium sm153 lexidronamm	a	\$489.90	Non-Drug
A9700		Echocardiography Contrast		\$195.78	Non-Drug
A9900		Supply/accessory/service		\$21.48	Non-Drug
A9901		Delivery/set up/dispensing		\$17.80	Non-Drug
B4034		Enter feed supkit syr by day		\$9.01	Non-Drug
B4035		Enteral feed supp pump per d		\$17.48	Non-Drug
B4036		Enteral feed sup kit grav by		\$11.77	Non-Drug
B4081		Enteral ng tubing w/ stylet		\$34.99	Non-Drug
B4082		Enteral ng tubing w/o stylet		\$25.27	Non-Drug
B4083		Enteral stomach tube levine		\$3.63	Non-Drug
B4086		Gastrostomy/jejunostomy tube		\$59.75	Non-Drug
B4150		Enteral formulae category i		\$1.00	Non-Drug
B4151		Enteral formulae cat1 natural		\$2.32	Non-Drug
B4152		Enteral formulae category ii		\$0.85	Non-Drug
B4153		Enteral formulae category III		\$2.82	Non-Drug
B4154		Enteral formulae category IV		\$1.81	Non-Drug
B4155		Enteral formulae category v		\$1.42	Non-Drug
B4156		Enteral formulae category vi		\$2.01	Non-Drug
B4164		Parenteral 50% dextrose solu		\$25.96	Non-Drug
B4168		Parenteral sol amino acid 3.		\$39.18	Non-Drug
B4172		Parenteral sol amino acid 5.		\$58.94	Non-Drug
B4176		Parenteral sol amino acid 7-		\$78.70	Non-Drug
B4178		Parenteral sol amino acid >		\$95.09	Non-Drug
B4180		Parenteral sol carb > 50%		\$38.51	Non-Drug
B4184		Parenteral sol lipids 10%		\$133.21	Non-Drug
B4186		Parenteral sol lipids 20%		\$178.65	Non-Drug
B4189		Parenteral sol amino acid &		\$300.14	Non-Drug
B4193		Parenteral sol 52-73 gm prot		\$388.75	Non-Drug
B4197		Parenteral sol 74-100 gm pro		\$473.93	Non-Drug
B4199		Parenteral sol > 100gm prote		\$542.01	Non-Drug
B4216		Parenteral nutrition additiv		\$11.04	Non-Drug
B4220		Parenteral supply kit premix		\$11.43	Non-Drug
B4222		Parenteral supply kit homemi		\$14.09	Non-Drug
B4224		Parenteral administration ki		\$39.61	Non-Drug
B5000		Parenteral sol renal-amirosoy		\$17.22	Non-Drug
B5100		Parenteral sol hepatic-fream		\$6.65	Non-Drug
B5200		Parenteral sol stres-bmch c		\$533.49	Non-Drug
B9000	NU	Enter infusion pump w/o alm		\$2,154.62	Non-Drug
B9000	RR	Enter infusion pump w/o alm		\$195.22	Non-Drug
B9000	UE	Enter infusion pump w/o alm		\$1,615.21	Non-Drug
B9002	NU	Enteral infusion pump w/ ala		\$2,154.62	Non-Drug
B9002	RR	Enteral infusion pump w/ ala		\$205.93	Non-Drug
B9004	NU	Parenteral infus pump portab		\$4,300.91	Non-Drug
B9004	RR	Parenteral infus pump portab		\$678.31	Non-Drug
B9004	UE	Parenteral infus pump portab		\$3,224.91	Non-Drug
B9006	NU	Parenteral infus pump statio		\$4,300.91	Non-Drug
B9006	RR	Parenteral infus pump statio		\$678.31	Non-Drug
B9006	UE	Parenteral infus pump statio		\$3,224.91	Non-Drug
B9998		Enteral supp not otherwise c		\$8.84	Non-Drug
B9999		Parenteral supp not othrws c		\$264.01	Non-Drug
E0100	NU	Cane adjust/fixd with tip		\$33.01	Non-Drug
E0100	RR	Cane adjust/fixd with tip		\$12.13	Non-Drug
E0100	UE	Cane adjust/fixd with tip		\$27.11	Non-Drug
E0105	NU	Cane adjust/fixd quad/3 pro		\$76.12	Non-Drug
E0105	RR	Cane adjust/fixd quad/3 pro		\$16.17	Non-Drug
E0105	UE	Cane adjust/fixd quad/3 pro		\$56.50	Non-Drug
E0110	NU	Crutch forearm pair		\$125.84	Non-Drug
E0110	RR	Crutch forearm pair		\$26.01	Non-Drug
E0110	UE	Crutch forearm pair		\$91.96	Non-Drug
E0111	NU	Crutch forearm each		\$83.37	Non-Drug
E0111	RR	Crutch forearm each		\$15.57	Non-Drug
E0111	UE	Crutch forearm each		\$62.14	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 9 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0112	NU	Crutch underarm pair wood		\$54.99	Non-Drug
E0112	RR	Crutch underarm pair wood		\$17.64	Non-Drug
E0112	UE	Crutch underarm pair wood		\$42.88	Non-Drug
E0113	NU	Crutch underarm each wood		\$33.09	Non-Drug
E0113	RR	Crutch underarm each wood		\$11.05	Non-Drug
E0113	UE	Crutch underarm each wood		\$25.82	Non-Drug
E0114	NU	Crutch underarm pair no wood		\$72.77	Non-Drug
E0114	RR	Crutch underarm pair no wood		\$15.76	Non-Drug
E0114	UE	Crutch underarm pair no wood		\$53.16	Non-Drug
E0116	NU	Crutch underarm each no wood		\$42.21	Non-Drug
E0116	RR	Crutch underarm each no wood		\$11.38	Non-Drug
E0116	UE	Crutch underarm each no wood		\$32.75	Non-Drug
E0117	NU	Underarm springassist crutch		\$326.79	Non-Drug
E0117	RR	Underarm springassist crutch		\$30.51	Non-Drug
E0117	UE	Underarm springassist crutch		\$242.73	Non-Drug
E0130	NU	Walker rigid adjust/fixd ht		\$112.98	Non-Drug
E0130	RR	Walker rigid adjust/fixd ht		\$27.14	Non-Drug
E0130	UE	Walker rigid adjust/fixd ht		\$85.94	Non-Drug
E0135	NU	Walker folding adjust/fixd		\$136.75	Non-Drug
E0135	RR	Walker folding adjust/fixd		\$27.75	Non-Drug
E0135	UE	Walker folding adjust/fixd		\$102.67	Non-Drug
E0141	NU	Rigid wheeled walker adj/fix		\$191.64	Non-Drug
E0141	RR	Rigid wheeled walker adj/fix		\$34.79	Non-Drug
E0141	UE	Rigid wheeled walker adj/fix		\$141.35	Non-Drug
E0143	NU	Walker folding wheeled w/o s		\$200.26	Non-Drug
E0143	RR	Walker folding wheeled w/o s		\$33.72	Non-Drug
E0143	UE	Walker folding wheeled w/o s		\$147.47	Non-Drug
E0144	NU	Enclosed walker w rear seat		\$546.27	Non-Drug
E0144	RR	Enclosed walker w rear seat		\$47.90	Non-Drug
E0144	UE	Enclosed walker w rear seat		\$407.30	Non-Drug
E0147	NU	Walker variable wheel resist		\$993.75	Non-Drug
E0147	RR	Walker variable wheel resist		\$90.74	Non-Drug
E0147	UE	Walker variable wheel resist		\$742.95	Non-Drug
E0148	NU	Heavyduty walker no wheels		\$212.18	Non-Drug
E0148	RR	Heavyduty walker no wheels		\$21.49	Non-Drug
E0148	UE	Heavyduty walker no wheels		\$156.72	Non-Drug
E0149	NU	Heavy duty wheeled walker		\$380.01	Non-Drug
E0149	RR	Heavy duty wheeled walker		\$34.74	Non-Drug
E0149	UE	Heavy duty wheeled walker		\$282.60	Non-Drug
E0153	NU	Forearm crutch platform atta		\$111.51	Non-Drug
E0153	RR	Forearm crutch platform atta		\$14.75	Non-Drug
E0153	UE	Forearm crutch platform atta		\$81.22	Non-Drug
E0154	NU	Walker platform attachment		\$113.48	Non-Drug
E0154	RR	Walker platform attachment		\$15.75	Non-Drug
E0154	UE	Walker platform attachment		\$83.90	Non-Drug
E0155	NU	Walker wheel attachment,pair		\$47.48	Non-Drug
E0155	RR	Walker wheel attachment,pair		\$9.25	Non-Drug
E0155	UE	Walker wheel attachment,pair		\$37.13	Non-Drug
E0156	NU	Walker seat attachment		\$40.41	Non-Drug
E0156	RR	Walker seat attachment		\$8.60	Non-Drug
E0156	UE	Walker seat attachment		\$31.33	Non-Drug
E0157	NU	Walker crutch attachment		\$133.40	Non-Drug
E0157	RR	Walker crutch attachment		\$16.34	Non-Drug
E0157	UE	Walker crutch attachment		\$97.67	Non-Drug
E0158	NU	Walker leg extenders set of4		\$48.34	Non-Drug
E0158	RR	Walker leg extenders set of4		\$8.83	Non-Drug
E0158	UE	Walker leg extenders set of4		\$37.45	Non-Drug
E0159	NU	Brake for wheeled walker		\$28.60	Non-Drug
E0159	RR	Brake for wheeled walker		\$6.49	Non-Drug
E0159	UE	Brake for wheeled walker		\$22.42	Non-Drug
E0160	NU	Sitz type bath or equipment		\$49.55	Non-Drug
E0160	RR	Sitz type bath or equipment		\$9.91	Non-Drug
E0160	UE	Sitz type bath or equipment		\$38.11	Non-Drug
E0161	NU	Sitz bath/equipment w/faucet		\$40.13	Non-Drug
E0161	RR	Sitz bath/equipment w/faucet		\$8.86	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 10 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0161	UE	Sitz bath/equipment w/faucet		\$31.03	Non-Drug
E0162	NU	Sitz bath chair		\$244.73	Non-Drug
E0162	RR	Sitz bath chair		\$25.03	Non-Drug
E0162	UE	Sitz bath chair		\$187.64	Non-Drug
E0163	NU	Commode chair stationry fxd		\$182.92	Non-Drug
E0163	RR	Commode chair stationry fxd		\$37.64	Non-Drug
E0163	UE	Commode chair stationry fxd		\$138.87	Non-Drug
E0164	NU	Commode chair mobile fixed a		\$307.04	Non-Drug
E0164	RR	Commode chair mobile fixed a		\$40.41	Non-Drug
E0164	UE	Commode chair mobile fixed a		\$227.89	Non-Drug
E0165	NU	Commode chair stationry det		\$256.09	Non-Drug
E0165	RR	Commode chair stationry det		\$29.57	Non-Drug
E0165	UE	Commode chair stationry det		\$204.50	Non-Drug
E0166	NU	Commode chair mobile detach		\$391.28	Non-Drug
E0166	RR	Commode chair mobile detach		\$46.90	Non-Drug
E0166	UE	Commode chair mobile detach		\$312.19	Non-Drug
E0167	NU	Commode chair pail or pan		\$20.49	Non-Drug
E0167	RR	Commode chair pail or pan		\$5.13	Non-Drug
E0167	UE	Commode chair pail or pan		\$16.41	Non-Drug
E0168	NU	Heavyduty/wide commode chair		\$253.84	Non-Drug
E0168	RR	Heavyduty/wide commode chair		\$24.87	Non-Drug
E0168	UE	Heavyduty/wide commode chair		\$187.97	Non-Drug
E0169	NU	Seatlift incorp commodechair		\$508.42	Non-Drug
E0169	RR	Seatlift incorp commodechair		\$78.57	Non-Drug
E0169	UE	Seatlift incorp commodechair		\$380.51	Non-Drug
E0175	NU	Commode chair foot rest		\$106.01	Non-Drug
E0175	RR	Commode chair foot rest		\$13.07	Non-Drug
E0175	UE	Commode chair foot rest		\$75.47	Non-Drug
E0176	NU	Air pressre pad/cushion nonp		\$177.37	Non-Drug
E0176	RR	Air pressre pad/cushion nonp		\$23.46	Non-Drug
E0176	UE	Air pressre pad/cushion nonp		\$129.38	Non-Drug
E0177	NU	Water press pad/cushion nonp		\$175.68	Non-Drug
E0177	RR	Water press pad/cushion nonp		\$20.71	Non-Drug
E0177	UE	Water press pad/cushion nonp		\$129.38	Non-Drug
E0178	NU	Gel pressre pad/cushion nonp		\$202.21	Non-Drug
E0178	RR	Gel pressre pad/cushion nonp		\$24.65	Non-Drug
E0178	UE	Gel pressre pad/cushion nonp		\$149.25	Non-Drug
E0179	NU	Dry pressre pad/cushion nonp		\$20.44	Non-Drug
E0179	RR	Dry pressre pad/cushion nonp		\$5.05	Non-Drug
E0179	UE	Dry pressre pad/cushion nonp		\$16.92	Non-Drug
E0180		Press pad alternating w pump		\$307.88	Non-Drug
E0180	RR	Press pad alternating w pump		\$33.92	Non-Drug
E0181		Press pad alternating w/ pum		\$404.36	Non-Drug
E0181	RR	Press pad alternating w/ pum		\$37.17	Non-Drug
E0182		Pressure pad alternating pum		\$416.49	Non-Drug
E0182	RR	Pressure pad alternating pum		\$40.06	Non-Drug
E0184	NU	Dry pressure mattress		\$330.26	Non-Drug
E0184	RR	Dry pressure mattress		\$37.84	Non-Drug
E0184	UE	Dry pressure mattress		\$251.05	Non-Drug
E0185	NU	Gel pressure mattress pad		\$548.74	Non-Drug
E0185	RR	Gel pressure mattress pad		\$68.84	Non-Drug
E0185	UE	Gel pressure mattress pad		\$418.91	Non-Drug
E0186		Air pressure mattress		\$374.54	Non-Drug
E0186	RR	Air pressure mattress		\$31.95	Non-Drug
E0187	NU	Water pressure mattress		\$361.15	Non-Drug
E0187	RR	Water pressure mattress		\$35.97	Non-Drug
E0187	UE	Water pressure mattress		\$307.20	Non-Drug
E0188	NU	Synthetic sheepskin pad		\$39.27	Non-Drug
E0188	RR	Synthetic sheepskin pad		\$4.67	Non-Drug
E0188	UE	Synthetic sheepskin pad		\$29.53	Non-Drug
E0189	NU	Lambswool sheepskin pad		\$77.01	Non-Drug
E0189	RR	Lambswool sheepskin pad		\$8.46	Non-Drug
E0189	UE	Lambswool sheepskin pad		\$57.82	Non-Drug
E0191	NU	Protector heel or elbow		\$17.72	Non-Drug
E0191	RR	Protector heel or elbow		\$4.14	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 11 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
E0191	UE	Protector heel or elbow		\$14.23	Non-Drug
E0192	NU	Pad wheelchr low press/posit		\$513.69	Non-Drug
E0192	RR	Pad wheelchr low press/posit		\$52.83	Non-Drug
E0192	UE	Pad wheelchr low press/posit		\$385.41	Non-Drug
E0193	RR	Powered air flotation bed		\$1,270.03	Non-Drug
E0194		Air fluidized bed		\$44,065.97	Non-Drug
E0194	RR	Air fluidized bed		\$4,543.71	Non-Drug
E0194	UE	Air fluidized bed		\$33,058.77	Non-Drug
E0196		Gel pressure mattress		\$516.08	Non-Drug
E0196	RR	Gel pressure mattress		\$51.39	Non-Drug
E0196	UE	Gel pressure mattress		\$386.88	Non-Drug
E0197	NU	Air pressure pad for mattres		\$377.17	Non-Drug
E0197	RR	Air pressure pad for mattres		\$46.11	Non-Drug
E0197	UE	Air pressure pad for mattres		\$330.16	Non-Drug
E0198	NU	Water pressure pad for mattr		\$377.17	Non-Drug
E0198	RR	Water pressure pad for mattr		\$35.60	Non-Drug
E0198	UE	Water pressure pad for mattr		\$283.90	Non-Drug
E0199	NU	Dry pressure pad for mattres		\$48.15	Non-Drug
E0199	RR	Dry pressure pad for mattres		\$8.34	Non-Drug
E0199	UE	Dry pressure pad for mattres		\$37.10	Non-Drug
E0200	NU	Heat lamp without stand		\$128.78	Non-Drug
E0200	RR	Heat lamp without stand		\$18.79	Non-Drug
E0200	UE	Heat lamp without stand		\$94.25	Non-Drug
E0202	RR	Phototherapy light w/ photom		\$99.68	Non-Drug
E0205	NU	Heat lamp with stand		\$329.15	Non-Drug
E0205	RR	Heat lamp with stand		\$33.38	Non-Drug
E0205	UE	Heat lamp with stand		\$244.45	Non-Drug
E0210	NU	Electric heat pad standard		\$48.98	Non-Drug
E0210	RR	Electric heat pad standard		\$8.17	Non-Drug
E0210	UE	Electric heat pad standard		\$37.71	Non-Drug
E0215	NU	Electric heat pad moist		\$114.06	Non-Drug
E0215	RR	Electric heat pad moist		\$14.17	Non-Drug
E0215	UE	Electric heat pad moist		\$83.17	Non-Drug
E0217	NU	Water circ heat pad w pump		\$857.02	Non-Drug
E0217	RR	Water circ heat pad w pump		\$86.89	Non-Drug
E0217	UE	Water circ heat pad w pump		\$640.30	Non-Drug
E0218	NU	Water circ cold pad w pump		\$628.88	Non-Drug
E0220	NU	Hot water bottle		\$15.63	Non-Drug
E0220	RR	Hot water bottle		\$3.62	Non-Drug
E0220	UE	Hot water bottle		\$12.67	Non-Drug
E0221	NU	Infrared heating pad system		\$3,679.52	Non-Drug
E0221	RR	Infrared heating pad system		\$359.31	Non-Drug
E0221	UE	Infrared heating pad system		\$2,757.26	Non-Drug
E0225	NU	Hydrocollator unit		\$668.80	Non-Drug
E0225	RR	Hydrocollator unit		\$57.27	Non-Drug
E0225	UE	Hydrocollator unit		\$499.19	Non-Drug
E0230	NU	Ice cap or collar		\$15.64	Non-Drug
E0230	RR	Ice cap or collar		\$3.86	Non-Drug
E0230	UE	Ice cap or collar		\$12.68	Non-Drug
E0231		Wound warming device		\$152.64	Non-Drug
E0231	RR	Wound warming device		\$15.74	Non-Drug
E0235		Paraffin bath unit portable		\$279.12	Non-Drug
E0235	RR	Paraffin bath unit portable		\$27.75	Non-Drug
E0235	UE	Paraffin bath unit portable		\$209.48	Non-Drug
E0236		Pump for water circulating p		\$349.58	Non-Drug
E0236	RR	Pump for water circulating p		\$67.64	Non-Drug
E0236	UE	Pump for water circulating p		\$279.87	Non-Drug
E0238	NU	Heat pad non-electric moist		\$41.24	Non-Drug
E0238	RR	Heat pad non-electric moist		\$7.69	Non-Drug
E0238	UE	Heat pad non-electric moist		\$31.37	Non-Drug
E0239	NU	Hydrocollator unit portable		\$775.60	Non-Drug
E0239	RR	Hydrocollator unit portable		\$68.93	Non-Drug
E0239	UE	Hydrocollator unit portable		\$579.34	Non-Drug
E0241		Bath tub wall rail		\$39.32	Non-Drug
E0242		Bath tub rail floor		\$90.93	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 12 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/Usage Indicator	Charge	GAAP Category
E0243		Toilet rail		\$70.51	Non-Drug
E0244		Toilet seat raised		\$51.74	Non-Drug
E0245		Tub stool or bench		\$90.14	Non-Drug
E0246		Transfer tub rail attachment		\$127.05	Non-Drug
E0247	NU	Trans bench w/wo comm open		\$88.57	Non-Drug
E0249	NU	Pad water circulating heat u		\$164.26	Non-Drug
E0249	RR	Pad water circulating heat u		\$19.05	Non-Drug
E0249	UE	Pad water circulating heat u		\$120.80	Non-Drug
E0250		Hosp bed fixed ht w/ mattresses		\$1,973.26	Non-Drug
E0250	RR	Hosp bed fixed ht w/ mattresses		\$148.06	Non-Drug
E0250	UE	Hosp bed fixed ht w/ mattresses		\$1,277.98	Non-Drug
E0251		Hosp bed fixed ht w/o mattresses		\$1,143.36	Non-Drug
E0251	RR	Hosp bed fixed ht w/o mattresses		\$113.98	Non-Drug
E0251	UE	Hosp bed fixed ht w/o mattresses		\$914.69	Non-Drug
E0255		Hospital bed var ht w/ matr		\$2,010.94	Non-Drug
E0255	RR	Hospital bed var ht w/ matr		\$175.53	Non-Drug
E0255	UE	Hospital bed var ht w/ matr		\$1,505.70	Non-Drug
E0256		Hospital bed var ht w/o matt		\$1,277.82	Non-Drug
E0256	RR	Hospital bed var ht w/o matt		\$127.92	Non-Drug
E0256	UE	Hospital bed var ht w/o matt		\$1,021.97	Non-Drug
E0260		Hosp bed semi-electr w/ matt		\$1,994.94	Non-Drug
E0260	RR	Hosp bed semi-electr w/ matt		\$245.79	Non-Drug
E0260	UE	Hosp bed semi-electr w/ matt		\$1,540.94	Non-Drug
E0261		Hosp bed semi-electr w/o mat		\$1,946.88	Non-Drug
E0261	RR	Hosp bed semi-electr w/o mat		\$202.63	Non-Drug
E0261	UE	Hosp bed semi-electr w/o mat		\$1,297.92	Non-Drug
E0265		Hosp bed total electr w/ mat		\$2,412.27	Non-Drug
E0265	RR	Hosp bed total electr w/ mat		\$290.28	Non-Drug
E0265	UE	Hosp bed total electr w/ mat		\$1,561.53	Non-Drug
E0266		Hosp bed total elec w/o matt		\$2,589.65	Non-Drug
E0266	RR	Hosp bed total elec w/o matt		\$259.23	Non-Drug
E0266	UE	Hosp bed total elec w/o matt		\$1,780.38	Non-Drug
E0270		Hospital bed institutional t		\$534.86	Non-Drug
E0270	RR	Hospital bed institutional t		\$55.15	Non-Drug
E0270	UE	Hospital bed institutional t		\$401.26	Non-Drug
E0271	NU	Mattress innerspring		\$321.13	Non-Drug
E0271	RR	Mattress innerspring		\$37.20	Non-Drug
E0271	UE	Mattress innerspring		\$253.48	Non-Drug
E0272	NU	Mattress foam rubber		\$293.74	Non-Drug
E0272	RR	Mattress foam rubber		\$34.30	Non-Drug
E0272	UE	Mattress foam rubber		\$222.27	Non-Drug
E0273		Bed board		\$42.16	Non-Drug
E0273	RR	Bed board		\$18.11	Non-Drug
E0273	UE	Bed board		\$33.71	Non-Drug
E0274		Over-bed table		\$66.85	Non-Drug
E0274	RR	Over-bed table		\$30.46	Non-Drug
E0274	UE	Over-bed table		\$54.50	Non-Drug
E0275	NU	Bed pan standard		\$25.06	Non-Drug
E0275	RR	Bed pan standard		\$6.14	Non-Drug
E0275	UE	Bed pan standard		\$19.78	Non-Drug
E0276	NU	Bed pan fracture		\$22.29	Non-Drug
E0276	RR	Bed pan fracture		\$6.10	Non-Drug
E0276	UE	Bed pan fracture		\$18.45	Non-Drug
E0277		Powered pres-redu air matr		\$10,371.02	Non-Drug
E0277	RR	Powered pres-redu air matr		\$1,069.37	Non-Drug
E0277	UE	Powered pres-redu air matr		\$7,780.45	Non-Drug
E0280	NU	Bed cradle		\$59.99	Non-Drug
E0280	RR	Bed cradle		\$8.70	Non-Drug
E0280	UE	Bed cradle		\$45.62	Non-Drug
E0290		Hosp bed fx ht w/o rails w/m		\$1,182.64	Non-Drug
E0290	RR	Hosp bed fx ht w/o rails w/m		\$114.97	Non-Drug
E0290	UE	Hosp bed fx ht w/o rails w/m		\$946.39	Non-Drug
E0291		Hosp bed fx ht w/o rail w/o		\$838.65	Non-Drug
E0291	RR	Hosp bed fx ht w/o rail w/o		\$84.21	Non-Drug
E0291	UE	Hosp bed fx ht w/o rail w/o		\$620.81	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 13 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
E0292		Hosp bed var ht w/o rail w/o		\$1,290.96	Non-Drug
E0292	RR	Hosp bed var ht w/o rail w/o		\$128.95	Non-Drug
E0292	UE	Hosp bed var ht w/o rail w/o		\$1,032.34	Non-Drug
E0293		Hosp bed var ht w/o rail w/		\$1,098.96	Non-Drug
E0293	RR	Hosp bed var ht w/o rail w/		\$110.11	Non-Drug
E0293	UE	Hosp bed var ht w/o rail w/		\$603.00	Non-Drug
E0294		Hosp bed semi-elect w/ mattr		\$1,881.60	Non-Drug
E0294	RR	Hosp bed semi-elect w/ mattr		\$193.86	Non-Drug
E0294	UE	Hosp bed semi-elect w/ mattr		\$1,293.31	Non-Drug
E0295		Hosp bed semi-elect w/o matt		\$1,732.72	Non-Drug
E0295	RR	Hosp bed semi-elect w/o matt		\$189.27	Non-Drug
E0295	UE	Hosp bed semi-elect w/o matt		\$1,124.27	Non-Drug
E0296		Hosp bed total elect w/ matt		\$2,403.87	Non-Drug
E0296	RR	Hosp bed total elect w/ matt		\$240.59	Non-Drug
E0296	UE	Hosp bed total elect w/ matt		\$1,922.69	Non-Drug
E0297		Hosp bed total elect w/o mat		\$2,078.83	Non-Drug
E0297	RR	Hosp bed total elect w/o mat		\$207.81	Non-Drug
E0297	UE	Hosp bed total elect w/o mat		\$1,391.54	Non-Drug
E0301		HD hosp bed, 350-600 lbs		\$3,128.83	Non-Drug
E0301	RR	HD hosp bed, 350-600 lbs		\$323.50	Non-Drug
E0303	RR	Hosp bed hvy dty xtra wide		\$435.23	Non-Drug
E0304	RR	Hosp bed xtra hvy dty x wide		\$1,085.11	Non-Drug
E0305		Rails bed side half length		\$289.74	Non-Drug
E0305	RR	Rails bed side half length		\$29.27	Non-Drug
E0305	UE	Rails bed side half length		\$207.92	Non-Drug
E0310	NU	Rails bed side full length		\$282.28	Non-Drug
E0310	RR	Rails bed side full length		\$36.76	Non-Drug
E0310	UE	Rails bed side full length		\$216.52	Non-Drug
E0315		Bed accessory brd/tbl/supprt		\$50.98	Non-Drug
E0316	RR	Bed safety enclosure		\$306.15	Non-Drug
E0325	NU	Urinal male jug-type		\$17.88	Non-Drug
E0325	RR	Urinal male jug-type		\$6.02	Non-Drug
E0325	UE	Urinal male jug-type		\$13.17	Non-Drug
E0326	NU	Urinal female jug-type		\$18.42	Non-Drug
E0326	RR	Urinal female jug-type		\$4.81	Non-Drug
E0326	UE	Urinal female jug-type		\$14.80	Non-Drug
E0352		Disposable pack w/bowel syst		\$61.18	Non-Drug
E0370		Air elevator for heel		\$21.28	Non-Drug
E0371	RR	Nonpower mattress overlay		\$766.25	Non-Drug
E0372	RR	Powered air mattress overlay		\$931.85	Non-Drug
E0373	RR	Nonpowered pressure mattress		\$1,062.98	Non-Drug
E0424	RR	Stationary compressed gas O2		\$507.73	Non-Drug
E0425	NU	Gas system stationary compre		\$6,925.21	Non-Drug
E0430	NU	Oxygen system gas portabl		\$3,137.80	Non-Drug
E0430	RR	Oxygen system gas portabl		\$323.54	Non-Drug
E0430	UE	Oxygen system gas portabl		\$2,354.85	Non-Drug
E0431	RR	Portable gaseous O2		\$83.36	Non-Drug
E0434	RR	Portable liquid O2		\$83.36	Non-Drug
E0435	NU	Oxygen system liquid portabl		\$2,158.89	Non-Drug
E0435	UE	Oxygen system liquid portabl		\$1,619.76	Non-Drug
E0439	RR	Stationary liquid O2		\$507.73	Non-Drug
E0440	NU	Oxygen system liquid station		\$4,378.59	Non-Drug
E0440	UE	Oxygen system liquid station		\$3,285.00	Non-Drug
E0441		Oxygen contents, gaseous		\$362.88	Non-Drug
E0442		Oxygen contents, liquid		\$362.88	Non-Drug
E0443		Portable O2 contents, gas		\$49.43	Non-Drug
E0444		Portable O2 contents, liquid		\$49.43	Non-Drug
E0445		Oximeter non-invasive		\$119.38	Non-Drug
E0450	NU	Volume vent stationary/porta		\$16,065.56	Non-Drug
E0450	RR	Volume vent stationary/porta		\$1,656.54	Non-Drug
E0450	UE	Volume vent stationary/porta		\$12,052.56	Non-Drug
E0454	RR	Pressure ventilator		\$2,434.39	Non-Drug
E0457	NU	Chest shell		\$1,063.04	Non-Drug
E0457	RR	Chest shell		\$97.67	Non-Drug
E0457	UE	Chest shell		\$794.84	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 14 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
E0459	NU	Chest wrap		\$789.90	Non-Drug
E0459	RR	Chest wrap		\$79.24	Non-Drug
E0459	UE	Chest wrap		\$592.73	Non-Drug
E0460	NU	Neg press vent portabl/statn		\$12,325.18	Non-Drug
E0460	RR	Neg press vent portabl/statn		\$1,270.87	Non-Drug
E0460	UE	Neg press vent portabl/statn		\$9,246.48	Non-Drug
E0461	RR	Vol vent noninvasive interfa		\$1,739.51	Non-Drug
E0462	NU	Rocking bed w/ or w/o side r		\$4,175.48	Non-Drug
E0462	RR	Rocking bed w/ or w/o side r		\$417.72	Non-Drug
E0462	UE	Rocking bed w/ or w/o side r		\$3,132.03	Non-Drug
E0470	RR	RAD w/o backup non-inv intrfc		\$438.31	Non-Drug
E0471	RR	RAD w/backup non inv intrfc		\$1,111.34	Non-Drug
E0472	RR	RAD w backup invasive intrfc		\$1,111.34	Non-Drug
E0480	NU	Percussor elect/pneum home m		\$648.61	Non-Drug
E0480	RR	Percussor elect/pneum home m		\$67.10	Non-Drug
E0480	UE	Percussor elect/pneum home m		\$569.08	Non-Drug
E0481		Intrpulumnry percuss vent sys		\$1,063.99	Non-Drug
E0482	RR	Cough stimulating device		\$741.02	Non-Drug
E0483	RR	Chest compression gen system		\$1,846.14	Non-Drug
E0484	NU	Non-elec oscillatory pep dvc		\$54.88	Non-Drug
E0484	RR	Non-elec oscillatory pep dvc		\$9.03	Non-Drug
E0484	UE	Non-elec oscillatory pep dvc		\$42.15	Non-Drug
E0500	NU	Ippb all types		\$2,002.21	Non-Drug
E0500	RR	Ippb all types		\$182.02	Non-Drug
E0500	UE	Ippb all types		\$1,319.45	Non-Drug
E0550	NU	Humidif extens suppl w ippb		\$473.73	Non-Drug
E0550	RR	Humidif extens suppl w ippb		\$77.90	Non-Drug
E0550	UE	Humidif extens suppl w ippb		\$378.98	Non-Drug
E0555	NU	Humidifier for use w/ regula		\$15.78	Non-Drug
E0555	RR	Humidifier for use w/ regula		\$11.00	Non-Drug
E0555	UE	Humidifier for use w/ regula		\$12.91	Non-Drug
E0560	NU	Humidifier supplemental w/ i		\$289.79	Non-Drug
E0560	RR	Humidifier supplemental w/ i		\$31.67	Non-Drug
E0560	UE	Humidifier supplemental w/ i		\$214.95	Non-Drug
E0561	NU	Humidifier nonheated w PAP		\$177.18	Non-Drug
E0561	RR	Humidifier nonheated w PAP		\$18.68	Non-Drug
E0561	UE	Humidifier nonheated w PAP		\$130.47	Non-Drug
E0562	NU	Humidifier heated used w PAP		\$516.20	Non-Drug
E0562	RR	Humidifier heated used w PAP		\$45.48	Non-Drug
E0562	UE	Humidifier heated used w PAP		\$384.73	Non-Drug
E0565	NU	Compressor air power source		\$969.71	Non-Drug
E0565	RR	Compressor air power source		\$96.90	Non-Drug
E0565	UE	Compressor air power source		\$682.75	Non-Drug
E0570	NU	Nebulizer with compression		\$285.46	Non-Drug
E0570	RR	Nebulizer with compression		\$31.15	Non-Drug
E0570	UE	Nebulizer with compression		\$114.47	Non-Drug
E0571	RR	Aerosol compressor for svneb		\$45.29	Non-Drug
E0572	RR	Aerosol compressor adjust pr		\$89.79	Non-Drug
E0574	RR	Ultrasonic generator w svneb		\$94.67	Non-Drug
E0575	NU	Nebulizer ultrasonic		\$1,691.59	Non-Drug
E0575	RR	Nebulizer ultrasonic		\$169.81	Non-Drug
E0575	UE	Nebulizer ultrasonic		\$1,102.15	Non-Drug
E0580	NU	Nebulizer for use w/ regulat		\$224.37	Non-Drug
E0580	RR	Nebulizer for use w/ regulat		\$22.42	Non-Drug
E0580	UE	Nebulizer for use w/ regulat		\$165.86	Non-Drug
E0585	NU	Nebulizer w/ compressor & he		\$521.21	Non-Drug
E0585	RR	Nebulizer w/ compressor & he		\$52.33	Non-Drug
E0585	UE	Nebulizer w/ compressor & he		\$336.31	Non-Drug
E0590		Dispensing fee drme neb drug		\$7.83	Non-Drug
E0600	NU	Suction pump portab hom modl		\$637.83	Non-Drug
E0600	RR	Suction pump portab hom modl		\$70.33	Non-Drug
E0600	UE	Suction pump portab hom modl		\$382.28	Non-Drug
E0601	NU	Cont airway pressure device		\$1,708.46	Non-Drug
E0601	RR	Cont airway pressure device		\$185.40	Non-Drug
E0601	UE	Cont airway pressure device		\$1,022.99	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 15 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0602	NU	Manual breast pump		\$44.67	Non-Drug
E0602	RR	Manual breast pump		\$8.02	Non-Drug
E0602	UE	Manual breast pump		\$34.48	Non-Drug
E0603	NU	Electric breast pump		\$132.55	Non-Drug
E0603	RR	Electric breast pump		\$41.18	Non-Drug
E0603	UE	Electric breast pump		\$104.28	Non-Drug
E0604	NU	Hosp grade elec breast pump		\$399.56	Non-Drug
E0604	RR	Hosp grade elec breast pump		\$147.47	Non-Drug
E0604	UE	Hosp grade elec breast pump		\$296.68	Non-Drug
E0605	NU	Vaporizer room type		\$40.41	Non-Drug
E0605	RR	Vaporizer room type		\$8.17	Non-Drug
E0605	UE	Vaporizer room type		\$33.98	Non-Drug
E0606	NU	Drainage board postural		\$355.87	Non-Drug
E0606	RR	Drainage board postural		\$35.59	Non-Drug
E0606	UE	Drainage board postural		\$266.90	Non-Drug
E0607	NU	Blood glucose monitor home		\$81.50	Non-Drug
E0607	RR	Blood glucose monitor home		\$11.39	Non-Drug
E0607	UE	Blood glucose monitor home		\$72.08	Non-Drug
E0610	NU	Pacemaker monitr audible/vis		\$405.60	Non-Drug
E0610	RR	Pacemaker monitr audible/vis		\$38.56	Non-Drug
E0610	UE	Pacemaker monitr audible/vis		\$301.85	Non-Drug
E0615	NU	Pacemaker monitr digital/vis		\$826.21	Non-Drug
E0615	RR	Pacemaker monitr digital/vis		\$92.52	Non-Drug
E0615	UE	Pacemaker monitr digital/vis		\$617.26	Non-Drug
E0617	RR	Automatic ext defibrillator		\$521.14	Non-Drug
E0618	NU	Apnea monitor		\$507.15	Non-Drug
E0618	RR	Apnea monitor		\$479.77	Non-Drug
E0620	NU	Cap bld skin piercing laser		\$1,516.68	Non-Drug
E0620	RR	Cap bld skin piercing laser		\$143.02	Non-Drug
E0620	UE	Cap bld skin piercing laser		\$1,135.11	Non-Drug
E0621	NU	Patient lift sling or seat		\$157.96	Non-Drug
E0621	RR	Patient lift sling or seat		\$16.69	Non-Drug
E0621	UE	Patient lift sling or seat		\$116.71	Non-Drug
E0625	NU	Patient lift bathroom or toi		\$1,396.13	Non-Drug
E0625	RR	Patient lift bathroom or toi		\$143.96	Non-Drug
E0625	UE	Patient lift bathroom or toi		\$1,047.39	Non-Drug
E0627	NU	Seat lift incorp lift-chair		\$579.20	Non-Drug
E0627	RR	Seat lift incorp lift-chair		\$50.49	Non-Drug
E0627	UE	Seat lift incorp lift-chair		\$432.02	Non-Drug
E0628	NU	Seat lift for pt furn-electr		\$579.20	Non-Drug
E0628	RR	Seat lift for pt furn-electr		\$50.49	Non-Drug
E0628	UE	Seat lift for pt furn-electr		\$432.02	Non-Drug
E0629	NU	Seat lift for pt furn-non-el		\$567.66	Non-Drug
E0629	RR	Seat lift for pt furn-non-el		\$49.57	Non-Drug
E0629	UE	Seat lift for pt furn-non-el		\$423.32	Non-Drug
E0630	NU	Patient lift hydraulic		\$1,806.00	Non-Drug
E0630	RR	Patient lift hydraulic		\$168.26	Non-Drug
E0630	UE	Patient lift hydraulic		\$1,283.60	Non-Drug
E0635	NU	Patient lift electric		\$2,038.16	Non-Drug
E0635	RR	Patient lift electric		\$203.99	Non-Drug
E0635	UE	Patient lift electric		\$1,390.77	Non-Drug
E0636	RR	PT support & positioning sys		\$1,831.18	Non-Drug
E0650	NU	Pneuma compresor non-segment		\$1,247.57	Non-Drug
E0650	RR	Pneuma compresor non-segment		\$145.54	Non-Drug
E0650	UE	Pneuma compresor non-segment		\$933.27	Non-Drug
E0651	NU	Pneum compresor segmental		\$1,593.54	Non-Drug
E0651	RR	Pneum compresor segmental		\$154.17	Non-Drug
E0651	UE	Pneum compresor segmental		\$1,192.77	Non-Drug
E0652	NU	Pneum compres w/cal pressure		\$9,244.28	Non-Drug
E0652	RR	Pneum compres w/cal pressure		\$904.97	Non-Drug
E0652	UE	Pneum compres w/cal pressure		\$6,924.60	Non-Drug
E0655	NU	Pneumatic appliance half arm		\$178.79	Non-Drug
E0655	RR	Pneumatic appliance half arm		\$21.44	Non-Drug
E0655	UE	Pneumatic appliance half arm		\$131.88	Non-Drug
E0660	NU	Pneumatic appliance full leg		\$269.24	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 16 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0660	RR	Pneumatic appliance full leg		\$26.88	Non-Drug
E0660	UE	Pneumatic appliance full leg		\$199.53	Non-Drug
E0665	NU	Pneumatic appliance full arm		\$229.53	Non-Drug
E0665	RR	Pneumatic appliance full arm		\$23.36	Non-Drug
E0665	UE	Pneumatic appliance full arm		\$169.98	Non-Drug
E0666	NU	Pneumatic appliance half leg		\$231.43	Non-Drug
E0666	RR	Pneumatic appliance half leg		\$23.57	Non-Drug
E0666	UE	Pneumatic appliance half leg		\$171.23	Non-Drug
E0667	NU	Seg pneumatic appl full leg		\$555.56	Non-Drug
E0667	RR	Seg pneumatic appl full leg		\$54.38	Non-Drug
E0667	UE	Seg pneumatic appl full leg		\$414.27	Non-Drug
E0668	NU	Seg pneumatic appl full arm		\$761.72	Non-Drug
E0668	RR	Seg pneumatic appl full arm		\$66.53	Non-Drug
E0668	UE	Seg pneumatic appl full arm		\$568.91	Non-Drug
E0669	NU	Seg pneumatic appli half leg		\$310.38	Non-Drug
E0669	RR	Seg pneumatic appli half leg		\$29.25	Non-Drug
E0669	UE	Seg pneumatic appli half leg		\$230.44	Non-Drug
E0671	NU	Pressure pneum appl full leg		\$715.41	Non-Drug
E0671	RR	Pressure pneum appl full leg		\$62.91	Non-Drug
E0671	UE	Pressure pneum appl full leg		\$534.14	Non-Drug
E0672	NU	Pressure pneum appl full arm		\$553.74	Non-Drug
E0672	RR	Pressure pneum appl full arm		\$48.48	Non-Drug
E0672	UE	Pressure pneum appl full arm		\$412.92	Non-Drug
E0673	NU	Pressure pneum appl half leg		\$458.50	Non-Drug
E0673	RR	Pressure pneum appl half leg		\$40.94	Non-Drug
E0673	UE	Pressure pneum appl half leg		\$341.51	Non-Drug
E0691	NU	Uvl pnl 2 sq ft or less		\$1,558.92	Non-Drug
E0691	RR	Uvl pnl 2 sq ft or less		\$147.26	Non-Drug
E0691	UE	Uvl pnl 2 sq ft or less		\$1,166.79	Non-Drug
E0692	NU	Uvl sys panel 4 ft		\$1,960.02	Non-Drug
E0692	RR	Uvl sys panel 4 ft		\$187.35	Non-Drug
E0692	UE	Uvl sys panel 4 ft		\$1,467.63	Non-Drug
E0693	NU	Uvl sys panel 6 ft		\$2,418.41	Non-Drug
E0693	RR	Uvl sys panel 6 ft		\$233.21	Non-Drug
E0693	UE	Uvl sys panel 6 ft		\$1,811.42	Non-Drug
E0694	NU	Uvl md cabinet sys 6 ft		\$7,718.48	Non-Drug
E0694	RR	Uvl md cabinet sys 6 ft		\$763.21	Non-Drug
E0694	UE	Uvl md cabinet sys 6 ft		\$5,786.51	Non-Drug
E0700		Safety equipment		\$45.12	Non-Drug
E0701	NU	Helmet w face guard prefab		\$258.08	Non-Drug
E0701	RR	Helmet w face guard prefab		\$25.09	Non-Drug
E0701	UE	Helmet w face guard prefab		\$191.20	Non-Drug
E0710		Restraints any type		\$15.96	Non-Drug
E0720	NU	Tens two lead		\$632.03	Non-Drug
E0720	RR	Tens two lead		\$182.11	Non-Drug
E0720	UE	Tens two lead		\$347.56	Non-Drug
E0730	NU	Tens four lead		\$637.23	Non-Drug
E0730	RR	Tens four lead		\$216.68	Non-Drug
E0730	UE	Tens four lead		\$350.65	Non-Drug
E0731	NU	Conductive garment for tens/		\$613.02	Non-Drug
E0731	RR	Conductive garment for tens/		\$63.21	Non-Drug
E0740	NU	Incontinence treatment systm		\$903.09	Non-Drug
E0740	RR	Incontinence treatment systm		\$81.68	Non-Drug
E0740	UE	Incontinence treatment systm		\$674.97	Non-Drug
E0744	NU	Neuromuscular stim for scoli		\$1,003.39	Non-Drug
E0744	RR	Neuromuscular stim for scoli		\$150.24	Non-Drug
E0744	UE	Neuromuscular stim for scoli		\$909.98	Non-Drug
E0745	NU	Neuromuscular stim for shock		\$1,422.21	Non-Drug
E0745	RR	Neuromuscular stim for shock		\$146.65	Non-Drug
E0745	UE	Neuromuscular stim for shock		\$1,066.96	Non-Drug
E0746	NU	Electromyograph biofeedback		\$196.86	Non-Drug
E0746	RR	Electromyograph biofeedback		\$20.30	Non-Drug
E0746	UE	Electromyograph biofeedback		\$147.69	Non-Drug
E0747	NU	Elec osteogen stim not spine		\$6,147.28	Non-Drug
E0747	RR	Elec osteogen stim not spine		\$602.23	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 17 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0747	UE	Elec osteogen stim not spine		\$4,564.84	Non-Drug
E0748	NU	Elec osteogen stim spinal		\$6,107.37	Non-Drug
E0748	RR	Elec osteogen stim spinal		\$602.09	Non-Drug
E0748	UE	Elec osteogen stim spinal		\$4,578.16	Non-Drug
E0749		Elec osteogen stim implanted		\$5,973.82	Non-Drug
E0749	RR	Elec osteogen stim implanted		\$437.49	Non-Drug
E0752		Neurostimulator electrode		\$520.89	Non-Drug
E0754		Pulsegenerator pt programmer		\$1,415.41	Non-Drug
E0756		Implantable pulse generator		\$10,214.99	Non-Drug
E0757		Implantable RF receiver		\$7,285.89	Non-Drug
E0758		External RF transmitter		\$6,407.99	Non-Drug
E0759		Replce rfrquency transmitt		\$877.24	Non-Drug
E0760	NU	Osteogen ultrasound stimtor		\$5,073.49	Non-Drug
E0760	RR	Osteogen ultrasound stimtor		\$498.73	Non-Drug
E0760	UE	Osteogen ultrasound stimtor		\$3,802.72	Non-Drug
E0765	NU	Nerve stimulator for bx n&v		\$137.26	Non-Drug
E0765	RR	Nerve stimulator for bx n&v		\$15.57	Non-Drug
E0765	UE	Nerve stimulator for bx n&v		\$100.59	Non-Drug
E0776	NU	Iv pole		\$240.30	Non-Drug
E0776	RR	Iv pole		\$29.67	Non-Drug
E0776	UE	Iv pole		\$174.26	Non-Drug
E0779	RR	Amb infusion pump mechanical		\$27.02	Non-Drug
E0780	NU	Mech amb infusion pump <8hrs		\$18.25	Non-Drug
E0781	RR	Extern:al ambulatory infus pu		\$452.74	Non-Drug
E0782	NU	Non-programble infusion pump		\$6,740.54	Non-Drug
E0782	RR	Non-programble infusion pump		\$665.44	Non-Drug
E0782	UE	Non-programble infusion pump		\$5,053.01	Non-Drug
E0783	NU	Programmable infusion pump		\$12,861.88	Non-Drug
E0783	RR	Programmable infusion pump		\$1,277.57	Non-Drug
E0783	UE	Programmable infusion pump		\$9,644.03	Non-Drug
E0784		Ext amb infusn pump insulin		\$5,289.80	Non-Drug
E0784	RR	Ext amb infusn pump insulin		\$719.29	Non-Drug
E0785		Replacement impl pump cathet		\$733.27	Non-Drug
E0786	NU	Implantable pump replacement		\$12,545.76	Non-Drug
E0786	RR	Implantable pump replacement		\$1,245.92	Non-Drug
E0786	UE	Implantable pump replacement		\$9,406.92	Non-Drug
E0791		Parenteral infusion pump sta		\$5,803.62	Non-Drug
E0791	RR	Parenteral infusion pump sta		\$598.42	Non-Drug
E0791	UE	Parenteral infusion pump sta		\$4,353.94	Non-Drug
E0830		Ambulatory traction device		\$2,327.47	Non-Drug
E0840	NU	Tract frame attach headboard		\$112.77	Non-Drug
E0840	RR	Tract frame attach headboard		\$27.06	Non-Drug
E0840	UE	Tract frame attach headboard		\$85.16	Non-Drug
E0850	NU	Traction stand free standing		\$158.24	Non-Drug
E0850	RR	Traction stand free standing		\$24.22	Non-Drug
E0850	UE	Traction stand free standing		\$121.07	Non-Drug
E0855	NU	Cervical traction equipment		\$867.77	Non-Drug
E0855	RR	Cervical traction equipment		\$78.14	Non-Drug
E0855	UE	Cervical traction equipment		\$648.41	Non-Drug
E0860	NU	Tract equip cervical tract		\$60.49	Non-Drug
E0860	RR	Tract equip cervical tract		\$12.31	Non-Drug
E0860	UE	Tract equip cervical tract		\$46.91	Non-Drug
E0870	NU	Tract frame attach footboard		\$173.89	Non-Drug
E0870	RR	Tract frame attach footboard		\$22.67	Non-Drug
E0870	UE	Tract frame attach footboard		\$133.95	Non-Drug
E0880	NU	Trac stand free stand extrem		\$186.76	Non-Drug
E0880	RR	Trac stand free stand extrem		\$32.16	Non-Drug
E0880	UE	Trac stand free stand extrem		\$144.26	Non-Drug
E0890	NU	Traction frame attach pelvic		\$179.61	Non-Drug
E0890	RR	Traction frame attach pelvic		\$51.91	Non-Drug
E0890	UE	Traction frame attach pelvic		\$147.00	Non-Drug
E0900	NU	Trac stand free stand pelvic		\$190.34	Non-Drug
E0900	RR	Trac stand free stand pelvic		\$44.07	Non-Drug
E0900	UE	Trac stand free stand pelvic		\$145.79	Non-Drug
E0910		Trapeze bar attached to bed		\$325.46	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 18 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAFF Category
E0910	RR	Trapeze bar attached to bed		\$32.60	Non-Drug
E0910	UE	Trapeze bar attached to bed		\$243.95	Non-Drug
E0920		Fracture frame attached to b		\$719.37	Non-Drug
E0920	RR	Fracture frame attached to b		\$71.94	Non-Drug
E0920	UE	Fracture frame attached to b		\$597.22	Non-Drug
E0930		Fracture frame free standing		\$714.01	Non-Drug
E0930	RR	Fracture frame free standing		\$71.26	Non-Drug
E0930	UE	Fracture frame free standing		\$525.63	Non-Drug
E0935	RR	Exercise device passive moti		\$35.30	Non-Drug
E0940		Trapeze bar free standing		\$515.64	Non-Drug
E0940	RR	Trapeze bar free standing		\$54.83	Non-Drug
E0940	UE	Trapeze bar free standing		\$364.87	Non-Drug
E0941	NU	Gravity assisted traction de		\$676.89	Non-Drug
E0941	RR	Gravity assisted traction de		\$67.83	Non-Drug
E0941	UE	Gravity assisted traction de		\$511.78	Non-Drug
E0942	NU	Cervical head harness/halter		\$32.38	Non-Drug
E0942	RR	Cervical head harness/halter		\$6.03	Non-Drug
E0942	UE	Cervical head harness/halter		\$24.90	Non-Drug
E0944	NU	Pelvic belt/harness/boot		\$61.58	Non-Drug
E0944	RR	Pelvic belt/harness/boot		\$9.04	Non-Drug
E0944	UE	Pelvic belt/harness/boot		\$47.02	Non-Drug
E0945	NU	Belt/harness extremity		\$59.60	Non-Drug
E0945	RR	Belt/harness extremity		\$8.72	Non-Drug
E0945	UE	Belt/harness extremity		\$46.91	Non-Drug
E0946	NU	Fracture frame dual w cross		\$918.30	Non-Drug
E0946	RR	Fracture frame dual w cross		\$91.52	Non-Drug
E0946	UE	Fracture frame dual w cross		\$689.19	Non-Drug
E0947	NU	Fracture frame attachmnts pe		\$856.45	Non-Drug
E0947	RR	Fracture frame attachmnts pe		\$97.14	Non-Drug
E0947	UE	Fracture frame attachmnts pe		\$645.31	Non-Drug
E0948	NU	Fracture frame attachmnts ce		\$828.78	Non-Drug
E0948	RR	Fracture frame attachmnts ce		\$90.74	Non-Drug
E0948	UE	Fracture frame attachmnts ce		\$588.03	Non-Drug
E0950	NU	Tray		\$138.36	Non-Drug
E0950	RR	Tray		\$16.61	Non-Drug
E0950	UE	Tray		\$103.92	Non-Drug
E0951	NU	Loop heel		\$27.48	Non-Drug
E0951	RR	Loop heel		\$3.85	Non-Drug
E0951	UE	Loop heel		\$21.44	Non-Drug
E0952	NU	Toe loop/holder, each		\$27.29	Non-Drug
E0952	RR	Toe loop/holder, each		\$3.85	Non-Drug
E0952	UE	Toe loop/holder, each		\$21.33	Non-Drug
E0953	NU	Pneumatic tire		\$60.54	Non-Drug
E0953	RR	Pneumatic tire		\$9.10	Non-Drug
E0953	UE	Pneumatic tire		\$46.13	Non-Drug
E0954	NU	Wheelchair semi-pneumatic ca		\$61.08	Non-Drug
E0954	RR	Wheelchair semi-pneumatic ca		\$10.89	Non-Drug
E0954	UE	Wheelchair semi-pneumatic ca		\$37.05	Non-Drug
E0958	NU	Whlchr att- conv 1 arm drive		\$586.42	Non-Drug
E0958	RR	Whlchr att- conv 1 arm drive		\$58.73	Non-Drug
E0958	UE	Whlchr att- conv 1 arm drive		\$440.04	Non-Drug
E0959	NU	Amputee adapter		\$59.46	Non-Drug
E0959	RR	Amputee adapter		\$8.73	Non-Drug
E0959	UE	Amputee adapter		\$45.83	Non-Drug
E0961	NU	Wheelchair brake extension		\$41.11	Non-Drug
E0961	RR	Wheelchair brake extension		\$6.10	Non-Drug
E0961	UE	Wheelchair brake extension		\$22.25	Non-Drug
E0962	NU	Wheelchair 1 inch cushion		\$79.42	Non-Drug
E0962	RR	Wheelchair 1 inch cushion		\$10.94	Non-Drug
E0962	UE	Wheelchair 1 inch cushion		\$59.97	Non-Drug
E0963	NU	Wheelchair 2 inch cushion		\$94.75	Non-Drug
E0963	RR	Wheelchair 2 inch cushion		\$12.56	Non-Drug
E0963	UE	Wheelchair 2 inch cushion		\$71.36	Non-Drug
E0964	NU	Wheelchair 3 inch cushion		\$105.65	Non-Drug
E0964	RR	Wheelchair 3 inch cushion		\$13.54	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 19 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E0964	UE	Wheelchair 3 inch cushion		\$79.42	Non-Drug
E0965	NU	Wheelchair 4 inch cushion		\$112.91	Non-Drug
E0965	RR	Wheelchair 4 inch cushion		\$14.16	Non-Drug
E0965	UE	Wheelchair 4 inch cushion		\$84.84	Non-Drug
E0966	NU	Wheelchair head rest extensi		\$95.17	Non-Drug
E0966	RR	Wheelchair head rest extensi		\$12.34	Non-Drug
E0966	UE	Wheelchair head rest extensi		\$71.49	Non-Drug
E0967	NU	Wheelchair hand rims		\$87.64	Non-Drug
E0967	RR	Wheelchair hand rims		\$11.74	Non-Drug
E0967	UE	Wheelchair hand rims		\$65.85	Non-Drug
E0968	NU	Wheelchair commode seat		\$263.80	Non-Drug
E0968	RR	Wheelchair commode seat		\$26.15	Non-Drug
E0968	UE	Wheelchair commode seat		\$167.93	Non-Drug
E0969	NU	Wheelchair narrowing device		\$208.22	Non-Drug
E0969	RR	Wheelchair narrowing device		\$23.08	Non-Drug
E0969	UE	Wheelchair narrowing device		\$156.31	Non-Drug
E0970	NU	Wheelchair no. 2 footplates		\$68.66	Non-Drug
E0970	RR	Wheelchair no. 2 footplates		\$9.10	Non-Drug
E0970	UE	Wheelchair no. 2 footplates		\$52.53	Non-Drug
E0971	NU	Wheelchair anti-tipping devi		\$87.71	Non-Drug
E0971	RR	Wheelchair anti-tipping devi		\$12.87	Non-Drug
E0971	UE	Wheelchair anti-tipping devi		\$65.93	Non-Drug
E0972	NU	Transfer board or device		\$81.69	Non-Drug
E0972	RR	Transfer board or device		\$8.44	Non-Drug
E0972	UE	Transfer board or device		\$59.86	Non-Drug
E0973	NU	W/Ch access det adj armrest		\$152.97	Non-Drug
E0973	RR	W/Ch access det adj armrest		\$17.29	Non-Drug
E0973	UE	W/Ch access det adj armrest		\$114.87	Non-Drug
E0974	NU	W/Ch access anti-rollback		\$104.51	Non-Drug
E0974	RR	W/Ch access anti-rollback		\$13.94	Non-Drug
E0974	UE	W/Ch access anti-rollback		\$79.09	Non-Drug
E0977	NU	Wheelchair wedge cushion		\$87.26	Non-Drug
E0977	RR	Wheelchair wedge cushion		\$11.40	Non-Drug
E0977	UE	Wheelchair wedge cushion		\$65.64	Non-Drug
E0978	NU	W/C acc,saf belt pelv strap		\$57.55	Non-Drug
E0978	RR	W/C acc,saf belt pelv strap		\$8.41	Non-Drug
E0978	UE	W/C acc,saf belt pelv strap		\$43.55	Non-Drug
E0980	NU	Wheelchair safety vest		\$45.32	Non-Drug
E0980	RR	Wheelchair safety vest		\$6.48	Non-Drug
E0980	UE	Wheelchair safety vest		\$34.68	Non-Drug
E0981	NU	Seat upholstery, replacement		\$63.19	Non-Drug
E0981	RR	Seat upholstery, replacement		\$9.43	Non-Drug
E0981	UE	Seat upholstery, replacement		\$48.67	Non-Drug
E0982	NU	Back upholstery, replacement		\$68.86	Non-Drug
E0982	RR	Back upholstery, replacement		\$9.94	Non-Drug
E0982	UE	Back upholstery, replacement		\$52.40	Non-Drug
E0983	RR	Add pwr joystick		\$331.93	Non-Drug
E0984	NU	Add pwr tiller		\$2,533.82	Non-Drug
E0984	RR	Add pwr tiller		\$236.01	Non-Drug
E0984	UE	Add pwr tiller		\$1,955.31	Non-Drug
E0990	NU	Wheelchair elevating leg res		\$156.24	Non-Drug
E0990	RR	Wheelchair elevating leg res		\$20.18	Non-Drug
E0990	UE	Wheelchair elevating leg res		\$122.19	Non-Drug
E0992	NU	Wheelchair solid seat insert		\$126.70	Non-Drug
E0992	RR	Wheelchair solid seat insert		\$15.13	Non-Drug
E0992	UE	Wheelchair solid seat insert		\$95.17	Non-Drug
E0994	NU	Wheelchair arm rest		\$25.76	Non-Drug
E0994	RR	Wheelchair arm rest		\$3.50	Non-Drug
E0994	UE	Wheelchair arm rest		\$20.19	Non-Drug
E0995	NU	Wheelchair calf rest		\$41.96	Non-Drug
E0995	RR	Wheelchair calf rest		\$5.98	Non-Drug
E0995	UE	Wheelchair calf rest		\$32.29	Non-Drug
E0996	NU	Wheelchair tire solid		\$41.86	Non-Drug
E0996	RR	Wheelchair tire solid		\$6.62	Non-Drug
E0996	UE	Wheelchair tire solid		\$32.78	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 20 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
E0997	NU	Wheelchair caster w/ a fork		\$88.73	Non-Drug
E0997	RR	Wheelchair caster w/ a fork		\$12.45	Non-Drug
E0997	UE	Wheelchair caster w/ a fork		\$66.69	Non-Drug
E0998	NU	Wheelchair caster w/o a fork		\$51.94	Non-Drug
E0998	RR	Wheelchair caster w/o a fork		\$7.77	Non-Drug
E0998	UE	Wheelchair caster w/o a fork		\$39.83	Non-Drug
E0999	NU	Wheelchr pneumatic tire w/wh		\$152.97	Non-Drug
E0999	RR	Wheelchr pneumatic tire w/wh		\$18.00	Non-Drug
E0999	UE	Wheelchr pneumatic tire w/wh		\$114.87	Non-Drug
E1000	NU	Wheelchair tire pneumatic ca		\$52.53	Non-Drug
E1000	RR	Wheelchair tire pneumatic ca		\$9.82	Non-Drug
E1000	UE	Wheelchair tire pneumatic ca		\$40.25	Non-Drug
E1001	NU	Wheelchair wheel		\$130.56	Non-Drug
E1001	RR	Wheelchair wheel		\$16.46	Non-Drug
E1001	UE	Wheelchair wheel		\$98.05	Non-Drug
E1012	NU	Int seat sys planar ped w/c		\$672.85	Non-Drug
E1012	RR	Int seat sys planar ped w/c		\$67.75	Non-Drug
E1012	UE	Int seat sys planar ped w/c		\$504.79	Non-Drug
E1013	NU	Int seat sys contour ped w/c		\$1,111.57	Non-Drug
E1013	RR	Int seat sys contour ped w/c		\$111.65	Non-Drug
E1013	UE	Int seat sys contour ped w/c		\$833.83	Non-Drug
E1014	NU	Reclining back add ped w/c		\$484.69	Non-Drug
E1014	RR	Reclining back add ped w/c		\$49.72	Non-Drug
E1014	UE	Reclining back add ped w/c		\$363.64	Non-Drug
E1015	NU	Shock absorber for man w/c		\$152.62	Non-Drug
E1015	RR	Shock absorber for man w/c		\$17.94	Non-Drug
E1015	UE	Shock absorber for man w/c		\$114.60	Non-Drug
E1016	NU	Shock absorber for power w/c		\$174.65	Non-Drug
E1016	RR	Shock absorber for power w/c		\$20.08	Non-Drug
E1016	UE	Shock absorber for power w/c		\$131.12	Non-Drug
E1020	NU	Residual limb support system		\$323.28	Non-Drug
E1020	RR	Residual limb support system		\$34.24	Non-Drug
E1020	UE	Residual limb support system		\$242.58	Non-Drug
E1025	NU	Pedw/c lat/thor sup nocontour		\$166.74	Non-Drug
E1025	RR	Pedw/c lat/thor sup nocontour		\$19.32	Non-Drug
E1025	UE	Pedw/c lat/thor sup nocontour		\$125.19	Non-Drug
E1026	NU	Pedw/c contoured lat/thor sup		\$256.31	Non-Drug
E1026	RR	Pedw/c contoured lat/thor sup		\$27.87	Non-Drug
E1026	UE	Pedw/c contoured lat/thor sup		\$192.36	Non-Drug
E1027	NU	Ped w/c lat/ant support		\$365.25	Non-Drug
E1027	RR	Ped w/c lat/ant support		\$38.27	Non-Drug
E1027	UE	Ped w/c lat/ant support		\$274.05	Non-Drug
E1031	NU	Rollabout chair with casters		\$673.50	Non-Drug
E1031	RR	Rollabout chair with casters		\$67.51	Non-Drug
E1031	UE	Rollabout chair with casters		\$505.25	Non-Drug
E1035	RR	Patient transfer system		\$813.60	Non-Drug
E1037	RR	Transport chair, ped size		\$144.39	Non-Drug
E1038	RR	Transport chair, adult size		\$54.14	Non-Drug
E1050	NU	Wheelchr fxd full length arms		\$1,520.90	Non-Drug
E1050	RR	Wheelchr fxd full length arms		\$135.57	Non-Drug
E1050	UE	Wheelchr fxd full length arms		\$1,140.80	Non-Drug
E1060	NU	Wheelchair detachable arms		\$1,986.78	Non-Drug
E1060	RR	Wheelchair detachable arms		\$167.70	Non-Drug
E1060	UE	Wheelchair detachable arms		\$1,489.78	Non-Drug
E1070	NU	Wheelchair detachable foot r		\$1,792.08	Non-Drug
E1070	RR	Wheelchair detachable foot r		\$145.76	Non-Drug
E1070	UE	Wheelchair detachable foot r		\$1,343.79	Non-Drug
E1083	NU	Hemi-wheelchair fixed arms		\$1,047.85	Non-Drug
E1083	RR	Hemi-wheelchair fixed arms		\$104.94	Non-Drug
E1083	UE	Hemi-wheelchair fixed arms		\$764.53	Non-Drug
E1084	NU	Hemi-wheelchair detachable a		\$1,596.97	Non-Drug
E1084	RR	Hemi-wheelchair detachable a		\$130.61	Non-Drug
E1084	UE	Hemi-wheelchair detachable a		\$1,140.78	Non-Drug
E1085	NU	Hemi-wheelchair fixed arms		\$1,050.36	Non-Drug
E1085	RR	Hemi-wheelchair fixed arms		\$105.52	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 21 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E1085	UE	Hemi-wheelchair fixed arms		\$754.40	Non-Drug
E1086	NU	Hemi-wheelchair detachable a		\$1,279.31	Non-Drug
E1086	RR	Hemi-wheelchair detachable a		\$116.69	Non-Drug
E1086	UE	Hemi-wheelchair detachable a		\$929.18	Non-Drug
E1087	NU	Wheelchair lightwt fixed arm		\$1,684.00	Non-Drug
E1087	RR	Wheelchair lightwt fixed arm		\$168.28	Non-Drug
E1087	UE	Wheelchair lightwt fixed arm		\$1,228.06	Non-Drug
E1088	NU	Wheelchair lightweight det a		\$2,009.33	Non-Drug
E1088	RR	Wheelchair lightweight det a		\$200.45	Non-Drug
E1088	UE	Wheelchair lightweight det a		\$1,378.48	Non-Drug
E1089	NU	Wheelchair lightwt fixed arm		\$1,697.56	Non-Drug
E1089	RR	Wheelchair lightwt fixed arm		\$170.29	Non-Drug
E1089	UE	Wheelchair lightwt fixed arm		\$1,273.16	Non-Drug
E1090	NU	Wheelchair lightweight det a		\$1,750.05	Non-Drug
E1090	RR	Wheelchair lightweight det a		\$170.29	Non-Drug
E1090	UE	Wheelchair lightweight det a		\$1,279.31	Non-Drug
E1092	NU	Wheelchair wide w/ leg rests		\$1,885.68	Non-Drug
E1092	RR	Wheelchair wide w/ leg rests		\$170.93	Non-Drug
E1092	UE	Wheelchair wide w/ leg rests		\$1,378.30	Non-Drug
E1093	NU	Wheelchair wide w/ foot rest		\$1,438.02	Non-Drug
E1093	RR	Wheelchair wide w/ foot rest		\$147.08	Non-Drug
E1093	UE	Wheelchair wide w/ foot rest		\$1,070.05	Non-Drug
E1100	NU	Whchr s-recl fxd arm leg res		\$1,380.32	Non-Drug
E1100	RR	Whchr s-recl fxd arm leg res		\$138.18	Non-Drug
E1100	UE	Whchr s-recl fxd arm leg res		\$1,035.61	Non-Drug
E1110	NU	Wheelchair semi-recl detach		\$1,350.97	Non-Drug
E1110	RR	Wheelchair semi-recl detach		\$135.32	Non-Drug
E1110	UE	Wheelchair semi-recl detach		\$982.37	Non-Drug
E1130	NU	Whlchr stand fxd arm ft rest		\$673.43	Non-Drug
E1130	RR	Whlchr stand fxd arm ft rest		\$68.10	Non-Drug
E1130	UE	Whlchr stand fxd arm ft rest		\$512.04	Non-Drug
E1140	NU	Wheelchair standard detach a		\$969.39	Non-Drug
E1140	RR	Wheelchair standard detach a		\$97.70	Non-Drug
E1140	UE	Wheelchair standard detach a		\$686.83	Non-Drug
E1150	NU	Wheelchair standard w/ leg r		\$1,124.07	Non-Drug
E1150	RR	Wheelchair standard w/ leg r		\$108.70	Non-Drug
E1150	UE	Wheelchair standard w/ leg r		\$744.23	Non-Drug
E1160	NU	Wheelchair fixed arms		\$910.84	Non-Drug
E1160	RR	Wheelchair fixed arms		\$83.40	Non-Drug
E1160	UE	Wheelchair fixed arms		\$636.03	Non-Drug
E1161	NU	Manual adult wc w tiltinspac		\$3,137.80	Non-Drug
E1161	RR	Manual adult wc w tiltinspac		\$314.27	Non-Drug
E1161	UE	Manual adult wc w tiltinspac		\$2,353.52	Non-Drug
E1170	NU	Whlchr ampu fxd arm leg rest		\$1,188.55	Non-Drug
E1170	RR	Whlchr ampu fxd arm leg rest		\$118.96	Non-Drug
E1170	UE	Whlchr ampu fxd arm leg rest		\$891.68	Non-Drug
E1171	NU	Wheelchair amputee w/o leg r		\$1,065.37	Non-Drug
E1171	RR	Wheelchair amputee w/o leg r		\$106.81	Non-Drug
E1171	UE	Wheelchair amputee w/o leg r		\$799.03	Non-Drug
E1172	NU	Wheelchair amputee detach ar		\$1,301.02	Non-Drug
E1172	RR	Wheelchair amputee detach ar		\$130.41	Non-Drug
E1172	UE	Wheelchair amputee detach ar		\$975.88	Non-Drug
E1180	NU	Wheelchair amputee w/ foot r		\$1,350.13	Non-Drug
E1180	RR	Wheelchair amputee w/ foot r		\$134.91	Non-Drug
E1180	UE	Wheelchair amputee w/ foot r		\$1,012.34	Non-Drug
E1190	NU	Wheelchair amputee w/ leg re		\$1,558.77	Non-Drug
E1190	RR	Wheelchair amputee w/ leg re		\$155.76	Non-Drug
E1190	UE	Wheelchair amputee w/ leg re		\$1,138.15	Non-Drug
E1195	NU	Wheelchair amputee heavy dut		\$1,671.15	Non-Drug
E1195	RR	Wheelchair amputee heavy dut		\$167.11	Non-Drug
E1195	UE	Wheelchair amputee heavy dut		\$1,253.85	Non-Drug
E1200	NU	Wheelchair amputee fixed arm		\$1,157.23	Non-Drug
E1200	RR	Wheelchair amputee fixed arm		\$115.91	Non-Drug
E1200	UE	Wheelchair amputee fixed arm		\$867.69	Non-Drug
E1210	NU	Whlchr moto ful arm leg rest		\$5,452.04	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 22 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E1210	RR	Whichr moto ful arm leg rest		\$545.31	Non-Drug
E1210	UE	Whichr moto ful arm leg rest		\$4,089.03	Non-Drug
E1211	NU	Wheelchair motorized w/ det		\$5,555.04	Non-Drug
E1211	RR	Wheelchair motorized w/ det		\$555.45	Non-Drug
E1211	UE	Wheelchair motorized w/ det		\$4,166.41	Non-Drug
E1212	NU	Wheelchair motorized w full		\$5,727.09	Non-Drug
E1212	RR	Wheelchair motorized w full		\$572.91	Non-Drug
E1212	UE	Wheelchair motorized w full		\$4,295.31	Non-Drug
E1213	NU	Wheelchair motorized w/ det		\$6,159.30	Non-Drug
E1213	RR	Wheelchair motorized w/ det		\$616.47	Non-Drug
E1213	UE	Wheelchair motorized w/ det		\$4,619.19	Non-Drug
E1220		Whichr special size/constrc		\$3,366.87	Non-Drug
E1221	NU	Wheelchair spec size w foot		\$637.02	Non-Drug
E1221	RR	Wheelchair spec size w foot		\$63.65	Non-Drug
E1221	UE	Wheelchair spec size w foot		\$477.90	Non-Drug
E1222	NU	Wheelchair spec size w/ leg		\$906.97	Non-Drug
E1222	RR	Wheelchair spec size w/ leg		\$90.42	Non-Drug
E1222	UE	Wheelchair spec size w/ leg		\$652.57	Non-Drug
E1223	NU	Wheelchair spec size w foot		\$983.92	Non-Drug
E1223	RR	Wheelchair spec size w foot		\$98.68	Non-Drug
E1223	UE	Wheelchair spec size w foot		\$703.77	Non-Drug
E1224	NU	Wheelchair spec size w/ leg		\$1,136.51	Non-Drug
E1224	RR	Wheelchair spec size w/ leg		\$108.13	Non-Drug
E1224	UE	Wheelchair spec size w/ leg		\$762.66	Non-Drug
E1225	NU	Wheelchair spec sz semi-recl		\$607.19	Non-Drug
E1225	RR	Wheelchair spec sz semi-recl		\$60.72	Non-Drug
E1225	UE	Wheelchair spec sz semi-recl		\$455.64	Non-Drug
E1226	NU	W/C access fully reclineback		\$724.03	Non-Drug
E1226	RR	W/C access fully reclineback		\$75.00	Non-Drug
E1226	UE	W/C access fully reclineback		\$543.10	Non-Drug
E1227	NU	Wheelchair spec sz spec ht a		\$368.48	Non-Drug
E1227	RR	Wheelchair spec sz spec ht a		\$38.59	Non-Drug
E1227	UE	Wheelchair spec sz spec ht a		\$276.53	Non-Drug
E1228	NU	Wheelchair spec sz spec ht b		\$387.86	Non-Drug
E1228	RR	Wheelchair spec sz spec ht b		\$38.94	Non-Drug
E1228	UE	Wheelchair spec sz spec ht b		\$290.77	Non-Drug
E1230	NU	Power operated vehicle		\$2,999.51	Non-Drug
E1230	RR	Power operated vehicle		\$295.49	Non-Drug
E1230	UE	Power operated vehicle		\$2,372.37	Non-Drug
E1232	NU	Folding ped wc tilt-in-space		\$2,835.92	Non-Drug
E1232	RR	Folding ped wc tilt-in-space		\$284.08	Non-Drug
E1232	UE	Folding ped wc tilt-in-space		\$2,127.08	Non-Drug
E1233	NU	Rig ped wc tltnspc w/o seat		\$2,938.43	Non-Drug
E1233	RR	Rig ped wc tltnspc w/o seat		\$294.32	Non-Drug
E1233	UE	Rig ped wc tltnspc w/o seat		\$2,203.95	Non-Drug
E1234	NU	Fld ped wc tltnspc w/o seat		\$2,558.19	Non-Drug
E1234	RR	Fld ped wc tltnspc w/o seat		\$256.32	Non-Drug
E1234	UE	Fld ped wc tltnspc w/o seat		\$1,918.75	Non-Drug
E1235	NU	Rigid ped wc adjustable		\$2,463.36	Non-Drug
E1235	RR	Rigid ped wc adjustable		\$246.83	Non-Drug
E1235	UE	Rigid ped wc adjustable		\$1,847.64	Non-Drug
E1236	NU	Folding ped wc adjustable		\$2,173.37	Non-Drug
E1236	RR	Folding ped wc adjustable		\$217.81	Non-Drug
E1236	UE	Folding ped wc adjustable		\$1,630.17	Non-Drug
E1237	NU	Rgd ped wc adjstabl w/o seat		\$2,192.35	Non-Drug
E1237	RR	Rgd ped wc adjstabl w/o seat		\$219.71	Non-Drug
E1237	UE	Rgd ped wc adjstabl w/o seat		\$1,644.43	Non-Drug
E1238	NU	Fld ped wc adjstabl w/o seat		\$2,285.83	Non-Drug
E1238	RR	Fld ped wc adjstabl w/o seat		\$229.09	Non-Drug
E1238	UE	Fld ped wc adjstabl w/o seat		\$1,714.49	Non-Drug
E1240	NU	Whchr litwt det arm leg rest		\$1,371.29	Non-Drug
E1240	RR	Whchr litwt det arm leg rest		\$137.13	Non-Drug
E1240	UE	Whchr litwt det arm leg rest		\$981.46	Non-Drug
E1250	NU	Wheelchair lightwt fixed arm		\$1,036.96	Non-Drug
E1250	RR	Wheelchair lightwt fixed arm		\$94.91	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 23 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E1250	UE	Wheelchair lightwt fixed arm		\$821.41	Non-Drug
E1260	NU	Wheelchair lightwt foot rest		\$1,211.74	Non-Drug
E1260	RR	Wheelchair lightwt foot rest		\$121.71	Non-Drug
E1260	UE	Wheelchair lightwt foot rest		\$955.98	Non-Drug
E1270	NU	Wheelchair lightweight leg r		\$1,054.29	Non-Drug
E1270	RR	Wheelchair lightweight leg r		\$105.21	Non-Drug
E1270	UE	Wheelchair lightweight leg r		\$774.11	Non-Drug
E1280	NU	Whchr h-duty det arm leg res		\$1,747.03	Non-Drug
E1280	RR	Whchr h-duty det arm leg res		\$174.58	Non-Drug
E1280	UE	Whchr h-duty det arm leg res		\$1,252.28	Non-Drug
E1285	NU	Wheelchair heavy duty fixed		\$1,561.87	Non-Drug
E1285	RR	Wheelchair heavy duty fixed		\$156.89	Non-Drug
E1285	UE	Wheelchair heavy duty fixed		\$1,144.73	Non-Drug
E1290	NU	Wheelchair hvy duty detach a		\$1,615.47	Non-Drug
E1290	RR	Wheelchair hvy duty detach a		\$161.92	Non-Drug
E1290	UE	Wheelchair hvy duty detach a		\$1,178.23	Non-Drug
E1295	NU	Wheelchair heavy duty fixed		\$1,615.95	Non-Drug
E1295	RR	Wheelchair heavy duty fixed		\$161.60	Non-Drug
E1295	UE	Wheelchair heavy duty fixed		\$1,174.15	Non-Drug
E1296	NU	Wheelchair special seat heig		\$652.46	Non-Drug
E1296	RR	Wheelchair special seat heig		\$66.75	Non-Drug
E1296	UE	Wheelchair special seat heig		\$489.47	Non-Drug
E1297	NU	Wheelchair special seat dept		\$139.25	Non-Drug
E1297	RR	Wheelchair special seat dept		\$18.14	Non-Drug
E1297	UE	Wheelchair special seat dept		\$104.56	Non-Drug
E1298	NU	Wheelchair spec seat depth/w		\$562.27	Non-Drug
E1298	RR	Wheelchair spec seat depth/w		\$58.37	Non-Drug
E1298	UE	Wheelchair spec seat depth/w		\$421.82	Non-Drug
E1300	NU	Whirlpool portable		\$128.99	Non-Drug
E1300	RR	Whirlpool portable		\$13.30	Non-Drug
E1300	UE	Whirlpool portable		\$96.77	Non-Drug
E1310	NU	Whirlpool non-portable		\$3,738.78	Non-Drug
E1310	RR	Whirlpool non-portable		\$311.01	Non-Drug
E1310	UE	Whirlpool non-portable		\$2,801.68	Non-Drug
E1340		Repair for DME, per 15 min		\$17.81	Non-Drug
E1353	NU	Oxygen supplies regulator		\$167.65	Non-Drug
E1353	RR	Oxygen supplies regulator		\$9.09	Non-Drug
E1353	UE	Oxygen supplies regulator		\$135.14	Non-Drug
E1355	NU	Oxygen supplies stand/rack		\$115.28	Non-Drug
E1355	RR	Oxygen supplies stand/rack		\$12.91	Non-Drug
E1355	UE	Oxygen supplies stand/rack		\$93.60	Non-Drug
E1372	NU	Oxy suppl heater for nebuliz		\$274.97	Non-Drug
E1372	RR	Oxy suppl heater for nebuliz		\$36.63	Non-Drug
E1372	UE	Oxy suppl heater for nebuliz		\$201.05	Non-Drug
E1390	NU	Oxygen concentrator		\$3,861.52	Non-Drug
E1390	RR	Oxygen concentrator		\$507.73	Non-Drug
E1391	RR	Oxygen concentrator, dual		\$507.73	Non-Drug
E1399		Durable medical equipment mi		\$3.00	Non-Drug
E1405	NU	O2/water vapor enrich w/heat		\$5,102.88	Non-Drug
E1405	RR	O2/water vapor enrich w/heat		\$526.17	Non-Drug
E1405	UE	O2/water vapor enrich w/heat		\$3,828.24	Non-Drug
E1406	NU	O2/water vapor enrich w/o he		\$2,151.43	Non-Drug
E1406	RR	O2/water vapor enrich w/o he		\$221.84	Non-Drug
E1406	UE	O2/water vapor enrich w/o he		\$1,614.02	Non-Drug
E1510	NU	Kidney dialysate delivry sys		\$6,596.06	Non-Drug
E1510	RR	Kidney dialysate delivry sys		\$680.13	Non-Drug
E1510	UE	Kidney dialysate delivry sys		\$4,948.44	Non-Drug
E1520	NU	Heparin infusion pump		\$893.51	Non-Drug
E1520	RR	Heparin infusion pump		\$92.13	Non-Drug
E1520	UE	Heparin infusion pump		\$670.32	Non-Drug
E1530	NU	Replacement air bubble detec		\$1,292.73	Non-Drug
E1530	RR	Replacement air bubble detec		\$133.30	Non-Drug
E1530	UE	Replacement air bubble detec		\$969.82	Non-Drug
E1540	NU	Replacement pressure alarm		\$800.97	Non-Drug
E1540	RR	Replacement pressure alarm		\$82.59	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 24 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
E1540	UE	Replacement pressure alarm		\$600.90	Non-Drug
E1550	NU	Bath conductivity meter		\$521.89	Non-Drug
E1550	RR	Bath conductivity meter		\$53.81	Non-Drug
E1550	UE	Bath conductivity meter		\$391.52	Non-Drug
E1560	NU	Replace blood leak detector		\$1,470.47	Non-Drug
E1560	RR	Replace blood leak detector		\$151.62	Non-Drug
E1560	UE	Replace blood leak detector		\$1,103.16	Non-Drug
E1570	NU	Adjustable chair for esrd pt		\$579.87	Non-Drug
E1570	RR	Adjustable chair for esrd pt		\$59.79	Non-Drug
E1570	UE	Adjustable chair for esrd pt		\$435.03	Non-Drug
E1575	NU	Transducer protect/fld bar		\$77.12	Non-Drug
E1575	RR	Transducer protect/fld bar		\$7.95	Non-Drug
E1575	UE	Transducer protect/fld bar		\$57.86	Non-Drug
E1590	NU	Hemodialysis machine		\$1,445.97	Non-Drug
E1590	RR	Hemodialysis machine		\$149.10	Non-Drug
E1590	UE	Hemodialysis machine		\$1,084.79	Non-Drug
E1594	NU	Cycler dialysis machine		\$6,637.52	Non-Drug
E1594	RR	Cycler dialysis machine		\$684.40	Non-Drug
E1594	UE	Cycler dialysis machine		\$4,979.54	Non-Drug
E1610	NU	Reverse osmosis h2o puri sys		\$5,073.89	Non-Drug
E1610	RR	Reverse osmosis h2o puri sys		\$523.18	Non-Drug
E1610	UE	Reverse osmosis h2o puri sys		\$3,806.49	Non-Drug
E1637		Hemostats for dialysis, each		\$7.80	Non-Drug
E1639		Dialysis scale		\$147.06	Non-Drug
E1699		Dialysis equipment noc		\$80.08	Non-Drug
E1700	NU	Jaw motion rehab system		\$592.33	Non-Drug
E1700	RR	Jaw motion rehab system		\$50.60	Non-Drug
E1700	UE	Jaw motion rehab system		\$441.85	Non-Drug
E1701		Repl cushions for jaw motion		\$18.57	Non-Drug
E1702		Repl measr scales jaw motion		\$35.07	Non-Drug
E1800	RR	Adjust elbow ext/flex device		\$204.23	Non-Drug
E1801	RR	SPS elbow device		\$215.58	Non-Drug
E1802	RR	Adjst forearm pro/sup device		\$560.84	Non-Drug
E1805	RR	Adjust wrist ext/flex device		\$210.93	Non-Drug
E1806	RR	SPS wrist device		\$175.27	Non-Drug
E1810	RR	Adjust knee ext/flex device		\$207.87	Non-Drug
E1811	RR	SPS knee device		\$224.52	Non-Drug
E1815	RR	Adjust ankle ext/flex device		\$210.93	Non-Drug
E1816	RR	SPS ankle device		\$228.21	Non-Drug
E1818	RR	SPS forearm device		\$233.19	Non-Drug
E1820	NU	Soft interface material		\$133.09	Non-Drug
E1820	RR	Soft interface material		\$15.21	Non-Drug
E1820	UE	Soft interface material		\$97.43	Non-Drug
E1821	NU	Replacement interface SPSD		\$174.12	Non-Drug
E1821	RR	Replacement interface SPSD		\$18.44	Non-Drug
E1821	UE	Replacement interface SPSD		\$128.22	Non-Drug
E1825	RR	Adjust finger ext/flex devc		\$210.93	Non-Drug
E1830	RR	Adjust toe ext/flex device		\$210.93	Non-Drug
E1840	RR	Adj shoulder ext/flex device		\$658.44	Non-Drug
E2000	RR	Gastric suction pump hme mdl		\$80.88	Non-Drug
E2100	NU	Bld glucose monitor w voice		\$1,113.12	Non-Drug
E2100	RR	Bld glucose monitor w voice		\$102.67	Non-Drug
E2100	UE	Bld glucose monitor w voice		\$832.45	Non-Drug
E2101	NU	Bld glucose monitor w lance		\$319.54	Non-Drug
E2101	RR	Bld glucose monitor w lance		\$29.97	Non-Drug
E2101	UE	Bld glucose monitor w lance		\$237.26	Non-Drug
E2360	NU	22nf nonsealed leadacid		\$149.49	Non-Drug
E2360	RR	22nf nonsealed leadacid		\$17.73	Non-Drug
E2360	UE	22nf nonsealed leadacid		\$112.26	Non-Drug
E2361	NU	22nf sealed leadacid battery		\$185.46	Non-Drug
E2361	RR	22nf sealed leadacid battery		\$21.09	Non-Drug
E2361	UE	22nf sealed leadacid battery		\$139.26	Non-Drug
E2362	NU	Gr24 nonsealed leadacid		\$122.49	Non-Drug
E2362	RR	Gr24 nonsealed leadacid		\$15.07	Non-Drug
E2362	UE	Gr24 nonsealed leadacid		\$92.00	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 25 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
E2363	NU	Gr24 sealed leadacid battery		\$247.16	Non-Drug
E2363	RR	Gr24 sealed leadacid battery		\$27.00	Non-Drug
E2363	UE	Gr24 sealed leadacid battery		\$185.50	Non-Drug
E2364	NU	U1nonsealed leadacid battery		\$149.49	Non-Drug
E2364	RR	U1nonsealed leadacid battery		\$17.73	Non-Drug
E2364	UE	U1nonsealed leadacid battery		\$112.26	Non-Drug
E2365	NU	U1 sealed leadacid battery		\$149.27	Non-Drug
E2365	RR	U1 sealed leadacid battery		\$17.64	Non-Drug
E2365	UE	U1 sealed leadacid battery		\$112.12	Non-Drug
E2366	NU	Battery charger, single mode		\$350.08	Non-Drug
E2366	RR	Battery charger, single mode		\$36.93	Non-Drug
E2366	UE	Battery charger, single mode		\$262.70	Non-Drug
E2367	NU	Battery charger, dual mode		\$556.20	Non-Drug
E2367	RR	Battery charger, dual mode		\$56.55	Non-Drug
E2367	UE	Battery charger, dual mode		\$417.29	Non-Drug
E2402	RR	Neg press wound therapy pump		\$2,986.56	Non-Drug
E2500	NU	SGD digitized pre-rec <=8min		\$673.01	Non-Drug
E2500	RR	SGD digitized pre-rec <=8min		\$58.67	Non-Drug
E2500	UE	SGD digitized pre-rec <=8min		\$502.35	Non-Drug
E2502	NU	SGD prerec msg >8min <=20min		\$2,077.71	Non-Drug
E2502	RR	SGD prerec msg >8min <=20min		\$199.15	Non-Drug
E2502	UE	SGD prerec msg >8min <=20min		\$1,555.90	Non-Drug
E2504	NU	SGD prerec msg>20min <=40min		\$2,743.86	Non-Drug
E2504	RR	SGD prerec msg>20min <=40min		\$265.77	Non-Drug
E2504	UE	SGD prerec msg>20min <=40min		\$2,055.45	Non-Drug
E2506	NU	SGD prerec msg > 40 min		\$4,027.76	Non-Drug
E2506	RR	SGD prerec msg > 40 min		\$394.13	Non-Drug
E2506	UE	SGD prerec msg > 40 min		\$3,018.37	Non-Drug
E2508	NU	SGD spelling phys contact		\$6,233.51	Non-Drug
E2508	RR	SGD spelling phys contact		\$614.73	Non-Drug
E2508	UE	SGD spelling phys contact		\$4,672.75	Non-Drug
E2510	NU	SGD w multi methods msg/accs		\$11,804.63	Non-Drug
E2510	RR	SGD w multi methods msg/accs		\$1,171.81	Non-Drug
E2510	UE	SGD w multi methods msg/accs		\$8,851.06	Non-Drug
J0120		Tetracyclin injection		\$125.83	Drug
J0130		Abciximab injection	a	\$828.62	Drug
J0150		Injection adenosine 6 MG	a	\$73.25	Drug
J0170		Adrenalin epinephrin inject		\$5.00	Drug
J0200		Alatrofloxacin mesylate		\$41.05	Drug
J0205		Algucerase injection	a	\$77.24	Drug
J0207		Amifostine	a	\$810.84	Drug
J0210		Methyldopate hcl injection		\$24.83	Drug
J0256		Alpha 1 proteinase inhibitor	a	\$5.00	Drug
J0270		Alprostadil for injection		\$0.49	Drug
J0275		Alprostadil urethral suppos		\$43.75	Drug
J0280		Aminophyllin 250 MG inj		\$1.39	Drug
J0282		Amiodarone HCl		\$13.11	Drug
J0285		Amphotericin B		\$22.12	Drug
J0287		Amphotericin b lipid complex	a	\$45.98	Drug
J0288		Ampho b cholesteryl sulfate	a	\$32.04	Drug
J0289		Amphotericin b liposome inj	a	\$68.59	Drug
J0290		Ampicillin 500 MG inj		\$3.20	Drug
J0295		Ampicillin sodium per 1.5 gm		\$15.81	Drug
J0300		Amobarbital 125 MG inj		\$5.00	Drug
J0330		Succinylcholine chloride inj		\$0.49	Drug
J0360		Hydralazine hcl injection		\$33.84	Drug
J0380		Inj metaraminol bitartrate		\$2.30	Drug
J0390		Chloroquine injection		\$50.64	Drug
J0456		Azithromycin		\$51.97	Drug
J0460		Atropine sulfate injection		\$1.39	Drug
J0470		Dimecaprol injection		\$49.31	Drug
J0475		Baclofen 10 MG injection		\$354.52	Drug
J0476		Baclofen intrathecal trial		\$138.41	Drug
J0500		Dicyclomine injection		\$36.54	Drug
J0515		Inj benzotropine mesylate		\$7.70	Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 26 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
J0530		Penicillin g benzathine inj		\$25.73	Drug
J0540		Penicillin g benzathine inj		\$48.64	Drug
J0550		Penicillin g benzathine inj		\$91.20	Drug
J0560		Penicillin g benzathine inj		\$21.22	Drug
J0570		Penicillin g benzathine inj		\$41.95	Drug
J0580		Penicillin g benzathine inj		\$74.58	Drug
J0585		Botulinum toxin a per unit	a	\$10.41	Drug
J0587		Botulinum toxin type B	a	\$18.52	Drug
J0592		Buprenorphine hydrochloride		\$1.39	Drug
J0600		Edelate calcium disodium inj		\$81.89	Drug
J0610		Calcium gluconate injection		\$1.39	Drug
J0620		Calcium glycer & lact/10 ML		\$13.11	Drug
J0630		Calcitonin salmon injection		\$72.58	Drug
J0636		Inj calcitriol per 0.1 mcg		\$0.49	Drug
J0637		Caspofungin acetate	a	\$63.94	Drug
J0640		Leucovorin calcium injection		\$6.80	Drug
J0670		Inj mepivacaine HCL/10 ml		\$4.10	Drug
J0690		Cefazolin sodium injection		\$4.10	Drug
J0692		Cefepime HCl for injection		\$1.39	Drug
J0694		Cefoxitin sodium injection		\$23.02	Drug
J0696		Ceftriaxone sodium injection		\$32.04	Drug
J0697		Sterile cefuroxime injection		\$6.80	Drug
J0698		Cefotaxime sodium injection		\$20.32	Drug
J0702		Betamethasone acet&sod phosp		\$10.41	Drug
J0704		Betamethasone sod phosp/4 MG		\$2.30	Drug
J0706		Caffeine citrate injection		\$6.80	Drug
J0710		Cephapirin sodium injection		\$15.77	Drug
J0713		Inj ceftazidime per 500 mg		\$14.01	Drug
J0715		Ceftizoxime sodium / 500 MG		\$10.41	Drug
J0720		Chloramphenicol sodium injec		\$14.91	Drug
J0725		Chorionic gonadotropin/1000u		\$5.00	Drug
J0735		Clonidine hydrochloride		\$99.18	Drug
J0740		Cidofovir injection		\$1,355.92	Drug
J0743		Cilastatin sodium injection		\$33.84	Drug
J0744		Ciprofloxacin iv		\$29.33	Drug
J0745		Inj codeine phosphate /30 MG		\$0.49	Drug
J0760		Colchicine injection		\$14.91	Drug
J0770		Colistimethate sodium inj		\$97.85	Drug
J0780		Prochlorperazine injection		\$8.60	Drug
J0800		Corticotropin injection		\$159.69	Drug
J0835		Inj cosyntropin per 0.25 MG		\$39.25	Drug
J0850		Cytomegalovirus imm IV /vial	a	\$1,145.80	Drug
J0895		Deferoxamine mesylate inj		\$32.94	Drug
J0900		Testosterone enanthate inj		\$3.20	Drug
J0945		Brompheniramine maleate inj		\$1.39	Drug
J0970		Estradiol valerate injection		\$3.20	Drug
J1000		Depo-estradiol cypionate inj		\$4.10	Drug
J1020		Methylprednisolone 20 MG inj		\$5.00	Drug
J1030		Methylprednisolone 40 MG inj		\$8.60	Drug
J1040		Methylprednisolone 80 MG inj		\$17.62	Drug
J1051		Medroxyprogesterone inj		\$10.41	Drug
J1055		Medroxyprogester acetate inj		\$119.13	Drug
J1056		MA/EC contraceptive injection		\$50.64	Drug
J1060		Testosterone cypionate 1 ML		\$9.51	Drug
J1070		Testosterone cypionat 100 MG		\$10.41	Drug
J1080		Testosterone cypionat 200 MG		\$20.32	Drug
J1094		Inj dexamethasone acetate		\$1.39	Drug
J1100		Dexamethasone sodium phos		\$0.49	Drug
J1110		Inj dihydroergotamine mesylt		\$75.91	Drug
J1120		Acetazolamid sodium injectio		\$43.75	Drug
J1160		Digoxin injection		\$3.20	Drug
J1165		Phenytoin sodium injection		\$1.39	Drug
J1170		Hydromorphone injection		\$3.20	Drug
J1180		Dyphylline injection		\$19.42	Drug
J1190		Dexrazoxane HCl injection	a	\$384.44	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 27 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
J1200		Diphenhydramine hcl injectio		\$3.20	Drug
J1205		Chlorothiazide sodium inj		\$22.12	Drug
J1212		Dimethyl sulfoxide 50% 50 ML		\$82.56	Drug
J1230		Methadone injection		\$1.39	Drug
J1240		Dimenhydrinate injection		\$0.49	Drug
J1245		Dipyridamole injection	a	\$12.21	Drug
J1250		Inj dobutamine HCL/250 mg		\$9.51	Drug
J1260		Dolasetron mesylate		\$40.57	Drug
J1270		Injection, doxercaliferol		\$11.31	Drug
J1320		Amiripryline injection		\$5.90	Drug
J1325		Epoprostenol injection		\$26.25	Drug
J1327		Eptifibatide injection	a	\$27.53	Drug
J1364		Erythro lactobionate /500 MG		\$6.80	Drug
J1380		Estradiol valerate 10 MG inj		\$0.49	Drug
J1390		Estradiol valerate 20 MG inj		\$2.30	Drug
J1410		Inj estrogen conjugate 25 MG		\$109.15	Drug
J1435		Injection estrone per 1 MG		\$0.49	Drug
J1436		Ethronate disodium inj		\$133.76	Drug
J1438		Etanercept injection	a	\$258.77	Drug
J1440		Filgrastim 300 mcg injection	a	\$294.01	Drug
J1441		Filgrastim 480 mcg injection	a	\$488.17	Drug
J1450		Fluconazole		\$164.34	Drug
J1452		Intraocular Fomivirsen na		\$1,525.48	Drug
J1455		Foscarnet sodium injection		\$27.53	Drug
J1460		Gamma globulin 1 CC inj		\$23.93	Drug
J1470		Gamma globulin 2 CC inj		\$47.98	Drug
J1480		Gamma globulin 3 CC inj		\$65.93	Drug
J1490		Gamma globulin 4 CC inj		\$83.89	Drug
J1500		Gamma globulin 5 CC inj		\$102.50	Drug
J1510		Gamma globulin 6 CC inj		\$120.46	Drug
J1520		Gamma globulin 7 CC inj		\$138.41	Drug
J1530		Gamma globulin 8 CC inj		\$157.03	Drug
J1540		Gamma globulin 9 CC inj		\$174.98	Drug
J1550		Gamma globulin 10 CC inj		\$192.94	Drug
J1560		Gamma globulin > 10 CC inj		\$19.48	Drug
J1563		IV immune globulin	a	\$103.83	Drug
J1564		Immune globulin 10 mg	a	\$1.39	Drug
J1565		RSV-ivig	a	\$35.64	Drug
J1570		Ganciclovir sodium injection	a	\$67.26	Drug
J1580		Garamycin gentamicin inj		\$4.10	Drug
J1590		Gatifloxacin injection		\$1.39	Drug
J1600		Gold sodium thiomaleate inj		\$28.43	Drug
J1610		Glucagon hydrochloride/1 MG		\$83.89	Drug
J1620		Gonadorelin hydroch/ 100 mcg		\$333.24	Drug
J1626		Granisetron HCl injection	a	\$37.44	Drug
J1630		Haloperidol injection		\$14.01	Drug
J1631		Haloperidol decanoate inj		\$19.42	Drug
J1642		Inj heparin sodium per 10 u		\$0.49	Drug
J1644		Inj heparin sodium per 1000u		\$0.49	Drug
J1645		Dalteparin sodium		\$33.84	Drug
J1650		Inj enoxaparin sodium		\$13.11	Drug
J1652		Fondaparinux sodium		\$17.62	Drug
J1655		Tinzaparin sodium injection		\$7.70	Drug
J1670		Tetanus immune globulin inj		\$200.92	Drug
J1700		Hydrocortisone acetate inj		\$0.49	Drug
J1710		Hydrocortisone sodium ph inj		\$14.91	Drug
J1720		Hydrocortisone sodium succ i		\$4.10	Drug
J1730		Diazoxide injection		\$207.57	Drug
J1742		Ibutilide fumarate injection		\$411.70	Drug
J1745		Infliximab injection	a	\$115.80	Drug
J1750		Iron dextran		\$38.35	Drug
J1756		Iron sucrose injection		\$1.39	Drug
J1785		Injection imiglucerase /unit	a	\$8.60	Drug
J1790		Droperidol injection		\$5.90	Drug
J1800		Propranolol injection		\$24.83	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 28 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
J1810		Droperidol/fentanyl inj		\$13.03	Drug
J1815		Insulin injection		\$0.49	Drug
J1817		Insulin for insulin pump use		\$5.90	Drug
J1825		Interferon beta-1a	a	\$546.02	Drug
J1830		Interferon beta-1b / .25 MG	a	\$118.46	Drug
J1835		Itraconazole injection		\$69.92	Drug
J1840		Kanamycin sulfate 500 MG inj		\$6.80	Drug
J1850		Kanamycin sulfate 75 MG inj		\$0.49	Drug
J1885		Ketorolac tromethamine inj		\$7.70	Drug
J1890		Cephalothin sodium injection		\$22.12	Drug
J1940		Furosemide injection		\$1.39	Drug
J1950		Leuprolide acetate /3.75 MG	a	\$819.31	Drug
J1955		Inj levocarnitine per 1 gm		\$65.93	Drug
J1956		Levofloxacin injection		\$44.65	Drug
J1960		Levorphanol tartrate inj		\$7.70	Drug
J1980		Hyoscyamine sulfate inj		\$18.52	Drug
J1990		Chlordiazepoxide injection		\$51.30	Drug
J2010		Lincomycin injection		\$6.80	Drug
J2020		Linezolid injection	a	\$69.92	Drug
J2060		Lorazepam injection		\$6.80	Drug
J2150		Mannitol injection		\$6.80	Drug
J2175		Meperidine hydrochl /100 MG		\$0.49	Drug
J2180		Mependine/promethazine inj		\$9.51	Drug
J2210		Methylergonovin maleate inj		\$8.60	Drug
J2250		Inj midazolam hydrochloride		\$2.30	Drug
J2260		Inj milrinone lactate / 5 MG	a	\$93.86	Drug
J2270		Morphine sulfate injection		\$1.39	Drug
J2271		Morphine so4 injection 100mg		\$9.51	Drug
J2275		Morphine sulfate injection		\$4.10	Drug
J2300		Inj nalbuphine hydrochloride		\$3.20	Drug
J2310		Inj naloxone hydrochloride		\$5.00	Drug
J2320		Nandrolone decanoate 50 MG		\$7.70	Drug
J2321		Nandrolone decanoate 100 MG		\$14.91	Drug
J2322		Nandrolone decanoate 200 MG		\$33.84	Drug
J2324		Nesiritide	a	\$241.48	Drug
J2355		Oprelvekin injection	a	\$438.30	Drug
J2360		Orphenadrine injection		\$11.31	Drug
J2370		Phenylephrine hcl injection		\$2.30	Drug
J2400		Chloroprocaine hcl injection		\$13.11	Drug
J2405		Ondansetron hcl injection		\$13.11	Drug
J2410		Oxymorphone hcl injection		\$5.90	Drug
J2430		Pamidronate disodium /30 MG	a	\$434.98	Drug
J2440		Papaverin hcl injection		\$6.80	Drug
J2460		Oxytetracycline injection		\$1.39	Drug
J2501		Paricalcitol		\$10.41	Drug
J2510		Penicillin g procaine inj		\$20.32	Drug
J2515		Pentobarbital sodium inj		\$2.30	Drug
J2540		Penicillin g potassium inj		\$0.49	Drug
J2543		Piperacillin/tazobactam		\$10.41	Drug
J2545		Pentamidine isethionate/300mg	a	\$82.56	Drug
J2550		Promethazine hcl injection		\$5.90	Drug
J2560		Phenobarbital sodium inj		\$3.20	Drug
J2590		Oxytocin injection		\$2.30	Drug
J2597		Inj desmopressin acetate		\$6.80	Drug
J2650		Prednisolone acetate inj		\$0.49	Drug
J2670		Totazoline hcl injection		\$7.70	Drug
J2675		Inj progesterone per 50 MG		\$7.70	Drug
J2680		Fluphenazine decanoate 25 MG		\$18.52	Drug
J2690		Procainamide hcl injection		\$2.30	Drug
J2700		Oxacillin sodium injection		\$1.39	Drug
J2710		Neostigmine methylsulfte inj		\$1.39	Drug
J2720		Inj protamine sulfate/10 MG		\$1.39	Drug
J2725		Inj pralirelin per 250 mcg		\$49.97	Drug
J2730		Pralidoxime chloride inj		\$175.65	Drug
J2760		Phentolamine mesylate inj		\$61.94	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 29 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
J2765		Metoclopramide hcl injection		\$3.20	Drug
J2770		Quinupristin/dalfopristin		\$194.27	Drug
J2780		Ranitidine hydrochloride inj		\$2.30	Drug
J2788		Rho d immune globulin 50 mcg		\$93.20	Drug
J2790		Rho d immune globulin inj	a	\$170.99	Drug
J2792		Rho(D) immune globulin h, sd	a	\$43.75	Drug
J2795		Ropivacaine HCl injection		\$0.49	Drug
J2800		Methocarbamol injection		\$7.70	Drug
J2810		Inj theophylline per 40 MG		\$1.35	Drug
J2820		Sargramostim injection	a	\$55.29	Drug
J2910		Aurothioglucose injection		\$36.54	Drug
J2912		Sodium chloride injection		\$0.49	Drug
J2916		Na ferri gluconate complex		\$17.62	Drug
J2920		Methylprednisolone injection		\$3.20	Drug
J2930		Methylprednisolone injection		\$4.10	Drug
J2940		Somatrem injection		\$83.89	Drug
J2941		Somatropin injection	a	\$84.55	Drug
J2950		Promazine hcl injection		\$0.49	Drug
J2993		Retepase injection	a	\$2,092.67	Drug
J2995		Inj streptokinase /250000 IU	a	\$153.04	Drug
J2997		Alteplase recombinant	a	\$69.92	Drug
J3000		Streptomycin injection		\$13.11	Drug
J3010		Fentanyl citrate injection		\$1.39	Drug
J3030		Sumatriptan succinate / 6 MG		\$53.96	Drug
J3070		Pentazocine injection		\$11.31	Drug
J3100		Tenecteplase injection	a	\$4,298.95	Drug
J3105		Terbutaline sulfate inj		\$57.95	Drug
J3120		Testosterone enanthate inj		\$19.42	Drug
J3130		Testosterone enanthate inj		\$38.35	Drug
J3140		Testosterone suspension inj		\$13.19	Drug
J3150		Testosteron propionate inj		\$3.20	Drug
J3230		Chlorpromazine hcl injection		\$9.51	Drug
J3240		Thyrotropin injection	a	\$995.52	Drug
J3245		Tirofiban hydrochloride	a	\$762.79	Drug
J3250		Trimethobenzamide hcl inj		\$3.20	Drug
J3260		Tobramycin sulfate injection		\$9.51	Drug
J3265		Injection torsemide 10 mg/ml		\$3.20	Drug
J3280		Thiethylperazine maleate inj		\$12.21	Drug
J3301		Triamcinolone acetonide inj		\$3.20	Drug
J3302		Triamcinolone diacetate inj		\$0.49	Drug
J3303		Triamcinolone hexacetonid inj		\$1.39	Drug
J3305		Inj trimetrexate glucuronate	a	\$238.15	Drug
J3310		Perphenazine injection		\$19.42	Drug
J3315		Triptorelin pamoate	a	\$646.43	Drug
J3320		Spectinomycin di-hcl inj		\$56.62	Drug
J3350		Urea injection		\$185.62	Drug
J3360		Diazepam injection		\$1.39	Drug
J3364		Urokinase 5000 IU injection		\$22.12	Drug
J3365		Urokinase 250,000 IU inj	a	\$826.63	Drug
J3370		Vancoamycin hcl injection		\$5.90	Drug
J3395		Verteporfin injection	a	\$2,334.71	Drug
J3400		Triflupromazine hcl inj		\$75.14	Drug
J3410		Hydroxyzine hcl injection		\$2.30	Drug
J3420		Vitamin b12 injection		\$0.49	Drug
J3430		Vitamin k phytonadione inj		\$4.10	Drug
J3470		Hyaluronidase injection		\$54.63	Drug
J3475		Inj magnesium sulfate		\$0.49	Drug
J3480		Inj potassium chloride		\$0.49	Drug
J3485		Zidovudine		\$1.39	Drug
J3487		Zoledronic acid	a	\$357.84	Drug
J3490		Drugs unclassified injection		\$14.68	Drug
J3520		Edetate disodium per 150 mg		\$0.49	Drug
J3535		Metered dose inhaler drug		\$2.02	Drug
J3570		Laetrile amygdalin vit B17		\$36.18	Drug
J7030		Normal saline solution infus		\$17.62	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 30 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
J7040		Normal saline solution infus		\$9.51	Drug
J7042		5% dextrose/normal saline		\$20.32	Drug
J7050		Normal saline solution infus		\$3.20	Drug
J7051		Sterile saline/water		\$0.49	Drug
J7060		5% dextrose/water		\$18.52	Drug
J7070		D5w infusion		\$23.02	Drug
J7100		Dextran 40 infusion		\$51.30	Drug
J7110		Dextran 75 infusion		\$30.23	Drug
J7120		Ringers lactate infusion		\$24.83	Drug
J7130		Hypertonic saline solution		\$0.49	Drug
J7190		Factor viii	a	\$1.39	Drug
J7191		Factor VIII (porcine)	a	\$4.10	Drug
J7192		Factor viii recombinant	a	\$2.30	Drug
J7193		Factor IX non-recombinant	a	\$2.30	Drug
J7194		Factor ix complex	a	\$0.49	Drug
J7195		Factor IX recombinant	a	\$2.30	Drug
J7197		Antithrombin iii injection		\$3.20	Drug
J7198		Anti-inhibitor	a	\$3.20	Drug
J7300		Intraut copper contraceptive		\$467.47	Drug
J7302		Levonorgestrel iu contracept		\$786.73	Drug
J7308		Aminolevulinic acid hcl top		\$172.32	Drug
J7310		Ganciclovir long act implant	a	\$7,580.43	Drug
J7317		Sodium hyaluronate injection	a	\$232.17	Drug
J7320		Hylan G-F 20 injection	a	\$369.81	Drug
J7330		Cultured chondrocytes implnt		\$24,171.38	Drug
J7340		Metabolic active D/E tissue		\$57.95	Drug
J7342		Metabolically active tissue		\$24.32	Non-Drug
J7500		Azathioprine oral 50mg		\$2.30	Drug
J7501		Azathioprine parenteral		\$106.49	Drug
J7502		Cyclosporine oral 100 mg	a	\$11.31	Drug
J7504		Lymphocyte immune globulin	a	\$455.59	Drug
J7505		Monoclonal antibodies	a	\$1,635.86	Drug
J7506		Prednisone oral		\$0.49	Drug
J7507		Tacrolimus oral per 1 MG	a	\$6.80	Drug
J7509		Methylprednisolone oral		\$0.49	Drug
J7510		Prednisolone oral per 5 mg		\$0.49	Drug
J7511		Antithymocyte globulin rabbit	a	\$581.26	Drug
J7513		Daclizumab, parenteral	a	\$688.98	Drug
J7515		Cyclosporine oral 25 mg		\$2.30	Drug
J7516		Cyclosporin parenteral 250mg		\$63.94	Drug
J7517		Mycophenolate mofetil oral	a	\$5.90	Drug
J7520		Sirolimus, oral		\$14.91	Drug
J7525		Tacrolimus injection	a	\$200.92	Drug
J7599		Immunosuppressive drug noc		\$6.18	Drug
J7608		Acetylcysteine inh sol u d		\$57.29	Drug
J7618		Albuterol inh sol con	a	\$0.49	Drug
J7619		Albuterol inh sol u d	a	\$0.49	Drug
J7622		Beclomethasone inhalatr sol		\$0.49	Drug
J7624		Betamethasone inhalation sol		\$1.60	Drug
J7626		Budesonide inhalation sol		\$9.51	Drug
J7628		Bitolterol mes inhal sol con		\$0.56	Drug
J7629		Bitolterol mes inh sol u d		\$1.39	Drug
J7631		Cromolyn sodium inh sol u d		\$0.49	Drug
J7633		Budesonide concentrated sol		\$0.49	Drug
J7635		Atropine inhal sol con		\$0.49	Drug
J7636		Atropine inhal sol unit dose		\$0.49	Drug
J7637		Dexamethasone inhal sol con		\$0.49	Drug
J7638		Dexamethasone inhal sol u d		\$0.49	Drug
J7639		Domase alpha inhal sol u d		\$35.64	Drug
J7641		Flunisolide, inhalation sol		\$0.49	Drug
J7642		Glycopyrrolate inhal sol con		\$0.49	Drug
J7643		Glycopyrrolate inhal sol u d	a	\$0.49	Drug
J7644		Ipratropium brom inh sol u d	a	\$6.80	Drug
J7649		Isoetharine hcl inh sol u d		\$1.39	Drug
J7658		Isoproterenolhcl inh sol con		\$7.70	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 31 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
J7659		Isoproterenol hcl inh sol ud		\$7.70	Drug
J7668		Metaproterenol inh sol con		\$0.15	Drug
J7669		Metaproterenol inh sol u d		\$2.43	Drug
J7680		Terbutaline so4 inh sol con		\$0.49	Drug
J7681		Terbutaline so4 inh sol u d		\$0.49	Drug
J7682		Tobramycin inhalation sol		\$108.49	Drug
J7683		Triamcinolone inh sol con		\$0.49	Drug
J7684		Triamcinolone inh sol u d		\$0.49	Drug
J7699		Inhalation solution for DME	a	\$17.77	Drug
J7799		Non-inhalation drug for DME	a	\$62.92	Drug
J8499		Oral prescrip drug non chemo	a	\$2.25	Drug
J8510		Oral busulfan	a	\$6.58	Drug
J8520		Capecitabine, oral, 150 mg	a	\$8.77	Drug
J8521		Capecitabine, oral, 500 mg	a	\$30.71	Drug
J8530		Cyclophosphamide oral 25 MG		\$7.68	Drug
J8560		Etoposide oral 50 MG	a	\$163.74	Drug
J8600		Melphalan oral 2 MG		\$7.68	Drug
J8610		Methotrexate oral 2.5 MG		\$10.97	Drug
J8700		Temozolomide	a	\$21.93	Drug
J8999		Oral prescription drug chemo		\$17.64	Drug
J9000		Doxorubic hcl 10 MG v1 chemo	a	\$25.22	Drug
J9001		Doxorubicin hcl liposome inj	a	\$638.45	Drug
J9010		Alemtuzumab injection	a	\$942.99	Drug
J9015		Aldesleukin/single use vial	a	\$1,234.37	Drug
J9017		Arsenic trioxide	a	\$8.77	Drug
J9020		Asparaginase injection	a	\$141.26	Drug
J9031		Bcg live intravesical vac	a	\$343.51	Drug
J9040		Bleomycin sulfate injection	a	\$359.94	Drug
J9045		Carboplatin injection	a	\$305.48	Drug
J9050		Carmus bischl nitro inj		\$293.38	Drug
J9060		Cisplatin 10 MG injection	a	\$39.48	Drug
J9062		Cisplatin 50 MG injection		\$168.92	Drug
J9065		Inj cladribine per 1 MG	a	\$122.25	Drug
J9070		Cyclophosphamide 100 MG inj	a	\$15.35	Drug
J9080		Cyclophosphamide 200 MG inj		\$28.51	Drug
J9090		Cyclophosphamide 500 MG inj		\$59.15	Drug
J9091		Cyclophosphamide 1.0 grm inj		\$106.69	Drug
J9092		Cyclophosphamide 2.0 grm inj		\$200.90	Drug
J9093		Cyclophosphamide lyophilized	a	\$15.35	Drug
J9094		Cyclophosphamide lyophilized		\$30.71	Drug
J9095		Cyclophosphamide lyophilized		\$59.15	Drug
J9096		Cyclophosphamide lyophilized	a	\$106.69	Drug
J9097		Cyclophosphamide lyophilized		\$206.09	Drug
J9100		Cytarabine hcl 100 MG inj	a	\$21.93	Drug
J9110		Cytarabine hcl 500 MG inj		\$21.93	Drug
J9120		Dactinomycin actinomycin d		\$36.19	Drug
J9130		Dacarbazine 100 mg inj	a	\$29.61	Drug
J9140		Dacarbazine 200 MG inj		\$57.42	Drug
J9150		Daunorubicin	a	\$165.46	Drug
J9151		Daunorubicin citrate liposom	a	\$145.58	Drug
J9160		Denileukin difitox, 300 mcg	a	\$2,131.91	Drug
J9165		Diethylstilbestrol injection		\$38.38	Drug
J9170		Docetaxel	a	\$636.40	Drug
J9181		Etoposide 10 MG inj	a	\$4.39	Drug
J9182		Etoposide 100 MG inj	a	\$44.96	Drug
J9185		Fludarabine phosphate inj	a	\$665.27	Drug
J9190		Fluorouracil injection		\$5.48	Drug
J9200		Floxuridine injection	a	\$299.43	Drug
J9201		Gemcitabine HCl	a	\$247.57	Drug
J9202		Goserelin acetate implant	a	\$761.90	Drug
J9206		Irinotecan injection	a	\$295.98	Drug
J9208		Ifosfomide injection	a	\$322.77	Drug
J9209		Mesna injection	a	\$84.22	Drug
J9211		Idarubicin hcl injection	a	\$761.27	Drug
J9212		Interferon alfacon-1		\$8.60	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 32 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
J9213		Interferon alfa-2a inj	a	\$84.22	Drug
J9214		Interferon alfa-2b inj	a	\$39.48	Drug
J9215		Interferon alfa-n3 inj	a	\$20.84	Drug
J9216		Interferon gamma 1-b inj	a	\$444.40	Drug
J9217		Leuprolide acetate suspnsion	a	\$971.47	Drug
J9218		Leuprolide acetate injecton	a	\$65.20	Drug
J9219		Leuprolide acetate implant	a	\$8,249.33	Drug
J9230		Mechlorethamine hcl inj		\$31.80	Drug
J9245		Inj melphalan hydrochl 50 MG	a	\$761.90	Drug
J9250		Methotrexate sodium inj		\$1.10	Drug
J9260		Methotrexate sodium inj	a	\$12.06	Drug
J9265		Paclitaxel injection	a	\$335.73	Drug
J9266		Pegaspargase/singl dose vial		\$2,275.95	Drug
J9268		Pentostatin injection	a	\$2,893.36	Drug
J9270		Plicamycin (mithramycin) inj	a	\$206.09	Drug
J9280		Mitomycin 5 MG inj	a	\$143.86	Drug
J9290		Mitomycin 20 MG inj		\$441.18	Drug
J9291		Mitomycin 40 MG inj		\$558.60	Drug
J9293		Mitoxantrone hydrochl / 5 MG	a	\$670.29	Drug
J9300		Gemtuzumab ozogamicin	a	\$3,413.53	Drug
J9310		Rituximab cancer treatment	a	\$847.86	Drug
J9320		Streptozocin injection	a	\$304.62	Drug
J9340		Thiotepa injection	a	\$205.22	Drug
J9350		Topotecan	a	\$1,316.57	Drug
J9355		Trastuzumab	a	\$103.83	Drug
J9357		Valrubicin, 200 mg	a	\$850.56	Drug
J9360		Vinblastine sulfate inj		\$8.77	Drug
J9370		Vincristine sulfate 1 MG inj		\$47.15	Drug
J9375		Vincristine sulfate 2 MG inj		\$118.79	Drug
J9380		Vincristine sulfate 5 MG inj		\$196.58	Drug
J9390		Vinorelbine tartrate/10 mg	a	\$187.94	Drug
J9600		Porfimer sodium	a	\$4,044.75	Drug
J9999		Chemotherapy drug		\$30.43	Drug
K0001	NU	Standard wheelchair		\$723.37	Non-Drug
K0001	RR	Standard wheelchair		\$72.96	Non-Drug
K0001	UE	Standard wheelchair		\$542.53	Non-Drug
K0002	NU	Stnd hemi (low seat) whlchr		\$863.80	Non-Drug
K0002	RR	Stnd hemi (low seat) whlchr		\$109.04	Non-Drug
K0002	UE	Stnd hemi (low seat) whlchr		\$678.17	Non-Drug
K0003	NU	Lightweight wheelchair		\$1,357.38	Non-Drug
K0003	RR	Lightweight wheelchair		\$119.32	Non-Drug
K0003	UE	Lightweight wheelchair		\$1,018.68	Non-Drug
K0004	NU	High strength ltwt whlchr		\$2,116.52	Non-Drug
K0004	RR	High strength ltwt whlchr		\$177.74	Non-Drug
K0004	UE	High strength ltwt whlchr		\$1,587.22	Non-Drug
K0005	NU	Ultralightweight wheelchair		\$2,451.85	Non-Drug
K0005	RR	Ultralightweight wheelchair		\$245.64	Non-Drug
K0005	UE	Ultralightweight wheelchair		\$1,839.00	Non-Drug
K0006	NU	Heavy duty wheelchair		\$1,519.24	Non-Drug
K0006	RR	Heavy duty wheelchair		\$166.82	Non-Drug
K0006	UE	Heavy duty wheelchair		\$1,145.08	Non-Drug
K0007	NU	Extra heavy duty wheelchair		\$2,370.23	Non-Drug
K0007	RR	Extra heavy duty wheelchair		\$237.22	Non-Drug
K0007	UE	Extra heavy duty wheelchair		\$2,320.73	Non-Drug
K0009		Other manual wheelchair/base		\$555.58	Non-Drug
K0010	NU	Stnd wt frame power whlchr		\$5,652.10	Non-Drug
K0010	RR	Stnd wt frame power whlchr		\$565.37	Non-Drug
K0010	UE	Stnd wt frame power whlchr		\$4,240.03	Non-Drug
K0011	NU	Stnd wt pwr whlchr w control		\$9,524.19	Non-Drug
K0011	RR	Stnd wt pwr whlchr w control		\$702.81	Non-Drug
K0012		Ltwt portbl power whlchr		\$4,103.77	Non-Drug
K0012	RR	Ltwt portbl power whlchr		\$431.35	Non-Drug
K0014		Other power whlchr base		\$4.94	Non-Drug
K0015	NU	Detach non-adjus hght armrst		\$241.46	Non-Drug
K0015	RR	Detach non-adjus hght armrst		\$26.46	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 33 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
K0015	UE	Detach non-adjust hght armrst		\$181.22	Non-Drug
K0017	NU	Detach adjust armrest base		\$68.30	Non-Drug
K0017	RR	Detach adjust armrest base		\$9.89	Non-Drug
K0017	UE	Detach adjust armrest base		\$52.00	Non-Drug
K0018	NU	Detach adjust armrst upper		\$39.61	Non-Drug
K0018	RR	Detach adjust armrst upper		\$5.58	Non-Drug
K0018	UE	Detach adjust armrst upper		\$30.58	Non-Drug
K0019	NU	Arm pad each		\$25.27	Non-Drug
K0019	RR	Arm pad each		\$3.39	Non-Drug
K0019	UE	Arm pad each		\$19.80	Non-Drug
K0020	NU	Fixed adjust armrest pair		\$62.32	Non-Drug
K0020	RR	Fixed adjust armrest pair		\$9.14	Non-Drug
K0020	UE	Fixed adjust armrest pair		\$47.57	Non-Drug
K0023	NU	Planr back insrt foam w/strp		\$125.30	Non-Drug
K0023	RR	Planr back insrt foam w/strp		\$15.33	Non-Drug
K0023	UE	Planr back insrt foam w/strp		\$94.12	Non-Drug
K0024	NU	Ptnr back insrt foam w/hrdwr		\$148.23	Non-Drug
K0024	RR	Ptnr back insrt foam w/hrdwr		\$17.54	Non-Drug
K0024	UE	Ptnr back insrt foam w/hrdwr		\$111.32	Non-Drug
K0037	NU	High mount flip-up footrest		\$64.47	Non-Drug
K0037	RR	High mount flip-up footrest		\$8.45	Non-Drug
K0037	UE	High mount flip-up footrest		\$49.22	Non-Drug
K0038	NU	Leg strap each		\$34.17	Non-Drug
K0038	RR	Leg strap each		\$4.77	Non-Drug
K0038	UE	Leg strap each		\$26.48	Non-Drug
K0039	NU	Leg strap h style each		\$71.98	Non-Drug
K0039	RR	Leg strap h style each		\$10.25	Non-Drug
K0039	UE	Leg strap h style each		\$54.65	Non-Drug
K0040	NU	Adjustable angle footplate		\$99.55	Non-Drug
K0040	RR	Adjustable angle footplate		\$12.86	Non-Drug
K0040	UE	Adjustable angle footplate		\$74.78	Non-Drug
K0041	NU	Large size footplate each		\$70.70	Non-Drug
K0041	RR	Large size footplate each		\$10.14	Non-Drug
K0041	UE	Large size footplate each		\$53.73	Non-Drug
K0042	NU	Standard size footplate each		\$49.60	Non-Drug
K0042	RR	Standard size footplate each		\$7.14	Non-Drug
K0042	UE	Standard size footplate each		\$38.04	Non-Drug
K0043	NU	Frst lower extension tube		\$28.17	Non-Drug
K0043	RR	Frst lower extension tube		\$3.83	Non-Drug
K0043	UE	Frst lower extension tube		\$22.00	Non-Drug
K0044	NU	Frst upper hanger bracket		\$24.51	Non-Drug
K0044	RR	Frst upper hanger bracket		\$3.29	Non-Drug
K0044	UE	Frst upper hanger bracket		\$19.23	Non-Drug
K0045	NU	Footrest complete assembly		\$75.61	Non-Drug
K0045	RR	Footrest complete assembly		\$10.81	Non-Drug
K0045	UE	Footrest complete assembly		\$57.25	Non-Drug
K0046	NU	Elevat legrst low extension		\$28.17	Non-Drug
K0046	RR	Elevat legrst low extension		\$3.83	Non-Drug
K0046	UE	Elevat legrst low extension		\$22.00	Non-Drug
K0047	NU	Elevat legrst up hangr brack		\$101.95	Non-Drug
K0047	RR	Elevat legrst up hangr brack		\$13.13	Non-Drug
K0047	UE	Elevat legrst up hangr brack		\$76.56	Non-Drug
K0050	NU	Ratchet assembly		\$44.61	Non-Drug
K0050	RR	Ratchet assembly		\$6.37	Non-Drug
K0050	UE	Ratchet assembly		\$34.33	Non-Drug
K0051	NU	Cam relese assem frst/lgrst		\$70.29	Non-Drug
K0051	RR	Cam relese assem frst/lgrst		\$10.12	Non-Drug
K0051	UE	Cam relese assem frst/lgrst		\$53.42	Non-Drug
K0052	NU	Swingaway detach footrest		\$123.10	Non-Drug
K0052	RR	Swingaway detach footrest		\$15.12	Non-Drug
K0052	UE	Swingaway detach footrest		\$92.46	Non-Drug
K0053	NU	Elevate footrest articulate		\$135.79	Non-Drug
K0053	RR	Elevate footrest articulate		\$16.33	Non-Drug
K0053	UE	Elevate footrest articulate		\$101.99	Non-Drug
K0056	NU	Seat ht <17 or >=21 lbwt wc		\$126.64	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 34 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
K0056	RR	Seat ht <17 or >=21 lwt w		\$15.47	Non-Drug
K0056	UE	Seat ht <17 or >=21 lwt w		\$95.13	Non-Drug
K0059	NU	Plastic coated handrim each		\$43.63	Non-Drug
K0059	RR	Plastic coated handrim each		\$6.21	Non-Drug
K0059	UE	Plastic coated handrim each		\$33.57	Non-Drug
K0060	NU	Steel handrim each		\$38.59	Non-Drug
K0060	RR	Steel handrim each		\$5.46	Non-Drug
K0060	UE	Steel handrim each		\$29.79	Non-Drug
K0061	NU	Aluminum handrim each		\$53.33	Non-Drug
K0061	RR	Aluminum handrim each		\$7.73	Non-Drug
K0061	UE	Aluminum handrim each		\$40.86	Non-Drug
K0064	NU	Zero pressure tube flat free		\$41.97	Non-Drug
K0064	RR	Zero pressure tube flat free		\$5.98	Non-Drug
K0064	UE	Zero pressure tube flat free		\$32.31	Non-Drug
K0065	NU	Spoke protectors		\$59.78	Non-Drug
K0065	RR	Spoke protectors		\$8.73	Non-Drug
K0065	UE	Spoke protectors		\$45.68	Non-Drug
K0066	NU	Solid tire any size each		\$39.57	Non-Drug
K0066	RR	Solid tire any size each		\$5.41	Non-Drug
K0066	UE	Solid tire any size each		\$31.07	Non-Drug
K0067	NU	Pneumatic tire any size each		\$55.28	Non-Drug
K0067	RR	Pneumatic tire any size each		\$7.87	Non-Drug
K0067	UE	Pneumatic tire any size each		\$40.56	Non-Drug
K0068	NU	Pneumatic tire tube each		\$10.86	Non-Drug
K0068	RR	Pneumatic tire tube each		\$1.19	Non-Drug
K0068	UE	Pneumatic tire tube each		\$8.68	Non-Drug
K0069	NU	Rear whl complete solid tire		\$133.02	Non-Drug
K0069	RR	Rear whl complete solid tire		\$16.61	Non-Drug
K0069	UE	Rear whl complete solid tire		\$99.90	Non-Drug
K0070	NU	Rear whl compl pneum tire		\$243.40	Non-Drug
K0070	RR	Rear whl compl pneum tire		\$26.64	Non-Drug
K0070	UE	Rear whl compl pneum tire		\$182.67	Non-Drug
K0071	NU	Front castr compl pneum tire		\$145.39	Non-Drug
K0071	RR	Front castr compl pneum tire		\$17.27	Non-Drug
K0071	UE	Front castr compl pneum tire		\$109.16	Non-Drug
K0072	NU	Fmt cstr cml sem-pneum tir		\$87.73	Non-Drug
K0072	RR	Fmt cstr cml sem-pneum tir		\$11.74	Non-Drug
K0072	UE	Fmt cstr cml sem-pneum tir		\$65.95	Non-Drug
K0073	NU	Caster pin lock each		\$47.53	Non-Drug
K0073	RR	Caster pin lock each		\$6.83	Non-Drug
K0073	UE	Caster pin lock each		\$36.50	Non-Drug
K0074	NU	Pneumatic caster tire each		\$49.06	Non-Drug
K0074	RR	Pneumatic caster tire each		\$7.77	Non-Drug
K0074	UE	Pneumatic caster tire each		\$37.63	Non-Drug
K0075	NU	Semi-pneumatic caster tire		\$56.47	Non-Drug
K0075	RR	Semi-pneumatic caster tire		\$9.27	Non-Drug
K0075	UE	Semi-pneumatic caster tire		\$43.21	Non-Drug
K0076	NU	Solid caster tire each		\$35.81	Non-Drug
K0076	RR	Solid caster tire each		\$5.06	Non-Drug
K0076	UE	Solid caster tire each		\$27.72	Non-Drug
K0077	NU	Front caster assem complete		\$78.57	Non-Drug
K0077	RR	Front caster assem complete		\$10.86	Non-Drug
K0077	UE	Front caster assem complete		\$59.37	Non-Drug
K0078	NU	Pneumatic caster tire tube		\$15.58	Non-Drug
K0078	RR	Pneumatic caster tire tube		\$1.87	Non-Drug
K0078	UE	Pneumatic caster tire tube		\$12.51	Non-Drug
K0081	NU	Wheel lock assembly complete		\$54.98	Non-Drug
K0081	RR	Wheel lock assembly complete		\$7.98	Non-Drug
K0081	UE	Wheel lock assembly complete		\$42.08	Non-Drug
K0090	NU	Rear tire power wheelchair		\$101.55	Non-Drug
K0090	RR	Rear tire power wheelchair		\$13.08	Non-Drug
K0090	UE	Rear tire power wheelchair		\$76.30	Non-Drug
K0091	NU	Rear tire tube power whlchr		\$29.75	Non-Drug
K0091	RR	Rear tire tube power whlchr		\$4.06	Non-Drug
K0091	UE	Rear tire tube power whlchr		\$23.16	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 35 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
K0092	NU	Rear assem cmplt powr whlchr		\$322.91	Non-Drug
K0092	RR	Rear assem cmplt powr whlchr		\$34.22	Non-Drug
K0092	UE	Rear assem cmplt powr whlchr		\$242.32	Non-Drug
K0093	NU	Rear zero pressure tire tube		\$201.92	Non-Drug
K0093	RR	Rear zero pressure tire tube		\$22.67	Non-Drug
K0093	UE	Rear zero pressure tire tube		\$151.57	Non-Drug
K0094	NU	Wheel tire for power base		\$66.17	Non-Drug
K0094	RR	Wheel tire for power base		\$9.69	Non-Drug
K0094	UE	Wheel tire for power base		\$50.46	Non-Drug
K0095	NU	Wheel tire tube each base		\$66.17	Non-Drug
K0095	RR	Wheel tire tube each base		\$9.69	Non-Drug
K0095	UE	Wheel tire tube each base		\$50.46	Non-Drug
K0096	NU	Wheel assem powr base cmplt		\$364.22	Non-Drug
K0096	RR	Wheel assem powr base cmplt		\$38.18	Non-Drug
K0096	UE	Wheel assem powr base cmplt		\$273.31	Non-Drug
K0097	NU	Wheel zero presure tire tube		\$84.18	Non-Drug
K0097	RR	Wheel zero presure tire tube		\$11.41	Non-Drug
K0097	UE	Wheel zero presure tire tube		\$63.39	Non-Drug
K0098	NU	Drive belt power wheelchair		\$37.91	Non-Drug
K0098	RR	Drive belt power wheelchair		\$5.35	Non-Drug
K0098	UE	Drive belt power wheelchair		\$29.26	Non-Drug
K0099	NU	Pwr wheelchair front caster		\$107.82	Non-Drug
K0099	RR	Pwr wheelchair front caster		\$13.69	Non-Drug
K0099	UE	Pwr wheelchair front caster		\$80.99	Non-Drug
K0102	NU	Crutch and cane holder		\$58.37	Non-Drug
K0102	RR	Crutch and cane holder		\$8.52	Non-Drug
K0102	UE	Crutch and cane holder		\$44.63	Non-Drug
K0104	NU	Cylinder tank carrier		\$158.02	Non-Drug
K0104	RR	Cylinder tank carrier		\$18.46	Non-Drug
K0104	UE	Cylinder tank carrier		\$118.66	Non-Drug
K0105	NU	Iv hanger		\$132.38	Non-Drug
K0105	RR	Iv hanger		\$16.00	Non-Drug
K0105	UE	Iv hanger		\$99.42	Non-Drug
K0106	NU	Arm trough each		\$142.62	Non-Drug
K0106	RR	Arm trough each		\$17.03	Non-Drug
K0106	UE	Arm trough each		\$107.12	Non-Drug
K0108		W/c component-accessory NOS		\$92.84	Non-Drug
K0114	NU	Whlchr back suprt inr frame		\$1,005.85	Non-Drug
K0114	RR	Whlchr back suprt inr frame		\$101.09	Non-Drug
K0114	UE	Whlchr back suprt inr frame		\$754.52	Non-Drug
K0115	NU	Back module orthotic system		\$1,507.94	Non-Drug
K0115	RR	Back module orthotic system		\$142.20	Non-Drug
K0115	UE	Back module orthotic system		\$1,128.56	Non-Drug
K0116	NU	Back & seat modul orthot sys		\$3,157.86	Non-Drug
K0116	RR	Back & seat modul orthot sys		\$307.15	Non-Drug
K0116	UE	Back & seat modul orthot sys		\$2,366.03	Non-Drug
K0195		Elevating whlchair leg rests		\$148.52	Non-Drug
K0195	RR	Elevating whlchair leg rests		\$30.12	Non-Drug
K0415		RX antiemetic drg, oral NOS		\$5.01	Drug
K0452	NU	Wheelchair bearings		\$11.72	Non-Drug
K0452	RR	Wheelchair bearings		\$1.29	Non-Drug
K0452	UE	Wheelchair bearings		\$9.64	Non-Drug
K0455	RR	Pump uninterrupted infusion		\$452.74	Non-Drug
K0462		Temporary replacement eqpmnt		\$659.77	Non-Drug
K0552		Supply/ext inf pump syr type		\$7.60	Non-Drug
K0600	NU	Functional neuromuscularstim		\$17,389.68	Non-Drug
K0600	RR	Functional neuromuscularstim		\$1,730.33	Non-Drug
K0600	UE	Functional neuromuscularstim		\$13,039.87	Non-Drug
K0601	NU	Repl batt silver oxide 1.5 v		\$4.45	Non-Drug
K0602	NU	Repl batt silver oxide 3 v		\$12.71	Non-Drug
K0603	NU	Repl batt alkaline 1.5 v		\$2.31	Non-Drug
K0604	NU	Repl batt lithium 3.6 v		\$12.34	Non-Drug
K0605	NU	Repl batt lithium 4.5 v		\$24.09	Non-Drug
K0607	NU	Repl batt for AED		\$329.44	Non-Drug
K0607	RR	Repl batt for AED		\$30.75	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 36 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
K0607	UE	Repl batt for AED		\$244.68	Non-Drug
K0608	NU	Repl garment for AED		\$201.99	Non-Drug
K0608	RR	Repl garment for AED		\$20.68	Non-Drug
K0608	UE	Repl garment for AED		\$149.09	Non-Drug
K0609		Repl electrode for AED		\$1,397.47	Non-Drug
K0618		TLSO 2 piece rigid shell		\$887.76	Non-Drug
K0619		TLSO 3 piece rigid shell		\$561.06	Non-Drug
K0620		Tubular elastic dressing		\$1.71	Non-Drug
L0100		Cranial orthosis/helmet mold		\$687.16	Non-Drug
L0110		Cranial orthosis/helmet nonm		\$161.95	Non-Drug
L0120		Cerv flexible non-adjustable		\$31.83	Non-Drug
L0130		Flex thermoplastic collar mo		\$183.59	Non-Drug
L0140		Cervical semi-rigid adjustab		\$75.-7	Non-Drug
L0150		Cerv semi-rig adj molded chn		\$122.40	Non-Drug
L0160		Cerv semi-rig wire occ/mand		\$176.35	Non-Drug
L0170		Cervical collar molded to pt		\$774.96	Non-Drug
L0172		Cerv col thermplas foam 2 pi		\$143.39	Non-Drug
L0174		Cerv col foam 2 piece w thor		\$307.53	Non-Drug
L0180		Cer post col occ/man sup adj		\$426.58	Non-Drug
L0190		Cerv collar supp adj cerv ba		\$585.08	Non-Drug
L0200		Cerv col supp adj bar & thor		\$611.79	Non-Drug
L0210		Thoracic rib belt		\$51.55	Non-Drug
L0220		Thor rib belt custom fabrica		\$138.41	Non-Drug
L0450		TLSO flex prefab thoracic		\$195.44	Non-Drug
L0454		TLSO flex prefab sacrococ-T9		\$376.84	Non-Drug
L0456		TLSO flex prefab		\$1,162.61	Non-Drug
L0458		TLSO 2Mod symphis-xipho pre		\$1,037.98	Non-Drug
L0460		TLSO2Mod symphis-stem pre		\$1,173.81	Non-Drug
L0462		TLSO 3Mod sacro-scap pre		\$1,470.72	Non-Drug
L0464		TLSO 4Mod sacro-scap pre		\$1,759.25	Non-Drug
L0466		TLSO rigid frame pre soft ap		\$430.50	Non-Drug
L0468		TLSO rigid frame prefab pelv		\$538.13	Non-Drug
L0470		TLSO rigid frame pre subclav		\$765.63	Non-Drug
L0472		TLSO rigid frame hyperex pre		\$469.52	Non-Drug
L0476		TLSO flexion compres jac pre		\$1,171.47	Non-Drug
L0478		TLSO flexion compres jac cus		\$1,755.27	Non-Drug
L0480		TLSO rigid plastic custom fa		\$1,764.09	Non-Drug
L0482		TLSO rigid lined custom fab		\$1,925.04	Non-Drug
L0484		TLSO rigid plastic cust fab		\$2,212.53	Non-Drug
L0486		TLSO rigidlined cust fab two		\$2,350.03	Non-Drug
L0488		TLSO rigid lined pre one pie		\$1,173.81	Non-Drug
L0490		TLSO rigid plastic pre one		\$302.58	Non-Drug
L0500		Lso flex surgical support		\$153.01	Non-Drug
L0510		Lso flexible custom fabricat		\$308.55	Non-Drug
L0515		Lso flex elas w/ rig post pa		\$325.72	Non-Drug
L0520		Lso a-p-l control with apron		\$479.34	Non-Drug
L0530		Lso ant-pos control w apron		\$482.15	Non-Drug
L0540		Lso lumbar flexion a-p-l		\$522.66	Non-Drug
L0550		Lso a-p-l control molded		\$1,635.52	Non-Drug
L0560		Lso a-p-l w interface		\$1,790.89	Non-Drug
L0561		Prefab lso		\$374.88	Non-Drug
L0565		Lso a-p-l control custom		\$1,379.93	Non-Drug
L0600		Sacroiliac flex surg support		\$104.80	Non-Drug
L0610		Sacroiliac flexible custm fa		\$289.35	Non-Drug
L0620		Sacroiliac semi-rig w apron		\$493.70	Non-Drug
L0700		CtIso a-p-l control molded		\$2,523.05	Non-Drug
L0710		CtIso a-p-l control w/ inter		\$2,607.87	Non-Drug
L0810		Halo cervical into jckt vest		\$3,231.17	Non-Drug
L0820		Halo cervical into body jack		\$2,698.74	Non-Drug
L0830		Halo cerv into milwaukee typ		\$3,937.58	Non-Drug
L0860		Magnetic resonanc image comp		\$1,502.89	Non-Drug
L0960		Post surgical support pads		\$79.10	Non-Drug
L0970		Tiso corset front		\$129.32	Non-Drug
L0972		Lso corset front		\$116.68	Non-Drug
L0974		Tiso full corset		\$201.25	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 37 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
L0976		Lso full corset		\$179.98	Non-Drug
L0978		Axillary crutch extension		\$216.20	Non-Drug
L0980		Peroneal straps pair		\$21.75	Non-Drug
L0982		Stocking supp grips set of f		\$20.44	Non-Drug
L0984		Protective body sock each		\$68.85	Non-Drug
L0999		Add to spinal orthosis NOS		\$281.51	Non-Drug
L1000		Ctiso milwaukee initial model		\$2,533.89	Non-Drug
L1005		Tension based scoliosis orth		\$3,838.66	Non-Drug
L1010		Ctiso axilla sling		\$76.91	Non-Drug
L1020		Kyphosis pad		\$98.37	Non-Drug
L1025		Kyphosis pad floating		\$140.89	Non-Drug
L1030		Lumbar bolster pad		\$73.03	Non-Drug
L1040		Lumbar or lumbar nb pad		\$89.03	Non-Drug
L1050		Sternal pad		\$94.85	Non-Drug
L1060		Thoracic pad		\$108.59	Non-Drug
L1070		Trapezius sling		\$102.31	Non-Drug
L1080		Outrigger		\$63.83	Non-Drug
L1085		Outrigger bil w/ vert extens		\$173.35	Non-Drug
L1090		Lumbar sling		\$104.18	Non-Drug
L1100		Ring flange plastic/leather		\$179.01	Non-Drug
L1110		Ring flange plas/leather mol		\$286.07	Non-Drug
L1120		Covers for upright each		\$46.48	Non-Drug
L1200		Fumsh initial orthosis only		\$1,945.51	Non-Drug
L1210		Lateral thoracic extension		\$293.03	Non-Drug
L1220		Anterior thoracic extension		\$248.46	Non-Drug
L1230		Milwaukee type superstructur		\$677.88	Non-Drug
L1240		Lumbar derotation pad		\$88.62	Non-Drug
L1250		Anterior asis pad		\$82.62	Non-Drug
L1260		Anterior thoracic derotation		\$86.39	Non-Drug
L1270		Abdominal pad		\$88.43	Non-Drug
L1280		Rib gusset (elastic) each		\$98.19	Non-Drug
L1290		Lateral trochanteric pad		\$89.67	Non-Drug
L1300		Body jacket mold to patient		\$2,077.05	Non-Drug
L1310		Post-operative body jacket		\$2,138.56	Non-Drug
L1499		Spinal orthosis NOS		\$279.68	Non-Drug
L1500		Thkao mobility frame		\$2,367.85	Non-Drug
L1510		Thkao standing frame		\$1,481.89	Non-Drug
L1520		Thkao swivel walker		\$2,852.75	Non-Drug
L1600		Abduct hip flex frejka w cvr		\$145.51	Non-Drug
L1610		Abduct hip flex frejka covr		\$51.13	Non-Drug
L1620		Abduct hip flex pavlik harn		\$151.20	Non-Drug
L1630		Abduct control hip semi-flex		\$190.60	Non-Drug
L1640		Pelv band/spread bar thigh c		\$542.00	Non-Drug
L1650		HO abduction hip adjustable		\$259.56	Non-Drug
L1652		HO bi thighcuffs w sprdr bar		\$388.55	Non-Drug
L1660		HO abduction static plastic		\$192.47	Non-Drug
L1680		Pelvic & hip control thigh c		\$1,503.15	Non-Drug
L1685		Post-op hip abduct custom fa		\$1,466.39	Non-Drug
L1686		HO post-op hip abduction		\$1,114.33	Non-Drug
L1690		Combination bilateral HO		\$2,301.85	Non-Drug
L1700		Leg perthes orth toronto typ		\$1,895.08	Non-Drug
L1710		Legg perthes orth newington		\$2,225.88	Non-Drug
L1720		Legg perthes orthosis triat		\$1,629.21	Non-Drug
L1730		Legg perthes orth scottish r		\$1,393.15	Non-Drug
L1750		Legg perthes sling		\$220.91	Non-Drug
L1755		Legg perthes patten bottom t		\$1,966.35	Non-Drug
L1800		Knee orthoses elas w stays		\$76.26	Non-Drug
L1810		Ko elastic with joints		\$111.76	Non-Drug
L1815		Elastic with condylar pads		\$109.97	Non-Drug
L1820		Ko elas w/ condyle pads & jo		\$146.39	Non-Drug
L1825		Ko elastic knee cap		\$63.44	Non-Drug
L1830		Ko immobilizer canvas longit		\$99.54	Non-Drug
L1832		KO adj jnt pos rigid support		\$728.06	Non-Drug
L1834		Ko w/0 joint rigid molded to		\$941.73	Non-Drug
L1836		Rigid KO wo joints		\$143.97	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 38 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L1840		Ko derot ant cruciate custom		\$1,123.58	Non-Drug
L1843		KO single upright custom fit		\$1,044.56	Non-Drug
L1844		Ko w/adj jt rot cntrl molded		\$1,975.02	Non-Drug
L1845		Ko w/ adj flex/ext rotat cus		\$993.91	Non-Drug
L1846		Ko w adj flex/ext rotat mold		\$1,304.15	Non-Drug
L1847		KO adjustable w air chambers		\$653.83	Non-Drug
L1850		Ko swedish type		\$322.12	Non-Drug
L1855		Ko plas doub upright jnt mol		\$1,351.36	Non-Drug
L1858		Ko polycentric pneumatic pad		\$1,477.53	Non-Drug
L1860		Ko supracondylar socket mold		\$1,318.56	Non-Drug
L1870		Ko doub upright lacers molde		\$1,284.88	Non-Drug
L1880		Ko doub upright cuffs/lacers		\$854.81	Non-Drug
L1900		Afo sprng wir drsflx calf bd		\$302.04	Non-Drug
L1901		Prefab ankle orthosis		\$21.13	Non-Drug
L1902		Afo ankle gauntlet		\$91.03	Non-Drug
L1904		Afo molded ankle gauntlet		\$553.20	Non-Drug
L1906		Afo multiligamentous ankle su		\$135.96	Non-Drug
L1910		Afo sing bar clasp attach sh		\$299.43	Non-Drug
L1920		Afo sing upright w/ adjust s		\$400.01	Non-Drug
L1930		Afo plastic		\$265.15	Non-Drug
L1940		Afo molded to patient plasti		\$584.05	Non-Drug
L1945		Afo molded plas ng ant tib		\$1,131.47	Non-Drug
L1950		Afo spiral molded to pt plas		\$901.85	Non-Drug
L1960		Afo pos solid ank plastic mo		\$659.90	Non-Drug
L1970		Afo plastic molded w/ankle j		\$859.60	Non-Drug
L1980		Afo sing solid stirrup calf		\$422.11	Non-Drug
L1990		Afo doub solid stirrup calf		\$522.09	Non-Drug
L2000		Kafo sing fre stirr thi/calf		\$1,243.95	Non-Drug
L2010		Kafo sng solid stirrup w/o j		\$1,130.10	Non-Drug
L2020		Kafo dbl solid stirrup band/		\$1,438.69	Non-Drug
L2030		Kafo dbl solid stirrup w/o j		\$1,242.38	Non-Drug
L2035		KAFO plastic pediatric size		\$187.37	Non-Drug
L2036		Kafo plas doub free knee mol		\$2,311.81	Non-Drug
L2037		Kafo plas sing free knee mol		\$2,070.91	Non-Drug
L2038		Kafo w/o joint multi-axis an		\$1,771.44	Non-Drug
L2039		KAFO,plstic,medlat rotat con		\$2,651.98	Non-Drug
L2040		Hkafo torsion bil rot straps		\$199.59	Non-Drug
L2050		Hkafo torsion cable hip pelv		\$560.96	Non-Drug
L2060		Hkafo torsion ball bearing j		\$693.30	Non-Drug
L2070		Hkafo torsion unilat rot str		\$151.75	Non-Drug
L2080		Hkafo unilat torsion cable		\$412.81	Non-Drug
L2090		Hkafo unilat torsion ball br		\$512.88	Non-Drug
L2106		Afo tib fx cast plaster mold		\$819.40	Non-Drug
L2108		Afo tib fx cast molded to pt		\$1,312.73	Non-Drug
L2112		Afo tibial fracture soft		\$548.50	Non-Drug
L2114		Afo tib fx semi-rigid		\$693.10	Non-Drug
L2116		Afo tibial fracture rigid		\$860.02	Non-Drug
L2126		Kafo fem fx cast thermoplas		\$1,476.53	Non-Drug
L2128		Kafo fem fx cast molded to p		\$2,133.29	Non-Drug
L2132		Kafo femoral fx cast soft		\$980.35	Non-Drug
L2134		Kafo fem fx cast semi-rigid		\$1,184.13	Non-Drug
L2136		Kafo femoral fx cast rigid		\$1,457.66	Non-Drug
L2180		Plas shoe insert w ank joint		\$132.44	Non-Drug
L2182		Drop lock knee		\$104.17	Non-Drug
L2184		Limited motion knee joint		\$139.97	Non-Drug
L2186		Adj motion knee jnt lerman t		\$169.59	Non-Drug
L2188		Quadrilateral brim		\$336.40	Non-Drug
L2190		Waist belt		\$99.37	Non-Drug
L2192		Pelvic band & belt thigh fla		\$408.84	Non-Drug
L2200		Limited ankle motion ea jnt		\$55.17	Non-Drug
L2210		Dorsiflexion assist each joi		\$77.03	Non-Drug
L2220		Dorsi & plantar flex ass/res		\$93.33	Non-Drug
L2230		Split flat caliper stirr & p		\$87.60	Non-Drug
L2240		Round caliper and plate atta		\$95.26	Non-Drug
L2250		Foot plate molded stirrup at		\$407.29	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 39 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L2260		Reinforced solid stirrup		\$225.04	Non-Drug
L2265		Long tongue stirrup		\$133.18	Non-Drug
L2270		Varus/valgus strap padded/li		\$62.01	Non-Drug
L2275		Plastic mod low ext pad/line		\$141.68	Non-Drug
L2280		Molded inner boot		\$531.07	Non-Drug
L2300		Abduction bar jointed adjust		\$301.45	Non-Drug
L2310		Abduction bar-straight		\$139.02	Non-Drug
L2320		Non-molded lacer		\$230.92	Non-Drug
L2330		Lacer molded to patient mode		\$454.69	Non-Drug
L2335		Anterior swing band		\$254.72	Non-Drug
L2340		Pre-tibial shell molded to p		\$523.60	Non-Drug
L2350		Prosthetic type socket molde		\$1,087.49	Non-Drug
L2360		Extended steel shank		\$59.83	Non-Drug
L2370		Patten bottom		\$287.53	Non-Drug
L2375		Torsion ank & half solid sti		\$127.88	Non-Drug
L2380		Torsion straight knee joint		\$139.12	Non-Drug
L2385		Straight knee joint heavy du		\$151.15	Non-Drug
L2390		Offset knee joint each		\$123.95	Non-Drug
L2395		Offset knee joint heavy duty		\$176.16	Non-Drug
L2397		Suspension sleeve lower ext		\$127.21	Non-Drug
L2405		Knee joint drop lock ea jnt		\$94.89	Non-Drug
L2415		Knee joint cam lock each joi		\$131.27	Non-Drug
L2425		Knee disc/dial lock/adj flex		\$154.49	Non-Drug
L2430		Knee jnt ratchet lock ea jnt		\$154.49	Non-Drug
L2435		Knee joint polycentric joint		\$186.20	Non-Drug
L2492		Knee lift loop drop lock rin		\$115.64	Non-Drug
L2500		Thi/glut/schia wgt bearing		\$356.68	Non-Drug
L2510		Th/wght bear quad-lat brim m		\$878.40	Non-Drug
L2520		Th/wght bear quad-lat brim c		\$541.05	Non-Drug
L2525		Th/wght bear nar m-l brim mo		\$1,503.86	Non-Drug
L2526		Th/wght bear nar m-l brim cu		\$825.80	Non-Drug
L2530		Thigh/wght bear lacer non-mo		\$263.36	Non-Drug
L2540		Thigh/wght bear lacer molded		\$492.93	Non-Drug
L2550		Thigh/wght bear high roll cu		\$321.40	Non-Drug
L2570		Hip clevis type 2 posit jnt		\$560.89	Non-Drug
L2580		Pelvic control pelvic sling		\$545.39	Non-Drug
L2600		Hip clevis/thrust bearing fr		\$230.51	Non-Drug
L2610		Hip clevis/thrust bearing lo		\$272.13	Non-Drug
L2620		Pelvic control hip heavy dut		\$299.37	Non-Drug
L2622		Hip joint adjustable flexion		\$345.49	Non-Drug
L2624		Hip adj flex ext abduct cont		\$376.58	Non-Drug
L2627		Plastic mold recipro hip & c		\$2,132.73	Non-Drug
L2628		Metal frame recipro hip & ca		\$2,083.35	Non-Drug
L2630		Pelvic control band & belt u		\$277.43	Non-Drug
L2640		Pelvic control band & belt b		\$382.82	Non-Drug
L2650		Pelv & thor control gluteal		\$135.67	Non-Drug
L2660		Thoracic control thoracic ba		\$209.40	Non-Drug
L2670		Thorac cont paraspinal upng		\$191.85	Non-Drug
L2680		Thorac cont lat support upri		\$176.19	Non-Drug
L2750		Plating chrome/nickel pr bar		\$95.22	Non-Drug
L2755		Carbon graphite lamination		\$141.03	Non-Drug
L2760		Extension per extension per		\$69.85	Non-Drug
L2768		Ortho sidebar disconnect		\$140.65	Non-Drug
L2770		Low ext orthosis per bar/jnt		\$70.95	Non-Drug
L2780		Non-corrosive finish		\$77.54	Non-Drug
L2785		Drop lock retainer each		\$37.57	Non-Drug
L2795		Knee control full kneecap		\$96.75	Non-Drug
L2800		Knee cap medial or lateral p		\$120.84	Non-Drug
L2810		Knee control condylar pad		\$89.12	Non-Drug
L2820		Soft interface below knee se		\$98.83	Non-Drug
L2830		Soft interface above knee se		\$106.73	Non-Drug
L2840		Tibial length sock fx or equ		\$50.89	Non-Drug
L2850		Femoral lgth sock fx or equa		\$71.14	Non-Drug
L2860		Torsion mechanism knee/ankle		\$425.14	Non-Drug
L2999		Lower extremity orthosis NOS		\$57.38	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 40 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
L3000		Ft insert ucb berkeley shell		\$267.00	Non-Drug
L3001		Foot insert remov molded spe		\$158.36	Non-Drug
L3002		Foot insert plastazote or eq		\$131.06	Non-Drug
L3003		Foot insert silicone gel eac		\$160.59	Non-Drug
L3010		Foot longitudinal arch suppo		\$207.94	Non-Drug
L3020		Foot longitud/metatarsal sup		\$263.10	Non-Drug
L3030		Foot arch support remov prem		\$263.10	Non-Drug
L3040		Ft arch suprt premold longit		\$48.60	Non-Drug
L3050		Foot arch supp premold metat		\$45.26	Non-Drug
L3060		Foot arch supp longitud/meta		\$85.37	Non-Drug
L3070		Arch suprt att to sho longit		\$27.99	Non-Drug
L3080		Arch supp att to shoe metata		\$12.89	Non-Drug
L3090		Arch supp att to shoe long/m		\$18.52	Non-Drug
L3100		Hallus-valgus nght dynamic s		\$29.10	Non-Drug
L3140		Abduction rotation bar shoe		\$80.36	Non-Drug
L3150		Abduct rotation bar w/o shoe		\$67.54	Non-Drug
L3160		Shoe styled positioning dev		\$22.42	Non-Drug
L3170		Foot plastic heel stabilizer		\$36.34	Non-Drug
L3201		Oxford w supinat/pronator inf		\$79.80	Non-Drug
L3202		Oxford w/ supinat/pronator c		\$78.13	Non-Drug
L3203		Oxford w/ supinator/pronator		\$76.46	Non-Drug
L3204		Hightop w/ supp/pronator inf		\$76.46	Non-Drug
L3206		Hightop w/ supp/pronator chi		\$79.24	Non-Drug
L3207		Hightop w/ supp/pronator jun		\$80.36	Non-Drug
L3208		Surgical boot each infant		\$43.59	Non-Drug
L3209		Surgical boot each child		\$60.30	Non-Drug
L3211		Surgical boot each junior		\$64.20	Non-Drug
L3212		Benesch boot pair infant		\$88.72	Non-Drug
L3213		Benesch boot pair child		\$106.54	Non-Drug
L3214		Benesch boot pair junior		\$113.23	Non-Drug
L3215		Orthopedic fwear ladies oxf		\$143.32	Non-Drug
L3216		Orthoped ladies shoes dpth i		\$172.84	Non-Drug
L3217		Ladies shoes hightop depth i		\$187.33	Non-Drug
L3219		Orthopedic mens shoes oxford		\$160.59	Non-Drug
L3221		Orthopedic mens shoes dpth i		\$192.34	Non-Drug
L3222		Mens shoes hightop depth inl		\$212.40	Non-Drug
L3224		Woman's shoe oxford brace		\$67.68	Non-Drug
L3225		Man's shoe oxford brace		\$77.50	Non-Drug
L3230		Custom shoes depth inlay		\$249.17	Non-Drug
L3250		Custom mold shoe remov prost		\$505.69	Non-Drug
L3251		Shoe molded to pt silicone s		\$68.66	Non-Drug
L3252		Shoe molded plastazote cust		\$265.33	Non-Drug
L3253		Shoe molded plastazote cust		\$68.10	Non-Drug
L3254		Orth foot non-standard size/w		\$23.19	Non-Drug
L3255		Orth foot non-standard size/		\$25.77	Non-Drug
L3257		Orth foot add charge split s		\$50.27	Non-Drug
L3260		Ambulatory surgical boot eac		\$29.10	Non-Drug
L3265		Plastazote sandal each		\$31.33	Non-Drug
L3300		Sho lift taper to metatarsal		\$35.79	Non-Drug
L3310		Shoe lift elev heel/sole neo		\$69.77	Non-Drug
L3320		Shoe lift elev heel/sole cor		\$180.09	Non-Drug
L3330		Lifts elevation metal extens		\$290.40	Non-Drug
L3332		Shoe lifts tapered to one-ha		\$22.42	Non-Drug
L3334		Shoe lifts elevation heel /i		\$22.42	Non-Drug
L3340		Shoe wedge sach		\$50.83	Non-Drug
L3350		Shoe heel wedge		\$33.00	Non-Drug
L3360		Shoe sole wedge outside sole		\$25.20	Non-Drug
L3370		Shoe sole wedge between sole		\$29.66	Non-Drug
L3380		Shoe clubfoot wedge		\$49.72	Non-Drug
L3390		Shoe outflare wedge		\$68.10	Non-Drug
L3400		Shoe metatarsal bar wedge ro		\$65.32	Non-Drug
L3410		Shoe metatarsal bar between		\$109.33	Non-Drug
L3420		Full sole/heel wedge btween		\$36.34	Non-Drug
L3430		Sho heel count plast reinfor		\$88.16	Non-Drug
L3440		Heel leather reinforced		\$60.30	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 41 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L3450		Shoe heel sach cushion type		\$49.16	Non-Drug
L3455		Shoe heel new leather standa		\$21.86	Non-Drug
L3460		Shoe heel new rubber standar		\$36.34	Non-Drug
L3465		Shoe heel thomas with wedge		\$26.32	Non-Drug
L3470		Shoe heel thomas extend to b		\$61.42	Non-Drug
L3480		Shoe heel pad & depress for		\$42.47	Non-Drug
L3485		Shoe heel pad removable for		\$29.10	Non-Drug
L3500		Ortho shoe add leather insol		\$31.89	Non-Drug
L3510		Orthopedic shoe add rub insl		\$29.66	Non-Drug
L3520		O shoe add felt w leath insl		\$47.49	Non-Drug
L3530		Ortho shoe add half sole		\$15.73	Non-Drug
L3540		Ortho shoe add full sole		\$51.94	Non-Drug
L3550		O shoe add standard toe tap		\$9.50	Non-Drug
L3560		O shoe add horseshoe toe tap		\$12.89	Non-Drug
L3570		O shoe add instep extension		\$46.93	Non-Drug
L3580		O shoe add instep velcro clo		\$68.10	Non-Drug
L3590		O shoe convert to sof counte		\$53.62	Non-Drug
L3595		Ortho shoe add march bar		\$17.40	Non-Drug
L3600		Trans shoe calip plate exist		\$85.37	Non-Drug
L3610		Trans shoe caliper plate new		\$136.63	Non-Drug
L3620		Trans shoe solid stirrup exi		\$85.37	Non-Drug
L3630		Trans shoe solid stirrup new		\$104.32	Non-Drug
L3640		Shoe dennis browne splint bo		\$35.79	Non-Drug
L3649		Orthopedic shoe modifica NOS		\$23.22	Non-Drug
L3650		Shlder fig 8 abduct restrain		\$66.83	Non-Drug
L3651		Prefab shoulder orthosis		\$65.96	Non-Drug
L3652		Prefab dbl shoulder orthosis		\$194.03	Non-Drug
L3660		Abduct restrainer canvas&web		\$114.08	Non-Drug
L3670		Acromio/clavicular canvas&we		\$125.29	Non-Drug
L3675		Canvas vest SO		\$171.86	Non-Drug
L3677		SO hard plastic stabilizer		\$196.80	Non-Drug
L3700		Elbow orthoses elas w stays		\$78.23	Non-Drug
L3701		Prefab elbow orthosis		\$22.03	Non-Drug
L3710		Elbow elastic with metal joi		\$136.74	Non-Drug
L3720		Forearm/arm cuffs free motio		\$768.79	Non-Drug
L3730		Forearm/arm cuffs ext/flex a		\$1,076.14	Non-Drug
L3740		Cuffs adj lock w/ active con		\$1,284.00	Non-Drug
L3760		EO withjoint, Prefabricated		\$508.22	Non-Drug
L3762		Rigid EO wo joints		\$106.21	Non-Drug
L3800		Whfo short opponen no attach		\$219.73	Non-Drug
L3805		Whfo long opponens no attach		\$353.64	Non-Drug
L3807		WHFO,no joint, prefabricated		\$243.87	Non-Drug
L3810		Whfo thumb abduction bar		\$72.81	Non-Drug
L3815		Whfo second m.p. abduction a		\$67.76	Non-Drug
L3820		Whfo ip ext asst w/ mp ext s		\$114.69	Non-Drug
L3825		Whfo m.p. extension stop		\$72.85	Non-Drug
L3830		Whfo m.p. extension assist		\$94.38	Non-Drug
L3835		Whfo m.p. spring extension a		\$102.12	Non-Drug
L3840		Whfo spring swivel thumb		\$70.69	Non-Drug
L3845		Whfo thumb ip ext ass w/ mp		\$90.60	Non-Drug
L3850		Action wrist w/ dorsiflex as		\$128.41	Non-Drug
L3855		Whfo adj m.p. flexion contro		\$129.42	Non-Drug
L3860		Whfo adj m.p. flex ctrl & i.		\$176.28	Non-Drug
L3890		Torsion mechanism wrist/elbo		\$311.31	Non-Drug
L3900		Hinge extension/flex wrist/f		\$1,563.80	Non-Drug
L3901		Hinge ext/flex wrist finger		\$1,952.78	Non-Drug
L3902		Whfo ext power compress gas		\$3,134.38	Non-Drug
L3904		Whfo electric custom fitted		\$3,594.57	Non-Drug
L3906		Wrist gauntlet molded to pt		\$447.08	Non-Drug
L3907		Whfo wrst gauntlt thmb spica		\$587.26	Non-Drug
L3908		Wrist cock-up non-molded		\$67.49	Non-Drug
L3909		Prefab wrist orthosis		\$16.01	Non-Drug
L3910		Whfo swanson design		\$422.17	Non-Drug
L3912		Flex glove w/elastic finger		\$105.45	Non-Drug
L3914		WHO wrist extension cock-up		\$95.53	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 42 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L3916		Who wrist extens w/ outrigg		\$140.42	Non-Drug
L3918		HFO knuckle bender		\$87.55	Non-Drug
L3920		Knuckle bender with outrigg		\$108.82	Non-Drug
L3922		Knuckle bend 2 seg to flex j		\$108.66	Non-Drug
L3923		HFO, no joint, prefabricated		\$39.94	Non-Drug
L3924		Oppenheimer		\$118.26	Non-Drug
L3926		Thomas suspension		\$103.28	Non-Drug
L3928		Finger extension w/ clock sp		\$65.63	Non-Drug
L3930		Finger extension with wrist		\$69.23	Non-Drug
L3932		Safety pin spring wire		\$53.45	Non-Drug
L3934		Safety pin modified		\$54.73	Non-Drug
L3936		Palmer		\$99.18	Non-Drug
L3938		Dorsal wrist		\$103.75	Non-Drug
L3940		Dorsal wrist w/ outrigger at		\$119.22	Non-Drug
L3942		Reverse knuckle bender		\$83.18	Non-Drug
L3944		Reverse knuckle bend w/ outr		\$109.11	Non-Drug
L3946		HFO composite elastic		\$98.70	Non-Drug
L3948		Finger knuckle bender		\$62.26	Non-Drug
L3950		Oppenheimer w/ knuckle bend		\$165.37	Non-Drug
L3952		Oppenheimer w/ rev knuckle 2		\$183.28	Non-Drug
L3954		Spreading hand		\$122.40	Non-Drug
L3956		Add joint upper ext orthosis		\$46.38	Non-Drug
L3960		Sewho airplan desig abdu pos		\$669.24	Non-Drug
L3962		Sewho erbs palsey design abd		\$847.58	Non-Drug
L3963		Molded w/ articulating elbow		\$2,028.93	Non-Drug
L3964	NU	Seo mobile arm sup att to wc		\$74.85	Non-Drug
L3964	RR	Seo mobile arm sup att to wc		\$71.09	Non-Drug
L3964	UE	Seo mobile arm sup att to wc		\$545.38	Non-Drug
L3965	NU	Arm supp att to wc rancho ty		\$1,209.92	Non-Drug
L3965	RR	Arm supp att to wc rancho ty		\$112.07	Non-Drug
L3965	UE	Arm supp att to wc rancho ty		\$896.47	Non-Drug
L3966	NU	Mobile arm supports reclinin		\$900.66	Non-Drug
L3966	RR	Mobile arm supports reclinin		\$85.01	Non-Drug
L3966	UE	Mobile arm supports reclinin		\$664.53	Non-Drug
L3968	NU	Friction dampening arm supp		\$1,151.41	Non-Drug
L3968	RR	Friction dampening arm supp		\$106.92	Non-Drug
L3968	UE	Friction dampening arm supp		\$852.60	Non-Drug
L3969	NU	Monosuspension arm/hand supp		\$792.00	Non-Drug
L3969	RR	Monosuspension arm/hand supp		\$75.50	Non-Drug
L3969	UE	Monosuspension arm/hand supp		\$583.01	Non-Drug
L3970	NU	Elevat proximal arm support		\$294.90	Non-Drug
L3970	RR	Elevat proximal arm support		\$31.62	Non-Drug
L3970	UE	Elevat proximal arm support		\$221.76	Non-Drug
L3972	NU	Offset/lat rocker arm w/ ela		\$188.38	Non-Drug
L3972	RR	Offset/lat rocker arm w/ ela		\$20.96	Non-Drug
L3972	UE	Offset/lat rocker arm w/ ela		\$141.87	Non-Drug
L3974	NU	Mobile arm support supinator		\$160.13	Non-Drug
L3974	RR	Mobile arm support supinator		\$18.15	Non-Drug
L3974	UE	Mobile arm support supinator		\$120.69	Non-Drug
L3980		Upp ext fx orthosis humeral		\$340.23	Non-Drug
L3982		Upper ext fx orthosis rad/ul		\$419.96	Non-Drug
L3984		Upper ext fx orthosis wrist		\$383.78	Non-Drug
L3985		Forearm hand fx orth w/ wr h		\$682.32	Non-Drug
L3986		Humeral rad/ulna wrist fx or		\$652.53	Non-Drug
L3995		Sock fracture or equal each		\$37.91	Non-Drug
L3999		Upper limb orthosis NOS		\$35.97	Non-Drug
L4000		Repl girdle milwaukee orth		\$1,575.04	Non-Drug
L4010		Replace trilateral socket br		\$808.24	Non-Drug
L4020		Replace quadlat socket brim		\$1,049.75	Non-Drug
L4030		Replace socket brim cust fit		\$597.17	Non-Drug
L4040		Replace molded thigh lacer		\$474.41	Non-Drug
L4045		Replace non-molded thigh lac		\$372.63	Non-Drug
L4050		Replace molded calf lacer		\$480.31	Non-Drug
L4055		Replace non-molded calf lace		\$299.33	Non-Drug
L4060		Replace high roll cuff		\$359.64	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 43 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L4070		Replace prox & dist upright		\$314.98	Non-Drug
L4080		Repl met band kafo-af0 prox		\$114.72	Non-Drug
L4090		Repl met band kafo-af0 calf/		\$102.68	Non-Drug
L4100		Repl leath cuff kafo prox lh		\$118.23	Non-Drug
L4110		Repl leath cuff kafo-af0 cal		\$96.56	Non-Drug
L4130		Replace pretibial shell		\$586.06	Non-Drug
L4205		Ortho dvc repair per 15 min.		\$32.31	Non-Drug
L4210		Orth dev repair/repl minor p		\$43.12	Non-Drug
L4350		Ankle control orthosi prefab		\$101.66	Non-Drug
L4360		Pneumat walking boot prefab		\$309.94	Non-Drug
L4370		Pneumatic full leg splint		\$212.08	Non-Drug
L4380		Pneumatic knee splint		\$121.68	Non-Drug
L4386		Non-pneum walk boot prefab		\$170.63	Non-Drug
L4392		Replace AFO soft interface		\$27.29	Non-Drug
L4394		Replace foot drop spint		\$20.55	Non-Drug
L4396		Static AFO		\$180.15	Non-Drug
L4398		Foot drop splint recumbent		\$84.19	Non-Drug
L5000		Sho insert w arch toe filler		\$639.58	Non-Drug
L5010		Mold socket ank hgt w/ toe f		\$1,602.94	Non-Drug
L5020		Tibial tubercle hgt w/ toe f		\$2,636.83	Non-Drug
L5050		Ank symes mold sckt sach ft		\$3,060.50	Non-Drug
L5060		Symes met fr leath socket ar		\$3,692.27	Non-Drug
L5100		Molded socket shin sach foot		\$3,100.00	Non-Drug
L5105		Plast socket jts/thgh lacer		\$4,655.31	Non-Drug
L5150		Mold sckt ext knee shin sach		\$4,706.35	Non-Drug
L5160		Mold socket bent knee shin s		\$5,122.86	Non-Drug
L5200		Kne sing axis fric shin sach		\$4,424.71	Non-Drug
L5210		No knee/ankle joints w/ ft b		\$3,238.54	Non-Drug
L5220		No knee joint with artic ali		\$3,687.18	Non-Drug
L5230		Fem focal defic constant fri		\$5,102.00	Non-Drug
L5250		Hip canad sing axi cons fric		\$6,974.63	Non-Drug
L5270		Tilt table locking hip sing		\$6,913.15	Non-Drug
L5280		Hemipelvect canad sing axis		\$6,843.58	Non-Drug
L5301		BK mold socket SACH ft endo		\$3,061.95	Non-Drug
L5311		Knee disart, SACH ft, endo		\$4,417.97	Non-Drug
L5321		AK open end SACH		\$4,402.03	Non-Drug
L5331		Hip disart canadian SACH ft		\$6,247.23	Non-Drug
L5341		Hemipelvectomy canadian SACH		\$6,792.57	Non-Drug
L5400		Postop dress & 1 cast chg bk		\$1,584.15	Non-Drug
L5410		Postop dsq bk ea add cast ch		\$521.31	Non-Drug
L5420		Postop dsq & 1 cast chg ak/d		\$2,012.25	Non-Drug
L5430		Postop dsq ak ea add cast ch		\$636.82	Non-Drug
L5450		Postop app non-wgt bear dsq		\$507.22	Non-Drug
L5460		Postop app non-wgt bear dsq		\$693.73	Non-Drug
L5500		Init bk ptb plaster direct		\$1,693.43	Non-Drug
L5505		Init ak ischal plstr direct		\$2,308.90	Non-Drug
L5510		Prep BK ptb plaster molded		\$1,925.47	Non-Drug
L5520		Prep BK ptb thermopls direct		\$1,901.37	Non-Drug
L5530		Prep BK ptb thermopls molded		\$2,292.55	Non-Drug
L5535		Prep BK ptb open end socket		\$2,250.03	Non-Drug
L5540		Prep BK ptb laminated socket		\$2,404.45	Non-Drug
L5560		Prep AK ischal plast molded		\$2,585.20	Non-Drug
L5570		Prep AK ischal direct form		\$2,689.44	Non-Drug
L5580		Prep AK ischal thermo mold		\$3,147.07	Non-Drug
L5585		Prep AK ischal open end		\$3,417.07	Non-Drug
L5590		Prep AK ischal laminated		\$3,207.91	Non-Drug
L5595		Hip disartic sach thermopls		\$5,402.74	Non-Drug
L5600		Hip disart sach laminat mold		\$5,970.82	Non-Drug
L5610		Above knee hydracadence		\$2,756.73	Non-Drug
L5611		AK 4 bar link w/fnc swing		\$2,135.56	Non-Drug
L5613		AK 4 bar link w/hydraul swig		\$3,271.17	Non-Drug
L5614		4-bar link above knee w/swng		\$2,007.09	Non-Drug
L5616		AK unlv multiplex sys frict		\$1,793.29	Non-Drug
L5617		AK/BK self-aligning unit ea		\$640.53	Non-Drug
L5618		Test socket symes		\$336.55	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 44 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
L5620		Test socket below knee		\$332.20	Non-Drug
L5622		Test socket knee disarticula		\$446.51	Non-Drug
L5624		Test socket above knee		\$447.91	Non-Drug
L5626		Test socket hip disarticulat		\$601.08	Non-Drug
L5628		Test socket hemipelvectomy		\$609.24	Non-Drug
L5629		Below knee acrylic socket		\$386.02	Non-Drug
L5630		Syme typ expandabl wall sckt		\$563.21	Non-Drug
L5631		Ak/knee disartic acrylic soc		\$550.47	Non-Drug
L5632		Symes type ptb brim design s		\$265.14	Non-Drug
L5634		Symes type poster opening so		\$367.60	Non-Drug
L5636		Symes type medial opening so		\$303.92	Non-Drug
L5637		Below knee total contact		\$346.90	Non-Drug
L5638		Below knee leather socket		\$614.44	Non-Drug
L5639		Below knee wood socket		\$1,472.74	Non-Drug
L5640		Knee disarticulat leather so		\$821.09	Non-Drug
L5642		Above knee leather socket		\$794.21	Non-Drug
L5643		Hip flex inner socket ext fr		\$2,061.52	Non-Drug
L5644		Above knee wood socket		\$755.09	Non-Drug
L5645		Bk flex inner socket ext fra		\$1,035.42	Non-Drug
L5646		Below knee cushion socket		\$697.29	Non-Drug
L5647		Below knee suction socket		\$1,032.14	Non-Drug
L5648		Above knee cushion socket		\$846.71	Non-Drug
L5649		Isch containmt/narrow m-l so		\$2,531.56	Non-Drug
L5650		Tot contact ak/knee disart s		\$616.49	Non-Drug
L5651		Ak flex inner socket ext fra		\$1,580.60	Non-Drug
L5652		Suction susp ak/knee disart		\$545.88	Non-Drug
L5653		Knee disart expand wall sock		\$743.39	Non-Drug
L5654		Socket insert symes		\$404.73	Non-Drug
L5655		Socket insert below knee		\$316.27	Non-Drug
L5656		Socket insert knee articulat		\$457.92	Non-Drug
L5658		Socket insert above knee		\$447.97	Non-Drug
L5661		Multi-durometer symes		\$779.30	Non-Drug
L5665		Multi-durometer below knee		\$648.74	Non-Drug
L5666		Below knee cuff suspension		\$85.20	Non-Drug
L5668		Socket insert w/o lock lower		\$121.87	Non-Drug
L5670		Bk molded supracondylar susp		\$323.49	Non-Drug
L5671		BK/AK locking mechanism		\$628.97	Non-Drug
L5672		Bk removable medial brim sus		\$359.48	Non-Drug
L5673		Socket insert w lock mech		\$860.02	Non-Drug
L5674		Bk suspension sleeve		\$77.99	Non-Drug
L5675		Bk heavy duty susp sleeve		\$104.89	Non-Drug
L5676		Bk knee joints single axis p		\$446.31	Non-Drug
L5677		Bk knee joints polycentric p		\$623.08	Non-Drug
L5678		Bk joint covers pair		\$49.35	Non-Drug
L5679		Socket insert w/o lock mech		\$709.34	Non-Drug
L5680		Bk thigh lacer non-molded		\$367.86	Non-Drug
L5681		Int'l custm cong/latyp insert		\$1,555.28	Non-Drug
L5682		Bk thigh lacer glut/ischia m		\$802.09	Non-Drug
L5683		Initial custom socket insert		\$1,555.28	Non-Drug
L5684		Bk fork strap		\$59.31	Non-Drug
L5686		Bk back check		\$62.82	Non-Drug
L5688		Bk waist belt webbing		\$74.64	Non-Drug
L5690		Bk waist belt padded and lin		\$118.17	Non-Drug
L5692		Ak pelvic control belt light		\$159.62	Non-Drug
L5694		Ak pelvic control belt pad/l		\$217.06	Non-Drug
L5695		Ak sleeve susp neoprene/equa		\$195.37	Non-Drug
L5696		Ak/knee disartic pelvic join		\$221.33	Non-Drug
L5697		Ak/knee disartic pelvic band		\$97.36	Non-Drug
L5698		Ak/knee disartic silesian ba		\$125.81	Non-Drug
L5699		Shoulder harness		\$223.03	Non-Drug
L5700		Replace socket below knee		\$3,660.54	Non-Drug
L5701		Replace socket above knee		\$4,555.44	Non-Drug
L5702		Replace socket hip		\$5,833.10	Non-Drug
L5704		Custom shape cover BK		\$668.39	Non-Drug
L5705		Custom shape cover AK		\$1,212.67	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 45 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L5706		Custom shape cvr knee disart		\$1,188.90	Non-Drug
L5707		Custom shape cvr hip disart		\$1,629.47	Non-Drug
L5710		Knee-shin exo sng axi mnl loc		\$442.64	Non-Drug
L5711		Knee-shin exo mnl lock ultra		\$662.44	Non-Drug
L5712		Knee-shin exo frict swg & st		\$539.00	Non-Drug
L5714		Knee-shin exo variable frict		\$521.93	Non-Drug
L5716		Knee-shin exo mech stance ph		\$942.03	Non-Drug
L5718		Knee-shin exo frct swg & sta		\$1,188.39	Non-Drug
L5722		Knee-shin pneum swg frct exo		\$1,177.44	Non-Drug
L5724		Knee-shin exo fluid swing ph		\$1,997.90	Non-Drug
L5726		Knee-shin ext jnts fld swg e		\$2,309.23	Non-Drug
L5728		Knee-shin fluid swg & stance		\$3,174.84	Non-Drug
L5780		Knee-shin pneum/hydra pneum		\$1,504.84	Non-Drug
L5781		Lower limb pros vacuum pump		\$4,819.22	Non-Drug
L5785		Exoskeletal bk ultralt mater		\$658.93	Non-Drug
L5790		Exoskeletal ak ultra-light m		\$928.75	Non-Drug
L5795		Exoskel hip ultra-light mate		\$1,408.50	Non-Drug
L5810		Endoskel knee-shin mnl lock		\$614.70	Non-Drug
L5811		Endo knee-shin mnl lck ultra		\$942.67	Non-Drug
L5812		Endo knee-shin frct swg & st		\$720.80	Non-Drug
L5814		Endo knee-shin hydral swg ph		\$4,470.01	Non-Drug
L5816		Endo knee-shin polyc mch sta		\$1,106.52	Non-Drug
L5818		Endo knee-shin frct swg & st		\$1,255.15	Non-Drug
L5822		Endo knee-shin pneum swg frc		\$2,259.62	Non-Drug
L5824		Endo knee-shin fluid swing p		\$2,030.56	Non-Drug
L5826		Miniature knee joint		\$3,775.56	Non-Drug
L5828		Endo knee-shin fluid swg/sta		\$3,776.04	Non-Drug
L5830		Endo knee-shin pneum/swg pha		\$2,522.90	Non-Drug
L5840		Multi-axial knee/shin system		\$4,540.93	Non-Drug
L5845		Knee-shin sys stance flexion		\$2,134.59	Non-Drug
L5846		Knee-shin sys microprocessor		\$6,586.70	Non-Drug
L5847		Microprocessor cntrl feature		\$18,780.07	Non-Drug
L5848		Knee-shin sys hydraul stance		\$1,263.09	Non-Drug
L5850		Endo ak/hip knee extens assi		\$153.77	Non-Drug
L5855		Mech hip extension assist		\$373.89	Non-Drug
L5910		Endo below knee alignable sy		\$446.04	Non-Drug
L5920		Endo ak/hip alignable system		\$673.84	Non-Drug
L5925		Above knee manual lock		\$410.64	Non-Drug
L5930		High activity knee frame		\$4,073.32	Non-Drug
L5940		Endo bk ultra-light material		\$634.65	Non-Drug
L5950		Endo ak ultra-light material		\$1,008.54	Non-Drug
L5960		Endo hip ultra-light materia		\$1,260.18	Non-Drug
L5962		Below knee flex cover system		\$751.23	Non-Drug
L5964		Above knee flex cover system		\$1,222.96	Non-Drug
L5965		Hip flexible cover system		\$1,570.37	Non-Drug
L5968		Multiaxial ankle w dorsiflex		\$4,372.85	Non-Drug
L5970		Foot external keel sach foot		\$242.72	Non-Drug
L5972		Flexible keel foot		\$432.85	Non-Drug
L5974		Foot single axis ankle/foot		\$278.15	Non-Drug
L5975		Combo ankle/foot prosthesis		\$519.59	Non-Drug
L5976		Energy storing foot		\$713.66	Non-Drug
L5978		Ft prosth multiaxial ankl/ft		\$350.89	Non-Drug
L5979		Multi-axial ankle/ft prosth		\$3,042.64	Non-Drug
L5980		Flex foot system		\$4,971.52	Non-Drug
L5981		Flex-walk sys low ext prosth		\$3,852.12	Non-Drug
L5982		Exoskeletal axial rotation u		\$738.14	Non-Drug
L5984		Endoskeletal axial rotation		\$726.72	Non-Drug
L5985		Lwr ext dynamic prosth pylon		\$304.56	Non-Drug
L5986		Multi-axial rotation unit		\$813.31	Non-Drug
L5987		Shank ft w vert load pylon		\$8,699.50	Non-Drug
L5988		Vertical shock reducing pylo		\$2,384.15	Non-Drug
L5989		Pylon w elctmc force sensor		\$3,720.90	Non-Drug
L5990		User adjustable heel height		\$2,161.13	Non-Drug
L5999		Low extremity prosthes NOS		\$227.01	Non-Drug
L6000		Par hand robin-aids thum rem		\$1,753.45	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 46 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L6010		Hand robin-aids little/ring		\$1,956.24	Non-Drug
L6020		Part hand robin-aids no fing		\$1,820.91	Non-Drug
L6025		Part hand disart myoelectric		\$9,682.33	Non-Drug
L6050		Wrst MLd sock fix hng trn pad		\$2,525.72	Non-Drug
L6055		Wrst mold sock w/exp interfa		\$3,537.49	Non-Drug
L6100		Elb mold sock flex hinge pad		\$2,559.52	Non-Drug
L6110		Elbow mold sock suspension t		\$2,717.47	Non-Drug
L6120		Elbow mold doub splnt soc ste		\$3,174.08	Non-Drug
L6130		Elbow stump activated lock h		\$3,457.86	Non-Drug
L6200		Elbow mold outsid lock hinge		\$3,646.39	Non-Drug
L6205		Elbow molded w/ expand inter		\$4,882.05	Non-Drug
L6250		Elbow inter loc elbow forarm		\$3,588.58	Non-Drug
L6300		Shldr disart int lock elbow		\$4,995.75	Non-Drug
L6310		Shoulder passive restor comp		\$4,061.00	Non-Drug
L6320		Shoulder passive restor cap		\$2,267.80	Non-Drug
L6350		Thoracic intem lock elbow		\$5,254.52	Non-Drug
L6360		Thoracic passive restor comp		\$4,264.69	Non-Drug
L6370		Thoracic passive restor cap		\$2,703.55	Non-Drug
L6380		Postop dsq cast chg wrst/elb		\$1,512.09	Non-Drug
L6382		Postop dsq cast chg elb dis/		\$1,959.02	Non-Drug
L6384		Postop dsq cast chg shldr/t		\$2,535.18	Non-Drug
L6386		Postop ea cast chg & realign		\$499.35	Non-Drug
L6388		Postop applicat rigid dsq on		\$550.80	Non-Drug
L6400		Below elbow prosth tiss shap		\$3,094.90	Non-Drug
L6450		Elb disart prosth tiss shap		\$4,126.59	Non-Drug
L6500		Above elbow prosth tiss shap		\$4,130.00	Non-Drug
L6550		Shldr disar prosth tiss shap		\$5,114.28	Non-Drug
L6570		Scap thorac prosth tiss shap		\$5,876.69	Non-Drug
L6580		Wrist/elbow bowden cable mol		\$2,070.60	Non-Drug
L6582		Wrist/elbow bowden cbl dir f		\$1,817.85	Non-Drug
L6584		Elbow fair lead cable molded		\$2,724.82	Non-Drug
L6586		Elbow fair lead cable dir fo		\$2,503.82	Non-Drug
L6588		Shdr fair lead cable molded		\$3,779.53	Non-Drug
L6590		Shdr fair lead cable direct		\$3,514.94	Non-Drug
L6600		Polycentric hinge pair		\$224.35	Non-Drug
L6605		Single pivot hinge pair		\$221.55	Non-Drug
L6610		Flexible metal hinge pair		\$199.39	Non-Drug
L6615		Disconnect locking wrist uni		\$207.96	Non-Drug
L6616		Disconnect insert locking wr		\$79.12	Non-Drug
L6620		Flexion/extension wrist unit		\$366.28	Non-Drug
L6623		Spring-ass rot wrst w/ latch		\$823.84	Non-Drug
L6625		Rotation wrst w/ cable lock		\$675.57	Non-Drug
L6628		Quick disconn hook adapter o		\$604.14	Non-Drug
L6629		Lamination collar w/ couplin		\$175.51	Non-Drug
L6630		Stainless steel any wrist		\$257.42	Non-Drug
L6632		Latex suspension sleeve each		\$79.25	Non-Drug
L6635		Lift assist for elbow		\$210.81	Non-Drug
L6637		Nudge control elbow lock		\$452.83	Non-Drug
L6638		Elec lock on manual pw elbow		\$2,995.56	Non-Drug
L6640		Shoulder abduction joint pai		\$335.03	Non-Drug
L6641		Excursion amplifier pulley t		\$192.22	Non-Drug
L6642		Excursion amplifier lever ty		\$259.71	Non-Drug
L6645		Shoulder flexion-abduction j		\$387.95	Non-Drug
L6646		Multipo locking shoulder jnt		\$3,789.53	Non-Drug
L6647		Shoulder lock actuator		\$587.22	Non-Drug
L6648		Ext pwrd shldr lock/unlock		\$3,909.74	Non-Drug
L6650		Shoulder universal joint		\$414.00	Non-Drug
L6655		Standard control cable extra		\$91.26	Non-Drug
L6660		Heavy duty control cable		\$110.99	Non-Drug
L6665		Teflon or equal cable lining		\$56.86	Non-Drug
L6670		Hook to hand cable adapter		\$59.11	Non-Drug
L6672		Harness chest/shldr saddle		\$201.91	Non-Drug
L6675		Harness figure of 8 sing con		\$144.49	Non-Drug
L6676		Harness figure of 8 dual con		\$145.89	Non-Drug
L6680		Test sock wrist disart/bel e		\$276.95	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 47 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
L6682		Test sock elbw disart/above		\$305.94	Non-Drug
L6684		Test socket shldr disart/tho		\$427.64	Non-Drug
L6686		Suction socket		\$754.71	Non-Drug
L6687		Frame typ socket bel elbow/w		\$736.38	Non-Drug
L6688		Frame typ sock above elb/dis		\$672.70	Non-Drug
L6689		Frame typ socket shoulder di		\$867.58	Non-Drug
L6690		Frame typ sock interscap-tho		\$886.26	Non-Drug
L6691		Removable insert each		\$423.07	Non-Drug
L6692		Silicone gel insert or equal		\$712.60	Non-Drug
L6693		Lockingelbow forearm cntrbal		\$3,406.70	Non-Drug
L6700		Terminal device model #3		\$657.82	Non-Drug
L6705		Terminal device model #5		\$368.08	Non-Drug
L6710		Terminal device model #5x		\$422.99	Non-Drug
L6715		Terminal device model #5xa		\$419.87	Non-Drug
L6720		Terminal device model #6		\$1,110.12	Non-Drug
L6725		Terminal device model #7		\$514.83	Non-Drug
L6730		Terminal device model #7lo		\$820.52	Non-Drug
L6735		Terminal device model #8		\$359.19	Non-Drug
L6740		Terminal device model #8x		\$481.62	Non-Drug
L6745		Terminal device model #88x		\$436.96	Non-Drug
L6750		Terminal device model #10p		\$431.39	Non-Drug
L6755		Terminal device model #10x		\$430.04	Non-Drug
L6765		Terminal device model #12p		\$451.25	Non-Drug
L6770		Terminal device model #99x		\$433.44	Non-Drug
L6775		Terminal device model #555		\$521.68	Non-Drug
L6780		Terminal device model #ss555		\$560.66	Non-Drug
L6790		Hooks-accu hook or equal		\$567.36	Non-Drug
L6795		Hooks-2 load or equal		\$1,630.23	Non-Drug
L6800		Hooks-aprl vc or equal		\$1,326.69	Non-Drug
L6805		Modifier wrist flexion unit		\$416.36	Non-Drug
L6806		Trs grip vc or equal		\$1,921.84	Non-Drug
L6807		Term device grip1/2 or equal		\$1,738.63	Non-Drug
L6808		Term device infant or child		\$1,478.20	Non-Drug
L6809		Trs super sport passive		\$458.04	Non-Drug
L6810		Pincher tool otto bock or eq		\$223.12	Non-Drug
L6825		Hands dorrance vo		\$1,351.73	Non-Drug
L6830		Hand aprl vc		\$1,787.93	Non-Drug
L6835		Hand sierra vo		\$1,551.80	Non-Drug
L6840		Hand becker imperial		\$1,064.68	Non-Drug
L6845		Hand becker lock grip		\$985.21	Non-Drug
L6850		Term dvc-hand becker plylite		\$888.14	Non-Drug
L6855		Hand robin-aids vo		\$1,141.55	Non-Drug
L6860		Hand robin-aids vo soft		\$855.17	Non-Drug
L6865		Hand passive hand		\$396.60	Non-Drug
L6867		Hand detroit infant hand		\$1,255.68	Non-Drug
L6868		Passive inf hand steeper/hos		\$286.11	Non-Drug
L6870		Hand child mitt		\$283.66	Non-Drug
L6872		Hand nyu child hand		\$1,230.11	Non-Drug
L6873		Hand mech inf steeper or eq		\$588.91	Non-Drug
L6875		Hand bock vc		\$1,007.52	Non-Drug
L6880		Hand bock vo		\$638.22	Non-Drug
L6881		Autograsp feature ul term dv		\$4,925.04	Non-Drug
L6882		Microprocessor control uplmb		\$3,725.29	Non-Drug
L6890		Production glove		\$203.65	Non-Drug
L6895		Custom glove		\$711.46	Non-Drug
L6900		Hand restorat thumb/1 finger		\$1,999.32	Non-Drug
L6905		Hand restoration multiple fi		\$1,942.16	Non-Drug
L6910		Hand restoration no fingers		\$1,890.93	Non-Drug
L6915		Hand restoration replacmnt g		\$802.95	Non-Drug
L6920		Wrist disarticul switch ctrl		\$8,983.62	Non-Drug
L6925		Wrist disart myoelectronic c		\$10,378.23	Non-Drug
L6930		Below elbow switch control		\$9,039.60	Non-Drug
L6935		Below elbow myoelectronic ct		\$10,573.34	Non-Drug
L6940		Elbow disarticulation switch		\$11,824.27	Non-Drug
L6945		Elbow disart myoelectronic c		\$13,763.33	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 48 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
L6950		Above elbow switch control		\$13,445.95	Non-Drug
L6955		Above elbow myoelectronic ct		\$16,112.02	Non-Drug
L6960		Shldr disartic switch contro		\$16,250.56	Non-Drug
L6965		Shldr disartic myoelectronic		\$19,127.29	Non-Drug
L6970		Interscapular-thor switch ct		\$19,685.02	Non-Drug
L6975		Interscap-thor myoelectronic		\$21,572.75	Non-Drug
L7010		Hand otto back steeper/eq sw		\$4,896.63	Non-Drug
L7015		Hand sys teknik village swit		\$7,806.95	Non-Drug
L7020		Electronic greifer switch ct		\$4,559.21	Non-Drug
L7025		Electron hand myoelectronic		\$4,601.32	Non-Drug
L7030		Hand sys teknik vill myoelec		\$7,059.36	Non-Drug
L7035		Electron greifer myoelectro		\$4,713.34	Non-Drug
L7040		Prehensile actuator hosmer s		\$3,769.61	Non-Drug
L7045		Electron hook child michigan		\$2,142.52	Non-Drug
L7170		Electronic elbow hosmer swit		\$7,887.64	Non-Drug
L7180		Electronic elbow utah myoele		\$44,144.61	Non-Drug
L7185		Electron elbow adolescent sw		\$7,987.85	Non-Drug
L7186		Electron elbow child switch		\$11,921.43	Non-Drug
L7190		Elbow adolescent myoelectron		\$10,174.97	Non-Drug
L7191		Elbow child myoelectronic ct		\$12,459.16	Non-Drug
L7260		Electron wrist rotator otto		\$2,618.25	Non-Drug
L7261		Electron wrist rotator utah		\$4,802.22	Non-Drug
L7266		Servo control steeper or equ		\$1,295.39	Non-Drug
L7272		Analogue control unb or equa		\$2,686.88	Non-Drug
L7274		Proportional ctl 12 volt uta		\$7,725.43	Non-Drug
L7360		Six volt bat otto bock/eq ea		\$271.48	Non-Drug
L7362		Battery chrgr six volt otto		\$298.88	Non-Drug
L7364		Twelve volt battery utah/equ		\$495.14	Non-Drug
L7366		Battery chrgr 12 volt utah/e		\$682.21	Non-Drug
L7367		Replacemnt lithium ionbatter		\$429.32	Non-Drug
L7368		Lithium ion battery charger		\$569.54	Non-Drug
L7499		Upper extremity prosthes NOS		\$144.36	Non-Drug
L7500		Prosthetic dvc repair hourly		\$103.06	Non-Drug
L7510		Prosthetic device repair rep		\$30.67	Non-Drug
L7520		Repair prosthesis per 15 min		\$32.94	Non-Drug
L7900		Male vacuum erection system		\$607.95	Non-Drug
L8000		Mastectomy bra		\$45.57	Non-Drug
L8001		Breast prosthesis bra & form		\$135.73	Non-Drug
L8002		Brst prsth bra & bilat form		\$177.80	Non-Drug
L8010		Mastectomy sleeve		\$62.53	Non-Drug
L8015		Ext breastprosthesis garment		\$66.24	Non-Drug
L8020		Mastectomy form		\$239.78	Non-Drug
L8030		Breast prosthesis silicone/e		\$382.88	Non-Drug
L8035		Custom breast prosthesis		\$4,408.94	Non-Drug
L8039		Breast prosthesis NOS		\$247.87	Non-Drug
L8040	KM	Nasal prosthesis		\$2,815.90	Non-Drug
L8040	KN	Nasal prosthesis		\$1,160.24	Non-Drug
L8041	KM	Midfacial prosthesis		\$3,403.11	Non-Drug
L8041	KN	Midfacial prosthesis		\$1,407.50	Non-Drug
L8042	KM	Orbital prosthesis		\$3,829.14	Non-Drug
L8042	KN	Orbital prosthesis		\$1,586.87	Non-Drug
L8043	KM	Upper facial prosthesis		\$4,293.91	Non-Drug
L8043	KN	Upper facial prosthesis		\$1,782.56	Non-Drug
L8044	KM	Hemi-facial prosthesis		\$4,758.68	Non-Drug
L8044	KN	Hemi-facial prosthesis		\$1,978.25	Non-Drug
L8045	KM	Auricular prosthesis		\$3,116.21	Non-Drug
L8045	KN	Auricular prosthesis		\$1,286.70	Non-Drug
L8046	KM	Partial facial prosthesis		\$3,054.55	Non-Drug
L8046	KN	Partial facial prosthesis		\$1,260.73	Non-Drug
L8047	KM	Nasal septal prosthesis		\$1,544.08	Non-Drug
L8047	KN	Nasal septal prosthesis		\$624.74	Non-Drug
L8049		Repair maxillofacial prosth		\$38.86	Non-Drug
L8100		Compression stocking BK18-30		\$27.99	Non-Drug
L8110		Compression stocking BK30-40		\$30.85	Non-Drug
L8120		Compression stocking BK40-50		\$31.50	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 49 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
L8130		Gc stocking thighlngh 18-30		\$42.47	Non-Drug
L8140		Gc stocking thighlngh 30-40		\$42.47	Non-Drug
L8150		Gc stocking thighlngh 40-50		\$37.46	Non-Drug
L8160		Gc stocking full lngth 18-30		\$47.49	Non-Drug
L8170		Gc stocking full lngth 30-40		\$47.49	Non-Drug
L8180		Gc stocking full lngth 40-50		\$47.49	Non-Drug
L8190		Gc stocking waistlngh 18-30		\$183.43	Non-Drug
L8195		Gc stocking waistlngh 30-40		\$163.61	Non-Drug
L8200		Gc stocking waistlngh 40-50		\$183.43	Non-Drug
L8210		Gc stocking custom made		\$93.17	Non-Drug
L8220		Gc stocking lymphedema		\$29.10	Non-Drug
L8230		Gc stocking garter belt		\$30.77	Non-Drug
L8239		G compression stocking NOS		\$28.12	Non-Drug
L8300		Truss single w/ standard pad		\$102.19	Non-Drug
L8310		Truss double w/ standard pad		\$159.98	Non-Drug
L8320		Truss addition to std pad wa		\$65.62	Non-Drug
L8330		Truss add to std pad scrotal		\$60.79	Non-Drug
L8400		Sheath below knee		\$20.98	Non-Drug
L8410		Sheath above knee		\$26.88	Non-Drug
L8415		Sheath upper limb		\$27.72	Non-Drug
L8417		Pros sheath/sock w gel cushn		\$82.30	Non-Drug
L8420		Prosthetic sock multi ply BK		\$25.37	Non-Drug
L8430		Prosthetic sock multi ply AK		\$28.55	Non-Drug
L8435		Pros sock multi ply upper lm		\$27.25	Non-Drug
L8440		Shrinker below knee		\$51.86	Non-Drug
L8460		Shrinker above knee		\$81.23	Non-Drug
L8465		Shrinker upper limb		\$60.08	Non-Drug
L8470		Pros sock single ply BK		\$9.62	Non-Drug
L8480		Pros sock single ply AK		\$13.25	Non-Drug
L8485		Pros sock single ply upper l		\$15.52	Non-Drug
L8490		Air seal suction reten systm		\$159.61	Non-Drug
L8499		Unlisted misc prosthetic ser		\$49.93	Non-Drug
L8500		Artificial larynx		\$848.85	Non-Drug
L8501		Tracheostomy speaking valve		\$145.32	Non-Drug
L8505		Artificial larynx, accessory		\$28.87	Non-Drug
L8507		Trach-esoph voice pros pt in		\$46.90	Non-Drug
L8509		Trach-esoph voice pros md in		\$118.49	Non-Drug
L8510		Voice amplifier		\$271.07	Non-Drug
L8600		Implant breast silicone/eq		\$800.82	Non-Drug
L8603		Collagen imp urinary 2.5 ml		\$623.76	Non-Drug
L8606		Synthetic implnt urinary 1ml		\$312.88	Non-Drug
L8610		Ocular implant		\$747.87	Non-Drug
L8612		Aqueous shunt prosthesis		\$778.61	Non-Drug
L8613		Ossicular implant		\$306.68	Non-Drug
L8614		Cochlear device/system		\$23,465.07	Non-Drug
L8619		Replace cochlear processor		\$10,047.09	Non-Drug
L8630		Metacarpophalangeal implant		\$411.85	Non-Drug
L8631		MCP joint repl 2 pc or more		\$2,630.82	Non-Drug
L8641		Metatarsal joint implant		\$429.63	Non-Drug
L8642		Hallux implant		\$340.19	Non-Drug
L8658		Interphalangeal joint spacer		\$368.98	Non-Drug
L8659		Interphalangeal joint repl		\$2,302.08	Non-Drug
L8670		Vascular graft, synthetic		\$633.80	Non-Drug
L8699		Prosthetic implant NOS		\$313.16	Non-Drug
L9900		O&P supply/accessory/service		\$44.89	Non-Drug
Q0081		Infusion ther other than che	a	\$86.33	Non-Drug
Q0083		Chemo by other than infusion	a	\$222.51	Drug
Q0084		Chemotherapy by Infusion	a	\$371.17	Drug
Q0085		Chemo by both infusion and o	a	\$423.31	Drug
Q0111		Wet mounts/ w preparations		\$7.95	Non-Drug
Q0112		Potassium hydroxide preps		\$7.95	Non-Drug
Q0113		Pinworm examinations		\$9.94	Non-Drug
Q0114		Fern test		\$13.41	Non-Drug
Q0115		Post-coital mucous exam		\$18.38	Non-Drug
Q0136		Non esrd epoetin alpha inj	a	\$27.53	Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 50 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
Q0137		Darbepoetin alfa, non-esrd	a	\$9.51	Drug
Q0144		Azithromycin dihydrate, oral		\$31.14	Drug
Q0163		Diphenhydramine HCl 50mg		\$1.10	Drug
Q0164		Prochlorperazine maleate 5mg		\$1.10	Drug
Q0165		Prochlorperazine maleate 10mg		\$2.19	Drug
Q0166		Granisetron HCl 1 mg oral	a	\$104.10	Drug
Q0167		Dronabinol 2.5mg oral		\$8.77	Drug
Q0168		Dronabinol 5mg oral		\$23.03	Drug
Q0169		Promethazine HCl 12.5mg oral		\$1.10	Drug
Q0170		Promethazine HCl 25 mg oral		\$1.10	Drug
Q0171		Chlorpromazine HCl 10mg oral		\$1.10	Drug
Q0172		Chlorpromazine HCl 25mg oral		\$1.10	Drug
Q0173		Trimethobenzamide HCl 250mg		\$1.10	Drug
Q0174		Thiethylperazine maleate 10mg		\$2.19	Drug
Q0175		Perphenazine 4mg oral		\$1.10	Drug
Q0176		Perphenazine 8mg oral		\$2.19	Drug
Q0177		Hydroxyzine pamoate 25mg		\$1.10	Drug
Q0178		Hydroxyzine pamoate 50mg		\$1.10	Drug
Q0179		Ondansetron HCl 8mg oral		\$74.71	Drug
Q0180		Dolasetron mesylate oral	a	\$162.01	Drug
Q0181		Unspecified oral anti-emetic		\$0.82	Drug
Q0183		Nonmetabolic active tissue		\$32.94	Drug
Q0187		Factor viia recombinant	a	\$3,006.30	Drug
Q1001		Ntiol category 1		\$64.16	Non-Drug
Q1002		Ntiol category 2		\$64.16	Non-Drug
Q2001		Oral cabergoline 0.5 mg		\$61.94	Drug
Q2002		Elliotts b solution per ml		\$32.94	Drug
Q2003		Aprotinin, 10,000 kiu	a	\$4.10	Drug
Q2004		Bladder calculi irrig sol		\$53.30	Drug
Q2005		Corticotrelin ovine tnfutat	a	\$639.78	Drug
Q2006		Digoxin immune fab (ovine)	a	\$953.63	Drug
Q2007		Ethanolamine oleate 100 mg	a	\$108.49	Drug
Q2009		Fosphenytoin, 50 mg	a	\$13.11	Drug
Q2011		Hemin, per 1 mg	a	\$3,701.17	Drug
Q2012		Pegademase bovine, 25 iu		\$249.46	Drug
Q2014		Sermorelin acetate, 0.5 mg		\$36.54	Drug
Q2017		Teniposide, 50 mg	a	\$513.42	Drug
Q2018		Urofollitropin, 75 iu	a	\$171.66	Drug
Q2019		Basiliximab	a	\$2,437.78	Drug
Q2021		Lepirudin		\$234.16	Drug
Q2022		VonWillebrandFacrCmpjxperIU	a	\$2.30	Drug
Q3001		Brachytherapy Radioelements		\$70.53	Non-Drug
Q3002		Gallium ga 67	a	\$48.45	Non-Drug
Q3003		Technetium tc99m bicisate	a	\$623.24	Non-Drug
Q3004		Xenon xe 133		\$47.11	Non-Drug
Q3005		Technetium tc99m mertiatide	a	\$125.01	Non-Drug
Q3008		Indium 111-in pentetateotide	a	\$1,951.51	Non-Drug
Q3009		Technetium tc99m oxidronate		\$3.98	Non-Drug
Q3010		Technetium tc99mlabeledrbcs		\$15.12	Non-Drug
Q3014		Telehealth facility fee		\$36.47	Non-Drug
Q3019		ALS emer trans no ALS serv		\$486.53	Non-Drug
Q3020		ALS nonemer trans no ALS ser		\$483.40	Non-Drug
Q3025		IM inj interferon beta 1-a	a	\$147.06	Drug
Q4001		Cast sup body cast plaster		\$263.88	Non-Drug
Q4002		Cast sup body cast fiberglas		\$561.53	Non-Drug
Q4003		Cast sup shoulder cast plstr		\$143.12	Non-Drug
Q4004		Cast sup shoulder cast fbrgl		\$304.35	Non-Drug
Q4005		Cast sup long arm adult plst		\$79.15	Non-Drug
Q4006		Cast sup long arm adult fbrg		\$167.93	Non-Drug
Q4007		Cast sup long arm ped plster		\$39.34	Non-Drug
Q4008		Cast sup long arm ped fbrgl		\$83.72	Non-Drug
Q4009		Cast sup sht arm adult plstr		\$60.88	Non-Drug
Q4010		Cast sup sht arm adult fbrgl		\$129.42	Non-Drug
Q4011		Cast sup sht arm ped plaster		\$30.20	Non-Drug
Q4012		Cast sup sht arm ped fbrgl		\$64.79	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 51 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
Q4013		Cast sup gauntlet plaster		\$56.96	Non-Drug
Q4014		Cast sup gauntlet fiberglass		\$122.24	Non-Drug
Q4015		Cast sup gauntlet ped plaster		\$28.89	Non-Drug
Q4016		Cast sup gauntlet ped fibrils		\$60.88	Non-Drug
Q4017		Cast sup lng arm splint plst		\$49.78	Non-Drug
Q4018		Cast sup lng arm splint fibr		\$106.57	Non-Drug
Q4019		Cast sup lng arm splint ped p		\$24.98	Non-Drug
Q4020		Cast sup lng arm splint ped f		\$53.70	Non-Drug
Q4021		Cast sup sht arm splint plst		\$49.78	Non-Drug
Q4022		Cast sup sht arm splint fibr		\$106.57	Non-Drug
Q4023		Cast sup sht arm splint ped p		\$24.98	Non-Drug
Q4024		Cast sup sht arm splint ped f		\$53.70	Non-Drug
Q4025		Cast sup hip spica plaster		\$222.11	Non-Drug
Q4026		Cast sup hip spica fiberglass		\$472.21	Non-Drug
Q4027		Cast sup hip spica ped plaster		\$111.14	Non-Drug
Q4028		Cast sup hip spica ped fibril		\$236.47	Non-Drug
Q4029		Cast sup long leg plaster		\$109.83	Non-Drug
Q4030		Cast sup long leg fiberglass		\$232.55	Non-Drug
Q4031		Cast sup lng leg ped plaster		\$55.00	Non-Drug
Q4032		Cast sup lng leg ped fibrils		\$116.36	Non-Drug
Q4033		Cast sup lng leg cylinder pl		\$93.51	Non-Drug
Q4034		Cast sup lng leg cylinder fb		\$197.95	Non-Drug
Q4035		Cast sup lng leg cylindr ped p		\$46.52	Non-Drug
Q4036		Cast sup lng leg cylindr ped f		\$98.74	Non-Drug
Q4037		Cast sup shrt leg plaster		\$125.50	Non-Drug
Q4038		Cast sup shrt leg fiberglass		\$266.49	Non-Drug
Q4039		Cast sup shrt leg ped plaster		\$62.83	Non-Drug
Q4040		Cast sup shrt leg ped fibrils		\$133.33	Non-Drug
Q4041		Cast sup lng leg splint plaster		\$71.97	Non-Drug
Q4042		Cast sup lng leg splint fibril		\$152.26	Non-Drug
Q4043		Cast sup lng leg splint ped p		\$36.07	Non-Drug
Q4044		Cast sup lng leg splint ped f		\$76.54	Non-Drug
Q4045		Cast sup shrt leg splint plaster		\$46.52	Non-Drug
Q4046		Cast sup shrt leg splint fibril		\$98.74	Non-Drug
Q4047		Cast sup shrt leg splint ped p		\$23.02	Non-Drug
Q4048		Cast sup shrt leg splint ped f		\$49.78	Non-Drug
Q4049		Finger splint, static		\$60.88	Non-Drug
Q4050		Cast supplies unlisted		\$28.70	Non-Drug
Q4051		Splint supplies misc	a	\$25.62	Non-Drug
Q4054		Darbepoetin alfa, esrd use		\$9.51	Drug
Q4055		Epoetin alfa, esrd use		\$23.93	Drug
Q4075		Acyclovir, 5 mg		\$0.49	Drug
Q4076		Dopamine hcl, 40 mg		\$0.49	Drug
Q4077		Treprostinil, 1 mg		\$121.12	Drug
R0070		Transport portable x-ray		\$143.08	Non-Drug
R0075		Transport port x-ray multipl		\$74.72	Non-Drug
R0076		Transport portable EKG		\$146.24	Non-Drug
S0012		Butorphanol tartrate, nasal		\$159.51	Non-Drug
S0014		Tacrine hydrochloride, 10 mg		\$2.25	Non-Drug
S0016		Injection, amikacin sulfate		\$54.65	Non-Drug
S0017		Injection, aminocaproic acid		\$3.95	Non-Drug
S0020		Injection, bupivacaine hydro		\$4.35	Non-Drug
S0023		Injection, cimetidine hydroc		\$9.00	Non-Drug
S0028		Injection, famotidine, 20 mg		\$9.78	Non-Drug
S0030		Injection, metronidazole		\$27.31	Non-Drug
S0032		Injection, nafcillin sodium		\$10.38	Non-Drug
S0039		Injection, sulfamethoxazole		\$19.62	Non-Drug
S0040		Injection, ticarcillin disod		\$29.11	Non-Drug
S0071		Injection, acyclovir sodium		\$4.14	Non-Drug
S0072		Injection, amikacin sulfate		\$218.48	Non-Drug
S0073		Injection, aztreonam, 500 mg		\$28.02	Non-Drug
S0074		Injection, cefotetan disodi		\$13.17	Non-Drug
S0077		Injection, clindamycin phosp		\$19.46	Non-Drug
S0080		Injection, pentamidine iseth		\$160.29	Non-Drug
S0081		Injection, piperacillin sodi		\$70.31	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 52 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Category
S0088		Imatinib 100 mg		\$23.29	Non-Drug
S0090		Sildenafil citrate, 25 mg		\$16.45	Non-Drug
S0091		Granisetron 1mg		\$362.42	Non-Drug
S0092		Hydromorphone 250 mg		\$164.84	Non-Drug
S0093		Morphine 500 mg		\$19.63	Non-Drug
S0104		Zidovudine, oral, 100 mg		\$4.22	Non-Drug
S0108		Mercaptopurine 50 mg		\$7.77	Non-Drug
S0122		Inj menotropins 75 iu		\$141.92	Non-Drug
S0126		Inj follitropin alfa 75 iu		\$187.38	Non-Drug
S0128		Inj follitropin beta 75 iu		\$180.61	Non-Drug
S0155		Epoprostenol dilutant		\$21.94	Non-Drug
S0156		Exemestane, 25 mg		\$13.28	Non-Drug
S0170		Anastrozole 1 mg		\$12.02	Non-Drug
S0171		Bumetanide 0.5 mg		\$2.67	Non-Drug
S0172		Chlorambucil 2 mg		\$3.07	Non-Drug
S0173		Dexamethasone 4 mg		\$1.79	Non-Drug
S0174		Dolasetron 50 mg		\$119.38	Non-Drug
S0175		Flutamide 125 mg		\$3.66	Non-Drug
S0176		Hydroxyurea 500 mg		\$2.37	Non-Drug
S0177		Levamisole 50 mg		\$11.80	Non-Drug
S0178		Lomustine 10 mg		\$11.87	Non-Drug
S0179		Megestrol 20 mg		\$1.23	Non-Drug
S0181		Ondansetron 4 mg		\$30.99	Non-Drug
S0182		Procarbazine 5 mg		\$1.29	Non-Drug
S0183		Prochlorperazine 5 mg		\$1.04	Non-Drug
S0187		Tamoxifen 10 mg		\$4.10	Non-Drug
S0190		Mifepristone, oral, 200 mg		\$159.61	Non-Drug
S0191		Misoprostol, oral, 200 mcg		\$1.85	Non-Drug
S0209		WC van mileage per mi		\$1.41	Non-Drug
S0215		Nonemerg transp mileage		\$1.41	Non-Drug
S0302		Completed EPSDT		\$66.09	Non-Drug
S0395		Impression casting ft		\$70.31	Non-Drug
S0500		Dispos cont lens		\$126.56	Non-Drug
S0504		Singl prscrp lens		\$17.76	Non-Drug
S0506		Bifoc prscrp lens		\$30.52	Non-Drug
S0508		Trifoc prscrp lens		\$39.42	Non-Drug
S0510		Non-prscrp lens		\$25.09	Non-Drug
S0512		Daily cont lens		\$225.68	Non-Drug
S0514		Color cont lens		\$258.69	Non-Drug
S0516		Safety frames		\$73.43	Non-Drug
S0518		Sunglass frames		\$42.46	Non-Drug
S0580		Polycarb lens		\$35.16	Non-Drug
S0605		Digital rectal examination,		\$21.09	Non-Drug
S0610		Annual gynecological examina		\$147.65	Non-Drug
S0612		Annual gynecological examina		\$112.50	Non-Drug
S0620		Routine ophthalmological exa		\$77.34	Non-Drug
S0621		Routine ophthalmological exa		\$85.78	Non-Drug
S0630		Removal of sutures		\$53.44	Non-Drug
S0800		Laser in situ keratomileusis		\$1,610.11	Non-Drug
S0820		Computerized corneal topogra		\$113.90	Non-Drug
S0830		Ultrasound pachymetry		\$84.37	Non-Drug
S1015		IV tubing extension set		\$35.26	Non-Drug
S1016		Non-pvc intravenous administ		\$22.50	Non-Drug
S3620		Newborn metabolic screening		\$42.19	Non-Drug
S4993		Contraceptive pills for bc		\$33.75	Non-Drug
S5000		Prescription drug, generic		\$15.47	Non-Drug
S5001		Prescription drug,brand name		\$68.09	Non-Drug
S5010		5% dextrose and 0.45% saline		\$11.25	Non-Drug
S5497		HIT cath care noc		\$20.62	Non-Drug
S5498		HIT simple cath care		\$21.09	Non-Drug
S5501		HIT complex cath care		\$28.12	Non-Drug
S5502		HIT interim cath care		\$12.66	Non-Drug
S8085		Fluorine-18 fluorodeoxygluco		\$722.79	Non-Drug
S8092		Electron beam computed tomog		\$555.45	Non-Drug
S8095		Wig (for medically-induced h		\$421.86	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 53 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
S8096		Portable peak flow meter		\$28.12	Non-Drug
S8110		Peak expiratory flow rate (p		\$26.72	Non-Drug
S8182		Humidifier non-servo		\$190.39	Non-Drug
S8183		Humidifier dual servo		\$292.34	Non-Drug
S8185		Flutter device		\$51.39	Non-Drug
S8186		Swivel adaptor		\$47.81	Non-Drug
S8189		Trach supply noc		\$25.31	Non-Drug
S8190		Electronic spirometer		\$47.06	Non-Drug
S8260		Oral orthotic for treatment		\$1,328.87	Non-Drug
S8420		Custom gradient sleeve/glov		\$174.32	Non-Drug
S8421		Ready gradient sleeve/glov		\$33.41	Non-Drug
S8422		Custom grad sleeve med		\$116.07	Non-Drug
S8423		Custom grad sleeve heavy		\$108.10	Non-Drug
S8424		Ready gradient sleeve		\$59.16	Non-Drug
S8425		Custom grad glove med		\$28.13	Non-Drug
S8427		Ready gradient glove		\$15.12	Non-Drug
S8429		Gradient pressure wrap		\$215.12	Non-Drug
S8450		Splint digit		\$9.84	Non-Drug
S8451		Splint wrist or ankle		\$39.37	Non-Drug
S8452		Splint elbow		\$76.23	Non-Drug
S9001		Home uterine monitor with or		\$104.06	Non-Drug
S9015		Automated EEG monitoring		\$123.75	Non-Drug
S9075		Smoking cessation treatment		\$246.09	Non-Drug
S9088		Services provided in urgent		\$126.56	Non-Drug
S9090		Vertebral axial decompressio		\$91.40	Non-Drug
S9122		Home health aide or certifie		\$60.57	Non-Drug
S9123		Nursing care in home RN		\$103.28	Non-Drug
S9124		Nursing care, in the home; b		\$54.84	Non-Drug
S9126		Hospice care, in the home, p		\$281.24	Non-Drug
S9127		Social work visit, in the ho		\$217.12	Non-Drug
S9129		Occupational therapy, in the		\$184.13	Non-Drug
S9131		PT in the home per diem		\$179.99	Non-Drug
S9140		Diabetic Management Program,		\$88.89	Non-Drug
S9325		HIT pain mgmt per diem		\$330.46	Non-Drug
S9326		HIT cont pain per diem		\$133.59	Non-Drug
S9330		HIT cont chem diem		\$126.56	Non-Drug
S9331		HIT intermit chemo diem		\$351.55	Non-Drug
S9338		HIT immunotherapy diem		\$168.74	Non-Drug
S9340		HIT enteral per diem		\$175.78	Non-Drug
S9342		HIT enteral pump diem		\$64.69	Non-Drug
S9347		HIT longterm infusion diem		\$91.40	Non-Drug
S9348		HIT sympathomim diem		\$12.66	Non-Drug
S9349		HIT tocolysis diem		\$281.24	Non-Drug
S9364		HIT tpn total diem		\$605.37	Non-Drug
S9365		HIT tpn 1 liter diem		\$605.37	Non-Drug
S9366		HIT tpn 2 liter diem		\$605.37	Non-Drug
S9367		HIT tpn 3 liter diem		\$605.37	Non-Drug
S9368		HIT tpn over 3l diem		\$605.37	Non-Drug
S9373		HIT hydra total diem		\$307.40	Non-Drug
S9374		HIT hydra 1 liter diem		\$307.40	Non-Drug
S9375		HIT hydra 2 liter diem		\$307.40	Non-Drug
S9376		HIT hydra 3 liter diem		\$307.40	Non-Drug
S9377		HIT hydra over 3l diem		\$307.40	Non-Drug
S9379		HIT noc per diem		\$307.40	Non-Drug
S9435		Medical foods for inborn err		\$14.06	Non-Drug
S9455		Diabetic Management Program,		\$70.31	Non-Drug
S9460		Diabetic Management Program,		\$98.43	Non-Drug
S9465		Diabetic Management Program,		\$87.48	Non-Drug
S9470		Nutritional counseling, diet		\$78.71	Non-Drug
S9494		HIT antibiotic total diem		\$4.22	Non-Drug
S9497		HIT antibiotic q3h diem		\$288.27	Non-Drug
S9500		HIT antibiotic q24h diem		\$147.65	Non-Drug
S9501		HIT antibiotic q12h diem		\$227.81	Non-Drug
S9502		HIT antibiotic q8h diem		\$246.09	Non-Drug
S9503		HIT antibiotic q6h diem		\$267.18	Non-Drug

See end of table for note regarding Status/Usage Indicators.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 54 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
S9504		HIT antibiotic q4h diem		\$288.27	Non-Drug
S9529		Venipuncture home/snf		\$168.74	Non-Drug
S9537		HT hem horm inj diem		\$70.31	Non-Drug
S9558		HT inj growth horm diem		\$5.62	Non-Drug
V2020		Vision svcs frames purchases		\$84.01	Non-Drug
V2025		Eyeglasses delux frames		\$115.79	Non-Drug
V2100		Lens spher single plano 4.00		\$49.30	Non-Drug
V2101		Single visn sphere 4.12-7.00		\$51.83	Non-Drug
V2102		Singl visn sphere 7.12-20.00		\$71.94	Non-Drug
V2103		Sphero cylindr 4.00d/12-2.00d		\$43.13	Non-Drug
V2104		Sphero cylindr 4.00d/2.12-4d		\$47.50	Non-Drug
V2105		Sphero cylindr 4.00d/4.25-6d		\$51.51	Non-Drug
V2106		Sphero cylindr 4.00d/6.00d		\$56.90	Non-Drug
V2107		Sphero cylindr 4.25d/12-2d		\$54.23	Non-Drug
V2108		Sphero cylindr 4.25d/2.12-4d		\$56.06	Non-Drug
V2109		Sphero cylindr 4.25d/4.25-6d		\$61.78	Non-Drug
V2110		Sphero cylindr 4.25d/over 6d		\$60.99	Non-Drug
V2111		Sphero cylindr 7.25d/25-2.25		\$63.48	Non-Drug
V2112		Sphero cylindr 7.25d/2.25-4d		\$69.08	Non-Drug
V2113		Sphero cylindr 7.25d/4.25-6d		\$77.23	Non-Drug
V2114		Sphero cylindr over 12.00d		\$82.26	Non-Drug
V2115		Lens lenticular bifocal		\$88.03	Non-Drug
V2118		Lens aniseikonic single		\$87.41	Non-Drug
V2121		Lenticular lens, single		\$89.69	Non-Drug
V2199		Lens single vision not oth c		\$94.78	Non-Drug
V2200		Lens spher bifoc plano 4.00d		\$63.80	Non-Drug
V2201		Lens sphere bifocal 4.12-7.0		\$69.32	Non-Drug
V2202		Lens sphere bifocal 7.12-20.		\$80.13	Non-Drug
V2203		Lens sphcyl bifocal 4.00d/1		\$64.34	Non-Drug
V2204		Lens sphcyl bifocal 4.00d/2.1		\$67.16	Non-Drug
V2205		Lens sphcyl bifocal 4.00d/4.2		\$72.43	Non-Drug
V2206		Lens sphcyl bifocal 4.00d/love		\$77.29	Non-Drug
V2207		Lens sphcyl bifocal 4.25-7d/.		\$70.83	Non-Drug
V2208		Lens sphcyl bifocal 4.25-7/2.		\$74.23	Non-Drug
V2209		Lens sphcyl bifocal 4.25-7/4.		\$78.98	Non-Drug
V2210		Lens sphcyl bifocal 4.25-7/ov		\$85.36	Non-Drug
V2211		Lens sphcyl bifo 7.25-12/25-		\$87.91	Non-Drug
V2212		Lens sphcyl bifo 7.25-12/2.2		\$90.21	Non-Drug
V2213		Lens sphcyl bifo 7.25-12/4.2		\$90.96	Non-Drug
V2214		Lens sphcyl bifocal over 12.		\$97.41	Non-Drug
V2215		Lens lenticular bifocal		\$98.62	Non-Drug
V2218		Lens aniseikonic bifocal		\$114.14	Non-Drug
V2219		Lens bifocal seg width over		\$55.72	Non-Drug
V2220		Lens bifocal add over 3.25d		\$45.64	Non-Drug
V2221		Lenticular lens, bifocal		\$101.82	Non-Drug
V2299		Lens bifocal speciality		\$66.11	Non-Drug
V2300		Lens sphere trifocal 4.00d		\$79.65	Non-Drug
V2301		Lens sphere trifocal 4.12-7.		\$90.87	Non-Drug
V2302		Lens sphere trifocal 7.12-20		\$95.74	Non-Drug
V2303		Lens sphcyl trifocal 4.0/12-		\$78.65	Non-Drug
V2304		Lens sphcyl trifocal 4.0/2.25		\$81.51	Non-Drug
V2305		Lens sphcyl trifocal 4.0/4.25		\$91.75	Non-Drug
V2306		Lens sphcyl trifocal 4.00/6		\$93.97	Non-Drug
V2307		Lens sphcyl trifocal 4.25-7/.		\$89.88	Non-Drug
V2308		Lens sphc trifocal 4.25-7/2.		\$93.37	Non-Drug
V2309		Lens sphc trifocal 4.25-7/4.		\$100.21	Non-Drug
V2310		Lens sphc trifocal 4.25-7/6		\$99.22	Non-Drug
V2311		Lens sphc trifo 7.25-12/25-		\$102.56	Non-Drug
V2312		Lens sphc trifo 7.25-12/2.25		\$103.05	Non-Drug
V2313		Lens sphc trifo 7.25-12/4.25		\$113.11	Non-Drug
V2314		Lens sphcyl trifocal over 12		\$120.22	Non-Drug
V2315		Lens lenticular trifocal		\$131.60	Non-Drug
V2318		Lens aniseikonic trifocal		\$157.91	Non-Drug
V2319		Lens trifocal seg width > 28		\$61.87	Non-Drug
V2320		Lens trifocal add over 3.25d		\$65.15	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 55 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
V2321		Lenticular lens, trifocal		\$129.96	Non-Drug
V2399		Lens trifocal speciality		\$66.11	Non-Drug
V2410		Lens variab asphericity sing		\$103.10	Non-Drug
V2430		Lens variable asphericity bi		\$120.79	Non-Drug
V2499		Variable asphericity lens		\$40.75	Non-Drug
V2500		Contact lens pmma spherical		\$95.05	Non-Drug
V2501		Cntct lens pmma-toric/prism		\$135.92	Non-Drug
V2502		Contact lens pmma bifocal		\$163.51	Non-Drug
V2503		Cntct lens pmma color vision		\$151.93	Non-Drug
V2510		Cntct gas permeable spherid		\$123.57	Non-Drug
V2511		Cntct toric prism ballast		\$170.14	Non-Drug
V2512		Cntct lens gas permbl bifocd		\$197.98	Non-Drug
V2513		Contact lens extended wear		\$168.93	Non-Drug
V2520		Contact lens hydrophilic		\$117.17	Non-Drug
V2521		Cntct lens hydrophilic toric		\$191.43	Non-Drug
V2522		Cntct lens hydrophil bifocd		\$186.74	Non-Drug
V2523		Cntct lens hydrophil extend		\$161.65	Non-Drug
V2530		Contact lens gas impermeable		\$231.27	Non-Drug
V2531		Contact lens gas permeable		\$487.48	Non-Drug
V2599		Contact lens/es other type		\$67.16	Non-Drug
V2600		Hand held low vision aids		\$61.18	Non-Drug
V2610		Single lens spectacle mount		\$310.48	Non-Drug
V2615		Telescop/otr compound lens		\$1,318.11	Non-Drug
V2623		Plastic eye prosth custom		\$2,186.17	Non-Drug
V2624		Polishing artificial eye		\$79.76	Non-Drug
V2625		Enlargemnt of eye prosthesis		\$817.97	Non-Drug
V2626		Reduction of eye prosthesis		\$402.94	Non-Drug
V2627		Scleral cover shell		\$3,199.99	Non-Drug
V2628		Fabrication & fitting		\$647.14	Non-Drug
V2629		Prosthetic eye other type		\$705.63	Non-Drug
V2630		Anter chamber intraocul lens		\$272.30	Non-Drug
V2632		Post chmbr intraocular lens		\$368.96	Non-Drug
V2700		Balance lens		\$54.87	Non-Drug
V2710		Glass/plastic slab off prism		\$78.55	Non-Drug
V2715		Prism lens/es		\$16.30	Non-Drug
V2718		Fresnell prism press-on lens		\$36.58	Non-Drug
V2730		Special base curve		\$27.64	Non-Drug
V2744		Tint photochromatic lens/es		\$22.03	Non-Drug
V2745		Tint, any color/solid/grad		\$14.69	Non-Drug
V2750		Anti-reflective coating		\$25.24	Non-Drug
V2755		UV lens/es		\$22.28	Non-Drug
V2760		Scratch resistant coating		\$21.57	Non-Drug
V2762		Polarization, any lens		\$17.29	Non-Drug
V2770		Occluder lens/es		\$25.76	Non-Drug
V2780		Oversize lens/es		\$17.39	Non-Drug
V2781		Progressive lens per lens		\$153.00	Non-Drug
V2785		Corneal tissue processing		\$2,750.45	Non-Drug
V2790		Amniotic membrane		\$49.39	Non-Drug
V2799		Miscellaneous vision service		\$57.45	Non-Drug
V5008		Hearing screening		\$70.39	Non-Drug
V5010		Assessment for hearing aid		\$91.75	Non-Drug
V5011		Hearing aid fitting/checking		\$143.29	Non-Drug
V5014		Hearing aid repair/modifying		\$172.82	Non-Drug
V5020		Conformity evaluation		\$80.44	Non-Drug
V5030		Body-worn hearing aid air		\$1,808.02	Non-Drug
V5040		Body-worn hearing aid bone		\$1,337.58	Non-Drug
V5050		Hearing aid monaural in ear		\$1,570.87	Non-Drug
V5060		Behind ear hearing aid		\$1,287.25	Non-Drug
V5070		Glasses air conduction		\$647.42	Non-Drug
V5080		Glasses bone conduction		\$1,858.35	Non-Drug
V5090		Hearing aid dispensing fee		\$562.24	Non-Drug
V5100		Body-worn bilat hearing aid		\$3,074.13	Non-Drug
V5110		Hearing aid dispensing fee		\$573.85	Non-Drug
V5120		Body-worn binaur hearing aid		\$2,667.58	Non-Drug
V5130		In ear binaural hearing aid		\$2,847.62	Non-Drug

See end of table for note regarding Status/Usage Indicators

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE CHARGES BY HCPCS CODE

PAGE 56 OF 56

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAP Category
V5140		Behind ear binaur hearing ai		\$2,967.65	Non-Drug
V5150		Glasses binaural hearing aid		\$3,178.67	Non-Drug
V5160		Dispensing fee binaural		\$718.08	Non-Drug
V5170		Within ear cros hearing aid		\$2,164.23	Non-Drug
V5180		Behind ear cros hearing aid		\$1,808.02	Non-Drug
V5190		Glasses cros hearing aid		\$2,139.07	Non-Drug
V5200		Cros hearing aid dispens fee		\$568.05	Non-Drug
V5210		In ear bicros hearing aid		\$2,365.57	Non-Drug
V5220		Behind ear bicros hearing ai		\$2,266.64	Non-Drug
V5230		Glasses bicros hearing aid		\$2,348.15	Non-Drug
V5240		Dispensing fee bicros		\$593.21	Non-Drug
V5241		Dispensing fee, monaural		\$113.57	Non-Drug
V5242		Hearing aid, monaural, cic		\$1,309.33	Non-Drug
V5243		Hearing aid, monaural, itc		\$1,379.10	Non-Drug
V5244		Hearing aid, prog, mon, cic		\$3,082.69	Non-Drug
V5245		Hearing aid, prog, mon, itc		\$2,433.71	Non-Drug
V5246		Hearing aid, prog, mon, ite		\$1,505.67	Non-Drug
V5247		Hearing aid, prog, mon, bte		\$2,086.55	Non-Drug
V5248		Hearing aid, binaural, cic		\$1,657.07	Non-Drug
V5249		Hearing aid, binaural, itc		\$2,105.97	Non-Drug
V5250		Hearing aid, prog, bin, cic		\$5,824.67	Non-Drug
V5251		Hearing aid, prog, bin, itc		\$5,500.17	Non-Drug
V5252		Hearing aid, prog, bin, ite		\$5,191.90	Non-Drug
V5253		Hearing aid, prog, bin, bte		\$2,352.58	Non-Drug
V5254		Hearing id, digit, mon, cic		\$3,650.56	Non-Drug
V5255		Hearing aid, digit, mon, itc		\$2,888.00	Non-Drug
V5256		Hearing aid, digit, mon, ite		\$3,447.75	Non-Drug
V5257		Hearing aid, digit, mon, bte		\$2,531.05	Non-Drug
V5258		Hearing aid, digit, bin, cic		\$5,514.78	Non-Drug
V5259		Hearing aid, digit, bin, itc		\$6,489.88	Non-Drug
V5260		Hearing aid, digit, bin, ite		\$7,463.36	Non-Drug
V5261		Hearing aid, digit, bin, bte		\$6,165.39	Non-Drug
V5262		Hearing aid, disp, monaural		\$126.55	Non-Drug
V5263		Hearing aid, disp, binaural		\$63.28	Non-Drug
V5264		Ear mold/insert		\$79.99	Non-Drug
V5265		Ear mold/insert, disp		\$11.36	Non-Drug
V5266		Battery for hearing device		\$2.22	Non-Drug
V5267		Hearing aid supply/accessory		\$24.34	Non-Drug
V5268		ALD Telephone Amplifier		\$343.77	Non-Drug
V5269		Alerting device, any type		\$503.28	Non-Drug
V5270		ALD, TV amplifier, any type		\$614.23	Non-Drug
V5271		ALD, TV caption decoder		\$3,191.15	Non-Drug
V5272		Tdd		\$722.95	Non-Drug
V5273		ALD for cochlear implant		\$476.93	Non-Drug
V5274		ALD unspecified		\$1,057.34	Non-Drug
V5275		Ear impression		\$48.67	Non-Drug
V5298		Hearing aid noc		\$3,089.10	Non-Drug
V5299		Hearing service		\$792.40	Non-Drug
V5336		Repair communication device		\$282.22	Non-Drug

Key to Status/Usage Indicators:

a Cannot be billed by VA Hospital Outpatients and Provider-Based Clinics (because the service is separately priced as outpatient facility charges — see Table F).

No entry: Can be billed at all VA locations.

See end of table for note regarding Status/Usage Indicators.

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 1 OF 16

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																	
	Work Expense	Practice Expense	Total Unit Value	Office/Home/ Urgent Care Visits	Inpatient Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Concussions	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/ Speech Exams	Physical Exams	Chiropractor	Psych/Alcohol & Drug Abuse	Sur-gery	Radiology	Pathology	Anesthesias	Normal Deliv-eries	Cesarean Deliv-eries	Non-ear Deliv-eries	
Nationwide Average	1.000	1.000	1.000	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
002	1.000	1.030	1.02	0.96	1.02	0.97	0.84	1.07	0.72	0.63	0.68	0.82	0.95	1.15	0.87	0.71	1.09	1.00	0.92	0.89	0.94	0.87	0.78	0.68	0.80	0.76	0.84	
005	1.068	1.251	1.17	0.93	1.01	0.98	0.84	1.07	0.72	0.63	0.68	0.82	0.95	1.15	0.87	0.71	1.09	1.00	0.92	0.89	0.94	0.87	0.78	0.68	0.80	0.76	0.84	
006	1.000	0.712	0.84	0.58	0.64	0.76	0.71	0.98	0.85	0.69	0.68	0.76	0.74	1.70	0.25	0.95	1.20	0.34	0.91	0.62	0.77	0.78	0.53	1.02	0.80	0.78	0.91	
007	1.000	0.712	0.84	0.52	0.70	0.94	0.47	0.89	0.64	0.62	0.58	0.65	0.53	1.18	0.21	0.78	0.83	0.29	0.80	0.62	0.77	0.78	0.53	1.02	0.80	0.78	0.91	
008	1.000	0.712	0.84	0.56	0.84	1.26	0.71	0.89	0.64	0.62	0.58	0.65	0.53	1.18	0.21	0.78	0.83	0.29	0.80	0.62	0.77	0.78	0.53	1.02	0.80	0.78	0.91	
009	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
010	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
011	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
012	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
013	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
014	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
015	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
016	1.010	1.129	1.08	0.91	0.97	0.60	0.88	0.95	0.75	1.06	0.97	1.18	0.85	0.43	1.05	0.98	0.88	1.08	0.82	0.89	0.94	0.93	0.84	1.03	1.09	1.05	1.05	
017	1.041	1.239	1.15	0.86	0.93	0.75	0.81	1.03	0.91	0.89	0.89	1.24	0.84	0.52	1.04	0.96	0.95	0.98	0.94	0.90	0.87	1.04	0.91	1.03	0.83	0.87	0.89	
018	1.041	1.239	1.15	0.86	0.93	0.75	0.81	1.03	0.91	0.89	0.89	1.24	0.84	0.52	1.04	0.96	0.95	0.98	0.94	0.90	0.87	1.04	0.91	1.03	0.83	0.87	0.89	
019	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
020	1.041	1.239	1.15	0.84	0.89	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
021	1.041	1.239	1.15	0.84	0.89	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
022	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
023	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
024	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
025	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
026	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
027	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
028	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
029	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
030	1.010	1.129	1.08	0.88	0.88	0.76	0.81	1.09	1.04	0.91	0.89	1.05	0.93	0.50	1.01	0.86	1.02	1.01	0.87	0.92	0.88	0.87	0.93	1.02	0.89	0.86	1.01	
031	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
032	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
033	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
034	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
035	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
036	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
037	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
038	1.000	1.030	1.02	1.04	0.96	0.90	1.11	1.21	0.83	0.82	0.82	1.02	1.05	0.94	1.04	0.89	0.83	1.09	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
039	1.000	0.999	1.00	0.95	0.94	0.97	0.89	1.03	0.91	0.81	0.81	0.96	0.96	0.73	0.82	0.92	0.87	1.32	0.96	1.04	0.82	0.97	0.95	0.85	0.98	0.89	0.95	
040	1.000	0.999	1.00	0.95	0.94	0.97	0.89	1.03	0.91	0.81	0.81	0.96	0.96	0.73	0.82	0.92	0.87	1.32	0.96	1.04	0.82	0.97	0.95	0.85	0.98	0.89	0.95	
041	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
042	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
043	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
044	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
045	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
046	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
047	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94	0.67	0.67	0.82	0.82	0.33	0.26	0.26	1.26	1.05	0.65	1.02	0.98	0.80	0.84	0.83	0.86	0.83	0.80	
048	1.000	0.910	0.95	0.98	0.99	0.63	0.84	0.99	0.94																			

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 2 OF 16

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Impatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Consultations	Physician/ Medical Director	Cardiovascular	Immunizations	Well Baby Exams	Well Child Exams	Hearing/ Vision/ Speech Exams	Physical Exams	Chiropractor	Psych/Alcohol & Drug Abuse	Surgey	Radiology	Pathology	Anesthesia	Normal Deliv-eries	Cesarean Deliv-eries
069	1.000	0.986	0.99	0.89	0.87	0.62	1.03	1.02	0.78	0.95	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.94	0.89	0.95	0.70
060	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
061	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
062	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
063	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
064	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
065	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
066	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
067	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
068	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
069	1.050	1.156	1.11	0.91	0.88	0.94	1.12	1.12	0.90	0.85	0.86	1.02	0.78	1.20	1.20	0.94	1.11	1.19	0.93	1.02	1.01	0.92	0.94	1.02	1.08	
070	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
071	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
072	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
073	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
074	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
075	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
076	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
077	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
078	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
079	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
080	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
081	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
082	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
083	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
084	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
085	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
086	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
087	1.029	1.110	1.07	0.94	0.91	0.80	1.14	0.90	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	0.95	1.02	
088	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
089	1.058	1.193	1.13	0.97	0.98	0.90	1.21	1.07	1.00	1.11	0.94	0.88	1.08	1.08	1.08	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	
090	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.89	1.00	1.12	1.37	0.92	1.05	1.09	1.09	1.09	1.09	1.09	1.09	1.09	
101	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.89	1.00	1.12	1.37	0.92	1.05	1.09	1.09	1.09	1.09	1.09	1.09	1.09	
102	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.89	1.00	1.12	1.37	0.92	1.05	1.09	1.09	1.09	1.09	1.09	1.09	1.09	
103	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
104	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
105	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
106	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
107	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
108	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
109	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
110	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
111	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
112	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
113	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
114	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
115	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
116	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
117	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84	1.05	1.12	1.05	1.20	1.06	1.05	1.05	1.05		
118	1.068	1.251	1.17	0.92	1.08	1.09	1.00	1.32	0.85	0.95	1.00	0.68	1.08	0.91	1.12	0.84										

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE PAGE 3 OF 16

Table with columns: Zip Code, RVU GAAFs (Work Expense, Practice Expense, Total Unit Value), Office/Home/Inpatient Care, Therapeutic/Inpatient, Allergy/Immunology, Misc. Medical, ER/Visits, Con. Sults, Physical Med., Cardiovascular, Immunizations, Well Baby Exams, Vision Exams, Hearing/Speech Exams, Physical Exams, Chiropractor, Psych/Alcohol/Drug, Surgery, Radiology, Pathology, Anesthesia, Normal Delivery, Cesarean Delivery, Non-Delivery.

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 4 OF 16

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Procedures	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/ Speech Exams	Physical Exams	Chiropractor	Phyto./ Alcohol/ & Drug Abuse	Surgey	Radiology	Pathology	Anesthesiology	Normal Delivery	Cesarean Delivery	Non-Delivery
187	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
188	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
189	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
190	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
191	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
192	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
193	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
194	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
195	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
196	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
197	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
198	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
199	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
200	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
201	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
202	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
203	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
204	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
205	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
206	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
207	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
208	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
209	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
210	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
211	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
212	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
213	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
214	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
215	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
216	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
217	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
218	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
219	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
220	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
221	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
222	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
223	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
224	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
225	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
226	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
227	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
228	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
229	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
230	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
231	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87	0.89	0.89	1.07
232	1.000	0.929	0.96	0.87	0.86	0.74	1.24	1.01	0.83	0.83	0.84	0.96	1.50	1.08	0.80	0.84	1.15	0.71	0.80	0.83	1.00	1.13	0.84	0.87			

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 6 OF 16

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																	
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Consultations	Physician Services	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Health/Spent Exams	Physical Exams	Chiropractor	Psych/Alcohol & Drug Abuse	Surgery	Religiosity	Pathology	Anesthesia	Normative	Certain Derivatives	Non-Derivatives	
307	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
308	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
309	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
310	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
311	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
312	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
313	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
314	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
315	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
316	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
317	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
318	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
319	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
320	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
321	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
322	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
323	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
324	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
325	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
326	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
327	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
328	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
329	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
330	1.000	0.682	0.94	0.96	0.97	1.00	1.08	1.04	1.06	1.11	0.87	0.89	1.37	1.07	0.88	0.98	1.03	0.97	0.93	1.04	1.06	1.13	1.04	1.04	0.97	1.00	0.99	1.02
331	1.015	1.052	1.04	1.25	1.19	0.81	1.20	0.99	0.83	1.38	1.13	1.11	1.31	1.27	1.07	0.95	1.08	1.02	1.25	1.32	1.07	1.08	1.07	1.08	0.97	1.06	0.96	1.10
332	1.015	1.052	1.04	1.25	1.19	0.81	1.20	0.99	0.83	1.38	1.13	1.11	1.31	1.27	1.07	0.95	1.08	1.02	1.25	1.32	1.07	1.08	1.07	1.08	0.97	1.06	0.96	1.10
333	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
334	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
335	1.000	0.946	0.97	1.01	0.97	1.01	1.02	1.03	0.93	1.45	1.00	1.15	1.13	0.86	1.22	1.10	0.89	0.89	1.05	1.12	1.03	1.05	0.96	0.83	1.07	0.89	0.87	0.77
336	1.000	0.946	0.97	1.01	0.97	1.01	1.02	1.03	0.93	1.45	1.00	1.15	1.13	0.86	1.22	1.10	0.89	0.89	1.05	1.12	1.03	1.05	0.96	0.83	1.07	0.89	0.87	0.77
337	1.000	0.946	0.97	1.01	0.97	1.01	1.02	1.03	0.93	1.45	1.00	1.15	1.13	0.86	1.22	1.10	0.89	0.89	1.05	1.12	1.03	1.05	0.96	0.83	1.07	0.89	0.87	0.77
338	1.000	0.946	0.97	1.01	0.97	1.01	1.02	1.03	0.93	1.45	1.00	1.15	1.13	0.86	1.22	1.10	0.89	0.89	1.05	1.12	1.03	1.05	0.96	0.83	1.07	0.89	0.87	0.77
339	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
341	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
342	1.000	0.948	0.97	0.88	0.96	0.93	0.91	1.02	0.97	1.40	0.89	0.99	0.75	1.10	0.89	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03	0.86
343	1.000	0.948	0.97	0.88	0.96	0.93	0.91	1.02	0.97	1.40	0.89	0.99	0.75	1.10	0.89	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03	0.86
344	1.000	0.948	0.97	0.88	0.96	0.93	0.91	1.02	0.97	1.40	0.89	0.99	0.75	1.10	0.89	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03	0.86
345	1.000	0.948	0.97	0.88	0.96	0.93	0.91	1.02	0.97	1.40	0.89	0.99	0.75	1.10	0.89	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03	0.86
346	1.000	0.948	0.97	0.88	0.96	0.93	0.91	1.02	0.97	1.40	0.89	0.99	0.75	1.10	0.89	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03	0.86
347	1.000	0.946	0.97	0.83	1.01	1.00	0.88	1.27	0.89	1.04	1.03	1.07	0.90	1.42	1.10	0.85	0.99	0.95	1.01	1.02	0.95	0.85	0.96	1.00	0.95	0.97	0.86	0.85
349	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
350	1.000	1.018	1.01	1.38	1.17	1.59	1.54	1.51	0.94	1.60	1.16	1.25	0.91	1.03	0.90	1.11	1.04	0.97	0.95	1.23	1.22	1.01	0.99	1.08	1.07	1.04	1.09	0.93
351	1.000	0.870	0.93	0.70	0.81	0.68	1.24	0.81	0.88	0.95	0.80	0.95	1.08	0.90	0.60	0.64	0.83	0.56	0.83	1.01	0.85	1.00	0.76	0.91	0.87	0.76	0.69	0.69
352	1.000	0.870	0.93	0.70	0.81	0.68	1.24	0.81	0.88	0.95	0.80	0.95	1.08	0.90	0.60	0.64	0.83	0.56	0.83	1.01	0.85	1.00	0.76	0.91	0.87	0.76	0.69	0.69
353	1.000	0.870	0.93	0.70	0.81																							

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 7 OF 16

Table with columns: Zip Code, RVU GAAFs (Work Expense, Total Unit Value, Incident Visits, Office/Home/ Urgent Care Visits, Therapeutic Injections, Allergy Testing, Allergy Immunotherapy, Misc Medical Call, ER Visits, Con-sults, Phys-ician, Card-iology, Immun-izations, Well-Baby Exams, Vision/ Speech Exams, Hear-ing/ Exams, Phys-ical Exams, Critic-practice, Psych/ Alcohol & Drug Abuse, Sur-gery, Reo-logy, Path-ology, Anal-ysis, Normal Deliv-eries, Cesare-an Deliv-eries, Non-deliv-eries) and Conversion Factor GAAFs By Category.

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 8 OF 16

Zip Code	RVU GAAFs		Conversion Factor GAAFs By Category																								
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc Medical	ER Visits	Conc Subst	Phys Med- Onc	Cardio-vascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/ Speech Exams	Physical Exams	Chronic Illness	Psych/Alcohol & Drug Abuse	Sur- gery	Radiology	Pathology	Anes- thesia	Normal Deliv- eries	Cesar- ean Deliv- eries	Non- Deliv- eries
434	1,000	1,000	0.94	0.91	0.94	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
435	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
436	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
437	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
438	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
439	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
440	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
441	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
442	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
443	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
444	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
445	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
446	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
447	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
448	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
449	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
450	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
451	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
452	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
453	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
454	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
455	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
456	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
457	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
458	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
459	1,000	1,000	0.94	0.91	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
460	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
461	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
462	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
463	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
464	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
465	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
466	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
467	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
468	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
469	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
470	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
471	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
472	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
473	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	1.02
474	1,000	1,000	0.92	0.89	1.05	0.92	0.93	0.98	0.99	0.80	0.90	0.84	0.75	0.93	1.01	0.96	0.97	1.08	0.82	0.85	0.96	0.97	1.08	0.82	0.79	0.85	

TABLE L.— PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

Table with columns: Zip Code, RVU GAAFs (Work Expense, Practice Expense, Total Unit Value, Inpatient Visits, Office/Home/ Urgent Care Visits, Therapeutic Injections, Allergy Testing, Allergy Immunotherapy, Misc. Medical, ER Visits, Concussion, Physical Medicine, Cardiovascular, Immunizations, Well Baby Exams, Vision Exams, Hearing/ Speech Exams, Physical Exams, Chiropractor, Psych/Alcohol & Drug Abuse, Surgery, Radiology, Pathology, Anesthesia, Normal Deliveries, Cesarean Deliveries, Non-ban Deliveries) and a final column with values ranging from 0.75 to 1.01.

PAGE 9 OF 16

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 10 OF 16

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																		
	Work Expense	Practice Expense	Total Unit Value	Inpatient Care Visits	Office/ Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunization	Mechanical	ER Visits	Consultants	Physician Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Speech Exams	Physical Exams	Chiropractic	Psych/ Alcohol & Drug	Surgeries	Radiology	Pathology	Anesthesia	Normal Deliveries	Cesarean Deliveries	Non-man Deliveries		
559	1.000	0.974	0.99	1.08	1.15	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
560	1.000	0.974	0.99	1.07	1.15	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
561	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
562	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
563	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
564	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
565	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
566	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
567	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
568	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
569	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
570	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
571	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
572	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
573	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
574	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
575	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
576	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
577	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
578	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
579	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
580	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
581	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
582	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
583	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
584	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
585	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
586	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
587	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
588	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
589	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
590	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
591	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
592	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
593	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
594	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
595	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
596	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11	1.14	0.85	1.27	1.07	1.23	1.08	1.41	1.20	1.08	1.22	0.98	1.18	1.21	1.21	1.14	1.14	1.14
597	1.000	0.974	0.99	1.05	1.09	1.03	1.25	1.38	0.95	1.14	1.11	1.11																	

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE PAGE 12 OF 16

Zip Code	RVU GAAFs			Conversion Factor GAAFs By Category																								
	Work Expense	Practice Expense	Total Unit Value	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Med.	ER Visits	Con- sults	Phys- ical Med- icine	Cardi- ovas- cular	Immun- izations	Well- Baby Exams	Vision Exams	Hear- ing/ Speech Exams	Phys- ical Exams	Chro- nic Dis- eases	Psych/ Alcohol & Drug Abuse	Sur- gery	Radi- ology	Path- ology	Anes- thesia	Normal Deliv- eries	Caes- ean Deliv- eries	Non- Deliv- eries		
688	1.000	0.877	0.33	0.67	0.64	1.00	0.94	0.93	0.71	0.96	0.73	0.89	0.98	0.97	1.00	0.83	0.90	0.80	0.89	0.87	1.11	0.87	0.75	0.89	0.81	0.71		
690	1.000	0.877	0.33	0.67	0.64	1.00	0.94	0.93	0.71	0.96	0.73	0.89	0.98	0.97	1.00	0.83	0.90	0.80	0.89	0.87	1.11	0.87	0.75	0.89	0.81	0.71		
692	1.000	0.877	0.33	0.67	0.64	1.00	0.94	0.93	0.71	0.96	0.73	0.89	0.98	0.97	1.00	0.83	0.90	0.80	0.89	0.87	1.11	0.87	0.75	0.89	0.81	0.71		
693	1.000	0.877	0.33	0.67	0.64	1.00	0.94	0.93	0.71	0.96	0.73	0.89	0.98	0.97	1.00	0.83	0.90	0.80	0.89	0.87	1.11	0.87	0.75	0.89	0.81	0.71		
700	1.000	0.945	0.97	0.98	0.94	1.04	1.54	1.03	0.96	1.16	1.04	1.44	1.09	1.02	0.95	0.90	1.02	1.21	0.94	0.99	0.97	1.17	0.97	0.80	0.86	0.83		
701	1.000	0.945	0.97	0.98	0.94	1.04	1.54	1.03	0.96	1.16	1.04	1.44	1.09	1.02	0.95	0.90	1.02	1.21	0.94	0.99	0.97	1.17	0.97	0.80	0.86	0.83		
703	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
704	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
705	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
706	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
707	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
708	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
710	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
711	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
712	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
713	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
714	1.000	0.870	0.83	0.85	0.97	0.90	1.03	0.96	0.79	1.05	0.96	1.08	1.19	1.17	1.00	0.97	1.06	1.25	0.96	1.02	1.03	1.18	0.97	0.84	0.90	0.96		
716	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
717	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
718	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
719	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
721	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
722	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
723	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
724	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
725	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
726	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
727	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
728	1.000	0.847	0.92	0.79	0.93	0.67	1.09	0.84	0.84	1.05	0.97	0.93	0.96	1.17	1.07	0.98	0.86	1.22	0.94	1.04	1.10	0.88	1.15	0.88	0.75	1.05	0.95	0.89
730	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
731	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
732	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
733	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
734	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
735	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
736	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
737	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
738	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
739	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
740	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
741	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
742	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
743	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
744	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
745	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92	0.48	0.94	1.02	1.18	1.11	1.19	0.85	0.93	1.09	1.38	1.41	0.99	1.04	0.97	1.11	0.88	0.84	0.84	0.84
746	1.000	0.876	0.83	0.83	0.98	1.01	1.58	0.95	0.92																			

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 13 OF 16

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medications	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/ Speech Exams	Physical Exams	Chiropractic	Psych/Alcohol/Drug Abuse	Surgey	Radiology	Pathology	Anesthesiology	Normal Deliveries	Cesarean Deliveries	Non-Emergencies
750	1.000	0.880	0.93	1.02	1.01	1.38	1.10	1.17	1.13	1.08	1.07	1.30	1.27	1.20	0.99	1.02	1.02	1.05	0.89	0.91	1.03	1.17	1.17	0.97	1.01	1.00	1.01
751	1.000	0.981	0.99	1.11	1.12	1.12	0.98	1.11	1.00	0.87	1.02	0.99	1.07	1.07	0.99	1.41	1.04	0.95	1.21	0.94	0.97	0.97	1.07	1.07	0.96	0.88	0.96
761	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
762	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
763	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
764	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
765	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
766	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
767	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
768	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
769	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
770	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
771	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
772	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
773	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
774	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
775	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
776	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
777	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
778	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
779	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
780	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
781	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
782	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
783	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
784	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
785	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
786	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
787	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
788	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
789	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
790	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
791	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
792	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
793	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
794	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
795	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
796	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
797	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
798	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
799	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
800	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
801	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
802	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
803	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92	1.12	1.10	1.07
804	1.000	0.880	0.93	1.06	1.17	1.18	0.95	0.92	1.11	0.94	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.80	1.09	1.10	1.08	0.92</			

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 14 OF 16

Table with columns: Zip Code, RVU GAAFs, Conversion Factor GAAFs By Category (Physician, Cardiology, Well Baby, Vision, Hearing, Physical, Chiropractor, Psych/Alcohol, Surgery, Radiology, Pathology, Anesthesia, Normal Delivery, Cesarean Delivery, Non-Delivery). Rows list zip codes from 822 to 858.

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
PAGE 16 OF 16

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Impatient Visits	Office/Home Care Visits	Therapeutic Injections	Allergy Testing	Allergy Therapy	Misc. Medical	ER Visits	Consultations	Phys. Medicine	Cardiovascular	Immunizations	Well-Baby Exams	Vision Exams	Hearing Speech Exams	Physical Exams	Chiropractor	Psych./Alcohol & Drug Abuse	Surgeries	Radiology	Pathology	Anesthesiology	Normal Deliveries	Cesarian Deliveries
961	1,007	1,034	1,022	0.88	0.91	0.75	0.84	1.20	0.85	0.92	0.87	0.94	0.98	0.97	1.02	1.01	0.98	0.91	0.85	0.66	0.95	0.87	0.93	0.85	0.83	0.84
962	1,000	1,124	1,071	1.09	1.09	0.65	0.90	1.37	1.18	1.64	0.70	0.91	0.86	0.78	1.06	1.05	0.87	0.84	1.17	0.95	0.84	0.86	0.86	0.85	0.79	0.78
969	1,000	1,124	1,071	1.09	1.09	0.65	0.90	1.37	1.18	1.64	0.70	0.91	0.86	0.78	1.06	1.05	0.87	0.84	1.17	0.95	0.84	0.86	0.85	0.79	0.78	0.74
970	1,000	1,049	1,033	0.99	1.11	0.59	0.99	1.05	0.71	1.09	1.04	0.95	1.01	1.31	0.98	0.90	1.24	1.06	0.95	0.85	0.77	0.82	0.97	0.99	0.99	0.85
971	1,000	0.933	0.96	1.02	1.18	0.64	1.11	1.17	0.78	1.12	1.20	1.04	0.95	1.31	0.98	0.90	1.24	1.06	0.95	0.85	0.77	0.82	0.97	0.99	0.99	0.85
972	1,000	1,049	1,033	0.99	1.11	0.59	0.99	1.05	0.71	1.09	1.04	0.95	1.01	1.31	0.98	0.90	1.24	1.06	0.95	0.85	0.77	0.82	0.97	0.99	0.99	0.85
973	1,000	1,049	1,033	0.99	1.11	0.59	0.99	1.05	0.71	1.09	1.04	0.95	1.01	1.31	0.98	0.90	1.24	1.06	0.95	0.85	0.77	0.82	0.97	0.99	0.99	0.85
974	1,000	0.933	0.96	0.97	1.19	0.67	1.11	1.18	0.97	0.95	1.07	0.70	0.85	1.29	0.95	1.15	1.19	1.03	0.98	0.87	0.80	0.81	0.76	0.99	0.99	0.69
975	1,000	0.933	0.96	0.97	1.19	0.67	1.11	1.18	0.97	0.95	1.07	0.70	0.85	1.29	0.95	1.15	1.19	1.03	0.98	0.87	0.80	0.81	0.76	0.99	0.99	0.69
976	1,000	0.933	0.96	0.97	1.19	0.67	1.11	1.18	0.97	0.95	1.07	0.70	0.85	1.29	0.95	1.15	1.19	1.03	0.98	0.87	0.80	0.81	0.76	0.99	0.99	0.69
977	1,000	0.933	0.96	0.97	1.19	0.67	1.11	1.18	0.97	0.95	1.07	0.70	0.85	1.29	0.95	1.15	1.19	1.03	0.98	0.87	0.80	0.81	0.76	0.99	0.99	0.69
978	1,000	0.933	0.96	0.88	1.09	0.60	1.10	1.11	0.64	0.81	1.10	0.87	0.72	0.85	1.20	0.86	1.14	1.12	0.93	0.90	0.84	0.81	0.69	0.86	1.02	1.01
979	1,000	0.933	0.96	0.88	1.09	0.60	1.10	1.11	0.64	0.81	1.10	0.87	0.72	0.85	1.20	0.86	1.14	1.12	0.93	0.90	0.84	0.81	0.69	0.86	1.02	1.01
980	1,005	1,100	1,061	0.99	0.97	0.75	0.89	1.13	0.83	0.99	1.08	0.93	0.72	0.43	1.07	0.99	0.77	1.07	0.97	0.92	0.79	0.82	0.57	0.71	0.96	0.72
981	1,005	1,100	1,061	0.99	0.97	0.75	0.89	1.13	0.83	0.99	1.08	0.93	0.72	0.43	1.07	0.99	0.77	1.07	0.97	0.92	0.79	0.82	0.57	0.71	0.96	0.72
982	1,000	0.972	0.98	1.00	1.04	0.64	0.87	1.13	0.81	0.85	1.07	0.88	0.75	0.53	1.25	1.02	0.92	1.12	0.95	1.00	0.83	0.89	0.82	0.66	0.94	0.61
983	1,000	0.972	0.98	1.18	1.15	0.76	0.87	1.08	0.79	0.90	1.00	0.84	1.30	0.48	1.21	1.09	1.01	1.33	0.94	0.94	0.85	0.76	0.81	0.84	1.11	0.85
984	1,000	0.972	0.98	1.15	0.76	0.87	0.87	1.08	0.79	0.90	1.00	0.84	1.30	0.48	1.21	1.09	1.01	1.33	0.94	0.94	0.85	0.76	0.81	0.84	1.11	0.85
985	1,000	0.972	0.98	1.01	1.01	0.22	0.82	0.95	0.92	0.77	1.16	1.03	0.63	0.46	1.18	0.88	0.73	1.31	0.99	1.00	0.78	0.81	0.88	0.78	0.93	0.72
986	1,000	0.972	0.98	0.98	0.98	0.69	0.96	1.08	1.01	0.88	0.98	0.82	0.88	0.50	0.98	1.07	0.89	1.09	0.88	0.90	0.81	0.89	0.80	0.84	1.02	0.97
988	1,000	0.972	0.98	0.98	0.98	0.69	0.96	1.08	1.01	0.88	0.98	0.82	0.88	0.50	0.98	1.07	0.89	1.09	0.88	0.90	0.81	0.89	0.80	0.84	1.02	0.97
989	1,000	0.972	0.98	0.98	0.98	0.69	0.96	1.08	1.01	0.88	0.98	0.82	0.88	0.50	0.98	1.07	0.89	1.09	0.88	0.90	0.81	0.89	0.80	0.84	1.02	0.97
990	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
991	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
992	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
993	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
994	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
995	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
996	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
997	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
998	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.76	0.66	0.81	0.80	0.84
999	1,000	0.972	0.98	0.89	0.95	0.62	0.88	0.95	0.98	0.97	0.94	0.80	0.66</													

TABLE M. — CHARGE ADJUSTMENT FACTORS FOR PROFESSIONAL SERVICES CHARGE MODIFIERS

CPT/ HCPCS Code Modifier	Description	Charge Factor
22	Unusual Procedure	1.20
50	Bilatera: Procedure	1.54
51	Multiple Procedures	0.94
52	Reduced Services	0.70
53	Discontinued Procedure	0.97
62	Two Surgeons	0.92
80	Assistant Surgeon	0.31

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 1 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
Nationwide Average	1.00	071	1.13	151	0.95	222	0.90
002	0.94	072	1.03	152	0.95	223	0.90
005	0.87	073	1.13	153	0.81	224	0.96
006	0.40	074	0.99	154	0.81	225	0.96
007	0.40	075	0.99	155	0.81	226	0.71
008	0.40	076	0.99	156	0.85	227	0.71
009	0.40	077	1.26	157	0.81	228	0.71
010	0.78	078	0.96	158	0.73	229	0.71
011	0.78	079	0.96	159	0.81	230	0.96
012	0.78	080	1.28	160	0.85	231	0.96
013	0.92	081	1.28	161	0.85	232	0.96
014	0.92	082	1.28	162	0.85	233	0.85
015	0.94	083	1.28	163	0.73	234	0.85
016	0.93	084	1.28	164	0.88	235	0.85
017	1.12	085	1.26	165	0.88	236	0.85
018	0.82	086	1.26	166	0.77	237	0.85
019	0.82	087	1.10	167	0.73	238	0.96
020	0.84	088	1.16	168	0.81	239	0.78
021	0.92	089	1.22	169	0.78	240	0.80
022	1.14	100	0.96	170	0.81	241	0.80
023	0.84	101	0.96	171	0.81	242	0.80
024	0.92	102	0.96	172	0.76	243	0.80
025	0.88	103	0.99	173	0.76	244	0.71
026	0.88	104	0.99	174	0.76	245	0.78
027	0.84	105	0.93	175	0.76	246	0.80
028	0.89	106	0.96	176	0.75	247	0.70
029	0.89	107	0.93	177	0.78	248	0.70
030	0.86	108	0.93	178	0.78	249	0.70
031	0.86	109	1.04	179	0.69	250	0.70
032	0.83	110	0.99	180	0.84	251	0.70
033	0.83	111	0.99	181	0.84	252	0.70
034	0.83	112	0.97	182	0.85	253	0.70
035	0.83	113	0.97	183	0.94	254	0.72
036	0.83	114	0.97	184	0.85	255	0.70
037	0.83	115	0.87	185	0.85	256	0.70
038	0.94	116	0.87	186	0.85	257	0.70
039	0.80	117	0.87	187	0.85	258	0.70
040	0.77	118	0.87	188	0.85	259	0.70
041	0.66	119	0.87	189	1.40	260	0.68
042	0.77	120	0.68	190	1.54	261	0.72
043	0.80	121	0.68	191	1.48	262	0.72
044	0.77	122	0.68	192	1.48	263	0.72
045	0.77	123	0.68	193	1.40	264	0.72
046	0.77	124	0.68	194	1.40	265	0.68
047	0.80	125	0.85	195	0.69	266	0.70
048	0.77	126	0.85	196	0.69	267	0.72
049	0.80	127	0.85	197	0.64	268	0.72
050	0.72	128	0.67	198	0.64	270	0.66
051	0.72	129	0.67	199	0.76	271	0.61
052	0.72	130	0.62	200	0.87	272	0.66
053	0.72	131	0.62	201	0.93	273	0.66
054	0.76	132	0.62	202	0.87	274	0.66
055	0.82	133	0.69	203	0.87	275	0.82
056	0.72	134	0.69	204	0.87	276	0.82
057	0.72	135	0.69	205	0.87	277	0.83
058	0.72	136	0.69	206	0.64	278	0.74
059	0.72	137	0.68	207	0.66	279	0.74
060	0.82	138	0.68	208	0.69	280	0.77
061	0.77	139	0.68	209	0.69	281	0.77
062	0.82	140	0.57	210	0.54	282	0.81
063	0.82	141	0.57	211	0.54	283	0.74
064	0.86	142	0.57	212	0.53	284	0.74
065	0.87	143	0.57	214	0.54	285	0.74
066	0.87	144	0.57	215	0.50	286	0.79
067	0.86	145	0.57	216	0.50	287	0.79
068	0.93	146	0.57	217	0.50	288	0.79
069	0.93	147	0.57	218	0.50	289	0.79
070	1.03	148	0.57	219	0.54	290	0.88
		149	0.57	220	0.93	291	0.88
		150	0.95	221	0.93	292	0.77

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 2 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
293	0.98	368	0.99	442	0.84	512	0.76
294	0.91	369	0.99	443	0.84	513	0.76
295	0.91	370	0.85	444	0.86	514	0.76
296	0.86	371	0.85	445	0.86	515	0.76
297	0.98	372	0.89	446	0.78	516	0.76
298	0.99	373	0.84	447	0.64	520	0.74
299	0.99	374	0.84	448	0.81	521	0.75
300	0.85	375	0.87	449	0.77	522	0.74
301	0.88	376	0.84	450	0.81	523	0.74
302	0.88	377	0.84	451	0.81	524	0.74
303	0.88	378	0.84	452	0.80	525	0.74
304	0.82	379	0.84	453	0.81	526	0.74
305	0.79	380	0.90	454	0.95	527	0.74
306	0.79	381	0.87	455	0.81	528	0.74
307	0.79	382	0.80	456	0.81	530	0.94
308	0.79	383	0.80	457	0.78	531	0.95
309	0.79	384	0.85	458	0.74	532	1.02
310	0.82	385	0.84	459	0.80	534	0.78
311	0.88	386	0.78	460	0.78	535	0.86
312	0.82	387	0.74	461	0.78	537	0.80
313	0.89	388	0.74	462	0.75	538	0.86
314	0.89	389	0.78	463	0.83	539	0.86
315	0.82	390	0.78	464	0.83	540	0.96
316	0.82	391	0.78	465	0.85	541	0.78
317	0.76	392	0.81	466	0.85	542	0.78
318	0.76	393	0.78	467	0.79	543	0.69
319	0.76	394	0.82	468	0.79	544	0.77
320	1.23	395	0.82	469	0.80	545	0.96
321	1.11	396	0.82	470	0.80	546	0.84
322	1.16	397	0.74	471	0.80	547	0.77
323	1.13	399	0.88	472	0.80	548	0.96
324	1.13	400	0.98	473	0.78	549	0.72
325	1.13	401	0.98	474	0.80	550	0.96
326	1.12	402	0.87	475	0.77	551	1.07
327	1.16	403	0.79	476	0.77	553	1.01
328	1.28	404	0.79	477	0.77	554	1.00
329	1.31	405	0.80	478	0.80	555	1.01
330	1.36	406	0.80	479	0.80	556	0.79
331	1.21	407	0.78	480	0.94	557	0.79
332	1.21	408	0.78	481	0.97	558	0.77
333	1.47	409	0.78	482	1.01	559	0.84
334	1.21	410	0.79	483	1.03	560	0.78
335	1.29	411	0.78	484	0.88	561	0.77
336	1.31	412	0.78	485	0.88	562	0.77
337	1.29	413	0.78	486	0.81	563	0.79
338	1.17	414	0.78	487	0.81	564	0.79
339	1.27	415	0.78	488	0.83	565	0.79
341	1.57	416	0.78	489	0.83	566	0.79
342	1.20	417	0.78	490	0.78	567	0.79
344	1.04	418	0.78	491	0.78	570	0.72
346	1.20	420	0.79	492	0.78	571	0.75
347	1.16	421	0.87	493	0.71	572	0.72
349	1.40	422	0.79	494	0.71	573	0.72
350	1.04	423	0.79	495	0.71	574	0.72
351	1.04	424	0.79	496	0.71	575	0.72
352	1.14	425	0.78	497	0.71	576	0.72
354	1.04	426	0.78	498	0.82	577	0.72
355	1.04	427	0.78	499	0.82	580	0.68
356	1.00	430	0.81	500	0.78	581	0.73
357	1.00	431	0.81	501	0.78	582	0.68
358	1.00	432	0.85	502	0.78	583	0.68
359	1.06	433	0.74	503	0.78	584	0.68
360	0.99	434	0.86	504	0.75	585	0.68
361	0.99	435	0.86	505	0.76	586	0.68
362	1.06	436	0.86	506	0.75	587	0.68
363	0.99	437	0.78	507	0.75	588	0.68
364	0.99	438	0.78	508	0.76	590	0.68
365	0.83	439	0.78	509	0.78	591	0.70
366	0.83	440	0.85	510	0.76	592	0.68
367	0.99	441	0.84	511	0.79	593	0.68

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 3 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
594	0.68	670	0.78	752	1.02	826	0.79
595	0.68	671	0.78	753	1.02	827	0.79
596	0.68	672	1.01	754	0.99	828	0.79
597	0.68	673	0.80	755	0.99	829	0.79
598	0.68	674	0.74	756	0.99	830	0.79
599	0.68	675	0.74	757	0.99	831	0.79
600	1.12	676	0.74	758	0.99	832	0.75
601	1.10	677	0.74	759	0.99	833	0.79
602	1.15	678	0.74	760	0.98	834	0.75
603	1.15	679	0.74	761	0.98	835	0.79
604	1.12	680	0.94	762	0.99	836	0.79
605	1.19	681	0.94	763	0.99	837	0.77
606	1.13	683	0.80	764	0.87	838	0.79
607	1.13	684	0.80	765	0.85	840	0.81
608	1.13	685	0.85	766	0.87	841	0.80
609	0.98	686	0.80	767	0.87	842	0.84
610	0.84	687	0.80	768	0.93	843	0.84
611	0.90	688	0.80	769	0.93	844	0.84
612	0.84	689	0.80	770	1.08	845	0.74
613	0.87	690	0.80	772	1.08	846	0.74
614	0.87	691	0.80	773	1.10	847	0.74
615	0.87	692	0.80	774	1.10	850	1.19
616	1.01	693	0.80	775	1.10	852	1.19
617	0.98	700	1.05	776	1.18	853	1.19
618	0.90	701	1.14	777	1.18	855	1.16
619	0.90	703	0.83	778	0.85	856	1.07
620	1.07	704	1.05	779	0.89	857	1.07
622	0.91	705	0.83	780	0.93	859	1.16
623	0.80	706	0.83	781	0.89	860	1.06
624	0.86	707	0.85	782	0.93	863	1.16
625	0.80	708	0.85	783	1.16	864	1.16
626	0.80	710	0.94	784	1.16	865	1.06
627	0.82	711	0.94	785	1.16	870	0.90
628	0.86	712	0.94	786	0.98	871	0.87
629	0.91	713	0.94	787	0.98	872	0.90
630	0.96	714	0.94	788	0.93	873	0.90
631	1.03	716	0.87	789	0.98	874	0.90
633	0.96	717	0.87	790	0.91	875	0.90
634	0.96	718	0.87	791	0.91	877	0.90
635	0.82	719	0.87	792	0.91	878	0.98
636	0.86	720	0.87	793	1.06	879	0.98
637	0.86	721	0.87	794	1.06	880	0.98
638	0.86	722	0.87	795	1.06	881	0.98
639	0.86	723	0.87	796	1.06	882	0.98
640	1.03	724	0.74	797	0.93	883	0.98
641	1.03	725	0.74	798	0.93	884	0.90
644	0.82	726	0.74	799	1.90	885	1.90
645	0.82	727	0.74	800	1.17	889	1.51
646	0.82	728	0.87	801	1.23	890	1.51
647	0.86	729	0.78	802	1.19	891	1.51
648	0.86	730	0.91	803	1.17	893	1.18
649	1.03	731	0.91	804	1.17	894	1.18
650	0.84	733	0.98	805	0.90	895	1.18
651	0.84	734	0.88	806	0.90	897	1.18
652	0.84	735	0.88	807	0.90	898	1.18
653	0.86	736	0.85	808	1.05	900	1.54
654	0.86	737	0.85	809	1.05	901	1.54
655	0.86	738	0.85	810	1.05	902	1.59
656	0.86	739	0.85	811	0.90	903	1.59
657	0.86	740	0.74	812	0.90	904	1.59
658	0.73	741	0.74	813	0.90	905	1.48
660	0.96	743	0.79	814	0.90	906	1.48
661	0.96	744	0.79	815	0.90	907	1.48
662	1.27	745	0.88	816	0.95	908	1.48
664	0.78	746	0.85	820	0.79	910	1.47
665	0.78	747	0.88	821	0.79	911	1.75
666	0.83	748	0.79	822	0.79	912	1.47
667	0.80	749	0.88	823	0.79	913	1.45
668	0.80	750	1.09	824	0.79	914	1.53
669	0.74	751	1.09	825	0.79	915	1.45

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 4 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
916	1.53	937	1.21	957	1.83	982	0.91
917	1.55	938	1.21	958	1.84	983	0.97
918	1.55	939	1.31	959	1.24	984	0.97
919	1.34	940	1.63	960	1.24	985	0.96
920	1.34	941	1.55	961	1.24	986	0.78
921	1.33	942	1.84	967	0.98	988	0.82
922	1.41	943	1.51	968	0.98	989	0.82
923	1.41	944	1.38	969	0.98	990	0.88
924	1.41	945	1.74	970	0.87	991	0.88
925	1.41	946	1.74	971	0.87	992	0.88
926	1.41	947	1.74	972	0.91	993	0.82
927	1.41	948	1.74	973	0.82	994	0.82
928	1.41	949	1.74	974	0.83	995	1.01
930	1.30	950	1.72	975	0.83	996	0.96
931	1.73	951	1.72	976	0.83	997	1.01
932	1.16	952	1.74	977	0.83	998	0.96
933	1.16	953	1.74	978	0.88	999	1.03
934	1.61	954	1.24	979	0.88		
935	1.16	955	1.24	980	0.86		
936	1.21	956	1.83	981	0.91		

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 1 OF 5

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
Nationwide Average	1.00	1.00	068	1.07	0.88	145	1.02	0.97
			069	1.07	0.88	146	1.02	0.97
			070	0.91	1.00	147	0.93	0.69
002	1.05	0.61	071	1.13	1.22	148	1.02	0.97
005	1.08	0.80	072	0.91	1.00	149	1.02	0.97
006	1.12	0.57	073	1.13	1.22	150	0.97	0.66
007	1.12	0.57	074	0.99	0.85	151	0.97	0.66
008	1.12	0.57	075	0.99	0.85	152	1.13	0.60
009	1.12	0.57	076	0.99	0.85	153	1.01	0.87
010	0.86	0.72	077	0.97	0.84	154	1.01	0.87
011	0.86	0.72	078	1.00	0.77	155	0.95	0.81
012	0.97	1.02	079	1.00	0.77	156	1.00	0.89
013	1.16	1.16	080	1.15	1.04	157	1.00	0.99
014	1.16	1.16	081	1.15	1.04	158	1.05	1.09
015	1.09	1.08	082	1.15	1.04	159	0.95	0.81
016	0.97	0.96	083	1.15	1.04	160	1.00	0.89
017	0.97	0.89	084	1.15	1.04	161	1.00	0.89
018	0.91	0.76	085	0.97	0.84	162	1.00	0.89
019	0.91	0.76	086	0.97	0.84	163	1.05	1.09
020	0.94	0.88	087	1.11	1.00	164	1.04	0.72
021	1.04	1.19	088	1.01	0.94	165	1.04	0.72
022	0.97	0.95	089	0.91	0.76	166	0.97	1.06
023	0.94	0.88	100	1.23	0.75	167	1.05	1.09
024	1.04	1.19	101	1.23	0.75	168	1.00	0.99
025	0.88	0.89	102	1.23	0.75	169	0.79	0.98
026	0.88	0.89	103	1.14	0.69	170	0.93	0.74
027	0.94	0.88	104	1.14	0.69	171	0.93	0.74
028	0.85	1.21	105	1.02	0.91	172	0.97	0.94
029	0.85	1.21	106	1.20	1.15	173	0.97	0.94
030	0.69	1.02	107	1.02	0.91	174	0.97	0.94
031	0.69	1.02	108	1.02	0.91	175	0.97	0.94
032	1.17	0.82	109	0.91	0.88	176	1.00	1.05
033	1.17	0.82	110	1.14	0.69	177	0.79	0.98
034	1.17	0.82	111	1.14	0.69	178	0.79	0.98
035	1.17	0.82	112	1.08	0.97	179	0.96	0.77
036	1.17	0.82	113	1.08	0.97	180	1.06	0.99
037	1.17	0.82	114	1.08	0.97	181	1.06	0.99
038	1.05	0.61	115	1.08	0.80	182	1.01	1.15
039	0.96	0.90	116	1.08	0.80	183	1.15	0.83
040	1.03	0.69	117	1.08	0.80	184	1.01	1.15
041	1.03	0.82	118	1.08	0.80	185	1.01	1.15
042	1.03	0.69	119	1.08	0.80	186	1.01	1.15
043	0.96	0.90	120	1.08	1.02	187	1.01	1.15
044	0.89	0.55	121	1.08	1.02	188	1.01	1.15
045	0.89	0.55	122	1.08	1.02	189	1.09	0.92
046	0.89	0.55	123	1.08	1.02	190	0.97	0.69
047	0.96	0.90	124	1.08	1.02	191	0.74	0.93
048	0.89	0.55	125	0.80	0.51	192	0.74	0.93
049	0.96	0.90	126	0.80	0.51	193	1.09	0.92
050	1.07	0.77	127	0.80	0.51	194	1.09	0.92
051	1.07	0.77	128	0.91	0.95	195	0.96	0.77
052	1.07	0.77	129	0.91	0.95	196	0.96	0.77
053	1.07	0.77	130	0.99	1.17	197	0.84	0.82
054	1.14	0.72	131	0.99	1.17	198	0.84	0.82
055	1.14	0.72	132	0.99	1.17	199	1.01	0.73
056	1.07	0.77	133	0.98	1.16	200	1.07	1.22
057	1.07	0.77	134	0.98	1.16	201	1.13	0.65
058	1.07	0.77	135	0.98	1.16	202	1.07	1.22
059	1.07	0.77	136	0.98	1.16	203	1.07	1.22
060	0.92	0.60	137	1.08	1.12	204	1.07	1.22
061	0.81	0.74	138	1.08	1.12	205	1.07	1.22
062	0.92	0.60	139	1.08	1.12	206	1.03	0.82
063	0.92	0.60	140	0.93	0.69	207	1.02	0.85
064	1.02	0.68	141	0.93	0.69	208	0.90	0.73
065	1.04	0.60	142	0.93	0.69	209	0.90	0.73
066	1.04	0.60	143	0.93	0.69	210	0.92	0.64
067	1.02	0.68	144	1.02	0.97	211	0.92	0.64

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 2 OF 5

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
212	1.05	1.01	281	1.05	1.02	352	0.99	1.02
214	0.92	0.64	282	1.10	1.06	354	0.83	1.39
215	0.96	0.92	283	1.09	0.96	355	0.83	1.39
216	0.82	0.66	284	1.09	0.96	356	0.88	0.75
217	0.96	0.92	285	1.09	0.96	357	0.88	0.75
218	0.82	0.66	286	0.99	1.08	358	0.88	0.75
219	0.92	0.64	287	0.99	1.08	359	0.98	1.24
220	1.13	0.65	288	0.99	1.08	360	1.05	0.78
221	1.13	0.65	289	0.99	1.08	361	1.05	0.78
222	1.07	0.94	290	1.09	1.02	362	0.98	1.24
223	1.07	0.94	291	1.09	1.02	363	1.05	0.78
224	0.97	1.11	292	1.10	1.18	364	1.05	0.78
225	0.97	1.11	293	0.96	1.48	365	0.79	1.03
226	0.90	0.93	294	1.01	1.00	366	0.79	1.03
227	0.90	0.93	295	1.01	1.00	367	1.05	0.78
228	0.90	0.93	296	1.06	1.01	368	1.05	0.78
229	0.90	0.93	297	0.96	1.48	369	1.05	0.78
230	0.97	1.11	298	0.94	1.05	370	1.00	1.03
231	0.97	1.11	299	0.94	1.05	371	1.00	1.03
232	0.97	1.11	300	0.99	1.12	372	0.93	0.85
233	1.08	1.01	301	1.06	1.12	373	1.01	1.27
234	1.08	1.01	302	1.06	1.12	374	1.01	1.27
235	1.08	1.01	303	1.06	1.12	375	1.01	1.27
236	1.08	1.01	304	0.99	1.24	376	1.01	1.27
237	1.08	1.01	305	0.92	1.14	377	1.01	1.27
238	0.97	1.11	306	0.92	1.14	378	1.01	1.27
239	0.97	0.64	307	0.92	1.14	379	1.08	0.95
240	1.11	1.00	308	0.92	1.14	380	0.92	1.14
241	1.11	1.00	309	0.92	1.14	381	0.97	1.05
242	1.11	1.00	310	0.99	1.12	382	0.90	1.07
243	1.11	1.00	311	1.06	1.12	383	0.90	1.07
244	0.90	0.93	312	0.99	1.12	384	1.00	1.03
245	0.97	0.64	313	1.02	0.87	385	1.01	1.27
246	1.11	1.00	314	1.02	0.87	386	0.99	1.33
247	1.04	0.92	315	0.99	1.24	387	0.96	0.79
248	1.04	0.92	316	0.99	1.24	388	0.96	0.79
249	1.04	0.92	317	1.11	1.12	389	1.10	1.21
250	1.04	0.92	318	1.11	1.12	390	1.10	1.21
251	1.04	0.92	319	1.11	1.12	391	1.10	1.21
252	1.04	0.92	320	0.87	1.11	392	1.04	0.85
253	1.04	0.92	321	0.95	1.38	393	1.10	1.21
254	0.92	0.82	322	0.96	1.01	394	1.01	1.06
255	1.04	0.92	323	0.89	1.05	395	1.01	1.06
256	1.04	0.92	324	0.89	1.05	396	1.01	1.06
257	1.04	0.92	325	0.89	1.05	397	0.96	0.79
258	1.04	0.92	326	0.94	0.71	399	1.11	1.12
259	1.04	0.92	327	0.99	1.33	400	0.91	0.78
260	1.00	1.10	328	1.03	1.41	401	0.91	0.78
261	0.92	0.82	329	1.02	1.00	402	0.91	1.05
262	0.92	0.82	330	1.16	1.38	403	0.92	0.99
263	0.92	0.82	331	1.07	1.11	404	0.92	0.99
264	0.92	0.82	332	1.07	1.11	405	1.08	0.94
265	1.00	1.10	333	1.09	1.11	406	1.08	0.94
266	1.04	0.92	334	1.43	1.34	407	1.01	1.14
267	0.92	0.82	335	1.25	0.92	408	1.01	1.14
268	0.92	0.82	336	0.93	0.90	409	0.82	1.00
270	0.97	1.17	337	1.25	0.92	410	0.92	0.99
271	1.13	1.02	338	1.07	0.93	411	0.82	1.00
272	0.97	1.17	339	1.03	0.77	412	0.82	1.00
273	0.97	1.17	341	1.09	0.72	413	0.82	1.00
274	0.97	1.17	342	1.02	0.99	414	0.82	1.00
275	1.11	1.03	344	0.96	0.96	415	0.82	1.00
276	1.11	1.03	346	1.02	0.99	416	0.82	1.00
277	0.87	1.03	347	0.99	1.33	417	0.82	1.00
278	1.09	0.96	349	1.42	1.09	418	0.82	1.00
279	1.09	0.96	350	0.83	1.39	420	0.98	0.96
280	1.05	1.02	351	0.83	1.39	421	0.90	0.89

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 3 OF 5

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
422	0.98	0.96	491	0.86	0.83	565	0.91	0.91
423	0.98	0.96	492	0.86	0.83	566	0.91	0.91
424	0.98	0.96	493	0.92	0.71	567	0.91	0.91
425	1.01	1.14	494	0.92	0.71	570	0.93	0.64
426	1.01	1.14	495	0.92	0.71	571	0.75	0.81
427	1.01	1.14	496	0.92	0.71	572	0.93	0.64
430	1.12	0.80	497	0.92	0.71	573	0.93	0.64
431	1.12	0.80	498	1.07	0.67	574	0.93	0.64
432	0.91	1.24	499	1.07	0.67	575	0.93	0.64
433	0.83	0.82	500	0.83	0.88	576	0.93	0.64
434	0.90	0.74	501	0.83	0.88	577	0.93	0.64
435	0.90	0.74	502	0.83	0.88	580	0.98	1.06
436	0.90	0.74	503	0.83	0.88	581	0.90	0.75
437	0.97	1.29	504	0.77	0.91	582	0.98	1.06
438	0.97	1.29	505	0.96	1.33	583	0.98	1.06
439	0.97	1.29	506	0.77	0.91	584	0.98	1.06
440	1.17	0.91	507	0.77	0.91	585	0.98	1.06
441	0.89	0.89	508	0.96	1.33	586	0.98	1.06
442	0.96	1.03	509	0.83	0.88	587	0.98	1.06
443	0.96	1.03	510	0.96	1.33	588	0.98	1.06
444	0.79	0.87	511	0.87	0.77	590	0.97	0.72
445	0.79	0.87	512	0.96	1.33	591	0.85	0.95
446	0.97	1.29	513	0.96	1.33	592	0.97	0.72
447	1.01	1.19	514	0.96	1.33	593	0.97	0.72
448	0.70	0.95	515	0.96	1.33	594	0.97	0.72
449	0.79	0.80	516	0.96	1.33	595	0.97	0.72
450	0.95	0.78	520	0.98	0.81	596	0.97	0.72
451	0.95	0.78	521	0.77	0.91	597	0.97	0.72
452	1.13	0.94	522	0.98	0.81	598	0.97	0.72
453	0.99	1.02	523	0.98	0.81	599	0.97	0.72
454	0.90	1.11	524	0.98	0.81	600	1.11	1.02
455	0.99	1.02	525	0.98	0.81	601	1.06	1.48
456	0.95	0.78	526	0.98	0.81	602	1.21	1.28
457	0.97	1.29	527	0.98	0.81	603	1.21	1.28
458	0.83	0.82	528	0.98	0.81	604	1.06	1.40
459	0.83	0.82	530	1.15	1.06	605	1.06	0.88
460	0.95	1.22	531	1.07	1.04	606	1.02	1.06
461	0.95	1.22	532	1.07	1.04	607	1.02	1.06
462	1.02	0.84	534	1.02	0.98	608	1.02	1.06
463	0.90	1.44	535	0.78	1.03	609	0.96	0.75
464	0.90	1.44	537	0.98	0.52	610	1.07	0.98
465	0.85	1.16	538	0.78	1.03	611	0.91	1.00
466	0.85	1.16	539	0.71	0.67	612	1.07	0.98
467	0.82	0.97	540	0.87	0.94	613	0.86	1.01
468	0.82	0.97	541	0.84	0.93	614	0.86	1.01
469	0.81	0.94	542	0.84	0.93	615	0.86	1.01
470	0.97	0.98	543	0.87	0.68	616	0.84	1.14
471	0.97	0.98	544	1.10	0.92	617	1.13	1.00
472	0.97	0.98	545	0.87	0.94	618	1.02	0.96
473	0.95	1.22	546	0.94	0.85	619	1.01	1.05
474	0.97	0.98	547	1.03	0.93	620	1.07	0.96
475	1.08	0.94	548	0.87	0.94	622	0.88	0.95
476	1.08	0.94	549	0.77	0.80	623	1.01	0.85
477	1.08	0.94	550	0.85	1.00	624	0.94	1.09
478	0.97	0.98	551	1.01	1.01	625	1.01	0.85
479	0.81	0.94	553	0.99	0.68	626	1.01	0.85
480	1.11	0.90	554	0.97	1.00	627	0.98	0.63
481	1.08	0.66	555	0.99	0.68	628	0.94	1.09
482	1.05	1.22	556	0.91	0.91	629	0.88	0.95
483	0.98	0.84	557	0.91	0.91	630	0.86	0.87
484	0.99	0.77	558	0.79	0.82	631	0.95	1.03
485	0.99	0.77	559	1.11	0.67	633	0.86	0.87
486	1.03	0.93	560	0.88	0.86	634	0.86	0.87
487	1.03	0.93	561	0.92	0.67	635	1.01	1.10
488	0.84	0.90	562	0.92	0.67	636	0.90	1.16
489	0.84	0.90	563	1.08	0.74	637	0.90	1.16
490	0.86	0.83	564	1.08	0.74	638	1.03	1.06

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 4 OF 5

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
639	1.03	1.06	720	0.93	1.00	790	1.08	1.08
640	0.99	1.07	721	0.93	1.00	791	1.08	1.08
641	0.99	1.07	722	0.93	1.00	792	1.08	1.08
644	1.01	1.10	723	0.96	1.08	793	0.97	1.11
645	1.01	1.10	724	1.14	0.92	794	0.97	1.11
646	1.01	1.10	725	1.14	0.92	795	0.97	1.11
647	1.03	1.06	726	1.14	0.92	796	0.97	1.11
648	0.99	1.09	727	1.14	0.92	797	1.03	1.11
649	0.99	1.09	728	0.96	1.08	798	1.03	1.11
650	0.96	1.10	729	1.01	1.11	799	1.24	1.10
651	0.96	1.10	730	1.06	1.17	800	0.91	0.95
652	0.96	1.10	731	1.06	1.17	801	1.13	0.76
653	1.03	1.06	733	1.06	1.17	802	0.91	1.00
654	1.03	1.06	734	1.01	1.17	803	0.91	0.95
655	1.03	1.06	735	1.01	1.17	804	0.91	0.95
656	0.99	1.09	736	0.84	1.13	805	0.88	0.94
657	0.99	1.09	737	0.84	1.13	806	0.88	0.94
658	1.25	0.86	738	0.84	1.13	807	0.88	0.94
660	0.97	1.09	739	0.84	1.13	808	0.94	0.91
661	0.97	1.09	740	1.03	1.39	809	0.94	0.91
662	1.02	1.02	741	1.03	1.39	810	0.94	0.91
664	0.82	0.70	743	0.70	1.45	811	0.91	0.94
665	0.82	0.70	744	0.70	1.45	812	0.91	0.94
666	1.03	0.64	745	1.01	1.17	813	0.91	0.94
667	0.90	1.07	746	0.84	1.13	814	0.91	0.94
668	0.90	1.07	747	1.01	1.17	815	0.91	0.94
669	1.00	1.17	748	0.70	1.45	816	0.98	1.25
670	1.05	1.17	749	1.01	1.17	820	0.95	1.04
671	1.05	1.17	750	1.12	1.06	821	0.95	1.04
672	0.79	0.93	751	1.12	1.06	822	0.95	1.04
673	0.90	1.07	752	1.14	1.06	823	0.95	1.04
674	1.00	1.17	753	1.14	1.06	824	0.95	1.04
675	1.00	1.17	754	1.03	1.00	825	0.95	1.04
676	1.00	1.17	755	1.03	1.00	826	0.95	1.04
677	1.00	1.17	756	1.03	1.00	827	0.95	1.04
678	1.00	1.17	757	1.03	1.00	828	0.95	1.04
679	1.00	1.17	758	1.03	1.00	829	0.95	1.04
680	0.93	0.86	759	1.03	1.00	830	0.95	1.04
681	0.93	0.86	760	0.85	1.11	831	0.95	1.04
683	0.92	0.74	761	0.85	1.11	832	0.87	0.75
684	0.92	0.74	762	0.86	1.18	833	0.84	0.79
685	0.82	0.88	763	0.86	1.18	834	0.87	0.75
686	0.92	0.74	764	1.06	1.07	835	0.84	0.79
687	0.93	0.83	765	1.01	1.01	836	0.84	0.79
688	0.92	0.74	766	1.06	1.07	837	0.60	0.68
689	0.92	0.74	767	1.06	1.07	838	0.84	0.79
690	0.92	0.74	768	1.03	1.11	840	0.84	0.89
691	0.92	0.74	769	1.03	1.11	841	0.90	0.66
692	0.92	0.74	770	1.01	1.34	842	0.84	0.75
693	0.92	0.74	772	1.01	1.34	843	0.84	0.75
700	0.93	1.07	773	1.04	1.14	844	0.84	0.75
701	1.02	1.02	774	1.04	1.14	845	1.01	0.89
703	0.94	1.10	775	1.04	1.14	846	1.01	0.89
704	0.93	1.07	776	0.89	1.05	847	1.01	0.89
705	0.94	1.10	777	0.89	1.05	850	1.18	0.95
706	0.94	1.10	778	1.01	1.01	852	0.99	0.77
707	0.83	1.09	779	1.04	1.19	853	0.99	0.77
708	0.83	1.09	780	1.00	1.08	855	1.18	1.04
710	0.98	1.13	781	1.04	1.19	856	0.96	1.03
711	0.98	1.13	782	1.00	1.08	857	0.96	1.03
712	0.98	1.13	783	1.01	0.95	859	1.18	1.04
713	0.98	1.13	784	1.01	0.95	860	0.75	1.01
714	0.98	1.13	785	1.01	0.95	863	1.18	1.04
716	0.96	1.08	786	0.91	1.10	864	1.18	1.04
717	0.96	1.08	787	0.91	1.10	865	0.75	1.01
718	0.96	1.08	788	1.03	1.11	870	0.95	1.01
719	0.96	1.08	789	0.91	1.10	871	1.02	0.97

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 5 OF 5

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
872	0.95	1.01	918	1.18	1.18	957	1.17	0.87
873	0.95	1.01	919	0.90	0.82	958	1.06	0.92
874	0.95	1.01	920	0.90	0.82	959	0.96	0.91
875	0.95	1.01	921	1.13	0.70	960	0.96	0.91
877	0.95	1.01	922	0.99	0.90	961	0.96	0.91
878	0.97	0.97	923	0.99	0.90	967	0.93	1.30
879	0.97	0.97	924	0.99	0.90	968	0.93	1.30
880	0.97	0.97	925	0.99	0.90	969	0.93	1.30
881	0.97	0.97	926	1.12	0.98	970	1.11	0.97
882	0.97	0.97	927	1.12	0.98	971	1.11	0.97
883	0.97	0.97	928	1.12	0.98	972	0.90	0.89
884	0.95	1.01	930	0.88	0.90	973	0.94	0.56
885	1.24	1.10	931	0.94	0.66	974	0.91	0.95
889	1.12	0.97	932	1.20	1.06	975	0.91	0.95
890	1.12	0.97	933	1.20	1.06	976	0.91	0.95
891	1.12	0.97	934	0.94	0.68	977	0.91	0.95
893	1.31	0.79	935	1.20	1.06	978	0.86	0.99
894	1.31	0.79	936	0.90	0.87	979	0.86	0.99
895	1.31	0.79	937	0.90	0.87	980	1.13	0.74
897	1.31	0.79	938	0.90	0.87	981	1.01	1.07
898	1.31	0.79	939	0.93	0.92	982	0.93	0.97
900	0.93	0.80	940	1.04	0.76	983	0.98	0.77
901	0.93	0.80	941	0.88	0.96	984	0.98	0.77
902	0.95	1.03	942	1.06	0.92	985	1.14	0.65
903	0.95	1.03	943	0.92	0.90	986	1.10	0.98
904	0.95	1.03	944	1.17	0.97	988	1.01	0.76
905	1.15	0.86	945	1.10	0.91	989	1.01	0.76
906	1.15	0.86	946	1.10	0.91	990	1.00	1.01
907	1.15	0.86	947	1.10	0.91	991	1.00	1.01
908	1.15	0.86	948	1.10	0.91	992	1.00	1.01
910	0.70	0.69	949	1.10	0.91	993	1.01	0.76
911	1.05	1.04	950	0.92	0.72	994	1.01	0.76
912	0.70	0.69	951	0.92	0.72	995	0.79	0.92
913	0.96	0.77	952	0.88	1.09	996	1.07	0.90
914	1.02	0.72	953	0.88	1.09	997	0.79	0.92
915	0.96	0.77	954	0.96	0.91	998	1.07	0.90
916	1.02	0.72	955	0.96	0.91	999	1.19	1.04
917	1.18	1.18	956	1.17	0.87			

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 1 OF 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
Nationwide Average	1.00	1.00	1.00	069	1.19	1.24	1.30	147	0.85	0.85	0.96
002	1.04	1.10	1.17	070	1.20	1.19	1.19	148	0.81	0.84	0.97
005	1.28	1.14	1.16	071	1.19	1.11	1.14	149	0.81	0.84	0.97
006	0.73	0.56	0.74	072	1.20	1.19	1.19	150	0.84	0.81	0.87
007	0.73	0.56	0.74	073	1.19	1.11	1.14	151	0.84	0.81	0.87
008	0.73	0.56	0.74	074	1.19	1.20	1.20	152	0.84	0.81	0.87
009	0.73	0.56	0.74	075	1.19	1.20	1.20	153	0.82	0.81	0.88
010	0.99	1.04	1.10	076	1.19	1.20	1.20	154	0.82	0.81	0.88
011	0.99	1.04	1.10	077	1.11	1.14	1.12	155	0.72	0.72	0.78
012	0.86	0.94	1.01	078	1.19	1.20	1.19	156	0.82	0.80	0.87
013	1.06	1.11	1.16	079	1.19	1.20	1.19	157	0.86	0.84	0.94
014	1.06	1.11	1.16	080	1.03	1.04	1.05	158	0.81	0.80	0.87
015	1.08	1.10	1.20	081	1.03	1.04	1.05	159	0.72	0.72	0.78
016	1.12	1.16	1.20	082	1.03	1.04	1.05	160	0.82	0.80	0.87
017	1.12	1.16	1.26	083	1.03	1.04	1.05	161	0.82	0.80	0.87
018	1.12	1.14	1.22	084	1.03	1.04	1.05	162	0.82	0.80	0.87
019	1.12	1.14	1.22	085	1.11	1.14	1.12	163	0.81	0.80	0.87
020	1.09	1.12	1.20	086	1.11	1.14	1.12	164	0.81	0.82	0.87
021	1.17	1.17	1.31	087	1.09	1.10	1.09	165	0.81	0.82	0.87
022	1.15	1.17	1.45	088	1.19	1.18	1.17	166	0.79	0.75	0.85
023	1.09	1.12	1.20	089	1.19	1.16	1.16	167	0.81	0.80	0.87
024	1.17	1.17	1.31	090	1.64	1.46	1.46	168	0.86	0.84	0.94
025	1.11	1.14	1.21	100	1.64	1.46	1.46	169	0.83	0.82	0.89
026	1.11	1.14	1.21	101	1.64	1.46	1.46	170	0.86	0.84	0.89
027	1.09	1.12	1.20	102	1.64	1.46	1.46	171	0.86	0.84	0.89
028	1.06	0.97	1.06	103	1.40	1.18	1.20	172	0.86	0.86	0.92
029	1.06	0.97	1.06	104	1.40	1.18	1.20	173	0.86	0.86	0.92
030	1.06	1.14	1.18	105	1.38	1.22	1.26	174	0.86	0.86	0.92
031	1.06	1.14	1.18	106	1.41	1.31	1.34	175	0.86	0.86	0.92
032	1.02	1.08	1.15	107	1.38	1.22	1.26	176	0.85	0.87	0.94
033	1.02	1.08	1.15	108	1.38	1.22	1.26	177	0.83	0.82	0.89
034	1.02	1.08	1.15	109	1.29	1.18	1.21	178	0.83	0.82	0.89
035	1.02	1.08	1.15	110	1.40	1.18	1.20	179	0.87	0.86	0.93
036	1.02	1.08	1.15	111	1.40	1.18	1.20	180	0.92	0.93	0.96
037	1.02	1.08	1.15	112	1.51	1.20	1.21	181	0.92	0.93	0.96
038	1.04	1.10	1.17	113	1.51	1.20	1.21	182	0.86	0.86	0.93
039	0.92	0.97	1.06	114	1.51	1.20	1.21	183	0.99	0.94	1.01
040	0.96	1.07	1.11	115	1.28	1.14	1.16	184	0.86	0.86	0.93
041	0.96	1.11	1.16	116	1.28	1.14	1.16	185	0.86	0.86	0.93
042	0.96	1.07	1.11	117	1.28	1.14	1.16	186	0.86	0.86	0.93
043	0.92	0.97	1.06	118	1.28	1.14	1.16	187	0.86	0.86	0.93
044	0.92	1.00	1.04	119	1.28	1.14	1.16	188	0.86	0.86	0.93
045	0.92	1.00	1.04	120	0.94	0.95	0.99	189	1.04	1.03	1.06
046	0.92	1.00	1.04	121	0.94	0.95	0.99	190	1.05	1.03	1.07
047	0.92	0.97	1.06	122	0.94	0.95	0.99	191	1.08	1.01	1.05
048	0.92	1.00	1.04	123	0.94	0.95	0.99	192	1.08	1.01	1.05
049	0.92	0.97	1.06	124	0.94	0.95	0.99	193	1.04	1.03	1.06
050	0.89	0.97	1.01	125	0.95	0.93	0.99	194	1.04	1.03	1.06
051	0.89	0.97	1.01	126	0.95	0.93	0.99	195	0.87	0.86	0.93
052	0.89	0.97	1.01	127	0.95	0.93	0.99	196	0.87	0.86	0.93
053	0.89	0.97	1.01	128	0.93	0.92	0.98	197	1.16	1.15	1.21
054	0.90	1.01	1.02	129	0.93	0.92	0.98	198	1.16	1.15	1.21
055	1.12	1.14	1.22	130	0.87	0.93	0.97	199	0.94	0.95	1.02
056	0.89	0.97	1.01	131	0.87	0.93	0.97	200	1.16	1.23	1.25
057	0.89	0.97	1.01	132	0.87	0.93	0.97	201	1.09	1.14	1.12
058	0.89	0.97	1.01	133	0.81	0.86	0.91	202	1.16	1.23	1.25
059	0.89	0.97	1.01	134	0.81	0.86	0.91	203	1.16	1.23	1.25
060	1.12	1.13	1.15	135	0.81	0.86	0.91	204	1.16	1.23	1.25
061	1.14	1.13	1.16	136	0.81	0.86	0.91	205	1.16	1.23	1.25
062	1.12	1.13	1.15	137	0.82	0.86	0.95	206	1.05	1.07	1.07
063	1.12	1.13	1.15	138	0.82	0.86	0.95	207	1.09	1.10	1.10
064	1.13	1.13	1.16	139	0.82	0.86	0.95	208	1.11	1.14	1.13
065	1.17	1.15	1.22	140	0.85	0.85	0.96	209	1.11	1.14	1.13
066	1.17	1.15	1.22	141	0.85	0.85	0.96	210	1.02	1.02	1.06
067	1.13	1.13	1.16	142	0.85	0.85	0.96	211	1.02	1.02	1.06
068	1.19	1.24	1.30	143	0.85	0.85	0.96	212	1.02	0.98	1.04
				144	0.81	0.84	0.97	214	1.02	1.02	1.06
				145	0.81	0.84	0.97	215	0.91	0.92	0.96
				146	0.81	0.84	0.97				

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

PAGE 2 OF 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
216	0.97	1.00	0.99	285	0.89	0.92	0.92	358	0.83	0.83	0.82
217	0.91	0.92	0.96	286	0.87	0.96	0.95	359	0.72	0.75	0.75
218	0.97	1.00	0.99	287	0.87	0.96	0.95	360	0.71	0.77	0.77
219	1.02	1.02	1.06	288	0.87	0.96	0.95	361	0.71	0.77	0.77
220	1.09	1.14	1.12	289	0.87	0.96	0.95	362	0.72	0.75	0.75
221	1.09	1.14	1.12	290	0.83	0.91	0.96	363	0.71	0.77	0.77
222	1.11	1.16	1.14	291	0.83	0.91	0.96	364	0.71	0.77	0.77
223	1.11	1.16	1.14	292	0.85	0.95	0.98	365	0.77	0.86	0.86
224	0.99	0.99	1.03	293	0.85	0.89	0.93	366	0.77	0.86	0.86
225	0.99	0.99	1.03	294	0.86	0.90	0.95	367	0.71	0.77	0.77
226	0.97	1.01	1.03	295	0.86	0.90	0.95	368	0.71	0.77	0.77
227	0.97	1.01	1.03	296	0.86	0.88	0.96	369	0.71	0.77	0.77
228	0.97	1.01	1.03	297	0.85	0.89	0.93	370	0.84	0.86	0.89
229	0.97	1.01	1.03	298	0.85	0.91	0.94	371	0.84	0.86	0.89
230	0.99	0.99	1.03	299	0.85	0.91	0.94	372	0.90	0.94	0.95
231	0.99	0.99	1.03	300	0.98	1.06	1.06	373	0.80	0.85	0.85
232	0.99	0.99	1.03	301	0.96	1.03	1.03	374	0.80	0.85	0.85
233	0.94	0.95	0.98	302	0.96	1.03	1.03	375	0.86	0.86	0.91
234	0.94	0.95	0.98	303	1.01	1.11	1.12	376	0.80	0.85	0.85
235	0.94	0.95	0.98	304	0.89	0.95	0.98	377	0.80	0.85	0.85
236	0.94	0.95	0.98	305	0.88	0.98	0.97	378	0.80	0.85	0.85
237	0.94	0.95	0.98	306	0.88	0.98	0.97	379	0.82	0.86	0.87
238	0.99	0.99	1.03	307	0.88	0.98	0.97	380	0.85	0.86	0.90
239	0.88	0.89	0.93	308	0.88	0.98	0.97	381	0.86	0.86	0.91
240	0.81	0.82	0.86	309	0.88	0.98	0.97	382	0.80	0.81	0.82
241	0.81	0.82	0.86	310	0.82	0.91	0.91	383	0.80	0.81	0.82
242	0.81	0.82	0.86	311	1.01	1.11	1.12	384	0.84	0.86	0.89
243	0.81	0.82	0.86	312	0.82	0.91	0.91	385	0.80	0.85	0.85
244	0.97	1.01	1.03	313	0.87	0.91	0.99	386	0.83	0.81	0.84
245	0.88	0.89	0.93	314	0.87	0.91	0.99	387	0.80	0.82	0.82
246	0.81	0.82	0.86	315	0.89	0.95	0.98	388	0.80	0.82	0.82
247	0.79	0.77	0.85	316	0.89	0.95	0.98	389	0.81	0.81	0.85
248	0.79	0.77	0.85	317	0.81	0.89	0.93	390	0.81	0.81	0.85
249	0.79	0.77	0.85	318	0.81	0.89	0.93	391	0.81	0.81	0.85
250	0.79	0.77	0.85	319	0.81	0.89	0.93	392	0.83	0.86	0.87
251	0.79	0.77	0.85	320	0.90	0.94	0.96	393	0.81	0.81	0.85
252	0.79	0.77	0.85	321	0.81	0.89	0.91	394	0.82	0.82	0.83
253	0.79	0.77	0.85	322	0.90	0.96	0.97	395	0.82	0.82	0.83
254	0.93	0.93	0.97	323	0.82	0.90	0.91	396	0.82	0.82	0.83
255	0.79	0.77	0.85	324	0.82	0.90	0.91	397	0.80	0.82	0.82
256	0.79	0.77	0.85	325	0.82	0.90	0.91	399	1.01	1.11	1.12
257	0.79	0.77	0.85	326	0.85	0.98	0.99	400	0.80	0.79	0.84
258	0.79	0.77	0.85	327	0.86	0.92	0.93	401	0.80	0.79	0.84
259	0.79	0.77	0.85	328	0.89	0.93	0.95	402	0.82	0.84	0.87
260	0.75	0.76	0.83	329	0.92	1.01	0.98	403	0.82	0.80	0.86
261	0.93	0.93	0.97	330	1.14	1.14	1.05	404	0.82	0.80	0.86
262	0.93	0.93	0.97	331	1.38	1.32	1.18	405	0.82	0.84	0.88
263	0.93	0.93	0.97	332	1.38	1.32	1.18	406	0.82	0.84	0.88
264	0.93	0.93	0.97	333	1.14	1.16	1.04	407	0.77	0.75	0.79
265	0.75	0.76	0.83	334	0.99	1.08	1.08	408	0.77	0.75	0.79
266	0.79	0.77	0.85	335	0.88	0.98	0.95	409	0.77	0.75	0.79
267	0.93	0.93	0.97	336	0.89	1.00	0.95	410	0.82	0.80	0.86
268	0.93	0.93	0.97	337	0.88	0.98	0.95	411	0.77	0.75	0.79
270	0.90	0.97	0.96	338	0.86	0.91	0.92	412	0.77	0.75	0.79
271	0.93	0.99	0.95	339	0.90	1.00	0.98	413	0.77	0.75	0.79
272	0.90	0.97	0.96	341	0.98	1.08	1.06	414	0.77	0.75	0.79
273	0.90	0.97	0.96	342	0.87	0.98	0.94	415	0.77	0.75	0.79
274	0.90	0.97	0.96	344	0.77	0.88	0.87	416	0.77	0.75	0.79
275	0.97	1.01	1.00	346	0.87	0.98	0.94	417	0.77	0.75	0.79
276	0.97	1.01	1.00	347	0.86	0.92	0.93	418	0.77	0.75	0.79
277	0.97	1.02	1.00	349	0.90	1.01	0.98	420	0.78	0.79	0.84
278	0.89	0.92	0.92	350	0.76	0.78	0.77	421	0.80	0.78	0.82
279	0.89	0.92	0.92	351	0.76	0.78	0.77	422	0.78	0.79	0.84
280	0.95	0.98	0.97	352	0.78	0.82	0.80	423	0.78	0.79	0.84
281	0.95	0.98	0.97	354	0.76	0.78	0.77	424	0.78	0.79	0.84
282	0.98	1.03	1.03	355	0.76	0.78	0.77	425	0.77	0.75	0.79
283	0.89	0.92	0.92	356	0.83	0.83	0.82	426	0.77	0.75	0.79
284	0.89	0.92	0.92	357	0.83	0.83	0.82	427	0.77	0.75	0.79

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 3 OF 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
430	0.90	0.95	0.98	498	0.93	0.88	0.92	575	0.85	0.81	0.82
431	0.90	0.95	0.98	499	0.93	0.88	0.92	576	0.85	0.81	0.82
432	0.91	0.97	0.99	500	0.86	0.87	0.88	577	0.85	0.81	0.82
433	0.81	0.86	0.91	501	0.86	0.87	0.88	580	0.84	0.81	0.86
434	0.86	0.89	0.95	502	0.86	0.87	0.88	581	0.88	0.86	0.90
435	0.86	0.89	0.95	503	0.86	0.87	0.88	582	0.84	0.81	0.86
436	0.86	0.89	0.95	504	0.77	0.78	0.80	583	0.84	0.81	0.86
437	0.83	0.85	0.90	505	0.76	0.78	0.81	584	0.84	0.81	0.86
438	0.83	0.85	0.90	506	0.77	0.78	0.80	585	0.84	0.81	0.86
439	0.83	0.85	0.90	507	0.77	0.78	0.80	586	0.84	0.81	0.86
440	0.91	0.94	0.98	508	0.76	0.78	0.81	587	0.84	0.81	0.86
441	0.93	0.97	1.01	509	0.86	0.87	0.88	588	0.84	0.81	0.86
442	0.88	0.92	0.98	510	0.76	0.78	0.81	590	0.90	0.90	0.91
443	0.88	0.92	0.98	511	0.84	0.86	0.87	591	0.92	0.95	0.96
444	0.83	0.83	0.89	512	0.76	0.78	0.81	592	0.90	0.90	0.91
445	0.83	0.83	0.89	513	0.76	0.78	0.81	593	0.90	0.90	0.91
446	0.83	0.85	0.90	514	0.76	0.78	0.81	594	0.90	0.90	0.91
447	0.84	0.88	0.93	515	0.76	0.78	0.81	595	0.90	0.90	0.91
448	0.78	0.83	0.88	516	0.76	0.78	0.81	596	0.90	0.90	0.91
449	0.80	0.84	0.91	520	0.79	0.80	0.83	597	0.90	0.90	0.91
450	0.85	0.88	0.92	521	0.77	0.78	0.80	598	0.90	0.90	0.91
451	0.85	0.88	0.92	522	0.79	0.80	0.83	599	0.90	0.90	0.91
452	0.87	0.91	0.95	523	0.79	0.80	0.83	600	1.03	1.07	1.07
453	0.82	0.84	0.91	524	0.79	0.80	0.83	601	1.01	1.04	1.05
454	0.84	0.88	0.92	525	0.79	0.80	0.83	602	1.05	1.09	1.07
455	0.82	0.84	0.91	526	0.79	0.80	0.83	603	1.05	1.09	1.07
456	0.85	0.88	0.92	527	0.79	0.80	0.83	604	1.00	1.01	1.03
457	0.83	0.85	0.90	528	0.79	0.80	0.83	605	1.02	1.04	1.05
458	0.81	0.86	0.91	530	0.91	0.92	0.95	606	1.08	1.07	1.09
459	0.87	0.91	0.95	531	0.92	0.93	0.94	607	1.08	1.07	1.09
460	0.86	0.91	0.92	532	0.92	0.92	0.95	608	1.08	1.07	1.09
461	0.86	0.91	0.92	534	0.92	0.97	0.95	609	0.99	1.01	1.05
462	0.87	0.93	0.94	535	0.83	0.85	0.89	610	0.86	0.88	0.92
463	0.92	0.94	0.97	537	0.93	0.97	0.96	611	0.89	0.94	0.97
464	0.92	0.94	0.97	538	0.83	0.85	0.89	612	0.86	0.88	0.92
465	0.83	0.89	0.91	539	0.89	0.92	0.92	613	0.89	0.91	0.94
466	0.83	0.89	0.91	540	0.92	0.93	0.95	614	0.89	0.91	0.94
467	0.78	0.84	0.87	541	0.86	0.89	0.93	615	0.89	0.91	0.94
468	0.78	0.84	0.87	542	0.86	0.89	0.93	616	0.85	0.88	0.86
469	0.83	0.88	0.91	543	0.90	0.96	1.00	617	0.85	0.84	0.91
470	0.83	0.85	0.90	544	0.87	0.89	0.92	618	0.85	0.84	0.88
471	0.83	0.85	0.90	545	0.92	0.93	0.95	619	0.87	0.89	0.93
472	0.83	0.85	0.90	546	0.83	0.84	0.89	620	0.85	0.87	0.88
473	0.86	0.91	0.92	547	0.86	0.88	0.92	622	0.86	0.87	0.89
474	0.83	0.85	0.90	548	0.92	0.93	0.95	623	0.85	0.87	0.90
475	0.80	0.85	0.89	549	0.87	0.91	0.93	624	0.86	0.86	0.90
476	0.80	0.85	0.89	550	0.99	1.02	1.00	625	0.85	0.87	0.90
477	0.80	0.85	0.89	551	1.01	1.03	1.04	626	0.85	0.87	0.90
478	0.83	0.85	0.90	553	1.00	1.03	1.03	627	0.83	0.84	0.92
479	0.83	0.88	0.91	554	1.04	1.05	1.06	628	0.86	0.86	0.90
480	1.07	0.96	0.96	555	1.00	1.03	1.03	629	0.86	0.87	0.89
481	1.05	0.96	0.96	556	0.92	0.89	0.92	630	0.92	0.93	0.94
482	1.08	0.95	0.96	557	0.92	0.89	0.92	631	0.92	0.93	0.96
483	1.07	0.97	0.97	558	0.84	0.84	0.88	633	0.92	0.93	0.94
484	1.05	0.94	0.93	559	0.85	0.84	0.90	634	0.92	0.93	0.94
485	1.05	0.94	0.93	560	0.90	0.90	0.93	635	0.79	0.80	0.83
486	0.93	0.89	0.87	561	0.88	0.87	0.89	636	0.82	0.83	0.85
487	0.93	0.89	0.87	562	0.88	0.87	0.89	637	0.82	0.83	0.85
488	0.96	0.91	0.90	563	0.86	0.85	0.90	638	0.79	0.78	0.82
489	0.96	0.91	0.90	564	0.86	0.85	0.90	639	0.79	0.78	0.82
490	0.91	0.89	0.92	565	0.92	0.89	0.92	640	0.89	0.91	0.92
491	0.91	0.89	0.92	566	0.92	0.89	0.92	641	0.89	0.91	0.92
492	0.91	0.89	0.92	567	0.92	0.89	0.92	644	0.79	0.80	0.83
493	0.89	0.88	0.92	570	0.85	0.81	0.82	645	0.79	0.80	0.83
494	0.89	0.88	0.92	571	0.84	0.82	0.82	646	0.79	0.80	0.83
495	0.89	0.88	0.92	572	0.85	0.81	0.82	647	0.79	0.78	0.82
496	0.89	0.88	0.92	573	0.85	0.81	0.82	648	0.79	0.78	0.82
497	0.89	0.88	0.92	574	0.85	0.81	0.82	649	0.89	0.91	0.92

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 4 OF 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
650	0.84	0.87	0.88	730	0.86	0.88	0.90	801	1.08	1.12	1.10
651	0.84	0.87	0.88	731	0.86	0.88	0.90	802	1.07	1.10	1.09
652	0.84	0.87	0.88	733	0.99	1.07	1.06	803	1.06	1.10	1.08
653	0.79	0.78	0.82	734	0.83	0.81	0.84	804	1.06	1.10	1.08
654	0.79	0.78	0.82	735	0.83	0.81	0.84	805	1.01	1.03	1.03
655	0.79	0.78	0.82	736	0.83	0.83	0.86	806	1.01	1.03	1.03
656	0.79	0.78	0.82	737	0.83	0.83	0.86	807	1.01	1.03	1.03
657	0.79	0.78	0.82	738	0.83	0.83	0.86	808	1.02	1.07	1.04
658	0.82	0.83	0.86	739	0.83	0.83	0.86	809	1.02	1.07	1.04
660	0.88	0.90	0.90	740	0.86	0.88	0.90	810	1.02	1.07	1.04
661	0.88	0.90	0.90	741	0.86	0.88	0.90	811	0.97	0.99	0.99
662	0.92	0.95	0.96	743	0.81	0.79	0.82	812	0.97	0.99	0.99
664	0.82	0.83	0.84	744	0.81	0.79	0.82	813	0.97	0.99	0.99
665	0.82	0.83	0.84	745	0.83	0.81	0.84	814	0.97	0.99	0.99
666	0.89	0.89	0.90	746	0.83	0.83	0.86	815	0.97	0.99	0.99
667	0.83	0.82	0.84	747	0.83	0.81	0.84	816	1.05	1.14	1.11
668	0.83	0.82	0.84	748	0.81	0.79	0.82	820	0.82	0.79	0.81
669	0.83	0.82	0.85	749	0.83	0.81	0.84	821	0.82	0.79	0.81
670	0.88	0.84	0.87	750	0.98	1.08	1.06	822	0.82	0.79	0.81
671	0.88	0.84	0.87	751	0.98	1.08	1.06	823	0.82	0.79	0.81
672	0.89	0.90	0.90	752	0.99	1.08	1.09	824	0.82	0.79	0.81
673	0.83	0.82	0.84	753	0.99	1.08	1.09	825	0.82	0.79	0.81
674	0.83	0.82	0.85	754	0.88	0.95	0.97	826	0.82	0.79	0.81
675	0.83	0.82	0.85	755	0.88	0.95	0.97	827	0.82	0.79	0.81
676	0.83	0.82	0.85	756	0.88	0.95	0.97	828	0.82	0.79	0.81
677	0.83	0.82	0.85	757	0.88	0.95	0.97	829	0.82	0.79	0.81
678	0.83	0.82	0.85	758	0.88	0.95	0.97	830	0.82	0.79	0.81
679	0.83	0.82	0.85	759	0.88	0.95	0.97	831	0.82	0.79	0.81
680	0.81	0.85	0.85	760	0.92	1.01	0.99	832	0.87	0.82	0.84
681	0.81	0.85	0.85	761	0.92	1.01	0.99	833	0.93	0.89	0.88
683	0.74	0.79	0.80	762	0.93	1.00	1.00	834	0.87	0.82	0.84
684	0.74	0.79	0.80	763	0.93	1.00	1.00	835	0.93	0.89	0.88
685	0.75	0.81	0.86	764	0.87	0.94	0.96	836	0.93	0.89	0.88
686	0.74	0.79	0.80	765	0.80	0.85	0.87	837	0.95	0.93	0.92
687	0.74	0.79	0.80	766	0.87	0.94	0.96	838	0.93	0.89	0.88
688	0.74	0.79	0.80	767	0.87	0.94	0.96	840	0.81	0.78	0.81
689	0.74	0.79	0.80	768	0.87	0.92	0.94	841	0.84	0.82	0.84
690	0.74	0.79	0.80	769	0.87	0.92	0.94	842	0.80	0.78	0.79
691	0.74	0.79	0.80	770	0.97	1.04	1.04	843	0.80	0.78	0.79
692	0.74	0.79	0.80	772	0.97	1.04	1.04	844	0.80	0.78	0.79
693	0.74	0.79	0.80	773	0.93	1.02	1.02	845	0.80	0.77	0.81
700	0.80	0.90	0.90	774	0.93	1.02	1.02	846	0.80	0.77	0.81
701	0.83	0.90	0.92	775	0.93	1.02	1.02	847	0.80	0.77	0.81
703	0.77	0.85	0.89	776	0.81	0.85	0.86	850	1.03	1.04	1.01
704	0.80	0.90	0.90	777	0.81	0.85	0.86	852	1.03	1.04	1.01
705	0.77	0.85	0.89	778	0.80	0.85	0.87	853	1.03	1.04	1.01
706	0.77	0.85	0.89	779	0.79	0.87	0.89	855	0.96	0.97	0.97
707	0.80	0.89	0.91	780	0.87	0.91	0.92	856	1.00	1.03	1.00
708	0.80	0.89	0.91	781	0.79	0.87	0.89	857	1.00	1.03	1.00
710	0.79	0.85	0.87	782	0.87	0.91	0.92	859	0.96	0.97	0.97
711	0.79	0.85	0.87	783	0.82	0.89	0.88	860	1.00	0.98	1.01
712	0.79	0.85	0.87	784	0.82	0.89	0.88	863	0.96	0.97	0.97
713	0.79	0.85	0.87	785	0.82	0.89	0.88	864	0.96	0.97	0.97
714	0.79	0.85	0.87	786	0.99	1.07	1.06	865	1.00	0.98	1.01
716	0.76	0.76	0.79	787	0.99	1.07	1.06	870	0.98	0.98	0.99
717	0.76	0.76	0.79	788	0.87	0.92	0.94	871	0.99	1.00	1.00
718	0.76	0.76	0.79	789	0.99	1.07	1.06	872	0.98	0.98	0.99
719	0.76	0.76	0.79	790	0.89	0.93	0.94	873	0.98	0.98	0.99
720	0.84	0.84	0.83	791	0.89	0.93	0.94	874	0.98	0.98	0.99
721	0.84	0.84	0.83	792	0.89	0.93	0.94	875	0.98	0.98	0.99
722	0.84	0.84	0.83	793	0.86	0.93	0.94	877	0.98	0.98	0.99
723	0.76	0.76	0.79	794	0.86	0.93	0.94	878	0.92	0.90	0.93
724	0.84	0.84	0.84	795	0.86	0.93	0.94	879	0.92	0.90	0.93
725	0.84	0.84	0.84	796	0.86	0.93	0.94	880	0.92	0.90	0.93
726	0.84	0.84	0.84	797	0.87	0.92	0.94	881	0.92	0.90	0.93
727	0.84	0.84	0.84	798	0.87	0.92	0.94	882	0.92	0.90	0.93
728	0.76	0.76	0.79	799	0.91	0.93	0.89	883	0.92	0.90	0.93
729	0.84	0.81	0.84	800	1.06	1.10	1.08	884	0.98	0.98	0.99

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES
GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 5 OF 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
885	0.91	0.93	0.89	926	1.26	1.22	1.10	961	1.11	1.17	1.03
889	1.12	1.09	1.03	927	1.26	1.22	1.10	967	1.16	1.03	1.00
890	1.12	1.09	1.03	928	1.26	1.22	1.10	968	1.16	1.03	1.00
891	1.12	1.09	1.03	930	1.18	1.14	1.05	969	1.16	1.03	1.00
893	1.12	1.16	1.05	931	1.21	1.32	1.15	970	1.16	1.05	0.99
894	1.12	1.16	1.05	932	1.12	1.07	0.97	971	1.16	1.05	0.99
895	1.12	1.16	1.05	933	1.12	1.07	0.97	972	1.16	1.04	0.98
897	1.12	1.16	1.05	934	1.09	1.10	0.99	973	1.09	0.99	0.96
898	1.12	1.16	1.05	935	1.12	1.07	0.97	974	1.11	0.99	0.95
900	1.34	1.21	1.13	936	1.08	1.02	0.95	975	1.11	0.99	0.95
901	1.34	1.21	1.13	937	1.08	1.02	0.95	976	1.11	0.99	0.95
902	1.29	1.22	1.14	938	1.08	1.02	0.95	977	1.11	0.99	0.95
903	1.29	1.22	1.14	939	1.17	1.19	1.10	978	1.08	0.97	0.95
904	1.29	1.22	1.14	940	1.30	1.32	1.18	979	1.08	0.97	0.95
905	1.26	1.15	1.08	941	1.31	1.36	1.23	980	1.35	1.27	1.17
906	1.26	1.15	1.08	942	1.17	1.16	1.03	981	1.35	1.28	1.19
907	1.26	1.15	1.08	943	1.37	1.37	1.26	982	1.26	1.15	1.10
908	1.26	1.15	1.08	944	1.29	1.32	1.20	983	1.30	1.20	1.11
910	1.20	1.13	1.07	945	1.25	1.27	1.12	984	1.30	1.20	1.11
911	1.23	1.17	1.09	946	1.25	1.27	1.12	985	1.23	1.12	1.06
912	1.20	1.13	1.07	947	1.25	1.27	1.12	986	1.18	1.07	1.02
913	1.22	1.17	1.08	948	1.25	1.27	1.12	988	1.24	1.15	1.07
914	1.28	1.18	1.09	949	1.25	1.27	1.12	989	1.24	1.15	1.07
915	1.22	1.17	1.08	950	1.32	1.29	1.14	990	1.19	1.11	1.02
916	1.28	1.18	1.09	951	1.32	1.29	1.14	991	1.19	1.11	1.02
917	1.27	1.11	1.06	952	1.11	1.10	0.98	992	1.19	1.11	1.02
918	1.27	1.11	1.06	953	1.11	1.10	0.98	993	1.24	1.15	1.07
919	1.15	1.18	1.07	954	1.11	1.17	1.03	994	1.24	1.15	1.07
920	1.15	1.18	1.07	955	1.11	1.17	1.03	995	1.51	1.44	1.22
921	1.16	1.17	1.06	956	1.11	1.13	0.98	996	1.54	1.39	1.21
922	1.15	1.06	1.01	957	1.11	1.13	0.98	997	1.51	1.44	1.22
923	1.15	1.06	1.01	958	1.17	1.16	1.03	998	1.54	1.39	1.21
924	1.15	1.06	1.01	959	1.11	1.17	1.03	999	1.50	1.36	1.18
925	1.15	1.06	1.01	960	1.11	1.17	1.03				

TABLE S. — PROFESSIONAL SERVICES CONVERSION FACTORS

Category	Conversion Factor
Allergy Immunotherapy	\$56.29
Allergy Testing	\$71.61
Anesthesia	\$86.43
Cardiovascular	\$123.61
Chiropractor	\$63.08
Consults	\$65.44
Emergency Room Visits	\$117.15
Hearing/Speech Exams	\$75.50
Immunizations	\$80.55
Inpatient Visits	\$81.32
Maternity — Cesarean Deliveries	\$79.94
Maternity — Non-Deliveries	\$141.53
Maternity — Normal Deliveries	\$75.38
Miscellaneous Medical	\$85.43
Office/Home/Urgent Care Visits	\$58.22
OP Psych./Alc. & Drug Abuse	\$51.71
Pathology	\$106.64
Physical Exams	\$57.91
Physical Medicine	\$68.00
Radiology	\$114.87
Surgery	\$146.89
Therapeutic Injections	\$56.04
Vision Exams	\$39.69
Well Baby Exams	\$52.21

Supplementary Table 1
Reasonable Charges Data Sources - V2.1

V2p1 Data Sources 2004-3-19.xls - Sorted By Charge Type

Page 1 of 5

Charge Type	Paragraph	Subject	Data Source	Edition
PH	(d)(2)	per diem charge	Medicare SAF 5% Sample, outpatient facility component	CY 2002
PH	(d)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2002, as of Jan 2004
Opt	(e)(3)(i)	80th percentile charges, codes with APCs	Medicare APC payment amount	2004
Opt	(e)(3)(j)	80th percentile charges, codes with APCs	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	MDR database, outpatient facility component	July 2003
Opt	(e)(3)(iii)	80th percentile charges, codes with no APC	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Opt	(e)(3)(iv)	80th percentile charges, codes with no APC	MedStat claims database	1999
Opt	(e)(3)(v)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
Opt	(e)(4)	GAAFs	MDR database	July 2003
Opt	(e)(4)	GAAFs	Milliman USA, Inc., Health Cost Guidelines	2003
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Geographic Practice Cost Index, work expense	2004
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Physician Fee Schedule RVUs, work expense	2004
Phys	(f)(2)(i)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Geographic Practice Cost Index, practice expense	2004
Phys	(f)(2)(i)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Physician Fee Schedule RVUs, practice expense	2004
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Ingenix/IS, Anthony's RBRVS	2004
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	MDR database	Aug 2003
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Prevailing Healthcare Charges System	May 2003
Phys	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2003
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, practice expense	2004
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, work expense	2004
Phys	(f)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2003
Phys	(f)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2003
Phys	(f)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Phys	(f)(4)	modifiers: charge adjustment factors	Medicare SAF 5% Sample, Part B component	CY 2001
Anes	(g)(2)	RVUs	CMS anesthesia base units	2004
Anes	(g)(2)	RVUs for unlisted procedures	VA nationwide distribution of procedures and services	FY 2003
Anes	(g)(3)(i)	conversion factor, nationwide	CMS anesthesia base units	2004
Anes	(g)(3)(i)	conversion factor, nationwide	MDR database	Sep 2003
Anes	(g)(3)(i)	conversion factor, nationwide	Medicare SAF 5% Sample, Part B component	CY 2002
Anes	(g)(3)(i)	conversion factor, nationwide	Milliman USA, Inc., Health Cost Guidelines	2003
Anes	(g)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Dent	(h)(2)	charges, 80th percentile, nationwide	CPI-U, dental services component, seasonally adjusted	Dec 2003, as of Jan 2004
Dent	(h)(2)	charges, 80th percentile, nationwide	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2003
Dent	(h)(2)	charges, 80th percentile, nationwide	National Dental Advisory Service nationwide pricing index	2004
Dent	(h)(2)	charges, 80th percentile, nationwide	Prevailing Healthcare Charges System	May 2003
Dent	(h)(2)(ii)	charges, 80th percentile, nationwide, for unlisted procedures	Prevailing Healthcare Charges System	May 2003
Dent	(h)(2)(ii)	trending forward	CPI-U, dental services component, seasonally adjusted	Dec 2003, as of Jan 2004
Dent	(h)(3)	GAAFs	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2003
Dent	(h)(3)	GAAFs	Milliman USA, Inc., Dental Health Cost Guidelines	2003

Supplementary Table 1
Reasonable Charges Data Sources - V2.1

V2p1 Data Sources 2004-3-19.xls - Sorted By Charge Type

Page 2 of 5

Charge Type	Paragraph	Subject	Data Source	Edition
Lab	(f)(2)(i)	RVUs, codes with Medicare-based RVUs	MDR database	Aug 2003
Lab	(f)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Clinical Diagnostic Laboratory Fee Schedule	2004
Lab	(f)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare conversion factor	2004
Lab	(f)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Physician Fee Schedule payment levels	2004
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Ingenix/St. Anthony's RBRVS	2004
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	MDR database	Aug 2003
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Prevailing Healthcare Charges System	May 2003
Lab	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2003
Lab	(f)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, practice expense	2004
Lab	(f)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, work expense	2004
Lab	(f)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2003
Lab	(f)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2003
Lab	(f)(3)(i)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Obs	(f)(2)(i)	charges, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Obs	(f)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
Amb	(k)(2)(i)	base charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Amb	(k)(2)(ii)	mileage charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Amb	(k)(2)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
DME	(l)(2)(i)	RVUs	Ingenix/St. Anthony's RBRVS, practice expense RVUs	2004
DME	(l)(2)(i)	RVUs	Medicare DME Fee Schedule	2004
DME	(l)(2)(i)	RVUs	Medicare Parenteral and Enteral Nutrition Fee Schedule	2004
DME	(l)(2)(ii)	charge amounts	Medicare SAF 5% Sample, DME component	CY 2002
DME	(l)(2)(ii)	charge amounts	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(l)(2)(iii)	charge ratios, 80th percentile to median	MDR database	Sept 2003
DME	(l)(2)(iii)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, DME component	CY 2002
DME	(l)(2)(iii)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(l)(2)(iv)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Dec 2003, as of Jan 2004
DME	(l)(3)	charges for codes with no RVUs	MDR database	Sept 2003
DME	(l)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, DME component	CY 2002
DME	(l)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(l)(3)	charges for codes with no RVUs	Milliman USA, Inc., Optimized HMO Data Sets	2000
DME	(l)(3)(i)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Dec 2003, as of Jan 2004
DME	(l)(4)	charges for unlisted procedures	VA nationwide distribution of procedures, services, items, and supplies	FY 2003
DME	(l)(5)(ii)	charges, weighted average, area-specific	MDR database	Sept 2003
DME	(l)(5)(ii)	charges, weighted average, area-specific	Medicare SAF 5% Sample, DME component	CY 2002
DME	(l)(5)(ii)	charges, weighted average, area-specific	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(l)(5)(iii)	charges, weighted average, nationwide	Milliman USA, Inc., Health Cost Guidelines	2003

Supplementary Table 1
Reasonable Charges Data Sources - V2.1

V2p1 Data Sources 2004-3-19.xls - Sorted By Data Source

Page 3 of 5

Charge Type	Paragraph	Subject	Data Source	Edition
Anes	(g)(2)	RVUs	CMS anesthesia base units	2004
Anes	(g)(3)(i)	conversion factor, nationwide	CMS anesthesia base units	2004
Dent	(h)(2)	charges, 80th percentile, nationwide	CPI-U, dental services component, seasonally adjusted	Dec 2003, as of Jan 2004
Dent	(h)(2)(iii)	trending forward	CPI-U, dental services component, seasonally adjusted	Dec 2003, as of Jan 2004
DME	(i)(2)(iv)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Dec 2003, as of Jan 2004
DME	(i)(3)(i)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Dec 2003, as of Jan 2004
Amb	(k)(2)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
Obs	(l)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
Opt	(e)(3)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
PH	(d)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Dec 2003, as of Jan 2004
Anes	(g)(3)(i)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Lab	(i)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Phys	(f)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Dec 2003, as of Jan 2004
Dent	(h)(2)	charges, 80th percentile, nationwide	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2003
Dent	(h)(3)	GAAFs	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2003
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Ingenix/St. Anthony's RBRVS	2004
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Ingenix/St. Anthony's RBRVS	2004
DME	(i)(2)(i)	RVUs	Ingenix/St. Anthony's RBRVS, practice expense RVUs	2004
Anes	(g)(3)(i)	conversion factor, nationwide	MDR database	2004
DME	(i)(2)(iii)	charge ratios, 80th percentile to median	MDR database	2004
DME	(i)(3)	charges for codes with no RVUs	MDR database	2004
DME	(i)(5)(ii)	charges, weighted average, area-specific	MDR database	2004
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	MDR database	2004
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	MDR database	2004
Lab	(i)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	2004
Opt	(e)(4)	GAAFs	MDR database	2004
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	MDR database	2004
Phys	(f)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	2004
Opt	(e)(3)(iii)	80th percentile charges, codes with no APC	MDR database, outpatient facility component	2004
Opt	(e)(3)(i)	80th percentile charges, codes with APCs	MDR database, outpatient facility component	2004
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare APC payment amount	2004
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Clinical Diagnostic Laboratory Fee Schedule	2004
DME	(i)(2)(i)	RVUs	Medicare conversion factor	2004
Lab	(i)(2)(i)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare DME Fee Schedule	2004
Phys	(f)(2)(i)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Geographic Practice Cost Index, practice expense	2004
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, practice expense	2004
Lab	(i)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, work expense	2004
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Geographic Practice Cost Index, work expense	2004
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, work expense	2004
DME	(i)(2)(i)	RVUs	Medicare Parenteral and Enteral Nutrition Fee Schedule	2004
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Physician Fee Schedule payment levels	2004
Phys	(f)(2)(i)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Physician Fee Schedule RVUs, practice expense	2004
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Physician Fee Schedule RVUs, work expense	2004
DME	(i)(2)(i)	charge amounts	Medicare SAF 5% Sample, DME component	CY 2002

Supplementary Table 1
Reasonable Charges Data Sources - V2.1

V2p1 Data Sources 2004-3-19.xls - Sorted By Data Source

Charge Type	Paragraph	Subject	Data Source	Edition
DME	(f)(2)(ii)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, DME component	CY 2002
DME	(f)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, DME component	CY 2002
DME	(f)(5)(ii)	charges, weighted average, area-specific	Medicare SAF 5% Sample, DME component	CY 2002
Amb	(k)(2)(i)	base charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Amb	(k)(2)(ii)	mileage charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Obs	(j)(2)(i)	charges, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Opt	(e)(3)(i)	80th percentile charges, codes with APCs	Medicare SAF 5% Sample, outpatient facility component	CY 2002
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	Medicare SAF 5% Sample, outpatient facility component	CY 2002
PH	(d)(2)	per diem charge	Medicare SAF 5% Sample, Part B component	CY 2002
Anes	(g)(3)(i)	conversion factor, nationwide	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(f)(2)(i)	charge amounts	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(f)(2)(iii)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(f)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
DME	(f)(5)(ii)	charges, weighted average, area-specific	Medicare SAF 5% Sample, Part B component	CY 2002
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Medicare SAF 5% Sample, Part B component	CY 2002
Phys	(f)(4)	modifiers: charge adjustment factors	Medicare SAF 5% Sample, Part B component	CY 2001
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	MedStat claims database	1999
Dent	(h)(3)	GAAFs	Milliman USA, Inc., Denial Health Cost Guidelines	2003
Anes	(g)(3)(i)	conversion factor, nationwide	Milliman USA, Inc., Health Cost Guidelines	2003
DME	(f)(5)(iii)	charges, weighted average, nationwide	Milliman USA, Inc., Health Cost Guidelines	2003
Opt	(e)(4)	GAAFs	Milliman USA, Inc., Health Cost Guidelines	2003
Lab	(f)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines	2003
Phys	(f)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines	2003
DME	(f)(3)	charges for codes with no RVUs	Milliman USA, Inc., Health Cost Guidelines fee survey	2003
Dent	(h)(2)	charges, 80th percentile, nationwide	Milliman USA, Inc., Health Cost Guidelines fee survey	2000
Dent	(h)(2)	charges, 80th percentile, nationwide	Milliman USA, Inc., Optimized HMO Data Sets	2004
Dent	(h)(2)(ii)	charges, 80th percentile, nationwide, for unlisted procedures	National Dental Advisory Service nationwide pricing index	May 2003
Lab	(f)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Prevailing Healthcare Charges System	May 2003
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Prevailing Healthcare Charges System	May 2003
Anes	(g)(2)	RVUs for unlisted procedures	Prevailing Healthcare Charges System	May 2003
Lab	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2003
Phys	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2003
DME	(f)(4)	charges for unlisted procedures	VA nationwide distribution of procedures, services, items, and supplies	FY 2003

Supplementary Table 1
Reasonable Charges Data Sources - V2.1

V2p1 Data Sources 2004-3-19.xls - Sorted By Data Source

Charge Type	Paragraph	Subject	Data Source	Edition
Charge Type Abbreviations				
Amb		Ambulance	APC = Ambulatory Payment Classification	
Anes		Anesthesia	CMS = Centers for Medicare and Medicaid Services	
Dent		Dental HCPCS Level II	CPI-U = Consumer Price Index - All Urban Consumers	
DME		DME and other HCPCS Level II	CY = Calendar Year (January - December)	
Inpt		Acute inpatient facility charges	DME = Durable Medical Equipment	
Lab		Pathology and laboratory	FY = Fiscal Year (October - September)	
Obs		Observation care	GAAF = Geographic Area Adjustment Factor	
Opt		Outpatient facility charges	HMO = Health Maintenance Organizations	
PH		Partial hospitalization	ICU = Intensive Care Unit	
Phys		Physician and other professional charges	MDR = Medical Data Research	
SNF		Skilled nursing facility / sub-acute inpatient facility charges	MedPAR = Medicare Provider Analysis and Review	
			R&B = Room and Board	
			RBRVS = Resource-Based Relative Value Scale	
			RVU = Relative Value Unit	
			SAF = Standard Analytical File	
			UCR = Usual, Customary, or Reasonable	
			VA = Department of Veterans Affairs	

Supplementary Table 2
Reasonable Charges Data Sources - V2.1 - Where To Obtain

V2p1 Data Sources 2004-3-19.xls - Obtain

Database		Where To Obtain
CMS anesthesia base units		Centers for Medicare and Medicaid Services
CPI-U, various components, seasonally adjusted		Bureau of Labor Statistics Internet site, CPI section, http://www.bls.gov/cpi/
Ingenix Comprehensive Healthcare Payment System, Dental UCR Module		Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
Ingenix/St. Anthony's RBRVS		Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
MDR database		Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
MDR database, outpatient facility component		Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
Medicare APC payment amount		CMS Internet site, http://www.cms.gov/regulations/hopps/change2003.asp
Medicare Clinical Diagnostic Laboratory Fee Schedule		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare conversion factor		Federal Register, Vol. 68, No. 40, February 28, 2003, pages 9567-9568
Medicare DME Fee Schedule		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Geographic Practice Cost Index, practice expense		Federal Register, Vol. 67, No. 251, December 31, 2002, pages 80170-80172
Medicare Geographic Practice Cost Index, work expense		Federal Register, Vol. 67, No. 251, December 31, 2002, pages 80170-80172
Medicare Parenteral and Enteral Nutrition Fee Schedule		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/ (included as part of DME Fee Schedule download)
Medicare Physician Fee Schedule payment levels		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Physician Fee Schedule RVUs, practice expense		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Physician Fee Schedule RVUs, work expense		CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare SAF 5% Sample, DME component		CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, outpatient facility component		CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, Part B component		CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedPAR file		CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedPAR skilled nursing facility file		CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedStat claims database		MedStat Group, 777 E. Eisenhower Parkway, Ann Arbor, MI 48108
Milliman USA, Inc., Dental Health Cost Guidelines		Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines		Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines fee survey		Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Optimized HMO Data Sets		Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
National Dental Advisory Service nationwide pricing index		Wasserman Medical Publishers, Ltd., PO. Box 510949, Milwaukee, WI 53203
Prevailing Healthcare Charges System		Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
VA nationwide discharges		Veterans Health Administration
VA nationwide distribution of procedures and services		Veterans Health Administration
VA nationwide distribution of procedures, services, items, and supplies		Veterans Health Administration
Abbreviations		
APC	= Ambulatory Payment Classification	
CMS	= Centers for Medicare and Medicaid Services	
CPI-U	= Consumer Price Index - All Urban Consumers	
DME	= Durable Medical Equipment	
HMO	= Health Maintenance Organizations	
MDR	= Medical Data Research	
MedPAR	= Medicare Provider Analysis and Review	
RBRVS	= Resource-Based Relative Value Scale	
RVU	= Relative Value Unit	
SAF	= Standard Analytical File	
UCR	= Usual, Customary, or Reasonable	
VA	= Department of Veterans Affairs	

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 1 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
402	TOGUS, ME	ME	043	1	VAMC	PBH
402GA	CARIBOU, ME	ME	047	1	CBOC	NPB
402GB	CALAIS, ME	ME	046	1	CBOC	NPB
402GC	RUMFORD, ME	ME	042	1	CBOC	NPB
402GD	SACO, ME	ME	040	1	CBOC	NPB
402HB	BANGOR, ME	ME	044	1	CBOC	NPB
402HC	PORTLAND, ME	ME	041	1	CBOC	NPB
405	WHITE RIVER JCT, VT	VT	050	1	VAMC	PBH
405GA	BENNINGTON, VT	VT	052	1	CBOC	NPB
405HA	BURLINGTON, VT	VT	054	1	CBOC	NPB
405HC	SAINT JOHNSBURY, VT	VT	058	1	CBOC	NPB
405HD	NEWPORT, VT	VT	058	1	CBOC	NPB
405HF	RUTLAND, VT	VT	057	1	CBOC	NPB
405HG	WILDER, VT	VT	050	1	CBOC	NPB
436	FORT HARRISON, MT	MT	596	19	VAMC	PBH
436GA	ANACONDA, MT	MT	597	19	CBOC	NPB
436GB	GREAT FALLS, MT	MT	594	19	CBOC	NPB
436GC	MISSOULA, MT	MT	598	19	CBOC	NPB
436GD	BOZEMAN, MT	MT	597	19	CBOC	NPB
436GF	KALISPELL, MT	MT	599	19	CBOC	NPB
436GH	BILLINGS, MT	MT	591	19	CBOC	NPB
436GI	GLASGOW, MT	MT	592	19	CBOC	NPB
436GJ	MILES CITY, MT	MT	593	19	CBOC	NPB
436GK	SIDNEY, MT	MT	592	19	CBOC	NPB
437	FARGO, ND	ND	581	23	VAMC	PBH
437GA	GRAFTON, ND	ND	582	23	CBOC	NPB
437GB	BISMARCK, ND	ND	585	23	CBOC	NPB
437GC	FERGUS FALLS, MN	MN	565	23	CBOC	NPB
437GD	MINOT, ND	ND	587	23	CBOC	NPB
438	SIOUX FALLS, SD	SD	571	23	VAMC	PBH
438GC	SIOUX CITY, IA	IA	511	23	CBOC	NPB
438GD	ABERDEEN, SD	SD	574	23	CBOC	NPB
442	CHEYENNE, WY	WY	820	19	VAMC	PBH
442GB	SIDNEY, NE	NE	691	19	CBOC	NPB
442GC	FORT COLLINS, CO	CO	805	19	CBOC	NPB
442GD	GREELEY, CO	CO	806	19	CBOC	NPB
459	HONOLULU, HI	HI	968	21	VAMC	PBH
459GA	KAHULUI, HI	HI	967	21	CBOC	NPB
459GB	HILO, HI	HI	967	21	CBOC	NPB
459GC	KAILUA KONA, HI	HI	967	21	CBOC	NPB
459GD	LIHUE, HI	HI	967	21	CBOC	NPB
459GE	GUAM, GU	GU	969	21	CBOC	NPB
460	WILMINGTON, DE	DE	198	4	VAMC	PBH
460GA	MILLSBORO, DE	DE	199	4	CBOC	NPB
460HE	VENTNOR CITY, NJ	NJ	084	4	CBOC	NPB
460HG	VINELAND, NJ	NJ	083	4	CBOC	PBO
463	ANCHORAGE, AK	AK	995	20	IOC	PBO
463GA	FAIRBANKS, AK	AK	997	20	CBOC	NPB
463GB	KENAI, AK	AK	996	20	CBOC	NPB
501	ALBUQUERQUE, NM	NM	871	18	VAMC	PBH
501G2	LAS VEGAS, NM	NM	875	18	CBOC	NPB
501GA	ARTESIA, NM	NM	882	18	CBOC	NPB
501GB	FARMINGTON, NM	NM	874	18	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 2 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
501GC	SILVER CITY, NM	NM	880	18	CBOC	NPB
501GD	GALLUP, NM	NM	873	18	CBOC	NPB
501GE	ESPANOLA, NM	NM	884	18	CBOC	NPB
501GH	TRUTH OR CONSEQUENCES, NM	NM	879	18	CBOC	NPB
501GI	ALAMOGORDO, NM	NM	883	18	CBOC	NPB
501GJ	DURANGO, CO	CO	813	18	CBOC	NPB
501GK	SANTA FE, NM	NM	875	18	CBOC	NPB
501HB	RATON, NM	NM	877	18	CBOC	NPB
502	ALEXANDRIA, LA	LA	713	16	VAMC	PBH
502GA	JENNINGS, LA	LA	705	16	CBOC	NPB
502GB	LAFAYETTE, LA	LA	705	16	CBOC	NPB
503	ALTOONA, PA	PA	166	4	VAMC	PBH
503GA	JOHNSTOWN, PA	PA	159	4	CBOC	PBO
503GB	DU BOIS, PA	PA	158	4	CBOC	NPB
503GC	STATE COLLEGE, PA	PA	168	4	CBOC	PBO
504	AMARILLO, TX	TX	791	18	VAMC	PBH
504BY	LUBBOCK, TX	TX	794	18	CBOC	NPB
504BZ	CLOVIS, NM	NM	881	18	CBOC	NPB
504GA	CHILDRESS, TX	TX	792	18	CBOC	NPB
504GB	LIBERAL, KS	KS	679	18	CBOC	NPB
504HB	STRATFORD, TX	TX	790	18	CBOC	NPB
506	ANN ARBOR, MI	MI	481	11	VAMC	PBH
506GA	TOLEDO, OH	OH	436	11	CBOC	NPB
506GB	FLINT, MI	MI	485	11	CBOC	NPB
506GC	JACKSON, MI	MI	492	11	CBOC	NPB
508	ATLANTA/DECATUR, GA	GA	300	7	VAMC	PBH
508GA	ATLANTA/MIDTOWN, GA	GA	303	7	CBOC	PBO
508GE	OAKWOOD/NE CORRIDOR, GA	GA	305	7	CBOC	PBO
508GF	SMYRNA, GA	GA	300	7	CBOC	PBO
508GH	LAWRENCEVILLE, GA	GA	300	7	CBOC	PBO
509	AUGUSTA DOWNTOWN, GA	GA	309	7	VAMC	PBH
509A0	AUGUSTA UPTOWN, GA	GA	309	7	VAMC	PBH
512	BALTIMORE, MD	MD	212	5	VAMC	PBH
512A5	PERRY POINT, MD	MD	219	5	VAMC	PBH
512GA	CAMBRIDGE, MD	MD	216	5	CBOC	NPB
512GC	GLEN BURNIE, MD	MD	210	5	CBOC	PBO
512GD	BALTIMORE/LOCH RAVEN, MD	MD	212	5	CBOC	PBO
512GE	POCOMOKE CITY, MD	MD	218	5	CBOC	NPB
512GF	FORT HOWARD CBOC, MD	MD	210	5	CBOC	PBO
515	BATTLE CREEK, MI	MI	490	11	VAMC	PBH
515BY	GRAND RAPIDS, MI	MI	495	11	CBOC	NPB
515GA	MUSKEGON, MI	MI	494	11	CBOC	NPB
515GB	LANSING, MI	MI	489	11	CBOC	NPB
515GC	BENTON HARBOR, MI	MI	490	11	CBOC	NPB
516	BAY PINES, FL	FL	337	8	VAMC	PBH
516BZ	FORT MYERS, FL	FL	339	8	CBOC	NPB
516GA	SARASOTA, FL	FL	342	8	CBOC	NPB
516GB	SAINT PETERSBURG, FL	FL	337	8	CBOC	PBO
516GC	CLEARWATER, FL	FL	346	8	CBOC	NPB
516GD	ELLENTON, FL	FL	342	8	CBOC	PBO
516GE	PORT CHARLOTTE, FL	FL	339	8	CBOC	NPB
516GF	NAPLES, FL	FL	341	8	CBOC	NPB
516GH	AVON PARK, FL	FL	338	8	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 3 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
517	BECKLEY, WV	WV	258	6	VAMC	PBH
517GA	GASSAWAY, WV	WV	266	6	CBOC	NPB
518	BEDFORD, MA	MA	017	1	VAMC	PBH
518GA	LYNN, MA	MA	019	1	CBOC	PBO
518GB	HAVERTHILL, MA	MA	018	1	CBOC	PBO
518GC	WINCHINDON, MA	MA	014	1	CBOC	NPB
518GD	LOWELL, MA	MA	018	1	CBOC	PBO
518GE	GLOUCESTER, MA	MA	019	1	CBOC	PBO
518GG	FITCHBURG, MA	MA	014	1	CBOC	PBO
519	BIG SPRING, TX	TX	797	18	VAMC	PBH
519GA	ODESSA, TX	TX	797	18	CBOC	NPB
519GB	HOBBS, NM	NM	882	18	CBOC	NPB
519GD	FORT STOCKTON, TX	TX	797	18	CBOC	NPB
519HC	ABILENE, TX	TX	796	18	CBOC	NPB
519HD	STAMFORD, TX	TX	795	18	CBOC	NPB
519HF	SAN ANGELO, TX	TX	769	18	CBOC	NPB
520	BILOXI, MS	MS	395	16	VAMC	PBH
520A0	GULFPORT, MS	MS	395	16	VAMC	PBH
520BZ	PENSACOLA, FL	FL	325	16	CBOC	NPB
520GA	MOBILE, AL	AL	366	16	CBOC	NPB
520GB	PANAMA CITY, FL	FL	324	16	CBOC	NPB
521	BIRMINGHAM, AL	AL	352	7	VAMC	PBH
521GA	HUNTSVILLE, AL	AL	358	7	CBOC	NPB
521GB	DECATUR, AL	AL	356	7	CBOC	NPB
521GC	FLORENCE, AL	AL	356	7	CBOC	NPB
521GD	RAINBOW CITY, AL	AL	359	7	CBOC	NPB
521GE	ANNISTON, AL	AL	362	7	CBOC	NPB
521GF	JASPER, AL	AL	355	7	CBOC	NPB
523	BOSTON, MA	MA	021	1	VAMC	PBH
523A4	WEST ROXBURY, MA	MA	021	1	VAMC	PBH
523A5	BROCKTON, MA	MA	024	1	VAMC	PBH
523BZ	BOSTON CBOC, MA	MA	021	1	CBOC	PBO
523GA	FRAMINGHAM, MA	MA	017	1	CBOC	PBO
523GB	WORCESTER, MA	MA	016	1	CBOC	PBO
523GC	QUINCY, MA	MA	021	1	CBOC	PBO
523GD	PLYMOUTH, MA	MA	023	1	CBOC	NPB
523GE	DORCHESTER, MA	MA	021	1	CBOC	PBO
526	BRONX, NY	NY	104	3	VAMC	PBH
526GA	WHITE PLAINS/BRONX, NY	NY	106	3	CBOC	PBO
526GB	YONKERS, NY	NY	107	3	CBOC	PBO
526GC	SOUTH BRONX, NY	NY	104	3	CBOC	PBO
526GD	QUEENS, NY	NY	111	3	CBOC	PBO
528	BUFFALO, NY	NY	142	2	VAMC	PBH
528A4	BATAVIA, NY	NY	140	2	VAMC	PBH
528A5	CANANDAIGUA, NY	NY	144	2	VAMC	PBH
528A6	BATH, NY	NY	148	2	VAMC	PBH
528A7	SYRACUSE, NY	NY	132	2	VAMC	PBH
528A8	ALBANY, NY	NY	122	2	VAMC	PBH
528G1	MALONE, NY	NY	129	2	CBOC	NPB
528G2	ELIZABETHTOWN, NY	NY	129	2	CBOC	NPB
528G3	BAINBRIDGE, NY	NY	137	2	CBOC	NPB
528G4	ELMIRA, NY	NY	149	2	CBOC	PBO
528G5	AUBURN, NY	NY	130	2	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 4 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
528G6	FONDA, NY	NY	120	2	CBOC	NPB
528G7	CATSKILL, NY	NY	124	2	CBOC	NPB
528G8	WELLSVILLE, NY	NY	148	2	CBOC	NPB
528G9	CORTLAND, NY	NY	130	2	CBOC	NPB
528GB	JAMESTOWN, NY	NY	147	2	CBOC	NPB
528GC	DUNKIRK, NY	NY	140	2	CBOC	NPB
528GD	NIAGARA FALLS, NY	NY	143	2	CBOC	NPB
528GE	ROCHESTER, NY	NY	146	2	CBOC	PBO
528GK	LOCKPORT, NY	NY	140	2	CBOC	PBO
528GL	MASSENA, NY	NY	136	2	CBOC	NPB
528GM	ROME, NY	NY	134	2	CBOC	NPB
528GN	BINGHAMTON, NY	NY	139	2	CBOC	NPB
528GO	WATERTOWN/FORT DRUM, NY	NY	136	2	CBOC	NPB
528GP	OSWEGO, NY	NY	131	2	CBOC	NPB
528GQ	LACKAWANNA, NY	NY	142	2	CBOC	NPB
528GR	OLEAN, NY	NY	147	2	CBOC	NPB
528GT	GLENS FALLS, NY	NY	128	2	CBOC	NPB
528GV	PLATTSBURGH, NY	NY	129	2	CBOC	NPB
528GW	SCHENECTADY, NY	NY	123	2	CBOC	NPB
528GX	TROY, NY	NY	121	2	CBOC	NPB
528GY	CLIFTON PARK, NY	NY	120	2	CBOC	PBO
528GZ	KINGSTON, NY	NY	124	2	CBOC	NPB
529	BUTLER, PA	PA	160	4	VAMC	PBH
529GA	MERCER, PA	PA	161	4	CBOC	PBO
529GB	NEW CASTLE, PA	PA	161	4	CBOC	PBO
529GC	KITTANNING, PA	PA	162	4	CBOC	NPB
529GD	KNOX, PA	PA	162	4	CBOC	NPB
531	BOISE, ID	ID	837	20	VAMC	PBH
531GD	ONTARIO, OR	OR	979	20	CBOC	NPB
531GE	TWIN FALLS, ID	ID	833	20	CBOC	NPB
534	CHARLESTON, SC	SC	294	7	VAMC	PBH
534BY	SAVANNAH, GA	GA	314	7	CBOC	NPB
534GB	MYRTLE BEACH, SC	SC	295	7	CBOC	NPB
534GC	BEAUFORT, SC	SC	299	7	CBOC	NPB
537	CHICAGO WEST SIDE, IL	IL	606	12	VAMC	PBH
537A4	CHICAGO LAKESIDE, IL	IL	606	12	VAMC	PBH
537BY	CROWN POINT, IN	IN	463	12	CBOC	NPB
537GA	CHICAGO HEIGHTS, IL	IL	604	12	CBOC	PBO
537HA	CHICAGO/WOODLAWN, IL	IL	606	12	CBOC	PBO
538	CHILLICOTHE, OH	OH	456	10	VAMC	PBH
538GA	ATHENS, OH	OH	457	10	CBOC	NPB
538GB	PORTSMOUTH, OH	OH	456	10	CBOC	NPB
538GC	MARIETTA, OH	OH	457	10	CBOC	NPB
538GD	LANCASTER, OH	OH	431	10	CBOC	PBO
539	CINCINNATI, OH	OH	452	10	VAMC	PBH
539GA	BELLEVUE, KY	KY	410	10	CBOC	PBO
539GB	CINCINNATI CBOC, OH	OH	452	10	CBOC	PBO
539GC	LAWRENCEBURG, IN	IN	470	10	CBOC	PBO
540	CLARKSBURG, WV	WV	263	4	VAMC	PBH
540GA	PARSONS, WV	WV	262	4	CBOC	NPB
540GB	PARKERSBURG, WV	WV	261	4	CBOC	NPB
540GC	GASSAWAY, WV	WV	266	4	CBOC	NPB
541	CLEVELAND WADE PARK, OH	OH	441	10	VAMC	PBH

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 5 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
541A0	CLEVELAND BRECKSVILLE, OH	OH	441	10	VAMC	PBH
541BY	CANTON, OH	OH	447	10	CBOC	NPB
541BZ	YOUNGSTOWN, OH	OH	445	10	CBOC	NPB
541GB	LORAIN, OH	OH	440	10	CBOC	PBO
541GC	SANDUSKY, OH	OH	448	10	CBOC	NPB
541GD	MANSFIELD, OH	OH	449	10	CBOC	NPB
541GE	CLEVELAND CBOC, OH	OH	441	10	CBOC	PBO
541GF	PAINESVILLE, OH	OH	440	10	CBOC	PBO
541GG	AKRON, OH	OH	443	10	CBOC	NPB
541GH	EAST LIVERPOOL, OH	OH	439	10	CBOC	NPB
541GI	WARREN, OH	OH	444	10	CBOC	NPB
542	COATESVILLE, PA	PA	193	4	VAMC	PBH
542GA	SPRINGFIELD, PA	PA	190	4	CBOC	PBO
542GB	PHILADELPHIA CBOC, PA	PA	191	4	CBOC	NPB
542GC	READING, PA	PA	196	4	CBOC	PBO
542GD	LANCASTER, PA	PA	176	4	CBOC	PBO
542GE	SPRING CITY, PA	PA	194	4	CBOC	PBO
542GF	VINELAND, NJ	NJ	083	4	CBOC	NPB
542GG	COATESVILLE MSCEC, PA	PA	193	4	CBOC	PBO
542GH	COATESVILLE CBOC, PA	PA	193	4	CBOC	PBO
542GI	VENTNOR CITY, NJ	NJ	084	4	CBOC	NPB
544	COLUMBIA, SC	SC	292	7	VAMC	PBH
544BZ	GREENVILLE, SC	SC	296	7	CBOC	NPB
544GB	FLORENCE, SC	SC	295	7	CBOC	NPB
544GC	ROCK HILL, SC	SC	297	7	CBOC	NPB
544GD	ANDERSON, SC	SC	296	7	CBOC	NPB
544GE	ORANGEBURG, SC	SC	291	7	CBOC	NPB
544GF	SUMTER, SC	SC	291	7	CBOC	NPB
546	MIAMI, FL	FL	331	8	VAMC	PBH
546BZ	OAKLAND PARK, FL	FL	333	8	CBOC	PBO
546GA	MIAMI CBOC, FL	FL	331	8	CBOC	PBO
546GB	KEY WEST, FL	FL	330	8	CBOC	NPB
546GC	HOMESTEAD, FL	FL	330	8	CBOC	NPB
546GD	PEMBROKE PINES, FL	FL	330	8	CBOC	PBO
546GE	KEY LARGO, FL	FL	330	8	CBOC	NPB
546GF	HALLANDALE, FL	FL	330	8	CBOC	PBO
546GG	CORAL SPRINGS, FL	FL	330	8	CBOC	NPB
546GH	DEERFIELD BEACH, FL	FL	334	8	CBOC	NPB
548	WEST PALM BEACH, FL	FL	334	8	VAMC	PBH
548GA	FORT PIERCE, FL	FL	349	8	CBOC	NPB
548GB	DELRAY BEACH, FL	FL	334	8	CBOC	NPB
548GC	STUART, FL	FL	349	8	CBOC	NPB
548GD	BOCA RATON, FL	FL	334	8	CBOC	NPB
548GE	VERO BEACH, FL	FL	329	8	CBOC	NPB
548GF	OKEECHOBEE, FL	FL	349	8	CBOC	NPB
549	DALLAS, TX	TX	752	17	VAMC	PBH
549A4	BONHAM, TX	TX	754	17	VAMC	PBH
549BY	FORT WORTH SOC, TX	TX	761	17	CBOC	PBO
549GA	TYLER, TX	TX	757	17	CBOC	NPB
549GC	BONHAM CBOC, TX	TX	754	17	CBOC	NPB
549GD	DENTON, TX	TX	762	17	CBOC	NPB
549GE	DECATUR, TX	TX	762	17	CBOC	NPB
549GF	EASTLAND, TX	TX	764	17	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 6 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
549GH	GREENVILLE, TX	TX	754	17	CBOC	NPB
549GI	CLEBURNE, TX	TX	760	17	CBOC	NPB
550	DANVILLE, IL	IL	618	11	VAMC	PBH
550BY	PEORIA, IL	IL	616	11	CBOC	NPB
550GA	DECATUR, IL	IL	625	11	CBOC	NPB
550GC	LAFAYETTE, IN	IN	479	11	CBOC	NPB
550GD	SPRINGFIELD, IL	IL	627	11	CBOC	NPB
550GE	EFFINGHAM, IL	IL	624	11	CBOC	NPB
552	DAYTON, OH	OH	454	10	VAMC	PBH
552GA	MIDDLETOWN, OH	OH	450	10	CBOC	PBO
552GB	LIMA, OH	OH	458	10	CBOC	NPB
552GC	RICHMOND, IN	IN	473	10	CBOC	NPB
552GD	SPRINGFIELD, OH	OH	455	10	CBOC	PBO
553	DETROIT, MI	MI	482	11	VAMC	PBH
553GA	YALE, MI	MI	480	11	CBOC	NPB
553GB	PONTIAC, MI	MI	483	11	CBOC	NPB
554	DENVER, CO	CO	802	19	VAMC	PBH
554GB	AURORA, CO	CO	800	19	CBOC	PBO
554GC	LAKEWOOD, CO	CO	802	19	CBOC	PBO
554GD	PUEBLO, CO	CO	810	19	CBOC	NPB
554GE	COLORADO SPRINGS, CO	CO	809	19	CBOC	NPB
554GF	ALAMOSA, CO	CO	811	19	CBOC	NPB
554GG	LA JUNTA, CO	CO	810	19	CBOC	NPB
554GH	LAMAR, CO	CO	810	19	CBOC	NPB
554HB	FORT MORGAN, CO	CO	807	19	CBOC	NPB
556	NORTH CHICAGO, IL	IL	600	12	VAMC	PBH
556GA	EVANSTON, IL	IL	602	12	CBOC	PBO
556GC	MCHENRY, IL	IL	600	12	CBOC	PBO
556GD	KENOSHA, WI	WI	531	12	CBOC	PBO
557	DUBLIN, GA	GA	310	7	VAMC	PBH
557GA	MACON, GA	GA	312	7	CBOC	NPB
557GB	ALBANY, GA	GA	317	7	CBOC	NPB
558	DURHAM, NC	NC	277	6	VAMC	PBH
558GA	GREENVILLE, NC	NC	278	6	CBOC	NPB
558GB	RALEIGH, NC	NC	276	6	CBOC	NPB
558GC	MOOREHEAD CITY, NC	NC	285	6	CBOC	NPB
561	EAST ORANGE, NJ	NJ	070	3	VAMC	PBH
561A4	LYONS, NJ	NJ	079	3	VAMC	PBH
561BY	NEWARK SAC, NJ	NJ	071	3	CBOC	PBO
561BZ	BRICK, NJ	NJ	087	3	CBOC	NPB
561GA	TRENTON, NJ	NJ	086	3	CBOC	PBO
561GB	ELIZABETH, NJ	NJ	072	3	CBOC	PBO
561GD	HACKENSACK, NJ	NJ	076	3	CBOC	PBO
561GE	JERSEY CITY, NJ	NJ	073	3	CBOC	PBO
561GF	NEW BRUNSWICK, NJ	NJ	089	3	CBOC	PBO
561GG	NEWARK CBOC, NJ	NJ	071	3	CBOC	PBO
561GH	MORRISTOWN, NJ	NJ	079	3	CBOC	PBO
561GI	FORT MONMOUTH, NJ	NJ	077	3	CBOC	PBO
561HB	JAMESBURG, NJ	NJ	088	3	CBOC	PBO
562	ERIE, PA	PA	165	4	VAMC	PBH
562GA	MEADVILLE, PA	PA	163	4	CBOC	PBO
562GB	ASHTABULA, OH	OH	440	4	CBOC	NPB
562GC	SMETHPORT, PA	PA	167	4	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 7 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
564	FAYETTEVILLE, AR	AR	727	16	VAMC	PBH
564BY	MOUNT VERNON, MO	MO	657	16	CBOC	NPB
564GA	HARRISON, AR	AR	726	16	CBOC	NPB
564GB	FORT SMITH, AR	AR	729	16	CBOC	NPB
565	FAYETTEVILLE, NC	NC	283	6	VAMC	PBH
565GA	JACKSONVILLE UCJ, NC	NC	285	6	CBOC	NPB
565GC	WILMINGTON, NC	NC	284	6	CBOC	NPB
568	FORT MEADE, SD	SD	577	23	VAMC	PBH
568A4	HOT SPRINGS, SD	SD	577	23	VAMC	PBH
568GA	RAPID CITY, SD	SD	577	23	CBOC	PBO
568GB	PIERRE, SD	SD	575	23	CBOC	NPB
568HA	NEWCASTLE, WY	WY	827	23	CBOC	NPB
568HB	RUSHVILLE, NE	NE	693	23	CBOC	NPB
568HC	ALLIANCE, NE	NE	693	23	CBOC	NPB
568HH	GERING, NE	NE	693	23	CBOC	NPB
568HJ	ROSEBUD, SD	SD	575	23	CBOC	NPB
568HK	MCLAUGHLIN, SD	SD	576	23	CBOC	NPB
568HM	EAGLE BUTTE, SD	SD	576	23	CBOC	NPB
568HN	LAME DEER, MT	MT	590	23	CBOC	NPB
568HP	WINNER, SD	SD	575	23	CBOC	NPB
570	FRESNO, CA	CA	937	21	VAMC	PBH
570GA	ATWATER, CA	CA	953	21	CBOC	NPB
570GB	TULARE, CA	CA	932	21	CBOC	NPB
573	GAINESVILLE, FL	FL	326	8	VAMC	PBH
573A4	LAKE CITY, FL	FL	320	8	VAMC	PBH
573BY	JACKSONVILLE, FL	FL	322	8	CBOC	PBO
573BZ	DAYTONA BEACH, FL	FL	321	8	CBOC	NPB
573GA	VALDOSTA, GA	GA	316	8	CBOC	NPB
573GD	OCALA, FL	FL	344	8	CBOC	PBO
573GE	SAINT AUGUSTINE, FL	FL	320	8	CBOC	NPB
573GF	TALLAHASSEE, FL	FL	323	8	CBOC	NPB
573GG	INVERNESS, FL	FL	344	8	CBOC	NPB
573GH	LEESBURG, FL	FL	347	8	CBOC	NPB
575	GRAND JUNCTION, CO	CO	815	19	VAMC	PBH
575GA	MONTROSE, CO	CO	814	19	CBOC	NPB
578	HINES, IL	IL	601	12	VAMC	PBH
578GA	JOLIET, IL	IL	604	12	CBOC	PBO
578GB	OAK PARK, IL	IL	603	12	CBOC	PBO
578GC	MANTENO, IL	IL	609	12	CBOC	NPB
578GD	AURORA, IL	IL	605	12	CBOC	PBO
578GE	ELGIN, IL	IL	601	12	CBOC	PBO
578GF	LA SALLE, IL	IL	613	12	CBOC	NPB
578GG	OAK LAWN, IL	IL	604	12	CBOC	NPB
580	HOUSTON, TX	TX	770	16	VAMC	PBH
580BY	BEAUMONT, TX	TX	777	16	CBOC	NPB
580BZ	LUFKIN, TX	TX	759	16	CBOC	NPB
581	HUNTINGTON, WV	WV	257	9	VAMC	PBH
581GA	PRESTONSBURG, KY	KY	416	9	CBOC	NPB
581GB	CHARLESTON, WV	WV	253	9	CBOC	NPB
581GD	WILLIAMSON, WV	WV	256	9	CBOC	NPB
583	INDIANAPOLIS, IN	IN	462	11	VAMC	PBH
583GA	TERRE HAUTE, IN	IN	478	11	CBOC	NPB
583GB	BLOOMINGTON, IN	IN	474	11	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 8 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
585	IRON MOUNTAIN, MI	MI	498	12	VAMC	PBH
585GA	HANCOCK/PORTAGE, MI	MI	499	12	CBOC	NPB
585GB	RHINELANDER, WI	WI	545	12	CBOC	NPB
585GC	MENOMINEE, MI	MI	498	12	CBOC	NPB
585GD	IRONWOOD, MI	MI	499	12	CBOC	NPB
585HA	MARQUETTE, MI	MI	498	12	CBOC	NPB
585HB	SAULT SAINTE MARIE, MI	MI	497	12	CBOC	NPB
586	JACKSON, MS	MS	392	16	VAMC	PBII
586GA	KOSCIUSKO, MS	MS	390	16	CBOC	NPB
586GB	MERIDIAN, MS	MS	393	16	CBOC	NPB
586GC	GREENVILLE, MS	MS	387	16	CBOC	NPB
586GD	HATTIESBURG, MS	MS	394	16	CBOC	NPB
586GE	NATCHEZ, MS	MS	391	16	CBOC	NPB
589	KANSAS CITY, MO	MO	641	15	VAMC	PBH
589A4	COLUMBIA, MO	MO	652	15	VAMC	PBH
589A5	TOPEKA, KS	KS	666	15	VAMC	PBH
589A6	LEAVENWORTH, KS	KS	660	15	VAMC	PBII
589A7	WICHITA, KS	KS	672	15	VAMC	PBH
589G1	WARRENSBURG, MO	MO	640	15	CBOC	NPB
589G2	DODGE CITY, KS	KS	678	15	CBOC	NPB
589G3	LIBERAL, KS	KS	679	15	CBOC	NPB
589G4	HAYS, KS	KS	676	15	CBOC	NPB
589G5	PARSONS, KS	KS	673	15	CBOC	NPB
589G6	SALINA, KS	KS	674	15	CBOC	NPB
589GB	BELTON, MO	MO	640	15	CBOC	PBO
589GC	PAOLA, KS	KS	660	15	CBOC	NPB
589GD	NEVADA, MO	MO	647	15	CBOC	NPB
589GE	KIRKSVILLE, MO	MO	635	15	CBOC	NPB
589GF	FORT LEONARD WOOD, MO	MO	654	15	CBOC	NPB
589GH	CAMDENTON, MO	MO	650	15	CBOC	NPB
589G1	SAINT JOSEPH, MO	MO	645	15	CBOC	PBO
589GJ	KANSAS CITY/WYANDOTTE, KS	KS	661	15	CBOC	PBO
589GK	ABILENE, KS	KS	674	15	CBOC	NPB
589GM	CHANUTE, KS	KS	667	15	CBOC	NPB
589GN	EMPORIA, KS	KS	668	15	CBOC	NPB
589GO	FORT RILEY, KS	KS	664	15	CBOC	NPB
589GP	GARNETT, KS	KS	660	15	CBOC	NPB
589GQ	HOLTON, KS	KS	664	15	CBOC	NPB
589GR	JUNCTION CITY, KS	KS	664	15	CBOC	NPB
589GS	RUSSELL, KS	KS	676	15	CBOC	NPB
589GT	SENECA, KS	KS	665	15	CBOC	NPB
589GU	LAWRENCE, KS	KS	660	15	CBOC	NPB
589GV	FORT SCOTT, KS	KS	667	15	CBOC	NPB
589GW	SALINA, KS	KS	674	15	CBOC	NPB
589GX	MEXICO, MO	MO	652	15	CBOC	PBO
589GY	SAINT JAMES, MO	MO	655	15	CBOC	NPB
589GZ	CAMERON, MO	MO	644	15	CBOC	NPB
589DS	KANSAS CITY NON-VA HOSPITAL, KS	KS	641	15	CMC	PBII
590	HAMPTON, VA	VA	236	6	VAMC	PBH
590GA	NORFOLK, VA	VA	235	6	CBOC	PBO
593	LAS VEGAS, NV	NV	891	22	VAMC	PBH
593GA	LAS VEGAS CBOC, NV	NV	891	22	CBOC	PBO
593GB	HENDERSON, NV	NV	890	22	CBOC	PBO

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 9 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
593GC	PAHRUMP, NV	NV	890	22	CBOC	NPB
595	LEBANON, PA	PA	170	4	VAMC	PBH
595GA	CAMP HILL, PA	PA	170	4	CBOC	PBO
595GB	POTTSVILLE/SCHUYLKILL/SHENA	PA	179	4	CBOC	PBO
595GC	LANCASTER, PA	PA	176	4	CBOC	PBO
595GD	READING, PA	PA	196	4	CBOC	PBO
595GE	YORK, PA	PA	174	4	CBOC	PBO
596	LEXINGTON LEESTOWN, KY	KY	405	9	VAMC	PBH
596A4	LEXINGTON COOPER DRIVE, KY	KY	405	9	VAMC	PBH
596GA	SOMERSET, KY	KY	425	9	CBOC	NPB
596HA	LEXINGTON MSORC, KY	KY	405	9	CBOC	PBO
598	LITTLE ROCK, AR	AR	722	16	VAMC	PBH
598A0	NORTH LITTLE ROCK, AR	AR	721	16	VAMC	PBH
598GA	MOUNTAIN HOME, AR	AR	726	16	CBOC	NPB
598GB	EL DORADO, AR	AR	717	16	CBOC	NPB
598GC	HOT SPRINGS, AR	AR	719	16	CBOC	NPB
600	LONG BEACH, CA	CA	908	22	VAMC	PBH
600GA	ANAHEIM, CA	CA	928	22	CBOC	PBO
600GB	SANTA ANA, CA	CA	927	22	CBOC	PBO
600GC	LONG BEACH CBOC, CA	CA	908	22	CBOC	PBO
600GD	SANTA FE SPRINGS, CA	CA	906	22	CBOC	PBO
603	LOUISVILLE, KY	KY	402	9	VAMC	PBH
603GA	FORT KNOX, KY	KY	401	9	CBOC	NPB
603GB	NEW ALBANY, IN	IN	471	9	CBOC	NPB
603GC	LOUISVILLE CBOC, KY	KY	402	9	CBOC	PBO
605	LOMA LINDA, CA	CA	923	22	VAMC	PBH
605GA	VICTORVILLE, CA	CA	923	22	CBOC	PBO
605GB	SUN CITY, CA	CA	923	22	CBOC	PBO
605GC	PALM DESERT, CA	CA	922	22	CBOC	NPB
605GD	CORONA, CA	CA	928	22	CBOC	PBO
605GE	UPLAND, CA	CA	917	22	CBOC	PBO
607	MADISON, WI	WI	537	12	VAMC	PBH
607GC	JANESVILLE, WI	WI	535	12	CBOC	NPB
607GD	BARABOO, WI	WI	539	12	CBOC	PBO
607GE	BEAVER DAM, WI	WI	539	12	CBOC	NPB
607HA	ROCKFORD, IL	IL	611	12	CBOC	NPB
608	MANCHESTER, NH	NH	031	1	VAMC	PBH
608GA	PORTSMOUTH, NH	NH	038	1	CBOC	PBO
608GC	WOLFEBORO, NH	NH	038	1	CBOC	NPB
608GD	CONWAY, NH	NH	038	1	CBOC	NPB
608HA	TILTON, NH	NH	032	1	CBOC	PBO
610	MARION, IN	IN	469	11	VAMC	PBH
610A4	FORT WAYNE, IN	IN	468	11	VAMC	PBH
610GA	SOUTH BEND, IN	IN	466	11	CBOC	NPB
610GB	MUNCIE, IN	IN	473	11	CBOC	NPB
612	MARTINEZ, CA	CA	945	21	VAMC	PBH
612A4	SACRAMENTO/MATHER AFB, CA	CA	958	21	VAMC	PBH
612B4	REDDING, CA	CA	960	21	CBOC	NPB
612BY	OAKLAND, CA	CA	946	21	CBOC	PBO
612CZ	TRAVIS AFB, CA	CA	945	21	CBOC	PBO
612GD	FAIRFIELD, CA	CA	945	21	CBOC	PBO
612GE	MARE ISLAND, CA	CA	945	21	CBOC	PBO
612GF	MARTINEZ CBOC, CA	CA	945	21	CBOC	PBO

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 10 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
612GG	CHICO, CA	CA	959	21	CBOC	NPB
612GH	MCCLELLAN AFB, CA	CA	956	21	CBOC	PBO
613	MARTINSBURG, WV	WV	254	5	VAMC	PBH
613GA	CUMBERLAND, MD	MD	215	5	CBOC	NPB
613GB	HAGERSTOWN, MD	MD	217	5	CBOC	PBO
613GC	STEPHENS CITY, VA	VA	226	5	CBOC	PBO
613GD	FRANKLIN, WV	WV	268	5	CBOC	NPB
613GE	PETERSBURG, WV	WV	268	5	CBOC	NPB
613GF	HARRISONBURG, VA	VA	228	5	CBOC	NPB
614	MEMPHIS, TN	TN	381	9	VAMC	PBH
614GA	SMITHVILLE, MS	MS	388	9	CBOC	NPB
614GB	JONESBORO, AR	AR	724	9	CBOC	NPB
614GC	BYHALIA, MS	MS	386	9	CBOC	NPB
614GD	SAVANNAH, TN	TN	383	9	CBOC	NPB
618	MINNEAPOLIS, MN	MN	554	23	VAMC	PBH
618BY	SUPERIOR, WI	WI	548	23	CBOC	NPB
618GA	MANKATO, MN	MN	560	23	CBOC	NPB
618GB	HIBING, MN	MN	557	23	CBOC	NPB
618GD	SAINT PAUL, MN	MN	551	23	CBOC	PBO
618GE	CHIPPEWA FALLS, WI	WI	547	23	CBOC	NPB
618GG	ROCHESTER, MN	MN	559	23	CBOC	NPB
619	MONTGOMERY, AL	AL	361	7	VAMC	PBH
619A4	TUSKEGEE, AL	AL	360	7	VAMC	PBH
619GA	COLUMBUS, GA	GA	319	7	CBOC	NPB
619GB	DOTHAN, AL	AL	363	7	CBOC	NPB
619GC	DOTHAN MHC, AL	AL	363	7	CBOC	NPB
620	MONTROSE, NY	NY	105	3	VAMC	PBH
620A4	CASTLE POINT, NY	NY	125	3	VAMC	PBH
620GA	NEW CITY, NY	NY	109	3	CBOC	PBO
620GB	CARMEL, NY	NY	105	3	CBOC	PBO
620GD	WALLKILL, NY	NY	125	3	CBOC	PBO
620GE	PORT JERVIS, NY	NY	127	3	CBOC	NPB
620GF	HARRIS, NY	NY	127	3	CBOC	NPB
620GG	POUGHKEEPSIE, NY	NY	126	3	CBOC	PBO
621	MOUNTAIN HOME, TN	TN	376	9	VAMC	PBH
621GA	ROGERSVILLE, TN	TN	378	9	CBOC	NPB
621GB	MOUNTAIN CITY, TN	TN	376	9	CBOC	NPB
621GC	NORTON, VA	VA	242	9	CBOC	NPB
621GD	SAINT CHARLES, VA	VA	242	9	CBOC	NPB
623	MUSKOGEE, OK	OK	744	16	VAMC	PBH
623BY	TULSA, OK	OK	741	16	CBOC	NPB
623GA	MCALISTER, OK	OK	745	16	CBOC	NPB
626	NASHVILLE, TN	TN	372	9	VAMC	PBH
626A4	MURFREESBORO, TN	TN	371	9	VAMC	PBH
626BY	KNOXVILLE, TN	TN	379	9	CBOC	NPB
626GA	DOVER, TN	TN	370	9	CBOC	NPB
626GC	BOWLING GREEN, KY	KY	421	9	CBOC	NPB
626GD	HOPKINSVILLE, KY	KY	422	9	CBOC	NPB
626GE	CLARKSVILLE, TN	TN	370	9	CBOC	NPB
626GF	CHATTANOOGA, TN	TN	374	9	CBOC	NPB
626GG	TULLAHOMA/ARNOLD AFB, TN	TN	373	9	CBOC	NPB
626GH	COOKEVILLE, TN	TN	385	9	CBOC	NPB
629	NEW ORLEANS, LA	LA	701	16	VAMC	PBH

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 11 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
629BY	BATON ROUGE, LA	LA	708	16	CBOC	NPB
630	NEW YORK, NY	NY	100	3	VAMC	PBH
630A4	BROOKLYN, NY	NY	112	3	VAMC	PBH
630A5	SAINT ALBANS, NY	NY	114	3	VAMC	PBH
630B2	NEW YORK SOHO C&P UNIT, NY	NY	100	3	CBOC	PBO
630BZ	NEW YORK METHADONE, NY	NY	100	3	CBOC	PBO
630GA	HARLEM, NY	NY	100	3	CBOC	PBO
630GB	STATEN ISLAND, NY	NY	103	3	CBOC	PBO
630GC	BROOKLYN CHAPEL STREET, NY	NY	112	3	CBOC	PBO
630GD	BROOKLYN BEDFORD-STUY VESA NY	NY	112	3	CBOC	PBO
631	NORTHAMPTON, MA	MA	010	1	VAMC	PBH
631BY	SPRINGFIELD SOC, MA	MA	011	1	CBOC	PBO
631GA	NORTHAMPTON CBOC, MA	MA	010	1	CBOC	PBO
631GB	SPRINGFIELD CBOC, MA	MA	011	1	CBOC	PBO
631GC	PITTSFIELD, MA	MA	012	1	CBOC	PBO
631GD	GREENFIELD, MA	MA	013	1	CBOC	PBO
632	NORTHPORT/LONG ISLAND, NY	NY	117	3	VAMC	PBH
632GA	PLAINVIEW, NY	NY	118	3	CBOC	PBO
632HA	LYNBROOK, NY	NY	115	3	CBOC	PBO
632HB	RIVERHEAD, NY	NY	119	3	CBOC	NPB
632HC	ISLIP, NY	NY	117	3	CBOC	PBO
632HD	PATCHOGUE, NY	NY	117	3	CBOC	PBO
632HE	MOUNT SINAI, NY	NY	117	3	CBOC	PBO
632HF	LINDENHURST, NY	NY	117	3	CBOC	PBO
635	OKLAHOMA CITY, OK	OK	731	16	VAMC	PBH
635GA	LAWTON/FORT SILL, OK	OK	735	16	CBOC	NPB
635GB	WICHITA FALLS, TX	TX	763	16	CBOC	NPB
635GC	PONCA CITY, OK	OK	746	16	CBOC	NPB
635GD	KONAWA, OK	OK	748	16	CBOC	NPB
635HB	ARDMORE, OK	OK	734	16	CBOC	NPB
636	OMAHA, NE	NE	681	23	VAMC	PBH
636A4	GRAND ISLAND, NE	NE	688	23	VAMC	PBH
636A5	LINCOLN, NE	NE	685	23	VAMC	PBH
636A6	DES MOINES, IA	IA	503	23	VAMC	PBH
636A7	KNOXVILLE, IA	IA	501	23	VAMC	PBH
636A8	IOWA CITY, IA	IA	522	23	VAMC	PBH
636GA	NORFOLK, NE	NE	687	23	CBOC	NPB
636GB	NORTH PLATTE, NE	NE	691	23	CBOC	NPB
636GC	MASON CITY, IA	IA	504	23	CBOC	NPB
636GF	BETTENDORF, IA	IA	527	23	CBOC	NPB
636GG	QUINCY, IL	IL	623	23	CBOC	NPB
636GH	WATERLOO, IA	IA	507	23	CBOC	NPB
636GI	GALESBURG, IL	IL	614	23	CBOC	NPB
636GJ	DUBUQUE, IA	IA	520	23	CBOC	NPB
636GK	FORT DODGE, IA	IA	505	23	CBOC	NPB
637	ASHEVILLE, NC	NC	288	6	VAMC	PBH
640	PALO ALTO, CA	CA	943	21	VAMC	PBH
640A0	MENLO PARK, CA	CA	940	21	VAMC	PBH
640A4	LIVERMORE, CA	CA	945	21	VAMC	PBH
640BY	SAN JOSE, CA	CA	951	21	CBOC	PBO
640GA	CAPITOLA, CA	CA	950	21	CBOC	PBO
640GB	SONORA, CA	CA	953	21	CBOC	NPB
640HA	STOCKTON, CA	CA	952	21	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 12 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
640HB	MODESTO, CA	CA	953	21	CBOC	NPB
640HC	MONTEREY/FORT ORD, CA	CA	939	21	CBOC	NPB
642	PHILADELPHIA, PA	PA	191	4	VAMC	PRH
642GA	FORT DIX, NJ	NJ	086	4	CBOC	PBO
642GB	CAPE MAY, NJ	NJ	082	4	CBOC	NPB
642GC	WILLOW GROVE, PA	PA	190	4	CBOC	PBO
644	PHOENIX, AZ	AZ	850	18	VAMC	PBH
644BY	MESA/WILLIAMS AFB, AZ	AZ	852	18	CBOC	PBO
644GA	SUN CITY, AZ	AZ	853	18	CBOC	PBO
644GB	SHOW LOW, AZ	AZ	859	18	CBOC	NPB
644GC	BUCKEYE, AZ	AZ	853	18	CBOC	NPB
644GD	PAYSON, AZ	AZ	855	18	CBOC	NPB
646	PITTSBURGH UNIV DR, PA	PA	152	4	VAMC	PBH
646A4	PITTSBURGH ASPINWALL, PA	PA	152	4	VAMC	PBH
646A5	PITTSBURGH HIGHLAND DR, PA	PA	152	4	VAMC	PBH
646GA	SAINT CLAIRSVILLE, OH	OH	439	4	CBOC	NPB
646GB	GREENSBURG, PA	PA	156	4	CBOC	PBO
646GC	ALQUIPPA, PA	PA	150	4	CBOC	PBO
646GD	WASHINGTON, PA	PA	153	4	CBOC	PBO
648	PORTLAND, OR	OR	972	20	VAMC	PBH
648A4	VANCOUVER, WA	WA	986	20	VAMC	PBH
648GA	BEND, OR	OR	977	20	CBOC	NPB
648GB	SALEM, OR	OR	973	20	CBOC	NPB
648GC	LONGVIEW, WA	WA	986	20	CBOC	NPB
648GD	NORTH COAST, OR	OR	971	20	CBOC	NPB
649	PRESCOTT, AZ	AZ	863	18	VAMC	PBH
649GA	KINGMAN, AZ	AZ	864	18	CBOC	NPB
649GB	BELLEMONT, AZ	AZ	860	18	CBOC	NPB
649GC	LAKE HAVASU CITY, AZ	AZ	864	18	CBOC	NPB
649GD	BLACK CANYON CITY, AZ	AZ	853	18	CBOC	NPB
649GE	COTTONWOOD, AZ	AZ	863	18	CBOC	PBO
650	PROVIDENCE, RI	RI	029	1	VAMC	PBH
650GA	NEW BEDFORD, MA	MA	027	1	CBOC	PBO
650GB	HYANNIS, MA	MA	026	1	CBOC	NPB
650GC	OAK BLUFFS, MA	MA	025	1	CBOC	NPB
650GD	MIDDLETOWN, RI	RI	028	1	CBOC	PBO
650GE	NANTUCKET, MA	MA	025	1	CBOC	NPB
652	RICHMOND, VA	VA	232	6	VAMC	PBH
652GA	FREDERICKSBURG, VA	VA	224	6	CBOC	NPB
653	ROSEBURG, OR	OR	974	20	VAMC	PBH
653BY	EUGENE, OR	OR	974	20	CBOC	NPB
653GA	BANDON, OR	OR	974	20	CBOC	NPB
653GB	BROOKINGS, OR	OR	974	20	CBOC	NPB
654	RENO, NV	NV	895	21	VAMC	PBH
654GA	AUBURN, CA	CA	956	21	CBOC	NPB
654GB	MINDEN, NV	NV	894	21	CBOC	PBO
655	SAGINAW, MI	MI	486	11	VAMC	PBH
655GA	GAYLORD, MI	MI	497	11	CBOC	NPB
655GB	TRAVERSE CITY, MI	MI	496	11	CBOC	NPB
655GC	OSCODA, MI	MI	487	11	CBOC	NPB
656	SAINT CLOUD, MN	MN	563	23	VAMC	PBH
656GA	BRAINERD, MN	MN	564	23	CBOC	NPB
656GB	MONTEVIDEO, MN	MN	562	23	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 13 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
657	SAINT LOUIS JOHN COCHRAN, MC	MO	631	15	VAMC	PBH
657A0	SAINT LOUIS JEFF BARRACKS, MC	MO	631	15	VAMC	PBH
657A4	POPLAR BLUFF, MO	MO	639	15	VAMC	PBH
657A5	MARION, IL	IL	629	15	VAMC	PBH
657GA	BELLEVILLE, IL	IL	622	15	CBOC	PBO
657GB	SAINT LOUIS CBOC, MO	MO	631	15	CBOC	PBO
657GC	EFFINGHAM, IL	IL	624	15	CBOC	NPB
657GD	SAINT CHARLES, MO	MO	633	15	CBOC	PBO
657GE	SPRINGFIELD, IL	IL	627	15	CBOC	NPB
657GF	WEST PLAINS, MO	MO	657	15	CBOC	NPB
657GG	PARAGOULD, AR	AR	724	15	CBOC	NPB
657GH	CAPE GIRARDEAU, MO	MO	637	15	CBOC	NPB
657GI	FARMINGTON, MO	MO	636	15	CBOC	NPB
657GJ	EVANSVILLE, IN	IN	477	15	CBOC	NPB
657GK	MOUNT VERNON, IL	IL	628	15	CBOC	NPB
657GL	PADUCAH, KY	KY	420	15	CBOC	NPB
657GM	EFFINGHAM, IL	IL	624	15	CBOC	NPB
657HK	SALEM, MO	MO	655	15	CBOC	NPB
657DS	ST. LOUIS NON-VA HOSPITAL, IL	IL	631	15	CMC	PBH
658	SALEM, VA	VA	241	6	VAMC	PBH
658GA	TAZEWELL, VA	VA	246	6	CBOC	NPB
658GB	DANVILLE, VA	VA	245	6	CBOC	NPB
658HA	STUARTS DRAFT, VA	VA	244	6	CBOC	NPB
658HB	PULASKI, VA	VA	243	6	CBOC	NPB
658HC	LYNCHBURG, VA	VA	245	6	CBOC	NPB
658HD	HILLSVILLE, VA	VA	243	6	CBOC	NPB
658HE	MARTINSVILLE, VA	VA	241	6	CBOC	NPB
658HG	COVINGTON, VA	VA	244	6	CBOC	NPB
658HH	MARION, VA	VA	243	6	CBOC	NPB
659	SALISBURY, NC	NC	281	6	VAMC	PBH
659BY	WINSTON-SALEM, NC	NC	271	6	CBOC	PBO
659GA	CHARLOTTE, NC	NC	282	6	CBOC	NPB
660	SALT LAKE CITY, UT	UT	841	19	VAMC	PBH
660GA	POCATELLO, ID	ID	832	19	CBOC	NPB
660GB	OGDEN, UT	UT	844	19	CBOC	PBO
660GC	ELY, NV	NV	893	19	CBOC	NPB
660GD	ROOSEVELT, UT	UT	840	19	CBOC	NPB
660GE	OREM, UT	UT	840	19	CBOC	PBO
660GF	GREEN RIVER, WY	WY	829	19	CBOC	NPB
660GG	SAINT GEORGE, UT	UT	847	19	CBOC	NPB
660GI	NEPHI, UT	UT	846	19	CBOC	NPB
662	SAN FRANCISCO, CA	CA	941	21	VAMC	PBH
662BU	SAN FRANCISCO HOMELESS CTR.	CA	941	21	CBOC	PBO
662GA	SANTA ROSA, CA	CA	954	21	CBOC	NPB
662GC	EUREKA, CA	CA	955	21	CBOC	NPB
662GD	UKIAH, CA	CA	954	21	CBOC	NPB
663	SEATTLE, WA	WA	981	20	VAMC	PBH
663A4	AMERICAN LAKE/TACOMA, WA	WA	984	20	VAMC	PBH
663GA	LYNNWOOD/NORTHGATE, WA	WA	980	20	CBOC	PBO
663GB	BREMERTON, WA	WA	983	20	CBOC	PBO
664	SAN DIEGO, CA	CA	921	22	VAMC	PBH
664BY	SAN DIEGO CBOC, CA	CA	921	22	CBOC	PBO
664GA	EL CENTRO, CA	CA	922	22	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 14 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
664GB	VISTA, CA	CA	920	22	CBOC	PBO
664GC	CHULA VISTA, CA	CA	919	22	CBOC	PBO
664GD	ESCONDIDO, CA	CA	920	22	CBOC	PBO
666	SHERIDAN, WY	WY	828	19	VAMC	PBH
666GB	CASPER, WY	WY	826	19	CBOC	NPB
666GC	RIVERTON, WY	WY	825	19	CBOC	NPB
666GD	POWELL, WY	WY	824	19	CBOC	NPB
666GE	GILLETTE, WY	WY	827	19	CBOC	NPB
667	SHREVEPORT, LA	LA	711	16	VAMC	PBH
667GA	TEXARKANA, TX	TX	755	16	CBOC	NPB
667GB	MONROE, LA	LA	712	16	CBOC	NPB
667GC	LONGVIEW, TX	TX	756	16	CBOC	NPB
668	SPOKANE, WA	WA	992	20	VAMC	PBH
668HK	SPOKANE MOC, WA	WA	992	20	CBOC	PBO
671	SAN ANTONIO, TX	TX	782	17	VAMC	PBH
671A4	KERRVILLE, TX	TX	780	17	VAMC	PBH
671B0	MCALLEN, TX	TX	785	17	CBOC	NPB
671BY	SAN ANTONIO CBOC, TX	TX	782	17	CBOC	PBO
671BZ	CORPUS CHRISTI, TX	TX	784	17	CBOC	NPB
671GA	BROWNSVILLE, TX	TX	785	17	CBOC	NPB
671GB	VICTORIA, TX	TX	779	17	CBOC	NPB
671GE	LAREDO, TX	TX	780	17	CBOC	NPB
671GF	SOUTH BEXAR COUNTY, TX	TX	782	17	CBOC	PBO
671GG	ALICE, TX	TX	783	17	CBOC	NPB
671GH	BEEVILLE, TX	TX	781	17	CBOC	NPB
671GI	KINGSVILLE, TX	TX	783	17	CBOC	NPB
671GJ	UVALDE, TX	TX	788	17	CBOC	NPB
671GK	SAN ANTONIO CBOC, TX	TX	782	17	CBOC	NPB
671GL	NEW BRAUNFELS, TX	TX	781	17	CBOC	NPB
672	SAN JUAN, PR	PR	009	8	VAMC	PBH
672B0	PONCE, PR	PR	007	8	CBOC	NPB
672BZ	MAYAGUEZ, PR	PR	006	8	CBOC	NPB
672GA	SAINT CROIX, VI	VI	008	8	CBOC	NPB
672GB	SAINT THOMAS, VI	VI	008	8	CBOC	NPB
672GC	ARECIBO, PR	PR	006	8	CBOC	NPB
672GD	KINGSHILL, VI	VI	008	8	CBOC	NPB
672GE	GUAYAMA, PR	PR	007	8	CBOC	PBO
673	TAMPA, FL	FL	336	8	VAMC	PBH
673BY	ORLANDO, FL	FL	328	8	CBOC	NPB
673BZ	PORT RICHEY, FL	FL	346	8	CBOC	NPB
673GA	VIERA/MELBOURNE, FL	FL	329	8	CBOC	NPB
673GB	LAKELAND, FL	FL	338	8	CBOC	PBO
673GC	BROOKSVILLE, FL	FL	346	8	CBOC	NPB
673GD	SANFORD, FL	FL	327	8	CBOC	NPB
673GE	KISSIMMEE, FL	FL	347	8	CBOC	NPB
673GF	ZEPHYRHILLS, FL	FL	335	8	CBOC	NPB
674	TEMPLE, TX	TX	765	17	VAMC	PBH
674A4	WACO, TX	TX	767	17	VAMC	PBH
674A5	MARLIN, TX	TX	766	17	VAMC	PBH
674BY	AUSTIN, TX	TX	787	17	CBOC	NPB
674GA	PALESTINE, TX	TX	758	17	CBOC	NPB
674GB	BROWNWOOD, TX	TX	768	17	CBOC	NPB
674GC	BRYAN/COLLEGE STATION, TX	TX	778	17	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1

RC V2p1 Facility List 2004-4-1FR.xls

Page 15 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
674GD	CEDAR PARK, TX	TX	786	17	CBOC	NPB
676	TOMAH, WI	WI	546	12	VAMC	PBH
676GA	WAUSAU, WI	WI	544	12	CBOC	NPB
676GC	LA CROSSE, WI	WI	546	12	CBOC	NPB
676GD	WISCONSIN RAPIDS, WI	WI	544	12	CBOC	NPB
676GE	LOYAL, WI	WI	544	12	CBOC	NPB
676HB	WAUTOMA, WI	WI	549	12	CBOC	NPB
678	TUCSON, AZ	AZ	857	18	VAMC	PBH
678GA	SIERRA VISTA, AZ	AZ	856	18	CBOC	NPB
678GB	YUMA, AZ	AZ	853	18	CBOC	NPB
678GC	CASA GRANDE, AZ	AZ	852	18	CBOC	NPB
678GD	SAFFORD, AZ	AZ	855	18	CBOC	NPB
678GE	GREEN VALLEY, AZ	AZ	856	18	CBOC	PBO
679	TUSCALOOSA, AL	AL	354	7	VAMC	PBH
687	WALLA WALLA, WA	WA	993	20	VAMC	PBH
687GA	RICHLAND, WA	WA	993	20	CBOC	NPB
687GB	LEWISTON, ID	ID	835	20	CBOC	NPB
687HA	YAKIMA, WA	WA	989	20	CBOC	NPB
688	WASHINGTON, DC	DC	204	5	VAMC	PBH
688GA	ALEXANDRIA, VA	VA	223	5	CBOC	PBO
688GB	WASHINGTON SE, DC	DC	200	5	CBOC	PBO
688GC	LANDOVER, MD	MD	207	5	CBOC	PBO
688GD	CHARLOTTE HALL, MD	MD	206	5	CBOC	PBO
689	WEST HAVEN, CT	CT	065	1	VAMC	PBH
689A4	NEWINGTON, CT	CT	061	1	CBOC	PBO
689GA	WATERBURY, CT	CT	067	1	CBOC	PBO
689GB	STAMFORD, CT	CT	069	1	CBOC	PBO
689GC	WINDHAM, CT	CT	062	1	CBOC	NPB
689GD	WINSTED, CT	CT	060	1	CBOC	NPB
689GE	DANBURY, CT	CT	068	1	CBOC	PBO
689HA	WILLIMANTIC, CT	CT	062	1	CBOC	NPB
689HB	NORWICH, CT	CT	063	1	CBOC	NPB
689HC	NEW LONDON, CT	CT	063	1	CBOC	NPB
691	WEST LOS ANGELES, CA	CA	900	22	VAMC	PBH
691A4	SEPULVEDA, CA	CA	913	22	CBOC	PBO
691GA	WEST LOS ANGELES CBOC, CA	CA	900	22	CBOC	PBO
691GB	SANTA BARBARA, CA	CA	931	22	CBOC	NPB
691GC	GARDENA, CA	CA	902	22	CBOC	PBO
691GD	BAKERSFIELD, CA	CA	933	22	CBOC	NPB
691GE	LOS ANGELES CBOC, CA	CA	900	22	CBOC	PBO
691GF	EAST LOS ANGELES, CA	CA	900	22	CBOC	PBO
691GG	LANCASTER/ANTELOPE VALLEY, CA	CA	935	22	CBOC	NPB
691GK	SAN LUIS OBISPO, CA	CA	934	22	CBOC	NPB
691GL	LOMPOC, CA	CA	934	22	CBOC	NPB
691GM	PORT HUENEME/OXNARD, CA	CA	930	22	CBOC	NPB
691GN	LYNWOOD, CA	CA	902	22	CBOC	NPB
691GO	PASADENA, CA	CA	911	22	CBOC	NPB
692	WHITE CITY, OR	OR	975	20	DOM	PBO
692GA	KLAMATH FALLS, OR	OR	976	20	CBOC	NPB
693	WILKES-BARRE, PA	PA	187	4	VAMC	PBH
693B4	ALLENTOWN, PA	PA	181	4	CBOC	NPB
693GA	SAYRE, PA	PA	188	4	CBOC	NPB
693GB	WILLIAMSPORT, PA	PA	177	4	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations
Reasonable Charges Version 2.1


RC V2p1 Facility List 2004-4-1FR.xls

Page 16 of 16

Sta #	VA Facility Location	ST	ZIP 3	VN	Type	PB
693GC	TOBYHANNA, PA	PA	184	4	CBOC	PBO
693GD	SCRANTON, PA	PA	185	4	CBOC	PBO
693GE	POTTSVILLE/SCHUYLKILL/SHENA	PA	179	4	CBOC	PBO
693GF	BERWICK, PA	PA	186	4	CBOC	PBO
693HK	WILKES-BARRE MOC, PA	PA	187	4	CBOC	PBO
695	MILWAUKEE, WI	WI	532	12	VAMC	PBH
695BY	APPLETON, WI	WI	549	12	CBOC	NPB
695GA	UNION GROVE, WI	WI	531	12	CBOC	PBO
695GC	CLEVELAND, WI	WI	530	12	CBOC	NPB
695GD	GREEN BAY, WI	WI	543	12	CBOC	NPB
695HK	MILWAUKEE MOC, WI	WI	532	12	CBOC	NPB
756	EL PASO, TX	TX	799	18	IOC	PBO
756GA	LAS CRUCES, NM	NM	880	18	CBOC	NPB
757	COLUMBUS, OH	OH	432	10	IOC	PBO
757GA	ZANESVILLE, OH	OH	437	10	CBOC	NPB
757GB	GROVE CITY, OH	OH	431	10	CBOC	PBO
589DQ	WICHITA NON-VA HOSP, KS	KS	627	15	CMC	PBH
657DP	MARION NON-VA HOSPITALS, IL		629	15	CMC	PBH

Abbreviations**Code**

CBOC = Community-Based Outpatient Clinic
 DOM = Independent Domiciliary
 Fac # = VA Facility Number
 IOC = Independent Outpatient Clinic
 MOC = Mobile Outreach Clinic
 NPB = Non-Provider-Based Outpatient Facility 3
 PB = Provider-Based/Non-Provider-Based Designation
 PBH = Provider-Based Hospital 1
 PBO = Provider-Based Outpatient Facility 2
 ST = State
 VAMC = VA Medical Center
 VN = Veterans Integrated Service Network
 ZIP 3 = First three digits of ZIP Code
 CMC = Civilian Medical Center





Federal Register

Thursday,
April 15, 2004

Part III

Federal Trade Commission

**Public Workshop: Radio Frequency
Identification: Applications and
Implications for Consumers; Notice**

FEDERAL TRADE COMMISSION

Public Workshop: Radio Frequency Identification: Applications and Implications for Consumers

AGENCY: Federal Trade Commission (FTC).

ACTION: Notice announcing Public Workshop and Requesting Public Comment.

SUMMARY: The FTC is planning to host a public workshop that will explore the uses, efficiencies, and implications for consumers associated with radio frequency identification (RFID) technology. The workshop will address both current and anticipated uses of RFID tags and their impact on the marketplace.

DATES: The workshop will be held on Monday, June 21, 2004, from 8:30 a.m. to 5:30 p.m. at the Federal Trade Commission's Satellite Building, which is located at 601 New Jersey Avenue, NW., Washington, DC. The event is open to the public and there is no fee for attendance. Pre-registration is not required.

Requests to Participate as a Panelist: As discussed below, written requests to participate as a panelist must be received on or before Friday, May 7, 2004. Persons filing requests to participate as a panelist in the workshop will be notified on or before Friday, May 21, 2004, if they have been selected. For further instructions, please see the "Requests to Participate as a Panelist in the Workshop" section below.

Written Comments Filed in Paper or Electronic Form: Regardless of whether they are selected to participate, persons may submit written comments, in paper or electronic form, on the topics to be discussed by the panelists. Such comments must be received on or before Friday, May 21, 2004. For further instructions on submitting comments, please see the "Form and Availability of Comments" section below. To read our policy on how we handle the information you submit, please visit <http://www.ftc.gov/ftc/privacy.htm>.

ADDRESSES: Written comments and requests to participate as a panelist in the workshop should respectively refer to "RFID Workshop—Comment, P049106" or "RFID Workshop—Request to Participate, P049106" to facilitate the organization of comments and requests. A comment or request filed in paper form should include this reference both in the text and on the envelope, and the original and two copies should be mailed or delivered to the following address: Federal Trade Commission/Office of the Secretary, Room 159-H

(Annex G), 600 Pennsylvania Avenue, NW., Washington, DC 20580. Comments and requests containing confidential material must be filed in paper form, as explained in the Supplementary Information section. The Commission is requesting that any comment or request filed in paper form be sent by courier or overnight service, if possible, because U.S. postal mail in the Washington area and at the Commission is subject to delay due to heightened security precautions. Comments and requests to participate filed in electronic form (except comments containing any confidential material) should be sent, as prescribed in the Supplementary Information section, to the following email box: rfidworkshop@ftc.gov.

FOR FURTHER INFORMATION CONTACT: Julie K. Brof, Attorney, (206) 220-4475, Northwest Region, Federal Trade Commission, 915 Second Avenue, Suite 2896, Seattle, WA 98174. Prior to the workshop, an agenda and additional information for attendees will be posted on the FTC's Web site, <http://www.ftc.gov/bcp/workshop/rfid>.

SUPPLEMENTARY INFORMATION:

Background and Workshop Goals

The emergence of RFID as a technology with seemingly unlimited applications has implications for business and consumers alike. RFID plays an important role in supply chain management, enhancing efficiencies through multiple stages of production as well as in the retail environment. Consumers may already be using RFID tags on the highway, to buy gas and groceries, and to protect their pets. RFID also has enormous potential as a public safety and anti-counterfeiting tool and, as the cost of RFID chips declines, new applications will undoubtedly be developed. In the meantime, suppliers to major domestic retailers and the Department of Defense are rushing to comply with mandates for RFID use, as are drug manufacturers, spurred by a recent Food and Drug Administration initiative calling for RFID tags on pharmaceuticals by 2007.¹ As a result, investment in this technology is expected to jump from an estimated \$90 million in 2003 to potentially more than \$4 billion by 2008.²

The FTC's workshop, "Radio Frequency Identification: Applications and Implications for Consumers," will continue the Commission's efforts to address the impact on consumers of

new and significant technologies. The workshop will provide an opportunity to learn about how RFID works and to highlight its numerous and rapidly growing applications. It will also address the privacy and security concerns associated with RFID use, particularly on an item-level basis. By bringing together RFID proponents, privacy advocates, and other interested parties, the workshop will facilitate discussion of core public policy issues and encourage the development of best practices that capitalize on the efficiencies generated by RFID without compromising consumers' privacy and security.

Questions expected to be addressed at the workshop include:

1. What is RFID all about?
 - How does RFID technology work? How does it differ from UPC bar codes and other competing technologies?
 - RFID is a popular term and technology. What kinds of systems are properly defined as "RFID"?
2. How is RFID technology currently being deployed?
 - What are the significant commercial uses for RFID tags?
 - What are the current or intended applications of RFID technology in the public sector, such as food and drug safety?
 - How is RFID being used abroad? Are these uses different from or similar to domestic applications?
 - What impact will these global applications have upon domestic uses?
3. What is the future of RFID?
 - What additional applications are envisioned over the next decade and beyond?
 - What might constrain development of these applications?
4. How are consumers impacted by current and/or anticipated RFID uses?
 - What do consumers already know about RFID technology? Are there any studies that address consumer understanding of RFID?
 - What benefits may accrue to consumers from RFID technology? Which benefits do consumers value most?
 - Will RFID use in the supply chain impact the cost, availability, and quality of consumer goods and services? If so, in what way?
 - What privacy and security concerns do current and anticipated uses of RFID technology raise? Are they different from concerns raised by other, more familiar technologies or devices?
5. What approaches have led or will lead to use of RFID in a way that accommodates privacy and security concerns?
 - How can communication between RFID proponents and consumer

¹ Marc Kaufman, FDA Looks to Chips to Thwart Drug Counterfeiters, Washington Post, Feb. 19, 2004.

² RFID/IT Infrastructure worth \$4.2 billion next decade, Feb. 19, 2004, UsingRFID.com.

advocates be improved? Are there examples that can be followed?

- Do studies suggest that education can help protect consumers from threats to their privacy and security?
- Are there examples of "best practices" being implemented by business that address these issues?
- What legislative steps are underway domestically? Do these initiatives propose effective solutions? What are the consequences of a patchwork of state regulation?
- What technological or other solutions exist to remedy consumers' privacy and security concerns? How do the costs of these measures relate to their benefits?
- What is an appropriate role for the FTC at this juncture?

Requests To Participate as a Panelist in the Workshop

Parties seeking to participate as panelists in the workshop must notify the FTC in writing of their interest in participating on or before Friday, May 7, 2004, either by mail to the Secretary of the FTC or by e-mail to rfidworkshop@ftc.gov. Requests to participate as a panelist should be captioned "RFID Workshop—Request to Participate, P049106," and should be filed in the same manner as prescribed for written comments in the "Form and Availability of Comments" section below. Parties are asked to include in their requests a statement setting forth their expertise in or knowledge of the issues on which the workshop will focus and their contact information, including a telephone number, facsimile number, and e-mail address (if available), to enable the FTC to notify them if they are selected. For requests filed in paper form, an original and two copies of each document should be provided. Panelists will be notified on

or before Friday, May 21, 2004, whether they have been selected.

Using the following criteria, FTC staff will select a number of panelists to participate in the workshop. The number of parties selected will not be so large as to inhibit effective discussion among them.

1. The party has expertise in or knowledge of the issues that are the focus of the workshop.
2. The party's participation would promote a balance of interests being represented at the workshop.
3. The party has been designated by one or more interested parties (who timely file requests to participate) as a party who shares group interests with the designator(s).

Form and Availability of Comments

The FTC requests that interested parties, regardless of whether they are also seeking to participate as a panelist, submit written comments on the above questions to foster greater understanding of the issues. Especially useful are any studies, surveys, research, and empirical data. Written comments must be received on or before Friday, May 21, 2004, and may be filed in either paper or electronic form. Written comments should refer to "RFID Workshop—Comment, P049106" to facilitate the organization of comments. A comment filed in paper form should include this reference both in the text and on the envelope, and the original and two copies should be mailed or delivered to the following address: Federal Trade Commission/Office of the Secretary, Room 159-H (Annex G), 600 Pennsylvania Avenue, NW., Washington, DC 20580. If the comment contains any material for which confidential treatment is requested, it must be filed in paper (rather than electronic) form, and the first page of

the document must be clearly labeled "Confidential."³ The FTC is requesting that any comment filed in paper form be sent by courier or overnight service, if possible, because U.S. postal mail in the Washington area and at the Commission is subject to delay due to heightened security precautions. Comments filed in electronic form (except comments containing any confidential material) should be sent to the following e-mail box: rfidworkshop@ftc.gov.

The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. All timely and responsive public comments, whether filed in paper or electronic form, will be considered by the Commission, and will be available to the public on the FTC Web site, to the extent practicable, at <http://www.ftc.gov>. As a matter of discretion, the FTC makes every effort to remove home contact information for individuals from the public comments it receives before placing those comments on the FTC Web site. More information, including routine uses permitted by the Privacy Act, may be found in the FTC's privacy policy, at <http://www.ftc.gov/ftc/privacy.htm>.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 04-8625 Filed 4-14-04; 8:45 am]

BILLING CODE 6750-01-P

³ Commission Rule 4.2(d), 16 CFR 4.2(d). The comment must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. The request will be granted or denied by the Commission's General Counsel, consistent with applicable law and the public interest. See Commission Rule 4.9(c), 16 CFR 4.9(c).

1901
10 10

10 10



Federal Register

Thursday,
April 15, 2004

Part IV

Department of Homeland Security

8 CFR Part 103

Adjustment of the Immigration Benefit
Application Fee Schedule; Final Rule

DEPARTMENT OF HOMELAND SECURITY

8 CFR Part 103

[CIS No. 2233-02]

RIN 1615-AA84

Adjustment of the Immigration Benefit Application Fee Schedule

AGENCY: Department of Homeland Security, Bureau of Citizenship and Immigration Services.

ACTION: Final rule and confirmation of interim rules.

SUMMARY: This rule adjusts the fee schedule of the Immigration Examinations Fee Account (IEFA) for immigration benefit applications and petitions, as well as the fee for capturing biometric information of applicants or petitioners who apply for certain immigration benefits. Fees collected from persons filing immigration benefit applications are deposited into the IEFA and used to fund the full cost of providing immigration benefits; the full cost of providing similar benefits to asylum and refugee applicants; and the full cost of similar benefits provided to other immigrants, as specified in the regulation, at no charge. This rule adjusts the immigration benefit application fees by approximately \$55 per application, and increases the biometric fee by \$20, in order to ensure sufficient funding to process incoming applications. In addition, on January 24, 2003, and February 27, 2003, the former Immigration and Naturalization Service (INS) published two interim rules that first adjusted fees lower based on section 457 of the Homeland Security Act of 2002, and then readjusted the fees to preexisting levels, based upon the repeal of section 457. Accordingly, this final rule will adopt the two interim rules as final without change, and will adopt the fee structure that was proposed on February 3, 2004.

DATES: This final rule is effective April 30, 2004. Applications or petitions mailed, postmarked, or otherwise filed, on or after this date require the new fee.

FOR FURTHER INFORMATION CONTACT: Paul L. Schlesinger, Acting Budget Director, Office of Budget, U.S. Citizenship and Immigration Services, 425 I Street, NW., Room 5307, Washington, DC 20536, telephone (202) 514-3206.

SUPPLEMENTARY INFORMATION:

I. Introduction

The Bureau of Citizenship and Immigration Services (BCIS) published a proposed rule in the *Federal Register* on February 3, 2004, at 69 FR 5088, to

adjust the application fee schedule of the IEFA. The proposed rule was published with a 30-day comment period, which closed on March 4, 2004. The BCIS received 278 comments pertaining to the adjustment of the immigration benefit application fee schedule. This final rule implements the fee structure as outlined in the proposed rule, without change except for several nonsubstantive technical changes (described further below) to update references in light of the Homeland Security Act and revise references to fees that relate to Department of Justice (DOJ) proceedings in light of DOJ fee regulations at 8 CFR parts 1003 and 1103. Any applications or petitions mailed, postmarked, or otherwise filed, on or after April 30, 2004, will require the new fee.

Comments were received from a broad spectrum of individuals and organizations, including 1 caucus of members of Congress, 16 refugee and immigrant service organizations, 15 public policy and advocacy groups, 8 educational institutions, 8 attorney organizations, 2 public corporations, 37 past and present adopting parents, 2 municipalities, and 189 other concerned individuals. Many commenters addressed multiple issues in their comments, and as a result, the number of comments discussed below in reference to specific issues exceeds the total number of comments received. All of the comments were carefully considered before preparing this final rule.

In addition, on January 24, 2003 (at 68 FR 3798), and February 27, 2003 (at 68 FR 8989), the former INS published interim rules first adjusting fees lower, and then readjusting them to the preexisting levels, based upon section 457 of the Homeland Security Act of 2002, Public Law 107-296, and the subsequent repeal of section 457 in section 107 of the Homeland Security Act Amendments of 2003, Div. L. of Public Law 108-7. The former INS received five comments on the January 24 rule and one comment on the February 27 rule. Comments included urging the BCIS to seek appropriated funding to pay for asylum and refugee services instead of application fees, and contending that the high fees are putting the benefit of naturalization beyond the reach of many of our nation's immigrants. In creating the Immigration Examinations Fee Account, Congress intended that the activities supported by this account be self-sustaining, and not be funded by tax dollars (Pub. L. 100-459), with the exception of appropriated funds dedicated specifically towards backlog reduction. The BCIS has been

managing this account consistent with federal law and congressional direction. Additionally, the BCIS does have the ability to waive fees on a case-by-case basis. Any applicant or petitioner who has an "inability to pay" the fees may request a fee waiver. This final rule adopts the fee structure proposed on February 3, 2004, but, in so doing, the BCIS has reviewed and considered the comments made in response to the January 24, 2003, and February 27, 2003, interim rules.

The following is a discussion of the comments received for the February 3, 2004, proposed rule and the BCIS' response.

II. Summary of Comments

A. Form I-600/600A, Petition to Classify an Orphan as an Immediate Relative/ Application for Advance Processing of Orphan Petitions

Forty-two comments were received expressing dissatisfaction with the fee increases associated with Forms I-600 and I-600A, Petition to Classify an Orphan as an Immediate Relative, and the Application for Advance Processing of Orphan Petition, respectively. The combined cost of the Form I-600 and Form I-600A (\$525) necessarily reflects the fact that the Form I-600 and Form I-600A consist of two separate, highly labor-intensive adjudications.

Adjudication of the Forms I-600 and I-600A "orphan petitions" has been, and continues to be, a priority as evidenced by the commitment established in the regulations at 8 CFR 204.3(a)(2). Specifically, orphan petitions are filed at district offices and adjudicated by experienced District Adjudication Officers. This is due to both the complexity of the international adoption process in general and the adjudication process required by statute and regulation. In addition, because of the importance the BCIS places on international adoptions, handling these cases in district offices by experienced officers allows for personalized customer service. District Adjudication Officers may be in constant contact with the petitioner throughout the process of a U.S. citizen's effort to adopt a child from abroad. The earliest contact may be a request for information and forms, followed by the filing of the Form I-600A and the home study. The adjudication of the Form I-600A petition requires knowledge of State law requirements regarding adoptions, including pre-adoption requirements such as counseling in certain States. Each petition must be accompanied by a home study, for which there are State requirements as well as Federal

requirements. Since there is no single national standard, it makes sense to assign these petitions to adjudication officers located in district offices that are better able to stay on top of ever-changing State requirements and establish effective local liaisons.

The home study process is complex and often the adjudication officer must request that additional information be provided in the home study. When the child to be adopted is identified, further information and contact may ensue. To accommodate prospective adoptive parents, the BCIS allows petitioners to submit supporting evidence after initial filing of a Form I-600A. Thus, documentation is usually added to the petition as the adoption process progresses. It is not unusual for a case to be with the BCIS for several months, demanding an intense and protracted level of customer service. There may be frequent communications in person, telephonically, and in writing, between the BCIS, adoption agencies, social workers, and prospective adoptive parents.

The home study review makes this petition particularly labor-intensive. The adjudication officer is tasked with the careful review of the home study, perhaps 10-20 pages long, addressing a number of issues including any history of abuse or arrests. This information is carefully compared against Federal Bureau of Investigation (FBI) fingerprint checks. If necessary, the officer must request and review the arrest dispositions of petitioners with criminal records. When there are discrepancies, the home study must be revised or supplemented to include the new information and consider the impact it has on the placement.

The Form I-600 petition establishes eligibility of a child as an orphan. Adjudication of these petitions requires the BCIS to determine if the child meets the regulatory definition of an orphan. Accordingly, the adjudication officer must develop and maintain a level of expertise in the laws and processes governing adoption in countries from which children are adopted. This assessment may require working with the Department of State or BCIS offices overseas to verify the validity of documents and interpret laws regarding international adoptions in countries other than the United States.

Finally, the Form I-600 adjudication also includes a Form I-604 investigation. The Form I-604, *Request for and Report on Overseas Orphan Investigation*, is used to document the investigations that must be completed in every orphan case before the Form I-600 can be approved. It includes: The

child's birth name; date and place of birth; where the child lives; and if the child lives at an orphanage or with someone other than the biological parent(s), how and why that placement occurred; the child's physical and mental condition, and information about any known physical or mental illnesses (e.g., is the child a special needs child); if the child has siblings, and if so, if the child lives with the brothers or sisters; information concerning the child's biological parents and the determination that the child is an orphan because he or she has a "sole parent" or "surviving parent" (as defined in the regulations); and any other pertinent facts that the investigation uncovers. The purpose of the investigation is to verify that the child is an orphan, address specific concerns articulated by the adjudicating officer or consular officer that can only be resolved by an investigation, and resolve significant differences between the facts presented in the advanced processing application (Form I-600A) or advanced processing of the application (a Form I-600 approved by a BCIS office in the United States) and evidence available at later stages of processing. The investigation is conducted at the overseas visa-issuing post by the BCIS, or by the Department of State if there is no BCIS office at that U.S. Embassy or Consulate. A Form I-604 investigation may require a field investigation entailing travel to a remote location to establish whether or not a child is actually an orphan.

Since the BCIS relies on fees to recover the full cost of processing immigration and naturalization benefits, the increase in fees for the Forms I-600 and I-600A to \$525 is necessary to recover the full costs associated with processing orphan petitions, including security enhancements instituted post September 11, 2001. Accordingly, the BCIS will charge a fee of \$525 for processing Forms I-600 and I-600A.

B. How Will the BCIS Improve Service?

One hundred and eighty-one comments were received opposing the increase in the fees given the current level of services provided by the BCIS. Many people noted the lengthy waiting times to process their benefit applications as well as the need to improve overall customer service.

The BCIS has made progress in many areas of customer service such as eliminating the lines at a number of its offices (including New York and Miami), introducing on-line options for certain application filing and case status updates, and establishing a bilingual, toll-free customer help-line.

Nonetheless, the BCIS is committed to taking further steps to fundamentally transform the administration of citizenship and immigration services. Over the coming year, the BCIS will prioritize customer service and improve application processing times, in addition to security. The agency has already begun implementing significant information technology and process improvements including electronic filing for certain immigration benefit applications. In FY 2002, the President launched a multi-year initiative to eliminate the application backlog and ensure a six-month processing time standard for all immigration benefit applications. The FY 2005 Budget provides an additional \$60 million in appropriated funds to support this effort for a total of \$160 million in funds available for the backlog efforts. The BCIS plans to achieve the President's goal by FY 2006.

A number of commenters also suggested that the high fees are putting immigration benefits beyond the reach of many of our nation's immigrants. The BCIS does have the ability to waive fees on a case-by-case basis. Any applicant or petitioner who has an "inability to pay" the fees may request a fee waiver. However, it should be noted that the biometric fee cannot be waived.

A number of commenters also made specific service improvement ideas, including extending validity periods for Employment Authorizations and Advance Parole documents beyond the current one year, issuing fewer Requests for Evidence, and using SEVIS (Student and Exchange Visitor Information System) information more broadly for other adjudication purposes. The BCIS welcomes public input in this area and will consider it as it moves forward to improve customer service. To the extent processing improvements can be adopted in the future that further increase efficiency or reduce costs, they will be taken into account in any future fee adjustments.

Lastly, a number of commenters mentioned the recent General Accounting Office (GAO) Report on *Immigration Application Fees: Current Fees Are Not Sufficient to Fund U.S. Citizenship and Immigration Services' Operations*. Comments noted that the BCIS does not have a system to track the status of each application as it moves through the process. While such a system undoubtedly would provide additional information on the cost to process pending applications, it is not necessary in order to identify the cost elements that have led to shortfalls in the IEFA, will continue to be incurred, and must be recovered for the BCIS to

process applications. Those costs, as discussed in the proposed and this final rule, are the basis for these fee adjustments. Furthermore, the GAO also concluded that the existing fee schedule is not sufficient to fully fund the BCIS's operations, that the current fee schedule is based on a fee study that did not include all costs of the BCIS's operations, and that costs have increased due to additional processing requirements and other actions not covered by current fees.

Several commenters noted the significant percentage increase in the application fees over the last several years. The vast majority of this increase is attributed to an exhaustive fee review completed in FY 1997, employing an activity-based costing (ABC) methodology to more accurately capture the direct and indirect costs of providing immigration and naturalization services. The ABC methodology represented a significantly improved methodology over previous ones employed by the former INS. This methodology involved time and motion studies to capture the cycle times of individual form types, and allowed the former INS to identify the individual costs of activities involved in the processing of each application and petition. The methodology also allowed for the recovery of costs of services provided to other immigrants at no charge, including services to refugees and asylum applicants. This improved methodology was the basis for the significant fee increases in FY 1999. A General Accounting Office report in September 1998, entitled "INS User Fee Revisions," reviewed this methodology and concluded that "On the basis of our discussions with OMB staff and our review of INS' efforts to identify the costs associated with processing applications, we believe that INS complied, to the extent it was able, with available OMB guidance that requires agencies to recover the full costs of providing services." The fee adjustments in this rule are based on an incremental increase in application costs of this established methodology.

C. Fee Increases are Necessary

Fifty-six comments were received in favor of the fee increases. In general, these can be divided into two groups: those who supported the proposed fee increases as long as they are accompanied with actual significant improvements in processing times and other customer service, and those whose support for increased fees was not coupled with any stated concern about BCIS customer service. A few commenters stated that the fee increases

should be higher. Several others suggested expanding the premium processing fee to the Form I-485 or other BCIS applications, while still others supported sharp increases in EB-5 fees to support the regional center program. Although the reasons provided for supporting the fee increases, or for supporting higher fees, varied substantially from general concerns about immigration levels or the Federal deficit to more specific points about immigration benefit processing, several of the more frequently stated rationales included:

- (1) Current fees are too low in relation to the value of the benefit received (U.S. citizenship, for example);
- (2) Taxpayers should not pay for the increasing costs of providing immigration and naturalization benefits;
- (3) Fee increases are necessary to enhance security;
- (4) Fee increases are justified given the increasing demand for immigration and naturalization benefits over the last several years; and
- (5) Fee increases are necessary in order to increase the current level of services.

The BCIS believes that the proposed fee increases will lead to and support improved services as previously stated, and disagrees with those commenters who stated that the increases are too small. The BCIS also notes that the \$1,000 premium processing fee is a statutory authorization (section 286(u) of the Immigration and Nationality Act) specifically limited to employment-based applications and petitions, and does not seek in this final rule to expand the premium processing service.

D. Why Is BCIS Raising the Fees Instead of Seeking Additional Sources of Funding?

Seventeen commenters urged BCIS to seek additional appropriated funds to cover the costs of military naturalizations, the Refugee Corps, and other immigration benefit services, especially those that the commenters perceived as not directly related to the actual adjudication of the specific application for which the fee was paid. In creating the Immigration Examinations Fee Account, Congress intended that the activities supported by this account be self-sustaining, and not be funded by tax dollars (Pub. L. 100-459), with the exception of appropriated funds dedicated specifically towards backlog reduction. The BCIS has been managing this account consistent with Federal law and congressional direction.

Some of the individual cost elements are discussed more specifically below. With respect to all of the challenged

elements, however, the costs are either: (1) Part of the full direct and indirect costs of providing the adjudication to the applicant under the principles of Office of Management and Budget (OMB) Circular A-25, which allocate costs to include, but not be limited to, an appropriate share of direct and indirect personnel costs, physical overhead, consulting, other indirect costs, and management and supervisory costs; or (2) are part of the full costs of providing services to immigrants other than the applicant, as authorized by section 286(m) of the Act; or both.

In a variant on these comments, at least one commenter suggested that because security checks and some other aspects of immigration services funded by these fees provide a public rather than a purely personal benefit, the increases are unwarranted and beyond the scope of the authorizing statutes. Security checks are an integral part of determining the applicant's eligibility for a benefit and are appropriately an item that may be fully recovered through the applicable fee under the OMB Circular A-25 guidance. In addition, the fact that a process benefits the public interest as well as a private party does not mean that it cannot be funded by a user fee paid by the private party. Rather, when the service enables the beneficiary to obtain more immediate or substantial gains or values than those that accrue to the general public, a user fee is appropriate. The entire legal immigration and citizenship process—with respect both to grants of benefits and to denials for national security or other reasons—is one that benefits the public as well as private interests, but its focus on the adjudication of eligibility for individual benefits, as confirmed by section 286(m) of the Act and other broadly-based fee authorizing provisions, makes the fee-based structure entirely lawful and appropriate even when the public as a whole benefits as a result. As OMB Circular A-25 states at paragraph 6.a.3, "when the public obtains benefits as a necessary consequence of an agency's provision of special benefits to an identifiable recipient (*i.e.*, the public benefits are not independent of, but merely incidental to, the special benefits), an agency need not allocate any costs to the public and should seek to recover from the identifiable recipient either the full cost to the Federal Government of providing the special benefit or the market price, whichever applies." Furthermore, under the authority of section 286(m) of the Act, user fees may be used—and are used now—not only for the benefit of the user

who paid them and any collateral benefit resulting to the public, but also to benefit the interests of certain others, such as asylum applicants, who do not pay fees.

Some of these commenters suggested, in effect, that fees should be funding of last recourse for immigration services; that is, that the BCIS should be required to have exhausted all possible means of seeking appropriated funds before imposing fee increases. The BCIS disagrees with this characterization. The Immigration and Nationality Act authorizes the recovery of the full costs of providing immigration and naturalization services, including services provided free of charge to many applicants, through application fees. It does not require the BCIS either to seek or to obtain other sources of funding for this purpose, although the President has requested, and Congress to date has provided, appropriations to supplement fee revenues in the area of backlog reduction.

One commenter expressed surprise that the proposed rule had not cited 8 U.S.C. 1573 and other indicia of Congress's strong interest in backlog reduction and directive to the BCIS to achieve this goal. The proposed rule discussed those legal authorities most directly relevant to fee-setting authority. The BCIS agrees with the commenter that Congress desires it to reduce backlogs, and seeks in this rule to obtain a level of resources that will prevent existing backlogs actually from increasing.

E. Litigation Settlements

Six commenters strongly objected to the inclusion of litigation costs as an element in the fee adjustment calculation. As one commenter correctly stated, "The Equal Access to Justice Act ('EAJA') mandates that government agencies pay certain costs when they take a substantially unjustified position in litigation." What the commenter describes as "certain costs" are, more specifically, attorneys' fee awards, which must be paid from agency budgets rather than from the Judgment Fund. See 28 U.S.C. 2412(d).

The commenters' assumption that these payments necessarily result from "lost" cases and EAJA awards by courts, though, is mistaken. Most attorneys' fee payments arise from settlements in which the government admits neither legal liability under EAJA or any other statute, nor that its position was unjustified—and in fact maintains that its course of conduct was legally correct—but in which the posture of the case, risk management concerns, and the public interest support settling the

case and putting the litigation to rest. These are cases in which settlement mutually benefits both parties, otherwise it would not happen. It is not accurate to state or imply that when the United States settles civil litigation with an agreement that includes payment of attorneys' fees it necessarily has "lost" the case or has by the fact of settlement and payment in any way conceded that its conduct was unlawful or its legal position unjustified.

The comments also fail to recognize that most attorneys' fee payments are currently paid out of fee receipts. That is the way a fee-funded agency, without appropriated funds designated for that purpose, is able to pay them. Accounting for these costs in fee-setting is not a new imposition on the fee-paying public. In other words, this fee increase only changes the form in which the fee-paying public bears the cost of attorneys' fee payments from reduced service on the back end to a very slightly higher fee payment up front.

The BCIS seeks to minimize its litigation exposure by seeking to take responsible legal positions both with respect to setting policies in the first place and the merits of lawsuits against it. The BCIS would greatly prefer not to have to pay attorneys' fees from its budget as opposed to what it would view as more productive uses of resources, but it recognizes its potential obligations under the EAJA statute. It also recognizes that it cannot avoid a measure of litigation exposure as a cost of doing the public's business, and it would not be responsible to pretend that these costs do not exist or that they have no financial effect on the agency's fee-funded operations.

Instead, the BCIS believes that the more appropriate and responsible course of action is to account for attorneys' fee awards, based on actual experience with these costs as an unavoidable element of providing immigration services. It does this so that the provision of adjudication services to fee-paying and other BCIS customers will not be negatively affected by them. To do so does not encourage taking unjustified positions in litigation.

F. Competitive Sourcing Study

Six commenters objected to the inclusion of the cost of a competitive sourcing study. The BCIS needs to be open to new methods of providing immigration and naturalization services that may in time save the fee-paying public both time and money, and this openness from time to time requires up-front investment. Whether that is the case with outsourcing immigration information officers remains to be seen;

that is the purpose of the study. Some of the comments appear to be based upon objection to outsourcing this or other functions. While the BCIS respects that view, it disagrees that it is an appropriate basis not to continue with or to fund the study to determine whether it is a substantially valid view in this instance.

G. Nicaraguan Adjustment and Central American Relief Act (NACARA) fees

One commenter objected to increasing fees for NACARA-related applications, primarily on the ground that as an established program with known standards for adjudication, the cost of processing should be declining. In response, the BCIS notes that the fee adjustments relate to costs, including security enhancements conducted since July 2002, that affect NACARA applicants as much as any others. In addition, the premise of the comment that experience with a particular program necessarily results in reduced processing costs is incorrect. The basic nature of a NACARA adjudication—reviewing the evidence in the application and case file (which may be voluminous) in light of relevant legal standards and conducting security and other necessary record checks—is the same now as it was when the program began.

H. Refugee Corps

Eleven commenters objected to funding refugee processing with fee revenues. Although the commenters supported free refugee services, in their view appropriated funds should be used pay for them. This subject has frequently been discussed in former INS rule making publications relating to fees. In repealing section 457 of the Homeland Security Act of 2002 in Public Law 108-7, and thereby restoring the authority of the BCIS to set fees at a level that will recover the costs of refugee and asylum processing, fee waivers, and other free services, Congress reaffirmed its expectation that such services be paid for through the fee account, after a brief period during which it had withdrawn that authority.

I. Inflation Adjustment

Several commenters expressed concern about the provision for inflation adjustments through future notice in the **Federal Register**, including a contention that the phrase "inflation rate enacted by Congress" was not clear or specific. This provision will permit the BCIS to adjust on a timely basis for regular, fixed increases in costs based on Federal civilian pay increases and non-pay inflationary increases. The BCIS agrees

that the phrase should be clarified to more specifically refer to Federal civilian salary and benefits costs and non-pay costs and therefore has revised the regulation to reference the pay and non-pay inflation adjustments that the Office of Management and Budget (OMB) issues annually for agency use in implementing OMB Circular A-76,

Performance of Commercial Activities. In other words, the regulation will enable BCIS to adjust its fees and charges on an annual basis using the inflationary adjustments that the Federal government already uses under Circular A-76 to reflect the impact of inflation on agency costs. If Congress enacts a Federal civilian pay inflation

factor that is different than the factor issued by OMB for Circular A-76, BCIS may adjust for these costs during the current year or in a following year.

III. Fee Adjustments

The fee adjustments, as adopted in this rule, are shown as follows:

NEW APPLICATION AND PETITION FEES

Form No.	Description	Fee
I-90	Application to Replace Permanent Resident Card	\$185
I-102	Application for Replacement/Initial Nonimmigrant Arrival/Departure Record	155
I-129	Petition for a Nonimmigrant Worker	185
I-129F	Petition for Alien Fiance(e)	165
I-130	Petition for Alien Relative	185
I-131	Application for Travel Document	165
I-140	Immigrant Petition for Alien Worker	190
I-191	Application for Permission to Return to an Unrelinquished Domicile	250
I-192	Application for Advance Permission to Enter as a Nonimmigrant	250
I-193	Application for Waiver of Passport and/or Visa	250
I-212	Application for Permission to Reapply for Admission into the U.S. After Deportation or Removal	250
I-360	Petition for Amerasian, Widow(er), or Special Immigrant	185
I-485	Application to Register Permanent Residence or to Adjust Status	315
I-526	Immigrant Petition by Alien Entrepreneur	465
I-539	Application to Extend/Change Nonimmigrant Status	195
I-600/600A	Petition to Classify Orphan as an Immediate Relative/Application for Advance Processing or Orphan Petition	525
I-601	Application for Waiver of Grounds of Excludability	250
I-612	Application for Waiver of the Foreign Residence Requirement	250
I-687	For Filing Application for Status as a Temporary Resident	240
I-690	Application for Waiver of Excludability	90
I-694	Notice of Appeal of Decision	105
I-695	Application for Replacement Employment Authorization or Temporary Residence Card	65
I-698	Application to Adjust Status from Temporary to Permanent Resident	175
I-751	Petition to Remove the Conditions on Residence	200
I-765	Application for Employment Authorization	175
I-817	Application for Family Unity Benefits	195
I-824	Application for Action on an Approved Application or Petition	195
I-829	Petition by Entrepreneur to Remove Conditions	455
I-881	NACARA—Suspension of Deportation or Application for Special Rule Cancellation of Removal for adjudication by the Department of Homeland Security.	275
I-881	NACARA—Suspension of Deportation or Application for Special Rule Cancellation of Removal for adjudication by the Immigration Court.	155
I-914	Application for T Nonimmigrant Status	255
N-300	Application to File Declaration of Intention	115
N-336	Request for Hearing on a Decision in Naturalization Procedures	250
N-400	Application for Naturalization	320
N-470	Application to Preserve Residence for Naturalization Purposes	150
N-565	Application for Replacement Naturalization Citizenship Document	210
N-600	Application for Certification of Citizenship	240
N-600K	Application for Citizenship and Issuance of Certificate under Section 322	240
	For Capturing Biometric Information	70

IV. Technical Improvements

This final rule also makes several minor, nonsubstantive changes to 8 CFR 103.7 that were not included in the proposed rule. In particular, these changes replace references to the former INS with reference to the Department of Homeland Security (DHS). In so doing, they conform the published text of the regulations with the changes already in fact made to them by the "deeming" provision (section 1512(d)) of the Homeland Security Act. The changes also remove references to Department of Justice forms and procedures now

covered by 8 CFR part 1003. The reference to the discontinued Form I-290A, which was replaced in 1996 by Forms EOIR-26 and EOIR-29, has also been removed.

The Department of Justice intends to make similar updates and improvements to its regulations in 8 CFR parts 1003 and 1103. Until conforming changes are promulgated, the fee adjustments made by this final rule shall supersede any fee amounts stated in 8 CFR 1103.7(b) with respect to any fee paid to the Department of Homeland Security by any person,

including any alien in proceedings before the Executive Office for Immigration Review, to the extent there are any inconsistencies between the fees as stated in the two regulations.

Good Cause Exception

Although this rule falls under the category of major rule as that term is defined in 5 U.S.C. 804(2)(A), the DHS finds that under 5 U.S.C. 808(2) and 5 U.S.C. 553(d)(3) good cause exists to make the rule take effect 15 days from the date of publication in the **Federal Register**, for the following reasons: the

BCIS must collect fee funds to provide immigration and naturalization benefits, but absent prompt change in the fee schedule, the BCIS will not have sufficient resources to process immigration benefit applications and adequately perform its mission. In particular, the security enhancements funded by the increased fees are important to the national security interests of the United States. To continue performing comprehensive security enhancements to fully meet homeland security needs, it is essential that the BCIS recover the costs of this workload as promptly as possible. In addition, implementing this rule at the earliest feasible date will assist the BCIS in enhancing its services and reducing processing times, which is to the benefit of BCIS customers and the public interest. In particular, the vast majority of customers who do not present a danger to the national security or public safety will benefit from the increased resources available in this fiscal year through more rapid implementation. Accordingly, the DHS finds that it would be contrary to the public interest for this rule to go into effect 60 days after its publication, and that there is good cause for the rule to go into effect 15 days from its publication. In order to assist the public and mitigate any potential harmful effect on customers as a result of this implementation schedule, the BCIS plans an aggressive outreach and informational campaign involving the internet and other media resources.

Regulatory Flexibility Act

This rule has been reviewed in accordance with 5 U.S.C. 605(b), and the Department of Homeland Security certifies that this rule will not have a significant economic impact on a substantial number of small entities. The majority of applications and petitions are submitted by individuals and not small entities as that term is defined in 5 U.S.C. 601(6).

BCIS acknowledges, however, that a number of small entities, particularly those filing business-related applications and petitions, such as Form I-140, Immigrant Petition for Alien Worker; Form I-526, Immigrant Petition by Alien Entrepreneur; and Form I-829, Petition by Entrepreneur to Remove Conditions, may be affected by this rule. For the FY 2004/2005 biennial time period, BCIS projects that approximately 190,000 Forms I-140, 435 Forms I-526, and 508 Forms I-829 will be filed. This volume represents petitions filed by a variety of businesses, ranging from large multinational corporations to small domestic

businesses. However, even if all of the employers applying for benefits met the definition of small businesses, the resulting degree of economic impact would not require a Regulatory Flexibility Analysis to be performed. None of the public comments indicated that the rule would have a significant economic impact on small entities.

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local and tribal governments, in the aggregate, or by the private sector of \$100 million or more in any one year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is a major rule as defined by section 804 of the Small Business Regulatory Enforcement Act of 1996. This rule will result in an annual effect on the economy of more than \$100 million, in order to generate the revenue necessary to fully fund the increased cost associated with the processing of immigration benefit applications and associated support benefits; the full cost of providing similar benefits to asylum and refugee applicants; and the full cost of similar benefits provided to other immigrants, as specified in the regulation, at no charge. The increased costs will be recovered through the fees charged for various immigration benefit applications.

Executive Order 12866

This rule is considered by the Department of Homeland Security to be a "significant regulatory action" under Executive Order 12866, section 3(f), Regulatory Planning and Review. The implementation of this final rule would provide BCIS with an additional \$232 million in FY 2004 and \$394 million in FY 2005 in annual fee revenue, based on a projected annual fee-paying volume of 6.8 million applications and petitions, over the fee revenue that would be collected under the current fee structure. This increase in revenue will be used pursuant to subsections 286(m) and (n) of the Immigration and Nationality Act (Act) to fund the full costs of processing immigration benefit applications and associated support benefits; the full cost of providing similar benefits to asylum and refugee applicants; and the full cost of similar benefits provided to other immigrants at no charge. Activities not directly comprising the processing of fee paid-

applications are discussed elsewhere in the preamble, such as the section of the summary of the comments entitled "Refugee Corps" and "Why is BCIS Raising the Fees Instead of Seeking Additional Sources of Funding?". If the BCIS does not adjust the current fees to recover the full costs of processing immigration benefit applications, the backlog will likely increase. The revenue increase is based on BCIS' costs and projected volumes that were available at the time of the rule. Accordingly, this rule has been submitted to the Office of Management and Budget for clearance.

Executive Order 13132

This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with section 6 of Executive Order 13132, the Department of Homeland Security has determined that this rule does not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement.

Executive Order 12988: Civil Justice Reform

This rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988.

Paperwork Reduction Act

Under the Paperwork Reduction Act of 1995, Public Law 104-13, 109 Stat. 163 (1995), all Departments are required to submit to OMB, for review and approval, any reporting or recordkeeping requirements inherent in a rule. This rule does not impose any new reporting or recordkeeping requirements under the Paperwork Reduction Act.

However, it should be noted that BCIS solicited public comments on the change of fees in the proposed rule which was published in the **Federal Register** on February 3, 2004. It should also be noted that the changes to the fees will require changes to the application/petition forms to reflect the new fees. OMB has approved changes to the appropriate forms, consistent with the provisions in this final rule.

List of Subjects in 8 CFR Part 103

Administrative practice and procedures, Authority delegations (government agencies), Freedom of Information, Privacy, Reporting and recordkeeping requirements, Surety bonds.

■ Accordingly, the interim rules amending 8 CFR part 103 which were published at 68 FR 3798 on January 24, 2003, and 68 FR 8989 on February 27, 2003, are adopted as a final rule without change. In addition, part 103 of chapter I of title 8 of the Code of Federal Regulations is amended as follows:

PART 103—POWERS AND DUTIES; AVAILABILITY OF RECORDS

■ 1. The authority citation for part 103 continues to read as follows:

Authority: 5 U.S.C. 301, 552, 552(a); 8 U.S.C. 1101, 1103, 1304, 1356; 31 U.S.C. 9701; Public Law 107-296, 116 Stat. 2135 (6 U.S.C. 1 *et seq.*); E.O. 12356, 47 FR 14874, 15557; 3 CFR, 1982 Comp., p. 166; 8 CFR part 2.

- 2. Section 103.7 is amended by:
 - a. Revising paragraph (a);
 - b. In paragraph (b), by removing the entry "For fingerprinting by the Service" and adding the entry "For capturing biometric information" in its place, and by revising the entries for the forms set forth below, except for Form N-600K;
 - c. Adding the entry for "Form N-600K" and revising the entry for "Motion" the second time it appears in paragraph (b)(1);
 - d. Removing the entries "Form EOIR-40", "Form EOIR-42", "Form I-290A", "Form N-643", and "Motion" the first time it appears in paragraph (b)(1);
 - e. Revising paragraph (b)(2);
 - f. Adding new paragraphs (b)(3) and (b)(4); and by
 - g. Revising paragraph (c).

The revisions and additions read as follows:

§ 103.7 Fees.

(a) Remittances.

(1) Fees shall be submitted with any formal application or petition prescribed in this chapter in the amount prescribed by law or regulation. Except for fees remitted directly to the Board of Immigration Appeals pursuant to the provisions of 8 CFR 1003.8, or as the Attorney General otherwise may provide by regulation, any fee relating to any Department of Justice Executive Office for Immigration Review proceeding shall be paid to, and accepted by, any BCIS office authorized to accept fees. The immigration court does not collect fees. Payment of any fee under this section does not constitute filing of the document with the Board of Immigration Appeals or with the Immigration Court. The Department of Homeland Security shall return to the payer, at the time of payment, a receipt for any fee paid. The BCIS shall also return to the payer any documents, submitted with the fee, relating to any Immigration Court proceeding.

(2) Remittances must be drawn on a bank or other institution located in the United States and be payable in United States currency. Fees in the form of postage stamps shall not be accepted. Remittances to the Department of Homeland Security shall be made payable to the "Department of Homeland Security" except that in case of applicants residing in the Virgin Islands of the United States, the remittances shall be made payable to the "Commissioner of Finance of the Virgin Islands" and, in the case of applicants residing in Guam, the remittances shall be made payable to the "Treasurer, Guam." If an application to the Department of Homeland Security is submitted from outside the United States, remittance may be made by bank international money order or foreign draft drawn on a financial institution in the United States and payable to the Department of Homeland Security. Remittances to the Board of Immigration Appeals shall be made payable to the "United States Department of Justice," in accordance with 8 CFR 1003.8. A charge of \$30.00 will be imposed if a check in payment of a fee or any other matter is not honored by the bank or financial institution on which it is drawn. A receipt issued by a Department of Homeland Security officer for any remittance shall not be binding upon the Department of Homeland Security if the remittance is found uncollectible. Furthermore, legal and statutory deadlines will not be deemed to have been met if payment is not made within 10 business days after notification by the Department of Homeland Security of the dishonored check.

(b) * * *
(1) * * *

* * * * *
For capturing biometric information. A service fee of \$70 will be charged for any individual who is required to have biometric information captured in connection with an application or petition for certain immigration and naturalization benefits (other than asylum), and whose residence is in the United States.

* * * * *

Form I-90. For filing an application for a Permanent Resident Card (Form I-551) in lieu of an obsolete card or in lieu of one lost, mutilated, or destroyed, or for a change in name—\$185.

* * * * *

Form I-102. For filing a petition for an application (Form I-102) for Arrival/Departure Record (Form I-94) or Crewman's Landing (Form I-95), in lieu of one lost, mutilated, or destroyed—\$155.

Form I-129. For filing a petition for a nonimmigrant worker—\$185.

* * * * *

Form I-129F. For filing a petition to classify a nonimmigrant as a fiancée or fiancé under section 214(d) of the Act—\$165.

Form I-130. For filing a petition to classify status of an alien relative for issuance of an immigrant visa under section 204(a) of the Act—\$185.

Form I-131. For filing an application for travel documents—\$165.

Form I-140. For filing a petition to classify preference status of an alien on the basis of profession or occupation under section 204(a) of the Act—\$190.

Form I-191. For filing an application for discretionary relief under section 212(c) of the Act—\$250.

Form I-192. For filing an application for discretionary relief under section 212(d)(3) of the Act, except in an emergency case, or where the approval of the application is in the interest of the United States Government—\$250.

Form I-193. For filing an application for waiver of passport and/or visa—\$250.

Form I-212. For filing an application for permission to reapply for an excluded, deported or removed alien, an alien who has fallen into distress, an alien who has been removed as an alien enemy, or an alien who has been removed at government expense in lieu of deportation—\$250.

* * * * *

Form I-360. For filing a petition for an Amerasian, Widow(er), or Special Immigrant—\$185, except there is no fee for a petition seeking classification as an Amerasian.

Form I-485. For filing an application for permanent resident status or creation of a record of lawful permanent residence—\$315 for an applicant 14 years of age or older; \$215 for an applicant under the age of 14 years; no fee for an applicant filing as a refugee under section 209(a) of the Act.

* * * * *

Form I-526. For filing a petition for an alien entrepreneur—\$465.

Form I-539. For filing an application to extend or change nonimmigrant status—\$195.

* * * * *

Form I-600. For filing a petition to classify an orphan as an immediate relative for issuance of an immigrant visa under section 204(a) of the Act. (When more than one petition is submitted by the same petitioner on behalf of orphans who are brothers or sisters, only one fee will be required.)—\$525.

Form I-600A. For filing an application for advance processing of orphan petition. (When more than one petition is submitted by the same petitioner on behalf of orphans who are brothers or sisters, only one fee will be required.)—\$525.

Form I-601. For filing an application for waiver of ground of inadmissibility under section 212(h) or (i) of the Act. (Only a single application and fee shall be required when the alien is applying simultaneously for a waiver under both those subsections.)—\$250.

Form I-612. For filing an application for waiver of the foreign-residence requirement under section 212(e) of the Act—\$250.

Form I-687. For filing an application for status as a temporary resident under section

245A(a) of the Act. A fee of \$240 for each application or \$105 for each application for a minor child (under 18 years of age) is required at the time of filing with the Department of Homeland Security. The maximum amount payable by a family (husband, wife, and any minor children) shall be \$585.

Form I-690. For filing an application for waiver of a ground of inadmissibility under section 212(a) of the Act as amended, in conjunction with the application under sections 210 or 245A of the Act, or a petition under section 210A of the Act—\$90.

Form I-694. For appealing the denial of an application under sections 210 or 245A of the Act, or a petition under section 210A of the Act—\$105.

Form I-695. For filing an application for replacement of temporary resident card (Form I-688)—\$65.

Form I-698. For filing an application for adjustment from temporary resident status to that of lawful permanent resident under section 245A(b)(1) of the Act. For applicants filing within 31 months from the date of adjustment to temporary resident status, a fee of \$135 for each application is required at the time of filing with the Department of Homeland Security. The maximum amount payable by a family (husband, wife, and any minor children (under 18 years of age living at home)) shall be \$405. For applicants filing after 31 months from the date of approval of temporary resident status, who file their applications on or after July 9, 1991, a fee of \$175 (a maximum of \$525 per family) is required. The adjustment date is the date of filing of the application for permanent residence or the applicant's eligibility date, whichever is later.

* * * * *

Form I-751. For filing a petition to remove the conditions on residence, based on marriage—\$200.

Form I-765. For filing an application for employment authorization pursuant to 8 CFR 274a.13—\$175.

* * * * *

Form I-817. For filing an application for voluntary departure under the Family Unity Program—\$195.

* * * * *

Form I-824. For filing for action on an approved application or petition—\$195.

Form I-829. For filing a petition by entrepreneur to remove conditions—\$455.

Form I-881. For filing an application for suspension of deportation or special rule cancellation of removal (pursuant to section 203 of Public Law 105-100):

— \$275 for adjudication by the Department of Homeland Security, except that the maximum amount payable by family members (related as husband, wife, unmarried child under 21, unmarried son, or unmarried daughter) who submit applications at the same time shall be \$550.

— \$155 for adjudication by the Immigration Court (a single fee of \$155 will be charged whenever applications are filed by two or more aliens in the same proceedings). The \$155 fee is not required if the Form I-881

is referred to the Immigration Court by the Department of Homeland Security.

* * * * *

Form I-914. For filing an application to classify an alien as a nonimmigrant under section 101(a)(15)(T) of the Act (victims of a severe form of trafficking in persons and their immediate family members)—\$255. For each immediate family member included on the same application, an additional fee of \$105 per person, up to a maximum amount payable per application of \$510.

Form N-300. For filing an application for declaration of intention—\$115.

Form N-336. For filing a request for hearing on a decision in naturalization proceedings under section 336 of the Act—\$250.

Form N-400. For filing an application for naturalization—\$320. (There is no fee charged for an application filed on or after October 1, 2004, by an applicant who meets the requirements of sections 328 or 329 of the Act with respect to military service.)

* * * * *

Form N-470. For filing an application for benefits under section 316(b) or 317 of the Act—\$150.

Form N-565. For filing an application for a certificate of naturalization or declaration of intention in lieu of a certificate or declaration alleged to have been lost, mutilated, or destroyed; for a certificate of citizenship in a changed name under section 343(c) of the Act; or for a special certificate of naturalization to obtain recognition as a citizen of the United States by a foreign state under section 343(b) of the Act—\$210.

Form N-600. For filing an application for a certificate of citizenship under section 309(c) or section 341 of the Act—\$240, for applications filed on behalf of a biological child and \$200 for applications filed on behalf of an adopted child.

Form N-600K. For filing an application for citizenship and issuance of certificate under section 322 of the Act—\$240, for an application filed on behalf of a biological child and \$200 for an application filed on behalf of an adopted child.

* * * * *

Motion. For filing a motion to reopen or reconsider any decision under the immigration laws in any type of proceeding over which the Executive Office for Immigration Review does not have jurisdiction. No fee shall be charged for a motion to reopen or reconsider a decision on an application for relief for which no fee is chargeable or for any motion to reopen or reconsider made concurrently with any initial application for relief under the immigration laws for which no fee is chargeable. (The fee of \$110 shall be charged whenever an appeal or motion is filed by or on behalf of two or more aliens and all such aliens are covered by one decision. When a motion to reopen or reconsider is made concurrently with any application for relief under the immigration laws for which a fee is chargeable, the motion is filed and, if the motion is granted, the requisite fee for filing the application for relief will be charged and

must be paid within the time specified in order to complete the application.)—\$110.

* * * * *

(2) Fees for production or disclosure of records under 5 U.S.C. 552 shall be charged in accordance with the regulations of the Department of Homeland Security at 6 CFR 5.11.

(3) The fees prescribed in paragraph (b)(1) of this section shall be adjusted annually on or after October 1, 2005, by publication of an inflation adjustment. The inflation adjustment will be announced by notice in the **Federal Register**, and the adjustment shall be a composite of the Federal civilian pay raise assumption and non-pay inflation factor for that fiscal year issued by the Office of Management and Budget for agency use in implementing OMB Circular A-76, weighted by pay and non-pay proportions of total funding for that fiscal year. If Congress enacts a different Federal civilian pay raise percentage than the percentage issued by OMB for Circular A-76, the Department of Homeland Security may adjust the fees, during the current year or a following year to reflect the enacted level. The prescribed fee or charge shall be the amount prescribed in paragraph (b)(1) of this section, plus the latest inflation adjustment, rounded to the nearest \$5 increment.

(4) For the schedule of fees relating to proceedings before the immigration judges and the Board of Immigration Appeals, see 8 CFR 1103.7.

(c) *Waiver of fees.* (1) Except as otherwise provided in this paragraph (c), any of the fees prescribed in paragraph (b) of this section relating to applications, petitions, appeals, motions, or requests may be waived by the Department of Homeland Security in any case under its jurisdiction in which the alien or other party affected is able to substantiate that he or she is unable to pay the prescribed fee. The person seeking a fee waiver must file his or her affidavit, or unsworn declaration made pursuant to 28 U.S.C. 1746, asking for permission to prosecute without payment of fee of the application, petition, appeal, motion, or request, and stating his or her belief that he or she is entitled to or deserving of the benefit requested and the reasons for his or her inability to pay. The officer of the Department of Homeland Security having jurisdiction to render a decision on the application, petition, appeal, motion, or request may, in his or her discretion, grant the waiver of fee. Fees for "Passenger Travel Reports via Sea and Air" and for special statistical tabulations may not be waived. The payment of the additional sum prescribed by section 245(i) of the Act

when applying for adjustment of status under section 245 of the Act may not be waived. The fee for Form I-907, Request for Premium Processing Services, may not be waived. For provisions relating to the authority of the immigration judges or the Board to waive fees prescribed in paragraph (b) of this section in cases under their jurisdiction, see 8 CFR 1003.24 and 1003.8.

(2) Fees under the Freedom of Information Act, as amended, may be waived or reduced where the Department of Homeland Security determines such action would be in the

public interest because furnishing the information can be considered as primarily benefiting the general public.

(3) When the prescribed fee is for services to be performed by the clerk of court under section 344(a) of the Act, the affidavit for waiver of the fee shall be filed with the district director or officer in charge of the BCIS having administrative jurisdiction over the place in which the court is located at least 7 days prior to the date the fee is required to be paid. If the waiver is granted, there shall be delivered to the clerk of court by a BCIS representative

on or before the date the fee is required to be paid, a notice prepared on BCIS letterhead and signed by the officer granting the waiver, that the fee has been waived pursuant to this paragraph.

(4) Fees for applications for Temporary Protected Status may be waived pursuant to 8 CFR 244.20.

* * * * *

Dated: April 13, 2004.

Tom Ridge,

Secretary of Homeland Security.

[FR Doc. 04-8699 Filed 4-13-04; 3:38 pm]

BILLING CODE 4410-10-P

Reader Aids

Federal Register

Vol. 69, No. 73

Thursday, April 15, 2004

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations	
General Information, indexes and other finding aids	202-741-6000
Laws	741-6000
Presidential Documents	
Executive orders and proclamations	741-6000
The United States Government Manual	741-6000
Other Services	
Electronic and on-line services (voice)	741-6020
Privacy Act Compilation	741-6064
Public Laws Update Service (numbers, dates, etc.)	741-6043
TTY for the deaf-and-hard-of-hearing	741-6086

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications is located at: <http://www.gpoaccess.gov/nara/index.html>

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access are located at: http://www.archives.gov/federal_register/

E-mail

FEDREGTOC-L (Federal Register Table of Contents LISTSERV) is an open e-mail service that provides subscribers with a digital form of the Federal Register Table of Contents. The digital form of the Federal Register Table of Contents includes HTML and PDF links to the full text of each document.

To join or leave, go to <http://listserv.access.gpo.gov> and select *Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings)*; then follow the instructions.

PENS (Public Law Electronic Notification Service) is an e-mail service that notifies subscribers of recently enacted laws.

To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html> and select *Join or leave the list* (or change settings); then follow the instructions.

FEDREGTOC-L and **PENS** are mailing lists only. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to: fedreg.info@nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, APRIL

17033-17282	1
17283-17584	2
17585-17898	5
17899-18244	6
18245-18470	7
18471-18800	8
18801-19076	9
19077-19310	12
19311-19752	13
19753-19920	14
19921-20536	15

CFR PARTS AFFECTED DURING APRIL

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

1 CFR	335.....19085
51.....18801	1700.....18808
3 CFR	Proposed Rules:
Proclamations:	222.....19123
7765.....18465	1710.....19126
7766.....18467	14 CFR
7767.....18469	25.....18246, 19311
7768.....19077	39.....17033, 17034, 17901,
7769.....19307	17903, 17905, 17906, 17909,
7770.....19751	17911, 17913, 17914, 17915,
Executive Orders:	17917, 17918, 17919, 17921,
13334.....19917	17924, 17925, 18250, 19313,
5 CFR	19618, 19756, 19758, 19759
Proposed Rules:	71.....17283, 19314, 19315,
1650.....18294	19316, 19317, 19318, 19319,
1653.....18294	19922, 19923
1655.....18294	73.....18471
1690.....18294	97.....17284
7 CFR	121.....19761
772.....18471	135.....18472
905.....19079	Proposed Rules:
916.....19753	39.....17072, 17073, 17076,
917.....19753	17077, 17080, 17082, 17084,
929.....18803	17086, 17088, 17091, 17095,
982.....19082	17097, 17101, 17103, 17105,
983.....17844	17107, 17109, 17111, 17113,
984.....17899	17115, 17610, 17984, 17987,
Proposed Rules:	17989, 17991, 17993, 17996,
301.....19950	18304, 18306, 18843, 18845,
330.....17984	18848, 19132, 19135, 19777,
926.....19118	19950, 19952, 19954, 19956
1033.....19292	71.....18308, 18309, 18508,
1124.....18834	19359, 19360, 19958, 19960,
8 CFR	19961, 19962, 19963
103.....20528	15 CFR
Proposed Rules:	774.....17926
103.....18296	16 CFR
9 CFR	1210.....19762
1.....17899	Proposed Rules:
2.....17899	316.....18851
3.....17899	801.....18686
301.....18245	802.....18686
309.....18245	803.....18686
309.....18245	17 CFR
310.....18245	Proposed Rules:
311.....18245	30.....17998
313.....18245	232.....17864
318.....18245	240.....17864
319.....18245	249.....17864
320.....18245	19 CFR
11 CFR	Proposed Rules:
Proposed Rules:	24.....18296
110.....18301, 18841	20 CFR
12 CFR	404.....19924
229.....19921	641.....19014
	Proposed Rules:
	404.....18310

21 CFR	33 CFR	465.....18166	606.....19329
Ch. 1.....17285	101.....17927	42 CFR	609.....19329
1.....19763, 19765, 19766	104.....17927	411.....17933	611.....19329
20.....19766	117.....17055, 17057, 17595,	414.....17935	612.....19329
173.....17297	17597, 18473, 19103, 19325	424.....17933	613.....19329
201.....18255	147.....19933	44 CFR	616.....19329
206.....18728	165.....18473, 19326	64.....17310	617.....19329
250.....18728	167.....18476	65.....17597, 17600	619.....19329
312.....17927	402.....18811	67.....17312, 17606, 17608	622.....19329
314.....18728	Proposed Rules:	Proposed Rules:	623.....19329
522.....17585	100.....18002	67.....17381, 17619, 17620	625.....19329
573.....19320	110.....17119	45 CFR	626.....19329
600.....18728	117.....17122, 17616, 17618,	1206.....19110	628.....19329
601.....18728	18004	2552.....19774	630.....19329
606.....18255	165.....18794, 18797	46 CFR	632.....19329
610.....18255	36 CFR	515.....19774	636.....19329
807.....18472	223.....18813	47 CFR	637.....19329
1308.....17034	400.....17928	1.....17946	642.....19329
Proposed Rules:	Proposed Rules:	2.....18275, 18832	651.....19329
Ch. 1.....17615	13.....17355	22.....17063	652.....19329
22 CFR	242.....19964	24.....17063	653.....19329
126.....18810	37 CFR	25.....18275	Proposed Rules:
24 CFR	401.....17299	27.....17946	19.....18244
Proposed Rules:	38 CFR	73.....17070, 17071, 19328	45.....17584
30.....19906	20.....19935	74.....17946	52.....17584
203.....19906	39 CFR	80.....19947	49 CFR
320.....19746	111.....17059	90.....17946, 17959	192.....18228
26 CFR	Proposed Rules:	101.....17946	219.....19270
1.....17586	111.....19363	Proposed Rules:	375.....17313
Proposed Rules:	40 CFR	0.....17124	541.....17960
1.....17117, 17477, 18314	9.....19105	1.....17124, 18006, 19779	542.....17960
301.....17117	52.....17302, 17929, 18815,	11.....18857	543.....17960
29 CFR	19937, 19939	13.....18007	571.....18496
35.....17570	63.....19106, 19734, 19943	54.....18508	1104.....18498
1981.....17587	68.....18819	61.....17124, 18006	1572.....17969
4022.....19925	80.....17932	69.....17124, 18006	Proposed Rules:
4044.....19925	147.....18478	73.....17124, 17125, 18860,	541.....18010
Proposed Rules:	166.....17303	19363, 19364	544.....18861
1910.....17774	180.....17304, 18255, 18263,	80.....18007	571.....17622, 18015
1917.....19361	18275, 18480, 19767	87.....19140	572.....17622
1918.....19361	257.....17308	48 CFR	50 CFR
30 CFR	745.....18489	Ch. 1.....17740, 17770	17.....18279, 18499
75.....17480	Proposed Rules:	1.....17741	92.....17318
925.....19927	52.....17368, 17374, 18006,	2.....17741, 17764	216.....17973
931.....19321	18319, 18323, 18853, 19968	4.....17768	223.....18444
Proposed Rules:	63.....18327, 18338, 19139,	8.....17741	224.....18444
200.....19137	19743, 19968	15.....17768	622.....19346
31 CFR	81.....17374, 18853	29.....17769	648.....17980, 18291
1.....17298	86.....17532	31.....17764	660.....17329, 18444, 19347
103.....19093, 19098	122.....18166	45.....17741	679.....17982, 19116, 19358,
240.....17272	136.....18166	49.....17741	19776
32 CFR	141.....18166	52.....17741, 17770	Proposed Rules:
199.....17035	143.....18166	53.....17741	17.....17383, 17627, 17634,
2001.....17052	257.....17380	601.....19329	18016, 18018, 18035, 18515,
Proposed Rules:	300.....19363	602.....19329	18516, 18770, 19364, 19620
519.....18314	403.....18166	603.....19329	100.....19964
	430.....18166	604.....19329	229.....19365
	455.....18166	605.....19329	300.....19147
			635.....19147
			648.....19805

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT APRIL 15, 2004**AGRICULTURE DEPARTMENT****Agricultural Marketing Service**

Nectarines and fresh pears and peaches grown in—
California; published 4-14-04

EDUCATION DEPARTMENT

Postsecondary education:
Institutional eligibility for Federal funds; published 3-16-04

ENVIRONMENTAL PROTECTION AGENCY

Air quality implementation plans; approval and promulgation; various States:

District of Columbia, Maryland and Virginia; published 4-15-04

FEDERAL RESERVE SYSTEM

Credit by brokers and dealers (Regulation T):
Foreign margin stocks; list; published 3-8-04

HEALTH AND HUMAN SERVICES DEPARTMENT**Food and Drug Administration**

Medical devices:
Hematology and pathology devices—
Factor V Leiden DNA mutation detection systems devices classification; published 3-16-04

HOMELAND SECURITY DEPARTMENT**Coast Guard**

Drawbridge operations:
Louisiana; published 3-31-04

INTERIOR DEPARTMENT**Fish and Wildlife Service**

Endangered and threatened species:

Critical habitat designations—
Desert yellowhead; published 3-16-04

INTERIOR DEPARTMENT

Permanent program and abandoned mine land reclamation plan submissions:

Missouri; published 4-15-04

PEACE CORPS

Organization; CFR part removed; published 3-16-04

SOCIAL SECURITY ADMINISTRATION

Social security benefits:
Federal old age, survivors, and disability insurance—
Primary insurance amounts; cost-of-living increases; published 4-15-04

TRANSPORTATION DEPARTMENT**Federal Aviation Administration**

Airworthiness directives:
Bombardier; published 3-31-04
McDonnell Douglas; published 3-11-04
Sikorsky Aircraft Corporation; published 3-31-04

Airworthiness standards:

Transport category airplanes—
Electrical equipment and installations, storage battery installations; electronic equipment; and electrical system components fire protection; published 3-16-04

Class D airspace; published 3-5-04

Class D and E airspace; published 2-3-04

Class E airspace; published 12-2-03

Class E airspace; correction; published 12-17-03

IFR altitudes; published 3-8-04
Restricted areas; published 1-22-04

VOR Federal airways; published 2-5-04

COMMENTS DUE NEXT WEEK**AGRICULTURE DEPARTMENT****Agricultural Marketing Service**

Dried prunes produced in—
California; comments due by 4-23-04; published 3-26-04 [FR 04-06704]

AGRICULTURE DEPARTMENT**Animal and Plant Health Inspection Service**

Interstate transportation of animals and animal products (quarantine):
Brucellosis in cattle and bison—

State and area classifications;
comments due by 4-20-04; published 2-20-04 [FR 04-03723]

Plant-related quarantine, domestic:

Mexican fruit fly; comments due by 4-19-04; published 2-18-04 [FR 04-03429]

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:
Caribbean, Gulf, and South Atlantic fisheries—

Gulf of Mexico reef fish; red grouper rebuilding plan; comments due by 4-20-04; published 2-20-04 [FR 04-03754]

COURT SERVICES AND OFFENDER SUPERVISION AGENCY FOR THE DISTRICT OF COLUMBIA

Semi-annual agenda; Open for comments until further notice; published 12-22-03 [FR 03-25121]

DEFENSE DEPARTMENT

Acquisition regulations:
Competition requirements; comments due by 4-23-04; published 2-23-04 [FR 04-03705]

Contractor qualifications relating to contract placement; comments due by 4-23-04; published 2-23-04 [FR 04-03702]

Cost principles and procedures; comments due by 4-23-04; published 2-23-04 [FR 04-03708]

Debarment, suspension, and business ethics; improper business practices and contractor qualifications; comments due by 4-23-04; published 2-23-04 [FR 04-03703]

Freedom of Information Act; implementation; comments due by 4-23-04; published 2-23-04 [FR 04-03693]

Government supply sources; contractor use; comments due by 4-23-04; published 2-23-04 [FR 04-03694]

Insurance requirements; comments due by 4-23-04; published 2-23-04 [FR 04-03692]

Laws inapplicable to commercial subcontracts; comments due by 4-23-04; published 2-23-04 [FR 04-03706]

Major systems acquisition; comments due by 4-23-

04; published 2-23-04 [FR 04-03707]

Obsolete research and development contracting procedures; removal; comments due by 4-23-04; published 2-23-04 [FR 04-03695]

Procedures, guidance, and information; comments due by 4-23-04; published 2-23-04 [FR 04-03699]

Publicizing contract actions; comments due by 4-23-04; published 2-23-04 [FR 04-03704]

Research and development contracting; comments due by 4-23-04; published 2-23-04 [FR 04-03696]

Sealed bidding; comments due by 4-23-04; published 2-23-04 [FR 04-03697]

Federal Acquisition Regulation (FAR):

Special emergency procurement authority; comments due by 4-23-04; published 2-23-04 [FR 04-03690]

EDUCATION DEPARTMENT

Nondiscrimination on basis of sex in education programs receiving Federal assistance; comments due by 4-23-04; published 3-9-04 [FR 04-05156]

ENERGY DEPARTMENT

Physician panel determinations on worker requests for assistance in filing for State workers' compensation benefits; guidelines; comments due by 4-23-04; published 3-24-04 [FR 04-06555]

ENERGY DEPARTMENT Federal Energy Regulatory Commission

Electric rate and corporate regulation filings:
Virginia Electric & Power Co. et al.; Open for comments until further notice; published 10-1-03 [FR 03-24818]

ENVIRONMENTAL PROTECTION AGENCY

Air quality implementation plans; approval and promulgation; various States:
California; comments due by 4-21-04; published 3-22-04 [FR 04-06212]
Delaware; comments due by 4-23-04; published 3-24-04 [FR 04-06562]
Illinois; comments due by 4-21-04; published 3-22-04 [FR 04-06307]

- Indiana; comments due by 4-21-04; published 3-22-04 [FR 04-06214]
- Maine; comments due by 4-21-04; published 3-22-04 [FR 04-06209]
- Maryland; comments due by 4-21-04; published 3-22-04 [FR 04-06305]
- Ohio; comments due by 4-21-04; published 3-22-04 [FR 04-06303]
- Environmental statements; availability, etc.:
- Coastal nonpoint pollution control program—
- Minnesota and Texas; Open for comments until further notice; published 10-16-03 [FR 03-26087]
- Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
- Aminoethoxyvinylglycine hydrochloride; comments due by 4-19-04; published 2-18-04 [FR 04-03371]
- FEDERAL COMMUNICATIONS COMMISSION**
- Common carrier services:
- Federal-State Joint Board on Universal Service—
- Interstate services of non-price cap incumbent local exchange carriers and interexchange carriers; multi-association group plan; comments due by 4-23-04; published 3-24-04 [FR 04-06560]
- Telecommunications Act of 1996; implementation—
- Pay telephone reclassification and compensation provisions; comments due by 4-21-04; published 4-6-04 [FR 04-07804]
- Telecommunications service providers; biennial regulatory review; comments due by 4-19-04; published 3-18-04 [FR 04-05657]
- Wireless telecommunications services—
- Wireless radio services; rules streamlining and harmonization; biennial regulatory review; comments due by 4-23-04; published 2-23-04 [FR 04-03730]
- Practice and procedure:
- Regulatory fees; assessment and collection; comments due by 4-21-04; published 4-14-04 [FR 04-08260]
- Radio stations; table of assignments:
- Georgia; comments due by 4-19-04; published 3-16-04 [FR 04-05918]
- Kentucky; comments due by 4-19-04; published 3-16-04 [FR 04-05911]
- FEDERAL DEPOSIT INSURANCE CORPORATION**
- Agency information collection activities; proposals, submissions, and approvals; comments due by 4-20-04; published 1-21-04 [FR 04-01161]
- FEDERAL RESERVE SYSTEM**
- Agency information collection activities; proposals, submissions, and approvals; comments due by 4-20-04; published 1-21-04 [FR 04-01161]
- FEDERAL TRADE COMMISSION**
- Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003: Definitions, implementation, and reporting requirements; comments due by 4-20-04; published 3-11-04 [FR 04-05500]
- Fair and Accurate Credit Transactions Act; implementation:
- Fair credit reporting provisions; comments due by 4-23-04; published 2-24-04 [FR 04-03978]
- GENERAL SERVICES ADMINISTRATION**
- Federal Acquisition Regulation (FAR):
- Special emergency procurement authority; comments due by 4-23-04; published 2-23-04 [FR 04-03690]
- HEALTH AND HUMAN SERVICES DEPARTMENT**
- Food and Drug Administration**
- Human drugs:
- Prescription drug marketing; effective date delay; comments due by 4-23-04; published 2-23-04 [FR 04-03856]
- Reports and guidance documents; availability, etc.:
- Evaluating safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern; Open for comments until further notice; published 10-27-03 [FR 03-27113]
- HOMELAND SECURITY DEPARTMENT**
- Coast Guard**
- Anchorage regulations:
- Maryland; Open for comments until further notice; published 1-14-04 [FR 04-00749]
- Ports and waterways safety:
- San Francisco Bay, et al., CA; regulated navigation area; comments due by 4-19-04; published 2-19-04 [FR 04-03596]
- JUSTICE DEPARTMENT**
- Drug Enforcement Administration**
- Precursors and essential chemicals; importation and exportation:
- International sales of listed chemicals; use of Internet to arrange; comments due by 4-19-04; published 2-17-04 [FR 04-03355]
- NATIONAL AERONAUTICS AND SPACE ADMINISTRATION**
- Federal Acquisition Regulation (FAR):
- Special emergency procurement authority; comments due by 4-23-04; published 2-23-04 [FR 04-03690]
- NATIONAL ARCHIVES AND RECORDS ADMINISTRATION**
- Organization, functions, and authority delegations:
- Official seals and logos; comments due by 4-20-04; published 2-20-04 [FR 04-03573]
- POSTAL SERVICE**
- Procurement system:
- Purchasing of property and services; comments due by 4-23-04; published 3-24-04 [FR 04-06395]
- SECURITIES AND EXCHANGE COMMISSION**
- Securities:
- International financial reporting standards; Form 20-F amendment; comments due by 4-19-04; published 3-18-04 [FR 04-05982]
- SMALL BUSINESS ADMINISTRATION**
- Disaster loan areas:
- Maine; Open for comments until further notice; published 2-17-04 [FR 04-03374]
- TRANSPORTATION DEPARTMENT**
- Federal Aviation Administration**
- Air carrier certification and operations:
- National air tour safety standards; comments due by 4-19-04; published 1-16-04 [FR 04-01129]
- Airworthiness directives:
- Airbus; comments due by 4-19-04; published 3-5-04 [FR 04-04936]
- BAE Systems (Operations) Ltd.; comments due by 4-23-04; published 3-24-04 [FR 04-06504]
- Boeing; comments due by 4-19-04; published 3-5-04 [FR 04-04928]
- General Electric Co.; comments due by 4-23-04; published 2-23-04 [FR 04-03679]
- McDonnell Douglas; comments due by 4-19-04; published 3-5-04 [FR 04-04927]
- Pratt & Whitney; comments due by 4-20-04; published 2-20-04 [FR 04-03682]
- Rolls-Royce Corp.; comments due by 4-23-04; published 2-23-04 [FR 04-03681]
- Schweizer Aircraft Corp.; comments due by 4-19-04; published 2-19-04 [FR 04-03495]
- Airworthiness standards:
- Special conditions—
- Boeing Model 727-100/-200 series airplanes; comments due by 4-19-04; published 3-19-04 [FR 04-06150]
- GenTex Aerospace, Inc.; diamond DA20-C1 katana airplanes; comments due by 4-22-04; published 3-23-04 [FR 04-06454]
- Class E airspace; comments due by 4-19-04; published 3-5-04 [FR 04-05033]
- TRANSPORTATION DEPARTMENT**
- Federal Railroad Administration**
- Railroad safety:
- Locomotive horns use at highway-rail grade crossings; requirement for sounding; comments due by 4-19-04; published 2-13-04 [FR 04-03181]
- TRANSPORTATION DEPARTMENT**
- National Highway Traffic Safety Administration**
- Motor vehicle safety standards:
- Child restraint systems—
- Harnesses for use on school bus seats; comments due by 4-23-

04; published 3-9-04
[FR 04-05168]

Harnesses for use on
school bus seats;
correction; comments
due by 4-23-04;
published 3-24-04 [FR
C4-05168]

TREASURY DEPARTMENT
Comptroller of the Currency
Agency information collection
activities; proposals,
submissions, and approvals;
comments due by 4-20-04;
published 1-21-04 [FR 04-
01161]

TREASURY DEPARTMENT
Thrift Supervision Office
Agency information collection
activities; proposals,
submissions, and approvals;

comments due by 4-20-04;
published 1-21-04 [FR 04-
01161]

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "PLUS" (Public Laws Update Service) on 202-741-6043. This list is also available online at http://www.archives.gov/federal_register/public_laws/public_laws.html.

The text of laws is not published in the **Federal Register** but may be ordered

in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202-512-1808). The text will also be made available on the Internet from GPO Access at <http://www.gpoaccess.gov/plaws/index.html>. Some laws may not yet be available.

H.R. 2584/P.L. 108-219

To provide for the conveyance to the Utrok Atoll local government of a decommissioned National Oceanic and Atmospheric Administration ship, and for other purposes. (Apr. 13, 2004; 118 Stat. 615)
Last List April 14, 2004


Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html>

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.

The authentic text behind the news . . .

The Weekly Compilation of Presidential Documents



This unique service provides up-to-date information on Presidential policies and announcements. It contains the full text of the President's public speeches, statements, messages to Congress, news conferences, and other Presidential materials released by the White House.



The Weekly Compilation carries a Monday dateline and covers materials released during the preceding week. Each issue includes a Table of Contents, lists of acts approved by the President, nominations submitted to the Senate, a checklist of White House press releases, and a

digest of other Presidential activities and White House announcements. Indexes are published quarterly.

**Published by the Office of the
Federal Register, National
Archives and Records
Administration.**

Superintendent of Documents **Subscription** Order Form

Order Processing Code:
* **5420**

**Charge your order.
It's Easy!**  
To fax your orders (202) 512-2250
Phone your orders (202) 512-1800

YES, please enter _____ one year subscriptions for the **Weekly Compilation of Presidential Documents (PD)** so I can keep up to date on Presidential activities.

\$151.00 First Class Mail \$92.00 Regular Mail

The total cost of my order is \$ _____. **Price includes regular domestic postage and handling** and is subject to change. International customers please add 25%.

Company or personal name (Please type or print)

Additional address/attention line

Street address

City, State, ZIP code

Daytime phone including area code

Purchase order number (optional)

May we make your name/address available to other mailers? YES NO

Please Choose Method of Payment:

Check Payable to the Superintendent of Documents

GPO Deposit Account -

VISA MasterCard Account

(Credit card expiration date) **Thank you for your order!**

Authorizing signature 4/00

Mail To: Superintendent of Documents
P.O. Box 371954, Pittsburgh, PA 15250-7954

INFORMATION ABOUT THE SUPERINTENDENT OF DOCUMENTS' SUBSCRIPTION SERVICE

Know when to expect your renewal notice and keep a good thing coming. To keep our subscription prices down, the Government Printing Office mails each subscriber *only one renewal notice*. You can learn when you will get your renewal notice by checking the number that follows month/year code on the top line of your label as shown in this example:

A renewal notice will be sent approximately 90 days before the shown date.

A renewal notice will be sent approximately 90 days before the shown date.

..... /

DEC97 R 1

AEB SMITH212J
JOHN SMITH
212 MAIN STREET
FORESTVILLE MD 20704

..... /

DEC97 R 1

AERDO SMITH212J
JOHN SMITH
212 MAIN STREET
FORESTVILLE MD 20704

To be sure that your service continues without interruption, please return your renewal notice promptly. If your subscription service is discontinued, simply send your mailing label from any issue to the Superintendent of Documents, Washington, DC 20402-9372 with the proper remittance. Your service will be reinstated.


To change your address: Please SEND YOUR MAILING LABEL, along with your new address to the Superintendent of Documents, Attn: Chief, Mail List Branch, Mail Stop: SSOM, Washington, DC 20402-9373.

To inquire about your subscription service: Please SEND YOUR MAILING LABEL, along with your correspondence, to the Superintendent of Documents, Attn: Chief, Mail List Branch, Mail Stop: SSOM, Washington, DC 20402-9373.

To order a new subscription: Please use the order form provided below.

Superintendent of Documents **Subscription Order Form**

Order Processing Code
* 5468

Charge your order.  
It's Easy!

YES, enter my subscription(s) as follows:

To fax your orders (202) 512-2250
Phone your orders (202) 512-1800

- _____ subscriptions to **Federal Register (FR)**; including the daily Federal Register, monthly Index and List of CFR Sections Affected (LSA), at \$764 each per year.
- _____ subscriptions to **Federal Register, daily only (FRDO)**, at \$699 each per year.

The total cost of my order is \$ _____. Price includes regular domestic postage and handling, and is subject to change. International customers please add 25%.

Company or personal name _____ (Please type or print)

Additional address/attention line _____

Street address _____

City, State, ZIP code _____

Daytime phone including area code _____

Purchase order number (optional) _____


May we make your name/address available to other mailers? YES NO

Please Choose Method of Payment:

- Check Payable to the Superintendent of Documents
- GPO Deposit Account -
- VISA MasterCard Account
- _____
- _____ (Credit card expiration date) **Thank you for your order!**

Authorizing signature _____ 1001

Mail To: Superintendent of Documents
P.O. Box 371954, Pittsburgh, PA 15250-7954





Printed on recycled paper

